<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4246609/results/search/disease/results.xml">
   <result pre="lymph nodes. Magnetic resonance imaging ( Fig. 1) identified a" exact="neoplasm" post="of ~2 cm in diameter located in the deep"/>
   <result pre="including atypical ductal hyperplasia and micropapillary and cribriform low-grade ductal" exact="carcinoma in situ" post="( 7). Low-grade SDC has subsequently been defined as"/>
   <result pre="defines high-grade SDCs as tumors that consist of solid invasive" exact="cancer" post="nests with polygonal cancer cells surrounding a comedo-like necrosis."/>
   <result pre="tumors that consist of solid invasive cancer nests with polygonal" exact="cancer" post="cells surrounding a comedo-like necrosis. In the present case"/>
   <result pre="ER and PR is found in 75% of cases of" exact="breast cancer," post="however, positivity for these markers is rare in SDC"/>
   <result pre="Palma S Whitaker S Potter K Pitkin L Carcinoma ex" exact="pleomorphic adenoma" post="successfully treated with trastuzumab and radiotherapy Virchows Arch 461"/>
   <result pre="S Whitaker S Potter K Pitkin L Carcinoma ex pleomorphic" exact="adenoma" post="successfully treated with trastuzumab and radiotherapy Virchows Arch 461"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4261061/results/search/disease/results.xml">
   <result pre="Targeting HER2 with antibodies or small molecule inhibitors in HER2-positive" exact="breast cancer" post="leads to improved survival, but resistance is a common"/>
   <result pre="HER2 with antibodies or small molecule inhibitors in HER2-positive breast" exact="cancer" post="leads to improved survival, but resistance is a common"/>
   <result pre="To uncover novel mechanisms of resistance to anti-HER2 therapy in" exact="breast cancer," post="we performed a kinase open reading frame (ORF) screen"/>
   <result pre="reading frame (ORF) screen to identify genes that rescue HER2-amplified" exact="breast cancer" post="cells from HER2 inhibition or suppression. In addition to"/>
   <result pre="frame (ORF) screen to identify genes that rescue HER2-amplified breast" exact="cancer" post="cells from HER2 inhibition or suppression. In addition to"/>
   <result pre="anti-HER2 therapy. Furthermore, we observed elevated PRKACA expression in trastuzumab-resistant" exact="breast cancer" post="samples, indicating that this pathway is activated in breast"/>
   <result pre="therapy. Furthermore, we observed elevated PRKACA expression in trastuzumab-resistant breast" exact="cancer" post="samples, indicating that this pathway is activated in breast"/>
   <result pre="BCL-XL/BCL-2 anti-apoptotic pathway may increase responses to anti-HER2 therapy in" exact="breast cancer" post="and decrease the emergence of resistant disease. breast cancer"/>
   <result pre="anti-apoptotic pathway may increase responses to anti-HER2 therapy in breast" exact="cancer" post="and decrease the emergence of resistant disease. breast cancer"/>
   <result pre="in breast cancer and decrease the emergence of resistant disease." exact="breast cancer" post="drug resistance HER2 PRKACA PIM1 INTRODUCTION The receptor tyrosine"/>
   <result pre="breast cancer and decrease the emergence of resistant disease. breast" exact="cancer" post="drug resistance HER2 PRKACA PIM1 INTRODUCTION The receptor tyrosine"/>
   <result pre="trastuzumab or lapatinib has led to clinical benefit in HER2-positive" exact="breast cancer" post="patients ( 3– 7). However, many patients with early-stage"/>
   <result pre="or lapatinib has led to clinical benefit in HER2-positive breast" exact="cancer" post="patients ( 3– 7). However, many patients with early-stage"/>
   <result pre="inhibits intracellular tyrosine kinase activity, can be induced in HER2-amplified" exact="breast cancer" post="cells by activating PIK3CA mutations, loss of PTEN ("/>
   <result pre="intracellular tyrosine kinase activity, can be induced in HER2-amplified breast" exact="cancer" post="cells by activating PIK3CA mutations, loss of PTEN ("/>
   <result pre="or by activation of mTORC1 ( 19). Since clinically resistant" exact="breast cancer" post="samples have not been extensively molecularly characterized, due in"/>
   <result pre="by activation of mTORC1 ( 19). Since clinically resistant breast" exact="cancer" post="samples have not been extensively molecularly characterized, due in"/>
   <result pre="Here we describe a systematic interrogation of resistance mechanisms to" exact="suppression" post="of HER2 to identify the major mechanisms of resistance"/>
   <result pre="resistance to the lapatinib-like dual EGFR/HER2 inhibitor AEE788 and to" exact="suppression" post="of HER2 with a short hairpin RNA (shRNA). We"/>
   <result pre="was a strong correlation between the degree of HER2 protein" exact="suppression" post="and loss of viability/proliferation. We chose the most effective"/>
   <result pre="in the setting of ectopic PRKACA expression in three HER2-amplified" exact="breast cancer" post="cell lines. PRKACA expression increased the viability of BT474,"/>
   <result pre="the setting of ectopic PRKACA expression in three HER2-amplified breast" exact="cancer" post="cell lines. PRKACA expression increased the viability of BT474,"/>
   <result pre="the setting of acquired resistance to anti-HER2 therapy in human" exact="breast cancer" post="samples. To examine this question, we performed PRKACA immunohistochemistry"/>
   <result pre="setting of acquired resistance to anti-HER2 therapy in human breast" exact="cancer" post="samples. To examine this question, we performed PRKACA immunohistochemistry"/>
   <result pre="samples. To examine this question, we performed PRKACA immunohistochemistry on" exact="breast cancer" post="samples taken from patients prior to the administration of"/>
   <result pre="To examine this question, we performed PRKACA immunohistochemistry on breast" exact="cancer" post="samples taken from patients prior to the administration of"/>
   <result pre="Specifically, patient #1 was diagnosed with de novo HER2-positive metastatic" exact="breast cancer," post="confirmed by biopsy of a sternal lesion ( Fig."/>
   <result pre="panel b). Patient #2 was diagnosed with early stage HER2-positive" exact="breast cancer," post="treated with lumpectomy, axillary lymph node dissection, and radiation."/>
   <result pre="panel d). Patient #3 was diagnosed with de novo metastatic" exact="breast cancer," post="confirmed by fine needle aspirate of a liver lesion."/>
   <result pre="needle aspirate of a liver lesion. A biopsy of her" exact="breast cancer" post="at diagnosis is shown ( Fig. 3C, panel e)."/>
   <result pre="aspirate of a liver lesion. A biopsy of her breast" exact="cancer" post="at diagnosis is shown ( Fig. 3C, panel e)."/>
   <result pre="that PRKACA confers resistance to trastuzumab and lapatinib in HER2-amplified" exact="breast cancer" post="cells, these observations strongly suggest that PRKACA overexpression contributes"/>
   <result pre="PRKACA confers resistance to trastuzumab and lapatinib in HER2-amplified breast" exact="cancer" post="cells, these observations strongly suggest that PRKACA overexpression contributes"/>
   <result pre="We found that, compared to normal breast tissue or benign" exact="breast disease," post="a large proportion of invasive breast cancers expressed high"/>
   <result pre="recurrent and resistant disease. DISCUSSION Resistance to targeted therapy in" exact="breast cancer" post="remains a major clinical problem. Although significant clinical benefit"/>
   <result pre="and resistant disease. DISCUSSION Resistance to targeted therapy in breast" exact="cancer" post="remains a major clinical problem. Although significant clinical benefit"/>
   <result pre="clinical responses are observed, it is evident that residual viable" exact="cancer" post="cells remain which ultimately give rise to resistant disease."/>
   <result pre="therapy. Efforts to target resistant or residual disease in HER2-positive" exact="breast cancer" post="thus far have largely focused on canonical downstream targets"/>
   <result pre="Efforts to target resistant or residual disease in HER2-positive breast" exact="cancer" post="thus far have largely focused on canonical downstream targets"/>
   <result pre="We found that both lapatinib and trastuzumab treatment of HER2-positive" exact="breast cancer" post="cells results in BAD de-phosphorylation, suggesting that the anti-cancer"/>
   <result pre="found that both lapatinib and trastuzumab treatment of HER2-positive breast" exact="cancer" post="cells results in BAD de-phosphorylation, suggesting that the anti-cancer"/>
   <result pre="increased levels of PRKACA expression in three out of five" exact="breast cancer" post="samples that developed clinical resistance to trastuzumab. Together with"/>
   <result pre="levels of PRKACA expression in three out of five breast" exact="cancer" post="samples that developed clinical resistance to trastuzumab. Together with"/>
   <result pre="results showing that PRKACA expression activates survival signaling in HER2-positive" exact="breast cancer" post="cells treated with anti-HER2 therapy, these findings support the"/>
   <result pre="showing that PRKACA expression activates survival signaling in HER2-positive breast" exact="cancer" post="cells treated with anti-HER2 therapy, these findings support the"/>
   <result pre="high levels of PRKACA expression mediate treatment resistance in HER2-positive" exact="breast cancer." post="Results from a tissue microarray of primary invasive breast"/>
   <result pre="cancers also suggests that PRKACA may play a role in" exact="breast cancer" post="progression. Indeed, a recent report showed that bi-allelic ablation"/>
   <result pre="also suggests that PRKACA may play a role in breast" exact="cancer" post="progression. Indeed, a recent report showed that bi-allelic ablation"/>
   <result pre="ER- or HER2-directed therapies may represent a useful strategy across" exact="breast cancer" post="subtypes ( 42). ABT-263 is currently under investigation in"/>
   <result pre="or HER2-directed therapies may represent a useful strategy across breast" exact="cancer" post="subtypes ( 42). ABT-263 is currently under investigation in"/>
   <result pre="of cancers, although not in combination with anti-HER2 therapy in" exact="breast cancer" post="( Clinicaltrials.gov). Although our observations strongly suggest that the"/>
   <result pre="cancers, although not in combination with anti-HER2 therapy in breast" exact="cancer" post="( Clinicaltrials.gov). Although our observations strongly suggest that the"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer" post="Science 1989 5 12 244 4905 707 712 2470152"/>
   <result pre="Studies of the HER-2/neu proto-oncogene in human breast and ovarian" exact="cancer" post="Science 1989 5 12 244 4905 707 712 2470152"/>
   <result pre="JD et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic" exact="breast cancer" post="that progressed on first- or second-line trastuzumab-containing regimens Ann"/>
   <result pre="et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast" exact="cancer" post="that progressed on first- or second-line trastuzumab-containing regimens Ann"/>
   <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="Fehrenbacher L et al. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic" exact="breast cancer." post="a preliminary report Eur J Cancer 2001 1 37"/>
   <result pre="as a single agent in first-line treatment of HER2-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 2002 2 1 20 3 719"/>
   <result pre="a single agent in first-line treatment of HER2-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 2002 2 1 20 3 719"/>
   <result pre="Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 10 20 353 16"/>
   <result pre="I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 10 20 353 16"/>
   <result pre="LX Du Y Esteva FJ Lapatinib induces apoptosis in trastuzumab-resistant" exact="breast cancer" post="cells: effects on insulin-like growth factor I signaling Mol"/>
   <result pre="Du Y Esteva FJ Lapatinib induces apoptosis in trastuzumab-resistant breast" exact="cancer" post="cells: effects on insulin-like growth factor I signaling Mol"/>
   <result pre="PI3K pathway as a major determinant of trastuzumab resistance in" exact="breast cancer" post="Cancer Cell 2007 10 12 4 395 402 17936563"/>
   <result pre="pathway as a major determinant of trastuzumab resistance in breast" exact="cancer" post="Cancer Cell 2007 10 12 4 395 402 17936563"/>
   <result pre="mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified" exact="breast cancer" post="cell lines Ann Oncol 2010 2 21 2 255"/>
   <result pre="in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast" exact="cancer" post="cell lines Ann Oncol 2010 2 21 2 255"/>
   <result pre="with trastuzumab response and survival in patients with HER2-positive metastatic" exact="breast cancer" post="Am J Pathol 2010 10 177 4 1647 1656"/>
   <result pre="trastuzumab response and survival in patients with HER2-positive metastatic breast" exact="cancer" post="Am J Pathol 2010 10 177 4 1647 1656"/>
   <result pre="E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+" exact="breast cancer" post="patients Proc Natl Acad Sci U S A 2011"/>
   <result pre="amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast" exact="cancer" post="patients Proc Natl Acad Sci U S A 2011"/>
   <result pre="independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+" exact="breast cancer" post="cells Breast Cancer Res Treat 2012 10 23 20"/>
   <result pre="activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast" exact="cancer" post="cells Breast Cancer Res Treat 2012 10 23 20"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 12 28 355 26"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 12 28 355 26"/>
   <result pre="YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 1 12 366 2"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 1 12 366 2"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 3"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 3"/>
   <result pre="M Baselga J et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 11 8 367 19"/>
   <result pre="Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 11 8 367 19"/>
   <result pre="al. Phase II trial of temsirolimus in patients with metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2012 11 136 2 355"/>
   <result pre="Phase II trial of temsirolimus in patients with metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2012 11 136 2 355"/>
   <result pre="in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic" exact="breast cancer" post="who progressed on trastuzumab-based therapy J Clin Oncol 2011"/>
   <result pre="combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast" exact="cancer" post="who progressed on trastuzumab-based therapy J Clin Oncol 2011"/>
   <result pre="Protein kinase A activation confers resistance to trastuzumab in human" exact="breast cancer" post="cell lines Clin Cancer Res 2009 12 1 15"/>
   <result pre="kinase A activation confers resistance to trastuzumab in human breast" exact="cancer" post="cell lines Clin Cancer Res 2009 12 1 15"/>
   <result pre="al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar" exact="hepatocellular carcinoma" post="Science 2014 2 28 343 6174 1010 1014 24578576"/>
   <result pre="human breast cancers. Immunohistochemical analysis for PRKACA expression in matched" exact="breast cancer" post="samples from patients prior to any treatment (panels a,"/>
   <result pre="breast cancers. Immunohistochemical analysis for PRKACA expression in matched breast" exact="cancer" post="samples from patients prior to any treatment (panels a,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4293298/results/search/disease/results.xml">
   <result pre="pmcid: 4293298 doi: 10.2147/CIA.S50670 cia-10-157 : Review Optimal management of" exact="breast cancer" post="in the elderly patient: current perspectives Le Saux Olivia"/>
   <result pre="4293298 doi: 10.2147/CIA.S50670 cia-10-157 : Review Optimal management of breast" exact="cancer" post="in the elderly patient: current perspectives Le Saux Olivia"/>
   <result pre="Press Limited, provided the work is properly attributed. Abstract Breast" exact="cancer" post="(BC) is the most common female malignancy in the"/>
   <result pre="benefits and risks, especially in the adjuvant setting. Keywords elderly" exact="breast cancer" post="geriatric assessment surgery chemotherapy radiotherapy Introduction Breast cancer (BC)"/>
   <result pre="and risks, especially in the adjuvant setting. Keywords elderly breast" exact="cancer" post="geriatric assessment surgery chemotherapy radiotherapy Introduction Breast cancer (BC)"/>
   <result pre="elderly breast cancer geriatric assessment surgery chemotherapy radiotherapy Introduction Breast" exact="cancer" post="(BC) now represents the most common female malignancy in"/>
   <result pre="and in developing countries, and is the leading cause of" exact="cancer" post="death among women worldwide. 1 Approximately one third of"/>
   <result pre="for detecting frailty risk. 35 Early stage and locally advanced" exact="breast cancer" post="Neoadjuvant therapy Preoperative therapy may be offered to render"/>
   <result pre="detecting frailty risk. 35 Early stage and locally advanced breast" exact="cancer" post="Neoadjuvant therapy Preoperative therapy may be offered to render"/>
   <result pre="92.5%, P=0.3386). However, 5 years after therapy, the rate of" exact="lymphedema" post="in the surgery group was twice as high when"/>
   <result pre="4-year mortality prognostic index developed by Lee et al), 116" exact="cancer" post="prognosis, 117 and the estimated reduction in risk of"/>
   <result pre="risk factor for the development of myelodysplasia and acute myelogenous" exact="leukemia" post="after anthracycline-based adjuvant chemotherapy for BC. 126 In a"/>
   <result pre="are another option. However, the risk of being diagnosed with" exact="congestive heart failure" post="is increased in elderly women. 137 In this regard,"/>
   <result pre="therapy in women aged 70–80 years, is ongoing. 147 Metastatic" exact="breast cancer" post="Endocrine therapy Elderly women with HR-positive metastatic BC should"/>
   <result pre="in women aged 70–80 years, is ongoing. 147 Metastatic breast" exact="cancer" post="Endocrine therapy Elderly women with HR-positive metastatic BC should"/>
   <result pre="similar in terms of OS. 153 In the BOLERO (Breast" exact="cancer" post="trials of OraL EveROlimus)-2 trial, 154 addition of everolimus"/>
   <result pre="( Table 2), anthracyclines are important drugs in BC. However," exact="congestive heart failure" post="is more frequent in patients aged 65 years and"/>
   <result pre="capecitabine and vinorelbine in patients with advanced breast, prostate, or" exact="lung cancer." post="173 After three cycles, 42.9% had stabilized disease. Compliance"/>
   <result pre="toxicities were hematologic (17.9%) and gastrointestinal (7.7%). The treatment of" exact="cancer" post="patients near death is becoming increasingly aggressive over time,"/>
   <result pre="regimen was safe, with a higher incidence of grade 3" exact="diarrhea" post="in the pertuzumab arm and more fatigue, asthenia, decreased"/>
   <result pre="single-agent paclitaxel in 46% of older patients. Only hypertension and" exact="proteinuria" post="were more common in older patients when compared with"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 2 69"/>
   <result pre="D Mathers C Parkin DM Estimates of worldwide burden of" exact="cancer" post="in 2008: GLOBOCAN 2008 Int J Cancer 2010 127"/>
   <result pre="B The relation between survival and age at diagnosis in" exact="breast cancer" post="N Engl J Med 1986 315 9 559 563"/>
   <result pre="The relation between survival and age at diagnosis in breast" exact="cancer" post="N Engl J Med 1986 315 9 559 563"/>
   <result pre="et al. Lack of survival gain for elderly women with" exact="breast cancer" post="Oncologist 2011 16 4 415 423 21406470 5 Bergman"/>
   <result pre="al. Lack of survival gain for elderly women with breast" exact="cancer" post="Oncologist 2011 16 4 415 423 21406470 5 Bergman"/>
   <result pre="influence of age on treatment choice and survival of elderly" exact="breast cancer" post="patients in south-eastern Netherlands: a population-based study Eur J"/>
   <result pre="of age on treatment choice and survival of elderly breast" exact="cancer" post="patients in south-eastern Netherlands: a population-based study Eur J"/>
   <result pre="Wei S Dimitrov NV HER2 status in elderly women with" exact="breast cancer" post="J Geriatr Oncol 2013 4 4 362 367 24472480"/>
   <result pre="S Dimitrov NV HER2 status in elderly women with breast" exact="cancer" post="J Geriatr Oncol 2013 4 4 362 367 24472480"/>
   <result pre="GM Tumor characteristics and clinical outcome of elderly women with" exact="breast cancer" post="J Natl Cancer Inst 2000 92 7 550 556"/>
   <result pre="Tumor characteristics and clinical outcome of elderly women with breast" exact="cancer" post="J Natl Cancer Inst 2000 92 7 550 556"/>
   <result pre="556 10749910 12 Yancik R Ries LG Yates JW Breast" exact="cancer" post="in aging women. A population-based study of contrasts in"/>
   <result pre="between age and axillary lymph node involvement in women with" exact="breast cancer" post="J Clin Oncol 2009 27 18 2931 2937 19451448"/>
   <result pre="age and axillary lymph node involvement in women with breast" exact="cancer" post="J Clin Oncol 2009 27 18 2931 2937 19451448"/>
   <result pre="SH Hortobagyi GN Kau SW Theriault RL Bondy ML Breast" exact="cancer" post="treatment guidelines in older women J Clin Oncol 2005"/>
   <result pre="C et al. Adjuvant chemotherapy in elderly patients with early" exact="breast cancer." post="Impact of age and comprehensive geriatric assessment on tumor"/>
   <result pre="SM Pharmacokinetic considerations of oral chemotherapy in elderly patients with" exact="cancer" post="Drugs Aging 2002 19 1 25 42 11929325 19"/>
   <result pre="information to Eastern Cooperative Oncology Group performance status in elderly" exact="cancer" post="patients: an Italian Group for Geriatric Oncology Study J"/>
   <result pre="Silliman RA Examining five-and ten-year survival in older women with" exact="breast cancer" post="using cancer-specific geriatric assessment Eur J Cancer 2012 48"/>
   <result pre="RA Examining five-and ten-year survival in older women with breast" exact="cancer" post="using cancer-specific geriatric assessment Eur J Cancer 2012 48"/>
   <result pre="effect of comorbidity on 3-year survival of women with primary" exact="breast cancer" post="Ann Intern Med 1994 120 2 104 110 8256968"/>
   <result pre="of comorbidity on 3-year survival of women with primary breast" exact="cancer" post="Ann Intern Med 1994 120 2 104 110 8256968"/>
   <result pre="27 Clough-Gorr KM Stuck AE Thwin SS Silliman RA Older" exact="breast cancer" post="survivors: geriatric assessment domains are associated with poor tolerance"/>
   <result pre="Clough-Gorr KM Stuck AE Thwin SS Silliman RA Older breast" exact="cancer" post="survivors: geriatric assessment domains are associated with poor tolerance"/>
   <result pre="al. A comprehensive geriatric intervention detects multiple problems in older" exact="breast cancer" post="patients Crit Rev Oncol Hematol 2004 49 1 69"/>
   <result pre="A comprehensive geriatric intervention detects multiple problems in older breast" exact="cancer" post="patients Crit Rev Oncol Hematol 2004 49 1 69"/>
   <result pre="Bellera CA Rainfray M Mathoulin-Pélissier S et al. Screening older" exact="cancer" post="patients: first evaluation of the G-8 geriatric screening tool"/>
   <result pre="Abbreviated Comprehensive Geriatric Assessment (aCGA) for use in the older" exact="cancer" post="patient as a prescreen: scoring and interpretation Crit Rev"/>
   <result pre="of two frailty screening tools in older women with early" exact="breast cancer" post="Crit Rev Oncol Hematol 2011 79 1 51 64"/>
   <result pre="two frailty screening tools in older women with early breast" exact="cancer" post="Crit Rev Oncol Hematol 2011 79 1 51 64"/>
   <result pre="van de Velde CJ Preoperative chemotherapy for women with operable" exact="breast cancer" post="Cochrane Database Syst Rev 2007 2 CD005002 17443564 37"/>
   <result pre="de Velde CJ Preoperative chemotherapy for women with operable breast" exact="cancer" post="Cochrane Database Syst Rev 2007 2 CD005002 17443564 37"/>
   <result pre="endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive" exact="breast cancer" post="Cancer 2007 110 2 244 254 17538978 38 Alba"/>
   <result pre="therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast" exact="cancer" post="Cancer 2007 110 2 244 254 17538978 38 Alba"/>
   <result pre="Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal" exact="breast cancer" post="patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II"/>
   <result pre="(CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast" exact="cancer" post="patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II"/>
   <result pre="Chemotherapy or letrozole before surgery in treating postmenopausal women with" exact="breast cancer" post="that can be removed by surgery Available from: http://clinicaltrials.gov/show/NCT00963729"/>
   <result pre="or letrozole before surgery in treating postmenopausal women with breast" exact="cancer" post="that can be removed by surgery Available from: http://clinicaltrials.gov/show/NCT00963729"/>
   <result pre="S Loibl S Müller BM et al. Identification of biology-based" exact="breast cancer" post="types with distinct predictive and prognostic features: role of"/>
   <result pre="Loibl S Müller BM et al. Identification of biology-based breast" exact="cancer" post="types with distinct predictive and prognostic features: role of"/>
   <result pre="aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive" exact="breast cancer" post="Cancer Chemother Pharmacol 2009 63 2 261 266 18365197"/>
   <result pre="inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast" exact="cancer" post="Cancer Chemother Pharmacol 2009 63 2 261 266 18365197"/>
   <result pre="Response to neoadjuvant chemotherapy in elderly patients with locally advanced" exact="breast cancer" post="Cancer Res 2011 71 24 Suppl Abstr nr P3-14-22"/>
   <result pre="to neoadjuvant chemotherapy in elderly patients with locally advanced breast" exact="cancer" post="Cancer Res 2011 71 24 Suppl Abstr nr P3-14-22"/>
   <result pre="45 Rocco N Rispoli C Pagano G et al. Breast" exact="cancer" post="surgery in elderly patients: postoperative complications and survival BMC"/>
   <result pre="Bastiaannet E et al. Postoperative complications and survival of elderly" exact="breast cancer" post="patients: a FOCUS study analysis Breast Cancer Res Treat"/>
   <result pre="E et al. Postoperative complications and survival of elderly breast" exact="cancer" post="patients: a FOCUS study analysis Breast Cancer Res Treat"/>
   <result pre="CR Cuschieri A Tamoxifen as initial sole treatment of localised" exact="breast cancer" post="in elderly women: a pilot study Br Med (J"/>
   <result pre="Cuschieri A Tamoxifen as initial sole treatment of localised breast" exact="cancer" post="in elderly women: a pilot study Br Med (J"/>
   <result pre="van Zijl J Karydas I et al. Treatment of operable" exact="breast cancer" post="in the elderly: a randomised clinical trial EORTC 10850"/>
   <result pre="Zijl J Karydas I et al. Treatment of operable breast" exact="cancer" post="in the elderly: a randomised clinical trial EORTC 10850"/>
   <result pre="IS Christiaens MR Paridaens R et al. Treatment of operable" exact="breast cancer" post="in the elderly: a randomised clinical trial EORTC 10851"/>
   <result pre="Christiaens MR Paridaens R et al. Treatment of operable breast" exact="cancer" post="in the elderly: a randomised clinical trial EORTC 10851"/>
   <result pre="endocrine therapy for elderly postmenopausal women with hormone receptor-positive early-stage" exact="breast cancer" post="Int J Surg Oncol 2012 2012 180574 22970358 52"/>
   <result pre="therapy for elderly postmenopausal women with hormone receptor-positive early-stage breast" exact="cancer" post="Int J Surg Oncol 2012 2012 180574 22970358 52"/>
   <result pre="tamoxifen alone in women aged over 70 years with operable" exact="breast cancer" post="Br J Surg 2004 91 6 699 704 15164437"/>
   <result pre="alone in women aged over 70 years with operable breast" exact="cancer" post="Br J Surg 2004 91 6 699 704 15164437"/>
   <result pre="S et al. Tamoxifen alone versus adjuvant tamoxifen for operable" exact="breast cancer" post="of the elderly: long-term results of the phase III"/>
   <result pre="et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast" exact="cancer" post="of the elderly: long-term results of the phase III"/>
   <result pre="only versus tamoxifen for treating elderly patients with operable primary" exact="breast cancer" post="– final results at 20-year follow-up Crit Rev Oncol"/>
   <result pre="versus tamoxifen for treating elderly patients with operable primary breast" exact="cancer" post="– final results at 20-year follow-up Crit Rev Oncol"/>
   <result pre="BA Wallace RB Folsom AR Functional limitations in elderly female" exact="cancer" post="survivors J Natl Cancer Inst 2006 98 8 521"/>
   <result pre="Psychological outcomes of different treatment policies in women with early" exact="breast cancer" post="outside a clinical trial BMJ 1990 301 6752 575"/>
   <result pre="outcomes of different treatment policies in women with early breast" exact="cancer" post="outside a clinical trial BMJ 1990 301 6752 575"/>
   <result pre="6752 575 580 2242455 58 Singletary SE Radiofrequency ablation of" exact="breast cancer" post="Am Surg 2003 69 1 37 40 12575778 59"/>
   <result pre="575 580 2242455 58 Singletary SE Radiofrequency ablation of breast" exact="cancer" post="Am Surg 2003 69 1 37 40 12575778 59"/>
   <result pre="prognostic factor for survival in elderly patients with node positive" exact="breast cancer?" post="The Anatolian Society of Medical Oncology Ann Ital Chir"/>
   <result pre="GV Morbidity after conventional dissection of axillary lymph nodes in" exact="breast cancer" post="patients World J Surg Oncol 2014 12 67 24670000"/>
   <result pre="Morbidity after conventional dissection of axillary lymph nodes in breast" exact="cancer" post="patients World J Surg Oncol 2014 12 67 24670000"/>
   <result pre="Axillary dissection versus no axillary dissection in elderly patients with" exact="breast cancer" post="and no palpable axillary nodes: results after 15 years"/>
   <result pre="dissection versus no axillary dissection in elderly patients with breast" exact="cancer" post="and no palpable axillary nodes: results after 15 years"/>
   <result pre="Axillary dissection vs no axillary dissection in women with invasive" exact="breast cancer" post="and sentinel node metastasis: a randomized clinical trial JAMA"/>
   <result pre="dissection vs no axillary dissection in women with invasive breast" exact="cancer" post="and sentinel node metastasis: a randomized clinical trial JAMA"/>
   <result pre="sentinel node in the administration of adjuvant therapy in early" exact="breast cancer" post="J Clin Oncol 2010 28 5 731 737 20038733"/>
   <result pre="node in the administration of adjuvant therapy in early breast" exact="cancer" post="J Clin Oncol 2010 28 5 731 737 20038733"/>
   <result pre="in women 70 years of age or older with early" exact="breast cancer" post="N Engl J Med 2004 351 10 971 977"/>
   <result pre="women 70 years of age or older with early breast" exact="cancer" post="N Engl J Med 2004 351 10 971 977"/>
   <result pre="and of differences in the extent of surgery for early" exact="breast cancer" post="on local recurrence and 15-year survival: an overview of"/>
   <result pre="of differences in the extent of surgery for early breast" exact="cancer" post="on local recurrence and 15-year survival: an overview of"/>
   <result pre="BG Effectiveness of radiation therapy for older women with early" exact="breast cancer" post="J Natl Cancer Inst 2006 98 10 681 690"/>
   <result pre="Effectiveness of radiation therapy for older women with early breast" exact="cancer" post="J Natl Cancer Inst 2006 98 10 681 690"/>
   <result pre="Five versus more than five years of tamoxifen therapy for" exact="breast cancer" post="patients with negative lymph nodes and estrogen receptor-positive tumors"/>
   <result pre="versus more than five years of tamoxifen therapy for breast" exact="cancer" post="patients with negative lymph nodes and estrogen receptor-positive tumors"/>
   <result pre="postoperative whole breast irradiation in women ≥65 years with early" exact="breast cancer" post="managed by breast conservation Abstract S2-01 presented at the"/>
   <result pre="whole breast irradiation in women ≥65 years with early breast" exact="cancer" post="managed by breast conservation Abstract S2-01 presented at the"/>
   <result pre="E et al. The management of elderly patients with T1–T2" exact="breast cancer" post="treated with or without radiotherapy Eur J Surg Oncol"/>
   <result pre="et al. The management of elderly patients with T1–T2 breast" exact="cancer" post="treated with or without radiotherapy Eur J Surg Oncol"/>
   <result pre="in women 50 years of age or older with early" exact="breast cancer" post="N Engl J Med 2004 351 10 963 970"/>
   <result pre="women 50 years of age or older with early breast" exact="cancer" post="N Engl J Med 2004 351 10 963 970"/>
   <result pre="associated with reduced breast cancer-specific survival in elderly women with" exact="breast cancer" post="Am J Surg 2006 191 6 749 755 16720143"/>
   <result pre="with reduced breast cancer-specific survival in elderly women with breast" exact="cancer" post="Am J Surg 2006 191 6 749 755 16720143"/>
   <result pre="al. Effectiveness of radiation for prevention of mastectomy in older" exact="breast cancer" post="patients treated with conservative surgery Cancer 2012 118 19"/>
   <result pre="Effectiveness of radiation for prevention of mastectomy in older breast" exact="cancer" post="patients treated with conservative surgery Cancer 2012 118 19"/>
   <result pre="xi 1 57 21366974 86 Scalliet PG Kirkove C Breast" exact="cancer" post="in elderly women: can radiotherapy be omitted? Eur J"/>
   <result pre="to predict the benefit of radiation for older patients with" exact="breast cancer" post="treated with conservative surgery J Clin Oncol 2012 30"/>
   <result pre="predict the benefit of radiation for older patients with breast" exact="cancer" post="treated with conservative surgery J Clin Oncol 2012 30"/>
   <result pre="Gross CP Postmastectomy radiation and survival in older women with" exact="breast cancer" post="J Clin Oncol 2006 24 30 4901 4907 17050874"/>
   <result pre="CP Postmastectomy radiation and survival in older women with breast" exact="cancer" post="J Clin Oncol 2006 24 30 4901 4907 17050874"/>
   <result pre="MN et al. Long-term results of hypofractionated radiation therapy for" exact="breast cancer" post="N Engl J Med 2010 362 6 513 520"/>
   <result pre="et al. Long-term results of hypofractionated radiation therapy for breast" exact="cancer" post="N Engl J Med 2010 362 6 513 520"/>
   <result pre="results of hypofractionated radiotherapy and hormonal therapy without surgery for" exact="breast cancer" post="in elderly patients Radiother Oncol 2006 79 2 156"/>
   <result pre="of hypofractionated radiotherapy and hormonal therapy without surgery for breast" exact="cancer" post="in elderly patients Radiother Oncol 2006 79 2 156"/>
   <result pre="tumour-bed irradiation after local excision and axillary dissection for early" exact="breast cancer" post="Clin Oncol (R Coll Radiol) 2005 17 8 618"/>
   <result pre="irradiation after local excision and axillary dissection for early breast" exact="cancer" post="Clin Oncol (R Coll Radiol) 2005 17 8 618"/>
   <result pre="et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for" exact="breast cancer" post="(TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3"/>
   <result pre="al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast" exact="cancer" post="(TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3"/>
   <result pre="P et al. Intraoperative radiotherapy versus external radiotherapy for early" exact="breast cancer" post="(ELIOT): a randomised controlled equivalence trial Lancet Oncol 2013"/>
   <result pre="et al. Intraoperative radiotherapy versus external radiotherapy for early breast" exact="cancer" post="(ELIOT): a randomised controlled equivalence trial Lancet Oncol 2013"/>
   <result pre="Ejlertsen B et al. Mortality rates among early-stage hormone receptor-positive" exact="breast cancer" post="patients: a population-based cohort study in Denmark J Natl"/>
   <result pre="B et al. Mortality rates among early-stage hormone receptor-positive breast" exact="cancer" post="patients: a population-based cohort study in Denmark J Natl"/>
   <result pre="comparison of letrozole and tamoxifen in postmenopausal women with early" exact="breast cancer" post="N Engl J Med 2005 353 26 2747 2757"/>
   <result pre="of letrozole and tamoxifen in postmenopausal women with early breast" exact="cancer" post="N Engl J Med 2005 353 26 2747 2757"/>
   <result pre="toxicity, and quality of life in older women with early-stage" exact="breast cancer" post="treated with letrozole or placebo after 5 years of"/>
   <result pre="and quality of life in older women with early-stage breast" exact="cancer" post="treated with letrozole or placebo after 5 years of"/>
   <result pre="function in postmenopausal women receiving adjuvant letrozole or tamoxifen for" exact="breast cancer" post="in the BIG 1-98 randomized trial Breast 2010 19"/>
   <result pre="in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast" exact="cancer" post="in the BIG 1-98 randomized trial Breast 2010 19"/>
   <result pre="al. Adherence to adjuvant endocrine therapy in postmenopausal women with" exact="breast cancer" post="Ann Oncol 2009 20 3 431 436 19150950 112"/>
   <result pre="Adherence to adjuvant endocrine therapy in postmenopausal women with breast" exact="cancer" post="Ann Oncol 2009 20 3 431 436 19150950 112"/>
   <result pre="health in older women treated with aromatase inhibitors for early-stage" exact="breast cancer" post="J Am Geriatr Soc 2012 60 9 1761 1767"/>
   <result pre="in older women treated with aromatase inhibitors for early-stage breast" exact="cancer" post="J Am Geriatr Soc 2012 60 9 1761 1767"/>
   <result pre="Zanghì A et al. Prognostic factors in elderly patients with" exact="breast cancer" post="BMC Surg 2013 13 Suppl 2 S2 24268048 118"/>
   <result pre="A et al. Prognostic factors in elderly patients with breast" exact="cancer" post="BMC Surg 2013 13 Suppl 2 S2 24268048 118"/>
   <result pre="Collaborative Group Effects of chemotherapy and hormonal therapy for early" exact="breast cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="Group Effects of chemotherapy and hormonal therapy for early breast" exact="cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="in making decisions about adjuvant therapy for women with early" exact="breast cancer" post="J Clin Oncol 2001 19 4 980 991 11181660"/>
   <result pre="making decisions about adjuvant therapy for women with early breast" exact="cancer" post="J Clin Oncol 2001 19 4 980 991 11181660"/>
   <result pre="as prognostic factor for elderly women with hormone receptor-positive, HER2-negative" exact="breast cancer" post="Breast Care (Basel) 2012 7 1 19 24 22553468"/>
   <result pre="prognostic factor for elderly women with hormone receptor-positive, HER2-negative breast" exact="cancer" post="Breast Care (Basel) 2012 7 1 19 24 22553468"/>
   <result pre="from a randomized trial of extended adjuvant endocrine therapy for" exact="breast cancer" post="J Natl Cancer Inst 2008 100 4 252 260"/>
   <result pre="a randomized trial of extended adjuvant endocrine therapy for breast" exact="cancer" post="J Natl Cancer Inst 2008 100 4 252 260"/>
   <result pre="CT et al. Adjuvant chemotherapy in older women with early-stage" exact="breast cancer" post="N Engl J Med 2009 360 20 2055 2065"/>
   <result pre="et al. Adjuvant chemotherapy in older women with early-stage breast" exact="cancer" post="N Engl J Med 2009 360 20 2055 2065"/>
   <result pre="126 Lyman GH Dale DC Wolff DA et al. Acute" exact="myeloid leukemia" post="or myelodysplastic syndrome in randomized controlled clinical trials of"/>
   <result pre="Lyman GH Dale DC Wolff DA et al. Acute myeloid" exact="leukemia" post="or myelodysplastic syndrome in randomized controlled clinical trials of"/>
   <result pre="Dale DC Wolff DA et al. Acute myeloid leukemia or" exact="myelodysplastic syndrome" post="in randomized controlled clinical trials of cancer chemotherapy with"/>
   <result pre="leukemia or myelodysplastic syndrome in randomized controlled clinical trials of" exact="cancer" post="chemotherapy with granulocyte colony-stimulating factor: a systematic review J"/>
   <result pre="cytotoxic chemotherapy on markers of molecular age in patients with" exact="breast cancer" post="J Natl Cancer Inst 2014 106 4 dju057 24681605"/>
   <result pre="chemotherapy on markers of molecular age in patients with breast" exact="cancer" post="J Natl Cancer Inst 2014 106 4 dju057 24681605"/>
   <result pre="et al. Compliance and toxicity of adjuvant CMF in elderly" exact="breast cancer" post="patients: a single-center experience BMC Cancer 2005 5 30"/>
   <result pre="al. Compliance and toxicity of adjuvant CMF in elderly breast" exact="cancer" post="patients: a single-center experience BMC Cancer 2005 5 30"/>
   <result pre="Use and outcomes of adjuvant chemotherapy in older women with" exact="breast cancer" post="J Clin Oncol 2006 24 18 2750 2756 16782915"/>
   <result pre="and outcomes of adjuvant chemotherapy in older women with breast" exact="cancer" post="J Clin Oncol 2006 24 18 2750 2756 16782915"/>
   <result pre="Adjuvant chemotherapy in older and younger women with lymph node-positive" exact="breast cancer" post="JAMA 2005 293 9 1073 1081 15741529 136 Fargeot"/>
   <result pre="chemotherapy in older and younger women with lymph node-positive breast" exact="cancer" post="JAMA 2005 293 9 1073 1081 15741529 136 Fargeot"/>
   <result pre="versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly" exact="breast cancer" post="patients: 6-year follow-up results of the French adjuvant study"/>
   <result pre="tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast" exact="cancer" post="patients: 6-year follow-up results of the French adjuvant study"/>
   <result pre="failure in older women treated with adjuvant anthracycline chemotherapy for" exact="breast cancer" post="J Clin Oncol 2007 25 25 3808 3815 17664460"/>
   <result pre="in older women treated with adjuvant anthracycline chemotherapy for breast" exact="cancer" post="J Clin Oncol 2007 25 25 3808 3815 17664460"/>
   <result pre="C Brain EG et al. Anthracycline cardiotoxicity in the elderly" exact="cancer" post="patient: a SIOG expert position paper Ann Oncol 2011"/>
   <result pre="G Campone M Peron J et al. Adjuvant docetaxel/cyclophosphamide in" exact="breast cancer" post="patients over the age of 70: results of an"/>
   <result pre="Campone M Peron J et al. Adjuvant docetaxel/cyclophosphamide in breast" exact="cancer" post="patients over the age of 70: results of an"/>
   <result pre="study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese" exact="breast cancer" post="patients Jpn J Clin Oncol 2009 39 8 478"/>
   <result pre="of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast" exact="cancer" post="patients Jpn J Clin Oncol 2009 39 8 478"/>
   <result pre="Haj R Leung MG et al. High rate of febrile" exact="neutropenia" post="in patients with operable breast cancer receiving docetaxel and"/>
   <result pre="al. High rate of febrile neutropenia in patients with operable" exact="breast cancer" post="receiving docetaxel and cyclophosphamide J Clin Oncol 2009 27"/>
   <result pre="High rate of febrile neutropenia in patients with operable breast" exact="cancer" post="receiving docetaxel and cyclophosphamide J Clin Oncol 2009 27"/>
   <result pre="145 Balducci L Al-Halawani H Charu V et al. Elderly" exact="cancer" post="patients receiving chemotherapy benefit from first-cycle pegfilgrastim Oncologist 2007"/>
   <result pre="without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly" exact="breast cancer" post="patients: randomized controlled trial [RESPECT (N-SAS BC07)] Jpn J"/>
   <result pre="chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast" exact="cancer" post="patients: randomized controlled trial [RESPECT (N-SAS BC07)] Jpn J"/>
   <result pre="B Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced" exact="breast cancer" post="in postmenopausal women: survival analysis and updated safety results"/>
   <result pre="Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast" exact="cancer" post="in postmenopausal women: survival analysis and updated safety results"/>
   <result pre="as a function of age in postmenopausal women with advanced" exact="breast cancer" post="Oncologist 2004 9 5 497 506 15477634 151 Mouridsen"/>
   <result pre="a function of age in postmenopausal women with advanced breast" exact="cancer" post="Oncologist 2004 9 5 497 506 15477634 151 Mouridsen"/>
   <result pre="study of letrozole versus tamoxifen as first-line therapy of advanced" exact="breast cancer" post="in postmenopausal women: analysis of survival and update of"/>
   <result pre="of letrozole versus tamoxifen as first-line therapy of advanced breast" exact="cancer" post="in postmenopausal women: analysis of survival and update of"/>
   <result pre="tamoxifen as first-line hormone therapy for postmenopausal women with metastatic" exact="breast cancer" post="Ann Oncol 2003 14 9 1391 1398 12954578 153"/>
   <result pre="as first-line hormone therapy for postmenopausal women with metastatic breast" exact="cancer" post="Ann Oncol 2003 14 9 1391 1398 12954578 153"/>
   <result pre="vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive" exact="breast cancer" post="in BOLERO-2 Clin Breast Cancer 2013 13 6 421"/>
   <result pre="exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast" exact="cancer" post="in BOLERO-2 Clin Breast Cancer 2013 13 6 421"/>
   <result pre="low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly" exact="breast cancer" post="patients J Clin Oncol 2006 24 22 3623 3628"/>
   <result pre="metronomic oral cyclophosphamide as primary systemic treatment in elderly breast" exact="cancer" post="patients J Clin Oncol 2006 24 22 3623 3628"/>
   <result pre="doxorubicin (Caelyx) in the treatment of elderly patients with metastatic" exact="breast cancer" post="Crit Rev Oncol Hematol 2007 61 1 84 89"/>
   <result pre="(Caelyx) in the treatment of elderly patients with metastatic breast" exact="cancer" post="Crit Rev Oncol Hematol 2007 61 1 84 89"/>
   <result pre="on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic" exact="breast cancer" post="patients: final results of the DOGMES multicentre GINECO trial"/>
   <result pre="pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast" exact="cancer" post="patients: final results of the DOGMES multicentre GINECO trial"/>
   <result pre="A Brunello A et al. Bi-weekly liposomal doxorubicin for advanced" exact="breast cancer" post="in elderly women (≥70 years) J Geriatr Oncol 2013"/>
   <result pre="Brunello A et al. Bi-weekly liposomal doxorubicin for advanced breast" exact="cancer" post="in elderly women (≥70 years) J Geriatr Oncol 2013"/>
   <result pre="two different doses of capecitabine in the treatment of advanced" exact="breast cancer" post="in older women J Clin Oncol 2005 23 10"/>
   <result pre="different doses of capecitabine in the treatment of advanced breast" exact="cancer" post="in older women J Clin Oncol 2005 23 10"/>
   <result pre="Longo F et al. Capecitabine in elderly patients with metastatic" exact="breast cancer" post="Tumori 2012 98 3 303 307 22825504 163 Sorio"/>
   <result pre="F et al. Capecitabine in elderly patients with metastatic breast" exact="cancer" post="Tumori 2012 98 3 303 307 22825504 163 Sorio"/>
   <result pre="Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic" exact="breast cancer" post="Eur J Cancer 1997 33 2 301 303 9135505"/>
   <result pre="and tolerance of vinorelbine in elderly patients with metastatic breast" exact="cancer" post="Eur J Cancer 1997 33 2 301 303 9135505"/>
   <result pre="vinorelbine in the first-line treatment of elderly patients with metastatic" exact="breast cancer" post="Clin Breast Cancer 2010 10 4 301 306 20705563"/>
   <result pre="in the first-line treatment of elderly patients with metastatic breast" exact="cancer" post="Clin Breast Cancer 2010 10 4 301 306 20705563"/>
   <result pre="et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced" exact="breast cancer" post="patients: a phase II study of the Gruppo Italiano"/>
   <result pre="al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast" exact="cancer" post="patients: a phase II study of the Gruppo Italiano"/>
   <result pre="Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic" exact="breast cancer." post="A multicentre phase II trial Eur J Cancer 2004"/>
   <result pre="monotherapy in patients aged 70 years and older with metastatic" exact="breast cancer" post="Oncologist 2014 19 4 318 327 24682463 172 Dong"/>
   <result pre="in patients aged 70 years and older with metastatic breast" exact="cancer" post="Oncologist 2014 19 4 318 327 24682463 172 Dong"/>
   <result pre="with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic" exact="breast cancer" post="Cancer Chemother Pharmacol 2012 69 5 1315 1322 22307763"/>
   <result pre="vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast" exact="cancer" post="Cancer Chemother Pharmacol 2012 69 5 1315 1322 22307763"/>
   <result pre="JZ Block SD Weeks JC Trends in the aggressiveness of" exact="cancer" post="care near the end of life J Clin Oncol"/>
   <result pre="of chemotherapy beyond the first line in patients with metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2008 107 2 275 279"/>
   <result pre="chemotherapy beyond the first line in patients with metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2008 107 2 275 279"/>
   <result pre="and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic" exact="breast cancer" post="Ann Oncol 2013 24 1 264 265 23251010 179"/>
   <result pre="activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast" exact="cancer" post="Ann Oncol 2013 24 1 264 265 23251010 179"/>
   <result pre="toxicities from trastuzumab, alone or in combination, in an elderly" exact="breast cancer" post="population Oncology 2014 86 1 16 21 24335608 180"/>
   <result pre="from trastuzumab, alone or in combination, in an elderly breast" exact="cancer" post="population Oncology 2014 86 1 16 21 24335608 180"/>
   <result pre="of activity and safety of trastuzumab plus chemotherapy in advanced" exact="breast cancer" post="in elderly women (&amp;gt;70 years) J Clin Oncol 2008"/>
   <result pre="activity and safety of trastuzumab plus chemotherapy in advanced breast" exact="cancer" post="in elderly women (&amp;gt;70 years) J Clin Oncol 2008"/>
   <result pre="D et al. Treatment of older patients with HER2-positive metastatic" exact="breast cancer" post="with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a"/>
   <result pre="et al. Treatment of older patients with HER2-positive metastatic breast" exact="cancer" post="with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a"/>
   <result pre="and placebo as first-line therapy for post-menopausal hormone receptor-positive metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 33 5538 5546 19786658"/>
   <result pre="placebo as first-line therapy for post-menopausal hormone receptor-positive metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 33 5538 5546 19786658"/>
   <result pre="a large, multicenter, non-interventional study in patients with HER2-negative metastatic" exact="breast cancer" post="Cancer Res 2009 69 24 Suppl Abstr nr 6085"/>
   <result pre="large, multicenter, non-interventional study in patients with HER2-negative metastatic breast" exact="cancer" post="Cancer Res 2009 69 24 Suppl Abstr nr 6085"/>
   <result pre="CMF in the adjuvant treatment of elderly women with high-risk" exact="breast cancer" post="Available from: http://clinicaltrials.gov/show/NCT00193011 Accessed August 15, 2014 191 collab:"/>
   <result pre="in the adjuvant treatment of elderly women with high-risk breast" exact="cancer" post="Available from: http://clinicaltrials.gov/show/NCT00193011 Accessed August 15, 2014 191 collab:"/>
   <result pre="chemotherapy as a postoperative adjuvant therapy in HER2 positive elderly" exact="breast cancer" post="patients (RESPECT) Available from: http://clinicaltrials.gov/show/NCT01104935 Accessed August 15, 2014"/>
   <result pre="as a postoperative adjuvant therapy in HER2 positive elderly breast" exact="cancer" post="patients (RESPECT) Available from: http://clinicaltrials.gov/show/NCT01104935 Accessed August 15, 2014"/>
   <result pre="whole breast irradiation in elderly women operated on for early" exact="breast cancer" post="Available from: http://clinicaltrials.gov/show/NCT00892814 Accessed August 15, 2014 194 collab:"/>
   <result pre="breast irradiation in elderly women operated on for early breast" exact="cancer" post="Available from: http://clinicaltrials.gov/show/NCT00892814 Accessed August 15, 2014 194 collab:"/>
   <result pre="http://clinicaltrials.gov/show/NCT00892814 Accessed August 15, 2014 194 collab: Regione Emilia-Romagna Breast" exact="cancer" post="with low risk of local recurrence: partial and accelerated"/>
   <result pre="E Fioretta G et al. Undertreatment strongly decreases prognosis of" exact="breast cancer" post="in elderly women J Clin Oncol 2003 21 19"/>
   <result pre="Fioretta G et al. Undertreatment strongly decreases prognosis of breast" exact="cancer" post="in elderly women J Clin Oncol 2003 21 19"/>
   <result pre="Rapiti E Blagojevic S Vlastos AT Vlastos G Older female" exact="cancer" post="patients: importance, causes, and consequences of undertreatment J Clin"/>
   <result pre="Exemestane as primary systemic treatment for hormone receptor positive post-menopausal" exact="breast cancer" post="patients: a phase II trial of the Austrian Breast"/>
   <result pre="as primary systemic treatment for hormone receptor positive post-menopausal breast" exact="cancer" post="patients: a phase II trial of the Austrian Breast"/>
   <result pre="Dowsett M Ebbs SR et al. Neoadjuvant treatment of postmenopausal" exact="breast cancer" post="with anastrozole, tamoxifen, or both in combination: the Immediate"/>
   <result pre="M Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast" exact="cancer" post="with anastrozole, tamoxifen, or both in combination: the Immediate"/>
   <result pre="Paepke S Appfelstaedt J et al. Preoperative treatment of postmenopausal" exact="breast cancer" post="patients with letrozole: a randomized double-blind multicenter study Ann"/>
   <result pre="S Appfelstaedt J et al. Preoperative treatment of postmenopausal breast" exact="cancer" post="patients with letrozole: a randomized double-blind multicenter study Ann"/>
   <result pre="Winer E et al. Vinorelbine as first-line chemotherapy for advanced" exact="breast cancer" post="in women 60 years of age or older Ann"/>
   <result pre="E et al. Vinorelbine as first-line chemotherapy for advanced breast" exact="cancer" post="in women 60 years of age or older Ann"/>
   <result pre="ixabepilone plus capecitabine in elderly patients with anthracycline-and taxane-pretreated metastatic" exact="breast cancer" post="J Geriatr Oncol 2013 4 4 346 352 24472478"/>
   <result pre="plus capecitabine in elderly patients with anthracycline-and taxane-pretreated metastatic breast" exact="cancer" post="J Geriatr Oncol 2013 4 4 346 352 24472478"/>
   <result pre="gemcitabine and vinorelbine as first line therapy in elderly advanced" exact="breast cancer" post="Breast Cancer Res Treat 2005 89 1 1 3"/>
   <result pre="and vinorelbine as first line therapy in elderly advanced breast" exact="cancer" post="Breast Cancer Res Treat 2005 89 1 1 3"/>
   <result pre="vinorelbine in elderly (&amp;gt; or =70 years) women with metastatic" exact="breast cancer?" post="Early interruption of a phase II study Ann Oncol"/>
   <result pre="pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic" exact="breast cancer" post="in elderly women &amp;gt; or =65 years of age"/>
   <result pre="doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast" exact="cancer" post="in elderly women &amp;gt; or =65 years of age"/>
   <result pre="with vinorelbine as first-line treatment in elderly patients with metastatic" exact="breast cancer" post="Onkologie 2009 32 1–2 18 24 19209014 Table 1"/>
   <result pre="vinorelbine as first-line treatment in elderly patients with metastatic breast" exact="cancer" post="Onkologie 2009 32 1–2 18 24 19209014 Table 1"/>
   <result pre="line ORR 20% PFS 6.1 months OS 15.7 months Febrile" exact="neutropenia" post="1.7% Congestive heart failure 3.4% 40 mg/m 2 every"/>
   <result pre="SD 33% TTP 3 months OS 17 months Grade 4" exact="neutropenia" post="6% No cardiotoxicity reported Two toxic deaths with 7.5"/>
   <result pre="patients First line Disease control rate 81.3% Grade 3 events:" exact="diarrhea" post="(12%), hand–foot syndrome (8%), mucositis (8%) Vinorelbine 30 mg/m"/>
   <result pre="56 patients First line ORR 38% TTP 6 months Febrile" exact="neutropenia" post="11% 70 mg/m 2 orally on days 1, 3,"/>
   <result pre="line ORR 38% PFS 7.7 months OS 15.9 months Febrile" exact="neutropenia" post="6% Paclitaxel 80 mg/m 2 weekly for 3 weeks"/>
   <result pre="25% ORR 36% TTP 7 months OS 13 months Severe" exact="neutropenia" post="0.4% Grade 3/4 fatigue 20% 36 mg/m 2 per"/>
   <result pre="47 patients Median: 2 prior chemotherapy regimens ORR 37% Febrile" exact="neutropenia" post="8.5% Grade 3 neurotoxicity 2% 36 mg/m 2 per"/>
   <result pre="(66–84) Phase I, 20 patients Prostate, lung, and breast (50%)" exact="cancer" post="≥ Grade 3 58% ≥ Hematologic grade 3 16%"/>
   <result pre="response; SD, stable disease; CBR, clinical benefit rate; MBC, metastatic" exact="breast cancer." post="Table 3 Comparison of chemotherapy regimens Chemotherapy regimen Dosage"/>
   <result pre="ORR 37% versus 19% OS 13.9 versus 12.2 months Febrile" exact="neutropenia" post="10% (ixabepilone + capecitabine) Paclitaxel versus docetaxel Weekly paclitaxel"/>
   <result pre="versus 12.7 weeks OS 55.7 weeks versus 32 weeks More" exact="anemia" post="and neurotoxicity for paclitaxel and more edema and fatigue"/>
   <result pre="Phase II, 34 patients First line ORR 53% Grade 3/4" exact="neutropenia" post="20% Vinorelbine 25 mg/m 2 plus gemcitabine 1,000 mg/m"/>
   <result pre="patients First line ORR 11.1% TTP 3 months Grade 3" exact="neutropenia" post="25% Grade 3 anemia and grade 3 GI toxicity"/>
   <result pre="11.1% TTP 3 months Grade 3 neutropenia 25% Grade 3" exact="anemia" post="and grade 3 GI toxicity 25% Gemcitabine 1,000 mg/m"/>
   <result pre="(54.9%) RR 33.3% PFS 6.2 months OS 17 months Febrile" exact="neutropenia" post="4% One toxic death because of GI hemorrhage PLD"/>
   <result pre="13 months TTP 8 months Neutropenia grade 3/4 26% Febrile" exact="neutropenia" post="8.8% PLD 40 mg/m 2 IV on day 1"/>
   <result pre="line ORR 8.6% 1-year PFS 9.8% 1-year OS 54.9% Febrile" exact="neutropenia" post="1.3% grade 3/4 hematological toxicity: 17.9% Grade 3/4 GI"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4303336/results/search/disease/results.xml">
   <result pre="work is properly attributed. Abstract As the number of long-term" exact="breast cancer" post="survivors has increased, the side effects of adjuvant cancer"/>
   <result pre="is properly attributed. Abstract As the number of long-term breast" exact="cancer" post="survivors has increased, the side effects of adjuvant cancer"/>
   <result pre="breast cancer survivors has increased, the side effects of adjuvant" exact="cancer" post="therapy, such as cardiac toxicity, remain clinically important. Although"/>
   <result pre="This review summarizes the incidence of cardiac toxicity due to" exact="breast cancer" post="adjuvant therapy and highlights the current trends in early"/>
   <result pre="review summarizes the incidence of cardiac toxicity due to breast" exact="cancer" post="adjuvant therapy and highlights the current trends in early"/>
   <result pre="toxicities. Keywords adjuvant anthracyclines cardiac toxicity radiotherapy trastuzumab Introduction Breast" exact="cancer" post="is the most common cancer in women worldwide, with"/>
   <result pre="toxicity radiotherapy trastuzumab Introduction Breast cancer is the most common" exact="cancer" post="in women worldwide, with nearly 1.7 million new cases"/>
   <result pre="2012. 1 The advances in the diagnosis and treatment of" exact="breast cancer" post="have led to an improved outcome and a large"/>
   <result pre="1 The advances in the diagnosis and treatment of breast" exact="cancer" post="have led to an improved outcome and a large"/>
   <result pre="to an improved outcome and a large proportion of long-term" exact="breast cancer" post="survivors. It is estimated that nearly 90% of women"/>
   <result pre="an improved outcome and a large proportion of long-term breast" exact="cancer" post="survivors. It is estimated that nearly 90% of women"/>
   <result pre="It is estimated that nearly 90% of women diagnosed with" exact="breast cancer" post="will survive for 5 years or longer. 2 The"/>
   <result pre="is estimated that nearly 90% of women diagnosed with breast" exact="cancer" post="will survive for 5 years or longer. 2 The"/>
   <result pre="survive for 5 years or longer. 2 The cornerstone of" exact="breast cancer" post="therapy is surgery. It is well documented that many"/>
   <result pre="for 5 years or longer. 2 The cornerstone of breast" exact="cancer" post="therapy is surgery. It is well documented that many"/>
   <result pre="surgery. It is well documented that many patients with early" exact="breast cancer" post="benefit from postoperative adjuvant therapy (radiotherapy, chemotherapy, targeted therapy,"/>
   <result pre="It is well documented that many patients with early breast" exact="cancer" post="benefit from postoperative adjuvant therapy (radiotherapy, chemotherapy, targeted therapy,"/>
   <result pre="and molecular characteristics of the tumor. Several adjuvant therapies against" exact="breast cancer" post="can potentially cause a wide range of acute and"/>
   <result pre="molecular characteristics of the tumor. Several adjuvant therapies against breast" exact="cancer" post="can potentially cause a wide range of acute and"/>
   <result pre="is of rising concern considering the increased number of long-term" exact="breast cancer" post="survivors and the trend to combine two or more"/>
   <result pre="of rising concern considering the increased number of long-term breast" exact="cancer" post="survivors and the trend to combine two or more"/>
   <result pre="knowledge on the incidence of cardiac toxicity in different adjuvant" exact="breast cancer" post="therapies and highlight the current trends in early detection"/>
   <result pre="on the incidence of cardiac toxicity in different adjuvant breast" exact="cancer" post="therapies and highlight the current trends in early detection"/>
   <result pre="and not on experimental therapies. Radiotherapy-induced cardiac toxicity in early" exact="breast cancer" post="Adjuvant radiotherapy is recommended in most of the patients"/>
   <result pre="not on experimental therapies. Radiotherapy-induced cardiac toxicity in early breast" exact="cancer" post="Adjuvant radiotherapy is recommended in most of the patients"/>
   <result pre="Adjuvant radiotherapy is recommended in most of the patients undergoing" exact="breast cancer" post="surgery. Adjuvant whole breast radiotherapy after breast-conserving surgery reduces"/>
   <result pre="radiotherapy is recommended in most of the patients undergoing breast" exact="cancer" post="surgery. Adjuvant whole breast radiotherapy after breast-conserving surgery reduces"/>
   <result pre="status. 4 In node-positive patients, radiotherapy reduces the risk of" exact="breast cancer" post="mortality and increases overall survival; 5 for these patients,"/>
   <result pre="4 In node-positive patients, radiotherapy reduces the risk of breast" exact="cancer" post="mortality and increases overall survival; 5 for these patients,"/>
   <result pre="and increases overall survival; 5 for these patients, approximately one" exact="breast cancer" post="death is avoided for every 1.5 recurrences of any"/>
   <result pre="increases overall survival; 5 for these patients, approximately one breast" exact="cancer" post="death is avoided for every 1.5 recurrences of any"/>
   <result pre="major concern when radiotherapy is administered in patients with early" exact="breast cancer" post="with an expected long-term survival is the unintentional irradiation"/>
   <result pre="concern when radiotherapy is administered in patients with early breast" exact="cancer" post="with an expected long-term survival is the unintentional irradiation"/>
   <result pre="deaths after longer follow-up that partly counterbalance the decrease in" exact="breast cancer" post="death. 6– 8 The underlying pathophysiological mechanisms of radiation-induced"/>
   <result pre="after longer follow-up that partly counterbalance the decrease in breast" exact="cancer" post="death. 6– 8 The underlying pathophysiological mechanisms of radiation-induced"/>
   <result pre="cancer death. 6– 8 The underlying pathophysiological mechanisms of radiation-induced" exact="heart disease" post="(RIHD) are related to micro- and macrovascular damage, which"/>
   <result pre="leads to clinical manifestations such as pericarditis, coronary artery disease," exact="acute myocardial infarction," post="valvular heart disease, and cardiomyopathy. 9 Most data regarding"/>
   <result pre="manifestations such as pericarditis, coronary artery disease, acute myocardial infarction," exact="valvular heart disease," post="and cardiomyopathy. 9 Most data regarding the risk of"/>
   <result pre="such as pericarditis, coronary artery disease, acute myocardial infarction, valvular" exact="heart disease," post="and cardiomyopathy. 9 Most data regarding the risk of"/>
   <result pre="heart dose in patients treated with locoregional radiotherapy of left-sided" exact="breast cancer." post="25 Recently, the use of proton therapy (intensity-modulated proton"/>
   <result pre="RIHD, such as smoking, diabetes, or a history of ischemic" exact="heart disease." post="12, 13 The only way of totally avoiding the"/>
   <result pre="a safe to omit radiotherapy in older patients with low-risk" exact="breast cancer." post="27 Chemotherapy-induced cardiac toxicity in early breast cancer Anthracycline-based"/>
   <result pre="with low-risk breast cancer. 27 Chemotherapy-induced cardiac toxicity in early" exact="breast cancer" post="Anthracycline-based chemotherapy Anthracycline-based regimens, including epirubicin or doxorubicin, have"/>
   <result pre="low-risk breast cancer. 27 Chemotherapy-induced cardiac toxicity in early breast" exact="cancer" post="Anthracycline-based chemotherapy Anthracycline-based regimens, including epirubicin or doxorubicin, have"/>
   <result pre="regimens, including epirubicin or doxorubicin, have been the cornerstone of" exact="breast cancer" post="chemotherapy in both adjuvant and metastatic settings. 28 A"/>
   <result pre="including epirubicin or doxorubicin, have been the cornerstone of breast" exact="cancer" post="chemotherapy in both adjuvant and metastatic settings. 28 A"/>
   <result pre="cardiotoxicity, and a fivefold increased risk of cardiac death among" exact="cancer" post="patients treated with anthracyclines compared to those treated with"/>
   <result pre="chemotherapeutic agents (trastuzumab), concurrent or prior chest irradiation, and preexisting" exact="cardiovascular disease" post="(including coronary artery disease, hypertension, peripheral vascular disease, diabetes)."/>
   <result pre="investigated the role of liposomal doxorubicin in patients with metastatic" exact="breast cancer." post="The role of liposomal doxorubicin in the adjuvant setting"/>
   <result pre="the efficacy and safety of liposomal doxorubicin in elderly early" exact="breast cancer" post="populations are ongoing. Advances in the liposome formulation, with"/>
   <result pre="efficacy and safety of liposomal doxorubicin in elderly early breast" exact="cancer" post="populations are ongoing. Advances in the liposome formulation, with"/>
   <result pre="of which only three examined dexrazoxane use in a homogenous" exact="breast cancer" post="population receiving initial anthracycline-based therapy, dexrazoxane given with either"/>
   <result pre="which only three examined dexrazoxane use in a homogenous breast" exact="cancer" post="population receiving initial anthracycline-based therapy, dexrazoxane given with either"/>
   <result pre="antitumor efficacy, dexrazoxane is not recommended for use in early" exact="breast cancer." post="Finally, avoidance of anthracycline-based chemotherapy in the adjuvant setting"/>
   <result pre="in patients with human epidermal growth factor 2 (HER2) early" exact="breast cancer." post="44 Addition of taxanes The addition of taxanes to"/>
   <result pre="affect cardiac function? Adjuvant endocrine therapy in estrogen receptor-positive early" exact="breast cancer" post="significantly reduces the risk of breast cancer recurrence and"/>
   <result pre="cardiac function? Adjuvant endocrine therapy in estrogen receptor-positive early breast" exact="cancer" post="significantly reduces the risk of breast cancer recurrence and"/>
   <result pre="estrogen receptor-positive early breast cancer significantly reduces the risk of" exact="breast cancer" post="recurrence and improves overall survival. 53– 55 Tamoxifen is"/>
   <result pre="receptor-positive early breast cancer significantly reduces the risk of breast" exact="cancer" post="recurrence and improves overall survival. 53– 55 Tamoxifen is"/>
   <result pre="in the normal estrogen system could influence the risk of" exact="cardiovascular disease." post="Tamoxifen has been shown to reduce plasma levels of"/>
   <result pre="with AI is outweighed by the treatment’s significant improvement in" exact="breast cancer" post="survival. When choosing treatment for the individual patient, it"/>
   <result pre="AI is outweighed by the treatment’s significant improvement in breast" exact="cancer" post="survival. When choosing treatment for the individual patient, it"/>
   <result pre="antibody, is the standard of care in patients with HER2-positive" exact="breast cancer" post="in any treatment setting. The importance of trastuzumab in"/>
   <result pre="is the standard of care in patients with HER2-positive breast" exact="cancer" post="in any treatment setting. The importance of trastuzumab in"/>
   <result pre="in any treatment setting. The importance of trastuzumab in HER2-positive" exact="breast cancer" post="disease was first demonstrated in the metastatic setting, in"/>
   <result pre="any treatment setting. The importance of trastuzumab in HER2-positive breast" exact="cancer" post="disease was first demonstrated in the metastatic setting, in"/>
   <result pre="from a clinical entity with poor prognosis (patients with HER2-positive" exact="breast cancer" post="had the worst prognosis among breast cancer patients) to"/>
   <result pre="a clinical entity with poor prognosis (patients with HER2-positive breast" exact="cancer" post="had the worst prognosis among breast cancer patients) to"/>
   <result pre="(patients with HER2-positive breast cancer had the worst prognosis among" exact="breast cancer" post="patients) to a disease with comparable or even better"/>
   <result pre="with HER2-positive breast cancer had the worst prognosis among breast" exact="cancer" post="patients) to a disease with comparable or even better"/>
   <result pre="first approved in 1998 for the treatment of HER2-positive metastatic" exact="breast cancer," post="and cardiac dysfunction was recognized early on as a"/>
   <result pre="adjuvant randomized trials were lower than in metastatic ones (symptomatic" exact="congestive heart failure" post="rate ranged between 0.8% and 14.2%). 67 However, a"/>
   <result pre="risk for both left ventricular ejection fraction (LVEF) decline and" exact="congestive heart failure" post="was observed in the trastuzumab-treated arm. 68 In the"/>
   <result pre="borderline cardiac function at baseline, 79 and a history of" exact="heart disease." post="81 Some efforts have been made to identify certain"/>
   <result pre="setting are ongoing. Assessment and monitoring of cardiac health in" exact="breast cancer" post="patients with adjuvant therapy There are several recommendations and"/>
   <result pre="are ongoing. Assessment and monitoring of cardiac health in breast" exact="cancer" post="patients with adjuvant therapy There are several recommendations and"/>
   <result pre="the assessment and monitoring of cardiac toxicity during and after" exact="breast cancer" post="treatment. 9, 91– 95 These recommendations are mainly based"/>
   <result pre="assessment and monitoring of cardiac toxicity during and after breast" exact="cancer" post="treatment. 9, 91– 95 These recommendations are mainly based"/>
   <result pre="for an appropriate and well-structured cardiac monitoring during and after" exact="cancer" post="therapy to identify patients with asymptomatic cardiac dysfunction, so"/>
   <result pre="therapy to identify patients with asymptomatic cardiac dysfunction, so that" exact="breast cancer" post="treatments can be modified and cardiac medication can be"/>
   <result pre="to identify patients with asymptomatic cardiac dysfunction, so that breast" exact="cancer" post="treatments can be modified and cardiac medication can be"/>
   <result pre="regarding assessment, monitoring, and treatment of cardiac toxicity due to" exact="cancer" post="therapy in patients with early breast cancer. Baseline assessment/evaluation"/>
   <result pre="cardiac toxicity due to cancer therapy in patients with early" exact="breast cancer." post="Baseline assessment/evaluation The purpose of the baseline evaluation is"/>
   <result pre="identify patients with high risk for cardiac toxicity due to" exact="cancer" post="therapy. We discussed earlier in the review that several"/>
   <result pre="to perform baseline imaging evaluation on all the patients with" exact="breast cancer" post="before adjuvant treatment and recommend evaluation only for women"/>
   <result pre="perform baseline imaging evaluation on all the patients with breast" exact="cancer" post="before adjuvant treatment and recommend evaluation only for women"/>
   <result pre="systolic function before conventional changes in LVEF, irrespective of the" exact="cancer" post="therapy (anthracyclines, radiotherapy, trastuzumab) that was responsible for the"/>
   <result pre="can be used in the baseline assessment of patients with" exact="breast cancer" post="before adjuvant therapy is unknown. Further studies are necessary"/>
   <result pre="be used in the baseline assessment of patients with breast" exact="cancer" post="before adjuvant therapy is unknown. Further studies are necessary"/>
   <result pre="LVEF assessment and volume and mass measurements. Early studies in" exact="cancer" post="patients allow accurate identification of subclinical or established cardiotoxicity"/>
   <result pre="patients allow accurate identification of subclinical or established cardiotoxicity from" exact="cancer" post="therapy. 109 However, its lack of availability and high"/>
   <result pre="a screening tool for all the patients treated with cardiotoxic" exact="cancer" post="therapy. 109 Besides imaging modalities, a new approach based"/>
   <result pre="as a tool for both baseline assessment and monitoring during" exact="cancer" post="therapy. In patients treated with anthracyclines, an early elevation"/>
   <result pre="detect any clinical value of cardiac troponins during or following" exact="cancer" post="therapy. 107, 115 The family of natriuretic peptides (BNP,"/>
   <result pre="also been investigated as markers of early cardiac damage during" exact="cancer" post="therapy with less reliable and consistent results than troponin."/>
   <result pre="studies that limit their widespread application as early markers of" exact="cancer" post="therapy-induced cardiac toxicity. First, the timing of biomarker assessment"/>
   <result pre="addition, most of the available studies are small with heterogeneous" exact="cancer" post="populations who received multiple types of cancer therapy. As"/>
   <result pre="small with heterogeneous cancer populations who received multiple types of" exact="cancer" post="therapy. As a result, the utility of cardiac biomarkers"/>
   <result pre="predictive tools for cardiac dysfunction in patients with potential cardiotoxic" exact="cancer" post="therapy remains to be clarified when results from larger"/>
   <result pre="evaluation are also available as methods for cardiac monitoring during" exact="cancer" post="therapy. Echocardiography or MUGA for the calculation of LVEF"/>
   <result pre="backbone to all the current guidelines regarding cardiac monitoring during" exact="cancer" post="therapy. 9, 91– 95 The ESMO guidelines recommend serial"/>
   <result pre="There are no recommendations about the assessment and monitoring of" exact="breast cancer" post="patients treated with radiotherapy in the ESMO guidelines. 91"/>
   <result pre="are no recommendations about the assessment and monitoring of breast" exact="cancer" post="patients treated with radiotherapy in the ESMO guidelines. 91"/>
   <result pre="guidelines about assessment and cardiac monitoring in adult patients with" exact="cancer" post="treated with radiotherapy that will result in a radiation"/>
   <result pre="physical examination with close attention to symptoms and signs of" exact="heart disease" post="is recommended. In asymptomatic patients, screening echocardiography is recommended"/>
   <result pre="after radiotherapy. 9 Prevention and management of cardiac toxicity in" exact="breast cancer" post="survivors Strategies to prevent cardiac toxicity There is a"/>
   <result pre="radiotherapy. 9 Prevention and management of cardiac toxicity in breast" exact="cancer" post="survivors Strategies to prevent cardiac toxicity There is a"/>
   <result pre="of standard cardiovascular medications to prevent cardiac toxicity due to" exact="cancer" post="therapy in breast cancer patients. HMG-CoA reductase inhibitors (statins)"/>
   <result pre="medications to prevent cardiac toxicity due to cancer therapy in" exact="breast cancer" post="patients. HMG-CoA reductase inhibitors (statins) have been shown to"/>
   <result pre="to prevent cardiac toxicity due to cancer therapy in breast" exact="cancer" post="patients. HMG-CoA reductase inhibitors (statins) have been shown to"/>
   <result pre="statins in reducing heart failure and maintaining cardiac function in" exact="breast cancer" post="patients treated with anthracyclines. No clinical data on the"/>
   <result pre="in reducing heart failure and maintaining cardiac function in breast" exact="cancer" post="patients treated with anthracyclines. No clinical data on the"/>
   <result pre="Several studies that investigate the use of statins to prevent" exact="cancer" post="therapy-associated cardiac toxicity in breast cancer patients are ongoing"/>
   <result pre="use of statins to prevent cancer therapy-associated cardiac toxicity in" exact="breast cancer" post="patients are ongoing and the results will enlighten their"/>
   <result pre="of statins to prevent cancer therapy-associated cardiac toxicity in breast" exact="cancer" post="patients are ongoing and the results will enlighten their"/>
   <result pre="also been studied as preventive agents against cardiac toxicity in" exact="breast cancer" post="patients. Although the exact mechanism of cardioprotection with beta-blockers"/>
   <result pre="been studied as preventive agents against cardiac toxicity in breast" exact="cancer" post="patients. Although the exact mechanism of cardioprotection with beta-blockers"/>
   <result pre="In the only published randomized trial dedicated to patients with" exact="breast cancer," post="the administration of nebivolol (n=27) under anthracycline-based chemotherapy was"/>
   <result pre="randomized trial investigating the protective effect of cardiovascular medication in" exact="cancer" post="treatment-related cardiotoxicity that presented not only data on surrogate"/>
   <result pre="cardiovascular medication with potential benefit as a cardioprotective agent for" exact="cancer" post="therapy-related cardiotoxicity is ACE-i/angiotensin II receptor blockers (ARB). Several"/>
   <result pre="a protective intervention against anthracycline- or trastuzumab-related cardiac toxicity in" exact="breast cancer" post="patients needs to be studied in further randomized trials."/>
   <result pre="protective intervention against anthracycline- or trastuzumab-related cardiac toxicity in breast" exact="cancer" post="patients needs to be studied in further randomized trials."/>
   <result pre="should be obtained in patients with cardiac dysfunction due to" exact="cancer" post="therapy as well. 91 However, the evidence behind this"/>
   <result pre="well. 91 However, the evidence behind this treatment strategy for" exact="cancer" post="patients is coming from relatively small prospective studies 138,"/>
   <result pre="trastuzumab. 146 In cases of symptomatic heart failure due to" exact="cancer" post="therapy, the recommended treatment strategy does not differ from"/>
   <result pre="important parts of postoperative therapy for many women with early" exact="breast cancer." post="These treatment strategies are associated with cardiac adverse events"/>
   <result pre="monitoring to reveal cardiac dysfunction at an early stage of" exact="cancer" post="therapy. However, several important issues remain unresolved including the"/>
   <result pre="develop and implement adequate cardioprotective strategies for patients with early" exact="breast cancer." post="Disclosure The authors report no conflict of interest in"/>
   <result pre="of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year" exact="breast cancer" post="death: meta-analysis of individual patient data for 10,801 women"/>
   <result pre="radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast" exact="cancer" post="death: meta-analysis of individual patient data for 10,801 women"/>
   <result pre="after mastectomy and axillary surgery on 10-year recurrence and 20-year" exact="breast cancer" post="mortality: meta-analysis of individual patient data for 8135 women"/>
   <result pre="mastectomy and axillary surgery on 10-year recurrence and 20-year breast" exact="cancer" post="mortality: meta-analysis of individual patient data for 8135 women"/>
   <result pre="and of differences in the extent of surgery for early" exact="breast cancer" post="on local recurrence and 15-year survival: an overview of"/>
   <result pre="of differences in the extent of surgery for early breast" exact="cancer" post="on local recurrence and 15-year survival: an overview of"/>
   <result pre="MJ Botma A Aleman BM et al. Long-term risk of" exact="cardiovascular disease" post="in 10-year survivors of breast cancer J Natl Cancer"/>
   <result pre="al. Long-term risk of cardiovascular disease in 10-year survivors of" exact="breast cancer" post="J Natl Cancer Inst 2007 99 5 365 375"/>
   <result pre="Long-term risk of cardiovascular disease in 10-year survivors of breast" exact="cancer" post="J Natl Cancer Inst 2007 99 5 365 375"/>
   <result pre="Delaloge S et al. Long-term cardiovascular mortality after radiotherapy for" exact="breast cancer" post="J Am Coll Cardiol 2011 57 4 445 452"/>
   <result pre="S et al. Long-term cardiovascular mortality after radiotherapy for breast" exact="cancer" post="J Am Coll Cardiol 2011 57 4 445 452"/>
   <result pre="SC McGale P Taylor CW Peto R Long-term mortality from" exact="heart disease" post="and lung cancer after radiotherapy for early breast cancer:"/>
   <result pre="Taylor CW Peto R Long-term mortality from heart disease and" exact="lung cancer" post="after radiotherapy for early breast cancer: prospective cohort study"/>
   <result pre="CW Peto R Long-term mortality from heart disease and lung" exact="cancer" post="after radiotherapy for early breast cancer: prospective cohort study"/>
   <result pre="prospective cohort study of about 300,000 women in US SEER" exact="cancer" post="registries Lancet Oncol 2005 6 8 557 565 16054566"/>
   <result pre="WT et al. Late cardiac mortality and morbidity in early-stage" exact="breast cancer" post="patients after breast-conservation treatment J Clin Oncol 2006 24"/>
   <result pre="et al. Late cardiac mortality and morbidity in early-stage breast" exact="cancer" post="patients after breast-conservation treatment J Clin Oncol 2006 24"/>
   <result pre="SC Ewertz M McGale P et al. Risk of ischemic" exact="heart disease" post="in women after radiotherapy for breast cancer N Engl"/>
   <result pre="Risk of ischemic heart disease in women after radiotherapy for" exact="breast cancer" post="N Engl J Med 2013 368 11 987 998"/>
   <result pre="of ischemic heart disease in women after radiotherapy for breast" exact="cancer" post="N Engl J Med 2013 368 11 987 998"/>
   <result pre="CW Nisbet A McGale P Darby SC Cardiac exposures in" exact="breast cancer" post="radiotherapy: 1950s–1990s Int J Radiat Oncol Biol Phys 2007"/>
   <result pre="Nisbet A McGale P Darby SC Cardiac exposures in breast" exact="cancer" post="radiotherapy: 1950s–1990s Int J Radiat Oncol Biol Phys 2007"/>
   <result pre="Povall JM McGale P et al. Cardiac dose from tangential" exact="breast cancer" post="radiotherapy in the year 2006 Int J Radiat Oncol"/>
   <result pre="JM McGale P et al. Cardiac dose from tangential breast" exact="cancer" post="radiotherapy in the year 2006 Int J Radiat Oncol"/>
   <result pre="et al. Distribution of coronary artery stenosis after radiation for" exact="breast cancer" post="J Clin Oncol 2012 30 4 380 386 22203772"/>
   <result pre="al. Distribution of coronary artery stenosis after radiation for breast" exact="cancer" post="J Clin Oncol 2012 30 4 380 386 22203772"/>
   <result pre="findings after left-sided compared with right-sided radiation treatment for early-stage" exact="breast cancer" post="J Clin Oncol 2007 25 21 3031 3037 17634481"/>
   <result pre="after left-sided compared with right-sided radiation treatment for early-stage breast" exact="cancer" post="J Clin Oncol 2007 25 21 3031 3037 17634481"/>
   <result pre="cancer: 10 years results of the EORTC radiation oncology and" exact="breast cancer" post="groups phase III trial 22922/10925 Eur J Cancer 2013"/>
   <result pre="10 years results of the EORTC radiation oncology and breast" exact="cancer" post="groups phase III trial 22922/10925 Eur J Cancer 2013"/>
   <result pre="MA.20: an intergroup trial of regional nodal irradiation in early" exact="breast cancer" post="J Clin Oncol 2011 29 LBA1003 22 Hennequin C"/>
   <result pre="an intergroup trial of regional nodal irradiation in early breast" exact="cancer" post="J Clin Oncol 2011 29 LBA1003 22 Hennequin C"/>
   <result pre="Mast ME van Kempen-Harteveld L Heijenbrok MW et al. Left-sided" exact="breast cancer" post="radiotherapy with and without breath-hold: does IMRT reduce the"/>
   <result pre="ME van Kempen-Harteveld L Heijenbrok MW et al. Left-sided breast" exact="cancer" post="radiotherapy with and without breath-hold: does IMRT reduce the"/>
   <result pre="breast proton irradiation for maximal reduction of heart dose in" exact="breast cancer" post="patients Breast Cancer Res Treat 2014 148 1 33"/>
   <result pre="proton irradiation for maximal reduction of heart dose in breast" exact="cancer" post="patients Breast Cancer Res Treat 2014 148 1 33"/>
   <result pre="which is the anthracycline of choice for the treatment of" exact="breast cancer?" post="Clin Breast Cancer 2003 4 Suppl 1 S26 S33"/>
   <result pre="1 S26 S33 12756076 29 Singal PK Iliskovic N Doxorubicin-induced" exact="cardiomyopathy" post="N Engl J Med 1998 339 900 905 9744975"/>
   <result pre="P Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic" exact="breast cancer" post="J Clin Oncol 1998 16 3502 3508 9817267 36"/>
   <result pre="Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast" exact="cancer" post="J Clin Oncol 1998 16 3502 3508 9817267 36"/>
   <result pre="insight into epirubicin cardiac toxicity: competing risks analysis of 1097" exact="breast cancer" post="patients J Natl Cancer Inst 2008 100 1058 1067"/>
   <result pre="into epirubicin cardiac toxicity: competing risks analysis of 1097 breast" exact="cancer" post="patients J Natl Cancer Inst 2008 100 1058 1067"/>
   <result pre="HN Kremer LC Different dosage schedules for reducing cardiotoxicity in" exact="cancer" post="patients receiving anthracycline chemotherapy Cochrane Database Syst Rev 2006"/>
   <result pre="Eiermann W Robert N et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="W Robert N et al. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="49 Gianni L Salvatorelli E Minotti G Anthracycline cardiotoxicity in" exact="breast cancer" post="patients: synergism with trastuzumab and taxanes Cardiovasc Toxicol 2007"/>
   <result pre="Gianni L Salvatorelli E Minotti G Anthracycline cardiotoxicity in breast" exact="cancer" post="patients: synergism with trastuzumab and taxanes Cardiovasc Toxicol 2007"/>
   <result pre="doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic" exact="breast cancer" post="Clin Cancer Res 2002 8 3360 3368 12429622 51"/>
   <result pre="and one- or three-hour-infusion paclitaxel in patients with metastatic breast" exact="cancer" post="Clin Cancer Res 2002 8 3360 3368 12429622 51"/>
   <result pre="Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early" exact="breast cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="(EBCTCG) Effects of chemotherapy and hormonal therapy for early breast" exact="cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="comparison of letrozole and tamoxifen in postmenopausal women with early" exact="breast cancer" post="N Engl J Med 2005 353 26 2747 2757"/>
   <result pre="of letrozole and tamoxifen in postmenopausal women with early breast" exact="cancer" post="N Engl J Med 2005 353 26 2747 2757"/>
   <result pre="Combination) trial after completion of 5 years’ adjuvant treatment for" exact="breast cancer" post="Lancet 2005 365 9453 60 62 15639680 57 Smith"/>
   <result pre="trial after completion of 5 years’ adjuvant treatment for breast" exact="cancer" post="Lancet 2005 365 9453 60 62 15639680 57 Smith"/>
   <result pre="62 15639680 57 Smith IE Dowsett M Aromatase inhibitors in" exact="breast cancer" post="N Engl J Med 2003 348 24 2431 2442"/>
   <result pre="15639680 57 Smith IE Dowsett M Aromatase inhibitors in breast" exact="cancer" post="N Engl J Med 2003 348 24 2431 2442"/>
   <result pre="SJ Chen DR Adjuvant tamoxifen influences the lipid profile in" exact="breast cancer" post="patients Breast Care (Basel) 2014 9 1 35 39"/>
   <result pre="Chen DR Adjuvant tamoxifen influences the lipid profile in breast" exact="cancer" post="patients Breast Care (Basel) 2014 9 1 35 39"/>
   <result pre="al. Cardiovascular adverse events during adjuvant endocrine therapy for early" exact="breast cancer" post="using letrozole or tamoxifen: safety analysis of BIG 1-98"/>
   <result pre="Cardiovascular adverse events during adjuvant endocrine therapy for early breast" exact="cancer" post="using letrozole or tamoxifen: safety analysis of BIG 1-98"/>
   <result pre="AU Hortobagyi GN Giordano SH Prognosis of women with metastatic" exact="breast cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="Hortobagyi GN Giordano SH Prognosis of women with metastatic breast" exact="cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="L Balduzzi S et al. Trastuzumab containing regimens for early" exact="breast cancer" post="Cochrane Database Syst Rev 2012 4 CD006243 22513938 69"/>
   <result pre="Balduzzi S et al. Trastuzumab containing regimens for early breast" exact="cancer" post="Cochrane Database Syst Rev 2012 4 CD006243 22513938 69"/>
   <result pre="R Feigelson HS et al. Risk of heart failure in" exact="breast cancer" post="patients after anthracycline and trastuzumab treatment: a retrospective cohort"/>
   <result pre="Feigelson HS et al. Risk of heart failure in breast" exact="cancer" post="patients after anthracycline and trastuzumab treatment: a retrospective cohort"/>
   <result pre="trastuzumab-related cardiotoxicity in a real-world population of women with HER2+" exact="breast cancer" post="Anticancer Res 2013 33 4 1717 1720 23564821 71"/>
   <result pre="cardiotoxicity in a real-world population of women with HER2+ breast" exact="cancer" post="Anticancer Res 2013 33 4 1717 1720 23564821 71"/>
   <result pre="Melegari E Aquilina M et al. Trastuzumab-induced cardiotoxicity in early" exact="breast cancer" post="patients: a retrospective study of possible risk and protective"/>
   <result pre="E Aquilina M et al. Trastuzumab-induced cardiotoxicity in early breast" exact="cancer" post="patients: a retrospective study of possible risk and protective"/>
   <result pre="development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early" exact="breast cancer" post="Intern Emerg Med 2012 7 5 439 446 22714882"/>
   <result pre="of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast" exact="cancer" post="Intern Emerg Med 2012 7 5 439 446 22714882"/>
   <result pre="predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in" exact="breast cancer" post="Breast Cancer Res Treat 2011 130 3 845 854"/>
   <result pre="factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast" exact="cancer" post="Breast Cancer Res Treat 2011 130 3 845 854"/>
   <result pre="FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive" exact="breast cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast" exact="cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant" exact="breast cancer" post="trial J Clin Oncol 2008 26 8 1231 1238"/>
   <result pre="in the North Central Cancer Treatment Group N9831 adjuvant breast" exact="cancer" post="trial J Clin Oncol 2008 26 8 1231 1238"/>
   <result pre="C Steingart RM Gross CP Incidence of heart failure or" exact="cardiomyopathy" post="after adjuvant trastuzumab therapy for breast cancer J Am"/>
   <result pre="of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for" exact="breast cancer" post="J Am Coll Cardiol 2012 60 24 2504 2512"/>
   <result pre="heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast" exact="cancer" post="J Am Coll Cardiol 2012 60 24 2504 2512"/>
   <result pre="Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in" exact="breast cancer" post="treated with trastuzumab Anticancer Res 2013 33 6 2569"/>
   <result pre="and HER2 polymorphisms as risk factor for cardiotoxicity in breast" exact="cancer" post="treated with trastuzumab Anticancer Res 2013 33 6 2569"/>
   <result pre="Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 2743 17192538"/>
   <result pre="D et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 2743 17192538"/>
   <result pre="SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 109 119 22149875"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 109 119 22149875"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="A Nearchou A Polyzos NP Lind P Cardiac toxicity in" exact="breast cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="Nearchou A Polyzos NP Lind P Cardiac toxicity in breast" exact="cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="for multi-modality imaging evaluation of adult patients during and after" exact="cancer" post="therapy: a report from the American Society of Echocardiography"/>
   <result pre="for patients with node-positive, human epidermal growth factor receptor 2-positive" exact="breast cancer" post="J Clin Oncol 2012 30 31 3792 3799 22987084"/>
   <result pre="patients with node-positive, human epidermal growth factor receptor 2-positive breast" exact="cancer" post="J Clin Oncol 2012 30 31 3792 3799 22987084"/>
   <result pre="DJ de Vries EG Gietema JA Cardiovascular toxicity caused by" exact="cancer" post="treatment: strategies for early detection Lancet Oncol 2009 10"/>
   <result pre="left ventricular ejection fraction and volumes: application to patients undergoing" exact="cancer" post="chemotherapy J Am Coll Cardiol 2013 61 1 77"/>
   <result pre="pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with" exact="breast cancer" post="J Am Soc Echocardiogr 2008 21 12 1283 1289"/>
   <result pre="liposomal doxorubicin as adjuvant therapy in elderly patients with breast" exact="cancer" post="J Am Soc Echocardiogr 2008 21 12 1283 1289"/>
   <result pre="detect preclinical myocardial dysfunction before conventional measures in patients undergoing" exact="breast cancer" post="treatment with trastuzumab Am Heart J 2009 158 2"/>
   <result pre="preclinical myocardial dysfunction before conventional measures in patients undergoing breast" exact="cancer" post="treatment with trastuzumab Am Heart J 2009 158 2"/>
   <result pre="dysfunction in patients with human epidermal growth factor receptor II-positive" exact="breast cancer" post="treated with adjuvant trastuzumab therapy J Am Coll Cardiol"/>
   <result pre="in patients with human epidermal growth factor receptor II-positive breast" exact="cancer" post="treated with adjuvant trastuzumab therapy J Am Coll Cardiol"/>
   <result pre="effects on cardiac function detected by strain rate imaging in" exact="breast cancer" post="patients Int J Radiat Oncol Biol Phys 2011 79"/>
   <result pre="on cardiac function detected by strain rate imaging in breast" exact="cancer" post="patients Int J Radiat Oncol Biol Phys 2011 79"/>
   <result pre="JH et al. Evaluation of newer risk markers for coronary" exact="heart disease" post="risk classification: a cohort study Ann Intern Med 2012"/>
   <result pre="MRI in the assessment of cardiac injury and toxicity from" exact="cancer" post="chemotherapy: a systematic review Circ Cardiovasc Imaging 2013 6"/>
   <result pre="Prognostic value of troponin I in cardiac risk stratification of" exact="cancer" post="patients undergoing high-dose chemotherapy Circulation 2004 109 22 2749"/>
   <result pre="trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive" exact="breast cancer" post="J Clin Oncol 2007 25 18S 579 17242396 115"/>
   <result pre="of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast" exact="cancer" post="J Clin Oncol 2007 25 18S 579 17242396 115"/>
   <result pre="measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in" exact="breast cancer" post="patients Br J Cancer 2011 105 11 1663 1668"/>
   <result pre="of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast" exact="cancer" post="patients Br J Cancer 2011 105 11 1663 1668"/>
   <result pre="on the risk for incident heart failure in patients with" exact="breast cancer" post="receiving anthracycline chemotherapy: an observational clinical cohort study J"/>
   <result pre="the risk for incident heart failure in patients with breast" exact="cancer" post="receiving anthracycline chemotherapy: an observational clinical cohort study J"/>
   <result pre="et al. Efficiency of atorvastatin in the protection of anthracycline-induced" exact="cardiomyopathy" post="J Am Coll Cardiol 2011 58 9 988 989"/>
   <result pre="Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced" exact="cardiomyopathy" post="J Am Coll Cardiol 2006 48 11 2258 2262"/>
   <result pre="Mizushige K Noma T et al. Prevention of doxorubicin (adriamycin)-induced" exact="cardiomyopathy" post="by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by"/>
   <result pre="1 Assessment, monitoring, and management of cardiac toxicity due to" exact="breast cancer" post="treatment Cancer treatment Assessment/monitoring Prevention Treatment Current recommendations Under"/>
   <result pre="Assessment, monitoring, and management of cardiac toxicity due to breast" exact="cancer" post="treatment Cancer treatment Assessment/monitoring Prevention Treatment Current recommendations Under"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4307685/results/search/disease/results.xml">
   <result pre="malignant cancers in China [ 1]. More than 95% of" exact="esophageal cancer" post="in China is esophageal squamous cell carcinoma (ESCC). Due"/>
   <result pre="cancers in China [ 1]. More than 95% of esophageal" exact="cancer" post="in China is esophageal squamous cell carcinoma (ESCC). Due"/>
   <result pre="human primary tumors, including gastric, breast, colorectal, liver and renal" exact="cancer" post="[ 8]. Recently, a meta-analysis focusing on c-Met overexpression"/>
   <result pre="meta-analysis focusing on c-Met overexpression and the prognosis of gastric" exact="cancer" post="including 14 studies [ 9] indicated that higher amplification"/>
   <result pre="that higher amplification and expression of c-Met gene in gastric" exact="cancer" post="is an indicator of poor prognosis. c-Met was overexpressed"/>
   <result pre="may cause the different results. In China, more than 95%" exact="esophageal cancer" post="patients are ESCC. c-Met overexpression of ESCC in China"/>
   <result pre="cause the different results. In China, more than 95% esophageal" exact="cancer" post="patients are ESCC. c-Met overexpression of ESCC in China"/>
   <result pre="found that higher c-Met gene amplification and expression in gastric" exact="cancer" post="was an indicator of poor prognosis. Up to now,"/>
   <result pre="c-Met expression before. However, a study finds out that in" exact="lung cancer," post="amplification of c-Met causes gefitinib resistance by driving ERBB3-dependent"/>
   <result pre="to EGFR/ERBB family receptors [ 16]. Recently, another study in" exact="colorectal cancer" post="highlights the role of c-Met in mediating primary and"/>
   <result pre="EGFR/ERBB family receptors [ 16]. Recently, another study in colorectal" exact="cancer" post="highlights the role of c-Met in mediating primary and"/>
   <result pre="as a result of c-Met amplification [ 17]. In the" exact="breast cancer," post="c-Met contributes to trastuzumab resistance, as inhibition of c-Met"/>
   <result pre="an increased risk of trastuzumab-based therapy failure in HER2-positive metastatic" exact="breast cancer" post="[ 19]. In gastric cancer, HGF activation of c-Met"/>
   <result pre="increased risk of trastuzumab-based therapy failure in HER2-positive metastatic breast" exact="cancer" post="[ 19]. In gastric cancer, HGF activation of c-Met"/>
   <result pre="small sample size. Secondly, due to a retrospective study, only" exact="cancer" post="tissues before treatment were detected. It would be better"/>
   <result pre="tissues before treatment were detected. It would be better that" exact="cancer" post="tissues after treatment, lymph nodes, distant metastasis, and normal"/>
   <result pre="treatment, lymph nodes, distant metastasis, and normal tissues adjacent to" exact="cancer" post="could be detected for c-Met IHC and c-Met gene"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA:Cancer J Clin 2011 61 2 69 90"/>
   <result pre="C Comoglio PM Invasive growth: a MET-driven genetic programme for" exact="cancer" post="and stem cells Nat Rev Cancer 2006 6 8"/>
   <result pre="amplification of the met/HGF receptor gene during the progression of" exact="colorectal cancer" post="Clin Cancer Res Off J Am Assoc Cancer Res"/>
   <result pre="of the met/HGF receptor gene during the progression of colorectal" exact="cancer" post="Clin Cancer Res Off J Am Assoc Cancer Res"/>
   <result pre="A novel germ line juxtamembrane Met mutation in human gastric" exact="cancer" post="Oncogene 2000 19 43 4947 53 10.1038/sj.onc.1203874 11042681 8."/>
   <result pre="II trial of paclitaxel and cisplatin in patients with advanced" exact="squamous-cell carcinoma" post="of the esophagus Am J Clin Oncol 2008 31"/>
   <result pre="received standard chemotherapy for stage IIIB or IV met-positive non-small-cell" exact="lung cancer" post="Clin Lung Cancer 2012 13 6 500 4 10.1016/j.cllc.2012.05.009"/>
   <result pre="standard chemotherapy for stage IIIB or IV met-positive non-small-cell lung" exact="cancer" post="Clin Lung Cancer 2012 13 6 500 4 10.1016/j.cllc.2012.05.009"/>
   <result pre="JO et al. MET amplification leads to gefitinib resistance in" exact="lung cancer" post="by activating ERBB3 signaling Science 2007 316 5827 1039"/>
   <result pre="et al. MET amplification leads to gefitinib resistance in lung" exact="cancer" post="by activating ERBB3 signaling Science 2007 316 5827 1039"/>
   <result pre="of the MET receptor drives resistance to anti-EGFR therapies in" exact="colorectal cancer" post="Cancer Discov 2013 3 6 658 73 10.1158/2159-8290.CD-12-0558 23729478"/>
   <result pre="the MET receptor drives resistance to anti-EGFR therapies in colorectal" exact="cancer" post="Cancer Discov 2013 3 6 658 73 10.1158/2159-8290.CD-12-0558 23729478"/>
   <result pre="Sweeney C Met receptor contributes to trastuzumab resistance of Her2-overexpressing" exact="breast cancer" post="cells Cancer Res 2008 68 5 1471 7 10.1158/0008-5472.CAN-07-5962"/>
   <result pre="C Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast" exact="cancer" post="cells Cancer Res 2008 68 5 1471 7 10.1158/0008-5472.CAN-07-5962"/>
   <result pre="copy numbers are associated with trastuzumab failure in HER2-positive metastatic" exact="breast cancer" post="Br J Cancer 2012 107 5 793 9 10.1038/bjc.2012.335"/>
   <result pre="numbers are associated with trastuzumab failure in HER2-positive metastatic breast" exact="cancer" post="Br J Cancer 2012 107 5 793 9 10.1038/bjc.2012.335"/>
   <result pre="MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric" exact="cancer" post="cells Mol Cancer Ther 2012 11 3 660 9"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4309158/results/search/disease/results.xml">
   <result pre="an anti-panHER approach to blockade of these pathways as a" exact="cancer" post="treatment may provide a solution to this resistance. This"/>
   <result pre="a new direction to research and has potential in clinical" exact="cancer" post="therapy in the future. targeted therapy panHER inhibitors drug"/>
   <result pre="of disease (19%) ( 1). In 2007, the incidence of" exact="cancer" post="was 485 cases per 100,000 people and the death"/>
   <result pre="was 176 per 100,000 people. The most common cancers are" exact="prostate cancer," post="bowel cancer, breast cancer, melanoma of skin, and lung"/>
   <result pre="people. The most common cancers are prostate cancer, bowel cancer," exact="breast cancer," post="melanoma of skin, and lung cancer. While surgery, radiotherapy,"/>
   <result pre="prostate cancer, bowel cancer, breast cancer, melanoma of skin, and" exact="lung cancer." post="While surgery, radiotherapy, and chemotherapy have led to major"/>
   <result pre="NSCLC, breast, glioma, head and neck, bladder, kidney, soft tissue" exact="sarcoma" post="HER2/HER3 EPR, NRG1-α, NRG2-β Breast HER3 NRG1-β, NRG2-β Breast,"/>
   <result pre="NRG1-β, NRG2-β Breast, colon, gastric, prostate, other carcinomas, soft tissue" exact="sarcoma" post="HER4 HB-EGF, BTC, EPR, NRG1-β, NRG2-β, NRG4 Childhood medullo-blastoma"/>
   <result pre="pathways including the JAK/STAT pathway ( 22). Several types of" exact="cancer" post="are associated with HER2 over-expression, being most thoroughly studied"/>
   <result pre="are associated with HER2 over-expression, being most thoroughly studied in" exact="breast cancer" post="where there is gene amplification in 15–30% of invasive"/>
   <result pre="associated with HER2 over-expression, being most thoroughly studied in breast" exact="cancer" post="where there is gene amplification in 15–30% of invasive"/>
   <result pre="to have major clinical benefits when used in HER2 overexpressing" exact="breast cancer," post="which otherwise carries a very poor prognosis ( 24)."/>
   <result pre="gene amplification and over-expression ( 30). In malignancies such as" exact="ovarian cancer" post="where HER3 is frequently expressed (53.4%), expression has been"/>
   <result pre="amplification and over-expression ( 30). In malignancies such as ovarian" exact="cancer" post="where HER3 is frequently expressed (53.4%), expression has been"/>
   <result pre="in combination with conventional chemotherapeutics in treating a variety of" exact="cancer" post="subtypes. Their mechanism of action is via inhibition of"/>
   <result pre="gene mutation that increases TKI sensitivity. Analysis of non-small cell" exact="lung cancer" post="(NSCLC) patients has shown that 70–80% of EGFR/HER1 gene-mutated"/>
   <result pre="mutation that increases TKI sensitivity. Analysis of non-small cell lung" exact="cancer" post="(NSCLC) patients has shown that 70–80% of EGFR/HER1 gene-mutated"/>
   <result pre="which is a set of published rules that define when" exact="cancer" post="patients improve (&quot;respond&quot;), stay the same (&quot;stable&quot;), or worse"/>
   <result pre="also reported as another common EGFR TKI resistance mechanism in" exact="lung cancer." post="MET amplification was observed in 21% of patients with"/>
   <result pre="gefitinib by driving HER3-dependent activation of PI3K in a gefitinib-sensitive" exact="lung cancer" post="cell line (HCC827) ( 6, 7), as well as"/>
   <result pre="by driving HER3-dependent activation of PI3K in a gefitinib-sensitive lung" exact="cancer" post="cell line (HCC827) ( 6, 7), as well as"/>
   <result pre="HER2 and was approved for the treatment of HER2-overexpressed metastatic" exact="breast cancer" post="in 1998 ( 16). However, the majority of patients"/>
   <result pre="and was approved for the treatment of HER2-overexpressed metastatic breast" exact="cancer" post="in 1998 ( 16). However, the majority of patients"/>
   <result pre="therapy. Their study revealed that resistance to cetuximab in metastatic" exact="colorectal cancer" post="&quot;xenopatients&quot; (patient-derived xenografts) was frequently coupled with HER2 over-expression."/>
   <result pre="Their study revealed that resistance to cetuximab in metastatic colorectal" exact="cancer" post="&quot;xenopatients&quot; (patient-derived xenografts) was frequently coupled with HER2 over-expression."/>
   <result pre="and afatinib have been extensively tested in a range of" exact="cancer" post="types and are currently undergoing Phase III studies ("/>
   <result pre="Tables 3 and 4 include examples of targeting panHER for" exact="cancer" post="therapy. Both compounds have two attractive features including irreversible"/>
   <result pre="( n = 14) showed tumor shrinkage. Treatment-related adverse event were: diarrhea," exact="dermatitis" post="acneiform, and stomatitis NSCLC ( 72) 2011 Phase I:"/>
   <result pre="tumor shrinkage. Treatment-related adverse event were: diarrhea, dermatitis acneiform, and" exact="stomatitis" post="NSCLC ( 72) 2011 Phase I: 121 patients treated"/>
   <result pre="pts with advanced solid tumors Breast, colon, lung, and metastatic" exact="neoplasm" post="( 74) 2012 Phase II: observing efficacy of dacomitinib"/>
   <result pre="activity of dacomitinib as first-line treatment in recurrent and/or metastatic" exact="squamous-cell carcinoma" post="of the head and neck ( n = 69) In the"/>
   <result pre="treatment with afatinib daily. The most common adverse events were" exact="diarrhea" post="and rash or acne Advanced lung adenocarcinoma with EGFR"/>
   <result pre="afatinib daily. The most common adverse events were diarrhea and" exact="rash" post="or acne Advanced lung adenocarcinoma with EGFR mutations ("/>
   <result pre="number ( n = 3) of heavily pre-treated unselected patients with triple-negative" exact="breast cancer." post="The most common treatment-related adverse events were diarrhea and"/>
   <result pre="triple-negative breast cancer. The most common treatment-related adverse events were" exact="diarrhea" post="and skin HER2-negative metastatic breast cancer ( 84) 2012"/>
   <result pre="common treatment-related adverse events were diarrhea and skin HER2-negative metastatic" exact="breast cancer" post="( 84) 2012 Phase IIb/III: afatinib vs. placebo as"/>
   <result pre="treatment-related adverse events were diarrhea and skin HER2-negative metastatic breast" exact="cancer" post="( 84) 2012 Phase IIb/III: afatinib vs. placebo as"/>
   <result pre="trials for NSCLC and Phase II for Head and Neck" exact="cancer" post="(published clinical trials involving dacomitinib to date are summarized"/>
   <result pre="vitro and in vivo in a broad range of human" exact="cancer" post="cell lines including lung cancer, gastric cancer, biliary tract"/>
   <result pre="in a broad range of human cancer cell lines including" exact="lung cancer," post="gastric cancer, biliary tract cancer, breast cancer, head and"/>
   <result pre="of human cancer cell lines including lung cancer, gastric cancer," exact="biliary tract cancer," post="breast cancer, head and neck cancer, ovarian carcinoma, and"/>
   <result pre="cell lines including lung cancer, gastric cancer, biliary tract cancer," exact="breast cancer," post="head and neck cancer, ovarian carcinoma, and squamous-cell carcinoma"/>
   <result pre="including lung cancer, gastric cancer, biliary tract cancer, breast cancer," exact="head and neck cancer," post="ovarian carcinoma, and squamous-cell carcinoma ( 63, 89– 93)."/>
   <result pre="cancer, breast cancer, head and neck cancer, ovarian carcinoma, and" exact="squamous-cell carcinoma" post="( 63, 89– 93). Treatment with dacomitinib reduced phosphorylation"/>
   <result pre="dacomitinib demonstrated clinical benefits in patients with recurrent and/or metastatic" exact="squamous-cell carcinoma" post="of the head and neck (RM-SCCHN) and advanced NSCLC"/>
   <result pre="demonstrated in NSCLC may also have an application within other" exact="cancer" post="types with positive HER-family expression such as other epithelial"/>
   <result pre="HER-family expression such as other epithelial cancers ( 96) and" exact="sarcoma" post="( 97). Representative panHER inhibitor: Afatinib Afatinib, an aniline–quinazoline"/>
   <result pre="99). Afatinib inhibited auto-phosphorylation of HER members and proliferation in" exact="cancer" post="cell lines representing different mutational status of EGFR and"/>
   <result pre="xenograft models carrying epidermoid carcinoma A431 with wild-type EGFR, gastric" exact="cancer" post="NCI-N87 with HER2 over-expression, lung cancer NCI-H1975 with L858R-T790M"/>
   <result pre="A431 with wild-type EGFR, gastric cancer NCI-N87 with HER2 over-expression," exact="lung cancer" post="NCI-H1975 with L858R-T790M mutant EGFR, and adenosquamous lung tumor"/>
   <result pre="with wild-type EGFR, gastric cancer NCI-N87 with HER2 over-expression, lung" exact="cancer" post="NCI-H1975 with L858R-T790M mutant EGFR, and adenosquamous lung tumor"/>
   <result pre="20 ( 83). However, afatinib had limited activity in HER2-negative" exact="breast cancer" post="( 84). None of the fifty patients achieved an"/>
   <result pre="( 83). However, afatinib had limited activity in HER2-negative breast" exact="cancer" post="( 84). None of the fifty patients achieved an"/>
   <result pre="achieved an objective response, while three patients with triple-negative metastatic" exact="breast cancer" post="had stable disease for more than four treatment courses."/>
   <result pre="an objective response, while three patients with triple-negative metastatic breast" exact="cancer" post="had stable disease for more than four treatment courses."/>
   <result pre="when used in combination with radiotherapy in head and neck" exact="squamous-cell carcinoma" post="in mice. panHER inhibitors in combination with chemotherapy have"/>
   <result pre="of phase III studies showing improved PFS in HER2 positive" exact="breast cancer" post="(12.0 weeks in combination therapy vs. 8.4 weeks in lapatinib alone)"/>
   <result pre="phase III studies showing improved PFS in HER2 positive breast" exact="cancer" post="(12.0 weeks in combination therapy vs. 8.4 weeks in lapatinib alone)"/>
   <result pre="prevent the development of HER3-driven drug resistance in gastric and" exact="breast cancer" post="cells and xenografts ( 113– 115). Currently, a Phase"/>
   <result pre="the development of HER3-driven drug resistance in gastric and breast" exact="cancer" post="cells and xenografts ( 113– 115). Currently, a Phase"/>
   <result pre="agents may be therapeutic in patients with primary or metastatic" exact="central nervous system disease" post="( 117). By contrast more clarity about the potential"/>
   <result pre="may be therapeutic in patients with primary or metastatic central" exact="nervous system disease" post="( 117). By contrast more clarity about the potential"/>
   <result pre="chemotherapy. Similarly, cetuximab has minimal activity in EGFR positive advanced" exact="sarcoma" post="( 122). Recently, a phase II trial in osteosarcoma"/>
   <result pre="advanced sarcoma ( 122). Recently, a phase II trial in" exact="osteosarcoma" post="patients with HER2 over-expression showed that blocking HER2 using"/>
   <result pre="outcomes in NSCLC and head and neck cancers. In some" exact="cancer" post="patients, the panHER inhibition approach met resistance from HER-independent"/>
   <result pre="a new direction to explore and has potential in clinical" exact="cancer" post="therapy in the future. Conflict of Interest Statement The"/>
   <result pre="tolerated dose; mTOR, mammalian target of rapamycin; NSCLC, non-small cell" exact="lung cancer;" post="PI3K/AKT, the phosphoinositide 3-kinase/AKT; PKB, protein kinase B; SHC,"/>
   <result pre="during chronic exposure to gefitinib in a non small cell" exact="lung cancer" post="cell line . Cancer Res ( 2007) 67( 16):"/>
   <result pre="chronic exposure to gefitinib in a non small cell lung" exact="cancer" post="cell line . Cancer Res ( 2007) 67( 16):"/>
   <result pre="tyrosine kinase inhibitors via activation of alternative HER receptors in" exact="breast cancer" post="cells . PLoS One ( 2008) 3( 8): e2881."/>
   <result pre="kinase inhibitors via activation of alternative HER receptors in breast" exact="cancer" post="cells . PLoS One ( 2008) 3( 8): e2881."/>
   <result pre="JO et al. MET amplification leads to gefitinib resistance in" exact="lung cancer" post="by activating ERBB3 signaling . Science ( 2007) 316("/>
   <result pre="et al. MET amplification leads to gefitinib resistance in lung" exact="cancer" post="by activating ERBB3 signaling . Science ( 2007) 316("/>
   <result pre="Newman WG Siriwardena AK . Epidermal growth factor receptor in" exact="pancreatic cancer." post="Cancers (Basel) ( 2011) 3( 2): 1513– 26. 10.3390/cancers3021513"/>
   <result pre="16 Nahta R New developments in the treatment of HER2-positive" exact="breast cancer." post="Breast Cancer Targets Ther ( 2012) 4: 53– 64"/>
   <result pre="growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of" exact="breast cancer" post="cells . Cancer Res ( 2005) 65( 23): 11118–"/>
   <result pre="factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast" exact="cancer" post="cells . Cancer Res ( 2005) 65( 23): 11118–"/>
   <result pre="Mechanisms of disease: understanding resistance to HER2-targeted therapy in human" exact="breast cancer" post=". Nat Clin Pract Oncol ( 2006) 3( 5):"/>
   <result pre="of disease: understanding resistance to HER2-targeted therapy in human breast" exact="cancer" post=". Nat Clin Pract Oncol ( 2006) 3( 5):"/>
   <result pre="Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive" exact="breast cancer" post="cells . Ann Oncol ( 2011) 22( 1): 68–"/>
   <result pre="of IGF1R activity enhances response to trastuzumab in HER-2-positive breast" exact="cancer" post="cells . Ann Oncol ( 2011) 22( 1): 68–"/>
   <result pre="Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic" exact="breast cancer" post=". Cancer Res ( 2001) 61( 14): 5345– 8."/>
   <result pre="of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast" exact="cancer" post=". Cancer Res ( 2001) 61( 14): 5345– 8."/>
   <result pre="Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive" exact="breast cancer" post=". J Natl Cancer Inst ( 2004) 96( 12):"/>
   <result pre="of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast" exact="cancer" post=". J Natl Cancer Inst ( 2004) 96( 12):"/>
   <result pre="28 Hsieh AC Moasser MM . Targeting HER proteins in" exact="cancer" post="therapy and the role of the non-target HER3. Br"/>
   <result pre="into its functions and role in signaling, tumor biology, and" exact="cancer" post="therapy . Clin Cancer Res ( 2010) 16( 5):"/>
   <result pre="Bezler M Hermes M et al. ErbB-3 predicts survival in" exact="ovarian cancer." post="J Clin Oncol ( 2006) 24( 26): 4317– 23."/>
   <result pre="A Scholar EM . Role of tyrosine kinase inhibitors in" exact="cancer" post="therapy. J Pharmacol Exp Ther ( 2005) 315( 3):"/>
   <result pre="Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing" exact="breast cancer" post=". Ann Oncol ( 2007) 18( 6): 977– 84."/>
   <result pre="mechanism of action, resistance and future perspectives in HER2-overexpressing breast" exact="cancer" post=". Ann Oncol ( 2007) 18( 6): 977– 84."/>
   <result pre="and development of a new generation of drugs in non-small-cell" exact="lung cancer" post=". J Biomed Biotechnol ( 2011) 2011: 165214. 10.1155/2011/165214"/>
   <result pre="development of a new generation of drugs in non-small-cell lung" exact="cancer" post=". J Biomed Biotechnol ( 2011) 2011: 165214. 10.1155/2011/165214"/>
   <result pre="EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell" exact="lung cancer" post=". J Carcinog ( 2008) 7: 9. 10.4103/1477-3163.44372 19240370"/>
   <result pre="and c-Met pathways, cross-talk and inhibition, in non-small cell lung" exact="cancer" post=". J Carcinog ( 2008) 7: 9. 10.4103/1477-3163.44372 19240370"/>
   <result pre="Floor K et al. Role of cMET expression in non-small-cell" exact="lung cancer" post="patients treated with EGFR tyrosine kinase inhibitors . Ann"/>
   <result pre="K et al. Role of cMET expression in non-small-cell lung" exact="cancer" post="patients treated with EGFR tyrosine kinase inhibitors . Ann"/>
   <result pre="The role of MET receptor tyrosine kinase in non-small cell" exact="lung cancer" post="and clinical development of targeted anti-MET agents . Oncologist"/>
   <result pre="role of MET receptor tyrosine kinase in non-small cell lung" exact="cancer" post="and clinical development of targeted anti-MET agents . Oncologist"/>
   <result pre="the invasive potential of Human Epidermal Growth Factor Receptor 2-overexpressing" exact="breast cancer" post="cells via Src-Focal Adhesion Kinase and Foxhead Box Protein"/>
   <result pre="invasive potential of Human Epidermal Growth Factor Receptor 2-overexpressing breast" exact="cancer" post="cells via Src-Focal Adhesion Kinase and Foxhead Box Protein"/>
   <result pre="et al. K-ras mutations and benefit from cetuximab in advanced" exact="colorectal cancer." post="N Engl J Med ( 2008) 359( 17): 1757–"/>
   <result pre="cetuximab: a furthermore step toward personalised medicine for patients with" exact="colorectal cancer" post=". Cancer Discov ( 2011) 1( 6): 472– 4."/>
   <result pre="a furthermore step toward personalised medicine for patients with colorectal" exact="cancer" post=". Cancer Discov ( 2011) 1( 6): 472– 4."/>
   <result pre="Wagner S Pfitzner EB et al. Persistent STAT3 activation in" exact="colon cancer" post="is associated with enhanced cell proliferation and tumor growth"/>
   <result pre="S Pfitzner EB et al. Persistent STAT3 activation in colon" exact="cancer" post="is associated with enhanced cell proliferation and tumor growth"/>
   <result pre="et al. Progesterone receptor induces ErbB-2 nuclear translocation to promote" exact="breast cancer" post="growth via a novel transcriptional effect: ErbB-2 Function as"/>
   <result pre="al. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast" exact="cancer" post="growth via a novel transcriptional effect: ErbB-2 Function as"/>
   <result pre="et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in" exact="lung cancer" post="models with EGFR and ERBB2 mutations that are resistant"/>
   <result pre="al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung" exact="cancer" post="models with EGFR and ERBB2 mutations that are resistant"/>
   <result pre="phase II trial of oral CI-1033 for previously treated advanced" exact="ovarian cancer" post=". J Clin Oncol ( 2005) 23( 24): 5597–"/>
   <result pre="II trial of oral CI-1033 for previously treated advanced ovarian" exact="cancer" post=". J Clin Oncol ( 2005) 23( 24): 5597–"/>
   <result pre="10.1200/jco.2005.08.091 16110019 68 Wong K-K . HKI-272 in non-small cell" exact="lung cancer." post="Clin Cancer Res ( 2007) 13( 15): 4593s– 6s."/>
   <result pre="factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell" exact="lung cancer" post=". J Clin Oncol ( 2012) 30( 27): 3337–"/>
   <result pre="receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung" exact="cancer" post=". J Clin Oncol ( 2012) 30( 27): 3337–"/>
   <result pre="eds. PF-00299804 (PF299) in Asian patients (pts) with non-small cell" exact="lung cancer" post="(NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or"/>
   <result pre="PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung" exact="cancer" post="(NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or"/>
   <result pre="(tx) of selected patients (pts) with advanced (adv) non-small cell" exact="lung cancer" post="(NSCLC) . J Clin Oncol ( 2010) 28( 15"/>
   <result pre="of selected patients (pts) with advanced (adv) non-small cell lung" exact="cancer" post="(NSCLC) . J Clin Oncol ( 2010) 28( 15"/>
   <result pre="receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic" exact="squamous-cell carcinoma" post="of the head and neck . Ann Oncol ("/>
   <result pre="continuous afatinib (BIBW 2992) in patients with advanced non-small cell" exact="lung cancer" post="after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4) . Cancer Chemother Pharmacol"/>
   <result pre="afatinib (BIBW 2992) in patients with advanced non-small cell lung" exact="cancer" post="after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4) . Cancer Chemother Pharmacol"/>
   <result pre="safety of afatinib in extensively pretreated patients with HER2-negative metastatic" exact="breast cancer" post=". Breast Cancer Res Treat ( 2012) 134( 3):"/>
   <result pre="of afatinib in extensively pretreated patients with HER2-negative metastatic breast" exact="cancer" post=". Breast Cancer Res Treat ( 2012) 134( 3):"/>
   <result pre="al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell" exact="lung cancer" post="after failure of erlotinib, gefitinib, or both, and one"/>
   <result pre="Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung" exact="cancer" post="after failure of erlotinib, gefitinib, or both, and one"/>
   <result pre="or in combination with chemotherapy or targeted agents in gastric" exact="cancer" post=". Mol Cancer Ther ( 2012) 11( 2): 439–"/>
   <result pre="alone or combined with gemcitabine has an antitumor effect in" exact="biliary tract cancer" post="cell lines . Invest New Drugs ( 2012) 30("/>
   <result pre="combined with gemcitabine has an antitumor effect in biliary tract" exact="cancer" post="cell lines . Invest New Drugs ( 2012) 30("/>
   <result pre="Dacomitinib (PF-00299804), an irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified" exact="breast cancer" post="cell lines resistant to trastuzumab and lapatinib . Mol"/>
   <result pre="(PF-00299804), an irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast" exact="cancer" post="cell lines resistant to trastuzumab and lapatinib . Mol"/>
   <result pre="al. Dacomitinib, an irreversible pan-ErbB inhibitor significantly abrogates growth in" exact="head and neck cancer" post="models that exhibit low response to cetuximab . PLoS"/>
   <result pre="irreversible pan-ErbB inhibitor significantly abrogates growth in head and neck" exact="cancer" post="models that exhibit low response to cetuximab . PLoS"/>
   <result pre="de novo resistance to irreversible EGFR inhibitors in non-small cell" exact="lung cancer" post="with T790M resistance mutation . Mol Cancer Ther ("/>
   <result pre="novo resistance to irreversible EGFR inhibitors in non-small cell lung" exact="cancer" post="with T790M resistance mutation . Mol Cancer Ther ("/>
   <result pre="phase II trial in patients (pts) with advanced non-small cell" exact="lung cancer" post="(NSCLC) after failure of chemotherapy (CT) . J Clin"/>
   <result pre="II trial in patients (pts) with advanced non-small cell lung" exact="cancer" post="(NSCLC) after failure of chemotherapy (CT) . J Clin"/>
   <result pre="et al. Prognostic and therapeutic relevance of HER2 expression in" exact="osteosarcoma" post="and Ewing’s sarcoma . Eur J Cancer ( 2005)"/>
   <result pre="and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s" exact="sarcoma" post=". Eur J Cancer ( 2005) 41( 9): 1349–"/>
   <result pre="al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical" exact="lung cancer" post="models . Oncogene ( 2008) 27( 34): 4702– 11."/>
   <result pre="BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung" exact="cancer" post="models . Oncogene ( 2008) 27( 34): 4702– 11."/>
   <result pre="C Jin P Shepard HM . A pan-HER approach for" exact="cancer" post="therapy: background, current status and future development. Expert Opin"/>
   <result pre="combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell" exact="lung cancer" post="with the T790M mutation of epidermal growth factor receptor"/>
   <result pre="of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung" exact="cancer" post="with the T790M mutation of epidermal growth factor receptor"/>
   <result pre="carboplatin as first-line chemotherapy in patients with advanced non-small cell" exact="lung cancer" post=". J Thorac Oncol ( 2006) 1( 9): 1010–"/>
   <result pre="as first-line chemotherapy in patients with advanced non-small cell lung" exact="cancer" post=". J Thorac Oncol ( 2006) 1( 9): 1010–"/>
   <result pre="lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive" exact="breast cancer" post=". J Clin Oncol ( 2008) 26( 20): 3317–"/>
   <result pre="in combination with trastuzumab in patients with advanced ErbB2-positive breast" exact="cancer" post=". J Clin Oncol ( 2008) 26( 20): 3317–"/>
   <result pre="combines with trastuzumab and paclitaxel in preclincal models of gastric" exact="cancer" post=". Cancer Res ( 2013) 73( 8 Suppl): 4633"/>
   <result pre="ErbB2/ErbB3 antibody in previously treated ErbB-2-positive gastric and gastrophageal junction" exact="cancer" post=". J Clin Oncol ( 2013) 31( 4 Suppl):"/>
   <result pre="Yarar D Paragas V et al. Computational modeling of ERBB2-amplified" exact="breast cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
   <result pre="D Paragas V et al. Computational modeling of ERBB2-amplified breast" exact="cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
   <result pre="patients with metastatic or locally advanced soft tissue or bone" exact="sarcoma" post=". Am J Clin Oncol ( 2013) 36( 1):"/>
   <result pre="trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic" exact="osteosarcoma" post="with human epidermal growth factor receptor 2 overexpression: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4310719/results/search/disease/results.xml">
   <result pre="10.2147/CMAR.S72592 cmar-7-037 : Review Management of patients with hormone receptor–positive" exact="breast cancer" post="with visceral disease: challenges and treatment options Harb Wael"/>
   <result pre="cmar-7-037 : Review Management of patients with hormone receptor–positive breast" exact="cancer" post="with visceral disease: challenges and treatment options Harb Wael"/>
   <result pre="important treatment option for women with hormone receptor–positive (HR+) advanced" exact="breast cancer" post="(ABC), yet many tumors are either intrinsically resistant or"/>
   <result pre="treatment option for women with hormone receptor–positive (HR+) advanced breast" exact="cancer" post="(ABC), yet many tumors are either intrinsically resistant or"/>
   <result pre="LINK Keywords endocrine resistance endocrine therapy targeted therapy Introduction Breast" exact="cancer" post="(BC) is the most common cancer and leading cause"/>
   <result pre="targeted therapy Introduction Breast cancer (BC) is the most common" exact="cancer" post="and leading cause of cancer death in women worldwide;"/>
   <result pre="(BC) is the most common cancer and leading cause of" exact="cancer" post="death in women worldwide; in 2008 there were 1.38"/>
   <result pre="50% in premenopausal women. 4 The ER was the first" exact="cancer" post="target used in the management of BC; at least"/>
   <result pre="most premenopausal patients with HR+ ABC after tamoxifen therapy, ovarian" exact="suppression" post="or ablation in combination with endocrine therapy is recommended."/>
   <result pre="considered, while initial treatment with an antiestrogen alone, or ovarian" exact="suppression" post="or ablation plus endocrine therapy is advised for those"/>
   <result pre="and tamoxifen, are being utilized in the setting of endocrine-resistant" exact="breast cancer," post="44– 46 with data available for patients with visceral"/>
   <result pre="grade 3/4 AEs in the everolimus plus exemestane arm were" exact="stomatitis" post="(8% vs 1% with placebo plus exemestane), anemia (6%"/>
   <result pre="arm were stomatitis (8% vs 1% with placebo plus exemestane)," exact="anemia" post="(6% vs &amp;lt;1%), dyspnea (4% vs 1%), hyperglycemia (4%"/>
   <result pre="plus exemestane), anemia (6% vs &amp;lt;1%), dyspnea (4% vs 1%)," exact="hyperglycemia" post="(4% vs &amp;lt;1%), fatigue (4% vs 1%), and pneumonitis"/>
   <result pre="receiving everolimus plus exemestane with visceral vs nonvisceral disease were" exact="stomatitis" post="(59% and 59%, respectively), rash (40% and 39%, respectively),"/>
   <result pre="visceral vs nonvisceral disease were stomatitis (59% and 59%, respectively)," exact="rash" post="(40% and 39%, respectively), fatigue (40% and 36%, respectively),"/>
   <result pre="and 36%, respectively), decreased appetite (36% and 24%, respectively), and" exact="diarrhea" post="(34% and 34%, respectively). The frequency and type of"/>
   <result pre="identifier: NCT01783444). Other mTOR inhibitors undergoing clinical evaluation in advanced" exact="breast cancer" post="include temsirolimus and ridaforolimus, although data in the setting"/>
   <result pre="NCT01783444). Other mTOR inhibitors undergoing clinical evaluation in advanced breast" exact="cancer" post="include temsirolimus and ridaforolimus, although data in the setting"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 2 69"/>
   <result pre="KR Wilkens LR Kolonel LN Pike MC Henderson BE Breast" exact="cancer" post="risk factors defined by estrogen and progesterone receptor status:"/>
   <result pre="TE Cant EL Horsfall DJ Tilley WD Risk factors for" exact="breast cancer" post="by oestrogen receptor status: a population-based case-control study Br"/>
   <result pre="Cant EL Horsfall DJ Tilley WD Risk factors for breast" exact="cancer" post="by oestrogen receptor status: a population-based case-control study Br"/>
   <result pre="Mourits MJ Willemse PH The influence of endocrine treatments for" exact="breast cancer" post="on health-related quality of life Cancer Treat Rev 2008"/>
   <result pre="MJ Willemse PH The influence of endocrine treatments for breast" exact="cancer" post="on health-related quality of life Cancer Treat Rev 2008"/>
   <result pre="al. A review of the treatment of endocrine responsive metastatic" exact="breast cancer" post="in postmenopausal women Cancer Treat Rev 2013 39 5"/>
   <result pre="A review of the treatment of endocrine responsive metastatic breast" exact="cancer" post="in postmenopausal women Cancer Treat Rev 2013 39 5"/>
   <result pre="Garcia Mata J et al. Management of patients with metastatic" exact="breast cancer" post="Adv Ther 2011 28 Suppl 6 S50 S65 11"/>
   <result pre="Mata J et al. Management of patients with metastatic breast" exact="cancer" post="Adv Ther 2011 28 Suppl 6 S50 S65 11"/>
   <result pre="anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal" exact="breast cancer" post="J Clin Oncol 2012 30 16 1919 1925 22370325"/>
   <result pre="alone as first-line therapy for patients with receptor-positive postmenopausal breast" exact="cancer" post="J Clin Oncol 2012 30 16 1919 1925 22370325"/>
   <result pre="Dawson C Bliss J Aromatase inhibitors for treatment of advanced" exact="breast cancer" post="in postmenopausal women Cochrane Database Syst Rev 2009 4"/>
   <result pre="C Bliss J Aromatase inhibitors for treatment of advanced breast" exact="cancer" post="in postmenopausal women Cochrane Database Syst Rev 2009 4"/>
   <result pre="CD003370 19821307 13 Higgins MJ Baselga J Targeted therapies for" exact="breast cancer" post="J Clin Invest 2011 121 10 3797 3803 21965336"/>
   <result pre="19821307 13 Higgins MJ Baselga J Targeted therapies for breast" exact="cancer" post="J Clin Invest 2011 121 10 3797 3803 21965336"/>
   <result pre="2013 15 Johnson RH Chien FL Bleyer A Incidence of" exact="breast cancer" post="with distant involvement among women in the United States,"/>
   <result pre="15 Johnson RH Chien FL Bleyer A Incidence of breast" exact="cancer" post="with distant involvement among women in the United States,"/>
   <result pre="Caguioa PB Predictors of early distant metastasis in women with" exact="breast cancer" post="J Cancer Res Clin Oncol 2013 139 4 645"/>
   <result pre="PB Predictors of early distant metastasis in women with breast" exact="cancer" post="J Cancer Res Clin Oncol 2013 139 4 645"/>
   <result pre="of the efficacy of anastrozole in postmenopausal women with advanced" exact="breast cancer" post="with visceral metastases Breast Cancer Res Treat 2003 82"/>
   <result pre="the efficacy of anastrozole in postmenopausal women with advanced breast" exact="cancer" post="with visceral metastases Breast Cancer Res Treat 2003 82"/>
   <result pre="Ghersi D Chemotherapy alone versus endocrine therapy alone for metastatic" exact="breast cancer" post="Cochrane Database Syst Rev 2003 2 CD002747 12804433 23"/>
   <result pre="D Chemotherapy alone versus endocrine therapy alone for metastatic breast" exact="cancer" post="Cochrane Database Syst Rev 2003 2 CD002747 12804433 23"/>
   <result pre="G Bines J Activity of fulvestrant versus exemestane in advanced" exact="breast cancer" post="patients with or without visceral metastases: data from the"/>
   <result pre="Bines J Activity of fulvestrant versus exemestane in advanced breast" exact="cancer" post="patients with or without visceral metastases: data from the"/>
   <result pre="What is the role of chemotherapy in estrogen receptor-positive, advanced" exact="breast cancer?" post="Ann Oncol 2009 20 7 1157 1162 19221149 26"/>
   <result pre="20 7 1157 1162 19221149 26 Smith NZ Treating metastatic" exact="breast cancer" post="with systemic chemotherapies: current trends and future perspectives Clin"/>
   <result pre="7 1157 1162 19221149 26 Smith NZ Treating metastatic breast" exact="cancer" post="with systemic chemotherapies: current trends and future perspectives Clin"/>
   <result pre="Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced" exact="breast cancer" post="after progression or recurrence on nonsteroidal aromatase inhibitor therapy:"/>
   <result pre="therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast" exact="cancer" post="after progression or recurrence on nonsteroidal aromatase inhibitor therapy:"/>
   <result pre="comparative study of exemestane versus anastrozole in patients with postmenopausal" exact="breast cancer" post="with visceral metastases Clin Breast Cancer 2009 9 1"/>
   <result pre="study of exemestane versus anastrozole in patients with postmenopausal breast" exact="cancer" post="with visceral metastases Clin Breast Cancer 2009 9 1"/>
   <result pre="therapy behavior is associated to disease flares in patients with" exact="rheumatoid arthritis" post="who have achieved remission with disease-modifying antirheumatic drugs Am"/>
   <result pre="behavior is associated to disease flares in patients with rheumatoid" exact="arthritis" post="who have achieved remission with disease-modifying antirheumatic drugs Am"/>
   <result pre="Musgrove EA Sutherland RL Biological determinants of endocrine resistance in" exact="breast cancer" post="Nat Rev Cancer 2009 9 9 631 643 19701242"/>
   <result pre="EA Sutherland RL Biological determinants of endocrine resistance in breast" exact="cancer" post="Nat Rev Cancer 2009 9 9 631 643 19701242"/>
   <result pre="Ceci M Repetto L Naso G Overcoming endocrine resistance in" exact="breast cancer" post="Curr Cancer Drug Targets 2010 10 5 519 528"/>
   <result pre="M Repetto L Naso G Overcoming endocrine resistance in breast" exact="cancer" post="Curr Cancer Drug Targets 2010 10 5 519 528"/>
   <result pre="Morgensztern D McLeod HL PI3K/Akt/mTOR pathway as a target for" exact="cancer" post="therapy Anticancer Drugs 2005 16 8 797 803 16096426"/>
   <result pre="37 Advani SH Targeting mTOR pathway: A new concept in" exact="cancer" post="therapy Indian J Med Paediatr Oncol 2010 31 4"/>
   <result pre="in the first line treatment of hormone receptor positive advanced" exact="breast cancer" post="Breast Cancer Res Treat 2013 138 3 961 965"/>
   <result pre="the first line treatment of hormone receptor positive advanced breast" exact="cancer" post="Breast Cancer Res Treat 2013 138 3 961 965"/>
   <result pre="target of rapamycin (mTOR) inhibition in the treatment of advanced" exact="breast cancer" post="Curr Oncol Rep 2013 15 1 14 23 23054937"/>
   <result pre="of rapamycin (mTOR) inhibition in the treatment of advanced breast" exact="cancer" post="Curr Oncol Rep 2013 15 1 14 23 23054937"/>
   <result pre="Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced" exact="breast cancer" post="in subgroups of postmenopausal women with visceral and non-visceral"/>
   <result pre="(Faslodex) versus anastrozole for the second-line treatment of advanced breast" exact="cancer" post="in subgroups of postmenopausal women with visceral and non-visceral"/>
   <result pre="fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced" exact="breast cancer" post="J Clin Oncol 2010 28 30 4594 4600 20855825"/>
   <result pre="500 mg in postmenopausal women with estrogen receptor-positive advanced breast" exact="cancer" post="J Clin Oncol 2010 28 30 4594 4600 20855825"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 33 5538 5546 19786658"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 33 5538 5546 19786658"/>
   <result pre="gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic" exact="breast cancer" post="Clin Cancer Res 2010 16 6 1904 1914 20215537"/>
   <result pre="or placebo in postmenopausal women with hormone receptor-positive metastatic breast" exact="cancer" post="Clin Cancer Res 2010 16 6 1904 1914 20215537"/>
   <result pre="in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive" exact="breast cancer" post="progressing on treatment with a nonsteroidal aromatase inhibitor J"/>
   <result pre="postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast" exact="cancer" post="progressing on treatment with a nonsteroidal aromatase inhibitor J"/>
   <result pre="letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced" exact="breast cancer" post="(BC) [abstract 100O] Ann Oncol 2012 23 suppl 2"/>
   <result pre="vs letrozole alone for first-line treatment of ER+/HER2− advanced breast" exact="cancer" post="(BC) [abstract 100O] Ann Oncol 2012 23 suppl 2"/>
   <result pre="anastrozole (A) in women with endocrine therapy (ET) naive advanced" exact="breast cancer" post="(MINT) [abstract] J Clin Oncol 2013 Suppl 31 S531"/>
   <result pre="(A) in women with endocrine therapy (ET) naive advanced breast" exact="cancer" post="(MINT) [abstract] J Clin Oncol 2013 Suppl 31 S531"/>
   <result pre="with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic" exact="breast cancer" post="with prior exposure to aromatase inhibitors: a GINECO study"/>
   <result pre="hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast" exact="cancer" post="with prior exposure to aromatase inhibitors: a GINECO study"/>
   <result pre="Piccart M et al. Everolimus in postmenopausal hormone receptor–positive advanced" exact="breast cancer" post="N Engl J Med 2012 366 520 529 22149876"/>
   <result pre="M et al. Everolimus in postmenopausal hormone receptor–positive advanced breast" exact="cancer" post="N Engl J Med 2012 366 520 529 22149876"/>
   <result pre="S Raju RN Chemoendocrine therapy vs chemotherapy alone for advanced" exact="breast cancer" post="in postmenopausal women: preliminary report of a randomized study"/>
   <result pre="Raju RN Chemoendocrine therapy vs chemotherapy alone for advanced breast" exact="cancer" post="in postmenopausal women: preliminary report of a randomized study"/>
   <result pre="versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive" exact="breast cancer" post="patients. Very late results of the ‘gruppo di ricerca"/>
   <result pre="tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast" exact="cancer" post="patients. Very late results of the ‘gruppo di ricerca"/>
   <result pre="di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)’ 01-Trial in early" exact="breast cancer" post="Breast Cancer Res Treat 2011 126 3 653 661"/>
   <result pre="ricerca per la chemio-ormonoterapia adiuvante (GROCTA)’ 01-Trial in early breast" exact="cancer" post="Breast Cancer Res Treat 2011 126 3 653 661"/>
   <result pre="receptor signaling in vitro induces cell death in models of" exact="breast cancer" post="Clin Cancer Res 2005 11 14 5319 5328 16033851"/>
   <result pre="signaling in vitro induces cell death in models of breast" exact="cancer" post="Clin Cancer Res 2005 11 14 5319 5328 16033851"/>
   <result pre="et al. Inhibition of mTOR activity restores tamoxifen response in" exact="breast cancer" post="cells with aberrant Akt Activity Clin Cancer Res 2004"/>
   <result pre="al. Inhibition of mTOR activity restores tamoxifen response in breast" exact="cancer" post="cells with aberrant Akt Activity Clin Cancer Res 2004"/>
   <result pre="endocrine therapy in postmenopausal women with locally advanced or metastatic" exact="breast cancer" post="J Clin Oncol 2013 31 2 195 202 23233719"/>
   <result pre="therapy in postmenopausal women with locally advanced or metastatic breast" exact="cancer" post="J Clin Oncol 2013 31 2 195 202 23233719"/>
   <result pre="et al. Health-related quality of life of patients with advanced" exact="breast cancer" post="treated with everolimus plus exemestane versus placebo plus exemestane"/>
   <result pre="al. Health-related quality of life of patients with advanced breast" exact="cancer" post="treated with everolimus plus exemestane versus placebo plus exemestane"/>
   <result pre="life in relation to tamoxifen or exemestane treatment in postmenopausal" exact="breast cancer" post="patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side"/>
   <result pre="in relation to tamoxifen or exemestane treatment in postmenopausal breast" exact="cancer" post="patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side"/>
   <result pre="and disease symptoms in postmenopausal women with HR(+), HER2(−) advanced" exact="breast cancer" post="treated with everolimus plus exemestane versus exemestane monotherapy Curr"/>
   <result pre="disease symptoms in postmenopausal women with HR(+), HER2(−) advanced breast" exact="cancer" post="treated with everolimus plus exemestane versus exemestane monotherapy Curr"/>
   <result pre="AZD20 vs PBO; c AZD40 vs PBO. Abbreviations: ABC, advanced" exact="breast cancer;" post="ANA, anastrozole; AZD20, AZD8931 20 mg; AZD40, AZD8931 40"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4315003/results/search/disease/results.xml">
   <result pre="neoadjuvant therapy in human epidermal growth factor receptor (HER) 2-positive" exact="breast cancer." post="Three electronic databases, MEDLINE, Embase and Cochrane Central Register"/>
   <result pre="that the addition of lapatinib to neoadjuvant chemotherapy for HER2-positive" exact="breast cancer" post="improves the probability of achieving a higher pCR rate,"/>
   <result pre="the addition of lapatinib to neoadjuvant chemotherapy for HER2-positive breast" exact="cancer" post="improves the probability of achieving a higher pCR rate,"/>
   <result pre="is associated with a higher risk of adverse events. lapatinib" exact="breast cancer" post="neoadjuvant meta-analysis Introduction Neoadjuvant chemotherapy for the treatment of"/>
   <result pre="associated with a higher risk of adverse events. lapatinib breast" exact="cancer" post="neoadjuvant meta-analysis Introduction Neoadjuvant chemotherapy for the treatment of"/>
   <result pre="cancer neoadjuvant meta-analysis Introduction Neoadjuvant chemotherapy for the treatment of" exact="breast cancer" post="has been reported to be equivalent to adjuvant chemotherapy"/>
   <result pre="neoadjuvant meta-analysis Introduction Neoadjuvant chemotherapy for the treatment of breast" exact="cancer" post="has been reported to be equivalent to adjuvant chemotherapy"/>
   <result pre="2. Combined with neoadjuvant chemotherapy for the treatment of HER2-positive" exact="breast cancer" post="patients, trastuzumab offers a substantial benefit in terms of"/>
   <result pre="Combined with neoadjuvant chemotherapy for the treatment of HER2-positive breast" exact="cancer" post="patients, trastuzumab offers a substantial benefit in terms of"/>
   <result pre="trials have demonstrated that lapatinib is efficacious in HER2-positive metastatic" exact="breast cancer" post="( 8). A potential therapeutic option to improve HER2"/>
   <result pre="have demonstrated that lapatinib is efficacious in HER2-positive metastatic breast" exact="cancer" post="( 8). A potential therapeutic option to improve HER2"/>
   <result pre="lapatinib combined with neoadjuvant therapy for the treatment of HER2-positive" exact="breast cancer," post="a meta-analysis of all relevant published RCTs was performed."/>
   <result pre="the relative risk of each outcome in patients with HER2-positive" exact="breast cancer" post="receiving trastuzumab-based chemotherapy versus combination of lapatinib as neoadjuvant"/>
   <result pre="relative risk of each outcome in patients with HER2-positive breast" exact="cancer" post="receiving trastuzumab-based chemotherapy versus combination of lapatinib as neoadjuvant"/>
   <result pre="all subgroups demonstrating I 2&amp;lt;40%. The incidence of grade 3–4" exact="diarrhea" post="(RR, 12.94; 95% CI, 6.67–25.13; P&amp;lt;0.0001) and grade 3–4"/>
   <result pre="significant difference between the groups, grade 3–4 hepatic toxicity and" exact="neutropenia" post="appeared to occur more frequently in the lapatinib group"/>
   <result pre="that the addition of lapatinib to neoadjuvant chemotherapy in HER2-positive" exact="breast cancer" post="patients results in a significant increase in the pCR"/>
   <result pre="the addition of lapatinib to neoadjuvant chemotherapy in HER2-positive breast" exact="cancer" post="patients results in a significant increase in the pCR"/>
   <result pre="16), in which patients with HER2-positive locally advanced or inflammatory" exact="breast cancer" post="were randomly allocated to the chemotherapy or chemotherapy plus"/>
   <result pre="in which patients with HER2-positive locally advanced or inflammatory breast" exact="cancer" post="were randomly allocated to the chemotherapy or chemotherapy plus"/>
   <result pre="depends on several parameters, including tumor location, presence of ductal" exact="carcinoma in situ," post="breast size, contraindication to radiation therapy and patient willingness."/>
   <result pre="lapatinib, as expected, was associated with two well-documented adverse events," exact="diarrhea" post="and dermatological toxicity ( 18), despite the recommended dosage"/>
   <result pre="recommended dosage reduction for lapatinib ( 19), the grade 3–4" exact="diarrhea" post="and dermatological toxicity were found to be statistically more"/>
   <result pre="5). Anti-HER2 therapy is the treatment of choice for HER2-positive" exact="breast cancer." post="Dramatic clinical success has been achieved by blocking the"/>
   <result pre="achieved by blocking the HER-2 signaling pathway in women with" exact="breast cancer" post="that overexpresses HER2 ( 20– 22). The previously reported"/>
   <result pre="by blocking the HER-2 signaling pathway in women with breast" exact="cancer" post="that overexpresses HER2 ( 20– 22). The previously reported"/>
   <result pre="be highly effective as a first-line treatment for HER2-positive metastatic" exact="breast cancer" post="( 24). Similar to pertuzumab, lapatinib demonstrates a complementary"/>
   <result pre="highly effective as a first-line treatment for HER2-positive metastatic breast" exact="cancer" post="( 24). Similar to pertuzumab, lapatinib demonstrates a complementary"/>
   <result pre="been demonstrated in the metastatic setting ( 28). For HER2-positive" exact="breast cancer," post="a previous study also supported the indication that a"/>
   <result pre="a combination of the two, to neoadjuvant chemotherapy in HER2-positive" exact="breast cancer." post="This study included similar objectives and results on this"/>
   <result pre="present study revealed that the administration of lapatinib in HER2-positive" exact="breast cancer" post="in the neoadjuvant setting improves the probability of achieving"/>
   <result pre="study revealed that the administration of lapatinib in HER2-positive breast" exact="cancer" post="in the neoadjuvant setting improves the probability of achieving"/>
   <result pre="role of lapatinib in neoadjuvant therapy in patients with HER2-positive" exact="breast cancer." post="References References 1 Mauri D Pavlidis N Ioannidis JP"/>
   <result pre="Swain SM Byrd DR Mankoff DA Locally advanced and inflammatory" exact="breast cancer" post="J Clin Oncol 26 786 790 2008 10.1200/JCO.2008.15.0243 18258987"/>
   <result pre="SM Byrd DR Mankoff DA Locally advanced and inflammatory breast" exact="cancer" post="J Clin Oncol 26 786 790 2008 10.1200/JCO.2008.15.0243 18258987"/>
   <result pre="of preoperative chemotherapy on the outcome of women with operable" exact="breast cancer" post="J Clin Oncol 16 2672 2685 1998 9704717 4"/>
   <result pre="preoperative chemotherapy on the outcome of women with operable breast" exact="cancer" post="J Clin Oncol 16 2672 2685 1998 9704717 4"/>
   <result pre="HM Newman LA Smith TL et al. Clinical course of" exact="breast cancer" post="patients with complete pathologic primary tumor and axillary lymph"/>
   <result pre="Newman LA Smith TL et al. Clinical course of breast" exact="cancer" post="patients with complete pathologic primary tumor and axillary lymph"/>
   <result pre="of a meta-analysis of randomized phase III trials in metastatic" exact="breast cancer" post="Cancer Treat Rev 36 410 415 2010 10.1016/j.ctrv.2009.12.012 20100635"/>
   <result pre="a meta-analysis of randomized phase III trials in metastatic breast" exact="cancer" post="Cancer Treat Rev 36 410 415 2010 10.1016/j.ctrv.2009.12.012 20100635"/>
   <result pre="al. NeoALTTO Study Team: Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="NeoALTTO Study Team: Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="Lapatinib as a component of neoadjuvant therapy for HER2-positive operable" exact="breast cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="as a component of neoadjuvant therapy for HER2-positive operable breast" exact="cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced" exact="breast cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast" exact="cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified" exact="breast cancer" post="is not feasible because of excessive diarrhea J Clin"/>
   <result pre="by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast" exact="cancer" post="is not feasible because of excessive diarrhea J Clin"/>
   <result pre="in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive" exact="diarrhea" post="J Clin Oncol 28 2982 2988 2010 10.1200/JCO.2009.26.5900 20479410"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 344 783"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 344 783"/>
   <result pre="J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 353 1673 1684 2005 10.1056/NEJMoa052122"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 353 1673 1684 2005 10.1056/NEJMoa052122"/>
   <result pre="Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 353 1659 1672 2005 10.1056/NEJMoa052306"/>
   <result pre="B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 353 1659 1672 2005 10.1056/NEJMoa052306"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 366 109 119 2012 10.1056/NEJMoa1113216"/>
   <result pre="Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 366 109 119 2012 10.1056/NEJMoa1113216"/>
   <result pre="the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated" exact="breast cancer" post="cells Cancer Res 66 1630 1639 2006 10.1158/0008-5472.CAN-05-1182 16452222"/>
   <result pre="dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast" exact="cancer" post="cells Cancer Res 66 1630 1639 2006 10.1158/0008-5472.CAN-05-1182 16452222"/>
   <result pre="Lapatinib as a component of neoadjuvant therapy for HER2-positive operable" exact="breast cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="as a component of neoadjuvant therapy for HER2-positive operable breast" exact="cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant" exact="breast cancer" post="chemotherapy J Clin Oncol (Meeting Abstracts) 29 506 2011"/>
   <result pre="lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast" exact="cancer" post="chemotherapy J Clin Oncol (Meeting Abstracts) 29 506 2011"/>
   <result pre="bias was low. CHER-LOB, chemotherapy, Herceptin and lapatinib in operable" exact="breast cancer;" post="NeoALTTO, Neo-adjuvant Lapatinib and/or Trastuzumab Treatment Organisation; NSABP, National"/>
   <result pre="HR, hormone receptor; CHER-LOB, chemotherapy, Herceptin and lapatinib in operable" exact="breast cancer;" post="NeoALTTO, Neo-adjuvant Lapatinib and/or Trastuzumab Treatment Organisation; NSABP, National"/>
   <result pre="HR, hormone receptor; CHER-LOB, chemotherapy, Herceptin and lapatinib in operable" exact="breast cancer;" post="NeoALTTO, Neo-adjuvant Lapatinib and/or Trastuzumab Treatment Organisation; NSABP, National"/>
   <result pre="mg/kg weekly 16 CHER-LOB, chemotherapy, Herceptin and lapatinib in operable" exact="breast cancer;" post="NeoALTTO, Neo-adjuvant Lapatinib and/or Trastuzumab Treatment Organisation; NSABP, National"/>
   <result pre="grades 3–4 2 3/219 2/214 1.31 0.27–6.24 0.74 31 Febrile" exact="neutropenia" post="3 14/250 11/246 1.28 0.60–2.75 0.52 0 Dyspnoea 2"/>
   <result pre="baseline. L, lapatinib; RR, risk ratio; CI, confidence interval; CHF," exact="congestive heart failure;" post="LVEF, left ventricular ejection fraction."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4316710/results/search/disease/results.xml">
   <result pre="Article ErbB polymorphisms: insights and implications for response to targeted" exact="cancer" post="therapeutics Alaoui-Jamali Moulay A. 1 * Morand Grégoire B."/>
   <result pre="that overexpress hyperactive variants of ErbB receptors, in particular ErbB2-positive" exact="breast cancer" post="and non-small cell lung carcinomas. However, their clinical benefit"/>
   <result pre="overexpress hyperactive variants of ErbB receptors, in particular ErbB2-positive breast" exact="cancer" post="and non-small cell lung carcinomas. However, their clinical benefit"/>
   <result pre="the era of stratified targeted therapeutics is discussed. ErbB receptors" exact="cancer" post="SNPs anti-ErbB therapeutics drug response resistance fig-count: table-count: equation-count:"/>
   <result pre="carcinogenesis (Bargmann et al., 1986; Bouchard et al., 1989). In" exact="cancer" post="cells, aberrant activation due to gene overexpression and/or amplification"/>
   <result pre="proliferation, resistance to apoptosis, and higher cell invasiveness. In several" exact="cancer" post="types, in particular breast, ovarian, gastric, and non-small cell"/>
   <result pre="clinical prognosis, including high incidence of metastasis and recurrence. In" exact="breast cancer," post="molecular profiling studies have enabled identification of ErbB2-positivebreast cancer"/>
   <result pre="breast cancer, molecular profiling studies have enabled identification of ErbB2-positivebreast" exact="cancer" post="molecular subtype, which represents up to 30% of breast"/>
   <result pre="progress in the understanding the biology of ErbB signaling in" exact="cancer" post="has led to the discovery of several targeted agents"/>
   <result pre="(pertuzumab), are becoming major therapeutics, in particular for the ErbB2-positive" exact="breast cancer" post="subtype where combination of anti-ErbB2, e.g., trastuzumab with conventional"/>
   <result pre="are becoming major therapeutics, in particular for the ErbB2-positive breast" exact="cancer" post="subtype where combination of anti-ErbB2, e.g., trastuzumab with conventional"/>
   <result pre="for patient selection for the pertuzumab-based regimen in ErbB2-positive metastatic" exact="breast cancer" post="or locally recurrent unresectable tumor (Baselga et al., 2014;"/>
   <result pre="patient selection for the pertuzumab-based regimen in ErbB2-positive metastatic breast" exact="cancer" post="or locally recurrent unresectable tumor (Baselga et al., 2014;"/>
   <result pre="et al., 2001) Pertuzumab (Perjeta®) ErbB2 Humanized IgG1 MAb ErbB2-positive" exact="breast cancer" post="(2008) Binds to ErbB2 near the center of domain"/>
   <result pre="al., 2001) Pertuzumab (Perjeta®) ErbB2 Humanized IgG1 MAb ErbB2-positive breast" exact="cancer" post="(2008) Binds to ErbB2 near the center of domain"/>
   <result pre="et al., 1997) Lapatinib (Tykerb/Tyverb®) EGFR, ErbB2 Small molecule ErbB2-positive" exact="breast cancer" post="(2007) ATP-competitive TKI (Rusnak et al., 2001) Vandetanib (Caprelsa®)"/>
   <result pre="al., 1997) Lapatinib (Tykerb/Tyverb®) EGFR, ErbB2 Small molecule ErbB2-positive breast" exact="cancer" post="(2007) ATP-competitive TKI (Rusnak et al., 2001) Vandetanib (Caprelsa®)"/>
   <result pre="al., 2001) Vandetanib (Caprelsa®) EGFR, RET, VEGFR Small molecule Medullary" exact="thyroid cancer" post="(2011) ATP-competitive TKI (Carlomagno et al., 2002) Afatinib (Gilotrif®)"/>
   <result pre="2001) Vandetanib (Caprelsa®) EGFR, RET, VEGFR Small molecule Medullary thyroid" exact="cancer" post="(2011) ATP-competitive TKI (Carlomagno et al., 2002) Afatinib (Gilotrif®)"/>
   <result pre="Competitive TKI (Walter et al., 2013) * NSCLC, non-small cell" exact="lung carcinoma." post="† HNSCC, Head and neck squamous cell carcinoma. ‡"/>
   <result pre="~20 and ~70% of ErbB2-positive patients with early and metastatic" exact="breast cancer" post="treated with trastuzumab monotherapy, respectively (Harris et al., 2007;"/>
   <result pre="and ~70% of ErbB2-positive patients with early and metastatic breast" exact="cancer" post="treated with trastuzumab monotherapy, respectively (Harris et al., 2007;"/>
   <result pre="receptors not recognized by the inhibitor, e.g., trastuzumab resistance in" exact="breast cancer" post="has been associated with the expression of a truncated"/>
   <result pre="not recognized by the inhibitor, e.g., trastuzumab resistance in breast" exact="cancer" post="has been associated with the expression of a truncated"/>
   <result pre="differences seen in earlier studies examining SNPs in relation to" exact="cancer" post="via distinct regulatory mechanisms (Jin and Lee, 2013). Clearly,"/>
   <result pre="al., 2011). Conversely, low CA-SSR1 number was associated with increased" exact="breast cancer" post="risk in young women (Brandt et al., 2004), while"/>
   <result pre="2011). Conversely, low CA-SSR1 number was associated with increased breast" exact="cancer" post="risk in young women (Brandt et al., 2004), while"/>
   <result pre="CA-SSR1 number was correlated with better prognosis in luminal A" exact="breast cancer" post="(Leite et al., 2014). Studies analyzing Asian population showed"/>
   <result pre="number was correlated with better prognosis in luminal A breast" exact="cancer" post="(Leite et al., 2014). Studies analyzing Asian population showed"/>
   <result pre="R521K polymorphism has been associated with good prognostic features in" exact="breast cancer" post="especially in patients with luminal A subtypes, as well"/>
   <result pre="polymorphism has been associated with good prognostic features in breast" exact="cancer" post="especially in patients with luminal A subtypes, as well"/>
   <result pre="indicate that SNP in individual gene, whether it would affect" exact="cancer" post="cell proliferation or not, may influence the chromosome instability"/>
   <result pre="not, may influence the chromosome instability (CIN) and even that" exact="cancer" post="progression is not altered remarkably it can result different"/>
   <result pre="EGFR polymorphisms (rs2252586 and rs11979158) to be associated with increased" exact="glioma" post="risk (Sanson et al., 2011). Two further polymorphisms in"/>
   <result pre="particular microdeletions of exon 19. These deletions are common in" exact="lung cancer" post="and were reported to strongly predict response to TKI"/>
   <result pre="microdeletions of exon 19. These deletions are common in lung" exact="cancer" post="and were reported to strongly predict response to TKI"/>
   <result pre="cancers types according to the cataloge of somatic mutations in" exact="cancer" post="(COSMIC) database in human primary tumors . Each panel"/>
   <result pre="( http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). ERBB2 The most investigated ERBB2 polymorphism related to" exact="cancer" post="risk is I655V (rs1136201) located at the codon 655"/>
   <result pre="systematic review and meta-analysis studying ErbB2 polymorphism in over 45,000" exact="breast cancer" post="patients showed that there is a lack of experiments"/>
   <result pre="review and meta-analysis studying ErbB2 polymorphism in over 45,000 breast" exact="cancer" post="patients showed that there is a lack of experiments"/>
   <result pre="experiments replication for association studies between the polymorphic variants and" exact="cancer" post="risk, as well as lack of quality control of"/>
   <result pre="to genetic susceptibility and was associated with higher risk of" exact="lung cancer" post="in never-smokers (Sung et al., 2012). Noticeable, one research"/>
   <result pre="genetic susceptibility and was associated with higher risk of lung" exact="cancer" post="in never-smokers (Sung et al., 2012). Noticeable, one research"/>
   <result pre="to tamoxifen as well as to small molecule TKI in" exact="breast cancer;" post="however, a possible contribution of SNPs was not addressed"/>
   <result pre="and -815A/T (rs62626347), were investigated in a large cohort of" exact="breast cancer" post="patients. 782G/T conferred highest cancer risk (Rokavec et al.,"/>
   <result pre="-815A/T (rs62626347), were investigated in a large cohort of breast" exact="cancer" post="patients. 782G/T conferred highest cancer risk (Rokavec et al.,"/>
   <result pre="a large cohort of breast cancer patients. 782G/T conferred highest" exact="cancer" post="risk (Rokavec et al., 2007) but another study observed"/>
   <result pre="survival and proposed as a prognostic marker in high-risk early" exact="breast cancer" post="(Kurppa et al., 2014). A genome-wide association study (GWAS)"/>
   <result pre="and proposed as a prognostic marker in high-risk early breast" exact="cancer" post="(Kurppa et al., 2014). A genome-wide association study (GWAS)"/>
   <result pre="et al., 2014). A genome-wide association study (GWAS) identified a" exact="breast cancer" post="risk variant in ERBB4 at 2q34 (rs13393577) to occur"/>
   <result pre="al., 2014). A genome-wide association study (GWAS) identified a breast" exact="cancer" post="risk variant in ERBB4 at 2q34 (rs13393577) to occur"/>
   <result pre="breast cancer: pertuzumab for the treatment of patients with HER2-positive" exact="breast cancer" post=". Clin. Cancer Res. 20, 5359– 5364. 10.1158/1078-0432.CCR-14-1268 25204553"/>
   <result pre="cancer: pertuzumab for the treatment of patients with HER2-positive breast" exact="cancer" post=". Clin. Cancer Res. 20, 5359– 5364. 10.1158/1078-0432.CCR-14-1268 25204553"/>
   <result pre="factor receptor tyrosine kinase inhibitor targeted to the treatment of" exact="cancer" post=". Bioorg. Med. Chem. Lett. 11, 1911– 1914. 10.1016/S0960-894X(01)00344-4"/>
   <result pre="pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic" exact="breast cancer" post=". J. Clin. Oncol. 32, 3753– 3761. 10.1200/JCO.2013.54.5384 25332247"/>
   <result pre="in human epidermal growth factor receptor 2-positive, first-line metastatic breast" exact="cancer" post=". J. Clin. Oncol. 32, 3753– 3761. 10.1200/JCO.2013.54.5384 25332247"/>
   <result pre="Tidow N. Buerger H. Chang-Claude J. ( 2004). Modification of" exact="breast cancer" post="risk in young women by a polymorphic sequence in"/>
   <result pre="N. Buerger H. Chang-Claude J. ( 2004). Modification of breast" exact="cancer" post="risk in young women by a polymorphic sequence in"/>
   <result pre=". ( 1992). Humanization of an anti-p185HER2 antibody for human" exact="cancer" post="therapy. Proc. Natl. Acad. Sci. U.S.A. 89, 4285– 4289."/>
   <result pre="1981). Purified EGF receptor-kinase interacts specifically with antibodies to Rous" exact="sarcoma" post="virus transforming protein . Nature 290, 516– 519. 10.1038/290516a0"/>
   <result pre="of replication for the association between HER2 I655V polymorphism and" exact="breast cancer" post="risk: a systematic review and meta-analysis . Cancer Epidemiol"/>
   <result pre="replication for the association between HER2 I655V polymorphism and breast" exact="cancer" post="risk: a systematic review and meta-analysis . Cancer Epidemiol"/>
   <result pre="2011). Pharmacogenetic profiling and cetuximab outcome in patients with advanced" exact="colorectal cancer" post=". BMC Cancer 11, 496. 10.1186/1471-2407-11-496 22117530 Engelman J."/>
   <result pre="Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal" exact="cancer" post=". BMC Cancer 11, 496. 10.1186/1471-2407-11-496 22117530 Engelman J."/>
   <result pre="( 2007). PF00299804, an irreversible pan-ERBB inhibitor, is effective in" exact="lung cancer" post="models with EGFR and ERBB2 mutations that are resistant"/>
   <result pre="2007). PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung" exact="cancer" post="models with EGFR and ERBB2 mutations that are resistant"/>
   <result pre="for the treatment of her2-positive metastatic or locally recurrent unresectable" exact="breast cancer" post=". Pharmacoeconomics 33, 13– 23 10.1007/s40273-014-0206-2 25138171 Garrett T."/>
   <result pre="the treatment of her2-positive metastatic or locally recurrent unresectable breast" exact="cancer" post=". Pharmacoeconomics 33, 13– 23 10.1007/s40273-014-0206-2 25138171 Garrett T."/>
   <result pre="al. . ( 2006). Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer." post="N. Engl. J. Med. 355, 2733– 2743. 10.1056/NEJMoa064320 17192538"/>
   <result pre="( 2004). The discovery of receptor tyrosine kinases: targets for" exact="cancer" post="therapy. Nat. Rev. Cancer 4, 361– 370. 10.1038/nrc1360 15122207"/>
   <result pre="polymorphism and response to trastuzumab in women with operable primary" exact="breast cancer" post=". Ann. Oncol. 25, 1158– 1164. 10.1093/annonc/mdu111 24608202 Harris"/>
   <result pre="and response to trastuzumab in women with operable primary breast" exact="cancer" post=". Ann. Oncol. 25, 1158– 1164. 10.1093/annonc/mdu111 24608202 Harris"/>
   <result pre="of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early" exact="breast cancer" post=". Clin. Cancer Res. 13, 1198– 1207. 10.1158/1078-0432.CCR-06-1304 17317830"/>
   <result pre="resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast" exact="cancer" post=". Clin. Cancer Res. 13, 1198– 1207. 10.1158/1078-0432.CCR-06-1304 17317830"/>
   <result pre="ERBB3: a unique agent for simultaneous ERBB receptor blockade in" exact="cancer" post=". Clin. Cancer Res. 16, 1159– 1169. 10.1158/1078-0432.CCR-09-2353 20145185"/>
   <result pre="factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type" exact="colorectal cancer" post="patients treated with cetuximab-based chemotherapy . Cancer Sci. 103,"/>
   <result pre="receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal" exact="cancer" post="patients treated with cetuximab-based chemotherapy . Cancer Sci. 103,"/>
   <result pre="factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell" exact="lung cancer" post=". Int. J. Cancer 120, 1239– 1247. 10.1002/ijc.22513 17192902"/>
   <result pre="receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung" exact="cancer" post=". Int. J. Cancer 120, 1239– 1247. 10.1002/ijc.22513 17192902"/>
   <result pre="2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for" exact="breast cancer." post="N. Engl. J. Med. 354, 809– 820. 10.1056/NEJMoa053028 16495393"/>
   <result pre="HER-2 is associated with development and malignant phenotype of gastric" exact="cancer" post=". Int. J. Cancer 107, 593– 596. 10.1002/ijc.11450 14520697"/>
   <result pre="is associated with poor distant disease-free survival in high-risk early" exact="breast cancer" post=". PLoS ONE 9: e102388. 10.1371/journal.pone.0102388 25036186 Leite M."/>
   <result pre="associated with poor distant disease-free survival in high-risk early breast" exact="cancer" post=". PLoS ONE 9: e102388. 10.1371/journal.pone.0102388 25036186 Leite M."/>
   <result pre="factor receptor gene polymorphisms are associated with prognostic features of" exact="breast cancer" post=". BMC Cancer 14: 190. 10.1186/1471-2407-14-190 24629097 Lemmon M."/>
   <result pre="receptor gene polymorphisms are associated with prognostic features of breast" exact="cancer" post=". BMC Cancer 14: 190. 10.1186/1471-2407-14-190 24629097 Lemmon M."/>
   <result pre="2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical" exact="lung cancer" post="models . Oncogene 27, 4702– 4711. 10.1038/onc.2008.109 18408761 Li"/>
   <result pre="BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung" exact="cancer" post="models . Oncogene 27, 4702– 4711. 10.1038/onc.2008.109 18408761 Li"/>
   <result pre="( 2007). Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in" exact="breast cancer" post="cells . Int. J. Cancer 120, 1874– 1882. 10.1002/ijc.22423"/>
   <result pre="2007). Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast" exact="cancer" post="cells . Int. J. Cancer 120, 1874– 1882. 10.1002/ijc.22423"/>
   <result pre="may confer risk for EGFR somatic mutations in non-small cell" exact="lung cancer," post="with a predominant effect on exon 19 microdeletions ."/>
   <result pre="are associated with progression-free survival independent of K-ras in metastatic" exact="colorectal cancer" post="patients treated with single-agent cetuximab . Clin. Cancer Res."/>
   <result pre="associated with progression-free survival independent of K-ras in metastatic colorectal" exact="cancer" post="patients treated with single-agent cetuximab . Clin. Cancer Res."/>
   <result pre="al. . ( 2005). Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer." post="N. Engl. J. Med. 353, 1659– 1672. 10.1056/NEJMoa052306 16236737"/>
   <result pre="2006). Allelic imbalance of HER2 variant in sporadic breast and" exact="ovarian cancer." post="Cancer Genet. Cytogenet. 167, 32– 38. 10.1016/j.cancergencyto.2004.09.023 16682283 Red"/>
   <result pre="the promoter region of ERBB4 is associated with breast and" exact="colorectal cancer" post="risk . Clin. Cancer Res. 13, 7506– 7514. 10.1158/1078-0432.CCR-07-0457"/>
   <result pre="promoter region of ERBB4 is associated with breast and colorectal" exact="cancer" post="risk . Clin. Cancer Res. 13, 7506– 7514. 10.1158/1078-0432.CCR-07-0457"/>
   <result pre=". ( 2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer." post="N. Engl. J. Med. 353, 1673– 1684. 10.1056/NEJMoa052122 16236738"/>
   <result pre="of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for" exact="cancer" post=". Cancer Res. 61, 7196– 7203. 11585755 Sanson M."/>
   <result pre="et al. . ( 2011). Chromosome 7p11.2 (EGFR) variation influences" exact="glioma" post="risk. Hum. Mol. Genet. 20, 2897– 2904. 10.1093/hmg/ddr192 21531791"/>
   <result pre="EGFR R497K polymorphism is a favorable prognostic factor for advanced" exact="lung cancer." post="J. Cancer Res. Clin. Oncol. 135, 313– 318. 10.1007/s00432-008-0464-5"/>
   <result pre="1989). Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer." post="Science 244, 707– 712. 10.1126/science.2470152 2470152 Smaill J. B."/>
   <result pre="Association between -276 C/T polymorphism of the ERBB3 gene and" exact="lung cancer" post="risk in a Korean population . Anticancer Res. 32,"/>
   <result pre="between -276 C/T polymorphism of the ERBB3 gene and lung" exact="cancer" post="risk in a Korean population . Anticancer Res. 32,"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post=". Arch. Pathol. Lab. Med. 131, 18– 43. 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post=". Arch. Pathol. Lab. Med. 131, 18– 43. 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2"/>
   <result pre="of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for" exact="cancer" post="therapy . Crit. Rev. Oncol. Hematol. 38, 17– 23."/>
   <result pre="Y. Pines G. ( 2012). The ERBB network: at last," exact="cancer" post="therapy meets systems biology. Nat. Rev. Cancer 12, 553–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4322830/results/search/disease/results.xml">
   <result pre="with other malignancies such as colon, anal, renal, bladder, and" exact="prostate cancer" post="and in recent surveillance, epidemiology, and end results (SEER)"/>
   <result pre="other malignancies such as colon, anal, renal, bladder, and prostate" exact="cancer" post="and in recent surveillance, epidemiology, and end results (SEER)"/>
   <result pre="of tumor cells. According to HER2 test guideline recommendations for" exact="breast cancer," post="this HER2 result would be considered to be positive"/>
   <result pre="chest, abdomen, and pelvis which showed left cervical and axillary" exact="lymphadenopathy" post="as well as a pathologic fracture through a lytic"/>
   <result pre="third week treatment with 6 mg/kg, a standard dosing regimen for" exact="breast cancer." post="The patient tolerated therapy without any significant side effects,"/>
   <result pre="(Figures 3 and 4) revealed left axillary and left supraclavicular" exact="lymphadenopathy" post="that had resolved, returning to normal size, consistent with"/>
   <result pre="suppressor or an oncogene, but mutations are particularly seen in" exact="acute myeloid leukemia" post="and myelodysplastic syndrome. DNA methyltransferase inhibitors include azacitidine and"/>
   <result pre="or an oncogene, but mutations are particularly seen in acute" exact="myeloid leukemia" post="and myelodysplastic syndrome. DNA methyltransferase inhibitors include azacitidine and"/>
   <result pre="an oncogene, but mutations are particularly seen in acute myeloid" exact="leukemia" post="and myelodysplastic syndrome. DNA methyltransferase inhibitors include azacitidine and"/>
   <result pre="but mutations are particularly seen in acute myeloid leukemia and" exact="myelodysplastic syndrome." post="DNA methyltransferase inhibitors include azacitidine and decitabine and this"/>
   <result pre="mutations have been seen in other aggressive tumors such as" exact="pancreatic cancer" post="and small cell lung cancer. No approved therapies exist"/>
   <result pre="have been seen in other aggressive tumors such as pancreatic" exact="cancer" post="and small cell lung cancer. No approved therapies exist"/>
   <result pre="other aggressive tumors such as pancreatic cancer and small cell" exact="lung cancer." post="No approved therapies exist to target this mutation. ERBB2"/>
   <result pre="26]. One chronic hemodialysis patient with recurrent metastatic HER2 (3+)" exact="breast cancer" post="was treated with trastuzumab without development of significant adverse"/>
   <result pre="One chronic hemodialysis patient with recurrent metastatic HER2 (3+) breast" exact="cancer" post="was treated with trastuzumab without development of significant adverse"/>
   <result pre="also received trastuzumab in the adjuvant setting for invasive ductal" exact="carcinoma in situ" post="and had clinical response without adverse effects. Serum concentrations"/>
   <result pre="and optimizing quality-of-life in the treatment of a non-curable metastatic" exact="cancer" post="such as EMPD, delaying cytotoxic therapy in favor of"/>
   <result pre="2 Paget J. On disease of the mammary areola preceeding" exact="cancer" post="of the mammary gland St. Bartholomew's Hospital Reports 1874"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4322880/results/search/disease/results.xml">
   <result pre="of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive" exact="breast cancer" post="patient with brain metastases Ricciardi Giuseppina Rosaria Rita 1"/>
   <result pre="nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast" exact="cancer" post="patient with brain metastases Ricciardi Giuseppina Rosaria Rita 1"/>
   <result pre="patient’s quality of life and, often, a dismal prognosis. Breast" exact="cancer" post="(BC) is the second most common solid malignancy that"/>
   <result pre="because, until recently, nearly all randomized clinical trials in metastatic" exact="breast cancer" post="(MBC) excluded such patients. Therefore, novel approaches in this"/>
   <result pre="until recently, nearly all randomized clinical trials in metastatic breast" exact="cancer" post="(MBC) excluded such patients. Therefore, novel approaches in this"/>
   <result pre="good toxicity profile, even in heavily pretreated patients. Keywords HER-2" exact="breast cancer" post="nab-paclitaxel brain metastases trastuzumab long survivor Background Brain metastases"/>
   <result pre="toxicity profile, even in heavily pretreated patients. Keywords HER-2 breast" exact="cancer" post="nab-paclitaxel brain metastases trastuzumab long survivor Background Brain metastases"/>
   <result pre="patient’s quality of life and, often, a dismal prognosis. Breast" exact="cancer" post="(BC) is the second most common solid malignancy that"/>
   <result pre="kDa), the growing incidence of BM among patients with metastatic" exact="breast cancer" post="(MBC) treated with trastuzumab, especially in the setting of"/>
   <result pre="the growing incidence of BM among patients with metastatic breast" exact="cancer" post="(MBC) treated with trastuzumab, especially in the setting of"/>
   <result pre="the management of brain metastases in patients with HER2-positive metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2013 137 1 1 12"/>
   <result pre="management of brain metastases in patients with HER2-positive metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2013 137 1 1 12"/>
   <result pre="metastases as site of first recurrence in patients with HER2-positive" exact="breast cancer" post="treated with adjuvant trastuzumab Ann Oncol 2013 24 6"/>
   <result pre="as site of first recurrence in patients with HER2-positive breast" exact="cancer" post="treated with adjuvant trastuzumab Ann Oncol 2013 24 6"/>
   <result pre="barrier permeability determines drug efficacy in experimental brain metastases of" exact="breast cancer" post="Clin Cancer Res 2010 16 23 5664 5678 20829328"/>
   <result pre="permeability determines drug efficacy in experimental brain metastases of breast" exact="cancer" post="Clin Cancer Res 2010 16 23 5664 5678 20829328"/>
   <result pre="the blood–brain barrier by brain metastases of triple-negative and basal-type" exact="breast cancer" post="but not HER2/neu-positive breast cancer Cancer 2010 116 2"/>
   <result pre="blood–brain barrier by brain metastases of triple-negative and basal-type breast" exact="cancer" post="but not HER2/neu-positive breast cancer Cancer 2010 116 2"/>
   <result pre="metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive" exact="breast cancer" post="Cancer 2010 116 2 302 308 19937674 11 van"/>
   <result pre="of triple-negative and basal-type breast cancer but not HER2/neu-positive breast" exact="cancer" post="Cancer 2010 116 2 302 308 19937674 11 van"/>
   <result pre="J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="overall survival in patients with brain metastases from Her2 positive" exact="breast cancer" post="J Neurooncol 2007 85 3 311 317 17557136 16"/>
   <result pre="survival in patients with brain metastases from Her2 positive breast" exact="cancer" post="J Neurooncol 2007 85 3 311 317 17557136 16"/>
   <result pre="Extended survival in women with brain metastases from HER2 overexpressing" exact="breast cancer" post="Am J Clin Oncol 2008 31 3 250 254"/>
   <result pre="survival in women with brain metastases from HER2 overexpressing breast" exact="cancer" post="Am J Clin Oncol 2008 31 3 250 254"/>
   <result pre="Shin KH Trastuzumab treatment beyond brain progression in HER2-positive metastatic" exact="breast cancer" post="Ann Oncol 2009 20 1 56 62 18664558 18"/>
   <result pre="KH Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast" exact="cancer" post="Ann Oncol 2009 20 1 56 62 18664558 18"/>
   <result pre="and lapatinib uptake in surgically resected brain metastases from metastatic" exact="breast cancer" post="patients: a prospective study Neuro Oncol 2015 17 2"/>
   <result pre="lapatinib uptake in surgically resected brain metastases from metastatic breast" exact="cancer" post="patients: a prospective study Neuro Oncol 2015 17 2"/>
   <result pre="weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic" exact="breast cancer" post="Clin Breast Cancer 2011 11 2 121 128 21569998"/>
   <result pre="nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast" exact="cancer" post="Clin Breast Cancer 2011 11 2 121 128 21569998"/>
   <result pre="and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic" exact="breast cancer" post="Clin Breast Cancer 2010 10 4 281 287 20705560"/>
   <result pre="trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast" exact="cancer" post="Clin Breast Cancer 2010 10 4 281 287 20705560"/>
   <result pre="CLEOPATRA Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="of the GBG 26/BIG 3-05 phase III study in HER2-positive" exact="breast cancer" post="Eur J Cancer 2011 47 15 2273 2281 21741829"/>
   <result pre="the GBG 26/BIG 3-05 phase III study in HER2-positive breast" exact="cancer" post="Eur J Cancer 2011 47 15 2273 2281 21741829"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4323263/results/search/disease/results.xml">
   <result pre="4323263 523 doi: 10.1186/s13058-015-0523-1 : Review Patient-derived xenograft models of" exact="breast cancer" post="and their predictive power Whittle James R jim.whittle@mh.org.au Lewis"/>
   <result pre="523 doi: 10.1186/s13058-015-0523-1 : Review Patient-derived xenograft models of breast" exact="cancer" post="and their predictive power Whittle James R jim.whittle@mh.org.au Lewis"/>
   <result pre="advances in the treatment of patients with early and metastatic" exact="breast cancer," post="mortality remains high due to intrinsic or acquired resistance"/>
   <result pre="sequencing has revealed somatic mutations common to specific subtypes of" exact="breast cancer," post="provided new prognostic and predictive markers, and highlighted potential"/>
   <result pre="(PDXs) generated from fresh tumor specimens recapitulate the diversity of" exact="breast cancer" post="and reflect histopathology, tumor behavior, and the metastatic properties"/>
   <result pre="generated from fresh tumor specimens recapitulate the diversity of breast" exact="cancer" post="and reflect histopathology, tumor behavior, and the metastatic properties"/>
   <result pre="step towards personalized medicine. Here we review the utility of" exact="breast cancer" post="PDX models to study the clonal evolution of tumors"/>
   <result pre="towards personalized medicine. Here we review the utility of breast" exact="cancer" post="PDX models to study the clonal evolution of tumors"/>
   <result pre="and to evaluate novel therapies and drug resistance. Introduction Breast" exact="cancer" post="is not a single disease but a diverse set"/>
   <result pre="the need for identifying new therapeutic strategies. The heterogeneity of" exact="breast cancer" post="is a significant stumbling block for the application of"/>
   <result pre="need for identifying new therapeutic strategies. The heterogeneity of breast" exact="cancer" post="is a significant stumbling block for the application of"/>
   <result pre="[ 1]. To date, these platforms do not exist for" exact="breast cancer." post="Nevertheless, a more refined breast cancer classification system has"/>
   <result pre="do not exist for breast cancer. Nevertheless, a more refined" exact="breast cancer" post="classification system has been developed over the past 15"/>
   <result pre="not exist for breast cancer. Nevertheless, a more refined breast" exact="cancer" post="classification system has been developed over the past 15"/>
   <result pre="cellular mechanisms that contribute to tumor evolution. Inter-tumoral heterogeneity in" exact="breast cancer" post="The traditional histopathological markers used in the clinic do"/>
   <result pre="mechanisms that contribute to tumor evolution. Inter-tumoral heterogeneity in breast" exact="cancer" post="The traditional histopathological markers used in the clinic do"/>
   <result pre="small number of genes that are frequently mutated across multiple" exact="breast cancer" post="subtypes such as TP53 and PIK3CA/PTEN [ 14]. Interestingly,"/>
   <result pre="number of genes that are frequently mutated across multiple breast" exact="cancer" post="subtypes such as TP53 and PIK3CA/PTEN [ 14]. Interestingly,"/>
   <result pre="number alteration and gene expression analyses, 10 novel subclassifications of" exact="breast cancer" post="were proposed [ 15]. These subclassifications overlap with the"/>
   <result pre="alteration and gene expression analyses, 10 novel subclassifications of breast" exact="cancer" post="were proposed [ 15]. These subclassifications overlap with the"/>
   <result pre="were proposed [ 15]. These subclassifications overlap with the intrinsic" exact="breast cancer" post="subtypes and revealed further heterogeneity within the estrogen receptor"/>
   <result pre="proposed [ 15]. These subclassifications overlap with the intrinsic breast" exact="cancer" post="subtypes and revealed further heterogeneity within the estrogen receptor"/>
   <result pre="large cohorts, recurrent mutations in genes not previously associated with" exact="breast cancer" post="(for example, TBX3, MLL3, RUNX1 and CBFB) and novel"/>
   <result pre="cohorts, recurrent mutations in genes not previously associated with breast" exact="cancer" post="(for example, TBX3, MLL3, RUNX1 and CBFB) and novel"/>
   <result pre="identified [ 16, 17]. With respect to clonal heterogeneity in" exact="breast cancer," post="genomic analysis of triple-negative breast cancers has indicated that"/>
   <result pre="15 [ 18]. Whole genome sequencing of a primary lobular" exact="breast cancer" post="and a metastasis occurring in the patient diagnosed 9"/>
   <result pre="[ 18]. Whole genome sequencing of a primary lobular breast" exact="cancer" post="and a metastasis occurring in the patient diagnosed 9"/>
   <result pre="majority of heterogeneity occurs within, and not across, the different" exact="breast cancer" post="subtypes. Derivation of patient-derived xenograft models The use of"/>
   <result pre="of heterogeneity occurs within, and not across, the different breast" exact="cancer" post="subtypes. Derivation of patient-derived xenograft models The use of"/>
   <result pre="use of preclinical models to test hypotheses is central to" exact="cancer" post="research. Unfortunately, long-established human cell lines, and many transgenic"/>
   <result pre="[ 1]. Indeed, transcriptome studies of clinical samples versus established" exact="cancer" post="cell lines showed that cell lines were more closely"/>
   <result pre="in vitro culture. Multiple groups have now established cohorts of" exact="breast cancer" post="PDXs [ 23- 32]. Importantly, like cell lines, PDXs"/>
   <result pre="vitro culture. Multiple groups have now established cohorts of breast" exact="cancer" post="PDXs [ 23- 32]. Importantly, like cell lines, PDXs"/>
   <result pre="patient-derived xenograft models The methodology underpinning the generation of human" exact="breast cancer" post="xenograft models has been comprehensively described [ 33, 34]."/>
   <result pre="xenograft models The methodology underpinning the generation of human breast" exact="cancer" post="xenograft models has been comprehensively described [ 33, 34]."/>
   <result pre="progress has been made in improving the take rates of" exact="breast cancer" post="xenografts. This progress has included implantation into the orthotopic"/>
   <result pre="has been made in improving the take rates of breast" exact="cancer" post="xenografts. This progress has included implantation into the orthotopic"/>
   <result pre="37]. Figure 1 Derivation of patient-derived xenograft models of human" exact="breast cancer" post="in mice. Tumor slices are implanted into the cleared"/>
   <result pre="Figure 1 Derivation of patient-derived xenograft models of human breast" exact="cancer" post="in mice. Tumor slices are implanted into the cleared"/>
   <result pre="comparison has not yet been performed in the case of" exact="breast cancer." post="Table 1 Generation of orthotopic patient-derived xenografts from primary"/>
   <result pre="cancer. Table 1 Generation of orthotopic patient-derived xenografts from primary" exact="breast cancer" post="and metastatic tissue Study Mouse strain Supportive conditions Stable"/>
   <result pre="Table 1 Generation of orthotopic patient-derived xenografts from primary breast" exact="cancer" post="and metastatic tissue Study Mouse strain Supportive conditions Stable"/>
   <result pre="NR, not reported; PDX, patient-derived xenograft; PR, progesterone receptor; SCID," exact="severe combined immunodeficiency;" post="TNC, triple-negative cancer. aIrradiated and unirradiated for humanization. Given"/>
   <result pre="engraftment of human mammary epithelial cells in nonobese diabetic (NOD)/" exact="severe combined immunodeficiency" post="(SCID) mice by co-introduction of an immortalized human fibroblast"/>
   <result pre="as reducing necrosis [ 34]. Exogenous estrogen stimulates growth of" exact="breast cancer" post="PDXs and is critical for engraftment; for example, estrogen"/>
   <result pre="reducing necrosis [ 34]. Exogenous estrogen stimulates growth of breast" exact="cancer" post="PDXs and is critical for engraftment; for example, estrogen"/>
   <result pre="mice are more immunosuppressed and demonstrate higher engraftment rates. In" exact="breast cancer," post="however, NSG and SCID/Beige mice appear to have similar"/>
   <result pre="xenograft models for preclinical research All clinically defined subtypes of" exact="breast cancer" post="have been established as PDX models [ 25, 28,"/>
   <result pre="models for preclinical research All clinically defined subtypes of breast" exact="cancer" post="have been established as PDX models [ 25, 28,"/>
   <result pre="over several generations. Although the gene expression profiles of triple-negative" exact="breast cancer" post="PDXs recapitulate that of the parent tumor, passaging can"/>
   <result pre="several generations. Although the gene expression profiles of triple-negative breast" exact="cancer" post="PDXs recapitulate that of the parent tumor, passaging can"/>
   <result pre="model of tumor evolution [ 52]. In the context of" exact="breast cancer," post="deep genomic analyses of a basal-like primary tumor and"/>
   <result pre="patient-derived xenograft models Basal-like tumors represent ~20% of patients with" exact="breast cancer," post="are typically triple-negative, and carry a worse prognosis due"/>
   <result pre="enhance the efficacy of chemotherapy in the preclinical studies. Triple-negative" exact="breast cancer" post="shows relatively fewer somatic mutations but a high degree"/>
   <result pre="the efficacy of chemotherapy in the preclinical studies. Triple-negative breast" exact="cancer" post="shows relatively fewer somatic mutations but a high degree"/>
   <result pre="of these tumors. Impairment of apoptosis is a hallmark of" exact="cancer" post="[ 64], thus generating intense interest in the BCL-2"/>
   <result pre="termed BH3 mimetics. BCL-2 is overexpressed in approximately 75% of" exact="breast cancer" post="– including 83% of luminal tumors, 50% of HER2-positive"/>
   <result pre="BH3 mimetics. BCL-2 is overexpressed in approximately 75% of breast" exact="cancer" post="– including 83% of luminal tumors, 50% of HER2-positive"/>
   <result pre="potentiate the response to docetaxel in PDX models of triple-negative" exact="breast cancer" post="[ 35], suggesting that elevated BCL-2 expression in this"/>
   <result pre="the response to docetaxel in PDX models of triple-negative breast" exact="cancer" post="[ 35], suggesting that elevated BCL-2 expression in this"/>
   <result pre="Patient-derived xenograft models of drug-resistance Although the majority of ER-positive" exact="breast cancer" post="diagnoses respond to anti-estrogens such as tamoxifen and aromatase"/>
   <result pre="xenograft models of drug-resistance Although the majority of ER-positive breast" exact="cancer" post="diagnoses respond to anti-estrogens such as tamoxifen and aromatase"/>
   <result pre="inter-tumoral heterogeneity to explain de novo endocrine-therapy resistance in ER-positive" exact="breast cancer" post="and discovered point mutations or rearrangements affecting the ESR1"/>
   <result pre="heterogeneity to explain de novo endocrine-therapy resistance in ER-positive breast" exact="cancer" post="and discovered point mutations or rearrangements affecting the ESR1"/>
   <result pre="loop. This has been investigated in PDX models of basal-like" exact="breast cancer" post="using combined mTOR and AKT inhibitors. Synergy was demonstrated,"/>
   <result pre="This has been investigated in PDX models of basal-like breast" exact="cancer" post="using combined mTOR and AKT inhibitors. Synergy was demonstrated,"/>
   <result pre="Given the prevalence of PTEN-inactivating mutations in patients with basal-like" exact="breast cancer," post="this therapeutic approach could be explored further. PDX models"/>
   <result pre="for preclinical research. Prolonged exposure to cisplatin in high-grade serous" exact="ovarian cancer" post="has led to the generation of platinum-resistant models ["/>
   <result pre="preclinical research. Prolonged exposure to cisplatin in high-grade serous ovarian" exact="cancer" post="has led to the generation of platinum-resistant models ["/>
   <result pre="a new treatment strategy [ 74]. In the case of" exact="breast cancer," post="continuous treatment of HER2-amplified PDX models with trastuzumab could"/>
   <result pre="have been made for other solid malignancies including high-grade serous" exact="ovarian cancer" post="for platinum sensitivity [ 75]. Figure 3 Idealized personalized"/>
   <result pre="been made for other solid malignancies including high-grade serous ovarian" exact="cancer" post="for platinum sensitivity [ 75]. Figure 3 Idealized personalized"/>
   <result pre="patient-derived xenograft models with patient treatment. Rather than directly assigning" exact="breast cancer" post="patients to standard therapy, patients are treated on the"/>
   <result pre="xenograft models with patient treatment. Rather than directly assigning breast" exact="cancer" post="patients to standard therapy, patients are treated on the"/>
   <result pre="future patients. Rx, treatment of patient. Patient-derived xenograft models for" exact="breast cancer" post="stem cell characterization The cancer stem cell hypothesis provides"/>
   <result pre="patients. Rx, treatment of patient. Patient-derived xenograft models for breast" exact="cancer" post="stem cell characterization The cancer stem cell hypothesis provides"/>
   <result pre="Patient-derived xenograft models for breast cancer stem cell characterization The" exact="cancer" post="stem cell hypothesis provides a cellular mechanism to account"/>
   <result pre="as eventual tumor relapse. A number of potential markers of" exact="breast cancer" post="stem cells have been identified (CD44 +CD24 −, ALDH1"/>
   <result pre="eventual tumor relapse. A number of potential markers of breast" exact="cancer" post="stem cells have been identified (CD44 +CD24 −, ALDH1"/>
   <result pre="+CD24 −, ALDH1 +), but these do not universally mark" exact="breast cancer" post="stem cells, with variation evident between individual tumors. In"/>
   <result pre="−, ALDH1 +), but these do not universally mark breast" exact="cancer" post="stem cells, with variation evident between individual tumors. In"/>
   <result pre="may be a useful tool for evaluating the existence of" exact="cancer" post="stem cells and determining their intrinsic resistance to therapy"/>
   <result pre="has been speculated that some ER-positive tumors may have luminal-type" exact="cancer" post="stem cells that are yet to be discovered ["/>
   <result pre="have indicated that CD44 + breast tumor cells enriched for" exact="cancer" post="stem cells spontaneously metastasize to the lungs and lymph"/>
   <result pre="the lungs and lymph nodes, thus suggesting a role for" exact="cancer" post="stem cells in primary tumor growth as well as"/>
   <result pre="metastatic spread [ 76]. Further definition of the role of" exact="cancer" post="stem cells through xenotransplantation studies may provide strategies that"/>
   <result pre="cells through xenotransplantation studies may provide strategies that target both" exact="cancer" post="stem cells and non-cancer stem cells, which is ultimately"/>
   <result pre="stromal compartment and immune system play an important role in" exact="breast cancer" post="progression [ 77], the loss of human stroma following"/>
   <result pre="compartment and immune system play an important role in breast" exact="cancer" post="progression [ 77], the loss of human stroma following"/>
   <result pre="precluding PDX models for the preclinical testing of immunotherapies in" exact="breast cancer." post="Rather, syngeneic mice must be utilized for this purpose."/>
   <result pre="Phenotypic and molecular characterization of the claudin-low intrinsic subtype of" exact="breast cancer" post="Breast Cancer Res. 2010 12 R68 10.1186/bcr2635 20813035 3."/>
   <result pre="and molecular characterization of the claudin-low intrinsic subtype of breast" exact="cancer" post="Breast Cancer Res. 2010 12 R68 10.1186/bcr2635 20813035 3."/>
   <result pre="Voduc D Vickery T et al. Supervised risk predictor of" exact="breast cancer" post="based on intrinsic subtypes J Clin Oncol. 2009 27"/>
   <result pre="D Vickery T et al. Supervised risk predictor of breast" exact="cancer" post="based on intrinsic subtypes J Clin Oncol. 2009 27"/>
   <result pre="13 10.1038/nm.2000 19648928 7. Visvader JE Cells of origin in" exact="cancer" post="Nature. 2011 469 314 22 10.1038/nature09781 21248838 8. Prat"/>
   <result pre="8. Prat A Perou CM Deconstructing the molecular portraits of" exact="breast cancer" post="Mol Oncol. 2011 5 5 23 10.1016/j.molonc.2010.11.003 21147047 9."/>
   <result pre="Prat A Perou CM Deconstructing the molecular portraits of breast" exact="cancer" post="Mol Oncol. 2011 5 5 23 10.1016/j.molonc.2010.11.003 21147047 9."/>
   <result pre="C Leung S McKinney S Chia SK et al. Basal-like" exact="breast cancer" post="defined by five biomarkers has superior prognostic value than"/>
   <result pre="Leung S McKinney S Chia SK et al. Basal-like breast" exact="cancer" post="defined by five biomarkers has superior prognostic value than"/>
   <result pre="index, HER2 status, and prognosis of patients with luminal B" exact="breast cancer" post="J Natl Cancer Inst. 2009 101 736 50 10.1093/jnci/djp082"/>
   <result pre="HER2 status, and prognosis of patients with luminal B breast" exact="cancer" post="J Natl Cancer Inst. 2009 101 736 50 10.1093/jnci/djp082"/>
   <result pre="al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative" exact="breast cancer" post="N Engl J Med. 2004 351 2817 26 10.1056/NEJMoa041588"/>
   <result pre="A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast" exact="cancer" post="N Engl J Med. 2004 351 2817 26 10.1056/NEJMoa041588"/>
   <result pre="J Suman VJ Wallis JW et al. Whole-genome analysis informs" exact="breast cancer" post="response to aromatase inhibition Nature. 2012 486 353 60"/>
   <result pre="Suman VJ Wallis JW et al. Whole-genome analysis informs breast" exact="cancer" post="response to aromatase inhibition Nature. 2012 486 353 60"/>
   <result pre="AM et al. Sequence analysis of mutations and translocations across" exact="breast cancer" post="subtypes Nature. 2012 486 405 9 10.1038/nature11154 22722202 18."/>
   <result pre="et al. Sequence analysis of mutations and translocations across breast" exact="cancer" post="subtypes Nature. 2012 486 405 9 10.1038/nature11154 22722202 18."/>
   <result pre="LJ Vora MI et al. Redefining the relevance of established" exact="cancer" post="cell lines to the study of mechanisms of clinical"/>
   <result pre="Benito-Hernandez A Morrison SJ Clarke MF Prospective identification of tumorigenic" exact="breast cancer" post="cells Proc Natl Acad Sci U S A. 2003"/>
   <result pre="A Morrison SJ Clarke MF Prospective identification of tumorigenic breast" exact="cancer" post="cells Proc Natl Acad Sci U S A. 2003"/>
   <result pre="G Foerster J et al. Efficient engraftment of human primary" exact="breast cancer" post="transplants in nonconditioned NOD/Scid mice Int J Cancer. 2003"/>
   <result pre="Foerster J et al. Efficient engraftment of human primary breast" exact="cancer" post="transplants in nonconditioned NOD/Scid mice Int J Cancer. 2003"/>
   <result pre="Ebbert MT et al. Tumor grafts derived from women with" exact="breast cancer" post="authentically reflect tumor pathology, growth, metastasis and disease outcomes"/>
   <result pre="MT et al. Tumor grafts derived from women with breast" exact="cancer" post="authentically reflect tumor pathology, growth, metastasis and disease outcomes"/>
   <result pre="Cremoux P et al. A new model of patient tumor-derived" exact="breast cancer" post="xenografts for preclinical assays Clin Cancer Res. 2007 13"/>
   <result pre="P et al. A new model of patient tumor-derived breast" exact="cancer" post="xenografts for preclinical assays Clin Cancer Res. 2007 13"/>
   <result pre="Auger N Assayag F et al. Molecular profiling of patient-derived" exact="breast cancer" post="xenografts Breast Cancer Res. 2012 14 R11 10.1186/bcr3095 22247967"/>
   <result pre="N Assayag F et al. Molecular profiling of patient-derived breast" exact="cancer" post="xenografts Breast Cancer Res. 2012 14 R11 10.1186/bcr3095 22247967"/>
   <result pre="Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive" exact="breast cancer" post="Cancer Cell. 2013 24 120 9 10.1016/j.ccr.2013.06.002 23845444 31."/>
   <result pre="BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast" exact="cancer" post="Cancer Cell. 2013 24 120 9 10.1016/j.ccr.2013.06.002 23845444 31."/>
   <result pre="EJ Santoli D Growth characteristics and metastatic properties of human" exact="breast cancer" post="xenografts in immunodeficient mice Am J Pathol. 1998 152"/>
   <result pre="Santoli D Growth characteristics and metastatic properties of human breast" exact="cancer" post="xenografts in immunodeficient mice Am J Pathol. 1998 152"/>
   <result pre="resource of phenotypically stable, biologically and ethnically diverse, patient-derived human" exact="breast cancer" post="xenograft models Cancer Res. 2013 73 4885 97 10.1158/0008-5472.CAN-12-4081"/>
   <result pre="of phenotypically stable, biologically and ethnically diverse, patient-derived human breast" exact="cancer" post="xenograft models Cancer Res. 2013 73 4885 97 10.1158/0008-5472.CAN-12-4081"/>
   <result pre="Lewis MT Establishment of patient-derived xenograft (PDX) models of human" exact="breast cancer" post="Curr Protoc Mouse Biol. 2013 3 21 9 34."/>
   <result pre="MT Establishment of patient-derived xenograft (PDX) models of human breast" exact="cancer" post="Curr Protoc Mouse Biol. 2013 3 21 9 34."/>
   <result pre="Kline E Finlayson C Wisell J et al. Patient-derived luminal" exact="breast cancer" post="xenografts retain hormone receptor heterogeneity and help define unique"/>
   <result pre="E Finlayson C Wisell J et al. Patient-derived luminal breast" exact="cancer" post="xenografts retain hormone receptor heterogeneity and help define unique"/>
   <result pre="Pietenpol JA Chang JC Patient-derived breast tumor xenografts facilitating personalized" exact="cancer" post="therapy Breast Cancer Res. 2013 15 201 10.1186/bcr3355 23339383"/>
   <result pre="al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to" exact="breast cancer" post="invasion Cancer Res. 2011 71 2455 65 10.1158/0008-5472.CAN-10-3323 21459803"/>
   <result pre="Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast" exact="cancer" post="invasion Cancer Res. 2011 71 2455 65 10.1158/0008-5472.CAN-10-3323 21459803"/>
   <result pre="associated macrophages in tumor stroma as a prognostic marker for" exact="breast cancer" post="patients BMC Cancer. 2012 12 306 10.1186/1471-2407-12-306 22824040 41."/>
   <result pre="macrophages in tumor stroma as a prognostic marker for breast" exact="cancer" post="patients BMC Cancer. 2012 12 306 10.1186/1471-2407-12-306 22824040 41."/>
   <result pre="predict poor survival and resistance to gemcitabine in patients with" exact="pancreatic cancer" post="Clin Cancer Res. 2011 17 5793 800 10.1158/1078-0432.CCR-11-0341 21742805"/>
   <result pre="poor survival and resistance to gemcitabine in patients with pancreatic" exact="cancer" post="Clin Cancer Res. 2011 17 5793 800 10.1158/1078-0432.CCR-11-0341 21742805"/>
   <result pre="Molecular profiling and characterization of luminal-like and basal-like in vivo" exact="breast cancer" post="xenograft models Mol Oncol. 2009 3 469 82 10.1016/j.molonc.2009.07.003"/>
   <result pre="profiling and characterization of luminal-like and basal-like in vivo breast" exact="cancer" post="xenograft models Mol Oncol. 2009 3 469 82 10.1016/j.molonc.2009.07.003"/>
   <result pre="et al. Interplay of choline metabolites and genes in patient-derived" exact="breast cancer" post="xenografts Breast Cancer Res. 2014 16 R5 10.1186/bcr3597 24447408"/>
   <result pre="al. Interplay of choline metabolites and genes in patient-derived breast" exact="cancer" post="xenografts Breast Cancer Res. 2014 16 R5 10.1186/bcr3597 24447408"/>
   <result pre="Rance R Goodhead I et al. Subclonal phylogenetic structures in" exact="cancer" post="revealed by ultra-deep sequencing Proc Natl Acad Sci U"/>
   <result pre="K Wallis JW et al. Genome remodelling in a basal-like" exact="breast cancer" post="metastasis and xenograft Nature. 2010 464 999 1005 10.1038/nature08989"/>
   <result pre="Wallis JW et al. Genome remodelling in a basal-like breast" exact="cancer" post="metastasis and xenograft Nature. 2010 464 999 1005 10.1038/nature08989"/>
   <result pre="Mitchell T, et al. Circulating and disseminated tumor cells from" exact="breast cancer" post="patient-derived xenograft-bearing mice as a novel model to study"/>
   <result pre="T, et al. Circulating and disseminated tumor cells from breast" exact="cancer" post="patient-derived xenograft-bearing mice as a novel model to study"/>
   <result pre="of mTOR and AKT is an effective strategy for basal-like" exact="breast cancer" post="in patient-derived xenograft models Mol Cancer Ther. 2013 12"/>
   <result pre="mTOR and AKT is an effective strategy for basal-like breast" exact="cancer" post="in patient-derived xenograft models Mol Cancer Ther. 2013 12"/>
   <result pre="KC et al. PIK3CA mutations in androgen receptor-positive triple negative" exact="breast cancer" post="confer sensitivity to the combination of PI3K and androgen"/>
   <result pre="et al. PIK3CA mutations in androgen receptor-positive triple negative breast" exact="cancer" post="confer sensitivity to the combination of PI3K and androgen"/>
   <result pre="Z Schaiff WT et al. Targeting Chk1 in p53-deficient triple-negative" exact="breast cancer" post="is therapeutically beneficial in human-in-mouse tumor models J Clin"/>
   <result pre="Schaiff WT et al. Targeting Chk1 in p53-deficient triple-negative breast" exact="cancer" post="is therapeutically beneficial in human-in-mouse tumor models J Clin"/>
   <result pre="growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative" exact="breast cancer" post="xenografts Mol Cancer Ther. 2012 11 2693 703 10.1158/1535-7163.MCT-12-0441-T"/>
   <result pre="and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast" exact="cancer" post="xenografts Mol Cancer Ther. 2012 11 2693 703 10.1158/1535-7163.MCT-12-0441-T"/>
   <result pre="signaling enhances the antitumor efficacy of chemotherapy in triple negative" exact="breast cancer" post="through reduction of cancer stem cells Cancer Lett. 2013"/>
   <result pre="enhances the antitumor efficacy of chemotherapy in triple negative breast" exact="cancer" post="through reduction of cancer stem cells Cancer Lett. 2013"/>
   <result pre="of chemotherapy in triple negative breast cancer through reduction of" exact="cancer" post="stem cells Cancer Lett. 2013 328 261 70 10.1016/j.canlet.2012.09.023"/>
   <result pre="64. Adams JM Cory S The Bcl-2 apoptotic switch in" exact="cancer" post="development and therapy Oncogene. 2007 26 1324 37 10.1038/sj.onc.1210220"/>
   <result pre="HER2 blockade results in antitumor activity in preclinical models of" exact="breast cancer" post="resistant to anti-HER2 therapy Clin Cancer Res. 2012 18"/>
   <result pre="blockade results in antitumor activity in preclinical models of breast" exact="cancer" post="resistant to anti-HER2 therapy Clin Cancer Res. 2012 18"/>
   <result pre="treatments is associated to tumor-specific molecular changes in patient-derived luminal" exact="breast cancer" post="xenografts Clin Cancer Res. 2014 20 4314 25 10.1158/1078-0432.CCR-13-3230"/>
   <result pre="is associated to tumor-specific molecular changes in patient-derived luminal breast" exact="cancer" post="xenografts Clin Cancer Res. 2014 20 4314 25 10.1158/1078-0432.CCR-13-3230"/>
   <result pre="Musgrove EA Sutherland RL Biological determinants of endocrine resistance in" exact="breast cancer" post="Nat Rev Cancer. 2009 9 631 43 10.1038/nrc2713 19701242"/>
   <result pre="EA Sutherland RL Biological determinants of endocrine resistance in breast" exact="cancer" post="Nat Rev Cancer. 2009 9 631 43 10.1038/nrc2713 19701242"/>
   <result pre="HS Sahmoud T et al. Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med. 2012 366 520 9 10.1056/NEJMoa1109653"/>
   <result pre="Sahmoud T et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med. 2012 366 520 9 10.1056/NEJMoa1109653"/>
   <result pre="Veeriah S Deng G et al. Patient-derived xenografts of triple-negative" exact="breast cancer" post="reproduce molecular features of patient tumors and respond to"/>
   <result pre="S Deng G et al. Patient-derived xenografts of triple-negative breast" exact="cancer" post="reproduce molecular features of patient tumors and respond to"/>
   <result pre="A Mills GB Maelandsmo GM et al. Proteomic characterization of" exact="breast cancer" post="xenografts identifies early and late bevacizumab-induced responses and predicts"/>
   <result pre="Mills GB Maelandsmo GM et al. Proteomic characterization of breast" exact="cancer" post="xenografts identifies early and late bevacizumab-induced responses and predicts"/>
   <result pre="binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial" exact="ovarian cancer" post="Clin Cancer Res. 2012 18 5399 411 10.1158/1078-0432.CCR-12-1513 22896654"/>
   <result pre="inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian" exact="cancer" post="Clin Cancer Res. 2012 18 5399 411 10.1158/1078-0432.CCR-12-1513 22896654"/>
   <result pre="al. Molecular correlates of platinum response in human high-grade serous" exact="ovarian cancer" post="patient-derived xenografts Mol Oncol. 2014 8 656 68 10.1016/j.molonc.2014.01.008"/>
   <result pre="Molecular correlates of platinum response in human high-grade serous ovarian" exact="cancer" post="patient-derived xenografts Mol Oncol. 2014 8 656 68 10.1016/j.molonc.2014.01.008"/>
   <result pre="H et al. Stromal gene expression predicts clinical outcome in" exact="breast cancer" post="Nat Med. 2008 14 518 27 10.1038/nm1764 18438415 78."/>
   <result pre="et al. Stromal gene expression predicts clinical outcome in breast" exact="cancer" post="Nat Med. 2008 14 518 27 10.1038/nm1764 18438415 78."/>
   <result pre="et al. Patient-derived xenograft models: an emerging platform for translational" exact="cancer" post="research Cancer Discov. 2014 4 1 16 10.1158/2159-8290.CD-14-0001 79."/>
   <result pre="mice: an improved animal recipient for therapy response-testing of patient-derived" exact="breast cancer" post="xenotransplants [abstract] Cancer Res. 2012 72 S1 8 10.1158/0008-5472.SABCS12-S1-8"/>
   <result pre="an improved animal recipient for therapy response-testing of patient-derived breast" exact="cancer" post="xenotransplants [abstract] Cancer Res. 2012 72 S1 8 10.1158/0008-5472.SABCS12-S1-8"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4325954/results/search/disease/results.xml">
   <result pre="factor antagonists are a mainstay of treatment. However, triple negative" exact="breast cancer" post="(TNBC) cells lack receptor expression, are frequently more aggressive"/>
   <result pre="antagonists are a mainstay of treatment. However, triple negative breast" exact="cancer" post="(TNBC) cells lack receptor expression, are frequently more aggressive"/>
   <result pre="undertaken a systematic review of FOXO3a as a target for" exact="breast cancer" post="therapeutics. Methods Articles from NCBI were retrieved systematically when"/>
   <result pre="a systematic review of FOXO3a as a target for breast" exact="cancer" post="therapeutics. Methods Articles from NCBI were retrieved systematically when"/>
   <result pre="retrieved systematically when reporting primary data about FOXO3a expression in" exact="breast cancer" post="cells after cytotoxic drug treatment. Results Increased FOXO3a expression"/>
   <result pre="systematically when reporting primary data about FOXO3a expression in breast" exact="cancer" post="cells after cytotoxic drug treatment. Results Increased FOXO3a expression"/>
   <result pre="tangible therapeutic target that merits wider evaluation. Keywords Triple negative" exact="breast cancer" post="Phosphatidylinositol 3-kinase Metabolism Glycolysis Oxidative stress Apoptosis Background Breast"/>
   <result pre="therapeutic target that merits wider evaluation. Keywords Triple negative breast" exact="cancer" post="Phosphatidylinositol 3-kinase Metabolism Glycolysis Oxidative stress Apoptosis Background Breast"/>
   <result pre="cancer Phosphatidylinositol 3-kinase Metabolism Glycolysis Oxidative stress Apoptosis Background Breast" exact="cancer" post="is the third most frequent cancer worldwide. Amongst women,"/>
   <result pre="stress Apoptosis Background Breast cancer is the third most frequent" exact="cancer" post="worldwide. Amongst women, it is the most common malignancy,"/>
   <result pre="the most common malignancy, making up 21% of all new" exact="cancer" post="diagnoses. Survival rates have been steadily extending over the"/>
   <result pre="improvements in diagnosis and treatment. The drivers of proliferation in" exact="breast cancer" post="are also the phenotypic drug targets; hormone (estrogen, progesterone"/>
   <result pre="in diagnosis and treatment. The drivers of proliferation in breast" exact="cancer" post="are also the phenotypic drug targets; hormone (estrogen, progesterone"/>
   <result pre="knowledge has been harnessed in development of targeted therapies for" exact="breast cancer" post="patients which inhibit hormone receptor activity and can be"/>
   <result pre="has been harnessed in development of targeted therapies for breast" exact="cancer" post="patients which inhibit hormone receptor activity and can be"/>
   <result pre="anti-angiogenic agents [ 1, 2]. The highly aggressive triple negative" exact="breast cancer" post="(TNBC), with a prevalence of 15% of breast cancer"/>
   <result pre="agents [ 1, 2]. The highly aggressive triple negative breast" exact="cancer" post="(TNBC), with a prevalence of 15% of breast cancer"/>
   <result pre="negative breast cancer (TNBC), with a prevalence of 15% of" exact="breast cancer" post="cases often presenting in younger patients, is characterised by"/>
   <result pre="breast cancer (TNBC), with a prevalence of 15% of breast" exact="cancer" post="cases often presenting in younger patients, is characterised by"/>
   <result pre="There is no targeted treatment regime for this type of" exact="breast cancer" post="and many patients experience relapse to cytotoxic chemotherapy within"/>
   <result pre="is no targeted treatment regime for this type of breast" exact="cancer" post="and many patients experience relapse to cytotoxic chemotherapy within"/>
   <result pre="tumorigenesis [ 16, 17]. Despite evidence for FOXO3a down-regulation in" exact="breast cancer," post="the AMPK-FOXO3a pathway is still inducible, providing a potential"/>
   <result pre="pathway is still inducible, providing a potential therapeutic target for" exact="cancer" post="chemotherapy which is independent of receptor status [ 6]."/>
   <result pre="analysis of the published literature which describes the effects of" exact="breast cancer" post="chemotherapeutic agents on FOXO3a. The goal is to determine"/>
   <result pre="of the published literature which describes the effects of breast" exact="cancer" post="chemotherapeutic agents on FOXO3a. The goal is to determine"/>
   <result pre="a critical target of therapeutics used in the treatment of" exact="breast cancer," post="and therefore whether the evidence supports direct targeting of"/>
   <result pre="ER signaling plays a major role in tumour progression, ER-positive" exact="cancer" post="is also associated with better prognosis than ER-negative breast"/>
   <result pre="1 Growth factor receptor antagonists consistently activated FOXO3a in sensitive" exact="breast cancer" post="cells First author (Year) Treatment Effect on FOXO3a (Activates/Inactivates)"/>
   <result pre="Growth factor receptor antagonists consistently activated FOXO3a in sensitive breast" exact="cancer" post="cells First author (Year) Treatment Effect on FOXO3a (Activates/Inactivates)"/>
   <result pre="illustration of mechanisms of action of chemotherapeutic agents used in" exact="breast cancer" post="therapy upstream of FOXO3a expression. Chemotherapeutic agents in green"/>
   <result pre="of mechanisms of action of chemotherapeutic agents used in breast" exact="cancer" post="therapy upstream of FOXO3a expression. Chemotherapeutic agents in green"/>
   <result pre="down [ 24]. The bisphosphonate, zoledronic acid, originally used for" exact="osteoporosis" post="management, is now in clinical trials as a chemotherapeutic"/>
   <result pre="to endocrine therapy in premenopausal women with hormone receptor-positive early" exact="breast cancer" post="provides clinical benefit and is cost-effective [ 26]. Table"/>
   <result pre="endocrine therapy in premenopausal women with hormone receptor-positive early breast" exact="cancer" post="provides clinical benefit and is cost-effective [ 26]. Table"/>
   <result pre="[ 26]. Table 2 PI3k inhibition causes FOXO3a activation in" exact="breast cancer" post="cells First author (Year) Treatment Effect on FOXO3a (Activates/Inactivates)"/>
   <result pre="26]. Table 2 PI3k inhibition causes FOXO3a activation in breast" exact="cancer" post="cells First author (Year) Treatment Effect on FOXO3a (Activates/Inactivates)"/>
   <result pre="[ 27, 34]. Table 3 AKT inhibition activates FOXO3a in" exact="breast cancer" post="cells First author (Year) Treatment Effect on FOXO3a (Activates/Inactivates)"/>
   <result pre="27, 34]. Table 3 AKT inhibition activates FOXO3a in breast" exact="cancer" post="cells First author (Year) Treatment Effect on FOXO3a (Activates/Inactivates)"/>
   <result pre="inhibits AKT directly or indirectly. Activates in MCF-7 and MDA-MB-231" exact="breast cancer" post="cell lines) and in vivo in a tumour xenograft"/>
   <result pre="AKT directly or indirectly. Activates in MCF-7 and MDA-MB-231 breast" exact="cancer" post="cell lines) and in vivo in a tumour xenograft"/>
   <result pre="Increased apoptosis. Lin (2011) [ 28] FLOT1 silencing associated with" exact="suppression" post="of Akt activity Activates in MCF7 and MDA-231 measured"/>
   <result pre="(Table 4; [ 35- 40]). Table 4 FOXO3a activation in" exact="breast cancer" post="cells increases apoptosis First author (Year) Treatment Effect on"/>
   <result pre="4; [ 35- 40]). Table 4 FOXO3a activation in breast" exact="cancer" post="cells increases apoptosis First author (Year) Treatment Effect on"/>
   <result pre="There is a growing need for new drug targets in" exact="cancer" post="treatment. These should efficiently combine fewer side-effects with lower"/>
   <result pre="in solid tumours but despite evidence for FOXO3a down-regulation in" exact="breast cancer," post="the AMPK-FOXO3a pathway is still inducible. This systematic review"/>
   <result pre="key steps in the pathway downstream of the receptor in" exact="breast cancer" post="cell lines irrespective of hormone receptor status. There is"/>
   <result pre="steps in the pathway downstream of the receptor in breast" exact="cancer" post="cell lines irrespective of hormone receptor status. There is"/>
   <result pre="as a mechanism for FOXO3a up-regulation in slowing growth of" exact="breast cancer" post="cells has been reported in one study only, probably"/>
   <result pre="a mechanism for FOXO3a up-regulation in slowing growth of breast" exact="cancer" post="cells has been reported in one study only, probably"/>
   <result pre="If FOXO3a expression changes occur early in the lifecycle of" exact="breast cancer," post="the metabolic switch through a FOXO3a node may prove"/>
   <result pre="and death. FOXO3a expression is a positive prognostic marker for" exact="breast cancer" post="[ 43]. The activity of FOXO3a, which regulates ERα"/>
   <result pre="death. FOXO3a expression is a positive prognostic marker for breast" exact="cancer" post="[ 43]. The activity of FOXO3a, which regulates ERα"/>
   <result pre="nuclear receptor represents a crucial switch in FOXO3a control of" exact="breast cancer" post="cell aggressiveness [ 18]. Stratification of patients according to"/>
   <result pre="receptor represents a crucial switch in FOXO3a control of breast" exact="cancer" post="cell aggressiveness [ 18]. Stratification of patients according to"/>
   <result pre="including neuroblastoma, gastric adrenocarcinoma, hepatocarcinoma and poor metastasis-free survival in" exact="renal cell carcinoma" post="[ 47- 50]. In common with observations in breast"/>
   <result pre="cell carcinoma [ 47- 50]. In common with observations in" exact="breast cancer" post="cells, treatment of colon cancer cells with selenite induced"/>
   <result pre="carcinoma [ 47- 50]. In common with observations in breast" exact="cancer" post="cells, treatment of colon cancer cells with selenite induced"/>
   <result pre="In common with observations in breast cancer cells, treatment of" exact="colon cancer" post="cells with selenite induced ROS-dependent, FOXO3a-mediated apoptosis [ 51]."/>
   <result pre="common with observations in breast cancer cells, treatment of colon" exact="cancer" post="cells with selenite induced ROS-dependent, FOXO3a-mediated apoptosis [ 51]."/>
   <result pre="the effects of specific miR which affect FOXO3a expression in" exact="breast cancer" post="cells. It has been estimated that there may be"/>
   <result pre="effects of specific miR which affect FOXO3a expression in breast" exact="cancer" post="cells. It has been estimated that there may be"/>
   <result pre="with miR-96 using antisense miRNA (antagomiR) molecules increase apoptosis in" exact="breast cancer" post="cells. More work is needed before to understand potential"/>
   <result pre="miR-96 using antisense miRNA (antagomiR) molecules increase apoptosis in breast" exact="cancer" post="cells. More work is needed before to understand potential"/>
   <result pre="potential off-target effects before their potential as therapeutic targets for" exact="breast cancer" post="can be appreciated [ 53]. Chemotherapeutic drug resistance can"/>
   <result pre="off-target effects before their potential as therapeutic targets for breast" exact="cancer" post="can be appreciated [ 53]. Chemotherapeutic drug resistance can"/>
   <result pre="therapies. Acquired resistance to lapatinib and trastuzumab frequently occurs in" exact="breast cancer" post="patients, possibly as a consequence of FOXO3a de-repression and"/>
   <result pre="Acquired resistance to lapatinib and trastuzumab frequently occurs in breast" exact="cancer" post="patients, possibly as a consequence of FOXO3a de-repression and"/>
   <result pre="PI3k/mTOR pathway in combination with trastuzumab is beneficial in trastuzumab-resistant" exact="breast cancer" post="[ 56]. The studies highlighted here show the potential"/>
   <result pre="pathway in combination with trastuzumab is beneficial in trastuzumab-resistant breast" exact="cancer" post="[ 56]. The studies highlighted here show the potential"/>
   <result pre="on FOXO3a in: human cell lines or primary cells from" exact="breast cancer" post="patients and from immunohistochemical analyses of tissue. PubMed/Medline, Cochrane"/>
   <result pre="FOXO3a in: human cell lines or primary cells from breast" exact="cancer" post="patients and from immunohistochemical analyses of tissue. PubMed/Medline, Cochrane"/>
   <result pre="N-terminal kinases PI3k Phosphatidylinositol 3-kinase MiR microRNA TNBC Triple negative" exact="breast cancer" post="Competing interests The authors declare that they have no"/>
   <result pre="kinases PI3k Phosphatidylinositol 3-kinase MiR microRNA TNBC Triple negative breast" exact="cancer" post="Competing interests The authors declare that they have no"/>
   <result pre="Zielinski CC Optimal strategies for the treatment of metastatic triple-negative" exact="breast cancer" post="with currently approved agents Ann Oncol 2012 23 Suppl"/>
   <result pre="CC Optimal strategies for the treatment of metastatic triple-negative breast" exact="cancer" post="with currently approved agents Ann Oncol 2012 23 Suppl"/>
   <result pre="to neoadjuvant therapy and long-term survival in patients with triple-negative" exact="breast cancer" post="J Clin Oncol 2008 26 8 1275 81 10.1200/JCO.2007.14.4147"/>
   <result pre="neoadjuvant therapy and long-term survival in patients with triple-negative breast" exact="cancer" post="J Clin Oncol 2008 26 8 1275 81 10.1200/JCO.2007.14.4147"/>
   <result pre="F Simone C The AMPK-FoxO3A axis as a target for" exact="cancer" post="treatment Cell Cycle 2010 9 6 1091 6 10.4161/cc.9.6.11035"/>
   <result pre="W Garcia-Prieto C Huang P The Warburg effect and its" exact="cancer" post="therapeutic implications J Bioenerg Biomembr 2007 39 3 267"/>
   <result pre="regulator of the bifunctional role of FoxO3a transcription factor in" exact="breast cancer" post="motility and invasiveness Cell Cycle 2013 12 21 3405"/>
   <result pre="of the bifunctional role of FoxO3a transcription factor in breast" exact="cancer" post="motility and invasiveness Cell Cycle 2013 12 21 3405"/>
   <result pre="FOXO3a is a crucial cellular target of gefitinib (Iressa) in" exact="breast cancer" post="cells Mol Cancer Ther 2007 6 12 Pt 1"/>
   <result pre="is a crucial cellular target of gefitinib (Iressa) in breast" exact="cancer" post="cells Mol Cancer Ther 2007 6 12 Pt 1"/>
   <result pre="P et al. Blockade of epidermal growth factor receptors chemosensitizes" exact="breast cancer" post="cells through up-regulation of Bnip3L Cancer Res 2005 65"/>
   <result pre="et al. Blockade of epidermal growth factor receptors chemosensitizes breast" exact="cancer" post="cells through up-regulation of Bnip3L Cancer Res 2005 65"/>
   <result pre="et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in" exact="breast cancer" post="Mol Cancer Ther 2009 8 3 582 91 10.1158/1535-7163.MCT-08-0805"/>
   <result pre="al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast" exact="cancer" post="Mol Cancer Ther 2009 8 3 582 91 10.1158/1535-7163.MCT-08-0805"/>
   <result pre="al. Delineation of molecular mechanisms of sensitivity to lapatinib in" exact="breast cancer" post="cell lines using global gene expression profiles Mol Cancer"/>
   <result pre="Delineation of molecular mechanisms of sensitivity to lapatinib in breast" exact="cancer" post="cell lines using global gene expression profiles Mol Cancer"/>
   <result pre="FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in" exact="breast cancer" post="Oncogene 2012 31 14 1845 58 10.1038/onc.2011.368 21860419 24."/>
   <result pre="represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast" exact="cancer" post="Oncogene 2012 31 14 1845 58 10.1038/onc.2011.368 21860419 24."/>
   <result pre="R CCN1, a candidate target for zoledronic acid treatment in" exact="breast cancer" post="Mol Cancer Ther 2011 10 5 732 41 10.1158/1535-7163.MCT-10-0836"/>
   <result pre="CCN1, a candidate target for zoledronic acid treatment in breast" exact="cancer" post="Mol Cancer Ther 2011 10 5 732 41 10.1158/1535-7163.MCT-10-0836"/>
   <result pre="acid plus endocrine therapy in premenopausal women with hormone-responsive early" exact="breast cancer" post="Clin Breast Cancer 2010 10 4 267 74 10.3816/CBC.2010.n.034"/>
   <result pre="plus endocrine therapy in premenopausal women with hormone-responsive early breast" exact="cancer" post="Clin Breast Cancer 2010 10 4 267 74 10.3816/CBC.2010.n.034"/>
   <result pre="of indole-3-carbinol cyclic tri- and tetrameric derivatives mixture in human" exact="breast cancer" post="cells: in vitro and in vivo studies Anticancer Agents"/>
   <result pre="indole-3-carbinol cyclic tri- and tetrameric derivatives mixture in human breast" exact="cancer" post="cells: in vitro and in vivo studies Anticancer Agents"/>
   <result pre="al. Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in" exact="breast cancer" post="through upregulation of FOXO3a Clin Cancer Res 2011 17"/>
   <result pre="Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast" exact="cancer" post="through upregulation of FOXO3a Clin Cancer Res 2011 17"/>
   <result pre="R Zhang H Dong Y Ip C Selenium sensitizes MCF-7" exact="breast cancer" post="cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and"/>
   <result pre="Zhang H Dong Y Ip C Selenium sensitizes MCF-7 breast" exact="cancer" post="cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and"/>
   <result pre="Regulation of the FOXO3a/Bim signaling pathway by 5,7-dihydroxy-8-nitrochrysin in MDA-MB-453" exact="breast cancer" post="cells Oncol Lett 2013 5 3 929 34 23425937"/>
   <result pre="of the FOXO3a/Bim signaling pathway by 5,7-dihydroxy-8-nitrochrysin in MDA-MB-453 breast" exact="cancer" post="cells Oncol Lett 2013 5 3 929 34 23425937"/>
   <result pre="is a potent inducer of apoptosis with anticancer activity by" exact="suppression" post="of the Akt/FOXO pathway Br J Pharmacol 2010 159"/>
   <result pre="Cook SJ et al. Paclitaxel-induced nuclear translocation of FOXO3a in" exact="breast cancer" post="cells is mediated by c-Jun NH2-terminal kinase and Akt"/>
   <result pre="SJ et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast" exact="cancer" post="cells is mediated by c-Jun NH2-terminal kinase and Akt"/>
   <result pre="acid induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human" exact="breast cancer" post="MCF-7 cells J Cell Physiol 2012 227 5 1923"/>
   <result pre="induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human breast" exact="cancer" post="MCF-7 cells J Cell Physiol 2012 227 5 1923"/>
   <result pre="regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in" exact="breast cancer" post="J Biol Chem 2010 285 23 17869 79 10.1074/jbc.M110.101055"/>
   <result pre="cell survival, growth, and chemosensitivity by targeting FOXO3a in breast" exact="cancer" post="J Biol Chem 2010 285 23 17869 79 10.1074/jbc.M110.101055"/>
   <result pre="Moran MS Zhao Y Yang Q Inhibition of metadherin sensitizes" exact="breast cancer" post="cells to AZD6244 Cancer Biol Ther 2012 13 1"/>
   <result pre="MS Zhao Y Yang Q Inhibition of metadherin sensitizes breast" exact="cancer" post="cells to AZD6244 Cancer Biol Ther 2012 13 1"/>
   <result pre="cretica induces DNA damage, cell cycle arrest and apoptosis in" exact="breast cancer" post="cells via FOXO3a and p53 expression PLoS ONE 2012"/>
   <result pre="induces DNA damage, cell cycle arrest and apoptosis in breast" exact="cancer" post="cells via FOXO3a and p53 expression PLoS ONE 2012"/>
   <result pre="C et al. Unregulated miR-96 induces cell proliferation in human" exact="breast cancer" post="by downregulating transcriptional factor FOXO3a PLoS One 2010 5"/>
   <result pre="et al. Unregulated miR-96 induces cell proliferation in human breast" exact="cancer" post="by downregulating transcriptional factor FOXO3a PLoS One 2010 5"/>
   <result pre="S Liu H et al. Arsenic trioxide-induced growth arrest of" exact="breast cancer" post="MCF-7 cells involving FOXO3a and IkappaB kinase beta expression"/>
   <result pre="Liu H et al. Arsenic trioxide-induced growth arrest of breast" exact="cancer" post="MCF-7 cells involving FOXO3a and IkappaB kinase beta expression"/>
   <result pre="causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human" exact="breast cancer" post="cells in vivo Cancer Res 2008 68 18 7661"/>
   <result pre="FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast" exact="cancer" post="cells in vivo Cancer Res 2008 68 18 7661"/>
   <result pre="Adaptation and learning of molecular networks as a description of" exact="cancer" post="development at the systems-level: Potential use in anti-cancer therapies"/>
   <result pre="Y Shen AG Foxo3a expression is a prognostic marker in" exact="breast cancer" post="PLoS One 2013 8 8 e70746 10.1371/journal.pone.0070746 23967095 44."/>
   <result pre="Shen AG Foxo3a expression is a prognostic marker in breast" exact="cancer" post="PLoS One 2013 8 8 e70746 10.1371/journal.pone.0070746 23967095 44."/>
   <result pre="comparison between anastrozole and tamoxifen for the treatment of postmenopausal" exact="breast cancer" post="BMC Cancer. 2013 13 425 10.1186/1471-2407-13-425 24047421 45. Wong"/>
   <result pre="between anastrozole and tamoxifen for the treatment of postmenopausal breast" exact="cancer" post="BMC Cancer. 2013 13 425 10.1186/1471-2407-13-425 24047421 45. Wong"/>
   <result pre="RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in" exact="breast cancer" post="J Biol Chem 2001 276 45 42259 67 10.1074/jbc.M105888200"/>
   <result pre="is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast" exact="cancer" post="J Biol Chem 2001 276 45 42259 67 10.1074/jbc.M105888200"/>
   <result pre="a major target of inactivation by PI3K/AKT signaling in aggressive" exact="neuroblastoma" post="Cancer Res 2013 73 7 2189 98 10.1158/0008-5472.CAN-12-3767 23378341"/>
   <result pre="et al. Upregulator of cell proliferation predicts poor prognosis in" exact="hepatocellular carcinoma" post="and contributes to hepatocarcinogenesis by downregulating FOXO3a PLoS One"/>
   <result pre="is associated with metastasis-free survival of patients with clear cell" exact="renal cell carcinoma" post="Clin Cancer Res 2014 20 7 1779 90 10.1158/1078-0432.CCR-13-1687"/>
   <result pre="reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human" exact="cancer" post="Cancer Res 2010 70 11 4709 18 10.1158/0008-5472.CAN-09-4524 20484037"/>
   <result pre="EK Papavassiliou AG MicroRNAs as regulatory elements in triple negative" exact="breast cancer" post="Cancer Lett 2014 354 1 1 4 10.1016/j.canlet.2014.07.036 25107641"/>
   <result pre="Papavassiliou AG MicroRNAs as regulatory elements in triple negative breast" exact="cancer" post="Cancer Lett 2014 354 1 1 4 10.1016/j.canlet.2014.07.036 25107641"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4330173/results/search/disease/results.xml">
   <result pre="provided the original work is properly cited. Abstract Background Breast" exact="cancer" post="is the most common type of cancer in females."/>
   <result pre="Abstract Background Breast cancer is the most common type of" exact="cancer" post="in females. Aberrant expression of microRNA-21 (miR-21) has previously"/>
   <result pre="Aberrant expression of microRNA-21 (miR-21) has previously been reported in" exact="breast cancer" post="tissue. The aim of this study was to investigate"/>
   <result pre="expression of microRNA-21 (miR-21) has previously been reported in breast" exact="cancer" post="tissue. The aim of this study was to investigate"/>
   <result pre="study was to investigate expression levels of serum miR-21 in" exact="breast cancer" post="patients and evaluate its prognostic value in Chinese females."/>
   <result pre="was to investigate expression levels of serum miR-21 in breast" exact="cancer" post="patients and evaluate its prognostic value in Chinese females."/>
   <result pre="tissue, and adjacent normal tissue from 549 participants (326 with" exact="breast cancer," post="223 without breast cancer). We also analyzed associations between"/>
   <result pre="cancer). We also analyzed associations between serum miR-21 expression and" exact="breast cancer" post="subtypes and patient prognosis. Recurrence and survival were analyzed"/>
   <result pre="We also analyzed associations between serum miR-21 expression and breast" exact="cancer" post="subtypes and patient prognosis. Recurrence and survival were analyzed"/>
   <result pre="hazards model. Results Expression of miR-21 was significantly higher in" exact="breast cancer" post="tissues compared with normal adjacent breast tissues ( P&amp;lt;0.001)."/>
   <result pre="model. Results Expression of miR-21 was significantly higher in breast" exact="cancer" post="tissues compared with normal adjacent breast tissues ( P&amp;lt;0.001)."/>
   <result pre="P&amp;lt;0.001). The 2 -ΔΔ Ct values for serum miR-21 in" exact="breast cancer" post="patients versus healthy controls were 9.12±3.43 and 2.96±0.73, respectively."/>
   <result pre="The 2 -ΔΔ Ct values for serum miR-21 in breast" exact="cancer" post="patients versus healthy controls were 9.12±3.43 and 2.96±0.73, respectively."/>
   <result pre="[CI]=1.420-8.325; P=0.008) and disease-free survival (HR=2.732; 95% CI=1.038-7.273, P=0.003) in" exact="breast cancer." post="Conclusions Increased serum miR-21 expression level was correlated with"/>
   <result pre="serum miR-21 expression level was correlated with poor prognosis of" exact="breast cancer" post="patients, indicating that serum miR-21 may be a novel"/>
   <result pre="miR-21 expression level was correlated with poor prognosis of breast" exact="cancer" post="patients, indicating that serum miR-21 may be a novel"/>
   <result pre="be a novel prognostic marker for recurrence and survival of" exact="breast cancer" post="patients before resection. Biomarker Breast cancer Prognosis Serum miR-21"/>
   <result pre="a novel prognostic marker for recurrence and survival of breast" exact="cancer" post="patients before resection. Biomarker Breast cancer Prognosis Serum miR-21"/>
   <result pre="and survival of breast cancer patients before resection. Biomarker Breast" exact="cancer" post="Prognosis Serum miR-21 Funding First Hospital of Zibo City"/>
   <result pre="Natural Scientific Foundation of Shandong Province ZR2010CQ031 INTRODUCTION In females," exact="breast cancer" post="(BC) is the most common type of cancer and"/>
   <result pre="Scientific Foundation of Shandong Province ZR2010CQ031 INTRODUCTION In females, breast" exact="cancer" post="(BC) is the most common type of cancer and"/>
   <result pre="females, breast cancer (BC) is the most common type of" exact="cancer" post="and the second leading cause of death from cancer"/>
   <result pre="of cancer and the second leading cause of death from" exact="cancer" post="[ 1]. Though recent studies have focused on elucidating"/>
   <result pre="tissue type, and are aberrantly expressed in various types of" exact="cancer" post="[ 3, 4]. Many recent studies have identified expression"/>
   <result pre="derived not only from circulating blood cells but also from" exact="cancer" post="cells. The miR-21 is a novel and promising biomarker"/>
   <result pre="a novel and promising biomarker for detection and diagnosis of" exact="biliary tract cancer" post="[ 6, 7]. In particular, miR-21 has emerged as"/>
   <result pre="and promising biomarker for detection and diagnosis of biliary tract" exact="cancer" post="[ 6, 7]. In particular, miR-21 has emerged as"/>
   <result pre="BC has been previously demonstrated, it is not clear whether" exact="suppression" post="of miR-21 alone will affect tumorigenesis [ 13]. In"/>
   <result pre="site FRA17B. This region is frequently amplified in breast and" exact="lung cancer" post="[ 14]. In BC, miR-21 is an onco-miRNA. Elevated"/>
   <result pre="FRA17B. This region is frequently amplified in breast and lung" exact="cancer" post="[ 14]. In BC, miR-21 is an onco-miRNA. Elevated"/>
   <result pre="a number of small differences in females who later develop" exact="cancer" post="versus those who remain cancer-free. Microarray analysis of miRNAs"/>
   <result pre="that serum miR-21 was a more sensitive BC marker than" exact="cancer" post="antigen (CA)15-3 or carcinoembryonic antigen; in particular, miR-21 was"/>
   <result pre="promising biomarkers for diagnosis and assessment of the prognosis of" exact="cancer" post="patients. Sensitive techniques allow the expression levels of many"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 69 90"/>
   <result pre="et al. Plasma miR-21 is a novel diagnostic biomarker for" exact="biliary tract cancer" post="Cancer Sci 2013 104 1626 1631 24118467 8 Zhao"/>
   <result pre="Plasma miR-21 is a novel diagnostic biomarker for biliary tract" exact="cancer" post="Cancer Sci 2013 104 1626 1631 24118467 8 Zhao"/>
   <result pre="study of circulating miRNAs as potential biomarkers of early stage" exact="breast cancer" post="PLos One 2010 5 e13735 21060830 9 Edge SB"/>
   <result pre="of circulating miRNAs as potential biomarkers of early stage breast" exact="cancer" post="PLos One 2010 5 e13735 21060830 9 Edge SB"/>
   <result pre="M Compton CC Fritz AG Greene FL et al. AJCC" exact="cancer" post="staging manual 7th ed New York Springer-Verlag 2009 10"/>
   <result pre="Direct serum assay for microRNA-21 concentrations in early and advanced" exact="breast cancer" post="Clin Chem 2011 57 84 91 21036945 11 Mar-Aguilar"/>
   <result pre="serum assay for microRNA-21 concentrations in early and advanced breast" exact="cancer" post="Clin Chem 2011 57 84 91 21036945 11 Mar-Aguilar"/>
   <result pre="et al. Serum circulating microRNA profiling for identification of potential" exact="breast cancer" post="biomarkers Dis Markers 2013 34 163 169 23334650 12"/>
   <result pre="al. Serum circulating microRNA profiling for identification of potential breast" exact="cancer" post="biomarkers Dis Markers 2013 34 163 169 23334650 12"/>
   <result pre="Thike AA et al. Identification of circulating microRNA signatures for" exact="breast cancer" post="detection Clin Cancer Res 2013 19 4477 4487 23797906"/>
   <result pre="AA et al. Identification of circulating microRNA signatures for breast" exact="cancer" post="detection Clin Cancer Res 2013 19 4477 4487 23797906"/>
   <result pre="Sabbioni S et al. MicroRNA gene expression deregulation in human" exact="breast cancer" post="Cancer Res 2005 65 7065 7070 16103053 14 Calin"/>
   <result pre="S et al. MicroRNA gene expression deregulation in human breast" exact="cancer" post="Cancer Res 2005 65 7065 7070 16103053 14 Calin"/>
   <result pre="Calin GA Croce CM Chromosomal rearrangements and microRNAs: a new" exact="cancer" post="link with clinical implications J Clin Invest 2007 117"/>
   <result pre="Durango A Arisio R et al. High miR-21 expression in" exact="breast cancer" post="associated with poor disease-free survival in early stage disease"/>
   <result pre="A Arisio R et al. High miR-21 expression in breast" exact="cancer" post="associated with poor disease-free survival in early stage disease"/>
   <result pre="DZ Hou JH et al. Knockdown of miR-21 in human" exact="breast cancer" post="cell lines inhibits proliferation, in vitro migration and in"/>
   <result pre="Hou JH et al. Knockdown of miR-21 in human breast" exact="cancer" post="cell lines inhibits proliferation, in vitro migration and in"/>
   <result pre="Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of" exact="breast cancer" post="patients Indian J Biochem Biophys 2013 50 210 214"/>
   <result pre="of circulating miRNA-21 and miRNA-146a in plasma samples of breast" exact="cancer" post="patients Indian J Biochem Biophys 2013 50 210 214"/>
   <result pre="Guo L Li X Clinical significance of serum miR-21 in" exact="breast cancer" post="compared with CA153 and CEA Chin J Cancer Res"/>
   <result pre="L Li X Clinical significance of serum miR-21 in breast" exact="cancer" post="compared with CA153 and CEA Chin J Cancer Res"/>
   <result pre="in serum levels of miR-21, miR-210, and miR-373 in HER2-positive" exact="breast cancer" post="patients undergoing neoadjuvant therapy: a translational research project within"/>
   <result pre="serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast" exact="cancer" post="patients undergoing neoadjuvant therapy: a translational research project within"/>
   <result pre="of clinically relevant values of Ki-67 labeling index in Japanese" exact="breast cancer" post="patients Breast Cancer 2014 21 325 333 22782361 21"/>
   <result pre="clinically relevant values of Ki-67 labeling index in Japanese breast" exact="cancer" post="patients Breast Cancer 2014 21 325 333 22782361 21"/>
   <result pre="analysis to identify microRNAs regulating estrogen receptor signaling in braest" exact="cancer" post="cell lines Oncogene 2009 28 3926 3936 19684618 22"/>
   <result pre="28 3926 3936 19684618 22 Fackenthal JD Olopade Ol Breast" exact="cancer" post="risk associated with BRCA1and BRCA2 in diverse populations Nat"/>
   <result pre="Li J Shen L Xiao XG Fang L MicroRNAs in" exact="breast cancer" post="and breast cancer stem cells and their potential for"/>
   <result pre="J Shen L Xiao XG Fang L MicroRNAs in breast" exact="cancer" post="and breast cancer stem cells and their potential for"/>
   <result pre="L Xiao XG Fang L MicroRNAs in breast cancer and" exact="breast cancer" post="stem cells and their potential for breast cancer therapy"/>
   <result pre="Xiao XG Fang L MicroRNAs in breast cancer and breast" exact="cancer" post="stem cells and their potential for breast cancer therapy"/>
   <result pre="cancer and breast cancer stem cells and their potential for" exact="breast cancer" post="therapy Chin Med J (Engl) 2013 126 2556 2563"/>
   <result pre="and breast cancer stem cells and their potential for breast" exact="cancer" post="therapy Chin Med J (Engl) 2013 126 2556 2563"/>
   <result pre="Guo L Ge Q Analysis of serum genome-wide microRNAs for" exact="breast cancer" post="detection Clin Chim Acta 2012 413 1058 1065 22387599"/>
   <result pre="L Ge Q Analysis of serum genome-wide microRNAs for breast" exact="cancer" post="detection Clin Chim Acta 2012 413 1058 1065 22387599"/>
   <result pre="27 Fu SW Chen L Man YG miRNA biomarkers in" exact="breast cancer" post="detection and management J Cancer 2011 2 116 122"/>
   <result pre="Fu SW Chen L Man YG miRNA biomarkers in breast" exact="cancer" post="detection and management J Cancer 2011 2 116 122"/>
   <result pre="tumor-node-metastasis. Fig. 2 Kaplan-Meier curves for recurrence-free survival in 326" exact="breast cancer" post="patients. Recurrence-free survival was significantly lower in patients with"/>
   <result pre="Fig. 2 Kaplan-Meier curves for recurrence-free survival in 326 breast" exact="cancer" post="patients. Recurrence-free survival was significantly lower in patients with"/>
   <result pre="expression. Fig. 3 Kaplan-Meier curves for disease-free survival in 326" exact="breast cancer" post="patients. Disease-free survival was significantly lower in patients with"/>
   <result pre="Fig. 3 Kaplan-Meier curves for disease-free survival in 326 breast" exact="cancer" post="patients. Disease-free survival was significantly lower in patients with"/>
   <result pre="*Significant: 2-sided Pearson's chi-square test, P&amp;lt;0.05. Abbreviations: miR-21, microRNA-21; BRCA1/2," exact="breast cancer" post="1/2, early onset; ER, estrogen receptor; HER2, human epithelial"/>
   <result pre="2-sided Pearson's chi-square test, P&amp;lt;0.05. Abbreviations: miR-21, microRNA-21; BRCA1/2, breast" exact="cancer" post="1/2, early onset; ER, estrogen receptor; HER2, human epithelial"/>
   <result pre="Prognosis of serum miR-21 for recurrence or disease-free survival in" exact="breast cancer" post="*Significant: 2-sided Pearson's chi-square test, P&amp;lt;0.05. Abbreviations: miR-21, microRNA-21;"/>
   <result pre="of serum miR-21 for recurrence or disease-free survival in breast" exact="cancer" post="*Significant: 2-sided Pearson's chi-square test, P&amp;lt;0.05. Abbreviations: miR-21, microRNA-21;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4331616/results/search/disease/results.xml">
   <result pre="and biomarker findings in patients with HER2-positive advanced or metastatic" exact="breast cancer" post="treated with lapatinib in combination with capecitabine: results from"/>
   <result pre="biomarker findings in patients with HER2-positive advanced or metastatic breast" exact="cancer" post="treated with lapatinib in combination with capecitabine: results from"/>
   <result pre="with capecitabine alone in patients with HER2-positive advanced or metastatic" exact="breast cancer." post="In this clinical study of lapatinib in combination with"/>
   <result pre="were investigated in Japanese patients with HER2-positive advanced or metastatic" exact="breast cancer" post="treated with prior trastuzumab. Methods Eligible women received lapatinib"/>
   <result pre="investigated in Japanese patients with HER2-positive advanced or metastatic breast" exact="cancer" post="treated with prior trastuzumab. Methods Eligible women received lapatinib"/>
   <result pre="common adverse events reported were palmar-plantar erythrodysesthesia syndrome (76 %)," exact="diarrhea" post="(67 %) and stomatitis (41 %). Conclusions Lapatinib in"/>
   <result pre="were palmar-plantar erythrodysesthesia syndrome (76 %), diarrhea (67 %) and" exact="stomatitis" post="(41 %). Conclusions Lapatinib in combination with capecitabine in"/>
   <result pre="%). Conclusions Lapatinib in combination with capecitabine in Japanese HER2-positive" exact="breast cancer" post="patients was well tolerated. Overall, our findings on the"/>
   <result pre="Conclusions Lapatinib in combination with capecitabine in Japanese HER2-positive breast" exact="cancer" post="patients was well tolerated. Overall, our findings on the"/>
   <result pre="reported from the overseas studies. Keywords Lapatinib Capecitabine HER2 Breast" exact="cancer" post="Biomarker Introduction Approximately 20 % of breast cancers exhibit"/>
   <result pre="combination with capecitabine in women with HER2-positive advanced or metastatic" exact="breast cancer" post="(MBC) that progressed following prior therapy including trastuzumab provided"/>
   <result pre="with capecitabine in women with HER2-positive advanced or metastatic breast" exact="cancer" post="(MBC) that progressed following prior therapy including trastuzumab provided"/>
   <result pre="the earliest date of disease progression or death due to" exact="breast cancer," post="whichever is sooner), progression-free survival (PFS), 6-month progression-free survival,"/>
   <result pre="the presence of supportive care; hematological toxicity (grade 4 drug-related" exact="neutropenia" post="lasting ≥ 5 days, febrile neutropenia ≥ grade 3"/>
   <result pre="toxicity (grade 4 drug-related neutropenia lasting ≥ 5 days, febrile" exact="neutropenia" post="≥ grade 3 or thrombocytopenia ≤ 25000/mm 3); inability"/>
   <result pre="lasting ≥ 5 days, febrile neutropenia ≥ grade 3 or" exact="thrombocytopenia" post="≤ 25000/mm 3); inability to start the next treatment"/>
   <result pre="(stage IIIB, stage IIIC with T4 lesion or stage IV)" exact="breast cancer" post="that was HER2-positive [confirmed immunohistochemistry (IHC) 3 + or"/>
   <result pre="IIIB, stage IIIC with T4 lesion or stage IV) breast" exact="cancer" post="that was HER2-positive [confirmed immunohistochemistry (IHC) 3 + or"/>
   <result pre="and/or HER2 inhibitor other than trastuzumab, or if they had" exact="malabsorption" post="syndrome or other conditions that would prevent the efficacy"/>
   <result pre="(Table 1). Most subjects (71 %) had estrogen receptor (ER)-negative" exact="breast cancer" post="as assessed by a local laboratory. The majority of"/>
   <result pre="1). Most subjects (71 %) had estrogen receptor (ER)-negative breast" exact="cancer" post="as assessed by a local laboratory. The majority of"/>
   <result pre="protocol, all subjects experienced drug-related adverse events, such as fatigue," exact="diarrhea" post="and pruritus. All adverse events were grade 1 or"/>
   <result pre="3 neutrophil count decrease. This subject also experienced grade 2" exact="cystitis" post="and a grade 2 white blood cell (WBC) count"/>
   <result pre="most common adverse events reported were palmar-plantar erythrodysesthesia (PPE) syndrome," exact="diarrhea" post="and stomatitis (Table 2). In addition, all subjects experienced"/>
   <result pre="adverse events reported were palmar-plantar erythrodysesthesia (PPE) syndrome, diarrhea and" exact="stomatitis" post="(Table 2). In addition, all subjects experienced drug-related adverse"/>
   <result pre="alanine aminotransferase increase, neutrophil count decrease, bone marrow failure and" exact="pericardial effusion." post="Table 2 Summary of adverse events experienced by at"/>
   <result pre="dysfunction were observed in one subject each, and grade 2" exact="pulmonary tuberculosis" post="was observed in one subject. Cardiac events, which are"/>
   <result pre="were observed in one subject each, and grade 2 pulmonary" exact="tuberculosis" post="was observed in one subject. Cardiac events, which are"/>
   <result pre="reasoned. One of the possibilities is, as previously reported, that" exact="breast cancer" post="is a heterogeneous disease, and, in particular, HER2-positive breast"/>
   <result pre="One of the possibilities is, as previously reported, that breast" exact="cancer" post="is a heterogeneous disease, and, in particular, HER2-positive breast"/>
   <result pre="breast cancer is a heterogeneous disease, and, in particular, HER2-positive" exact="breast cancer" post="is known to have variable biological features based upon"/>
   <result pre="cancer is a heterogeneous disease, and, in particular, HER2-positive breast" exact="cancer" post="is known to have variable biological features based upon"/>
   <result pre="this regimen offers a clinically beneficial therapeutic option for HER2-positive" exact="breast cancer" post="patients in Japan. Most recently, the results from clinical"/>
   <result pre="regimen offers a clinically beneficial therapeutic option for HER2-positive breast" exact="cancer" post="patients in Japan. Most recently, the results from clinical"/>
   <result pre="these agents can be considered as options in the HER2-positive" exact="breast cancer" post="treatment algorithm [ 19, 20]. As stated in this"/>
   <result pre="agents can be considered as options in the HER2-positive breast" exact="cancer" post="treatment algorithm [ 19, 20]. As stated in this"/>
   <result pre="and capecitabine should still be options for long-term treatment of" exact="breast cancer." post="In order to maximize the treatment options for HER2-positive"/>
   <result pre="cancer. In order to maximize the treatment options for HER2-positive" exact="breast cancer" post="patients, the suitable clinical position of the lapatinib and"/>
   <result pre="In order to maximize the treatment options for HER2-positive breast" exact="cancer" post="patients, the suitable clinical position of the lapatinib and"/>
   <result pre="inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell" exact="lung cancer" post="and other solid tumors: results of a phase I"/>
   <result pre="ZD1839 is generally well-tolerated and has activity in non-small-cell lung" exact="cancer" post="and other solid tumors: results of a phase I"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="lapatinib plus capecitabine versus capecitabine alone in women with advanced" exact="breast cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="plus capecitabine versus capecitabine alone in women with advanced breast" exact="cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="Wardley A Davidson N et al. Treatment of HER2-positive metastatic" exact="breast cancer" post="with lapatinib and capecitabine in the lapatinib expanded access"/>
   <result pre="A Davidson N et al. Treatment of HER2-positive metastatic breast" exact="cancer" post="with lapatinib and capecitabine in the lapatinib expanded access"/>
   <result pre="al. Clinical outcome of patients with brain metastases from HER2-positive" exact="breast cancer" post="treated with lapatinib and capecitabine Ann Oncol 2011 22"/>
   <result pre="Clinical outcome of patients with brain metastases from HER2-positive breast" exact="cancer" post="treated with lapatinib and capecitabine Ann Oncol 2011 22"/>
   <result pre="Changes of serum HER2 status during clinical course of metastatic" exact="breast cancer" post="patients Anticancer Res 2004 6 4205 4210 15739264 12."/>
   <result pre="of serum HER2 status during clinical course of metastatic breast" exact="cancer" post="patients Anticancer Res 2004 6 4205 4210 15739264 12."/>
   <result pre="DS Nobel AB et al. Concordance among gene-expression-based predictors for" exact="breast cancer" post="N Engl J Med 2006 355 560 569 10.1056/NEJMoa052933"/>
   <result pre="Nobel AB et al. Concordance among gene-expression-based predictors for breast" exact="cancer" post="N Engl J Med 2006 355 560 569 10.1056/NEJMoa052933"/>
   <result pre="or placebo as first-line treatment in HER2-negative or unknown metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 24 3908 3915 10.1200/JCO.2008.18.1925"/>
   <result pre="placebo as first-line treatment in HER2-negative or unknown metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 24 3908 3915 10.1200/JCO.2008.18.1925"/>
   <result pre="YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="IE, Welslau M, et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med. 2012;367(19):1783–91."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4332983/results/search/disease/results.xml">
   <result pre="there are no published reports regarding treatment of lacrimal gland" exact="cancer" post="with Her-2 directed medications. This case report describes treatment"/>
   <result pre="thoracic spine, as well as bilateral lung nodules and thoracic" exact="lymphadenopathy" post="suggestive of systemic metastases. A biopsy was performed of"/>
   <result pre="felt to be indeterminate for progression of malignancy versus radiation" exact="myelitis" post="from prior radiotherapy. PET imaging was ordered to further"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4333494/results/search/disease/results.xml">
   <result pre="systemic therapy (NST). Patients and methods: Patients with primary HER2-positive" exact="breast cancer" post="treated with trastuzumab-based NST were categorised according to adjuvant"/>
   <result pre="therapy (NST). Patients and methods: Patients with primary HER2-positive breast" exact="cancer" post="treated with trastuzumab-based NST were categorised according to adjuvant"/>
   <result pre="Anderson Cancer Center was performed. Women with HER2-positive primary invasive" exact="breast cancer" post="who received trastuzumab-based NST from 2001 to 2012 were"/>
   <result pre="Cancer Center was performed. Women with HER2-positive primary invasive breast" exact="cancer" post="who received trastuzumab-based NST from 2001 to 2012 were"/>
   <result pre="endocrine therapy. pCR was defined as no evidence of invasive" exact="cancer" post="in the breast and lymph nodes (yT0/is,N0). Patient characteristics"/>
   <result pre="TX, USA). Results A total of 589 women with HER2-positive" exact="breast cancer" post="diagnosed between 2001 and 2012 were identified. Patients received"/>
   <result pre="USA). Results A total of 589 women with HER2-positive breast" exact="cancer" post="diagnosed between 2001 and 2012 were identified. Patients received"/>
   <result pre="published retrospective study evaluating the outcomes of patients with HER2-positive" exact="breast cancer" post="reported that 65 (8.4%) of the 776 patients in"/>
   <result pre="retrospective study evaluating the outcomes of patients with HER2-positive breast" exact="cancer" post="reported that 65 (8.4%) of the 776 patients in"/>
   <result pre="to find biomarkers capable of identifying those patients with HER2-positive" exact="breast cancer" post="who need less extensive or less complex therapies, and"/>
   <result pre="find biomarkers capable of identifying those patients with HER2-positive breast" exact="cancer" post="who need less extensive or less complex therapies, and"/>
   <result pre="NeoALTTO Study Team 2012 Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="Study Team 2012 Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive" exact="breast cancer" post="Cancer 118 (9 2385 2393 21953213 Buzdar AU Ibrahim"/>
   <result pre="trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast" exact="cancer" post="Cancer 118 (9 2385 2393 21953213 Buzdar AU Ibrahim"/>
   <result pre="randomized trial in human epidermal growth factor receptor 2-positive operable" exact="breast cancer" post="J Clin Oncol 23 (16 3676 3685 15738535 Buzdar"/>
   <result pre="trial in human epidermal growth factor receptor 2-positive operable breast" exact="cancer" post="J Clin Oncol 23 (16 3676 3685 15738535 Buzdar"/>
   <result pre="FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive" exact="breast cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast" exact="cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="of preoperative chemotherapy on the outcome of women with operable" exact="breast cancer" post="J Clin Oncol 16 (8 2672 2685 9704717 Gianni"/>
   <result pre="preoperative chemotherapy on the outcome of women with operable breast" exact="cancer" post="J Clin Oncol 16 (8 2672 2685 9704717 Gianni"/>
   <result pre="Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced" exact="breast cancer" post="(NOAH): follow-up of a randomised controlled superiority trial with"/>
   <result pre="and adjuvant trastuzumab in patients with HER2-positive locally advanced breast" exact="cancer" post="(NOAH): follow-up of a randomised controlled superiority trial with"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="2 years versus 1 year of adjuvant trastuzumab for HER2-positive" exact="breast cancer" post="(HERA): an open-label, randomised controlled trial Lancet 382 (9897"/>
   <result pre="years versus 1 year of adjuvant trastuzumab for HER2-positive breast" exact="cancer" post="(HERA): an open-label, randomised controlled trial Lancet 382 (9897"/>
   <result pre="with trastuzumab predicts for improved survival in women with HER2-overexpressing" exact="breast cancer" post="Ann Oncol 24 (8 1999 2004 23562929 Pivot X"/>
   <result pre="trastuzumab predicts for improved survival in women with HER2-overexpressing breast" exact="cancer" post="Ann Oncol 24 (8 1999 2004 23562929 Pivot X"/>
   <result pre="12 months of adjuvant trastuzumab for patients with HER2-positive early" exact="breast cancer" post="(PHARE): a randomised phase 3 trial Lancet Oncol 14"/>
   <result pre="months of adjuvant trastuzumab for patients with HER2-positive early breast" exact="cancer" post="(PHARE): a randomised phase 3 trial Lancet Oncol 14"/>
   <result pre="T Morita S Toi M 2014 Survival of HER2-positive primary" exact="breast cancer" post="patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter"/>
   <result pre="Morita S Toi M 2014 Survival of HER2-positive primary breast" exact="cancer" post="patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4335966/results/search/disease/results.xml">
   <result pre="between basic scientists and clinicians involved in the management of" exact="breast cancer." post="The symposium included six general sessions, poster discussion, and"/>
   <result pre="the fields of advancing endocrine therapy; hormone receptor positive advanced" exact="breast cancer" post="and hormonal resistant therapy; targeted therapies; genetics and genomics;"/>
   <result pre="fields of advancing endocrine therapy; hormone receptor positive advanced breast" exact="cancer" post="and hormonal resistant therapy; targeted therapies; genetics and genomics;"/>
   <result pre="supportive (adjunct) care; chemotherapy treatments; breast screening and risk stratification;" exact="male breast cancer" post="and future potential directions were included here. San Antonio"/>
   <result pre="(adjunct) care; chemotherapy treatments; breast screening and risk stratification; male" exact="breast cancer" post="and future potential directions were included here. San Antonio"/>
   <result pre="care; chemotherapy treatments; breast screening and risk stratification; male breast" exact="cancer" post="and future potential directions were included here. San Antonio"/>
   <result pre="resistance targeted therapy genetics and genomics supportive care clinical chemotherapy" exact="breast cancer" post="screening male breast cancer Original research presentations The latest"/>
   <result pre="targeted therapy genetics and genomics supportive care clinical chemotherapy breast" exact="cancer" post="screening male breast cancer Original research presentations The latest"/>
   <result pre="genetics and genomics supportive care clinical chemotherapy breast cancer screening" exact="male breast cancer" post="Original research presentations The latest updates on endocrine treatment"/>
   <result pre="and genomics supportive care clinical chemotherapy breast cancer screening male" exact="breast cancer" post="Original research presentations The latest updates on endocrine treatment"/>
   <result pre="genomics supportive care clinical chemotherapy breast cancer screening male breast" exact="cancer" post="Original research presentations The latest updates on endocrine treatment"/>
   <result pre="Original research presentations The latest updates on endocrine treatment of" exact="breast cancer" post="The conference provided significant advancement in the knowledge of"/>
   <result pre="research presentations The latest updates on endocrine treatment of breast" exact="cancer" post="The conference provided significant advancement in the knowledge of"/>
   <result pre="endocrine treatment in terms of long-term outcomes, applicability to lobular" exact="cancer" post="and the adjunct of ovarian suppression: Dr Jack Cuzick"/>
   <result pre="and colleagues presented the 16-year long-term follow-up of the IBIS-I" exact="breast cancer" post="prevention trial of 7154 pre and postmenopausal women randomised"/>
   <result pre="colleagues presented the 16-year long-term follow-up of the IBIS-I breast" exact="cancer" post="prevention trial of 7154 pre and postmenopausal women randomised"/>
   <result pre="1]. They described how tamoxifen reduced the incidence of all" exact="breast cancer" post="overall by 29% (hazard ratio (HR) = 0.71 (0.60–0.83),"/>
   <result pre="They described how tamoxifen reduced the incidence of all breast" exact="cancer" post="overall by 29% (hazard ratio (HR) = 0.71 (0.60–0.83),"/>
   <result pre="0.71) and years 10–20 (HR = 0.70). No differences in" exact="breast cancer" post="mortality were seen (24 tamoxifen versus 27 placebo; odds"/>
   <result pre="and years 10–20 (HR = 0.70). No differences in breast" exact="cancer" post="mortality were seen (24 tamoxifen versus 27 placebo; odds"/>
   <result pre="the survival advantage of anastrozole compared to tamoxifen in lobular" exact="breast cancer" post="in the ABCSG-8 study. They identified a significant improvement"/>
   <result pre="survival advantage of anastrozole compared to tamoxifen in lobular breast" exact="cancer" post="in the ABCSG-8 study. They identified a significant improvement"/>
   <result pre="a significant improvement in overall survival (OS) for invasive lobular" exact="cancer" post="treated with anastrozole compared to tamoxifen (HR 0.56, 95%CI"/>
   <result pre="a randomised comparison of adjuvant tamoxifen (T) plus ovarian function" exact="suppression" post="(OFS) versus tamoxifen in premenopausal women with hormone receptor-positive"/>
   <result pre="versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early" exact="breast cancer" post="(BC): analysis of the suppression of ovarian function (SOFT)"/>
   <result pre="tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast" exact="cancer" post="(BC): analysis of the suppression of ovarian function (SOFT)"/>
   <result pre="hormone receptor-positive (HR+) early breast cancer (BC): analysis of the" exact="suppression" post="of ovarian function (SOFT) trial [ 2]. A total"/>
   <result pre="premenopausal after chemotherapy experiencing a 4.5% absolute improvement in five-year" exact="breast cancer" post="free interval (BCFI) with T+OFS versus T. This suggests"/>
   <result pre="after chemotherapy experiencing a 4.5% absolute improvement in five-year breast" exact="cancer" post="free interval (BCFI) with T+OFS versus T. This suggests"/>
   <result pre="received chemotherapy and who remained premenopausal, the addition of ovarian" exact="suppression" post="improved breast cancer outcomes. Dr Karin Ribi from the"/>
   <result pre="and who remained premenopausal, the addition of ovarian suppression improved" exact="breast cancer" post="outcomes. Dr Karin Ribi from the International Breast Cancer"/>
   <result pre="who remained premenopausal, the addition of ovarian suppression improved breast" exact="cancer" post="outcomes. Dr Karin Ribi from the International Breast Cancer"/>
   <result pre="treatments were no longer apparent thereafter. Hormone receptor positive advanced" exact="breast cancer" post="and resistance to hormonal therapy The importance of the"/>
   <result pre="were no longer apparent thereafter. Hormone receptor positive advanced breast" exact="cancer" post="and resistance to hormonal therapy The importance of the"/>
   <result pre="The importance of the management of hormone receptor positive advanced" exact="breast cancer" post="and hormone resistance was one of the conference’s priorities,"/>
   <result pre="importance of the management of hormone receptor positive advanced breast" exact="cancer" post="and hormone resistance was one of the conference’s priorities,"/>
   <result pre="168 patients with ER positive, aromatase inhibitors(AI)-resistant advanced or metastatic" exact="breast cancer." post="They identified an overall progress-free survival (PFS) of 6.6"/>
   <result pre="in combination with bortezomib (proteasome inhibitor) in ER positive metastatic" exact="breast cancer" post="resistant to AI. Postmenopausal women with metastatic ER positive"/>
   <result pre="combination with bortezomib (proteasome inhibitor) in ER positive metastatic breast" exact="cancer" post="resistant to AI. Postmenopausal women with metastatic ER positive"/>
   <result pre="cancer resistant to AI. Postmenopausal women with metastatic ER positive" exact="cancer" post="resistant to AI were randomised either to fulvestrant alone"/>
   <result pre="trial: A correlative analysis of advanced oestrogen receptor (ER) positive" exact="breast cancer." post="They demonstrated by subgroup analysis of the fulvestrant 500mg"/>
   <result pre="versus anastrozole as first line endocrine monotherapy treatment for advanced" exact="breast cancer." post="A total of 205 postmenopausal ER positive patients were"/>
   <result pre="bispecific antibody (HER-2-TDB) for the treatment of HER-2 positive resistant" exact="breast cancer." post="The use of HER2-TDB can conditionally activate T-cells resulting"/>
   <result pre="can conditionally activate T-cells resulting in lysis of HER-2 expressing" exact="cancer" post="cells and because of its unique mechanism of action"/>
   <result pre="treatment of pertuzumab plus T-DM1 (monoclonal antibody therapy) in HER-2+" exact="breast cancer" post="cell lines as a preclinical model system. They aimed"/>
   <result pre="of pertuzumab plus T-DM1 (monoclonal antibody therapy) in HER-2+ breast" exact="cancer" post="cell lines as a preclinical model system. They aimed"/>
   <result pre="and paclitaxel as first-line therapy in women with HER-2+ advanced" exact="breast cancer." post="The rationale for the BOLERO-1 trial is trastuzumab resistance"/>
   <result pre="rationale for the BOLERO-1 trial is trastuzumab resistance in HER-2+" exact="breast cancer" post="is because of the hyperactivation of the PI3K/AKT/mTOR pathway."/>
   <result pre="for the BOLERO-1 trial is trastuzumab resistance in HER-2+ breast" exact="cancer" post="is because of the hyperactivation of the PI3K/AKT/mTOR pathway."/>
   <result pre="differs based on ER expression in patients with HER-2+ advanced" exact="breast cancer" post="in the absence of hormonal therapy. Dr M Rimawi"/>
   <result pre="based on ER expression in patients with HER-2+ advanced breast" exact="cancer" post="in the absence of hormonal therapy. Dr M Rimawi"/>
   <result pre="12 weeks versus 24 weeks in patients with HER-2 overexpressing" exact="breast cancer." post="No chemotherapy was given as this trial was based"/>
   <result pre="leads to a meaningful increase in pCR rate in ER+/HER-2+" exact="breast cancer" post="and warrants further study. Dr Soonmyung Paik on behalf"/>
   <result pre="to a meaningful increase in pCR rate in ER+/HER-2+ breast" exact="cancer" post="and warrants further study. Dr Soonmyung Paik on behalf"/>
   <result pre="(MK-3475) –a humanised IgG4, anti-PD-1 antibody- in advanced triple negative" exact="breast cancer." post="The PD-1 receptor-ligand pathway once activated can be used"/>
   <result pre="who were programmed death ligand 1 (PDL1) positive, advanced triple-negative" exact="breast cancer" post="(TNBC) and an overall response rate (ORR) of 18.5%"/>
   <result pre="were programmed death ligand 1 (PDL1) positive, advanced triple-negative breast" exact="cancer" post="(TNBC) and an overall response rate (ORR) of 18.5%"/>
   <result pre="alone in 73 patients with ER positive, HER-2 negative operable" exact="breast cancer" post="(OPPORTUNE study). They identified in their primary outcome measure"/>
   <result pre="in 73 patients with ER positive, HER-2 negative operable breast" exact="cancer" post="(OPPORTUNE study). They identified in their primary outcome measure"/>
   <result pre="They identified in their primary outcome measure a mean Ki67" exact="suppression" post="of 83.8% versus 66% for the pictilisib (plus anastrazole)"/>
   <result pre="forming a therapeutic target for anti-Notch therapy in ER positive" exact="breast cancer." post="Radiotherapy targeting: Dr Livi from Florence, Italy and colleagues"/>
   <result pre="40 years of age who were diagnosed with early stage" exact="breast cancer" post="were randomly assigned with a 1:1 ratio to either"/>
   <result pre="years of age who were diagnosed with early stage breast" exact="cancer" post="were randomly assigned with a 1:1 ratio to either"/>
   <result pre="of various PARP inhibitors at a preclinical level might allow" exact="breast cancer" post="research to take a step forward for their introduction"/>
   <result pre="various PARP inhibitors at a preclinical level might allow breast" exact="cancer" post="research to take a step forward for their introduction"/>
   <result pre="colleagues the prognostic effects of gene mutations in ER positive" exact="breast cancer" post="from a cohort of 636 patients treated with tamoxifen"/>
   <result pre="the prognostic effects of gene mutations in ER positive breast" exact="cancer" post="from a cohort of 636 patients treated with tamoxifen"/>
   <result pre="Research, London and colleagues assessed exome sequencing of post-menopausal ER-positive" exact="breast cancer" post="treated pre-surgically with AIs in the perioperative endocrine therapy"/>
   <result pre="London and colleagues assessed exome sequencing of post-menopausal ER-positive breast" exact="cancer" post="treated pre-surgically with AIs in the perioperative endocrine therapy"/>
   <result pre="with colleagues performed a comprehensive analysis of genomic alterations in" exact="breast cancer" post="progression (hormone-resistant recurrence). They identified a novel fusion gene"/>
   <result pre="colleagues performed a comprehensive analysis of genomic alterations in breast" exact="cancer" post="progression (hormone-resistant recurrence). They identified a novel fusion gene"/>
   <result pre="genomic alterations revealing key recurrent mutational differences between invasive lobular" exact="breast cancer" post="(FOXA1) from invasive ductal breast cancer (GATA3) tumourigenesis and"/>
   <result pre="alterations revealing key recurrent mutational differences between invasive lobular breast" exact="cancer" post="(FOXA1) from invasive ductal breast cancer (GATA3) tumourigenesis and"/>
   <result pre="differences between invasive lobular breast cancer (FOXA1) from invasive ductal" exact="breast cancer" post="(GATA3) tumourigenesis and a potential therapeutic target for invasive"/>
   <result pre="between invasive lobular breast cancer (FOXA1) from invasive ductal breast" exact="cancer" post="(GATA3) tumourigenesis and a potential therapeutic target for invasive"/>
   <result pre="(GATA3) tumourigenesis and a potential therapeutic target for invasive lobular" exact="breast cancer" post="(Akt). These findings provide further insight into the molecular"/>
   <result pre="tumourigenesis and a potential therapeutic target for invasive lobular breast" exact="cancer" post="(Akt). These findings provide further insight into the molecular"/>
   <result pre="provide further insight into the molecular heterogeneity of ER positive" exact="breast cancer." post="Dr Christine Desmedt from the University of Brussels, Belgium"/>
   <result pre="were more frequently mutated in ER positive/HER-2 negative invasive lobular" exact="cancer" post="( n = 451) compared to the ER positive/HER-2"/>
   <result pre="= 451) compared to the ER positive/HER-2 negative invasive ductal" exact="cancer" post="( n = 266) from The Cancer Genome Atlas,"/>
   <result pre="mutated. This provided an inisight into genomic alterations in lobular" exact="cancer" post="and also avenues for targeted therapeutic responses. Dr Christos"/>
   <result pre="their assessment of the principles governing A-to-I RNA editing in" exact="breast cancer" post="transcriptome. The exome and transcriptome of 58 breast cancer"/>
   <result pre="assessment of the principles governing A-to-I RNA editing in breast" exact="cancer" post="transcriptome. The exome and transcriptome of 58 breast cancer"/>
   <result pre="in breast cancer transcriptome. The exome and transcriptome of 58" exact="breast cancer" post="samples representing the four main known subtypes, namely TN,"/>
   <result pre="breast cancer transcriptome. The exome and transcriptome of 58 breast" exact="cancer" post="samples representing the four main known subtypes, namely TN,"/>
   <result pre="that A-to-I editing is a pervasive and well-controlled phenomenon in" exact="cancer" post="that can drive aberrant transcriptome expression in breast and"/>
   <result pre="Boston, MA and colleagues focused their research on replication stress" exact="suppression" post="leading to a predisposition to hereditary breast cancer. They"/>
   <result pre="on replication stress suppression leading to a predisposition to hereditary" exact="breast cancer." post="They carried out a study on fibroblasts and mammary"/>
   <result pre="to standard supportive care alone in anaemic patients with metastatic" exact="breast cancer" post="receiving standard chemotherapy. The study aimed to rule out"/>
   <result pre="standard supportive care alone in anaemic patients with metastatic breast" exact="cancer" post="receiving standard chemotherapy. The study aimed to rule out"/>
   <result pre="in the 1st and 2nd line chemotherapy treatment of metastatic" exact="breast cancer," post="transfusion would be the preferred approach. If the EPO"/>
   <result pre="(WINS). They aimed to evaluate dietary fat reduction as adjuvant" exact="breast cancer" post="therapy. A total of 2437 patients diagnosed with early"/>
   <result pre="They aimed to evaluate dietary fat reduction as adjuvant breast" exact="cancer" post="therapy. A total of 2437 patients diagnosed with early"/>
   <result pre="therapy. A total of 2437 patients diagnosed with early stage" exact="breast cancer" post="were randomly assigned 60:40 within one year after surgery"/>
   <result pre="A total of 2437 patients diagnosed with early stage breast" exact="cancer" post="were randomly assigned 60:40 within one year after surgery"/>
   <result pre="as part of neoadjuvant chemotherapy in 1200 patients with early" exact="breast cancer." post="The team identified that whilst the side-effect profile of"/>
   <result pre="of Adriamycin and cyclophosphamide (AC) in patients with node negative" exact="breast cancer." post="They did not identify a significant difference between the"/>
   <result pre="weekly in patients with axillary node-positive or high risk node-negative" exact="breast cancer" post="[ 7]. They were unable to identify a significant"/>
   <result pre="in patients with axillary node-positive or high risk node-negative breast" exact="cancer" post="[ 7]. They were unable to identify a significant"/>
   <result pre="without capecitabine in elderly patients with moderate or high-risk early" exact="breast cancer." post="They identified no difference in DFS at five years"/>
   <result pre="her colleagues upon stromal tumour-infiltrating lymphocytes (S-TILS) in HER-2 positive" exact="breast cancer" post="demonstrated that lymphocyte predominant (LPBC) HER-2 positive breast cancer"/>
   <result pre="colleagues upon stromal tumour-infiltrating lymphocytes (S-TILS) in HER-2 positive breast" exact="cancer" post="demonstrated that lymphocyte predominant (LPBC) HER-2 positive breast cancer"/>
   <result pre="positive breast cancer demonstrated that lymphocyte predominant (LPBC) HER-2 positive" exact="breast cancer" post="when treated with chemotherapy alone was associated with a"/>
   <result pre="breast cancer demonstrated that lymphocyte predominant (LPBC) HER-2 positive breast" exact="cancer" post="when treated with chemotherapy alone was associated with a"/>
   <result pre="and trastuzumab (H) with or without lapatinib (L) for HER-2-positive" exact="breast cancer," post="in which they identified the presence of a TP53"/>
   <result pre="spectroscopic imaging (DOSI) in predicting pre-surgical neoadjuvant chemotherapy response in" exact="breast cancer." post="They used this to evaluate whether changes from baseline"/>
   <result pre="a DOSI-derived tissue optical index (TOI) could predict pCR in" exact="breast cancer" post="neoadjuvant chemotherapy (NACT). Using -40% as a threshold for"/>
   <result pre="DOSI-derived tissue optical index (TOI) could predict pCR in breast" exact="cancer" post="neoadjuvant chemotherapy (NACT). Using -40% as a threshold for"/>
   <result pre="of immune evasion and outcome in TNBC. New approaches to" exact="breast cancer" post="screening and risk stratification of in situ disease The"/>
   <result pre="immune evasion and outcome in TNBC. New approaches to breast" exact="cancer" post="screening and risk stratification of in situ disease The"/>
   <result pre="breast tissue) with additional ultrasound. She showed a stable incremental" exact="cancer" post="detection of 3.2/1000 and an increased positive predictive value"/>
   <result pre="the first year to 17.2 by the fourth year. The" exact="cancer" post="detection rate were continued at the same rate/1000 over"/>
   <result pre="as 50% and this plays a major role in masking" exact="breast cancer" post="during mammography. Notification law has been enacted in 19"/>
   <result pre="50% and this plays a major role in masking breast" exact="cancer" post="during mammography. Notification law has been enacted in 19"/>
   <result pre="in a reduction in recall rate and 30–50% increase in" exact="cancer" post="detection, but long-term follow-up is required. Dr Lipson concluded"/>
   <result pre="that the benefits of additional screening measures are the increased" exact="cancer" post="detection rate, whilst limitations of elevated false positive rates–much"/>
   <result pre="behalf of colleagues a population-based validation study of the ductal" exact="carcinoma in situ" post="(DCIS) score predicting recurrence risk in individuals treated by"/>
   <result pre="and may help in risk stratification of DCIS patients. Male" exact="breast cancer" post="Advancements in the characterisation and genomic mapping of male"/>
   <result pre="may help in risk stratification of DCIS patients. Male breast" exact="cancer" post="Advancements in the characterisation and genomic mapping of male"/>
   <result pre="breast cancer Advancements in the characterisation and genomic mapping of" exact="male breast cancer" post="were discussed. Dr Fatima Cardoso from Champalimaud Cancer Centre,"/>
   <result pre="cancer Advancements in the characterisation and genomic mapping of male" exact="breast cancer" post="were discussed. Dr Fatima Cardoso from Champalimaud Cancer Centre,"/>
   <result pre="Advancements in the characterisation and genomic mapping of male breast" exact="cancer" post="were discussed. Dr Fatima Cardoso from Champalimaud Cancer Centre,"/>
   <result pre="median age at diagnosis for males was 68.4 years and" exact="male breast cancer" post="received more aggressive surgical intervention (96% of mastectomies and"/>
   <result pre="age at diagnosis for males was 68.4 years and male" exact="breast cancer" post="received more aggressive surgical intervention (96% of mastectomies and"/>
   <result pre="at diagnosis for males was 68.4 years and male breast" exact="cancer" post="received more aggressive surgical intervention (96% of mastectomies and"/>
   <result pre="and 15% of N2 patients did not receive it. Male" exact="breast cancer" post="presents usually as luminal A like subtype, 88% express"/>
   <result pre="15% of N2 patients did not receive it. Male breast" exact="cancer" post="presents usually as luminal A like subtype, 88% express"/>
   <result pre="negative, and 9% HER-2 positive. A total of 77% of" exact="male breast cancer" post="is treated by adjuvant endocrine therapy—mainly tamoxifen (88%)– and"/>
   <result pre="and 9% HER-2 positive. A total of 77% of male" exact="breast cancer" post="is treated by adjuvant endocrine therapy—mainly tamoxifen (88%)– and"/>
   <result pre="9% HER-2 positive. A total of 77% of male breast" exact="cancer" post="is treated by adjuvant endocrine therapy—mainly tamoxifen (88%)– and"/>
   <result pre="a platform containing the genes most frequently mutated in female" exact="breast cancer" post="and genes involved in DNA repair. On the gene"/>
   <result pre="platform containing the genes most frequently mutated in female breast" exact="cancer" post="and genes involved in DNA repair. On the gene"/>
   <result pre="repair. On the gene analysis of 59 patients diagnosed with" exact="male breast cancer," post="they found that the ER positive subgroup is characterised"/>
   <result pre="On the gene analysis of 59 patients diagnosed with male" exact="breast cancer," post="they found that the ER positive subgroup is characterised"/>
   <result pre="compared to luminal A cancers. From a comparative analysis of" exact="male breast cancer" post="and luminal female breast cancer, it has emerged that"/>
   <result pre="to luminal A cancers. From a comparative analysis of male" exact="breast cancer" post="and luminal female breast cancer, it has emerged that"/>
   <result pre="luminal A cancers. From a comparative analysis of male breast" exact="cancer" post="and luminal female breast cancer, it has emerged that"/>
   <result pre="a comparative analysis of male breast cancer and luminal female" exact="breast cancer," post="it has emerged that PI3K and TP53 mutations are"/>
   <result pre="copy alterations. Reis-Filho and colleagues concluded that genes mutated in" exact="male breast cancer" post="are enriched for DNA repair-related genes and hypothesised that"/>
   <result pre="alterations. Reis-Filho and colleagues concluded that genes mutated in male" exact="breast cancer" post="are enriched for DNA repair-related genes and hypothesised that"/>
   <result pre="Reis-Filho and colleagues concluded that genes mutated in male breast" exact="cancer" post="are enriched for DNA repair-related genes and hypothesised that"/>
   <result pre="thought-provoking lecture on the genomic analysis of inherited breast and" exact="ovarian cancer" post="calling for a population-based screening approach to BRCA1 and"/>
   <result pre="lecture on the genomic analysis of inherited breast and ovarian" exact="cancer" post="calling for a population-based screening approach to BRCA1 and"/>
   <result pre="BRCA2 mutations have no close family history of breast or" exact="ovarian cancer." post="Concluding that every breast and ovarian patient with a"/>
   <result pre="And Localizer of BRCA2) was presented as a new high-risk" exact="breast cancer" post="gene identified and the reasons why it should be"/>
   <result pre="Localizer of BRCA2) was presented as a new high-risk breast" exact="cancer" post="gene identified and the reasons why it should be"/>
   <result pre="added to genetic testing for BRCA1/BRCA2 were clearly explained. Breast" exact="cancer" post="intra-tumoural heterogeneity was confirmed as a common phenomenon and"/>
   <result pre="prevention of breast cancer: extended long-term follow-up of the IBIS-I" exact="breast cancer" post="prevention trial Lancet Oncol 2014 14 71171 4 10.1016/S1470-2045"/>
   <result pre="of breast cancer: extended long-term follow-up of the IBIS-I breast" exact="cancer" post="prevention trial Lancet Oncol 2014 14 71171 4 10.1016/S1470-2045"/>
   <result pre="F et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced" exact="breast cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Lancet"/>
   <result pre="et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast" exact="cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Lancet"/>
   <result pre="JA et al. Weekly paclitaxel in the adjuvant treatment of" exact="breast cancer" post="N Engl J Med 2008 358 1 1663 71"/>
   <result pre="et al. Weekly paclitaxel in the adjuvant treatment of breast" exact="cancer" post="N Engl J Med 2008 358 1 1663 71"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4339844/results/search/disease/results.xml">
   <result pre="trastuzumab is a major problem in the treatment of HER2-positive" exact="breast cancer." post="A deeper understanding of the underlying mechanisms could help"/>
   <result pre="polymorphisms (SNPs) affecting trastuzumab efficiency in cell culture. Three HER2-positive" exact="breast cancer" post="cell lines with different resistance phenotypes were analyzed. We"/>
   <result pre="(SNPs) affecting trastuzumab efficiency in cell culture. Three HER2-positive breast" exact="cancer" post="cell lines with different resistance phenotypes were analyzed. We"/>
   <result pre="and its Supporting Information files. Introduction The ‘HER2-positive’ subtype of" exact="breast cancer" post="overexpresses the human epidermal growth factor receptor 2 (HER2)."/>
   <result pre="its Supporting Information files. Introduction The ‘HER2-positive’ subtype of breast" exact="cancer" post="overexpresses the human epidermal growth factor receptor 2 (HER2)."/>
   <result pre="of the adjuvant treatment of patients with HER2-positive (HER2+) early" exact="breast cancer" post="[ 4]. The improved outcome by adding trastuzumab to"/>
   <result pre="the adjuvant treatment of patients with HER2-positive (HER2+) early breast" exact="cancer" post="[ 4]. The improved outcome by adding trastuzumab to"/>
   <result pre="angiogenesis. Although trastuzumab provides clinical benefit to women with HER2+" exact="breast cancer," post="not all patients respond [ 6]. Primary or acquired"/>
   <result pre="literature. The remaining ones, partially known to be involved in" exact="breast cancer," post="could also contribute to novel strategies preventing trastuzumab resistance."/>
   <result pre="patient stratification. Materials and Methods Cell lines Three human HER2-amplified" exact="breast cancer" post="cell lines (BT474, HCC1954 and BTR50) were chosen as"/>
   <result pre="stratification. Materials and Methods Cell lines Three human HER2-amplified breast" exact="cancer" post="cell lines (BT474, HCC1954 and BTR50) were chosen as"/>
   <result pre="cell pellet using the miRNeasy kit (Qiagen). BT474 The human" exact="breast cancer" post="cell line BT474 was directly obtained from the American"/>
   <result pre="pellet using the miRNeasy kit (Qiagen). BT474 The human breast" exact="cancer" post="cell line BT474 was directly obtained from the American"/>
   <result pre="cells were split three times per week. HCC1954 The human" exact="breast cancer" post="cell line HCC1954 was directly obtained from ATCC, catalogue"/>
   <result pre="were split three times per week. HCC1954 The human breast" exact="cancer" post="cell line HCC1954 was directly obtained from ATCC, catalogue"/>
   <result pre="Resistant cells (BTR) were developed by culturing the epithelial BT474" exact="breast cancer" post="cells (wild type, wt) in the presence of 50"/>
   <result pre="cells (BTR) were developed by culturing the epithelial BT474 breast" exact="cancer" post="cells (wild type, wt) in the presence of 50"/>
   <result pre="data, we performed DE analyses on six samples, i.e. the" exact="breast cancer" post="cell lines BT474, HCC1954 and BTR50 with and without"/>
   <result pre="we performed DE analyses on six samples, i.e. the breast" exact="cancer" post="cell lines BT474, HCC1954 and BTR50 with and without"/>
   <result pre="discovered 54 genes that might determine trastuzumab efficiency in HER2+" exact="breast cancer" post="cell lines. Annotation and functional association of the candidate"/>
   <result pre="54 genes that might determine trastuzumab efficiency in HER2+ breast" exact="cancer" post="cell lines. Annotation and functional association of the candidate"/>
   <result pre="kit (Applied Biosystems, Darmstadt, Germany) from total RNA isolated from" exact="breast cancer" post="cell lines. Primer combinations for the respective genes were"/>
   <result pre="(Applied Biosystems, Darmstadt, Germany) from total RNA isolated from breast" exact="cancer" post="cell lines. Primer combinations for the respective genes were"/>
   <result pre="literature support for association of genes with trastuzumab efficiency or" exact="breast cancer." post="Six of the candidate genes were selected from the"/>
   <result pre="phosphatase (PLAP) which is known as a tumor marker in" exact="seminoma" post="and ovarian cancer [ 28]. CYP1A2 (cytochrome P450, family"/>
   <result pre="which is known as a tumor marker in seminoma and" exact="ovarian cancer" post="[ 28]. CYP1A2 (cytochrome P450, family 1, subfamily A,"/>
   <result pre="is known as a tumor marker in seminoma and ovarian" exact="cancer" post="[ 28]. CYP1A2 (cytochrome P450, family 1, subfamily A,"/>
   <result pre="be modulated by specific polymorphisms, is already supposed to influence" exact="breast cancer," post="as it is involved in breast carcinogen activation on"/>
   <result pre="suppressor efficacy may be related to a HER2 downregulation in" exact="breast cancer" post="cells, CAV1 and caveolae deficiency might be preferable under"/>
   <result pre="efficacy may be related to a HER2 downregulation in breast" exact="cancer" post="cells, CAV1 and caveolae deficiency might be preferable under"/>
   <result pre="treatment [ 30]. Based on observations in the HER2+ human" exact="breast cancer" post="cell line SKBR3, in which CAV1 was stably transduced,"/>
   <result pre="[ 30]. Based on observations in the HER2+ human breast" exact="cancer" post="cell line SKBR3, in which CAV1 was stably transduced,"/>
   <result pre="analyzed its expression in public available data from the transNOAH" exact="breast cancer" post="trial (GEO series GSE50948) [ 31]. The original NeOAdjuvant"/>
   <result pre="its expression in public available data from the transNOAH breast" exact="cancer" post="trial (GEO series GSE50948) [ 31]. The original NeOAdjuvant"/>
   <result pre="of trastuzumab addition to treatment with neoadjuvant chemotherapy in HER2+" exact="breast cancer" post="patients [ 32]. We selected 11 patient samples with"/>
   <result pre="trastuzumab addition to treatment with neoadjuvant chemotherapy in HER2+ breast" exact="cancer" post="patients [ 32]. We selected 11 patient samples with"/>
   <result pre="(gray). The patient data samples were selected from the transNOAH" exact="breast cancer" post="trial (GEO series GSE50948). For IGFBP3, an insulin-like growth"/>
   <result pre="The patient data samples were selected from the transNOAH breast" exact="cancer" post="trial (GEO series GSE50948). For IGFBP3, an insulin-like growth"/>
   <result pre="HER2 and IGF-IR pathways via rhIGFBP3 plus trastuzumab for HER2+" exact="breast cancer" post="patients. Lu et al. also reported a relation between"/>
   <result pre="and IGF-IR pathways via rhIGFBP3 plus trastuzumab for HER2+ breast" exact="cancer" post="patients. Lu et al. also reported a relation between"/>
   <result pre="a relation between IGF-IR signaling and trastuzumab resistance in HER2+" exact="breast cancer" post="cell models [ 36]. Their explanation for enhanced trastuzumab-induced"/>
   <result pre="relation between IGF-IR signaling and trastuzumab resistance in HER2+ breast" exact="cancer" post="cell models [ 36]. Their explanation for enhanced trastuzumab-induced"/>
   <result pre="keratin 81 -9.53 4.6e-02 LCN2 lipocalin 2 -8.34 4.6e-02 LIF" exact="leukemia" post="inhibitory factor -9.29 4.9e-02 MYEOV myeloma overexpressed -9.44 4.6e-02"/>
   <result pre="A9 -8.45 4.6e-02 TGM2 transglutaminase 2 -9.29 4.6e-02 TINAGL1 tubulointerstitial" exact="nephritis" post="antigen-like 1 -8.55 4.6e-02 AFF3 AF4/FMR2 family member 3"/>
   <result pre="member 12 9.79 4.6e-02 GREB1 growth regulation by estrogen in" exact="breast cancer" post="1 8.62 4.6e-02 NCAM2 neural cell adhesion molecule 2"/>
   <result pre="12 9.79 4.6e-02 GREB1 growth regulation by estrogen in breast" exact="cancer" post="1 8.62 4.6e-02 NCAM2 neural cell adhesion molecule 2"/>
   <result pre="genes of this group more generally in the context of" exact="breast cancer." post="Upregulated genes in HCC1954 compared to BT474 IL8 (interleukin"/>
   <result pre="participate in an inflammatory loop, mediating trastuzumab resistance in HER2+" exact="breast cancer" post="by expanding the cancer stem cell population [ 38]."/>
   <result pre="in an inflammatory loop, mediating trastuzumab resistance in HER2+ breast" exact="cancer" post="by expanding the cancer stem cell population [ 38]."/>
   <result pre="mediating trastuzumab resistance in HER2+ breast cancer by expanding the" exact="cancer" post="stem cell population [ 38]. This loop implies AKT"/>
   <result pre="overexpression was shown to correlate with HER2 oncogene amplification in" exact="breast cancer" post="[ 39]. Wang et al. also reported that nuclear"/>
   <result pre="was shown to correlate with HER2 oncogene amplification in breast" exact="cancer" post="[ 39]. Wang et al. also reported that nuclear"/>
   <result pre="with t10c12 conjugated linoleic acid (CLA) and observed a HER2" exact="suppression" post="as well as enhanced apoptosis [ 41]. This confirmed"/>
   <result pre="feedback loop. Indeed, PTGS2 inhibition reduced HER2 protein levels, increased" exact="cancer" post="cells sensitivity to chemotherapeutic treatment and acted synergistically with"/>
   <result pre="prostaglandins are known to promote angiogenesis and invasiveness of diverse" exact="cancer" post="types. We inferred the GO term ‘positive regulation of"/>
   <result pre="PTGS2 inhibition decreased cell growth and promoted apoptosis in metastatic" exact="breast cancer" post="[ 46]. Indeed, PTGS2 is known to positively regulate"/>
   <result pre="inhibition decreased cell growth and promoted apoptosis in metastatic breast" exact="cancer" post="[ 46]. Indeed, PTGS2 is known to positively regulate"/>
   <result pre="is assumed between overexpression of HER2 and PTGS2 activity in" exact="breast cancer," post="Gianni speculated that a combination of PTGS2 inhibitors with"/>
   <result pre="study, Dang et al. tested a combined treatment of metastatic" exact="breast cancer" post="patients who have progressed after prior trastuzumab-based treatments with"/>
   <result pre="Dang et al. tested a combined treatment of metastatic breast" exact="cancer" post="patients who have progressed after prior trastuzumab-based treatments with"/>
   <result pre="PTGS2 inhibitor [ 48], which already showed promising results in" exact="colorectal cancer" post="[ 49]. Unfortunately, they revealed that the combination was"/>
   <result pre="inhibitor [ 48], which already showed promising results in colorectal" exact="cancer" post="[ 49]. Unfortunately, they revealed that the combination was"/>
   <result pre="analogs to increase endoplasmic reticulum stress and toxicity in human" exact="breast cancer" post="cell lines that were resistant to trastuzumab [ 50]."/>
   <result pre="to increase endoplasmic reticulum stress and toxicity in human breast" exact="cancer" post="cell lines that were resistant to trastuzumab [ 50]."/>
   <result pre="copy number of PTGS2 with objective trastuzumab response in metastatic" exact="breast cancer" post="[ 51]. GDF15 (growth differentiation factor 15) was overexpressed"/>
   <result pre="number of PTGS2 with objective trastuzumab response in metastatic breast" exact="cancer" post="[ 51]. GDF15 (growth differentiation factor 15) was overexpressed"/>
   <result pre="al. observed GDF15-mediated HER2 phosphorylation reducing trastuzumab sensitivity of HER2+" exact="breast cancer" post="cells [ 52]. They regarded GDF15-mediated activation of TGF-"/>
   <result pre="observed GDF15-mediated HER2 phosphorylation reducing trastuzumab sensitivity of HER2+ breast" exact="cancer" post="cells [ 52]. They regarded GDF15-mediated activation of TGF-"/>
   <result pre="in HCC1954 have already been mentioned in the context of" exact="breast cancer," post="mainly as tumor promoters. Regarding AKR1C1 (aldo-keto reductase family"/>
   <result pre="activation, which plays an essential role in breast development and" exact="cancer" post="formation. This fits to our observation that AKR1C1 was"/>
   <result pre="(myeloma overexpressed), which DNA amplification correlated with ER+ and PR+" exact="cancer" post="in a study of Janssen et al. [ 56]."/>
   <result pre="overexpression was a predictor of reduced DFS and OS in" exact="breast cancer," post="and hence a marker of poor prognosis. They regarded"/>
   <result pre="general downregulated with a similar pattern of differential expression in" exact="breast cancer" post="[ 62]. A promoting effect on tumorigenesis and metastasis"/>
   <result pre="downregulated with a similar pattern of differential expression in breast" exact="cancer" post="[ 62]. A promoting effect on tumorigenesis and metastasis"/>
   <result pre="[ 62]. A promoting effect on tumorigenesis and metastasis of" exact="breast cancer" post="via the AKT/mTOR signaling pathway, independent of ER status,"/>
   <result pre="62]. A promoting effect on tumorigenesis and metastasis of breast" exact="cancer" post="via the AKT/mTOR signaling pathway, independent of ER status,"/>
   <result pre="overexpression has been observed in several types of cancers including" exact="breast cancer" post="and is associated with a poorer relapse-free survival. They"/>
   <result pre="has been observed in several types of cancers including breast" exact="cancer" post="and is associated with a poorer relapse-free survival. They"/>
   <result pre="They showed that LIF promotes cell proliferation and growth of" exact="breast cancer" post="cells in vitro, and growth of xenograft breast tumors"/>
   <result pre="showed that LIF promotes cell proliferation and growth of breast" exact="cancer" post="cells in vitro, and growth of xenograft breast tumors"/>
   <result pre="tumors in vivo. Furthermore it promoted invasion and migration of" exact="breast cancer" post="cells in vitro and metastasis of breast cancer in"/>
   <result pre="in vivo. Furthermore it promoted invasion and migration of breast" exact="cancer" post="cells in vitro and metastasis of breast cancer in"/>
   <result pre="migration of breast cancer cells in vitro and metastasis of" exact="breast cancer" post="in vivo. A further gene upregulated in HCC1954 was"/>
   <result pre="of breast cancer cells in vitro and metastasis of breast" exact="cancer" post="in vivo. A further gene upregulated in HCC1954 was"/>
   <result pre="loop. Above that TG2 expression induces epithelial-to-mesenchymal transition and confers" exact="cancer" post="stem cell trait, both of which have been implicated"/>
   <result pre="to dominate. Its expression is elevated in advanced stages of" exact="breast cancer," post="and Chen et al. observed enhanced cellular migratory ability"/>
   <result pre="and Chen et al. observed enhanced cellular migratory ability in" exact="breast cancer" post="cells overexpressing CTGF [ 65]. According to them, CTGF"/>
   <result pre="Chen et al. observed enhanced cellular migratory ability in breast" exact="cancer" post="cells overexpressing CTGF [ 65]. According to them, CTGF"/>
   <result pre="metastasis or related CTGF to angiogenesis and bone metastasis in" exact="breast cancer." post="Interestingly, Chen et al. detected extremely low or no"/>
   <result pre="found an association between S100A9, a protein expressed in invasive" exact="breast cancer," post="with basal subtypes as well as corresponding poor differentiation"/>
   <result pre="that PTRF (cavin-1) and caveolin 1 are lost coordinately in" exact="cancer" post="cells [ 67]. Membrane recruitment of the cavin complex"/>
   <result pre="as a tumor suppressor or as an oncogene, but in" exact="breast cancer" post="they assumed a tumor suppressor role, since CLDN1 is"/>
   <result pre="a tumor suppressor or as an oncogene, but in breast" exact="cancer" post="they assumed a tumor suppressor role, since CLDN1 is"/>
   <result pre="which showed low CLDN1 expression. According to their results, in" exact="breast cancer," post="CLDN1 expression varies according to the molecular subtype. While"/>
   <result pre="of the CLDN1 promoter CpG island was frequent in ER+" exact="breast cancer," post="it was not the case in most of the"/>
   <result pre="status, as dysadherin is expressed in the more aggressive ER-" exact="breast cancer" post="[ 70]. In their study the introduction of dysadherin"/>
   <result pre="as dysadherin is expressed in the more aggressive ER- breast" exact="cancer" post="[ 70]. In their study the introduction of dysadherin"/>
   <result pre="predictor of metastasis, invasion and poor prognosis, might contribute to" exact="breast cancer" post="progression through ER-dependent AKT activation. Upregulated genes in BT474"/>
   <result pre="of metastasis, invasion and poor prognosis, might contribute to breast" exact="cancer" post="progression through ER-dependent AKT activation. Upregulated genes in BT474"/>
   <result pre="composed of ER+ tumors, demonstrates a better prognosis than other" exact="breast cancer" post="subtypes and is characterized by overexpression of estrogen-related genes"/>
   <result pre="of ER+ tumors, demonstrates a better prognosis than other breast" exact="cancer" post="subtypes and is characterized by overexpression of estrogen-related genes"/>
   <result pre="with low histological grade. Nevertheless, they speculated that in invasive" exact="cancer" post="the positive characteristics of TFF3 turn into oncogenic ones"/>
   <result pre="is known to be coexpressed with TFF3 in ER+ malignant" exact="breast cancer" post="cells and is likewise upregulated by estrogens. Although TFF1"/>
   <result pre="known to be coexpressed with TFF3 in ER+ malignant breast" exact="cancer" post="cells and is likewise upregulated by estrogens. Although TFF1"/>
   <result pre="components of a luminal epithelial signature defining a well-differentiated, low-grade" exact="breast cancer" post="subtype [ 74]. The upregulation of NRCAM (neuronal cell"/>
   <result pre="of a luminal epithelial signature defining a well-differentiated, low-grade breast" exact="cancer" post="subtype [ 74]. The upregulation of NRCAM (neuronal cell"/>
   <result pre="too. This gene was reported to be expressed in ER+" exact="breast cancer" post="cell lines but not in ER- ones [ 75]."/>
   <result pre="This gene was reported to be expressed in ER+ breast" exact="cancer" post="cell lines but not in ER- ones [ 75]."/>
   <result pre="upregulated in BT474 was GREB1 (growth regulation by estrogen in" exact="breast cancer" post="1). It is an important factor in ER induced"/>
   <result pre="in BT474 was GREB1 (growth regulation by estrogen in breast" exact="cancer" post="1). It is an important factor in ER induced"/>
   <result pre="It is an important factor in ER induced proliferation in" exact="breast cancer" post="cells [ 76]. Liu et al. reported that overexpression"/>
   <result pre="is an important factor in ER induced proliferation in breast" exact="cancer" post="cells [ 76]. Liu et al. reported that overexpression"/>
   <result pre="the ER cofactor GREB1 also increased the clonogenic ability in" exact="breast cancer" post="cells and that overexpression was observed in ER+ breast"/>
   <result pre="ER cofactor GREB1 also increased the clonogenic ability in breast" exact="cancer" post="cells and that overexpression was observed in ER+ breast"/>
   <result pre="breast cancer cells and that overexpression was observed in ER+" exact="breast cancer" post="patients compared to ER- ones [ 77]. They stressed"/>
   <result pre="cancer cells and that overexpression was observed in ER+ breast" exact="cancer" post="patients compared to ER- ones [ 77]. They stressed"/>
   <result pre="levels of GREB1 are predictive of worse disease outcome for" exact="breast cancer" post="patients in general, and for ER+ patients in particular."/>
   <result pre="of GREB1 are predictive of worse disease outcome for breast" exact="cancer" post="patients in general, and for ER+ patients in particular."/>
   <result pre="more deeply in literature, even less in the context of" exact="breast cancer." post="10.1371/journal.pone.0117818.t003 Table 3 SNPs called in the HCC1954 cell"/>
   <result pre="HER2, Einarsdóttir et al. did not observe an association with" exact="breast cancer" post="survival [ 80]. Analogously, Benusiglio et al. analyzed whether"/>
   <result pre="Einarsdóttir et al. did not observe an association with breast" exact="cancer" post="survival [ 80]. Analogously, Benusiglio et al. analyzed whether"/>
   <result pre="common polymorphisms (frequency ≥ 5%) in HER2 were associated with" exact="breast cancer" post="risk in a white British population [ 81]. Although"/>
   <result pre="polymorphisms (frequency ≥ 5%) in HER2 were associated with breast" exact="cancer" post="risk in a white British population [ 81]. Although"/>
   <result pre="there was no evidence that these variations were associated with" exact="breast cancer." post="Breyer et al. analyzed the role of genetic variation"/>
   <result pre="the role of genetic variation of the HER2 gene in" exact="breast cancer" post="risk in a study of invasive breast cancer cases"/>
   <result pre="role of genetic variation of the HER2 gene in breast" exact="cancer" post="risk in a study of invasive breast cancer cases"/>
   <result pre="gene in breast cancer risk in a study of invasive" exact="breast cancer" post="cases from the Shanghai Breast Cancer Study [ 82]."/>
   <result pre="in breast cancer risk in a study of invasive breast" exact="cancer" post="cases from the Shanghai Breast Cancer Study [ 82]."/>
   <result pre="did not observe an association of the SNP haplotypes with" exact="breast cancer" post="predisposition. For PTGS2 we detected the polymorphism rs5275 in"/>
   <result pre="not observe an association of the SNP haplotypes with breast" exact="cancer" post="predisposition. For PTGS2 we detected the polymorphism rs5275 in"/>
   <result pre="value on clinical outcome, i.e. risk of tumor recurrence, of" exact="breast cancer" post="[ 83]. Their study involved women under treatment for"/>
   <result pre="on clinical outcome, i.e. risk of tumor recurrence, of breast" exact="cancer" post="[ 83]. Their study involved women under treatment for"/>
   <result pre="[ 83]. Their study involved women under treatment for non-metastatic" exact="breast cancer" post="who were genotyped for rs689465, rs689466, rs20417 and rs5275."/>
   <result pre="83]. Their study involved women under treatment for non-metastatic breast" exact="cancer" post="who were genotyped for rs689465, rs689466, rs20417 and rs5275."/>
   <result pre="found no associations between rs5275 and DFS or OS of" exact="breast cancer" post="patients. Above that two breast cancer meta-analyses indicated no"/>
   <result pre="no associations between rs5275 and DFS or OS of breast" exact="cancer" post="patients. Above that two breast cancer meta-analyses indicated no"/>
   <result pre="DFS or OS of breast cancer patients. Above that two" exact="breast cancer" post="meta-analyses indicated no strong risk association for rs5275 ["/>
   <result pre="or OS of breast cancer patients. Above that two breast" exact="cancer" post="meta-analyses indicated no strong risk association for rs5275 ["/>
   <result pre="impact on the survival of patients with early invasive ductal" exact="breast cancer" post="[ 89]. The PTGS2 gene polymorphism rs5275 in a"/>
   <result pre="on the survival of patients with early invasive ductal breast" exact="cancer" post="[ 89]. The PTGS2 gene polymorphism rs5275 in a"/>
   <result pre="the Nurses’ Health Study to test for an association with" exact="breast cancer" post="risk [ 90]. The SNP rs5275 was associated with"/>
   <result pre="Nurses’ Health Study to test for an association with breast" exact="cancer" post="risk [ 90]. The SNP rs5275 was associated with"/>
   <result pre="90]. The SNP rs5275 was associated with a decrease in" exact="breast cancer" post="risk and further genotyped in the Nurses’ Health Study"/>
   <result pre="The SNP rs5275 was associated with a decrease in breast" exact="cancer" post="risk and further genotyped in the Nurses’ Health Study"/>
   <result pre="T allele at rs5275 had a 20% lower risk of" exact="breast cancer" post="than those homozygous for the C allele. Cox et"/>
   <result pre="allele at rs5275 had a 20% lower risk of breast" exact="cancer" post="than those homozygous for the C allele. Cox et"/>
   <result pre="that this polymorphism may be associated with a decrease in" exact="breast cancer" post="risk among Caucasian women, but is not associated with"/>
   <result pre="this polymorphism may be associated with a decrease in breast" exact="cancer" post="risk among Caucasian women, but is not associated with"/>
   <result pre="women, but is not associated with an increased risk of" exact="breast cancer." post="We further identified the IGFBP3 SNP rs2854746. Qian et"/>
   <result pre="their phenotypes in local breast tissues and in association with" exact="breast cancer" post="risk for Chinese women [ 91]. No association was"/>
   <result pre="phenotypes in local breast tissues and in association with breast" exact="cancer" post="risk for Chinese women [ 91]. No association was"/>
   <result pre="for Chinese women [ 91]. No association was found between" exact="breast cancer" post="risk and the IGFBP3 SNP rs2854746, but the genotype"/>
   <result pre="Chinese women [ 91]. No association was found between breast" exact="cancer" post="risk and the IGFBP3 SNP rs2854746, but the genotype"/>
   <result pre="and circulating levels of IGF-I and IGFBP3 with proliferative benign" exact="breast disease" post="(BBD), a marker of increased breast cancer risk. Higher"/>
   <result pre="with proliferative benign breast disease (BBD), a marker of increased" exact="breast cancer" post="risk. Higher circulating IGFBP3 levels were significantly associated with"/>
   <result pre="proliferative benign breast disease (BBD), a marker of increased breast" exact="cancer" post="risk. Higher circulating IGFBP3 levels were significantly associated with"/>
   <result pre="with mammographic density, one of the strongest risk factors for" exact="breast cancer" post="[ 96]. Regarding PIK3CA, we inferred the SNP rs121913279,"/>
   <result pre="mammographic density, one of the strongest risk factors for breast" exact="cancer" post="[ 96]. Regarding PIK3CA, we inferred the SNP rs121913279,"/>
   <result pre="in HCC1954. Tong et al. detected this SNP in Chinese" exact="breast cancer" post="patients with invasive ductal carcinomas [ 97]. SNPs in"/>
   <result pre="HCC1954. Tong et al. detected this SNP in Chinese breast" exact="cancer" post="patients with invasive ductal carcinomas [ 97]. SNPs in"/>
   <result pre="more deeply in literature, even less in the context of" exact="breast cancer." post="Approximately 60% of the SNPs were also detected in"/>
   <result pre="genes and corresponding variations, which influence trastuzumab action in HER2+" exact="breast cancer." post="Comparing gene expression in three cell line models of"/>
   <result pre="of them have already been reported in the context of" exact="breast cancer" post="but just a small proportion in the context of"/>
   <result pre="them have already been reported in the context of breast" exact="cancer" post="but just a small proportion in the context of"/>
   <result pre="upregulation in HCC1954 which have already been ascribed to ER-" exact="breast cancer" post="subtypes. Outstanding candidates were IL8, PTGS2, GDF15 and LCN2,"/>
   <result pre="in HCC1954 which have already been ascribed to ER- breast" exact="cancer" post="subtypes. Outstanding candidates were IL8, PTGS2, GDF15 and LCN2,"/>
   <result pre="of the inferred SNPs are already in the focus of" exact="breast cancer" post="research, but mostly no influence on survival or risk"/>
   <result pre="the inferred SNPs are already in the focus of breast" exact="cancer" post="research, but mostly no influence on survival or risk"/>
   <result pre="PTGS2 in HCC1954, we found hints at a relation to" exact="breast cancer" post="risk. Additionally, the SNP rs2854746 of IGFBP3 in HCC1954"/>
   <result pre="in HCC1954, we found hints at a relation to breast" exact="cancer" post="risk. Additionally, the SNP rs2854746 of IGFBP3 in HCC1954"/>
   <result pre="results provide a basis to improve personalized medicine for HER2+" exact="breast cancer" post="patients. Supporting Information S1 Table Primers used for RT-qPCR"/>
   <result pre="provide a basis to improve personalized medicine for HER2+ breast" exact="cancer" post="patients. Supporting Information S1 Table Primers used for RT-qPCR"/>
   <result pre="Fig Expression data of the candidate genes in the transNOAH" exact="breast cancer" post="trial. The boxplot displays expression (log2) data of the"/>
   <result pre="Expression data of the candidate genes in the transNOAH breast" exact="cancer" post="trial. The boxplot displays expression (log2) data of the"/>
   <result pre="(gray). The patient data samples were selected from the transNOAH" exact="breast cancer" post="trial (GEO series GSE50948). (PDF) LINK Click here for"/>
   <result pre="The patient data samples were selected from the transNOAH breast" exact="cancer" post="trial (GEO series GSE50948). (PDF) LINK Click here for"/>
   <result pre="et al. ( 2012) Outcome analysis of patients with primary" exact="breast cancer" post="initially treated at a certified academic breast unit ."/>
   <result pre="al. ( 2012) Outcome analysis of patients with primary breast" exact="cancer" post="initially treated at a certified academic breast unit ."/>
   <result pre=", Wolff AC ( 2012) The adjuvant treatment of HER2-positive" exact="breast cancer." post="Curr Treat Options Oncol 13( 2): 230– 239. doi:"/>
   <result pre="Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing" exact="breast cancer" post=". Ann Oncol 18( 6): 977– 984. doi: 10.1093/annonc/mdl475"/>
   <result pre="mechanism of action, resistance and future perspectives in HER2-overexpressing breast" exact="cancer" post=". Ann Oncol 18( 6): 977– 984. doi: 10.1093/annonc/mdl475"/>
   <result pre="Connolly RM , Wolff AC ( 2014) Treatment of HER2-positive" exact="breast cancer." post="The Breast 23( 2): 128– 136. doi: 10.1016/j.breast.2013.11.011 24360619"/>
   <result pre="2012) Strong EGFR signaling in cell line models of ERBB2-amplified" exact="breast cancer" post="attenuates response towards ERBB2-targeting drugs . Oncogenesis 1: e16"/>
   <result pre="Strong EGFR signaling in cell line models of ERBB2-amplified breast" exact="cancer" post="attenuates response towards ERBB2-targeting drugs . Oncogenesis 1: e16"/>
   <result pre="mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified" exact="breast cancer" post="cell lines . Ann Oncol 21( 2): 255– 262."/>
   <result pre="in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast" exact="cancer" post="cell lines . Ann Oncol 21( 2): 255– 262."/>
   <result pre=", et al. ( 2013) Role of CYP1A2 polymorphisms in" exact="breast cancer" post="risk in women. Mol Med Rep 7: 280– 286."/>
   <result pre="et al. ( 2013) Role of CYP1A2 polymorphisms in breast" exact="cancer" post="risk in women. Mol Med Rep 7: 280– 286."/>
   <result pre="potential causative factor in the generation of trastuzumab resistance in" exact="breast cancer" post="cells . J Cancer 4( 5): 391– 401. doi:"/>
   <result pre="causative factor in the generation of trastuzumab resistance in breast" exact="cancer" post="cells . J Cancer 4( 5): 391– 401. doi:"/>
   <result pre="predictor identifies higher responses and improved survival outcomes in HER2-positive" exact="breast cancer" post="in the NOAH study . Clin Cancer Res 20("/>
   <result pre="identifies higher responses and improved survival outcomes in HER2-positive breast" exact="cancer" post="in the NOAH study . Clin Cancer Res 20("/>
   <result pre="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced" exact="breast cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast" exact="cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during" exact="breast cancer" post="progression . Breast Cancer Res 14( 3): R95 doi:"/>
   <result pre="and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast" exact="cancer" post="progression . Breast Cancer Res 14( 3): R95 doi:"/>
   <result pre="of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+" exact="breast cancer" post="by expanding the cancer stem cell population . Mol"/>
   <result pre="an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast" exact="cancer" post="by expanding the cancer stem cell population . Mol"/>
   <result pre="mediates trastuzumab resistance in HER2+ breast cancer by expanding the" exact="cancer" post="stem cell population . Mol Cell 47( 4): 570–"/>
   <result pre="al. ( 2002) Prognostic significance of elevated cyclooxygenase-2 expression in" exact="breast cancer." post="Cancer Res 62( 3): 632– 635. 11830510 40 Wang"/>
   <result pre="linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3" exact="breast cancer" post="cells: possible role of COX2 . PLoS ONE 4("/>
   <result pre="acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast" exact="cancer" post="cells: possible role of COX2 . PLoS ONE 4("/>
   <result pre="2001) Cyclooxygenase-2: a target for the prevention and treatment of" exact="breast cancer." post="Endocr Relat Cancer 8( 2): 97– 114. doi: 10.1677/erc.0.0080097"/>
   <result pre=", et al. ( 2004) Cyclooxygenase-2 inhibitor induces apoptosis in" exact="breast cancer" post="cells in an in vivo model of spontaneous metastatic"/>
   <result pre="et al. ( 2004) Cyclooxygenase-2 inhibitor induces apoptosis in breast" exact="cancer" post="cells in an in vivo model of spontaneous metastatic"/>
   <result pre="cancer cells in an in vivo model of spontaneous metastatic" exact="breast cancer" post=". Mol Cancer Res 2( 11): 632– 642. 15561779"/>
   <result pre="cells in an in vivo model of spontaneous metastatic breast" exact="cancer" post=". Mol Cancer Res 2( 11): 632– 642. 15561779"/>
   <result pre="2004) Phase II study of celecoxib and trastuzumab in metastatic" exact="breast cancer" post="patients who have progressed after prior trastuzumab-based treatments ."/>
   <result pre="Phase II study of celecoxib and trastuzumab in metastatic breast" exact="cancer" post="patients who have progressed after prior trastuzumab-based treatments ."/>
   <result pre="FM , et al. ( 2009) Enhanced killing of chemoresistant" exact="breast cancer" post="cells via controlled aggravation of ER stress . Cancer"/>
   <result pre=", et al. ( 2009) Enhanced killing of chemoresistant breast" exact="cancer" post="cells via controlled aggravation of ER stress . Cancer"/>
   <result pre="3, and 10 on patient response to trastuzumab in metastatic" exact="breast cancer" post=". Genes Chromosomes Cancer 46( 4): 397– 405. doi:"/>
   <result pre="and 10 on patient response to trastuzumab in metastatic breast" exact="cancer" post=". Genes Chromosomes Cancer 46( 4): 397– 405. doi:"/>
   <result pre="factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing" exact="breast cancer" post="cells . Biochem Pharmacol 82( 9): 1090– 1099. doi:"/>
   <result pre="15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast" exact="cancer" post="cells . Biochem Pharmacol 82( 9): 1090– 1099. doi:"/>
   <result pre="al. ( 2004) Selective loss of AKR1C1 and AKR1C2 in" exact="breast cancer" post="and their potential effect on progesterone signaling . Cancer"/>
   <result pre="( 2004) Selective loss of AKR1C1 and AKR1C2 in breast" exact="cancer" post="and their potential effect on progesterone signaling . Cancer"/>
   <result pre="gene for DNA amplification events occurring centromeric to CCND1 in" exact="breast cancer" post=". Int J Cancer 102( 6): 608– 614. doi:"/>
   <result pre="for DNA amplification events occurring centromeric to CCND1 in breast" exact="cancer" post=". Int J Cancer 102( 6): 608– 614. doi:"/>
   <result pre="et al. ( 2013) Progesterone-inducible cytokeratin 5-positive cells in luminal" exact="breast cancer" post="exhibit progenitor properties . Horm Cancer 4: 36– 49."/>
   <result pre="al. ( 2013) Progesterone-inducible cytokeratin 5-positive cells in luminal breast" exact="cancer" post="exhibit progenitor properties . Horm Cancer 4: 36– 49."/>
   <result pre="by quantitative PCR: an independent indicator of poor prognosis in" exact="breast cancer" post=". Clin Chem 48( 8): 1241– 1250. 12142380 61"/>
   <result pre="quantitative PCR: an independent indicator of poor prognosis in breast" exact="cancer" post=". Clin Chem 48( 8): 1241– 1250. 12142380 61"/>
   <result pre="JA ( 2002) Higher expression of human kallikrein 10 in" exact="breast cancer" post="tissue predicts tamoxifen resistance . Br J Cancer 86("/>
   <result pre="( 2002) Higher expression of human kallikrein 10 in breast" exact="cancer" post="tissue predicts tamoxifen resistance . Br J Cancer 86("/>
   <result pre="A , et al. ( 2004) Kallikrein gene downregulation in" exact="breast cancer." post="Br J Cancer 90: 167– 172. doi: 10.1038/sj.bjc.6601451 14710225"/>
   <result pre="et al. ( 2014) LIF promotes tumorigenesis and metastasis of" exact="breast cancer" post="through the AKT-mTOR pathway. Oncotarget 5( 3): 788– 801."/>
   <result pre="al. ( 2014) LIF promotes tumorigenesis and metastasis of breast" exact="cancer" post="through the AKT-mTOR pathway. Oncotarget 5( 3): 788– 801."/>
   <result pre="Tissue transglutaminase as a central mediator in inflammation-induced progression of" exact="breast cancer" post=". Breast Cancer Res 15: 202 doi: 10.1186/bcr3371 23673317"/>
   <result pre="transglutaminase as a central mediator in inflammation-induced progression of breast" exact="cancer" post=". Breast Cancer Res 15: 202 doi: 10.1186/bcr3371 23673317"/>
   <result pre=", et al. ( 2007) CTGF enhances the motility of" exact="breast cancer" post="cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway . J Cell"/>
   <result pre="et al. ( 2007) CTGF enhances the motility of breast" exact="cancer" post="cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway . J Cell"/>
   <result pre="is associated with loss of expression in estrogen receptor positive" exact="breast cancer" post=". PLoS ONE 8( 7): e68630 doi: 10.1371/journal.pone.0068630 23844228"/>
   <result pre="associated with loss of expression in estrogen receptor positive breast" exact="cancer" post=". PLoS ONE 8( 7): e68630 doi: 10.1371/journal.pone.0068630 23844228"/>
   <result pre="2012) Dysadherin expression promotes the motility and survival of human" exact="breast cancer" post="cells by AKT activation . Cancer Sci 103( 7):"/>
   <result pre="Dysadherin expression promotes the motility and survival of human breast" exact="cancer" post="cells by AKT activation . Cancer Sci 103( 7):"/>
   <result pre="epithelial protein and is associated with differentiated phenotype in early" exact="breast cancer" post="but predisposes to invasion and metastasis in advanced disease"/>
   <result pre="protein and is associated with differentiated phenotype in early breast" exact="cancer" post="but predisposes to invasion and metastasis in advanced disease"/>
   <result pre="Zhang L , et al. ( 2006) An estrogen receptor-negative" exact="breast cancer" post="subset characterized by a hormonally regulated transcriptional program and"/>
   <result pre="L , et al. ( 2006) An estrogen receptor-negative breast" exact="cancer" post="subset characterized by a hormonally regulated transcriptional program and"/>
   <result pre="Lacroix M ( 2006) Significance, detection and markers of disseminated" exact="breast cancer" post="cells. Endocr Relat Cancer 13( 4): 1033– 1067. doi:"/>
   <result pre="M ( 2006) Significance, detection and markers of disseminated breast" exact="cancer" post="cells. Endocr Relat Cancer 13( 4): 1033– 1067. doi:"/>
   <result pre="the genome-wide predicted estrogen response element-related sequences is associated with" exact="breast cancer" post="development . Breast Cancer Res 13: R13 doi: 10.1186/bcr2821"/>
   <result pre="genome-wide predicted estrogen response element-related sequences is associated with breast" exact="cancer" post="development . Breast Cancer Res 13: R13 doi: 10.1186/bcr2821"/>
   <result pre="as a growth promoter and is modulated by IL6/STAT3 in" exact="breast cancer." post="PLoS ONE 7( 10): e46410 doi: 10.1371/journal.pone.0046410 23056300 78"/>
   <result pre="( 2010) EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive" exact="breast cancer" post="cells but functions synergistically with endocrine therapy . Br"/>
   <result pre="2010) EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast" exact="cancer" post="cells but functions synergistically with endocrine therapy . Br"/>
   <result pre="( 2014) Growth factor receptor/steroid receptor cross talk in trastuzumab-treated" exact="breast cancer." post="Oncogene [Epub ahead of print] doi: 10.1038/onc.2013.586 80 Einarsdóttir"/>
   <result pre="et al. ( 2005) Common ERBB2 polymorphisms and risk of" exact="breast cancer" post="in a white British population: a case-control study ."/>
   <result pre="al. ( 2005) Common ERBB2 polymorphisms and risk of breast" exact="cancer" post="in a white British population: a case-control study ."/>
   <result pre=", et al. ( 2009) Heritable variation of ERBB2 and" exact="breast cancer" post="risk. Cancer Epidemiol Biomarkers Prev 18( 4): 1252– 1258."/>
   <result pre="et al. ( 2009) Heritable variation of ERBB2 and breast" exact="cancer" post="risk. Cancer Epidemiol Biomarkers Prev 18( 4): 1252– 1258."/>
   <result pre=", et al. ( 2012) Polymorphisms in cycloxygenase-2 gene and" exact="breast cancer" post="prognosis: association between PTGS2 haplotypes and histopathological features ."/>
   <result pre="et al. ( 2012) Polymorphisms in cycloxygenase-2 gene and breast" exact="cancer" post="prognosis: association between PTGS2 haplotypes and histopathological features ."/>
   <result pre="et al. ( 2010) Association of interleukin-10 gene variation with" exact="breast cancer" post="prognosis. Breast Cancer Res Treat 119( 3): 701– 705."/>
   <result pre="al. ( 2010) Association of interleukin-10 gene variation with breast" exact="cancer" post="prognosis. Breast Cancer Res Treat 119( 3): 701– 705."/>
   <result pre="polymorphisms in the prostaglandin pathway genes and their association with" exact="breast cancer" post="susceptibility and survival . Clin Cancer Res 15( 6):"/>
   <result pre="in the prostaglandin pathway genes and their association with breast" exact="cancer" post="susceptibility and survival . Clin Cancer Res 15( 6):"/>
   <result pre="on the relationship between polymorphisms in the COX-2 gene and" exact="breast cancer" post="risk: a meta-analysis . Breast Cancer Res Treat 122:"/>
   <result pre="the relationship between polymorphisms in the COX-2 gene and breast" exact="cancer" post="risk: a meta-analysis . Breast Cancer Res Treat 122:"/>
   <result pre="P ( 2010) -765G&amp;gt;C and 8473T&amp;gt;C polymorphisms of COX-2 and" exact="cancer" post="risk: a meta-analysis based on 33 case-control studies ."/>
   <result pre="2010) TNF superfamily gene polymorphism as prognostic factor in early" exact="breast cancer." post="J Cancer Res Clin Oncol 136( 5): 685– 694."/>
   <result pre="endoperoxide synthase 2 is not associated with an increase in" exact="breast cancer" post="risk: a nested case-control study . Breast Cancer Res"/>
   <result pre="synthase 2 is not associated with an increase in breast" exact="cancer" post="risk: a nested case-control study . Breast Cancer Res"/>
   <result pre="IGF-I and IGFBP-3 in relation to risk of proliferative benign" exact="breast disease" post=". Int J Cancer 126: 180– 190. doi: 10.1002/ijc.24674"/>
   <result pre="IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not" exact="breast cancer" post="risk: findings from the breast and prostate cancer cohort"/>
   <result pre="and IGFBP-3 polymorphisms predict circulating IGF levels but not breast" exact="cancer" post="risk: findings from the breast and prostate cancer cohort"/>
   <result pre="but not breast cancer risk: findings from the breast and" exact="prostate cancer" post="cohort consortium (BPC3) . PLoS ONE 3( 7): e2578"/>
   <result pre="not breast cancer risk: findings from the breast and prostate" exact="cancer" post="cohort consortium (BPC3) . PLoS ONE 3( 7): e2578"/>
   <result pre="2012) Mutational analysis of key EGFR pathway genes in Chinese" exact="breast cancer" post="patients. Asian Pac J Cancer Prev 13( 11): 5599–"/>
   <result pre="Mutational analysis of key EGFR pathway genes in Chinese breast" exact="cancer" post="patients. Asian Pac J Cancer Prev 13( 11): 5599–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4341429/results/search/disease/results.xml">
   <result pre="circulating tumor cells (CTCs) due to their purported role in" exact="breast cancer" post="metastasis, and their potential as a &quot;liquid biopsy&quot; tool"/>
   <result pre="tumor cells (CTCs) due to their purported role in breast" exact="cancer" post="metastasis, and their potential as a &quot;liquid biopsy&quot; tool"/>
   <result pre="metastasis, and their potential as a &quot;liquid biopsy&quot; tool in" exact="breast cancer" post="diagnosis and management. There are, however, questions with regards"/>
   <result pre="and their potential as a &quot;liquid biopsy&quot; tool in breast" exact="cancer" post="diagnosis and management. There are, however, questions with regards"/>
   <result pre="analysis and note further research that is required before the" exact="breast cancer" post="&quot;liquid biopsy&quot; can be realized. circulating tumor cells epithelial–mesenchymal"/>
   <result pre="and note further research that is required before the breast" exact="cancer" post="&quot;liquid biopsy&quot; can be realized. circulating tumor cells epithelial–mesenchymal"/>
   <result pre="&quot;liquid biopsy&quot; can be realized. circulating tumor cells epithelial–mesenchymal transition" exact="breast cancer" post="clinical application metastasis Funding Foundation’s National Collaborative Research Program"/>
   <result pre="biopsy&quot; can be realized. circulating tumor cells epithelial–mesenchymal transition breast" exact="cancer" post="clinical application metastasis Funding Foundation’s National Collaborative Research Program"/>
   <result pre="(St.Vincent’s Institute) fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Breast" exact="cancer" post="is the most common cause of cancer death among"/>
   <result pre="word-count: Introduction Breast cancer is the most common cause of" exact="cancer" post="death among women ( 1). Prognosis for most patients"/>
   <result pre="among women ( 1). Prognosis for most patients with early" exact="breast cancer" post="(EBC) is generally very good, however, a significant proportion"/>
   <result pre="women ( 1). Prognosis for most patients with early breast" exact="cancer" post="(EBC) is generally very good, however, a significant proportion"/>
   <result pre="relapse with metastatic disease ( 2). How to identify those" exact="breast cancer" post="patients who will relapse in the future and develop"/>
   <result pre="with metastatic disease ( 2). How to identify those breast" exact="cancer" post="patients who will relapse in the future and develop"/>
   <result pre="(CTCs) that originate from the primary tumor and spread the" exact="cancer" post="in the body via the blood circulatory system. These"/>
   <result pre="seen in all patients, it is seen more frequently in" exact="breast cancer" post="patients with persistent DTCs ( 3). Although considerable research"/>
   <result pre="in all patients, it is seen more frequently in breast" exact="cancer" post="patients with persistent DTCs ( 3). Although considerable research"/>
   <result pre="12). We focus our review on CTCs, their role in" exact="breast cancer" post="progression, and how CTC molecular variation and epithelial–mesenchymal transition"/>
   <result pre="We focus our review on CTCs, their role in breast" exact="cancer" post="progression, and how CTC molecular variation and epithelial–mesenchymal transition"/>
   <result pre="due to the substantial pleomorphism CTCs exhibit ( 14). Breast" exact="cancer" post="CTCs have a mean diameter of 13.1 μm ( 15),"/>
   <result pre="strongly with poor prognosis than single CTCs do in metastatic" exact="breast cancer" post="(MBC) patients ( 18). Epithelial–Mesenchymal Transition Most breast cancers"/>
   <result pre="with poor prognosis than single CTCs do in metastatic breast" exact="cancer" post="(MBC) patients ( 18). Epithelial–Mesenchymal Transition Most breast cancers"/>
   <result pre="EMT in response to specific stimuli ( 23). However in" exact="cancer" post="cells, activation of this process is dysregulated ( 22)."/>
   <result pre="including taxanes and anthracyclines ( 24) and is elevated in" exact="breast cancer" post="tissues remaining after neoadjuvant therapies ( 25). Tumor cells"/>
   <result pre="taxanes and anthracyclines ( 24) and is elevated in breast" exact="cancer" post="tissues remaining after neoadjuvant therapies ( 25). Tumor cells"/>
   <result pre="27, 30). Whilst EMT/mesenchymal markers have been demonstrated on CTCs," exact="breast cancer" post="metastases in liver, lung, and brain often express higher"/>
   <result pre="30). Whilst EMT/mesenchymal markers have been demonstrated on CTCs, breast" exact="cancer" post="metastases in liver, lung, and brain often express higher"/>
   <result pre="Sub-populations of tumor cells at any point may also acquire" exact="cancer" post="&quot;stem-cell&quot; (CSC) attributes such as quiescence, self-renewal, asymmetric division,"/>
   <result pre="(ALDH1) ( 45). These CSC markers have been identified in" exact="breast cancer" post="CTCs populations by a number of researchers ( 46–"/>
   <result pre="( 45). These CSC markers have been identified in breast" exact="cancer" post="CTCs populations by a number of researchers ( 46–"/>
   <result pre="Prognostic Tools Both CTCs and DTCs have been detected in" exact="breast cancer" post="patients with disease states ranging from ductal carcinoma in"/>
   <result pre="Tools Both CTCs and DTCs have been detected in breast" exact="cancer" post="patients with disease states ranging from ductal carcinoma in"/>
   <result pre="in breast cancer patients with disease states ranging from ductal" exact="carcinoma in situ" post="to MBC ( 55– 60), and their detection is"/>
   <result pre="67, 68). Mixed results have been seen when considering receptor-defined" exact="breast cancer" post="subtypes. Detection of CTCs is prognostic in EBC patients"/>
   <result pre="68). Mixed results have been seen when considering receptor-defined breast" exact="cancer" post="subtypes. Detection of CTCs is prognostic in EBC patients"/>
   <result pre="need. Multiple studies have shown that in EBC, locally advanced" exact="breast cancer," post="and MBC, detection of CTCs after the completion of"/>
   <result pre="of ongoing clinical trials examining the utility of CTCs in" exact="breast cancer" post="treatment. Details of some of the interventional studies employing"/>
   <result pre="ongoing clinical trials examining the utility of CTCs in breast" exact="cancer" post="treatment. Details of some of the interventional studies employing"/>
   <result pre="trials examining the clinical utility of circulating tumor cells in" exact="breast cancer" post="treatment . Trial name (ClinicalTrial.gov registry number) Rationale Patient"/>
   <result pre="examining the clinical utility of circulating tumor cells in breast" exact="cancer" post="treatment . Trial name (ClinicalTrial.gov registry number) Rationale Patient"/>
   <result pre="resistance to chemotherapy. Gazzaniga et al. ( 98) screened 105" exact="cancer" post="patients (of which 14 had breast cancer) for CTCs"/>
   <result pre="&quot;liquid biopsy&quot; to diagnose, characterize, monitor, and influence treatment of" exact="cancer" post="is still some way off. However profiling the presence"/>
   <result pre="et al. Persistent tumor cells in bone marrow of non-metastatic" exact="breast cancer" post="patients after primary surgery are associated with inferior outcome"/>
   <result pre="al. Persistent tumor cells in bone marrow of non-metastatic breast" exact="cancer" post="patients after primary surgery are associated with inferior outcome"/>
   <result pre="inhibitor protein XIAP contributes to anoikis resistance of circulating human" exact="prostate cancer" post="metastasis precursor cells . Cancer Res ( 2005) 65("/>
   <result pre="protein XIAP contributes to anoikis resistance of circulating human prostate" exact="cancer" post="metastasis precursor cells . Cancer Res ( 2005) 65("/>
   <result pre="Persistence of disseminated tumor cells in the bone marrow of" exact="breast cancer" post="patients predicts increased risk for relapse – a European"/>
   <result pre="of disseminated tumor cells in the bone marrow of breast" exact="cancer" post="patients predicts increased risk for relapse – a European"/>
   <result pre="Meta-analysis of the prognostic value of circulating tumor cells in" exact="breast cancer." post="Clin Cancer Res ( 2012) 18( 20): 5701– 10."/>
   <result pre="System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic" exact="breast cancer" post=". Br J Cancer ( 2010) 102( 2): 276–"/>
   <result pre="the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast" exact="cancer" post=". Br J Cancer ( 2010) 102( 2): 276–"/>
   <result pre="update of recommendations for the use of tumor markers in" exact="breast cancer" post=". J Clin Oncol ( 2007) 25( 33): 5287–"/>
   <result pre="of recommendations for the use of tumor markers in breast" exact="cancer" post=". J Clin Oncol ( 2007) 25( 33): 5287–"/>
   <result pre="et al. Circulating tumor cell clusters are oligoclonal precursors of" exact="breast cancer" post="metastasis. Cell ( 2014) 158( 5): 1110– 22. 10.1016/j.cell.2014.07.013"/>
   <result pre="al. Circulating tumor cell clusters are oligoclonal precursors of breast" exact="cancer" post="metastasis. Cell ( 2014) 158( 5): 1110– 22. 10.1016/j.cell.2014.07.013"/>
   <result pre="Thompson EW Thiery JP . Epithelial to mesenchymal transition and" exact="breast cancer." post="Breast Cancer Res ( 2009) 11( 6): 213. 10.1186/bcr2416"/>
   <result pre="EW Waltham M . Vimentin and epithelial-mesenchymal transition in human" exact="breast cancer" post="observations in vitro and in vivo . Cells Tissues"/>
   <result pre="Waltham M . Vimentin and epithelial-mesenchymal transition in human breast" exact="cancer" post="observations in vitro and in vivo . Cells Tissues"/>
   <result pre="H Beppu T Nakamori S et al. Epithelial-mesenchymal transition in" exact="cancer" post="development and its clinical significance. Cancer Sci ( 2010)"/>
   <result pre="C Weinberg RA et al. Identification of selective inhibitors of" exact="cancer" post="stem cells by high-throughput screening. Cell ( 2009) 138("/>
   <result pre="transition (EMT) in tumor-initiating cells and its clinical implications in" exact="breast cancer" post=". J Mammary Gland Biol Neoplasia ( 2010) 15("/>
   <result pre="(EMT) in tumor-initiating cells and its clinical implications in breast" exact="cancer" post=". J Mammary Gland Biol Neoplasia ( 2010) 15("/>
   <result pre="Bednarz-Knoll N Alix-Panabieres C Pantel K . Plasticity of disseminating" exact="cancer" post="cells in patients with epithelial malignancies. Cancer Metastasis Rev"/>
   <result pre="B . Mechanisms that link the oncogenic epithelial-mesenchymal transition to" exact="suppression" post="of anoikis . J Cell Sci ( 2013) 126("/>
   <result pre="Cano A Moreno-Bueno G Palacios J . Epithelial-mesenchymal transition in" exact="breast cancer" post="relates to the basal-like phenotype. Cancer Res ( 2008)"/>
   <result pre="A Moreno-Bueno G Palacios J . Epithelial-mesenchymal transition in breast" exact="cancer" post="relates to the basal-like phenotype. Cancer Res ( 2008)"/>
   <result pre="T et al. Direct targeting of Sec23a by miR-200s influences" exact="cancer" post="cell secretome and promotes metastatic colonization . Nat Med"/>
   <result pre="of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of" exact="breast cancer" post=". Oncogene ( 2012) 31( 33): 3741– 53. 10.1038/onc.2011.540"/>
   <result pre="epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast" exact="cancer" post=". Oncogene ( 2012) 31( 33): 3741– 53. 10.1038/onc.2011.540"/>
   <result pre="Epithelial-mesenchymal transition and stemness features in circulating tumor cells from" exact="breast cancer" post="patients . Breast Cancer Res Treat ( 2011) 130("/>
   <result pre="transition and stemness features in circulating tumor cells from breast" exact="cancer" post="patients . Breast Cancer Res Treat ( 2011) 130("/>
   <result pre="a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell" exact="lung cancer" post=". Br J Cancer ( 2011) 105( 9): 1338–"/>
   <result pre="hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung" exact="cancer" post=". Br J Cancer ( 2011) 105( 9): 1338–"/>
   <result pre="al. Circulating tumor cells from patients with advanced prostate and" exact="breast cancer" post="display both epithelial and mesenchymal markers . Mol Cancer"/>
   <result pre="Circulating tumor cells from patients with advanced prostate and breast" exact="cancer" post="display both epithelial and mesenchymal markers . Mol Cancer"/>
   <result pre="C Hinkal G Ansieau S Puisieux A . Generation of" exact="breast cancer" post="stem cells through epithelial-mesenchymal transition. PLoS One ( 2008)"/>
   <result pre="Hinkal G Ansieau S Puisieux A . Generation of breast" exact="cancer" post="stem cells through epithelial-mesenchymal transition. PLoS One ( 2008)"/>
   <result pre="A Morrison SJ Clarke MF . Prospective identification of tumorigenic" exact="breast cancer" post="cells. Proc Natl Acad Sci U S A ("/>
   <result pre="Morrison SJ Clarke MF . Prospective identification of tumorigenic breast" exact="cancer" post="cells. Proc Natl Acad Sci U S A ("/>
   <result pre="W Kumar D et al. The identification and characterization of" exact="breast cancer" post="CTCs competent for brain metastasis . Sci Transl Med"/>
   <result pre="Kumar D et al. The identification and characterization of breast" exact="cancer" post="CTCs competent for brain metastasis . Sci Transl Med"/>
   <result pre="putative stem cell phenotype in peripheral blood of patients with" exact="breast cancer" post=". Cancer Lett ( 2010) 288( 1): 99– 106."/>
   <result pre="stem cell phenotype in peripheral blood of patients with breast" exact="cancer" post=". Cancer Lett ( 2010) 288( 1): 99– 106."/>
   <result pre="circulating tumor cells and tumor stem cells in patients with" exact="breast cancer" post="by using flow cytometry: a valuable tool for diagnosis"/>
   <result pre="tumor cells and tumor stem cells in patients with breast" exact="cancer" post="by using flow cytometry: a valuable tool for diagnosis"/>
   <result pre="markers are frequently overexpressed in circulating tumor cells of metastatic" exact="breast cancer" post="patients . Breast Cancer Res ( 2009) 11( 4):"/>
   <result pre="are frequently overexpressed in circulating tumor cells of metastatic breast" exact="cancer" post="patients . Breast Cancer Res ( 2009) 11( 4):"/>
   <result pre="G Criscitiello C et al. HER2-positive circulating tumor cells in" exact="breast cancer." post="PLoS One ( 2011) 6( 1): e15624. 10.1371/journal.pone.0015624 21264346"/>
   <result pre="tumor cells in the bone marrow of patients with ductal" exact="carcinoma in situ" post=". Int J Cancer ( 2011) 129( 10): 2522–"/>
   <result pre="al. Circulating tumor cells, disease progression, and survival in metastatic" exact="breast cancer." post="N Engl J Med ( 2004) 351( 8): 781–"/>
   <result pre="circulating tumor cells after adjuvant chemotherapy in patients with early" exact="breast cancer" post=". J Clin Oncol ( 2009) 27( 13): 2177–"/>
   <result pre="tumor cells after adjuvant chemotherapy in patients with early breast" exact="cancer" post=". J Clin Oncol ( 2009) 27( 13): 2177–"/>
   <result pre="Holle R von Minckwitz G Solomayer EF et al. Micrometastatic" exact="breast cancer" post="cells in bone marrow at primary surgery: prognostic value"/>
   <result pre="R von Minckwitz G Solomayer EF et al. Micrometastatic breast" exact="cancer" post="cells in bone marrow at primary surgery: prognostic value"/>
   <result pre="al. Circulating tumor cells predict survival in early average-to-high risk" exact="breast cancer" post="patients . J Natl Cancer Inst ( 2014) 106("/>
   <result pre="Circulating tumor cells predict survival in early average-to-high risk breast" exact="cancer" post="patients . J Natl Cancer Inst ( 2014) 106("/>
   <result pre="cells at each follow-up time point during therapy of metastatic" exact="breast cancer" post="patients predict progression-free and overall survival . Clin Cancer"/>
   <result pre="at each follow-up time point during therapy of metastatic breast" exact="cancer" post="patients predict progression-free and overall survival . Clin Cancer"/>
   <result pre="the detection of circulating tumour cells in patients with early-stage" exact="breast cancer" post=". Br J Cancer ( 2011) 104( 12): 1913–"/>
   <result pre="detection of circulating tumour cells in patients with early-stage breast" exact="cancer" post=". Br J Cancer ( 2011) 104( 12): 1913–"/>
   <result pre="the presence of circulating tumor cells in patients with operable" exact="breast cancer" post=". Breast Cancer Res Treat ( 2009) 113( 3):"/>
   <result pre="presence of circulating tumor cells in patients with operable breast" exact="cancer" post=". Breast Cancer Res Treat ( 2009) 113( 3):"/>
   <result pre="and HER2 expression of circulating tumor cells: prospective monitoring in" exact="breast cancer" post="patients treated in the neoadjuvant GeparQuattro trial . Clin"/>
   <result pre="HER2 expression of circulating tumor cells: prospective monitoring in breast" exact="cancer" post="patients treated in the neoadjuvant GeparQuattro trial . Clin"/>
   <result pre="cells according to estrogen receptor and HER2 status in early-stage" exact="breast cancer" post=". J Clin Oncol ( 2007) 25( 33): 5194–"/>
   <result pre="according to estrogen receptor and HER2 status in early-stage breast" exact="cancer" post=". J Clin Oncol ( 2007) 25( 33): 5194–"/>
   <result pre="Hu H et al. Circulating tumor cells in HER2-positive metastatic" exact="breast cancer" post="patients: a valuable prognostic and predictive biomarker . BMC"/>
   <result pre="H et al. Circulating tumor cells in HER2-positive metastatic breast" exact="cancer" post="patients: a valuable prognostic and predictive biomarker . BMC"/>
   <result pre="EZ Huth JF et al. Circulating tumor in patients with" exact="breast cancer" post="dormancy. Clin Cancer Res ( 2004) 10( 24): 8152–"/>
   <result pre="Huth JF et al. Circulating tumor in patients with breast" exact="cancer" post="dormancy. Clin Cancer Res ( 2004) 10( 24): 8152–"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer." post="Science ( 1989) 244( 4905): 707– 12. 10.1126/science.2470152 2470152"/>
   <result pre="cells compared with the primary tumor during treatment for advanced" exact="breast cancer" post=". Clin Breast Cancer ( 2010) 10( 5): 392–"/>
   <result pre="compared with the primary tumor during treatment for advanced breast" exact="cancer" post=". Clin Breast Cancer ( 2010) 10( 5): 392–"/>
   <result pre="value of HER2-positive circulating tumor cells in patients with metastatic" exact="breast cancer" post=". Int J Clin Oncol ( 2012) 17( 2):"/>
   <result pre="of HER2-positive circulating tumor cells in patients with metastatic breast" exact="cancer" post=". Int J Clin Oncol ( 2012) 17( 2):"/>
   <result pre="cells indicate poor clinical outcome in stage I to III" exact="breast cancer" post="patients . Clin Cancer Res ( 2006) 12( 6):"/>
   <result pre="indicate poor clinical outcome in stage I to III breast" exact="cancer" post="patients . Clin Cancer Res ( 2006) 12( 6):"/>
   <result pre="facilitates molecular characterisation and recognition of discordant HER2 amplification in" exact="breast cancer" post=". Br J Cancer ( 2010) 102( 10): 1495–"/>
   <result pre="molecular characterisation and recognition of discordant HER2 amplification in breast" exact="cancer" post=". Br J Cancer ( 2010) 102( 10): 1495–"/>
   <result pre="decreases the incidence of clinical relapses in patients with early" exact="breast cancer" post="presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of"/>
   <result pre="the incidence of clinical relapses in patients with early breast" exact="cancer" post="presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of"/>
   <result pre="S et al. HER-2 gene amplification can be acquired as" exact="breast cancer" post="progresses. Proc Natl Acad Sci U S A ("/>
   <result pre="et al. HER-2 gene amplification can be acquired as breast" exact="cancer" post="progresses. Proc Natl Acad Sci U S A ("/>
   <result pre="Appleby DE . The variability of estrogen receptors in metastatic" exact="breast cancer." post="Am J Surg ( 1979) 137( 2): 260– 2."/>
   <result pre="JV . Variation in receptor status between primary and metastatic" exact="breast cancer." post="Cancer ( 1983) 52( 3): 479– 85. 10.1002/1097-0142(19830801)52:3&amp;lt;479::AID-CNCR2820520317&amp;gt;3.0.CO;2-O 6861087"/>
   <result pre=". Estrogen and progesterone receptor concordance between primary and recurrent" exact="breast cancer" post=". J Surg Oncol ( 1994) 57( 2): 71–"/>
   <result pre="Estrogen and progesterone receptor concordance between primary and recurrent breast" exact="cancer" post=". J Surg Oncol ( 1994) 57( 2): 71–"/>
   <result pre="of circulating tumor cells and the primary tumor in metastatic" exact="breast cancer" post="patients . Gynecol Oncol ( 2011) 122( 2): 356–"/>
   <result pre="circulating tumor cells and the primary tumor in metastatic breast" exact="cancer" post="patients . Gynecol Oncol ( 2011) 122( 2): 356–"/>
   <result pre="and characterization of circulating tumor cells in blood of primary" exact="breast cancer" post="patients by RT-PCR and comparison to status of bone"/>
   <result pre="characterization of circulating tumor cells in blood of primary breast" exact="cancer" post="patients by RT-PCR and comparison to status of bone"/>
   <result pre="of disseminated tumor cells after neoadjuvant treatment for locally advanced" exact="breast cancer" post="predicts poor survival . Breast Cancer Res ( 2012)"/>
   <result pre="disseminated tumor cells after neoadjuvant treatment for locally advanced breast" exact="cancer" post="predicts poor survival . Breast Cancer Res ( 2012)"/>
   <result pre="bone marrow, disseminated tumour cells and blood-circulating tumour cells in" exact="breast cancer" post="patients after primary treatment . Br J Cancer ("/>
   <result pre="marrow, disseminated tumour cells and blood-circulating tumour cells in breast" exact="cancer" post="patients after primary treatment . Br J Cancer ("/>
   <result pre="Single circulating tumor cell detection and overall survival in nonmetastatic" exact="breast cancer" post=". Ann Oncol ( 2010) 21( 4): 729– 33."/>
   <result pre="circulating tumor cell detection and overall survival in nonmetastatic breast" exact="cancer" post=". Ann Oncol ( 2010) 21( 4): 729– 33."/>
   <result pre="surrogate for response to treatment and overall survival in metastatic" exact="breast cancer" post=". Breast Cancer ( 2010) 17( 3): 199– 204."/>
   <result pre="for response to treatment and overall survival in metastatic breast" exact="cancer" post=". Breast Cancer ( 2010) 17( 3): 199– 204."/>
   <result pre="response of circulating epithelial tumor cells to adjuvant chemotherapy in" exact="breast cancer" post="allows detection of patients at risk of early relapse"/>
   <result pre="of circulating epithelial tumor cells to adjuvant chemotherapy in breast" exact="cancer" post="allows detection of patients at risk of early relapse"/>
   <result pre="biopsies: can circulating tumor cell monitoring guide treatment selection in" exact="breast cancer?" post="J Clin Oncol ( 2014) 32( 31): 3470– 1."/>
   <result pre="relapse after neoadjuvant chemotherapy in large operable and locally advanced" exact="breast cancer" post="in a phase II randomized trial . Clin Cancer"/>
   <result pre="after neoadjuvant chemotherapy in large operable and locally advanced breast" exact="cancer" post="in a phase II randomized trial . Clin Cancer"/>
   <result pre="Circulating tumor cells as predictors of response and failure in" exact="breast cancer" post="patients treated with preoperative chemotherapy . Int J Biol"/>
   <result pre="tumor cells as predictors of response and failure in breast" exact="cancer" post="patients treated with preoperative chemotherapy . Int J Biol"/>
   <result pre="Vincenzi B et al. Circulating tumor cells (CTCs) in metastatic" exact="breast cancer" post="(MBC): prognosis, drug resistance and phenotypic characterization . Ann"/>
   <result pre="B et al. Circulating tumor cells (CTCs) in metastatic breast" exact="cancer" post="(MBC): prognosis, drug resistance and phenotypic characterization . Ann"/>
   <result pre="O Gianni W et al. Chemosensitivity profile assay of circulating" exact="cancer" post="cells: prognostic and predictive value in epithelial tumors ."/>
   <result pre="profiling of circulating tumor cells: transcriptional heterogeneity and diversity from" exact="breast cancer" post="cell lines . PLoS One ( 2012) 7( 5):"/>
   <result pre="of circulating tumor cells: transcriptional heterogeneity and diversity from breast" exact="cancer" post="cell lines . PLoS One ( 2012) 7( 5):"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4342830/results/search/disease/results.xml">
   <result pre=": Preclinical Study Regulation of cell survival by HUNK mediates" exact="breast cancer" post="resistance to HER2 inhibitors Yeh Elizabeth S. yeh@musc.edu Abt"/>
   <result pre="Preclinical Study Regulation of cell survival by HUNK mediates breast" exact="cancer" post="resistance to HER2 inhibitors Yeh Elizabeth S. yeh@musc.edu Abt"/>
   <result pre="the original author(s) and the source are credited. Abstract Breast" exact="cancer" post="patients who are HER2-positive receive targeted inhibitors to HER2,"/>
   <result pre="trastuzumab and lapatinib resistance and demonstrate that impairing autophagy in" exact="breast cancer" post="cells is therapeutically beneficial. Moreover, autophagy is mechanistically linked"/>
   <result pre="and lapatinib resistance and demonstrate that impairing autophagy in breast" exact="cancer" post="cells is therapeutically beneficial. Moreover, autophagy is mechanistically linked"/>
   <result pre="areas of therapeutic intervention to combat or prevent resistance in" exact="breast cancer." post="We previously characterized the protein kinase HUNK as a"/>
   <result pre="through modulation of autophagy using HER2 inhibitor sensitive and resistant" exact="breast cancer" post="models. Furthermore, we investigate whether inhibiting HUNK impairs in"/>
   <result pre="modulation of autophagy using HER2 inhibitor sensitive and resistant breast" exact="cancer" post="models. Furthermore, we investigate whether inhibiting HUNK impairs in"/>
   <result pre="in vivo tumor growth that is initiated by HER2 inhibitor-resistant" exact="breast cancer" post="cells. Our findings indicate that therapeutically targeting HUNK is"/>
   <result pre="vivo tumor growth that is initiated by HER2 inhibitor-resistant breast" exact="cancer" post="cells. Our findings indicate that therapeutically targeting HUNK is"/>
   <result pre="is a potential strategy for overcoming resistance and that resistant" exact="breast cancer" post="cells maintain HUNK expression to drive tumorigenesis, an observation"/>
   <result pre="a potential strategy for overcoming resistance and that resistant breast" exact="cancer" post="cells maintain HUNK expression to drive tumorigenesis, an observation"/>
   <result pre="indicate that HUNK is preferentially expressed in aggressive subsets of" exact="breast cancer" post="and may play a pivotal role in mediating breast"/>
   <result pre="that HUNK is preferentially expressed in aggressive subsets of breast" exact="cancer" post="and may play a pivotal role in mediating breast"/>
   <result pre="breast cancer and may play a pivotal role in mediating" exact="breast cancer" post="metastasis [ 2, 3]. Consistent with these assertions, our"/>
   <result pre="cancer and may play a pivotal role in mediating breast" exact="cancer" post="metastasis [ 2, 3]. Consistent with these assertions, our"/>
   <result pre="survival and show that the outcome of this activity impacts" exact="breast cancer" post="resistance to HER2-targeted therapy. Materials and methods Cell culture"/>
   <result pre="and show that the outcome of this activity impacts breast" exact="cancer" post="resistance to HER2-targeted therapy. Materials and methods Cell culture"/>
   <result pre="10 % super calf serum (SCS, Gemini). BT474 (ATCC) human" exact="breast cancer" post="cells were grown in RPMI-1640 (Hyclone) supplemented with 10"/>
   <result pre="% super calf serum (SCS, Gemini). BT474 (ATCC) human breast" exact="cancer" post="cells were grown in RPMI-1640 (Hyclone) supplemented with 10"/>
   <result pre="maintained as previously described [ 4]. JIMT-1 (Addex Bio) trastuzumab-resistant" exact="breast cancer" post="cells were grown in DMEM (Hyclone) supplemented with 10"/>
   <result pre="as previously described [ 4]. JIMT-1 (Addex Bio) trastuzumab-resistant breast" exact="cancer" post="cells were grown in DMEM (Hyclone) supplemented with 10"/>
   <result pre="indicated that impairing HUNK in mammary epithelial, mammary tumor, and" exact="breast cancer" post="cells results in an increase in the number of"/>
   <result pre="that impairing HUNK in mammary epithelial, mammary tumor, and breast" exact="cancer" post="cells results in an increase in the number of"/>
   <result pre="of HUNK, autophagy is impaired. HUNK down-regulation in primary HER2-positive" exact="breast cancer" post="cells induces cell death in response to lapatinib and"/>
   <result pre="HUNK, autophagy is impaired. HUNK down-regulation in primary HER2-positive breast" exact="cancer" post="cells induces cell death in response to lapatinib and"/>
   <result pre="by HER2/neu and acts as a tumor-promoting factor in HER2+" exact="breast cancer" post="[ 4], we next sought to examine cell death"/>
   <result pre="HER2/neu and acts as a tumor-promoting factor in HER2+ breast" exact="cancer" post="[ 4], we next sought to examine cell death"/>
   <result pre="sought to examine cell death and autophagy response in HER2+" exact="breast cancer" post="cells. Therefore, we used BT474 cells engineered to express"/>
   <result pre="to examine cell death and autophagy response in HER2+ breast" exact="cancer" post="cells. Therefore, we used BT474 cells engineered to express"/>
   <result pre="BT474 cells (Fig. 2c). Previously, it was determined that HER2+" exact="breast cancer" post="cells respond to HER2 inhibition by inducing autophagy as"/>
   <result pre="cells (Fig. 2c). Previously, it was determined that HER2+ breast" exact="cancer" post="cells respond to HER2 inhibition by inducing autophagy as"/>
   <result pre="autophagy is impaired due to HUNK deficiency in BT474 HER2+" exact="breast cancer" post="cells. HUNK regulates cell survival in breast cancer cells"/>
   <result pre="is impaired due to HUNK deficiency in BT474 HER2+ breast" exact="cancer" post="cells. HUNK regulates cell survival in breast cancer cells"/>
   <result pre="BT474 HER2+ breast cancer cells. HUNK regulates cell survival in" exact="breast cancer" post="cells resistant to HER2-targeted therapy As autophagy is induced"/>
   <result pre="HER2+ breast cancer cells. HUNK regulates cell survival in breast" exact="cancer" post="cells resistant to HER2-targeted therapy As autophagy is induced"/>
   <result pre="resistant to HER2-targeted therapy As autophagy is induced by HER2+" exact="breast cancer" post="cells in response to HER2 inhibition as a means"/>
   <result pre="to HER2-targeted therapy As autophagy is induced by HER2+ breast" exact="cancer" post="cells in response to HER2 inhibition as a means"/>
   <result pre="also alters cell survival response. Therefore, we examined the JIMT-1" exact="breast cancer" post="cell line [ 18] for autophagy response by LC3B"/>
   <result pre="alters cell survival response. Therefore, we examined the JIMT-1 breast" exact="cancer" post="cell line [ 18] for autophagy response by LC3B"/>
   <result pre="data suggest that targeting HUNK in HER2+ primary and resistant" exact="breast cancer" post="cells induces cell death and impacts the ability of"/>
   <result pre="suggest that targeting HUNK in HER2+ primary and resistant breast" exact="cancer" post="cells induces cell death and impacts the ability of"/>
   <result pre="Targeting HUNK impairs tumor initiation and growth in vivo of" exact="breast cancer" post="cells resistant to HER2-targeted therapy To determine if the"/>
   <result pre="HUNK impairs tumor initiation and growth in vivo of breast" exact="cancer" post="cells resistant to HER2-targeted therapy To determine if the"/>
   <result pre="cell death and autophagy has an effect on tumorigenesis of" exact="breast cancer" post="cells resistant to HER2-targeted therapy, we next assessed tumorigenesis"/>
   <result pre="death and autophagy has an effect on tumorigenesis of breast" exact="cancer" post="cells resistant to HER2-targeted therapy, we next assessed tumorigenesis"/>
   <result pre="our in vivo finding that inhibiting HUNK in resistant JIMT-1" exact="breast cancer" post="cells impairs tumor growth is in line with our"/>
   <result pre="in vivo finding that inhibiting HUNK in resistant JIMT-1 breast" exact="cancer" post="cells impairs tumor growth is in line with our"/>
   <result pre="therapeutically beneficial. Discussion Although a role for HUNK in promoting" exact="breast cancer" post="initiation [ 4, 5] and metastasis [ 2, 3]"/>
   <result pre="beneficial. Discussion Although a role for HUNK in promoting breast" exact="cancer" post="initiation [ 4, 5] and metastasis [ 2, 3]"/>
   <result pre="finding is significant because autophagy is a mechanism by which" exact="breast cancer" post="cells have been shown to survive treatment and acquire"/>
   <result pre="is significant because autophagy is a mechanism by which breast" exact="cancer" post="cells have been shown to survive treatment and acquire"/>
   <result pre="However, to some degree, the role of autophagy in human" exact="cancer" post="is still unclear as this process is reported as"/>
   <result pre="inhibitory [ 26– 28]. This paradox is exemplified in HER2+" exact="breast cancer" post="in which monoallelic deletion of the autophagy gene BECN-"/>
   <result pre="[ 26– 28]. This paradox is exemplified in HER2+ breast" exact="cancer" post="in which monoallelic deletion of the autophagy gene BECN-"/>
   <result pre="effective. Consequently, to clarify how to therapeutically target autophagy in" exact="breast cancer," post="carefully mapping the cell signaling pathways and molecules that"/>
   <result pre="molecules that control these processes is critical to develop effective" exact="breast cancer" post="therapies. Consistent with the idea that autophagy status influences"/>
   <result pre="that control these processes is critical to develop effective breast" exact="cancer" post="therapies. Consistent with the idea that autophagy status influences"/>
   <result pre="to evade resistance. This strategy is directly applicable to HER2+" exact="breast cancer" post="because chronic application of HER2 inhibitors (i.e., trastuzumab and"/>
   <result pre="evade resistance. This strategy is directly applicable to HER2+ breast" exact="cancer" post="because chronic application of HER2 inhibitors (i.e., trastuzumab and"/>
   <result pre="17] and survival signaling pathways, like the PI3K/Akt pathway, in" exact="breast cancer" post="cells to promote cell survival [ 30]. Our new"/>
   <result pre="and survival signaling pathways, like the PI3K/Akt pathway, in breast" exact="cancer" post="cells to promote cell survival [ 30]. Our new"/>
   <result pre="demonstrate that HUNK is a critical survival protein in HER2+" exact="breast cancer" post="cells. We have shown that HUNK regulates tumor cell"/>
   <result pre="that HUNK is a critical survival protein in HER2+ breast" exact="cancer" post="cells. We have shown that HUNK regulates tumor cell"/>
   <result pre="these findings implicate HUNK as a potential target in HER2+" exact="breast cancer" post="that has the potential to be therapeutically beneficial in"/>
   <result pre="findings implicate HUNK as a potential target in HER2+ breast" exact="cancer" post="that has the potential to be therapeutically beneficial in"/>
   <result pre="Wen A Autophagy facilitates the Lapatinib resistance of HER2 positive" exact="breast cancer" post="cells Med Hypotheses 2011 77 2 206 208 10.1016/j.mehy.2011.04.013"/>
   <result pre="A Autophagy facilitates the Lapatinib resistance of HER2 positive breast" exact="cancer" post="cells Med Hypotheses 2011 77 2 206 208 10.1016/j.mehy.2011.04.013"/>
   <result pre="utility of transcriptome analysis of the autophagy interactome to guide" exact="breast cancer" post="treatment Oncotarget 2012 3 12 1600 1614 23307622 16."/>
   <result pre="of transcriptome analysis of the autophagy interactome to guide breast" exact="cancer" post="treatment Oncotarget 2012 3 12 1600 1614 23307622 16."/>
   <result pre="overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive" exact="breast cancer" post="Sci Rep 2013 3 2469 23965851 17. Vazquez-Martin A"/>
   <result pre="primary resistance and restores sensitivity to trastuzumab in HER2-positive breast" exact="cancer" post="Sci Rep 2013 3 2469 23965851 17. Vazquez-Martin A"/>
   <result pre="A Oliveras-Ferraros C Menendez JA Autophagy facilitates the development of" exact="breast cancer" post="resistance to the anti-HER2 monoclonal antibody trastuzumab PLoS ONE"/>
   <result pre="Oliveras-Ferraros C Menendez JA Autophagy facilitates the development of breast" exact="cancer" post="resistance to the anti-HER2 monoclonal antibody trastuzumab PLoS ONE"/>
   <result pre="a novel cell line established from a patient with Herceptin-resistant" exact="breast cancer" post="Mol Cancer Ther 2004 3 12 1585 1592 15634652"/>
   <result pre="novel cell line established from a patient with Herceptin-resistant breast" exact="cancer" post="Mol Cancer Ther 2004 3 12 1585 1592 15634652"/>
   <result pre="Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1" exact="breast cancer" post="cells Cancer Lett 2010 294 2 211 219 10.1016/j.canlet.2010.02.002"/>
   <result pre="molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast" exact="cancer" post="cells Cancer Lett 2010 294 2 211 219 10.1016/j.canlet.2010.02.002"/>
   <result pre="KL Shajahan AN Clarke R Autophagy and endocrine resistance in" exact="breast cancer" post="Expert Rev Anticancer Ther 2011 11 8 1283 1294"/>
   <result pre="Shajahan AN Clarke R Autophagy and endocrine resistance in breast" exact="cancer" post="Expert Rev Anticancer Ther 2011 11 8 1283 1294"/>
   <result pre="G et al. The acquisition of resistance to TNFalpha in" exact="breast cancer" post="cells is associated with constitutive activation of autophagy as"/>
   <result pre="et al. The acquisition of resistance to TNFalpha in breast" exact="cancer" post="cells is associated with constitutive activation of autophagy as"/>
   <result pre="Jackson WH Barrett JT Autophagy facilitates the progression of ERalpha-positive" exact="breast cancer" post="cells to antiestrogen resistance Autophagy 2009 5 3 400"/>
   <result pre="WH Barrett JT Autophagy facilitates the progression of ERalpha-positive breast" exact="cancer" post="cells to antiestrogen resistance Autophagy 2009 5 3 400"/>
   <result pre="Sun WL Chen J Wang YP Zheng H Autophagy protects" exact="breast cancer" post="cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development Autophagy"/>
   <result pre="WL Chen J Wang YP Zheng H Autophagy protects breast" exact="cancer" post="cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development Autophagy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346363/results/search/disease/results.xml">
   <result pre="Review Critical analysis of the potential for microRNA biomarkers in" exact="breast cancer" post="management Graveel Carrie R 1 Calderone Heather M 2"/>
   <result pre="Critical analysis of the potential for microRNA biomarkers in breast" exact="cancer" post="management Graveel Carrie R 1 Calderone Heather M 2"/>
   <result pre="Press Limited, provided the work is properly attributed. Abstract Breast" exact="cancer" post="is a complex and heterogeneous disease. Signaling by estrogen"/>
   <result pre="been incorporated into clinical practice, several challenges remain to improve" exact="breast cancer" post="management and patient survival, for which the integration of"/>
   <result pre="incorporated into clinical practice, several challenges remain to improve breast" exact="cancer" post="management and patient survival, for which the integration of"/>
   <result pre="rapidly emerging as novel potential approaches to manage and treat" exact="breast cancer." post="Rapid technological development enables specific and sensitive detection of"/>
   <result pre="entire miRNome in tissues, blood, and other biological specimens from" exact="breast cancer" post="patients. This review focuses on recent miRNA research and"/>
   <result pre="miRNome in tissues, blood, and other biological specimens from breast" exact="cancer" post="patients. This review focuses on recent miRNA research and"/>
   <result pre="and HER2; diagnostic and prognostic biomarkers for subgrouping of triple-negative" exact="breast cancer," post="for which there are currently no targeted therapies; and"/>
   <result pre="targeted therapies; and biomarkers for monitoring and characterization of metastatic" exact="breast cancer." post="The review concludes with a critical analysis of the"/>
   <result pre="with a critical analysis of the current state of miRNA" exact="breast cancer" post="research and the need for further studies using large"/>
   <result pre="a critical analysis of the current state of miRNA breast" exact="cancer" post="research and the need for further studies using large"/>
   <result pre="miR blood formalin-fixed paraffin-embedded tissues diagnostics FFPE tissues Introduction Breast" exact="cancer" post="is a highly heterogeneous disease that has multiple subtypes"/>
   <result pre="us a more thorough understanding of the molecular heterogeneity of" exact="breast cancer." post="Breast cancer is currently classified into six molecular intrinsic"/>
   <result pre="thorough understanding of the molecular heterogeneity of breast cancer. Breast" exact="cancer" post="is currently classified into six molecular intrinsic subtypes: luminal"/>
   <result pre="significantly overlap with the immunohistological subtype referred to as triple-negative" exact="breast cancer" post="(TNBC), which lacks ER, PR, and HER2 expression. Basal/TNBC"/>
   <result pre="overlap with the immunohistological subtype referred to as triple-negative breast" exact="cancer" post="(TNBC), which lacks ER, PR, and HER2 expression. Basal/TNBC"/>
   <result pre="no approved targeted therapies for these patients. 3, 4 Breast" exact="cancer" post="is a forerunner in the use of targeted therapeutic"/>
   <result pre="the lack of effective monitoring methods and treatments for metastatic" exact="breast cancer" post="(MBC; Table 6). In order to make advances in"/>
   <result pre="lack of effective monitoring methods and treatments for metastatic breast" exact="cancer" post="(MBC; Table 6). In order to make advances in"/>
   <result pre="that dysregulation of individual miRNAs influences signaling networks involved in" exact="breast cancer" post="progression. These studies suggest potential applications for miRNAs as"/>
   <result pre="dysregulation of individual miRNAs influences signaling networks involved in breast" exact="cancer" post="progression. These studies suggest potential applications for miRNAs as"/>
   <result pre="overview of miRNA biogenesis and detection methods with implications for" exact="breast cancer" post="management. We also discuss the potential clinical applications for"/>
   <result pre="of miRNA biogenesis and detection methods with implications for breast" exact="cancer" post="management. We also discuss the potential clinical applications for"/>
   <result pre="breakthroughs that have enabled high-throughput characterization of miRNA expression in" exact="cancer" post="tissues. Typically, these platforms require a large amount of"/>
   <result pre="limitations, have been applied to expression profiling of miRNAs in" exact="breast cancer" post="tissues and blood samples from breast cancer patients. 12–"/>
   <result pre="have been applied to expression profiling of miRNAs in breast" exact="cancer" post="tissues and blood samples from breast cancer patients. 12–"/>
   <result pre="of miRNAs in breast cancer tissues and blood samples from" exact="breast cancer" post="patients. 12– 15 miRNA biomarkers for early disease detection"/>
   <result pre="miRNAs in breast cancer tissues and blood samples from breast" exact="cancer" post="patients. 12– 15 miRNA biomarkers for early disease detection"/>
   <result pre="15 miRNA biomarkers for early disease detection The prognosis for" exact="breast cancer" post="patients is strongly influenced by the stage of the"/>
   <result pre="miRNA biomarkers for early disease detection The prognosis for breast" exact="cancer" post="patients is strongly influenced by the stage of the"/>
   <result pre="also correlates with poorer prognosis. Therefore, it is essential that" exact="breast cancer" post="lesions are diagnosed at the earliest stages. Mammography, ultrasound,"/>
   <result pre="correlates with poorer prognosis. Therefore, it is essential that breast" exact="cancer" post="lesions are diagnosed at the earliest stages. Mammography, ultrasound,"/>
   <result pre="earliest stages. 17 Mammography is the current gold standard for" exact="breast cancer" post="detection for women over the age of 39 years."/>
   <result pre="stages. 17 Mammography is the current gold standard for breast" exact="cancer" post="detection for women over the age of 39 years."/>
   <result pre="lesion or systemically, and reflect: 1) the number of lysed" exact="cancer" post="cells or other cells in the tumor microenvironment, 2)"/>
   <result pre="Ideally for analysis, circulating miRNAs would reflect the number of" exact="cancer" post="cells or other cell types specific to breast cancer"/>
   <result pre="number of cancer cells or other cell types specific to" exact="breast cancer" post="in the primary tumor. Many studies have compared changes"/>
   <result pre="of cancer cells or other cell types specific to breast" exact="cancer" post="in the primary tumor. Many studies have compared changes"/>
   <result pre="studies have compared changes in miRNA levels in blood between" exact="breast cancer" post="cases and age-matched healthy controls in order to identify"/>
   <result pre="have compared changes in miRNA levels in blood between breast" exact="cancer" post="cases and age-matched healthy controls in order to identify"/>
   <result pre="studies analyzed changes in miRNA levels between fewer than 30" exact="breast cancer" post="and 30 control samples in a single patient cohort,"/>
   <result pre="analyzed changes in miRNA levels between fewer than 30 breast" exact="cancer" post="and 30 control samples in a single patient cohort,"/>
   <result pre="might be useful for early detection of all types of" exact="breast cancer," post="whereas others might be useful for specific subtypes, histologies,"/>
   <result pre="found very few miRNAs whose changes in circulating levels between" exact="breast cancer" post="and control samples were consistent even when using similar"/>
   <result pre="very few miRNAs whose changes in circulating levels between breast" exact="cancer" post="and control samples were consistent even when using similar"/>
   <result pre="performed their own study that included plasma samples from 20" exact="breast cancer" post="patients before surgery, 20 age- and race-matched healthy controls,"/>
   <result pre="their own study that included plasma samples from 20 breast" exact="cancer" post="patients before surgery, 20 age- and race-matched healthy controls,"/>
   <result pre="age- and race-matched healthy controls, an independent set of 20" exact="breast cancer" post="patients after surgery, and ten patients with lung or"/>
   <result pre="and race-matched healthy controls, an independent set of 20 breast" exact="cancer" post="patients after surgery, and ten patients with lung or"/>
   <result pre="cancer patients after surgery, and ten patients with lung or" exact="colorectal cancer." post="Forty-six circulating miRNAs showed significant changes between pre-surgery breast"/>
   <result pre="colorectal cancer. Forty-six circulating miRNAs showed significant changes between pre-surgery" exact="breast cancer" post="patients and healthy controls. Using other reference groups in"/>
   <result pre="cancer. Forty-six circulating miRNAs showed significant changes between pre-surgery breast" exact="cancer" post="patients and healthy controls. Using other reference groups in"/>
   <result pre="amount of 13 of these miRNAs was similar between post-surgery" exact="breast cancer" post="cases and healthy controls, suggesting that the changes in"/>
   <result pre="of 13 of these miRNAs was similar between post-surgery breast" exact="cancer" post="cases and healthy controls, suggesting that the changes in"/>
   <result pre="miRNAs in pre-surgery patients reflected the presence of a primary" exact="breast cancer" post="tumor. 26 However, ten of the 13 miRNAs also"/>
   <result pre="in pre-surgery patients reflected the presence of a primary breast" exact="cancer" post="tumor. 26 However, ten of the 13 miRNAs also"/>
   <result pre="miRNAs also showed altered plasma levels in patients with other" exact="cancer" post="types, suggesting that they may more generally reflect a"/>
   <result pre="samples from a training set of 52 patients with invasive" exact="breast cancer," post="35 with noninvasive ductal carcinoma in situ (DCIS), and"/>
   <result pre="52 patients with invasive breast cancer, 35 with noninvasive ductal" exact="carcinoma in situ" post="(DCIS), and 35 healthy controls; 27 all study subjects"/>
   <result pre="independent cohort of 50 patients with stage I and II" exact="breast cancer" post="and 50 healthy controls. Moreover, miR-133a and miR-148b were"/>
   <result pre="cohort of 50 patients with stage I and II breast" exact="cancer" post="and 50 healthy controls. Moreover, miR-133a and miR-148b were"/>
   <result pre="and MDA-MB-231 cells, suggesting that they are secreted by the" exact="cancer" post="cells. The authors did not investigate the mechanism of"/>
   <result pre="monitored longitudinally in serum samples from a cohort of 63" exact="breast cancer" post="patients collected 1 day before surgery, 2–4 weeks after"/>
   <result pre="longitudinally in serum samples from a cohort of 63 breast" exact="cancer" post="patients collected 1 day before surgery, 2–4 weeks after"/>
   <result pre="biomarkers for detecting a wide array of heterogeneous presentations of" exact="breast cancer?" post="Longitudinal studies that collect blood from breast cancer patients,"/>
   <result pre="presentations of breast cancer? Longitudinal studies that collect blood from" exact="breast cancer" post="patients, ideally before diagnosis (healthy baseline), at diagnosis, before"/>
   <result pre="of breast cancer? Longitudinal studies that collect blood from breast" exact="cancer" post="patients, ideally before diagnosis (healthy baseline), at diagnosis, before"/>
   <result pre="BRCA gene mutation carriers, those with other genetic predispositions to" exact="breast cancer," post="or breast cancer survivors at high risk of recurrence,"/>
   <result pre="carriers, those with other genetic predispositions to breast cancer, or" exact="breast cancer" post="survivors at high risk of recurrence, could provide cohorts"/>
   <result pre="those with other genetic predispositions to breast cancer, or breast" exact="cancer" post="survivors at high risk of recurrence, could provide cohorts"/>
   <result pre="membrane-bound particles may more directly reflect the secretory phenotype of" exact="cancer" post="cells or other cells in the tumor microenvironment, than"/>
   <result pre="studies. Risk alleles of miRNA or target genes associated with" exact="breast cancer" post="By mining the genome for allele variants of miRNA"/>
   <result pre="Risk alleles of miRNA or target genes associated with breast" exact="cancer" post="By mining the genome for allele variants of miRNA"/>
   <result pre="some promise in helping identify individuals at risk of developing" exact="breast cancer." post="Single nucleotide polymorphisms (SNPs) in the miRNA precursor hairpin"/>
   <result pre="a protein, disruption of miRNA-mediated regulation can increase or decrease" exact="cancer" post="risk. According to the miRdSNP database, there are currently"/>
   <result pre="2 provides a comprehensive summary of miRNA-related SNPs linked to" exact="breast cancer;" post="some well-studied SNPs are highlighted below. SNPs in the"/>
   <result pre="with increased risk of developing certain types of cancer, including" exact="breast cancer." post="31 Race, ethnicity, and molecular subtype can influence the"/>
   <result pre="and is associated with a lower risk of developing familial" exact="breast cancer." post="34 The same allele was associated with lower risk"/>
   <result pre="The same allele was associated with lower risk of sporadic" exact="breast cancer" post="in a patient cohort of young Chinese women, 35"/>
   <result pre="same allele was associated with lower risk of sporadic breast" exact="cancer" post="in a patient cohort of young Chinese women, 35"/>
   <result pre="but the allele had no prognostic value in individuals with" exact="breast cancer" post="in this cohort. 35 The [C] allele of rs11614913"/>
   <result pre="the allele had no prognostic value in individuals with breast" exact="cancer" post="in this cohort. 35 The [C] allele of rs11614913"/>
   <result pre="in the pre-miR-499 were associated with increased risk of developing" exact="breast cancer" post="in a case–control study of Chinese women (1,009 breast"/>
   <result pre="the pre-miR-499 were associated with increased risk of developing breast" exact="cancer" post="in a case–control study of Chinese women (1,009 breast"/>
   <result pre="breast cancer in a case–control study of Chinese women (1,009" exact="breast cancer" post="patients and 1,093 healthy controls). 36 In contrast, the"/>
   <result pre="cancer in a case–control study of Chinese women (1,009 breast" exact="cancer" post="patients and 1,093 healthy controls). 36 In contrast, the"/>
   <result pre="contrast, the same variant alleles were not associated with increased" exact="breast cancer" post="risk in a case–control study of Italian and German"/>
   <result pre="the same variant alleles were not associated with increased breast" exact="cancer" post="risk in a case–control study of Italian and German"/>
   <result pre="in a case–control study of Italian and German women (1,894" exact="breast cancer" post="cases and 2,760 healthy controls). 37 The [C] allele"/>
   <result pre="a case–control study of Italian and German women (1,894 breast" exact="cancer" post="cases and 2,760 healthy controls). 37 The [C] allele"/>
   <result pre="bp and 10 kb of pre-miR-101, were associated with increased" exact="breast cancer" post="risk in a case– control study of Chinese women"/>
   <result pre="and 10 kb of pre-miR-101, were associated with increased breast" exact="cancer" post="risk in a case– control study of Chinese women"/>
   <result pre="risk in a case– control study of Chinese women (1,064" exact="breast cancer" post="cases and 1,073 healthy controls). 38 The authors suggest"/>
   <result pre="in a case– control study of Chinese women (1,064 breast" exact="cancer" post="cases and 1,073 healthy controls). 38 The authors suggest"/>
   <result pre="an increased risk of developing certain types of cancer, including" exact="breast cancer." post="The [G] allele of rs61764370 was associated with the"/>
   <result pre="women in case–control studies from Connecticut, US cohort with 415" exact="breast cancer" post="cases and 475 healthy controls, as well as from"/>
   <result pre="in case–control studies from Connecticut, US cohort with 415 breast" exact="cancer" post="cases and 475 healthy controls, as well as from"/>
   <result pre="controls, as well as from an Irish cohort with 690" exact="breast cancer" post="cases and 360 healthy controls. 39 This allele was"/>
   <result pre="as well as from an Irish cohort with 690 breast" exact="cancer" post="cases and 360 healthy controls. 39 This allele was"/>
   <result pre="controls. 39 This allele was also associated with familial BRCA1" exact="breast cancer" post="in a case– control study with 268 mutated BRCA1"/>
   <result pre="39 This allele was also associated with familial BRCA1 breast" exact="cancer" post="in a case– control study with 268 mutated BRCA1"/>
   <result pre="found in an independent case–control study with 530 sporadic postmenopausal" exact="breast cancer" post="cases, 165 familial breast cancer cases (regardless of BRCA"/>
   <result pre="in an independent case–control study with 530 sporadic postmenopausal breast" exact="cancer" post="cases, 165 familial breast cancer cases (regardless of BRCA"/>
   <result pre="study with 530 sporadic postmenopausal breast cancer cases, 165 familial" exact="breast cancer" post="cases (regardless of BRCA status), and 270 postmenopausal healthy"/>
   <result pre="with 530 sporadic postmenopausal breast cancer cases, 165 familial breast" exact="cancer" post="cases (regardless of BRCA status), and 270 postmenopausal healthy"/>
   <result pre="binding site for let-7. This allele is associated with decreased" exact="breast cancer" post="risk in two independent case–control studies of Chinese women"/>
   <result pre="site for let-7. This allele is associated with decreased breast" exact="cancer" post="risk in two independent case–control studies of Chinese women"/>
   <result pre="independent case–control studies of Chinese women with 878 and 914" exact="breast cancer" post="cases and 900 and 967 healthy controls, respectively. 42"/>
   <result pre="case–control studies of Chinese women with 878 and 914 breast" exact="cancer" post="cases and 900 and 967 healthy controls, respectively. 42"/>
   <result pre="of this DNA repair protein, which could be protective against" exact="cancer" post="development. The [T] allele of rs1434536 in the 3′-UTR"/>
   <result pre="for miR-125b. 43 This variant allele was associated with increased" exact="breast cancer" post="risk in a case–control study with 428 breast cancer"/>
   <result pre="miR-125b. 43 This variant allele was associated with increased breast" exact="cancer" post="risk in a case–control study with 428 breast cancer"/>
   <result pre="increased breast cancer risk in a case–control study with 428" exact="breast cancer" post="cases and 1,064 healthy controls. 43 Prognostic and predictive"/>
   <result pre="breast cancer risk in a case–control study with 428 breast" exact="cancer" post="cases and 1,064 healthy controls. 43 Prognostic and predictive"/>
   <result pre="1,064 healthy controls. 43 Prognostic and predictive miRNA biomarkers in" exact="breast cancer" post="subtypes with targeted therapies ER + breast cancers account"/>
   <result pre="healthy controls. 43 Prognostic and predictive miRNA biomarkers in breast" exact="cancer" post="subtypes with targeted therapies ER + breast cancers account"/>
   <result pre="46 Even though trastuzumab is effective, almost half of the" exact="breast cancer" post="patients that overexpress HER2 are either nonresponsive to trastuzumab"/>
   <result pre="Even though trastuzumab is effective, almost half of the breast" exact="cancer" post="patients that overexpress HER2 are either nonresponsive to trastuzumab"/>
   <result pre="Profiling of miRNA expression in clinical tissue specimens and/or in" exact="breast cancer" post="cell line models of drug resistance has linked individual"/>
   <result pre="of miRNA expression in clinical tissue specimens and/or in breast" exact="cancer" post="cell line models of drug resistance has linked individual"/>
   <result pre="and miR-302c have been shown to regulate ER expression in" exact="breast cancer" post="cell line models and, in some instances, miRNA overexpression"/>
   <result pre="miR-302c have been shown to regulate ER expression in breast" exact="cancer" post="cell line models and, in some instances, miRNA overexpression"/>
   <result pre="cluster and of miR-342 is driven by ER signaling in" exact="breast cancer" post="cell lines and their expression correlates with ER status"/>
   <result pre="and of miR-342 is driven by ER signaling in breast" exact="cancer" post="cell lines and their expression correlates with ER status"/>
   <result pre="sites on the 3′-UTR of its mRNA in HER2 +" exact="breast cancer" post="cell lines (eg, BT-474, MDA-MB-453, and SK-BR-3). 71– 73"/>
   <result pre="on the 3′-UTR of its mRNA in HER2 + breast" exact="cancer" post="cell lines (eg, BT-474, MDA-MB-453, and SK-BR-3). 71– 73"/>
   <result pre="76 Altered expression of these miRNAs has been associated with" exact="breast cancer," post="but for most of them, there is not a"/>
   <result pre="studies (but not others) to be overexpressed in HER2 +" exact="breast cancer" post="tissues. 56, 77, 78 Indeed, miR-4728 is cotranscribed with"/>
   <result pre="(but not others) to be overexpressed in HER2 + breast" exact="cancer" post="tissues. 56, 77, 78 Indeed, miR-4728 is cotranscribed with"/>
   <result pre="are known to be expressed in cell types other than" exact="breast cancer" post="cells, 87– 91 and thus, their altered expression may"/>
   <result pre="known to be expressed in cell types other than breast" exact="cancer" post="cells, 87– 91 and thus, their altered expression may"/>
   <result pre="phyllodes tumors, 94 as well as in colorectal 95 and" exact="pancreatic cancer," post="96 upregulation of miR-21 expression promotes myofibrogenesis and regulates"/>
   <result pre="cell type(s) that express miRNAs associated with TNBC or other" exact="breast cancer" post="subtypes. miRNA biomarkers for monitoring and characterization of metastatic"/>
   <result pre="type(s) that express miRNAs associated with TNBC or other breast" exact="cancer" post="subtypes. miRNA biomarkers for monitoring and characterization of metastatic"/>
   <result pre="significant progress has been made in detecting and treating primary" exact="breast cancer," post="advances in the treatment of MBC have been marginal."/>
   <result pre="in primary tumor tissues, as well as in blood from" exact="breast cancer" post="cases with concurrent metastatic disease, either regional (lymph node"/>
   <result pre="primary tumor tissues, as well as in blood from breast" exact="cancer" post="cases with concurrent metastatic disease, either regional (lymph node"/>
   <result pre="bone, lung). miR-10b promotes invasion and metastatic programs in human" exact="breast cancer" post="cell lines and mouse models via HoxD10 inhibition, which"/>
   <result pre="lung). miR-10b promotes invasion and metastatic programs in human breast" exact="cancer" post="cell lines and mouse models via HoxD10 inhibition, which"/>
   <result pre="correlated with concurrent metastasis in a patient cohort of five" exact="breast cancer" post="cases without metastasis and 18 MBC cases. 100 Higher"/>
   <result pre="with concurrent metastasis in a patient cohort of five breast" exact="cancer" post="cases without metastasis and 18 MBC cases. 100 Higher"/>
   <result pre="cohort of 20 MBC cases with brain metastasis and ten" exact="breast cancer" post="cases without brain metastasis. 101 In another study, miR-10b"/>
   <result pre="of 20 MBC cases with brain metastasis and ten breast" exact="cancer" post="cases without brain metastasis. 101 In another study, miR-10b"/>
   <result pre="progression or clinical outcome in a cohort of 84 early-stage" exact="breast cancer" post="patients 106 or in another cohort of 219 breast"/>
   <result pre="or clinical outcome in a cohort of 84 early-stage breast" exact="cancer" post="patients 106 or in another cohort of 219 breast"/>
   <result pre="breast cancer patients 106 or in another cohort of 219" exact="breast cancer" post="patients, 107 both with long-term (.10 years) clinical follow-up"/>
   <result pre="cancer patients 106 or in another cohort of 219 breast" exact="cancer" post="patients, 107 both with long-term (.10 years) clinical follow-up"/>
   <result pre="tissues in a large cohort. This could provide information about" exact="cancer" post="cell evolution, as well as the tumor microenvironment niche"/>
   <result pre="108 A recent ISH-based study in a limited number of" exact="breast cancer" post="cases reported that expression of miR-708 was markedly downregulated"/>
   <result pre="A recent ISH-based study in a limited number of breast" exact="cancer" post="cases reported that expression of miR-708 was markedly downregulated"/>
   <result pre="of the miR-23 cluster (miR-23, miR-24, and miR-27b) 114 in" exact="breast cancer." post="The prognostic value of these miRNAs needs to be"/>
   <result pre="miR-29a, and miR-126 were relatively higher in plasma samples from" exact="breast cancer" post="patients relative to those of healthy controls, there were"/>
   <result pre="and miR-126 were relatively higher in plasma samples from breast" exact="cancer" post="patients relative to those of healthy controls, there were"/>
   <result pre="we discussed above for miRNA-based early-disease detection assays. Conclusion Breast" exact="cancer" post="has been widely studied and characterized at the molecular"/>
   <result pre="a general look at the state of miRNA research on" exact="breast cancer." post="We limited our discussion to studies that associated miRNA"/>
   <result pre="detection ( Tables 1 and 2), management of a specific" exact="breast cancer" post="subtype ( Tables 3– 5), or new opportunities to"/>
   <result pre="( Tables 1 and 2), management of a specific breast" exact="cancer" post="subtype ( Tables 3– 5), or new opportunities to"/>
   <result pre="that use qRT-PCR-based detection of miRNAs for differential diagnosis of" exact="pancreatic cancer," post="subtyping of lung and kidney cancers, and identification of"/>
   <result pre="origin for cancers having an unknown primary. 121, 122 For" exact="breast cancer" post="applications, there is little agreement on the reported individual"/>
   <result pre="for cancers having an unknown primary. 121, 122 For breast" exact="cancer" post="applications, there is little agreement on the reported individual"/>
   <result pre="the context of TNBC. Stromal features are known to influence" exact="cancer" post="cell characteristics. 123, 124 Therefore, it is likely that"/>
   <result pre="in other cellular compartments of the tumor microenvironment also influences" exact="cancer" post="cells. Detection methods that incorporate the context of altered"/>
   <result pre="specific recommendations for clinical implementation of miRNA biomarkers in managing" exact="breast cancer." post="More research is needed that includes multi-institutional participation and"/>
   <result pre="clinical characteristics to validate the clinical value of miRNAs in" exact="breast cancer." post="Acknowledgments We thank David Nadziejka for technical editing. Disclosure"/>
   <result pre="1 Prat A Perou CM Deconstructing the molecular portraits of" exact="breast cancer" post="Mol Oncol 2011 5 1 5 23 21147047 2"/>
   <result pre="Prat A Perou CM Deconstructing the molecular portraits of breast" exact="cancer" post="Mol Oncol 2011 5 1 5 23 21147047 2"/>
   <result pre="142 25284793 3 Foulkes WD Smith IE Reis-Filho JS Triple-negative" exact="breast cancer" post="N Engl J Med 2010 363 20 1938 1948"/>
   <result pre="25284793 3 Foulkes WD Smith IE Reis-Filho JS Triple-negative breast" exact="cancer" post="N Engl J Med 2010 363 20 1938 1948"/>
   <result pre="5 Di Leva G Garofalo M Croce CM MicroRNAs in" exact="cancer" post="Annu Rev Pathol 2014 9 287 314 24079833 6"/>
   <result pre="I Calin GA Epigenetically regulated microRNAs and their prospect in" exact="cancer" post="diagnosis Expert Rev Mol Diagn 2014 14 6 673"/>
   <result pre="et al. Mammographic density and the risk and detection of" exact="breast cancer" post="N Engl J Med 2007 356 3 227 236"/>
   <result pre="al. Mammographic density and the risk and detection of breast" exact="cancer" post="N Engl J Med 2007 356 3 227 236"/>
   <result pre="GJ The emerging role of the molecular diagnostics laboratory in" exact="breast cancer" post="personalized medicine Am J Pathol 2013 183 4 1075"/>
   <result pre="The emerging role of the molecular diagnostics laboratory in breast" exact="cancer" post="personalized medicine Am J Pathol 2013 183 4 1075"/>
   <result pre="22 Haizhong M Liang C Wang G et al. MicroRNA-mediated" exact="cancer" post="metastasis regulation via heterotypic signals in the microenvironment Curr"/>
   <result pre="Li L Thompson CL Dampening enthusiasm for circulating microRNA in" exact="breast cancer" post="PLoS One 2013 8 3 e57841 23472110 27 Shen"/>
   <result pre="L Thompson CL Dampening enthusiasm for circulating microRNA in breast" exact="cancer" post="PLoS One 2013 8 3 e57841 23472110 27 Shen"/>
   <result pre="M et al. Circulating miR-148b and miR-133a as biomarkers for" exact="breast cancer" post="detection Oncotarget 2014 5 14 5284 5294 25051376 28"/>
   <result pre="et al. Circulating miR-148b and miR-133a as biomarkers for breast" exact="cancer" post="detection Oncotarget 2014 5 14 5284 5294 25051376 28"/>
   <result pre="HJ Alterations in circulating miRNA levels following early-stage estrogen receptor-positive" exact="breast cancer" post="resection in post-menopausal women PLoS One 2014 9 7"/>
   <result pre="Alterations in circulating miRNA levels following early-stage estrogen receptor-positive breast" exact="cancer" post="resection in post-menopausal women PLoS One 2014 9 7"/>
   <result pre="microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early" exact="breast cancer" post="in serum BMC Cancer 2014 14 448 24938880 30"/>
   <result pre="miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast" exact="cancer" post="in serum BMC Cancer 2014 14 448 24938880 30"/>
   <result pre="Yu L Jiang de K Association between microRNA polymorphisms and" exact="cancer" post="risk based on the findings of 66 case-control studies"/>
   <result pre="et al. Different effects of three polymorphisms in MicroRNAs on" exact="cancer" post="risk in Asian population: evidence from published literatures PLoS"/>
   <result pre="K Shen J et al. Genetic variants in microRNAs and" exact="breast cancer" post="risk in African American and European American women Breast"/>
   <result pre="Shen J et al. Genetic variants in microRNAs and breast" exact="cancer" post="risk in African American and European American women Breast"/>
   <result pre="in the pre-miR-27a oncogene is associated with a reduced familial" exact="breast cancer" post="risk Breast Cancer Res Treat 2010 121 3 693"/>
   <result pre="the pre-miR-27a oncogene is associated with a reduced familial breast" exact="cancer" post="risk Breast Cancer Res Treat 2010 121 3 693"/>
   <result pre="A genetic variant in pre-miR-27a is associated with a reduced" exact="breast cancer" post="risk in younger Chinese population Gene 2013 529 1"/>
   <result pre="genetic variant in pre-miR-27a is associated with a reduced breast" exact="cancer" post="risk in younger Chinese population Gene 2013 529 1"/>
   <result pre="genetic variants in pre-microRNAs were associated with increased risk of" exact="breast cancer" post="in Chinese women Hum Mutat 2009 30 1 79"/>
   <result pre="variants in pre-microRNAs were associated with increased risk of breast" exact="cancer" post="in Chinese women Hum Mutat 2009 30 1 79"/>
   <result pre="and miR-499 as low-penetrance alleles in German and Italian familial" exact="breast cancer" post="cases Hum Mutat 2010 31 1 E1052 E1057 19847796"/>
   <result pre="miR-499 as low-penetrance alleles in German and Italian familial breast" exact="cancer" post="cases Hum Mutat 2010 31 1 E1052 E1057 19847796"/>
   <result pre="flanking regions of miR-101-2 are associated with increased risk of" exact="breast cancer" post="PLoS One 2014 9 1 e86319 24475105 39 Paranjape"/>
   <result pre="regions of miR-101-2 are associated with increased risk of breast" exact="cancer" post="PLoS One 2014 9 1 e86319 24475105 39 Paranjape"/>
   <result pre="the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2" exact="breast cancer" post="families Breast Cancer Res Treat 2011 128 1 79"/>
   <result pre="3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast" exact="cancer" post="families Breast Cancer Res Treat 2011 128 1 79"/>
   <result pre="Novakovic S KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated" exact="breast cancer" post="in hormone replacement therapy users: a case control study"/>
   <result pre="S KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast" exact="cancer" post="in hormone replacement therapy users: a case control study"/>
   <result pre="in a hsa-let-7 binding site in RAD52 is associated with" exact="breast cancer" post="susceptibility Carcinogenesis 2013 34 3 689 693 23188672 43"/>
   <result pre="a hsa-let-7 binding site in RAD52 is associated with breast" exact="cancer" post="susceptibility Carcinogenesis 2013 34 3 689 693 23188672 43"/>
   <result pre="in an miR-125b binding site in BMPR1B is associated with" exact="breast cancer" post="pathogenesis Cancer Res 2009 69 18 7459 7465 19738052"/>
   <result pre="an miR-125b binding site in BMPR1B is associated with breast" exact="cancer" post="pathogenesis Cancer Res 2009 69 18 7459 7465 19738052"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="J Clin Oncol 2007 25 1 118 145 17159189"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="J Clin Oncol 2007 25 1 118 145 17159189"/>
   <result pre="Wolmark N HER2 status and benefit from adjuvant trastuzumab in" exact="breast cancer" post="N Engl J Med 2008 358 13 1409 1411"/>
   <result pre="N HER2 status and benefit from adjuvant trastuzumab in breast" exact="cancer" post="N Engl J Med 2008 358 13 1409 1411"/>
   <result pre="as a single agent in first-line treatment of HER2-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 2002 20 3 719 726 11821453"/>
   <result pre="a single agent in first-line treatment of HER2-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 2002 20 3 719 726 11821453"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="of microRNAs that directly target estrogen receptor alpha in human" exact="breast cancer" post="Breast Cancer Res Treat 2011 130 1 331 339"/>
   <result pre="microRNAs that directly target estrogen receptor alpha in human breast" exact="cancer" post="Breast Cancer Res Treat 2011 130 1 331 339"/>
   <result pre="X Di Leva G Li M et al. MicroRNA-221/222 confers" exact="breast cancer" post="fulvestrant resistance by regulating multiple signaling pathways Oncogene 2011"/>
   <result pre="Di Leva G Li M et al. MicroRNA-221/222 confers breast" exact="cancer" post="fulvestrant resistance by regulating multiple signaling pathways Oncogene 2011"/>
   <result pre="Lu J Meng QH Downregulation of miR-221/222 enhances sensitivity of" exact="breast cancer" post="cells to tamoxifen through upregulation of TIMP3 Cancer Gene"/>
   <result pre="J Meng QH Downregulation of miR-221/222 enhances sensitivity of breast" exact="cancer" post="cells to tamoxifen through upregulation of TIMP3 Cancer Gene"/>
   <result pre="alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human" exact="breast cancer" post="cell lines and clinical samples FEBS J 2010 277"/>
   <result pre="suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast" exact="cancer" post="cell lines and clinical samples FEBS J 2010 277"/>
   <result pre="predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in" exact="breast cancer" post="Breast Cancer Res 2009 11 3 R27 19432961 57"/>
   <result pre="oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast" exact="cancer" post="Breast Cancer Res 2009 11 3 R27 19432961 57"/>
   <result pre="et al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of" exact="breast cancer" post="cells depending on estrogen receptor status PLoS Genet 2013"/>
   <result pre="al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast" exact="cancer" post="cells depending on estrogen receptor status PLoS Genet 2013"/>
   <result pre="associated with estrogen receptor-alpha expression and response to tamoxifen in" exact="breast cancer" post="Exp Ther Med 2013 5 3 813 818 23408138"/>
   <result pre="with estrogen receptor-alpha expression and response to tamoxifen in breast" exact="cancer" post="Exp Ther Med 2013 5 3 813 818 23408138"/>
   <result pre="and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive" exact="breast cancer" post="following tamoxifen treatment Eur J Cancer 2013 49 17"/>
   <result pre="miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast" exact="cancer" post="following tamoxifen treatment Eur J Cancer 2013 49 17"/>
   <result pre="clinical benefit of endocrine therapy in advanced estrogen receptor positive" exact="breast cancer" post="Breast Cancer Res Treat 2011 127 1 43 51"/>
   <result pre="benefit of endocrine therapy in advanced estrogen receptor positive breast" exact="cancer" post="Breast Cancer Res Treat 2011 127 1 43 51"/>
   <result pre="associated with tumor proliferation, invasion and poor clinical outcome in" exact="breast cancer" post="PLoS One 2011 6 6 e20980 21738599 63 Ward"/>
   <result pre="with tumor proliferation, invasion and poor clinical outcome in breast" exact="cancer" post="PLoS One 2011 6 6 e20980 21738599 63 Ward"/>
   <result pre="resistance by targeting a network of tumour-suppressor genes in ER+" exact="breast cancer" post="J Pathol 2014 233 4 368 379 24752803 64"/>
   <result pre="by targeting a network of tumour-suppressor genes in ER+ breast" exact="cancer" post="J Pathol 2014 233 4 368 379 24752803 64"/>
   <result pre="associated with aggressiveness of lymph node-negative, estrogen receptor- positive human" exact="breast cancer" post="Proc Natl Acad Sci U S A 2008 105"/>
   <result pre="with aggressiveness of lymph node-negative, estrogen receptor- positive human breast" exact="cancer" post="Proc Natl Acad Sci U S A 2008 105"/>
   <result pre="an independent factor indicating a poor prognosis in Japanese triple-negative" exact="breast cancer" post="patients Jpn J Clin Oncol 2012 42 4 256"/>
   <result pre="independent factor indicating a poor prognosis in Japanese triple-negative breast" exact="cancer" post="patients Jpn J Clin Oncol 2012 42 4 256"/>
   <result pre="targets identified by integrated mRNA and microRNA expression profiling in" exact="breast cancer" post="Cancer Res 2011 71 17 5635 5645 21737487 68"/>
   <result pre="identified by integrated mRNA and microRNA expression profiling in breast" exact="cancer" post="Cancer Res 2011 71 17 5635 5645 21737487 68"/>
   <result pre="induced by hypoxia and is an independent prognostic factor in" exact="breast cancer" post="Clin Cancer Res 2008 14 5 1340 1348 18316553"/>
   <result pre="by hypoxia and is an independent prognostic factor in breast" exact="cancer" post="Clin Cancer Res 2008 14 5 1340 1348 18316553"/>
   <result pre="A Bhaumik D Berger CE Sullivan CS Benz CC Coordinate" exact="suppression" post="of ERBB2 and ERBB3 by enforced expression of micro-RNA"/>
   <result pre="et al. High-throughput screens identify microRNAs essential for HER2 positive" exact="breast cancer" post="cell growth Mol Oncol 2014 8 1 93 104"/>
   <result pre="al. High-throughput screens identify microRNAs essential for HER2 positive breast" exact="cancer" post="cell growth Mol Oncol 2014 8 1 93 104"/>
   <result pre="Fang C Zhao Y Guo B MiR-199b-5p targets HER2 in" exact="breast cancer" post="cells J Cell Biochem 2013 114 7 1457 1463"/>
   <result pre="C Zhao Y Guo B MiR-199b-5p targets HER2 in breast" exact="cancer" post="cells J Cell Biochem 2013 114 7 1457 1463"/>
   <result pre="P Piovan C et al. microRNA-205 regulates HER3 in human" exact="breast cancer" post="Cancer Res 2009 69 6 2195 2200 19276373 75"/>
   <result pre="Piovan C et al. microRNA-205 regulates HER3 in human breast" exact="cancer" post="Cancer Res 2009 69 6 2195 2200 19276373 75"/>
   <result pre="Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in" exact="breast cancer" post="cells PLoS One 2012 7 2 e31422 22384020 76"/>
   <result pre="produces therapeutic actions by upregulating miR-26a and miR-30b in breast" exact="cancer" post="cells PLoS One 2012 7 2 e31422 22384020 76"/>
   <result pre="Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in" exact="breast cancer" post="PLoS One 2012 7 7 e41170 22829924 77 Lee"/>
   <result pre="of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast" exact="cancer" post="PLoS One 2012 7 7 e41170 22829924 77 Lee"/>
   <result pre="al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for" exact="breast cancer" post="J Biol Chem 2011 286 21 19127 19137 21471222"/>
   <result pre="Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast" exact="cancer" post="J Biol Chem 2011 286 21 19127 19137 21471222"/>
   <result pre="expression profiling provides novel biomarker assessment of clinical prostate and" exact="breast cancer" post="biopsies Mol Cancer 2006 5 24 16784538 83 Gao"/>
   <result pre="profiling provides novel biomarker assessment of clinical prostate and breast" exact="cancer" post="biopsies Mol Cancer 2006 5 24 16784538 83 Gao"/>
   <result pre="et al. The association between two polymorphisms in pre-miRNAs and" exact="breast cancer" post="risk: a meta-analysis Breast Cancer Res Treat 2011 125"/>
   <result pre="al. The association between two polymorphisms in pre-miRNAs and breast" exact="cancer" post="risk: a meta-analysis Breast Cancer Res Treat 2011 125"/>
   <result pre="200b and receptor status in core biopsies from stage III" exact="breast cancer" post="patients DNA Cell Biol 2014 33 9 624 629"/>
   <result pre="and receptor status in core biopsies from stage III breast" exact="cancer" post="patients DNA Cell Biol 2014 33 9 624 629"/>
   <result pre="al. MicroRNA profiling implies new markers of chemoresistance of triple-negative" exact="breast cancer" post="PLoS One 2014 9 5 e96228 24788655 87 Sempere"/>
   <result pre="MicroRNA profiling implies new markers of chemoresistance of triple-negative breast" exact="cancer" post="PLoS One 2014 9 5 e96228 24788655 87 Sempere"/>
   <result pre="Altered MicroRNA expression confined to specific epithelial cell subpopulations in" exact="breast cancer" post="Cancer Res 2007 67 24 11612 11620 18089790 88"/>
   <result pre="MicroRNA expression confined to specific epithelial cell subpopulations in breast" exact="cancer" post="Cancer Res 2007 67 24 11612 11620 18089790 88"/>
   <result pre="High expression of miR-21 in tumor stroma correlates with increased" exact="cancer" post="cell proliferation in human breast cancer APMIS 2011 119"/>
   <result pre="tumor stroma correlates with increased cancer cell proliferation in human" exact="breast cancer" post="APMIS 2011 119 10 663 673 21917003 92 Susman"/>
   <result pre="stroma correlates with increased cancer cell proliferation in human breast" exact="cancer" post="APMIS 2011 119 10 663 673 21917003 92 Susman"/>
   <result pre="A Berindan-Neagoe I The importance of microRNAs in the stroma-breast" exact="cancer" post="cell interplay Cancer Biomark 2014 14 2–3 137 144"/>
   <result pre="microRNA characterization of tumors: how detailed could diagnosis become for" exact="cancer" post="medicine? Expert Rev Mol Diagn 2014 14 7 853"/>
   <result pre="miR-21 highlight the critical role of deregulated stromal microRNAs during" exact="colorectal cancer" post="progression Cell Death Dis 2013 4 e684 23788041 96"/>
   <result pre="highlight the critical role of deregulated stromal microRNAs during colorectal" exact="cancer" post="progression Cell Death Dis 2013 4 e684 23788041 96"/>
   <result pre="al. Stromal expression of miR-21 identifies high-risk group in triple-negative" exact="breast cancer" post="Am J Pathol 2014 184 12 3217 3225 25440114"/>
   <result pre="Stromal expression of miR-21 identifies high-risk group in triple-negative breast" exact="cancer" post="Am J Pathol 2014 184 12 3217 3225 25440114"/>
   <result pre="12 3217 3225 25440114 98 Wang L Wang J MicroRNA-mediated" exact="breast cancer" post="metastasis: from primary site to distant organs Oncogene 2012"/>
   <result pre="3217 3225 25440114 98 Wang L Wang J MicroRNA-mediated breast" exact="cancer" post="metastasis: from primary site to distant organs Oncogene 2012"/>
   <result pre="Weinberg RA Tumour invasion and metastasis initiated by microRNA-10b in" exact="breast cancer" post="Nature 2007 449 7163 682 688 17898713 101 Ahmad"/>
   <result pre="RA Tumour invasion and metastasis initiated by microRNA-10b in breast" exact="cancer" post="Nature 2007 449 7163 682 688 17898713 101 Ahmad"/>
   <result pre="Up- regulation of microRNA-10b is associated with the development of" exact="breast cancer" post="brain metastasis Am J Transl Res 2014 6 4"/>
   <result pre="regulation of microRNA-10b is associated with the development of breast" exact="cancer" post="brain metastasis Am J Transl Res 2014 6 4"/>
   <result pre="Evaluation of microRNA-10b prognostic significance in a prospective cohort of" exact="breast cancer" post="patients Mol Cancer 2014 13 142 24897960 103 Chen"/>
   <result pre="of microRNA-10b prognostic significance in a prospective cohort of breast" exact="cancer" post="patients Mol Cancer 2014 13 142 24897960 103 Chen"/>
   <result pre="Serum overexpression of microRNA-10b in patients with bone metastatic primary" exact="breast cancer" post="J Int Med Res 2012 40 3 859 866"/>
   <result pre="overexpression of microRNA-10b in patients with bone metastatic primary breast" exact="cancer" post="J Int Med Res 2012 40 3 859 866"/>
   <result pre="et al. High serum miR-19a levels are associated with inflammatory" exact="breast cancer" post="and are predictive of favorable clinical outcome in patients"/>
   <result pre="al. High serum miR-19a levels are associated with inflammatory breast" exact="cancer" post="and are predictive of favorable clinical outcome in patients"/>
   <result pre="of favorable clinical outcome in patients with metastatic HER2+ inflammatory" exact="breast cancer" post="PLoS One 2014 9 1 e83113 24416156 106 Markou"/>
   <result pre="favorable clinical outcome in patients with metastatic HER2+ inflammatory breast" exact="cancer" post="PLoS One 2014 9 1 e83113 24416156 106 Markou"/>
   <result pre="V Lianidou E Prognostic significance of metastasis-related microRNAs in early" exact="breast cancer" post="patients with a long follow-up Clin Chem 2014 60"/>
   <result pre="Lianidou E Prognostic significance of metastasis-related microRNAs in early breast" exact="cancer" post="patients with a long follow-up Clin Chem 2014 60"/>
   <result pre="Gee HE Camps C Buffa FM et al. MicroRNA-10b and" exact="breast cancer" post="metastasis Nature 2008 455 7216 E8 E9 ; author"/>
   <result pre="HE Camps C Buffa FM et al. MicroRNA-10b and breast" exact="cancer" post="metastasis Nature 2008 455 7216 E8 E9 ; author"/>
   <result pre="exhibit differential expression in primary versus corresponding metastatic tissue in" exact="breast cancer" post="Breast Cancer Res Treat 2012 134 1 207 217"/>
   <result pre="differential expression in primary versus corresponding metastatic tissue in breast" exact="cancer" post="Breast Cancer Res Treat 2012 134 1 207 217"/>
   <result pre="F Pandey PR et al. miR-7 suppresses brain metastasis of" exact="breast cancer" post="stem-like cells by modulating KLF4 Cancer Res 2013 73"/>
   <result pre="Pandey PR et al. miR-7 suppresses brain metastasis of breast" exact="cancer" post="stem-like cells by modulating KLF4 Cancer Res 2013 73"/>
   <result pre="Qiu Q Wei Y et al. The MicroRNA-23b/27b/24 cluster promotes" exact="breast cancer" post="lung metastasis by targeting metastasis- suppressive gene prosaposin J"/>
   <result pre="Q Wei Y et al. The MicroRNA-23b/27b/24 cluster promotes breast" exact="cancer" post="lung metastasis by targeting metastasis- suppressive gene prosaposin J"/>
   <result pre="Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in" exact="cancer" post="patients Expert Rev Mol Diagn 2011 11 3 259"/>
   <result pre="profiles in circulating tumor cells and primary tumors of metastatic" exact="breast cancer" post="patients Clin Cancer Res 2011 17 11 3600 3618"/>
   <result pre="in circulating tumor cells and primary tumors of metastatic breast" exact="cancer" post="patients Clin Cancer Res 2011 17 11 3600 3618"/>
   <result pre="markers for circulating tumor cells and prognostic markers in metastatic" exact="breast cancer" post="Clin Cancer Res 2012 18 21 5972 5982 22952344"/>
   <result pre="for circulating tumor cells and prognostic markers in metastatic breast" exact="cancer" post="Clin Cancer Res 2012 18 21 5972 5982 22952344"/>
   <result pre="serum may predict the sensitivity of luminal A subtype of" exact="breast cancer" post="patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel PLoS"/>
   <result pre="may predict the sensitivity of luminal A subtype of breast" exact="cancer" post="patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel PLoS"/>
   <result pre="levels correlate with sensitivity to trastuzumab and tumor presence in" exact="breast cancer" post="patients Cancer 2012 118 10 2603 2614 22370716 120"/>
   <result pre="correlate with sensitivity to trastuzumab and tumor presence in breast" exact="cancer" post="patients Cancer 2012 118 10 2603 2614 22370716 120"/>
   <result pre="in serum levels of miR-21, miR-210, and miR-373 in HER2-positive" exact="breast cancer" post="patients undergoing neoadjuvant therapy: a translational research project within"/>
   <result pre="serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast" exact="cancer" post="patients undergoing neoadjuvant therapy: a translational research project within"/>
   <result pre="F et al. Stromal gene expression predicts clinical outcome in" exact="breast cancer" post="Nat Med 2008 14 5 518 527 18438415 124"/>
   <result pre="et al. Stromal gene expression predicts clinical outcome in breast" exact="cancer" post="Nat Med 2008 14 5 518 527 18438415 124"/>
   <result pre="al. Integrated molecular profiles of invasive breast tumors and ductal" exact="carcinoma in situ" post="(DCIS) reveal differential vascular and interleukin signaling Proc Natl"/>
   <result pre="RNA, let-7b and miR-202 in the blood of patients with" exact="breast cancer" post="and benign breast diseases Br J Cancer 2014 111"/>
   <result pre="let-7b and miR-202 in the blood of patients with breast" exact="cancer" post="and benign breast diseases Br J Cancer 2014 111"/>
   <result pre="Ji SM et al. Identification of circulating microRNA signatures for" exact="breast cancer" post="detection Clin Cancer Res 2013 19 16 4477 4487"/>
   <result pre="SM et al. Identification of circulating microRNA signatures for breast" exact="cancer" post="detection Clin Cancer Res 2013 19 16 4477 4487"/>
   <result pre="et al. Serum circulating microRNA profiling for identification of potential" exact="breast cancer" post="biomarkers Dis Markers 2013 34 3 163 169 23334650"/>
   <result pre="al. Serum circulating microRNA profiling for identification of potential breast" exact="cancer" post="biomarkers Dis Markers 2013 34 3 163 169 23334650"/>
   <result pre="screen for aberrantly expressed miRNAs reveals miRNA profile signature in" exact="breast cancer" post="Mol Biol Rep 2013 40 3 2175 2186 23196705"/>
   <result pre="for aberrantly expressed miRNAs reveals miRNA profile signature in breast" exact="cancer" post="Mol Biol Rep 2013 40 3 2175 2186 23196705"/>
   <result pre="et al. Serum microRNA expression as an early marker for" exact="breast cancer" post="risk in prospectively collected samples from the Sister Study"/>
   <result pre="al. Serum microRNA expression as an early marker for breast" exact="cancer" post="risk in prospectively collected samples from the Sister Study"/>
   <result pre="Guo L Li X Clinical significance of serum miR-21 in" exact="breast cancer" post="compared with CA153 and CEA Chin J Cancer Res"/>
   <result pre="L Li X Clinical significance of serum miR-21 in breast" exact="cancer" post="compared with CA153 and CEA Chin J Cancer Res"/>
   <result pre="microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary" exact="breast cancer" post="J Cancer Res Clin Oncol 2013 139 2 223"/>
   <result pre="and microRNA-21 as novel minimally invasive biomarkers for primary breast" exact="cancer" post="J Cancer Res Clin Oncol 2013 139 2 223"/>
   <result pre="provides a sensitive and specific tool for the diagnosis of" exact="breast cancer" post="Mol Med Rep 2014 10 2 785 791 24866395"/>
   <result pre="a sensitive and specific tool for the diagnosis of breast" exact="cancer" post="Mol Med Rep 2014 10 2 785 791 24866395"/>
   <result pre="of miRNA-30a in human plasma is a novel marker for" exact="breast cancer" post="Med Oncol 2013 30 1 477 23389917 135 Cuk"/>
   <result pre="miRNA-30a in human plasma is a novel marker for breast" exact="cancer" post="Med Oncol 2013 30 1 477 23389917 135 Cuk"/>
   <result pre="et al. Plasma microRNA panel for minimally invasive detection of" exact="breast cancer" post="PLoS One 2013 8 10 e76729 24194846 136 Waters"/>
   <result pre="al. Plasma microRNA panel for minimally invasive detection of breast" exact="cancer" post="PLoS One 2013 8 10 e76729 24194846 136 Waters"/>
   <result pre="al. Impact of tumour epithelial subtype on circulating microRNAs in" exact="breast cancer" post="patients PLoS One 2014 9 3 e90605 24626163 137"/>
   <result pre="Impact of tumour epithelial subtype on circulating microRNAs in breast" exact="cancer" post="patients PLoS One 2014 9 3 e90605 24626163 137"/>
   <result pre="al. Circulating microRNAs in plasma as early detection markers for" exact="breast cancer" post="Int J Cancer 2013 132 7 1602 1612 22927033"/>
   <result pre="Circulating microRNAs in plasma as early detection markers for breast" exact="cancer" post="Int J Cancer 2013 132 7 1602 1612 22927033"/>
   <result pre="Analysis of miR-205 and miR-155 expression in the blood of" exact="breast cancer" post="patients Chin J Cancer Res 2013 25 1 46"/>
   <result pre="of miR-205 and miR-155 expression in the blood of breast" exact="cancer" post="patients Chin J Cancer Res 2013 25 1 46"/>
   <result pre="Higher expression of circulating miR-182 as a novel biomarker for" exact="breast cancer" post="Oncol Lett 2013 6 6 1681 1686 24260062 140"/>
   <result pre="expression of circulating miR-182 as a novel biomarker for breast" exact="cancer" post="Oncol Lett 2013 6 6 1681 1686 24260062 140"/>
   <result pre="al. MicroRNA-484 is more highly expressed in serum of early" exact="breast cancer" post="patients compared to healthy volunteers BMC Cancer 2014 14"/>
   <result pre="MicroRNA-484 is more highly expressed in serum of early breast" exact="cancer" post="patients compared to healthy volunteers BMC Cancer 2014 14"/>
   <result pre="B Ethnicity modifies the association between functional microRNA polymorphisms and" exact="breast cancer" post="risk: a HuGE meta-analysis Tumour Biol 2014 35 1"/>
   <result pre="Ethnicity modifies the association between functional microRNA polymorphisms and breast" exact="cancer" post="risk: a HuGE meta-analysis Tumour Biol 2014 35 1"/>
   <result pre="polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian" exact="cancer" post="risk modifiers in Jewish high-risk women Int J Cancer"/>
   <result pre="Xu J Li W Zhao J Pre-mir-27a rs895819 polymorphism and" exact="cancer" post="risk: a meta-analysis Mol Biol Rep 2013 40 4"/>
   <result pre="Association of germline microRNA SNPs in pre-miRNA flanking region and" exact="breast cancer" post="risk and survival: the Carolina Breast Cancer Study Cancer"/>
   <result pre="of germline microRNA SNPs in pre-miRNA flanking region and breast" exact="cancer" post="risk and survival: the Carolina Breast Cancer Study Cancer"/>
   <result pre="hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and" exact="ovarian cancer" post="patients Carcinogenesis 2010 31 12 2124 2126 20810544 147"/>
   <result pre="genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian" exact="cancer" post="patients Carcinogenesis 2010 31 12 2124 2126 20810544 147"/>
   <result pre="of single nucleotide polymorphisms in miR-146a, miR-196a and miR-499 with" exact="breast cancer" post="susceptibility PLoS One 2013 8 9 e70656 24039706 148"/>
   <result pre="single nucleotide polymorphisms in miR-146a, miR-196a and miR-499 with breast" exact="cancer" post="susceptibility PLoS One 2013 8 9 e70656 24039706 148"/>
   <result pre="Genetic polymorphism of miR-196a as a prognostic biomarker for early" exact="breast cancer" post="Anticancer Res 2014 34 6 2943 2949 24922658 149"/>
   <result pre="polymorphism of miR-196a as a prognostic biomarker for early breast" exact="cancer" post="Anticancer Res 2014 34 6 2943 2949 24922658 149"/>
   <result pre="polymorphisms in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with" exact="breast cancer" post="BMC Med Genet 2012 13 119 23228090 150 Smith"/>
   <result pre="in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast" exact="cancer" post="BMC Med Genet 2012 13 119 23228090 150 Smith"/>
   <result pre="A genetic variant located in miR-423 is associated with reduced" exact="breast cancer" post="risk Cancer Genomics Proteomics 2012 9 3 115 118"/>
   <result pre="genetic variant located in miR-423 is associated with reduced breast" exact="cancer" post="risk Cancer Genomics Proteomics 2012 9 3 115 118"/>
   <result pre="Zhang J Zhou F miR-499 rs3746444 polymorphism is associated with" exact="cancer" post="development among Asians and related to breast cancer susceptibility"/>
   <result pre="is associated with cancer development among Asians and related to" exact="breast cancer" post="susceptibility Mol Biol Rep 2012 39 12 10433 10438"/>
   <result pre="associated with cancer development among Asians and related to breast" exact="cancer" post="susceptibility Mol Biol Rep 2012 39 12 10433 10438"/>
   <result pre="assessment of the association between microRNA-499 rs3746444 A/G polymorphism and" exact="cancer" post="risk Tumour Biol 2014 35 3 2351 2358 24258110"/>
   <result pre="D The association between common genetic variant of microRNA-499 and" exact="cancer" post="susceptibility: a meta-analysis Mol Biol Rep 2013 40 4"/>
   <result pre="binding site SNP rs8752 in HPGD gene is associated with" exact="breast cancer" post="risk PLoS One 2014 9 7 e102093 25003827 156"/>
   <result pre="site SNP rs8752 in HPGD gene is associated with breast" exact="cancer" post="risk PLoS One 2014 9 7 e102093 25003827 156"/>
   <result pre="E et al. Involvement of IGF-1R regulation by miR-515-5p modifies" exact="breast cancer" post="risk among BRCA1 carriers Breast Cancer Res Treat 2013"/>
   <result pre="et al. Involvement of IGF-1R regulation by miR-515-5p modifies breast" exact="cancer" post="risk among BRCA1 carriers Breast Cancer Res Treat 2013"/>
   <result pre="the 3′-UTR region of the IL23R gene is associated with" exact="breast cancer" post="PLoS One 2012 7 12 e49823 23239971 158 Zheng"/>
   <result pre="3′-UTR region of the IL23R gene is associated with breast" exact="cancer" post="PLoS One 2012 7 12 e49823 23239971 158 Zheng"/>
   <result pre="gene are associated with risk of breast, lung and nasopharyngeal" exact="cancer" post="in Chinese populations Carcinogenesis 2012 33 12 2409 2416"/>
   <result pre="site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to" exact="breast cancer" post="Int J Oncol 2011 38 4 1153 1161 21318219"/>
   <result pre="on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast" exact="cancer" post="Int J Oncol 2011 38 4 1153 1161 21318219"/>
   <result pre="of the calcium channel ryanodine receptor gene 3 (RYR3) affects" exact="breast cancer" post="risk and calcification Proc Natl Acad Sci U S"/>
   <result pre="the calcium channel ryanodine receptor gene 3 (RYR3) affects breast" exact="cancer" post="risk and calcification Proc Natl Acad Sci U S"/>
   <result pre="SET8 3′UTR is associated with the age of onset of" exact="breast cancer" post="Zhonghua Zhong Liu Za Zhi 2012 34 11 835"/>
   <result pre="3′UTR is associated with the age of onset of breast" exact="cancer" post="Zhonghua Zhong Liu Za Zhi 2012 34 11 835"/>
   <result pre="al. Biological and prognostic associations of miR-205 and let-7b in" exact="breast cancer" post="revealed by in situ hybridization analysis of micro-RNA expression"/>
   <result pre="Biological and prognostic associations of miR-205 and let-7b in breast" exact="cancer" post="revealed by in situ hybridization analysis of micro-RNA expression"/>
   <result pre="EN MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu)" exact="breast cancer" post="Cell Cycle 2011 10 3 507 517 21270527 165"/>
   <result pre="MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast" exact="cancer" post="Cell Cycle 2011 10 3 507 517 21270527 165"/>
   <result pre="microRNA and mRNA signatures associated with survival in triple negative" exact="breast cancer" post="PLoS One 2013 8 2 e55910 23405235 166 Dong"/>
   <result pre="and mRNA signatures associated with survival in triple negative breast" exact="cancer" post="PLoS One 2013 8 2 e55910 23405235 166 Dong"/>
   <result pre="et al. MiR-34b is associated with clinical outcome in triple-negative" exact="breast cancer" post="patients Diagn Pathol 2012 7 31 22439831 168 Berber"/>
   <result pre="al. MiR-34b is associated with clinical outcome in triple-negative breast" exact="cancer" post="patients Diagn Pathol 2012 7 31 22439831 168 Berber"/>
   <result pre="predictive micro RNAs for lymph node metastasis in triple negative" exact="breast cancer" post="J Breast Cancer 2014 17 2 143 148 25013435"/>
   <result pre="micro RNAs for lymph node metastasis in triple negative breast" exact="cancer" post="J Breast Cancer 2014 17 2 143 148 25013435"/>
   <result pre="circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human" exact="breast cancer" post="development and progression Clin Chem 2013 59 10 1489"/>
   <result pre="cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast" exact="cancer" post="development and progression Clin Chem 2013 59 10 1489"/>
   <result pre="expression and clinical significance of microRNA-1258 and heparanase in human" exact="breast cancer" post="Clin Biochem 2013 46 10–11 926 932 23415719 Table"/>
   <result pre="and clinical significance of microRNA-1258 and heparanase in human breast" exact="cancer" post="Clin Biochem 2013 46 10–11 926 932 23415719 Table"/>
   <result pre="Methodology Clinical observation Reference let-7b 102 BC cases, 26 benign" exact="breast disease" post="cases, and 37 healthy controls Serum (pre- and post-surgery"/>
   <result pre="(Qiagen NV) miRNAs with highest changes between participants that developed" exact="cancer" post="and those who stayed cancer-free. Signature did not validate"/>
   <result pre="I–II [95%] vs Stage III–IV [5%]), ten cases with other" exact="cancer" post="types and 20 healthy controls Plasma Illumina miRNA arrays"/>
   <result pre="miRNA changes separate BC cases specifically (not present in other" exact="cancer" post="types) from controls. 26 miR-107, miR-148a, miR-223, miR-338-3p 24"/>
   <result pre="[40.9%]; Stage I–II [78.3%] vs Stage III–IV [21.7%]), 30 benign" exact="breast disease" post="cases, and 60 healthy controls Plasma TaqMan qRT-PCR (Thermo"/>
   <result pre="miR-127-3p, miR-376a, miR-376c, and miR-409-3p separate BC cases from benign" exact="breast disease." post="135 miR-133a, miR-148b Training set: 52 early-stage BC cases,"/>
   <result pre="of 20 recent studies found on a PubMed query (breast" exact="cancer" post="blood miRNA miR) that describe individual miRNAs or miRNA"/>
   <result pre="recurrent presence in at least three independent studies. Abbreviations: BC," exact="breast cancer;" post="DCIS, ductal carcinoma in situ; ER, estrogen receptor; LN,"/>
   <result pre="least three independent studies. Abbreviations: BC, breast cancer; DCIS, ductal" exact="carcinoma in situ;" post="ER, estrogen receptor; LN, lymph node status; miRNA, microRNA;"/>
   <result pre="33 nuclear export European Americans No risk association Abbreviations: BC," exact="breast cancer;" post="ER, estrogen receptor; HER2, human EGF-like receptor 2; miRNA,"/>
   <result pre="miRNA signatures for prognosis and treatment response in ER +" exact="breast cancer" post="subtypes miRNA(s) Patient cohort Sample Methodology Clinical observation(s) Reference"/>
   <result pre="signatures for prognosis and treatment response in ER + breast" exact="cancer" post="subtypes miRNA(s) Patient cohort Sample Methodology Clinical observation(s) Reference"/>
   <result pre="miRNA signatures for prognosis and treatment response in HER +" exact="breast cancer" post="subtypes miRNA(s) Patient cohort Sample Methodology Clinical observation(s) Reference"/>
   <result pre="signatures for prognosis and treatment response in HER + breast" exact="cancer" post="subtypes miRNA(s) Patient cohort Sample Methodology Clinical observation(s) Reference"/>
   <result pre="Abbreviations: FFPE, formalin-fixed paraffin-embedded; LN, lymph node status; TNBC, triple-negative" exact="breast cancer;" post="miRNA, microRNA; qRT-PCR, quantitative real-time polymerase chain reaction. Table"/>
   <result pre="cases (M0 [48.7%] vs M1 [51.3%]), 62 cases with benign" exact="breast disease" post="and 54 healthy controls Serum (post- surgery but before"/>
   <result pre="recurrent presence in at least three independent studies. Abbreviations: BC," exact="breast cancer;" post="ER, estrogen receptor; FFPE, formalin-fixed paraffin-embedded; LN, lymph node"/>
   <result pre="receptor; FFPE, formalin-fixed paraffin-embedded; LN, lymph node status; MBC, metastatic" exact="breast cancer;" post="miRNA, microRNA; HER2, human EGF-like receptor 2; qRT-PCR, quantitative"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346691/results/search/disease/results.xml">
   <result pre="Abstract Histological classification of adenocarcinoma or squamous cell carcinoma for" exact="esophageal cancer" post="or using the Lauren classification for intestinal and diffuse"/>
   <result pre="Histological classification of adenocarcinoma or squamous cell carcinoma for esophageal" exact="cancer" post="or using the Lauren classification for intestinal and diffuse"/>
   <result pre="using the Lauren classification for intestinal and diffuse type gastric" exact="cancer" post="has limited clinical utility in the management of advanced"/>
   <result pre="Genome Atlas Research Network has proposed four subtypes of gastric" exact="cancer" post="dividing tumors into those positive for Epstein-Barr virus, microsatellite"/>
   <result pre="in preselected patients. 1. Introduction While the incidence of gastric" exact="cancer" post="is decreasing in the United States, the rates of"/>
   <result pre="cancer is decreasing in the United States, the rates of" exact="esophageal cancer" post="are increasing. In 2014 it is anticipated that 22,220"/>
   <result pre="is decreasing in the United States, the rates of esophageal" exact="cancer" post="are increasing. In 2014 it is anticipated that 22,220"/>
   <result pre="22,220 and 18,170 patients will be newly diagnosed with gastric" exact="cancer" post="and esophageal cancer, respectively, while 26,440 men and women"/>
   <result pre="18,170 patients will be newly diagnosed with gastric cancer and" exact="esophageal cancer," post="respectively, while 26,440 men and women will die as"/>
   <result pre="a result of upper gastrointestinal (GI) tumors [ 1]. Gastroesophageal" exact="cancer" post="remains endemic in many parts of the world with"/>
   <result pre="in many parts of the world with an estimated new" exact="cancer" post="incidence of 1,471,000 or 11.6% of the global cancer"/>
   <result pre="new cancer incidence of 1,471,000 or 11.6% of the global" exact="cancer" post="burden and a death rate annually of 1,144,000 people"/>
   <result pre="1,144,000 people or 15.1% of cancer-related deaths worldwide. Taken together," exact="esophageal cancer" post="and gastric cancer are second only to lung cancer"/>
   <result pre="people or 15.1% of cancer-related deaths worldwide. Taken together, esophageal" exact="cancer" post="and gastric cancer are second only to lung cancer"/>
   <result pre="of cancer-related deaths worldwide. Taken together, esophageal cancer and gastric" exact="cancer" post="are second only to lung cancer in incidence and"/>
   <result pre="together, esophageal cancer and gastric cancer are second only to" exact="lung cancer" post="in incidence and in mortality [ 2]. Despite these"/>
   <result pre="esophageal cancer and gastric cancer are second only to lung" exact="cancer" post="in incidence and in mortality [ 2]. Despite these"/>
   <result pre="now accounting for more than half of the cases of" exact="esophageal cancer." post="Through the 1980s, the increases in the rates of"/>
   <result pre="per year, a faster pace than for virtually any other" exact="cancer" post="in the United States [ 3]. This has been"/>
   <result pre="pylori and an increased incidence of gastroesophageal reflux disease and" exact="obesity" post="[ 4– 6]. 2. Cytotoxic Chemotherapy for Gastroesophageal Cancer"/>
   <result pre="Gastroesophageal Cancer The treatment of metastatic gastroesophageal junction and gastric" exact="cancer" post="has been poorly investigated and at present there is"/>
   <result pre="5 FU, and taxanes) are available for the treatment of gastroesophageal" exact="cancer" post="but no means of selecting therapy based upon the"/>
   <result pre="may predict responsiveness to systemic therapies. Earlier studies in gastric" exact="cancer" post="concentrated on molecular signatures which characterized the processes of"/>
   <result pre="which readily discern premalignant from malignant tissues [ 15]. Chronic" exact="gastritis" post="tissue expressed a marked mitochondrial gene expression signature possibly"/>
   <result pre="(intestinal and diffuse) identified from in vitro studies in gastric" exact="cancer" post="and validated in primary tumors were found to be"/>
   <result pre="not seen in gastric MSI tumors unlike its counterpart in" exact="colorectal cancer." post="Genomically stable gastric tumors are enriched for the diffuse"/>
   <result pre="added to our knowledge of the molecular subtyping of gastric" exact="cancer" post="and hopefully will permit improved patient selection for clinical"/>
   <result pre="Chromosomal aberrations leading to gene dysregulation have been reported in" exact="esophageal cancer" post="including amplifications on 8q and 17q mapped to the"/>
   <result pre="aberrations leading to gene dysregulation have been reported in esophageal" exact="cancer" post="including amplifications on 8q and 17q mapped to the"/>
   <result pre="19, 20]. The role of MYC in the pathogenesis of" exact="esophageal cancer" post="is not well defined and additional research is required."/>
   <result pre="20]. The role of MYC in the pathogenesis of esophageal" exact="cancer" post="is not well defined and additional research is required."/>
   <result pre="of TP53 occurs in greater than 50% of cases of" exact="esophageal cancer" post="and is considered a strong predictor of disease progression"/>
   <result pre="TP53 occurs in greater than 50% of cases of esophageal" exact="cancer" post="and is considered a strong predictor of disease progression"/>
   <result pre="In addition, two genes reported to have homozygous deletions in" exact="esophageal cancer" post="are p16/CDKN2A and FHIT [ 24]. Abeloff et al."/>
   <result pre="addition, two genes reported to have homozygous deletions in esophageal" exact="cancer" post="are p16/CDKN2A and FHIT [ 24]. Abeloff et al."/>
   <result pre="host of additional genes have been studied for mutations in" exact="esophageal cancer," post="but in most of these single gene studies, very"/>
   <result pre="for mutations, Agrawal et al. performed a comprehensive study of" exact="esophageal cancer" post="exomes including both adenocarcinomas and squamous cell carcinomas ["/>
   <result pre="mutations, Agrawal et al. performed a comprehensive study of esophageal" exact="cancer" post="exomes including both adenocarcinomas and squamous cell carcinomas ["/>
   <result pre="suggesting that some of these may be viable targets in" exact="esophageal cancer" post="although amplification of some of these may be more"/>
   <result pre="that some of these may be viable targets in esophageal" exact="cancer" post="although amplification of some of these may be more"/>
   <result pre="kinase [ 28]. While originally known for its effects in" exact="breast cancer," post="HER2 overexpression has been shown to result in worse"/>
   <result pre="has been shown to result in worse prognosis in gastric" exact="cancer" post="[ 29, 30] although there are conflicting studies which"/>
   <result pre="HER2 IHC 2+ or FISH amplified metastatic gastroesophageal or gastric" exact="cancer" post="[ 33]. In this trial, 594 patients were randomly"/>
   <result pre="evidence of disease progression are commonplace in the management of" exact="breast cancer" post="[ 34, 35] but there is a lack of"/>
   <result pre="of disease progression are commonplace in the management of breast" exact="cancer" post="[ 34, 35] but there is a lack of"/>
   <result pre="data indicating that this is a successful strategy in gastroesophageal" exact="cancer" post="although a Japanese trial is currently investigating this approach"/>
   <result pre="compared paclitaxel with or without lapatinib in HER2 positive gastric" exact="cancer" post="in the second-line setting in Asian patients [ 38]."/>
   <result pre="patients with previously treated HER2-positive metastatic or locally advanced gastric" exact="cancer" post="[ 43]. 5.2. EGFR The epidermal growth factor receptor"/>
   <result pre="concluded that EGFR expression correlates with decreased survival in gastric" exact="cancer" post="[ 45]. In addition, preclinical data suggest that a"/>
   <result pre="and was shown to improve outcomes in kras wild-type metastatic" exact="colorectal cancer" post="[ 47]. The EXPAND study was a phase III"/>
   <result pre="was shown to improve outcomes in kras wild-type metastatic colorectal" exact="cancer" post="[ 47]. The EXPAND study was a phase III"/>
   <result pre="without cetuximab in the first line setting in advanced gastric" exact="cancer" post="[ 48]. Median PFS for chemotherapy/cetuximab was 4.4 months"/>
   <result pre="EGFR-targeting drug matuzumab also gave disappointing results in advanced esophagogastric" exact="cancer" post="[ 50]. A combination of ECX chemotherapy/matuzumab failed to"/>
   <result pre="tumor proliferation, invasion, and angiogenesis and has antiapoptotic functions in" exact="cancer" post="cells [ 52, 53]. Tumors which harbor high C-MET"/>
   <result pre="shown to function independently of the c-MET pathway. Studies on" exact="lung cancer" post="cell lines have shown that tivantinib does not inhibit"/>
   <result pre="to function independently of the c-MET pathway. Studies on lung" exact="cancer" post="cell lines have shown that tivantinib does not inhibit"/>
   <result pre="monoclonal antibody against VEGF-A, in combination with chemotherapy in gastric" exact="cancer" post="[ 60, 61]. The failure of bevacizumab to improve"/>
   <result pre="it appeared that those with type 3 (distal nondiffuse) gastric" exact="cancer" post="and those from European/American populations derived more benefit from"/>
   <result pre="European/American populations derived more benefit from bevacizumab than other gastric" exact="cancer" post="subtypes or patients from Asian/Pacific populations. The VEGFR-2 (vascular"/>
   <result pre="CI 5.2–9.6 months). 7. Cancer Cell Stemness The characteristic of" exact="cancer" post="cells' ability to grow indefinitely has led to the"/>
   <result pre="with stem cells [ 70]. BB1608 is an orally available" exact="cancer" post="cell stemness inhibitor whose exact target has not been"/>
   <result pre="P = 0.34). However, the expression of CD44, a gastric" exact="cancer" post="stem cell marker, was associated with improved survival in"/>
   <result pre="77]. Cixutumumab was combined with paclitaxel in metastatic esophageal/GE junction" exact="cancer" post="in a randomized phase II study [ 78]. The"/>
   <result pre="that it was well-tolerated and a single patient with gastric" exact="cancer" post="achieved a partial response [ 82]. 11. FGFR Therapy"/>
   <result pre="tumor progression/metastasis and is associated with poor survival in gastric" exact="cancer" post="[ 84]. There is currently a phase II trial"/>
   <result pre="inhibitor, in combination with docetaxel as second-line chemotherapy in gastric" exact="cancer" post="[ 85]. 12. PI3K/mTOR Therapy The PI3K (phosphatidylinositol 3-kinase)"/>
   <result pre="been associated with tumor progression and worse prognosis in gastric" exact="cancer" post="patients [ 89]. Genetic alterations affecting the PI3K/Akt/mTOR pathway"/>
   <result pre="alterations affecting the PI3K/Akt/mTOR pathway are frequently found in gastric" exact="cancer" post="[ 90– 92]. There are several potential approaches to"/>
   <result pre="inhibitor BYL719 with a HSP inhibitor AUY922 in metastatic gastric" exact="cancer" post="patients whose tumors are HER2 amplified or who harbor"/>
   <result pre="Everolimus, an oral mTOR inhibitor, was investigated in advanced gastric" exact="cancer" post="in the GRANITE-1 study [ 94]. Patients who had"/>
   <result pre="of the clinical trials involving molecularly targeted agents in gastroesophageal" exact="cancer" post="have had initially promising results which do not persist"/>
   <result pre="may represent the future of targeted therapy evaluation in gastroesophageal" exact="cancer" post="where a variety of targeted therapies are now available"/>
   <result pre="14. Conclusion The development of new therapies for advanced gastroesophageal" exact="cancer" post="has been slow compared to other common tumors. Upper"/>
   <result pre="consumption. Taken together, upper GI tumors are second only to" exact="lung cancer" post="in terms of cancer related morbidity. In recent years"/>
   <result pre="Taken together, upper GI tumors are second only to lung" exact="cancer" post="in terms of cancer related morbidity. In recent years"/>
   <result pre="tumors are second only to lung cancer in terms of" exact="cancer" post="related morbidity. In recent years incremental breakthroughs in our"/>
   <result pre="to enrolling patients on clinical trials has failed in gastroesophageal" exact="cancer" post="as it has in other tumor types. The Cancer"/>
   <result pre="it appears likely that the four molecular subtypes of gastric" exact="cancer" post="described in this study should advance clinical research in"/>
   <result pre="Mathers C. Parkin D. M. Estimates of worldwide burden of" exact="cancer" post="in 2008: GLOBOCAN 2008 International Journal of Cancer 2010"/>
   <result pre="6 Hampel H. Abraham N. S. El-Serag H. B. Meta-analysis:" exact="obesity" post="and the risk for gastroesophageal reflux disease and its"/>
   <result pre="Rao S. et al. Capecitabine and oxaliplatin for advanced esophagogastric" exact="cancer" post="The New England Journal of Medicine 2008 358 1"/>
   <result pre="5-fluorouracil as initial therapy for patients with advanced gastric and" exact="esophageal cancer" post="Cancer 2010 116 6 1446 1453 10.1002/cncr.24925 20108336 9"/>
   <result pre="as initial therapy for patients with advanced gastric and esophageal" exact="cancer" post="Cancer 2010 116 6 1446 1453 10.1002/cncr.24925 20108336 9"/>
   <result pre="al. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric" exact="cancer" post="European Journal of Cancer 2011 47 8 1146 1151"/>
   <result pre="Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric" exact="cancer" post="Gastric Cancer 2006 9 1 14 18 10.1007/s10120-005-0351-6 16557431"/>
   <result pre="patterns of gene expression in premalignant gastric mucosa and gastric" exact="cancer" post="Cancer Research 2003 63 10 2569 2577 12750281 16"/>
   <result pre="Das K. et al. Identification of molecular subtypes of gastric" exact="cancer" post="with different responses to pi3-kinase inhibitors and 5-fluorouracil Gastroenterology"/>
   <result pre="C. C. Frequent mutation of the p53 gene in human" exact="esophageal cancer" post="Proceedings of the National Academy of Sciences of the"/>
   <result pre="C. Frequent mutation of the p53 gene in human esophageal" exact="cancer" post="Proceedings of the National Academy of Sciences of the"/>
   <result pre="Roth J. A. p53 gene mutations in Barrett's epithelium and" exact="esophageal cancer" post="Cancer Research 1991 51 16 4495 4499 1868473 24"/>
   <result pre="J. A. p53 gene mutations in Barrett's epithelium and esophageal" exact="cancer" post="Cancer Research 1991 51 16 4495 4499 1868473 24"/>
   <result pre="Olayioye M. A. Update on HER-2 as a target for" exact="cancer" post="therapy—intracellular signaling pathways of ErbB2/HER-2 and family members Breast"/>
   <result pre="al. HER-2/neu amplification is an independent prognostic factor in gastric" exact="cancer" post="Digestive Diseases and Sciences 2006 51 8 1371 1379"/>
   <result pre="C. et al. Prognosis of metastatic gastric and gastroesophageal junction" exact="cancer" post="by HER2 status: a European and USA International collaborative"/>
   <result pre="for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric" exact="cancer" post="Journal of Clinical Pathology 2012 65 8 751 757"/>
   <result pre="for treatment of HER2- positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial The"/>
   <result pre="2 years versus 1 year of adjuvant trastuzumab for HER2-positive" exact="breast cancer" post="(HERA): an open-label, randomised controlled trial The Lancet 2013"/>
   <result pre="years versus 1 year of adjuvant trastuzumab for HER2-positive breast" exact="cancer" post="(HERA): an open-label, randomised controlled trial The Lancet 2013"/>
   <result pre="of the GBG 26/BIG 3-05 phase III study in HER2-positive" exact="breast cancer" post="European Journal of Cancer 2011 47 15 2273 2281"/>
   <result pre="the GBG 26/BIG 3-05 phase III study in HER2-positive breast" exact="cancer" post="European Journal of Cancer 2011 47 15 2273 2281"/>
   <result pre="paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric" exact="cancer" post="in Asian populations: TyTAN–a randomized, phase III study Journal"/>
   <result pre="conjugate in development for human epidermal growth factor receptor 2-positive" exact="cancer" post="Clinical Cancer Research 2011 17 20 6437 6447 10.1158/1078-0432.ccr-11-0762"/>
   <result pre="W. C. et al. Antibody-maytansinoid conjugates are activated in targeted" exact="cancer" post="cells by lysosomal degradation and linker-dependent intracellular processing Cancer"/>
   <result pre="or without cetuximab for patients with previously untreated advanced gastric" exact="cancer" post="(EXPAND): a randomised, open-label phase 3 trial The Lancet"/>
   <result pre="or without panitumumab for patients with previously untreated advanced oesophagogastric" exact="cancer" post="(REAL3): a randomised, open-label phase 3 trial The Lancet"/>
   <result pre="Activation of c-Met (hepatocyte growth factor receptor) in human gastric" exact="cancer" post="tissue Cancer Science 2004 95 10 803 808 10.1111/j.1349-7006.2004.tb02185.x"/>
   <result pre="(ARQ 197) efficacy is independent of MET inhibition in non-small-cell" exact="lung cancer" post="cell lines Molecular Oncology 2015 9 1 260 269"/>
   <result pre="197) efficacy is independent of MET inhibition in non-small-cell lung" exact="cancer" post="cell lines Molecular Oncology 2015 9 1 260 269"/>
   <result pre="second- or third-line therapy in the patients with metastatic gastric" exact="cancer" post="Investigational New Drugs 2014 32 2 355 361 10.1007/s10637-013-0057-2"/>
   <result pre="bevacizumab (bev) or placebo in patients (pts) with advanced gastric" exact="cancer" post="Journal of Clinical Oncology 2012 30 supplement 4, abstract"/>
   <result pre="II study of sunitinib as second-line treatment for advanced gastric" exact="cancer" post="Investigational New Drugs 2011 29 6 1449 1458 10.1007/s10637-010-9438-y"/>
   <result pre="trial of docetaxel and sunitinib in patients with metastatic gastric" exact="cancer" post="who were previously treated with fluoropyrimidine and platinum British"/>
   <result pre="70 Wong D. J. Segal E. Chang H. Y. Stemness," exact="cancer" post="and cancer stem cells Cell Cycle 2008 7 23"/>
   <result pre="D. J. Segal E. Chang H. Y. Stemness, cancer and" exact="cancer" post="stem cells Cell Cycle 2008 7 23 3622 3624"/>
   <result pre="K. N. et al. A phase 1b study of the" exact="cancer" post="stem cell inhibitor BBI608 administered with paclitaxel in patients"/>
   <result pre="B. et al. CD44 expression denotes a subpopulation of gastric" exact="cancer" post="cells in which Hedgehog signaling promotes chemotherapy resistance Clinical"/>
   <result pre="cixutumumab in patients with previously treated advanced or metastatic soft-tissue" exact="sarcoma" post="or Ewing family of tumours European Journal of Cancer"/>
   <result pre="second-line treatment for patients with metastatic esophageal or GE junction" exact="cancer" post="Journal of Clinical Oncology 2014 32 5, supplement ASCO"/>
   <result pre="polo-like kinase activity by antisense oligonucleotides induces growth inhibition in" exact="cancer" post="cells Oncogene 2002 21 20 3162 3171 10.1038/sj/onc/1205412 12082631"/>
   <result pre="al. Expression patterns of polo-like kinase 1 in human gastric" exact="cancer" post="Cancer Science 2006 97 4 271 276 10.1111/j.1349-7006.2006.00170.x 16630118"/>
   <result pre="fibroblast growth factor receptors 1, 2 and 4 in gastric" exact="cancer" post="Molecular and Clinical Oncology 2014 2 4 509 517"/>
   <result pre="Cejas P. Belda-Iniesta C. González-Barón M. PI3K/Akt signalling pathway and" exact="cancer" post="Cancer Treatment Reviews 2004 30 2 193 204 10.1016/j.ctrv.2003.07.007"/>
   <result pre="Relation between outcomes and localisation of p-mTOR expression in gastric" exact="cancer" post="British Journal of Cancer 2009 100 5 782 788"/>
   <result pre="et al. The prevalence of PIK3CA mutations in gastric and" exact="colon cancer" post="European Journal of Cancer 2005 41 11 1649 1654"/>
   <result pre="al. The prevalence of PIK3CA mutations in gastric and colon" exact="cancer" post="European Journal of Cancer 2005 41 11 1649 1654"/>
   <result pre="human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric" exact="cancer" post="World Journal of Gastroenterology 2012 18 45 6577 6586"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4353460/results/search/disease/results.xml">
   <result pre="10.1186/s12885-015-1022-6 : Research Article Dermcidin exerts its oncogenic effects in" exact="breast cancer" post="via modulation of ERBB signaling Bancovik Jasna jasnam@ibiss.bg.ac.rs Moreira"/>
   <result pre=": Research Article Dermcidin exerts its oncogenic effects in breast" exact="cancer" post="via modulation of ERBB signaling Bancovik Jasna jasnam@ibiss.bg.ac.rs Moreira"/>
   <result pre="overexpressed in a subset of breast tumors. Patients with DCD-positive" exact="breast cancer" post="have worse prognostic features. We therefore searched for specific"/>
   <result pre="in a subset of breast tumors. Patients with DCD-positive breast" exact="cancer" post="have worse prognostic features. We therefore searched for specific"/>
   <result pre="tumorigenesis, we analyzed the consequences of its downregulation in human" exact="breast cancer" post="cell lines using three specific shRNA lentiviral vectors. Genes"/>
   <result pre="we analyzed the consequences of its downregulation in human breast" exact="cancer" post="cell lines using three specific shRNA lentiviral vectors. Genes"/>
   <result pre="supplementary material, which is available to authorized users. Keywords Breast" exact="cancer" post="Dermcidin ERBB signaling Oncogene Apoptosis Background We previously described"/>
   <result pre="Background We previously described DCD as a candidate oncogene in" exact="breast cancer" post="based on its copy number gain and overexpression in"/>
   <result pre="We previously described DCD as a candidate oncogene in breast" exact="cancer" post="based on its copy number gain and overexpression in"/>
   <result pre="in a subset of tumors [ 1]. Patients with DCD-positive" exact="breast cancer" post="are more likely to have metastatic lymph nodes, larger"/>
   <result pre="a subset of tumors [ 1]. Patients with DCD-positive breast" exact="cancer" post="are more likely to have metastatic lymph nodes, larger"/>
   <result pre="to a candidate receptor present on the cell surface of" exact="breast cancer" post="cells and neurons [ 1]. In normal human tissues"/>
   <result pre="a candidate receptor present on the cell surface of breast" exact="cancer" post="cells and neurons [ 1]. In normal human tissues"/>
   <result pre="such as acting as a growth and survival factor in" exact="breast cancer" post="[ 1] and in neural cells [ 10, 11],"/>
   <result pre="as acting as a growth and survival factor in breast" exact="cancer" post="[ 1] and in neural cells [ 10, 11],"/>
   <result pre="13], and inducing cancer-associated cachexia in animal models and in" exact="cancer" post="patients [ 14, 15]. In addition, a recent study"/>
   <result pre="signaling pathways. To further investigate the function of DCD in" exact="breast cancer," post="here we describe the identification of a DCD splice"/>
   <result pre="consequences of downregulating DCD expression in the MDA-MB-361 human HER2+" exact="breast cancer" post="cell line and upregulating DCD in the MCF-7 human"/>
   <result pre="of downregulating DCD expression in the MDA-MB-361 human HER2+ breast" exact="cancer" post="cell line and upregulating DCD in the MCF-7 human"/>
   <result pre="cell line and upregulating DCD in the MCF-7 human HER2-" exact="breast cancer" post="cell line and in the SK-BR-3 human HER2+ amplified"/>
   <result pre="line and upregulating DCD in the MCF-7 human HER2- breast" exact="cancer" post="cell line and in the SK-BR-3 human HER2+ amplified"/>
   <result pre="consent was waived as the human specimens were deidentified. Breast" exact="cancer" post="cell lines were previously described [ 1] and updated"/>
   <result pre="Association between the clinical-pathological features and molecular markers in DCD-positive" exact="breast cancer" post="patient samples Characteristics Invasive Breast Carcinoma, n = 26 Median age,"/>
   <result pre="between the clinical-pathological features and molecular markers in DCD-positive breast" exact="cancer" post="patient samples Characteristics Invasive Breast Carcinoma, n = 26 Median age,"/>
   <result pre="B. Association between DCD and ERBBs mRNA expression in 55" exact="breast cancer" post="cell lines DCD expression (RMA,log2) &amp;lt;4 ≥4 no. (%)"/>
   <result pre="Association between DCD and ERBBs mRNA expression in 55 breast" exact="cancer" post="cell lines DCD expression (RMA,log2) &amp;lt;4 ≥4 no. (%)"/>
   <result pre="we compiled freely available microarray data sets of 55 human" exact="breast cancer" post="cell lines obtained from Cancer Cell Line Encyclopedia ("/>
   <result pre="compiled freely available microarray data sets of 55 human breast" exact="cancer" post="cell lines obtained from Cancer Cell Line Encyclopedia ("/>
   <result pre="of DCD downregulation To assess the function of DCD in" exact="breast cancer" post="cells with high endogenous expression, we generated derivatives of"/>
   <result pre="DCD downregulation To assess the function of DCD in breast" exact="cancer" post="cells with high endogenous expression, we generated derivatives of"/>
   <result pre="high endogenous expression, we generated derivatives of the MDA-MB-361 human" exact="breast cancer" post="cell line expressing three different shRNAs against DCD (IBC-I,"/>
   <result pre="endogenous expression, we generated derivatives of the MDA-MB-361 human breast" exact="cancer" post="cell line expressing three different shRNAs against DCD (IBC-I,"/>
   <result pre="in agreement with prior studies describing higher apoptosis resistance of" exact="cancer" post="cells overexpressing DCD [ 1, 6, 7, 9]. Next,"/>
   <result pre="underlying the growth and survival-promoting effects of DCD in MDA-MB-361" exact="breast cancer" post="cells, we analyzed the global gene expression profiles of"/>
   <result pre="the growth and survival-promoting effects of DCD in MDA-MB-361 breast" exact="cancer" post="cells, we analyzed the global gene expression profiles of"/>
   <result pre="31, 32] and it is associated with better prognosis in" exact="breast cancer" post="patients [ 33, 34]. ERBB4 may execute its differentiation-inducing"/>
   <result pre="32] and it is associated with better prognosis in breast" exact="cancer" post="patients [ 33, 34]. ERBB4 may execute its differentiation-inducing"/>
   <result pre="heterodimers such as ERBB3/ERBB2 [ 35]. Correlating with this, MDA-MB-361" exact="breast cancer" post="cells expressing DCD shRNA displayed a more differentiated luminal"/>
   <result pre="such as ERBB3/ERBB2 [ 35]. Correlating with this, MDA-MB-361 breast" exact="cancer" post="cells expressing DCD shRNA displayed a more differentiated luminal"/>
   <result pre="derivatives of the MCF-7 estrogen receptor positive and HER2-non-amplified luminal" exact="breast cancer" post="cells stably expressing DCD. We compared cell growth and"/>
   <result pre="of the MCF-7 estrogen receptor positive and HER2-non-amplified luminal breast" exact="cancer" post="cells stably expressing DCD. We compared cell growth and"/>
   <result pre="HER/ErbB receptor family to stimulate the growth and proliferation of" exact="breast cancer" post="cells. Figure 7 Enhanced effect of anti-DCD rabbit polyclonal"/>
   <result pre="receptor family to stimulate the growth and proliferation of breast" exact="cancer" post="cells. Figure 7 Enhanced effect of anti-DCD rabbit polyclonal"/>
   <result pre="co-expression of DCD and DCD-SV in normal skin tissue and" exact="breast cancer" post="cell lines using validated and novel specific antibodies against"/>
   <result pre="of DCD and DCD-SV in normal skin tissue and breast" exact="cancer" post="cell lines using validated and novel specific antibodies against"/>
   <result pre="reactivity and overall survival in this small cohort of 26" exact="breast cancer" post="patients. These results are in line with our previous"/>
   <result pre="and overall survival in this small cohort of 26 breast" exact="cancer" post="patients. These results are in line with our previous"/>
   <result pre="if it influences the growth rate of malignant cells. Human" exact="breast cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="it influences the growth rate of malignant cells. Human breast" exact="cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="that DCD acts as a growth and survival-promoting factor in" exact="breast cancer." post="Furthermore, we demonstrated that these effects are due to"/>
   <result pre="S1. ER/PR/ERBBs/DCD status, source, clinical and pathological features of the" exact="breast cancer" post="cell lines. Figure S1. The average of RMA (robust"/>
   <result pre="ER/PR/ERBBs/DCD status, source, clinical and pathological features of the breast" exact="cancer" post="cell lines. Figure S1. The average of RMA (robust"/>
   <result pre="values for DCD, HER2, HER3, HER4 and EGFR in 55" exact="breast cancer" post="cell lines. LINK Additional file 2: GEO deposit GSE57578"/>
   <result pre="for DCD, HER2, HER3, HER4 and EGFR in 55 breast" exact="cancer" post="cell lines. LINK Additional file 2: GEO deposit GSE57578"/>
   <result pre="performed real time PCR assays, cellular and biochemical experiments in" exact="breast cancer" post="cell lines and analyzed data. DM and JEB performed"/>
   <result pre="real time PCR assays, cellular and biochemical experiments in breast" exact="cancer" post="cell lines and analyzed data. DM and JEB performed"/>
   <result pre="al. A neural survival factor is a candidate oncogene in" exact="breast cancer" post="Proc Natl Acad Sci U S A 2003 100"/>
   <result pre="A neural survival factor is a candidate oncogene in breast" exact="cancer" post="Proc Natl Acad Sci U S A 2003 100"/>
   <result pre="FK Ross JA Dermcidin expression confers a survival advantage in" exact="prostate cancer" post="cells subjected to oxidative stress or hypoxia Prostate 2007"/>
   <result pre="Ross JA Dermcidin expression confers a survival advantage in prostate" exact="cancer" post="cells subjected to oxidative stress or hypoxia Prostate 2007"/>
   <result pre="Ross JA Tisdale MJ Fearon KC Characteristics of patients with" exact="pancreatic cancer" post="expressing a novel cancer cachectic factor Br J Surg"/>
   <result pre="JA Tisdale MJ Fearon KC Characteristics of patients with pancreatic" exact="cancer" post="expressing a novel cancer cachectic factor Br J Surg"/>
   <result pre="KC Characteristics of patients with pancreatic cancer expressing a novel" exact="cancer" post="cachectic factor Br J Surg 2000 87 53 8"/>
   <result pre="Genome-wide functional synergy between amplified and mutated genes in human" exact="breast cancer" post="Cancer Res 2008 68 9532 40 10.1158/0008-5472.CAN-08-3082 19010930 25."/>
   <result pre="functional synergy between amplified and mutated genes in human breast" exact="cancer" post="Cancer Res 2008 68 9532 40 10.1158/0008-5472.CAN-08-3082 19010930 25."/>
   <result pre="EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER-2-overexpressing" exact="breast cancer" post="cells Clin Cancer Res 2003 9 1274 83 12684395"/>
   <result pre="and EGFR/HER3 heterodimers and prevents heregulin signaling in HER-2-overexpressing breast" exact="cancer" post="cells Clin Cancer Res 2003 9 1274 83 12684395"/>
   <result pre="of breast cell lines for the study of functionally distinct" exact="cancer" post="subtypes Cancer Cell 2006 10 515 27 10.1016/j.ccr.2006.10.008 17157791"/>
   <result pre="Powis G Kirkpatrick DL Thioredoxin signaling as a target for" exact="cancer" post="therapy Curr Opin Pharmacol 2007 7 392 7 10.1016/j.coph.2007.04.003"/>
   <result pre="Hornez L Bonneterre J Peyrat JP ErbB/HER ligands in human" exact="breast cancer," post="and relationships with their receptors, the bio-pathological features and"/>
   <result pre="human homologue of proteolysis inducing factor and its role in" exact="cancer" post="cachexia Clin Cancer Res 2004 10 5862 9 10.1158/1078-0432.CCR-04-0435"/>
   <result pre="C Guix M Dugger T Engelman JA et al. Human" exact="breast cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="Guix M Dugger T Engelman JA et al. Human breast" exact="cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4353882/results/search/disease/results.xml">
   <result pre="on clinicopathological factors and gene expression analysis in advanced HER2-positive" exact="breast cancer" post="patients Duchnowska Renata +48 22 6817110 rdtt@wp.pl Jassem Jacek"/>
   <result pre="clinicopathological factors and gene expression analysis in advanced HER2-positive breast" exact="cancer" post="patients Duchnowska Renata +48 22 6817110 rdtt@wp.pl Jassem Jacek"/>
   <result pre="tumor samples from two independent cohorts of advanced HER2 positive" exact="breast cancer" post="patients. Additionally, we analyzed predictive relevance of clinicopathological factors"/>
   <result pre="samples from two independent cohorts of advanced HER2 positive breast" exact="cancer" post="patients. Additionally, we analyzed predictive relevance of clinicopathological factors"/>
   <result pre="apparently increase the likelihood of early BM in advanced HER2-positive" exact="breast cancer." post="Keywords Breast cancer Brain metastasis HER2 RAD51 HDGF TPR"/>
   <result pre="of early BM in advanced HER2-positive breast cancer. Keywords Breast" exact="cancer" post="Brain metastasis HER2 RAD51 HDGF TPR Introduction The overexpression"/>
   <result pre="of brain metastasis (BM). Approximately 30–50 % of advanced HER2-positive" exact="breast cancer" post="patients will develop BM, with an annual risk of"/>
   <result pre="brain metastasis (BM). Approximately 30–50 % of advanced HER2-positive breast" exact="cancer" post="patients will develop BM, with an annual risk of"/>
   <result pre="treating established BM. The development of BM predictors in advanced" exact="breast cancer" post="patients might have practical clinical implications. First, the use"/>
   <result pre="established BM. The development of BM predictors in advanced breast" exact="cancer" post="patients might have practical clinical implications. First, the use"/>
   <result pre="pathological variables in two well annotated cohorts of advanced HER2-positive" exact="breast cancer" post="patients. Materials and methods Patients This study was approved"/>
   <result pre="variables in two well annotated cohorts of advanced HER2-positive breast" exact="cancer" post="patients. Materials and methods Patients This study was approved"/>
   <result pre="were derived from a consecutive series of 315 advanced HER2-positive" exact="breast cancer" post="patients treated in nine oncology centers in Poland and"/>
   <result pre="derived from a consecutive series of 315 advanced HER2-positive breast" exact="cancer" post="patients treated in nine oncology centers in Poland and"/>
   <result pre="71 54 72 0.89 Positive 24 29 21 28 Breast" exact="cancer" post="surgery No 16 19 15 20 0.91 Yes 67"/>
   <result pre="each patient was a formalin-fixed, paraffin embedded specimen of primary" exact="breast cancer." post="A pre-cut section of each tumor, stained with hematoxylin"/>
   <result pre="(SB and WB) to confirm the presence of sufficient invasive" exact="breast cancer" post="component (1 cm 2 invasive tissue, ≥30 % tumor"/>
   <result pre="and WB) to confirm the presence of sufficient invasive breast" exact="cancer" post="component (1 cm 2 invasive tissue, ≥30 % tumor"/>
   <result pre="Cancer Panel v1 to provide expression data on 502 known" exact="cancer" post="genes. DASL was performed with the Sentrix universal array"/>
   <result pre="1 Hs00184427_m1 73 RAD51 RAD51 homolog Hs00153418_m1 58 FANCG Fanconi" exact="anemia" post="group G Hs00184947_m1 116 PCNA Proliferating cell nuclear antigen"/>
   <result pre="were plotted using Kaplan–Meier method starting from date of primary" exact="breast cancer" post="diagnosis to date of death or last follow-up. The"/>
   <result pre="plotted using Kaplan–Meier method starting from date of primary breast" exact="cancer" post="diagnosis to date of death or last follow-up. The"/>
   <result pre="a primary endpoint and was defined from date of primary" exact="breast cancer" post="diagnosis to date of BM diagnosis, death of any"/>
   <result pre="primary endpoint and was defined from date of primary breast" exact="cancer" post="diagnosis to date of BM diagnosis, death of any"/>
   <result pre="of patients lapatinib was administered at trastuzumab relapse. Follow-up from" exact="breast cancer" post="diagnosis varied from 1 to 185 months. Within this"/>
   <result pre="patients lapatinib was administered at trastuzumab relapse. Follow-up from breast" exact="cancer" post="diagnosis varied from 1 to 185 months. Within this"/>
   <result pre="48 patients developed symptomatic BM. The median time from initial" exact="breast cancer" post="to BM diagnosis was 36 months (range 2–141 months)."/>
   <result pre="patients developed symptomatic BM. The median time from initial breast" exact="cancer" post="to BM diagnosis was 36 months (range 2–141 months)."/>
   <result pre="The median overall survival (OS) from the initial diagnosis of" exact="breast cancer" post="was 44 months (range 0.9–185 months). Validation Cohort B"/>
   <result pre="median overall survival (OS) from the initial diagnosis of breast" exact="cancer" post="was 44 months (range 0.9–185 months). Validation Cohort B"/>
   <result pre="RING domain 1 ( BARD1), RAD51 homolog ( RAD51), Fanconi" exact="anemia" post="group G ( FANCG), proliferating cell nuclear antigen ("/>
   <result pre="identify molecular predictors of the BM development in advanced HER2-positive" exact="breast cancer" post="patients. This subset of breast cancer patients carry particularly"/>
   <result pre="molecular predictors of the BM development in advanced HER2-positive breast" exact="cancer" post="patients. This subset of breast cancer patients carry particularly"/>
   <result pre="development in advanced HER2-positive breast cancer patients. This subset of" exact="breast cancer" post="patients carry particularly high risk of BM. Additionally, some"/>
   <result pre="in advanced HER2-positive breast cancer patients. This subset of breast" exact="cancer" post="patients carry particularly high risk of BM. Additionally, some"/>
   <result pre="high throughput DASL technology based on the expression of 502" exact="cancer" post="related genes in addition to analysis of the clinicopathologic"/>
   <result pre="but it is also possible that BM in advanced HER2-positive" exact="breast cancer" post="patients is a biologically determined, stochastic and inevitable event."/>
   <result pre="it is also possible that BM in advanced HER2-positive breast" exact="cancer" post="patients is a biologically determined, stochastic and inevitable event."/>
   <result pre="importantly, less frequently received neoadjuvant chemotherapy. Gene expression alterations of" exact="breast cancer" post="were recently demonstrated to be drug-specific, and drug-induced tumor"/>
   <result pre="less frequently received neoadjuvant chemotherapy. Gene expression alterations of breast" exact="cancer" post="were recently demonstrated to be drug-specific, and drug-induced tumor"/>
   <result pre="[ 20] showed that BM gene set tested in various" exact="breast cancer" post="cohorts was less BM predictive in patients whom received"/>
   <result pre="20] showed that BM gene set tested in various breast" exact="cancer" post="cohorts was less BM predictive in patients whom received"/>
   <result pre="preventive effect, may also alter the pattern of relapse in" exact="breast cancer." post="In this study, patients in Cohort B, compared to"/>
   <result pre="have previously reported that high cytoplasmic expression of RAD51 in" exact="breast cancer" post="is associated with significantly increased risk of BM, particularly"/>
   <result pre="previously reported that high cytoplasmic expression of RAD51 in breast" exact="cancer" post="is associated with significantly increased risk of BM, particularly"/>
   <result pre="that BARD1 and RAD51 are frequently overexpressed in BMs from" exact="breast cancer" post="and may constitute a mechanism to overcome reactive oxygen"/>
   <result pre="BARD1 and RAD51 are frequently overexpressed in BMs from breast" exact="cancer" post="and may constitute a mechanism to overcome reactive oxygen"/>
   <result pre="data suggest that RAD51 targeting might be important in HER2-positive" exact="breast cancer." post="High nuclear expression of HDGF, another gene constituting our"/>
   <result pre="Ki-67 &amp;gt;20 %, lymph node involvement and poor prognosis in" exact="breast cancer" post="patients [ 28, 29]. Chen et al. [ 29]"/>
   <result pre="&amp;gt;20 %, lymph node involvement and poor prognosis in breast" exact="cancer" post="patients [ 28, 29]. Chen et al. [ 29]"/>
   <result pre="29] demonstrated that nuclear HDGF over-expression stimulates epithelial–mesenchymal transition of" exact="breast cancer" post="cells by down-regulation of E-cadherin and up-regulation of vimentin."/>
   <result pre="demonstrated that nuclear HDGF over-expression stimulates epithelial–mesenchymal transition of breast" exact="cancer" post="cells by down-regulation of E-cadherin and up-regulation of vimentin."/>
   <result pre="is partly consistent with our earlier study in advanced HER2-positive" exact="breast cancer" post="patients, showing the association between the risk of BM"/>
   <result pre="partly consistent with our earlier study in advanced HER2-positive breast" exact="cancer" post="patients, showing the association between the risk of BM"/>
   <result pre="association between ER-negativity and the occurrence of BM in HER2-positive" exact="breast cancer" post="patients was earlier reported by other authors [ 2,"/>
   <result pre="between ER-negativity and the occurrence of BM in HER2-positive breast" exact="cancer" post="patients was earlier reported by other authors [ 2,"/>
   <result pre="and sites of recurrence in ER-positive/HER2 positive (HER2-positive luminal B)" exact="breast cancer" post="is different compared to that in non-luminal HER2 enriched"/>
   <result pre="sites of recurrence in ER-positive/HER2 positive (HER2-positive luminal B) breast" exact="cancer" post="is different compared to that in non-luminal HER2 enriched"/>
   <result pre="apparently increase the likelihood of early BM in advanced HER2-positive" exact="breast cancer," post="and the 3-gene classifier does not improve their predictive"/>
   <result pre="of cerebral metastases in patients treated with trastuzumab for metastatic" exact="breast cancer" post="Br J Cancer 2004 91 639 643 15266327 3."/>
   <result pre="cerebral metastases in patients treated with trastuzumab for metastatic breast" exact="cancer" post="Br J Cancer 2004 91 639 643 15266327 3."/>
   <result pre="patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic" exact="breast cancer" post="Breast 2006 15 219 225 10.1016/j.breast.2005.04.017 16026983 4. Brufsky"/>
   <result pre="with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast" exact="cancer" post="Breast 2006 15 219 225 10.1016/j.breast.2005.04.017 16026983 4. Brufsky"/>
   <result pre="Szczylik C Risk factors for brain relapse in HER2-positive metastatic" exact="breast cancer" post="patients Breast Cancer Res Treat 2009 117 297 303"/>
   <result pre="C Risk factors for brain relapse in HER2-positive metastatic breast" exact="cancer" post="patients Breast Cancer Res Treat 2009 117 297 303"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="JN Wolmark N Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122"/>
   <result pre="Wolmark N Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122"/>
   <result pre="McFadden E et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1659 1672 10.1056/NEJMoa052306"/>
   <result pre="E et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1659 1672 10.1056/NEJMoa052306"/>
   <result pre="Investigators Adjuvant docetaxel or vinorelbine with or without trastuzumab for" exact="breast cancer" post="N Engl J Med 2006 354 809 820 10.1056/NEJMoa053028"/>
   <result pre="Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast" exact="cancer" post="N Engl J Med 2006 354 809 820 10.1056/NEJMoa053028"/>
   <result pre="collab: Breast Cancer International Research Group Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 1273 1283 10.1056/NEJMoa0910383"/>
   <result pre="Breast Cancer International Research Group Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 1273 1283 10.1056/NEJMoa0910383"/>
   <result pre="levels in serum and cerebrospinal fluid is altered in HER2-positive" exact="breast cancer" post="patients with brain metastases and impairment of the blood–brain"/>
   <result pre="in serum and cerebrospinal fluid is altered in HER2-positive breast" exact="cancer" post="patients with brain metastases and impairment of the blood–brain"/>
   <result pre="expression analysis for prediction of rapid brain metastasis in HER2-positive" exact="breast cancer" post="patients [abstract] J Clin Oncol 2008 26 s45 16."/>
   <result pre="analysis for prediction of rapid brain metastasis in HER2-positive breast" exact="cancer" post="patients [abstract] J Clin Oncol 2008 26 s45 16."/>
   <result pre="rapid development of brain metastases in patients with HER2-positive advanced" exact="breast cancer" post="[abstract] J Clin Oncol 2012 30 Suppl 505 17."/>
   <result pre="development of brain metastases in patients with HER2-positive advanced breast" exact="cancer" post="[abstract] J Clin Oncol 2012 30 Suppl 505 17."/>
   <result pre="17. Duchnowska R Szczylik C Central nervous system metastases in" exact="breast cancer" post="patients administered trastuzumab Cancer Treat Rev 2005 31 312"/>
   <result pre="Duchnowska R Szczylik C Central nervous system metastases in breast" exact="cancer" post="patients administered trastuzumab Cancer Treat Rev 2005 31 312"/>
   <result pre="are more predictive of treatment outcomes than baseline signatures in" exact="breast cancer" post="Pharmacogenet Genomics 2009 19 833 842 10.1097/FPC.0b013e328330a39f 19809382 20."/>
   <result pre="more predictive of treatment outcomes than baseline signatures in breast" exact="cancer" post="Pharmacogenet Genomics 2009 19 833 842 10.1097/FPC.0b013e328330a39f 19809382 20."/>
   <result pre="MJ Gerald WL Foekens JA Massagué J Genes that mediate" exact="breast cancer" post="metastasis to the brain Nature 2009 459 1005 1009"/>
   <result pre="Gerald WL Foekens JA Massagué J Genes that mediate breast" exact="cancer" post="metastasis to the brain Nature 2009 459 1005 1009"/>
   <result pre="Stein S Cameron D Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="S Cameron D Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="Steeg PS Effect of lapatinib on the outgrowth of metastatic" exact="breast cancer" post="cells to the brain J Natl Cancer Inst 2008"/>
   <result pre="PS Effect of lapatinib on the outgrowth of metastatic breast" exact="cancer" post="cells to the brain J Natl Cancer Inst 2008"/>
   <result pre="recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary" exact="breast cancer" post="Clin Cancer Res 2010 16 6159 6168 10.1158/1078-0432.CCR-10-1027 20802015"/>
   <result pre="predicts pathologic complete response to neoadjuvant chemotherapy in primary breast" exact="cancer" post="Clin Cancer Res 2010 16 6159 6168 10.1158/1078-0432.CCR-10-1027 20802015"/>
   <result pre="Wu W Iwase H Fukuda M Ohta T Prediction of" exact="breast cancer" post="sensitivity to neoadjuvant chemotherapy based on the status of"/>
   <result pre="W Iwase H Fukuda M Ohta T Prediction of breast" exact="cancer" post="sensitivity to neoadjuvant chemotherapy based on the status of"/>
   <result pre="break repair genes and oxidative damage in brain metastasis of" exact="breast cancer." post="J Natl Cancer Inst 106(7):dju145 28. Chen X Yun"/>
   <result pre="of nuclear hepatoma-derived growth factor (HDGF) localization in patients with" exact="breast cancer" post="Pathol Res Pract 2012 208 437 443 10.1016/j.prp.2012.03.004 22682760"/>
   <result pre="nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast" exact="cancer" post="Pathol Res Pract 2012 208 437 443 10.1016/j.prp.2012.03.004 22682760"/>
   <result pre="Liu JK Yeh MH Tai MH Hepatoma-derived growth factor regulates" exact="breast cancer" post="cell invasion by modulating epithelial–mesenchymal transition J Pathol 2012"/>
   <result pre="JK Yeh MH Tai MH Hepatoma-derived growth factor regulates breast" exact="cancer" post="cell invasion by modulating epithelial–mesenchymal transition J Pathol 2012"/>
   <result pre="and clinical outcomes among patients with human epidermal growth factor-2-positive" exact="breast cancer" post="in the National Comprehensive Cancer Network: a prospective cohort"/>
   <result pre="clinical outcomes among patients with human epidermal growth factor-2-positive breast" exact="cancer" post="in the National Comprehensive Cancer Network: a prospective cohort"/>
   <result pre="D Speers CH Nielsen TO Gelmon K Metastatic behavior of" exact="breast cancer" post="subtypes J Clin Oncol 2010 28 3271 3277 10.1200/JCO.2009.25.9820"/>
   <result pre="Speers CH Nielsen TO Gelmon K Metastatic behavior of breast" exact="cancer" post="subtypes J Clin Oncol 2010 28 3271 3277 10.1200/JCO.2009.25.9820"/>
   <result pre="unique pattern of metastatic spread and increased survival among HER2-overexpressing" exact="breast cancer" post="patients Am J Clin Oncol 2009 32 504 508"/>
   <result pre="pattern of metastatic spread and increased survival among HER2-overexpressing breast" exact="cancer" post="patients Am J Clin Oncol 2009 32 504 508"/>
   <result pre="TK Hortobagyi GN Gonzalez-Angulo AM Defining prognosis for women with" exact="breast cancer" post="and CNC metastases by HER2 status Ann Oncol 2008"/>
   <result pre="Hortobagyi GN Gonzalez-Angulo AM Defining prognosis for women with breast" exact="cancer" post="and CNC metastases by HER2 status Ann Oncol 2008"/>
   <result pre="Shin KH Trastuzumab treatment beyond brain progression in HER2-positive metastatic" exact="breast cancer" post="Ann Oncol 2009 20 56 62 10.1093/annonc/mdn539 18664558 37."/>
   <result pre="KH Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast" exact="cancer" post="Ann Oncol 2009 20 56 62 10.1093/annonc/mdn539 18664558 37."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4358700/results/search/disease/results.xml">
   <result pre="been implicated in promoting the aggressiveness and metastatic potential of" exact="breast cancer." post="Upregulation of HER3 has been found to be a"/>
   <result pre="kinase inhibitors and to endocrine therapy in the treatment of" exact="breast cancer." post="Thus, agents that reduce HER3 expression at the plasma"/>
   <result pre="signaling downstream of HER3. Consistent with these results, perhexiline inhibited" exact="breast cancer" post="cell proliferation in vitro and tumor growth in vivo."/>
   <result pre="downstream of HER3. Consistent with these results, perhexiline inhibited breast" exact="cancer" post="cell proliferation in vitro and tumor growth in vivo."/>
   <result pre="HER3 ablation modulators as innovative therapeutics to improve survival in" exact="breast cancer" post="patients. Electronic supplementary material The online version of this"/>
   <result pre="ablation modulators as innovative therapeutics to improve survival in breast" exact="cancer" post="patients. Electronic supplementary material The online version of this"/>
   <result pre="as one of the most potent oncogenic factors in promoting" exact="breast cancer" post="tumorigenesis [ 5]. In animal models of breast cancer"/>
   <result pre="one of the most potent oncogenic factors in promoting breast" exact="cancer" post="tumorigenesis [ 5]. In animal models of breast cancer"/>
   <result pre="promoting breast cancer tumorigenesis [ 5]. In animal models of" exact="breast cancer" post="driven by HER2, HER3 expression and phosphorylation are upregulated"/>
   <result pre="breast cancer tumorigenesis [ 5]. In animal models of breast" exact="cancer" post="driven by HER2, HER3 expression and phosphorylation are upregulated"/>
   <result pre="HER3 has been shown to significantly enhance the invasiveness of" exact="breast cancer" post="cells. Specifically, HER3 promotes invasion and metastasis through its"/>
   <result pre="has been shown to significantly enhance the invasiveness of breast" exact="cancer" post="cells. Specifically, HER3 promotes invasion and metastasis through its"/>
   <result pre="expression and the detection HER2/HER3 dimers have prognostic significance in" exact="breast cancer" post="[ 10, 11]. Therapies targeting epidermal growth factor receptor"/>
   <result pre="and the detection HER2/HER3 dimers have prognostic significance in breast" exact="cancer" post="[ 10, 11]. Therapies targeting epidermal growth factor receptor"/>
   <result pre="gefitinib, erlotinib) and to endocrine therapy in the treatment of" exact="breast cancer" post="[ 12- 14]. For example, it has been shown"/>
   <result pre="erlotinib) and to endocrine therapy in the treatment of breast" exact="cancer" post="[ 12- 14]. For example, it has been shown"/>
   <result pre="mounting evidence highlights the importance of targeting HER3 to decrease" exact="breast cancer" post="mortality [ 3]. In this report, we engineered an"/>
   <result pre="evidence highlights the importance of targeting HER3 to decrease breast" exact="cancer" post="mortality [ 3]. In this report, we engineered an"/>
   <result pre="internalization and downregulation, inhibits signaling downstream of HER3, and inhibits" exact="cancer" post="cell proliferation in vitro and in vivo. Materials and"/>
   <result pre="System (Bio-Rad Laboratories, Hercules, CA, USA). Cell proliferation assay The" exact="breast cancer" post="cell lines MDA-MB-468, SK-BR-3, AU565, and BT474 were used"/>
   <result pre="(Bio-Rad Laboratories, Hercules, CA, USA). Cell proliferation assay The breast" exact="cancer" post="cell lines MDA-MB-468, SK-BR-3, AU565, and BT474 were used"/>
   <result pre="of perhexiline on decreasing HER3 expression was detected in triple-negative" exact="breast cancer" post="MDA-MB-468 cells that express EGFR and HER3, but not"/>
   <result pre="perhexiline on decreasing HER3 expression was detected in triple-negative breast" exact="cancer" post="MDA-MB-468 cells that express EGFR and HER3, but not"/>
   <result pre="in Additional file 3). Perhexiline inhibits neuregulin-mediated signaling activation and" exact="breast cancer" post="cell proliferation To determine the effect of perhexiline on"/>
   <result pre="Additional file 3). Perhexiline inhibits neuregulin-mediated signaling activation and breast" exact="cancer" post="cell proliferation To determine the effect of perhexiline on"/>
   <result pre="determine the effect of perhexiline on HER3-mediated oncogenic signaling in" exact="breast cancer" post="cells, serum-starved MDA-MB-468 cells were pretreated with perhexiline and"/>
   <result pre="the effect of perhexiline on HER3-mediated oncogenic signaling in breast" exact="cancer" post="cells, serum-starved MDA-MB-468 cells were pretreated with perhexiline and"/>
   <result pre="the mean. To further determine the effect of perhexiline on" exact="breast cancer" post="cell proliferation, MDA-MB-468 and SK-BR-3 cells were treated with"/>
   <result pre="mean. To further determine the effect of perhexiline on breast" exact="cancer" post="cell proliferation, MDA-MB-468 and SK-BR-3 cells were treated with"/>
   <result pre="combined with lapatinib, an agent commonly used to treat HER2-positive" exact="breast cancer." post="Treatment of MDA-MB-468 cells with 100 nM lapatinib for"/>
   <result pre="family tyrosine kinase inhibitors (Figure 4C). Figure 4 Perhexiline inhibits" exact="breast cancer" post="cell proliferation and functions synergistically with lapatinib. (A-B) MDA-MB-468"/>
   <result pre="tyrosine kinase inhibitors (Figure 4C). Figure 4 Perhexiline inhibits breast" exact="cancer" post="cell proliferation and functions synergistically with lapatinib. (A-B) MDA-MB-468"/>
   <result pre="point was below 1 (Figure 4E). We chose two additional" exact="breast cancer" post="cell lines, AU565 and BT474, to test the inhibitory"/>
   <result pre="was below 1 (Figure 4E). We chose two additional breast" exact="cancer" post="cell lines, AU565 and BT474, to test the inhibitory"/>
   <result pre="line was less robust. These data indicate that perhexiline inhibits" exact="breast cancer" post="cells growth and its inhibitory effect is synergized with"/>
   <result pre="was less robust. These data indicate that perhexiline inhibits breast" exact="cancer" post="cells growth and its inhibitory effect is synergized with"/>
   <result pre="inducing receptor internalization. Consistent with this mechanism, perhexiline also inhibits" exact="breast cancer" post="cell proliferation in vitro and tumor growth in vivo"/>
   <result pre="receptor internalization. Consistent with this mechanism, perhexiline also inhibits breast" exact="cancer" post="cell proliferation in vitro and tumor growth in vivo"/>
   <result pre="tumor growth in vivo and synergizes with lapatinib to inhibit" exact="breast cancer" post="cell growth. Increasing evidence has identified HER3 as one"/>
   <result pre="growth in vivo and synergizes with lapatinib to inhibit breast" exact="cancer" post="cell growth. Increasing evidence has identified HER3 as one"/>
   <result pre="as one of the most potent oncogenic factors in promoting" exact="breast cancer" post="tumorigenesis [ 5]. In animal models of breast cancer"/>
   <result pre="one of the most potent oncogenic factors in promoting breast" exact="cancer" post="tumorigenesis [ 5]. In animal models of breast cancer"/>
   <result pre="promoting breast cancer tumorigenesis [ 5]. In animal models of" exact="breast cancer" post="driven by HER2, HER3 expression and phosphorylation are upregulated"/>
   <result pre="breast cancer tumorigenesis [ 5]. In animal models of breast" exact="cancer" post="driven by HER2, HER3 expression and phosphorylation are upregulated"/>
   <result pre="HER3 has been shown to significantly enhance the invasiveness of" exact="breast cancer" post="cells. Specifically, HER3 promotes invasion and metastasis through its"/>
   <result pre="has been shown to significantly enhance the invasiveness of breast" exact="cancer" post="cells. Specifically, HER3 promotes invasion and metastasis through its"/>
   <result pre="the detection HER2/HER3 dimers [ 11] have prognostic significance in" exact="breast cancer." post="With the exception of HER3, the HER family of"/>
   <result pre="been reported that perhexiline has an effect on adriamycin-resistant human" exact="breast cancer" post="cells. Simultaneous exposure to tamoxifen or perhexiline decreased resistance"/>
   <result pre="reported that perhexiline has an effect on adriamycin-resistant human breast" exact="cancer" post="cells. Simultaneous exposure to tamoxifen or perhexiline decreased resistance"/>
   <result pre="an undefined mechanism [ 30]. Here, we report the anti-breast" exact="cancer" post="properties of perhexiline through HER3 degradation and HER3-mediated signaling"/>
   <result pre="lapatinib on tumor growth may provide immediate therapeutic benefits for" exact="breast cancer" post="patients with drug resistance and metastasis. In summary, our"/>
   <result pre="on tumor growth may provide immediate therapeutic benefits for breast" exact="cancer" post="patients with drug resistance and metastasis. In summary, our"/>
   <result pre="factor receptor (EGFR) family members and inhibit downstream signaling in" exact="breast cancer" post="cells and tumors. As a clinically used drug, perhexiline"/>
   <result pre="receptor (EGFR) family members and inhibit downstream signaling in breast" exact="cancer" post="cells and tumors. As a clinically used drug, perhexiline"/>
   <result pre="such as lapatinib, to overcome drug resistance and metastasis in" exact="cancer" post="treatment. Perhexiline is a first-in-class small molecule that targets"/>
   <result pre="pharmaceutical properties could provide improved derivatives with greater benefit to" exact="breast cancer" post="patients. Clinical evaluation of perhexiline and its improved derivatives"/>
   <result pre="properties could provide improved derivatives with greater benefit to breast" exact="cancer" post="patients. Clinical evaluation of perhexiline and its improved derivatives"/>
   <result pre="derivatives may directly lead to a new therapy to treat" exact="breast cancer" post="and other HER3-dependent cancers. Conclusions Ablating HER3 offers the"/>
   <result pre="may directly lead to a new therapy to treat breast" exact="cancer" post="and other HER3-dependent cancers. Conclusions Ablating HER3 offers the"/>
   <result pre="Conclusions Ablating HER3 offers the potential to decrease mortality in" exact="breast cancer" post="in patients. Using a novel image-based high-throughput screening assay,"/>
   <result pre="Ablating HER3 offers the potential to decrease mortality in breast" exact="cancer" post="in patients. Using a novel image-based high-throughput screening assay,"/>
   <result pre="perhexiline inhibits HER3-mediated signaling as well as the growth of" exact="breast cancer" post="cells in vitro and in vivo. Our approach overcomes"/>
   <result pre="inhibits HER3-mediated signaling as well as the growth of breast" exact="cancer" post="cells in vitro and in vivo. Our approach overcomes"/>
   <result pre="modulators represent an innovative therapeutic approach to improve survival in" exact="breast cancer" post="patients. Additional files LINK Additional file 1: Figure S1."/>
   <result pre="represent an innovative therapeutic approach to improve survival in breast" exact="cancer" post="patients. Additional files LINK Additional file 1: Figure S1."/>
   <result pre="by arrows. LINK Additional file 4: Figure S4. Perhexiline inhibits" exact="breast cancer" post="cell proliferation and functions synergistically with lapatinib. (A and"/>
   <result pre="arrows. LINK Additional file 4: Figure S4. Perhexiline inhibits breast" exact="cancer" post="cell proliferation and functions synergistically with lapatinib. (A and"/>
   <result pre="antiproliferative effects of perhexiline on AU565 (A) and BT474 (C)" exact="breast cancer" post="cells. Cells were treated with different concentrations of perhexiline"/>
   <result pre="effects of perhexiline on AU565 (A) and BT474 (C) breast" exact="cancer" post="cells. Cells were treated with different concentrations of perhexiline"/>
   <result pre="of HER3, the unpretentious member of the HER family, in" exact="cancer" post="biology and cancer therapeutics Semin Cell Dev Biol 2010"/>
   <result pre="unpretentious member of the HER family, in cancer biology and" exact="cancer" post="therapeutics Semin Cell Dev Biol 2010 21 944 50"/>
   <result pre="Stern DF ERBB3/HER3 and ERBB2/HER2 duet in mammary development and" exact="breast cancer" post="J Mammary Gland Biol Neoplasia 2008 13 215 23"/>
   <result pre="DF ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast" exact="cancer" post="J Mammary Gland Biol Neoplasia 2008 13 215 23"/>
   <result pre="induction of mammary tumors in transgenic mice: implications for human" exact="breast cancer" post="EMBO J 1999 18 2149 64 10.1093/emboj/18.8.2149 10205169 7."/>
   <result pre="of mammary tumors in transgenic mice: implications for human breast" exact="cancer" post="EMBO J 1999 18 2149 64 10.1093/emboj/18.8.2149 10205169 7."/>
   <result pre="M et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven" exact="breast cancer" post="cell motility and metastasis Oncogene 2012 31 706 15"/>
   <result pre="et al. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast" exact="cancer" post="cell motility and metastasis Oncogene 2012 31 706 15"/>
   <result pre="Huntsman DG et al. HER-3 overexpression is prognostic of reduced" exact="breast cancer" post="survival: a study of 4046 patients Ann Surg 2010"/>
   <result pre="DG et al. HER-3 overexpression is prognostic of reduced breast" exact="cancer" post="survival: a study of 4046 patients Ann Surg 2010"/>
   <result pre="HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early" exact="breast cancer" post="Breast Cancer Res Treat 2011 132 463 70 10.1007/s10549-011-1606-z"/>
   <result pre="and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast" exact="cancer" post="Breast Cancer Res Treat 2011 132 463 70 10.1007/s10549-011-1606-z"/>
   <result pre="activation mapping reveals molecular networks associated with antiestrogen resistance in" exact="breast cancer" post="cell lines Int J Cancer 2012 131 1998 2007"/>
   <result pre="mapping reveals molecular networks associated with antiestrogen resistance in breast" exact="cancer" post="cell lines Int J Cancer 2012 131 1998 2007"/>
   <result pre="of heregulin-beta2 in the acquisition of the hormone-independent phenotype of" exact="breast cancer" post="cells Cancer Res 1996 56 3350 8 8764133 16."/>
   <result pre="heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast" exact="cancer" post="cells Cancer Res 1996 56 3350 8 8764133 16."/>
   <result pre="ErbB3, EGFR and Erk is essential for growth of human" exact="breast cancer" post="cell lines with acquired resistance to fulvestrant Breast Cancer"/>
   <result pre="EGFR and Erk is essential for growth of human breast" exact="cancer" post="cell lines with acquired resistance to fulvestrant Breast Cancer"/>
   <result pre="predict when to implement treatment with aromatase inhibitors in invasive" exact="breast cancer?" post="Clin Cancer Res 2005 11 4835 42 10.1158/1078-0432.CCR-05-0196 16000581"/>
   <result pre="Liu B Targeting of erbB3 receptor to overcome resistance in" exact="cancer" post="treatment Mol Cancer 2014 13 105 10.1186/1476-4598-13-105 24886126 27."/>
   <result pre="efficacy and safety of perhexiline in the treatment of ischemic" exact="heart disease" post="Am J Cardiovasc Drugs 2001 1 193 204 10.2165/00129784-200101030-00005"/>
   <result pre="TC Modulation of induced resistance to adriamycin in two human" exact="breast cancer" post="cell lines with tamoxifen or perhexiline maleate Cancer Chemother"/>
   <result pre="Modulation of induced resistance to adriamycin in two human breast" exact="cancer" post="cell lines with tamoxifen or perhexiline maleate Cancer Chemother"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4359239/results/search/disease/results.xml">
   <result pre="author and source are credited. HER2 and HER3 cooperatively regulate" exact="cancer" post="cell growth and determine sensitivity to the novel investigational"/>
   <result pre="HER2, HER3, and HER4, have been widely implicated in human" exact="cancer" post="[ 1]. For example, EGFR activating mutations are seen"/>
   <result pre="currently undergoing clinical evaluation. In the current era of personalized" exact="cancer" post="medicine, biomarkers that can be measured in tumor biopsies"/>
   <result pre="of the EGFR and HER2 kinases, in a panel of" exact="breast cancer" post="cell lines. They observed a broad range of sensitivity"/>
   <result pre="the EGFR and HER2 kinases, in a panel of breast" exact="cancer" post="cell lines. They observed a broad range of sensitivity"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4359299/results/search/disease/results.xml">
   <result pre="Review Advances in targeted therapies and new promising targets in" exact="esophageal cancer" post="Belkhiri Abbes 1 El-Rifai Wael 1 2 [], 1"/>
   <result pre="Advances in targeted therapies and new promising targets in esophageal" exact="cancer" post="Belkhiri Abbes 1 El-Rifai Wael 1 2 [], 1"/>
   <result pre="limited efficacy in the treatment of a significant number of" exact="cancer" post="patients. The molecular analysis of cancer cells has uncovered"/>
   <result pre="a significant number of cancer patients. The molecular analysis of" exact="cancer" post="cells has uncovered key genetic and epigenetic alterations underlying"/>
   <result pre="highlight recent progress in the development of targeted therapies in" exact="esophageal cancer." post="This will include a review of drugs targeting receptor"/>
   <result pre="of drugs targeting receptor tyrosine kinases and other kinases in" exact="esophageal cancer." post="Additional studies will be required to develop a rational"/>
   <result pre="of these targeted agents with respect to histologic types of" exact="esophageal cancer" post="and the optimal selection of cancer patients who would"/>
   <result pre="these targeted agents with respect to histologic types of esophageal" exact="cancer" post="and the optimal selection of cancer patients who would"/>
   <result pre="histologic types of esophageal cancer and the optimal selection of" exact="cancer" post="patients who would most likely benefit from targeted therapy."/>
   <result pre="drugs against these targets in clinical trials. adenocarcinoma esophageal gastric" exact="cancer" post="targeted therapy INTRODUCTION The increasing incidence and poor prognosis"/>
   <result pre="targeted therapy INTRODUCTION The increasing incidence and poor prognosis of" exact="esophageal cancer" post="represent a major public health problem worldwide. In 2013,"/>
   <result pre="therapy INTRODUCTION The increasing incidence and poor prognosis of esophageal" exact="cancer" post="represent a major public health problem worldwide. In 2013,"/>
   <result pre="In 2013, it was estimated that 17,990 new cases of" exact="esophageal cancer" post="will be diagnosed and only 15% of patients will"/>
   <result pre="2013, it was estimated that 17,990 new cases of esophageal" exact="cancer" post="will be diagnosed and only 15% of patients will"/>
   <result pre="factors and tumorigenesis. While smoking and alcohol [ 4], prior" exact="head and neck cancer" post="[ 5], and human papilloma virus infection [ 6]"/>
   <result pre="While smoking and alcohol [ 4], prior head and neck" exact="cancer" post="[ 5], and human papilloma virus infection [ 6]"/>
   <result pre="are risk factors in SCC; gastro-esophageal reflux disease (GERD) and" exact="obesity" post="have been associated with increased risk of AC ["/>
   <result pre="and characterize molecular signatures to distinguish the two types of" exact="esophageal cancer." post="Genomic, proteomic, and molecular epidemiologic studies have greatly helped"/>
   <result pre="eventually overcome the shortcomings of the current standard therapies of" exact="esophageal cancer." post="As part of the International Cancer Genome Consortium project,"/>
   <result pre="SCC. Of note, FAM135B has been characterized as a novel" exact="cancer" post="gene that promotes malignancy of SCC cells [ 13]."/>
   <result pre="provide a foundation for further investigations to characterize subsets of" exact="esophageal cancer" post="that may be clinically useful for developing more effective"/>
   <result pre="a foundation for further investigations to characterize subsets of esophageal" exact="cancer" post="that may be clinically useful for developing more effective"/>
   <result pre="therapeutic targets in esophageal SCC and AC. Targeted therapies for" exact="esophageal cancer" post="in development During the past two decades, the emerging"/>
   <result pre="targets in esophageal SCC and AC. Targeted therapies for esophageal" exact="cancer" post="in development During the past two decades, the emerging"/>
   <result pre="receptor tyrosine kinases; SCC, esophageal squamous cell carcinoma; Src, Rous" exact="sarcoma" post="virus tyrosine kinase homolog; VEGFR, vascular endothelial growth factor"/>
   <result pre="downstream effectors such as RAS, RAF, and PI3K can promote" exact="cancer" post="(reviewed by [ 16]). Our increasing knowledge of the"/>
   <result pre="increasing knowledge of the mechanisms of uncontrolled RTK signaling in" exact="cancer" post="has provided the rationale for the development of drugs"/>
   <result pre="addition, AXL has been implicated in promoting epithelial-to-mesenchymal transition (EMT)," exact="cancer" post="cell invasion, and drug resistance in many types of"/>
   <result pre="has proven its first clinical success in patients with advanced" exact="colorectal cancer," post="especially those with wild-type KRAS [ 19, 20]. EGFR"/>
   <result pre="and AC have provided the rationale for targeting EGFR in" exact="esophageal cancer" post="[ 22]. This suggests that EGFR amplification and overexpression"/>
   <result pre="AC have provided the rationale for targeting EGFR in esophageal" exact="cancer" post="[ 22]. This suggests that EGFR amplification and overexpression"/>
   <result pre="HER-2 and downstream signaling in preclinical cell models of gastro-esophageal" exact="cancer" post="[ 23]. In phase II clinical studies, cetuximab in"/>
   <result pre="significantly improved response rates in patients with gastro-esophageal junction (GEJ)" exact="cancer" post="[ 24] or SCC [ 25]. However, cetuximab as"/>
   <result pre="had no additional clinical advantage to chemotherapy alone in GEJ" exact="cancer" post="patients [ 27]. Nimotuzumab, a humanized EGFR mAb, in"/>
   <result pre="in combination with epirubicin, oxaliplatin and capecitabine in metastatic GEJ" exact="cancer" post="patients in a randomized phase III clinical trial ["/>
   <result pre="[ 38]. The initial success of trastuzumab targeted therapy in" exact="breast cancer" post="led to its investigation in other types of HER-"/>
   <result pre="38]. The initial success of trastuzumab targeted therapy in breast" exact="cancer" post="led to its investigation in other types of HER-"/>
   <result pre="combination with capecitabine/cisplatin or 5-fluorouracil/cisplatin in patients with advanced GEJ" exact="cancer" post="improved overall survival as compared to chemotherapy alone ["/>
   <result pre="both EGFR and HER-2, was effective in patients with trastuzumab-resistant" exact="breast cancer" post="[ 41]. In a phase II clinical study, lapatinib"/>
   <result pre="EGFR and HER-2, was effective in patients with trastuzumab-resistant breast" exact="cancer" post="[ 41]. In a phase II clinical study, lapatinib"/>
   <result pre="the FDA as second-line therapy for patients with advanced gastric" exact="cancer" post="or GEJ adenocarcinoma [ 55]. In a randomized phase"/>
   <result pre="its identification as a transforming gene in human chronic myelogenous" exact="leukemia" post="[ 61], AXL has been shown to be overexpressed"/>
   <result pre="67]. These studies highlight AXL as a promising target for" exact="cancer" post="therapy. In this regard, Holland and colleagues [ 68]"/>
   <result pre="I) to evaluate the AXL inhibitor BGB324 (formerly R428) in" exact="cancer" post="patients [ 70]. In another phase I clinical study,"/>
   <result pre="activation of AXL kinase mediates resistance to EGFR-targeted therapy in" exact="lung cancer" post="[ 72]. Another study showed that knockdown of AXL"/>
   <result pre="of AXL kinase mediates resistance to EGFR-targeted therapy in lung" exact="cancer" post="[ 72]. Another study showed that knockdown of AXL"/>
   <result pre="gene is frequently amplified and/or overexpressed in several types of" exact="cancer" post="including those of the stomach [ 77] and esophagus"/>
   <result pre="overexpression has been significantly associated with more advanced stages of" exact="cancer" post="and poor prognosis [ 79]. Pre-clinical studies showed that"/>
   <result pre="[ 81]; and Ser215 to suppress its transcriptional activity in" exact="cancer" post="cells [ 82]. Additionally, we uncovered that AURKA suppresses"/>
   <result pre="AURKA suppresses p53 through regulation of AKT-MDM-2 signaling in gastric" exact="cancer" post="cells [ 83], and attenuates TAp73 transcriptional activity in"/>
   <result pre="[ 83], and attenuates TAp73 transcriptional activity in p53 deficient" exact="cancer" post="cells (Figure 1) [ 84]. We [ 83], and"/>
   <result pre="others [ 85], have reported that AURKA promotes survival of" exact="cancer" post="cells through increased phosphorylation of AKT at Ser473. Because"/>
   <result pre="who have developed acquired resistance to first-line chemotherapy. Conclusions Esophageal" exact="cancer" post="is characterized by resistance to current first-line therapies and"/>
   <result pre="of both histologic types has been incomplete. Our understanding of" exact="cancer" post="biology coupled with the development of targeted drugs will"/>
   <result pre="drugs will have a positive impact in the treatment of" exact="esophageal cancer." post="The current ongoing clinical trials of targeted drugs in"/>
   <result pre="cancer. The current ongoing clinical trials of targeted drugs in" exact="esophageal cancer" post="patients have been mostly based on molecular targets identified"/>
   <result pre="The current ongoing clinical trials of targeted drugs in esophageal" exact="cancer" post="patients have been mostly based on molecular targets identified"/>
   <result pre="be useful in future clinical trials and rational management of" exact="cancer" post="patients. Authors’ contribution Abbes Belkhiri: Writing the manuscript and"/>
   <result pre="DM Bray F Ferlay J Pisani P Estimating the world" exact="cancer" post="burden: Globocan 2000 International Journal of Cancer 2001 94"/>
   <result pre="22847812 4 Blot WJ McLaughlin JK The changing epidemiology of" exact="esophageal cancer" post="Seminars in oncology 1999 26 2 8 10566604 5"/>
   <result pre="4 Blot WJ McLaughlin JK The changing epidemiology of esophageal" exact="cancer" post="Seminars in oncology 1999 26 2 8 10566604 5"/>
   <result pre="M Rovelli P Impact of esophageal screening in patients with" exact="head and neck cancer" post="The American surgeon 1990 56 289 292 2334068 6"/>
   <result pre="Impact of esophageal screening in patients with head and neck" exact="cancer" post="The American surgeon 1990 56 289 292 2334068 6"/>
   <result pre="prospective, seroepidemiological study of the role of human papillomavirus in" exact="esophageal cancer" post="in Norway Cancer research 1997 57 3989 3992 9307283"/>
   <result pre="seroepidemiological study of the role of human papillomavirus in esophageal" exact="cancer" post="in Norway Cancer research 1997 57 3989 3992 9307283"/>
   <result pre="Phase II trial of weekly irinotecan plus cisplatin in advanced" exact="esophageal cancer" post="Journal of clinical oncology: official journal of the American"/>
   <result pre="II trial of weekly irinotecan plus cisplatin in advanced esophageal" exact="cancer" post="Journal of clinical oncology: official journal of the American"/>
   <result pre="17 3270 3275 10506629 12 Enzinger PC Mayer RJ Esophageal" exact="cancer" post="The New England journal of medicine 2003 349 2241"/>
   <result pre="et al. Identification of genomic alterations in oesophageal squamous cell" exact="cancer" post="Nature 2014 509 91 95 24670651 14 Dulak AM"/>
   <result pre="G Hubert P Tyrosine kinase receptors as attractive targets of" exact="cancer" post="therapy Critical reviews in oncology/hematology 2004 50 23 38"/>
   <result pre="Perrone F Pricl S Pilotti S Targeted therapies: the rare" exact="cancer" post="paradigm Molecular oncology 2010 4 19 37 19913465 17"/>
   <result pre="BA Bunn PA Jr Epidermal growth factor receptor family in" exact="lung cancer" post="and premalignancy Seminars in oncology 2002 29 3 14"/>
   <result pre="Bunn PA Jr Epidermal growth factor receptor family in lung" exact="cancer" post="and premalignancy Seminars in oncology 2002 29 3 14"/>
   <result pre="KRAS is required for panitumumab efficacy in patients with metastatic" exact="colorectal cancer" post="Journal of clinical oncology: official journal of the American"/>
   <result pre="is required for panitumumab efficacy in patients with metastatic colorectal" exact="cancer" post="Journal of clinical oncology: official journal of the American"/>
   <result pre="Zalcberg JR K-ras mutations and benefit from cetuximab in advanced" exact="colorectal cancer" post="The New England journal of medicine 2008 359 1757"/>
   <result pre="JR K-ras mutations and benefit from cetuximab in advanced colorectal" exact="cancer" post="The New England journal of medicine 2008 359 1757"/>
   <result pre="chemotherapy regimens plus cetuximab in metastatic esophageal and GE junction" exact="cancer" post="Journal of Clinical Oncology, ASCO Annual Meeting Abstracts 2010"/>
   <result pre="or without cetuximab for patients with previously untreated advanced gastric" exact="cancer" post="(EXPAND): a randomised, open-label phase 3 trial The lancet"/>
   <result pre="or without panitumumab for patients with previously untreated advanced oesophagogastric" exact="cancer" post="(REAL3): a randomised, open-label phase 3 trial The lancet"/>
   <result pre="by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction" exact="cancer" post="Journal of thoracic oncology: official publication of the International"/>
   <result pre="A phase II trial of gefitinib for recurrent or metastatic" exact="cancer" post="of the esophagus or gastroesophageal junction Investigational new drugs"/>
   <result pre="35 Olayioye MA Update on HER-2 as a target for" exact="cancer" post="therapy: intracellular signaling pathways of ErbB2/HER-2 and family members"/>
   <result pre="therapy: intracellular signaling pathways of ErbB2/HER-2 and family members Breast" exact="cancer" post="research: BCR 2001 3 385 389 11737890 36 Yokota"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer" post="Science 1989 244 707 712 2470152 38 Baselga J"/>
   <result pre="Studies of the HER-2/neu proto-oncogene in human breast and ovarian" exact="cancer" post="Science 1989 244 707 712 2470152 38 Baselga J"/>
   <result pre="recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic" exact="breast cancer" post="Journal of clinical oncology: official journal of the American"/>
   <result pre="humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast" exact="cancer" post="Journal of clinical oncology: official journal of the American"/>
   <result pre="lapatinib plus capecitabine versus capecitabine alone in women with advanced" exact="breast cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="plus capecitabine versus capecitabine alone in women with advanced breast" exact="cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="has progressed on trastuzumab: updated efficacy and biomarker analyses Breast" exact="cancer" post="research and treatment 2008 112 533 543 18188694 42"/>
   <result pre="MET signalling: principles and functions in development, organ regeneration and" exact="cancer" post="Nature reviews Molecular cell biology 2010 11 834 848"/>
   <result pre="C et al. MET amplification leads to gefitinib resistance in" exact="lung cancer" post="by activating ERBB3 signaling Science 2007 316 1039 1043"/>
   <result pre="et al. MET amplification leads to gefitinib resistance in lung" exact="cancer" post="by activating ERBB3 signaling Science 2007 316 1039 1043"/>
   <result pre="M Jauch KW Bruns CJ Vascular endothelial growth factor in" exact="esophageal cancer" post="Journal of surgical oncology 2004 87 95 104 15282704"/>
   <result pre="Jauch KW Bruns CJ Vascular endothelial growth factor in esophageal" exact="cancer" post="Journal of surgical oncology 2004 87 95 104 15282704"/>
   <result pre="Kabbinavar F Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic" exact="colorectal cancer" post="The New England journal of medicine 2004 350 2335"/>
   <result pre="F Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal" exact="cancer" post="The New England journal of medicine 2004 350 2335"/>
   <result pre="2011 29 868 874 21189380 55 Ramucirumab approved for gastric" exact="cancer" post="Cancer discovery 2014 4 752 753 56 Fuchs CS"/>
   <result pre="II study of sunitinib as second-line treatment for advanced gastric" exact="cancer" post="Investigational new drugs 2011 29 1449 1458 20461441 58"/>
   <result pre="Bearss DJ Sharma S Targeting Axl and Mer kinases in" exact="cancer" post="Molecular cancer therapeutics 2011 10 1763 1773 21933973 61"/>
   <result pre="Sharma S Targeting Axl and Mer kinases in cancer Molecular" exact="cancer" post="therapeutics 2011 10 1763 1773 21933973 61 Neubauer A"/>
   <result pre="Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous" exact="leukemia" post="Seminars in hematology 1993 30 34 8235704 62 Shieh"/>
   <result pre="Lin WC Clinical significance of AXL kinase family in gastric" exact="cancer" post="Anticancer research 2002 22 1071 1078 12168903 64 Hong"/>
   <result pre="Belkhiri A ABL regulation by AXL promotes cisplatin resistance in" exact="esophageal cancer" post="Cancer research 2013 73 331 340 23117882 65 Hector"/>
   <result pre="A ABL regulation by AXL promotes cisplatin resistance in esophageal" exact="cancer" post="Cancer research 2013 73 331 340 23117882 65 Hector"/>
   <result pre="Lorens JB Axl is an essential epithelial-to-mesenchymal transition-induced regulator of" exact="breast cancer" post="metastasis and patient survival Proceedings of the National Academy"/>
   <result pre="JB Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast" exact="cancer" post="metastasis and patient survival Proceedings of the National Academy"/>
   <result pre="apoptosis, migration and invasion and predicts the clinical outcome of" exact="osteosarcoma" post="patients Biochemical and biophysical research communications 2013 435 493"/>
   <result pre="blocks tumor spread and prolongs survival in models of metastatic" exact="breast cancer" post="Cancer research 2010 70 1544 1554 20145120 69 Li"/>
   <result pre="tumor spread and prolongs survival in models of metastatic breast" exact="cancer" post="Cancer research 2010 70 1544 1554 20145120 69 Li"/>
   <result pre="of the proto-oncogene Axl and Mer receptor tyrosine kinases in" exact="colon cancer" post="Proceedings of the National Academy of Sciences of the"/>
   <result pre="the proto-oncogene Axl and Mer receptor tyrosine kinases in colon" exact="cancer" post="Proceedings of the National Academy of Sciences of the"/>
   <result pre="of the AXL kinase causes resistance to EGFR-targeted therapy in" exact="lung cancer" post="Nature genetics 2012 44 852 860 22751098 73 Linger"/>
   <result pre="the AXL kinase causes resistance to EGFR-targeted therapy in lung" exact="cancer" post="Nature genetics 2012 44 852 860 22751098 73 Linger"/>
   <result pre="apoptosis, blocks growth and enhances chemosensitivity of human non-small cell" exact="lung cancer" post="Oncogene 2013 32 3420 3431 22890323 74 Barr AR"/>
   <result pre="blocks growth and enhances chemosensitivity of human non-small cell lung" exact="cancer" post="Oncogene 2013 32 3420 3431 22890323 74 Barr AR"/>
   <result pre="cancers with possible involvement in aneuploid formation British journal of" exact="cancer" post="2001 84 824 831 11259099 78 Tong T Zhong"/>
   <result pre="to malignant development of human esophageal squamous cell carcinoma Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
   <result pre="Lin CY Hsu HC Overexpression and amplification of Aurora-A in" exact="hepatocellular carcinoma" post="Clinical cancer research: an official journal of the American"/>
   <result pre="HC Overexpression and amplification of Aurora-A in hepatocellular carcinoma Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
   <result pre="Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient" exact="cancer" post="cells Cancer research 2008 68 8998 9004 18974145 85"/>
   <result pre="a negative prognostic marker, increases migration and decreases radiosensitivity in" exact="cancer" post="cells Cancer research 2007 67 10436 10444 17974987 86"/>
   <result pre="MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells Molecular" exact="cancer" post="therapeutics 2012 11 763 774 22302096 89 Sehdev V"/>
   <result pre="Regulation by AURKA Promotes Cell Survival in Gastric Cancer Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
   <result pre="KL AXL induces epithelial-to-mesenchymal transition and regulates the function of" exact="breast cancer" post="stem cells Oncogene 2014 33 1316 1324 23474758 91"/>
   <result pre="AXL induces epithelial-to-mesenchymal transition and regulates the function of breast" exact="cancer" post="stem cells Oncogene 2014 33 1316 1324 23474758 91"/>
   <result pre="in NSCLC exposed by new molecular definition of EMT Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4361905/results/search/disease/results.xml">
   <result pre="Case Report A 34-year-old female with hormone-negative and HER2-positive metastatic" exact="breast cancer" post="was diagnosed with bulky radiographic LM 45 months after"/>
   <result pre="Report A 34-year-old female with hormone-negative and HER2-positive metastatic breast" exact="cancer" post="was diagnosed with bulky radiographic LM 45 months after"/>
   <result pre="with intra-CSF trastuzumab followed by intra-CSF liposomal cytarabine; however, the" exact="cancer" post="progressed 8 months after the diagnosis of LM. At"/>
   <result pre="of the third LM progression, the patient presented with a" exact="cauda equina syndrome" post="and cerebellar impairment resulting in an inability to walk."/>
   <result pre="radiographically bulky breast cancer-related LM. Key Words Leptomeningeal metastases Neoplastic" exact="meningitis" post="Breast cancer Bevacizumab Quality of life Symptom control fig-count:"/>
   <result pre="breast cancer-related LM. Key Words Leptomeningeal metastases Neoplastic meningitis Breast" exact="cancer" post="Bevacizumab Quality of life Symptom control fig-count: ref-count: page-count:"/>
   <result pre="Quality of life Symptom control fig-count: ref-count: page-count: Background Breast" exact="cancer" post="(BC) is the most common cause of solid tumor-related"/>
   <result pre="nodes was performed. No lymph node metastases or invasive residual" exact="cancer" post="was observed; however, in situ carcinoma was seen. According"/>
   <result pre="neurological function accompanied by severe headaches, vomiting, diplopia and a" exact="cauda equina syndrome" post="with urinary incontinence, sensory polyradiculopathy and lower limb weakness."/>
   <result pre="entail placement of a ventriculoperitoneal shunt in the case of" exact="hydrocephalus" post="or alternatively, and more commonly, implantation of a ventricular"/>
   <result pre="performance status, bulky radiographic LM disease, the presence of LM-related" exact="encephalopathy" post="and the presence of a block of CSF flow"/>
   <result pre="Galy G Blay JY Guastalla JP Bevacizumab and paclitaxel for" exact="breast cancer" post="patients with central nervous system metastases: a case series"/>
   <result pre="G Blay JY Guastalla JP Bevacizumab and paclitaxel for breast" exact="cancer" post="patients with central nervous system metastases: a case series"/>
   <result pre="Nagumo Y Bevacizumab in the treatment of five patients with" exact="breast cancer" post="and brain metastases: Japan Breast Cancer Research Network-07 trial"/>
   <result pre="Y Bevacizumab in the treatment of five patients with breast" exact="cancer" post="and brain metastases: Japan Breast Cancer Research Network-07 trial"/>
   <result pre="of carboplatin (C) and bevacizumab (BEV) in patients (pts) with" exact="breast cancer" post="brain metastases (BCBM) J Clin Oncol 2013 31 suppl"/>
   <result pre="carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast" exact="cancer" post="brain metastases (BCBM) J Clin Oncol 2013 31 suppl"/>
   <result pre="AL Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of" exact="breast cancer" post="progressing from radiotherapy: results of the first stage of"/>
   <result pre="Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast" exact="cancer" post="progressing from radiotherapy: results of the first stage of"/>
   <result pre="L Lawrence J Chan M Prolonged regression of metastatic leptomeningeal" exact="breast cancer" post="that has failed conventional therapy: a case report and"/>
   <result pre="Lawrence J Chan M Prolonged regression of metastatic leptomeningeal breast" exact="cancer" post="that has failed conventional therapy: a case report and"/>
   <result pre="Abrey LE Capecitabine therapy of central nervous system metastases from" exact="breast cancer" post="J Neurooncol 2007 85 223 227 17611719 15 Groves"/>
   <result pre="LE Capecitabine therapy of central nervous system metastases from breast" exact="cancer" post="J Neurooncol 2007 85 223 227 17611719 15 Groves"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4362606/results/search/disease/results.xml">
   <result pre="doi: 10.2478/raon-2014-0015 rado-49-01-50 : Research Article EGFR-expression in primary urinary" exact="bladder cancer" post="and corresponding metastases and the relation to HER2-expression. On"/>
   <result pre="10.2478/raon-2014-0015 rado-49-01-50 : Research Article EGFR-expression in primary urinary bladder" exact="cancer" post="and corresponding metastases and the relation to HER2-expression. On"/>
   <result pre="antibodies binding EGFR or HER2 for therapy of metastasized urinary" exact="bladder cancer" post="and these methods are therefore not routinely used. Targeting"/>
   <result pre="binding EGFR or HER2 for therapy of metastasized urinary bladder" exact="cancer" post="and these methods are therefore not routinely used. Targeting"/>
   <result pre="curative instead of palliative intention. EGFR HER2 radionuclides resistance urinary" exact="bladder cancer" post="metastases Introduction Biological resistance to both EGFR- and HER2-targeted"/>
   <result pre="instead of palliative intention. EGFR HER2 radionuclides resistance urinary bladder" exact="cancer" post="metastases Introduction Biological resistance to both EGFR- and HER2-targeted"/>
   <result pre="been observed for many types of cancer. 1– 4 Urinary" exact="bladder cancer" post="is at present not generally considered for therapy with"/>
   <result pre="observed for many types of cancer. 1– 4 Urinary bladder" exact="cancer" post="is at present not generally considered for therapy with"/>
   <result pre="cetuximab). Evidence for therapy efficacy of such agents in urinary" exact="bladder cancer" post="is lacking and it has been claimed that there"/>
   <result pre="Evidence for therapy efficacy of such agents in urinary bladder" exact="cancer" post="is lacking and it has been claimed that there"/>
   <result pre="the extracellular domains of EGFR and/or HER2 in metastatic urinary" exact="bladder cancer" post="patients with molecules that deliver suitable radionuclides not only"/>
   <result pre="extracellular domains of EGFR and/or HER2 in metastatic urinary bladder" exact="cancer" post="patients with molecules that deliver suitable radionuclides not only"/>
   <result pre="to effects of radiation is not a major problem in" exact="cancer" post="therapy. The radionuclides can be delivered to cancer cells"/>
   <result pre="problem in cancer therapy. The radionuclides can be delivered to" exact="cancer" post="cells with various types of molecules, e.g. antibodies, antibody"/>
   <result pre="authors, not been clinically applied for therapy of metastatic urinary" exact="bladder cancer." post="If this is tried, the strategy is that the"/>
   <result pre="is tried, the strategy is that the radionuclides can kill" exact="cancer" post="cells independent of possible intracellular mutations. This is also"/>
   <result pre="and HER2 in this study. The worldwide incidence of urinary" exact="bladder cancer" post="is high with 350–400.000 new cases per year and"/>
   <result pre="HER2 in this study. The worldwide incidence of urinary bladder" exact="cancer" post="is high with 350–400.000 new cases per year and"/>
   <result pre="recommended HercepTest scoring 25 made the same way as for" exact="breast cancer" post="is accepted at our hospital. Cytoplasmic staining was considered"/>
   <result pre="HercepTest scoring 25 made the same way as for breast" exact="cancer" post="is accepted at our hospital. Cytoplasmic staining was considered"/>
   <result pre="tissue sections; epithelial samples from skin for EGFR-positivity and HER2-positive" exact="breast cancer" post="samples complemented with HER2-positive sections from DAKO. All positive"/>
   <result pre="sections; epithelial samples from skin for EGFR-positivity and HER2-positive breast" exact="cancer" post="samples complemented with HER2-positive sections from DAKO. All positive"/>
   <result pre="stained with the same protocol as applied for the urinary" exact="bladder cancer" post="sections. As negative controls we used normal tissues which"/>
   <result pre="with the same protocol as applied for the urinary bladder" exact="cancer" post="sections. As negative controls we used normal tissues which"/>
   <result pre="HER2-stained and the staining should be as intense as for" exact="breast cancer" post="sections. 22 The internationally recommended DAKO procedure 25 which"/>
   <result pre="and the staining should be as intense as for breast" exact="cancer" post="sections. 22 The internationally recommended DAKO procedure 25 which"/>
   <result pre="least lack of therapy efficacy, has been reported for urinary" exact="bladder cancer." post="5– 8 The receptors themselves, and not intracellular mutations"/>
   <result pre="receptor expression has actually been reported from studies of urinary" exact="bladder cancer." post="26– 30 However, since our primary goal was to"/>
   <result pre="high grade. The expression frequency of EGFR in metastatic urinary" exact="bladder cancer" post="has in several articles been reported to be in"/>
   <result pre="grade. The expression frequency of EGFR in metastatic urinary bladder" exact="cancer" post="has in several articles been reported to be in"/>
   <result pre="values for HER2 positivity in our 2005 article on urinary" exact="bladder cancer" post="22 were also different from the values in the"/>
   <result pre="for HER2 positivity in our 2005 article on urinary bladder" exact="cancer" post="22 were also different from the values in the"/>
   <result pre="staining intensity should be comparable to that often seen in" exact="breast cancer" post="stainings. We do not apply that criteria anymore and"/>
   <result pre="intensity should be comparable to that often seen in breast" exact="cancer" post="stainings. We do not apply that criteria anymore and"/>
   <result pre="since then there has been reports on resistance of urinary" exact="bladder cancer" post="for both EGFR-and HER2-targeting agents (e.g. cetuximab, trastuzumab, lapatinib)."/>
   <result pre="then there has been reports on resistance of urinary bladder" exact="cancer" post="for both EGFR-and HER2-targeting agents (e.g. cetuximab, trastuzumab, lapatinib)."/>
   <result pre="L et al. Targeting Stat3 abrogates EGFR inhibitor resistance in" exact="cancer" post="Clin Cancer Res 2012 18 4986 96 22825581 3."/>
   <result pre="F Primary and acquired resistance to anti-EGFR targeted drugs in" exact="cancer" post="therapy Differentiation 2007 75 788 99 17608727 5. Calabrò"/>
   <result pre="Arora A et al. miR-200 expression regulates epithelial-to-mesenchymal transition in" exact="bladder cancer" post="cells and reverses resistance to epidermal growth factor receptor"/>
   <result pre="A et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder" exact="cancer" post="cells and reverses resistance to epidermal growth factor receptor"/>
   <result pre="signals defines resistance to the antiproliferative effect of Gefitinib in" exact="bladder cancer" post="cells Cancer Res 2005 65 10524 35 16288045 9."/>
   <result pre="defines resistance to the antiproliferative effect of Gefitinib in bladder" exact="cancer" post="cells Cancer Res 2005 65 10524 35 16288045 9."/>
   <result pre="16288045 9. Goldenberg DM Sharkey RM Using antibodies to target" exact="cancer" post="therapeutics Expert Opin Biol Ther 2012 12 1173 90"/>
   <result pre="J Baselga J The EGF receptor family as targets for" exact="cancer" post="therapy Oncogene 2000 19 6550 65 11426640 19. Parkin"/>
   <result pre="65 11426640 19. Parkin DM The global burden of urinary" exact="bladder cancer" post="Scand J Urol Nephrol Suppl 2008 218 12 20"/>
   <result pre="11426640 19. Parkin DM The global burden of urinary bladder" exact="cancer" post="Scand J Urol Nephrol Suppl 2008 218 12 20"/>
   <result pre="D Mathers C Parkin DM Estimates of worldwide burden of" exact="cancer" post="in 2008: GLOBOCAN 2008 Int J Cancer 2010 127"/>
   <result pre="is significantly more frequent in lymph node metastases from urothelial" exact="bladder cancer" post="than in the primary tumours Eur Urol 2011 60"/>
   <result pre="significantly more frequent in lymph node metastases from urothelial bladder" exact="cancer" post="than in the primary tumours Eur Urol 2011 60"/>
   <result pre="A et al. Molecular imaging of HER2-expressing malignant tumors in" exact="breast cancer" post="patients using synthetic 111In- or 68Ga-labeled Affibody molecules J"/>
   <result pre="et al. Molecular imaging of HER2-expressing malignant tumors in breast" exact="cancer" post="patients using synthetic 111In- or 68Ga-labeled Affibody molecules J"/>
   <result pre="34. Fox JJ Schöder H Larson SM Molecular imaging of" exact="prostate cancer" post="Curr Opin Urol 2012 22 320 7 22617062 35."/>
   <result pre="Fox JJ Schöder H Larson SM Molecular imaging of prostate" exact="cancer" post="Curr Opin Urol 2012 22 320 7 22617062 35."/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="J Clin Oncol 2006 24 2276 82 16710024 36."/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="J Clin Oncol 2006 24 2276 82 16710024 36."/>
   <result pre="significance of Her2/neu overexpression in patients with muscle invasive urinary" exact="bladder cancer" post="treated with radical cystectomy Int Urol Nephrol 2008 40"/>
   <result pre="of Her2/neu overexpression in patients with muscle invasive urinary bladder" exact="cancer" post="treated with radical cystectomy Int Urol Nephrol 2008 40"/>
   <result pre="O et al. Prognostic impact of HER2/neu protein in urothelial" exact="bladder cancer." post="Survival analysis of 80 cases and an overview of"/>
   <result pre="A Hedau S Epidermal growth factor receptor expression in urinary" exact="bladder cancer" post="Indian J Urol 2011 27 208 14 21814311 53."/>
   <result pre="Hedau S Epidermal growth factor receptor expression in urinary bladder" exact="cancer" post="Indian J Urol 2011 27 208 14 21814311 53."/>
   <result pre="62 1973830 55. Govindan SV Goldenberg DM Designing immunoconjugates for" exact="cancer" post="therapy Expert Opin Biol Ther 2012 12 873 90"/>
   <result pre="M Baselga J et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 1783 91 23020162"/>
   <result pre="Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 1783 91 23020162"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4363856/results/search/disease/results.xml">
   <result pre="10.4103/0971-5851.151797 : Conference Review Updates from the 2014 San antonio" exact="breast cancer" post="symposium Dawood Shaheenah [], Department of Medical Oncology, Dubai"/>
   <result pre=": Conference Review Updates from the 2014 San antonio breast" exact="cancer" post="symposium Dawood Shaheenah [], Department of Medical Oncology, Dubai"/>
   <result pre="the original work is properly cited. Abstract The san antonio" exact="breast cancer" post="syposium (SABCS 2014) was an exciting one this year."/>
   <result pre="original work is properly cited. Abstract The san antonio breast" exact="cancer" post="syposium (SABCS 2014) was an exciting one this year."/>
   <result pre="the treatment of pre menapausal women with hormone receptor positive" exact="breast cancer." post="In a phase II trial fulvestrant was found to"/>
   <result pre="first line treatment of women with hormone receptor positive metastatic" exact="breast cancer." post="We saw a number of intersting abstracts looking at"/>
   <result pre="role of blocking PD-1 among women with triple receptor negative" exact="breast cancer." post="We also saw the results of a number of"/>
   <result pre="most interesting abstracts presented this year at SABCS 2014. Breast" exact="cancer" post="ovarian suppression triple negative targeted therapy INTRODUCTION 2014 has"/>
   <result pre="abstracts presented this year at SABCS 2014. Breast cancer ovarian" exact="suppression" post="triple negative targeted therapy INTRODUCTION 2014 has certainly been"/>
   <result pre="has certainly been an exciting year in the realm of" exact="breast cancer" post="management. At ASCO 2014 we saw the results of"/>
   <result pre="certainly been an exciting year in the realm of breast" exact="cancer" post="management. At ASCO 2014 we saw the results of"/>
   <result pre="tamoxifen among premenopausal women with hormone receptor positive early stage" exact="breast cancer." post="At the SABCS 2014 symposium, we got to see"/>
   <result pre="SOFT trial, which asked the question of whether ovarian function" exact="suppression" post="added benefit when combined with tamoxifen among premenopausal women."/>
   <result pre="made in the management of women with hormone receptor positive" exact="breast cancer" post="both in the adjuvant and metastatic setting. In the"/>
   <result pre="in the management of women with hormone receptor positive breast" exact="cancer" post="both in the adjuvant and metastatic setting. In the"/>
   <result pre="first line treatment of women with estrogen receptor positive metastatic" exact="breast cancer" post="has resulted in unprecedented significant improvement in progression free"/>
   <result pre="line treatment of women with estrogen receptor positive metastatic breast" exact="cancer" post="has resulted in unprecedented significant improvement in progression free"/>
   <result pre="II study that randomized patients with estrogen receptor positive metastatic" exact="breast cancer" post="to either 500 mg of fulvestrant or anastrazole in"/>
   <result pre="study that randomized patients with estrogen receptor positive metastatic breast" exact="cancer" post="to either 500 mg of fulvestrant or anastrazole in"/>
   <result pre="trial that is randomizing patients with estrogen receptor positive metastatic" exact="breast cancer" post="to either 500 mg of fulvestrant or anastrzole. The"/>
   <result pre="that is randomizing patients with estrogen receptor positive metastatic breast" exact="cancer" post="to either 500 mg of fulvestrant or anastrzole. The"/>
   <result pre="the phase II FERGI study that randomized patients with metastatic" exact="breast cancer" post="who had received a prior aromatase inhibitor either in"/>
   <result pre="phase II FERGI study that randomized patients with metastatic breast" exact="cancer" post="who had received a prior aromatase inhibitor either in"/>
   <result pre="on a phase II trial that randomized women with metastatic" exact="breast cancer" post="who had received aromatase inhibitors either in the adjuvant"/>
   <result pre="a phase II trial that randomized women with metastatic breast" exact="cancer" post="who had received aromatase inhibitors either in the adjuvant"/>
   <result pre="endocrine management of women with estrogen receptor positive early stage" exact="breast cancer." post="In 2013 we saw the results of the ATLAS"/>
   <result pre="trials where premenopausal women with estrogen receptor positive early stage" exact="breast cancer" post="were randomized to receive either tamoxifen and ovarian function"/>
   <result pre="where premenopausal women with estrogen receptor positive early stage breast" exact="cancer" post="were randomized to receive either tamoxifen and ovarian function"/>
   <result pre="cancer were randomized to receive either tamoxifen and ovarian function" exact="suppression" post="or exemestane and ovarian function suppression. The combined analysis"/>
   <result pre="premenopausal women to either tamoxifen alone, tamoxifen and ovarian function" exact="suppression" post="or exemestane and ovarian function suppression.[ 5 6] Approximately,"/>
   <result pre="median follow-up of 5.6 years the addition of ovarian function" exact="suppression" post="to tamoxifen did not benefit premenopausal women compared to"/>
   <result pre="to receive adjuvant chemotherapy the absolute improvement in 5 years" exact="breast cancer" post="free interval was 4.5% among women who received tamoxifen"/>
   <result pre="receive adjuvant chemotherapy the absolute improvement in 5 years breast" exact="cancer" post="free interval was 4.5% among women who received tamoxifen"/>
   <result pre="interval was 4.5% among women who received tamoxifen and ovarian" exact="suppression" post="and 7.7% among women who received exemestane and ovarian"/>
   <result pre="suppression and 7.7% among women who received exemestane and ovarian" exact="suppression" post="when compared to tamoxifen alone respectively. Among premenopausal women"/>
   <result pre="clinicopathological features of disease) the absolute improvement in 5 years" exact="breast cancer" post="free interval was &amp;gt;95% across all three arms of"/>
   <result pre="features of disease) the absolute improvement in 5 years breast" exact="cancer" post="free interval was &amp;gt;95% across all three arms of"/>
   <result pre="of whom received chemotherapy, the authors reported a 5 years" exact="breast cancer" post="free interval of 67.7%, 78.9%, 83.4% among women who"/>
   <result pre="whom received chemotherapy, the authors reported a 5 years breast" exact="cancer" post="free interval of 67.7%, 78.9%, 83.4% among women who"/>
   <result pre="83.4% among women who received tamoxifen, tamoxifen plus ovarian function" exact="suppression" post="and exmestane plus ovarian function suppression respectively. The authors"/>
   <result pre="tamoxifen plus ovarian function suppression and exmestane plus ovarian function" exact="suppression" post="respectively. The authors concluded that premenopausal women at sufficiently"/>
   <result pre="who retain premenopausal estradiol levels the addition of ovarian function" exact="suppression" post="to tamoxifen reduced risk of recurrence. The use of"/>
   <result pre="tamoxifen reduced risk of recurrence. The use of ovarian function" exact="suppression" post="enabled the use of an aromatase inhibitor, which could"/>
   <result pre="reduction in higher risk cohorts. The addition of ovarian function" exact="suppression" post="however was associated with more side-effects in the form"/>
   <result pre="how long should endocrine therapy be given when ovarian function" exact="suppression" post="is used and how long should ovarian function suppression"/>
   <result pre="function suppression is used and how long should ovarian function" exact="suppression" post="be given if one were to consider going beyond"/>
   <result pre="advance made in the last decade in the realm of" exact="breast cancer" post="has been the understanding that this is a heterogenous"/>
   <result pre="made in the last decade in the realm of breast" exact="cancer" post="has been the understanding that this is a heterogenous"/>
   <result pre="regards to endocrine therapy for patients with hormone receptor positive" exact="breast cancer" post="and the introduction of several anti HER2 agents has"/>
   <result pre="to endocrine therapy for patients with hormone receptor positive breast" exact="cancer" post="and the introduction of several anti HER2 agents has"/>
   <result pre="HER2 agents has changed the natural history of HER2 positive" exact="breast cancer." post="Unfortunately, no targeted therapy are available for women triple"/>
   <result pre="Unfortunately, no targeted therapy are available for women triple negative" exact="breast cancer" post="and the prognostic outcome associated with this subtype compared"/>
   <result pre="no targeted therapy are available for women triple negative breast" exact="cancer" post="and the prognostic outcome associated with this subtype compared"/>
   <result pre="agents have been investigated in the realm of triple negative" exact="breast cancer." post="Last year at the ASCO 2013 and SABCS 2013"/>
   <result pre="increased pathological complete response rates among patients with triple negative" exact="breast cancer." post="The question then arose as to whether biomarkers were"/>
   <result pre="pathological response rates among patients with lymphocyte predominant triple negative" exact="breast cancer" post="and among patients whose tumors expressed immunologically relevant genes."/>
   <result pre="response rates among patients with lymphocyte predominant triple negative breast" exact="cancer" post="and among patients whose tumors expressed immunologically relevant genes."/>
   <result pre="× 2 factorial trial that randomized patients with triple negative" exact="breast cancer" post="who all received paclitaxel to receive in addition either"/>
   <result pre="2 factorial trial that randomized patients with triple negative breast" exact="cancer" post="who all received paclitaxel to receive in addition either"/>
   <result pre="of carboplatin. The role of platinum in metastatic triple negative" exact="breast cancer" post="was also investigated. The results of the phase III"/>
   <result pre="carboplatin. The role of platinum in metastatic triple negative breast" exact="cancer" post="was also investigated. The results of the phase III"/>
   <result pre="patients with triple negative or BRCA 1/2 mutation positive metastatic" exact="breast cancer" post="to either first line treatment with docetaxel or single"/>
   <result pre="with triple negative or BRCA 1/2 mutation positive metastatic breast" exact="cancer" post="to either first line treatment with docetaxel or single"/>
   <result pre="treatment in the metastatic setting among patients with triple negative" exact="breast cancer" post="the question arises as to whether platinums should be"/>
   <result pre="in the metastatic setting among patients with triple negative breast" exact="cancer" post="the question arises as to whether platinums should be"/>
   <result pre="be standard of care among women with this subtype of" exact="breast cancer." post="Indeed the results are provocative and hypothesis generating. However,"/>
   <result pre="also being actively investigated in the treatment of triple negative" exact="breast cancer." post="Results of the phase Ib KEYNOTE trial that investigated"/>
   <result pre="targeting HER2, has changed the natural history of HER2 positive" exact="breast cancer" post="impacting prognostic outcome positively in the both the adjuvant"/>
   <result pre="HER2, has changed the natural history of HER2 positive breast" exact="cancer" post="impacting prognostic outcome positively in the both the adjuvant"/>
   <result pre="phase III trial that randomized women with HER2 positive metastatic" exact="breast cancer" post="who had not received prior chemotherapy to either trastuzumab"/>
   <result pre="III trial that randomized women with HER2 positive metastatic breast" exact="cancer" post="who had not received prior chemotherapy to either trastuzumab"/>
   <result pre="However in the subgroup with HER2 positive, hormone receptor negative" exact="breast cancer" post="the addition of everolimus resulted a 7 months improvement"/>
   <result pre="in the subgroup with HER2 positive, hormone receptor negative breast" exact="cancer" post="the addition of everolimus resulted a 7 months improvement"/>
   <result pre="can be omitted among patients with early stage HER2 positive" exact="breast cancer." post="One subgroup that this may be feasible are patients"/>
   <result pre="this may be feasible are patients hormone receptor positive/HER2 positive" exact="breast cancer." post="This concept was the basis of the TBCRC023 phase"/>
   <result pre="that enrolled patients with stage II and III HER2 positive" exact="breast cancer" post="who were randomized to receive either 12 weeks or"/>
   <result pre="enrolled patients with stage II and III HER2 positive breast" exact="cancer" post="who were randomized to receive either 12 weeks or"/>
   <result pre="a phase III trial that randomized women with early stage" exact="breast cancer" post="to receive neoadjuvant paclitaxel followed by epirubicin, cyclophosphamide (EC)"/>
   <result pre="phase III trial that randomized women with early stage breast" exact="cancer" post="to receive neoadjuvant paclitaxel followed by epirubicin, cyclophosphamide (EC)"/>
   <result pre="abraxane, followed by EC.[ 12] Patients with HER 2 positive" exact="breast cancer" post="in addition received neoadjuvant trastuzumab and pertuzumab throughout the"/>
   <result pre="followed by EC.[ 12] Patients with HER 2 positive breast" exact="cancer" post="in addition received neoadjuvant trastuzumab and pertuzumab throughout the"/>
   <result pre="in pathological complete response was seen across all subtypes of" exact="breast cancer," post="this was particularly striking among patients with triple negative"/>
   <result pre="cancer, this was particularly striking among patients with triple negative" exact="breast cancer" post="(25.7% vs. 48.2%, P &amp;lt; 0.001). The authors further"/>
   <result pre="this was particularly striking among patients with triple negative breast" exact="cancer" post="(25.7% vs. 48.2%, P &amp;lt; 0.001). The authors further"/>
   <result pre="&amp;lt; 0.001). The authors further reported an increased incidence of" exact="neuropathy" post="with abraxane compared to paclitaxel. Long term follow-up will"/>
   <result pre="type of anthracycline among patients with node negative early stage" exact="breast cancer." post="The NSABP-36 is a phase III trial that randomized"/>
   <result pre="III trial that randomized women with node negative early stage" exact="breast cancer" post="to either four cycles of adjuvant adriamycin, cyclophosphamide (AC)"/>
   <result pre="trial that randomized women with node negative early stage breast" exact="cancer" post="to either four cycles of adjuvant adriamycin, cyclophosphamide (AC)"/>
   <result pre="letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced" exact="breast cancer" post="(PALOMA-1/TRIO-18): A randomised phase 2 study Lancet Oncol 2015"/>
   <result pre="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast" exact="cancer" post="(PALOMA-1/TRIO-18): A randomised phase 2 study Lancet Oncol 2015"/>
   <result pre="alone or in combination with bortezomib in hormone receptor-positive metastatic" exact="breast cancer" post="resistant to aromatase inhibitors: A New York cancer consortium"/>
   <result pre="or in combination with bortezomib in hormone receptor-positive metastatic breast" exact="cancer" post="resistant to aromatase inhibitors: A New York cancer consortium"/>
   <result pre="metastatic breast cancer resistant to aromatase inhibitors: A New York" exact="cancer" post="consortium trial S6-03 5 Francis PA Regan MM Fleming"/>
   <result pre="Investigators and the International Breast Cancer Study Group. Adjuvant ovarian" exact="suppression" post="in premenopausal breast cancer N Engl J Med 2015"/>
   <result pre="International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal" exact="breast cancer" post="N Engl J Med 2015 372 436 46 25495490"/>
   <result pre="Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast" exact="cancer" post="N Engl J Med 2015 372 436 46 25495490"/>
   <result pre="treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function" exact="suppression" post="(OFS) in premenopausal women with hormone receptor-positive (HR+) breast"/>
   <result pre="function suppression (OFS) in premenopausal women with hormone receptor-positive (HR+)" exact="breast cancer" post="(BC)-put name S3-09 7 Sikov WM Barry WT Hoadley"/>
   <result pre="suppression (OFS) in premenopausal women with hormone receptor-positive (HR+) breast" exact="cancer" post="(BC)-put name S3-09 7 Sikov WM Barry WT Hoadley"/>
   <result pre="gene signatures on pathologic complete response (pCR) rates in triple-negative" exact="breast cancer" post="(TNBC) after neoadjuvant chemotherapy (NACT) +/-carboplatin (Cb) or bevacizumab"/>
   <result pre="signatures on pathologic complete response (pCR) rates in triple-negative breast" exact="cancer" post="(TNBC) after neoadjuvant chemotherapy (NACT) +/-carboplatin (Cb) or bevacizumab"/>
   <result pre="with metastatic or recurrent locally advanced triple negative or BRCA1/2" exact="breast cancer" post="(CRUK/07/012) S3-01 9 A phase Ib study of pembrolizumab"/>
   <result pre="metastatic or recurrent locally advanced triple negative or BRCA1/2 breast" exact="cancer" post="(CRUK/07/012) S3-01 9 A phase Ib study of pembrolizumab"/>
   <result pre="Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative" exact="breast cancer" post="S1-09 10 Phase 3, randomized, double-blind, placebo-controlled multicenter trial"/>
   <result pre="study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast" exact="cancer" post="S1-09 10 Phase 3, randomized, double-blind, placebo-controlled multicenter trial"/>
   <result pre="for 12 vs. 24 weeks in patients with HER2 overexpressing" exact="breast cancer" post="S6-02 12 Untch M Jackisch C Schneeweiß A Conrad"/>
   <result pre="12 vs. 24 weeks in patients with HER2 overexpressing breast" exact="cancer" post="S6-02 12 Untch M Jackisch C Schneeweiß A Conrad"/>
   <result pre="with solventbased paclitaxel followed by anthracyline/cyclophosphamide for patients with early" exact="breast cancer" post="(GeparSepto); GBG 69 S2-07 13 Geyer CE Jr Samuel"/>
   <result pre="solventbased paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast" exact="cancer" post="(GeparSepto); GBG 69 S2-07 13 Geyer CE Jr Samuel"/>
   <result pre="of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative" exact="breast cancer" post="S3-02"/>
   <result pre="adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast" exact="cancer" post="S3-02"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4368842/results/search/disease/results.xml">
   <result pre="reported in other malignancies, previous studies generally focused on one" exact="cancer" post="type, making it challenging to compare HER2 positivity across"/>
   <result pre="HER family members [ 1, 2]. Overexpression of HER2 in" exact="breast cancer" post="leads to increased homodimerization (HER2:HER2) and heterodimerization (e.g., HER2:HER3),"/>
   <result pre="family members [ 1, 2]. Overexpression of HER2 in breast" exact="cancer" post="leads to increased homodimerization (HER2:HER2) and heterodimerization (e.g., HER2:HER3),"/>
   <result pre="with significant efficacy in treatment of HER2-positive breast and gastric" exact="cancer" post="[ 6, 7]. Indeed, trastuzumab in combination with cisplatin"/>
   <result pre="agents have remarkably improved the outcome of patients with HER2-positive" exact="breast cancer" post="[ 9, 10]. Breast and gastric cancers cases demonstrate"/>
   <result pre="have remarkably improved the outcome of patients with HER2-positive breast" exact="cancer" post="[ 9, 10]. Breast and gastric cancers cases demonstrate"/>
   <result pre="been focused on this group of HER2-positive breast or gastric" exact="cancer" post="cases. However, HER2 amplification/overexpression is known to exist in"/>
   <result pre="not limited to, non-small cell lung (NSCLC), ovarian, colon, and" exact="pancreatic cancer," post="overexpress HER2 protein and/or exhibit gene amplification in a"/>
   <result pre="of studies evaluating the percentage of HER2 positivity in individual" exact="cancer" post="types have shed some light on the distribution of"/>
   <result pre="some light on the distribution of HER2 positivity across individual" exact="cancer" post="types [ 13]; however, given a lack of standardized"/>
   <result pre="HER2 positivity determined by immunohistochemistry (IHC), and most types of" exact="cancer" post="had a subset of patients, albeit often small, who"/>
   <result pre="are detected using two color ISH in formalin-fixed, paraffin-embedded human" exact="cancer" post="tissue specimens following staining on VENTANA BenchMark XT automated"/>
   <result pre="Administration for selection of patients to HER2 targeted therapies in" exact="breast cancer." post="Statistical methods Descriptive statistics were used. For Table 2,"/>
   <result pre="from epithelial origin. The frequency ranged from 0.4 % in" exact="hepatocellular carcinoma" post="to 12.4 % in bladder cancer. Table 3 gives"/>
   <result pre="from 0.4 % in hepatocellular carcinoma to 12.4 % in" exact="bladder cancer." post="Table 3 gives examples of positivity rates found in"/>
   <result pre="samples Percentage of HER2 positivity (%) • N &amp;gt; 50 in each" exact="cancer" post="type N = 1013 N = 37,864 2.7 Bladder cancers 59 475 12.4"/>
   <result pre="2.1 Uterine cancers 111 3737 3.0 • N &amp;lt; 50 in each" exact="cancer" post="type N = 1 N = 128 0.8 Gliomas (low-grade) 0 41 0.0"/>
   <result pre="%) of them were also positive by ISH testing. Among" exact="breast cancer" post="cases, 286 samples tested IHC+; 266 of them (93"/>
   <result pre="of them were also positive by ISH testing. Among breast" exact="cancer" post="cases, 286 samples tested IHC+; 266 of them (93"/>
   <result pre="and tumor types. Herein, we have analyzed 37,992 patients with" exact="cancer" post="whose tumors were interrogated for HER2 protein expression in"/>
   <result pre="accredited laboratory setting. We report that 2.7 % of all" exact="cancer" post="samples demonstrated HER2 overexpression (3+ on IHC) (Table 1)."/>
   <result pre="inform future trials of anti-HER2 therapy outside of breast and" exact="stomach cancer." post="For example, the incidence of HER2 overexpression by IHC"/>
   <result pre="cancers (12.4 %) is even higher than that found in" exact="breast cancer" post="(10.5 %) (Fig. 1), suggesting that a trial of"/>
   <result pre="(12.4 %) is even higher than that found in breast" exact="cancer" post="(10.5 %) (Fig. 1), suggesting that a trial of"/>
   <result pre="of anti-HER2 agents may be warranted in patients with advanced" exact="bladder cancer." post="HER2 overexpression by IHC was also substantial in gallbladder"/>
   <result pre="13]. Of interest, we report that approximately 10.5 % of" exact="breast cancer" post="patients are HER2 positive by IHC, which appears to"/>
   <result pre="Of interest, we report that approximately 10.5 % of breast" exact="cancer" post="patients are HER2 positive by IHC, which appears to"/>
   <result pre="different patient population with less HER2 positive cases in early" exact="breast cancer" post="and with younger age at diagnosis [ 39, 40]."/>
   <result pre="patient population with less HER2 positive cases in early breast" exact="cancer" post="and with younger age at diagnosis [ 39, 40]."/>
   <result pre="study may be due to a higher proportion of triple-negative" exact="breast cancer" post="specimens sent to the testing laboratory (35.8 % (Caris,"/>
   <result pre="may be due to a higher proportion of triple-negative breast" exact="cancer" post="specimens sent to the testing laboratory (35.8 % (Caris,"/>
   <result pre="on file) as compared to 15–20 % of the general" exact="breast cancer" post="population [ 19, 41]). Due to the aggressive nature"/>
   <result pre="file) as compared to 15–20 % of the general breast" exact="cancer" post="population [ 19, 41]). Due to the aggressive nature"/>
   <result pre="[ 19, 41]). Due to the aggressive nature of triple-negative" exact="breast cancer," post="a higher percentage may be evaluated for the molecular"/>
   <result pre="gene amplification is the major mechanism driving HER2 overexpression in" exact="breast cancer" post="[ 39]. It has been noted before that HER2"/>
   <result pre="amplification is the major mechanism driving HER2 overexpression in breast" exact="cancer" post="[ 39]. It has been noted before that HER2"/>
   <result pre="Further, 90 % of all samples and 93 % of" exact="breast cancer" post="cases that were tested HER2 positive by IHC, were"/>
   <result pre="90 % of all samples and 93 % of breast" exact="cancer" post="cases that were tested HER2 positive by IHC, were"/>
   <result pre="ovarian, uterine, cervical, head and neck, non-small cell lung, and" exact="colorectal cancer" post="as well as tumors of unknown origin all showed"/>
   <result pre="uterine, cervical, head and neck, non-small cell lung, and colorectal" exact="cancer" post="as well as tumors of unknown origin all showed"/>
   <result pre="RD Muller WJ Insights from transgenic mouse models of ERBB2-induced" exact="breast cancer." post="Nature reviews Cancer 2007 7 5 389 397 17446858"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial. Lancet,"/>
   <result pre="Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer." post="The New England Journal of Medicine, 353(16), 1673–1684. doi:10.1056/NEJMoa052122."/>
   <result pre="… EMILIA Study Group. (2012). Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer." post="The New England Journal of Medicine, 367(19), 1783–1791. doi:10.1056/NEJMoa1209124."/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer." post="Journal of Clinical Oncology: Official Journal of the American"/>
   <result pre="F Tsao AS Bastida CC Stewart DJ Kurzrock R Non-small-cell" exact="lung cancer" post="with HER2 exon 20 mutation: regression with dual HER2"/>
   <result pre="Tsao AS Bastida CC Stewart DJ Kurzrock R Non-small-cell lung" exact="cancer" post="with HER2 exon 20 mutation: regression with dual HER2"/>
   <result pre="M HER2 mutation and response to trastuzumab therapy in non-small-cell" exact="lung cancer" post="The New England Journal of Medicine 2006 354 24"/>
   <result pre="HER2 mutation and response to trastuzumab therapy in non-small-cell lung" exact="cancer" post="The New England Journal of Medicine 2006 354 24"/>
   <result pre="Kelly RJ Carter CA Giaccone G HER2 mutations in non-small-cell" exact="lung cancer" post="can be continually targeted Journal of Clinical Oncology: Official"/>
   <result pre="RJ Carter CA Giaccone G HER2 mutations in non-small-cell lung" exact="cancer" post="can be continually targeted Journal of Clinical Oncology: Official"/>
   <result pre="is significantly more frequent in lymph node metastases from urothelial" exact="bladder cancer" post="than in the primary tumours European Urology 2011 60"/>
   <result pre="significantly more frequent in lymph node metastases from urothelial bladder" exact="cancer" post="than in the primary tumours European Urology 2011 60"/>
   <result pre="amplification as a potential target for therapy in invasive urothelial" exact="bladder cancer" post="with a standardized methodology: results in 1005 patients Annals"/>
   <result pre="as a potential target for therapy in invasive urothelial bladder" exact="cancer" post="with a standardized methodology: results in 1005 patients Annals"/>
   <result pre="HER2+ disease, and the utilization of HER2-directed therapy in early" exact="breast cancer." post="Breast Cancer (Dove Medical Press), 6, 169–177. doi:10.2147/BCTT.S69416 28."/>
   <result pre="M., Cetina, L., … Dueñas-Gonzalez, A. (2004). HER2 expression in" exact="cervical cancer" post="as a potential therapeutic target. BMC Cancer, 4(1), 59."/>
   <result pre="Cetina, L., … Dueñas-Gonzalez, A. (2004). HER2 expression in cervical" exact="cancer" post="as a potential therapeutic target. BMC Cancer, 4(1), 59."/>
   <result pre="W Zielinski C Wrba F HER 2/neu protein expression in" exact="colorectal cancer" post="BMC Cancer 2006 6 1 123 10.1186/1471-2407-6-123 16681853 32."/>
   <result pre="Zielinski C Wrba F HER 2/neu protein expression in colorectal" exact="cancer" post="BMC Cancer 2006 6 1 123 10.1186/1471-2407-6-123 16681853 32."/>
   <result pre="HER2/neu Gene: a new therapeutic possibility for patients with advanced" exact="gallbladder cancer" post="Gastrointestinal Cancer Research : GCR 2014 7 2 42"/>
   <result pre="Gene: a new therapeutic possibility for patients with advanced gallbladder" exact="cancer" post="Gastrointestinal Cancer Research : GCR 2014 7 2 42"/>
   <result pre="and fluorescence in situ hybridization testing for HER2 status in" exact="breast cancer" post="requires a normalized IHC scoring system Modern Pathology: An"/>
   <result pre="fluorescence in situ hybridization testing for HER2 status in breast" exact="cancer" post="requires a normalized IHC scoring system Modern Pathology: An"/>
   <result pre="assessment of HER2 in clinical trials of adjuvant therapy for" exact="breast cancer" post="(NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer"/>
   <result pre="of HER2 in clinical trials of adjuvant therapy for breast" exact="cancer" post="(NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer"/>
   <result pre="in situ hybridization (FISH) to detect HER2 gene overexpression in" exact="breast cancer" post="Breast cancer (Tokyo, Japan) 2014 44. Chmielecki, J., Ross,"/>
   <result pre="situ hybridization (FISH) to detect HER2 gene overexpression in breast" exact="cancer" post="Breast cancer (Tokyo, Japan) 2014 44. Chmielecki, J., Ross,"/>
   <result pre="(FISH) to detect HER2 gene overexpression in breast cancer Breast" exact="cancer" post="(Tokyo, Japan) 2014 44. Chmielecki, J., Ross, J. S.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4376930/results/search/disease/results.xml">
   <result pre="this license are included in any shared versions. Abstract Breast" exact="cancer" post="is the most common cancer in women worldwide. The"/>
   <result pre="any shared versions. Abstract Breast cancer is the most common" exact="cancer" post="in women worldwide. The majority of deaths attributed to"/>
   <result pre="cancer in women worldwide. The majority of deaths attributed to" exact="breast cancer" post="are a result of metastatic disease, and 30% of"/>
   <result pre="in women worldwide. The majority of deaths attributed to breast" exact="cancer" post="are a result of metastatic disease, and 30% of"/>
   <result pre="of patients with metastatic disease is estimated at 23%. Breast" exact="cancer" post="subtypes continue to be stratified histologically on oestrogen, progesterone"/>
   <result pre="(HER2) receptor expression. HER2-positive breast cancers represent 25% of all" exact="breast cancer" post="diagnoses. The therapies available for metastatic breast cancer (MBC)"/>
   <result pre="receptor expression. HER2-positive breast cancers represent 25% of all breast" exact="cancer" post="diagnoses. The therapies available for metastatic breast cancer (MBC)"/>
   <result pre="of all breast cancer diagnoses. The therapies available for metastatic" exact="breast cancer" post="(MBC) are expanding, in particular within the field of"/>
   <result pre="all breast cancer diagnoses. The therapies available for metastatic breast" exact="cancer" post="(MBC) are expanding, in particular within the field of"/>
   <result pre="an ongoing response. Key Words Human epidermal growth factor-2 Metastatic" exact="breast cancer" post="Hepatic dysfunction Trastuzumab emtansine fig-count: ref-count: page-count: Introduction Breast"/>
   <result pre="ongoing response. Key Words Human epidermal growth factor-2 Metastatic breast" exact="cancer" post="Hepatic dysfunction Trastuzumab emtansine fig-count: ref-count: page-count: Introduction Breast"/>
   <result pre="cancer Hepatic dysfunction Trastuzumab emtansine fig-count: ref-count: page-count: Introduction Breast" exact="cancer" post="is the most common cancer in women worldwide ["/>
   <result pre="fig-count: ref-count: page-count: Introduction Breast cancer is the most common" exact="cancer" post="in women worldwide [ 1]. One in 9 women"/>
   <result pre="lifetime [ 2]. In 2013, 230,000 women were diagnosed with" exact="breast cancer" post="in the United States of America and 39,000 women"/>
   <result pre="[ 2]. In 2013, 230,000 women were diagnosed with breast" exact="cancer" post="in the United States of America and 39,000 women"/>
   <result pre="America and 39,000 women died as a result of their" exact="breast cancer" post="[ 2, 3]. Early breast cancer (EBC) mortality rates"/>
   <result pre="and 39,000 women died as a result of their breast" exact="cancer" post="[ 2, 3]. Early breast cancer (EBC) mortality rates"/>
   <result pre="a result of their breast cancer [ 2, 3]. Early" exact="breast cancer" post="(EBC) mortality rates have declined by 30% over the"/>
   <result pre="result of their breast cancer [ 2, 3]. Early breast" exact="cancer" post="(EBC) mortality rates have declined by 30% over the"/>
   <result pre="contrast to EBC patients, overall survival of patients with metastatic" exact="breast cancer" post="(MBC) is approximately 22 months [ 5]. Breast cancer"/>
   <result pre="to EBC patients, overall survival of patients with metastatic breast" exact="cancer" post="(MBC) is approximately 22 months [ 5]. Breast cancer"/>
   <result pre="breast cancer (MBC) is approximately 22 months [ 5]. Breast" exact="cancer" post="is a heterogeneous disease with molecular signatures that vary"/>
   <result pre="likely to account for varying prognosis and treatment responses in" exact="breast cancer" post="patients [ 9]. Despite these complexities, breast cancer is"/>
   <result pre="to account for varying prognosis and treatment responses in breast" exact="cancer" post="patients [ 9]. Despite these complexities, breast cancer is"/>
   <result pre="responses in breast cancer patients [ 9]. Despite these complexities," exact="breast cancer" post="is still traditionally classified by oestrogen, progesterone and human"/>
   <result pre="in breast cancer patients [ 9]. Despite these complexities, breast" exact="cancer" post="is still traditionally classified by oestrogen, progesterone and human"/>
   <result pre="with a taxane and trastuzumab. TDM-1 demonstrated activity against trastuzumab-resistant" exact="breast cancer" post="models in pre-clinical studies [ 12]. Phase II clinical"/>
   <result pre="a taxane and trastuzumab. TDM-1 demonstrated activity against trastuzumab-resistant breast" exact="cancer" post="models in pre-clinical studies [ 12]. Phase II clinical"/>
   <result pre="trials will further evaluate the use of TDM-1 in HER2-positive" exact="breast cancer" post="[ 4]. There have been reports of drug-induced liver"/>
   <result pre="will further evaluate the use of TDM-1 in HER2-positive breast" exact="cancer" post="[ 4]. There have been reports of drug-induced liver"/>
   <result pre="use of TDM-1. Toxicities reported from the EMILIA trial included" exact="thrombocytopenia" post="(12.9%, grade 3), increased alanine transaminase (2.9%, grade 3)"/>
   <result pre="segment V of the liver (fig. 3). In addition, her" exact="cancer" post="antigen 15–3 (CA15–3) demonstrated an increase in line with"/>
   <result pre="therapies available for the treatment of MBC [ 7]. HER2-positive" exact="breast cancer" post="represents 25% of all breast cancer diagnoses [ 19]."/>
   <result pre="available for the treatment of MBC [ 7]. HER2-positive breast" exact="cancer" post="represents 25% of all breast cancer diagnoses [ 19]."/>
   <result pre="MBC [ 7]. HER2-positive breast cancer represents 25% of all" exact="breast cancer" post="diagnoses [ 19]. Over recent years, a number of"/>
   <result pre="[ 7]. HER2-positive breast cancer represents 25% of all breast" exact="cancer" post="diagnoses [ 19]. Over recent years, a number of"/>
   <result pre="evaluate the role of TDM-1 in the treatment of HER2-positive" exact="breast cancer" post="[ 4]. In the case reported, we demonstrated clinical,"/>
   <result pre="the role of TDM-1 in the treatment of HER2-positive breast" exact="cancer" post="[ 4]. In the case reported, we demonstrated clinical,"/>
   <result pre="reported toxicities associated with TDM-1 within the studies described are" exact="thrombocytopenia" post="and raised LFTs. In addition, there have been cases"/>
   <result pre="References 1 Hery C et al Quantification of changes in" exact="breast cancer" post="incidence and mortality since 1990 in 35 countries with"/>
   <result pre="1 Hery C et al Quantification of changes in breast" exact="cancer" post="incidence and mortality since 1990 in 35 countries with"/>
   <result pre="62 10 29 22237781 4 Tinoco G et al Treating" exact="breast cancer" post="in the 21st century: emerging biological therapies J Cancer"/>
   <result pre="10 29 22237781 4 Tinoco G et al Treating breast" exact="cancer" post="in the 21st century: emerging biological therapies J Cancer"/>
   <result pre="the impact of eliminating socioeconomic and racial disparities on premature" exact="cancer" post="deaths CA Cancer J Clin 2011 61 212 236"/>
   <result pre="21685461 6 O'Shaughnessy J Extending survival with chemotherapy in metastatic" exact="breast cancer" post="Oncologist 2005 10 suppl 3 20 29 16368868 7"/>
   <result pre="6 O'Shaughnessy J Extending survival with chemotherapy in metastatic breast" exact="cancer" post="Oncologist 2005 10 suppl 3 20 29 16368868 7"/>
   <result pre="29 16368868 7 Sharp A Harper-Wynne C Treatment of advanced" exact="breast cancer" post="(ABC): the expanding landscape of targeted therapies J Cancer"/>
   <result pre="16368868 7 Sharp A Harper-Wynne C Treatment of advanced breast" exact="cancer" post="(ABC): the expanding landscape of targeted therapies J Cancer"/>
   <result pre="K Sorlie T Lessons learned from the intrinsic subtypes of" exact="breast cancer" post="in the quest for precision therapy Br J Surg"/>
   <result pre="Sorlie T Lessons learned from the intrinsic subtypes of breast" exact="cancer" post="in the quest for precision therapy Br J Surg"/>
   <result pre="11553815 10 Li SG Li L Targeted therapy in HER2-positive" exact="breast cancer" post="Biomed Rep 2013 1 499 505 24648975 11 Dawood"/>
   <result pre="10 Li SG Li L Targeted therapy in HER2-positive breast" exact="cancer" post="Biomed Rep 2013 1 499 505 24648975 11 Dawood"/>
   <result pre="11 Dawood S et al Prognosis of women with metastatic" exact="breast cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="Dawood S et al Prognosis of women with metastatic breast" exact="cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="98 19933921 12 Lewis Phillips GD et al Targeting HER2-positive" exact="breast cancer" post="with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 2008"/>
   <result pre="19933921 12 Lewis Phillips GD et al Targeting HER2-positive breast" exact="cancer" post="with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 2008"/>
   <result pre="the treatment of human epidermal growth factor receptor 2 (HER2)-positive" exact="breast cancer" post="after prior HER2-directed therapy J Clin Oncol 2011 29"/>
   <result pre="treatment of human epidermal growth factor receptor 2 (HER2)-positive breast" exact="cancer" post="after prior HER2-directed therapy J Clin Oncol 2011 29"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="J Clin Oncol 2013 31 1157 1163 23382472 15"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="J Clin Oncol 2013 31 1157 1163 23382472 15"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="who were previously treated with trastuzumab, lapatinib, an anthracycline,"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="who were previously treated with trastuzumab, lapatinib, an anthracycline,"/>
   <result pre="16 Verma S et al Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 1783 1791 23020162"/>
   <result pre="Verma S et al Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 1783 1791 23020162"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="action of trastuzumab and efficiently inhibits growth of lapatinib insensitive" exact="breast cancer" post="Breast Cancer Res Treat 2011 128 347 356 20730488"/>
   <result pre="of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast" exact="cancer" post="Breast Cancer Res Treat 2011 128 347 356 20730488"/>
   <result pre="Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant" exact="breast cancer" post="cells in vivo Breast Cancer Res 2011 13 R46"/>
   <result pre="causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast" exact="cancer" post="cells in vivo Breast Cancer Res 2011 13 R46"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4381292/results/search/disease/results.xml">
   <result pre="Commons Attribution license ( http://creativecommons.org/licenses/by/4.0/). Abstract The metabolic profiles of" exact="breast cancer" post="cells are different from normal mammary epithelial cells. Breast"/>
   <result pre="Attribution license ( http://creativecommons.org/licenses/by/4.0/). Abstract The metabolic profiles of breast" exact="cancer" post="cells are different from normal mammary epithelial cells. Breast"/>
   <result pre="cancer cells are different from normal mammary epithelial cells. Breast" exact="cancer" post="cells that gain resistance to therapeutic interventions can reprogram"/>
   <result pre="despite high oxidative stress and hypoxic conditions. Drug resistance in" exact="breast cancer," post="regardless of subgroups, is a major clinical setback. Although"/>
   <result pre="new strategies to establish predictive, diagnostic and prognostic markers of" exact="breast cancer." post="Along with other &quot;omics&quot; technologies that include genomics, transcriptomics,"/>
   <result pre="a comprehensive systems biology approach to understand drug resistance in" exact="breast cancer." post="In this review, we highlight the challenges facing successful"/>
   <result pre="review, we highlight the challenges facing successful therapeutic treatment of" exact="breast cancer" post="and the innovative approaches that metabolomics offers to better"/>
   <result pre="we highlight the challenges facing successful therapeutic treatment of breast" exact="cancer" post="and the innovative approaches that metabolomics offers to better"/>
   <result pre="that metabolomics offers to better understand drug resistance in cancer." exact="breast cancer" post="drug resistance metabolomics cellular metabolism cell death 1. Introduction"/>
   <result pre="metabolomics offers to better understand drug resistance in cancer. breast" exact="cancer" post="drug resistance metabolomics cellular metabolism cell death 1. Introduction"/>
   <result pre="cell death 1. Introduction The fact that cellular metabolism of" exact="cancer" post="cells is different from that of normal cells has"/>
   <result pre="rather than the more energy-efficient mitochondrial oxidative phosphorylation, highlights the" exact="cancer" post="cell’s needs beyond energy. With aberrantly higher rates of"/>
   <result pre="glutaminolysis or fatty acid synthesis are also abnormally higher in" exact="cancer" post="cells to keep up with both energy and biomass"/>
   <result pre="understanding of the complex nature of cellular metabolic pathways in" exact="cancer" post="remains incomplete. Changes in gene expression and protein translation"/>
   <result pre="metabolite profiles or metabolome. Therefore, comparing the metabolite profile of" exact="cancer" post="cells versus normal cells can help researchers identify the"/>
   <result pre="advancement in mass spectrometry, high throughput metabolite profiling (metabolomics) of" exact="cancer" post="cells or tumors allows researchers to identify and validate"/>
   <result pre="regulatory regions while proteomics studies identify function of proteins in" exact="cancer" post="cells compared with cancer cells [ 4]. Gene expression"/>
   <result pre="studies identify function of proteins in cancer cells compared with" exact="cancer" post="cells [ 4]. Gene expression profiles [ 5, 6,"/>
   <result pre="have provided a glimpse into the complex genetic makeup of" exact="breast cancer" post="subtypes and their correlation with survival, chemotherapeutic response or"/>
   <result pre="provided a glimpse into the complex genetic makeup of breast" exact="cancer" post="subtypes and their correlation with survival, chemotherapeutic response or"/>
   <result pre="layer of &quot;omics&quot; data that is rapidly gaining attention of" exact="breast cancer" post="researchers worldwide. The metabolome of a cell comprises of"/>
   <result pre="of &quot;omics&quot; data that is rapidly gaining attention of breast" exact="cancer" post="researchers worldwide. The metabolome of a cell comprises of"/>
   <result pre="enabled researchers to design and implement novel strategies in following" exact="cancer" post="prognosis and development of customized therapeutics [ 9, 10,"/>
   <result pre="customized therapeutics [ 9, 10, 11]. Complex signaling associated with" exact="cancer" post="phenotypes occurs in the context of interactive networks ["/>
   <result pre="and mathematical modeling may be needed to uncover how the" exact="cancer" post="cell responds to external stress and adapts to acquire"/>
   <result pre="review, we discuss the current challenges in drug resistance in" exact="breast cancer" post="and what new opportunities metabolomics can provide for researchers."/>
   <result pre="we discuss the current challenges in drug resistance in breast" exact="cancer" post="and what new opportunities metabolomics can provide for researchers."/>
   <result pre="and Therapeutic Options Each year, 1.3 million new cases of" exact="breast cancer" post="are diagnosed worldwide, and account for almost 15% of"/>
   <result pre="Therapeutic Options Each year, 1.3 million new cases of breast" exact="cancer" post="are diagnosed worldwide, and account for almost 15% of"/>
   <result pre="deaths [ 14]. In the United States, the number of" exact="breast cancer" post="cases is projected to increase each year, and therefore,"/>
   <result pre="[ 14]. In the United States, the number of breast" exact="cancer" post="cases is projected to increase each year, and therefore,"/>
   <result pre="burden to health care and the economy [ 15]. Breast" exact="cancer" post="is a heterogeneous disease [ 6, 16, 17] with"/>
   <result pre="of reliable molecular predictors. The standard treatment option for localized" exact="breast cancer" post="is surgery or mastectomy with or without radiation while"/>
   <result pre="reliable molecular predictors. The standard treatment option for localized breast" exact="cancer" post="is surgery or mastectomy with or without radiation while"/>
   <result pre="are essential in determining the best therapeutic option for a" exact="breast cancer" post="patient. Other essential biochemical information required for therapeutic decisions"/>
   <result pre="essential in determining the best therapeutic option for a breast" exact="cancer" post="patient. Other essential biochemical information required for therapeutic decisions"/>
   <result pre="20]. Moreover, hormone receptor and HER2 status may change with" exact="cancer" post="progression and treatment [ 21, 22] necessitating the development"/>
   <result pre="[ 21, 22] necessitating the development of precise biomarkers for" exact="breast cancer" post="subtypes that can be monitored in real-time. Gene expression"/>
   <result pre="21, 22] necessitating the development of precise biomarkers for breast" exact="cancer" post="subtypes that can be monitored in real-time. Gene expression"/>
   <result pre="24] that can help assign a prognostic score in early" exact="breast cancer" post="to determine benefits of adjuvant treatment. Estrogen and estrogen"/>
   <result pre="that can help assign a prognostic score in early breast" exact="cancer" post="to determine benefits of adjuvant treatment. Estrogen and estrogen"/>
   <result pre="estrogen receptors play significant roles in the development of human" exact="breast cancer" post="in 70% of breast cancer cases that are ER-positive"/>
   <result pre="receptors play significant roles in the development of human breast" exact="cancer" post="in 70% of breast cancer cases that are ER-positive"/>
   <result pre="in the development of human breast cancer in 70% of" exact="breast cancer" post="cases that are ER-positive [ 25]. Pharmacological agents and"/>
   <result pre="the development of human breast cancer in 70% of breast" exact="cancer" post="cases that are ER-positive [ 25]. Pharmacological agents and"/>
   <result pre="therapy and is commonly used as initial treatment option for" exact="breast cancer" post="that is ER /PR-positive. The purpose of such therapy"/>
   <result pre="and is commonly used as initial treatment option for breast" exact="cancer" post="that is ER /PR-positive. The purpose of such therapy"/>
   <result pre="superior to Tamoxifen as a first-line treatment [ 33]. HER2-positive" exact="breast cancer" post="constitutes about 20% of all types of breast cancer"/>
   <result pre="to Tamoxifen as a first-line treatment [ 33]. HER2-positive breast" exact="cancer" post="constitutes about 20% of all types of breast cancer"/>
   <result pre="HER2-positive breast cancer constitutes about 20% of all types of" exact="breast cancer" post="and is characterized by aggressive disease progression and poor"/>
   <result pre="breast cancer constitutes about 20% of all types of breast" exact="cancer" post="and is characterized by aggressive disease progression and poor"/>
   <result pre="or trastuzumab emtansine (T-DM1), an antibody-drug conjugate [ 37]. Triple-negative" exact="breast cancer" post="(TNBC; ER-/PR-/HER2-) accounts for about 15-17% of all types"/>
   <result pre="trastuzumab emtansine (T-DM1), an antibody-drug conjugate [ 37]. Triple-negative breast" exact="cancer" post="(TNBC; ER-/PR-/HER2-) accounts for about 15-17% of all types"/>
   <result pre="(TNBC; ER-/PR-/HER2-) accounts for about 15-17% of all types of" exact="breast cancer" post="cases but this group has a heterogeneous molecular profile."/>
   <result pre="ER-/PR-/HER2-) accounts for about 15-17% of all types of breast" exact="cancer" post="cases but this group has a heterogeneous molecular profile."/>
   <result pre="are ineffective in treating TNBC, which remains a subgroup of" exact="breast cancer" post="without any specific target. Some TNBCs can be cured"/>
   <result pre="ineffective in treating TNBC, which remains a subgroup of breast" exact="cancer" post="without any specific target. Some TNBCs can be cured"/>
   <result pre="subtypes or clinical subgroups, drug resistance in all types of" exact="breast cancer" post="remains an unsolved clinical problem. While a vast majority"/>
   <result pre="or clinical subgroups, drug resistance in all types of breast" exact="cancer" post="remains an unsolved clinical problem. While a vast majority"/>
   <result pre="in endocrine resistant breast cancers [ 8, 44]. In HER2-positive" exact="breast cancer," post="treatment with trastuzumab along with standard chemotherapy has significantly"/>
   <result pre="among various other factors contributing to trastuzumab resistance in HER2-positive" exact="breast cancer" post="[ 38]. Chemoresistant TNBC tend to have an aggressive"/>
   <result pre="various other factors contributing to trastuzumab resistance in HER2-positive breast" exact="cancer" post="[ 38]. Chemoresistant TNBC tend to have an aggressive"/>
   <result pre="MYC, p53 and MTOR are mutated in various subgroups of" exact="breast cancer" post="[ 47, 48]. Since MYC, p53 and MTOR are"/>
   <result pre="p53 and MTOR are mutated in various subgroups of breast" exact="cancer" post="[ 47, 48]. Since MYC, p53 and MTOR are"/>
   <result pre="function, should be investigated to better understand the pathobiology of" exact="breast cancer" post="and drug responsiveness. While the molecular basis of drug"/>
   <result pre="should be investigated to better understand the pathobiology of breast" exact="cancer" post="and drug responsiveness. While the molecular basis of drug"/>
   <result pre="drug responsiveness. While the molecular basis of drug resistance in" exact="breast cancer" post="remains unknown, concomitant deregulation of cell death pathways to"/>
   <result pre="responsiveness. While the molecular basis of drug resistance in breast" exact="cancer" post="remains unknown, concomitant deregulation of cell death pathways to"/>
   <result pre="of apoptosis, autophagy and necrosis in cell death in ER+" exact="breast cancer" post="induced by antiestrogen or chemotherapeutic agents [ 52, 53,"/>
   <result pre="apoptosis, autophagy and necrosis in cell death in ER+ breast" exact="cancer" post="induced by antiestrogen or chemotherapeutic agents [ 52, 53,"/>
   <result pre="MYC [ 60, 61] are known to be overexpressed in" exact="breast cancer" post="cells or tumors that are resistant to antiestrogens. In"/>
   <result pre="[ 60, 61] are known to be overexpressed in breast" exact="cancer" post="cells or tumors that are resistant to antiestrogens. In"/>
   <result pre="metabolism [ 50]. Moreover, overexpression of these pro-survival molecules allows" exact="cancer" post="cells to achieve rapid recovery from disruptions in glucose/ATP"/>
   <result pre="the cells under normal conditions and helps restore homeostasis. In" exact="breast cancer" post="cells, UPR can be triggered by a variety of"/>
   <result pre="cells under normal conditions and helps restore homeostasis. In breast" exact="cancer" post="cells, UPR can be triggered by a variety of"/>
   <result pre="Both cytotoxic and endocrine therapeutics can induce UPR in different" exact="cancer" post="cells [ 53, 62]. Oncoproteins such as MYC that"/>
   <result pre="[ 60, 61, 64]. MYC can increase the dependency of" exact="breast cancer" post="cells on glutamine and glucose for cell survival ["/>
   <result pre="60, 61, 64]. MYC can increase the dependency of breast" exact="cancer" post="cells on glutamine and glucose for cell survival ["/>
   <result pre="MYC and the UPR. The endpoint of UPR induction in" exact="cancer" post="cells can be either prodeath or prosurvival and depends"/>
   <result pre="is relevant to many fields such as pharmacology, diabetes, and" exact="cancer" post="[ 68, 69]. Traditionally, Nuclear Magnetic Resonance (NMR) was"/>
   <result pre="for metabolomics profiling and early reports of biomarker discovery in" exact="breast cancer" post="used this technology [ 70, 71]. However, NMR lacked"/>
   <result pre="metabolomics profiling and early reports of biomarker discovery in breast" exact="cancer" post="used this technology [ 70, 71]. However, NMR lacked"/>
   <result pre="as specific and sensitive biomarkers for early detection and staging" exact="breast cancer" post="cases. Moreover, in the recent years, there have been"/>
   <result pre="specific and sensitive biomarkers for early detection and staging breast" exact="cancer" post="cases. Moreover, in the recent years, there have been"/>
   <result pre="Breast Cancer Given the high prevalence and mortality associated with" exact="breast cancer," post="there is an urgent need for biomarkers that can"/>
   <result pre="be used to develop predictive, diagnostic and prognostic markers of" exact="breast cancer." post="Early observation by Warburg established that cancer cells switch"/>
   <result pre="markers of breast cancer. Early observation by Warburg established that" exact="cancer" post="cells switch to a glycolytic phenotype thus reprograming metabolism"/>
   <result pre="have shown the role of glycolytic flux in oncogenesis of" exact="breast cancer" post="[ 79, 80, 81, 82]. Given the metabolic reprograming"/>
   <result pre="shown the role of glycolytic flux in oncogenesis of breast" exact="cancer" post="[ 79, 80, 81, 82]. Given the metabolic reprograming"/>
   <result pre="have thus used a metabolomic approach to discern alterations in" exact="breast cancer" post="that could be potentially used for disease stratification ["/>
   <result pre="thus used a metabolomic approach to discern alterations in breast" exact="cancer" post="that could be potentially used for disease stratification ["/>
   <result pre="metabolism in estrogen receptor positive (ER+) as compared to ER-" exact="breast cancer" post="[ 88]. Using an NMR approach, Jobard et al."/>
   <result pre="in estrogen receptor positive (ER+) as compared to ER- breast" exact="cancer" post="[ 88]. Using an NMR approach, Jobard et al."/>
   <result pre="mannose, glutamate and phenylalanine that could discriminate patients with metastatic" exact="breast cancer" post="from those with localized disease with a specificity of"/>
   <result pre="glutamate and phenylalanine that could discriminate patients with metastatic breast" exact="cancer" post="from those with localized disease with a specificity of"/>
   <result pre="has also been used for unraveling diagnostic biomarkers of non-invasive" exact="breast cancer" post="which has been comprehensively reviewed [ 10]. Qiu et"/>
   <result pre="also been used for unraveling diagnostic biomarkers of non-invasive breast" exact="cancer" post="which has been comprehensively reviewed [ 10]. Qiu et"/>
   <result pre="plasma metabolomics to identify a lipid panel that could distinguish" exact="breast cancer" post="patients from healthy controls [ 90]. Metabolomics had also"/>
   <result pre="metabolomics to identify a lipid panel that could distinguish breast" exact="cancer" post="patients from healthy controls [ 90]. Metabolomics had also"/>
   <result pre="response to neo-adjuvant chemotherapy, tumor microenvironment and response to hypoxia" exact="breast cancer" post="[ 91, 92, 93, 94]. Metabolomics has also helped"/>
   <result pre="to neo-adjuvant chemotherapy, tumor microenvironment and response to hypoxia breast" exact="cancer" post="[ 91, 92, 93, 94]. Metabolomics has also helped"/>
   <result pre="association of elevated ketones and lactate with increased &quot;stemness&quot; of" exact="breast cancer" post="cells while other metabolomic studies have reported increased oxidative"/>
   <result pre="of elevated ketones and lactate with increased &quot;stemness&quot; of breast" exact="cancer" post="cells while other metabolomic studies have reported increased oxidative"/>
   <result pre="is used to describe cellular metabolites that abnormally accumulate in" exact="cancer" post="cells and tumors and are associated with malignant phenotype"/>
   <result pre="oncogenesis partly by regulating epigenetic changes in certain types of" exact="cancer" post="[ 98]. Through metabolomic analysis, Jain et al have"/>
   <result pre="as an important metabolite that promotes rapid cell proliferation in" exact="breast cancer" post="cells [ 99]. Although a lot of studies in"/>
   <result pre="an important metabolite that promotes rapid cell proliferation in breast" exact="cancer" post="cells [ 99]. Although a lot of studies in"/>
   <result pre="known that although two individuals may be clinically diagnosed with" exact="breast cancer," post="their tumors’ response to therapy may vary depending on"/>
   <result pre="be used to customize response thus improving clinical outcomes in" exact="breast cancer" post="[ 103, 104]. The ability to simultaneously measure thousands"/>
   <result pre="used to customize response thus improving clinical outcomes in breast" exact="cancer" post="[ 103, 104]. The ability to simultaneously measure thousands"/>
   <result pre="over represented in breast carcinogenesis. To date, several studies in" exact="breast cancer" post="cell models, tumors, serum or urine have been used"/>
   <result pre="represented in breast carcinogenesis. To date, several studies in breast" exact="cancer" post="cell models, tumors, serum or urine have been used"/>
   <result pre="urine have been used to understand the underlying causes of" exact="breast cancer" post="progression and response to specific anti-cancer therapy ( Table"/>
   <result pre="have been used to understand the underlying causes of breast" exact="cancer" post="progression and response to specific anti-cancer therapy ( Table"/>
   <result pre="idea that metabolomics can be a useful tool to differentiate" exact="breast cancer" post="subtypes, and also provide a glimpse into the cellular"/>
   <result pre="that metabolomics can be a useful tool to differentiate breast" exact="cancer" post="subtypes, and also provide a glimpse into the cellular"/>
   <result pre="response to anti-cancer therapy. Comparing the changes in metabolites in" exact="cancer" post="cells and tumors that are sensitive or resistant to"/>
   <result pre="and tumors that are sensitive or resistant to commonly used" exact="breast cancer" post="therapies, for example, antiestrogens or taxol, can help investigators"/>
   <result pre="tumors that are sensitive or resistant to commonly used breast" exact="cancer" post="therapies, for example, antiestrogens or taxol, can help investigators"/>
   <result pre="normal and tumors tissue, and between the various sub-typed of" exact="breast cancer." post="Development of accurate detection tools with metabolites that can"/>
   <result pre="drug responsiveness. While the recent surge in metabolomics-driven research in" exact="cancer" post="is commendable, thorough studies involving the contributions of the"/>
   <result pre="analysis and validation. Thus, more in vivo metabolomics studies for" exact="breast cancer" post="subtypes and treatment groups are needed to determine the"/>
   <result pre="and validation. Thus, more in vivo metabolomics studies for breast" exact="cancer" post="subtypes and treatment groups are needed to determine the"/>
   <result pre="1 Table 1 Studies involving metabolomics analysis aimed at understanding" exact="breast cancer" post="progression and identifying new molecular targets. Biological materials Approach"/>
   <result pre="Table 1 Studies involving metabolomics analysis aimed at understanding breast" exact="cancer" post="progression and identifying new molecular targets. Biological materials Approach"/>
   <result pre="in glycerophospho-choline and -ethanolamine [ 108] serum: early and metastatic" exact="breast cancer" post="NMR None Increase in histidine, acetoacetate, glycerol, pyruvate, glycoproteins"/>
   <result pre="glycerophospho-choline and -ethanolamine [ 108] serum: early and metastatic breast" exact="cancer" post="NMR None Increase in histidine, acetoacetate, glycerol, pyruvate, glycoproteins"/>
   <result pre="in both cell lines [ 110] serum: recurrent and non-recurrent" exact="breast cancer" post="NMR &amp;amp; GC-MS None Changes in amino acids metabolism"/>
   <result pre="both cell lines [ 110] serum: recurrent and non-recurrent breast" exact="cancer" post="NMR &amp;amp; GC-MS None Changes in amino acids metabolism"/>
   <result pre="and fatty acid metabolism (nonanedioic acid) [ 83] urine: early-/late-stage" exact="breast cancer" post="and normal NMR None Changes in metabolites relating to"/>
   <result pre="fatty acid metabolism (nonanedioic acid) [ 83] urine: early-/late-stage breast" exact="cancer" post="and normal NMR None Changes in metabolites relating to"/>
   <result pre="115]. It relies on the premise that the pathophysiology of" exact="cancer" post="progression results from a malfunction of molecular networks and"/>
   <result pre="lavage fluids offers promise in identification of predictive biomarkers of" exact="breast cancer" post="that can be used for early detection, diagnosis and"/>
   <result pre="fluids offers promise in identification of predictive biomarkers of breast" exact="cancer" post="that can be used for early detection, diagnosis and"/>
   <result pre="126], to provide energy and substrates to the highly proliferative" exact="cancer" post="cell. In addition, increased glycolysis has been linked to"/>
   <result pre="addition, increased glycolysis has been linked to drug resistance in" exact="cervical cancer" post="cells through pyruvate dehydrogenase kinase (PDK) isoforms PDK1 and"/>
   <result pre="increased glycolysis has been linked to drug resistance in cervical" exact="cancer" post="cells through pyruvate dehydrogenase kinase (PDK) isoforms PDK1 and"/>
   <result pre="and PDK3 [ 127] and through increased lactate production in" exact="colon cancer" post="cells [ 128]. Inhibiting PDK with dichloroacetate (DCA), shifts"/>
   <result pre="PDK3 [ 127] and through increased lactate production in colon" exact="cancer" post="cells [ 128]. Inhibiting PDK with dichloroacetate (DCA), shifts"/>
   <result pre="inhibits tumor growth and induces apoptosis in several types of" exact="cancer" post="[ 129]. Intermediates generated via glycolysis promote the pentose"/>
   <result pre="High levels of GSH have been implicated in chemoresistance in" exact="cancer" post="[ 132]. Studies focused on specific enzymes and intermediate"/>
   <result pre="cell proliferation [ 137]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is overexpressed in" exact="cancer" post="[ 138] and may promote resistance to chemotherapy by"/>
   <result pre="by hypoxia-inducible factor-1 (HIF-1) in reprogramming of glucose metabolism in" exact="cancer" post="[ 141]. Specific isoforms of lactate dehydrogenase (LDH) and"/>
   <result pre="monocarboxylate transporters (MCTs) are differentially expressed in ER+ and ER-" exact="breast cancer" post="cells depending on the cellular demand for glycolysis ["/>
   <result pre="transporters (MCTs) are differentially expressed in ER+ and ER- breast" exact="cancer" post="cells depending on the cellular demand for glycolysis ["/>
   <result pre="demand for glycolysis [ 142]. Also, the MTOR pathway in" exact="cancer" post="cells can detect environmental conditions and adjust cellular metabolic"/>
   <result pre="available gene expression data with metabolites of pathways in different" exact="breast cancer" post="subtypes and treatment conditions, therefore, allows investigators to identify"/>
   <result pre="gene expression data with metabolites of pathways in different breast" exact="cancer" post="subtypes and treatment conditions, therefore, allows investigators to identify"/>
   <result pre="specific phenotype. Thus, knowledge of the metabolic pathways that sustain" exact="cancer" post="cell survival within tumors can be used to design"/>
   <result pre="better anti-cancer therapeutics to avert drug resistance. 5. Conclusions Breast" exact="cancer" post="is a heterogeneous disease and the recent progress in"/>
   <result pre="one-size-fits-all approach to treatment. Successful use of metabolomics in identifying" exact="breast cancer" post="biomarkers for specific subtypes or drug responsiveness will provide"/>
   <result pre="approach to treatment. Successful use of metabolomics in identifying breast" exact="cancer" post="biomarkers for specific subtypes or drug responsiveness will provide"/>
   <result pre="provide non-invasive methods to accurately define characteristics of a patient’s" exact="cancer" post="in the clinic from body fluids such as blood,"/>
   <result pre="management and analysis tools for large volume of data from" exact="breast cancer" post="cell models or patient samples and better mode of"/>
   <result pre="and analysis tools for large volume of data from breast" exact="cancer" post="cell models or patient samples and better mode of"/>
   <result pre="Carroll J.S. Approaches for assessing and discovering protein interactions in" exact="cancer" post="Mol. Cancer Res. 2013 11 1295 1302 10.1158/1541-7786.MCR-13-0454 24072816"/>
   <result pre="M. Soga T. Pollard P.J. Oncometabolites: Linking altered metabolism with" exact="cancer" post="J. Clin. Invest. 2013 123 3652 3658 10.1172/JCI67228 23999438"/>
   <result pre="3652 3658 10.1172/JCI67228 23999438 10 Zhang A.H. Metabolomics in noninvasive" exact="breast cancer" post="Clin. Chim. Acta 2013 424 3 7 10.1016/j.cca.2013.05.003 23669185"/>
   <result pre="3658 10.1172/JCI67228 23999438 10 Zhang A.H. Metabolomics in noninvasive breast" exact="cancer" post="Clin. Chim. Acta 2013 424 3 7 10.1016/j.cca.2013.05.003 23669185"/>
   <result pre="Y. Butler E.B. Tan M. Targeting cellular metabolism to improve" exact="cancer" post="therapeutics Cell Death Dis. 2013 4 e532 10.1038/cddis.2013.60 23470539"/>
   <result pre="network signaling in hormone responsiveness modifies apoptosis and autophagy in" exact="breast cancer" post="cells J. Steroid Biochem. Mol. Biol. 2009 114 8"/>
   <result pre="signaling in hormone responsiveness modifies apoptosis and autophagy in breast" exact="cancer" post="cells J. Steroid Biochem. Mol. Biol. 2009 114 8"/>
   <result pre="F. Center M.M. Ferlay J. Ward E. Forman D. Global" exact="cancer" post="statistics CA Cancer J. Clin. 2011 61 69 90"/>
   <result pre="recommendations for immunohistochemical testing of estrogen and progesterone receptors in" exact="breast cancer" post="J. Clin. Oncol. 2010 28 2784 2795 10.1200/JCO.2009.25.6529 20404251"/>
   <result pre="for immunohistochemical testing of estrogen and progesterone receptors in breast" exact="cancer" post="J. Clin. Oncol. 2010 28 2784 2795 10.1200/JCO.2009.25.6529 20404251"/>
   <result pre="HER-2/neu immunohistochemistry impacts on treatment for a small subset of" exact="breast cancer" post="patients transferring care to another institution Arch. Pathol. Lab."/>
   <result pre="immunohistochemistry impacts on treatment for a small subset of breast" exact="cancer" post="patients transferring care to another institution Arch. Pathol. Lab."/>
   <result pre="M.E. Changes in multiple or sequential estrogen receptor determinations in" exact="breast cancer" post="Cancer 1980 45 792 794 10.1002/1097-0142(19800215)45:4&amp;lt;792::AID-CNCR2820450430&amp;gt;3.0.CO;2-X 7357496 22 Liesenfeld"/>
   <result pre="Changes in multiple or sequential estrogen receptor determinations in breast" exact="cancer" post="Cancer 1980 45 792 794 10.1002/1097-0142(19800215)45:4&amp;lt;792::AID-CNCR2820450430&amp;gt;3.0.CO;2-X 7357496 22 Liesenfeld"/>
   <result pre="Scalbert A. Ulrich C.M. Review of mass spectrometry-based metabolomics in" exact="cancer" post="research Cancer Epidemiol. Biomarkers Prev. 2013 22 2182 2201"/>
   <result pre="A.T. et al. Gene expression profiling predicts clinical outcome of" exact="breast cancer" post="Nature 2002 415 530 536 10.1038/415530a 11823860 24 Paik"/>
   <result pre="et al. Gene expression profiling predicts clinical outcome of breast" exact="cancer" post="Nature 2002 415 530 536 10.1038/415530a 11823860 24 Paik"/>
   <result pre="al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative" exact="breast cancer" post="N. Engl. J. Med. 2004 351 2817 2826 10.1056/NEJMoa041588"/>
   <result pre="A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast" exact="cancer" post="N. Engl. J. Med. 2004 351 2817 2826 10.1056/NEJMoa041588"/>
   <result pre="Anderson W.F. Chatterjee N. Ershler W.B. Brawley O.W. Estrogen receptor" exact="breast cancer" post="phenotypes in the Surveillance, Epidemiology, and End Results database"/>
   <result pre="W.F. Chatterjee N. Ershler W.B. Brawley O.W. Estrogen receptor breast" exact="cancer" post="phenotypes in the Surveillance, Epidemiology, and End Results database"/>
   <result pre="trial evaluating tamoxifen in the treatment of patients with node-negative" exact="breast cancer" post="who have estrogen-receptor-positive tumors N. Engl. J. Med. 1989"/>
   <result pre="evaluating tamoxifen in the treatment of patients with node-negative breast" exact="cancer" post="who have estrogen-receptor-positive tumors N. Engl. J. Med. 1989"/>
   <result pre="is as effective as anastrozole in postmenopausal women with advanced" exact="breast cancer" post="progressing after prior endocrine treatment J. Clin. Oncol. 2002"/>
   <result pre="as effective as anastrozole in postmenopausal women with advanced breast" exact="cancer" post="progressing after prior endocrine treatment J. Clin. Oncol. 2002"/>
   <result pre="0.5 mg daily and aminoglutethimide in postmenopausal women with advanced" exact="breast cancer." post="Letrozole International Trial Group (AR/BC3) Ann. Oncol. 1998 9"/>
   <result pre="T. Knott A. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N. Engl. J. Med. 2012 366 109 119 10.1056/NEJMoa1113216"/>
   <result pre="Knott A. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N. Engl. J. Med. 2012 366 109 119 10.1056/NEJMoa1113216"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N. Engl. J. Med. 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N. Engl. J. Med. 2001 344"/>
   <result pre="Kaufman B. et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N. Engl. J. Med. 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="B. et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N. Engl. J. Med. 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="V. Guardino E. et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N. Engl. J. Med. 2012 367 1783 1791 10.1056/NEJMoa1209124"/>
   <result pre="Guardino E. et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N. Engl. J. Med. 2012 367 1783 1791 10.1056/NEJMoa1209124"/>
   <result pre="A. Krajewski K. Cakar B. Ma C.X. Targeted therapy for" exact="breast cancer" post="Am. J. Pathol. 2013 183 1096 1112 10.1016/j.ajpath.2013.07.005 23988612"/>
   <result pre="Krajewski K. Cakar B. Ma C.X. Targeted therapy for breast" exact="cancer" post="Am. J. Pathol. 2013 183 1096 1112 10.1016/j.ajpath.2013.07.005 23988612"/>
   <result pre="B. O’Brien K. Wang Y. et al. Antiestrogen resistance in" exact="breast cancer" post="and the role of estrogen receptor signaling Oncogene 2003"/>
   <result pre="O’Brien K. Wang Y. et al. Antiestrogen resistance in breast" exact="cancer" post="and the role of estrogen receptor signaling Oncogene 2003"/>
   <result pre="Profiling of estrogen up- and down-regulated gene expression in human" exact="breast cancer" post="cells: insights into gene networks and pathways underlying estrogenic"/>
   <result pre="of estrogen up- and down-regulated gene expression in human breast" exact="cancer" post="cells: insights into gene networks and pathways underlying estrogenic"/>
   <result pre="P.A. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N. Engl. J. Med. 2005 353 1673 1684 10.1056/NEJMoa052122"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N. Engl. J. Med. 2005 353 1673 1684 10.1056/NEJMoa052122"/>
   <result pre="P.C. Linn S.C. Sotiriou C. Understanding the biology of triple-negative" exact="breast cancer" post="Ann. Oncol. 2012 23 Suppl. 6 VI13 VI18 10.1093/annonc/mds188"/>
   <result pre="Linn S.C. Sotiriou C. Understanding the biology of triple-negative breast" exact="cancer" post="Ann. Oncol. 2012 23 Suppl. 6 VI13 VI18 10.1093/annonc/mds188"/>
   <result pre="10.1101/cshperspect.a006783 22687276 48 Ward P.S. Thompson C.B. Metabolic reprogramming: A" exact="cancer" post="hallmark even warburg did not anticipate Cancer Cell 2012"/>
   <result pre="unfolded protein response, and gene network modeling in antiestrogen resistant" exact="breast cancer" post="Horm. Mol. Biol. Clin. Investig. 2011 5 35 44"/>
   <result pre="protein response, and gene network modeling in antiestrogen resistant breast" exact="cancer" post="Horm. Mol. Biol. Clin. Investig. 2011 5 35 44"/>
   <result pre="the unfolded protein response, autophagy, and the integrated regulation of" exact="breast cancer" post="cell fate Cancer Res. 2012 72 1321 1331 10.1158/1538-7445.AM2012-1321"/>
   <result pre="unfolded protein response, autophagy, and the integrated regulation of breast" exact="cancer" post="cell fate Cancer Res. 2012 72 1321 1331 10.1158/1538-7445.AM2012-1321"/>
   <result pre="Liu M.C. Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in" exact="breast cancer" post="Vitam. Horm. 2005 71 201 237 16112269 52 Bouker"/>
   <result pre="M.C. Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast" exact="cancer" post="Vitam. Horm. 2005 71 201 237 16112269 52 Bouker"/>
   <result pre="binding protein-1 confers both estrogen independence and antiestrogen resistance in" exact="breast cancer" post="cell lines FASEB J. 2007 21 4013 4027 10.1096/fj.06-7990com"/>
   <result pre="protein-1 confers both estrogen independence and antiestrogen resistance in breast" exact="cancer" post="cell lines FASEB J. 2007 21 4013 4027 10.1096/fj.06-7990com"/>
   <result pre="affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant" exact="breast cancer" post="cells FASEB J. 2010 24 2040 2055 10.1096/fj.09-138305 20154269"/>
   <result pre="mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast" exact="cancer" post="cells FASEB J. 2010 24 2040 2055 10.1096/fj.09-138305 20154269"/>
   <result pre="inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant" exact="breast cancer" post="cells Mol. Cancer Ther. 2005 4 33 41 10.1186/1476-4598-4-33"/>
   <result pre="parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast" exact="cancer" post="cells Mol. Cancer Ther. 2005 4 33 41 10.1186/1476-4598-4-33"/>
   <result pre="Wu H. et al. A gene expression signature from human" exact="breast cancer" post="cells with acquired hormone independence identifies MYC as a"/>
   <result pre="H. et al. A gene expression signature from human breast" exact="cancer" post="cells with acquired hormone independence identifies MYC as a"/>
   <result pre="genes and their relationship to response to tamoxifen therapy in" exact="breast cancer" post="PLoS One 2008 3 e2987 10.1371/journal.pone.0002987 18714337 62 Wang"/>
   <result pre="and their relationship to response to tamoxifen therapy in breast" exact="cancer" post="PLoS One 2008 3 e2987 10.1371/journal.pone.0002987 18714337 62 Wang"/>
   <result pre="Liu D. Zhang Y. Jiang Y. Blockade of GRP78 sensitizes" exact="breast cancer" post="cells to microtubules-interfering agents that induce the unfolded protein"/>
   <result pre="D. Zhang Y. Jiang Y. Blockade of GRP78 sensitizes breast" exact="cancer" post="cells to microtubules-interfering agents that induce the unfolded protein"/>
   <result pre="protein response and glucose and glutamine uptake in endocrine resistant" exact="breast cancer" post="Mol. Cancer 2014 13 239 10.1186/1476-4598-13-239 25339305 65 Deyati"/>
   <result pre="response and glucose and glutamine uptake in endocrine resistant breast" exact="cancer" post="Mol. Cancer 2014 13 239 10.1186/1476-4598-13-239 25339305 65 Deyati"/>
   <result pre="624 10.1016/j.drudis.2012.12.011 23280501 66 Armitage E.G. Barbas C. Metabolomics in" exact="cancer" post="biomarker discovery: Current trends and future perspectives J. Pharm."/>
   <result pre="348 10.1586/erm.13.23 23638817 68 Gupta S. Chawla K. Oncometabolomics in" exact="cancer" post="research Expert Rev. Proteomics 2013 10 325 336 10.1586/14789450.2013.828947"/>
   <result pre="23992416 69 Wood S.L. Westbrook J.A. Brown J.E. Omic-profiling in" exact="breast cancer" post="metastasis to bone: implications for mechanisms, biomarkers and treatment"/>
   <result pre="69 Wood S.L. Westbrook J.A. Brown J.E. Omic-profiling in breast" exact="cancer" post="metastasis to bone: implications for mechanisms, biomarkers and treatment"/>
   <result pre="10.1016/j.ctrv.2013.07.006 23958309 70 Duarte I.F. Gil A.M. Metabolic signatures of" exact="cancer" post="unveiled by NMR spectroscopy of human biofluids Prog. Nucl."/>
   <result pre="spectroscopy of human body fluids and tissues in relation to" exact="prostate cancer" post="NMR Biomed. 2014 27 80 89 10.1002/nbm.2979 23828638 72"/>
   <result pre="of human body fluids and tissues in relation to prostate" exact="cancer" post="NMR Biomed. 2014 27 80 89 10.1002/nbm.2979 23828638 72"/>
   <result pre="F.M. Akman S. Torti S.V. Shulaev V. Bioinformatics tools for" exact="cancer" post="metabolomics Metabolomics 2011 7 329 343 10.1007/s11306-010-0270-3 21949492 74"/>
   <result pre="20953584 77 Vermeersch K.A. Styczynski M.P. Applications of metabolomics in" exact="cancer" post="research J. Carcinog. 2013 12 9 10.4103/1477-3163.113622 23858297 78"/>
   <result pre="J.W. Vander Heiden M.G. Cantley L.C. Rewiring of glycolysis in" exact="cancer" post="cell metabolism Cell Cycle 2010 9 4253 10.4161/cc.9.21.13925 21045562"/>
   <result pre="Owusu-Sarfo K. Ballas R.A. Raftery D. Early detection of recurrent" exact="breast cancer" post="using metabolite profiling Cancer Res. 2010 70 8309 8318"/>
   <result pre="K. Ballas R.A. Raftery D. Early detection of recurrent breast" exact="cancer" post="using metabolite profiling Cancer Res. 2010 70 8309 8318"/>
   <result pre="Cardoso S.M. Clish C.B. et al. SIRT3 opposes reprogramming of" exact="cancer" post="cell metabolism through HIF1alpha destabilization Cancer Cell 2011 19"/>
   <result pre="metabolomics identification of markers of hypoxia-induced metabolic shifts in a" exact="breast cancer" post="model system J. Biomol. NMR 2011 49 185 193"/>
   <result pre="identification of markers of hypoxia-induced metabolic shifts in a breast" exact="cancer" post="model system J. Biomol. NMR 2011 49 185 193"/>
   <result pre="serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human" exact="breast cancer" post="Cancer Lett. 2014 343 33 41 10.1016/j.canlet.2013.09.011 24041867 90"/>
   <result pre="nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast" exact="cancer" post="Cancer Lett. 2014 343 33 41 10.1016/j.canlet.2013.09.011 24041867 90"/>
   <result pre="Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in" exact="breast cancer" post="patients Int. J. Mol. Sci. 2013 14 8047 8061"/>
   <result pre="spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast" exact="cancer" post="patients Int. J. Mol. Sci. 2013 14 8047 8061"/>
   <result pre="Morvan D. Metabolomics reveals metabolic targets and biphasic responses in" exact="breast cancer" post="cells treated by curcumin alone and in association with"/>
   <result pre="D. Metabolomics reveals metabolic targets and biphasic responses in breast" exact="cancer" post="cells treated by curcumin alone and in association with"/>
   <result pre="Impact of tumor microenvironment and epithelial phenotypes on metabolism in" exact="breast cancer" post="Clin. Cancer Res. 2013 19 571 585 10.1158/1078-0432.CCR-12-2123 23236214"/>
   <result pre="of tumor microenvironment and epithelial phenotypes on metabolism in breast" exact="cancer" post="Clin. Cancer Res. 2013 19 571 585 10.1158/1078-0432.CCR-12-2123 23236214"/>
   <result pre="Marin-Hernandez A. Moreno-Sanchez R. Rodriguez-Enriquez S. Anti-mitochondrial therapy in human" exact="breast cancer" post="multi-cellular spheroids Biochim. Biophys. Acta 2013 1833 541 551"/>
   <result pre="A. Moreno-Sanchez R. Rodriguez-Enriquez S. Anti-mitochondrial therapy in human breast" exact="cancer" post="multi-cellular spheroids Biochim. Biophys. Acta 2013 1833 541 551"/>
   <result pre="al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for" exact="breast cancer" post="Mol. Oncol. 2013 7 297 307 10.1016/j.molonc.2012.10.003 23142658 95"/>
   <result pre="Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast" exact="cancer" post="Mol. Oncol. 2013 7 297 307 10.1016/j.molonc.2012.10.003 23142658 95"/>
   <result pre="23142658 95 Budczies J. Remodeling of central metabolism in invasive" exact="breast cancer" post="compared to normal breast tissue—a GC-TOFMS based metabolomics study"/>
   <result pre="95 Budczies J. Remodeling of central metabolism in invasive breast" exact="cancer" post="compared to normal breast tissue—a GC-TOFMS based metabolomics study"/>
   <result pre="Knudsen E.S. Howell A. et al. Ketones and lactate increase" exact="cancer" post="cell &quot;stemness,&quot; driving recurrence, metastasis and poor clinical outcome"/>
   <result pre="P.S. et al. IDH1 mutation is sufficient to establish the" exact="glioma" post="hypermethylator phenotype Nature 2012 483 479 483 10.1038/nature10866 22343889"/>
   <result pre="Metabolite profiling identifies a key role for glycine in rapid" exact="cancer" post="cell proliferation Science 2012 336 1040 1044 10.1126/science.1218595 22628656"/>
   <result pre="D.K. Global profiling strategies for mapping dysregulated metabolic pathways in" exact="cancer" post="Cell Metab. 2012 16 565 577 10.1016/j.cmet.2012.09.013 23063552 104"/>
   <result pre="al. Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in" exact="breast cancer" post="cells Metabolomics 2013 9 960 973 10.1007/s11306-013-0517-x 24039617 107"/>
   <result pre="Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast" exact="cancer" post="cells Metabolomics 2013 9 960 973 10.1007/s11306-013-0517-x 24039617 107"/>
   <result pre="uncovers metabolic alterations associated to severe oxidative stress in MCF7" exact="breast cancer" post="cells exposed to ascididemin Mar. Drugs 2013 11 3846"/>
   <result pre="metabolic alterations associated to severe oxidative stress in MCF7 breast" exact="cancer" post="cells exposed to ascididemin Mar. Drugs 2013 11 3846"/>
   <result pre="Morvan D. Metabolomics reveals metabolic targets and biphasic responses in" exact="breast cancer" post="cells treated by curcumin alone and in association with"/>
   <result pre="D. Metabolomics reveals metabolic targets and biphasic responses in breast" exact="cancer" post="cells treated by curcumin alone and in association with"/>
   <result pre="Sonntag D. Metabolomic analysis of resveratrol-induced effects in the human" exact="breast cancer" post="cell lines MCF-7 and MDA-MB-231 OMICS 2011 15 9"/>
   <result pre="D. Metabolomic analysis of resveratrol-induced effects in the human breast" exact="cancer" post="cell lines MCF-7 and MDA-MB-231 OMICS 2011 15 9"/>
   <result pre="G. Cen X. Zhao Y.L. Metabolomics: A revolution for novel" exact="cancer" post="marker identification Comb. Chem. High Throughput Screen. 2012 15"/>
   <result pre="Ganapathy-Kanniappan S. Geschwind J.F. Tumor glycolysis as a target for" exact="cancer" post="therapy: progress and prospects Mol. Cancer 2013 12 152"/>
   <result pre="The diverse functions of glutamine in metabolism, cell biology and" exact="cancer" post="Oncogene 2010 29 313 324 10.1038/onc.2009.358 19881548 127 Lu"/>
   <result pre="S. et al. A mitochondria-K+ channel axis is suppressed in" exact="cancer" post="and its normalization promotes apoptosis and inhibits cancer growth"/>
   <result pre="suppressed in cancer and its normalization promotes apoptosis and inhibits" exact="cancer" post="growth Cancer Cell 2007 11 37 51 10.1016/j.ccr.2006.10.020 17222789"/>
   <result pre="12403765 131 Estrela J.M. Ortega A. Obrador E. Glutathione in" exact="cancer" post="biology and therapy Crit. Rev. Clin. Lab. Sci. 2006"/>
   <result pre="al. Increased anaerobic metabolism is a distinctive signature in a" exact="colorectal cancer" post="cellular model of resistance to antiepidermal growth factor receptor"/>
   <result pre="Increased anaerobic metabolism is a distinctive signature in a colorectal" exact="cancer" post="cellular model of resistance to antiepidermal growth factor receptor"/>
   <result pre="over expression correlates with poor prognosis in non small cell" exact="lung cancer" post="patients Mol. Cancer 2013 12 97 10.1186/1476-4598-12-97 23988223 139"/>
   <result pre="expression correlates with poor prognosis in non small cell lung" exact="cancer" post="patients Mol. Cancer 2013 12 97 10.1186/1476-4598-12-97 23988223 139"/>
   <result pre="The M2 splice isoform of pyruvate kinase is important for" exact="cancer" post="metabolism and tumour growth Nature 2008 452 230 233"/>
   <result pre="by functioning as a coactivator for hypoxia-inducible factor 1 in" exact="cancer" post="cells Oncotarget 2011 2 551 556 21709315 142 Hussien"/>
   <result pre="plasma membrane lactate transporter and lactate dehydrogenase isoform expression in" exact="breast cancer" post="cell lines Physiol. Genomics 2011 43 255 264 10.1152/physiolgenomics.00177.2010"/>
   <result pre="membrane lactate transporter and lactate dehydrogenase isoform expression in breast" exact="cancer" post="cell lines Physiol. Genomics 2011 43 255 264 10.1152/physiolgenomics.00177.2010"/>
   <result pre="for destruction: the inhibition of glycolysis as a therapy for" exact="tuberous sclerosis" post="complex-related tumors BMC Biol. 2011 9 69 10.1186/1741-7007-9-69 22018140"/>
   <result pre="Differential expression of enzymes associated with serine/glycine metabolism in different" exact="breast cancer" post="subtypes PLoS One 2014 9 e101004 10.1371/journal.pone.0101004 24979213"/>
   <result pre="expression of enzymes associated with serine/glycine metabolism in different breast" exact="cancer" post="subtypes PLoS One 2014 9 e101004 10.1371/journal.pone.0101004 24979213"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4385942/results/search/disease/results.xml">
   <result pre="by Kruppel-like factors 4 and 5 mediates lapatinib resistance in" exact="breast cancer" post="KLF4 and KLF5 mediate lapatinib resistance Farrugia M K"/>
   <result pre="Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast" exact="cancer" post="KLF4 and KLF5 mediate lapatinib resistance Farrugia M K"/>
   <result pre="(HER2)-enriched subtype. Furthermore, KLF4/5 protein was rapidly upregulated in human" exact="breast cancer" post="cells following treatment with the HER2/epidermal growth factor receptor"/>
   <result pre="subtype. Furthermore, KLF4/5 protein was rapidly upregulated in human breast" exact="cancer" post="cells following treatment with the HER2/epidermal growth factor receptor"/>
   <result pre="tumor cells derived from this model as well as human" exact="breast cancer" post="cells, suppression of KLF4 and/or KLF5 sensitized HER2-overexpressing cells"/>
   <result pre="cells derived from this model as well as human breast" exact="cancer" post="cells, suppression of KLF4 and/or KLF5 sensitized HER2-overexpressing cells"/>
   <result pre="from this model as well as human breast cancer cells," exact="suppression" post="of KLF4 and/or KLF5 sensitized HER2-overexpressing cells to lapatinib."/>
   <result pre="mRNA and protein levels of the anti-apoptotic factors myeloid cell" exact="leukemia" post="1 (MCL1) and B-cell lymphoma-extra large (BCL-XL). Moreover, MCL1"/>
   <result pre="MCL1 in KLF4/5-deficient cells restored drug resistance. In addition, combined" exact="suppression" post="of KLF4/5 in cultured tumor cells additively inhibited anchorage-independent"/>
   <result pre="and other malignant properties, KLF4/5 levels selectively stratified human HER2-enriched" exact="breast cancer" post="by distant metastasis-free survival. These results identify KLF4 and"/>
   <result pre="other malignant properties, KLF4/5 levels selectively stratified human HER2-enriched breast" exact="cancer" post="by distant metastasis-free survival. These results identify KLF4 and"/>
   <result pre="survival in diverse contexts. 3, 6, 7, 8, 9 In" exact="breast cancer," post="KLF4/5 protein levels or mRNA abundance are elevated in"/>
   <result pre="Individually, both KLF4/5 exert oncogenic functions in experimental models of" exact="cancer" post="such as cellular transformation, migration, invasion and xenograft formation."/>
   <result pre="submitted). 18, 20 Although independently KLF4/5 have important roles in" exact="breast cancer," post="the relationship between the two genes in this disease"/>
   <result pre="expression in the human epidermal growth factor receptor 2 (HER2)-enriched" exact="breast cancer" post="subtype. In addition, in these patients the median expression"/>
   <result pre="in the human epidermal growth factor receptor 2 (HER2)-enriched breast" exact="cancer" post="subtype. In addition, in these patients the median expression"/>
   <result pre="also shows efficacy in combination with other agents in basal-like" exact="breast cancer" post="models. 36, 37 We observed that lapatinib treatment of"/>
   <result pre="shows efficacy in combination with other agents in basal-like breast" exact="cancer" post="models. 36, 37 We observed that lapatinib treatment of"/>
   <result pre="in the presence of lapatinib KLF4/5 coregulated the expression of" exact="myeloid leukemia" post="cell 1 (MCL1) and cooperated to confer lapatinib resistance."/>
   <result pre="the presence of lapatinib KLF4/5 coregulated the expression of myeloid" exact="leukemia" post="cell 1 (MCL1) and cooperated to confer lapatinib resistance."/>
   <result pre="and positively correlated in genetically engineered mouse models (GEMMs) of" exact="breast cancer" post="To better understand how the expression of these two"/>
   <result pre="positively correlated in genetically engineered mouse models (GEMMs) of breast" exact="cancer" post="To better understand how the expression of these two"/>
   <result pre="we analyzed the levels of Klf4/ 5 in GEMMs of" exact="breast cancer." post="38 As a complement to human tumor analysis, individual"/>
   <result pre="data, the protein expression of KLF4/5 in 10 different human" exact="breast cancer" post="cell lines was positively correlated ( R= 0.8847, P=0.0007;"/>
   <result pre="the protein expression of KLF4/5 in 10 different human breast" exact="cancer" post="cell lines was positively correlated ( R= 0.8847, P=0.0007;"/>
   <result pre="the smaller fragment of approximately 48 kDa present in the luminal" exact="breast cancer" post="cell lines may be attributed to estrogen-dependent processing. 39"/>
   <result pre="smaller fragment of approximately 48 kDa present in the luminal breast" exact="cancer" post="cell lines may be attributed to estrogen-dependent processing. 39"/>
   <result pre="processing. 39 Prognostic significance of KLF4 and KLF5 in HER2-enriched" exact="breast cancer" post="As KLF4/5 were correlated in breast cancer models, we"/>
   <result pre="39 Prognostic significance of KLF4 and KLF5 in HER2-enriched breast" exact="cancer" post="As KLF4/5 were correlated in breast cancer models, we"/>
   <result pre="KLF5 in HER2-enriched breast cancer As KLF4/5 were correlated in" exact="breast cancer" post="models, we next examined whether this relationship is informative"/>
   <result pre="in HER2-enriched breast cancer As KLF4/5 were correlated in breast" exact="cancer" post="models, we next examined whether this relationship is informative"/>
   <result pre="DMFS ( P=0.016). Endogenous KLF4/5 are induced by lapatinib in" exact="breast cancer" post="We next examined the transcript abundance of KLF4/ 5"/>
   <result pre="( P=0.016). Endogenous KLF4/5 are induced by lapatinib in breast" exact="cancer" post="We next examined the transcript abundance of KLF4/ 5"/>
   <result pre="via The Cancer Genome Atlas (TCGA) Research Network. Among the" exact="breast cancer" post="intrinsic subtypes, we observed the expression of the two"/>
   <result pre="The Cancer Genome Atlas (TCGA) Research Network. Among the breast" exact="cancer" post="intrinsic subtypes, we observed the expression of the two"/>
   <result pre="appeared to represent positively correlated prognostic factors in the HER2-enriched" exact="breast cancer" post="subtype, we subsequently investigated the interdependence of KLF4/5 expression"/>
   <result pre="to represent positively correlated prognostic factors in the HER2-enriched breast" exact="cancer" post="subtype, we subsequently investigated the interdependence of KLF4/5 expression"/>
   <result pre="cycloheximide. Nevertheless, the results indicate that lapatinib treatment of HER2-positive" exact="breast cancer" post="cells can enhance KLF4 protein expression and its transcriptional"/>
   <result pre="Nevertheless, the results indicate that lapatinib treatment of HER2-positive breast" exact="cancer" post="cells can enhance KLF4 protein expression and its transcriptional"/>
   <result pre="indicated by miR-206 levels. Endogenous KLF4/5 mediate lapatinib resistance in" exact="breast cancer" post="Based on these results, we hypothesized that KLF4/5 are"/>
   <result pre="by miR-206 levels. Endogenous KLF4/5 mediate lapatinib resistance in breast" exact="cancer" post="Based on these results, we hypothesized that KLF4/5 are"/>
   <result pre="therefore depleted KLF4/5 in HER2-amplified human BT474 and mouse M6" exact="breast cancer" post="cells, using distinct shRNA hairpins for each of the"/>
   <result pre="depleted KLF4/5 in HER2-amplified human BT474 and mouse M6 breast" exact="cancer" post="cells, using distinct shRNA hairpins for each of the"/>
   <result pre="Figure 3f, left panels). M6 cells are a HER2-overexpressing mammary" exact="cancer" post="cell line derived from a basal-like GEMM that is"/>
   <result pre="sensitized the cells to lapatinib, indicating cooperativity. In these experiments," exact="suppression" post="of KLF5 led to a subtle reduction of KLF4,"/>
   <result pre="cell lines had reduced MMI compared with the controls and" exact="suppression" post="of both KLF4/5 produced an additive effect. Supporting an"/>
   <result pre="KLF4/5 depletion is associated with reduced expression of anti-apoptotic B-cell" exact="lymphoma" post="2 (BCL2) family members As KLF4/5-depleted cells consistently exhibited"/>
   <result pre="its expression is correlates with a favorable patient outcome in" exact="breast cancer." post="46 Single knockdown of either KLF4 or KLF5 greatly"/>
   <result pre="activating phosphatidylinositide 3-kinase (PI3K) mutation present in this HER2-amplified, inflammatory" exact="breast cancer" post="cell line ( Figure 5b). 47 In both BT474"/>
   <result pre="phosphatidylinositide 3-kinase (PI3K) mutation present in this HER2-amplified, inflammatory breast" exact="cancer" post="cell line ( Figure 5b). 47 In both BT474"/>
   <result pre="5h). Discussion Targeted therapies have significantly improved the DFS of" exact="breast cancer" post="patients, including patients with ER+ or HER2+ breast cancers,"/>
   <result pre="Discussion Targeted therapies have significantly improved the DFS of breast" exact="cancer" post="patients, including patients with ER+ or HER2+ breast cancers,"/>
   <result pre="HER2+ breast cancers, and these therapies hold promise for triple-negative" exact="breast cancer" post="(TNBC), particularly when used in combination. 36, 37 For"/>
   <result pre="breast cancers, and these therapies hold promise for triple-negative breast" exact="cancer" post="(TNBC), particularly when used in combination. 36, 37 For"/>
   <result pre="(TNBC), particularly when used in combination. 36, 37 For HER2+" exact="breast cancer," post="clinically approved therapies include the monoclonal antibodies trastuzumab and"/>
   <result pre="coexpression of KLF4/5 and MCL1 in human breast tumors and" exact="breast cancer" post="models. Also, in mouse ES cells the Mcl1 locus"/>
   <result pre="of KLF4/5 and MCL1 in human breast tumors and breast" exact="cancer" post="models. Also, in mouse ES cells the Mcl1 locus"/>
   <result pre="56 As overall survival, DFS and DMFS correlate strongly in" exact="breast cancer," post="the utilization of these different endpoints seems unlikely to"/>
   <result pre="analyses, the compendium of gene expression array data sets of" exact="breast cancer" post="was previously compiled, with subtypes assigned as described elsewhere."/>
   <result pre="the compendium of gene expression array data sets of breast" exact="cancer" post="was previously compiled, with subtypes assigned as described elsewhere."/>
   <result pre="line and Robert A.Weinberg for donating HMLE cells. BCL2 B-cell" exact="lymphoma" post="2 BCL-XL B-cell lymphoma-extra large C3(1) Tag SV40 large"/>
   <result pre="integrity MMTV mouse mammary tumor virus promoter MCL1 myeloid cell" exact="leukemia" post="1 PI3K phosphatidylinositide 3-kinase qRT-PCR quantitative reverse transcription and"/>
   <result pre="receptor tyrosine kinase TCGA The Cancer Genome Atlas TNBC triple-negative" exact="breast cancer" post="Supplementary Information accompanies this paper on Cell Death and"/>
   <result pre="tyrosine kinase TCGA The Cancer Genome Atlas TNBC triple-negative breast" exact="cancer" post="Supplementary Information accompanies this paper on Cell Death and"/>
   <result pre="factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in" exact="cancer" post="cells Oncogene 2008 27 1 8 17603560 Li X"/>
   <result pre="KLF5 promotes hypoxia-induced survival and inhibits apoptosis in non-small cell" exact="lung cancer" post="cells via HIF-1alpha Int J Oncol 2014 45 1507"/>
   <result pre="promotes hypoxia-induced survival and inhibits apoptosis in non-small cell lung" exact="cancer" post="cells via HIF-1alpha Int J Oncol 2014 45 1507"/>
   <result pre="of KLF4 is associated with an aggressive phenotype in early-stage" exact="breast cancer" post="Clin Cancer Res 2004 10 2709 2719 15102675 Tong"/>
   <result pre="KLF4 is associated with an aggressive phenotype in early-stage breast" exact="cancer" post="Clin Cancer Res 2004 10 2709 2719 15102675 Tong"/>
   <result pre="factor for disease-free survival and overall survival in patients with" exact="breast cancer" post="Clin Cancer Res 2006 12 2442 2448 16638850 Ben-Porath"/>
   <result pre="for disease-free survival and overall survival in patients with breast" exact="cancer" post="Clin Cancer Res 2006 12 2442 2448 16638850 Ben-Porath"/>
   <result pre="4 and Kruppel-like Factor 5 with the clinical manifestations of" exact="breast cancer" post="Pathol Oncol Res 2012 18 161 168 21674249 Kamalakaran"/>
   <result pre="and Kruppel-like Factor 5 with the clinical manifestations of breast" exact="cancer" post="Pathol Oncol Res 2012 18 161 168 21674249 Kamalakaran"/>
   <result pre="al. Kruppel-like factor 4 (KLF4) is required for maintenance of" exact="breast cancer" post="stem cells and for cell migration and invasion Oncogene"/>
   <result pre="Kruppel-like factor 4 (KLF4) is required for maintenance of breast" exact="cancer" post="stem cells and for cell migration and invasion Oncogene"/>
   <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="Fehrenbacher L et al. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic" exact="breast cancer." post="a preliminary report Eur J Cancer 2001 37 25"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 2743 17192538"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 2743 17192538"/>
   <result pre="M Baselga J et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 1783 1791 23020162"/>
   <result pre="Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 1783 1791 23020162"/>
   <result pre="YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 109 119 22149875"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 109 119 22149875"/>
   <result pre="LX Du Y Esteva FJ Lapatinib induces apoptosis in trastuzumab-resistant" exact="breast cancer" post="cells: effects on insulin-like growth factor I signaling Mol"/>
   <result pre="Du Y Esteva FJ Lapatinib induces apoptosis in trastuzumab-resistant breast" exact="cancer" post="cells: effects on insulin-like growth factor I signaling Mol"/>
   <result pre="PI3K pathway as a major determinant of trastuzumab resistance in" exact="breast cancer" post="Cancer Cell 2007 12 395 402 17936563 Eichhorn PJ"/>
   <result pre="pathway as a major determinant of trastuzumab resistance in breast" exact="cancer" post="Cancer Cell 2007 12 395 402 17936563 Eichhorn PJ"/>
   <result pre="with trastuzumab response and survival in patients with HER2-positive metastatic" exact="breast cancer" post="Am J Pathol 2010 177 1647 1656 20813970 Dave"/>
   <result pre="trastuzumab response and survival in patients with HER2-positive metastatic breast" exact="cancer" post="Am J Pathol 2010 177 1647 1656 20813970 Dave"/>
   <result pre="Chang CJ Wang Q Bao Y et al. BikDD eliminates" exact="breast cancer" post="initiating cells and synergizes with lapatinib for breast cancer"/>
   <result pre="CJ Wang Q Bao Y et al. BikDD eliminates breast" exact="cancer" post="initiating cells and synergizes with lapatinib for breast cancer"/>
   <result pre="eliminates breast cancer initiating cells and synergizes with lapatinib for" exact="breast cancer" post="treatment Cancer Cell 2011 20 341 356 21907925 Valabrega"/>
   <result pre="breast cancer initiating cells and synergizes with lapatinib for breast" exact="cancer" post="treatment Cancer Cell 2011 20 341 356 21907925 Valabrega"/>
   <result pre="G Zaccarello G Petrelli A Migliardi G et al. HER2-positive" exact="breast cancer" post="cells resistant to trastuzumab and lapatinib lose reliance upon"/>
   <result pre="Zaccarello G Petrelli A Migliardi G et al. HER2-positive breast" exact="cancer" post="cells resistant to trastuzumab and lapatinib lose reliance upon"/>
   <result pre="L et al. PRKACA mediates resistance to HER2-targeted therapy in" exact="breast cancer" post="cells and restores anti-apoptotic signaling Oncogene 2014e-pub ahead of"/>
   <result pre="et al. PRKACA mediates resistance to HER2-targeted therapy in breast" exact="cancer" post="cells and restores anti-apoptotic signaling Oncogene 2014e-pub ahead of"/>
   <result pre="et al. Combinatorial effects of lapatinib and rapamycin in triple-negative" exact="breast cancer" post="cells Mol Cancer Ther 2011 10 1460 1469 21690228"/>
   <result pre="al. Combinatorial effects of lapatinib and rapamycin in triple-negative breast" exact="cancer" post="cells Mol Cancer Ther 2011 10 1460 1469 21690228"/>
   <result pre="interactions between EGFR and PARP inhibition in human triple negative" exact="breast cancer" post="cells PLoS One 2012 7 e46614 23071597 Herschkowitz JI"/>
   <result pre="between EGFR and PARP inhibition in human triple negative breast" exact="cancer" post="cells PLoS One 2012 7 e46614 23071597 Herschkowitz JI"/>
   <result pre="induction of KLF5 transcription factor by progesterone contributes to progesterone-induced" exact="breast cancer" post="cell proliferation and dedifferentiation Mol Endocrinol 2011 25 1137"/>
   <result pre="of KLF5 transcription factor by progesterone contributes to progesterone-induced breast" exact="cancer" post="cell proliferation and dedifferentiation Mol Endocrinol 2011 25 1137"/>
   <result pre="22157079 Peppercorn J Perou CM Carey LA Molecular subtypes in" exact="breast cancer" post="evaluation and management: divide and conquer Cancer Invest 2008"/>
   <result pre="Peppercorn J Perou CM Carey LA Molecular subtypes in breast" exact="cancer" post="evaluation and management: divide and conquer Cancer Invest 2008"/>
   <result pre="apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene—amplified" exact="breast cancer" post="cells Clin Cancer Res 2004 10 7747 7756 15570009"/>
   <result pre="induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene—amplified breast" exact="cancer" post="cells Clin Cancer Res 2004 10 7747 7756 15570009"/>
   <result pre="PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in" exact="breast cancer" post="Oncogenesis 2013 2 e83 24366379 Cerami E Gao J"/>
   <result pre="amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast" exact="cancer" post="Oncogenesis 2013 2 e83 24366379 Cerami E Gao J"/>
   <result pre="Gross BE Sumer SO Aksoy BA et al. The cBio" exact="cancer" post="genomics portal: an open platform for exploring multidimensional cancer"/>
   <result pre="cBio cancer genomics portal: an open platform for exploring multidimensional" exact="cancer" post="genomics data Cancer Discov 2012 2 401 404 22588877"/>
   <result pre="Gross B Sumer SO et al. Integrative analysis of complex" exact="cancer" post="genomics and clinical profiles using the cBioPortal Sci Signal"/>
   <result pre="ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive" exact="breast cancer" post="J Clin Oncol 2010 28 1301 1307 20142587 Holzer"/>
   <result pre="receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast" exact="cancer" post="J Clin Oncol 2010 28 1301 1307 20142587 Holzer"/>
   <result pre="Q Li W et al. KLF4 promotes hydrogen-peroxide-induced apoptosis of" exact="chronic myeloid leukemia" post="cells involving the bcl-2/bax pathway Cell Stress Chaperones 2010"/>
   <result pre="Li W et al. KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic" exact="myeloid leukemia" post="cells involving the bcl-2/bax pathway Cell Stress Chaperones 2010"/>
   <result pre="W et al. KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic myeloid" exact="leukemia" post="cells involving the bcl-2/bax pathway Cell Stress Chaperones 2010"/>
   <result pre="proteins and matrix metalloproteinases to control growth of human malignant" exact="neuroblastoma" post="SK-N-DZ and IMR-32 cells Mol Oncol 2013 7 464"/>
   <result pre="importance of extracapsular extension of axillary lymph node metastases in" exact="breast cancer" post="Tumori 2004 90 107 111 15143982 Gruber G Greiner"/>
   <result pre="of extracapsular extension of axillary lymph node metastases in breast" exact="cancer" post="Tumori 2004 90 107 111 15143982 Gruber G Greiner"/>
   <result pre="HER2-positive status predicts higher rates of locoregional recurrence in node-positive" exact="breast cancer" post="patients after mastectomy Int J Radiat Oncol Biol Phys"/>
   <result pre="status predicts higher rates of locoregional recurrence in node-positive breast" exact="cancer" post="patients after mastectomy Int J Radiat Oncol Biol Phys"/>
   <result pre="K et al. Isolation and characterization of a new human" exact="breast cancer" post="cell line, KPL-4, expressing the Erb B family receptors"/>
   <result pre="et al. Isolation and characterization of a new human breast" exact="cancer" post="cell line, KPL-4, expressing the Erb B family receptors"/>
   <result pre="F Fleming MD Zimonjic DB Donaher JL et al. Human" exact="breast cancer" post="cells generated by oncogenic transformation of primary mammary epithelial"/>
   <result pre="Fleming MD Zimonjic DB Donaher JL et al. Human breast" exact="cancer" post="cells generated by oncogenic transformation of primary mammary epithelial"/>
   <result pre="J Genefu: relevant functions for gene expression analysis, especially in" exact="breast cancer" post="2012 Creighton CJ The molecular profile of luminal B"/>
   <result pre="Genefu: relevant functions for gene expression analysis, especially in breast" exact="cancer" post="2012 Creighton CJ The molecular profile of luminal B"/>
   <result pre="cancer 2012 Creighton CJ The molecular profile of luminal B" exact="breast cancer" post="Biologics 2012 6 289 297 22956860 Howe EN Cochrane"/>
   <result pre="2012 Creighton CJ The molecular profile of luminal B breast" exact="cancer" post="Biologics 2012 6 289 297 22956860 Howe EN Cochrane"/>
   <result pre="autocrine signaling loop to enhance anoikis sensitivity in triple negative" exact="breast cancer" post="PLoS One 2012 7 e49987 23185507 Supplementary Material Supplementary"/>
   <result pre="signaling loop to enhance anoikis sensitivity in triple negative breast" exact="cancer" post="PLoS One 2012 7 e49987 23185507 Supplementary Material Supplementary"/>
   <result pre="Klf5 are differentially expressed and positively correlated in GEMMs of" exact="breast cancer." post="( a) Microarray analysis of Klf4/ 5 levels across"/>
   <result pre="a) Microarray analysis of Klf4/ 5 levels across GEMMs of" exact="breast cancer." post="Data for 58 mammary tumors from the Gene Expression"/>
   <result pre="analysis of KLF4/5 levels in whole-cell lysate of 10 different" exact="breast cancer" post="cell lines. KLF expression was determined using ImageJ and"/>
   <result pre="of KLF4/5 levels in whole-cell lysate of 10 different breast" exact="cancer" post="cell lines. KLF expression was determined using ImageJ and"/>
   <result pre="Figure 2 Prognostic significance of KLF4 and KLF5 in human" exact="breast cancer." post="Kaplan–Meier analysis utilized a previously described breast cancer microarray"/>
   <result pre="in human breast cancer. Kaplan–Meier analysis utilized a previously described" exact="breast cancer" post="microarray database. 40 Red (hi) and blue (lo) groups"/>
   <result pre="human breast cancer. Kaplan–Meier analysis utilized a previously described breast" exact="cancer" post="microarray database. 40 Red (hi) and blue (lo) groups"/>
   <result pre="using the median gene expression level within the tumors of" exact="breast cancer" post="patients. A total of 364 luminal A, 175 luminal"/>
   <result pre="the median gene expression level within the tumors of breast" exact="cancer" post="patients. A total of 364 luminal A, 175 luminal"/>
   <result pre="considered significant Figure 3 Endogenous KLF4/5 mediate lapatinib resistance in" exact="breast cancer" post="models. ( a) Levels of KLF4/ 5 in primary"/>
   <result pre="significant Figure 3 Endogenous KLF4/5 mediate lapatinib resistance in breast" exact="cancer" post="models. ( a) Levels of KLF4/ 5 in primary"/>
   <result pre="to promote malignant properties in M6 cells, a HER-2-overexpressing mammary" exact="cancer" post="model. ( a) Anchorage independence was assessed by incubation"/>
   <result pre="on tumor burden were obtained using distinct shRNAs for the" exact="suppression" post="of each KLF (right panel, N= 5; bars, S.E.)."/>
   <result pre="*** P&amp;lt;0.001 Table 1 The expression levels of KLF4/5 in" exact="breast cancer" post="are mutually inclusive with the anti-apoptotic BCL2 family members"/>
   <result pre="P&amp;lt;0.001 Table 1 The expression levels of KLF4/5 in breast" exact="cancer" post="are mutually inclusive with the anti-apoptotic BCL2 family members"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4389676/results/search/disease/results.xml">
   <result pre="doi: 10.1186/s13058-015-0561-8 : Review Quantification of HER family receptors in" exact="breast cancer" post="Nuciforo Paolo pnuciforo@vhio.net Radosevic-Robin Nina nina.radosevic.robin@gmail.com Ng Tony tony.ng@kcl.ac.uk"/>
   <result pre="10.1186/s13058-015-0561-8 : Review Quantification of HER family receptors in breast" exact="cancer" post="Nuciforo Paolo pnuciforo@vhio.net Radosevic-Robin Nina nina.radosevic.robin@gmail.com Ng Tony tony.ng@kcl.ac.uk"/>
   <result pre="unless otherwise stated. Abstract The clinical success of trastuzumab in" exact="breast cancer" post="taught us that appropriate tumor evaluation is mandatory for"/>
   <result pre="otherwise stated. Abstract The clinical success of trastuzumab in breast" exact="cancer" post="taught us that appropriate tumor evaluation is mandatory for"/>
   <result pre="expression and activity of HER family members is frequent in" exact="breast cancer." post="Overexpression of EGFR1, HER2 and HER3 is generally associated"/>
   <result pre="and afatinib) are the main strategies to target HER2 in" exact="breast cancer." post="Trastuzumab, in combination with chemotherapy, has significantly increased both"/>
   <result pre="in combination with capecitabine, has shown clinical activity in HER2-positive" exact="breast cancer" post="patients that became refractory to trastuzumab-based therapy [ 12]."/>
   <result pre="combination with capecitabine, has shown clinical activity in HER2-positive breast" exact="cancer" post="patients that became refractory to trastuzumab-based therapy [ 12]."/>
   <result pre="EGFR has been shown to be highly expressed in triple-negative" exact="breast cancer" post="(TNBC), both in cell lines and in patients ["/>
   <result pre="has been shown to be highly expressed in triple-negative breast" exact="cancer" post="(TNBC), both in cell lines and in patients ["/>
   <result pre="available. There are several unanswered questions about which patients with" exact="breast cancer" post="are most likely to benefit from one or another"/>
   <result pre="There are several unanswered questions about which patients with breast" exact="cancer" post="are most likely to benefit from one or another"/>
   <result pre="overexpression of HER2 is part of the management of a" exact="breast cancer" post="patient whereas EGFR, HER3, and HER4 determinations are still"/>
   <result pre="of HER2 is part of the management of a breast" exact="cancer" post="patient whereas EGFR, HER3, and HER4 determinations are still"/>
   <result pre="has combined the data of four trastuzumab trials in metastatic" exact="breast cancer" post="and showed that, from the combined dataset (N = 322 patients),"/>
   <result pre="combined the data of four trastuzumab trials in metastatic breast" exact="cancer" post="and showed that, from the combined dataset (N = 322 patients),"/>
   <result pre="approach was originally applied, by ourselves and others, to human" exact="cancer" post="tissues to detect the nano-proximity between a donor fluorophore-conjugated"/>
   <result pre="level of HER1-HER3 dimer formation in FFPE tissues from basal-like" exact="breast cancer" post="patients who were treated with a neoadjuvant anti-EGFR treatment"/>
   <result pre="of HER1-HER3 dimer formation in FFPE tissues from basal-like breast" exact="cancer" post="patients who were treated with a neoadjuvant anti-EGFR treatment"/>
   <result pre="Moreover, we have demonstrated the existence of EGFR-HER4 dimers in" exact="breast cancer" post="cells and how these dimers are important for cell"/>
   <result pre="we have demonstrated the existence of EGFR-HER4 dimers in breast" exact="cancer" post="cells and how these dimers are important for cell"/>
   <result pre="with a consequent profound impact on patient stratification and targeted" exact="cancer" post="therapeutics. Reverse phase protein array (RPPA) and collaborative enzyme"/>
   <result pre="heterogeneity can be missed and contamination with normal or ductal" exact="carcinoma in situ" post="may lead to both false-negative and false-positive results. HER"/>
   <result pre="the assay was approved as a prognostic test predictive of" exact="breast cancer" post="recurrence in women with newly diagnosed, early stage breast"/>
   <result pre="assay was approved as a prognostic test predictive of breast" exact="cancer" post="recurrence in women with newly diagnosed, early stage breast"/>
   <result pre="breast cancer recurrence in women with newly diagnosed, early stage" exact="breast cancer," post="it also assesses the benefit from certain types of"/>
   <result pre="of ER, PR and HER2 at the RNA level in" exact="breast cancer." post="Compared with IHC results, HER2 gene expression levels provided"/>
   <result pre="of distant recurrence in women with hormone receptor-positive early stage" exact="breast cancer" post="treated with 5 years of endocrine therapy [ 120-"/>
   <result pre="distant recurrence in women with hormone receptor-positive early stage breast" exact="cancer" post="treated with 5 years of endocrine therapy [ 120-"/>
   <result pre="of side effects. In the case of HER receptors in" exact="breast cancer" post="the target is a protein that, although not carrying"/>
   <result pre="side effects. In the case of HER receptors in breast" exact="cancer" post="the target is a protein that, although not carrying"/>
   <result pre="than IHC or central FISH studies in patients with metastatic" exact="breast cancer." post="Interestingly, patients with HER2 gene amplification by FISH but"/>
   <result pre="Similarly, absolute HER2 quantification in an homogeneous group of HER2-positive" exact="breast cancer" post="(IHC 3+) using triple quadrupole MS was predictive of"/>
   <result pre="absolute HER2 quantification in an homogeneous group of HER2-positive breast" exact="cancer" post="(IHC 3+) using triple quadrupole MS was predictive of"/>
   <result pre="described both in preclinical models and in patients with HER2-positive" exact="breast cancer" post="[ 152]. The addition of compounds blocking HER3 or"/>
   <result pre="both in preclinical models and in patients with HER2-positive breast" exact="cancer" post="[ 152]. The addition of compounds blocking HER3 or"/>
   <result pre="EGFR measurement may provide a method for personalizing treatment in" exact="breast cancer," post="beyond the single assay for HER2. Patients with high"/>
   <result pre="target, no response'. This has also been described in HER2-positive" exact="breast cancer" post="patients upon treatment with trastuzumab-based therapy [ 154]. Therefore,"/>
   <result pre="no response'. This has also been described in HER2-positive breast" exact="cancer" post="patients upon treatment with trastuzumab-based therapy [ 154]. Therefore,"/>
   <result pre="evident that the 'simple detection' of the HER receptors in" exact="breast cancer" post="is not sufficient to predict the benefit that patients"/>
   <result pre="that the 'simple detection' of the HER receptors in breast" exact="cancer" post="is not sufficient to predict the benefit that patients"/>
   <result pre="clinic. *Epidermal growth factor (EGFR), HER2 and HER3. #Approved for" exact="colorectal cancer." post="LDT, laboratory developed test; Q, quantitative; QL, qualitative; SQ,"/>
   <result pre="Silver in situ hybridization SRM Selected reaction monitoring TNBC Triple-negative" exact="breast cancer" post="This is an Open Access article distributed under the"/>
   <result pre="in situ hybridization SRM Selected reaction monitoring TNBC Triple-negative breast" exact="cancer" post="This is an Open Access article distributed under the"/>
   <result pre="Expression of the HER1-4 family of receptor tyrosine kinases in" exact="breast cancer" post="J Pathol 2003 200 290 297 12845624 8. Slamon"/>
   <result pre="of the HER1-4 family of receptor tyrosine kinases in breast" exact="cancer" post="J Pathol 2003 200 290 297 12845624 8. Slamon"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1659 1672 16236737"/>
   <result pre="I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1659 1672 16236737"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 2743 17192538"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 2743 17192538"/>
   <result pre="lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic" exact="breast cancer" post="J Clin Oncol 2008 26 2999 3005 18458039 14."/>
   <result pre="as first-line therapy for ErbB2-amplified locally advanced or metastatic breast" exact="cancer" post="J Clin Oncol 2008 26 2999 3005 18458039 14."/>
   <result pre="paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic" exact="breast cancer" post="J Clin Oncol 2008 26 5544 5552 18955454 15."/>
   <result pre="with placebo plus paclitaxel as first-line treatment for metastatic breast" exact="cancer" post="J Clin Oncol 2008 26 5544 5552 18955454 15."/>
   <result pre="Aura C et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="C et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 109 119 22149875"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 109 119 22149875"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="with cisplatin versus cisplatin alone in patients with metastatic triple-negative" exact="breast cancer" post="J Clin Oncol 2013 31 2586 2592 23733761 21."/>
   <result pre="cisplatin versus cisplatin alone in patients with metastatic triple-negative breast" exact="cancer" post="J Clin Oncol 2013 31 2586 2592 23733761 21."/>
   <result pre="of cetuximab in combination with carboplatin in stage IV triple-negative" exact="breast cancer" post="J Clin Oncol 2012 30 2615 2623 22665533 22."/>
   <result pre="cetuximab in combination with carboplatin in stage IV triple-negative breast" exact="cancer" post="J Clin Oncol 2012 30 2615 2623 22665533 22."/>
   <result pre="weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2007 106 S32 23. Nabholtz"/>
   <result pre="irinotecan/carboplatin with or without cetuximab in patients with metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2007 106 S32 23. Nabholtz"/>
   <result pre="assessment of HER2 in clinical trials of adjuvant therapy for" exact="breast cancer" post="(NCCTG N9831, BCIRG 006, and BCIRG 005) Breast Cancer"/>
   <result pre="of HER2 in clinical trials of adjuvant therapy for breast" exact="cancer" post="(NCCTG N9831, BCIRG 006, and BCIRG 005) Breast Cancer"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="J Clin Oncol 2007 25 118 145 17159189 30."/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="J Clin Oncol 2007 25 118 145 17159189 30."/>
   <result pre="C Mayotte J et al. Standardization of HER2 immunohistochemistry in" exact="breast cancer" post="by automated quantitative analysis Arch Pathol Laboratory Med 2009"/>
   <result pre="Mayotte J et al. Standardization of HER2 immunohistochemistry in breast" exact="cancer" post="by automated quantitative analysis Arch Pathol Laboratory Med 2009"/>
   <result pre="serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for" exact="breast cancer" post="Anticancer Res 2004 24 2C 1127 1130 15154635 38."/>
   <result pre="Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast" exact="cancer" post="Anticancer Res 2004 24 2C 1127 1130 15154635 38."/>
   <result pre="making: pooled analysis of four trials of trastuzumab in metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 1685 1693 19255335 39."/>
   <result pre="pooled analysis of four trials of trastuzumab in metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 1685 1693 19255335 39."/>
   <result pre="protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and" exact="breast cancer" post="tissue Diagn Mol Pathol 2009 18 11 21 19214113"/>
   <result pre="expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast" exact="cancer" post="tissue Diagn Mol Pathol 2009 18 11 21 19214113"/>
   <result pre="G EGFR over-expression and activation in high HER2, ER negative" exact="breast cancer" post="cell line induces trastuzumab resistance Breast Cancer Res Treat"/>
   <result pre="EGFR over-expression and activation in high HER2, ER negative breast" exact="cancer" post="cell line induces trastuzumab resistance Breast Cancer Res Treat"/>
   <result pre="antibody and correlation with outcome in a cohort of trastuzumab-treated" exact="breast cancer" post="patients Clin Cancer Res 2010 16 4226 4235 20664024"/>
   <result pre="and correlation with outcome in a cohort of trastuzumab-treated breast" exact="cancer" post="patients Clin Cancer Res 2010 16 4226 4235 20664024"/>
   <result pre="E Liu YT Lee D Ideker T Network-based classification of" exact="breast cancer" post="metastasis Mol Syst Biol 2007 3 140 17940530 50."/>
   <result pre="Liu YT Lee D Ideker T Network-based classification of breast" exact="cancer" post="metastasis Mol Syst Biol 2007 3 140 17940530 50."/>
   <result pre="D et al. Dynamic modularity in protein interaction networks predicts" exact="breast cancer" post="outcome Nat Biotechnol 2009 27 199 204 19182785 51."/>
   <result pre="et al. Dynamic modularity in protein interaction networks predicts breast" exact="cancer" post="outcome Nat Biotechnol 2009 27 199 204 19182785 51."/>
   <result pre="proteomic technologies to individualize prognosis and guide rational treatment for" exact="cancer" post="patients Target Oncol 2009 4 235 252 19756916 54."/>
   <result pre="transfer imaging improves the understanding of protein interaction networks in" exact="cancer" post="biology Chemphyschem 2011 12 442 461 21328516 55. Anilkumar"/>
   <result pre="et al. Imaging epidermal growth factor receptor phosphorylation in human" exact="colorectal cancer" post="cells and human tissues J Biol Chem 2005 280"/>
   <result pre="al. Imaging epidermal growth factor receptor phosphorylation in human colorectal" exact="cancer" post="cells and human tissues J Biol Chem 2005 280"/>
   <result pre="marker for epidermal growth factor receptor in tissue microarrays of" exact="head and neck cancer" post="Cancer Res 2006 66 2834 2843 16510606 69. Parsons"/>
   <result pre="growth factor receptor in tissue microarrays of head and neck" exact="cancer" post="Cancer Res 2006 66 2834 2843 16510606 69. Parsons"/>
   <result pre="tumour heterogeneity of the consequence of a PKC-substrate interaction in" exact="breast cancer" post="patients. Biochem Soc Trans. 2014;in press. 72. Berezin MY"/>
   <result pre="heterogeneity of the consequence of a PKC-substrate interaction in breast" exact="cancer" post="patients. Biochem Soc Trans. 2014;in press. 72. Berezin MY"/>
   <result pre="EGFR and HER3 enhances PI3K/Akt anti-tumor activity in triple negative" exact="breast cancer" post="Sci Signal 2014 7 ra29 24667376 75. Kiuchi T"/>
   <result pre="and HER3 enhances PI3K/Akt anti-tumor activity in triple negative breast" exact="cancer" post="Sci Signal 2014 7 ra29 24667376 75. Kiuchi T"/>
   <result pre="ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance" exact="cancer" post="cell motility Sci Signal 2014 7 ra78 25140053 76."/>
   <result pre="AJ et al. Differential proteomic analysis of late-stage and recurrent" exact="breast cancer" post="from formalin-fixed paraffin-embedded tissues J Proteome Res 2011 10"/>
   <result pre="et al. Differential proteomic analysis of late-stage and recurrent breast" exact="cancer" post="from formalin-fixed paraffin-embedded tissues J Proteome Res 2011 10"/>
   <result pre="Lucas DA Ringeisen BR et al. Proteomic analysis of formalin-fixed" exact="prostate cancer" post="tissue Mol Cell Proteomics 2005 4 1741 1753 16091476"/>
   <result pre="DA Ringeisen BR et al. Proteomic analysis of formalin-fixed prostate" exact="cancer" post="tissue Mol Cell Proteomics 2005 4 1741 1753 16091476"/>
   <result pre="Hood BL Flint MS Conrads TP Defining central themes in" exact="breast cancer" post="biology by differential proteomics: conserved regulation of cell spreading"/>
   <result pre="BL Flint MS Conrads TP Defining central themes in breast" exact="cancer" post="biology by differential proteomics: conserved regulation of cell spreading"/>
   <result pre="brain tumors 1 and tissue transglutaminase 2 are upregulated in" exact="pancreatic cancer" post="precursors Pancreatology 2008 8 608 616 18849643 89. DeSouza"/>
   <result pre="tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic" exact="cancer" post="precursors Pancreatology 2008 8 608 616 18849643 89. DeSouza"/>
   <result pre="HER2 status conversion in the circulating tumor cells of metastatic" exact="breast cancer" post="patients Proc Natl Acad Sci U S A 2011"/>
   <result pre="status conversion in the circulating tumor cells of metastatic breast" exact="cancer" post="patients Proc Natl Acad Sci U S A 2011"/>
   <result pre="(CISH) and FISH in the determination of HER2 status in" exact="breast cancer" post="Br J Cancer 2003 88 1587 1591 12771927 95."/>
   <result pre="and FISH in the determination of HER2 status in breast" exact="cancer" post="Br J Cancer 2003 88 1587 1591 12771927 95."/>
   <result pre="SR Bright-field in situ hybridization for HER2 gene amplification in" exact="breast cancer" post="using tissue microarrays: correlation between chromogenic (CISH) and automated"/>
   <result pre="Bright-field in situ hybridization for HER2 gene amplification in breast" exact="cancer" post="using tissue microarrays: correlation between chromogenic (CISH) and automated"/>
   <result pre="validation of an array CGH test for HER2 status in" exact="breast cancer" post="reveals that polysomy 17 is a rare event Modern"/>
   <result pre="of an array CGH test for HER2 status in breast" exact="cancer" post="reveals that polysomy 17 is a rare event Modern"/>
   <result pre="RA Ezendam C van Diest PJ HER-2/neu amplification testing in" exact="breast cancer" post="by multiplex ligation-dependent probe amplification: influence of manual- and"/>
   <result pre="Ezendam C van Diest PJ HER-2/neu amplification testing in breast" exact="cancer" post="by multiplex ligation-dependent probe amplification: influence of manual- and"/>
   <result pre="and HER2 gene amplification by multiplex ligation-dependent probe amplification in" exact="breast cancer" post="Modern Pathol 2010 23 62 70 109. Kuijpers CC"/>
   <result pre="HER2 gene amplification by multiplex ligation-dependent probe amplification in breast" exact="cancer" post="Modern Pathol 2010 23 62 70 109. Kuijpers CC"/>
   <result pre="HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive" exact="breast cancer" post="PLoS One 2013 8 e82018 24324739 110. Jackisch C"/>
   <result pre="amplification testing by multiplex ligation-dependent probe amplification in invasive breast" exact="cancer" post="PLoS One 2013 8 e82018 24324739 110. Jackisch C"/>
   <result pre="Witteveen AT Pover RC Bakx N et al. Converting a" exact="breast cancer" post="microarray signature into a high-throughput diagnostic test BMC Genomics"/>
   <result pre="AT Pover RC Bakx N et al. Converting a breast" exact="cancer" post="microarray signature into a high-throughput diagnostic test BMC Genomics"/>
   <result pre="of estrogen receptor, progesterone receptor, and HER2 receptor status in" exact="breast cancer" post="Clin Cancer Res 2009 15 7003 7011 19887485 117."/>
   <result pre="estrogen receptor, progesterone receptor, and HER2 receptor status in breast" exact="cancer" post="Clin Cancer Res 2009 15 7003 7011 19887485 117."/>
   <result pre="the best reference genes to quantify Urokinase Plasminogen Activator in" exact="breast cancer" post="BMC Res Notes 2011 4 215 21702980 118. Parker"/>
   <result pre="best reference genes to quantify Urokinase Plasminogen Activator in breast" exact="cancer" post="BMC Res Notes 2011 4 215 21702980 118. Parker"/>
   <result pre="Voduc D Vickery T et al. Supervised risk predictor of" exact="breast cancer" post="based on intrinsic subtypes J Clin Oncol 2009 27"/>
   <result pre="D Vickery T et al. Supervised risk predictor of breast" exact="cancer" post="based on intrinsic subtypes J Clin Oncol 2009 27"/>
   <result pre="with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive" exact="breast cancer" post="Clin Cancer Res 2010 16 5222 5232 20837693 120."/>
   <result pre="immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast" exact="cancer" post="Clin Cancer Res 2010 16 5222 5232 20837693 120."/>
   <result pre="recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early" exact="breast cancer" post="Clin Cancer Res 2014 20 1298 1305 24520097 122."/>
   <result pre="after endocrine therapy in postmenopausal women with endocrine-responsive early breast" exact="cancer" post="Clin Cancer Res 2014 20 1298 1305 24520097 122."/>
   <result pre="M Bago-Horvath Z et al. Predicting distant recurrence in receptor-positive" exact="breast cancer" post="patients with limited clinicopathological risk: using the PAM50 Risk"/>
   <result pre="Bago-Horvath Z et al. Predicting distant recurrence in receptor-positive breast" exact="cancer" post="patients with limited clinicopathological risk: using the PAM50 Risk"/>
   <result pre="MT Prat A Munarriz B Rowe L et al. PAM50" exact="breast cancer" post="subtyping by RT-qPCR and concordance with standard clinical molecular"/>
   <result pre="Prat A Munarriz B Rowe L et al. PAM50 breast" exact="cancer" post="subtyping by RT-qPCR and concordance with standard clinical molecular"/>
   <result pre="U Sotlar K Aydeniz B et al. Her-2/neu expression in" exact="breast cancer" post="- a comparison of different diagnostic methods Anticancer Res"/>
   <result pre="Sotlar K Aydeniz B et al. Her-2/neu expression in breast" exact="cancer" post="- a comparison of different diagnostic methods Anticancer Res"/>
   <result pre="HER2 homodimers in a clinic-based cohort of patients with metastatic" exact="breast cancer" post="BMC Cancer 2010 10 56 20178580 132. Cheng H"/>
   <result pre="homodimers in a clinic-based cohort of patients with metastatic breast" exact="cancer" post="BMC Cancer 2010 10 56 20178580 132. Cheng H"/>
   <result pre="long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic" exact="breast cancer" post="Mol Oncol 2014 8 20 26 24075779 134. Duchnowska"/>
   <result pre="benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast" exact="cancer" post="Mol Oncol 2014 8 20 26 24075779 134. Duchnowska"/>
   <result pre="protein expression and risk for brain metastases in HER-2+ advanced" exact="breast cancer" post="patients receiving trastuzumab-containing therapy Oncologist 2012 17 26 35"/>
   <result pre="expression and risk for brain metastases in HER-2+ advanced breast" exact="cancer" post="patients receiving trastuzumab-containing therapy Oncologist 2012 17 26 35"/>
   <result pre="predict outcome in fluorescence in situ hybridization-positive patients with metastatic" exact="breast cancer" post="treated with trastuzumab Cancer 2010 116 5168 5178 20661914"/>
   <result pre="outcome in fluorescence in situ hybridization-positive patients with metastatic breast" exact="cancer" post="treated with trastuzumab Cancer 2010 116 5168 5178 20661914"/>
   <result pre="the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for" exact="breast cancer" post="Br J Cancer 2010 103 1335 1342 20978512 139."/>
   <result pre="level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast" exact="cancer" post="Br J Cancer 2010 103 1335 1342 20978512 139."/>
   <result pre="and protein expression, and lapatinib efficacy in women with metastatic" exact="breast cancer" post="Clin Cancer Res 2008 14 7861 7870 19047115 141."/>
   <result pre="protein expression, and lapatinib efficacy in women with metastatic breast" exact="cancer" post="Clin Cancer Res 2008 14 7861 7870 19047115 141."/>
   <result pre="Fuchs EM et al. Identification of a subpopulation of metastatic" exact="breast cancer" post="patients with very high HER2 expression levels and possible"/>
   <result pre="EM et al. Identification of a subpopulation of metastatic breast" exact="cancer" post="patients with very high HER2 expression levels and possible"/>
   <result pre="Very high quantitative tumor HER2 content and outcome in early" exact="breast cancer" post="Ann Oncol 2011 22 2007 2013 21285132 143. Gullo"/>
   <result pre="high quantitative tumor HER2 content and outcome in early breast" exact="cancer" post="Ann Oncol 2011 22 2007 2013 21285132 143. Gullo"/>
   <result pre="of response to trastuzumab-based therapy in patients with HER2-positive metastatic" exact="breast cancer" post="Invest New Drugs 2009 27 179 183 18663410 144."/>
   <result pre="response to trastuzumab-based therapy in patients with HER2-positive metastatic breast" exact="cancer" post="Invest New Drugs 2009 27 179 183 18663410 144."/>
   <result pre="Wolmark N HER2 status and benefit from adjuvant trastuzumab in" exact="breast cancer" post="N Engl J Med 2008 358 1409 1411 18367751"/>
   <result pre="N HER2 status and benefit from adjuvant trastuzumab in breast" exact="cancer" post="N Engl J Med 2008 358 1409 1411 18367751"/>
   <result pre="NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1673 1684 16236738"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1673 1684 16236738"/>
   <result pre="their combination (T+L) in the adjuvant treatment of HER2-positive early" exact="breast cancer" post="(EBC) J Clin Oncol 2014 32 LBA2 156. Carey"/>
   <result pre="combination (T+L) in the adjuvant treatment of HER2-positive early breast" exact="cancer" post="(EBC) J Clin Oncol 2014 32 LBA2 156. Carey"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4391602/results/search/disease/results.xml">
   <result pre="of HER2 status is critical in determining appropriate therapy for" exact="breast cancer" post="patients but the best HER2 testing methodology has yet"/>
   <result pre="HER2 status is critical in determining appropriate therapy for breast" exact="cancer" post="patients but the best HER2 testing methodology has yet"/>
   <result pre="(FISH), and correlated HER2 results with overall survival (OS) of" exact="breast cancer" post="patients in a multicenter Collaborative Biomarker Study (CBS). Methods"/>
   <result pre="and correlated HER2 results with overall survival (OS) of breast" exact="cancer" post="patients in a multicenter Collaborative Biomarker Study (CBS). Methods"/>
   <result pre="Biomarker Study (CBS). Methods Two hundred and thirty-two formalin-fixed, paraffin-embedded" exact="breast cancer" post="tissues and local laboratory HER2 testing results were provided"/>
   <result pre="Study (CBS). Methods Two hundred and thirty-two formalin-fixed, paraffin-embedded breast" exact="cancer" post="tissues and local laboratory HER2 testing results were provided"/>
   <result pre="testing methodologies. While slide-based HER2 assessments on formalin-fixed, paraffin-embedded (FFPE)" exact="breast cancer" post="tissues are utilized, routine HER2 testing is subject to"/>
   <result pre="methodologies. While slide-based HER2 assessments on formalin-fixed, paraffin-embedded (FFPE) breast" exact="cancer" post="tissues are utilized, routine HER2 testing is subject to"/>
   <result pre="develop guidelines to improve the accuracy of HER2 testing in" exact="breast cancer" post="[ 7]. Recently published reports continue to show lack"/>
   <result pre="guidelines to improve the accuracy of HER2 testing in breast" exact="cancer" post="[ 7]. Recently published reports continue to show lack"/>
   <result pre="of HER2 signal intensity. A clinical study showed that when" exact="breast cancer" post="HER2 expression was measured using the HERmark assay, breast"/>
   <result pre="HER2 signal intensity. A clinical study showed that when breast" exact="cancer" post="HER2 expression was measured using the HERmark assay, breast"/>
   <result pre="breast cancer HER2 expression was measured using the HERmark assay," exact="breast cancer" post="patients with advanced disease whose tumors were HER2 positive"/>
   <result pre="cancer HER2 expression was measured using the HERmark assay, breast" exact="cancer" post="patients with advanced disease whose tumors were HER2 positive"/>
   <result pre="obtained by various HER2 methods with overall survival (OS) of" exact="breast cancer" post="patients in a multicenter Collaborative Biomarker Study (CBS) involving"/>
   <result pre="by various HER2 methods with overall survival (OS) of breast" exact="cancer" post="patients in a multicenter Collaborative Biomarker Study (CBS) involving"/>
   <result pre="who had tumor tissues from routine surgical excision of invasive" exact="breast cancer" post="between January 2000 and May 2005 from the following"/>
   <result pre="had tumor tissues from routine surgical excision of invasive breast" exact="cancer" post="between January 2000 and May 2005 from the following"/>
   <result pre="and clinical data were anonymized. A total of 232 FFPE" exact="breast cancer" post="blocks were collected by the 11 CBS study sites"/>
   <result pre="clinical data were anonymized. A total of 232 FFPE breast" exact="cancer" post="blocks were collected by the 11 CBS study sites"/>
   <result pre="(84%, 194/232) collected cases were determined to have adequate invasive" exact="breast cancer" post="tissues and yielded valid H2T results by HERmark assay."/>
   <result pre="194/232) collected cases were determined to have adequate invasive breast" exact="cancer" post="tissues and yielded valid H2T results by HERmark assay."/>
   <result pre="was defined as the time from initial diagnosis of invasive" exact="breast cancer" post="to death or censor. Estimates of survival were based"/>
   <result pre="defined as the time from initial diagnosis of invasive breast" exact="cancer" post="to death or censor. Estimates of survival were based"/>
   <result pre="who had tumor tissues from routine surgical excision of invasive" exact="breast cancer" post="between January 2000 and May 2005. HER2-targeted therapy was"/>
   <result pre="had tumor tissues from routine surgical excision of invasive breast" exact="cancer" post="between January 2000 and May 2005. HER2-targeted therapy was"/>
   <result pre="FDA approved outside of clinical trials for neoadjuvant or early-stage" exact="breast cancer" post="therapy during the study period. The median follow-up time"/>
   <result pre="approved outside of clinical trials for neoadjuvant or early-stage breast" exact="cancer" post="therapy during the study period. The median follow-up time"/>
   <result pre="purpose for identifying better responders in a clinical cohort of" exact="breast cancer" post="patients treated with anti-HER2 therapy [ 16]. The clinical"/>
   <result pre="for identifying better responders in a clinical cohort of breast" exact="cancer" post="patients treated with anti-HER2 therapy [ 16]. The clinical"/>
   <result pre="results by various HER2 testing methods with overall survival of" exact="breast cancer" post="patients from a multicenter Collaborative Biomarker Study. The quantitative"/>
   <result pre="by various HER2 testing methods with overall survival of breast" exact="cancer" post="patients from a multicenter Collaborative Biomarker Study. The quantitative"/>
   <result pre="broad continuum (approximately 3 logs) of HER2 expression levels in" exact="breast cancer" post="samples in this study. While distribution of H2T values"/>
   <result pre="continuum (approximately 3 logs) of HER2 expression levels in breast" exact="cancer" post="samples in this study. While distribution of H2T values"/>
   <result pre="data from the NSABP B31 study suggest that HER2 non-overexpressing" exact="breast cancer" post="may benefit from targeted HER2 therapy [ 21]. For"/>
   <result pre="from the NSABP B31 study suggest that HER2 non-overexpressing breast" exact="cancer" post="may benefit from targeted HER2 therapy [ 21]. For"/>
   <result pre="antibodies such as margetuximab and anti-HER2 vaccines targeting HER2 non-overexpressing" exact="breast cancer" post="patients [ 22- 24]. We evaluated HER2 status, stratified"/>
   <result pre="such as margetuximab and anti-HER2 vaccines targeting HER2 non-overexpressing breast" exact="cancer" post="patients [ 22- 24]. We evaluated HER2 status, stratified"/>
   <result pre="can be significant. Importantly, the results suggest that 10% of" exact="breast cancer" post="patients may be misclassified in routine HER2 testing as"/>
   <result pre="be significant. Importantly, the results suggest that 10% of breast" exact="cancer" post="patients may be misclassified in routine HER2 testing as"/>
   <result pre="with this scenario, HERmark may offer more accurate selection of" exact="breast cancer" post="patients for targeted HER2 therapy in a significant proportion"/>
   <result pre="this scenario, HERmark may offer more accurate selection of breast" exact="cancer" post="patients for targeted HER2 therapy in a significant proportion"/>
   <result pre="does not represent HER2 status in a general population of" exact="breast cancer" post="patients in which the expected rate of HER2 positivity"/>
   <result pre="not represent HER2 status in a general population of breast" exact="cancer" post="patients in which the expected rate of HER2 positivity"/>
   <result pre="‘real-world’ local HER2 status in a multicenter clinical cohort of" exact="breast cancer" post="patients. The HERmark assay may reclassify 10% of false-negative"/>
   <result pre="local HER2 status in a multicenter clinical cohort of breast" exact="cancer" post="patients. The HERmark assay may reclassify 10% of false-negative"/>
   <result pre="al. Studies of the HER2/neu proto-oncogene in human breast and" exact="ovarian cancer" post="Science 1989 244 707 12 10.1126/science.2470152 2470152 2. Yarden"/>
   <result pre="Studies of the HER2/neu proto-oncogene in human breast and ovarian" exact="cancer" post="Science 1989 244 707 12 10.1126/science.2470152 2470152 2. Yarden"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 43 10.1056/NEJMoa064320"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 43 10.1056/NEJMoa064320"/>
   <result pre="the treatment of human epidermal growth factor receptor 2 (HER2)-positive" exact="breast cancer" post="after prior HER2-directed therapy J Clin Oncol 2011 29"/>
   <result pre="treatment of human epidermal growth factor receptor 2 (HER2)-positive breast" exact="cancer" post="after prior HER2-directed therapy J Clin Oncol 2011 29"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="J Clin Oncol 2007 25 118 45 10.1200/JCO.2006.09.2775 17159189"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="J Clin Oncol 2007 25 118 45 10.1200/JCO.2006.09.2775 17159189"/>
   <result pre="response to neoadjuvant trastuzumab plus chemotherapy in patients with primary" exact="breast cancer" post="Breast Cancer Res 2013 15 R11 10.1186/bcr3384 23391338 13."/>
   <result pre="to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast" exact="cancer" post="Breast Cancer Res 2013 15 R11 10.1186/bcr3384 23391338 13."/>
   <result pre="assessment of HER2 in clinical trials of adjuvant therapy for" exact="breast cancer" post="(NCCTG N9831, BCIRG 006, and BCIRG 005) Breast Cancer"/>
   <result pre="of HER2 in clinical trials of adjuvant therapy for breast" exact="cancer" post="(NCCTG N9831, BCIRG 006, and BCIRG 005) Breast Cancer"/>
   <result pre="protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and" exact="breast cancer" post="tissue Diagn Mol Pathol 2009 18 11 21 10.1097/PDM.0b013e31818cbdb2"/>
   <result pre="expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast" exact="cancer" post="tissue Diagn Mol Pathol 2009 18 11 21 10.1097/PDM.0b013e31818cbdb2"/>
   <result pre="measurement of HER2 total protein and HER2 homodimers in FFPE" exact="breast cancer" post="tumor specimens Patholog Res Int 2010 28 814176 21151530"/>
   <result pre="of HER2 total protein and HER2 homodimers in FFPE breast" exact="cancer" post="tumor specimens Patholog Res Int 2010 28 814176 21151530"/>
   <result pre="predict outcome in fluorescence in situ hybridization-positive patients with metastatic" exact="breast cancer" post="treated with trastuzumab Cancer 2010 116 5168 78 10.1002/cncr.25430"/>
   <result pre="outcome in fluorescence in situ hybridization-positive patients with metastatic breast" exact="cancer" post="treated with trastuzumab Cancer 2010 116 5168 78 10.1002/cncr.25430"/>
   <result pre="Wolmark N HER2 status and benefit from adjuvant trastuzumab in" exact="breast cancer" post="N Engl J Med 2008 358 1409 11 10.1056/NEJMc0801440"/>
   <result pre="N HER2 status and benefit from adjuvant trastuzumab in breast" exact="cancer" post="N Engl J Med 2008 358 1409 11 10.1056/NEJMc0801440"/>
   <result pre="Clive KS et al. AE37: a novel T-cell-eliciting vaccine for" exact="breast cancer" post="Expert Opin Biol Ther 2011 11 1543 50 10.1517/14712598.2011.616889"/>
   <result pre="KS et al. AE37: a novel T-cell-eliciting vaccine for breast" exact="cancer" post="Expert Opin Biol Ther 2011 11 1543 50 10.1517/14712598.2011.616889"/>
   <result pre="Clinical trial results of the HER-2/neu (E75) vaccine to prevent" exact="breast cancer" post="recurrence in high-risk patients: from US military cancer institute"/>
   <result pre="trial results of the HER-2/neu (E75) vaccine to prevent breast" exact="cancer" post="recurrence in high-risk patients: from US military cancer institute"/>
   <result pre="prevent breast cancer recurrence in high-risk patients: from US military" exact="cancer" post="institute clinical trials group study I-01 and I-02 Cancer"/>
   <result pre="monoclonal antibody (mAb)] in patients with relapsed or refractory advanced" exact="breast cancer" post="whose tumors express HER2 at the 2+ level by"/>
   <result pre="antibody (mAb)] in patients with relapsed or refractory advanced breast" exact="cancer" post="whose tumors express HER2 at the 2+ level by"/>
   <result pre="potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage" exact="breast cancer" post="patients for HER2 status Cancer 2013 119 3113 22"/>
   <result pre="cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast" exact="cancer" post="patients for HER2 status Cancer 2013 119 3113 22"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4394616/results/search/disease/results.xml">
   <result pre="can respond vastly differently to chemotherapies. Data emanating from large-scale" exact="cancer" post="genomics projects such as the Cancer Genome Atlas (TCGA)"/>
   <result pre="the molecular basis of this phenomenon. The genome of every" exact="cancer" post="is essentially unique, such that even histologically identical tumors"/>
   <result pre="and feedback regulatory circuits embedded in the oncogenic pathways driving" exact="cancer" post="cell growth and survival. 3 Realizing the full potential"/>
   <result pre="a single, or at most a small number of immortalized" exact="cancer" post="cell lines to serve as prototypic experimental models of"/>
   <result pre="be considered the prototype for molecular targeted drugs. Many HER2+" exact="cancer" post="patients, however, do not respond to Herceptin, and those"/>
   <result pre="previously developed a semi-mechanistic model of ErbB signaling in HER2+" exact="cancer" post="cells, linking receptor engagement, via PI3K and MAPK pathway"/>
   <result pre="kinetics. This was, however, parameterized using data from a single" exact="breast cancer" post="cell line (BT-474), which is largely dependent on PI3K"/>
   <result pre="This was, however, parameterized using data from a single breast" exact="cancer" post="cell line (BT-474), which is largely dependent on PI3K"/>
   <result pre="to either (or both) varies widely both across and within" exact="cancer" post="indications. 29 We wished to explore whether differential dependence"/>
   <result pre="single prototypic cell line), we created two functional classes of" exact="cancer" post="cells, PI3K or MAPK pathway-dependent, by tuning a logic"/>
   <result pre="molecularly characterized cell lines, and clinical relevance using publicly available" exact="cancer" post="genomic data. Figure 1 Simulation-based strategy to identify effective"/>
   <result pre="be more widely applicable to designing treatment strategies in other" exact="cancer" post="indications. RESULTS Triple targeting of the HER2/HER3 complex is"/>
   <result pre="complex is broadly effective regardless of downstream pathway dependence Human" exact="cancer" post="cells display a diverse spectrum of dependencies on PI3K"/>
   <result pre="biomarker-response predictions experimentally using a panel of genetically characterized HER2+" exact="cancer" post="cell lines. PI3K and MAPK-activating mutations confer resistance to"/>
   <result pre="to drug treatment is unlikely. However, if drug effects are" exact="cancer" post="cell-autonomous (i.e., not dependent on microenvironment or immunologic effects)"/>
   <result pre="the general framework and approach may be expandable to other" exact="cancer" post="indications. Success largely depends on choosing appropriate and representative"/>
   <result pre="development of the combination regimens. Patients are diagnosed with HER2+" exact="cancer" post="based on the immunohistochemistry-based HercepTest and FISH-based gene amplification"/>
   <result pre="were ignored and in vivo effects simulated by constant target" exact="suppression" post="(95% inhibition of phospho-AKT, -ERK, and -HER2). Tumor growth"/>
   <result pre="Al-Lazikani B Banerji U Workman P Combinatorial drug therapy for" exact="cancer" post="in the post-genomic era Nat. Biotechnol 2012 30 679"/>
   <result pre="JM Straubinger RM Mager DE Combinatorial chemotherapeutic efficacy in non-Hodgkin" exact="lymphoma" post="can be predicted by a signaling model of CD20"/>
   <result pre="1641 22350416 Kirouac DC et al. Computational modeling of ERBB2-amplified" exact="breast cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
   <result pre="22350416 Kirouac DC et al. Computational modeling of ERBB2-amplified breast" exact="cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
   <result pre="23943608 Yarden Y Pines G The ERBB network: at last," exact="cancer" post="therapy meets systems biology Nat. Rev. Cancer 2012 12"/>
   <result pre="ERBB receptors: from oncogene discovery to basic science to mechanism-based" exact="cancer" post="therapeutics Cancer Cell 2014 25 282 303 24651011 Vu"/>
   <result pre="FX Personalized drug combinations to overcome trastuzumab resistance in HER2-positive" exact="breast cancer" post="Biochim. Biophys. Acta 2014 1846 353 365 25065528 Abramson"/>
   <result pre="Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast" exact="cancer" post="Biochim. Biophys. Acta 2014 1846 353 365 25065528 Abramson"/>
   <result pre="efficacy of single and combined PI3K- and MAPK-pathway inhibition in" exact="cancer" post="Proc. Natl. Acad. Sci. U. S. A 2009 106"/>
   <result pre="abstr 651) Gao J et al. Integrative analysis of complex" exact="cancer" post="genomics and clinical profiles using the cBioPortal Sci. Signal"/>
   <result pre="3-kinase pathway: role in tumor progression and therapeutic implications in" exact="breast cancer" post="Breast Cancer Res 2011 13 224 22114931 Chong CR"/>
   <result pre="pathway: role in tumor progression and therapeutic implications in breast" exact="cancer" post="Breast Cancer Res 2011 13 224 22114931 Chong CR"/>
   <result pre="P The quest to overcome resistance to EGFR-targeted therapies in" exact="cancer" post="Nat. Med 2013 19 1389 1400 24202392 Wilson TR"/>
   <result pre="is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant" exact="breast cancer" post="Sci. Transl. Med 2013 5 196ra99 ) Kholodenko B"/>
   <result pre="required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast" exact="cancer" post="Sci. Transl. Med 2013 5 196ra99 ) Kholodenko B"/>
   <result pre="strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced" exact="cancer" post="Clin. Cancer Res 2012 18 2316 2325 ) 22261800"/>
   <result pre="603 607 ) 22460905 Simon R Roychowdhury S Implementing personalized" exact="cancer" post="genomics in clinical trials Nat. Rev. Drug Discov 2013"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4396883/results/search/disease/results.xml">
   <result pre="476 doi: 10.1186/s12967-015-0476-2 : Research Oncogenic HER2 fusions in gastric" exact="cancer" post="Yu De-Hua yudehua@yahoo.com Tang Lili lily.tang@astrazeneca.com Dong Hua hua.dong@astrazeneca.com"/>
   <result pre="stated. Abstract Background Genetic amplification of HER2 drives tumorigenesis and" exact="cancer" post="progression in a subset of patients with gastric cancer"/>
   <result pre="and cancer progression in a subset of patients with gastric" exact="cancer" post="(GC), and treatment with trastuzumab, a humanized HER2-neutralizing antibody,"/>
   <result pre="which is available to authorized users. Keywords HER2 Fusion-gene Gastric" exact="cancer" post="Trastuzumab Lapatinib Background Gastric cancer (GC), as the second"/>
   <result pre="users. Keywords HER2 Fusion-gene Gastric cancer Trastuzumab Lapatinib Background Gastric" exact="cancer" post="(GC), as the second leading cause of cancer deaths"/>
   <result pre="Background Gastric cancer (GC), as the second leading cause of" exact="cancer" post="deaths worldwide, accounted for 989,600 new cases and 738,000"/>
   <result pre="HER2 gene amplification was initially discovered as an oncogene in" exact="breast cancer" post="(BC), which led to the development of HER2-targeted therapeutics"/>
   <result pre="gene amplification was initially discovered as an oncogene in breast" exact="cancer" post="(BC), which led to the development of HER2-targeted therapeutics"/>
   <result pre="significant. Results Novel HER2 fusion genes identified in HER2-positive gastric" exact="cancer" post="To uncover the genetic aberrations that might confer resistance"/>
   <result pre="fusion junctions. Table 1 A summary of patients with gastric" exact="cancer" post="harboring HER2 fusions Samples Country Sex Age Fusions* TNM"/>
   <result pre="sample, which naturally harbored HER2-Δ16. Surprisingly, its corresponding patient-derived gastric" exact="cancer" post="xenograft (PDGCX), which retains HER2-Δ16 (data not shown), responded"/>
   <result pre="small-molecule inhibitor against HER2 kinase is a potential option for" exact="cancer" post="patients with the HER2 fusions. This notion is further"/>
   <result pre="1. Parkin DM Bray F Ferlay J Pisani P Global" exact="cancer" post="statistics, 2002 CA Cancer J Clin 2005 55 74"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 69 90"/>
   <result pre="Grothey A Haerting J et al. Chemotherapy for advanced gastric" exact="cancer" post="The Cochrane database of systematic reviews 2010 3 CD004064"/>
   <result pre="copy number aberrations enables the identification of oncogenic drivers in" exact="hepatocellular carcinoma" post="Hepatology 2013 58 2 706 17 10.1002/hep.26402 23505090 9."/>
   <result pre="N Kitano S Suppression of tumor growth in human gastric" exact="cancer" post="with HER2 overexpression by an anti-HER2 antibody in a"/>
   <result pre="activity of trastuzumab in combination with chemotherapy in human gastric" exact="cancer" post="xenograft models Cancer Chemother Pharmacol 2007 59 795 805"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="L Zhang X et al. FGFR2 gene amplification in gastric" exact="cancer" post="predicts sensitivity to the selective FGFR inhibitor AZD4547 Clin"/>
   <result pre="Cho JY Molecular diagnosis for personalized target therapy in gastric" exact="cancer" post="Journal of gastric cancer 2013 13 129 35 10.5230/jgc.2013.13.3.129"/>
   <result pre="for personalized target therapy in gastric cancer Journal of gastric" exact="cancer" post="2013 13 129 35 10.5230/jgc.2013.13.3.129 24156032 19. Fleishman SJ"/>
   <result pre="D et al. Genetic and structural variation in the gastric" exact="cancer" post="kinome revealed through targeted deep sequencing Cancer Res 2011"/>
   <result pre="of the HER2 receptor, and response to anti-HER2 therapies in" exact="breast cancer" post="J Natl Cancer Inst 2007 99 628 38 10.1093/jnci/djk134"/>
   <result pre="the HER2 receptor, and response to anti-HER2 therapies in breast" exact="cancer" post="J Natl Cancer Inst 2007 99 628 38 10.1093/jnci/djk134"/>
   <result pre="al. An oncogenic isoform of HER2 associated with locally disseminated" exact="breast cancer" post="and trastuzumab resistance Mol Cancer Ther 2009 8 2152"/>
   <result pre="An oncogenic isoform of HER2 associated with locally disseminated breast" exact="cancer" post="and trastuzumab resistance Mol Cancer Ther 2009 8 2152"/>
   <result pre="of the RAF and mTOR kinases in malignant spindle cell" exact="neoplasm" post="harboring the KIAA1549-BRAF fusion protein J Hematol Oncol 2014"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4403678/results/search/disease/results.xml">
   <result pre="have been associated with enhanced drug efficacy and toxicity in" exact="cancer" post="therapy. SNP variations in the ErbB2 gene have been"/>
   <result pre="eligible if they had histologically or cytologically proven HER2-neu positive" exact="breast cancer" post="and more than 3 months of trastuzumab therapy. Cases"/>
   <result pre="if they had histologically or cytologically proven HER2-neu positive breast" exact="cancer" post="and more than 3 months of trastuzumab therapy. Cases"/>
   <result pre="patients in order to optimize clinical management. Keywords Her2-neu Breast" exact="cancer" post="Trastuzumab cardiotoxicity Single nucleotide polymorphisms Pro 1170 Ala polymorphism"/>
   <result pre="have been associated with enhanced drug efficacy and toxicity in" exact="cancer" post="therapy [ 1]. The monoclonal antibody trastuzumab has provided"/>
   <result pre="therapy that has dramatically improved the prognosis of 20-25% of" exact="breast cancer" post="patients whose tumor overexpresses the HER2-neu receptor [ 2]."/>
   <result pre="that has dramatically improved the prognosis of 20-25% of breast" exact="cancer" post="patients whose tumor overexpresses the HER2-neu receptor [ 2]."/>
   <result pre="decline of EF to &amp;lt;50%) and 4% developing signs of" exact="congestive heart failure" post="following treatment with trastuzumab as a single agent ["/>
   <result pre="control trials including 11,882 patients with early stage and metastatic" exact="breast cancer," post="trastuzumab therapy was associated with a 7.5% risk of"/>
   <result pre="knockout of ErbB2 in cardiac myocytes predisposes mice to dilated" exact="cardiomyopathy" post="in response to cardiac stress (including exposure to anthracyclines)"/>
   <result pre="SNPs on both outcomes and response to therapy in HER2" exact="breast cancer" post="is poorly understood [ 9]. The best studied is"/>
   <result pre="on both outcomes and response to therapy in HER2 breast" exact="cancer" post="is poorly understood [ 9]. The best studied is"/>
   <result pre="[ 11- 13]. In 1039 patients with invasive HER2 positive" exact="breast cancer," post="the Ile 655 Val polymorphism was found to be"/>
   <result pre="have been associated with a 2-fold increase in risk of" exact="breast cancer" post="[ 15]. In a recent meta-analysis of 27 case–control"/>
   <result pre="been associated with a 2-fold increase in risk of breast" exact="cancer" post="[ 15]. In a recent meta-analysis of 27 case–control"/>
   <result pre="[ 13]. In one study of 61 patients with advanced" exact="breast cancer" post="treated with trastuzumab, there was no association between the"/>
   <result pre="13]. In one study of 61 patients with advanced breast" exact="cancer" post="treated with trastuzumab, there was no association between the"/>
   <result pre="Results Clincopathologic characteristics of the patient population 140 patients with" exact="breast cancer" post="treated with trastuzumab were studied. There were 29 cases"/>
   <result pre="Clincopathologic characteristics of the patient population 140 patients with breast" exact="cancer" post="treated with trastuzumab were studied. There were 29 cases"/>
   <result pre="n (number), Tot (total). Association of Her2/neu polymorphisms with symptomatic" exact="cardiomyopathy" post="in the study population There was no association observed"/>
   <result pre="or Ala/Pro). Discussion We studied 140 women with HER2 positive" exact="breast cancer" post="treated with trastuzumab. Based upon predefined statistical considerations, we"/>
   <result pre="Ala/Pro). Discussion We studied 140 women with HER2 positive breast" exact="cancer" post="treated with trastuzumab. Based upon predefined statistical considerations, we"/>
   <result pre="have variation among the ethnically mixed population with HER2 positive" exact="breast cancer" post="in this study. For the Ile 655 Val polymorphism"/>
   <result pre="variation among the ethnically mixed population with HER2 positive breast" exact="cancer" post="in this study. For the Ile 655 Val polymorphism"/>
   <result pre="of the Ile 655 Val polymorphism with increased rates of" exact="congestive heart failure" post="[ 16], in our study the Ile 655 Val"/>
   <result pre="study the Ile 655 Val polymorphism was not associated with" exact="congestive heart failure." post="This difference may be due to the larger sample"/>
   <result pre="has been less well studied. In the only study evaluating" exact="breast cancer" post="and the Pro1170 Ala polymorphism that we could find,"/>
   <result pre="been less well studied. In the only study evaluating breast" exact="cancer" post="and the Pro1170 Ala polymorphism that we could find,"/>
   <result pre="that the Pro1170 Ala polymorphism did not correlate with increased" exact="breast cancer" post="risk [ 14]. Amino acid codon 1170 is located"/>
   <result pre="the Pro1170 Ala polymorphism did not correlate with increased breast" exact="cancer" post="risk [ 14]. Amino acid codon 1170 is located"/>
   <result pre="2.6-fold increased risk of cardiotoxicity in patients with HER2-neu positive" exact="breast cancer" post="treated with trastuzumab. This result suggests that Her2/neu single"/>
   <result pre="increased risk of cardiotoxicity in patients with HER2-neu positive breast" exact="cancer" post="treated with trastuzumab. This result suggests that Her2/neu single"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="Y et al. Risk of cardiac dysfunction with trastuzumab in" exact="breast cancer" post="patients: a meta-analysis Cancer Treat Rev 2011 37 4"/>
   <result pre="et al. Risk of cardiac dysfunction with trastuzumab in breast" exact="cancer" post="patients: a meta-analysis Cancer Treat Rev 2011 37 4"/>
   <result pre="et al. ErbB2 is essential in the prevention of dilated" exact="cardiomyopathy" post="Nat Med 2002 8 5 459 465 10.1038/nm0502-459 11984589"/>
   <result pre="of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated" exact="cardiomyopathy" post="Proc Natl Acad Sci U S A 2002 99"/>
   <result pre="et al. Predicting and preventing cardiotoxicity in the era of" exact="breast cancer" post="targeted therapies. Novel molecular tools for clinical issues Breast"/>
   <result pre="al. Predicting and preventing cardiotoxicity in the era of breast" exact="cancer" post="targeted therapies. Novel molecular tools for clinical issues Breast"/>
   <result pre="MR et al. The HER2 I655V polymorphism and risk of" exact="breast cancer" post="in women &amp;lt; age 40 years Cancer Epidemiol Biomarkers Prev 2003"/>
   <result pre="et al. The HER2 I655V polymorphism and risk of breast" exact="cancer" post="in women &amp;lt; age 40 years Cancer Epidemiol Biomarkers Prev 2003"/>
   <result pre="N Wacholder S Struewing J The HER2 I655V polymorphism and" exact="breast cancer" post="risk in Ashkenazim Epidemiology 2003 14 6 694 700"/>
   <result pre="Wacholder S Struewing J The HER2 I655V polymorphism and breast" exact="cancer" post="risk in Ashkenazim Epidemiology 2003 14 6 694 700"/>
   <result pre="polymorphism and response to trastuzumab in women with operable primary" exact="breast cancer" post="Ann Oncol 2014 25 6 1158 64 10.1093/annonc/mdu111 24608202"/>
   <result pre="and response to trastuzumab in women with operable primary breast" exact="cancer" post="Ann Oncol 2014 25 6 1158 64 10.1093/annonc/mdu111 24608202"/>
   <result pre="al. A haplotype analysis of HER-2 gene polymorphisms: association with" exact="breast cancer" post="risk, HER-2 protein expression in the tumor, and disease"/>
   <result pre="A haplotype analysis of HER-2 gene polymorphisms: association with breast" exact="cancer" post="risk, HER-2 protein expression in the tumor, and disease"/>
   <result pre="et al. Population-based, case–control study of HER2 genetic polymorphism and" exact="breast cancer" post="risk J Natl Cancer Inst 2000 92 5 412"/>
   <result pre="al. Population-based, case–control study of HER2 genetic polymorphism and breast" exact="cancer" post="risk J Natl Cancer Inst 2000 92 5 412"/>
   <result pre="Z Liu H Hao X HER2 Ile655Val polymorphism contributes to" exact="breast cancer" post="risk: evidence from 27 case–control studies Breast Cancer Res"/>
   <result pre="Liu H Hao X HER2 Ile655Val polymorphism contributes to breast" exact="cancer" post="risk: evidence from 27 case–control studies Breast Cancer Res"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4404037/results/search/disease/results.xml">
   <result pre="prediction refinement to personalize the treatment of patients with early" exact="breast cancer" post="Esposito Angela Criscitiello Carmen Curigliano Giuseppe [], Correspondence to:"/>
   <result pre="refinement to personalize the treatment of patients with early breast" exact="cancer" post="Esposito Angela Criscitiello Carmen Curigliano Giuseppe [], Correspondence to:"/>
   <result pre="and the prediction of response to multidisciplinary treatment for early" exact="breast cancer" post="has been the major theme of the 14 th"/>
   <result pre="the prediction of response to multidisciplinary treatment for early breast" exact="cancer" post="has been the major theme of the 14 th"/>
   <result pre="the world’s most experienced opinion leaders in the field of" exact="breast cancer" post="treatment. The panelist addressed the &quot;semantic&quot; classification of breast"/>
   <result pre="world’s most experienced opinion leaders in the field of breast" exact="cancer" post="treatment. The panelist addressed the &quot;semantic&quot; classification of breast"/>
   <result pre="breast cancer treatment. The panelist addressed the &quot;semantic&quot; classification of" exact="breast cancer" post="subtypes by pathology-based biomarkers (e.g. estrogen receptor, progesterone receptor"/>
   <result pre="cancer treatment. The panelist addressed the &quot;semantic&quot; classification of breast" exact="cancer" post="subtypes by pathology-based biomarkers (e.g. estrogen receptor, progesterone receptor"/>
   <result pre="pathologic variables in predicting the outcome of patients with early" exact="breast cancer" post="in terms of early and late relapse. Finally they"/>
   <result pre="variables in predicting the outcome of patients with early breast" exact="cancer" post="in terms of early and late relapse. Finally they"/>
   <result pre="chemotherapy and for personalizing local treatment of patients with early" exact="breast cancer." post="The vast majority of the questions asked during the"/>
   <result pre="subgroups. What St Gallen can provide is clinically useful updated" exact="breast cancer" post="treatment consensus for the majority of patients treated outside"/>
   <result pre="What St Gallen can provide is clinically useful updated breast" exact="cancer" post="treatment consensus for the majority of patients treated outside"/>
   <result pre="in most countries. 14th St Gallen Consensus Conference 2015 early" exact="breast cancer" post="Conference Report The primary aim of the 2015 St"/>
   <result pre="most countries. 14th St Gallen Consensus Conference 2015 early breast" exact="cancer" post="Conference Report The primary aim of the 2015 St"/>
   <result pre="personalizing the approach to the treatment of women with early" exact="breast cancer." post="Major issues that have been highlighted included: 1) Clinical"/>
   <result pre="this outstanding meeting. News since St Gallen 2013 Surgery of" exact="breast cancer" post="Dr Monica Morrow from New York, USA, opened the"/>
   <result pre="outstanding meeting. News since St Gallen 2013 Surgery of breast" exact="cancer" post="Dr Monica Morrow from New York, USA, opened the"/>
   <result pre="outstanding and comprehensive talk on the surgical management of early" exact="breast cancer." post="She stated that it is increasingly clear that local"/>
   <result pre="mortality in women with hormone receptor (HR) positive early stage" exact="breast cancer." post="These patients have ongoing recurrences over many years at"/>
   <result pre="recurrence. ET induces side effects such as hot flashes and" exact="sexual dysfunction" post="that will impact on quality of life. Accurate assessment"/>
   <result pre="assays have &quot;clinical validity&quot; for selecting women with ER positive" exact="breast cancer" post="who might be spared extended ET. Treatment of pre-menopausal"/>
   <result pre="have &quot;clinical validity&quot; for selecting women with ER positive breast" exact="cancer" post="who might be spared extended ET. Treatment of pre-menopausal"/>
   <result pre="SOFT and TEXT trials, dedicated to pre-menopausal women with HR+" exact="breast cancer," post="were developed to determine the role of ovarian function"/>
   <result pre="cancer, were developed to determine the role of ovarian function" exact="suppression" post="(OFS) in women who remain pre-menopausal and are treated"/>
   <result pre="considered in pre-menopausal patients with endocrine responsive tumors. In fact," exact="breast cancer" post="in pre-menopausal patients includes heterogeneous groups of tumors and"/>
   <result pre="in pre-menopausal patients with endocrine responsive tumors. In fact, breast" exact="cancer" post="in pre-menopausal patients includes heterogeneous groups of tumors and"/>
   <result pre="medicine. A distinguishing feature of medical oncology in general, and" exact="breast cancer" post="treatment in particular, has been a longstanding reliance on,"/>
   <result pre="A distinguishing feature of medical oncology in general, and breast" exact="cancer" post="treatment in particular, has been a longstanding reliance on,"/>
   <result pre="subsets. Changes in our understanding of the molecular biology of" exact="cancer" post="will challenge our historical approach. Breast cancer is not"/>
   <result pre="molecular biology of cancer will challenge our historical approach. Breast" exact="cancer" post="is not a single disease and molecular segmentation deriving"/>
   <result pre="Breast Cancer Three sessions were dedicated to the biology of" exact="breast cancer." post="The major topics addressed were role of genetic assay"/>
   <result pre="The major topics addressed were role of genetic assay in" exact="breast cancer" post="classification and treatment, tumor heterogeneity and role of immune"/>
   <result pre="major topics addressed were role of genetic assay in breast" exact="cancer" post="classification and treatment, tumor heterogeneity and role of immune"/>
   <result pre="profiling has had a considerable impact on our understanding of" exact="breast cancer" post="biology. During the last 15 years (yrs), 5 intrinsic"/>
   <result pre="has had a considerable impact on our understanding of breast" exact="cancer" post="biology. During the last 15 years (yrs), 5 intrinsic"/>
   <result pre="the last 15 years (yrs), 5 intrinsic molecular subtypes of" exact="breast cancer" post="(Luminal A, Luminal B, HER2-enriched, Basal-like and Claudin-low) and"/>
   <result pre="last 15 years (yrs), 5 intrinsic molecular subtypes of breast" exact="cancer" post="(Luminal A, Luminal B, HER2-enriched, Basal-like and Claudin-low) and"/>
   <result pre="intensively studied [ 7]. Within hormone receptor (HR)-positive and HER2-negative" exact="breast cancer," post="the Luminal A and B subtypes represent the vast"/>
   <result pre="Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast" exact="cancer" post="International Consortium (METABRIC) have dramatically increased our understanding of"/>
   <result pre="led to a continuous refinement of the molecular classification of" exact="breast cancer" post="with prognostic implications. The molecular stratification of Luminal A"/>
   <result pre="to a continuous refinement of the molecular classification of breast" exact="cancer" post="with prognostic implications. The molecular stratification of Luminal A"/>
   <result pre="much this more comprehensive understanding of the molecular heterogeneity of" exact="breast cancer" post="will affect the process of clinical decision making in"/>
   <result pre="this more comprehensive understanding of the molecular heterogeneity of breast" exact="cancer" post="will affect the process of clinical decision making in"/>
   <result pre="is considered to be one of the enabling characteristics of" exact="cancer" post="development. Chronic inflammatory disease increases the risk of some"/>
   <result pre="While there is exciting potential for targeting inflammatory pathways in" exact="cancer" post="prevention, targeting cancer-related inflammation and innate immunity in patients"/>
   <result pre="targeting cancer-related inflammation and innate immunity in patients with advanced" exact="cancer" post="has not yet proven as promising an approach as"/>
   <result pre="immune system. A fundamental &quot;dogma&quot; of tumor immunology and of" exact="cancer" post="immunosurveillance in particular is that cancer cells express antigens"/>
   <result pre="tumor immunology and of cancer immunosurveillance in particular is that" exact="cancer" post="cells express antigens that differentiate them from their non-transformed"/>
   <result pre="which their outgrowth is no longer blocked by immunity. Is" exact="breast cancer" post="immunogenic? Many observations demonstrated the prognostic role of TILs"/>
   <result pre="their outgrowth is no longer blocked by immunity. Is breast" exact="cancer" post="immunogenic? Many observations demonstrated the prognostic role of TILs"/>
   <result pre="the prognostic role of TILs in TNBC and HER2 positive" exact="breast cancer." post="TNBC are poorly differentiated tumors with high genetic instability"/>
   <result pre="whether TILs are prognostic or predictive in HER2+ and TN" exact="breast cancer" post="is needed, preferably in a large population set with"/>
   <result pre="TILs are prognostic or predictive in HER2+ and TN breast" exact="cancer" post="is needed, preferably in a large population set with"/>
   <result pre="be essential to incorporate an ‘immunoscore’ into traditional classification of" exact="breast cancer," post="thus providing an essential prognostic and potentially predictive tool"/>
   <result pre="report. Fourth, implement clinical trials for TN and HER2 positive" exact="breast cancer" post="in the metastatic setting with drugs that target immune-cell-intrinsic"/>
   <result pre="Fourth, implement clinical trials for TN and HER2 positive breast" exact="cancer" post="in the metastatic setting with drugs that target immune-cell-intrinsic"/>
   <result pre="activity of an immune-modulation approach in the treatment of a" exact="breast cancer." post="We need also to better assess the role of"/>
   <result pre="TILs in DCIS and to better explore the relationship between" exact="autoimmune disease" post="and cancer. The immune system remembers what it targets,"/>
   <result pre="a durable tumor response [ 10]. Emerging &quot;drugable&quot; pathways in" exact="breast cancer" post="Dr Finn R.S. discussed about the CDK 4-6 pathway."/>
   <result pre="durable tumor response [ 10]. Emerging &quot;drugable&quot; pathways in breast" exact="cancer" post="Dr Finn R.S. discussed about the CDK 4-6 pathway."/>
   <result pre="in combination with letrozole in the treatment of advanced ER+" exact="breast cancer" post="[ 11]. The PALOMA-1/TRIO 18 study represents a global"/>
   <result pre="combination with letrozole in the treatment of advanced ER+ breast" exact="cancer" post="[ 11]. The PALOMA-1/TRIO 18 study represents a global"/>
   <result pre="side effect profile with the most common adverse events being" exact="neutropenia" post="and fatigue. Based on these data, palbociclib was designated"/>
   <result pre="repair competency between and within the reported biological groups of" exact="breast cancer." post="It has long been recognised that there is an"/>
   <result pre="recognised that there is an association between familial predisposition to" exact="breast cancer" post="and the Triple Negative Breast Cancer (TNBC). This is"/>
   <result pre="that there is an association between familial predisposition to breast" exact="cancer" post="and the Triple Negative Breast Cancer (TNBC). This is"/>
   <result pre="reviewed the biological mechanisms relevant to these approaches within specific" exact="breast cancer" post="types and discussed some emerging companion diagnostic approaches that"/>
   <result pre="the biological mechanisms relevant to these approaches within specific breast" exact="cancer" post="types and discussed some emerging companion diagnostic approaches that"/>
   <result pre="PI3K/AKT/mTOR pathway as a key mediator of oncogenic signaling in" exact="breast cancer." post="PIK3CA, the gene encoding for p110α, is frequently mutated"/>
   <result pre="are found in over a third of estrogen receptor (ER)-positive" exact="breast cancer," post="representing the most common genomic alteration in this group"/>
   <result pre="the PI3K/AKT/mTOR signaling is, therefore, an attractive clinical strategy for" exact="breast cancer." post="More recently, PI3Kα specific inhibitors have shown remarkable clinical"/>
   <result pre="a fruitful approach in the treatment of patients with advanced" exact="breast cancer" post="and it is likely that determining the presence of"/>
   <result pre="fruitful approach in the treatment of patients with advanced breast" exact="cancer" post="and it is likely that determining the presence of"/>
   <result pre="is likely that determining the presence of PI3Kα mutations in" exact="breast cancer" post="will become useful in the daily clinical practice. Dr"/>
   <result pre="likely that determining the presence of PI3Kα mutations in breast" exact="cancer" post="will become useful in the daily clinical practice. Dr"/>
   <result pre="Growth Factor Receptors can be activated by diverse mechanisms in" exact="breast cancer," post="including amplification of FGFR1 and FGFR2, rare activating mutations"/>
   <result pre="10% of ER positive cancer, enriched in luminal B type" exact="breast cancer," post="with FGFR1 amplification associating with increased risk of relapse."/>
   <result pre="of activity for small molecule FGFR inhibitors in FGFR1 amplified" exact="breast cancer" post="[ 14, 15]. Pathology of breast cancer in 2015"/>
   <result pre="activity for small molecule FGFR inhibitors in FGFR1 amplified breast" exact="cancer" post="[ 14, 15]. Pathology of breast cancer in 2015"/>
   <result pre="in FGFR1 amplified breast cancer [ 14, 15]. Pathology of" exact="breast cancer" post="in 2015 In this session, Dr C. Denkert presented"/>
   <result pre="FGFR1 amplified breast cancer [ 14, 15]. Pathology of breast" exact="cancer" post="in 2015 In this session, Dr C. Denkert presented"/>
   <result pre="The proliferation marker Ki67 has been suggested as a promising" exact="breast cancer" post="biomarker, but the best cutpoints and the best methods"/>
   <result pre="proliferation marker Ki67 has been suggested as a promising breast" exact="cancer" post="biomarker, but the best cutpoints and the best methods"/>
   <result pre="rate in different types of tumors. Primary systemic therapy of" exact="breast cancer" post="Neoadjuvant chemotherapy Primary systemic therapy is a standard option"/>
   <result pre="in different types of tumors. Primary systemic therapy of breast" exact="cancer" post="Neoadjuvant chemotherapy Primary systemic therapy is a standard option"/>
   <result pre="is a standard option for treating patients with early stage" exact="breast cancer." post="Patients achieving a pathological complete response (pCR) have a"/>
   <result pre="PARP-inhibitors irrespective of the gene BRCA status. Whereas in HER2+" exact="breast cancer" post="the pCR could be increased to over 70% by"/>
   <result pre="irrespective of the gene BRCA status. Whereas in HER2+ breast" exact="cancer" post="the pCR could be increased to over 70% by"/>
   <result pre="match their relative impact on recurrence [ 20]. Radiotherapy in" exact="breast cancer" post="Dr John Yarnold, Dr Timothy Whelan, and Dr Ian"/>
   <result pre="their relative impact on recurrence [ 20]. Radiotherapy in breast" exact="cancer" post="Dr John Yarnold, Dr Timothy Whelan, and Dr Ian"/>
   <result pre="Kunkler addressed the special topic of radiation therapy in early" exact="breast cancer." post="The effectiveness of curative radiotherapy (RT) is enhanced by"/>
   <result pre="over the last 20 years providing high level evidence that" exact="breast cancer" post="is, against earlier assumptions, equally sensitive to fraction size"/>
   <result pre="the last 20 years providing high level evidence that breast" exact="cancer" post="is, against earlier assumptions, equally sensitive to fraction size"/>
   <result pre="DNA damage signalling and repair that are typical of human" exact="cancer" post="[ 21, 22]. Adjuvant systemic therapy Endocrine therapy in"/>
   <result pre="in her lecture the topic of endocrine therapy in premenopausal" exact="breast cancer" post="women. Multiple strategies for endocrine treatment of premenopausal women"/>
   <result pre="her lecture the topic of endocrine therapy in premenopausal breast" exact="cancer" post="women. Multiple strategies for endocrine treatment of premenopausal women"/>
   <result pre="strategies for endocrine treatment of premenopausal women with ER positive" exact="breast cancer" post="have been assessed and results have been presented over"/>
   <result pre="for endocrine treatment of premenopausal women with ER positive breast" exact="cancer" post="have been assessed and results have been presented over"/>
   <result pre="tamoxifen [ 7]. Given the long natural history of endocrine-responsive" exact="breast cancer," post="longer follow-up of all trials will be critical to"/>
   <result pre="of the adjuvant regimen for most premenopausal women with hormone-responsive" exact="breast cancer" post="and a subset of these women with luminal A-type"/>
   <result pre="the adjuvant regimen for most premenopausal women with hormone-responsive breast" exact="cancer" post="and a subset of these women with luminal A-type"/>
   <result pre="flashes and night sweats. Tamoxifen contributes to rare risks of" exact="uterine cancer" post="and thromboembolism. AIs cause accelerated osteoporosis and bone fracture,"/>
   <result pre="and night sweats. Tamoxifen contributes to rare risks of uterine" exact="cancer" post="and thromboembolism. AIs cause accelerated osteoporosis and bone fracture,"/>
   <result pre="rare risks of uterine cancer and thromboembolism. AIs cause accelerated" exact="osteoporosis" post="and bone fracture, a musculoskeletal syndrome associated with achiness"/>
   <result pre="associated with achiness and stiffness, and vaginal atrophy with associated" exact="sexual dysfunction." post="In comparison to 5 years of tamoxifen monotherapy, the"/>
   <result pre="therapy after 2–3 years of tamoxifen, lowers the risk of" exact="cancer" post="recurrence. Patient preferences factoring in side effect profiles and"/>
   <result pre="suggest emerging toxicity concerns. Predictors of recurrence in ER positive" exact="breast cancer" post="include tumor and nodal stage at presentation, tumor grade,"/>
   <result pre="emerging toxicity concerns. Predictors of recurrence in ER positive breast" exact="cancer" post="include tumor and nodal stage at presentation, tumor grade,"/>
   <result pre="recurrence with use of endocrine treatment. Adjuvant chemotherapy in early" exact="breast cancer" post="Triple negative breast cancer De Eric Winer presented an"/>
   <result pre="with use of endocrine treatment. Adjuvant chemotherapy in early breast" exact="cancer" post="Triple negative breast cancer De Eric Winer presented an"/>
   <result pre="endocrine treatment. Adjuvant chemotherapy in early breast cancer Triple negative" exact="breast cancer" post="De Eric Winer presented an overview on the treatment"/>
   <result pre="treatment. Adjuvant chemotherapy in early breast cancer Triple negative breast" exact="cancer" post="De Eric Winer presented an overview on the treatment"/>
   <result pre="presented an overview on the treatment of triple negative early" exact="breast cancer." post="Triple negative breast cancer accounts for approximately 10–15% of"/>
   <result pre="the treatment of triple negative early breast cancer. Triple negative" exact="breast cancer" post="accounts for approximately 10–15% of all breast cancer and"/>
   <result pre="treatment of triple negative early breast cancer. Triple negative breast" exact="cancer" post="accounts for approximately 10–15% of all breast cancer and"/>
   <result pre="Triple negative breast cancer accounts for approximately 10–15% of all" exact="breast cancer" post="and may be responsible for a higher proportion of"/>
   <result pre="negative breast cancer accounts for approximately 10–15% of all breast" exact="cancer" post="and may be responsible for a higher proportion of"/>
   <result pre="chemotherapy, triple negative disease accounts for a disproportionate share of" exact="breast cancer" post="mortality. Some triple negative cancers are exquisitely sensitive to"/>
   <result pre="triple negative disease accounts for a disproportionate share of breast" exact="cancer" post="mortality. Some triple negative cancers are exquisitely sensitive to"/>
   <result pre="At present, we cannot use investigational classifications of triple negative" exact="breast cancer" post="to determine appropriate systemic therapy. These approaches are in"/>
   <result pre="present, we cannot use investigational classifications of triple negative breast" exact="cancer" post="to determine appropriate systemic therapy. These approaches are in"/>
   <result pre="before utilizing these approaches outside of clinical trials. HER2 positive" exact="breast cancer" post="Dr Martine Piccart-Gebhart addressed the HER2 positive disease. Recently,"/>
   <result pre="utilizing these approaches outside of clinical trials. HER2 positive breast" exact="cancer" post="Dr Martine Piccart-Gebhart addressed the HER2 positive disease. Recently,"/>
   <result pre="trastuzumab-DM1, an antibody-drug conjugate, delivering potent cytotoxic chemotherapy to HER2-overexpressing" exact="cancer" post="cells, while retaining the biologic actions of trastuzumab; and"/>
   <result pre="further advance the field of treatment of patients with HER2-positive" exact="breast cancer." post="Treatment of special patient populations Very young patients Dr"/>
   <result pre="Partridge focused on the treatment of very young patients. Breast" exact="cancer" post="is the leading cause of cancer-related deaths in women"/>
   <result pre="and although generally improving, survival rates for young women with" exact="breast cancer" post="remain lower than for older women. Young women are"/>
   <result pre="although generally improving, survival rates for young women with breast" exact="cancer" post="remain lower than for older women. Young women are"/>
   <result pre="women are more likely to develop more aggressive subtypes of" exact="breast cancer" post="(more triple negative and HER2-positive disease) and present with"/>
   <result pre="are more likely to develop more aggressive subtypes of breast" exact="cancer" post="(more triple negative and HER2-positive disease) and present with"/>
   <result pre="subtypes. Recent preliminary evidence suggests potential unique biologic features of" exact="breast cancer" post="that occurs in young women although this has yet"/>
   <result pre="Recent preliminary evidence suggests potential unique biologic features of breast" exact="cancer" post="that occurs in young women although this has yet"/>
   <result pre="There are clearly host differences that affect the management of" exact="breast cancer" post="for young patients including generally being very premenopausal at"/>
   <result pre="are clearly host differences that affect the management of breast" exact="cancer" post="for young patients including generally being very premenopausal at"/>
   <result pre="Smith focused on treatment of elderly patients. The incidence of" exact="breast cancer" post="continues to rise, particularly in the elderly. The median"/>
   <result pre="focused on treatment of elderly patients. The incidence of breast" exact="cancer" post="continues to rise, particularly in the elderly. The median"/>
   <result pre="and Charlston index are available to assess prognosis independent of" exact="cancer" post="and fitness for treatment. In contrast to surgery and"/>
   <result pre="subgroups. What St Gallen can provide is clinically useful updated" exact="breast cancer" post="treatment consensus for the majority of patients treated outside"/>
   <result pre="What St Gallen can provide is clinically useful updated breast" exact="cancer" post="treatment consensus for the majority of patients treated outside"/>
   <result pre="of the ACOSOG Z0011 criteria in women with high-risk node-positive" exact="breast cancer" post="undergoing breast conserving surgery Ann Surg Oncol 2015 22"/>
   <result pre="the ACOSOG Z0011 criteria in women with high-risk node-positive breast" exact="cancer" post="undergoing breast conserving surgery Ann Surg Oncol 2015 22"/>
   <result pre="surgery of the axilla after a positive sentinel node in" exact="breast cancer" post="(EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3"/>
   <result pre="of the axilla after a positive sentinel node in breast" exact="cancer" post="(EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3"/>
   <result pre="surgery with whole-breast irradiation in stages I and II invasive" exact="breast cancer" post="J Clin Oncol 2014 32 1507 1515 24516019 4."/>
   <result pre="with whole-breast irradiation in stages I and II invasive breast" exact="cancer" post="J Clin Oncol 2014 32 1507 1515 24516019 4."/>
   <result pre="23816962 5. Pagani O et al. Adjuvant exemestane with ovarian" exact="suppression" post="in premenopausal breast cancer N Engl J Med 2014"/>
   <result pre="O et al. Adjuvant exemestane with ovarian suppression in premenopausal" exact="breast cancer" post="N Engl J Med 2014 371 107 118 24881463"/>
   <result pre="et al. Adjuvant exemestane with ovarian suppression in premenopausal breast" exact="cancer" post="N Engl J Med 2014 371 107 118 24881463"/>
   <result pre="107 118 24881463 6. Francis PA et al. Adjuvant ovarian" exact="suppression" post="in premenopausal breast cancer N Engl J Med 2015"/>
   <result pre="6. Francis PA et al. Adjuvant ovarian suppression in premenopausal" exact="breast cancer" post="N Engl J Med 2015 372 436 446 25495490"/>
   <result pre="Francis PA et al. Adjuvant ovarian suppression in premenopausal breast" exact="cancer" post="N Engl J Med 2015 372 436 446 25495490"/>
   <result pre="98 10869 10874 11553815 8. Bastien RR et al. PAM50" exact="breast cancer" post="subtyping by RT-qPCR and concordance with standard clinical molecular"/>
   <result pre="10869 10874 11553815 8. Bastien RR et al. PAM50 breast" exact="cancer" post="subtyping by RT-qPCR and concordance with standard clinical molecular"/>
   <result pre="letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced" exact="breast cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2015"/>
   <result pre="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast" exact="cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2015"/>
   <result pre="A The triple-negative subtype: new ideas for the poorest prognosis" exact="breast cancer" post="J Natl Cancer Inst Monogr 2011 2011 108 110"/>
   <result pre="The triple-negative subtype: new ideas for the poorest prognosis breast" exact="cancer" post="J Natl Cancer Inst Monogr 2011 2011 108 110"/>
   <result pre="Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in" exact="breast cancer" post="Clin Cancer Res 2013 19 3693 3702 23658459 15."/>
   <result pre="FGFR with dovitinib (TKI258): preclinical and clinical data in breast" exact="cancer" post="Clin Cancer Res 2013 19 3693 3702 23658459 15."/>
   <result pre="al. Ki67 levels as predictive and prognostic parameters in pretherapeutic" exact="breast cancer" post="core biopsies: a translational investigation in the neoadjuvant GeparTrio"/>
   <result pre="Ki67 levels as predictive and prognostic parameters in pretherapeutic breast" exact="cancer" post="core biopsies: a translational investigation in the neoadjuvant GeparTrio"/>
   <result pre="epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing" exact="breast cancer" post="J Clin Oncol 2014 32 3212 3220 25199759 19."/>
   <result pre="growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast" exact="cancer" post="J Clin Oncol 2014 32 3212 3220 25199759 19."/>
   <result pre="TJ et al. Long-term results of hypofractionated radiation therapy for" exact="breast cancer" post="N Engl J Med 2010 362 513 520 20147717"/>
   <result pre="et al. Long-term results of hypofractionated radiation therapy for breast" exact="cancer" post="N Engl J Med 2010 362 513 520 20147717"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4405013/results/search/disease/results.xml">
   <result pre="therapies provided a new interesting weapon to treat advanced gastric" exact="cancer" post="through anti-human epidermal growth factor receptor 2 (HER-2) therapies."/>
   <result pre="treatment of peptic ulcers and gastric mucosa-associated lymphoid tissue (MALT)" exact="lymphoma" post="as well as prevention of gastric cancer [ 1–"/>
   <result pre="lymphoid tissue (MALT) lymphoma as well as prevention of gastric" exact="cancer" post="[ 1– 3]. A randomized controlled trial (RCT) in"/>
   <result pre="papers, H. pylori eradication significantly reduces the prevalence of gastric" exact="cancer" post="by approximately one-third [ 4]. A recent meta-analysis of"/>
   <result pre="also shows that H. pylori eradication seems to reduce gastric" exact="cancer" post="risk [relative risk (RR): 0.65, 95% confidence interval (CI):"/>
   <result pre="indicating its possible involvement in gastric carcinogenesis [ 7]. Gastric" exact="cancer" post="arises from multiple genetic and epigenetic alterations in oncogenes,"/>
   <result pre="therapies provided a new interesting weapon to treat advanced gastric" exact="cancer" post="through anti-human epidermal growth factor receptor 2 (HER-2) therapies."/>
   <result pre="(CD44v), which is a cell-surface marker, that is associated with" exact="cancer" post="stem-like cells, interacts with a glutamate-cystine transporter and controls"/>
   <result pre="the intracellular level of reduced glutathione (GSH) [ 10]. Human" exact="gastrointestinal cancer" post="cells with a high level of CD44 expression revealed"/>
   <result pre="intracellular level of reduced glutathione (GSH) [ 10]. Human gastrointestinal" exact="cancer" post="cells with a high level of CD44 expression revealed"/>
   <result pre="glutathione synthesis and defense against ROS. These findings indicate that" exact="cancer" post="stem-like cells with CD44v expression could have an ROS"/>
   <result pre="risk of both intestinal and diffuse types of noncardia gastric" exact="cancer" post="[ 12]. The CagA protein of H. pylori, which"/>
   <result pre="strains dominate in countries with the highest rates of gastric" exact="cancer" post="[ 15]. On the other hand, CagA interacts with"/>
   <result pre="and short-lived. However, CagA, that is translocated into CD44v9-positive gastric" exact="cancer" post="stem-like cells, which are characterized by ROS resistance that"/>
   <result pre="tumors as well as gastric mucosal tissues with H. pylori-induced" exact="gastritis" post="were predominantly C : G &amp;gt; T :  A transitions in GpCpX"/>
   <result pre="be mutated (codon-12) in intestinal-type cancer, but not in diffuse-type" exact="cancer" post="[ 21]. K-RAS gene mutations in H. pylori-associated chronic"/>
   <result pre="cancer [ 21]. K-RAS gene mutations in H. pylori-associated chronic" exact="gastritis" post="are more frequent in gastric cancer patients than in"/>
   <result pre="in H. pylori-associated chronic gastritis are more frequent in gastric" exact="cancer" post="patients than in cancer-free patients, suggesting that K-RAS mutation"/>
   <result pre="not improve progression free survival in patients with advanced gastric" exact="cancer" post="[ 24]. Similarly, in phase III REAL-3 trial, the"/>
   <result pre="to the best supportive care in patients with advanced gastric" exact="cancer" post="that progressed after initial chemotherapy. In this study, median"/>
   <result pre="human genome, is frequently inactivated in the tissue of gastric" exact="cancer" post="as well as in preneoplastic lesions, by loss of"/>
   <result pre="The mutations of p53 have also been identified in gastric" exact="adenoma" post="and intestinal metaplasia. We have recently reported that p53"/>
   <result pre="APC mutations are the second most frequent mutations in gastric" exact="cancer" post="and have been observed in 30–40% of intestinal type"/>
   <result pre="cancer and have been observed in 30–40% of intestinal type" exact="cancer" post="and in less than 2% of diffuse type cancer"/>
   <result pre="type cancer and in less than 2% of diffuse type" exact="cancer" post="[ 29]. The mutations of APC have also been"/>
   <result pre="The mutations of APC have also been identified in gastric" exact="adenoma" post="and intestinal metaplasia, indicating that they occur during preneoplastic"/>
   <result pre="metaplasia, indicating that they occur during preneoplastic stage of gastric" exact="cancer" post="development. LOH and mutations of phosphatase and tensin homolog"/>
   <result pre="TSLC1, are known to be silenced by hypermethylation in gastric" exact="cancer" post="[ 31] ( Figure 3). Recent meta-analysis revealed that"/>
   <result pre="revealed that the frequencies of p16 promoter methylation in gastric" exact="cancer" post="tissue were higher than those of normal and adjacent"/>
   <result pre="of gastric cancer. Nanjo et al. identified seven novel gastric" exact="cancer" post="risk markers that reflect epigenomic damage, that is induced"/>
   <result pre="gerbil model [ 36]. Removal of induced DNA methylation and/or" exact="suppression" post="of DNA methylation induction could become a target for"/>
   <result pre="factor (VEGF) have been described in patients with advanced gastric" exact="cancer" post="and correlated with decreased survival. VEGF and VEGF receptors"/>
   <result pre="(anti-VEGF-A monoclonal antibody) to first-line platinum-fluoropyrimidine chemotherapy in advanced gastric" exact="cancer" post="patients but failed to demonstrate improved survival [ 37,"/>
   <result pre="the best supportive care (BSC) in patients with advanced gastric" exact="cancer" post="that progressed after previous chemotherapy. Median survival was 5.2"/>
   <result pre="and overall survival in heavily pretreated patients with metastatic gastric" exact="cancer" post="in phase II trial [ 40]. Phase III trial"/>
   <result pre="miR-101, miR-181, miR-449, miR-486, and let-7a, were downregulated in gastric" exact="cancer" post="[ 42, 43]. Shiotani et al. reported that the"/>
   <result pre="3 (RUNX3) is a tumor suppressor, that is silenced in" exact="cancer" post="via hypermethylation of its promoter. Previously, we reported that"/>
   <result pre="Wang et al. reported that miR-301a is upregulated in gastric" exact="cancer" post="and directly downregulates RUNX3 expression [ 47]. Furthermore, microR-34b/c"/>
   <result pre="resection of gastric cancer, the cumulative incidence of metachronous gastric" exact="cancer" post="was significantly higher among patients with elevated miR-34b/c methylation,"/>
   <result pre="a useful biomarker for predicting the risk of metachronous gastric" exact="cancer" post="[ 48]. 10. Cancer Stem Cell Cancer stem cells"/>
   <result pre="ability to initiate tumor growth and sustain tumor self-renewal. Gastric" exact="cancer" post="stem cells were first isolated and identified in 2009."/>
   <result pre="in 2009. Takaishi et al. identified CD44 as a gastric" exact="cancer" post="stem cell marker as CD44+ cells were able to"/>
   <result pre="pylori to the epithelial cells could accumulate in CD44v9-expressing gastric" exact="cancer" post="stem-like cells by escaping the autophagic degradation pathway due"/>
   <result pre="positively correlated with malignant transformation, metastasis, and relapse of gastric" exact="cancer" post="[ 50]. We previously reported that the recurrence rate"/>
   <result pre="We previously reported that the recurrence rate of early gastric" exact="cancer" post="was significantly higher in the CD44v9-positive than the CD44v9-negative"/>
   <result pre="[ 42]. CD44v9 expression in the tissue of primary gastric" exact="cancer" post="represents a potential predictive marker for recurrence. Additionally, there"/>
   <result pre="Additionally, there is another hypothesis. It is thought that gastric" exact="cancer" post="stem cells are derived from bone-marrow-derived mesenchymal stem cells."/>
   <result pre="number and gene expression profiles have been identified in gastric" exact="cancer" post="over the two decades. New strategies had been developed"/>
   <result pre="two decades. New strategies had been developed for advanced gastric" exact="cancer" post="treatment. However, the response rates remain in the 25–40%"/>
   <result pre="Takata S. Tatsugami M. et al. Clinical prevention of gastric" exact="cancer" post="by Helicobacter pylori eradication therapy: a systematic review Journal"/>
   <result pre="Yae T. et al. CD44 variant regulates redox status in" exact="cancer" post="cells by stabilizing the xCT subunit of system xc"/>
   <result pre="autophagic degradation of Helicobacter pylori CagA is specifically suppressed in" exact="cancer" post="stem-like cells Cell Host and Microbe 2012 12 6"/>
   <result pre="Kitadai Y. et al. K-ras mutation in Helicobacter pylori-associated chronic" exact="gastritis" post="in patients with and without gastric cancer International Journal"/>
   <result pre="Helicobacter pylori-associated chronic gastritis in patients with and without gastric" exact="cancer" post="International Journal of Cancer 2002 97 5 562 566"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial The"/>
   <result pre="or without cetuximab for patients with previously untreated advanced gastric" exact="cancer" post="(EXPAND): a randomised, open-label phase 3 trial The Lancet"/>
   <result pre="or without panitumumab for patients with previously untreated advanced oesophagogastric" exact="cancer" post="(REAL3): a randomised, open-label phase 3 trial The Lancet"/>
   <result pre="paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric" exact="cancer" post="in Asian populations: TyTAN-a randomized, phase III study Journal"/>
   <result pre="3943 10.1200/JCO.2012.48.3552 24043745 28 Grabsch H. I. Tan P. Gastric" exact="cancer" post="pathology and underlying molecular mechanisms Digestive Surgery 2013 30"/>
   <result pre="S. Miyoshi Y. et al. The APC gene, responsible for" exact="familial adenomatous polyposis," post="is mutated in human gastric cancer Cancer Research 1992"/>
   <result pre="responsible for familial adenomatous polyposis, is mutated in human gastric" exact="cancer" post="Cancer Research 1992 52 11 3231 3233 1317264 30"/>
   <result pre="in the study of methylated tumor suppressor genes in gastric" exact="cancer" post="Chinese Journal of Cancer 2013 32 1 31 41"/>
   <result pre="S. Asada K. Yamashita S. et al. Identification of gastric" exact="cancer" post="risk markers that are informative in individuals with past"/>
   <result pre="et al. CD44 variant 9 expression in primary early gastric" exact="cancer" post="as a predictive marker for recurrence British Journal of"/>
   <result pre="23778530 43 Ma Y.-Y. Tao H.-Q. Microribonucleic acids and gastric" exact="cancer" post="Cancer Science 2012 103 4 620 625 10.1111/j.1349-7006.2011.02185.x 22168593"/>
   <result pre="increases RUNX3 expression in the glandular epithelial cells in enlarged-fold" exact="gastritis" post="Journal of Clinical Biochemistry and Nutrition 2010 46 3"/>
   <result pre="et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric" exact="cancer" post="European Journal of Cancer 2010 46 8 1456 1463"/>
   <result pre="promotes cell proliferation and invasion by targeting RUNX3 in gastric" exact="cancer" post="Journal of Gastroenterology 2013 48 9 1023 1033 10.1007/s00535-012-0733-6"/>
   <result pre="methylation of microRNA-34b/c is a predictive marker of metachronous gastric" exact="cancer" post="risk Journal of Gastroenterology 2014 49 7 1135 1144"/>
   <result pre="S. Okumura T. Tu S. et al. Identification of gastric" exact="cancer" post="stem cells using the cell surface marker CD44 Stem"/>
   <result pre="Y. Sakamoto N. Oo H. Z. et al. Expression of" exact="cancer" post="stem cell markers ALDH1, CD44 and CD133 in primary"/>
   <result pre="CD133 in primary tumor and lymph node metastasis of gastric" exact="cancer" post="Pathology International 2012 62 2 112 119 10.1111/j.1440-1827.2011.02760.x 22243781"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4406526/results/search/disease/results.xml">
   <result pre="significantly improved the outcome of women diagnosed with HER2-positive invasive" exact="breast cancer." post="In this review, we sought to summarise the efficacy"/>
   <result pre="taking into consideration the development of modern anti-HER2 agents. breast" exact="neoplasm" post="trastuzumab neoadjuvant therapy adjuvant therapy antibodies, monoclonal, humanised Background"/>
   <result pre="trastuzumab neoadjuvant therapy adjuvant therapy antibodies, monoclonal, humanised Background Breast" exact="cancer" post="(BC) is a heterogeneous disease with several biological subtypes."/>
   <result pre="cases, with trastuzumabtreated patients being more likely to suffer from" exact="congestive heart failure" post="(CHF; relative risk [RR] 5.11, 90% CI 3–8.72) and"/>
   <result pre="also reported. The most relevant adverse events included grade 3" exact="neuropathy" post="(3.2%; 95% CI 1.7–5.4), symptomatic but reversible congestive heart"/>
   <result pre="grade 3 neuropathy (3.2%; 95% CI 1.7–5.4), symptomatic but reversible" exact="congestive heart failure" post="(0.5%; 95% CI 0.1–1.8) and asymptomatic declines in ejection"/>
   <result pre="to historical data, the authors argue that the risk of" exact="cancer" post="recurrence and serious toxic events were low. Finally, population-based"/>
   <result pre="nine cycles of weekly trastuzumab in the subset of HER2-positive" exact="breast cancer" post="(232 patients, 22.97%). The primary endpoint was recurrence-free survival"/>
   <result pre="cycles of weekly trastuzumab in the subset of HER2-positive breast" exact="cancer" post="(232 patients, 22.97%). The primary endpoint was recurrence-free survival"/>
   <result pre="phase III trial randomised 3222 patients with HER2-positive high-risk T1–T3" exact="breast cancer" post="to receive a standard adjuvant anthracycline-taxane containing chemotherapy regimen"/>
   <result pre="III trial randomised 3222 patients with HER2-positive high-risk T1–T3 breast" exact="cancer" post="to receive a standard adjuvant anthracycline-taxane containing chemotherapy regimen"/>
   <result pre="were more frequent in the TCH arm. Sensory and motor" exact="neuropathy" post="was more frequent in the AC-TH arm. Grounded on"/>
   <result pre="hybridization and correlation with immunohistochemistry in a cohort of 6556" exact="breast cancer" post="tissues Clin Breast Cancer 2004 5 1 63 9"/>
   <result pre="and correlation with immunohistochemistry in a cohort of 6556 breast" exact="cancer" post="tissues Clin Breast Cancer 2004 5 1 63 9"/>
   <result pre="EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1673 84"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1673 84"/>
   <result pre="Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1659 72"/>
   <result pre="MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1659 72"/>
   <result pre="16236737 4. Slamon D et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 14 1273 83"/>
   <result pre="4. Slamon D et al. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 14 1273 83"/>
   <result pre="al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for" exact="breast cancer" post="N Engl J Med 2006 354 8 809 20"/>
   <result pre="Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast" exact="cancer" post="N Engl J Med 2006 354 8 809 20"/>
   <result pre="8. Moja L et al. Trastuzumab containing regimens for early" exact="breast cancer" post="Cochrane Database Syst Rev 2012 4 Cd006243 10.1002/14651858.CD006243.pub2 22513938"/>
   <result pre="Moja L et al. Trastuzumab containing regimens for early breast" exact="cancer" post="Cochrane Database Syst Rev 2012 4 Cd006243 10.1002/14651858.CD006243.pub2 22513938"/>
   <result pre="SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive" exact="breast cancer" post="N Engl J Med 2015 372 2 134 41"/>
   <result pre="et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast" exact="cancer" post="N Engl J Med 2015 372 2 134 41"/>
   <result pre="clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic" exact="breast cancer" post="from registHER Oncologist 2013 18 5 501 10 10.1634/theoncologist.2012-0414"/>
   <result pre="outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast" exact="cancer" post="from registHER Oncologist 2013 18 5 501 10 10.1634/theoncologist.2012-0414"/>
   <result pre="toxicities from trastuzumab, alone or in combination, in an elderly" exact="breast cancer" post="population Oncology 2014 86 1 16 21 10.1159/000353450 24335608"/>
   <result pre="from trastuzumab, alone or in combination, in an elderly breast" exact="cancer" post="population Oncology 2014 86 1 16 21 10.1159/000353450 24335608"/>
   <result pre="randomized trial in human epidermal growth factor receptor 2–positive operable" exact="breast cancer" post="J Clin Oncol 2005 23 16 3676 85 10.1200/JCO.2005.07.032"/>
   <result pre="trial in human epidermal growth factor receptor 2–positive operable breast" exact="cancer" post="J Clin Oncol 2005 23 16 3676 85 10.1200/JCO.2005.07.032"/>
   <result pre="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced" exact="breast cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast" exact="cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced" exact="breast cancer" post="(NOAH): follow-up of a randomised controlled superiority trial with"/>
   <result pre="and adjuvant trastuzumab in patients with HER2-positive locally advanced breast" exact="cancer" post="(NOAH): follow-up of a randomised controlled superiority trial with"/>
   <result pre="Baselga J et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="J et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="their combination (T+L) in the adjuvant treatment of HER2-positive early" exact="breast cancer" post="(EBC) 2014 ASCO Annual Meeting Proceedings 25. Gianni L"/>
   <result pre="combination (T+L) in the adjuvant treatment of HER2-positive early breast" exact="cancer" post="(EBC) 2014 ASCO Annual Meeting Proceedings 25. Gianni L"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="12 months of adjuvant trastuzumab for patients with HER2-positive early" exact="breast cancer" post="(PHARE): a randomised phase 3 trial Lancet Oncol 2013"/>
   <result pre="months of adjuvant trastuzumab for patients with HER2-positive early breast" exact="cancer" post="(PHARE): a randomised phase 3 trial Lancet Oncol 2013"/>
   <result pre="2 years versus 1 year of adjuvant trastuzumab for HER2-positive" exact="breast cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="years versus 1 year of adjuvant trastuzumab for HER2-positive breast" exact="cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for" exact="breast cancer" post="J Clin Oncol 2011 29 34 4491 7 10.1200/JCO.2011.36.7045"/>
   <result pre="al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast" exact="cancer" post="J Clin Oncol 2011 29 34 4491 7 10.1200/JCO.2011.36.7045"/>
   <result pre="FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive" exact="breast cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast" exact="cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="of adjuvant trastuzumab in human epidermal growth factor receptor 2–positive" exact="breast cancer" post="J Clin Oncol 2007 25 6 625 33 10.1200/JCO.2006.06.4220"/>
   <result pre="adjuvant trastuzumab in human epidermal growth factor receptor 2–positive breast" exact="cancer" post="J Clin Oncol 2007 25 6 625 33 10.1200/JCO.2006.06.4220"/>
   <result pre="(neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III" exact="breast cancer" post="(HannaH study): a phase 3, open-label, multicentre, randomised trial"/>
   <result pre="adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast" exact="cancer" post="(HannaH study): a phase 3, open-label, multicentre, randomised trial"/>
   <result pre="or intravenous administration of trastuzumab in patients with HER2-positive early" exact="breast cancer" post="(PrefHer): an open-label randomised study Lancet Oncol 2013 14"/>
   <result pre="intravenous administration of trastuzumab in patients with HER2-positive early breast" exact="cancer" post="(PrefHer): an open-label randomised study Lancet Oncol 2013 14"/>
   <result pre="and PET imaging of HER2-positive lesions in patients with metastatic" exact="breast cancer" post="Clin Pharmcol Ther 2010 87 5 586 92 10.1038/clpt.2010.12"/>
   <result pre="PET imaging of HER2-positive lesions in patients with metastatic breast" exact="cancer" post="Clin Pharmcol Ther 2010 87 5 586 92 10.1038/clpt.2010.12"/>
   <result pre="KS et al. Beyond trastuzumab: new treatment options for HER2-positive" exact="breast cancer" post="Breast 2011 20 Supplement 3(0) S20 7 10.1016/S0960-9776(11)70289-2 22015288"/>
   <result pre="et al. Beyond trastuzumab: new treatment options for HER2-positive breast" exact="cancer" post="Breast 2011 20 Supplement 3(0) S20 7 10.1016/S0960-9776(11)70289-2 22015288"/>
   <result pre="J et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="New Engl J Med 2012 366 2 109 19"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="New Engl J Med 2012 366 2 109 19"/>
   <result pre="10.1093/annonc/mdt182 23704196 45. Lewis Phillips GD et al. Targeting HER2-positive" exact="breast cancer" post="with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 2008"/>
   <result pre="23704196 45. Lewis Phillips GD et al. Targeting HER2-positive breast" exact="cancer" post="with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 2008"/>
   <result pre="AM et al. High risk of recurrence for patients with" exact="breast cancer" post="who have human epidermal growth factor receptor 2-positive, node-negative"/>
   <result pre="et al. High risk of recurrence for patients with breast" exact="cancer" post="who have human epidermal growth factor receptor 2-positive, node-negative"/>
   <result pre="there a case for anti-HER2 therapy without chemotherapy in early" exact="breast cancer?" post="Breast 2011 20 Supplement 3(0) S158 61 10.1016/S0960-9776(11)70316-2 22015286"/>
   <result pre="Lapatinib as a component of neoadjuvant therapy for HER2-positive operable" exact="breast cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="as a component of neoadjuvant therapy for HER2-positive operable breast" exact="cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive" exact="breast cancer" post="J Clin Oncol 2013 31 15 Suppl 500 54."/>
   <result pre="paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast" exact="cancer" post="J Clin Oncol 2013 31 15 Suppl 500 54."/>
   <result pre="and carboplatin with trastuzumab and/or lapatinib in patients with HER2+" exact="breast cancer" post="(TRIO-US B07) Cancer Res 2013 73 24 Supplement S1"/>
   <result pre="carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast" exact="cancer" post="(TRIO-US B07) Cancer Res 2013 73 24 Supplement S1"/>
   <result pre="preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant" exact="breast cancer" post="chemotherapy J Clin Oncol 2011 29 suppl abstr 506"/>
   <result pre="lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast" exact="cancer" post="chemotherapy J Clin Oncol 2011 29 suppl abstr 506"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4407294/results/search/disease/results.xml">
   <result pre="10.1186/s13058-015-0560-9 : Review Molecular characterization and targeted therapeutic approaches in" exact="breast cancer" post="Toss Angela angela.toss@tin.it Cristofanilli Massimo massimo.cristofanilli@jefferson.edu [], [], epub:"/>
   <result pre=": Review Molecular characterization and targeted therapeutic approaches in breast" exact="cancer" post="Toss Angela angela.toss@tin.it Cristofanilli Massimo massimo.cristofanilli@jefferson.edu [], [], epub:"/>
   <result pre="article, unless otherwise stated. Abstract Despite the wide improvements in" exact="breast cancer" post="(BC) detection and adjuvant treatment, BC is still responsible"/>
   <result pre="unless otherwise stated. Abstract Despite the wide improvements in breast" exact="cancer" post="(BC) detection and adjuvant treatment, BC is still responsible"/>
   <result pre="explore new targets for drug development. Finally, the integration of" exact="cancer" post="stem cell-targeted therapies and immune therapies in future combination"/>
   <result pre="and utility, and the implication for therapeutic targeting. Introduction Breast" exact="cancer" post="(BC) represents the most common cancer among women; there"/>
   <result pre="therapeutic targeting. Introduction Breast cancer (BC) represents the most common" exact="cancer" post="among women; there were 232,670 estimated new cases and"/>
   <result pre="a combination of clinical and biological features that could predict" exact="cancer" post="features and behavior, allowing a more tailored approach to"/>
   <result pre="subtyping, prediction of treatment response, and surveillance, allowing a personalized" exact="cancer" post="management. The integration between novel biomarkers and routinely tested"/>
   <result pre="validity and utility, and the implication for therapeutic targeting. Breast" exact="cancer" post="subtypes and gene expression profile tests From the clinical"/>
   <result pre="luminal B, HER2-enriched, and basal-like (Table 1). Table 1 Breast" exact="cancer" post="intrinsic subtypes with prevalent immuno-histochemical profiles and options of"/>
   <result pre="in patients with HR +/HER2 −/grade 3 tumors, triple negative" exact="breast cancer" post="(TNBC), and HR −/HER2 + who received trastuzumab ["/>
   <result pre="patients with HR +/HER2 −/grade 3 tumors, triple negative breast" exact="cancer" post="(TNBC), and HR −/HER2 + who received trastuzumab ["/>
   <result pre="2 Main features of the principal available multi-gene assays in" exact="breast cancer" post="Assay MammaPrint Oncotype DX PAM50 Number of genes 70"/>
   <result pre="Main features of the principal available multi-gene assays in breast" exact="cancer" post="Assay MammaPrint Oncotype DX PAM50 Number of genes 70"/>
   <result pre="with ER-positive, node-negative disease Patients with stage I to III" exact="breast cancer" post="Output Low- or high-risk patients Recurrence score: low, intermediate,"/>
   <result pre="ER-positive, node-negative disease Patients with stage I to III breast" exact="cancer" post="Output Low- or high-risk patients Recurrence score: low, intermediate,"/>
   <result pre="of benefit of tamoxifen in pre-menopausal patients [ 9]. BC," exact="breast cancer;" post="CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; DFS, disease-free survival; ER,"/>
   <result pre="crosstalk with the RAS/RAF/MEK/MAPK pathway play a crucial role in" exact="cancer" post="cell growth, survival, differentiation, and proliferation (Figure 1). Moreover,"/>
   <result pre="O1; MEK1/2, MAPK/Erk kinase 1/2; PIP, phosphatidylinositol phosphate; Raf, murine" exact="sarcoma" post="viral oncogene homolog; Ras, rat sarcoma viral oncogene homolog;"/>
   <result pre="phosphatidylinositol phosphate; Raf, murine sarcoma viral oncogene homolog; Ras, rat" exact="sarcoma" post="viral oncogene homolog; RHEB, Ras homolog enriched in brain;"/>
   <result pre="Ras homolog enriched in brain; RTK, receptor tyrosine kinase; TSC1/2," exact="tuberous sclerosis" post="proteins 1 and 2. Although anti-estrogen therapies have been"/>
   <result pre="parallel pathway may provide alternative proliferation and survival stimuli to" exact="cancer" post="cells, even in the presence of inhibition in the"/>
   <result pre="cyclin-dependent kinase (CDK) 4/6 cooperate to phosphorylate and inactivate the" exact="retinoblastoma" post="tumor-suppressor protein (RB), allowing cell cycle progression even in"/>
   <result pre="and the FDA has approved azacitidine and decitabine for high-risk" exact="myelodysplastic syndrome" post="and two histone deacetylase (HDAC) inhibitors (vorinostat and romidepsin)"/>
   <result pre="histone deacetylase (HDAC) inhibitors (vorinostat and romidepsin) for cutaneous T-cell" exact="lymphoma" post="[ 24]. For what concerns BC, recent research highlighted"/>
   <result pre="trial (NCT02115282) that started at the beginning of 2014. HER2-positive" exact="breast cancer" post="DNA amplification of HER2 gene is considered the main"/>
   <result pre="(NCT02115282) that started at the beginning of 2014. HER2-positive breast" exact="cancer" post="DNA amplification of HER2 gene is considered the main"/>
   <result pre="targeted treatment choices. Table 4 Biologic anti-HER2 agents approved for" exact="breast cancer" post="treatment Agent Approval Mechanism of action Indications Trastuzumab 1998"/>
   <result pre="treatment choices. Table 4 Biologic anti-HER2 agents approved for breast" exact="cancer" post="treatment Agent Approval Mechanism of action Indications Trastuzumab 1998"/>
   <result pre="line if trastuzumab-resistance) Targeted intracellular delivery of cytotoxic emtansine. BC," exact="breast cancer;" post="EGFR, epidermal growth factor receptor; HER2, human epidermal growth"/>
   <result pre="products of oncogenes, Hsp90 may represent an important target in" exact="cancer" post="therapy. Moreover, because Hsp90 protects cells from stress-induced damage,"/>
   <result pre="HER2-positive tumors and TNBC (NCT01677455) [ 33]. Subtypes of triple-negative" exact="breast cancer" post="and p53 mutations TNBC constitutes about 15% to 20%"/>
   <result pre="tumors and TNBC (NCT01677455) [ 33]. Subtypes of triple-negative breast" exact="cancer" post="and p53 mutations TNBC constitutes about 15% to 20%"/>
   <result pre="is still unclear whether this genetic profile is reflective of" exact="cancer" post="cells or stromal immune infiltrate. M and MSL subtypes"/>
   <result pre="markers, high enrichment for EMT markers, immune response genes, and" exact="cancer" post="stem cell (CSC)-like features [ 36]. However, Lehmann and"/>
   <result pre="I trials for patients with TNBC and solid tumors. Breast" exact="cancer" post="heterogeneity BC represents a heterogeneous disease at the population"/>
   <result pre="model has been developed. The emerging CSC model suggests that" exact="cancer" post="initialization, progression, and metastasization are driven by a specific"/>
   <result pre="is a latent embryonic process that, when aberrantly activated in" exact="cancer" post="cells, promotes the reprogramming of epithelial cancer cells toward"/>
   <result pre="aberrantly activated in cancer cells, promotes the reprogramming of epithelial" exact="cancer" post="cells toward a mesenchymal motile phenotype with migratory and"/>
   <result pre="and multiple intermediate states and that contributes to increase the" exact="cancer" post="heterogeneity and plasticity. The transition is induced by several"/>
   <result pre="acquired stem-like capabilities [ 42]. On the other hand, disseminated" exact="cancer" post="cells can perform a mesenchymal-epithelial transition reverting to an"/>
   <result pre="pathways (Figure 2) [ 46]. Figure 2 Molecular pathways regulating" exact="breast cancer" post="stem cells (CSCs). Akt represents a central hub in"/>
   <result pre="(Figure 2) [ 46]. Figure 2 Molecular pathways regulating breast" exact="cancer" post="stem cells (CSCs). Akt represents a central hub in"/>
   <result pre="involving IL-6 and IL-8 has been shown to determine PTEN" exact="suppression" post="and thus the resistance to HER2-targeting agents. IkB, kinase"/>
   <result pre="agents. IkB, kinase B inhibitor; p50, protein 50; Src, rous" exact="sarcoma" post="oncogene cellular homolog; Stat3, signal transducer and activator of"/>
   <result pre="currently under investigation in clinical trials for Alzheimer’s disease, T-cell" exact="acute lymphoblastic leukemia," post="and BC [ 46]. Furthermore, Harrison and colleagues ["/>
   <result pre="under investigation in clinical trials for Alzheimer’s disease, T-cell acute" exact="lymphoblastic leukemia," post="and BC [ 46]. Furthermore, Harrison and colleagues ["/>
   <result pre="receptor of IL-8, has been found to be overexpressed in" exact="cancer" post="cells expressing the stem cell marker ALDH [ 49]."/>
   <result pre="women with metastatic BC. Abbreviations AR Androgen receptor BC Breast" exact="cancer" post="BL Basal-like CDK Cyclin-dependent kinase CSC Cancer stem cell"/>
   <result pre="protein microarray RS Recurrence score TIL Tumor-infiltrating lymphocytes TNBC Triple-negative" exact="breast cancer" post="Competing interests MC is a consultant for Dompé (Milan,"/>
   <result pre="microarray RS Recurrence score TIL Tumor-infiltrating lymphocytes TNBC Triple-negative breast" exact="cancer" post="Competing interests MC is a consultant for Dompé (Milan,"/>
   <result pre="WF Ibrahim N Cristofanilli M Anderson K et al. Breast" exact="cancer" post="molecular subtypes respond differently to preoperative chemotherapy Clin Cancer"/>
   <result pre="MC Voduc D Speers CH et al. Metastatic behavior of" exact="breast cancer" post="subtypes J Clin Oncol. 2010 28 3271 7 10.1200/JCO.2009.25.9820"/>
   <result pre="Voduc D Speers CH et al. Metastatic behavior of breast" exact="cancer" post="subtypes J Clin Oncol. 2010 28 3271 7 10.1200/JCO.2009.25.9820"/>
   <result pre="Voduc D Vickery T et al. Supervised risk predictor of" exact="breast cancer" post="based on intrinsic subtypes J Clin Oncol. 2009 27"/>
   <result pre="D Vickery T et al. Supervised risk predictor of breast" exact="cancer" post="based on intrinsic subtypes J Clin Oncol. 2009 27"/>
   <result pre="Bose R Using multigene tests to select treatment for early-stage" exact="breast cancer" post="J Natl Compr Canc Netw. 2013 11 174 82"/>
   <result pre="R Using multigene tests to select treatment for early-stage breast" exact="cancer" post="J Natl Compr Canc Netw. 2013 11 174 82"/>
   <result pre="recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early" exact="breast cancer" post="Clin Cancer Res. 2014 20 1298 305 10.1158/1078-0432.CCR-13-1845 24520097"/>
   <result pre="after endocrine therapy in postmenopausal women with endocrine-responsive early breast" exact="cancer" post="Clin Cancer Res. 2014 20 1298 305 10.1158/1078-0432.CCR-13-1845 24520097"/>
   <result pre="expression profiles in breast cancer: toward a unified understanding of" exact="breast cancer" post="subtyping and prognosis signatures Breast Cancer Res. 2008 10"/>
   <result pre="profiles in breast cancer: toward a unified understanding of breast" exact="cancer" post="subtyping and prognosis signatures Breast Cancer Res. 2008 10"/>
   <result pre="21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive" exact="breast cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast" exact="cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="et al. A diagnostic gene profile for molecular subtyping of" exact="breast cancer" post="associated with treatment response Breast Cancer Res Treat. 2012"/>
   <result pre="al. A diagnostic gene profile for molecular subtyping of breast" exact="cancer" post="associated with treatment response Breast Cancer Res Treat. 2012"/>
   <result pre="Peeters J Stork-Sloots L Somlo G Molecular subtyping of early-stage" exact="breast cancer" post="identifies a group of patients who do not benefit"/>
   <result pre="J Stork-Sloots L Somlo G Molecular subtyping of early-stage breast" exact="cancer" post="identifies a group of patients who do not benefit"/>
   <result pre="L Finetti P Saade MR et al. Candidate luminal B" exact="breast cancer" post="genes identified by genome, gene expression and DNA methylation"/>
   <result pre="Finetti P Saade MR et al. Candidate luminal B breast" exact="cancer" post="genes identified by genome, gene expression and DNA methylation"/>
   <result pre="R Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative" exact="breast cancer" post="Breast 2013 22 Suppl 2 S12 8 10.1016/j.breast.2013.08.001 24011769"/>
   <result pre="Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast" exact="cancer" post="Breast 2013 22 Suppl 2 S12 8 10.1016/j.breast.2013.08.001 24011769"/>
   <result pre="Balko JM Arteaga CL Phosphatidylinositol 3-kinase and antiestrogen resistance in" exact="breast cancer" post="J Clin Oncol. 2011 29 4452 61 10.1200/JCO.2010.34.4879 22010023"/>
   <result pre="JM Arteaga CL Phosphatidylinositol 3-kinase and antiestrogen resistance in breast" exact="cancer" post="J Clin Oncol. 2011 29 4452 61 10.1200/JCO.2010.34.4879 22010023"/>
   <result pre="HS Sahmoud T et al. Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med. 2012 366 520 9 10.1056/NEJMoa1109653"/>
   <result pre="Sahmoud T et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med. 2012 366 520 9 10.1056/NEJMoa1109653"/>
   <result pre="Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant" exact="breast cancer" post="Endocr Relat Cancer. 2011 18 333 45 10.1530/ERC-10-0262 21367843"/>
   <result pre="activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast" exact="cancer" post="Endocr Relat Cancer. 2011 18 333 45 10.1530/ERC-10-0262 21367843"/>
   <result pre="letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced" exact="breast cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2014;"/>
   <result pre="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast" exact="cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2014;"/>
   <result pre="Ramos KS The promise and failures of epigenetic therapies for" exact="cancer" post="treatment Cancer Treat Rev. 2014 40 153 69 10.1016/j.ctrv.2013.05.009"/>
   <result pre="Groep P et al. Twist contributes to hormone resistance in" exact="breast cancer" post="by downregulating estrogen receptor-α Oncogene. 2012 31 3223 34"/>
   <result pre="P et al. Twist contributes to hormone resistance in breast" exact="cancer" post="by downregulating estrogen receptor-α Oncogene. 2012 31 3223 34"/>
   <result pre="in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive" exact="breast cancer" post="progressing on treatment with a nonsteroidal aromatase inhibitor J"/>
   <result pre="postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast" exact="cancer" post="progressing on treatment with a nonsteroidal aromatase inhibitor J"/>
   <result pre="M Baselga J et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med. 2012 367 1783 91 10.1056/NEJMoa1209124"/>
   <result pre="Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med. 2012 367 1783 91 10.1056/NEJMoa1209124"/>
   <result pre="phase III study of trastuzumab emtansine (TDM1) in HER2-positive metastatic" exact="breast cancer" post="(MBC) [abstract]. Cancer Res. 2013;73:Abstract nr LB-63. 31. Garcia-Carbonero"/>
   <result pre="III study of trastuzumab emtansine (TDM1) in HER2-positive metastatic breast" exact="cancer" post="(MBC) [abstract]. Cancer Res. 2013;73:Abstract nr LB-63. 31. Garcia-Carbonero"/>
   <result pre="of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic" exact="breast cancer" post="progressing on trastuzumab Clin Cancer Res. 2011 17 5132"/>
   <result pre="tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast" exact="cancer" post="progressing on trastuzumab Clin Cancer Res. 2011 17 5132"/>
   <result pre="novel heat shock protein 90 inhibitor for patients with metastatic" exact="breast cancer" post="Clin Breast Cancer. 2014 14 154 60 10.1016/j.clbc.2013.12.012 24512858"/>
   <result pre="heat shock protein 90 inhibitor for patients with metastatic breast" exact="cancer" post="Clin Breast Cancer. 2014 14 154 60 10.1016/j.clbc.2013.12.012 24512858"/>
   <result pre="Chakravarthy AB Shyr Y et al. Identification of human triple-negative" exact="breast cancer" post="subtypes and preclinical models for selection of targeted therapies"/>
   <result pre="AB Shyr Y et al. Identification of human triple-negative breast" exact="cancer" post="subtypes and preclinical models for selection of targeted therapies"/>
   <result pre="Phenotypic and molecular characterization of the claudin-low intrinsic subtype of" exact="breast cancer" post="Breast Cancer Res. 2010 12 R68 10.1186/bcr2635 20813035 37."/>
   <result pre="and molecular characterization of the claudin-low intrinsic subtype of breast" exact="cancer" post="Breast Cancer Res. 2010 12 R68 10.1186/bcr2635 20813035 37."/>
   <result pre="Identification and use of biomarkers in treatment strategies for triple-negative" exact="breast cancer" post="subtypes J Pathol. 2014 232 142 50 10.1002/path.4280 24114677"/>
   <result pre="and use of biomarkers in treatment strategies for triple-negative breast" exact="cancer" post="subtypes J Pathol. 2014 232 142 50 10.1002/path.4280 24114677"/>
   <result pre="N Hicks J Borresen-Dale AL Insight into the heterogeneity of" exact="breast cancer" post="through next-generation sequencing J Clin Invest. 2011 121 3810"/>
   <result pre="Hicks J Borresen-Dale AL Insight into the heterogeneity of breast" exact="cancer" post="through next-generation sequencing J Clin Invest. 2011 121 3810"/>
   <result pre="KW Werden SJ Guo W Mani SA Epithelial-mesenchymal transition and" exact="cancer" post="stem cells: a dangerously dynamic duo in breast cancer"/>
   <result pre="transition and cancer stem cells: a dangerously dynamic duo in" exact="breast cancer" post="progression Breast Cancer Res. 2011 13 202 10.1186/bcr2789 21392411"/>
   <result pre="and cancer stem cells: a dangerously dynamic duo in breast" exact="cancer" post="progression Breast Cancer Res. 2011 13 202 10.1186/bcr2789 21392411"/>
   <result pre="D Sun Y Deng L Liu Y et al. Breast" exact="cancer" post="stem cells transition between epithelial and mesenchymal states reflective"/>
   <result pre="514 27 10.1016/j.celrep.2013.12.041 24462293 46. McDermott SP Wicha MS Targeting" exact="breast cancer" post="stem cells Mol Oncol. 2010 4 404 19 10.1016/j.molonc.2010.06.005"/>
   <result pre="27 10.1016/j.celrep.2013.12.041 24462293 46. McDermott SP Wicha MS Targeting breast" exact="cancer" post="stem cells Mol Oncol. 2010 4 404 19 10.1016/j.molonc.2010.06.005"/>
   <result pre="Rock RE Stylianou S Brennan KR et al. Regulation of" exact="breast cancer" post="stem cell activity by signaling through the Notch4 receptor"/>
   <result pre="RE Stylianou S Brennan KR et al. Regulation of breast" exact="cancer" post="stem cell activity by signaling through the Notch4 receptor"/>
   <result pre="M Brown M et al. CXCR1 blockade selectively targets human" exact="breast cancer" post="stem cells in vitro and in xenografts J Clin"/>
   <result pre="Brown M et al. CXCR1 blockade selectively targets human breast" exact="cancer" post="stem cells in vitro and in xenografts J Clin"/>
   <result pre="Shergill A Landberg G et al. Targeting CXCR1/2 significantly reduces" exact="breast cancer" post="stem cell activity and increases the efficacy of inhibiting"/>
   <result pre="A Landberg G et al. Targeting CXCR1/2 significantly reduces breast" exact="cancer" post="stem cell activity and increases the efficacy of inhibiting"/>
   <result pre="of immune pathways in the therapeutic response and outcome in" exact="breast cancer" post="Clin Cancer Res. 2013 19 28 33 10.1158/1078-0432.CCR-11-2701 23258741"/>
   <result pre="immune pathways in the therapeutic response and outcome in breast" exact="cancer" post="Clin Cancer Res. 2013 19 28 33 10.1158/1078-0432.CCR-11-2701 23258741"/>
   <result pre="et al. Tumor infiltrating lymphocytes are prognostic in triple negative" exact="breast cancer" post="and predictive for trastuzumab benefit in early breast cancer:"/>
   <result pre="al. Tumor infiltrating lymphocytes are prognostic in triple negative breast" exact="cancer" post="and predictive for trastuzumab benefit in early breast cancer:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4411474/results/search/disease/results.xml">
   <result pre="one year. After 18 months of the first treatment for" exact="breast cancer," post="her bone marrow biopsy was compatible with AML-M2. Here,"/>
   <result pre="AML-M2. Here, we are reporting a young woman case with" exact="breast cancer" post="that developed AML malignancy during short interval of therapy."/>
   <result pre="Here, we are reporting a young woman case with breast" exact="cancer" post="that developed AML malignancy during short interval of therapy."/>
   <result pre="developed AML malignancy during short interval of therapy. Acute myelogenous" exact="leukemia" post="Cyclophosphamide Paclitaxel Introduction Breast cancer is the most frequent"/>
   <result pre="interval of therapy. Acute myelogenous leukemia Cyclophosphamide Paclitaxel Introduction Breast" exact="cancer" post="is the most frequent malignancy among women that can"/>
   <result pre="agents and anthracyclines [ 1], improves survival rate in operable" exact="breast cancer" post="but treatment-induced Acute Myelogenous Leukemia (AML) is now widely"/>
   <result pre="and anthracyclines [ 1], improves survival rate in operable breast" exact="cancer" post="but treatment-induced Acute Myelogenous Leukemia (AML) is now widely"/>
   <result pre="have reported an increased risk of AML after treatment of" exact="breast cancer" post="( Table 1). The aim of this study is"/>
   <result pre="reported an increased risk of AML after treatment of breast" exact="cancer" post="( Table 1). The aim of this study is"/>
   <result pre="of this study is to evaluate the treatment agents for" exact="breast cancer" post="and their effect on risk of AML Expression. Case"/>
   <result pre="this study is to evaluate the treatment agents for breast" exact="cancer" post="and their effect on risk of AML Expression. Case"/>
   <result pre="axillary area. After 18 months of the first treatment for" exact="breast cancer," post="she referred again to our clinic with gingival hyperplasia"/>
   <result pre="She was treated with diagnosis of Leukemia as a secondary" exact="cancer" post="with 7+3 regiment that lead to complete remission and"/>
   <result pre="months of last consolidation. Discussion AML is an aggressive hematologic" exact="cancer" post="that is characterized by accumulation of immature myelogenous cells"/>
   <result pre="other reports [ 6, 7] have reported the incidence of" exact="leukemia" post="as a complication of adjuvant chemotherapy or radiotherapy for"/>
   <result pre="leukemia as a complication of adjuvant chemotherapy or radiotherapy for" exact="breast cancer." post="In these studies, increased risk of AML has been"/>
   <result pre="developed after two or more years of starting chemotherapy for" exact="breast cancer" post="and also the age of patients was between 36"/>
   <result pre="after two or more years of starting chemotherapy for breast" exact="cancer" post="and also the age of patients was between 36"/>
   <result pre="years. Table 1 also shows that majority of patients with" exact="breast cancer" post="develop AML-M2. In this study, the young aged patient"/>
   <result pre="Table 1 also shows that majority of patients with breast" exact="cancer" post="develop AML-M2. In this study, the young aged patient"/>
   <result pre="period of interval. She was a case of Her-2 positive" exact="breast cancer" post="and so treated with trastuzumab for one year +"/>
   <result pre="of interval. She was a case of Her-2 positive breast" exact="cancer" post="and so treated with trastuzumab for one year +"/>
   <result pre="treated with cyclophosphamide and anthracyclines and paclitaxel. Adjuvant chemotherapy for" exact="breast cancer" post="has been shown to make an increase in the"/>
   <result pre="with cyclophosphamide and anthracyclines and paclitaxel. Adjuvant chemotherapy for breast" exact="cancer" post="has been shown to make an increase in the"/>
   <result pre="and cyclophosphamide will reduce interval period between two malignancies (breast" exact="cancer" post="and AML). Acknowledgments There is no acknowledgment. Conflicts of"/>
   <result pre="Voso MT Caira M Leone G Pagano L Incidence of" exact="acute myeloid leukemia" post="after breast cancer. Mediterr J Hematol Infect Dis ."/>
   <result pre="MT Caira M Leone G Pagano L Incidence of acute" exact="myeloid leukemia" post="after breast cancer. Mediterr J Hematol Infect Dis ."/>
   <result pre="Caira M Leone G Pagano L Incidence of acute myeloid" exact="leukemia" post="after breast cancer. Mediterr J Hematol Infect Dis ."/>
   <result pre="Leone G Pagano L Incidence of acute myeloid leukemia after" exact="breast cancer." post="Mediterr J Hematol Infect Dis . 2011 3 1"/>
   <result pre="e2011069 22220266 2 Beadle G Baade P Fritschi L Acute" exact="myeloid leukemia" post="after breast cancer: a population-based comparison with hematological malignancies"/>
   <result pre="22220266 2 Beadle G Baade P Fritschi L Acute myeloid" exact="leukemia" post="after breast cancer: a population-based comparison with hematological malignancies"/>
   <result pre="al. The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of" exact="acute myeloid leukemia" post="and is associated with specific chromosomal abnormalities. PLoS One."/>
   <result pre="The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute" exact="myeloid leukemia" post="and is associated with specific chromosomal abnormalities. PLoS One."/>
   <result pre="G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute myeloid" exact="leukemia" post="and is associated with specific chromosomal abnormalities. PLoS One."/>
   <result pre="Takagi H Ikeda T Murase T et al. Occurrence of" exact="myelodysplastic syndrome" post="during paclitaxel- and carboplatin-based chemotherapy for recurrent ovarian cancer:"/>
   <result pre="S Seward S Semaan A Schiffer CA Munkarah AR Therapy-related" exact="myeloid leukemia" post="after treatment for epithelial ovarian carcinoma: an epidemiological analysis."/>
   <result pre="Seward S Semaan A Schiffer CA Munkarah AR Therapy-related myeloid" exact="leukemia" post="after treatment for epithelial ovarian carcinoma: an epidemiological analysis."/>
   <result pre="Jaffe BM Kahn MJ Therapy-induced leukemias and myelodysplastic syndromes after" exact="breast cancer" post="treatment: an underemphasized clinical problem. Ann Surg Oncol. 2002"/>
   <result pre="BM Kahn MJ Therapy-induced leukemias and myelodysplastic syndromes after breast" exact="cancer" post="treatment: an underemphasized clinical problem. Ann Surg Oncol. 2002"/>
   <result pre="C AML1/MTG16 fusion gene from a t(16;21)(q24;q22) translocation in treatment-induced" exact="leukemia" post="after breast cancer. Haematologica. 2001 86 2 212 3"/>
   <result pre="fusion gene from a t(16;21)(q24;q22) translocation in treatment-induced leukemia after" exact="breast cancer." post="Haematologica. 2001 86 2 212 3 11224496 10 Chalayer"/>
   <result pre="E Tavernier-Tardy E Clavreul G Bay JO Cornillon J Carcinomatosis" exact="lymphangitis" post="and pleurisy after allo-SCT in two patients with secondary"/>
   <result pre="E Clavreul G Bay JO Cornillon J Carcinomatosis lymphangitis and" exact="pleurisy" post="after allo-SCT in two patients with secondary leukemia after"/>
   <result pre="lymphangitis and pleurisy after allo-SCT in two patients with secondary" exact="leukemia" post="after breast cancer. Bone Marrow Transpl. 2012 47 1"/>
   <result pre="pleurisy after allo-SCT in two patients with secondary leukemia after" exact="breast cancer." post="Bone Marrow Transpl. 2012 47 1 155 6 11"/>
   <result pre="as a consequence of a rare translocation (12;12)(p13;q13) in treatment-induced" exact="acute myeloid leukemia" post="after breast cancer. Cancer Genet Cytogenet. 2008 180 1"/>
   <result pre="a consequence of a rare translocation (12;12)(p13;q13) in treatment-induced acute" exact="myeloid leukemia" post="after breast cancer. Cancer Genet Cytogenet. 2008 180 1"/>
   <result pre="consequence of a rare translocation (12;12)(p13;q13) in treatment-induced acute myeloid" exact="leukemia" post="after breast cancer. Cancer Genet Cytogenet. 2008 180 1"/>
   <result pre="a rare translocation (12;12)(p13;q13) in treatment-induced acute myeloid leukemia after" exact="breast cancer." post="Cancer Genet Cytogenet. 2008 180 1 37 42 18068531"/>
   <result pre="Masuda S Matsuura Y Wakita H Atypical onset of therapy-related" exact="acute promyelocytic leukemia" post="after combined modality therapy including (89)Sr for metastatic breast"/>
   <result pre="Matsuura Y Wakita H Atypical onset of therapy-related acute promyelocytic" exact="leukemia" post="after combined modality therapy including (89)Sr for metastatic breast"/>
   <result pre="promyelocytic leukemia after combined modality therapy including (89)Sr for metastatic" exact="breast cancer." post="Rinsho Ketsueki. 2013 54 8 759 63 24005436 13"/>
   <result pre="C Hiramoto N Goto Y Yonemori K et al. Therapy-related" exact="acute promyelocytic leukemia" post="caused by hormonal therapy and radiation in a patient"/>
   <result pre="N Goto Y Yonemori K et al. Therapy-related acute promyelocytic" exact="leukemia" post="caused by hormonal therapy and radiation in a patient"/>
   <result pre="by hormonal therapy and radiation in a patient with recurrent" exact="breast cancer." post="Jpn J Clin Oncol. 2008 38 8 567 70"/>
   <result pre="I Kannan M Choudhry VP Mahapatra M et al. Therapy-related" exact="acute promyelocytic leukemia" post="after treatment of carcinoma breast--a case report. Indian J"/>
   <result pre="M Choudhry VP Mahapatra M et al. Therapy-related acute promyelocytic" exact="leukemia" post="after treatment of carcinoma breast--a case report. Indian J"/>
   <result pre="Gabriel IH Abdalla SH Ryley S Bain BJ Case 34:" exact="acute leukemia" post="in a patient with a previous history of breast"/>
   <result pre="IH Abdalla SH Ryley S Bain BJ Case 34: acute" exact="leukemia" post="in a patient with a previous history of breast"/>
   <result pre="acute leukemia in a patient with a previous history of" exact="breast cancer." post="Leuk Lymphoma. 2007 48 2 403 5 17325903 17"/>
   <result pre="co-presence of deletion 7q, 20q and inversion 16 in therapy-related" exact="acute myeloid leukemia" post="developed secondary to treatment of breast cancer with cyclophosphamide,"/>
   <result pre="of deletion 7q, 20q and inversion 16 in therapy-related acute" exact="myeloid leukemia" post="developed secondary to treatment of breast cancer with cyclophosphamide,"/>
   <result pre="deletion 7q, 20q and inversion 16 in therapy-related acute myeloid" exact="leukemia" post="developed secondary to treatment of breast cancer with cyclophosphamide,"/>
   <result pre="in therapy-related acute myeloid leukemia developed secondary to treatment of" exact="breast cancer" post="with cyclophosphamide, doxorubicin, and radiotherapy: a case report. J"/>
   <result pre="therapy-related acute myeloid leukemia developed secondary to treatment of breast" exact="cancer" post="with cyclophosphamide, doxorubicin, and radiotherapy: a case report. J"/>
   <result pre="M Mori A Irie T Tanaka M Morioka M Therapy-related" exact="acute myeloid leukemia" post="with 11q23 abnormality due to paclitaxel coexisting with bone"/>
   <result pre="Mori A Irie T Tanaka M Morioka M Therapy-related acute" exact="myeloid leukemia" post="with 11q23 abnormality due to paclitaxel coexisting with bone"/>
   <result pre="A Irie T Tanaka M Morioka M Therapy-related acute myeloid" exact="leukemia" post="with 11q23 abnormality due to paclitaxel coexisting with bone"/>
   <result pre="abnormality due to paclitaxel coexisting with bone marrow metastasis of" exact="breast cancer." post="Rinsho Ketsueki. 2009 50 3 192 6 19352087 20"/>
   <result pre="massively pre-treated woman with extensive cutaneous involvement after recurrence of" exact="breast cancer." post="Invest New Drugs. 2001 19 1 93 100 11291839"/>
   <result pre="93 100 11291839 Table 1 Case reports about acute myelogenous" exact="leukemia" post="(AML) and its subtypes after breast cancer Reference subtypes"/>
   <result pre="reports about acute myelogenous leukemia (AML) and its subtypes after" exact="breast cancer" post="Reference subtypes Age Interval (month) Treatment between two malignancies"/>
   <result pre="about acute myelogenous leukemia (AML) and its subtypes after breast" exact="cancer" post="Reference subtypes Age Interval (month) Treatment between two malignancies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4413633/results/search/disease/results.xml">
   <result pre="interaction with the Her-1/2 pathway contributes to overall survival in" exact="breast cancer" post="Nie Weiwei 1 Huang Weisun 1 Zhang Wenwen 2"/>
   <result pre="with the Her-1/2 pathway contributes to overall survival in breast" exact="cancer" post="Nie Weiwei 1 Huang Weisun 1 Zhang Wenwen 2"/>
   <result pre="causes a strong decrease in thioredoxin interaction protein (TXNIP) in" exact="breast cancer" post="cells. However, little is known regarding the prognostic value"/>
   <result pre="a strong decrease in thioredoxin interaction protein (TXNIP) in breast" exact="cancer" post="cells. However, little is known regarding the prognostic value"/>
   <result pre="is known regarding the prognostic value of TXNIP in clinical" exact="breast cancer" post="patients with anti-Her-2 treatment. Using a tissue microarray, we"/>
   <result pre="known regarding the prognostic value of TXNIP in clinical breast" exact="cancer" post="patients with anti-Her-2 treatment. Using a tissue microarray, we"/>
   <result pre="a tissue microarray, we detected TXNIP and p27 expression in" exact="breast cancer" post="tissue, as well as corresponding noncancerous tissues. We found"/>
   <result pre="tissue microarray, we detected TXNIP and p27 expression in breast" exact="cancer" post="tissue, as well as corresponding noncancerous tissues. We found"/>
   <result pre="was associated with better overall survival (OS) in these 150" exact="breast cancer" post="patients and that TXNIP and Her-2 expression status were"/>
   <result pre="associated with better overall survival (OS) in these 150 breast" exact="cancer" post="patients and that TXNIP and Her-2 expression status were"/>
   <result pre="correlated (r=-0.334, P&amp;lt;0.001). These results were validated in another 101" exact="breast cancer" post="tissue samples (r=-0.422, P&amp;lt;0.001). Moreover, TXNIP expression increased significantly"/>
   <result pre="(r=-0.334, P&amp;lt;0.001). These results were validated in another 101 breast" exact="cancer" post="tissue samples (r=-0.422, P&amp;lt;0.001). Moreover, TXNIP expression increased significantly"/>
   <result pre="Moreover, TXNIP expression increased significantly following treatment of the human" exact="breast cancer" post="cell lines BT474 and SK-BR-3 with a Her-1/2 inhibitor."/>
   <result pre="TXNIP expression increased significantly following treatment of the human breast" exact="cancer" post="cell lines BT474 and SK-BR-3 with a Her-1/2 inhibitor."/>
   <result pre="anti-Her-1/Her-2 treatment and may be a potential prognostic marker in" exact="breast cancer." post="TXNIP p27 Her-1/2 inhibitor breast cancer INTRODUCTION As a"/>
   <result pre="potential prognostic marker in breast cancer. TXNIP p27 Her-1/2 inhibitor" exact="breast cancer" post="INTRODUCTION As a negative regulator of thioredoxin (TRX), thioredoxin"/>
   <result pre="prognostic marker in breast cancer. TXNIP p27 Her-1/2 inhibitor breast" exact="cancer" post="INTRODUCTION As a negative regulator of thioredoxin (TRX), thioredoxin"/>
   <result pre="suppressor gene in various solid tumors and hematological malignancies, including" exact="breast cancer" post="[ 2]. A recent study on the association of"/>
   <result pre="gene in various solid tumors and hematological malignancies, including breast" exact="cancer" post="[ 2]. A recent study on the association of"/>
   <result pre="on the association of TXNIP expression and metastasis-free survival of" exact="breast cancer" post="patients found that TXNIP was associated with better prognosis"/>
   <result pre="the association of TXNIP expression and metastasis-free survival of breast" exact="cancer" post="patients found that TXNIP was associated with better prognosis"/>
   <result pre="It has also been reported that the redox balance in" exact="cancer" post="cells is disrupted by oxidative stress caused by accelerated"/>
   <result pre="TXNIP has recently been proposed as a therapeutic target for" exact="cancer" post="treatment [ 4]. TXNIP may also be a prognostic"/>
   <result pre="[ 4]. TXNIP may also be a prognostic marker of" exact="breast cancer" post="response to anthracycline-based chemotherapy [ 5]. Based on immunohistochemical"/>
   <result pre="4]. TXNIP may also be a prognostic marker of breast" exact="cancer" post="response to anthracycline-based chemotherapy [ 5]. Based on immunohistochemical"/>
   <result pre="Based on immunohistochemical (IHC) staining of 98 locally advanced primary" exact="breast cancer" post="patients, TXNIP was found to be an independent prognostic"/>
   <result pre="on immunohistochemical (IHC) staining of 98 locally advanced primary breast" exact="cancer" post="patients, TXNIP was found to be an independent prognostic"/>
   <result pre="little is known about the prognostic value of TXNIP in" exact="breast cancer" post="patients receiving anti-Her-2 treatment and its relevance to overall"/>
   <result pre="is known about the prognostic value of TXNIP in breast" exact="cancer" post="patients receiving anti-Her-2 treatment and its relevance to overall"/>
   <result pre="survival (OS). Here, we investigated TXNIP expression in early stage" exact="breast cancer" post="patients and its association with OS. We further evaluated"/>
   <result pre="(OS). Here, we investigated TXNIP expression in early stage breast" exact="cancer" post="patients and its association with OS. We further evaluated"/>
   <result pre="Her-1/2 pathway as well as its effects on OS of" exact="breast cancer" post="patients. RESULTS TXNIP and p27 are associated with OS"/>
   <result pre="pathway as well as its effects on OS of breast" exact="cancer" post="patients. RESULTS TXNIP and p27 are associated with OS"/>
   <result pre="patients. RESULTS TXNIP and p27 are associated with OS in" exact="breast cancer" post="patients To evaluate the putative association between TXNIP and"/>
   <result pre="RESULTS TXNIP and p27 are associated with OS in breast" exact="cancer" post="patients To evaluate the putative association between TXNIP and"/>
   <result pre="collected and correlations of TXNIP expression with clinicopathological factors of" exact="breast cancer" post="patients were determined (Table 1). Of the 150 tumor"/>
   <result pre="and correlations of TXNIP expression with clinicopathological factors of breast" exact="cancer" post="patients were determined (Table 1). Of the 150 tumor"/>
   <result pre="low levels, respectively. TXNIP and p27 expressions were decreased in" exact="breast cancer" post="tissue compared with NCTs ( P =0.003, P &amp;lt;0.001,"/>
   <result pre="levels, respectively. TXNIP and p27 expressions were decreased in breast" exact="cancer" post="tissue compared with NCTs ( P =0.003, P &amp;lt;0.001,"/>
   <result pre="correlation was found between TXNIP and Her-2 status using the" exact="breast cancer" post="tissue-array (n=150) (r=-0.334, P&amp;lt;0.001), which was again validated in"/>
   <result pre="was found between TXNIP and Her-2 status using the breast" exact="cancer" post="tissue-array (n=150) (r=-0.334, P&amp;lt;0.001), which was again validated in"/>
   <result pre="correlation was found between p27 and Her-2 status using the" exact="breast cancer" post="tissue-array (n=150) (r=-0.344, P&amp;lt;0.001) that was confirmed in the"/>
   <result pre="was found between p27 and Her-2 status using the breast" exact="cancer" post="tissue-array (n=150) (r=-0.344, P&amp;lt;0.001) that was confirmed in the"/>
   <result pre="positive correlation was found between TXNIP and p27 using the" exact="breast cancer" post="tissue-array (n=150) (r=0.340, P&amp;lt;0.001) that was confirmed in the"/>
   <result pre="correlation was found between TXNIP and p27 using the breast" exact="cancer" post="tissue-array (n=150) (r=0.340, P&amp;lt;0.001) that was confirmed in the"/>
   <result pre="1 Relationship between expression of TXNIP and clinicopathologic characteristics of" exact="breast cancer" post="patients Variables TXNIP high (n=48) TXNIP low (n=102) P-value"/>
   <result pre="Relationship between expression of TXNIP and clinicopathologic characteristics of breast" exact="cancer" post="patients Variables TXNIP high (n=48) TXNIP low (n=102) P-value"/>
   <result pre="Note: NCTs: corresponding noncancerous tissues. TXNIP or p27 expression between" exact="breast cancer" post="and NCTs was tested by Two-Related-samples test. Table 3"/>
   <result pre="NCTs: corresponding noncancerous tissues. TXNIP or p27 expression between breast" exact="cancer" post="and NCTs was tested by Two-Related-samples test. Table 3"/>
   <result pre="1 The association of TXNIP and p27 with OS in" exact="breast cancer" post="tissues and NCTs in a tissue-array (A) Low expression"/>
   <result pre="The association of TXNIP and p27 with OS in breast" exact="cancer" post="tissues and NCTs in a tissue-array (A) Low expression"/>
   <result pre="breast cancers compared with NCTs were demonstrated by IHC of" exact="breast cancer" post="tissues and NCTs. (B) High TXNIP or positive p27"/>
   <result pre="cancers compared with NCTs were demonstrated by IHC of breast" exact="cancer" post="tissues and NCTs. (B) High TXNIP or positive p27"/>
   <result pre="cell cycle arrest and inhibits cell proliferation in Her-1/2 positive" exact="breast cancer" post="cell lines Recent studies suggest that TXNIP plays an"/>
   <result pre="cycle arrest and inhibits cell proliferation in Her-1/2 positive breast" exact="cancer" post="cell lines Recent studies suggest that TXNIP plays an"/>
   <result pre="TXNIP in the cell cycle control and cell proliferation in" exact="breast cancer," post="we found that TXNIP overexpression enhanced G 1 cell"/>
   <result pre="Her-1/Her-2 tyrosine kinase inhibitor, has potent antitumor effects against human" exact="breast cancer" post="[ 9]. To investigate whether TXNIP enhances lapatinib-induced inhibition"/>
   <result pre="tyrosine kinase inhibitor, has potent antitumor effects against human breast" exact="cancer" post="[ 9]. To investigate whether TXNIP enhances lapatinib-induced inhibition"/>
   <result pre="may enhance lapatinib-induced inhibition of cell proliferation in Her-1/2 positive" exact="breast cancer" post="cell lines. Figure 2 TXNIP causes G cell cycle"/>
   <result pre="enhance lapatinib-induced inhibition of cell proliferation in Her-1/2 positive breast" exact="cancer" post="cell lines. Figure 2 TXNIP causes G cell cycle"/>
   <result pre="cell cycle arrest and inhibits cell proliferation in HER-1/2 positive" exact="breast cancer" post="cell lines (A and B) The percentage of G"/>
   <result pre="cycle arrest and inhibits cell proliferation in HER-1/2 positive breast" exact="cancer" post="cell lines (A and B) The percentage of G"/>
   <result pre="investigate whether the Her-1/2 pathway affects TXNIP expression in human" exact="breast cancer" post="cells, BT474 and SK-BR-3 cells were treated with 10"/>
   <result pre="whether the Her-1/2 pathway affects TXNIP expression in human breast" exact="cancer" post="cells, BT474 and SK-BR-3 cells were treated with 10"/>
   <result pre="a significant negative correlation between TXNIP and Her-2 status in" exact="breast cancer," post="and showed that inhibition of the Her-1/2 pathway resulted"/>
   <result pre="reports indicating that Her-2 induction strongly inhibits TXNIP expression in" exact="breast cancer" post="cells [ 2]. Also, using a tissue array, we"/>
   <result pre="indicating that Her-2 induction strongly inhibits TXNIP expression in breast" exact="cancer" post="cells [ 2]. Also, using a tissue array, we"/>
   <result pre="array, we found decreased expression of TXNIP and p27 in" exact="breast cancer" post="tissue, compared with NCTs. Further study indicated that overexpression"/>
   <result pre="we found decreased expression of TXNIP and p27 in breast" exact="cancer" post="tissue, compared with NCTs. Further study indicated that overexpression"/>
   <result pre="is an independent prognostic factor for poor overall and disease-free" exact="cancer" post="survival [ 11]. The human EGFR family comprises four"/>
   <result pre="and Her-4 (also known as ErbB4) [ 1]. Treatment of" exact="breast cancer" post="cells with a combination of Her-1 and Her-2 inhibitors"/>
   <result pre="Her-4 (also known as ErbB4) [ 1]. Treatment of breast" exact="cancer" post="cells with a combination of Her-1 and Her-2 inhibitors"/>
   <result pre="availability for activation of the NLRP3 inflammasome [ 13]. Also," exact="hyperglycemia" post="regulates thioredoxin-ROS activity through induction of TXNIP in breast"/>
   <result pre="Also, hyperglycemia regulates thioredoxin-ROS activity through induction of TXNIP in" exact="breast cancer" post="derived cells [ 14, 15]. Inhibition of EGF signaling"/>
   <result pre="hyperglycemia regulates thioredoxin-ROS activity through induction of TXNIP in breast" exact="cancer" post="derived cells [ 14, 15]. Inhibition of EGF signaling"/>
   <result pre="cells [ 14, 15]. Inhibition of EGF signaling in Her-2-positive" exact="breast cancer" post="has been associated with glucose deprivation and energetic stress"/>
   <result pre="[ 14, 15]. Inhibition of EGF signaling in Her-2-positive breast" exact="cancer" post="has been associated with glucose deprivation and energetic stress"/>
   <result pre="network genes [ 17]. Therefore, TXNIP may be induced via" exact="hyperglycemia" post="regulated thioredoxin-ROS activity in Her-1/2 signaling pathway. Information regarding"/>
   <result pre="TXNIP interaction with the Her-1/2 pathway contributes to OS of" exact="breast cancer" post="(Figure 4). When treated with the anti-Her-1 monoclonal antibody"/>
   <result pre="interaction with the Her-1/2 pathway contributes to OS of breast" exact="cancer" post="(Figure 4). When treated with the anti-Her-1 monoclonal antibody"/>
   <result pre="inhibitor lapatinib, TXNIP mRNA and protein levels were increased in" exact="breast cancer" post="cells. Overexpression of TXNIP was accompanied by increased p27"/>
   <result pre="lapatinib, TXNIP mRNA and protein levels were increased in breast" exact="cancer" post="cells. Overexpression of TXNIP was accompanied by increased p27"/>
   <result pre="and p27 expression were associated with better OS in human" exact="breast cancer" post="patients. In conclusion, TXNIP may interrupt Her receptor family"/>
   <result pre="p27 expression were associated with better OS in human breast" exact="cancer" post="patients. In conclusion, TXNIP may interrupt Her receptor family"/>
   <result pre="Her receptor family mediated oncogenic pathways thereby increasing OS in" exact="breast cancer" post="patients. Our findings suggest TXNIP plays a critical role"/>
   <result pre="receptor family mediated oncogenic pathways thereby increasing OS in breast" exact="cancer" post="patients. Our findings suggest TXNIP plays a critical role"/>
   <result pre="anti-Her-1/Her-2 treatment and may be a potential prognostic marker in" exact="breast cancer." post="Figure 4 Schematic model demonstrating the critical role of"/>
   <result pre="of TXNIP and p27 in Her-1/2 mediated cell proliferation in" exact="breast cancer" post="cell MATERIALS AND METHODS Clinical samples Breast cancer tissues"/>
   <result pre="TXNIP and p27 in Her-1/2 mediated cell proliferation in breast" exact="cancer" post="cell MATERIALS AND METHODS Clinical samples Breast cancer tissues"/>
   <result pre="in breast cancer cell MATERIALS AND METHODS Clinical samples Breast" exact="cancer" post="tissues and corresponding noncancerous tissues (NCTs) sections containing HBre-Duc170Sur-01"/>
   <result pre="tissues and corresponding noncancerous tissues (NCTs) sections containing HBre-Duc170Sur-01 (170" exact="cancer" post="cases) and HBre-Duc090Sur-01 (90 NCTs) were provided by Outdo"/>
   <result pre="200; Carl Zeiss). Cell cultures and Her-1/2 inhibitor treatment Breast" exact="cancer" post="cell lines (BT474 and SK-BR-3) were purchased from the"/>
   <result pre="thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of" exact="breast cancer" post="Breast cancer research : BCR 2010 12 3 R44"/>
   <result pre="reductase 1 and thioredoxin interacting protein in prognosis of breast" exact="cancer" post="Breast cancer research : BCR 2010 12 3 R44"/>
   <result pre="and thioredoxin interacting protein in prognosis of breast cancer Breast" exact="cancer" post="research : BCR 2010 12 3 R44 20584310 3"/>
   <result pre="D Redox-sensitive signaling factors as a novel molecular targets for" exact="cancer" post="therapy Drug resistance updates : reviews and commentaries in"/>
   <result pre="Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in" exact="thyroid cancer" post="Molecular cancer 2014 13 62 24645981 5 Woolston CM"/>
   <result pre="interacting protein (TXNIP) is a novel tumor suppressor in thyroid" exact="cancer" post="Molecular cancer 2014 13 62 24645981 5 Woolston CM"/>
   <result pre="(TXNIP) is a novel tumor suppressor in thyroid cancer Molecular" exact="cancer" post="2014 13 62 24645981 5 Woolston CM Zhang L"/>
   <result pre="redox protein expression for anthracycline-based chemotherapy response in locally advanced" exact="breast cancer" post="Modern pathology : an official journal of the United"/>
   <result pre="protein expression for anthracycline-based chemotherapy response in locally advanced breast" exact="cancer" post="Modern pathology : an official journal of the United"/>
   <result pre="Sui L Tokuda M FOXO/TXNIP pathway is involved in the" exact="suppression" post="of hepatocellular carcinoma growth by glutamate antagonist MK-801 BMC"/>
   <result pre="Tokuda M FOXO/TXNIP pathway is involved in the suppression of" exact="hepatocellular carcinoma" post="growth by glutamate antagonist MK-801 BMC cancer 2013 13"/>
   <result pre="suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801 BMC" exact="cancer" post="2013 13 468 24112473 7 Zhou J Chng WJ"/>
   <result pre="of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and" exact="cancer" post="Mitochondrion 2013 13 3 163 169 22750447 8 Akli"/>
   <result pre="cyclin E is associated with p27-resistant, high-grade, high-stage and invasive" exact="bladder cancer" post="Cell cycle (Georgetown, Tex) 2012 11 7 1468 1476"/>
   <result pre="E is associated with p27-resistant, high-grade, high-stage and invasive bladder" exact="cancer" post="Cell cycle (Georgetown, Tex) 2012 11 7 1468 1476"/>
   <result pre="signal transduction and regulation of cell cycle regulatory proteins in" exact="breast cancer" post="cells Breast cancer research and treatment 2010 123 2"/>
   <result pre="transduction and regulation of cell cycle regulatory proteins in breast" exact="cancer" post="cells Breast cancer research and treatment 2010 123 2"/>
   <result pre="of cell cycle regulatory proteins in breast cancer cells Breast" exact="cancer" post="research and treatment 2010 123 2 387 396 19946741"/>
   <result pre="thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231 BMC" exact="cancer" post="2007 7 96 17555594 15 Turturro F Von Burton"/>
   <result pre="differs in breast cancer-derived cells and regulates paclitaxel IC50 Clinical" exact="cancer" post="research : an official journal of the American Association"/>
   <result pre="PT The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive" exact="breast cancer" post="cells Molecular systems biology 2012 8 596 22864381 18"/>
   <result pre="The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast" exact="cancer" post="cells Molecular systems biology 2012 8 596 22864381 18"/>
   <result pre="p73 gene by Nrf-2 and promoter CpG methylation in human" exact="breast cancer" post="Oncotarget 2014 5 16 6909 6922 25071010"/>
   <result pre="gene by Nrf-2 and promoter CpG methylation in human breast" exact="cancer" post="Oncotarget 2014 5 16 6909 6922 25071010"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4423419/results/search/disease/results.xml">
   <result pre="10.1186/s13058-015-0568-1 : Research Article Long-term hazard of recurrence in HER2+" exact="breast cancer" post="patients untreated with anti-HER2 therapy Strasser-Weippl Kathrin kathrin.strasserweippl@gmail.com Horick"/>
   <result pre=": Research Article Long-term hazard of recurrence in HER2+ breast" exact="cancer" post="patients untreated with anti-HER2 therapy Strasser-Weippl Kathrin kathrin.strasserweippl@gmail.com Horick"/>
   <result pre="patients with HER2+ (human epidermal growth factor receptor 2-positive) early" exact="breast cancer" post="(BC) do not receive adjuvant trastuzumab. Hazards of recurrence"/>
   <result pre="with HER2+ (human epidermal growth factor receptor 2-positive) early breast" exact="cancer" post="(BC) do not receive adjuvant trastuzumab. Hazards of recurrence"/>
   <result pre="localized high-risk human epidermal growth factor receptor 2-positive (HER2+) early" exact="breast cancer" post="(BC) substantially reduces the risk of disease recurrence and"/>
   <result pre="high-risk human epidermal growth factor receptor 2-positive (HER2+) early breast" exact="cancer" post="(BC) substantially reduces the risk of disease recurrence and"/>
   <result pre="Baseline clinical characteristics of placebo patients with centrally confirmed HER2+" exact="breast cancer" post="in TEACH N (%) All HR− HR+ ( N"/>
   <result pre="clinical characteristics of placebo patients with centrally confirmed HER2+ breast" exact="cancer" post="in TEACH N (%) All HR− HR+ ( N"/>
   <result pre="trial in participating centers. Abbreviations AIC Akaike information criterion BC" exact="breast cancer" post="DFS disease-free survival ER+ estrogen receptor positive ER- estrogen"/>
   <result pre="in participating centers. Abbreviations AIC Akaike information criterion BC breast" exact="cancer" post="DFS disease-free survival ER+ estrogen receptor positive ER- estrogen"/>
   <result pre="PE Barrios CH Simon SD Finkelstein DM Goss PE Breast" exact="cancer" post="in Brazil: present status and future goals Lancet Oncol"/>
   <result pre="arbitrarily censored and truncated data: application to age-specific incidence of" exact="dementia" post="Biometrics 1998 54 185 94 10.2307/2534006 9574965 6. Akaike"/>
   <result pre="expression and histopathology on annual hazard rates of death from" exact="breast cancer" post="Breast Cancer Res Treat 2006 100 121 6 10.1007/s10549-006-9231-y"/>
   <result pre="and histopathology on annual hazard rates of death from breast" exact="cancer" post="Breast Cancer Res Treat 2006 100 121 6 10.1007/s10549-006-9231-y"/>
   <result pre="GM Time-dependence of hazard ratios for prognostic factors in primary" exact="breast cancer" post="Breast Cancer Res Treat 1998 52 227 37 10.1023/A:1006133418245"/>
   <result pre="Time-dependence of hazard ratios for prognostic factors in primary breast" exact="cancer" post="Breast Cancer Res Treat 1998 52 227 37 10.1023/A:1006133418245"/>
   <result pre="Buzdar AU Hortobagyi GN Estrogen receptors and distinct patterns of" exact="breast cancer" post="relapse Breast Cancer Res Treat 2003 78 105 18"/>
   <result pre="AU Hortobagyi GN Estrogen receptors and distinct patterns of breast" exact="cancer" post="relapse Breast Cancer Res Treat 2003 78 105 18"/>
   <result pre="recurrence and adjuvant treatment effects over time in lymph node-negative" exact="breast cancer" post="Breast Cancer Res Treat 2009 116 595 602 10.1007/s10549-008-0200-5"/>
   <result pre="and adjuvant treatment effects over time in lymph node-negative breast" exact="cancer" post="Breast Cancer Res Treat 2009 116 595 602 10.1007/s10549-008-0200-5"/>
   <result pre="Tormey DC Gray R Annual hazard rates of recurrence for" exact="breast cancer" post="after primary therapy J Clin Oncol 1996 14 2738"/>
   <result pre="DC Gray R Annual hazard rates of recurrence for breast" exact="cancer" post="after primary therapy J Clin Oncol 1996 14 2738"/>
   <result pre="Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1659 72 10.1056/NEJMoa052306"/>
   <result pre="I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1659 72 10.1056/NEJMoa052306"/>
   <result pre="the clinical benefit of trastuzumab therapy for patients with metastatic" exact="breast cancer" post="Clin Breast Cancer 2005 6 247 52 10.3816/CBC.2005.n.027 16137436"/>
   <result pre="clinical benefit of trastuzumab therapy for patients with metastatic breast" exact="cancer" post="Clin Breast Cancer 2005 6 247 52 10.3816/CBC.2005.n.027 16137436"/>
   <result pre="adjuvant trastuzumab compared with no trastuzumab for patients with HER2-positive" exact="breast cancer" post="and tumors ≤2 cm: a meta-analysis of the randomized"/>
   <result pre="trastuzumab compared with no trastuzumab for patients with HER2-positive breast" exact="cancer" post="and tumors ≤2 cm: a meta-analysis of the randomized"/>
   <result pre="benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive" exact="breast cancer" post="patients J Clin Oncol 2005 23 4287 97 10.1200/JCO.2005.11.012"/>
   <result pre="from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast" exact="cancer" post="patients J Clin Oncol 2005 23 4287 97 10.1200/JCO.2005.11.012"/>
   <result pre="D et al. HER2 and response to paclitaxel in node-positive" exact="breast cancer" post="N Engl J Med 2007 357 1496 506 10.1056/NEJMoa071167"/>
   <result pre="et al. HER2 and response to paclitaxel in node-positive breast" exact="cancer" post="N Engl J Med 2007 357 1496 506 10.1056/NEJMoa071167"/>
   <result pre="NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1673 84 10.1056/NEJMoa052122"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1673 84 10.1056/NEJMoa052122"/>
   <result pre="NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive" exact="breast cancer" post="Proc Am Soc Clin Oncol 2007 25 512"/>
   <result pre="B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast" exact="cancer" post="Proc Am Soc Clin Oncol 2007 25 512"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4424224/results/search/disease/results.xml">
   <result pre="normal brain and brain metastases in patients with Her-2 overexpressing" exact="breast cancer" post="Saleem Azeem Azeem.Saleem@Imanova.co.uk Searle Graham E graham.searle@imanova.co.uk Kenny Laura"/>
   <result pre="brain and brain metastases in patients with Her-2 overexpressing breast" exact="cancer" post="Saleem Azeem Azeem.Saleem@Imanova.co.uk Searle Graham E graham.searle@imanova.co.uk Kenny Laura"/>
   <result pre="metastases are common in human epidermal growth factor receptor (Her)-2-positive" exact="breast cancer." post="Drug access to brain metastases and normal brain is"/>
   <result pre="evidence of cranial drug access. Methods Patients with Her-2+ metastatic" exact="breast cancer" post="either with at least one 1-cm diameter brain metastasis"/>
   <result pre="of cranial drug access. Methods Patients with Her-2+ metastatic breast" exact="cancer" post="either with at least one 1-cm diameter brain metastasis"/>
   <result pre="registration ClinicalTrials.gov: NCT01290354 Keywords Lapatinib bio-distribution in brain metastases Her-2-positive" exact="breast cancer" post="PET imaging Blood-brain barrier Background Overexpression of human epidermal"/>
   <result pre="ClinicalTrials.gov: NCT01290354 Keywords Lapatinib bio-distribution in brain metastases Her-2-positive breast" exact="cancer" post="PET imaging Blood-brain barrier Background Overexpression of human epidermal"/>
   <result pre="Background Overexpression of human epidermal growth factor receptor (Her)-2 in" exact="breast cancer" post="is considered an independent factor for development of brain"/>
   <result pre="Overexpression of human epidermal growth factor receptor (Her)-2 in breast" exact="cancer" post="is considered an independent factor for development of brain"/>
   <result pre="BBB. In addition, since lapatinib is a P-glycoprotein (Pgp) and" exact="breast cancer" post="resistance protein (BCRP) substrate, therapeutic doses of lapatinib may"/>
   <result pre="In addition, since lapatinib is a P-glycoprotein (Pgp) and breast" exact="cancer" post="resistance protein (BCRP) substrate, therapeutic doses of lapatinib may"/>
   <result pre="with carbon-11 radiolabelled lapatinib ([ 11C]lapatinib) in patients with Her-2-positive" exact="breast cancer." post="Further, in order to test our hypothesis that therapeutic"/>
   <result pre="design An open-label study was performed in patients with Her-2-positive" exact="breast cancer" post="with no brain metastases (cohort 1) and with at"/>
   <result pre="An open-label study was performed in patients with Her-2-positive breast" exact="cancer" post="with no brain metastases (cohort 1) and with at"/>
   <result pre="18 years with histologically or cytologically confirmed advanced or metastatic" exact="breast cancer" post="with overexpression of Her-2, Eastern Cooperative Oncology Group (ECOG)"/>
   <result pre="years with histologically or cytologically confirmed advanced or metastatic breast" exact="cancer" post="with overexpression of Her-2, Eastern Cooperative Oncology Group (ECOG)"/>
   <result pre="range of the half maximal inhibitory concentration (IC 50) for" exact="breast cancer" post="cell lines (0.025 to 5 μM) [ 4]. However,"/>
   <result pre="of the half maximal inhibitory concentration (IC 50) for breast" exact="cancer" post="cell lines (0.025 to 5 μM) [ 4]. However,"/>
   <result pre="of cranial disease remains a challenge in patients with Her-2-positive" exact="breast cancer" post="and is an unmet need [ 2]. Although lapatinib"/>
   <result pre="cranial disease remains a challenge in patients with Her-2-positive breast" exact="cancer" post="and is an unmet need [ 2]. Although lapatinib"/>
   <result pre="cost-saving and rational drug development. Key message Patients with Her-2-positive" exact="breast cancer" post="have higher incidence of brain metastases. PET scans were"/>
   <result pre="and rational drug development. Key message Patients with Her-2-positive breast" exact="cancer" post="have higher incidence of brain metastases. PET scans were"/>
   <result pre="MC Voduc D Speers CH et al. Metastatic behavior of" exact="breast cancer" post="subtypes J Clin Oncol 2010 28 20 3271 7"/>
   <result pre="Voduc D Speers CH et al. Metastatic behavior of breast" exact="cancer" post="subtypes J Clin Oncol 2010 28 20 3271 7"/>
   <result pre="increased risk of visceral metastasis and poor long-term survival in" exact="breast cancer" post="Int J Cancer 1991 49 5 650 5 10.1002/ijc.2910490504"/>
   <result pre="risk of visceral metastasis and poor long-term survival in breast" exact="cancer" post="Int J Cancer 1991 49 5 650 5 10.1002/ijc.2910490504"/>
   <result pre="al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of" exact="breast cancer" post="Pharm Res 2012 29 3 770 81 10.1007/s11095-011-0601-8 22011930"/>
   <result pre="Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast" exact="cancer" post="Pharm Res 2012 29 3 770 81 10.1007/s11095-011-0601-8 22011930"/>
   <result pre="and lapatinib uptake in surgically resected brain metastases from metastatic" exact="breast cancer" post="patients: a prospective study Neuro Oncol 2015 17 2"/>
   <result pre="lapatinib uptake in surgically resected brain metastases from metastatic breast" exact="cancer" post="patients: a prospective study Neuro Oncol 2015 17 2"/>
   <result pre="study of lapatinib in patients with brain metastases from HER2-positive" exact="breast cancer" post="Clin Cancer Res 2009 15 4 1452 9 10.1158/1078-0432.CCR-08-1080"/>
   <result pre="of lapatinib in patients with brain metastases from HER2-positive breast" exact="cancer" post="Clin Cancer Res 2009 15 4 1452 9 10.1158/1078-0432.CCR-08-1080"/>
   <result pre="in patients with previously untreated brain metastases from HER2-positive metastatic" exact="breast cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="patients with previously untreated brain metastases from HER2-positive metastatic breast" exact="cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="SM et al. An unexpected synergist role of P-glycoprotein and" exact="breast cancer" post="resistance protein on the central nervous system penetration of"/>
   <result pre="et al. An unexpected synergist role of P-glycoprotein and breast" exact="cancer" post="resistance protein on the central nervous system penetration of"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer." post="J Clin Oncol. 2015. Epub: 2015/01/22."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4427936/results/search/disease/results.xml">
   <result pre="10.1186/s12885-015-1407-6 : Research Article The prevention, detection and management of" exact="cancer" post="treatment-induced cardiotoxicity: a meta-review Conway Aaron aaron.conway@qut.edu.au McCarthy Alexandra"/>
   <result pre="unless otherwise stated. Abstract Background The benefits associated with some" exact="cancer" post="treatments do not come without risk. A serious side"/>
   <result pre="come without risk. A serious side effect of some common" exact="cancer" post="treatments is cardiotoxicity. Increased recognition of the public health"/>
   <result pre="is cardiotoxicity. Increased recognition of the public health implications of" exact="cancer" post="treatment-induced cardiotoxicity has resulted in a proliferation of systematic"/>
   <result pre="systematic reviews focused on the prevention, detection or management of" exact="cancer" post="treatment-induced cardiotoxicity. Methods Using Cochrane methodology, we searched databases,"/>
   <result pre="clinical decision-making with respect to the detection and management of" exact="cancer" post="treatment-associated cardiotoxicity. There is more evidence with respect to"/>
   <result pre="with respect to the prevention of this adverse effect of" exact="cancer" post="treatment. This evidence, however, only applies to anthracycline-based chemotherapy"/>
   <result pre="diagnostic imaging, advances in therapy and the implementation of multidisciplinary" exact="cancer" post="care [ 3], have contributed to improved cancer survival"/>
   <result pre="of multidisciplinary cancer care [ 3], have contributed to improved" exact="cancer" post="survival rates over recent decades [ 4, 5]. Advances"/>
   <result pre="in chemo- and radiotherapy have had the most impact on" exact="cancer" post="survival [ 6]. The benefits associated with some cancer"/>
   <result pre="on cancer survival [ 6]. The benefits associated with some" exact="cancer" post="treatments, however, do not come without risk. A devastating"/>
   <result pre="come without risk. A devastating side effect of some common" exact="cancer" post="treatments is cardiotoxicity-principally heart failure. The risk of cardiotoxicity"/>
   <result pre="of cardiotoxicity varies according to the type and intensity of" exact="cancer" post="treatment. Heart failure incidence rates associated with the commonly-prescribed"/>
   <result pre="13] is likely to become even more prevalent as the" exact="cancer" post="population ages and novel, so-called ‘targeted’ treatment regimens that"/>
   <result pre="is expected to increase as more people successfully complete acute" exact="cancer" post="treatment, has resulted in a great deal of research"/>
   <result pre="and non-systematic review methodology). Guidelines for preventing, monitoring and treating" exact="cancer" post="treatment-induced cardiotoxicity are available [ 8]. Non-systematic reviews have"/>
   <result pre="been published to support clinical practice and research related to" exact="cancer" post="treatment-induced cardiotoxicity [ 15]. In addition, a number of"/>
   <result pre="reviews and meta-analyses that have addressed the important issue of" exact="cancer" post="treatment-induced cardiotoxicity. Our aim was to appraise and synthesise"/>
   <result pre="have focused on the prevention, early detection and management of" exact="cancer" post="treatment-induced cardiotoxicity in order to aid policy and practice"/>
   <result pre="results) • Publication: Full peer-reviewed publication • Population: Patients with" exact="cancer" post="• Intervention: Any intervention applied to prevent, diagnose or"/>
   <result pre="• Intervention: Any intervention applied to prevent, diagnose or manage" exact="cancer" post="treatment-induced cardiotoxicity. • Comparison: Any comparison. • Outcome: Cardiotoxicity,"/>
   <result pre="focused on identifying the incidence of cardiotoxicity associated with particular" exact="cancer" post="treatment regimens. • Poor quality (Literature search was not"/>
   <result pre="• L-carnitine Itchaki et al. 2013 [ 33] P: advanced" exact="follicular lymphoma" post="• 8 RCT conducted between 1974 and 2011. •"/>
   <result pre="L-carnitine Itchaki et al. 2013 [ 33] P: advanced follicular" exact="lymphoma" post="• 8 RCT conducted between 1974 and 2011. •"/>
   <result pre="[ 32] P: child and adult patients with Breast or" exact="ovarian cancer," post="sarcoma, non-Hodgkin's or Hodgkin's lymphoma, myeloma • 55 RCT"/>
   <result pre="of follow-up was not reported Prevention of cardiotoxicity associated with" exact="prostate cancer" post="treatment Shelley et al. (2008) [ 27] P: Hormone-refractory"/>
   <result pre="follow-up was not reported Prevention of cardiotoxicity associated with prostate" exact="cancer" post="treatment Shelley et al. (2008) [ 27] P: Hormone-refractory"/>
   <result pre="cancer treatment Shelley et al. (2008) [ 27] P: Hormone-refractory" exact="prostate cancer" post="• 47 RCT published between 1977 and 2005 Drug"/>
   <result pre="treatment Shelley et al. (2008) [ 27] P: Hormone-refractory prostate" exact="cancer" post="• 47 RCT published between 1977 and 2005 Drug"/>
   <result pre="0.001) Sieswerda et al. 2011 [ 37] P: children with" exact="cancer" post="• 15 observational studies published between 1998 and 2007"/>
   <result pre="Van dalen et al. 2012 [ 28] P: children with" exact="cancer" post="• 8 RCT published from 1975 to 2009 1153"/>
   <result pre="25–60 mg/m2 Tumour response cardiotoxicity Prevention of cardiotoxicity associated with" exact="breast cancer" post="treatment Valachis et al. (2013) [ 24] P: Breast"/>
   <result pre="mg/m2 Tumour response cardiotoxicity Prevention of cardiotoxicity associated with breast" exact="cancer" post="treatment Valachis et al. (2013) [ 24] P: Breast"/>
   <result pre="cancer treatment Valachis et al. (2013) [ 24] P: Breast" exact="cancer" post="• 6 controlled trials that were all published in"/>
   <result pre="or pertuzumab) • Pooled OR for CHF in patients with" exact="breast cancer" post="receiving dual anti-HER2 therapy versus anti-HER2 monotherapy was 0.58"/>
   <result pre="pertuzumab) • Pooled OR for CHF in patients with breast" exact="cancer" post="receiving dual anti-HER2 therapy versus anti-HER2 monotherapy was 0.58"/>
   <result pre="3 or more. Viani et al. 2007 P: HER-2-positive early" exact="breast cancer" post="• 5 RCT published in 2005 and 2006 Doxorubicin"/>
   <result pre="or more. Viani et al. 2007 P: HER-2-positive early breast" exact="cancer" post="• 5 RCT published in 2005 and 2006 Doxorubicin"/>
   <result pre="(statistically significant heterogeneity) O: mortality, recurrance, metastases, second tumour no" exact="breast cancer" post="rate Docetaxel, carboplatin + trastuz. Cardiac toxicity and brain"/>
   <result pre="significant heterogeneity) O: mortality, recurrance, metastases, second tumour no breast" exact="cancer" post="rate Docetaxel, carboplatin + trastuz. Cardiac toxicity and brain"/>
   <result pre="docetaxel. Qin et al. 2011 [ 21] P: node negative" exact="breast cancer" post="• 19 RCT published from 2003 to 2010 Taxane"/>
   <result pre="Qin et al. 2011 [ 21] P: node negative breast" exact="cancer" post="• 19 RCT published from 2003 to 2010 Taxane"/>
   <result pre="favoured taxane C: chemo without taxane • increased toxicity for" exact="neutropenia" post="(OR = 2.28, 95 % CI 1.25–4.16), fatigue (OR"/>
   <result pre="CI 1.25–4.16), fatigue (OR = 2.10, 95 % CI 1.37–3.22)," exact="diarrhea" post="(OR = 2.16, 95 % CI 1.32–3.53), stomatitis (OR"/>
   <result pre="CI 1.37–3.22), diarrhea (OR = 2.16, 95 % CI 1.32–3.53)," exact="stomatitis" post="(OR 1.68, 95 % CI 1.04–2.71), oedema (OR 6.61,"/>
   <result pre="and recurrence Lord et al. 2008 [ 26] P: metastatic" exact="breast cancer" post="• 34 RCT published between 1974 and 2004 •"/>
   <result pre="recurrence Lord et al. 2008 [ 26] P: metastatic breast" exact="cancer" post="• 34 RCT published between 1974 and 2004 •"/>
   <result pre="the mitoxantrone comparison. Ferguson et al. 2007 [ 22] P:" exact="breast cancer" post="• 12 RCT published from 2002 to 2006 Any"/>
   <result pre="mitoxantrone comparison. Ferguson et al. 2007 [ 22] P: breast" exact="cancer" post="• 12 RCT published from 2002 to 2006 Any"/>
   <result pre="life, cost effectiveness Duarte et al. 2012 [ 25] P:" exact="breast cancer" post="• 4 RCT published between 2003 and 2009 Combinations"/>
   <result pre="cost effectiveness Duarte et al. 2012 [ 25] P: breast" exact="cancer" post="• 4 RCT published between 2003 and 2009 Combinations"/>
   <result pre="Management Sieswerda et al. 2011 [ 38] P: children with" exact="cancer" post="2 RCT published in 2004 and 2008 • Enalapril"/>
   <result pre="Randomised controlled trial. Key findings from systematic reviews Detection of" exact="cancer" post="treatment-induced cardiotoxicity Only one systematic review focused on interventions"/>
   <result pre="cardiotoxicity Only one systematic review focused on interventions to detect" exact="cancer" post="treatment-induced cardiotoxicity [ 36]. This systematic review identified one"/>
   <result pre="the literature search only current to January 2006. Prevention of" exact="cancer" post="treatment-induced cardiotoxicity The majority (n = 16; 89 %) of the"/>
   <result pre="89 %) of the systematic reviews investigated strategies to prevent" exact="cancer" post="treatment-induced cardiotoxicity [ 21– 35, 37]. These reviews were"/>
   <result pre="categorized into the following: Prevention of Cardiotoxicity specifically associated with" exact="breast cancer" post="treatment [ 21– 26] Cardiotoxicity specifically associated with prostate"/>
   <result pre="into the following: Prevention of Cardiotoxicity specifically associated with breast" exact="cancer" post="treatment [ 21– 26] Cardiotoxicity specifically associated with prostate"/>
   <result pre="breast cancer treatment [ 21– 26] Cardiotoxicity specifically associated with" exact="prostate cancer" post="treatment [ 27]; Anthracycline-induced cardiotoxicity in adult cancer patients"/>
   <result pre="cancer treatment [ 21– 26] Cardiotoxicity specifically associated with prostate" exact="cancer" post="treatment [ 27]; Anthracycline-induced cardiotoxicity in adult cancer patients"/>
   <result pre="with prostate cancer treatment [ 27]; Anthracycline-induced cardiotoxicity in adult" exact="cancer" post="patients [ 28, 30– 33] Cardiotoxicity through dietary supplementation"/>
   <result pre="heart failure as the outcome Prevention of cardiotoxicity associated with" exact="breast cancer" post="treatment Two of the breast cancer systematic reviews focused"/>
   <result pre="failure as the outcome Prevention of cardiotoxicity associated with breast" exact="cancer" post="treatment Two of the breast cancer systematic reviews focused"/>
   <result pre="of cardiotoxicity associated with breast cancer treatment Two of the" exact="breast cancer" post="systematic reviews focused on taxane-based chemotherapy [ 21, 22]."/>
   <result pre="cardiotoxicity associated with breast cancer treatment Two of the breast" exact="cancer" post="systematic reviews focused on taxane-based chemotherapy [ 21, 22]."/>
   <result pre="with or without taxanes in women with early or operable" exact="breast cancer" post="(OR 0.95; 95 % CI = 0.67–1.36) [ 21]. An earlier"/>
   <result pre="or without taxanes in women with early or operable breast" exact="cancer" post="(OR 0.95; 95 % CI = 0.67–1.36) [ 21]. An earlier"/>
   <result pre="adverse effects of taxane-based adjuvant chemotherapy in women with early" exact="breast cancer," post="produced similar results [ 22]. Meta-analysis of 6 trials"/>
   <result pre="In comparison, the risk for cardiotoxicity in women with early" exact="breast cancer" post="who received adjuvant chemotherapy without a taxane was 12"/>
   <result pre="comparison, the risk for cardiotoxicity in women with early breast" exact="cancer" post="who received adjuvant chemotherapy without a taxane was 12"/>
   <result pre="systematic reviews that examined the prevention of cardiotoxicity associated with" exact="breast cancer" post="treatment investigated the impact of anti-human epidermal growth factor"/>
   <result pre="reviews that examined the prevention of cardiotoxicity associated with breast" exact="cancer" post="treatment investigated the impact of anti-human epidermal growth factor"/>
   <result pre="determine whether there was an increased risk of cardiotoxicity in" exact="breast cancer" post="patients treated with dual HER-2 blockade (pertuzumab plus trastuzumab,"/>
   <result pre="whether there was an increased risk of cardiotoxicity in breast" exact="cancer" post="patients treated with dual HER-2 blockade (pertuzumab plus trastuzumab,"/>
   <result pre="in this population with no adverse cardiac effects. The second" exact="breast cancer" post="systematic review focused on the anti-HER-2 medication trastuzumab ["/>
   <result pre="this population with no adverse cardiac effects. The second breast" exact="cancer" post="systematic review focused on the anti-HER-2 medication trastuzumab ["/>
   <result pre="of randomized controlled trials of dose-dense anthracycline-based chemotherapy in early" exact="breast cancer," post="comprising a meta-analysis that combined n = 1,310 patients, revealed that"/>
   <result pre="A further systematic review focused on anthracycline regimens for metastatic" exact="breast cancer" post="[ 26]. The authors recommended careful consideration regarding the"/>
   <result pre="further systematic review focused on anthracycline regimens for metastatic breast" exact="cancer" post="[ 26]. The authors recommended careful consideration regarding the"/>
   <result pre="95 % CI = 3.16–8.48) [ 26]. Prevention of cardiotoxicity associated with" exact="prostate cancer" post="treatment One systematic review addressed the issue of cardiotoxicity"/>
   <result pre="% CI = 3.16–8.48) [ 26]. Prevention of cardiotoxicity associated with prostate" exact="cancer" post="treatment One systematic review addressed the issue of cardiotoxicity"/>
   <result pre="addressed the issue of cardiotoxicity associated with treatment for hormone-refractory" exact="prostate cancer" post="[ 27]. While 47 trials met the inclusion criteria"/>
   <result pre="the issue of cardiotoxicity associated with treatment for hormone-refractory prostate" exact="cancer" post="[ 27]. While 47 trials met the inclusion criteria"/>
   <result pre="authors of this review. Prevention of anthracycline-induced cardiotoxicity in adult" exact="cancer" post="patients In a systematic review of cardioprotective agents used"/>
   <result pre="focused on anthracycline use in people receiving treatment for advanced" exact="follicular lymphoma" post="[ 33]. Due to the increased risk ratio for"/>
   <result pre="on anthracycline use in people receiving treatment for advanced follicular" exact="lymphoma" post="[ 33]. Due to the increased risk ratio for"/>
   <result pre="of coenzyme Q10 (CoQ10) to reduce the adverse effects of" exact="cancer" post="treatment [ 34]. Only three randomized controlled trials, which"/>
   <result pre="concluded that CoQ10 could provide some protection against cardiotoxicity during" exact="cancer" post="treatment based on the fact that significant differences in"/>
   <result pre="not recommended, due to insufficient data [ 34]. Prevention of" exact="cancer" post="treatment-induced cardiotoxicity in children All of the systematic reviews"/>
   <result pre="for practice could not be made [ 35]. Management of" exact="cancer" post="treatment-induced cardiotoxicity Only one systematic review focused on interventions"/>
   <result pre="cardiotoxicity Only one systematic review focused on interventions to treat" exact="cancer" post="treatment-induced cardiotoxicity [ 38]. This review focused on the"/>
   <result pre="have focused on the prevention, early detection and management of" exact="cancer" post="treatment-induced cardiotoxicity in order to aid policy and practice"/>
   <result pre="regarding the utility of cardiac biomarkers for the detection of" exact="cancer" post="treatment-induced cardiotoxicity. Based on conclusions drawn from systematic reviews"/>
   <result pre="limited evidence pertaining to the effectiveness of interventions to manage" exact="cancer" post="treatment-induced cardiotoxicity. While two different medical interventions were identified"/>
   <result pre="review that focused on treatment strategies for cardiotoxicity in childhood" exact="cancer" post="(enalapril and phosphocreatine), neither was associated with statistically significant"/>
   <result pre="systematic reviews included in this meta-review addressed the prevention of" exact="cancer" post="therapy-induced cardiotoxicity. As demonstrated in Fig. 2, few strategies"/>
   <result pre="In particular, the evidence for strategies that protect children with" exact="cancer" post="from developing cardiac complications associated with their treatment is"/>
   <result pre="one previous overview of systematic reviews on the topic of" exact="cancer" post="treatment-induced cardiotoxicity has been published [ 39]. However, this"/>
   <result pre="meta-reviews that focus on the prevention, detection and management of" exact="cancer" post="treatment-induced toxicities should not include only Cochrane reviews, as"/>
   <result pre="Level 1 evidence for the detection, prevention and management of" exact="cancer" post="therapy-induced cardiotoxicity were identified in this meta-review. Only one"/>
   <result pre="2004. Recommendations for practice regarding interventions for the detection of" exact="cancer" post="treatment-induced cardiotoxicity were not able to be drawn from"/>
   <result pre="effectiveness of exercise as an intervention to aid prevention of" exact="cancer" post="treatment-induced cardiotoxicity is also emerging, similarly, no systematic reviews"/>
   <result pre="trials of exercise for the prevention of cardiotoxicity associated with" exact="cancer" post="treatment will be reported in the future [ 41]."/>
   <result pre="majority of evidence regarding the detection, prevention and management of" exact="cancer" post="treatment-induced cardiotoxicity included in this meta-review is from studies"/>
   <result pre="guide clinical practice decision-making regarding the detection and management of" exact="cancer" post="treatment associated cardiotoxicity. There is a greater amount of"/>
   <result pre="in regard to the prevention of this adverse effect of" exact="cancer" post="treatment. It is important to note, however, that the"/>
   <result pre="R et al. Euromelanoma: a dermatology‐led European campaign against nonmelanoma" exact="skin cancer" post="and cutaneous melanoma. Past, present and future Br J"/>
   <result pre="et al. Euromelanoma: a dermatology‐led European campaign against nonmelanoma skin" exact="cancer" post="and cutaneous melanoma. Past, present and future Br J"/>
   <result pre="A Jenkins V Catt S Fallowfield L Multidisciplinary teams in" exact="cancer" post="care: are they effective in the UK? Lancet Oncol"/>
   <result pre="4. Rachet B Maringe C Nur U et al. Population-based" exact="cancer" post="survival trends in England and Wales up to 2007:"/>
   <result pre="and Wales up to 2007: an assessment of the NHS" exact="cancer" post="plan for England Lancet Oncol 2009 10 351 69"/>
   <result pre="J Villanueva A Vinals F Capella G Recent advances in" exact="cancer" post="therapy: an overview Curr Pharm Des 2010 16 3"/>
   <result pre="20214614 7. Senkus E Jassem J Cardiovascular effects of systemic" exact="cancer" post="treatment Cancer Treat Rev 2011 37 300 11 10.1016/j.ctrv.2010.11.001"/>
   <result pre="12. Cardinale D Colombo A Lamantia G et al. Anthracycline-induced" exact="cardiomyopathy" post="J Am Coll Cardiol 2010 55 213 20 10.1016/j.jacc.2009.03.095"/>
   <result pre="C Kirov KM Bollet MA et al. Cardiac toxicity in" exact="breast cancer" post="patients: from a fractional point of view to a"/>
   <result pre="Kirov KM Bollet MA et al. Cardiac toxicity in breast" exact="cancer" post="patients: from a fractional point of view to a"/>
   <result pre="SD Sallan SE Cardiovascular disease in adult survivors of childhood" exact="cancer" post="Annu Rev Med 2015 66 161 76 10.1146/annurev-med-070213-054849 25587648"/>
   <result pre="Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early" exact="breast cancer." post="Cochrane Database Syst Rev. 2007, Issue 4 Art No."/>
   <result pre="A Nearchou A Polyzos NP Lind P Cardiac toxicity in" exact="breast cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="Nearchou A Polyzos NP Lind P Cardiac toxicity in breast" exact="cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="Wilcken N, Simes J. Antitumour antibiotic containing regimens for metastatic" exact="breast cancer." post="Cochrane Database Syst Rev. 2004, Issue 4. Art No."/>
   <result pre="B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory" exact="prostate cancer." post="Cochrane Database Syst Rev. 2006, Issue 4. Art No."/>
   <result pre="EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for" exact="cancer" post="patients receiving anthracyclines. Cochrane Database Syst Rev. 2011, Issue"/>
   <result pre="HN, Kremer L. Different anthracycline derivates for reducing cardiotoxicity in" exact="cancer" post="patients. Cochrane Database Syst Rev. 2010, Issue 5. Art"/>
   <result pre="HN, Kremer L. Different dosage schedules for reducing cardiotoxicity in" exact="cancer" post="patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009,"/>
   <result pre="Shpilberg O, Paul M. Anthracycline containing regimens for treatment of" exact="follicular lymphoma" post="in adults. Cochrane Database Syst Rev. 2013, Issue 7."/>
   <result pre="O, Paul M. Anthracycline containing regimens for treatment of follicular" exact="lymphoma" post="in adults. Cochrane Database Syst Rev. 2013, Issue 7."/>
   <result pre="Ernst E Efficacy of coenzyme Q10 for improved tolerability of" exact="cancer" post="treatments: a systematic review J Clin Oncol 2004 22"/>
   <result pre="Jones LW Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in" exact="breast cancer" post="current evidence and underlying mechanisms Circulation 2011 124 642"/>
   <result pre="LW Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast" exact="cancer" post="current evidence and underlying mechanisms Circulation 2011 124 642"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4436450/results/search/disease/results.xml">
   <result pre="by the US Food and Drug administration for use in" exact="cancer" post="patients. Since then, the panel of MoAbs that are"/>
   <result pre="a brief scientific background on the use of MoAbs in" exact="cancer" post="therapy, review all types of monoclonal antibodies-related adverse events"/>
   <result pre="are summarized in Table 1. Common adverse events (AEs) include" exact="allergy" post="(rash, infusion reactions), diarrhea, hypertension, proteinuria, hypothyroidism, and hepatotoxicity."/>
   <result pre="hypersensitivities and are relatively uncommon after administration of MoAbs. Immediate" exact="hypersensitivity" post="may affect a single organ such as the nasopharynx"/>
   <result pre="two MoAbs have also been reported to cause bronchospasm and" exact="angioedema" post="[ 2– 6]. A high prevalence of hypersensitivity reactions"/>
   <result pre="bronchospasm and angioedema [ 2– 6]. A high prevalence of" exact="hypersensitivity" post="reactions to cetuximab have been reported in some areas"/>
   <result pre="of the United States. In most subjects who had a" exact="hypersensitivity" post="reaction to cetuximab, IgE antibodies against cetuximab were present"/>
   <result pre="depends upon the drug, the severity of the reaction, the" exact="cancer" post="being treated, and whether there are reasonable treatment alternatives"/>
   <result pre="relatively limited. At some institutions, these are only performed by" exact="allergy" post="specialists [ 63]. 3. Immune-Related Adverse Events (irAEs) Ipilimumab"/>
   <result pre="can be serious or life-threatening (any grade 30%–35%, grade 3–5" exact="diarrhea" post="5%–8%) [ 57]. It remains unclear whether the effects"/>
   <result pre="relapsed or refractory CD20 positive, low-grade, follicular, or transformed non-Hodgkin's" exact="lymphoma" post="(NHL). Ibritumomabtiuxetan (Zevalin) is a murine anti-CD20 monoclonal antibody"/>
   <result pre="chemotherapy alone [ 75]. Ramucirumab-induced arterial thrombosis (including myocardial infarction," exact="cardiac arrest," post="cerebrovascular accident, and cerebral ischemia) was seen in 2%"/>
   <result pre="of five randomized trials involving a total of 3,784 metastatic" exact="breast cancer" post="patients analyzed the incidence of congestive heart failure (CHF)"/>
   <result pre="five randomized trials involving a total of 3,784 metastatic breast" exact="cancer" post="patients analyzed the incidence of congestive heart failure (CHF)"/>
   <result pre="of 3,784 metastatic breast cancer patients analyzed the incidence of" exact="congestive heart failure" post="(CHF) when using chemotherapy with or without bevacizumab. The"/>
   <result pre="as an important strategy to optimize the targeted treatment of" exact="breast cancer." post="The bevacizumab plus trastuzumab combination was evaluated in 50"/>
   <result pre="plus trastuzumab combination was evaluated in 50 heavily pretreated metastatic" exact="breast cancer" post="patients [ 76]. This combination was associated with a"/>
   <result pre="trastuzumab combination was evaluated in 50 heavily pretreated metastatic breast" exact="cancer" post="patients [ 76]. This combination was associated with a"/>
   <result pre="in older adults and those with a history of hypertension," exact="heart disease" post="or anthracycline exposure. Cardiac troponin and amino-terminal fragment B-type"/>
   <result pre="affect the lungs associated with the use of MoAbs, including" exact="interstitial lung disease" post="(ILD), hemorrhage, trachea-esophageal fistula, and thromboembolic disease. Since the"/>
   <result pre="the lungs associated with the use of MoAbs, including interstitial" exact="lung disease" post="(ILD), hemorrhage, trachea-esophageal fistula, and thromboembolic disease. Since the"/>
   <result pre="be grouped into 4 main categories: interstitial pneumonitis and fibrosis," exact="acute respiratory distress syndrome" post="(ARDS), bronchiolitis obliterans organizing pneumonia (BOOP), and hypersensitivity reactions."/>
   <result pre="categories: interstitial pneumonitis and fibrosis, acute respiratory distress syndrome (ARDS)," exact="bronchiolitis" post="obliterans organizing pneumonia (BOOP), and hypersensitivity reactions. Signs, symptoms,"/>
   <result pre="and fibrosis, acute respiratory distress syndrome (ARDS), bronchiolitis obliterans organizing" exact="pneumonia" post="(BOOP), and hypersensitivity reactions. Signs, symptoms, and clinical findings"/>
   <result pre="respiratory distress syndrome (ARDS), bronchiolitis obliterans organizing pneumonia (BOOP), and" exact="hypersensitivity" post="reactions. Signs, symptoms, and clinical findings include dyspnea, cough,"/>
   <result pre="patients. BOOP is the most common clinical diagnosis of rituximab-induced" exact="lung disease," post="followed by interstitial pneumonitis, ARDS, and hypersensitivity pneumonitis. Acute"/>
   <result pre="of rituximab-induced lung disease, followed by interstitial pneumonitis, ARDS, and" exact="hypersensitivity" post="pneumonitis. Acute or subacute rituximab-induced lung disease, most notably"/>
   <result pre="interstitial pneumonitis, ARDS, and hypersensitivity pneumonitis. Acute or subacute rituximab-induced" exact="lung disease," post="most notably organizing pneumonia, most likely reflects a hypersensitivity"/>
   <result pre="lung disease, most notably organizing pneumonia, most likely reflects a" exact="hypersensitivity" post="reaction to the potentially immunogenic chimeric anti-CD20 antibody. Arguments"/>
   <result pre="the potentially immunogenic chimeric anti-CD20 antibody. Arguments that support a" exact="hypersensitivity" post="reaction include the recurrence and increasing severity of the"/>
   <result pre="days after methylprednisolone infusion and favorable outcome with steroid therapy)," exact="rash" post="and eosinophilia, BALF lymphocytosis, and histological pattern of organizing"/>
   <result pre="rash and eosinophilia, BALF lymphocytosis, and histological pattern of organizing" exact="pneumonia" post="in many patients [ 43]. Interstitial lung disease (ILD)"/>
   <result pre="pattern of organizing pneumonia in many patients [ 43]. Interstitial" exact="lung disease" post="(ILD) has been reported in treatment with cetuximab and"/>
   <result pre="MoAb is advised in any patient who develops ILD or" exact="acute respiratory distress syndrome" post="(ARDS) during treatment. Improvement following treatment with glucocorticoids has"/>
   <result pre="through laboratory analysis. Reports of renal biopsies among patients with" exact="proteinuria" post="receiving VEGF-targeted agents are sparse; when reported, the most"/>
   <result pre="cryoglobulinemic and immune complex glomerulonephritis. The overall incidence of mild" exact="proteinuria" post="in patients treated with bevacizumab ranges from 21 to"/>
   <result pre="21 to up to 63%, but grade 3 or 4" exact="proteinuria" post="(defined as 3+ on dipstick, &amp;gt;3.5 g of protein/24 hours,"/>
   <result pre="ramucirumab were lower than bevacizumab, with only  5.1% of patients experiencing" exact="proteinuria" post="[ 28, 74]. Other less common renal problems that"/>
   <result pre="been reported with bevacizumab include acute renal dysfunction and proliferative" exact="glomerulonephritis" post="[ 27, 83]. Temporary cessation of bevacizumab is advised"/>
   <result pre="and permanent discontinuation is appropriate for patients who develop the" exact="nephrotic syndrome" post="[ 26]. 7. Enterotoxicity Enterocolitis, colitis, and gastrointestinal perforation"/>
   <result pre="In a study of pertuzumab monotherapy in patients with metastatic" exact="breast cancer," post="diarrhea of any grade developed in 48%, but it"/>
   <result pre="study of pertuzumab monotherapy in patients with metastatic breast cancer," exact="diarrhea" post="of any grade developed in 48%, but it was"/>
   <result pre="of best supportive care (BSC) with or without panitumumab reported" exact="diarrhea" post="of any grade in 21% of patients receiving this"/>
   <result pre="11% with BSC alone (none grade 3) [ 18]. Cetuximab-related" exact="diarrhea" post="is generally not severe, and while the rate of"/>
   <result pre="diarrhea is generally not severe, and while the rate of" exact="diarrhea" post="of any grade was 12.7%, rates of grade 3"/>
   <result pre="any grade was 12.7%, rates of grade 3 or 4" exact="diarrhea" post="in studies of single agent cetuximab have ranged from"/>
   <result pre="in up to one-third of patients. Severity of the acneiform" exact="rash" post="(all studies: 76% to 88%; grades 3/4: 1% to"/>
   <result pre="≤14 days) correlates with treatment response and prolonged survival in" exact="colorectal cancer" post="patients treated with cetuximab [ 86]. In the ASPECCT"/>
   <result pre="days) correlates with treatment response and prolonged survival in colorectal" exact="cancer" post="patients treated with cetuximab [ 86]. In the ASPECCT"/>
   <result pre="of nimotuzumab were very low, with only mild moderate skin" exact="rash" post="observed [ 20]. 8.2. Paronychial Inflammation Paronychia involving the"/>
   <result pre="Other less common specific cutaneous reactions include the following: erythematous" exact="exanthem" post="caused by cytomegalovirus, Stevens-Johnson syndrome, toxic epidermal necrolysis, and"/>
   <result pre="at low doses (20–30 mg/day) [ 88]. 8.4. Mucositis/Stomatitis Mucositis or" exact="stomatitis" post="is a frequent oral complication for cetuximab (grades 3/4:"/>
   <result pre="one to four weeks postnadir. The most common cytopenias are" exact="leukopenia" post="and thrombocytopenia, which are easily managed in the majority"/>
   <result pre="six to nine months. Severe and prolonged cytopenia, including both" exact="neutropenia" post="and thrombocytopenia is common [ 2, 3]. Hematologic events"/>
   <result pre="nine months. Severe and prolonged cytopenia, including both neutropenia and" exact="thrombocytopenia" post="is common [ 2, 3]. Hematologic events during ofatumumab"/>
   <result pre="42%; grade 4: 18%; may be prolonged &amp;gt;2 weeks) and" exact="anemia" post="(16%; grades 3/4: 5%) have been reported in treatment"/>
   <result pre="drug due to AEs [ 45]. Grade 3/4 bone marrow" exact="suppression" post="may occur in treatment with brentuximab vedotin, as shown"/>
   <result pre="may occur in treatment with brentuximab vedotin, as shown by" exact="neutropenia" post="(20%), thrombocytopenia (8%), and anemia (6%) [ 52– 54]."/>
   <result pre="in treatment with brentuximab vedotin, as shown by neutropenia (20%)," exact="thrombocytopenia" post="(8%), and anemia (6%) [ 52– 54]. Cytopenia in"/>
   <result pre="brentuximab vedotin, as shown by neutropenia (20%), thrombocytopenia (8%), and" exact="anemia" post="(6%) [ 52– 54]. Cytopenia in treatment with alemtuzumab"/>
   <result pre="treatment with alemtuzumab includes the following: lymphopenia (grades 3/4: 97%)," exact="neutropenia" post="(77%; grade 3/4: 42% to 64%), anemia (76%; grade"/>
   <result pre="(grades 3/4: 97%), neutropenia (77%; grade 3/4: 42% to 64%)," exact="anemia" post="(76%; grade 3/4: 12% to 38%), and thrombocytopenia (71%;"/>
   <result pre="to 64%), anemia (76%; grade 3/4: 12% to 38%), and" exact="thrombocytopenia" post="(71%; grade 3/4: 13% to 52%). Serious and fatal"/>
   <result pre="52%). Serious and fatal cytopenia (including pancytopenia, bone marrow hypoplasia," exact="autoimmune hemolytic anemia," post="and autoimmune idiopathic thrombocytopenia) has occurred. Single doses &amp;gt;30 mg"/>
   <result pre="Serious and fatal cytopenia (including pancytopenia, bone marrow hypoplasia, autoimmune" exact="hemolytic anemia," post="and autoimmune idiopathic thrombocytopenia) has occurred. Single doses &amp;gt;30 mg"/>
   <result pre="weekly doses &amp;gt;90 mg are associated with an increased incidence of" exact="pancytopenia" post="[ 15, 41, 42, 90]. Treatment should be discontinued"/>
   <result pre="less common AEs associated with therapeutic monoclonal antibodies used for" exact="cancer" post="therapy include the following: fatigue, vomiting, abdominal pain, anorexia,"/>
   <result pre="include the following: fatigue, vomiting, abdominal pain, anorexia, dysphonia, and" exact="peripheral neuropathy" post="[ 17, 33, 68, 74, 91]. Cetuximab and pannitumumab"/>
   <result pre="the following: fatigue, vomiting, abdominal pain, anorexia, dysphonia, and peripheral" exact="neuropathy" post="[ 17, 33, 68, 74, 91]. Cetuximab and pannitumumab"/>
   <result pre="can induce magnesium wasting resulting in clinically significant hypomagnesemia/hypokalemia and" exact="hypokalemia" post="[ 7, 11, 18]. 11. Other MoAbs in Ongoing"/>
   <result pre="phase I trial with expansion cohorts in NSCLC, melanoma, and" exact="renal cell carcinoma" post="[ 94, 95]. Further results from these studies are"/>
   <result pre="a brief scientific background on the use of MoAbs in" exact="cancer" post="therapy, review all types of monoclonal antibodies-related adverse events"/>
   <result pre="the molecular mechanisms that underlie MoAb-related reactions to accurately identify" exact="hypersensitivity" post="reactions and to develop new procedures for predicting AEs"/>
   <result pre="thromboembolic event BALF: Bronchoalveolar lavage fluid BOOP: Bronchiolitis obliterans organizing" exact="pneumonia" post="BSC: Best supportive care CHF: Congestive heart failure CTLA-4:"/>
   <result pre="failure CTLA-4: Cytotoxic T lymphocyte-associated protein 4 CLL: Chronic lymphocytic" exact="leukemia" post="EGFR: Epidermal growth factor receptor EpCAM: Epithelial cell adhesion"/>
   <result pre="and Drug Administration HNC: Head and neck carcinoma ILD: Interstitial" exact="lung disease" post="irAEs: Immune-related adverse events LVEF: Left ventricular ejection fraction"/>
   <result pre="LVEF: Left ventricular ejection fraction MoAb: Monoclonal antibody NHL: Non-Hodgkin's" exact="lymphoma" post="NSCLC: Non-small cell lung carcinoma PD-1: Programmed death 1"/>
   <result pre="fraction MoAb: Monoclonal antibody NHL: Non-Hodgkin's lymphoma NSCLC: Non-small cell" exact="lung carcinoma" post="PD-1: Programmed death 1 protein RPLS: Reversible posterior leukoencephalopathy"/>
   <result pre="2013, http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125011s102lbl.pdf 4 Gomes E. R. Demoly P. Epidemiology of" exact="hypersensitivity" post="drug reactions Current Opinion in Allergy and Clinical Immunology"/>
   <result pre="456 473 10.1016/j.ctrv.2005.05.007 16054760 6 Castells M. Rapid desensitization for" exact="hypersensitivity" post="reactions to medications Immunology and Allergy Clinics of North"/>
   <result pre="A. Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-Hodgkin" exact="lymphoma" post="Clinical Nuclear Medicine 2008 33 2 94 96 10.1097/RLU.0b013e31815ef825"/>
   <result pre="L. Philippe P. Rituximab-induced serum sickness in refractory immune thrombocytopenic" exact="purpura" post="Internal Medicine Journal 2011 41 2 202 205 10.1111/j.1445-5994.2010.02384.x"/>
   <result pre="16 Shablak A. Conn A. A case of fatal cetuximab-induced" exact="interstitial lung disease" post="during the first weeks of treatment Targeted Oncology 2014"/>
   <result pre="Shablak A. Conn A. A case of fatal cetuximab-induced interstitial" exact="lung disease" post="during the first weeks of treatment Targeted Oncology 2014"/>
   <result pre="al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic" exact="colorectal cancer" post="The New England Journal of Medicine 2004 351 4"/>
   <result pre="Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal" exact="cancer" post="The New England Journal of Medicine 2004 351 4"/>
   <result pre="with best supportive care alone in patients with chemotherapy-refractory metastatic" exact="colorectal cancer" post="Journal of Clinical Oncology 2007 25 13 1658 1664"/>
   <result pre="best supportive care alone in patients with chemotherapy-refractory metastatic colorectal" exact="cancer" post="Journal of Clinical Oncology 2007 25 13 1658 1664"/>
   <result pre="cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic" exact="colorectal cancer" post="(ASPECCT): a randomised , multicentre , open-label, non-inferiority phase"/>
   <result pre="in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal" exact="cancer" post="(ASPECCT): a randomised , multicentre , open-label, non-inferiority phase"/>
   <result pre="receptor (EGFR) antibody, in patients with locally advanced or metastatic" exact="pancreatic cancer" post="Investigational New Drugs 2012 30 3 1138 1143 10.1007/s10637-010-9619-8"/>
   <result pre="(EGFR) antibody, in patients with locally advanced or metastatic pancreatic" exact="cancer" post="Investigational New Drugs 2012 30 3 1138 1143 10.1007/s10637-010-9619-8"/>
   <result pre="Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in" exact="cancer" post="patients: a meta-analysis The Journal of the American Medical"/>
   <result pre="Y. et al. Congestive heart failure risk in patients with" exact="breast cancer" post="treated with bevacizumab Journal of Clinical Oncology 2011 29"/>
   <result pre="et al. Congestive heart failure risk in patients with breast" exact="cancer" post="treated with bevacizumab Journal of Clinical Oncology 2011 29"/>
   <result pre="Y. W. Increased risk of cerebrovascular events in patients with" exact="cancer" post="treated with bevacizumab: a meta-analysis PLoS ONE 2014 9"/>
   <result pre="VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular" exact="cancer" post="Clinical Cancer Research 2013 19 23 6614 6623 10.1158/1078-0432.CCR-13-1442"/>
   <result pre="phase 2, single-arm study of ramucirumab in patients with metastatic" exact="renal cell carcinoma" post="with disease progression on or intolerance to tyrosine kinase"/>
   <result pre="trastuzumab in a large nationwide cohort of older women with" exact="breast cancer," post="1998–2005 Medical Oncology 2011 28 supplement 1 S80 S90"/>
   <result pre="an antibody-drug conjugate in development for the treatment of HER2-positive" exact="cancer" post="Cancer Chemotherapy and Pharmacology 2012 69 5 1229 1240"/>
   <result pre="in patients with advanced human epidermal growth factor receptor 2-positive" exact="breast cancer" post="Journal of Clinical Oncology 2012 30 14 1594 1600"/>
   <result pre="patients with advanced human epidermal growth factor receptor 2-positive breast" exact="cancer" post="Journal of Clinical Oncology 2012 30 14 1594 1600"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="( NeoSphere ): a randomised multicentre , open-label, phase"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="( NeoSphere ): a randomised multicentre , open-label, phase"/>
   <result pre="J. Stenger M. Pertuzumab in neoadjuvant treatment of HER2-positive early" exact="breast cancer" post="Journal of Community and Supportive Oncology 2014 12 3"/>
   <result pre="Stenger M. Pertuzumab in neoadjuvant treatment of HER2-positive early breast" exact="cancer" post="Journal of Community and Supportive Oncology 2014 12 3"/>
   <result pre="in Japanese and Korean patients with relapsed or refractory B-cell" exact="chronic lymphocytic leukemia" post="International Journal of Hematology 2013 98 2 164 170"/>
   <result pre="and Korean patients with relapsed or refractory B-cell chronic lymphocytic" exact="leukemia" post="International Journal of Hematology 2013 98 2 164 170"/>
   <result pre="J. et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory" exact="chronic lymphocytic leukemia" post="Journal of Clinical Oncology 2010 28 10 1749 1755"/>
   <result pre="al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic" exact="leukemia" post="Journal of Clinical Oncology 2010 28 10 1749 1755"/>
   <result pre="C. et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large" exact="b-cell lymphoma" post="or mantle-cell lymphoma: results from the phase II GAUGUIN"/>
   <result pre="et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell" exact="lymphoma" post="or mantle-cell lymphoma: results from the phase II GAUGUIN"/>
   <result pre="study of brentuximabvedotin for patients with relapsed or refractory Hodgkin's" exact="lymphoma" post="Journal of Clinical Oncology 2012 30 18 2183 2189"/>
   <result pre="of brentuximabvedotin in the treatment of relapsed or refractory Hodgkin" exact="lymphoma" post="Pharmacogenomics and Personalized Medicine 2014 7 79 85 10.2147/PGPM.S57700"/>
   <result pre="Boonen S. et al. Denosumab treatment in postmenopausal women with" exact="osteoporosis" post="does not interfere with fracture-healing: results from the FREEDOM"/>
   <result pre="in the treatment of bone metastases in patients with advanced" exact="cancer" post="(excluding breast and prostate cancer) or multiple myeloma Journal"/>
   <result pre="patients with advanced cancer (excluding breast and prostate cancer) or" exact="multiple myeloma" post="Journal of Clinical Oncology 2011 29 9 1125 1132"/>
   <result pre="of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell" exact="non-hodgkin lymphoma," post="multiple myeloma, or castleman disease Clinical Cancer Research 2013"/>
   <result pre="an anti-IL-6 monoclonal antibody, in patients with B-cell non-hodgkin lymphoma," exact="multiple myeloma," post="or castleman disease Clinical Cancer Research 2013 19 13"/>
   <result pre="al. Safety, activity, and immune correlates of anti-PD-1 antibody in" exact="cancer" post="New England Journal of Medicine 2012 366 26 2443"/>
   <result pre="et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic" exact="colorectal cancer" post="The New England Journal of Medicine 2004 350 23"/>
   <result pre="al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal" exact="cancer" post="The New England Journal of Medicine 2004 350 23"/>
   <result pre="Trastuzumabemtansine versus treatment of physician's choice for pretreated HER2-positive advanced" exact="breast cancer" post="(TH3RESA): a randomised, open-label, phase 3 trial The Lancet"/>
   <result pre="versus treatment of physician's choice for pretreated HER2-positive advanced breast" exact="cancer" post="(TH3RESA): a randomised, open-label, phase 3 trial The Lancet"/>
   <result pre="et al. Suppression of the nitric oxide pathway in metastatic" exact="renal cell carcinoma" post="patients receiving vascular endothelial growth factor-signaling inhibitors Hypertension 2010"/>
   <result pre="phase 2, single-arm study of ramucirumab in patients with metastatic" exact="renal cell carcinoma" post="with disease progression on or intolerance to tyrosine kinase"/>
   <result pre="al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive" exact="breast cancer" post="(BEVERLY-2): an open-label, single-arm phase 2 study The Lancet"/>
   <result pre="Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast" exact="cancer" post="(BEVERLY-2): an open-label, single-arm phase 2 study The Lancet"/>
   <result pre="78 Radzikowska E. Szczepulska E. Chabowski M. Bestry I. Organising" exact="pneumonia" post="caused by transtuzumab (Herceptin) therapy for breast cancer European"/>
   <result pre="Bestry I. Organising pneumonia caused by transtuzumab (Herceptin) therapy for" exact="breast cancer" post="European Respiratory Journal 2003 21 3 552 555 10.1183/09031936.03.00035502"/>
   <result pre="I. Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast" exact="cancer" post="European Respiratory Journal 2003 21 3 552 555 10.1183/09031936.03.00035502"/>
   <result pre="Boomars K. A. van Kimmenade R. Hupperets P. S. Life-threatening" exact="interstitial lung disease" post="associated with trastuzumab: case report Breast Cancer Research and"/>
   <result pre="K. A. van Kimmenade R. Hupperets P. S. Life-threatening interstitial" exact="lung disease" post="associated with trastuzumab: case report Breast Cancer Research and"/>
   <result pre="A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated" exact="paronychia" post="Journal of the European Academy of Dermatology and Venereology"/>
   <result pre="fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic" exact="colorectal cancer." post="Journal of Clinical Oncology 2003 21 1 60 65"/>
   <result pre="Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in" exact="colorectal cancer" post="World Journal of Gastroenterology 2014 20 21 6691 6697"/>
   <result pre="posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal" exact="cancer" post="World Journal of Gastroenterology 2014 20 21 6691 6697"/>
   <result pre="93 Creelan B. C. Update on immune checkpoint inhibitors in" exact="lung cancer" post="Cancer Control 2014 21 1 80 89 24357746 94"/>
   <result pre="Creelan B. C. Update on immune checkpoint inhibitors in lung" exact="cancer" post="Cancer Control 2014 21 1 80 89 24357746 94"/>
   <result pre="Safety and activity of anti-PD-L1 antibody in patients with advanced" exact="cancer" post="The New England Journal of Medicine 2012 366 26"/>
   <result pre="associated with anaphylaxis. Table 1 Monoclonal antibodies (MoAbs) approved for" exact="cancer" post="therapy. MoAb Trade name Target Type Indication(s) Cetuximab Erbitux"/>
   <result pre="Type Indication(s) Cetuximab Erbitux EGFR Chimeric IgG1 κ HNC and" exact="colorectal cancer" post="Panitumomab Vectibix EGFR Human IgG2 κ Colorectal carcinoma Nimotuzumab"/>
   <result pre="Indication(s) Cetuximab Erbitux EGFR Chimeric IgG1 κ HNC and colorectal" exact="cancer" post="Panitumomab Vectibix EGFR Human IgG2 κ Colorectal carcinoma Nimotuzumab"/>
   <result pre="Bevacizumab Avastin VEGFR Humanized IgG1 κ Colorectal, renal, lung, and" exact="brain cancer" post="Ramucirumab Cyramza VEGFR Humanized IgG1 κ Gastric or gastresophageal"/>
   <result pre="Avastin VEGFR Humanized IgG1 κ Colorectal, renal, lung, and brain" exact="cancer" post="Ramucirumab Cyramza VEGFR Humanized IgG1 κ Gastric or gastresophageal"/>
   <result pre="Ramucirumab Cyramza VEGFR Humanized IgG1 κ Gastric or gastresophageal junction" exact="cancer" post="Trastuzumab Herceptin HER2 Humanized IgG1 κ Breast cancer, gastric"/>
   <result pre="HER2 Humanized IgG1 κ Breast cancer, gastric or gastroesophageal junction" exact="cancer" post="Trastuzumabemtansine Kadcyla HER2 Humanized IgG1 κ Breast cancer Pertuzumab"/>
   <result pre="gastroesophageal junction cancer Trastuzumabemtansine Kadcyla HER2 Humanized IgG1 κ Breast" exact="cancer" post="Pertuzumab Perjeta HER2 Humanized IgG1 κ Breast cancer Alemtuzumab"/>
   <result pre="κ Breast cancer Pertuzumab Perjeta HER2 Humanized IgG1 κ Breast" exact="cancer" post="Alemtuzumab Campath CD52 Humanized IgG1 κ Chronic lymphocytic leukemia"/>
   <result pre="Breast cancer Alemtuzumab Campath CD52 Humanized IgG1 κ Chronic lymphocytic" exact="leukemia" post="Rituximab Rituxan  MabThera CD20 Chimeric IgG1 κ Chronic lymphocytic"/>
   <result pre="leukemia Rituximab Rituxan  MabThera CD20 Chimeric IgG1 κ Chronic lymphocytic" exact="leukemia" post="and non-Hodgkin lymphoma Ofatumumab Arzerra CD20 Human IgG1 κ"/>
   <result pre="MabThera CD20 Chimeric IgG1 κ Chronic lymphocytic leukemia and non-Hodgkin" exact="lymphoma" post="Ofatumumab Arzerra CD20 Human IgG1 κ Chronic lymphocytic leukemia"/>
   <result pre="non-Hodgkin lymphoma Ofatumumab Arzerra CD20 Human IgG1 κ Chronic lymphocytic" exact="leukemia" post="Obinutuzumab Gazyva CD20 Human IgG1 CLL Ibritumomab Zevalin CD20"/>
   <result pre="Human IgG1 CLL Ibritumomab Zevalin CD20 Murine IgG1 κ Non-Hodgkin" exact="lymphoma" post="Tositumomab Bexxar CD20 Murine IgG2a λ Non-Hodgkin lymphoma Brentuximab"/>
   <result pre="κ Non-Hodgkin lymphoma Tositumomab Bexxar CD20 Murine IgG2a λ Non-Hodgkin" exact="lymphoma" post="Brentuximab Vedotin Adcetris CD30 Chimeric IgG1 κ Hodgkin's and"/>
   <result pre="Adcetris CD30 Chimeric IgG1 κ Hodgkin's and anaplastic large cell" exact="lymphoma" post="Ipilimumab Yervoy CTLA-4 Human IgG1 κ Melanoma Catumaxomab Removab"/>
   <result pre="IgG2b/mouse  IgG2a bispecific Malignant ascites in patients with ePCaM +" exact="cancer" post="Denosumab Prolia  Xgeva RANKL Human IgG2 κ Breast cancer,"/>
   <result pre="cancer Denosumab Prolia  Xgeva RANKL Human IgG2 κ Breast cancer," exact="prostate cancer," post="and giant cell tumors of the bone Nivolumab Opdivo"/>
   <result pre="the use of the adrenaline autoinjector. V D Specialist and" exact="food allergy" post="specialist dietitian (in food anaphylaxis) followup should be organized."/>
   <result pre="use of the adrenaline autoinjector. V D Specialist and food" exact="allergy" post="specialist dietitian (in food anaphylaxis) followup should be organized."/>
   <result pre="  paronychial inflammation [ 7, 11, 16, 17] Panitumumab IR;" exact="pulmonary fibrosis;" post="electrolyte depletion; peripheral edema; GI; fatigue Erythema; acneiform rash;"/>
   <result pre="edema; GI; fatigue Erythema; acneiform rash; pruritus; nail toxicity; exfoliation;" exact="paronychia" post="  skin fissures; photosensitivity [ 18, 19] Nimotuzumab Fever;"/>
   <result pre="hemorrhage; wound healing  complications; fistula/abscess formation; CHF; IR;   proteinurea;" exact="necrotizing fasciitis" post="Exfoliative dermatitis; xeroderma; alopecia [ 22– 27] Ramucirumab Hypertension;"/>
   <result pre="wound healing  complications; fistula/abscess formation; CHF; IR;   proteinurea; necrotizing" exact="fasciitis" post="Exfoliative dermatitis; xeroderma; alopecia [ 22– 27] Ramucirumab Hypertension;"/>
   <result pre="formation; CHF; IR;   proteinurea; necrotizing fasciitis Exfoliative dermatitis; xeroderma;" exact="alopecia" post="[ 22– 27] Ramucirumab Hypertension; IR; ATE; GIP; hemorrhage;"/>
   <result pre="IR; ATE; GIP; hemorrhage;   wound healing complications; RPIS Skin" exact="rash" post="[ 28– 30] Trastuzumab LVD;CHF; IR; pulmonary toxicity; neutropenia;"/>
   <result pre="fetal harm; hypothyroidism; secondary  malignancies; infection Rash; pruritus; sweating;  " exact="dermatitis" post="[ 44, 50, 51] Brentuximab Vedotin PN; IR; cytopenias;"/>
   <result pre="IR; cytopenias; TLS; infectionimmunogenicity;   PML; anaphylaxis SJS; rash; pruritus;" exact="alopecia" post="[ 52– 55] Ipilimumab IrAEs; diarrhea; fatigue; Dermatitis; pruritus;"/>
   <result pre="pruritus [ 59, 60] Nivolumab Fatigue; diarrhea; lymphopenia Rash; pruritus;" exact="vitiligo" post="[ 61] Siltuximab GIP; IR; IR/hypersensitivity reactions; elevated hemoglobin"/>
   <result pre="61] Siltuximab GIP; IR; IR/hypersensitivity reactions; elevated hemoglobin levels; infection;" exact="diarrhea" post="Pruritus; skin rash [ 62] CRS, cytokine release syndrome;"/>
   <result pre="IR; IR/hypersensitivity reactions; elevated hemoglobin levels; infection; diarrhea Pruritus; skin" exact="rash" post="[ 62] CRS, cytokine release syndrome; GI, gastrointestinal symptoms,"/>
   <result pre="gastrointestinal symptoms, for example, nausea, diarrhea, vomiting, and constipation; HBR," exact="hepatitis" post="B reactivation; IrAEs, immune-mediated reactions due to T cell"/>
   <result pre="and endocrinopathies); IR, infusion reactions; LVD, left ventricular dysfunction; ONJ," exact="osteonecrosis" post="of the jaw; PML, progressive multifocal leukoencephalopathy; PN, peripheral"/>
   <result pre="LVD, left ventricular dysfunction; ONJ, osteonecrosis of the jaw; PML," exact="progressive multifocal leukoencephalopathy;" post="PN, peripheral neuropathy; SIRS, systemic inflammatory response syndrome; SJS,"/>
   <result pre="ONJ, osteonecrosis of the jaw; PML, progressive multifocal leukoencephalopathy; PN," exact="peripheral neuropathy;" post="SIRS, systemic inflammatory response syndrome; SJS, Stevens-Johnson syndrome; SS,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4439018/results/search/disease/results.xml">
   <result pre="to standard treatment have been efficacious for HER2-positive (HER2+) advanced" exact="breast cancer." post="To our knowledge, no meta-analysis has evaluated HER2-targeted therapy"/>
   <result pre="treatment (NST, without any-targeted drugs) in targeted treatment of HER2+" exact="breast cancer" post="in adults. These treatment regimens were T-DM1, LC (lapatinib),"/>
   <result pre="(NST, without any-targeted drugs) in targeted treatment of HER2+ breast" exact="cancer" post="in adults. These treatment regimens were T-DM1, LC (lapatinib),"/>
   <result pre="analysis for the different treatment regimens in metastatic or advanced" exact="breast cancer." post="Results We identified 25 articles of 21 trials, with"/>
   <result pre="with LHC, LC, HC and PEC. The incidence of treatment-related" exact="rash" post="occurs more frequently in the patients who received LC"/>
   <result pre="effects as compared with other regimens, especially for advanced HER2+" exact="breast cancer." post="Impact This study suggests that both T-DM1 and PEHC"/>
   <result pre="PEHC therapy are potentially and equally useful treatments for HER2+" exact="breast cancer." post="Funding The author(s) received no specific funding for this"/>
   <result pre="year in the world[ 1], is the most frequently diagnosed" exact="cancer" post="and the leading cause of cancer death in females"/>
   <result pre="the most frequently diagnosed cancer and the leading cause of" exact="cancer" post="death in females worldwide. In 2008, breast cancer accounted"/>
   <result pre="leading cause of cancer death in females worldwide. In 2008," exact="breast cancer" post="accounted for 23% (1.38 million) of all new cancer"/>
   <result pre="cause of cancer death in females worldwide. In 2008, breast" exact="cancer" post="accounted for 23% (1.38 million) of all new cancer"/>
   <result pre="breast cancer accounted for 23% (1.38 million) of all new" exact="cancer" post="cases and 14% (458,400) of all cancer deaths ["/>
   <result pre="of all new cancer cases and 14% (458,400) of all" exact="cancer" post="deaths [ 1– 3]. Amplification of the human epidermal"/>
   <result pre="[ 4– 7]. With regard to the management of HER2-positive" exact="breast cancer," post="trastuzumab [ 8– 11], pertuzumab [ 12, 13], lapatinib"/>
   <result pre="care for inhibiting HER2 activity in the treatment of HER2-positive" exact="breast cancer" post="[ 16], increasing the incidence of progression-free survival (PFS),"/>
   <result pre="for inhibiting HER2 activity in the treatment of HER2-positive breast" exact="cancer" post="[ 16], increasing the incidence of progression-free survival (PFS),"/>
   <result pre="compared to trastuzumab in combination with docetaxel in HER2-positive metastatic" exact="breast cancer" post="[ 17]. The targeting of HER2 with more than"/>
   <result pre="to trastuzumab in combination with docetaxel in HER2-positive metastatic breast" exact="cancer" post="[ 17]. The targeting of HER2 with more than"/>
   <result pre="9, 12, 18– 20]. According to the CLEOPATRA study, HER2-positive" exact="breast cancer" post="patients received a regimen of combining pertuzumab with trastuzumab"/>
   <result pre="12, 18– 20]. According to the CLEOPATRA study, HER2-positive breast" exact="cancer" post="patients received a regimen of combining pertuzumab with trastuzumab"/>
   <result pre="than one of the above HER2-targeted drugs to treat HER2-positive" exact="breast cancer" post="patients[ 22, 23]. Furthermore, no randomized clinical trial has"/>
   <result pre="one of the above HER2-targeted drugs to treat HER2-positive breast" exact="cancer" post="patients[ 22, 23]. Furthermore, no randomized clinical trial has"/>
   <result pre="hormone therapy or endocrine therapy without HER2-targeted drugs) in HER2-positive" exact="breast cancer," post="we performed a comprehensive systematic network meta-analysis of HER2-targeted"/>
   <result pre="meta-analysis of HER2-targeted agents combined with standard treatment for HER2+" exact="breast cancer" post="and evaluated the relative merits of the different regimens."/>
   <result pre="of HER2-targeted agents combined with standard treatment for HER2+ breast" exact="cancer" post="and evaluated the relative merits of the different regimens."/>
   <result pre="HER2-targeted agents were combined with standard treatment in any-line HER2+" exact="breast cancer" post="without consideration whether the ages of these patients were"/>
   <result pre="agents were combined with standard treatment in any-line HER2+ breast" exact="cancer" post="without consideration whether the ages of these patients were"/>
   <result pre="most primary studies and original reviews comparing regimens for HER2+" exact="breast cancer." post="Two reviewers (Qiuyan Yu and Zhenli Zhu) independently assessed"/>
   <result pre="a subgroup analysis using a random-effects model for advanced HER2+" exact="breast cancer." post="Analysis involved use of STATA 12.0 (pair-wise meta-analysis and"/>
   <result pre="full-texts evaluating the effect of HER2-targeted drugs in treatment of" exact="breast cancer." post="Of these publications, 69 articles were excluded because 13"/>
   <result pre="excluded because they compared HER2-targeted agents for HER2-negative or triple-negative" exact="breast cancer," post="and 19 articles were excluded because they focused on"/>
   <result pre="grades 3-plus [ 42]. However, for the side effects of" exact="rash" post="and fatigue, we used the number of all grades"/>
   <result pre="side-effect analysis, we found significant heterogeneity in the meta-analysis of" exact="rash" post="for the comparisons LC versus NST, LVEF (10%-50%) for"/>
   <result pre="for HC versus NST, fatigue for HC versus NST, and" exact="diarrhea" post="for LC versus HC ( S3 Table). For the"/>
   <result pre="comparisons LC versus HC, which represented the difference of treatment-related" exact="diarrhea" post="between LC and LC have statistical significance. Network meta-analysis"/>
   <result pre="in S4 Table. The LHC regimen showed greater association with" exact="rash" post="than the T-DM1, HC, PEHC and NST regimens, and"/>
   <result pre="NST regimens, and the PEHC regimen was less associated with" exact="rash" post="than the LC regimen. The LC regimen was less"/>
   <result pre="the LC regimen. The LC regimen was less associated with" exact="diarrhea" post="than the NST and HC regimens. We found no"/>
   <result pre="the small sample size. Most loops were consistent. Only for" exact="rash" post="for LC versus HC versus NST showed low inconsistency"/>
   <result pre="S8 Tables). Many meta-analyses have focused on advanced or metastasized" exact="breast cancer," post="so we performed a subgroup analysis of HER2+ advanced"/>
   <result pre="cancer, so we performed a subgroup analysis of HER2+ advanced" exact="breast cancer" post="with the T-DM1, LC, HC, NST, PEHC regimens ("/>
   <result pre="so we performed a subgroup analysis of HER2+ advanced breast" exact="cancer" post="with the T-DM1, LC, HC, NST, PEHC regimens ("/>
   <result pre="to be better for HER2-targeted therapy for advanced or metastatic" exact="breast cancer" post="with HER2-overexpression ( S10 Table). Discussion In our network"/>
   <result pre="be better for HER2-targeted therapy for advanced or metastatic breast" exact="cancer" post="with HER2-overexpression ( S10 Table). Discussion In our network"/>
   <result pre="the LC, HC, and LHC regimens for treatment of HER2+" exact="breast cancer." post="In terms of side effects, rash was more associated"/>
   <result pre="treatment of HER2+ breast cancer. In terms of side effects," exact="rash" post="was more associated with the LHC regimen than PEHC,"/>
   <result pre="previously found to be associated with a significant risk of" exact="rash" post="[ 68]. Furthermore, risk of abnormal LVEF was greater"/>
   <result pre="the remaining side effects. With 7 treatment regimens for HER2+" exact="breast cancer," post="direct comparisons are limited clearly by the small number"/>
   <result pre="Some network or conventional analyses have been published for advanced" exact="breast cancer," post="but they either just focused on targeted therapy without"/>
   <result pre="HER2-targeted agents to standard treatments for HER2+ advanced or metastatic" exact="breast cancer," post="but the optimal duration of ErbB-family receptor inhibitors added"/>
   <result pre="LHC regimen than LC and HC regimens, although linked to" exact="rash" post="and gastrointestinal disorders. In the subgroup analysis, because of"/>
   <result pre="and equally as ideal HER2-targeted treatment regimens for treating HER2+" exact="breast cancer." post="Our study has some disadvantages. First, the network could"/>
   <result pre="performed a subgroup analysis for first/second-line HER2+ advanced or metastatic" exact="breast cancer" post="and got more reliable results. In addition, some trials"/>
   <result pre="a subgroup analysis for first/second-line HER2+ advanced or metastatic breast" exact="cancer" post="and got more reliable results. In addition, some trials"/>
   <result pre="analysis, we did not estimate the effect on early HER2+" exact="breast cancer" post="because only 4 trials were available on this topic,"/>
   <result pre="we did not estimate the effect on early HER2+ breast" exact="cancer" post="because only 4 trials were available on this topic,"/>
   <result pre="future, with the increasing number of clinical trials for HER2+" exact="breast cancer," post="we hope to provide details for HER2-targeted agents added"/>
   <result pre="docetaxel, currently is the best targeted drug regimen for HER2+" exact="breast cancer" post="in terms of overall survival rate (OSR) and overall"/>
   <result pre="currently is the best targeted drug regimen for HER2+ breast" exact="cancer" post="in terms of overall survival rate (OSR) and overall"/>
   <result pre="and with moderate toxicity, especially for HER2+ advanced or metastatic" exact="breast cancer." post="Naive standard treatment (NST) without the HER2-targeted agents showed"/>
   <result pre="for clinicians to choose a suitable targeted therapy for HER2+" exact="breast cancer." post="We hope that more and more randomized trials, consisting"/>
   <result pre="one HER2-targeted agent in combination with chemotherapy/hormone therapy in HER2-positive" exact="breast cancer" post="such as the comparable randomized trials that T-DM1+/- pertuzumab"/>
   <result pre="HER2-targeted agent in combination with chemotherapy/hormone therapy in HER2-positive breast" exact="cancer" post="such as the comparable randomized trials that T-DM1+/- pertuzumab"/>
   <result pre="models on efficacy and safety of HER2+ advance or metastatic" exact="breast cancer" post="(OR 95%CI). (DOC) LINK Click here for additional data"/>
   <result pre="on efficacy and safety of HER2+ advance or metastatic breast" exact="cancer" post="(OR 95%CI). (DOC) LINK Click here for additional data"/>
   <result pre="Ferlay J , Ward E , Forman D . Global" exact="cancer" post="statistics. CA: a cancer journal for clinicians. 2011; 61("/>
   <result pre="E , Forman D . Global cancer statistics. CA: a" exact="cancer" post="journal for clinicians. 2011; 61( 2): 69– 90. 21296855"/>
   <result pre="J , Thun MJ . Cancer statistics, 2007. CA: a" exact="cancer" post="journal for clinicians. 2007; 57( 1): 43– 66. 17237035"/>
   <result pre="R , et al. ErbB receptors: from oncogenes to targeted" exact="cancer" post="therapies. The Journal of clinical investigation. 2007; 117( 8):"/>
   <result pre=", et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer." post="The New England journal of medicine. 2012; 366( 2):"/>
   <result pre="doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic" exact="breast cancer" post=". Annals of oncology: official journal of the European"/>
   <result pre="in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast" exact="cancer" post=". Annals of oncology: official journal of the European"/>
   <result pre=", et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic" exact="breast cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast" exact="cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="of its use for first-line combination treatment of HER2-positive metastatic" exact="breast cancer" post=". Drugs. 2013; 73( 13): 1491– 1502. doi: 10.1007/s40265-013-0109-0"/>
   <result pre="its use for first-line combination treatment of HER2-positive metastatic breast" exact="cancer" post=". Drugs. 2013; 73( 13): 1491– 1502. doi: 10.1007/s40265-013-0109-0"/>
   <result pre="the treatment of human epidermal growth factor receptor 2-overexpressing metastatic" exact="breast cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast" exact="cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial ."/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial ."/>
   <result pre="docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic" exact="breast cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast" exact="cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="human epidermal growth factor receptor 2-positive, locally advanced, or metastatic" exact="breast cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast" exact="cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="III study combining pertuzumab with trastuzumab and docetaxel in metastatic" exact="breast cancer" post=". Annals of oncology: official journal of the European"/>
   <result pre="study combining pertuzumab with trastuzumab and docetaxel in metastatic breast" exact="cancer" post=". Annals of oncology: official journal of the European"/>
   <result pre="Lapatinib as a component of neoadjuvant therapy for HER2-positive operable" exact="breast cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="as a component of neoadjuvant therapy for HER2-positive operable breast" exact="cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre=". Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced" exact="breast cancer" post=". Journal of the National Cancer Institute. 2008; 100("/>
   <result pre="Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast" exact="cancer" post=". Journal of the National Cancer Institute. 2008; 100("/>
   <result pre="Owen A . Antithrombotic treatment for the primary prevention of" exact="stroke" post="in patients with non valvular atrial fibrillation: a reappraisal"/>
   <result pre="meta-analysis of common antiplatelet regimens after transient ischaemic attack or" exact="stroke" post=". European heart journal. 2008; 29( 9): 1086– 1092."/>
   <result pre=". A network meta-analysis combined direct and indirect comparisons between" exact="glaucoma" post="drugs to rank effectiveness in lowering intraocular pressure ."/>
   <result pre="al. Effects of glucosamine, chondroitin, or placebo in patients with" exact="osteoarthritis" post="of hip or knee: network meta-analysis . BMJ (Clinical"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 . The New England journal of"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 . The New England journal of"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="administered as first-line treatment: the M77001 study group ."/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="administered as first-line treatment: the M77001 study group ."/>
   <result pre="paclitaxel as first-line therapy of patients with Her-2 positive advanced" exact="breast cancer" post=". Breast cancer research and treatment. 2007; 101( 3):"/>
   <result pre="as first-line therapy of patients with Her-2 positive advanced breast" exact="cancer" post=". Breast cancer research and treatment. 2007; 101( 3):"/>
   <result pre="of patients with Her-2 positive advanced breast cancer . Breast" exact="cancer" post="research and treatment. 2007; 101( 3): 355– 365. 16850247"/>
   <result pre="Baselga J , et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer." post="The New England journal of medicine. 2012; 367( 19):"/>
   <result pre="T , et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer." post="The New England journal of medicine. 2006; 355( 26):"/>
   <result pre="plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic" exact="breast cancer" post=". The oncologist. 2010; 15( 2): 122– 129. doi:"/>
   <result pre="letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast" exact="cancer" post=". The oncologist. 2010; 15( 2): 122– 129. doi:"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic" exact="breast cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre="with placebo plus paclitaxel as first-line treatment for metastatic breast" exact="cancer" post=". Journal of clinical oncology: official journal of the"/>
   <result pre=", et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer." post="The New England journal of medicine. 2012; 366( 2):"/>
   <result pre="et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for" exact="breast cancer." post="Journal of clinical oncology: official journal of the American"/>
   <result pre=", Press M , et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer." post="The New England journal of medicine. 2011; 365( 14):"/>
   <result pre="al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for" exact="breast cancer." post="The New England journal of medicine. 2006; 354( 8):"/>
   <result pre="S , Dang CT , Lacouture ME . Risk of" exact="rash" post="with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast"/>
   <result pre="rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast" exact="cancer" post="research and treatment. 2012; 135( 2): 347– 354. doi:"/>
   <result pre=", et al. Risk of cardiac dysfunction with trastuzumab in" exact="breast cancer" post="patients: a meta-analysis. Cancer treatment reviews. 2011; 37( 4):"/>
   <result pre="et al. Risk of cardiac dysfunction with trastuzumab in breast" exact="cancer" post="patients: a meta-analysis. Cancer treatment reviews. 2011; 37( 4):"/>
   <result pre="emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic" exact="breast cancer" post=". Curr Opin Mol Ther. 2010; 12( 3): 350–"/>
   <result pre="an antibody-drug conjugate for the treatment of HER2+ metastatic breast" exact="cancer" post=". Curr Opin Mol Ther. 2010; 12( 3): 350–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4439944/results/search/disease/results.xml">
   <result pre="improves response to endocrine therapy in patients with HR-positive advanced" exact="breast cancer." post="We performed a Pubmed database systematic review to ascertain"/>
   <result pre="combination group compared to historical control subjects receiving AIs alone." exact="breast cancer" post="neoadjuvant endocrine therapy targeted therapy clinical response Introduction Neoadjuvant"/>
   <result pre="group compared to historical control subjects receiving AIs alone. breast" exact="cancer" post="neoadjuvant endocrine therapy targeted therapy clinical response Introduction Neoadjuvant"/>
   <result pre="Neoadjuvant systemic therapy is strategically used to reduce the primary" exact="breast cancer" post="volume and allow either surgery in patients initially judged"/>
   <result pre="systemic therapy is strategically used to reduce the primary breast" exact="cancer" post="volume and allow either surgery in patients initially judged"/>
   <result pre="pathologic complete response (pCR) after neoadjuvant treatment, i.e. absence of" exact="cancer" post="in breast and nodes, have a very good prognosis"/>
   <result pre="has been shown to be associated with biological aggressiveness of" exact="breast cancer" post="28. Among the downstream pathways activated by TKRs, the"/>
   <result pre="been shown to be associated with biological aggressiveness of breast" exact="cancer" post="28. Among the downstream pathways activated by TKRs, the"/>
   <result pre="has been showed to be involved in the resistance of" exact="breast cancer" post="cells to endocrine therapy 29, 30. Moreover, tumor cells"/>
   <result pre="been showed to be involved in the resistance of breast" exact="cancer" post="cells to endocrine therapy 29, 30. Moreover, tumor cells"/>
   <result pre="compared to AI alone in postmenopausal women with metastatic HER2-positive" exact="breast cancer" post="35, 36. In another study, the Bolero-2 trial, the"/>
   <result pre="to AI alone in postmenopausal women with metastatic HER2-positive breast" exact="cancer" post="35, 36. In another study, the Bolero-2 trial, the"/>
   <result pre="efficacy compared to exemestane alone in patients with HER2-negative advanced" exact="breast cancer" post="who progressed to non-steroidal AI 37. Differently from the"/>
   <result pre="compared to exemestane alone in patients with HER2-negative advanced breast" exact="cancer" post="who progressed to non-steroidal AI 37. Differently from the"/>
   <result pre="of adding a targeted agent to endocrine therapy in metastatic" exact="breast cancer" post="prompted us to carry out a systematic review to"/>
   <result pre="adding a targeted agent to endocrine therapy in metastatic breast" exact="cancer" post="prompted us to carry out a systematic review to"/>
   <result pre="endocrine therapy with targeted agents in the neoadjuvant setting of" exact="breast cancer" post="and published from November 2004 to November 2014 was"/>
   <result pre="therapy with targeted agents in the neoadjuvant setting of breast" exact="cancer" post="and published from November 2004 to November 2014 was"/>
   <result pre="the sorting key words according to the following algorithm: &quot;breast" exact="cancer" post="AND (neoadjuvant OR neo-adjuvant OR pre-operative OR preoperative OR"/>
   <result pre="most active endocrine agents currently used in the treatment of" exact="breast cancer," post="we limited the research to the last 10 years."/>
   <result pre="In the first study 38, patients with HR-positive and EGFR-positive" exact="breast cancer" post="were randomized to receive gefitinib 250 mg daily associated"/>
   <result pre="the first study 38, patients with HR-positive and EGFR-positive breast" exact="cancer" post="were randomized to receive gefitinib 250 mg daily associated"/>
   <result pre="lapatinib, was studied in 64 patients with locally advanced HER2-positive" exact="breast cancer" post="42. Patients received trastuzumab weekly (4 mg/kg loading, then"/>
   <result pre="was studied in 64 patients with locally advanced HER2-positive breast" exact="cancer" post="42. Patients received trastuzumab weekly (4 mg/kg loading, then"/>
   <result pre="letrozole in the neoadjuvant treatment of postmenopausal women with HR-positive" exact="breast cancer" post="43. One hundred thirty-eight patients received letrozole 2.5 mg"/>
   <result pre="in the neoadjuvant treatment of postmenopausal women with HR-positive breast" exact="cancer" post="43. One hundred thirty-eight patients received letrozole 2.5 mg"/>
   <result pre="VEGF, in the neoadjuvant treatment of postmenopausal women with HR-positive" exact="breast cancer" post="46. Twenty-five patients received letrozole 2.5 mg daily and"/>
   <result pre="in the neoadjuvant treatment of postmenopausal women with HR-positive breast" exact="cancer" post="46. Twenty-five patients received letrozole 2.5 mg daily and"/>
   <result pre="improve clinical response in women with a recent diagnosis of" exact="breast cancer" post="treated preoperatively with endocrine therapies. To evaluate the anti-tumor"/>
   <result pre="clinical response in women with a recent diagnosis of breast" exact="cancer" post="treated preoperatively with endocrine therapies. To evaluate the anti-tumor"/>
   <result pre="retain tumor resistance. Therefore, in a heterogeneous population of HR-positive" exact="breast cancer" post="it is conceivable that small dimensioned phase II studies"/>
   <result pre="tumor resistance. Therefore, in a heterogeneous population of HR-positive breast" exact="cancer" post="it is conceivable that small dimensioned phase II studies"/>
   <result pre="The biological rationale to add celecoxib to AIs is that" exact="breast cancer" post="self-production of estrogen is relevant for tumor growth. Prostaglandin"/>
   <result pre="biological rationale to add celecoxib to AIs is that breast" exact="cancer" post="self-production of estrogen is relevant for tumor growth. Prostaglandin"/>
   <result pre="of PGE2 and increased aromatase activity have been observed in" exact="breast cancer" post="51, 52. However, the contribution of tumor synthesized estrogens"/>
   <result pre="PGE2 and increased aromatase activity have been observed in breast" exact="cancer" post="51, 52. However, the contribution of tumor synthesized estrogens"/>
   <result pre="52. However, the contribution of tumor synthesized estrogens to the" exact="breast cancer" post="estrogen levels is negligible compared to systemic production. Intratumoral"/>
   <result pre="However, the contribution of tumor synthesized estrogens to the breast" exact="cancer" post="estrogen levels is negligible compared to systemic production. Intratumoral"/>
   <result pre="leads to a meaningful increase in pCR rate in HR+/HER2+" exact="breast cancer" post="(33% with 24 weeks vs 9% with 12 weeks"/>
   <result pre="to a meaningful increase in pCR rate in HR+/HER2+ breast" exact="cancer" post="(33% with 24 weeks vs 9% with 12 weeks"/>
   <result pre="a better clinical outcome. In conclusion, thus far, in the" exact="breast cancer" post="neoadjuvant setting, the attempts to increase endocrine response by"/>
   <result pre="better clinical outcome. In conclusion, thus far, in the breast" exact="cancer" post="neoadjuvant setting, the attempts to increase endocrine response by"/>
   <result pre="MM Fraschini G et al. Management of stage III primary" exact="breast cancer" post="with primary chemotherapy, surgery, and radiation therapy Cancer 1988"/>
   <result pre="Fraschini G et al. Management of stage III primary breast" exact="cancer" post="with primary chemotherapy, surgery, and radiation therapy Cancer 1988"/>
   <result pre="SM Effect of preoperative chemotherapy on mastectomy for locally advanced" exact="breast cancer" post="Am Surg 1990 56 6 11 2153011 3 Schwartz"/>
   <result pre="Effect of preoperative chemotherapy on mastectomy for locally advanced breast" exact="cancer" post="Am Surg 1990 56 6 11 2153011 3 Schwartz"/>
   <result pre="neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory" exact="breast cancer" post="participating in the NeOAdjuvant Herceptin (NOAH) study Eur J"/>
   <result pre="therapy in patients with HER2-positive locally advanced or inflammatory breast" exact="cancer" post="participating in the NeOAdjuvant Herceptin (NOAH) study Eur J"/>
   <result pre="Hage JA van de Velde CJ Neoadjuvant chemotherapy for operable" exact="breast cancer" post="Br J Surg 2007 94 1189 200 17701939 10"/>
   <result pre="JA van de Velde CJ Neoadjuvant chemotherapy for operable breast" exact="cancer" post="Br J Surg 2007 94 1189 200 17701939 10"/>
   <result pre="MD Buzdar AU Hortobagyi GN Singletary SE Clinical course of" exact="breast cancer" post="patients with complete pathologic primary tumor and axillary lymph"/>
   <result pre="Buzdar AU Hortobagyi GN Singletary SE Clinical course of breast" exact="cancer" post="patients with complete pathologic primary tumor and axillary lymph"/>
   <result pre="Peruzzotti G Goldhirsch A Increasing steroid hormone receptors expression defines" exact="breast cancer" post="subtypes non responsive to preoperative chemotherapy Breast Cancer Res"/>
   <result pre="G Goldhirsch A Increasing steroid hormone receptors expression defines breast" exact="cancer" post="subtypes non responsive to preoperative chemotherapy Breast Cancer Res"/>
   <result pre="Loibl S Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological" exact="breast cancer" post="phenotypes: overall results from the GeparTrio study Breast Cancer"/>
   <result pre="S Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast" exact="cancer" post="phenotypes: overall results from the GeparTrio study Breast Cancer"/>
   <result pre="Oldenburg HS Antonini N Vrancken Peeters MT The relevance of" exact="breast cancer" post="subtypes in the outcome of neoadjuvant chemotherapy Ann Surg"/>
   <result pre="HS Antonini N Vrancken Peeters MT The relevance of breast" exact="cancer" post="subtypes in the outcome of neoadjuvant chemotherapy Ann Surg"/>
   <result pre="tumor response to neoadjuvant chemotherapy in patients with locally advanced" exact="breast cancer" post="Oncology 2010 79 324 30 21430399 17 von Minckwitz"/>
   <result pre="response to neoadjuvant chemotherapy in patients with locally advanced breast" exact="cancer" post="Oncology 2010 79 324 30 21430399 17 von Minckwitz"/>
   <result pre="complete response on prognosis after neoadjuvant chemotherapy in various intrinsic" exact="breast cancer" post="subtypes J Clin Oncol 2012 30 1796 804 22508812"/>
   <result pre="response on prognosis after neoadjuvant chemotherapy in various intrinsic breast" exact="cancer" post="subtypes J Clin Oncol 2012 30 1796 804 22508812"/>
   <result pre="Chaudri-Ross HA Dugan M Borgs M Preoperative treatment of postmenopausal" exact="breast cancer" post="patients with letrozole: A randomized double-blind multicenter study Ann"/>
   <result pre="HA Dugan M Borgs M Preoperative treatment of postmenopausal breast" exact="cancer" post="patients with letrozole: A randomized double-blind multicenter study Ann"/>
   <result pre="Francis S Boeddinghaus I Walsh G Neoadjuvant treatment of postmenopausal" exact="breast cancer" post="with anastrozole, tamoxifen, or both in combination: the Immediate"/>
   <result pre="S Boeddinghaus I Walsh G Neoadjuvant treatment of postmenopausal breast" exact="cancer" post="with anastrozole, tamoxifen, or both in combination: the Immediate"/>
   <result pre="Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal" exact="breast cancer" post="(STAGE): a double-blind, randomised phase 3 trial Lancet Oncol"/>
   <result pre="anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast" exact="cancer" post="(STAGE): a double-blind, randomised phase 3 trial Lancet Oncol"/>
   <result pre="steroid hormone and growth factor cross-talk in endocrine response in" exact="breast cancer" post="Endocr Relat Cancer 1999 6 373 87 10516852 23"/>
   <result pre="hormone and growth factor cross-talk in endocrine response in breast" exact="cancer" post="Endocr Relat Cancer 1999 6 373 87 10516852 23"/>
   <result pre="pathway targets estrogen receptor and promotes hormone-independent growth in human" exact="breast cancer" post="cells Oncogene 1995 10 2435 46 7784095 26 Shin"/>
   <result pre="targets estrogen receptor and promotes hormone-independent growth in human breast" exact="cancer" post="cells Oncogene 1995 10 2435 46 7784095 26 Shin"/>
   <result pre="Schmitt F Overexpression of platelet-derived growth factor receptor alpha in" exact="breast cancer" post="is associated with tumour progression Breast Cancer Res 2005"/>
   <result pre="F Overexpression of platelet-derived growth factor receptor alpha in breast" exact="cancer" post="is associated with tumour progression Breast Cancer Res 2005"/>
   <result pre="Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in" exact="breast cancer" post="cells Mol Cancer Ther 2002 1 707 17 12479367"/>
   <result pre="activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast" exact="cancer" post="cells Mol Cancer Ther 2002 1 707 17 12479367"/>
   <result pre="Balko JM Arteaga CL Phosphatidylinositol 3-kinase and antiestrogen resistance in" exact="breast cancer" post="J Clin Oncol 2011 29 4452 61 22010023 31"/>
   <result pre="JM Arteaga CL Phosphatidylinositol 3-kinase and antiestrogen resistance in breast" exact="cancer" post="J Clin Oncol 2011 29 4452 61 22010023 31"/>
   <result pre="(ZD1839/Iressa) improves antihormone response and prevents development of resistance in" exact="breast cancer" post="in vitro Endocrinology 2003 144 5105 17 12960029 33"/>
   <result pre="improves antihormone response and prevents development of resistance in breast" exact="cancer" post="in vitro Endocrinology 2003 144 5105 17 12960029 33"/>
   <result pre="Hidalgo M Inhibition of mTOR activity restores tamoxifen response in" exact="breast cancer" post="cells with aberrant Akt Activity Clin Cancer Res 2004"/>
   <result pre="M Inhibition of mTOR activity restores tamoxifen response in breast" exact="cancer" post="cells with aberrant Akt Activity Clin Cancer Res 2004"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 5538 46 19786658 37"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 5538 46 19786658 37"/>
   <result pre="P Lebwohl D Hortobagyi GN Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2012 366 520 9 22149876"/>
   <result pre="Lebwohl D Hortobagyi GN Everolimus in postmenopausal hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2012 366 520 9 22149876"/>
   <result pre="trial of neoadjuvant anastrozole alone or with gefitinib in early" exact="breast cancer" post="J Clin Oncol 2007 25 3816 22 17679728 40"/>
   <result pre="of neoadjuvant anastrozole alone or with gefitinib in early breast" exact="cancer" post="J Clin Oncol 2007 25 3816 22 17679728 40"/>
   <result pre="and gefitinib in patients with newly diagnosed estrogen receptor positive" exact="breast cancer" post="Breast Cancer Res Treat 2011 129 819 27 21792626"/>
   <result pre="gefitinib in patients with newly diagnosed estrogen receptor positive breast" exact="cancer" post="Breast Cancer Res Treat 2011 129 819 27 21792626"/>
   <result pre="of neoadjuvant inhibition of aromatase activity and signal transduction in" exact="breast cancer" post="Cancer Lett 2008 262 232 8 18248884 42 Rimawi"/>
   <result pre="neoadjuvant inhibition of aromatase activity and signal transduction in breast" exact="cancer" post="Cancer Lett 2008 262 232 8 18248884 42 Rimawi"/>
   <result pre="compared with placebo plus letrozole in patients with estrogen receptor-positive" exact="breast cancer" post="J Clin Oncol 2009 27 2630 7 19380449 44"/>
   <result pre="with placebo plus letrozole in patients with estrogen receptor-positive breast" exact="cancer" post="J Clin Oncol 2009 27 2630 7 19380449 44"/>
   <result pre="Toi M Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced" exact="breast cancer" post="J Steroid Biochem Mol Biol 2008 111 13 17"/>
   <result pre="M Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast" exact="cancer" post="J Steroid Biochem Mol Biol 2008 111 13 17"/>
   <result pre="exemestane in combination with celecoxib in postmenopausal women who have" exact="breast cancer" post="Clin Breast Cancer 2011 11 221 7 21729671 46"/>
   <result pre="in combination with celecoxib in postmenopausal women who have breast" exact="cancer" post="Clin Breast Cancer 2011 11 221 7 21729671 46"/>
   <result pre="postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive" exact="breast cancer" post="Clin Breast Cancer 2010 10 275 80 20705559 47"/>
   <result pre="women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast" exact="cancer" post="Clin Breast Cancer 2010 10 275 80 20705559 47"/>
   <result pre="therapy with aromatase inhibitors in elderly women with hormone receptor-positive" exact="breast cancer" post="Ann Surg Oncol 2014 21 1575 82 24522992 48"/>
   <result pre="with aromatase inhibitors in elderly women with hormone receptor-positive breast" exact="cancer" post="Ann Surg Oncol 2014 21 1575 82 24522992 48"/>
   <result pre="acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in" exact="breast cancer" post="cell clones Cancer Lett 2012 323 77 87 22484466"/>
   <result pre="resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast" exact="cancer" post="cell clones Cancer Lett 2012 323 77 87 22484466"/>
   <result pre="letrozole alone in postmenopausal women with locally advanced or metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2006 100 suppl 1 abstr6091"/>
   <result pre="alone in postmenopausal women with locally advanced or metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2006 100 suppl 1 abstr6091"/>
   <result pre="endocrine therapy in postmenopausal women with locally advanced or metastatic" exact="breast cancer" post="J Clin Oncol 2013 31 195 202 23233719 51"/>
   <result pre="therapy in postmenopausal women with locally advanced or metastatic breast" exact="cancer" post="J Clin Oncol 2013 31 195 202 23233719 51"/>
   <result pre="and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human" exact="breast cancer" post="and metastasis Int J Cancer 2003 103 84 90"/>
   <result pre="levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast" exact="cancer" post="and metastasis Int J Cancer 2003 103 84 90"/>
   <result pre="FM Correlation of aromatase and cyclooxygenase gene expression in human" exact="breast cancer" post="specimens Cancer Lett 1999 140 27 35 10403538 53"/>
   <result pre="Correlation of aromatase and cyclooxygenase gene expression in human breast" exact="cancer" post="specimens Cancer Lett 1999 140 27 35 10403538 53"/>
   <result pre="AH Dunbier A Helle H Knappskog S Dowsett M Exploring" exact="breast cancer" post="estrogen disposition: the basis for endocrine manipulation Clin Cancer"/>
   <result pre="Dunbier A Helle H Knappskog S Dowsett M Exploring breast" exact="cancer" post="estrogen disposition: the basis for endocrine manipulation Clin Cancer"/>
   <result pre="long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive" exact="breast cancer" post="Br J Cancer 2013 108 1587 92 23579222 55"/>
   <result pre="neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast" exact="cancer" post="Br J Cancer 2013 108 1587 92 23579222 55"/>
   <result pre="for 12 vs. 24 weeks in patients with HER2 overexpressing" exact="breast cancer" post="San Antonio Breast Cancer Symposium (SABCS) 2014 S6 02"/>
   <result pre="12 vs. 24 weeks in patients with HER2 overexpressing breast" exact="cancer" post="San Antonio Breast Cancer Symposium (SABCS) 2014 S6 02"/>
   <result pre="omit postoperative irradiation in a highly selected group of elderly" exact="breast cancer" post="patients Breast Cancer Res Treat 1998 50 37 46"/>
   <result pre="postoperative irradiation in a highly selected group of elderly breast" exact="cancer" post="patients Breast Cancer Res Treat 1998 50 37 46"/>
   <result pre="complete response rates following different neoadjuvant chemotherapy regimens for operable" exact="breast cancer" post="according to ER status, in two parallel, randomized phase"/>
   <result pre="response rates following different neoadjuvant chemotherapy regimens for operable breast" exact="cancer" post="according to ER status, in two parallel, randomized phase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4440424/results/search/disease/results.xml">
   <result pre="PI3K pathway is the most frequently enhanced oncogenic pathway in" exact="breast cancer." post="Among mechanisms of PI3K enhancement, PIK3CA mutations are most"/>
   <result pre="routine genotyping of PIK3CA in clinical practice. Given that PIK3CA-mutant" exact="breast cancer" post="appears to have a distinct tumor biology, development of"/>
   <result pre="genotyping of PIK3CA in clinical practice. Given that PIK3CA-mutant breast" exact="cancer" post="appears to have a distinct tumor biology, development of"/>
   <result pre="care for solid tumors was pioneered in the treatment of" exact="breast cancer." post="In addition to classic pathological information, such as tumor"/>
   <result pre="little progression in the 21st century, and that patients with" exact="breast cancer" post="require more sophisticated molecular markers able to deliver more"/>
   <result pre="progression in the 21st century, and that patients with breast" exact="cancer" post="require more sophisticated molecular markers able to deliver more"/>
   <result pre="to oncogenic properties in a variety of malignancies. In particular," exact="breast cancer" post="tumorigenesis is believed to depend on the PI3K pathway."/>
   <result pre="oncogenic properties in a variety of malignancies. In particular, breast" exact="cancer" post="tumorigenesis is believed to depend on the PI3K pathway."/>
   <result pre="mutations. First discovered in 2004 in various solid tumors, including" exact="breast cancer," post="3 these mutations have the potential to become a"/>
   <result pre="and translation ( Figure 2). 4, 5 PI3K-enhancing mechanisms in" exact="breast cancer" post="PI3K alteration PIK3CA mutations Somatic mutations of PIK3CA coding"/>
   <result pre="translation ( Figure 2). 4, 5 PI3K-enhancing mechanisms in breast" exact="cancer" post="PI3K alteration PIK3CA mutations Somatic mutations of PIK3CA coding"/>
   <result pre="reported that the frequency of mutations was relatively low in" exact="breast cancer" post="(10%), later studies revealed that breast cancer was in"/>
   <result pre="that the frequency of mutations was relatively low in breast" exact="cancer" post="(10%), later studies revealed that breast cancer was in"/>
   <result pre="relatively low in breast cancer (10%), later studies revealed that" exact="breast cancer" post="was in fact among the most frequently affected cancers"/>
   <result pre="low in breast cancer (10%), later studies revealed that breast" exact="cancer" post="was in fact among the most frequently affected cancers"/>
   <result pre="reported in various malignancies, including approximately 10% of cases of" exact="breast cancer." post="4, 10 Like PIK3CA mutations, PIK3CA amplification has been"/>
   <result pre="by stabilizing p110α. 12 PIK3R1 mutations have been found in" exact="breast cancer," post="although with much lower occurrence than PIK3CA mutations (~3%)."/>
   <result pre="5 In contrast with the rarity of PIK3R1 mutations in" exact="breast cancer," post="reduced PIK3R1 messenger ribonucleic acid (RNA) expression, defined as"/>
   <result pre="proteins. Gene-amplified HER2 is the best-characterized RTK with regard to" exact="breast cancer" post="tumorigenesis. While HER2 can theoretically form four different types"/>
   <result pre="Gene-amplified HER2 is the best-characterized RTK with regard to breast" exact="cancer" post="tumorigenesis. While HER2 can theoretically form four different types"/>
   <result pre="the PI3K pathway. In fact, a study has suggested that" exact="breast cancer" post="cell lines expressing both HER2 and HER3 appear to"/>
   <result pre="PI3K pathway. In fact, a study has suggested that breast" exact="cancer" post="cell lines expressing both HER2 and HER3 appear to"/>
   <result pre="dysfunction of PTEN. While PTEN mutations are relatively uncommon in" exact="breast cancer" post="(&amp;lt;5%), PTEN protein loss is frequent (~30%). 22, 23"/>
   <result pre="of PTEN. While PTEN mutations are relatively uncommon in breast" exact="cancer" post="(&amp;lt;5%), PTEN protein loss is frequent (~30%). 22, 23"/>
   <result pre="answers, a large-scale genotyping effort (547 breast tumor and 41" exact="breast cancer" post="cell lines) revealed that AKT1 mutations were exclusively observed"/>
   <result pre="a large-scale genotyping effort (547 breast tumor and 41 breast" exact="cancer" post="cell lines) revealed that AKT1 mutations were exclusively observed"/>
   <result pre="both ER and PgR. 23 Relationship between PI3K-enhancing mechanisms in" exact="breast cancer" post="Molecular changes on the same signaling axis can be"/>
   <result pre="ER and PgR. 23 Relationship between PI3K-enhancing mechanisms in breast" exact="cancer" post="Molecular changes on the same signaling axis can be"/>
   <result pre="mutations and PTEN loss, another PI3K-enhancing change frequently observed in" exact="breast cancer," post="were present in a nearly mutually exclusive fashion. 26"/>
   <result pre="marker that provides information on the likely course of the" exact="cancer" post="disease in an untreated individual. In contrast, predictive biomarkers"/>
   <result pre="1.14, 95% CI 0.72–1.82; P=0.57). 30 Prognostic value for advanced" exact="breast cancer" post="Unlike the case for early breast cancer, the prognostic"/>
   <result pre="95% CI 0.72–1.82; P=0.57). 30 Prognostic value for advanced breast" exact="cancer" post="Unlike the case for early breast cancer, the prognostic"/>
   <result pre="value for advanced breast cancer Unlike the case for early" exact="breast cancer," post="the prognostic value of PIK3CA mutations for advanced cases"/>
   <result pre="by transfecting wild-type and mutant forms of PIK3CA in HER2-amplified" exact="breast cancer" post="cells. 50, 51 Results showed that mutant PIK3CA transfection"/>
   <result pre="transfecting wild-type and mutant forms of PIK3CA in HER2-amplified breast" exact="cancer" post="cells. 50, 51 Results showed that mutant PIK3CA transfection"/>
   <result pre="51 Consistent with these previous studies, our study using HER2-amplified" exact="breast cancer" post="cell lines showed that cell lines with PIK3CA hot-spot"/>
   <result pre="Consistent with these previous studies, our study using HER2-amplified breast" exact="cancer" post="cell lines showed that cell lines with PIK3CA hot-spot"/>
   <result pre="those without mutations. 52 However, another preclinical study using HER2-amplified" exact="breast cancer" post="cell lines provided different conclusions. It showed that while"/>
   <result pre="without mutations. 52 However, another preclinical study using HER2-amplified breast" exact="cancer" post="cell lines provided different conclusions. It showed that while"/>
   <result pre="the PIK3CA genotype in tumor samples from 240 HER2-positive early" exact="breast cancer" post="patients who had been treated with cyclophosphamide, epirubicin, and"/>
   <result pre="PIK3CA genotype in tumor samples from 240 HER2-positive early breast" exact="cancer" post="patients who had been treated with cyclophosphamide, epirubicin, and"/>
   <result pre="trastuzumab, lapatinib, or their combination in patients with early HER2-positive" exact="breast cancer." post="57 Patients received anti-HER2 therapy for 6 weeks. Paclitaxel"/>
   <result pre="had no influence ( Table 2). 57 Trastuzumab in metastatic" exact="breast cancer" post="An initial study analyzing the PIK3CA genotype in tumor"/>
   <result pre="no influence ( Table 2). 57 Trastuzumab in metastatic breast" exact="cancer" post="An initial study analyzing the PIK3CA genotype in tumor"/>
   <result pre="the PIK3CA genotype in tumor samples obtained from HER2-positive metastatic" exact="breast cancer" post="patients who had undergone trastuzumab-based therapy showed an association"/>
   <result pre="PIK3CA genotype in tumor samples obtained from HER2-positive metastatic breast" exact="cancer" post="patients who had undergone trastuzumab-based therapy showed an association"/>
   <result pre="another retrospectively identified cohort of 139 patients with HER2-positive metastatic" exact="cancer" post="treated with trastuzumab alone or in combination with chemotherapy,"/>
   <result pre="a Phase II trial of lapatinib monotherapy in HER2-positive metastatic" exact="breast cancer," post="three PIK3CA-mutant patients were detected, and one durable PR"/>
   <result pre="with pertuzumab for first-line chemotherapy in HER2-positive recurrent or metastatic" exact="breast cancer" post="patients. 60 Results of a biomarker study analyzing tumor"/>
   <result pre="pertuzumab for first-line chemotherapy in HER2-positive recurrent or metastatic breast" exact="cancer" post="patients. 60 Results of a biomarker study analyzing tumor"/>
   <result pre="only drug targeting the PI3K pathway, which is indicated for" exact="breast cancer." post="While a preclinical study demonstrated that PIK3CA mutations can"/>
   <result pre="mere 13.8%. 65 Discussion Vigorous investigations of PIK3CA mutations in" exact="breast cancer" post="have led to the carving of several matters in"/>
   <result pre="13.8%. 65 Discussion Vigorous investigations of PIK3CA mutations in breast" exact="cancer" post="have led to the carving of several matters in"/>
   <result pre="mutations to be good prognostic markers in patients with early" exact="breast cancer." post="However, it has to be emphasized that at this"/>
   <result pre="marker that provides information on the likely course of the" exact="cancer" post="disease in an untreated individual&quot;. In fact, two studies"/>
   <result pre="usefulness of PIK3CA genotyping in daily practice. Given that PIK3CA-mutant" exact="breast cancer" post="appears to have distinct tumor biology, the development of"/>
   <result pre="of PIK3CA genotyping in daily practice. Given that PIK3CA-mutant breast" exact="cancer" post="appears to have distinct tumor biology, the development of"/>
   <result pre="Roberts TM Zhao JJ Targeting the phosphoinositide 3-kinase pathway in" exact="cancer" post="Nat Rev Drug Discov 2009 8 8 627 644"/>
   <result pre="Y Hon WC et al. Mechanism of two classes of" exact="cancer" post="mutations in the phosphoinositide 3-kinase catalytic subunit Science 2007"/>
   <result pre="elevation and correlation with outcome in patients with early stage" exact="breast cancer" post="Cancer 2013 119 1 7 15 22736407 11 Wu"/>
   <result pre="and correlation with outcome in patients with early stage breast" exact="cancer" post="Cancer 2013 119 1 7 15 22736407 11 Wu"/>
   <result pre="mutation and gain of copy number of PIK3CA in human" exact="breast cancer" post="Breast Cancer Res 2005 7 5 R609 R616 16168105"/>
   <result pre="and gain of copy number of PIK3CA in human breast" exact="cancer" post="Breast Cancer Res 2005 7 5 R609 R616 16168105"/>
   <result pre="et al. PIK3R1 underexpression is an independent prognostic marker in" exact="breast cancer" post="BMC Cancer 2013 13 545 24229379 13 collab: Cancer"/>
   <result pre="al. PIK3R1 underexpression is an independent prognostic marker in breast" exact="cancer" post="BMC Cancer 2013 13 545 24229379 13 collab: Cancer"/>
   <result pre="PT Lu Y Mills GB Exploiting the PI3K/AKT pathway for" exact="cancer" post="drug discovery Nat Rev Drug Discov 2005 4 12"/>
   <result pre="and proteomic analysis of PIK3CA, PTEN, and AKT mutations in" exact="breast cancer" post="Cancer Res 2008 68 15 6084 6091 18676830 24"/>
   <result pre="proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast" exact="cancer" post="Cancer Res 2008 68 15 6084 6091 18676830 24"/>
   <result pre="transforming mutation in the pleckstrin homology domain of AKT1 in" exact="cancer" post="Nature 2007 448 7152 439 444 17611497 25 Gainor"/>
   <result pre="or KRAS: an analysis of 1,683 patients with non-small cell" exact="lung cancer" post="Clin Cancer Res 2013 19 15 4273 4281 23729361"/>
   <result pre="KRAS: an analysis of 1,683 patients with non-small cell lung" exact="cancer" post="Clin Cancer Res 2013 19 15 4273 4281 23729361"/>
   <result pre="with similar prognostic factors and are not mutually exclusive in" exact="breast cancer" post="Clin Cancer Res 2007 13 12 3577 3584 17575221"/>
   <result pre="similar prognostic factors and are not mutually exclusive in breast" exact="cancer" post="Clin Cancer Res 2007 13 12 3577 3584 17575221"/>
   <result pre="with trastuzumab response and survival in patients with HER2-positive metastatic" exact="breast cancer" post="Am J Pathol 2010 177 4 1647 1656 20813970"/>
   <result pre="trastuzumab response and survival in patients with HER2-positive metastatic breast" exact="cancer" post="Am J Pathol 2010 177 4 1647 1656 20813970"/>
   <result pre="and PTEN loss with efficacy of trastuzumab therapy in metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2011 128 2 447 456"/>
   <result pre="PTEN loss with efficacy of trastuzumab therapy in metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2011 128 2 447 456"/>
   <result pre="A et al. PIK3CA mutation associates with improved outcome in" exact="breast cancer" post="Clin Cancer Res 2009 15 16 5049 5059 19671852"/>
   <result pre="et al. PIK3CA mutation associates with improved outcome in breast" exact="cancer" post="Clin Cancer Res 2009 15 16 5049 5059 19671852"/>
   <result pre="Vacher S et al. PIK3CA mutation impact on survival in" exact="breast cancer" post="patients and in ERα, PR and ERBB2-based subgroups Breast"/>
   <result pre="S et al. PIK3CA mutation impact on survival in breast" exact="cancer" post="patients and in ERα, PR and ERBB2-based subgroups Breast"/>
   <result pre="growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal" exact="breast cancer" post="patients Breast Cancer Res 2014 16 1 R13 24467828"/>
   <result pre="factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast" exact="cancer" post="patients Breast Cancer Res 2014 16 1 R13 24467828"/>
   <result pre="profiling and associations with prognosis and trastuzumab benefit in early" exact="breast cancer" post="J Natl Cancer Inst 2013 105 13 960 967"/>
   <result pre="and associations with prognosis and trastuzumab benefit in early breast" exact="cancer" post="J Natl Cancer Inst 2013 105 13 960 967"/>
   <result pre="receptor levels and association with PIK3CA mutations and prognosis in" exact="breast cancer" post="Clin Cancer Res 2009 15 7 2472 2478 19276248"/>
   <result pre="levels and association with PIK3CA mutations and prognosis in breast" exact="cancer" post="Clin Cancer Res 2009 15 7 2472 2478 19276248"/>
   <result pre="and response to neoadjuvant endocrine therapy for estrogen receptor positive" exact="breast cancer" post="Breast Cancer Res Treat 2010 119 2 379 390"/>
   <result pre="response to neoadjuvant endocrine therapy for estrogen receptor positive breast" exact="cancer" post="Breast Cancer Res Treat 2010 119 2 379 390"/>
   <result pre="and predictive value of p-Akt, EGFR, and p-mTOR in early" exact="breast cancer" post="Strahlenther Onkol 2014 190 7 636 638 640 645"/>
   <result pre="predictive value of p-Akt, EGFR, and p-mTOR in early breast" exact="cancer" post="Strahlenther Onkol 2014 190 7 636 638 640 645"/>
   <result pre="MAPK pathways are potential good prognostic markers in node-positive, triple-negative" exact="breast cancer" post="Ann Oncol 2014 25 10 1973 1979 25009009 44"/>
   <result pre="pathways are potential good prognostic markers in node-positive, triple-negative breast" exact="cancer" post="Ann Oncol 2014 25 10 1973 1979 25009009 44"/>
   <result pre="modifying clinicopathological characteristics and overall survival of Bulgarian patients with" exact="breast cancer" post="J Cancer Res Clin Oncol 2010 136 11 1657"/>
   <result pre="clinicopathological characteristics and overall survival of Bulgarian patients with breast" exact="cancer" post="J Cancer Res Clin Oncol 2010 136 11 1657"/>
   <result pre="and pHER2 expression and impact on outcome in HER2-positive early-stage" exact="breast cancer" post="patients treated with adjuvant chemotherapy and trastuzumab Ann Oncol"/>
   <result pre="pHER2 expression and impact on outcome in HER2-positive early-stage breast" exact="cancer" post="patients treated with adjuvant chemotherapy and trastuzumab Ann Oncol"/>
   <result pre="on outcome in human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="patients treated with first-line lapatinib plus paclitaxel or paclitaxel"/>
   <result pre="outcome in human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="patients treated with first-line lapatinib plus paclitaxel or paclitaxel"/>
   <result pre="PI3K pathway as a major determinant of trastuzumab resistance in" exact="breast cancer" post="Cancer Cell 2007 12 4 395 402 17936563 51"/>
   <result pre="pathway as a major determinant of trastuzumab resistance in breast" exact="cancer" post="Cancer Cell 2007 12 4 395 402 17936563 51"/>
   <result pre="mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified" exact="breast cancer" post="cell lines Ann Oncol 2010 21 2 255 262"/>
   <result pre="in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast" exact="cancer" post="cell lines Ann Oncol 2010 21 2 255 262"/>
   <result pre="J et al. Outcome impact of PIK3CA mutations in HER2-positive" exact="breast cancer" post="patients treated with trastuzumab Br J Cancer 2013 108"/>
   <result pre="et al. Outcome impact of PIK3CA mutations in HER2-positive breast" exact="cancer" post="patients treated with trastuzumab Br J Cancer 2013 108"/>
   <result pre="epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing" exact="breast cancer" post="J Clin Oncol 2014 32 29 3212 3220 25199759"/>
   <result pre="growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast" exact="cancer" post="J Clin Oncol 2014 32 29 3212 3220 25199759"/>
   <result pre="to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in" exact="breast cancer" post="J Clin Oncol Epub 1 5 2015 58 Toi"/>
   <result pre="neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast" exact="cancer" post="J Clin Oncol Epub 1 5 2015 58 Toi"/>
   <result pre="SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic" exact="breast cancer" post="J Clin Oncol 2014 32 33 3753 3761 25332247"/>
   <result pre="in human epidermal growth factor receptor 2-positive, first-line metastatic breast" exact="cancer" post="J Clin Oncol 2014 32 33 3753 3761 25332247"/>
   <result pre="3-kinase pathway: role in tumor progression and therapeutic implications in" exact="breast cancer" post="Breast Cancer Res 2011 13 6 224 22114931 65"/>
   <result pre="pathway: role in tumor progression and therapeutic implications in breast" exact="cancer" post="Breast Cancer Res 2011 13 6 224 22114931 65"/>
   <result pre="Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="H et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="a potential surrogate for the clinical outcome in patients with" exact="breast cancer" post="after neoadjuvant therapy: a meta-regression of 29 randomized prospective"/>
   <result pre="potential surrogate for the clinical outcome in patients with breast" exact="cancer" post="after neoadjuvant therapy: a meta-regression of 29 randomized prospective"/>
   <result pre="unlikely to guarantee dramatic response. Abbreviations: T-mab, trastuzumab; MBC, metastatic" exact="breast cancer;" post="P-mab, pertuzumab; p-CR, pathologic complete response; DFS, disease-free survival;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4444439/results/search/disease/results.xml">
   <result pre="the lumen of the intra- and extrahepatic biliary system or" exact="portal vein thrombosis" post="[ 4]. Patient's age is also an essential factor"/>
   <result pre="gives grounds for diagnosing cholestasis. In people with neoplastic disease," exact="cholestasis" post="can be a result of damage to intrahepatic bile"/>
   <result pre="of complications during chemotherapy. It is proven that coexistence of" exact="hepatitis" post="B virus infection can lead to fulminant hepatic necrosis."/>
   <result pre="Liver cell damage can be of chemical type or immunologic" exact="hypersensitivity" post="type [ 12]. Another classification describes damage of hepatocytes"/>
   <result pre="an enzyme (immunological idiosyncrasy) or as a result of metabolic" exact="hypersensitivity" post="to the drug (metabolic idiosyncrasy). These mechanisms are generally"/>
   <result pre="9]. Jaundice lasting over 6 months or elevated markers of" exact="cholestasis" post="lasting over 12 months is consistent with permanent damage"/>
   <result pre="hepatocytes and blood hepatocyte necrosis, inflammation, acute liver failure Hepatocellular" exact="cholestasis" post="disorder of production and intracanalicular secretion of bile caused"/>
   <result pre="duct obstruction, impaired bile flow in extrahepatic bile ducts Ischemic" exact="cholangitis" post="intra-arterial administration of cytostatic drugs ischemic cholangitis Drug toxicity"/>
   <result pre="bile ducts Ischemic cholangitis intra-arterial administration of cytostatic drugs ischemic" exact="cholangitis" post="Drug toxicity can also lead to cirrhosis. Concentric narrowing"/>
   <result pre="caused by damage of the sinus vessel endothelium, are called" exact="peliosis hepatis." post="When focal nodular hyperplasia is diagnosed, it is associated"/>
   <result pre="70% of melanomas, but they are present in colorectal and" exact="ovarian cancer" post="as well [ 15]. Bevacizumab is a humanized recombined"/>
   <result pre="of melanomas, but they are present in colorectal and ovarian" exact="cancer" post="as well [ 15]. Bevacizumab is a humanized recombined"/>
   <result pre="Aim Registration indications [ 18] Hepatotoxicity Monoclonal antibodies bevacizumab VEGF" exact="colon cancer," post="rectum cancer, breast cancer, non-small-cell lung cancer, ovarian epithelial"/>
   <result pre="indications [ 18] Hepatotoxicity Monoclonal antibodies bevacizumab VEGF colon cancer," exact="rectum cancer," post="breast cancer, non-small-cell lung cancer, ovarian epithelial cancer –"/>
   <result pre="18] Hepatotoxicity Monoclonal antibodies bevacizumab VEGF colon cancer, rectum cancer," exact="breast cancer," post="non-small-cell lung cancer, ovarian epithelial cancer – rituximab membrane"/>
   <result pre="antibodies bevacizumab VEGF colon cancer, rectum cancer, breast cancer, non-small-cell" exact="lung cancer," post="ovarian epithelial cancer – rituximab membrane antigen CD 20"/>
   <result pre="cancer, rectum cancer, breast cancer, non-small-cell lung cancer, ovarian epithelial" exact="cancer" post="– rituximab membrane antigen CD 20 follicular lymphoma, diffuse"/>
   <result pre="cancer, ovarian epithelial cancer – rituximab membrane antigen CD 20" exact="follicular lymphoma," post="diffuse large B-cell lymphoma – ipilimumab CTLA-4 malignant melanoma"/>
   <result pre="rituximab membrane antigen CD 20 follicular lymphoma, diffuse large B-cell" exact="lymphoma" post="– ipilimumab CTLA-4 malignant melanoma + trastuzumab HER 2"/>
   <result pre="lymphoma – ipilimumab CTLA-4 malignant melanoma + trastuzumab HER 2" exact="breast cancer," post="stomach cancer + cetuximab EGFR colon and rectum cancer,"/>
   <result pre="ipilimumab CTLA-4 malignant melanoma + trastuzumab HER 2 breast cancer," exact="stomach cancer" post="+ cetuximab EGFR colon and rectum cancer, head and"/>
   <result pre="CTLA-4 malignant melanoma + trastuzumab HER 2 breast cancer, stomach" exact="cancer" post="+ cetuximab EGFR colon and rectum cancer, head and"/>
   <result pre="2 breast cancer, stomach cancer + cetuximab EGFR colon and" exact="rectum cancer," post="head and neck squamous cell carcinoma – panitumumab EGFR"/>
   <result pre="and neck squamous cell carcinoma – panitumumab EGFR colon and" exact="rectum cancer" post="– Kinase inhibitors erlotinib EGFR non-small-cell lung cancer, pancreatic"/>
   <result pre="neck squamous cell carcinoma – panitumumab EGFR colon and rectum" exact="cancer" post="– Kinase inhibitors erlotinib EGFR non-small-cell lung cancer, pancreatic"/>
   <result pre="colon and rectum cancer – Kinase inhibitors erlotinib EGFR non-small-cell" exact="lung cancer," post="pancreatic cancer + gefitinib EGFR non-small-cell lung cancer +"/>
   <result pre="rectum cancer – Kinase inhibitors erlotinib EGFR non-small-cell lung cancer," exact="pancreatic cancer" post="+ gefitinib EGFR non-small-cell lung cancer + lapatinib EGFR,"/>
   <result pre="cancer – Kinase inhibitors erlotinib EGFR non-small-cell lung cancer, pancreatic" exact="cancer" post="+ gefitinib EGFR non-small-cell lung cancer + lapatinib EGFR,"/>
   <result pre="EGFR non-small-cell lung cancer, pancreatic cancer + gefitinib EGFR non-small-cell" exact="lung cancer" post="+ lapatinib EGFR, HER 2 breast cancer +++ sorafenib"/>
   <result pre="non-small-cell lung cancer, pancreatic cancer + gefitinib EGFR non-small-cell lung" exact="cancer" post="+ lapatinib EGFR, HER 2 breast cancer +++ sorafenib"/>
   <result pre="gefitinib EGFR non-small-cell lung cancer + lapatinib EGFR, HER 2" exact="breast cancer" post="+++ sorafenib RAF, VEGFR type 1, 2 and 3,"/>
   <result pre="EGFR non-small-cell lung cancer + lapatinib EGFR, HER 2 breast" exact="cancer" post="+++ sorafenib RAF, VEGFR type 1, 2 and 3,"/>
   <result pre="sorafenib RAF, VEGFR type 1, 2 and 3, PDGFR, c-KIT" exact="hepatocellular carcinoma," post="kidney cancer ++ pazopanib PDGFR, c-KIT, VEGFR type 1"/>
   <result pre="VEGFR type 1, 2 and 3, PDGFR, c-KIT hepatocellular carcinoma," exact="kidney cancer" post="++ pazopanib PDGFR, c-KIT, VEGFR type 1 and 2"/>
   <result pre="type 1, 2 and 3, PDGFR, c-KIT hepatocellular carcinoma, kidney" exact="cancer" post="++ pazopanib PDGFR, c-KIT, VEGFR type 1 and 2"/>
   <result pre="cancer ++ pazopanib PDGFR, c-KIT, VEGFR type 1 and 2" exact="renal cell carcinoma," post="some forms of soft tissue sarcoma +++ sunitinib VEGFR"/>
   <result pre="and 2 renal cell carcinoma, some forms of soft tissue" exact="sarcoma" post="+++ sunitinib VEGFR type 1 and 2, PDGFR, c-KIT,"/>
   <result pre="1 and 2, PDGFR, c-KIT, FLT-3, RET gastrointestinal stromal tumors," exact="renal cell carcinoma," post="neuroendocrine pancreatic tumors +++ imatinib BCR-ABL, KIT, PDGFR chronic"/>
   <result pre="cell carcinoma, neuroendocrine pancreatic tumors +++ imatinib BCR-ABL, KIT, PDGFR" exact="chronic myeloid leukemia," post="acute lymphoblastic leukemia, in myelodysplastic or myeloproliferative disease, gastrointestinal"/>
   <result pre="carcinoma, neuroendocrine pancreatic tumors +++ imatinib BCR-ABL, KIT, PDGFR chronic" exact="myeloid leukemia," post="acute lymphoblastic leukemia, in myelodysplastic or myeloproliferative disease, gastrointestinal"/>
   <result pre="pancreatic tumors +++ imatinib BCR-ABL, KIT, PDGFR chronic myeloid leukemia," exact="acute lymphoblastic leukemia," post="in myelodysplastic or myeloproliferative disease, gastrointestinal stromal tumors, skin"/>
   <result pre="tumors +++ imatinib BCR-ABL, KIT, PDGFR chronic myeloid leukemia, acute" exact="lymphoblastic leukemia," post="in myelodysplastic or myeloproliferative disease, gastrointestinal stromal tumors, skin"/>
   <result pre="in myelodysplastic or myeloproliferative disease, gastrointestinal stromal tumors, skin nodular" exact="fibrosarcoma" post="++ temsirolimus mTOR renal cell carcinoma, mantle cell lymphoma"/>
   <result pre="disease, gastrointestinal stromal tumors, skin nodular fibrosarcoma ++ temsirolimus mTOR" exact="renal cell carcinoma," post="mantle cell lymphoma – everolimus mTOR breast cancer, pancreatic"/>
   <result pre="tumors, skin nodular fibrosarcoma ++ temsirolimus mTOR renal cell carcinoma," exact="mantle cell lymphoma" post="– everolimus mTOR breast cancer, pancreatic neuroendocrine tumors, renal"/>
   <result pre="nodular fibrosarcoma ++ temsirolimus mTOR renal cell carcinoma, mantle cell" exact="lymphoma" post="– everolimus mTOR breast cancer, pancreatic neuroendocrine tumors, renal"/>
   <result pre="mTOR renal cell carcinoma, mantle cell lymphoma – everolimus mTOR" exact="breast cancer," post="pancreatic neuroendocrine tumors, renal cell carcinoma – Proteasome inhibitor"/>
   <result pre="cell lymphoma – everolimus mTOR breast cancer, pancreatic neuroendocrine tumors," exact="renal cell carcinoma" post="– Proteasome inhibitor bortezomib UP-S multiple myeloma + +"/>
   <result pre="neuroendocrine tumors, renal cell carcinoma – Proteasome inhibitor bortezomib UP-S" exact="multiple myeloma" post="+ + single cases of hepatotoxicity diagnosed ++ hepatotoxicity"/>
   <result pre="(CTLA-4), associated with cytotoxic T lymphocyte. CTLA-4 takes part in" exact="suppression" post="of the pathway that stimulates T lymphocytes ( Table"/>
   <result pre="receptor is observed in the histopathologic specimen of breast or" exact="stomach cancer." post="In the literature, there is one report concerning drug-induced"/>
   <result pre="African American woman who was suffering from advanced locally invasive" exact="breast cancer." post="As a result of using trastuzumab, an increase of"/>
   <result pre="to gemcitabine monotherapy in patients with locally advanced or disseminated" exact="pancreatic cancer," post="an increase of ASPAT consistent with third degree liver"/>
   <result pre="attempting to assess the effectiveness of tyrosine kinase inhibitors in" exact="neoplasm" post="treatment, were analyzed; 5 of them were phase II,"/>
   <result pre="Wen W Adjei A Novel agents on the horizon for" exact="cancer" post="therapy Ca Cancer J Clin 2009 59 111 37"/>
   <result pre="Chan A Risk of tyrosine kinase inhibitors- induces hepatotoxicyty In" exact="cancer" post="patients: A meta-analysis Cancer Treat Rev 2013 39 199"/>
   <result pre="Lapatinib: a tyrosine kinase inhibitor with a clinical role in" exact="breast cancer" post="Expert Opin Pharmacother 2007 8 2189 204 17714070 18"/>
   <result pre="a tyrosine kinase inhibitor with a clinical role in breast" exact="cancer" post="Expert Opin Pharmacother 2007 8 2189 204 17714070 18"/>
   <result pre="Keating G Bevacizumab: in first-line treatment of advanced and/or metastatic" exact="renal cell carcinoma" post="BioDrugs 2008 22 113 20 18345708 20 Zalinski S"/>
   <result pre="of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell" exact="lung cancer" post="N Engl J Med 2005 353 123 32 16014882"/>
   <result pre="Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung" exact="cancer" post="N Engl J Med 2005 353 123 32 16014882"/>
   <result pre="single agent treatment with gefitinib in patients with advanced non-small-cell" exact="lung cancer" post="J Exp Clin Cancer Res 2010 29 126 20843324"/>
   <result pre="agent treatment with gefitinib in patients with advanced non-small-cell lung" exact="cancer" post="J Exp Clin Cancer Res 2010 29 126 20843324"/>
   <result pre="idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with" exact="renal cell carcinoma" post="BMC Cancer 2012 12 590 23231599 31 Sternberg C"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4445592/results/search/disease/results.xml">
   <result pre="The expanding role of pertuzumab in the treatment of HER2-positive" exact="breast cancer" post="Moya-Horno I 1 Cortés J 1 2 [1], [2],"/>
   <result pre="expanding role of pertuzumab in the treatment of HER2-positive breast" exact="cancer" post="Moya-Horno I 1 Cortés J 1 2 [1], [2],"/>
   <result pre="Press Limited, provided the work is properly attributed. Abstract Breast" exact="cancer" post="tumors that demonstrate gene amplification or overexpression of human"/>
   <result pre="many new therapies have become available for the treatment of" exact="breast cancer." post="Particularly, the treatment of patients with HER2-positive breast cancer"/>
   <result pre="of breast cancer. Particularly, the treatment of patients with HER2-positive" exact="breast cancer" post="has developed with the arrival of anti-HER2 targeted therapies"/>
   <result pre="breast cancer. Particularly, the treatment of patients with HER2-positive breast" exact="cancer" post="has developed with the arrival of anti-HER2 targeted therapies"/>
   <result pre="a monoclonal antibody targeting HER2, significantly improves survival in HER2-positive" exact="breast cancer." post="Nevertheless, it is still a challenge to evolve anti-HER2"/>
   <result pre="been demonstrated in both advanced and early stages of HER2-positive" exact="breast cancer." post="Herein, we review the available data on the use"/>
   <result pre="use of pertuzumab for the treatment of patients with HER2-positive" exact="breast cancer." post="Keywords pertuzumab anti-HER2 targeted therapies HER2-positive breast cancer Introduction"/>
   <result pre="with HER2-positive breast cancer. Keywords pertuzumab anti-HER2 targeted therapies HER2-positive" exact="breast cancer" post="Introduction Breast cancer is the most common malignancy in"/>
   <result pre="HER2-positive breast cancer. Keywords pertuzumab anti-HER2 targeted therapies HER2-positive breast" exact="cancer" post="Introduction Breast cancer is the most common malignancy in"/>
   <result pre="Keywords pertuzumab anti-HER2 targeted therapies HER2-positive breast cancer Introduction Breast" exact="cancer" post="is the most common malignancy in women worldwide. The"/>
   <result pre="Society estimates that 235,000 Americans would be diagnosed with invasive" exact="breast cancer" post="and 40,430 would have died of the disease in"/>
   <result pre="estimates that 235,000 Americans would be diagnosed with invasive breast" exact="cancer" post="and 40,430 would have died of the disease in"/>
   <result pre="the disease in the US in 2014. The incidence of" exact="breast cancer" post="has increased steadily over the past few decades, but"/>
   <result pre="disease in the US in 2014. The incidence of breast" exact="cancer" post="has increased steadily over the past few decades, but"/>
   <result pre="cancer has increased steadily over the past few decades, but" exact="breast cancer" post="mortality appears to be declining, suggesting a benefit from"/>
   <result pre="has increased steadily over the past few decades, but breast" exact="cancer" post="mortality appears to be declining, suggesting a benefit from"/>
   <result pre="of the most important therapeutic targets in the management of" exact="breast cancer." post="With the development of anti-HER2 targeted therapies, the prognosis"/>
   <result pre="the development of anti-HER2 targeted therapies, the prognosis of HER2-positive" exact="breast cancer" post="has improved significantly. Currently, there are four licensed anti-HER2"/>
   <result pre="development of anti-HER2 targeted therapies, the prognosis of HER2-positive breast" exact="cancer" post="has improved significantly. Currently, there are four licensed anti-HER2"/>
   <result pre="with trastuzumab has significantly altered the natural history of HER2-positive" exact="breast cancer." post="Trastuzumab is currently the anti-HER2 treatment of choice in"/>
   <result pre="treatment of choice in the first-line treatment of HER2-positive metastatic" exact="breast cancer" post="(MBC) and in the neoadjuvant and adjuvant setting for"/>
   <result pre="of choice in the first-line treatment of HER2-positive metastatic breast" exact="cancer" post="(MBC) and in the neoadjuvant and adjuvant setting for"/>
   <result pre="and in the neoadjuvant and adjuvant setting for HER2-positive early" exact="breast cancer" post="(EBC). 5, 6 Before the advent of trastuzumab, first-line"/>
   <result pre="in the neoadjuvant and adjuvant setting for HER2-positive early breast" exact="cancer" post="(EBC). 5, 6 Before the advent of trastuzumab, first-line"/>
   <result pre="docetaxel, paclitaxel, or nabpaclitaxel) in patients with HER2-positive locally recurrent" exact="cancer" post="or MBC is also consistent with previous clinical experience"/>
   <result pre="T4a-c, any N, M0), or inflammatory (T4d, any N, M0)" exact="breast cancer" post="with primary tumors larger than 2 cm in diameter"/>
   <result pre="any N, M0), or inflammatory (T4d, any N, M0) breast" exact="cancer" post="with primary tumors larger than 2 cm in diameter"/>
   <result pre="any N, M0), inflammatory (T4d, any N, M0), or early-stage" exact="breast cancer" post="(tumors greater than 2 cm in diameter) were enrolled"/>
   <result pre="N, M0), inflammatory (T4d, any N, M0), or early-stage breast" exact="cancer" post="(tumors greater than 2 cm in diameter) were enrolled"/>
   <result pre="adverse events were mild or moderate, the most frequent being" exact="diarrhea" post="(64%), asthenia (33%), and nausea (27%). 17 In the"/>
   <result pre="in the pertuzumab group, compared to the control group, were" exact="diarrhea" post="(66.8% versus 46.3%), rash (33.7% versus 24.2%), mucosal inflammation"/>
   <result pre="compared to the control group, were diarrhea (66.8% versus 46.3%)," exact="rash" post="(33.7% versus 24.2%), mucosal inflammation (27.8% versus 19.9%), febrile"/>
   <result pre="rash (33.7% versus 24.2%), mucosal inflammation (27.8% versus 19.9%), febrile" exact="neutropenia" post="(13.8% versus 7.6%), and dry skin (10.6% versus 4.3%)."/>
   <result pre="and dry skin (10.6% versus 4.3%). However, peripheral edema and" exact="constipation" post="were greater in the control group (23.1% versus 30%,"/>
   <result pre="trastuzumab and docetaxel also prolonged the time to worsening of" exact="breast cancer" post="symptoms. The analysis yielded a median time to deterioration"/>
   <result pre="and docetaxel also prolonged the time to worsening of breast" exact="cancer" post="symptoms. The analysis yielded a median time to deterioration"/>
   <result pre="symptoms. The analysis yielded a median time to deterioration in" exact="breast cancer" post="symptoms of 18.3 weeks in the control group compared"/>
   <result pre="The analysis yielded a median time to deterioration in breast" exact="cancer" post="symptoms of 18.3 weeks in the control group compared"/>
   <result pre="pertuzumab, or trastuzumab and lapatinib) with or without chemotherapy in" exact="breast cancer," post="regardless of treatment setting (metastatic or neoadjuvant), showed that"/>
   <result pre="and 2.9% (95% CI: 2.1–4.1), respectively. The odds ratios of" exact="congestive heart failure" post="and LVEF decline between anti-HER2 combination and monotherapy were"/>
   <result pre="A pooled analysis of clinical trials of neoadjuvant treatment for" exact="breast cancer" post="showed that patients who attain pCR defined as ypT0,"/>
   <result pre="pooled analysis of clinical trials of neoadjuvant treatment for breast" exact="cancer" post="showed that patients who attain pCR defined as ypT0,"/>
   <result pre="blockade), resulting in augmented anticancer activity in patients with HER2-positive" exact="breast cancer." post="Based on the available published data, candidates for treatment"/>
   <result pre="Collaborators Effect of screening and adjuvant therapy on mortality from" exact="breast cancer" post="N Engl J Med 2005 353 1784 1792 16251534"/>
   <result pre="Effect of screening and adjuvant therapy on mortality from breast" exact="cancer" post="N Engl J Med 2005 353 1784 1792 16251534"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="Arch Pathol Lab Med 2007 131 18 43 19548375"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="Arch Pathol Lab Med 2007 131 18 43 19548375"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="collab: Breast Cancer International Research Group Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="Breast Cancer International Research Group Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="administered as first-line treatment: the M77001 study group J"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="administered as first-line treatment: the M77001 study group J"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 33 5538 5546 19786658"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 33 5538 5546 19786658"/>
   <result pre="randomized trial in human epidermal growth factor receptor 2-positive operable" exact="breast cancer" post="J Clin Oncol 2005 23 3676 3685 15738535 12"/>
   <result pre="trial in human epidermal growth factor receptor 2-positive operable breast" exact="cancer" post="J Clin Oncol 2005 23 3676 3685 15738535 12"/>
   <result pre="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced" exact="breast cancer" post="(the NOAH trial): a randomized controlled superiority trial with"/>
   <result pre="neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast" exact="cancer" post="(the NOAH trial): a randomized controlled superiority trial with"/>
   <result pre="CLEOPATRA Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="in patients with advanced human epidermal growth factor receptor 2-positive" exact="breast cancer" post="J Clin Oncol 2012 30 14 1594 1600 22393084"/>
   <result pre="patients with advanced human epidermal growth factor receptor 2-positive breast" exact="cancer" post="J Clin Oncol 2012 30 14 1594 1600 22393084"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="Clin Cancer Res 2008 14 9 2710 2716 18451236"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="Clin Cancer Res 2008 14 9 2710 2716 18451236"/>
   <result pre="pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic" exact="breast cancer" post="J Clin Oncol 2014 32 33 3753 3761 25332247"/>
   <result pre="in human epidermal growth factor receptor 2-positive, first-line metastatic breast" exact="cancer" post="J Clin Oncol 2014 32 33 3753 3761 25332247"/>
   <result pre="J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic" exact="breast cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast" exact="cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="first-line pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic" exact="breast cancer" post="Presented at: ESMO 2014 September 28, 2014 Madrid 23"/>
   <result pre="pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast" exact="cancer" post="Presented at: ESMO 2014 September 28, 2014 Madrid 23"/>
   <result pre="of central nervous system metastases in patients with HER2-positive metastatic" exact="breast cancer" post="treated with pertuzumab, trastuzumab, and docetaxel: results from the"/>
   <result pre="central nervous system metastases in patients with HER2-positive metastatic breast" exact="cancer" post="treated with pertuzumab, trastuzumab, and docetaxel: results from the"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="J Clin Oncol 2015 33 5 442 447 25547504"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="J Clin Oncol 2015 33 5 442 447 25547504"/>
   <result pre="human epidermal growth factor receptor 2-positive, locally advanced, or metastatic" exact="breast cancer" post="J Clin Oncol 2014 32 14 1437 1444 24733796"/>
   <result pre="epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast" exact="cancer" post="J Clin Oncol 2014 32 14 1437 1444 24733796"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic" exact="breast cancer" post="in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study"/>
   <result pre="plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast" exact="cancer" post="in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study"/>
   <result pre="III study combining pertuzumab with trastuzumab and docetaxel in metastatic" exact="breast cancer" post="Ann Oncol 2013 24 10 2630 2635 23868905 33"/>
   <result pre="study combining pertuzumab with trastuzumab and docetaxel in metastatic breast" exact="cancer" post="Ann Oncol 2013 24 10 2630 2635 23868905 33"/>
   <result pre="33 Valachis A Nearchou A Polyzos NP Cardiac toxicity in" exact="breast cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="Valachis A Nearchou A Polyzos NP Cardiac toxicity in breast" exact="cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="al. collab: EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 1783 1791 23020162"/>
   <result pre="collab: EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 1783 1791 23020162"/>
   <result pre="Main clinical trials evaluating pertuzumab in the treatment of HER2-positive" exact="breast cancer" post="Trial reference Phase Setting Schema Primary end point Reported"/>
   <result pre="clinical trials evaluating pertuzumab in the treatment of HER2-positive breast" exact="cancer" post="Trial reference Phase Setting Schema Primary end point Reported"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4447178/results/search/disease/results.xml">
   <result pre="ott-8-1149 : Review Tracking the 2015 Gastrointestinal Cancers Symposium: bridging" exact="cancer" post="biology to clinical gastrointestinal oncology Aprile Giuseppe 1 Leone"/>
   <result pre="their experiences on how to bridge the recent novelties in" exact="cancer" post="biology with everyday medical practice. In this article, the"/>
   <result pre="gastroesophageal malignancies, pancreatic and biliary cancers, and colorectal adenocarcinomas. Keywords" exact="colorectal cancer" post="gastric cancer ramucirumab pembrolizumab target therapy onartuzumab AMG 337"/>
   <result pre="malignancies, pancreatic and biliary cancers, and colorectal adenocarcinomas. Keywords colorectal" exact="cancer" post="gastric cancer ramucirumab pembrolizumab target therapy onartuzumab AMG 337"/>
   <result pre="and biliary cancers, and colorectal adenocarcinomas. Keywords colorectal cancer gastric" exact="cancer" post="ramucirumab pembrolizumab target therapy onartuzumab AMG 337 Introduction Significant"/>
   <result pre="on the method for refining optimal candidates for sorafenib in" exact="hepatocellular carcinoma" post="(HCC), and discuss how to expand valuable treatment options"/>
   <result pre="upper gastrointestinal malignancies Recent advances in the understanding of gastric" exact="cancer" post="biology and the comprehensive molecular analysis performed by the"/>
   <result pre="amplification of the MET factor has been observed in gastric" exact="cancer" post="4 and been correlated with unfavorable clinical outcomes. 5"/>
   <result pre="presented. 8 One hundred and twenty-three patients with advanced gastroesophageal" exact="cancer" post="were enrolled from 25 centers; key eligibility criteria included"/>
   <result pre="becoming a major methodological approach. T-lymphocytes may recognize and eliminate" exact="cancer" post="antigens, while immune checkpoints such as cytotoxic T-lymphocyte-associated antigen"/>
   <result pre="chemotherapy is a standard of care in locally advanced gastroesophageal" exact="cancer" post="in Europe. 17, 18 In the MAGIC population, the"/>
   <result pre="and may promote the use of trastuzumab in resectable gastric" exact="cancer" post="patients. Significant advances in HCC, pancreatic cancer, and ciliary"/>
   <result pre="trastuzumab in resectable gastric cancer patients. Significant advances in HCC," exact="pancreatic cancer," post="and ciliary tract adenocarcinoma Ramucirumab is a humanized monoclonal"/>
   <result pre="model was also suggested for patients with locally advanced unresectable" exact="pancreatic cancer" post="included in the LAP 07 trial. 27 In the"/>
   <result pre="was also suggested for patients with locally advanced unresectable pancreatic" exact="cancer" post="included in the LAP 07 trial. 27 In the"/>
   <result pre="and future trial design. Novel potential therapeutic options for metastatic" exact="pancreatic cancer" post="have been suggested from analyses of randomized trials. In"/>
   <result pre="future trial design. Novel potential therapeutic options for metastatic pancreatic" exact="cancer" post="have been suggested from analyses of randomized trials. In"/>
   <result pre="type 2 inhibitor) in combination with FOLFIRINOX for locally advanced" exact="pancreatic cancer." post="29 Among 23 evaluable patients, 21 (91%) completed all"/>
   <result pre="with borderline resectable disease and in two with locally advanced" exact="pancreatic cancer." post="Globally, these very initial findings suggest that PF-04136309 and"/>
   <result pre="suggest that PF-04136309 and MM-398+5FU/LV should undergo further investigation in" exact="pancreatic cancer." post="Relevant information about the genomic landscape of biliary tract"/>
   <result pre="in pancreatic cancer. Relevant information about the genomic landscape of" exact="biliary tract cancer" post="was derived from an analysis including &amp;gt;500 hundred patients."/>
   <result pre="cancer. Relevant information about the genomic landscape of biliary tract" exact="cancer" post="was derived from an analysis including &amp;gt;500 hundred patients."/>
   <result pre="candidates for targeted agents. Findings from this analysis showed that" exact="intrahepatic cholangiocarcinoma" post="(IHCCA), extrahepatic cholangiocarcinoma (EHCCA) and gall bladder carcinoma (GBCA)"/>
   <result pre="for targeted agents. Findings from this analysis showed that intrahepatic" exact="cholangiocarcinoma" post="(IHCCA), extrahepatic cholangiocarcinoma (EHCCA) and gall bladder carcinoma (GBCA)"/>
   <result pre="Findings from this analysis showed that intrahepatic cholangiocarcinoma (IHCCA), extrahepatic" exact="cholangiocarcinoma" post="(EHCCA) and gall bladder carcinoma (GBCA) share genomic alterations"/>
   <result pre="data deriving from the 2015 Gastrointestinal Cancers Symposium on HCC," exact="pancreatic cancer," post="and biliary tract cancer will serve as relevant integration"/>
   <result pre="the 2015 Gastrointestinal Cancers Symposium on HCC, pancreatic cancer, and" exact="biliary tract cancer" post="will serve as relevant integration to our scientific knowledge"/>
   <result pre="Gastrointestinal Cancers Symposium on HCC, pancreatic cancer, and biliary tract" exact="cancer" post="will serve as relevant integration to our scientific knowledge"/>
   <result pre="Similar considerations are applicable to data presented on patients with" exact="pancreatic cancer" post="and biliary tract cancer. Colorectal cancers: integrating novel drugs"/>
   <result pre="considerations are applicable to data presented on patients with pancreatic" exact="cancer" post="and biliary tract cancer. Colorectal cancers: integrating novel drugs"/>
   <result pre="applicable to data presented on patients with pancreatic cancer and" exact="biliary tract cancer." post="Colorectal cancers: integrating novel drugs in innovative strategies Results"/>
   <result pre="(EORTC) Screening Patients for Efficient Clinical Trial Access in advanced" exact="colorectal cancer" post="(SPECTAcolor), a pan-European network, has already analyzed 406 patients"/>
   <result pre="Screening Patients for Efficient Clinical Trial Access in advanced colorectal" exact="cancer" post="(SPECTAcolor), a pan-European network, has already analyzed 406 patients"/>
   <result pre="and has planned to use next-generation sequencing for 360 key" exact="cancer" post="alterations. 38 A nationwide genomic screening project in Japan"/>
   <result pre="A retrospective review of 145 patients with locally advanced rectal" exact="cancer" post="who received standard neoadjuvant chemoradiation suggests that patients who"/>
   <result pre="the patients. The optimal timing of surgical resection of rectal" exact="cancer" post="after preoperative chemoradiation was investigated in a retrospective analysis"/>
   <result pre="1 Mayer RJ Venook AP Schilsky RL Progress against GI" exact="cancer" post="during the American Society of Clinical Oncology’s first 50"/>
   <result pre="M et al. The challenge of targeted therapies for gastric" exact="cancer" post="patients: the beginning of a long journey Expert Opin"/>
   <result pre="and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric" exact="cancer" post="after chemotherapy Cancer 2014 120 5 675 682 24804300"/>
   <result pre="pathway and prognosis of patients with high-risk, radically resected gastric" exact="cancer" post="J Clin Oncol 2011 29 36 4789 4795 22042954"/>
   <result pre="with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E)" exact="cancer" post="J Clin Oncol 2015 33 suppl 3 abstr 1"/>
   <result pre="17212704 13 Pardoll DM The blockade of immune checkpoints in" exact="cancer" post="immunotherapy Nat Rev Cancer 2012 12 4 252 264"/>
   <result pre="of pembrolizumab (PEMBRO; MK-3475) in patients (PTS) with advanced gastric" exact="cancer" post="Ann Oncol 2014 25 suppl 5 v1 v41 15"/>
   <result pre="expression and clinical outcomes in patients (Pts) with advanced gastric" exact="cancer" post="treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475)"/>
   <result pre="Trial Participants Perioperative chemotherapy versus surgery alone for resectable gastroesophageal" exact="cancer" post="N Engl J Med 2006 355 1 11 20"/>
   <result pre="Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced" exact="hepatocellular carcinoma" post="(HCC): analysis of patients with elevated α-fetoprotein (AFP) from"/>
   <result pre="front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced" exact="hepatocellular carcinoma" post="(HCC) J Clin Oncol 2015 33 suppl 3 abstr"/>
   <result pre="and safety of nintedanib versus sorafenib in patients with advanced" exact="hepatocellular carcinoma" post="(HCC) J Clin Oncol 2015 33 suppl 3 abstr"/>
   <result pre="the multivariate survival analysis (MVA) of the patients with unresectable" exact="hepatocellular carcinoma" post="(HCC) treated with doxorubicin drug eluting beads transarterial chemoembolization"/>
   <result pre="without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic" exact="pancreatic cancer" post="(mPAC) previously treated with gemcitabine-based therapy J Clin Oncol"/>
   <result pre="5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic" exact="cancer" post="(mPAC) previously treated with gemcitabine-based therapy J Clin Oncol"/>
   <result pre="Berardi R Bianconi M Cascinu S Pancreatic cancer: progress in" exact="cancer" post="therapy Crit Rev Oncol Hematol 2008 67 1 27"/>
   <result pre="clinical study of famitinib in the treatment of advanced metastatic" exact="colorectal cancer" post="J Clin Oncol 2015 33 suppl 3 abstr 513"/>
   <result pre="study of famitinib in the treatment of advanced metastatic colorectal" exact="cancer" post="J Clin Oncol 2015 33 suppl 3 abstr 513"/>
   <result pre="al. Evidence-based appraisal of the upfront treatment for unresectable metastatic" exact="colorectal cancer" post="patients World J Gastroenterol 2013 19 46 8474 8488"/>
   <result pre="Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal" exact="cancer" post="patients World J Gastroenterol 2013 19 46 8474 8488"/>
   <result pre="in the prediction of clinical outcome during anti-EGFR treatment in" exact="colorectal cancer" post="patients Curr Drug Targets 2014 15 13 1225 1230"/>
   <result pre="the prediction of clinical outcome during anti-EGFR treatment in colorectal" exact="cancer" post="patients Curr Drug Targets 2014 15 13 1225 1230"/>
   <result pre="Denda T et al. The nationwide genomic screening project for" exact="gastrointestinal cancer" post="in Japan (GI-SCREEN): simultaneous identification of KRAS, NRAS, BRAF,"/>
   <result pre="T et al. The nationwide genomic screening project for gastrointestinal" exact="cancer" post="in Japan (GI-SCREEN): simultaneous identification of KRAS, NRAS, BRAF,"/>
   <result pre="identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced" exact="colorectal cancer" post="(aCRC) (GI-SCREEN 2013-01) J Clin Oncol 2015 33 suppl"/>
   <result pre="of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal" exact="cancer" post="(aCRC) (GI-SCREEN 2013-01) J Clin Oncol 2015 33 suppl"/>
   <result pre="panitumumab combination therapy in patients with BRAF V600E mutated metastatic" exact="colorectal cancer" post="J Clin Oncol 2015 33 suppl 3 abstr 611"/>
   <result pre="combination therapy in patients with BRAF V600E mutated metastatic colorectal" exact="cancer" post="J Clin Oncol 2015 33 suppl 3 abstr 611"/>
   <result pre="irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic" exact="colorectal cancer" post="(mCRC) J Clin Oncol 2015 33 suppl 3 abstr"/>
   <result pre="and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal" exact="cancer" post="(mCRC) J Clin Oncol 2015 33 suppl 3 abstr"/>
   <result pre="et al. Therapeutic dual inhibition of HER2 pathway for metastatic" exact="colorectal cancer" post="(mCRC): the HERACLES trial J Clin Oncol 2015 33"/>
   <result pre="al. Therapeutic dual inhibition of HER2 pathway for metastatic colorectal" exact="cancer" post="(mCRC): the HERACLES trial J Clin Oncol 2015 33"/>
   <result pre="Eaton A et al. Organ preservation in patients with rectal" exact="cancer" post="with clinical complete response after neoadjuvant therapy J Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4453607/results/search/disease/results.xml">
   <result pre="of EGFR overexpression and EGFR copy number alteration in HER2-positive" exact="breast cancer" post="EGFR in HER2-positive breast cancer Lee H J 1"/>
   <result pre="EGFR overexpression and EGFR copy number alteration in HER2-positive breast" exact="cancer" post="EGFR in HER2-positive breast cancer Lee H J 1"/>
   <result pre="copy number alteration in HER2-positive breast cancer EGFR in HER2-positive" exact="breast cancer" post="Lee H J 1 2 10 Seo A N"/>
   <result pre="number alteration in HER2-positive breast cancer EGFR in HER2-positive breast" exact="cancer" post="Lee H J 1 2 10 Seo A N"/>
   <result pre="and clinical outcome in 447 primary, and 112 metastatic HER2-positive" exact="breast cancer" post="patients treated by trastuzumab. Results: Of the 242 primary"/>
   <result pre="clinical outcome in 447 primary, and 112 metastatic HER2-positive breast" exact="cancer" post="patients treated by trastuzumab. Results: Of the 242 primary"/>
   <result pre="the subgroup not receiving adjuvant trastuzumab. In 447 HER2-positive primary" exact="breast cancer" post="patients treated with adjuvant trastuzumab, EGFR overexpression was also"/>
   <result pre="subgroup not receiving adjuvant trastuzumab. In 447 HER2-positive primary breast" exact="cancer" post="patients treated with adjuvant trastuzumab, EGFR overexpression was also"/>
   <result pre="copy number, is a poor prognostic factor in HER2-positive primary" exact="breast cancer." post="Epidermal growth factor receptor overexpression is a predictive factor"/>
   <result pre="is a predictive factor for trastuzumab response in HER2-positive primary" exact="breast cancer," post="but not in metastatic breast cancer. breast carcinoma gene"/>
   <result pre="response in HER2-positive primary breast cancer, but not in metastatic" exact="breast cancer." post="breast carcinoma gene amplification EGFR HER2 trastuzumab immunohistochemistry Epidermal"/>
   <result pre="factor receptor (EGFR, ERBB1) expression has been widely studied in" exact="breast cancer" post="by immunohistochemistry (IHC), and the frequency of EGFR overexpression"/>
   <result pre="receptor (EGFR, ERBB1) expression has been widely studied in breast" exact="cancer" post="by immunohistochemistry (IHC), and the frequency of EGFR overexpression"/>
   <result pre="by immunohistochemistry (IHC), and the frequency of EGFR overexpression in" exact="breast cancer" post="is quite variable, ranging from 7 to 43% ("/>
   <result pre="immunohistochemistry (IHC), and the frequency of EGFR overexpression in breast" exact="cancer" post="is quite variable, ranging from 7 to 43% ("/>
   <result pre="EGFR is associated with worse survival in patients with HER2-positive" exact="breast cancer" post="( Suo et al, 2002 ; DiGiovanna et al,"/>
   <result pre="is associated with worse survival in patients with HER2-positive breast" exact="cancer" post="( Suo et al, 2002 ; DiGiovanna et al,"/>
   <result pre="(2009) evaluated the expression of EGFR in 45 HER2-positive metastatic" exact="breast cancer" post="patients treated with trastuzumab, and found that EGFR overexpression"/>
   <result pre="evaluated the expression of EGFR in 45 HER2-positive metastatic breast" exact="cancer" post="patients treated with trastuzumab, and found that EGFR overexpression"/>
   <result pre="expression was associated with decreased overall survival of HER2-positive metastatic" exact="breast cancer" post="patients treated with trastuzumab ( Gallardo et al, 2012"/>
   <result pre="was associated with decreased overall survival of HER2-positive metastatic breast" exact="cancer" post="patients treated with trastuzumab ( Gallardo et al, 2012"/>
   <result pre="the mechanisms of EGFR overexpression, is also highly variable in" exact="breast cancer," post="with amplification frequencies up to 24% in triple-negative breast"/>
   <result pre="breast cancer, with amplification frequencies up to 24% in triple-negative" exact="breast cancer" post="( Bhargava et al, 2005 ; Gumuskaya et al,"/>
   <result pre="cancer, with amplification frequencies up to 24% in triple-negative breast" exact="cancer" post="( Bhargava et al, 2005 ; Gumuskaya et al,"/>
   <result pre="prognostic factor for poor disease-free survival in patients with triple-negative" exact="breast cancer" post="( Park et al, 2014 ). However, the prognostic"/>
   <result pre="factor for poor disease-free survival in patients with triple-negative breast" exact="cancer" post="( Park et al, 2014 ). However, the prognostic"/>
   <result pre="However, the prognostic significance of EGFR copy number in HER2-positive" exact="breast cancer" post="is not clear. In this study, we assessed the"/>
   <result pre="the prognostic significance of EGFR copy number in HER2-positive breast" exact="cancer" post="is not clear. In this study, we assessed the"/>
   <result pre="trastuzumab response and clinical outcome in HER2-positive primary and metastatic" exact="breast cancer" post="patients treated by trastuzumab. Materials and methods Patients and"/>
   <result pre="response and clinical outcome in HER2-positive primary and metastatic breast" exact="cancer" post="patients treated by trastuzumab. Materials and methods Patients and"/>
   <result pre="Patients and tissue samples We used three different sets of" exact="breast cancer" post="samples in this study. First, we retrospectively examined 242"/>
   <result pre="and tissue samples We used three different sets of breast" exact="cancer" post="samples in this study. First, we retrospectively examined 242"/>
   <result pre="S1. The second set comprised 447 cases of HER2-positive primary" exact="breast cancer" post="treated with chemotherapy and with adjuvant trastuzumab for 1"/>
   <result pre="The second set comprised 447 cases of HER2-positive primary breast" exact="cancer" post="treated with chemotherapy and with adjuvant trastuzumab for 1"/>
   <result pre="study. The third set was 112 cases of HER2-positive metastatic" exact="breast cancer" post="treated with trastuzumab at Seoul National University Bundang Hospital,"/>
   <result pre="The third set was 112 cases of HER2-positive metastatic breast" exact="cancer" post="treated with trastuzumab at Seoul National University Bundang Hospital,"/>
   <result pre="the 112 metastatic cases, the tissue originated from the primary" exact="cancer" post="site, and in the remaining cases it was obtained"/>
   <result pre="sites. Trastuzumab was administered as the first-line treatment for metastatic" exact="breast cancer" post="in 99 patients (88.4%). Taxane was used most frequently"/>
   <result pre="Trastuzumab was administered as the first-line treatment for metastatic breast" exact="cancer" post="in 99 patients (88.4%). Taxane was used most frequently"/>
   <result pre="and gene amplification). Assessment of trastuzumab response for HER2-positive metastatic" exact="breast cancer" post="Responses to trastuzumab-based therapy were evaluated every 8 to"/>
   <result pre="gene amplification). Assessment of trastuzumab response for HER2-positive metastatic breast" exact="cancer" post="Responses to trastuzumab-based therapy were evaluated every 8 to"/>
   <result pre="EGFR overexpression and EGFR copy number alteration in HER2-positive primary" exact="breast cancer" post="The EGFR IHC and FISH results obtained in the"/>
   <result pre="overexpression and EGFR copy number alteration in HER2-positive primary breast" exact="cancer" post="The EGFR IHC and FISH results obtained in the"/>
   <result pre="there is no standardised cutoff point for EGFR overexpression in" exact="breast cancer." post="Clinicopathologic characteristics of tumours showing EGFR overexpression or high"/>
   <result pre="analysed EGFR overexpression in an independent set of HER2-positive primary" exact="breast cancer" post="patients treated with adjuvant trastuzumab. Correlation between EGFR overexpression"/>
   <result pre="EGFR overexpression in an independent set of HER2-positive primary breast" exact="cancer" post="patients treated with adjuvant trastuzumab. Correlation between EGFR overexpression"/>
   <result pre="Correlation between EGFR overexpression and clinical outcome in HER2-positive primary" exact="breast cancer" post="patients treated with adjuvant trastuzumab In the second set,"/>
   <result pre="between EGFR overexpression and clinical outcome in HER2-positive primary breast" exact="cancer" post="patients treated with adjuvant trastuzumab In the second set,"/>
   <result pre="trastuzumab In the second set, which comprised 447 HER2-positive primary" exact="breast cancer" post="patients treated with adjuvant trastuzumab for 1 year, EGFR"/>
   <result pre="In the second set, which comprised 447 HER2-positive primary breast" exact="cancer" post="patients treated with adjuvant trastuzumab for 1 year, EGFR"/>
   <result pre="EGFR overexpression and response to trastuzumab-based therapy in HER2-positive metastatic" exact="breast cancer" post="in the third set We also examined EGFR overexpression"/>
   <result pre="overexpression and response to trastuzumab-based therapy in HER2-positive metastatic breast" exact="cancer" post="in the third set We also examined EGFR overexpression"/>
   <result pre="characterised by metastatic competence, and EGFR is thought to promote" exact="cancer" post="cell migration and invasion ( Masuda et al, 2012"/>
   <result pre="poor prognostic factor in two independent sets of HER2-positive primary" exact="breast cancer" post="patients. In the first set, patients with EGFR-overexpressing tumours"/>
   <result pre="prognostic factor in two independent sets of HER2-positive primary breast" exact="cancer" post="patients. In the first set, patients with EGFR-overexpressing tumours"/>
   <result pre="studies that showed prognostic significance of EGFR overexpression in HER2-positive" exact="breast cancer" post="also used different cutoff values for EGFR expression ("/>
   <result pre="that showed prognostic significance of EGFR overexpression in HER2-positive breast" exact="cancer" post="also used different cutoff values for EGFR expression ("/>
   <result pre="EGFR pharmDx Kit, which is approved for the identification of" exact="colorectal cancer" post="patients eligible for treatment with cetuximab or panitumumab, but"/>
   <result pre="pharmDx Kit, which is approved for the identification of colorectal" exact="cancer" post="patients eligible for treatment with cetuximab or panitumumab, but"/>
   <result pre="method should be determined to predict the prognosis of HER2-positive" exact="breast cancer" post="patients, but, in the study, EGFR overexpression of 3+"/>
   <result pre="should be determined to predict the prognosis of HER2-positive breast" exact="cancer" post="patients, but, in the study, EGFR overexpression of 3+"/>
   <result pre="EGFR overexpression was associated with poor prognosis in HER2-positive primary" exact="breast cancer" post="patients, high EGFR copy number did not have prognostic"/>
   <result pre="overexpression was associated with poor prognosis in HER2-positive primary breast" exact="cancer" post="patients, high EGFR copy number did not have prognostic"/>
   <result pre="from that in an adjuvant setting. However, the third metastatic" exact="breast cancer" post="set has some limitations; not all patients were treated"/>
   <result pre="that in an adjuvant setting. However, the third metastatic breast" exact="cancer" post="set has some limitations; not all patients were treated"/>
   <result pre="change in EGFR status during tumour progression. In HER2-positive primary" exact="breast cancer," post="EGFR overexpression was associated with worse survival in the"/>
   <result pre="in combination with trastuzuamb to treat patients with HER2-positive metastatic" exact="breast cancer" post="( Arteaga et al, 2008 ; Somlo et al,"/>
   <result pre="combination with trastuzuamb to treat patients with HER2-positive metastatic breast" exact="cancer" post="( Arteaga et al, 2008 ; Somlo et al,"/>
   <result pre="EGFR-targeted therapy and as a prognostic factor for HER2-positive metastatic" exact="breast cancer" post="should be validated in large studies. There are treatments"/>
   <result pre="therapy and as a prognostic factor for HER2-positive metastatic breast" exact="cancer" post="should be validated in large studies. There are treatments"/>
   <result pre="in ongoing trials in the context of trastuzumab-resistant metastatic HER2-positive" exact="breast cancer" post="( Gradishar, 2013). In conclusion, our study showed that"/>
   <result pre="ongoing trials in the context of trastuzumab-resistant metastatic HER2-positive breast" exact="cancer" post="( Gradishar, 2013). In conclusion, our study showed that"/>
   <result pre="overexpression is an independent poor prognostic factor in HER2-positive primary" exact="breast cancer," post="and it is also a predictive factor for trastuzumab"/>
   <result pre="also a predictive factor for trastuzumab response in HER2-positive primary" exact="breast cancer," post="but not in metastatic breast cancer. This research was"/>
   <result pre="response in HER2-positive primary breast cancer, but not in metastatic" exact="breast cancer." post="This research was supported by the Basic Science Research"/>
   <result pre="with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic" exact="breast cancer" post="Clin Cancer Res 14 6277 6283 18829509 Bhargava R"/>
   <result pre="trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast" exact="cancer" post="Clin Cancer Res 14 6277 6283 18829509 Bhargava R"/>
   <result pre="factor receptor gene and protein and gefitinib sensitivity in non-small-cell" exact="lung cancer" post="J Natl Cancer Inst 97 643 655 15870435 Cho"/>
   <result pre="receptor gene and protein and gefitinib sensitivity in non-small-cell lung" exact="cancer" post="J Natl Cancer Inst 97 643 655 15870435 Cho"/>
   <result pre="factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing" exact="breast cancer" post="cells via specific erbB-receptor interaction and activation Exp Cell"/>
   <result pre="receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast" exact="cancer" post="cells via specific erbB-receptor interaction and activation Exp Cell"/>
   <result pre="factor receptor expression to ErbB-2 signaling activity and prognosis in" exact="breast cancer" post="patients J Clin Oncol 23 1152 1160 15718311 Eisenhauer"/>
   <result pre="receptor expression to ErbB-2 signaling activity and prognosis in breast" exact="cancer" post="patients J Clin Oncol 23 1152 1160 15718311 Eisenhauer"/>
   <result pre="gene copy number may predict lapatinib sensitivity in HER2-positive metastatic" exact="breast cancer" post="Expert Opin Pharmacother 14 699 706 23472669 Franklin MC"/>
   <result pre="copy number may predict lapatinib sensitivity in HER2-positive metastatic breast" exact="cancer" post="Expert Opin Pharmacother 14 699 706 23472669 Franklin MC"/>
   <result pre="S Cameron D 2006 Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 355 2733 2743 17192538 Gori"/>
   <result pre="Cameron D 2006 Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 355 2733 2743 17192538 Gori"/>
   <result pre="status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic" exact="breast cancer" post="patients treated with trastuzumab Ann Oncol 20 648 654"/>
   <result pre="by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast" exact="cancer" post="patients treated with trastuzumab Ann Oncol 20 648 654"/>
   <result pre="19188134 Gradishar WJ 2013 Emerging approaches for treating HER2-positive metastatic" exact="breast cancer" post="beyond trastuzumab Ann Oncol 24 2492 2500 23827380 Gumuskaya"/>
   <result pre="Gradishar WJ 2013 Emerging approaches for treating HER2-positive metastatic breast" exact="cancer" post="beyond trastuzumab Ann Oncol 24 2492 2500 23827380 Gumuskaya"/>
   <result pre="recommendations for immunohistochemical testing of estrogen and progesterone receptors in" exact="breast cancer" post="J Oncol Pract 6 195 197 21037871 Hwangbo W"/>
   <result pre="for immunohistochemical testing of estrogen and progesterone receptors in breast" exact="cancer" post="J Oncol Pract 6 195 197 21037871 Hwangbo W"/>
   <result pre="different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive" exact="breast cancer" post="Breast Cancer Res Treat 145 615 623 24820412 Lee"/>
   <result pre="diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast" exact="cancer" post="Breast Cancer Res Treat 145 615 623 24820412 Lee"/>
   <result pre="affects trastuzumab responses and survival in patients with HER2-positive metastatic" exact="breast cancer" post="Am J Clin Patholin press. Lv N Xie X"/>
   <result pre="trastuzumab responses and survival in patients with HER2-positive metastatic breast" exact="cancer" post="Am J Clin Patholin press. Lv N Xie X"/>
   <result pre="Ueno NT 2012 Role of epidermal growth factor receptor in" exact="breast cancer" post="Breast Cancer Res Treat 136 331 345 23073759 Nieto"/>
   <result pre="NT 2012 Role of epidermal growth factor receptor in breast" exact="cancer" post="Breast Cancer Res Treat 136 331 345 23073759 Nieto"/>
   <result pre="(EGFR) and the presence of truncated EGFRvIII in locoregionally advanced" exact="breast cancer" post="J Clin Oncol 25 4405 4413 17906204 Park HS"/>
   <result pre="and the presence of truncated EGFRvIII in locoregionally advanced breast" exact="cancer" post="J Clin Oncol 25 4405 4413 17906204 Park HS"/>
   <result pre="High EGFR gene copy number predicts poor outcome in triple-negative" exact="breast cancer" post="Mod Pathol 27 1212 1222 24406864 Ritter CA Perez-Torres"/>
   <result pre="EGFR gene copy number predicts poor outcome in triple-negative breast" exact="cancer" post="Mod Pathol 27 1212 1222 24406864 Ritter CA Perez-Torres"/>
   <result pre="Guix M Dugger T Engelman JA Arteaga CL 2007 Human" exact="breast cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="M Dugger T Engelman JA Arteaga CL 2007 Human breast" exact="cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="and docetaxel in patients with stage IV HER-2 positive metastatic" exact="breast cancer" post="Breast Cancer Res Treat 131 899 906 22042372 Suo"/>
   <result pre="docetaxel in patients with stage IV HER-2 positive metastatic breast" exact="cancer" post="Breast Cancer Res Treat 131 899 906 22042372 Suo"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="J Clin Oncol 25 118 145 17159189 Wrba F"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="J Clin Oncol 25 118 145 17159189 Wrba F"/>
   <result pre="EGFR overexpression and EGFR copy number alteration in HER2-positive primary" exact="breast cancer" post=". EGFR overexpression defined as 3+ ( A) and"/>
   <result pre="overexpression and EGFR copy number alteration in HER2-positive primary breast" exact="cancer" post=". EGFR overexpression defined as 3+ ( A) and"/>
   <result pre="and overall survival according to EGFR overexpression in HER2-positive primary" exact="breast cancer" post="patients treated with adjuvant trastuzumab . EGFR overexpression defined"/>
   <result pre="overall survival according to EGFR overexpression in HER2-positive primary breast" exact="cancer" post="patients treated with adjuvant trastuzumab . EGFR overexpression defined"/>
   <result pre="and overall survival according to EGFR expression in HER2-positive metastatic" exact="breast cancer" post=". EGFR overexpression defined as 3+ ( A) and"/>
   <result pre="overall survival according to EGFR expression in HER2-positive metastatic breast" exact="cancer" post=". EGFR overexpression defined as 3+ ( A) and"/>
   <result pre="factors associated with disease-free and overall survival for HER2-positive primary" exact="breast cancer" post="patients in the first set Disease-free survival Overall survival"/>
   <result pre="associated with disease-free and overall survival for HER2-positive primary breast" exact="cancer" post="patients in the first set Disease-free survival Overall survival"/>
   <result pre="HR=hazard ratio. Table 4 Multivariate survival analyses for HER2-positive primary" exact="breast cancer" post="patients treated with adjuvant trastuzumab in the second set"/>
   <result pre="ratio. Table 4 Multivariate survival analyses for HER2-positive primary breast" exact="cancer" post="patients treated with adjuvant trastuzumab in the second set"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4456592/results/search/disease/results.xml">
   <result pre="doi: 10.1186/s40064-015-1015-6 : Short Report Monitoring serum HER2 levels in" exact="breast cancer" post="patients Tchou Julia Julia.Tchou@uphs.upenn.edu Lam Lian lianlam@mail.med.upenn.edu Li Yun"/>
   <result pre="10.1186/s40064-015-1015-6 : Short Report Monitoring serum HER2 levels in breast" exact="cancer" post="patients Tchou Julia Julia.Tchou@uphs.upenn.edu Lam Lian lianlam@mail.med.upenn.edu Li Yun"/>
   <result pre="to detect serum soluble HER2/neu (sHER2) in early stage primary" exact="breast cancer" post="and monitor its change during treatments. Findings We collected"/>
   <result pre="detect serum soluble HER2/neu (sHER2) in early stage primary breast" exact="cancer" post="and monitor its change during treatments. Findings We collected"/>
   <result pre="during treatments. Findings We collected sera preoperatively from 118 primary" exact="breast cancer" post="patients. Serum samples were also collected sequentially from a"/>
   <result pre="treatments. Findings We collected sera preoperatively from 118 primary breast" exact="cancer" post="patients. Serum samples were also collected sequentially from a"/>
   <result pre="sHER2 is worth further study as a biomarker to monitor" exact="breast cancer" post="patients during treatments. Keywords HER2/neu SHER2 Biomarker MBB buffer"/>
   <result pre="is worth further study as a biomarker to monitor breast" exact="cancer" post="patients during treatments. Keywords HER2/neu SHER2 Biomarker MBB buffer"/>
   <result pre="patients during treatments. Keywords HER2/neu SHER2 Biomarker MBB buffer Breast" exact="cancer" post="Findings Introduction Currently, women with breast cancer are eligible"/>
   <result pre="Biomarker MBB buffer Breast cancer Findings Introduction Currently, women with" exact="breast cancer" post="are eligible for HER2/neu (HER2) based therapy if their"/>
   <result pre="MBB buffer Breast cancer Findings Introduction Currently, women with breast" exact="cancer" post="are eligible for HER2/neu (HER2) based therapy if their"/>
   <result pre="In addition, heterogeneous expression of HER2/neu has been reported in" exact="breast cancer" post="at both the cellular and tissue level and may"/>
   <result pre="addition, heterogeneous expression of HER2/neu has been reported in breast" exact="cancer" post="at both the cellular and tissue level and may"/>
   <result pre="compared tested sHER2 and tHER2 in 118 patients undergoing primary" exact="breast cancer" post="surgery. Because a subset of these patients with tHER2"/>
   <result pre="tested sHER2 and tHER2 in 118 patients undergoing primary breast" exact="cancer" post="surgery. Because a subset of these patients with tHER2"/>
   <result pre="Under institutional review board (IRB) approved protocol, we prospectively enrolled" exact="breast cancer" post="patients undergoing breast cancer surgery at our institution. The"/>
   <result pre="institutional review board (IRB) approved protocol, we prospectively enrolled breast" exact="cancer" post="patients undergoing breast cancer surgery at our institution. The"/>
   <result pre="(IRB) approved protocol, we prospectively enrolled breast cancer patients undergoing" exact="breast cancer" post="surgery at our institution. The first patient cohort consisted"/>
   <result pre="approved protocol, we prospectively enrolled breast cancer patients undergoing breast" exact="cancer" post="surgery at our institution. The first patient cohort consisted"/>
   <result pre="at our institution. The first patient cohort consisted of 118" exact="breast cancer" post="patients treated at our institution between 2010 and 2014."/>
   <result pre="our institution. The first patient cohort consisted of 118 breast" exact="cancer" post="patients treated at our institution between 2010 and 2014."/>
   <result pre="Serum samples were collected preoperatively on the day of their" exact="breast cancer" post="surgery after the patients signed the informed consent form."/>
   <result pre="samples were collected preoperatively on the day of their breast" exact="cancer" post="surgery after the patients signed the informed consent form."/>
   <result pre="race, age at diagnosis (defined as the date of initial" exact="breast cancer" post="surgery), tumor subtypes according to receptor status, tumor size"/>
   <result pre="age at diagnosis (defined as the date of initial breast" exact="cancer" post="surgery), tumor subtypes according to receptor status, tumor size"/>
   <result pre="classified into three groups: Group 1 was comprised of ER+" exact="breast cancer" post="which expressed either ER or PR and lacks HER2"/>
   <result pre="into three groups: Group 1 was comprised of ER+ breast" exact="cancer" post="which expressed either ER or PR and lacks HER2"/>
   <result pre="and lacks HER2 expression; Group 2 was comprised of HER2+" exact="breast cancer" post="which expressed HER2 as determined by IHC and/or FISH"/>
   <result pre="lacks HER2 expression; Group 2 was comprised of HER2+ breast" exact="cancer" post="which expressed HER2 as determined by IHC and/or FISH"/>
   <result pre="of serum levels with tissue HER2 status As results of" exact="breast cancer" post="serum samples using our own MBB sHER2 assay were"/>
   <result pre="serum levels with tissue HER2 status As results of breast" exact="cancer" post="serum samples using our own MBB sHER2 assay were"/>
   <result pre="log-rank score test, p = 0.0098). Fig. 3 Disease free survival of" exact="breast cancer" post="patients after surgery. Kaplan-Meier analyses showing the association of"/>
   <result pre="score test, p = 0.0098). Fig. 3 Disease free survival of breast" exact="cancer" post="patients after surgery. Kaplan-Meier analyses showing the association of"/>
   <result pre="a useful predictive marker for tHER2 positive status in primary" exact="breast cancer" post="patients The ability to measure sHER2 as a non-invasive"/>
   <result pre="useful predictive marker for tHER2 positive status in primary breast" exact="cancer" post="patients The ability to measure sHER2 as a non-invasive"/>
   <result pre="We found that only 16.7% of tHER2 positive early stage" exact="breast cancer" post="patients had dramatically elevated sHER2 levels. Our results are"/>
   <result pre="found that only 16.7% of tHER2 positive early stage breast" exact="cancer" post="patients had dramatically elevated sHER2 levels. Our results are"/>
   <result pre="to those from larger clinical trials involving early stage primary" exact="breast cancer" post="patients. In one study, only 12 % of 2318"/>
   <result pre="those from larger clinical trials involving early stage primary breast" exact="cancer" post="patients. In one study, only 12 % of 2318"/>
   <result pre="another recent study of 2862 cases of stage I–III primary" exact="breast cancer" post="patients, 24 % were found to be tHER2 positive,"/>
   <result pre="recent study of 2862 cases of stage I–III primary breast" exact="cancer" post="patients, 24 % were found to be tHER2 positive,"/>
   <result pre="Therefore, sHER2 is a poor diagnostic marker for early stage" exact="breast cancer" post="and should not be used to replace conventional IHC"/>
   <result pre="sHER2 is a poor diagnostic marker for early stage breast" exact="cancer" post="and should not be used to replace conventional IHC"/>
   <result pre="a previous study when we examined a cohort of invasive" exact="breast cancer" post="patients that included late stage metastatic cases, elevated sHER2"/>
   <result pre="previous study when we examined a cohort of invasive breast" exact="cancer" post="patients that included late stage metastatic cases, elevated sHER2"/>
   <result pre="Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant" exact="breast cancer" post="cells in vivo Breast Cancer Res 2011 13 2"/>
   <result pre="causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast" exact="cancer" post="cells in vivo Breast Cancer Res 2011 13 2"/>
   <result pre="shedding of the extracellular domain and with prognostic factors in" exact="breast cancer" post="Cancer Res 1998 58 22 5123 5129 9823322 Colomer"/>
   <result pre="of the extracellular domain and with prognostic factors in breast" exact="cancer" post="Cancer Res 1998 58 22 5123 5129 9823322 Colomer"/>
   <result pre="Circulating HER2 extracellular domain and resistance to chemotherapy in advanced" exact="breast cancer" post="Clin Cancer Res 2000 6 6 2356 2362 10873087"/>
   <result pre="HER2 extracellular domain and resistance to chemotherapy in advanced breast" exact="cancer" post="Clin Cancer Res 2000 6 6 2356 2362 10873087"/>
   <result pre="HER2/neu in monitoring and prediction of progression-free survival in metastatic" exact="breast cancer" post="patients treated with trastuzumab-based therapies Breast Cancer Res 2005"/>
   <result pre="in monitoring and prediction of progression-free survival in metastatic breast" exact="cancer" post="patients treated with trastuzumab-based therapies Breast Cancer Res 2005"/>
   <result pre="Zhang H Interference-free HER2 ECD as a serum biomarker in" exact="breast cancer" post="J Mol Biomark Diagn 2014 4 3 151 25089226"/>
   <result pre="H Interference-free HER2 ECD as a serum biomarker in breast" exact="cancer" post="J Mol Biomark Diagn 2014 4 3 151 25089226"/>
   <result pre="SH Preoperative serum HER2 extracellular domain levels in primary invasive" exact="breast cancer" post="BMC Cancer 2014 14 929 10.1186/1471-2407-14-929 25491647 Liu PC"/>
   <result pre="Preoperative serum HER2 extracellular domain levels in primary invasive breast" exact="cancer" post="BMC Cancer 2014 14 929 10.1186/1471-2407-14-929 25491647 Liu PC"/>
   <result pre="major source of HER2 ectodomain sheddase activity in HER2 overexpressing" exact="breast cancer" post="cells Cancer Biol Ther 2006 5 6 657 664"/>
   <result pre="source of HER2 ectodomain sheddase activity in HER2 overexpressing breast" exact="cancer" post="cells Cancer Biol Ther 2006 5 6 657 664"/>
   <result pre="Crino L Evaluation of serum HER2 extracellular domain in early" exact="breast cancer" post="patients: correlation with clinicopathological parameters and survival Ann Oncol"/>
   <result pre="L Evaluation of serum HER2 extracellular domain in early breast" exact="cancer" post="patients: correlation with clinicopathological parameters and survival Ann Oncol"/>
   <result pre="growth factor receptor 2 (HER2) levels in patients with HER2-positive" exact="breast cancer" post="receiving chemotherapy with or without Trastuzumab: results from north"/>
   <result pre="factor receptor 2 (HER2) levels in patients with HER2-positive breast" exact="cancer" post="receiving chemotherapy with or without Trastuzumab: results from north"/>
   <result pre="receiving chemotherapy with or without Trastuzumab: results from north central" exact="cancer" post="treatment group adjuvant trial N9831 Cancer 2013 119 15"/>
   <result pre="GD Schmechel SC Lange H Evaluating tumor heterogeneity in immunohistochemistry-stained" exact="breast cancer" post="tissue Lab Invest 2012 92 9 1342 1357 10.1038/labinvest.2012.91"/>
   <result pre="Schmechel SC Lange H Evaluating tumor heterogeneity in immunohistochemistry-stained breast" exact="cancer" post="tissue Lab Invest 2012 92 9 1342 1357 10.1038/labinvest.2012.91"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="and serum HER2 extracellular domain: biology and clinical utility in" exact="breast cancer" post="Cancer Treat Rev 2012 38 2 133 142 10.1016/j.ctrv.2011.03.008"/>
   <result pre="serum HER2 extracellular domain: biology and clinical utility in breast" exact="cancer" post="Cancer Treat Rev 2012 38 2 133 142 10.1016/j.ctrv.2011.03.008"/>
   <result pre="Murali R Greene MI ErbB receptors: from oncogenes to targeted" exact="cancer" post="therapies J Clin Invest 2007 117 8 2051 2058"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4457853/results/search/disease/results.xml">
   <result pre="systemic treatment of complex multigene diseases such as cancer, diabetes," exact="arthritis" post="and hypertension. Most currently used combinations were found in"/>
   <result pre="systemic chemotherapy in HER2-receptor (erb-b2 receptor tyrosine kinase 2) positive" exact="breast cancer." post="Funding LB and RV are graduate students at the"/>
   <result pre="loops which can be utilized to compensate various perturbations. In" exact="cancer" post="therapy, drugs acting on the HER2 (erb-b2 receptor tyrosine"/>
   <result pre="by experience and intuition [ 7, 8]. About one-fourth of" exact="breast cancer" post="patients express HER2 (human epidermal growth factor receptor-2), a"/>
   <result pre="experience and intuition [ 7, 8]. About one-fourth of breast" exact="cancer" post="patients express HER2 (human epidermal growth factor receptor-2), a"/>
   <result pre="approved for use in adjuvant settings in HER2 positive early" exact="breast cancer." post="Anti-HER2 therapy is highly successful: although high HER2 expression"/>
   <result pre="Numerous other agents are also included in protocols used for" exact="breast cancer" post="patients including Methothrexate, Epirubicine, Fluorouracil and protocols containing combinations"/>
   <result pre="other agents are also included in protocols used for breast" exact="cancer" post="patients including Methothrexate, Epirubicine, Fluorouracil and protocols containing combinations"/>
   <result pre="state of the art in systemic treatment for HER2 positive" exact="breast cancer." post="However, finding the most efficient combinations of these is"/>
   <result pre="with anthracycline- and taxane- based systemic chemotherapy in HER2-receptor positive" exact="breast cancer." post="Results 2.1. TOS: A network-based Target Overlap Score for"/>
   <result pre="collateral pathways including PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) and RALA (v-ral simian" exact="leukemia" post="viral oncogene homolog A (ras related)) will also be"/>
   <result pre="major, moderate and minor. In the selection we considered only" exact="cancer" post="related drug pairs i.e. those in which one of"/>
   <result pre="agents was or was proposed to be used in treating" exact="cancer" post="which resulted in 10323 strongly, 92958 moderately and 17193"/>
   <result pre="were included 5All approved drug combinations that are used in" exact="cancer" post="treatment. 6We made all possible binary combinations of FDA-approved"/>
   <result pre="random combinations. Next we carried out the same comparisons for" exact="cancer" post="related drugs. In this case the datasets were naturally"/>
   <result pre="set of beneficial combinations included 33 combinations specifically suggested for" exact="cancer" post="(dataset H, Table 1). The results presented in Fig"/>
   <result pre="from the average and the AUC value of 0.91 in" exact="cancer" post="related combinations can be considered especially convincing. iv) In"/>
   <result pre="pairwise combination with all the 43 chemotherapeutic agents approved for" exact="breast cancer" post="(amsacrine, azacitidine, bleomycin, cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cladribine,"/>
   <result pre="combination with all the 43 chemotherapeutic agents approved for breast" exact="cancer" post="(amsacrine, azacitidine, bleomycin, cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cladribine,"/>
   <result pre="trials) and the set of known combinations (i.e. previously approved" exact="cancer" post="combinations). The first step is to compute the Target"/>
   <result pre="After the selection of the training sample (both the positive—known" exact="cancer" post="combinations—and the negative one—random combinations) a logistic regression was"/>
   <result pre="reported; 2All the known detrimental and beneficial drug interactions; 3All" exact="cancer" post="related drug combinations; 4For detailed description of datasets see"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre="GN , Giordano SH . Prognosis of women with metastatic" exact="breast cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre=", Giordano SH . Prognosis of women with metastatic breast" exact="cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4464713/results/search/disease/results.xml">
   <result pre="Research Article The prognostic role of HER2 expression in ductal" exact="breast carcinoma in situ" post="(DCIS); a population-based cohort study Borgquist Signe signe.borgquist@med.lu.se Zhou"/>
   <result pre="Article The prognostic role of HER2 expression in ductal breast" exact="carcinoma in situ" post="(DCIS); a population-based cohort study Borgquist Signe signe.borgquist@med.lu.se Zhou"/>
   <result pre="HER2 is a well-established prognostic and predictive factor in invasive" exact="breast cancer." post="The role of HER2 in ductal breast carcinoma in"/>
   <result pre="in invasive breast cancer. The role of HER2 in ductal" exact="breast carcinoma in situ" post="(DCIS) is debated and recent data have suggested that"/>
   <result pre="invasive breast cancer. The role of HER2 in ductal breast" exact="carcinoma in situ" post="(DCIS) is debated and recent data have suggested that"/>
   <result pre="in situ and 51 invasive recurrences. Eighteen women died from" exact="breast cancer" post="and another 114 had died from other causes. The"/>
   <result pre="situ and 51 invasive recurrences. Eighteen women died from breast" exact="cancer" post="and another 114 had died from other causes. The"/>
   <result pre="primary DCIS is associated with lower risk of recurrent invasive" exact="breast cancer." post="Keywords Ductal carcinoma in situ (DCIS) HER2 Prognostic marker"/>
   <result pre="with lower risk of recurrent invasive breast cancer. Keywords Ductal" exact="carcinoma in situ" post="(DCIS) HER2 Prognostic marker Breast cancer Background In general,"/>
   <result pre="Keywords Ductal carcinoma in situ (DCIS) HER2 Prognostic marker Breast" exact="cancer" post="Background In general, patients with ductal breast carcinoma in"/>
   <result pre="Prognostic marker Breast cancer Background In general, patients with ductal" exact="breast carcinoma in situ" post="(DCIS) have an excellent prognosis in terms of survival"/>
   <result pre="marker Breast cancer Background In general, patients with ductal breast" exact="carcinoma in situ" post="(DCIS) have an excellent prognosis in terms of survival"/>
   <result pre="ipsilateral events (IBE) is high, even higher than following invasive" exact="breast cancer" post="[ 2]. Almost half of all IBEs subsequent to"/>
   <result pre="events (IBE) is high, even higher than following invasive breast" exact="cancer" post="[ 2]. Almost half of all IBEs subsequent to"/>
   <result pre="half of all IBEs subsequent to a DCIS are invasive" exact="cancer" post="and survival after an invasive IBE has, not surprisingly,"/>
   <result pre="of DCIS might be more prone to recur as invasive" exact="cancer" post="and new biological markers may provide additional prognostic and/or"/>
   <result pre="10]. HER2 is an established negative prognostic factor in invasive" exact="breast cancer" post="[ 11]. The prognostic significance of HER2 status in"/>
   <result pre="HER2 is an established negative prognostic factor in invasive breast" exact="cancer" post="[ 11]. The prognostic significance of HER2 status in"/>
   <result pre="its role in the progression from in situ to invasive" exact="cancer" post="have been debated [ 12]. HER2 over-expression is reported"/>
   <result pre="reported to be more frequent in DCIS than in invasive" exact="cancer" post="[ 13]. This may seem counterintuitive as HER2 is"/>
   <result pre="report an even higher proportion of HER2 positivity in micro-invasive" exact="cancer" post="[ 14, 15] and, in pre-operative tumour biopsies displaying"/>
   <result pre="HER2 is associated with high histopathological grade both in invasive" exact="cancer" post="and in DCIS [ 18]. HER2 amplification is an"/>
   <result pre="important factor in the classification of molecular subtypes of invasive" exact="breast cancer" post="[ 19]. An approximation of the gene expression based"/>
   <result pre="factor in the classification of molecular subtypes of invasive breast" exact="cancer" post="[ 19]. An approximation of the gene expression based"/>
   <result pre="and progesterone receptor (PR) expression has been suggested for invasive" exact="breast cancer" post="[ 20]. DCIS has been divided into the same"/>
   <result pre="progesterone receptor (PR) expression has been suggested for invasive breast" exact="cancer" post="[ 20]. DCIS has been divided into the same"/>
   <result pre="been divided into the same surrogate molecular subtypes as invasive" exact="breast cancer" post="[ 6, 21– 23] but the prognostic value of"/>
   <result pre="divided into the same surrogate molecular subtypes as invasive breast" exact="cancer" post="[ 6, 21– 23] but the prognostic value of"/>
   <result pre="SAS 9.3 (Cary, NC, USA). Primary endpoints were Ipsilateral Breast" exact="cancer" post="Events (IBE) and Invasive Breast Cancer Recurrences (IBCR). IBEs"/>
   <result pre="as an invasive IBE, a regional recurrence, a contralateral invasive" exact="breast cancer" post="or distant metastasis. IBCR free survival was calculated based"/>
   <result pre="an invasive IBE, a regional recurrence, a contralateral invasive breast" exact="cancer" post="or distant metastasis. IBCR free survival was calculated based"/>
   <result pre="time from primary surgery to the date of any invasive" exact="breast cancer" post="event, date of death or date of last follow-up"/>
   <result pre="from primary surgery to the date of any invasive breast" exact="cancer" post="event, date of death or date of last follow-up"/>
   <result pre="distant metastasis only in twelve cases and a contralateral invasive" exact="cancer" post="in 40 cases. In total, 32 patients developed generalized"/>
   <result pre="subsequently to an invasive IBE, eight after an invasive contralateral" exact="cancer" post="and nine had no reported prior local or regional"/>
   <result pre="reported prior local or regional recurrence. Eighteen women died from" exact="breast cancer" post="and another 114 had died from other causes. HER2"/>
   <result pre="prior local or regional recurrence. Eighteen women died from breast" exact="cancer" post="and another 114 had died from other causes. HER2"/>
   <result pre="of the primary DCIS in relation to risk of a" exact="breast cancer" post="event. Risk of an ipsilateral breast cancer event (IBE)"/>
   <result pre="the primary DCIS in relation to risk of a breast" exact="cancer" post="event. Risk of an ipsilateral breast cancer event (IBE)"/>
   <result pre="risk of a breast cancer event. Risk of an ipsilateral" exact="breast cancer" post="event (IBE) including risk of in situ IBEs and"/>
   <result pre="of a breast cancer event. Risk of an ipsilateral breast" exact="cancer" post="event (IBE) including risk of in situ IBEs and"/>
   <result pre="BCS breast conserving surgery, IBE ipsilateral breast events, IBCR invasive" exact="breast cancer" post="recurrence HER2 and survival analyses Among the 420 women"/>
   <result pre="breast conserving surgery, IBE ipsilateral breast events, IBCR invasive breast" exact="cancer" post="recurrence HER2 and survival analyses Among the 420 women"/>
   <result pre="from the univariate analyses (Table 3). Fig. 1 Ipsilateral Breast" exact="cancer" post="Events (IBE) according to HER2 status of the primary"/>
   <result pre="in the primary lesion predicted lower risk of late invasive" exact="breast cancer" post="recurrence compared to negative HER2 status in the primary"/>
   <result pre="the primary lesion predicted lower risk of late invasive breast" exact="cancer" post="recurrence compared to negative HER2 status in the primary"/>
   <result pre="The subtypes were based on the proposed classification for invasive" exact="breast cancer" post="according to the St Gallen consensus meeting in 2011"/>
   <result pre="subtypes were based on the proposed classification for invasive breast" exact="cancer" post="according to the St Gallen consensus meeting in 2011"/>
   <result pre="is a strong predictor for impaired recurrence-free survival in invasive" exact="breast cancer," post="opposing the results on DCIS in this study. This"/>
   <result pre="may either have been lost in the progression from ductal" exact="carcinoma in situ" post="to invasive breast cancer, or that the invasive component"/>
   <result pre="in the progression from ductal carcinoma in situ to invasive" exact="breast cancer," post="or that the invasive component has arisen from a"/>
   <result pre="invasive disease. In line with the models developed for invasive" exact="breast cancer," post="such as Adjuvant! [ 40], a comprehensive set of"/>
   <result pre="Abbreviations BCS Breast conserving surgery CI Confidence interval DCIS Ductal" exact="carcinoma in situ" post="of the breast ER Estrogen receptor HER2 Human epidermal"/>
   <result pre="factor receptor 2 HR Hazard ratio IHC Immunohistochemical IBCR Invasive" exact="breast cancer" post="recurrences (invasive ipsilateral/regional/contralateral recurrence or distant metastasis) IBE Ipsilateral"/>
   <result pre="receptor 2 HR Hazard ratio IHC Immunohistochemical IBCR Invasive breast" exact="cancer" post="recurrences (invasive ipsilateral/regional/contralateral recurrence or distant metastasis) IBE Ipsilateral"/>
   <result pre="cancer recurrences (invasive ipsilateral/regional/contralateral recurrence or distant metastasis) IBE Ipsilateral" exact="breast cancer" post="event PR Progesterone receptor RT Postoperative radiotherapy SISH Silver-enhanced"/>
   <result pre="recurrences (invasive ipsilateral/regional/contralateral recurrence or distant metastasis) IBE Ipsilateral breast" exact="cancer" post="event PR Progesterone receptor RT Postoperative radiotherapy SISH Silver-enhanced"/>
   <result pre="S Overview of the randomized trials of radiotherapy in ductal" exact="carcinoma in situ" post="of the breast J Natl Cancer Inst Monogr 2010"/>
   <result pre="for ipsilateral breast events after breast conserving treatment for ductal" exact="carcinoma in situ" post="of the breast–results from the Swedish randomised trial Eur"/>
   <result pre="RF Crow JR Luo S Hunt KK Evaluation of a" exact="breast cancer" post="nomogram for predicting risk of ipsilateral breast tumor recurrences"/>
   <result pre="Crow JR Luo S Hunt KK Evaluation of a breast" exact="cancer" post="nomogram for predicting risk of ipsilateral breast tumor recurrences"/>
   <result pre="risk of ipsilateral breast tumor recurrences in patients with ductal" exact="carcinoma in situ" post="after local excision J Clin Oncol 2012 30 600"/>
   <result pre="Duffy SW Jones JL Molecular subtyping of DCIS: heterogeneity of" exact="breast cancer" post="reflected in pre-invasive disease Br J Cancer 2011 104"/>
   <result pre="SW Jones JL Molecular subtyping of DCIS: heterogeneity of breast" exact="cancer" post="reflected in pre-invasive disease Br J Cancer 2011 104"/>
   <result pre="O Warnberg F Long-term survival of women with basal-like ductal" exact="carcinoma in situ" post="of the breast: a population-based cohort study BMC Cancer"/>
   <result pre="Warnberg F A comparison of tumor biology in primary ductal" exact="carcinoma in situ" post="recurring as invasive carcinoma versus a New in situ"/>
   <result pre="multigene expression assay to predict local recurrence risk for ductal" exact="carcinoma in situ" post="of the breast J Natl Cancer Inst 2013 105"/>
   <result pre="The role of HER2/neu overexpression/amplification in the progression of ductal" exact="carcinoma in situ" post="to invasive carcinoma of the breast Mod Pathol 2002"/>
   <result pre="J Di GH Shen ZZ Shao ZM Different distribution of" exact="breast cancer" post="subtypes in breast ductal carcinoma in situ (DCIS), DCIS"/>
   <result pre="Di GH Shen ZZ Shao ZM Different distribution of breast" exact="cancer" post="subtypes in breast ductal carcinoma in situ (DCIS), DCIS"/>
   <result pre="ZM Different distribution of breast cancer subtypes in breast ductal" exact="carcinoma in situ" post="(DCIS), DCIS with microinvasion, and DCIS with invasion component"/>
   <result pre="M Kasumi F Significance of HER2 protein examination in ductal" exact="carcinoma in situ" post="J Surg Res 2011 167 e205 10 10.1016/j.jss.2009.07.030 20018297"/>
   <result pre="status is an independent predictor for coexisting invasion of ductal" exact="carcinoma in situ" post="of the breast presenting extensive DCIS component Pathol Res"/>
   <result pre="a predictor for the transition from in situ to invasive" exact="breast cancer" post="Cancer Epidemiol Biomarkers Prev 2009 18 1386 9 10.1158/1055-9965.EPI-08-1101"/>
   <result pre="predictor for the transition from in situ to invasive breast" exact="cancer" post="Cancer Epidemiol Biomarkers Prev 2009 18 1386 9 10.1158/1055-9965.EPI-08-1101"/>
   <result pre="Millikan RC Identification of a basal-like subtype of breast ductal" exact="carcinoma in situ" post="Hum Pathol 2007 38 197 204 10.1016/j.humpath.2006.08.017 17234468 22."/>
   <result pre="Borresen-Dale AL Sorlie T Warnberg F Molecular diversity in ductal" exact="carcinoma in situ" post="(DCIS) and early invasive breast cancer Mol Oncol 2010"/>
   <result pre="diversity in ductal carcinoma in situ (DCIS) and early invasive" exact="breast cancer" post="Mol Oncol 2010 4 357 68 10.1016/j.molonc.2010.06.007 20663721 23."/>
   <result pre="in ductal carcinoma in situ (DCIS) and early invasive breast" exact="cancer" post="Mol Oncol 2010 4 357 68 10.1016/j.molonc.2010.06.007 20663721 23."/>
   <result pre="B Peterse JL van de Vijver MJ Classification of ductal" exact="carcinoma in situ" post="by gene expression profiling Breast Cancer Res 2006 8"/>
   <result pre="Sorlie T Blomqvist C Warnberg F Molecular subtypes in ductal" exact="carcinoma in situ" post="of the breast and their relation to prognosis: a"/>
   <result pre="O, Warnberg F. Long-term survival of women with basal-like ductal" exact="carcinoma in situ" post="of the breast: a population-based cohort study. BMC Cancer."/>
   <result pre="SR Bright-field in situ hybridization for HER2 gene amplification in" exact="breast cancer" post="using tissue microarrays: correlation between chromogenic (CISH) and automated"/>
   <result pre="Bright-field in situ hybridization for HER2 gene amplification in breast" exact="cancer" post="using tissue microarrays: correlation between chromogenic (CISH) and automated"/>
   <result pre="JR Outcome after invasive local recurrence in patients with ductal" exact="carcinoma in situ" post="of the breast J Clin Oncol 1998 16 1367"/>
   <result pre="Department of Health/United Kingdom, England: The benefits and harms of" exact="breast cancer" post="screening: an independent review. Lancet. 2012;380:1778–86. 29. Benson JR"/>
   <result pre="of Health/United Kingdom, England: The benefits and harms of breast" exact="cancer" post="screening: an independent review. Lancet. 2012;380:1778–86. 29. Benson JR"/>
   <result pre="29. Benson JR Wishart GC Predictors of recurrence for ductal" exact="carcinoma in situ" post="after breast-conserving surgery Lancet Oncol 2013 14 e348 57"/>
   <result pre="CK Hicks J King TA Reis-Filho JS Progression from ductal" exact="carcinoma in situ" post="to invasive breast cancer: revisited Mol Oncol 2013 7"/>
   <result pre="Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal" exact="carcinoma in situ" post="Br J Cancer 2012 106 1160 5 10.1038/bjc.2012.41 22361634"/>
   <result pre="Biomarker expression and risk of subsequent tumors after initial ductal" exact="carcinoma in situ" post="diagnosis J Natl Cancer Inst 2010 102 627 37"/>
   <result pre="CE Jr Costantino JP et al. Adjuvant tamoxifen reduces subsequent" exact="breast cancer" post="in women with estrogen receptor-positive ductal carcinoma in situ:"/>
   <result pre="Jr Costantino JP et al. Adjuvant tamoxifen reduces subsequent breast" exact="cancer" post="in women with estrogen receptor-positive ductal carcinoma in situ:"/>
   <result pre="the tissue microarray technique in a population-based cohort with ductal" exact="carcinoma in situ" post="of the breast Histopathology 2008 53 642 9 10.1111/j.1365-2559.2008.03156.x"/>
   <result pre="Molecular effects of lapatinib in patients with HER2 positive ductal" exact="carcinoma in situ" post="Breast Cancer Res 2014 16 R76 10.1186/bcr3695 25186428 39."/>
   <result pre="WF Biologic and immunologic effects of preoperative trastuzumab for ductal" exact="carcinoma in situ" post="of the breast Cancer 2011 117 39 47 10.1002/cncr.25399"/>
   <result pre="KA Population-based validation of the prognostic model ADJUVANT! for early" exact="breast cancer" post="J Clin Oncol 2005 23 2716 25 10.1200/JCO.2005.06.178 15837986"/>
   <result pre="Population-based validation of the prognostic model ADJUVANT! for early breast" exact="cancer" post="J Clin Oncol 2005 23 2716 25 10.1200/JCO.2005.06.178 15837986"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4465168/results/search/disease/results.xml">
   <result pre="587 doi: 10.1186/s13058-015-0587-y : Review nab-Paclitaxel dose and schedule in" exact="breast cancer" post="Martín Miguel mmartin@geicam.org [], epub: 2015-6-6 pmc-release: 2015-6-6 ppub:"/>
   <result pre="doi: 10.1186/s13058-015-0587-y : Review nab-Paclitaxel dose and schedule in breast" exact="cancer" post="Martín Miguel mmartin@geicam.org [], epub: 2015-6-6 pmc-release: 2015-6-6 ppub:"/>
   <result pre="stated. Abstract nab-Paclitaxel is approved for the treatment of metastatic" exact="breast cancer" post="on an every-3-week schedule based on positive findings from"/>
   <result pre="Abstract nab-Paclitaxel is approved for the treatment of metastatic breast" exact="cancer" post="on an every-3-week schedule based on positive findings from"/>
   <result pre="in efforts to optimize nab-paclitaxel-based therapy for metastatic and early-stage" exact="breast cancer." post="The goal of this review is to evaluate the"/>
   <result pre="be the best treatment approach for unselected patients with metastatic" exact="breast cancer," post="but may suit a subset of patients for whom"/>
   <result pre="control is required. The growing number of nab-paclitaxel trials in" exact="breast cancer" post="will lead to greater refinements in tailoring therapy to"/>
   <result pre="is required. The growing number of nab-paclitaxel trials in breast" exact="cancer" post="will lead to greater refinements in tailoring therapy to"/>
   <result pre="used chemotherapy agents in the treatment of early-stage and metastatic" exact="breast cancer" post="(MBC) [ 1– 4]. Taxanes stabilize microtubules, leading to"/>
   <result pre="chemotherapy agents in the treatment of early-stage and metastatic breast" exact="cancer" post="(MBC) [ 1– 4]. Taxanes stabilize microtubules, leading to"/>
   <result pre="and docetaxel have demonstrated clinical benefit in the treatment of" exact="breast cancer" post="(BC); however, their chemical formulations have presented several limitations."/>
   <result pre="docetaxel have demonstrated clinical benefit in the treatment of breast" exact="cancer" post="(BC); however, their chemical formulations have presented several limitations."/>
   <result pre="solvent polysorbate 80), and these solvents have been associated with" exact="hypersensitivity" post="and other toxicities, including prolonged peripheral neuropathy [ 8–"/>
   <result pre="have been associated with hypersensitivity and other toxicities, including prolonged" exact="peripheral neuropathy" post="[ 8– 10]. To ameliorate the risk of hypersensitivity"/>
   <result pre="been associated with hypersensitivity and other toxicities, including prolonged peripheral" exact="neuropathy" post="[ 8– 10]. To ameliorate the risk of hypersensitivity"/>
   <result pre="peripheral neuropathy [ 8– 10]. To ameliorate the risk of" exact="hypersensitivity" post="reactions from solvents, patients are routinely pretreated with corticosteroids"/>
   <result pre="is, to increase antitumor activity and reduce toxicities such as" exact="hypersensitivity" post="reactions) [ 2, 17]. Compared with sb-paclitaxel, nab-paclitaxel has"/>
   <result pre="patients with BC) [ 26]. Dose-limiting toxicities included grade 4" exact="neutropenia" post="and grade 3 peripheral neuropathy, and a partial response"/>
   <result pre="26]. Dose-limiting toxicities included grade 4 neutropenia and grade 3" exact="peripheral neuropathy," post="and a partial response was noted in one patient"/>
   <result pre="other cytotoxic agents were excluded. Results nab-Paclitaxel monotherapy in metastatic" exact="breast cancer" post="The literature search revealed five trials of nab-paclitaxel monotherapy"/>
   <result pre="cytotoxic agents were excluded. Results nab-Paclitaxel monotherapy in metastatic breast" exact="cancer" post="The literature search revealed five trials of nab-paclitaxel monotherapy"/>
   <result pre="III, n = 1; Table 1). Table 1 nab-Paclitaxel monotherapy in metastatic" exact="breast cancer" post="Trial Phase Patient population nab-Paclitaxel regimen Patients receiving protocol-specified"/>
   <result pre="n = 1; Table 1). Table 1 nab-Paclitaxel monotherapy in metastatic breast" exact="cancer" post="Trial Phase Patient population nab-Paclitaxel regimen Patients receiving protocol-specified"/>
   <result pre="mg/m 2 occurred in 16 patients (25 %) due to" exact="neutropenia" post="( n = 7), sensory neuropathy ( n = 4), febrile neutropenia ("/>
   <result pre="16 patients (25 %) due to neutropenia ( n = 7), sensory" exact="neuropathy" post="( n = 4), febrile neutropenia ( n = 3), myalgia ( n = 3),"/>
   <result pre="due to neutropenia ( n = 7), sensory neuropathy ( n = 4), febrile" exact="neutropenia" post="( n = 3), myalgia ( n = 3), and fatigue ( n = 2)."/>
   <result pre="or metastatic setting (34 %). The incidence of grade 4" exact="neutropenia" post="was low with nab-paclitaxel treatment, and although grade 3"/>
   <result pre="was low with nab-paclitaxel treatment, and although grade 3 sensory" exact="neuropathy" post="occurred in 10 % of patients, improvements to grade"/>
   <result pre="(35 % and 39 %, respectively, for docetaxel). Grade 3/4" exact="neutropenia" post="and grade 3 sensory neuropathy were significantly more frequent"/>
   <result pre="respectively, for docetaxel). Grade 3/4 neutropenia and grade 3 sensory" exact="neuropathy" post="were significantly more frequent in patients treated with nab-paclitaxel"/>
   <result pre="other patients. nab-Paclitaxel in combination with targeted agents in metastatic" exact="breast cancer" post="According to search criteria, five trials have evaluated combination"/>
   <result pre="patients. nab-Paclitaxel in combination with targeted agents in metastatic breast" exact="cancer" post="According to search criteria, five trials have evaluated combination"/>
   <result pre="nab -Paclitaxel in combination with select targeted therapies in metastatic" exact="breast cancer" post="Trial Phase Patient population nab-Paclitaxel regimen Patients receiving protocol-specified"/>
   <result pre="-Paclitaxel in combination with select targeted therapies in metastatic breast" exact="cancer" post="Trial Phase Patient population nab-Paclitaxel regimen Patients receiving protocol-specified"/>
   <result pre="vs 52 % vs 53 %, respectively), primarily resulting from" exact="peripheral neuropathy." post="Although there were no significant differences in response rates,"/>
   <result pre="feasibility of this schedule, although the incidence of grade 3/4" exact="neutropenia" post="was 50 % (Table 2; grade 4, 16 %)"/>
   <result pre="3 adverse events were pain (11 %), infection (9 %)," exact="neutropenia" post="(8 %), sensory neuropathy (6 %), and fatigue (5"/>
   <result pre="pain (11 %), infection (9 %), neutropenia (8 %), sensory" exact="neuropathy" post="(6 %), and fatigue (5 %). Only one grade"/>
   <result pre="after one cycle of treatment, with four patients having experienced" exact="neutropenia" post="and one patient having experienced neutropenic fever and diarrhea."/>
   <result pre="nonhematologic toxicity. The most common grade 3/4 adverse events were" exact="diarrhea" post="(22 %) and neutropenia (22 %). A regimen of"/>
   <result pre="common grade 3/4 adverse events were diarrhea (22 %) and" exact="neutropenia" post="(22 %). A regimen of weekly nab-paclitaxel 100 mg/m"/>
   <result pre="a feasible treatment in this patient population. nab-Paclitaxel in early" exact="breast cancer" post="Various doses and schedules of nab-paclitaxel have also been"/>
   <result pre="feasible treatment in this patient population. nab-Paclitaxel in early breast" exact="cancer" post="Various doses and schedules of nab-paclitaxel have also been"/>
   <result pre="Table 3). Table 3 nab -Paclitaxel in patients with early-stage" exact="breast cancer" post="Trial Phase Patient population nab-Paclitaxel regimen Patients receiving protocol-specified"/>
   <result pre="3). Table 3 nab -Paclitaxel in patients with early-stage breast" exact="cancer" post="Trial Phase Patient population nab-Paclitaxel regimen Patients receiving protocol-specified"/>
   <result pre="epidermal growth factor receptor 2-positive; HR+, hormone receptor-positive; IBC, inflammatory" exact="breast cancer;" post="LABC, locally advanced breast cancer; LN, lymph node; nab-P,"/>
   <result pre="HR+, hormone receptor-positive; IBC, inflammatory breast cancer; LABC, locally advanced" exact="breast cancer;" post="LN, lymph node; nab-P, nab-paclitaxel; NR, not reported; ORR,"/>
   <result pre="3/4, during the first 3 of 4 weeks; RCB, residual" exact="cancer" post="burden; trastuz, trastuzumab; vin, vinorelbine In the neoadjuvant setting,"/>
   <result pre="nab-Paclitaxel was associated with significantly more grade 3/4 peripheral sensory" exact="neuropathy" post="compared with sb-paclitaxel (10 % vs 3 %, P &amp;lt; 0.001)."/>
   <result pre="reductions occurred in 30 % of patients, 12 % for" exact="neutropenia" post="and 16 % for neuropathy. The most common grade"/>
   <result pre="% for neuropathy. The most common grade 3/4 toxicity was" exact="neutropenia" post="(16 %), and 25 % of patients had no"/>
   <result pre="(16 %), and 25 % of patients had no residual" exact="cancer" post="cells or only microscopic residual disease burden (residual cancer"/>
   <result pre="residual cancer cells or only microscopic residual disease burden (residual" exact="cancer" post="burden 0 or 1 by Symann’s classification [ 40])."/>
   <result pre="and effective neoadjuvant treatment option for patients with locally advanced" exact="breast cancer" post="[ 41]. Patients with HER2-positive tumors received concomitant trastuzumab."/>
   <result pre="effective neoadjuvant treatment option for patients with locally advanced breast" exact="cancer" post="[ 41]. Patients with HER2-positive tumors received concomitant trastuzumab."/>
   <result pre="two regimens was similar except for significantly more grade 3/4" exact="leukopenia" post="in the sb-paclitaxel arm. Phase III trials are necessary"/>
   <result pre="by &amp;gt;5 % of patients in the neoadjuvant trial was" exact="neutropenia" post="(16 %), and the median relative dose intensity was"/>
   <result pre="dose intensity was 98.5 % [ 39]. Grade 3 sensory" exact="neuropathy" post="occurred in two patients (2.5 %), and there were"/>
   <result pre="(2.5 %), and there were no cases of grade 4" exact="neuropathy" post="[ 39]. Furthermore, the regimen was effective, eliciting a"/>
   <result pre="of 77 % and a 25 % rate of residual" exact="cancer" post="burden 0 or 1 [ 38]. In the GeparSepto"/>
   <result pre="in a 38 % pCR rate and grade 3/4 sensory" exact="neuropathy" post="in 10 % of patients [ 36]. Thus, although"/>
   <result pre="aggressive disease subtypes [ 47]. Abbreviations AC Doxorubicin/cyclophosphamide BC Breast" exact="cancer" post="HER2 Human epidermal growth factor receptor 2 MBC Metastatic"/>
   <result pre="cancer HER2 Human epidermal growth factor receptor 2 MBC Metastatic" exact="breast cancer" post="ORR Overall response rate OS Overall survival pCR Pathologic"/>
   <result pre="HER2 Human epidermal growth factor receptor 2 MBC Metastatic breast" exact="cancer" post="ORR Overall response rate OS Overall survival pCR Pathologic"/>
   <result pre="National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:" exact="breast cancer." post="V I.2015. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (2015). Accessed 26 Feb 2015. 2."/>
   <result pre="WJ Sparreboom A Pharmacological effects of formulation vehicles: implications for" exact="cancer" post="chemotherapy Clin Pharmacokinet 2003 42 665 85 10.2165/00003088-200342070-00005 12844327"/>
   <result pre="trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic" exact="breast cancer" post="J Clin Oncol 2005 23 6019 26 10.1200/JCO.2005.11.013 16135470"/>
   <result pre="of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast" exact="cancer" post="J Clin Oncol 2005 23 6019 26 10.1200/JCO.2005.11.013 16135470"/>
   <result pre="paclitaxel compared with polyethylated castor oil-based paclitaxel in women with" exact="breast cancer" post="J Clin Oncol 2005 23 7794 803 10.1200/JCO.2005.04.937 16172456"/>
   <result pre="compared with polyethylated castor oil-based paclitaxel in women with breast" exact="cancer" post="J Clin Oncol 2005 23 7794 803 10.1200/JCO.2005.04.937 16172456"/>
   <result pre="Economic analysis of albumin-bound paclitaxel for the treatment of metastatic" exact="breast cancer" post="J Oncol Pharm Pract 2009 15 67 78 10.1177/1078155208098584"/>
   <result pre="analysis of albumin-bound paclitaxel for the treatment of metastatic breast" exact="cancer" post="J Oncol Pharm Pract 2009 15 67 78 10.1177/1078155208098584"/>
   <result pre="analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic" exact="breast cancer" post="patients: the COSTANza study Clinicoecon Outcomes Res 2013 5"/>
   <result pre="of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast" exact="cancer" post="patients: the COSTANza study Clinicoecon Outcomes Res 2013 5"/>
   <result pre="III trial of weekly compared with every-3-weeks paclitaxel for metastatic" exact="breast cancer," post="with trastuzumab for all HER-2 overexpressors and random assignment"/>
   <result pre="T et al. Weekly paclitaxel in the adjuvant treatment of" exact="breast cancer" post="N Engl J Med 2008 358 1663 71 10.1056/NEJMoa0707056"/>
   <result pre="et al. Weekly paclitaxel in the adjuvant treatment of breast" exact="cancer" post="N Engl J Med 2008 358 1663 71 10.1056/NEJMoa0707056"/>
   <result pre="paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic" exact="breast cancer" post="Asia Pac J Clin Oncol 2009 5 165 74"/>
   <result pre="compared with solvent-based paclitaxel in Chinese patients with metastatic breast" exact="cancer" post="Asia Pac J Clin Oncol 2009 5 165 74"/>
   <result pre="II study of weekly albumin-bound paclitaxel for patients with metastatic" exact="breast cancer" post="heavily pretreated with taxanes Clin Breast Cancer 2007 7"/>
   <result pre="study of weekly albumin-bound paclitaxel for patients with metastatic breast" exact="cancer" post="heavily pretreated with taxanes Clin Breast Cancer 2007 7"/>
   <result pre="with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 3611 9 10.1200/JCO.2008.18.5397 19470941"/>
   <result pre="nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 3611 9 10.1200/JCO.2008.18.5397 19470941"/>
   <result pre="nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic" exact="breast cancer" post="Clin Breast Cancer 2013 13 239 46.e1 10.1016/j.clbc.2013.02.008 23829890"/>
   <result pre="albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast" exact="cancer" post="Clin Breast Cancer 2013 13 239 46.e1 10.1016/j.clbc.2013.02.008 23829890"/>
   <result pre="nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic" exact="breast cancer" post="[abstract 1075]. J Clin Oncol. 2008;26 15 Suppl. 33."/>
   <result pre="in combination with bevacizumab as first-line treatment in metastatic breast" exact="cancer" post="[abstract 1075]. J Clin Oncol. 2008;26 15 Suppl. 33."/>
   <result pre="or ixabepilone ± bevacizumab as first-line therapy for locally recurrent or metastatic" exact="breast cancer" post="[abstract CRA1002]. J Clin Oncol. 2012;30 15 Suppl. 34."/>
   <result pre="ixabepilone ± bevacizumab as first-line therapy for locally recurrent or metastatic breast" exact="cancer" post="[abstract CRA1002]. J Clin Oncol. 2012;30 15 Suppl. 34."/>
   <result pre="weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic" exact="breast cancer" post="Clin Breast Cancer 2011 11 121 8 10.1016/j.clbc.2011.03.007 21569998"/>
   <result pre="nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast" exact="cancer" post="Clin Breast Cancer 2011 11 121 8 10.1016/j.clbc.2011.03.007 21569998"/>
   <result pre="study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic" exact="breast cancer" post="patients who have received no more than one prior"/>
   <result pre="evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast" exact="cancer" post="patients who have received no more than one prior"/>
   <result pre="with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early" exact="breast cancer" post="(GeparSepto); GBG 69 [abstract S2-07] 2014 San Antonio, TX"/>
   <result pre="solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast" exact="cancer" post="(GeparSepto); GBG 69 [abstract S2-07] 2014 San Antonio, TX"/>
   <result pre="without bevacizumab in treating women with inflammatory or locally advanced" exact="breast cancer" post="(NCI CDR0000636131) [abstract P3-11-16] 2014 San Antonio, TX Poster"/>
   <result pre="bevacizumab in treating women with inflammatory or locally advanced breast" exact="cancer" post="(NCI CDR0000636131) [abstract P3-11-16] 2014 San Antonio, TX Poster"/>
   <result pre="García-Martínez E, Seguí MA, et al. Nabrax: neoadjuvant therapy of" exact="breast cancer" post="with weekly single-agent nab-paclitaxel - final efficacy and biomarkers"/>
   <result pre="E, Seguí MA, et al. Nabrax: neoadjuvant therapy of breast" exact="cancer" post="with weekly single-agent nab-paclitaxel - final efficacy and biomarkers"/>
   <result pre="Garcia-Martinez E Segui MA et al. Nabrax: neoadjuvant therapy of" exact="breast cancer" post="with weekly nab-paclitaxel: final safety of GEICAM 2011–02 [abstract"/>
   <result pre="E Segui MA et al. Nabrax: neoadjuvant therapy of breast" exact="cancer" post="with weekly nab-paclitaxel: final safety of GEICAM 2011–02 [abstract"/>
   <result pre="R Kuerer H Valero V et al. Measurement of residual" exact="breast cancer" post="burden to predict survival after neoadjuvant chemotherapy J Clin"/>
   <result pre="Kuerer H Valero V et al. Measurement of residual breast" exact="cancer" post="burden to predict survival after neoadjuvant chemotherapy J Clin"/>
   <result pre="sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced" exact="breast cancer" post="Clin Breast Cancer 2010 10 81 6 10.3816/CBC.2010.n.011 20133263"/>
   <result pre="nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast" exact="cancer" post="Clin Breast Cancer 2010 10 81 6 10.3816/CBC.2010.n.011 20133263"/>
   <result pre="ClinicalTrials.gov. Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-Negative high-risk" exact="breast cancer" post="(ETNA). http://www.clinicaltrials.gov/show/NCT01822314 (2014). Accessed 26 Feb 2015. 43. Zelnak"/>
   <result pre="Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-Negative high-risk breast" exact="cancer" post="(ETNA). http://www.clinicaltrials.gov/show/NCT01822314 (2014). Accessed 26 Feb 2015. 43. Zelnak"/>
   <result pre="2 trial using a novel non-anthracycline neoadjuvant chemotherapy in Her2-positive" exact="breast cancer" post="[abstract 2703] 2012 Chicago, IL Poster presentation at American"/>
   <result pre="trial using a novel non-anthracycline neoadjuvant chemotherapy in Her2-positive breast" exact="cancer" post="[abstract 2703] 2012 Chicago, IL Poster presentation at American"/>
   <result pre="dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage" exact="breast cancer" post="Clin Cancer Res 2011 17 3398 407 10.1158/1078-0432.CCR-10-1969 21350003"/>
   <result pre="doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast" exact="cancer" post="Clin Cancer Res 2011 17 3398 407 10.1158/1078-0432.CCR-10-1969 21350003"/>
   <result pre="is safe as adjuvant therapy in patients with early stage" exact="breast cancer" post="Breast Cancer Res Treat 2011 130 825 31 10.1007/s10549-011-1678-9"/>
   <result pre="safe as adjuvant therapy in patients with early stage breast" exact="cancer" post="Breast Cancer Res Treat 2011 130 825 31 10.1007/s10549-011-1678-9"/>
   <result pre="10.1007/s10549-011-1678-9 46. US Food and Drug Administration. FDA Commissioner removes" exact="breast cancer" post="indication from Avastin label (press release). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm (2014). Accessed"/>
   <result pre="46. US Food and Drug Administration. FDA Commissioner removes breast" exact="cancer" post="indication from Avastin label (press release). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm (2014). Accessed"/>
   <result pre="trial optimizing risk assessment and therapy response prediction in early" exact="breast cancer" post="(ADAPT). http://www.clinicaltrials.gov/show/NCT01781338 (2014). Accessed 26 Feb 2015."/>
   <result pre="optimizing risk assessment and therapy response prediction in early breast" exact="cancer" post="(ADAPT). http://www.clinicaltrials.gov/show/NCT01781338 (2014). Accessed 26 Feb 2015."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467394/results/search/disease/results.xml">
   <result pre="to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified" exact="breast cancer" post="Leung Wing-yin 1 Roxanis Ioannis 2 Sheldon Helen 1"/>
   <result pre="overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast" exact="cancer" post="Leung Wing-yin 1 Roxanis Ioannis 2 Sheldon Helen 1"/>
   <result pre="NRG1 in cells treated with lapatinib. Exogenous NRG1 partially rescued" exact="breast cancer" post="cells from growth inhibition by lapatinib. In addition, both"/>
   <result pre="in cells treated with lapatinib. Exogenous NRG1 partially rescued breast" exact="cancer" post="cells from growth inhibition by lapatinib. In addition, both"/>
   <result pre="growth inhibition by lapatinib. In addition, both parental and lapatinib-resistant" exact="breast cancer" post="cells were sensitive to SGP1, which inhibits binding of"/>
   <result pre="inhibition by lapatinib. In addition, both parental and lapatinib-resistant breast" exact="cancer" post="cells were sensitive to SGP1, which inhibits binding of"/>
   <result pre="clinical HER2-targeted therapy and may inhibit a subset of lapatinib-resistant" exact="breast cancer," post="although the group of patients that will respond to"/>
   <result pre="pathway has been implicated in various epithelial cancers; for example," exact="breast cancer," post="head and neck, and lung cancers [ 2]. Overexpression"/>
   <result pre="amplification of the HER2 gene occurs in around 20% of" exact="breast cancer" post="patients and correlates with adverse prognosis and poor clinical"/>
   <result pre="of the HER2 gene occurs in around 20% of breast" exact="cancer" post="patients and correlates with adverse prognosis and poor clinical"/>
   <result pre="the European Medicines Agency and are now used in HER2-positive" exact="breast cancer" post="patients. Trastuzumab is also used in HER2-positive gastric patients."/>
   <result pre="European Medicines Agency and are now used in HER2-positive breast" exact="cancer" post="patients. Trastuzumab is also used in HER2-positive gastric patients."/>
   <result pre="shown to be synergistic in inhibiting the survival of HER2-overexpressing" exact="breast cancer" post="cell line BT-474 [ 10]. In conjunction with chemotherapy,"/>
   <result pre="to be synergistic in inhibiting the survival of HER2-overexpressing breast" exact="cancer" post="cell line BT-474 [ 10]. In conjunction with chemotherapy,"/>
   <result pre="been shown to prolong PFS compared to trastuzumab in metastatic" exact="breast cancer" post="as first line treatment [ 11] and improve pathological"/>
   <result pre="shown to prolong PFS compared to trastuzumab in metastatic breast" exact="cancer" post="as first line treatment [ 11] and improve pathological"/>
   <result pre="response (pCR) when used as a neoadjuvant therapy in early" exact="breast cancer" post="[ 12]. Therefore, the FDA has approved the use"/>
   <result pre="(pCR) when used as a neoadjuvant therapy in early breast" exact="cancer" post="[ 12]. Therefore, the FDA has approved the use"/>
   <result pre="the combination of pertuzumab and trastuzumab with chemotherapy in metastatic" exact="breast cancer" post="and early HER2-overexpressing breast cancer in the neoadjuvant setting."/>
   <result pre="combination of pertuzumab and trastuzumab with chemotherapy in metastatic breast" exact="cancer" post="and early HER2-overexpressing breast cancer in the neoadjuvant setting."/>
   <result pre="trastuzumab with chemotherapy in metastatic breast cancer and early HER2-overexpressing" exact="breast cancer" post="in the neoadjuvant setting. Lapatinib is a small molecule"/>
   <result pre="with chemotherapy in metastatic breast cancer and early HER2-overexpressing breast" exact="cancer" post="in the neoadjuvant setting. Lapatinib is a small molecule"/>
   <result pre="13, 14]. Lapatinib is used in patients with advanced HER2-positive" exact="breast cancer" post="that have progressed after previous trastuzumab containing regimens and"/>
   <result pre="14]. Lapatinib is used in patients with advanced HER2-positive breast" exact="cancer" post="that have progressed after previous trastuzumab containing regimens and"/>
   <result pre="Society of Clinical Oncology Annual Meeting found that, metastatic HER2-positive" exact="breast cancer" post="patients who received lapatinib and chemotherapy had shorter PFS"/>
   <result pre="of Clinical Oncology Annual Meeting found that, metastatic HER2-positive breast" exact="cancer" post="patients who received lapatinib and chemotherapy had shorter PFS"/>
   <result pre="been proposed to explain the resistance to lapatinib in HER2-overexpressing" exact="breast cancer." post="Lapatinib derepresses FOXO3a, which stimulates oestrogen receptor (ER) transcription"/>
   <result pre="may counteract lapatinib inhibition, we treated two commonly used HER2-overexpressing" exact="breast cancer" post="cell lines, SK-BR-3 and BT-474, with lapatinib for 24"/>
   <result pre="counteract lapatinib inhibition, we treated two commonly used HER2-overexpressing breast" exact="cancer" post="cell lines, SK-BR-3 and BT-474, with lapatinib for 24"/>
   <result pre="2A and B). We generated lapatinib-resistant cell lines from HER2-overexpressing" exact="breast cancer" post="cell lines SK-BR-3 and BT-474 by chronic lapatinib treatment"/>
   <result pre="and B). We generated lapatinib-resistant cell lines from HER2-overexpressing breast" exact="cancer" post="cell lines SK-BR-3 and BT-474 by chronic lapatinib treatment"/>
   <result pre="and/or SGP1 on cell growth in parental and lapatinib-resistant HER2-over-expressing" exact="breast cancer" post="cells (A) SK-BR-3 and (B) BT-474 cells were treated"/>
   <result pre="SGP1 on cell growth in parental and lapatinib-resistant HER2-over-expressing breast" exact="cancer" post="cells (A) SK-BR-3 and (B) BT-474 cells were treated"/>
   <result pre="gefitinib [ 32] and trastuzumab [ 33] treatment in HER2-overexpressing" exact="breast cancer" post="cells. Our study demonstrated that the NRG1 protein expression"/>
   <result pre="[ 32] and trastuzumab [ 33] treatment in HER2-overexpressing breast" exact="cancer" post="cells. Our study demonstrated that the NRG1 protein expression"/>
   <result pre="expression levels increased in response to lapatinib treatment in HER2-overexpressing" exact="breast cancer" post="cell lines, and lapatinib could not sustain its inhibition"/>
   <result pre="levels increased in response to lapatinib treatment in HER2-overexpressing breast" exact="cancer" post="cell lines, and lapatinib could not sustain its inhibition"/>
   <result pre="high NRG1 expression predicts a decreased recurrence-free survival in HER2-overexpressing" exact="breast cancer" post="patients compared to patients with low NRG1 expression ["/>
   <result pre="NRG1 expression predicts a decreased recurrence-free survival in HER2-overexpressing breast" exact="cancer" post="patients compared to patients with low NRG1 expression ["/>
   <result pre="as other HER ligands in mediating lapatinib resistance in HER2-positive" exact="breast cancer." post="The addition of pertuzumab to lapatinib inhibited the phosphorylation"/>
   <result pre="also be additive in vitro and in vivo for HER2-positive" exact="breast cancer." post="HER4 expression levels were high in the tumours treated"/>
   <result pre="not cytoplasmic HER4 is associated with poor outcome in HER2-positive" exact="breast cancer" post="[ 40]. Therefore, further analysis of HER4 isoforms as"/>
   <result pre="cytoplasmic HER4 is associated with poor outcome in HER2-positive breast" exact="cancer" post="[ 40]. Therefore, further analysis of HER4 isoforms as"/>
   <result pre="lapatinib-resistant cell lines could be generated from other lapatinib-sensitive HER2-overexpressing" exact="breast cancer" post="cell lines to further understand the difference mechanisms of"/>
   <result pre="cell lines could be generated from other lapatinib-sensitive HER2-overexpressing breast" exact="cancer" post="cell lines to further understand the difference mechanisms of"/>
   <result pre="monoclonal antibody was synergistic with lapatinib in PC9ZD, a gefitinib-resistant" exact="lung cancer" post="cell line which harbours the T790M mutation [ 42]."/>
   <result pre="antibody was synergistic with lapatinib in PC9ZD, a gefitinib-resistant lung" exact="cancer" post="cell line which harbours the T790M mutation [ 42]."/>
   <result pre="one of the mechanisms of acquired lapatinib resistance in HER2-overexpressing" exact="breast cancer" post="cell lines, this pathway might also have a potential"/>
   <result pre="of the mechanisms of acquired lapatinib resistance in HER2-overexpressing breast" exact="cancer" post="cell lines, this pathway might also have a potential"/>
   <result pre="lines, this pathway might also have a potential role in" exact="breast cancer" post="cells that have innate resistance to lapatinib. Thus, it"/>
   <result pre="this pathway might also have a potential role in breast" exact="cancer" post="cells that have innate resistance to lapatinib. Thus, it"/>
   <result pre="with lapatinib in a larger panel of lapatinib-sensitive and innate-resistant" exact="breast cancer" post="cell lines. It may also be important to consider"/>
   <result pre="lapatinib in a larger panel of lapatinib-sensitive and innate-resistant breast" exact="cancer" post="cell lines. It may also be important to consider"/>
   <result pre="HER3 activation, but lapatinib could reduce the tumour growth of" exact="breast cancer" post="cells overexpressing NTS and NTSR1 [ 43]. Therefore, it"/>
   <result pre="activation, but lapatinib could reduce the tumour growth of breast" exact="cancer" post="cells overexpressing NTS and NTSR1 [ 43]. Therefore, it"/>
   <result pre="initiated, the roadmap for anti-HER2 treatments has changed. For metastatic" exact="breast cancer," post="the combination of pertuzumab and trastuzumab with docetaxel chemotherapy"/>
   <result pre="and overall survivals, and it caused less toxicity in HER2-positive" exact="breast cancer" post="patients previously treated with trastuzumab and a taxane ["/>
   <result pre="overall survivals, and it caused less toxicity in HER2-positive breast" exact="cancer" post="patients previously treated with trastuzumab and a taxane ["/>
   <result pre="increasingly being used as a third-line anti-HER2 treatment for metastatic" exact="breast cancer." post="Although we showed that pertuzumab and lapatinib could potentially"/>
   <result pre="clinical HER2-targeted therapy and may inhibit a subset of lapatinib-resistant" exact="breast cancer," post="although the group of patients that will respond to"/>
   <result pre="further stratification. MATERIALS AND METHODS Cell culture and reagents Human" exact="breast cancer" post="cell lines SK-BR-3 and BT-474 were obtained from cell"/>
   <result pre="stratification. MATERIALS AND METHODS Cell culture and reagents Human breast" exact="cancer" post="cell lines SK-BR-3 and BT-474 were obtained from cell"/>
   <result pre="LA Gullick WJ The epidermal growth factor receptor family Endocrine-related" exact="cancer" post="2005 12 Suppl 1 S17 27 16113093 2 Mendelsohn"/>
   <result pre="Mendelsohn J Baselga J Epidermal growth factor receptor targeting in" exact="cancer" post="Seminars in oncology 2006 33 369 385 16890793 3"/>
   <result pre="S Piccart-Gebhart MJ Pertuzumab: new hope for patients with HER2-positive" exact="breast cancer" post="Annals of oncology : official journal of the European"/>
   <result pre="Piccart-Gebhart MJ Pertuzumab: new hope for patients with HER2-positive breast" exact="cancer" post="Annals of oncology : official journal of the European"/>
   <result pre="pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell" exact="lung cancer" post="Clinical cancer research : an official journal of the"/>
   <result pre="a HER-2 dimerization inhibitor, in patients with non-small cell lung" exact="cancer" post="Clinical cancer research : an official journal of the"/>
   <result pre="dimerization inhibitor, in patients with non-small cell lung cancer Clinical" exact="cancer" post="research : an official journal of the American Association"/>
   <result pre="HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of" exact="breast cancer" post="cells Cancer research 2004 64 2343 2346 15059883 11"/>
   <result pre="antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast" exact="cancer" post="cells Cancer research 2004 64 2343 2346 15059883 11"/>
   <result pre="SM Group CS Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="The New England journal of medicine 2012 366 109"/>
   <result pre="Group CS Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="The New England journal of medicine 2012 366 109"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial The"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial The"/>
   <result pre="and tumor-derived cell lines in vitro and in vivo Molecular" exact="cancer" post="therapeutics 2001 1 85 94 12467226 14 Konecny GE"/>
   <result pre="the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated" exact="breast cancer" post="cells Cancer research 2006 66 1630 1639 16452222 15"/>
   <result pre="dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast" exact="cancer" post="cells Cancer research 2006 66 1630 1639 16452222 15"/>
   <result pre="lapatinib plus capecitabine versus capecitabine alone in women with advanced" exact="breast cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="plus capecitabine versus capecitabine alone in women with advanced breast" exact="cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="has progressed on trastuzumab: updated efficacy and biomarker analyses Breast" exact="cancer" post="research and treatment 2008 112 533 543 18188694 17"/>
   <result pre="Rubin SD et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="The New England journal of medicine 2006 355 2733"/>
   <result pre="SD et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="The New England journal of medicine 2006 355 2733"/>
   <result pre="Lapatinib as a component of neoadjuvant therapy for HER2-positive operable" exact="breast cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="as a component of neoadjuvant therapy for HER2-positive operable breast" exact="cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="Domont J et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="J et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="chemotherapy for breast cancer: a meta-analysis of randomized evidence Breast" exact="cancer" post="research and treatment 2012 135 655 662 22875745 22"/>
   <result pre="inhibitor and a therapeutic strategy to prevent its onset in" exact="breast cancer" post="Proceedings of the National Academy of Sciences of the"/>
   <result pre="and a therapeutic strategy to prevent its onset in breast" exact="cancer" post="Proceedings of the National Academy of Sciences of the"/>
   <result pre="KM Spector NL Resistance to ErbB2 tyrosine kinase inhibitors in" exact="breast cancer" post="is mediated by calcium-dependent activation of RelA Molecular cancer"/>
   <result pre="Spector NL Resistance to ErbB2 tyrosine kinase inhibitors in breast" exact="cancer" post="is mediated by calcium-dependent activation of RelA Molecular cancer"/>
   <result pre="breast cancer is mediated by calcium-dependent activation of RelA Molecular" exact="cancer" post="therapeutics 2010 9 292 299 20124457 27 Xia W"/>
   <result pre="autocrine signaling axis can mediate acquired lapatinib resistance in HER2+" exact="breast cancer" post="models Breast cancer research : BCR 2013 15 R85"/>
   <result pre="signaling axis can mediate acquired lapatinib resistance in HER2+ breast" exact="cancer" post="models Breast cancer research : BCR 2013 15 R85"/>
   <result pre="mediate acquired lapatinib resistance in HER2+ breast cancer models Breast" exact="cancer" post="research : BCR 2013 15 R85 24044505 28 Blackburn"/>
   <result pre="binding and co-operates with Herceptin in inhibiting the growth of" exact="breast cancer" post="derived cell lines Breast cancer research and treatment 2012"/>
   <result pre="and co-operates with Herceptin in inhibiting the growth of breast" exact="cancer" post="derived cell lines Breast cancer research and treatment 2012"/>
   <result pre="inhibiting the growth of breast cancer derived cell lines Breast" exact="cancer" post="research and treatment 2012 134 53 59 22169894 29"/>
   <result pre="tyrosine kinase inhibitors via activation of alternative HER receptors in" exact="breast cancer" post="cells PloS one 2008 3 e2881 18682844 33 Gijsen"/>
   <result pre="kinase inhibitors via activation of alternative HER receptors in breast" exact="cancer" post="cells PloS one 2008 3 e2881 18682844 33 Gijsen"/>
   <result pre="PKB negative feedback loop in response to anti-HER2 herceptin in" exact="breast cancer" post="PLoS Biol 2010 8 e1000563 21203579 34 Toi M"/>
   <result pre="negative feedback loop in response to anti-HER2 herceptin in breast" exact="cancer" post="PLoS Biol 2010 8 e1000563 21203579 34 Toi M"/>
   <result pre="results from Japanese patients phase II studies British journal of" exact="cancer" post="2009 101 1676 1682 19844234 35 Feldinger K Generali"/>
   <result pre="trastuzumab resistance and is correlated with survival in HER2 positive" exact="breast cancer" post="Oncotarget 2014 5 6633 6646 24952873 36 Waterhouse BR"/>
   <result pre="resistance and is correlated with survival in HER2 positive breast" exact="cancer" post="Oncotarget 2014 5 6633 6646 24952873 36 Waterhouse BR"/>
   <result pre="J et al. Neratinib overcomes trastuzumab resistance in HER2 amplified" exact="breast cancer" post="Oncotarget 2013 4 1592 1605 24009064 38 Koutras AK"/>
   <result pre="et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast" exact="cancer" post="Oncotarget 2013 4 1592 1605 24009064 38 Koutras AK"/>
   <result pre="HP The upgraded role of HER3 and HER4 receptors in" exact="breast cancer" post="Critical reviews in oncology/hematology 2010 74 73 78 19481955"/>
   <result pre="The upgraded role of HER3 and HER4 receptors in breast" exact="cancer" post="Critical reviews in oncology/hematology 2010 74 73 78 19481955"/>
   <result pre="trastuzumab and is associated with poor outcome in HER2 positive" exact="breast cancer" post="Oncotarget 2014 5 5934 5949 25153719 41 Scheuer W"/>
   <result pre="and is associated with poor outcome in HER2 positive breast" exact="cancer" post="Oncotarget 2014 5 5934 5949 25153719 41 Scheuer W"/>
   <result pre="anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell" exact="lung cancer" post="Oncotarget 2013 4 1253 65 23896512 44 Axelrod M"/>
   <result pre="monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung" exact="cancer" post="Oncotarget 2013 4 1253 65 23896512 44 Axelrod M"/>
   <result pre="MW Olsen S Blackwell K Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 1783 1791 23020162"/>
   <result pre="Olsen S Blackwell K Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 1783 1791 23020162"/>
   <result pre="Steeg PS Effect of lapatinib on the outgrowth of metastatic" exact="breast cancer" post="cells to the brain Journal of the National Cancer"/>
   <result pre="PS Effect of lapatinib on the outgrowth of metastatic breast" exact="cancer" post="cells to the brain Journal of the National Cancer"/>
   <result pre="of the HER pathway in HER2/neu-overexpressing breast tumor xenografts Clinical" exact="cancer" post="research : an official journal of the American Association"/>
   <result pre="Schiff R Treatment of human epidermal growth factor receptor 2-overexpressing" exact="breast cancer" post="xenografts with multiagent HER-targeted therapy Journal of the National"/>
   <result pre="R Treatment of human epidermal growth factor receptor 2-overexpressing breast" exact="cancer" post="xenografts with multiagent HER-targeted therapy Journal of the National"/>
   <result pre="pertuzumab against human tumor xenografts is superior to monotherapy Clinical" exact="cancer" post="research : an official journal of the American Association"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467661/results/search/disease/results.xml">
   <result pre="Profile of neratinib and its potential in the treatment of" exact="breast cancer" post="Feldinger Katharina 1 Kong Anthony 2 [1], [2], Correspondence:"/>
   <result pre="of neratinib and its potential in the treatment of breast" exact="cancer" post="Feldinger Katharina 1 Kong Anthony 2 [1], [2], Correspondence:"/>
   <result pre="HKI 272 pan-HER inhibitor irreversible tyrosine kinase inhibitor HER (ErbB)" exact="breast cancer" post="Introduction The family of HER (ErbB) receptor tyrosine kinases"/>
   <result pre="272 pan-HER inhibitor irreversible tyrosine kinase inhibitor HER (ErbB) breast" exact="cancer" post="Introduction The family of HER (ErbB) receptor tyrosine kinases"/>
   <result pre="and gefitinib (Iressa ®), which are approved in non-small cell" exact="lung cancer" post="(NSCLC), or lapatinib (Tyverb), which is licensed for HER2-positive"/>
   <result pre="gefitinib (Iressa ®), which are approved in non-small cell lung" exact="cancer" post="(NSCLC), or lapatinib (Tyverb), which is licensed for HER2-positive"/>
   <result pre="cancer (NSCLC), or lapatinib (Tyverb), which is licensed for HER2-positive" exact="breast cancer," post="were designed as reversible compounds that directly compete with"/>
   <result pre="arrest and an increased sub-G1 population, indicating apoptosis. 14 HER2-positive" exact="breast cancer" post="Despite reasonable IC 50 values with regard to both"/>
   <result pre="and an increased sub-G1 population, indicating apoptosis. 14 HER2-positive breast" exact="cancer" post="Despite reasonable IC 50 values with regard to both"/>
   <result pre="is more effective in HER2-positive breast cancers relative to other" exact="breast cancer" post="subtypes. In a study using a panel of cell"/>
   <result pre="more effective in HER2-positive breast cancers relative to other breast" exact="cancer" post="subtypes. In a study using a panel of cell"/>
   <result pre="chemotherapeutic agents, in the treatment of various stages of HER2-positive" exact="breast cancer." post="30– 33 However, de novo or acquired resistance to"/>
   <result pre="which could benefit patients. Neratinib for CNS metastasis in HER2-positive" exact="breast cancer" post="A major problem in the treatment of patients with"/>
   <result pre="could benefit patients. Neratinib for CNS metastasis in HER2-positive breast" exact="cancer" post="A major problem in the treatment of patients with"/>
   <result pre="A major problem in the treatment of patients with HER2-positive" exact="breast cancer" post="is the high incidence of central nervous system (CNS)"/>
   <result pre="major problem in the treatment of patients with HER2-positive breast" exact="cancer" post="is the high incidence of central nervous system (CNS)"/>
   <result pre="using TKIs to target CNS disease in patients with HER2-positive" exact="breast cancer." post="One obvious advantage of these small-molecule compounds is their"/>
   <result pre="a clinical trial investigating the efficacy of neratinib in HER2-positive" exact="breast cancer" post="patients presenting with brain metastasis (ClinicalTrials.gov identifier NCT01494662, see"/>
   <result pre="clinical trial investigating the efficacy of neratinib in HER2-positive breast" exact="cancer" post="patients presenting with brain metastasis (ClinicalTrials.gov identifier NCT01494662, see"/>
   <result pre="that neratinib could help to control disease in some HER2-positive" exact="breast cancer" post="patients presenting with brain metastasis; however, the CNS overall"/>
   <result pre="neratinib could help to control disease in some HER2-positive breast" exact="cancer" post="patients presenting with brain metastasis; however, the CNS overall"/>
   <result pre="the CNS overall response rate was only 7.5%. 54 HER2-negative" exact="breast cancer" post="There is an interest in assessing whether neratinib could"/>
   <result pre="CNS overall response rate was only 7.5%. 54 HER2-negative breast" exact="cancer" post="There is an interest in assessing whether neratinib could"/>
   <result pre="tumors that do not fulfill the current criteria for HER2-positive" exact="breast cancer." post="HER2 testing and its criteria have not always been"/>
   <result pre="initial guidelines. 57 To be eligible for HER2 targeting treatments," exact="breast cancer" post="patients have to be classified as HER2-positive, depending on"/>
   <result pre="guidelines. 57 To be eligible for HER2 targeting treatments, breast" exact="cancer" post="patients have to be classified as HER2-positive, depending on"/>
   <result pre="lapatinib and neratinib, since there have been studies suggesting that" exact="breast cancer" post="with a lower HER2 level may benefit from TKIs."/>
   <result pre="and neratinib, since there have been studies suggesting that breast" exact="cancer" post="with a lower HER2 level may benefit from TKIs."/>
   <result pre="the addition of neratinib to chemotherapy (see below). 61 Triple-negative" exact="breast cancer" post="Triple negative breast cancer (TNBC) represents a group of"/>
   <result pre="addition of neratinib to chemotherapy (see below). 61 Triple-negative breast" exact="cancer" post="Triple negative breast cancer (TNBC) represents a group of"/>
   <result pre="to chemotherapy (see below). 61 Triple-negative breast cancer Triple negative" exact="breast cancer" post="(TNBC) represents a group of heterogeneous breast cancers that"/>
   <result pre="chemotherapy (see below). 61 Triple-negative breast cancer Triple negative breast" exact="cancer" post="(TNBC) represents a group of heterogeneous breast cancers that"/>
   <result pre="TNBC tend to have a poor prognosis and very aggressive" exact="breast cancer" post="with a lack of targeted therapy options. EGFR is"/>
   <result pre="tend to have a poor prognosis and very aggressive breast" exact="cancer" post="with a lack of targeted therapy options. EGFR is"/>
   <result pre="thus there is an interest in targeting this subtype of" exact="cancer" post="using EGFR inhibitors. 62 It was reported that ADAM17"/>
   <result pre="have demonstrated the clinical benefit of afatinib in patients with" exact="lung cancer" post="who had progressed on erlotinib or gefitinib. 69, 70"/>
   <result pre="demonstrated the clinical benefit of afatinib in patients with lung" exact="cancer" post="who had progressed on erlotinib or gefitinib. 69, 70"/>
   <result pre="the HER2 protein. A recent publication evaluated data from eight" exact="breast cancer" post="genome sequencing projects and identified a total of 13"/>
   <result pre="HER2 protein. A recent publication evaluated data from eight breast" exact="cancer" post="genome sequencing projects and identified a total of 13"/>
   <result pre="testing neratinib in patients with HER2 mutations, including those with" exact="breast cancer." post="HER3 Different studies have shown a 2%–4% prevalence of"/>
   <result pre="studies have shown a 2%–4% prevalence of HER3 mutations in" exact="breast cancer" post="with evidence for occurrence in other cancer types as"/>
   <result pre="have shown a 2%–4% prevalence of HER3 mutations in breast" exact="cancer" post="with evidence for occurrence in other cancer types as"/>
   <result pre="mutations in breast cancer with evidence for occurrence in other" exact="cancer" post="types as well. 73 A majority of these somatic"/>
   <result pre="is effective in tumors with HER4 mutations, including melanoma and" exact="breast cancer." post="Proposed resistance mechanisms Despite the encouraging results, experience has"/>
   <result pre="neuromedin U was associated with a poor prognosis in HER2-overexpressing" exact="breast cancer" post="and has been shown to correspond with resistance to"/>
   <result pre="U was associated with a poor prognosis in HER2-overexpressing breast" exact="cancer" post="and has been shown to correspond with resistance to"/>
   <result pre="AKT phosphorylation after 24 hours of neratinib treatment in HER2-positive" exact="breast cancer" post="cells, although we did not assess whether this was"/>
   <result pre="phosphorylation after 24 hours of neratinib treatment in HER2-positive breast" exact="cancer" post="cells, although we did not assess whether this was"/>
   <result pre="our previous work showed that ADAM10 was upregulated in neratinib-treated" exact="breast cancer" post="cells, albeit to a lesser extent compared with trastuzumab-treated"/>
   <result pre="previous work showed that ADAM10 was upregulated in neratinib-treated breast" exact="cancer" post="cells, albeit to a lesser extent compared with trastuzumab-treated"/>
   <result pre="and other potential markers for response to neratinib (see HER2-positive" exact="breast cancer" post="section above). However, there are not much data available"/>
   <result pre="other potential markers for response to neratinib (see HER2-positive breast" exact="cancer" post="section above). However, there are not much data available"/>
   <result pre="standard neoadjuvant chemotherapy may be beneficial for patients with HER2-positive" exact="breast cancer," post="and in particular for those who have hormone receptor-negative"/>
   <result pre="did not seem to benefit; 64 however, this subtype of" exact="breast cancer" post="is heterogeneous and other factors in addition to hormone"/>
   <result pre="not seem to benefit; 64 however, this subtype of breast" exact="cancer" post="is heterogeneous and other factors in addition to hormone"/>
   <result pre="section, the main focus is on trials involving patients with" exact="breast cancer" post="( Table 2). Clinical trials in breast cancer A"/>
   <result pre="the main focus is on trials involving patients with breast" exact="cancer" post="( Table 2). Clinical trials in breast cancer A"/>
   <result pre="patients with breast cancer ( Table 2). Clinical trials in" exact="breast cancer" post="A Phase I dose-escalation study examined the safety and"/>
   <result pre="with breast cancer ( Table 2). Clinical trials in breast" exact="cancer" post="A Phase I dose-escalation study examined the safety and"/>
   <result pre="the therapeutic dose. In this dose-escalation study, 25 patients with" exact="breast cancer" post="were evaluated for treatment efficacy; a partial response was"/>
   <result pre="therapeutic dose. In this dose-escalation study, 25 patients with breast" exact="cancer" post="were evaluated for treatment efficacy; a partial response was"/>
   <result pre="and taxanes. 78 Neratinib monotherapy in patients with HER2-positive advanced" exact="breast cancer" post="was associated with a 16-week progression-free survival rate of"/>
   <result pre="taxanes. 78 Neratinib monotherapy in patients with HER2-positive advanced breast" exact="cancer" post="was associated with a 16-week progression-free survival rate of"/>
   <result pre="the combination of neratinib with vinorelbine in pretreated HER2-positive metastatic" exact="breast cancer" post="showed an objective response of 8% in patients with"/>
   <result pre="combination of neratinib with vinorelbine in pretreated HER2-positive metastatic breast" exact="cancer" post="showed an objective response of 8% in patients with"/>
   <result pre="paclitaxel and trastuzumab in heavily pretreated patients with HER2-positive metastatic" exact="breast cancer" post="and showed an overall clinical benefit (complete response +"/>
   <result pre="and trastuzumab in heavily pretreated patients with HER2-positive metastatic breast" exact="cancer" post="and showed an overall clinical benefit (complete response +"/>
   <result pre="be tolerable and to be potentially beneficial in HER2-positive, trastuzumab-resistant" exact="breast cancer" post="and HER2-mutant NSCLC in a Phase I study; however,"/>
   <result pre="tolerable and to be potentially beneficial in HER2-positive, trastuzumab-resistant breast" exact="cancer" post="and HER2-mutant NSCLC in a Phase I study; however,"/>
   <result pre="83 Throughout the studies, the most common adverse event was" exact="diarrhea" post="of any grade (up to 93%), especially during the"/>
   <result pre="neutropenia, and anorexia. 79, 81 In the initial dose-escalation study," exact="diarrhea" post="(32%) was also the most common grade 3 or"/>
   <result pre="there was no difference in the onset or severity of" exact="diarrhea" post="in healthy subjects who were given neratinib either 240"/>
   <result pre="mg twice daily. 84 However, several studies have reported that" exact="diarrhea" post="could be controlled with concurrent use of antidiarrheal agents."/>
   <result pre="capecitabine with lapatinib + capecitabine in patients with HER2-positive metastatic" exact="breast cancer" post="who have received two or more prior HER2-directed regimens"/>
   <result pre="with lapatinib + capecitabine in patients with HER2-positive metastatic breast" exact="cancer" post="who have received two or more prior HER2-directed regimens"/>
   <result pre="to the secondary endpoint, ie, disease-free survival including for ductal" exact="carcinoma in situ," post="there was a 37% improvement in the neratinib arm"/>
   <result pre="that neratinib offers the greatest benefit to patients with HER2-positive" exact="breast cancer," post="some data indicate that some HER2-negative patients may also"/>
   <result pre="I Sawyers CL The phosphatidylinositol 3-kinase AKT pathway in human" exact="cancer" post="Nat Rev Cancer 2002 2 7 489 501 12094235"/>
   <result pre="distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human" exact="breast cancer" post="Mol Cell Biol 2001 21 5 1540 1551 11238891"/>
   <result pre="roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast" exact="cancer" post="Mol Cell Biol 2001 21 5 1540 1551 11238891"/>
   <result pre="its signaling and transforming functions and its role in human" exact="cancer" post="pathogenesis Oncogene 2007 26 45 6469 6487 17471238 9"/>
   <result pre="development of HKI-272 and related compounds for the treatment of" exact="cancer" post="Arch Pharm (Weinheim) 2008 341 8 465 477 18493974"/>
   <result pre="Britten CD Targeting ErbB receptor signaling: a pan-ErbB approach to" exact="cancer" post="Mol Cancer Ther 2004 3 10 1335 1342 15486201"/>
   <result pre="et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in" exact="lung cancer" post="models with EGFR and ERBB2 mutations that are resistant"/>
   <result pre="al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung" exact="cancer" post="models with EGFR and ERBB2 mutations that are resistant"/>
   <result pre="oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell" exact="lung cancer" post="Expert Opin Investig Drugs 2009 18 11 1735 1751"/>
   <result pre="irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung" exact="cancer" post="Expert Opin Investig Drugs 2009 18 11 1735 1751"/>
   <result pre="M et al. Neratinib overcomes trastuzumab resistance in HER2 amplified" exact="breast cancer" post="Oncotarget 2013 4 10 1592 1605 24009064 27 Nafi"/>
   <result pre="et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast" exact="cancer" post="Oncotarget 2013 4 10 1592 1605 24009064 27 Nafi"/>
   <result pre="trastuzumab and is associated with poor outcome in HER2 positive" exact="breast cancer" post="Oncotarget 2014 5 15 5934 5949 25153719 28 Seyhan"/>
   <result pre="and is associated with poor outcome in HER2 positive breast" exact="cancer" post="Oncotarget 2014 5 15 5934 5949 25153719 28 Seyhan"/>
   <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1659 1672"/>
   <result pre="B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1659 1672"/>
   <result pre="2005 353 16 1659 1672 16236737 34 Pandolfi PP Breast" exact="cancer" post="– loss of PTEN predicts resistance to treatment N"/>
   <result pre="Esteva FJ P27(kip1) downregulation is associated with trastuzumab resistance in" exact="breast cancer" post="cells Cancer Res 2004 64 11 3981 3986 15173011"/>
   <result pre="FJ P27(kip1) downregulation is associated with trastuzumab resistance in breast" exact="cancer" post="cells Cancer Res 2004 64 11 3981 3986 15173011"/>
   <result pre="of the HER2 receptor, and response to anti-HER2 therapies in" exact="breast cancer" post="J Natl Cancer Inst 2007 99 8 628 638"/>
   <result pre="the HER2 receptor, and response to anti-HER2 therapies in breast" exact="cancer" post="J Natl Cancer Inst 2007 99 8 628 638"/>
   <result pre="lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing" exact="breast cancer" post="cell line Cancer Res 2005 65 2 473 482"/>
   <result pre="of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast" exact="cancer" post="cell line Cancer Res 2005 65 2 473 482"/>
   <result pre="masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant" exact="breast cancer" post="Eur J Cancer 2007 43 16 2423 2433 17911008"/>
   <result pre="of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast" exact="cancer" post="Eur J Cancer 2007 43 16 2423 2433 17911008"/>
   <result pre="Sweeney C Met receptor contributes to trastuzumab resistance of Her2-overexpressing" exact="breast cancer" post="cells Cancer Res 2008 68 5 1471 1477 18316611"/>
   <result pre="C Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast" exact="cancer" post="cells Cancer Res 2008 68 5 1471 1477 18316611"/>
   <result pre="PKB negative feedback loop in response to anti-HER2 Herceptin in" exact="breast cancer" post="PloS Biol 2010 8 12 e1000563 21203579 43 Feldinger"/>
   <result pre="negative feedback loop in response to anti-HER2 Herceptin in breast" exact="cancer" post="PloS Biol 2010 8 12 e1000563 21203579 43 Feldinger"/>
   <result pre="trastuzumab resistance and is correlated with survival in HER2 positive" exact="breast cancer" post="Oncotarget 2014 5 16 6633 6646 24952873 44 Xia"/>
   <result pre="resistance and is correlated with survival in HER2 positive breast" exact="cancer" post="Oncotarget 2014 5 16 6633 6646 24952873 44 Xia"/>
   <result pre="autocrine signaling axis can mediate acquired lapatinib resistance in HER2+" exact="breast cancer" post="models Breast Cancer Res 2013 15 5 R85 24044505"/>
   <result pre="signaling axis can mediate acquired lapatinib resistance in HER2+ breast" exact="cancer" post="models Breast Cancer Res 2013 15 5 R85 24044505"/>
   <result pre="overcome lapatinib resistance due to NRG1-mediated signaling in HER2 amplified" exact="breast cancer" post="Oncotarget 1 21 2015 Epub ahead of print 46"/>
   <result pre="lapatinib resistance due to NRG1-mediated signaling in HER2 amplified breast" exact="cancer" post="Oncotarget 1 21 2015 Epub ahead of print 46"/>
   <result pre="iniparib and olaparib on a panel of triple-negative and non-triple-negative" exact="breast cancer" post="cell lines Cancer Biol Ther 2013 14 6 537"/>
   <result pre="and olaparib on a panel of triple-negative and non-triple-negative breast" exact="cancer" post="cell lines Cancer Biol Ther 2013 14 6 537"/>
   <result pre="of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic" exact="breast cancer" post="progressing on trastuzumab Clin Cancer Res 2011 17 15"/>
   <result pre="tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast" exact="cancer" post="progressing on trastuzumab Clin Cancer Res 2011 17 15"/>
   <result pre="ABCG2 multidrug transporter: implications for the emergence and reversal of" exact="cancer" post="drug resistance Biochem Pharmacol 2012 84 3 260 267"/>
   <result pre="patients (Pts) with human epidermal growth factor receptor 2 (HER2+)" exact="breast cancer" post="and brain metastases (BCBM) J Clin Oncol 2014 32"/>
   <result pre="(Pts) with human epidermal growth factor receptor 2 (HER2+) breast" exact="cancer" post="and brain metastases (BCBM) J Clin Oncol 2014 32"/>
   <result pre="Administration-approved scoring and test system of HER-2 protein expression in" exact="breast cancer" post="Clin Cancer Res 2001 7 6 1669 1675 11410505"/>
   <result pre="scoring and test system of HER-2 protein expression in breast" exact="cancer" post="Clin Cancer Res 2001 7 6 1669 1675 11410505"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="Arch Pathol Lab Med 2007 131 1 18 43"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="Arch Pathol Lab Med 2007 131 1 18 43"/>
   <result pre="Wolmark N HER2 status and benefit from adjuvant trastuzumab in" exact="breast cancer" post="N Engl J Med 2008 358 13 1409 1411"/>
   <result pre="N HER2 status and benefit from adjuvant trastuzumab in breast" exact="cancer" post="N Engl J Med 2008 358 13 1409 1411"/>
   <result pre="growth factor receptor as a potential therapeutic target in triple-negative" exact="breast cancer" post="Ann Oncol 2009 20 5 862 867 19150933 63"/>
   <result pre="factor receptor as a potential therapeutic target in triple-negative breast" exact="cancer" post="Ann Oncol 2009 20 5 862 867 19150933 63"/>
   <result pre="et al. ADAM-17: a novel therapeutic target for triple negative" exact="breast cancer" post="Ann Oncol 2013 24 2 362 369 22967992 64"/>
   <result pre="al. ADAM-17: a novel therapeutic target for triple negative breast" exact="cancer" post="Ann Oncol 2013 24 2 362 369 22967992 64"/>
   <result pre="2 trial: neoadjuvant neratinib improves pathologic complete response in HR-/HER2+" exact="breast cancer" post="Oncology Times 2014 36 10 25 26 65 Carey"/>
   <result pre="trial: neoadjuvant neratinib improves pathologic complete response in HR-/HER2+ breast" exact="cancer" post="Oncology Times 2014 36 10 25 26 65 Carey"/>
   <result pre="of cetuximab in combination with carboplatin in stage IV triple-negative" exact="breast cancer" post="J Clin Oncol 2012 30 21 2615 2623 22665533"/>
   <result pre="cetuximab in combination with carboplatin in stage IV triple-negative breast" exact="cancer" post="J Clin Oncol 2012 30 21 2615 2623 22665533"/>
   <result pre="with cisplatin versus cisplatin alone in patients with metastatic triple-negative" exact="breast cancer" post="J Clin Oncol 2013 31 20 2586 2592 23733761"/>
   <result pre="cisplatin versus cisplatin alone in patients with metastatic triple-negative breast" exact="cancer" post="J Clin Oncol 2013 31 20 2586 2592 23733761"/>
   <result pre="phase II trial of afatinib in patients with advanced non-small-cell" exact="lung cancer" post="who progressed during prior treatment with erlotinib, gefitinib, or"/>
   <result pre="II trial of afatinib in patients with advanced non-small-cell lung" exact="cancer" post="who progressed during prior treatment with erlotinib, gefitinib, or"/>
   <result pre="al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell" exact="lung cancer" post="after failure of erlotinib, gefitinib, or both, and one"/>
   <result pre="Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung" exact="cancer" post="after failure of erlotinib, gefitinib, or both, and one"/>
   <result pre="et al. Activating HER2 mutations in HER2 gene amplification negative" exact="breast cancer" post="Cancer Discov 2013 3 2 224 237 23220880 73"/>
   <result pre="al. Activating HER2 mutations in HER2 gene amplification negative breast" exact="cancer" post="Cancer Discov 2013 3 2 224 237 23220880 73"/>
   <result pre="targets IGF1R to regulate response to HER-targeting drugs and overall" exact="cancer" post="cell progression in HER2 over-expressing breast cancer Mol Cancer"/>
   <result pre="HER-targeting drugs and overall cancer cell progression in HER2 over-expressing" exact="breast cancer" post="Mol Cancer 2014 13 71 24655723 77 Rani S"/>
   <result pre="drugs and overall cancer cell progression in HER2 over-expressing breast" exact="cancer" post="Mol Cancer 2014 13 71 24655723 77 Rani S"/>
   <result pre="ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive" exact="breast cancer" post="J Clin Oncol 2010 28 8 1301 1307 20142587"/>
   <result pre="receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast" exact="cancer" post="J Clin Oncol 2010 28 8 1301 1307 20142587"/>
   <result pre="plus vinorelbine in the treatment of patients with ErbB2-positive metastatic" exact="breast cancer" post="pretreated with anti-HER2 therapy Ann Oncol 2013 24 1"/>
   <result pre="vinorelbine in the treatment of patients with ErbB2-positive metastatic breast" exact="cancer" post="pretreated with anti-HER2 therapy Ann Oncol 2013 24 1"/>
   <result pre="neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic" exact="breast cancer" post="Br J Cancer 2013 108 10 1985 1993 23632474"/>
   <result pre="(HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast" exact="cancer" post="Br J Cancer 2013 108 10 1985 1993 23632474"/>
   <result pre="double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of" exact="diarrhea" post="following two different dosing regimens of neratinib, an irreversible"/>
   <result pre="lapatinib plus capecitabine combination therapy in patients with HER2+ advanced" exact="breast cancer" post="Eur J Cancer 2013 49 18 3763 3772 23953056"/>
   <result pre="plus capecitabine combination therapy in patients with HER2+ advanced breast" exact="cancer" post="Eur J Cancer 2013 49 18 3763 3772 23953056"/>
   <result pre="top line results from phase III PB272 trial in adjuvant" exact="breast cancer" post="(ExteNET Trial) 2014 Available from: http://www.pumabiotechnology.com/pr2014072202.html Accessed March 28,"/>
   <result pre="line results from phase III PB272 trial in adjuvant breast" exact="cancer" post="(ExteNET Trial) 2014 Available from: http://www.pumabiotechnology.com/pr2014072202.html Accessed March 28,"/>
   <result pre="tyrosine kinase receptor. Table 2 Clinical trials involving neratinib in" exact="breast cancer" post="NCT identifier Title Study participants Study design Patients (n)"/>
   <result pre="kinase receptor. Table 2 Clinical trials involving neratinib in breast" exact="cancer" post="NCT identifier Title Study participants Study design Patients (n)"/>
   <result pre="paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive" exact="breast cancer" post="Women ≥18 years with metastatic HER2-positive BC Open-label, non-randomized,"/>
   <result pre="with neratinib and trastuzumab in women with metastatic HER2-positive breast" exact="cancer" post="Women ≥18 years with metastatic HER2-positive BC Open-label, non-randomized,"/>
   <result pre="in combination with trastuzumab (Herceptin ®) in subjects with advanced" exact="breast cancer" post="Patients aged ≥18 years with advanced HER2-positive BC that"/>
   <result pre="combination with trastuzumab (Herceptin ®) in subjects with advanced breast" exact="cancer" post="Patients aged ≥18 years with advanced HER2-positive BC that"/>
   <result pre="with paclitaxel (Taxol ®) in subjects with solid tumors and" exact="breast cancer" post="Patients aged ≥18 years with a pathologically confirmed solid"/>
   <result pre="paclitaxel (Taxol ®) in subjects with solid tumors and breast" exact="cancer" post="Patients aged ≥18 years with a pathologically confirmed solid"/>
   <result pre="Study evaluating neratinib vs lapatinib + capecitabine for ErbB2-positive advanced" exact="breast cancer" post="Women aged ≥18 years with locally advanced or metastatic"/>
   <result pre="evaluating neratinib vs lapatinib + capecitabine for ErbB2-positive advanced breast" exact="cancer" post="Women aged ≥18 years with locally advanced or metastatic"/>
   <result pre="trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive" exact="breast cancer" post="Women aged ≥18 years with metastatic HER2-positive BC with"/>
   <result pre="emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast" exact="cancer" post="Women aged ≥18 years with metastatic HER2-positive BC with"/>
   <result pre="of neratinib after adjuvant trastuzumab in women with early stage" exact="breast cancer" post="Women aged ≥18 years with early stage HER2-positive BC"/>
   <result pre="neratinib after adjuvant trastuzumab in women with early stage breast" exact="cancer" post="Women aged ≥18 years with early stage HER2-positive BC"/>
   <result pre="the combination of neratinib and capecitabine in solid tumors and" exact="breast cancer" post="Women aged ≥18 years with confirmed pathologic diagnosis of"/>
   <result pre="combination of neratinib and capecitabine in solid tumors and breast" exact="cancer" post="Women aged ≥18 years with confirmed pathologic diagnosis of"/>
   <result pre="neratinib + paclitaxel vs trastuzumab + paclitaxel in ErbB2-positive advanced" exact="breast cancer" post="Women aged ≥18 years with HER2-positive locally recurrent or"/>
   <result pre="+ paclitaxel vs trastuzumab + paclitaxel in ErbB2-positive advanced breast" exact="cancer" post="Women aged ≥18 years with HER2-positive locally recurrent or"/>
   <result pre="combination with vinorelbine in subjects with solid tumors and metastatic" exact="breast cancer" post="Women aged ≥18 years with confirmed pathologic diagnosis of"/>
   <result pre="with vinorelbine in subjects with solid tumors and metastatic breast" exact="cancer" post="Women aged ≥18 years with confirmed pathologic diagnosis of"/>
   <result pre="80 NCT00300781 Study evaluating HKI-272 (neratinib) in subjects with advanced" exact="breast cancer" post="Women aged ≥18 years with advanced HER2-positive BC Open-label,"/>
   <result pre="NCT00300781 Study evaluating HKI-272 (neratinib) in subjects with advanced breast" exact="cancer" post="Women aged ≥18 years with advanced HER2-positive BC Open-label,"/>
   <result pre="followed by postoperative trastuzumab in women with locally advanced HER2-positive" exact="breast cancer" post="Women aged ≥18 years with locally advanced HER2-positive BC"/>
   <result pre="by postoperative trastuzumab in women with locally advanced HER2-positive breast" exact="cancer" post="Women aged ≥18 years with locally advanced HER2-positive BC"/>
   <result pre="trastuzumab then doxorubicin and cyclophosphamide) Recruiting NCT01494662 HKI-272 for HER2-positive" exact="breast cancer" post="and brain metastases Patients aged ≥18 years with HER2-positive"/>
   <result pre="then doxorubicin and cyclophosphamide) Recruiting NCT01494662 HKI-272 for HER2-positive breast" exact="cancer" post="and brain metastases Patients aged ≥18 years with HER2-positive"/>
   <result pre="cohorts) Recruiting NCT01670877 Neratinib in metastatic HER2- non-amplified but HER2-mutant" exact="breast cancer" post="Patients aged ≥18 years with stage IV, HER2- negative"/>
   <result pre="Recruiting NCT01670877 Neratinib in metastatic HER2- non-amplified but HER2-mutant breast" exact="cancer" post="Patients aged ≥18 years with stage IV, HER2- negative"/>
   <result pre="progression and not receiving any other investigational agents or systemic" exact="cancer" post="therapy Open-label, Phase II 29 Efficacy study (see title)"/>
   <result pre="capecitabine vs lapatinib + capecitabine in patients with HER2-positive metastatic" exact="breast cancer" post="who have received two or more prior HER2-directed regimens"/>
   <result pre="vs lapatinib + capecitabine in patients with HER2-positive metastatic breast" exact="cancer" post="who have received two or more prior HER2-directed regimens"/>
   <result pre="+ neratinib for patients with metastatic HER2-amplified or triple negative" exact="breast cancer" post="Patients aged ≥18 years with metastatic HER2-positive BC progressed"/>
   <result pre="neratinib for patients with metastatic HER2-amplified or triple negative breast" exact="cancer" post="Patients aged ≥18 years with metastatic HER2-positive BC progressed"/>
   <result pre="ClinicalTrials.gov entries as of December 2014 are listed. Abbreviations: BC," exact="breast cancer;" post="CNS, central nervous system; EGFR, epidermal growth factor receptor;"/>
   <result pre="18–50 years Double-blind, randomized, Phase I 50 Safety, occurrence of" exact="diarrhea" post="(see title) Completed 84 NCT00781430 Study evaluating the PK"/>
   <result pre="safety of neratinib in healthy subjects and subjects with chronic" exact="liver disease" post="Healthy subjects, aged 18–65 years Open-label, non-randomized, Phase I"/>
   <result pre="solid tumors Patients aged ≥20 years with metastatic or advanced" exact="cancer" post="that has failed standard therapy Open-label, non-randomized, Phase I"/>
   <result pre="Safety/efficacy (see title) Completed 89 NCT01956253 Single subject neratinib in" exact="bladder cancer" post="One patient with metastatic bladder cancer harboring a HER2-GRB7"/>
   <result pre="(see title) Completed 89 NCT01956253 Single subject neratinib in bladder" exact="cancer" post="One patient with metastatic bladder cancer harboring a HER2-GRB7"/>
   <result pre="Single subject neratinib in bladder cancer One patient with metastatic" exact="bladder cancer" post="harboring a HER2-GRB7 gene fusion Open-label, non-randomized 1 Response"/>
   <result pre="subject neratinib in bladder cancer One patient with metastatic bladder" exact="cancer" post="harboring a HER2-GRB7 gene fusion Open-label, non-randomized 1 Response"/>
   <result pre="neratinib and cetuximab to treat patients with quadruple wild-type metastatic" exact="colorectal cancer" post="Patients aged ≥18 years with KRAS, NRAS, BRAF, PIK3CA"/>
   <result pre="and cetuximab to treat patients with quadruple wild-type metastatic colorectal" exact="cancer" post="Patients aged ≥18 years with KRAS, NRAS, BRAF, PIK3CA"/>
   <result pre="factor receptor; mTOR, mammalian target of rapamycin; NSCLC, non-small cell" exact="lung cancer;" post="TKI, tyrosine kinase inhibitor; vs, versus."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467984/results/search/disease/results.xml">
   <result pre="in Breast Cancer Cells Analysis by dual-ISH (DISH) of HER2-amplified" exact="breast cancer" post="cell lines treated with colchicine, which arrests cells in"/>
   <result pre="Breast Cancer Cells Analysis by dual-ISH (DISH) of HER2-amplified breast" exact="cancer" post="cell lines treated with colchicine, which arrests cells in"/>
   <result pre="tumor samples. Fig 1 HER2 gene amplification patterns in different" exact="breast cancer" post="cell lines and PDXs. A, The indicated cell lines"/>
   <result pre="samples. Fig 1 HER2 gene amplification patterns in different breast" exact="cancer" post="cell lines and PDXs. A, The indicated cell lines"/>
   <result pre="HER2 gene amplification patterns in tumors from a cohort of" exact="breast cancer" post="patients treated with neoadjuvant trastuzumab. Lower graph, pathologic complete"/>
   <result pre="gene amplification patterns in tumors from a cohort of breast" exact="cancer" post="patients treated with neoadjuvant trastuzumab. Lower graph, pathologic complete"/>
   <result pre="HER2 gene amplification patterns in tumors from a cohort of" exact="breast cancer" post="patients treated with adjuvant trastuzumab. Lower graph, disease-free survival"/>
   <result pre="gene amplification patterns in tumors from a cohort of breast" exact="cancer" post="patients treated with adjuvant trastuzumab. Lower graph, disease-free survival"/>
   <result pre="copies ( Fig 4). We concluded that acquired resistance of" exact="breast cancer" post="cells to anti-HER2 therapies, even when concomitant with the"/>
   <result pre="( Fig 4). We concluded that acquired resistance of breast" exact="cancer" post="cells to anti-HER2 therapies, even when concomitant with the"/>
   <result pre="a target, therapies against HER2 have prolonged the life of" exact="breast cancer" post="patients carrying HER2 gene amplification. Unfortunately, some HER2-positive tumors"/>
   <result pre="target, therapies against HER2 have prolonged the life of breast" exact="cancer" post="patients carrying HER2 gene amplification. Unfortunately, some HER2-positive tumors"/>
   <result pre="clearly disprove this hypothesis. On one hand, we showed that" exact="breast cancer" post="tumors with HER2 amplification in DM respond in a"/>
   <result pre="disprove this hypothesis. On one hand, we showed that breast" exact="cancer" post="tumors with HER2 amplification in DM respond in a"/>
   <result pre="loss of HER2 protein expression. In line with our conclusions," exact="breast cancer" post="patients with cluster amplification of HER2, treated with trastuzumab-based"/>
   <result pre="of HER2 protein expression. In line with our conclusions, breast" exact="cancer" post="patients with cluster amplification of HER2, treated with trastuzumab-based"/>
   <result pre="suggest that, in addition to HER2, the amplicon carried by" exact="breast cancer" post="cells includes other critical loci. The strongest indication is"/>
   <result pre="that, in addition to HER2, the amplicon carried by breast" exact="cancer" post="cells includes other critical loci. The strongest indication is"/>
   <result pre="have an effect on the levels of DMs in HER2-amplified" exact="breast cancer" post="cells (data not shown). These results point to the"/>
   <result pre="an effect on the levels of DMs in HER2-amplified breast" exact="cancer" post="cells (data not shown). These results point to the"/>
   <result pre="the amplicon of HER2 that contribute to the growth of" exact="breast cancer" post="cells. In agreement with this conclusion, it has been"/>
   <result pre="amplicon of HER2 that contribute to the growth of breast" exact="cancer" post="cells. In agreement with this conclusion, it has been"/>
   <result pre=", Pines G ( 2012) The ERBB network: at last," exact="cancer" post="therapy meets systems biology. Nature Publishing Group 12: 553–"/>
   <result pre="Loss and stabilization of amplified dihydrofolate reductase genes in mouse" exact="sarcoma" post="S-180 cell lines . Mol Cell Biol 1: 1084–"/>
   <result pre="et al. ( 2007) A new model of patient tumor-derived" exact="breast cancer" post="xenografts for preclinical assays. Clin Cancer Res 13: 3989–"/>
   <result pre="al. ( 2007) A new model of patient tumor-derived breast" exact="cancer" post="xenografts for preclinical assays. Clin Cancer Res 13: 3989–"/>
   <result pre="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced" exact="breast cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast" exact="cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="genes required for the growth and survival of HER2 positive" exact="breast cancer" post="cells . Molecular Oncology 7: 392– 401. doi: 10.1016/j.molonc.2012.10.012"/>
   <result pre="required for the growth and survival of HER2 positive breast" exact="cancer" post="cells . Molecular Oncology 7: 392– 401. doi: 10.1016/j.molonc.2012.10.012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4469402/results/search/disease/results.xml">
   <result pre="26022204 155 doi: 10.1186/s13045-015-0155-z : Research Article HER2/neu-directed therapy for" exact="biliary tract cancer" post="Javle Milind 713-792-2828 mjavle@mdanderson.org Churi Chaitanya Kang HyunSeon C."/>
   <result pre="doi: 10.1186/s13045-015-0155-z : Research Article HER2/neu-directed therapy for biliary tract" exact="cancer" post="Javle Milind 713-792-2828 mjavle@mdanderson.org Churi Chaitanya Kang HyunSeon C."/>
   <result pre="unknown. Patients and methods We retrospectively reviewed cases of advanced" exact="gallbladder cancer" post="and cholangiocarcinoma with HER2/neu genetic aberrations or protein overexpression"/>
   <result pre="Patients and methods We retrospectively reviewed cases of advanced gallbladder" exact="cancer" post="and cholangiocarcinoma with HER2/neu genetic aberrations or protein overexpression"/>
   <result pre="methods We retrospectively reviewed cases of advanced gallbladder cancer and" exact="cholangiocarcinoma" post="with HER2/neu genetic aberrations or protein overexpression who received"/>
   <result pre="and imaging studies were independently reviewed. Results Nine patients with" exact="gallbladder cancer" post="and five patients with cholangiocarcinoma had received HER2/neu-directed therapy"/>
   <result pre="imaging studies were independently reviewed. Results Nine patients with gallbladder" exact="cancer" post="and five patients with cholangiocarcinoma had received HER2/neu-directed therapy"/>
   <result pre="Results Nine patients with gallbladder cancer and five patients with" exact="cholangiocarcinoma" post="had received HER2/neu-directed therapy (trastuzumab, lapatinib, or pertuzumab) during"/>
   <result pre="(trastuzumab, lapatinib, or pertuzumab) during the study period. In the" exact="gallbladder cancer" post="group, HER2/neu gene amplification or overexpression was detected in"/>
   <result pre="lapatinib, or pertuzumab) during the study period. In the gallbladder" exact="cancer" post="group, HER2/neu gene amplification or overexpression was detected in"/>
   <result pre="secondary event after FGFR-directed therapy for FGF3-TACC3 gene fusion. The" exact="cholangiocarcinoma" post="cases treated in this series had a higher proportion"/>
   <result pre="therapy. Conclusions HER2/neu blockade is a promising treatment strategy for" exact="gallbladder cancer" post="patients with gene amplification and deserves further exploration in"/>
   <result pre="Conclusions HER2/neu blockade is a promising treatment strategy for gallbladder" exact="cancer" post="patients with gene amplification and deserves further exploration in"/>
   <result pre="ErbB-2 Gallbladder neoplasms Cancer of the biliary tract Introduction Gallbladder" exact="cancer" post="is one of the most aggressive solid tumors and"/>
   <result pre="outcome with standard chemotherapy contribute to the poor prognosis of" exact="gallbladder cancer." post="Understanding the molecular characterization of this disease may help"/>
   <result pre="5]. HER2/neu mutation or amplification has also been reported in" exact="cholangiocarcinoma" post="[ 6– 8]. These patients may be candidates for"/>
   <result pre="amplification of HER2/neu has also been demonstrated in gastricesophageal and" exact="endometrial cancer," post="and in these tumors, it is also usually associated"/>
   <result pre="number of downstream pathways like RAS-RAF-MEK-ERK1/2 or PI3k-AKT-mTOR resulting in" exact="cancer" post="cell proliferation and cell survival [ 15, 16]. Several"/>
   <result pre="of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) criteria for" exact="breast cancer" post="[ 22]. Results In the gallbladder cancer group, there"/>
   <result pre="American Pathologists/American Society of Clinical Oncology (CAP/ASCO) criteria for breast" exact="cancer" post="[ 22]. Results In the gallbladder cancer group, there"/>
   <result pre="(CAP/ASCO) criteria for breast cancer [ 22]. Results In the" exact="gallbladder cancer" post="group, there were seven females and two males, with"/>
   <result pre="criteria for breast cancer [ 22]. Results In the gallbladder" exact="cancer" post="group, there were seven females and two males, with"/>
   <result pre="5a– c). Fig. 5 A 73-year-old female with metastatic retroperitoneal" exact="lymphadenopathy" post="from gallbladder carcinoma. Axial contrast-enhanced CT images demonstrate a"/>
   <result pre="to HER2/neu inhibition after prior FGFR inhibitor therapy In the" exact="cholangiocarcinoma" post="group, the median age was 59 years; all patients"/>
   <result pre="no responses occurred from trastuzumab therapy, unlike the case with" exact="gallbladder cancer." post="In all cases, HER2/neu-directed therapies were well-tolerated without any"/>
   <result pre="Trastuzumab 6 8 Cholangioca Amplification PD Trastuzumab 10 12 Gallbladder" exact="cancer" post="Amplification PIK3CA, CDKN2A/B, TP53, ZNF703 MR Lapatinib 15 19"/>
   <result pre="Amplification PIK3CA, CDKN2A/B, TP53, ZNF703 MR Lapatinib 15 19 Gallbladder" exact="cancer" post="Amplification TP53 PR Trastuzumab &amp;gt;92 &amp;gt;92 Gallbladder cancer Amplification"/>
   <result pre="19 Gallbladder cancer Amplification TP53 PR Trastuzumab &amp;gt;92 &amp;gt;92 Gallbladder" exact="cancer" post="Amplification NRAS, PIK3CA, RB1,PTEN, TP53 PR Trastuzumab &amp;gt;40 &amp;gt;62"/>
   <result pre="Amplification NRAS, PIK3CA, RB1,PTEN, TP53 PR Trastuzumab &amp;gt;40 &amp;gt;62 Gallbladder" exact="cancer" post="Amplification PR Trastuzumab 168 178 Gallbladder cancer Amplification PR"/>
   <result pre="&amp;gt;40 &amp;gt;62 Gallbladder cancer Amplification PR Trastuzumab 168 178 Gallbladder" exact="cancer" post="Amplification PR Trastuzumab 38 113 Gallbladder cancer Amplification FGFR3-TACC3"/>
   <result pre="168 178 Gallbladder cancer Amplification PR Trastuzumab 38 113 Gallbladder" exact="cancer" post="Amplification FGFR3-TACC3 fusion, TP53, CCNE1, MCL1, MYC SD Trastuzumab"/>
   <result pre="of gene amplification is a critical target for therapy in" exact="breast cancer." post="Other solid tumors with reported overexpression of this gene"/>
   <result pre="%). There are several existing reports of HER2/neu overexpression in" exact="gallbladder cancer" post="and the incidence has varied widely, depending upon the"/>
   <result pre="There are several existing reports of HER2/neu overexpression in gallbladder" exact="cancer" post="and the incidence has varied widely, depending upon the"/>
   <result pre="Our group recently studied HER2/neu expression in 187 cases of" exact="gallbladder cancer;" post="this is the largest reported series to date using"/>
   <result pre="immunohistochemistry). Yoshikawa and colleagues reviewed 236 cases of surgically resected" exact="cholangiocarcinoma" post="and reported a 0.9 and 8.5 % incidence of"/>
   <result pre="others have described the remarkable success of HER2/neu-targeted therapy for" exact="breast cancer" post="[ 27– 29]. In gastric cancer, the trastuzumab for"/>
   <result pre="have described the remarkable success of HER2/neu-targeted therapy for breast" exact="cancer" post="[ 27– 29]. In gastric cancer, the trastuzumab for"/>
   <result pre="plus cisplatin in a randomized phase 3 trial of gastric" exact="cancer" post="patients with overexpression or gene amplification of HER2/neu ["/>
   <result pre="our knowledge, this is the largest reported case series of" exact="gallbladder cancer" post="with HER2/neu amplification or overexpression treated with targeted therapy."/>
   <result pre="knowledge, this is the largest reported case series of gallbladder" exact="cancer" post="with HER2/neu amplification or overexpression treated with targeted therapy."/>
   <result pre="experience demonstrates that HER2/neu-directed therapy appears to be beneficial for" exact="gallbladder cancer" post="cases with HER2/neu amplification. Only one case in our"/>
   <result pre="demonstrates that HER2/neu-directed therapy appears to be beneficial for gallbladder" exact="cancer" post="cases with HER2/neu amplification. Only one case in our"/>
   <result pre="case reports have described responses with trastuzumab in subjects with" exact="gallbladder cancer." post="In the first, a 45-year-old woman received paclitaxel and"/>
   <result pre="[ 31]. In the second, a 61-year-old woman also with" exact="gallbladder cancer" post="had a remarkable response to weekly paclitaxel and trastuzumab,"/>
   <result pre="31]. In the second, a 61-year-old woman also with gallbladder" exact="cancer" post="had a remarkable response to weekly paclitaxel and trastuzumab,"/>
   <result pre="a single agent [ 32]. An estimated 80–100,000 cases of" exact="gallbladder cancer" post="are diagnosed worldwide annually, and the benefit of targeted"/>
   <result pre="single agent [ 32]. An estimated 80–100,000 cases of gallbladder" exact="cancer" post="are diagnosed worldwide annually, and the benefit of targeted"/>
   <result pre="substantial. In this review, we also report a patient with" exact="gallbladder cancer" post="with FGF3-TACC3 fusion gene with negative HER2/neu gene amplification"/>
   <result pre="In this review, we also report a patient with gallbladder" exact="cancer" post="with FGF3-TACC3 fusion gene with negative HER2/neu gene amplification"/>
   <result pre="reported to be a mechanism leading to lapatinib resistance in" exact="breast cancer" post="[ 33]. However, to our knowledge this is the"/>
   <result pre="to be a mechanism leading to lapatinib resistance in breast" exact="cancer" post="[ 33]. However, to our knowledge this is the"/>
   <result pre="In contrast, trastuzumab was less effective in the case of" exact="cholangiocarcinoma" post="and there were no responses noted in our series."/>
   <result pre="responses noted in our series. Two of these cases with" exact="cholangiocarcinoma" post="had HER2/neu mutations, which are not known to be"/>
   <result pre="summary, HER2/neu-directed therapy is a promising avenue for patients with" exact="gallbladder cancer" post="with gene amplification and should be further explored in"/>
   <result pre="HER2/neu-directed therapy is a promising avenue for patients with gallbladder" exact="cancer" post="with gene amplification and should be further explored in"/>
   <result pre="S Zuo M Eterovic AK et al. Molecular characterization of" exact="gallbladder cancer" post="using somatic mutation profiling Hum Pathol 2014 45 4"/>
   <result pre="Zuo M Eterovic AK et al. Molecular characterization of gallbladder" exact="cancer" post="using somatic mutation profiling Hum Pathol 2014 45 4"/>
   <result pre="HER2/neu gene: a new therapeutic possibility for patients with advanced" exact="gallbladder cancer" post="Gastrointestinal Cancer Res 2014 7 2 42 48 5."/>
   <result pre="gene: a new therapeutic possibility for patients with advanced gallbladder" exact="cancer" post="Gastrointestinal Cancer Res 2014 7 2 42 48 5."/>
   <result pre="Gene amplification and protein overexpression of HER-2/neu in human extrahepatic" exact="cholangiocarcinoma" post="as detected by chromogenic in situ hybridization and immunohistochemistry:"/>
   <result pre="liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing" exact="cholangiocarcinoma" post="Hepatology 1999 29 5 1453 1462 10.1002/hep.510290524 10216129 8."/>
   <result pre="and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human" exact="intrahepatic cholangiocarcinoma" post="as detected by fluorescence in situ hybridization, in situ"/>
   <result pre="mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic" exact="cholangiocarcinoma" post="as detected by fluorescence in situ hybridization, in situ"/>
   <result pre="Couch FJ Nevanlinna H Milne RL et al. Associations of" exact="breast cancer" post="risk factors with tumor subtypes: a pooled analysis from"/>
   <result pre="FJ Nevanlinna H Milne RL et al. Associations of breast" exact="cancer" post="risk factors with tumor subtypes: a pooled analysis from"/>
   <result pre="Chua TC Merrett ND Clinicopathologic factors associated with HER2-positive gastric" exact="cancer" post="and its impact on survival outcomes—a systematic review Int"/>
   <result pre="2 78 87 10.1016/j.annpat.2011.03.001 21601111 14. Boku N HER2-positive gastric" exact="cancer" post="Gastric Cancer. 2014 17 1 12 10.1007/s10120-013-0252-z 23563986 15."/>
   <result pre="receptors EGFR and ERBB2 on survival in stage II/III gastric" exact="cancer" post="Clin Cancer Res 2012 18 21 5992 6000 10.1158/1078-0432.CCR-12-1318"/>
   <result pre="2 314 327 10.1038/modpathol.2013.122 20. Ross JS Cronin M Whole" exact="cancer" post="genome sequencing by next-generation methods Am J Clin Pathol"/>
   <result pre="beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in" exact="intrahepatic cholangiocarcinoma" post="J Clin Pathol 2005 58 12 1249 1254 10.1136/jcp.2005.026575"/>
   <result pre="catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic" exact="cholangiocarcinoma" post="J Clin Pathol 2005 58 12 1249 1254 10.1136/jcp.2005.026575"/>
   <result pre="and prognostic significance of EGFR, VEGF, and HER2 expression in" exact="cholangiocarcinoma" post="Br J Cancer 2008 98 2 418 425 10.1038/sj.bjc.6604129"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="M Baselga J et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="a patient with human epidermal growth factor receptor 2-positive metastatic" exact="cholangiocarcinoma" post="J Clin Oncol 2012 30 27 e271 e273 10.1200/JCO.2012.42.3061"/>
   <result pre="32. Sorscher S Marked radiographic response of a HER-2-overexpressing biliary" exact="cancer" post="to trastuzumab Cancer Manag Res. 2014 6 1 3"/>
   <result pre="et al. Activating HER2 mutations in HER2 gene amplification negative" exact="breast cancer" post="Cancer Discov 2013 3 2 224 237 10.1158/2159-8290.CD-12-0349 23220880"/>
   <result pre="al. Activating HER2 mutations in HER2 gene amplification negative breast" exact="cancer" post="Cancer Discov 2013 3 2 224 237 10.1158/2159-8290.CD-12-0349 23220880"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4470009/results/search/disease/results.xml">
   <result pre="quantitative digital image analysis and fluorescence in situ hybridization of" exact="breast cancer" post="equivocal human epidermal growth factor receptors 2 score 2"/>
   <result pre="digital image analysis and fluorescence in situ hybridization of breast" exact="cancer" post="equivocal human epidermal growth factor receptors 2 score 2"/>
   <result pre="and source are credited. Abstract Background: Optimization of workflow for" exact="breast cancer" post="samples with equivocal human epidermal growth factor receptors 2"/>
   <result pre="source are credited. Abstract Background: Optimization of workflow for breast" exact="cancer" post="samples with equivocal human epidermal growth factor receptors 2"/>
   <result pre="slides and compare its performance to FISH in cases of" exact="breast cancer" post="with equivocal HER2 score 2 +. Materials and Methods:"/>
   <result pre="and compare its performance to FISH in cases of breast" exact="cancer" post="with equivocal HER2 score 2 +. Materials and Methods:"/>
   <result pre="2 +. Materials and Methods: Fifteen specimens (previously diagnosed as" exact="breast cancer" post="and was evaluated as HER 2 - score 2"/>
   <result pre="+. Materials and Methods: Fifteen specimens (previously diagnosed as breast" exact="cancer" post="and was evaluated as HER 2 - score 2"/>
   <result pre="Therefore, it represents a potential reliable substitute for FISH in" exact="breast cancer" post="cases, which desire further refinement of equivocal IHC results."/>
   <result pre="it represents a potential reliable substitute for FISH in breast" exact="cancer" post="cases, which desire further refinement of equivocal IHC results."/>
   <result pre="cases, which desire further refinement of equivocal IHC results. Breast" exact="cancer" post="fluorescence in situ hybridization human epidermal growth factor receptors"/>
   <result pre="growth factor receptors 2 (HER2) co-expression are not uncommon in" exact="breast cancer;" post="approximately half of breast cancers with HER2 overexpression also"/>
   <result pre="routinely performed in patients with a new diagnosis of invasive" exact="breast cancer." post="Accurate testing to identify HER2 status for patients with"/>
   <result pre="cancer. Accurate testing to identify HER2 status for patients with" exact="breast cancer" post="who can benefit from anti-HER2 treatment (e.g., trastuzumab, lapatinib)"/>
   <result pre="Accurate testing to identify HER2 status for patients with breast" exact="cancer" post="who can benefit from anti-HER2 treatment (e.g., trastuzumab, lapatinib)"/>
   <result pre="and reliable laboratory assessment of HER2 status in patients with" exact="breast cancer" post="are a matter of significant concern to patients, pathologists,"/>
   <result pre="reliable laboratory assessment of HER2 status in patients with breast" exact="cancer" post="are a matter of significant concern to patients, pathologists,"/>
   <result pre="(Wolff AC et al., 2013).[ 4] Optimization of workflow for" exact="breast cancer" post="samples with equivocal HER2/neu score 2 + results in"/>
   <result pre="AC et al., 2013).[ 4] Optimization of workflow for breast" exact="cancer" post="samples with equivocal HER2/neu score 2 + results in"/>
   <result pre="slides and compare its performance to FISH in cases of" exact="breast cancer" post="with equivocal HER2 score 2 +. MATERIALS AND METHODS"/>
   <result pre="and compare its performance to FISH in cases of breast" exact="cancer" post="with equivocal HER2 score 2 +. MATERIALS AND METHODS"/>
   <result pre="Pathology Department, Cairo University labs archives; 2011–2012) diagnosed as invasive" exact="breast cancer" post="(ductal, lobular, tubular and medullary carcinomas). The 15 specimens"/>
   <result pre="Department, Cairo University labs archives; 2011–2012) diagnosed as invasive breast" exact="cancer" post="(ductal, lobular, tubular and medullary carcinomas). The 15 specimens"/>
   <result pre="stain score 2 + [ Figure 1]. Figure 1 Invasive" exact="breast cancer," post="score 2 + for human epidermal growth factor receptors"/>
   <result pre="lowest cost-effectiveness ratio involved screening all newly diagnosed cases of" exact="breast cancer" post="with immunohistochemical analysis and confirming scores of 2 +"/>
   <result pre="cost-effectiveness ratio involved screening all newly diagnosed cases of breast" exact="cancer" post="with immunohistochemical analysis and confirming scores of 2 +"/>
   <result pre="takes much more time than the simple quantitative analysis) in" exact="breast cancer" post="cases which desire further refinement of equivocal IHC results."/>
   <result pre="much more time than the simple quantitative analysis) in breast" exact="cancer" post="cases which desire further refinement of equivocal IHC results."/>
   <result pre="to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified" exact="breast cancer" post="J Clin Oncol 2009 27 5492 4 19786653 3"/>
   <result pre="treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast" exact="cancer" post="J Clin Oncol 2009 27 5492 4 19786653 3"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="J Clin Oncol 2007 25 118 45 17159189 6"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="J Clin Oncol 2007 25 118 45 17159189 6"/>
   <result pre="MA Reproducibility in the automated quantitative assessment of HER2/neu for" exact="breast cancer" post="J Pathol Inform 2013 4 19 23967384 7 Wolff"/>
   <result pre="Reproducibility in the automated quantitative assessment of HER2/neu for breast" exact="cancer" post="J Pathol Inform 2013 4 19 23967384 7 Wolff"/>
   <result pre="effectiveness of human epidermal growth receptor 2 testing strategies in" exact="breast cancer" post="patients Cancer 2009 115 5166 74 19753618 10 Dendukuri"/>
   <result pre="of human epidermal growth receptor 2 testing strategies in breast" exact="cancer" post="patients Cancer 2009 115 5166 74 19753618 10 Dendukuri"/>
   <result pre="Gavrielides MA Automated quantitative assessment of HER-2/neu immunohistochemical expression in" exact="breast cancer" post="IEEE Trans Med Imaging 2009 28 916 25 19164073"/>
   <result pre="MA Automated quantitative assessment of HER-2/neu immunohistochemical expression in breast" exact="cancer" post="IEEE Trans Med Imaging 2009 28 916 25 19164073"/>
   <result pre="C Mayotte J et al. Standardization of HER2 immunohistochemistry in" exact="breast cancer" post="by automated quantitative analysis Arch Pathol Lab Med 2009"/>
   <result pre="Mayotte J et al. Standardization of HER2 immunohistochemistry in breast" exact="cancer" post="by automated quantitative analysis Arch Pathol Lab Med 2009"/>
   <result pre="MT Gokaslan S et al. Assessment of HER-2/neu status in" exact="breast cancer." post="Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4471111/results/search/disease/results.xml">
   <result pre="HER2 tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic" exact="breast cancer" post="(MBC). Patients and Methods Patients with MBC and HER2-positive"/>
   <result pre="tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic breast" exact="cancer" post="(MBC). Patients and Methods Patients with MBC and HER2-positive"/>
   <result pre="Introduction Several lines of evidence suggest that metastatic spread in" exact="breast cancer" post="is the result of tumour cell dissemination from the"/>
   <result pre="Several lines of evidence suggest that metastatic spread in breast" exact="cancer" post="is the result of tumour cell dissemination from the"/>
   <result pre="CTCs) have been identified in otherwise metastasis-free patients with early" exact="breast cancer" post="by the use of immunocytochemistry or Reverse Transcription Polymerase"/>
   <result pre="have been identified in otherwise metastasis-free patients with early breast" exact="cancer" post="by the use of immunocytochemistry or Reverse Transcription Polymerase"/>
   <result pre="CTCs can be detected in 40–70% of patients with metastatic" exact="breast cancer" post="(MBC) [ 7, 8]. Using the CellSearch platform, the"/>
   <result pre="can be detected in 40–70% of patients with metastatic breast" exact="cancer" post="(MBC) [ 7, 8]. Using the CellSearch platform, the"/>
   <result pre="21]. Targeting these CTCs could be beneficial for patients with" exact="breast cancer." post="The primary objective of this pilot study was to"/>
   <result pre="both markers were included in each experiment. HER2 amplified SKBR3" exact="breast cancer" post="cells that express both HER2 and EGFR were used"/>
   <result pre="markers were included in each experiment. HER2 amplified SKBR3 breast" exact="cancer" post="cells that express both HER2 and EGFR were used"/>
   <result pre="6 Kaplan-Meier estimate of Progression-Free-Survival (PFS) in patients with metaststic" exact="breast cancer" post="receiving lapatinib (n = 21). In patients with clinically"/>
   <result pre="Kaplan-Meier estimate of Progression-Free-Survival (PFS) in patients with metaststic breast" exact="cancer" post="receiving lapatinib (n = 21). In patients with clinically"/>
   <result pre="common adverse events of any grade were fatigue, diarrhoea and" exact="rash" post="reported in 10 (45.4%), 12 (54.5%) and seven (31.8%)"/>
   <result pre="Table). Nausea and vomiting occurred in six (27.3%) patients, whereas" exact="paronychia" post="and epistaxis was recorded in four (18.2%) patients each."/>
   <result pre="profile of the regimen was easily manageable. One patient presented" exact="colitis" post="and gastritis of grade III on day 17 of"/>
   <result pre="the regimen was easily manageable. One patient presented colitis and" exact="gastritis" post="of grade III on day 17 of cycle 1"/>
   <result pre="consent after the completion of cycle 3 because of rash," exact="stomatitis" post="and diarrhea all grade II in severity. Discussion CTCs"/>
   <result pre="the completion of cycle 3 because of rash, stomatitis and" exact="diarrhea" post="all grade II in severity. Discussion CTCs have been"/>
   <result pre="has been shown that HER2 amplification may be acquired during" exact="breast cancer" post="progression [ 12], whereas in other studies, clinically relevant"/>
   <result pre="been shown that HER2 amplification may be acquired during breast" exact="cancer" post="progression [ 12], whereas in other studies, clinically relevant"/>
   <result pre="CTCs have been associated with poor clinical outcome in early" exact="breast cancer" post="[ 17, 28, 29]. We have previously demonstrated the"/>
   <result pre="have been associated with poor clinical outcome in early breast" exact="cancer" post="[ 17, 28, 29]. We have previously demonstrated the"/>
   <result pre="the effectiveness of trastuzumab in eliminating CK-19 mRNA-positive CTCs in" exact="breast cancer" post="patients after prior chemotherapy exposure [ 30]. In the"/>
   <result pre="effectiveness of trastuzumab in eliminating CK-19 mRNA-positive CTCs in breast" exact="cancer" post="patients after prior chemotherapy exposure [ 30]. In the"/>
   <result pre="to trastuzumab. Similarly, in preclinical studies, lapatinib was effective against" exact="breast cancer" post="with resistance to trastuzumab [ 31] whereas, lapatinib added"/>
   <result pre="trastuzumab. Similarly, in preclinical studies, lapatinib was effective against breast" exact="cancer" post="with resistance to trastuzumab [ 31] whereas, lapatinib added"/>
   <result pre="been shown that lapatinib lacks efficacy in HER2-negative, EGFR-overexpressing inflammatory" exact="breast cancer" post="[ 34]. In our study, the pool of HER2-negative"/>
   <result pre="shown that lapatinib lacks efficacy in HER2-negative, EGFR-overexpressing inflammatory breast" exact="cancer" post="[ 34]. In our study, the pool of HER2-negative"/>
   <result pre="of 6 cycles of trastuzumab in patients with HER2-negative early" exact="breast cancer" post="harbouring CK-19mRNA-positive CTCs both before and after the completion"/>
   <result pre="6 cycles of trastuzumab in patients with HER2-negative early breast" exact="cancer" post="harbouring CK-19mRNA-positive CTCs both before and after the completion"/>
   <result pre="studies such as the TREAT CTC trial (NCT01548677) in early" exact="breast cancer" post="and the DETECT III trial (NCT01619111) in metastatic disease,"/>
   <result pre="such as the TREAT CTC trial (NCT01548677) in early breast" exact="cancer" post="and the DETECT III trial (NCT01619111) in metastatic disease,"/>
   <result pre="characteristics of CTCs could be a practice changing approach in" exact="breast cancer." post="In conclusion, the results of this study demonstrate that"/>
   <result pre="present on CTCs could be clinically relevant in patients with" exact="breast cancer." post="To this end, standardized assays and validated cut-offs should"/>
   <result pre="al. ( 2008) Systemic spread is an early step in" exact="breast cancer." post="Cancer Cell 13: 58– 68. doi: 10.1016/j.ccr.2007.12.003 18167340 2"/>
   <result pre="V , Mavroudis D ( 2008) Circulating tumor cells in" exact="breast cancer." post="Curr Opin Obstet Gynecol 20: 55– 60. doi: 10.1097/GCO.0b013e3282f22b2e"/>
   <result pre="( 2005) A pooled analysis of bone marrow micrometastasis in" exact="breast cancer." post="N Engl J Med 353: 793– 802. 16120859 4"/>
   <result pre="mRNA-positive cells detected by real-time polymerase chain reaction in node-negative" exact="breast cancer" post="patients . J Clin Oncol 24: 3756– 3762. 16769987"/>
   <result pre="cells detected by real-time polymerase chain reaction in node-negative breast" exact="cancer" post="patients . J Clin Oncol 24: 3756– 3762. 16769987"/>
   <result pre="the peripheral blood and bone marrow of patients with operable" exact="breast cancer" post=". Br J Cancer 101: 589– 597. doi: 10.1038/sj.bjc.6605183"/>
   <result pre="peripheral blood and bone marrow of patients with operable breast" exact="cancer" post=". Br J Cancer 101: 589– 597. doi: 10.1038/sj.bjc.6605183"/>
   <result pre="CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic" exact="breast cancer" post=". Br J Cancer 106: 1917– 1925. doi: 10.1038/bjc.2012.202"/>
   <result pre="tumour cells before front-line treatment in patients with metastatic breast" exact="cancer" post=". Br J Cancer 106: 1917– 1925. doi: 10.1038/bjc.2012.202"/>
   <result pre="and mammaglobin gene expression in circulating tumor cells from metastatic" exact="breast cancer" post="patients enrolled in North Central Cancer Treatment Group trials,"/>
   <result pre="mammaglobin gene expression in circulating tumor cells from metastatic breast" exact="cancer" post="patients enrolled in North Central Cancer Treatment Group trials,"/>
   <result pre="2004) Circulating tumor cells, disease progression, and survival in metastatic" exact="breast cancer." post="N Engl J Med 351: 781– 791. 15317891 10"/>
   <result pre="profiling of circulating tumor cells: transcriptional heterogeneity and diversity from" exact="breast cancer" post="cell lines . PLoS One 7: e33788 doi: 10.1371/journal.pone.0033788"/>
   <result pre="of circulating tumor cells: transcriptional heterogeneity and diversity from breast" exact="cancer" post="cell lines . PLoS One 7: e33788 doi: 10.1371/journal.pone.0033788"/>
   <result pre="al. ( 2004) HER-2 gene amplification can be acquired as" exact="breast cancer" post="progresses. Proc Natl Acad Sci U S A 101:"/>
   <result pre="( 2004) HER-2 gene amplification can be acquired as breast" exact="cancer" post="progresses. Proc Natl Acad Sci U S A 101:"/>
   <result pre="profiles in circulating tumor cells and primary tumors of metastatic" exact="breast cancer" post="patients . Clin Cancer Res 17: 3600– 3618. doi:"/>
   <result pre="in circulating tumor cells and primary tumors of metastatic breast" exact="cancer" post="patients . Clin Cancer Res 17: 3600– 3618. doi:"/>
   <result pre="cells compared with the primary tumor during treatment for advanced" exact="breast cancer" post=". Clin Breast Cancer 10: 392– 397. doi: 10.3816/CBC.2010.n.052"/>
   <result pre="compared with the primary tumor during treatment for advanced breast" exact="cancer" post=". Clin Breast Cancer 10: 392– 397. doi: 10.3816/CBC.2010.n.052"/>
   <result pre="HER2 levels and circulating tumor cells in patients with recurrent" exact="breast cancer" post="whose primary tumor was HER2 negative or of unknown"/>
   <result pre="levels and circulating tumor cells in patients with recurrent breast" exact="cancer" post="whose primary tumor was HER2 negative or of unknown"/>
   <result pre="PI3K/Akt signaling kinases are expressed in circulating tumor cells of" exact="breast cancer" post="patients . Breast Cancer Res 10: R80 doi: 10.1186/bcr2149"/>
   <result pre="signaling kinases are expressed in circulating tumor cells of breast" exact="cancer" post="patients . Breast Cancer Res 10: R80 doi: 10.1186/bcr2149"/>
   <result pre="circulating tumor cells after adjuvant chemotherapy in patients with early" exact="breast cancer" post=". J Clin Oncol 27: 2177– 2184. doi: 10.1200/JCO.2008.18.0497"/>
   <result pre="tumor cells after adjuvant chemotherapy in patients with early breast" exact="cancer" post=". J Clin Oncol 27: 2177– 2184. doi: 10.1200/JCO.2008.18.0497"/>
   <result pre="detected during the adjuvant tamoxifen treatment in patients with early" exact="breast cancer" post=". Ann Oncol 18: 1623– 1631. 17515404 21 Hayes"/>
   <result pre="during the adjuvant tamoxifen treatment in patients with early breast" exact="cancer" post=". Ann Oncol 18: 1623– 1631. 17515404 21 Hayes"/>
   <result pre="cells at each follow-up time point during therapy of metastatic" exact="breast cancer" post="patients predict progression-free and overall survival . Clin Cancer"/>
   <result pre="at each follow-up time point during therapy of metastatic breast" exact="cancer" post="patients predict progression-free and overall survival . Clin Cancer"/>
   <result pre="et al. ( 2004) Circulating tumor cells in patients with" exact="breast cancer" post="dormancy. Clin Cancer Res 10: 8152– 8162. 15623589 24"/>
   <result pre="al. ( 2004) Circulating tumor cells in patients with breast" exact="cancer" post="dormancy. Clin Cancer Res 10: 8152– 8162. 15623589 24"/>
   <result pre="tumor cells: a novel prognostic factor for newly diagnosed metastatic" exact="breast cancer" post=". J Clin Oncol 23: 1420– 1430. 15735118 25"/>
   <result pre="cells: a novel prognostic factor for newly diagnosed metastatic breast" exact="cancer" post=". J Clin Oncol 23: 1420– 1430. 15735118 25"/>
   <result pre="Patterns of her-2/neu amplification and overexpression in primary and metastatic" exact="breast cancer" post=". J Natl Cancer Inst 93: 1141– 1146. 11481385"/>
   <result pre="of her-2/neu amplification and overexpression in primary and metastatic breast" exact="cancer" post=". J Natl Cancer Inst 93: 1141– 1146. 11481385"/>
   <result pre=", et al. ( 2011) HER2-positive circulating tumor cells in" exact="breast cancer." post="PLoS One 6: e15624 doi: 10.1371/journal.pone.0015624 21264346 28 Ignatiadis"/>
   <result pre="assay for cytokeratin 19, mammaglobin A, and HER2 in early" exact="breast cancer" post=". Clin Cancer Res 14: 2593– 2600. doi: 10.1158/1078-0432.CCR-07-4758"/>
   <result pre="for cytokeratin 19, mammaglobin A, and HER2 in early breast" exact="cancer" post=". Clin Cancer Res 14: 2593– 2600. doi: 10.1158/1078-0432.CCR-07-4758"/>
   <result pre="cells indicate poor clinical outcome in stage I to III" exact="breast cancer" post="patients . Clin Cancer Res 12: 1715– 1720. 16551854"/>
   <result pre="indicate poor clinical outcome in stage I to III breast" exact="cancer" post="patients . Clin Cancer Res 12: 1715– 1720. 16551854"/>
   <result pre="in the peripheral blood and bone marrow of patients with" exact="breast cancer" post=". Clin Cancer Res 10: 8185– 8194. 15623593 31"/>
   <result pre="the peripheral blood and bone marrow of patients with breast" exact="cancer" post=". Clin Cancer Res 10: 8185– 8194. 15623593 31"/>
   <result pre="et al. ( 2006) Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med 355: 2733– 2743. 17192538 33"/>
   <result pre="human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory" exact="breast cancer" post="with lapatinib monotherapy . J Clin Oncol 26: 1066–"/>
   <result pre="epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast" exact="cancer" post="with lapatinib monotherapy . J Clin Oncol 26: 1066–"/>
   <result pre="the activity of single-agent lapatinib in patients with HER2-negative metastatic" exact="breast cancer" post="and HER2-positive circulating tumor cells. A proof-of-concept study ."/>
   <result pre="activity of single-agent lapatinib in patients with HER2-negative metastatic breast" exact="cancer" post="and HER2-positive circulating tumor cells. A proof-of-concept study ."/>
   <result pre="et al. ( 2013) The efficacy of lapatinib in metastatic" exact="breast cancer" post="with HER2 non-amplified primary tumors and EGFR positive circulating"/>
   <result pre="al. ( 2013) The efficacy of lapatinib in metastatic breast" exact="cancer" post="with HER2 non-amplified primary tumors and EGFR positive circulating"/>
   <result pre="2006) Circulating tumor cells versus imaging—predicting overall survival in metastatic" exact="breast cancer" post=". Clin Cancer Res 12: 6403– 6409. 17085652 38"/>
   <result pre="Circulating tumor cells versus imaging—predicting overall survival in metastatic breast" exact="cancer" post=". Clin Cancer Res 12: 6403– 6409. 17085652 38"/>
   <result pre="decreases the incidence of clinical relapses in patients with early" exact="breast cancer" post="presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a"/>
   <result pre="the incidence of clinical relapses in patients with early breast" exact="cancer" post="presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4471791/results/search/disease/results.xml">
   <result pre="ribosome-binding protein 1 correlates with shorter survival in Her-2 positive" exact="breast cancer" post="Liang Xiaoshuan 1 Sun Shanshan 1 Zhang Xianyu 1"/>
   <result pre="protein 1 correlates with shorter survival in Her-2 positive breast" exact="cancer" post="Liang Xiaoshuan 1 Sun Shanshan 1 Zhang Xianyu 1"/>
   <result pre="investigate the expression of ribosome-binding protein 1 (RRBP1) in invasive" exact="breast cancer" post="and to analyze its relationship to clinical features and"/>
   <result pre="the expression of ribosome-binding protein 1 (RRBP1) in invasive breast" exact="cancer" post="and to analyze its relationship to clinical features and"/>
   <result pre="analyzed. RRBP1 mRNA and protein expression were significantly increased in" exact="breast cancer" post="tissues compared with normal tissues. The protein level of"/>
   <result pre="RRBP1 mRNA and protein expression were significantly increased in breast" exact="cancer" post="tissues compared with normal tissues. The protein level of"/>
   <result pre="overall survival. RRBP1 is a valuable prognostic factor in Her-2-positive" exact="breast cancer" post="patients, indicating that RRBP1 is a potentially important target"/>
   <result pre="survival. RRBP1 is a valuable prognostic factor in Her-2-positive breast" exact="cancer" post="patients, indicating that RRBP1 is a potentially important target"/>
   <result pre="a potentially important target for the prediction of prognosis. Breast" exact="cancer" post="Her-2 histological grade prognosis RRBP1 Breast cancer is the"/>
   <result pre="of prognosis. Breast cancer Her-2 histological grade prognosis RRBP1 Breast" exact="cancer" post="is the leading cancer in women and represents the"/>
   <result pre="Her-2 histological grade prognosis RRBP1 Breast cancer is the leading" exact="cancer" post="in women and represents the second leading cause of"/>
   <result pre="cancer in women and represents the second leading cause of" exact="cancer" post="death among all women. 1 Her-2, one of the"/>
   <result pre="all women. 1 Her-2, one of the most well characterized" exact="breast cancer" post="oncogenes, is found in approximately 25% of invasive breast"/>
   <result pre="women. 1 Her-2, one of the most well characterized breast" exact="cancer" post="oncogenes, is found in approximately 25% of invasive breast"/>
   <result pre="2, 3 Overexpression of Her-2 has been demonstrated to promote" exact="breast cancer" post="invasion and metastasis. 4 In particular, tumors with Her-2"/>
   <result pre="3 Overexpression of Her-2 has been demonstrated to promote breast" exact="cancer" post="invasion and metastasis. 4 In particular, tumors with Her-2"/>
   <result pre="to be associated with shortened overall survival. 5, 6 Although" exact="breast cancer" post="patients with Her-2 overexpression can benefit from a targeted"/>
   <result pre="be associated with shortened overall survival. 5, 6 Although breast" exact="cancer" post="patients with Her-2 overexpression can benefit from a targeted"/>
   <result pre="to predict. 7, 8 Thus, the identification of a new" exact="cancer" post="biomarker, in addition to common clinicopathological risk factors to"/>
   <result pre="or bad outcomes, will assist the follow-up management of Her-2-positive" exact="breast cancer" post="after surgery. During the early stages of tumor development,"/>
   <result pre="bad outcomes, will assist the follow-up management of Her-2-positive breast" exact="cancer" post="after surgery. During the early stages of tumor development,"/>
   <result pre="cancer after surgery. During the early stages of tumor development," exact="cancer" post="cells with high proliferation rates require the increased activity"/>
   <result pre="interact with KIF5B, a motor protein highly expressed in several" exact="cancer" post="cell lines. 13 With regard to the possible role"/>
   <result pre="in tumorigenesis and progression, RRBP1 overexpression has frequently occurred in" exact="colorectal cancer" post="14 and lung cancer. 15 However, thus far, there"/>
   <result pre="tumorigenesis and progression, RRBP1 overexpression has frequently occurred in colorectal" exact="cancer" post="14 and lung cancer. 15 However, thus far, there"/>
   <result pre="RRBP1 overexpression has frequently occurred in colorectal cancer 14 and" exact="lung cancer." post="15 However, thus far, there has been no evidence"/>
   <result pre="concerning the significance of RRBP1 mRNA and protein expression in" exact="breast cancer." post="In the present study, we examine the expression of"/>
   <result pre="Hospital, including tissue samples from 389 consecutive patients with histologically-confirmed" exact="breast cancer" post="and 117 paired-normal tissue samples, all from 2006 (Table"/>
   <result pre="including tissue samples from 389 consecutive patients with histologically-confirmed breast" exact="cancer" post="and 117 paired-normal tissue samples, all from 2006 (Table"/>
   <result pre="for 1 year at Harbin Medical University Cancer Hospital. Fresh" exact="cancer" post="tissues and matched normal tissues from 48 patients were"/>
   <result pre="diagnostically by two pathologists. All of the patients had invasive" exact="breast cancer." post="The patients who presented with recurrent tumors, metastatic disease"/>
   <result pre="The tumor size at the largest diameter of the invasive" exact="cancer" post="was measured in millimeters by the pathologist. Four-micron tissue"/>
   <result pre="sections were prepared from a formalin-fixed and paraffin-embedded sample. All" exact="breast cancer" post="patients were routinely tested for ER(estrogen receptor), PR(progesterone receptor),"/>
   <result pre="were prepared from a formalin-fixed and paraffin-embedded sample. All breast" exact="cancer" post="patients were routinely tested for ER(estrogen receptor), PR(progesterone receptor),"/>
   <result pre="μm and affixed to the slide. Blocks from 389 invasive" exact="breast cancer" post="patients and their matched normal breast samples were arrayed"/>
   <result pre="and affixed to the slide. Blocks from 389 invasive breast" exact="cancer" post="patients and their matched normal breast samples were arrayed"/>
   <result pre="primary antibody was substituted with PBS. The positive controls were" exact="lung cancer" post="tumors with positive expression of RRBP1. 15 Evaluation of"/>
   <result pre="antibody was substituted with PBS. The positive controls were lung" exact="cancer" post="tumors with positive expression of RRBP1. 15 Evaluation of"/>
   <result pre="RRBP1 were performed using specimens from 389 untreated female invasive" exact="breast cancer" post="patients. The clinical characteristics of the patients are listed"/>
   <result pre="were performed using specimens from 389 untreated female invasive breast" exact="cancer" post="patients. The clinical characteristics of the patients are listed"/>
   <result pre="III (65.3%). Ribosome-binding protein 1 mRNA and protein expression in" exact="breast cancer" post="tissues The analysis of real-time qPCR was used to"/>
   <result pre="(65.3%). Ribosome-binding protein 1 mRNA and protein expression in breast" exact="cancer" post="tissues The analysis of real-time qPCR was used to"/>
   <result pre="mRNA level. The mean expression value of RRBP1 mRNA in" exact="cancer" post="tissue (24.10 ± 45.03, normalized by GAPDH gene expression)"/>
   <result pre="defined twofold changes as upregulation of RRBP1 mRNA between the" exact="cancer" post="and corresponding normal tissues (Fig. 1a). The results revealed"/>
   <result pre="tissues (Fig. 1a). The results revealed that 83.3% (40/48) of" exact="breast cancer" post="tissues expressed RRBP1 compared to the matched normal tissues."/>
   <result pre="(Fig. 1a). The results revealed that 83.3% (40/48) of breast" exact="cancer" post="tissues expressed RRBP1 compared to the matched normal tissues."/>
   <result pre="tissues. Figure 1 Ribosome-binding protein 1 (RRBP1)-elevated expression in fresh" exact="breast cancer" post="tissues. (a) Histogram of RRBP1 mRNA expression in breast"/>
   <result pre="Figure 1 Ribosome-binding protein 1 (RRBP1)-elevated expression in fresh breast" exact="cancer" post="tissues. (a) Histogram of RRBP1 mRNA expression in breast"/>
   <result pre="breast cancer tissues. (a) Histogram of RRBP1 mRNA expression in" exact="breast cancer." post="The RRBP1 mRNA expression was calculated using the method"/>
   <result pre="as an internal control. The difference in RRBP1 expression between" exact="cancer" post="and normal tissues reflected at protein level was investigated"/>
   <result pre="protein level was investigated using western blotting and immunohistochemistry. Overall," exact="breast cancer" post="tissues exhibited dramatically higher levels of RRBP1 protein expression"/>
   <result pre="level was investigated using western blotting and immunohistochemistry. Overall, breast" exact="cancer" post="tissues exhibited dramatically higher levels of RRBP1 protein expression"/>
   <result pre="tissues. Significantly greater expression of RRBP1 protein was found in" exact="cancer" post="tissues than in matched normal tissues during western blotting"/>
   <result pre="color and presented diffusely in the cytosolic regions of invasive" exact="breast cancer" post="cells (Fig. 2). In 17 of 117 paired-normal tissues,"/>
   <result pre="and presented diffusely in the cytosolic regions of invasive breast" exact="cancer" post="cells (Fig. 2). In 17 of 117 paired-normal tissues,"/>
   <result pre="expression (i.e. 14.5% of the normal tissues). Of the 389" exact="breast cancer" post="specimens, we found positive expression in 164 (42.2%) samples"/>
   <result pre="(i.e. 14.5% of the normal tissues). Of the 389 breast" exact="cancer" post="specimens, we found positive expression in 164 (42.2%) samples"/>
   <result pre="staining in normal breast tissue. (b) RRBP1 positive expression in" exact="breast cancer" post="tissue. Relationship between immunoreactivity of ribosome-binding protein 1 and"/>
   <result pre="in normal breast tissue. (b) RRBP1 positive expression in breast" exact="cancer" post="tissue. Relationship between immunoreactivity of ribosome-binding protein 1 and"/>
   <result pre="and status of ER, PR, Her-2, Ki67 and P53 in" exact="breast cancer" post="patients (Table 2). RRBP1 was significantly correlated with histological"/>
   <result pre="status of ER, PR, Her-2, Ki67 and P53 in breast" exact="cancer" post="patients (Table 2). RRBP1 was significantly correlated with histological"/>
   <result pre="expression was much greater in early-stage than in late-stage invasive" exact="breast cancer." post="A total of 45 of 84 patients (53.6%) who"/>
   <result pre="Meanwhile, expression of RRBP1 protein was associated with subtypes of" exact="breast cancer;" post="the positive rate was higher in the Her-2-positive subtype"/>
   <result pre="significance of ribosome-binding protein 1 expression in different grades of" exact="breast cancer" post="patients To eliminate the effect of histological grade on"/>
   <result pre="of ribosome-binding protein 1 expression in different grades of breast" exact="cancer" post="patients To eliminate the effect of histological grade on"/>
   <result pre="= 0.042). However, no such association was observed in the" exact="breast cancer" post="patients with late-stage tumors ( P = 0.584). The"/>
   <result pre="0.042). However, no such association was observed in the breast" exact="cancer" post="patients with late-stage tumors ( P = 0.584). The"/>
   <result pre="tumors ( P = 0.584). The survival curves for the" exact="breast cancer" post="patients in the two groups stratified by histological stage"/>
   <result pre="( P = 0.584). The survival curves for the breast" exact="cancer" post="patients in the two groups stratified by histological stage"/>
   <result pre="showed the correlation of RRBP1 with overall survival (OS) in" exact="breast cancer" post="patients in different histological grades: (a) OS in histological"/>
   <result pre="the correlation of RRBP1 with overall survival (OS) in breast" exact="cancer" post="patients in different histological grades: (a) OS in histological"/>
   <result pre="significance of ribosome-binding protein 1 expression in Her-2 positive invasive" exact="breast cancer" post="patients The Kaplan–Meier 5-year survival curve stratified for RRBP1"/>
   <result pre="of ribosome-binding protein 1 expression in Her-2 positive invasive breast" exact="cancer" post="patients The Kaplan–Meier 5-year survival curve stratified for RRBP1"/>
   <result pre="that RRBP1 expression is associated with worse OS in Her-2-positive" exact="breast cancer." post="Figure 4 Kaplan–Meier analysis for overall survival (OS) based"/>
   <result pre="(OS) based on ribosome-binding protein 1 (RRBP1) expression in Her-2-positive" exact="breast cancer" post="patients. Both univariate and multivariate survival analyses were used"/>
   <result pre="based on ribosome-binding protein 1 (RRBP1) expression in Her-2-positive breast" exact="cancer" post="patients. Both univariate and multivariate survival analyses were used"/>
   <result pre="development of tumorigenesis. 14, 15 RRBP1 was highly expressed in" exact="lung cancer" post="tissue compared with adjacent normal tissues, as assessed by"/>
   <result pre="of tumorigenesis. 14, 15 RRBP1 was highly expressed in lung" exact="cancer" post="tissue compared with adjacent normal tissues, as assessed by"/>
   <result pre="compared with adjacent normal tissues, as assessed by immunohistochemistry using" exact="lung cancer" post="TMA and real-time qPCR using paired normal cancer tissues."/>
   <result pre="with adjacent normal tissues, as assessed by immunohistochemistry using lung" exact="cancer" post="TMA and real-time qPCR using paired normal cancer tissues."/>
   <result pre="using lung cancer TMA and real-time qPCR using paired normal" exact="cancer" post="tissues. 15 Elevated levels of RRBP1 proteins have been"/>
   <result pre="15 Elevated levels of RRBP1 proteins have been detected in" exact="colorectal cancer" post="tissues. 14 Although several studies on the expression of"/>
   <result pre="Elevated levels of RRBP1 proteins have been detected in colorectal" exact="cancer" post="tissues. 14 Although several studies on the expression of"/>
   <result pre="there has been no report of RRBP1 being involved in" exact="breast cancer" post="development. In the present study, we detected that the"/>
   <result pre="has been no report of RRBP1 being involved in breast" exact="cancer" post="development. In the present study, we detected that the"/>
   <result pre="RRBP1 is upregulated at both mRNA and protein levels in" exact="breast cancer." post="Our results concur with the data analysis from the"/>
   <result pre="Our results concur with the data analysis from the UCSC" exact="cancer" post="browser ( https://genome-cancer.ucsc.edu, TCGA), which shows higher RRBP1 expression"/>
   <result pre="( https://genome-cancer.ucsc.edu, TCGA), which shows higher RRBP1 expression levels in" exact="breast cancer" post="tissues than in normal breast tissues ( P &amp;lt;"/>
   <result pre="https://genome-cancer.ucsc.edu, TCGA), which shows higher RRBP1 expression levels in breast" exact="cancer" post="tissues than in normal breast tissues ( P &amp;lt;"/>
   <result pre="with published data and associate higher RRBP1 expression in human" exact="breast cancer" post="tissues with increasing propensity for tumor formation. We first"/>
   <result pre="published data and associate higher RRBP1 expression in human breast" exact="cancer" post="tissues with increasing propensity for tumor formation. We first"/>
   <result pre="first investigated the elevated expression of RRBP1 in human invasive" exact="breast cancer" post="at the level of mRNA and protein. We then"/>
   <result pre="investigated the elevated expression of RRBP1 in human invasive breast" exact="cancer" post="at the level of mRNA and protein. We then"/>
   <result pre="clinical, pathological and molecular factors to patient survival in invasive" exact="breast cancer" post="have been investigated. Although prognosis in general correlates with"/>
   <result pre="pathological and molecular factors to patient survival in invasive breast" exact="cancer" post="have been investigated. Although prognosis in general correlates with"/>
   <result pre="might be an early event in the progression of invasive" exact="breast cancer." post="Moreover, previous studies have shown that RRBP1 is associated"/>
   <result pre="could be a key player in the initial maintenance of" exact="breast cancer" post="cell survival. Furthermore, by performing a grade-stratified analysis of"/>
   <result pre="be a key player in the initial maintenance of breast" exact="cancer" post="cell survival. Furthermore, by performing a grade-stratified analysis of"/>
   <result pre="RRBP1 overexpression might be a prognostic indicator for early-stage invasive" exact="breast cancer." post="Amplification of Her-2 gene is observed in approximately 25%"/>
   <result pre="lung, 33 gastric 34, 35 and oral 36 cancers. Breast" exact="cancer" post="tumors overexpressing Her-2 oncoprotein are associated with a more"/>
   <result pre="behavior. 37, 38 The current standard of care for Her-2-positive" exact="breast cancer" post="is therapy with the humanized monoclonal antibody tratuzumab, 39"/>
   <result pre="37, 38 The current standard of care for Her-2-positive breast" exact="cancer" post="is therapy with the humanized monoclonal antibody tratuzumab, 39"/>
   <result pre="possible means of overriding the effect of trastuzumab in Her-2-positive" exact="cancer" post="cells. 41 In this study, correlation between Her-2 and"/>
   <result pre="observed ( P = 0.026). Statistical analysis of the UCSC" exact="cancer" post="browser database also revealed that RRBP1 expression is highly"/>
   <result pre="RRBP1 expression is highly correlated with Her-2 expression in human" exact="breast cancer" post="( P = 0.016). Moreover, high RRBP1 expression correlates"/>
   <result pre="expression is highly correlated with Her-2 expression in human breast" exact="cancer" post="( P = 0.016). Moreover, high RRBP1 expression correlates"/>
   <result pre="RRBP1 and histological grade, Her-2, P53 and molecular subtypes in" exact="breast cancer." post="Our data also imply that RRBP1 is a valuable"/>
   <result pre="imply that RRBP1 is a valuable prognostic factor in Her-2-positive" exact="breast cancer" post="patients, indicating that RRBP1 is a potentially important target"/>
   <result pre="that RRBP1 is a valuable prognostic factor in Her-2-positive breast" exact="cancer" post="patients, indicating that RRBP1 is a potentially important target"/>
   <result pre="for the prediction of prognosis. The roles of RRBP1 in" exact="breast cancer" post="need to be tested in vivo. Therefore, further studies"/>
   <result pre="the prediction of prognosis. The roles of RRBP1 in breast" exact="cancer" post="need to be tested in vivo. Therefore, further studies"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer" post="Science 1989 244 707 12 2470152 Slamon DJ Clark"/>
   <result pre="Studies of the HER-2/neu proto-oncogene in human breast and ovarian" exact="cancer" post="Science 1989 244 707 12 2470152 Slamon DJ Clark"/>
   <result pre="82 3798106 Yu D Hung MC Overexpression of ErbB2 in" exact="cancer" post="and ErbB2-targeting strategies Oncogene 2000 19 6115 21 11156524"/>
   <result pre="pathway targets estrogen receptor and promotes hormone-independent growth in human" exact="breast cancer" post="cells Oncogene 1995 10 2435 46 7784095 Alaoui-Jamali MA"/>
   <result pre="targets estrogen receptor and promotes hormone-independent growth in human breast" exact="cancer" post="cells Oncogene 1995 10 2435 46 7784095 Alaoui-Jamali MA"/>
   <result pre="the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated" exact="breast cancer" post="cells Cancer Res 2006 66 1630 9 16452222 Shepard"/>
   <result pre="dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast" exact="cancer" post="cells Cancer Res 2006 66 1630 9 16452222 Shepard"/>
   <result pre="distribution and stability and induces peri-nuclear accumulation of autophagosomes in" exact="cancer" post="cells PLoS One 2009 4 e4424 19242560 Krasnov GS"/>
   <result pre="19242560 Krasnov GS Oparina N Khankin SL et al. Colorectal" exact="cancer" post="2D-proteomics: identification of altered protein expression Mol Biol 2009"/>
   <result pre="reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in" exact="lung cancer" post="patients and alleviates intracellular stress-induced apoptosis through the enhancement"/>
   <result pre="ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung" exact="cancer" post="patients and alleviates intracellular stress-induced apoptosis through the enhancement"/>
   <result pre="recommendations for immunohistochemical testing of estrogen and progesterone receptors in" exact="breast cancer" post="J Clin Oncol 2010 28 2784 95 20404251 Hsu"/>
   <result pre="for immunohistochemical testing of estrogen and progesterone receptors in breast" exact="cancer" post="J Clin Oncol 2010 28 2784 95 20404251 Hsu"/>
   <result pre="index, HER2 status, and prognosis of patients with luminal B" exact="breast cancer" post="J Natl Cancer Inst 2009 101 736 50 19436038"/>
   <result pre="HER2 status, and prognosis of patients with luminal B breast" exact="cancer" post="J Natl Cancer Inst 2009 101 736 50 19436038"/>
   <result pre="McNeil CM et al. Prediction of outcome of early ER+" exact="breast cancer" post="is improved using a biomarker panel, which includes Ki-67"/>
   <result pre="CM et al. Prediction of outcome of early ER+ breast" exact="cancer" post="is improved using a biomarker panel, which includes Ki-67"/>
   <result pre="in the immunohistochemical determination of estrogen receptor status using a" exact="breast cancer" post="tissue microarray Am J Clin Pathol 2002 117 723"/>
   <result pre="the immunohistochemical determination of estrogen receptor status using a breast" exact="cancer" post="tissue microarray Am J Clin Pathol 2002 117 723"/>
   <result pre="485 93 18052927 Su HL Liao CL Lin YL Japanese" exact="encephalitis" post="virus infection initiates endoplasmic reticulum stress and an unfolded"/>
   <result pre="the unfolded protein response, autophagy, and the integrated regulation of" exact="breast cancer" post="cell fate Cancer Res 2012 72 1321 31 22422988"/>
   <result pre="unfolded protein response, autophagy, and the integrated regulation of breast" exact="cancer" post="cell fate Cancer Res 2012 72 1321 31 22422988"/>
   <result pre="overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human" exact="stomach cancer" post="Br J Cancer 1991 64 79 83 1677259 De"/>
   <result pre="of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach" exact="cancer" post="Br J Cancer 1991 64 79 83 1677259 De"/>
   <result pre="12648465 Yarden Y Biology of HER2 and its importance in" exact="breast cancer" post="Oncology 2001 61 Suppl 2 1 13 11694782 Harari"/>
   <result pre="Yarden Y Biology of HER2 and its importance in breast" exact="cancer" post="Oncology 2001 61 Suppl 2 1 13 11694782 Harari"/>
   <result pre="Harari D Yarden Y Molecular mechanisms underlying ErbB2/HER2 action in" exact="breast cancer" post="Oncogene 2000 19 6102 14 11156523 Fendly BM Winget"/>
   <result pre="D Yarden Y Molecular mechanisms underlying ErbB2/HER2 action in breast" exact="cancer" post="Oncogene 2000 19 6102 14 11156523 Fendly BM Winget"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4472207/results/search/disease/results.xml">
   <result pre="a prognostic marker and predictive tool in the treatment of" exact="breast cancer," post="and more recently in esophagogastric cancer 2, 3. In"/>
   <result pre="the treatment of breast cancer, and more recently in esophagogastric" exact="cancer" post="2, 3. In breast cancer, overexpression and ERBB2 DNA"/>
   <result pre="cancer, and more recently in esophagogastric cancer 2, 3. In" exact="breast cancer," post="overexpression and ERBB2 DNA amplification are generally closely linked."/>
   <result pre="and overexpression, mutations in ERBB2 have been reported in multiple" exact="cancer" post="types, including UC, and are oncogenic in vitro 5–"/>
   <result pre="new therapeutic opportunities in selected UC patients 7. Similar to" exact="breast cancer," post="the mechanisms of UC HER2 overexpression include DNA amplification"/>
   <result pre="address these issues, we undertook an analysis of HER2 in" exact="bladder cancer" post="in patients who developed metastatic disease, by evaluating immunohistochemical"/>
   <result pre="these issues, we undertook an analysis of HER2 in bladder" exact="cancer" post="in patients who developed metastatic disease, by evaluating immunohistochemical"/>
   <result pre="performed using the 2010 USCO/CAP HER2 guidelines as established for" exact="breast cancer" post="26, which has been previously employed to assess HER2"/>
   <result pre="using the 2010 USCO/CAP HER2 guidelines as established for breast" exact="cancer" post="26, which has been previously employed to assess HER2"/>
   <result pre="which has been previously employed to assess HER2 expression in" exact="bladder cancer" post="16, 27. HER2 staining and its categorization based on"/>
   <result pre="has been previously employed to assess HER2 expression in bladder" exact="cancer" post="16, 27. HER2 staining and its categorization based on"/>
   <result pre="amplification. Since there is no standard scoring for HER2 in" exact="bladder cancer," post="we followed the protocol used for breast cancer: all"/>
   <result pre="it is a reasonable screening test for HER2 status in" exact="bladder cancer." post="IHC sensitivity for gene amplification is quite low (53%)."/>
   <result pre="large population of patients with metastatic UC. The dependence of" exact="cancer" post="cells on oncogenes for proliferation is well known. Whether"/>
   <result pre="FISH. These findings are similar to those found in HER2-positive" exact="breast cancer" post="33, suggesting that in fact the genomic and IHC"/>
   <result pre="These findings are similar to those found in HER2-positive breast" exact="cancer" post="33, suggesting that in fact the genomic and IHC"/>
   <result pre="raises the hypothesis that there is significant etiologic heterogeneity within" exact="bladder cancer" post="that can lead to these differences. While we cannot"/>
   <result pre="the hypothesis that there is significant etiologic heterogeneity within bladder" exact="cancer" post="that can lead to these differences. While we cannot"/>
   <result pre="alterations are similar to those found in the TCGA for" exact="breast cancer," post="suggesting that these two tumors may share pathways for"/>
   <result pre="also been documented as an oncogenic mutation in gastric and" exact="breast cancer," post="and remains sensitive to lapatinib 32. Although these molecular"/>
   <result pre="(IHC and FISH), and findings of rare oncogenic mutations in" exact="bladder cancer." post="Limitations include the targeted rather than whole gene sequencing"/>
   <result pre="in the management of HER2-positive advanced gastric and gastroesophageal junction" exact="cancer" post="J. Clin. Gastroenterol 2012 46 637 648 22751336 Murphy"/>
   <result pre="Morris PG Recent advances in novel targeted therapies for HER2-positive" exact="breast cancer" post="Anticancer Drugs 2012 23 765 776 22824822 Sauter G"/>
   <result pre="PG Recent advances in novel targeted therapies for HER2-positive breast" exact="cancer" post="Anticancer Drugs 2012 23 765 776 22824822 Sauter G"/>
   <result pre="et al. Activating HER2 mutations in HER2 gene amplification negative" exact="breast cancer" post="Cancer Discov 2013 3 224 237 23220880 Ding L"/>
   <result pre="al. Activating HER2 mutations in HER2 gene amplification negative breast" exact="cancer" post="Cancer Discov 2013 3 224 237 23220880 Ding L"/>
   <result pre="et al. Functional analysis of receptor tyrosine kinase mutations in" exact="lung cancer" post="identifies oncogenic extracellular domain mutations of ERBB2 Proc. Natl."/>
   <result pre="al. Functional analysis of receptor tyrosine kinase mutations in lung" exact="cancer" post="identifies oncogenic extracellular domain mutations of ERBB2 Proc. Natl."/>
   <result pre="P Li Z et al. Whole-genome and whole-exome sequencing of" exact="bladder cancer" post="identifies frequent alterations in genes involved in sister chromatid"/>
   <result pre="Li Z et al. Whole-genome and whole-exome sequencing of bladder" exact="cancer" post="identifies frequent alterations in genes involved in sister chromatid"/>
   <result pre="is significantly more frequent in lymph node metastases from urothelial" exact="bladder cancer" post="than in the primary tumours Eur. Urol 2011 60"/>
   <result pre="significantly more frequent in lymph node metastases from urothelial bladder" exact="cancer" post="than in the primary tumours Eur. Urol 2011 60"/>
   <result pre="amplification as a potential target for therapy in invasive urothelial" exact="bladder cancer" post="with a standardized methodology: results in 1005 patients Ann."/>
   <result pre="as a potential target for therapy in invasive urothelial bladder" exact="cancer" post="with a standardized methodology: results in 1005 patients Ann."/>
   <result pre="al. Prevalence and co-occurrence of actionable genomic alterations in high-grade" exact="bladder cancer" post="J. Clin. Oncol 2013 31 3133 3140 23897969 Coogan"/>
   <result pre="Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder" exact="cancer" post="J. Clin. Oncol 2013 31 3133 3140 23897969 Coogan"/>
   <result pre="Heiss MM c-erbB-2 is of independent prognostic relevance in gastric" exact="cancer" post="and is associated with the expression of tumor-associated protease"/>
   <result pre="Pastan I et al. Expression of HER2 in human gastric" exact="cancer" post="cells directly correlates with antitumor activity of a recombinant"/>
   <result pre="[MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial" exact="cancer" post="J. Clin. Oncol 2011 29 4510 22025166 Hammond ME"/>
   <result pre="American Pathologists guideline recommendations on ER/PgR and HER2 testing in" exact="breast cancer" post="J. Clin. Oncol 2011 29 e458 21502545 Gunia S"/>
   <result pre="Pathologists guideline recommendations on ER/PgR and HER2 testing in breast" exact="cancer" post="J. Clin. Oncol 2011 29 e458 21502545 Gunia S"/>
   <result pre="expression profiles aid in the histologic differential diagnosis between urothelial" exact="carcinoma in situ" post="(CIS) and non-CIS conditions (dysplasia and reactive atypia) of"/>
   <result pre="Defining molecular profiles of poor outcome in patients with invasive" exact="bladder cancer" post="using oligonucleotide microarrays J. Clin. Oncol 2006 24 778"/>
   <result pre="molecular profiles of poor outcome in patients with invasive bladder" exact="cancer" post="using oligonucleotide microarrays J. Clin. Oncol 2006 24 778"/>
   <result pre="Predictive value of progression-related gene classifier in primary non-muscle invasive" exact="bladder cancer" post="Mol. Cancer 2013 9 3 Robinson MD McCarthy DJ"/>
   <result pre="value of progression-related gene classifier in primary non-muscle invasive bladder" exact="cancer" post="Mol. Cancer 2013 9 3 Robinson MD McCarthy DJ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4476721/results/search/disease/results.xml">
   <result pre="of lapatinib with HLA-DRB1*07:01 and its ligand peptide derived from" exact="tetanus" post="toxoid, has been evaluated in vitro. Here we show"/>
   <result pre="pathways approved for the treatment of HER2-positive advanced or metastatic" exact="breast cancer." post="It is used in combination with capecitabine for patients"/>
   <result pre="letrozole for the treatment of postmenopausal women with hormone receptor–positive" exact="breast cancer" post="[ 1, 2]. Although lapatinib has an acceptable safety"/>
   <result pre="for the treatment of postmenopausal women with hormone receptor–positive breast" exact="cancer" post="[ 1, 2]. Although lapatinib has an acceptable safety"/>
   <result pre="A retrospective case–control pharmacogenetic study of ALT elevation in lapatinib-treated" exact="breast cancer" post="patients revealed a strong genetic association between elevated ALT"/>
   <result pre="retrospective case–control pharmacogenetic study of ALT elevation in lapatinib-treated breast" exact="cancer" post="patients revealed a strong genetic association between elevated ALT"/>
   <result pre="rather than competed the binding of ligand peptide derived from" exact="tetanus" post="toxoid (TT) to HLA-DRB1*07:01 in a dose-dependent manner. Also"/>
   <result pre="peptides For in silico analysis, a peptide derived from the" exact="influenza" post="virus, haemagglutinin (HA 306–318), was used for DRB1*01:01 in"/>
   <result pre="T , et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med. 2006; 355: 2733– 2743. 17192538"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post=". J Clin Oncol. 2009; 27: 5538– 5546. doi:"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post=". J Clin Oncol. 2009; 27: 5538– 5546. doi:"/>
   <result pre="JD , et al. Hepatobiliary abnormalities in patients with metastatic" exact="cancer" post="treated with lapatinib. J Clin Oncol. 2009; 27( 51s):"/>
   <result pre="major risk factor for lapatinib-induced hepatotoxicity in women with advanced" exact="breast cancer" post=". J Clin Oncol. 2011; 29: 667– 673. doi:"/>
   <result pre="risk factor for lapatinib-induced hepatotoxicity in women with advanced breast" exact="cancer" post=". J Clin Oncol. 2011; 29: 667– 673. doi:"/>
   <result pre="Kwok WW , Nepom GT , et al. Antibiotic-refractory Lyme" exact="arthritis" post="is associated with HLA-DR molecules that bind a Borrelia"/>
   <result pre="self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug" exact="hypersensitivity" post=". AIDS. 2011; 26( 11): F21– 9. doi: 10.1097/QAD.0b013e328355fe8f"/>
   <result pre="peptides are recognized as T cell antigenic determinants in penicillin" exact="allergy" post=". Eur J Immunol. 1997; 27( 6): 1303– 7."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4477383/results/search/disease/results.xml">
   <result pre="Review Article Management of solitary and multiple brain metastases from" exact="breast cancer" post="Willett Addison 1 Wilkinson J. Ben 1 2 Shah"/>
   <result pre="Article Management of solitary and multiple brain metastases from breast" exact="cancer" post="Willett Addison 1 Wilkinson J. Ben 1 2 Shah"/>
   <result pre="is properly cited. Abstract As local and systemic control of" exact="breast cancer" post="improves, metastasis to the brain remains a common event"/>
   <result pre="properly cited. Abstract As local and systemic control of breast" exact="cancer" post="improves, metastasis to the brain remains a common event"/>
   <result pre="common event requiring a specialized management approach. Women diagnosed with" exact="breast cancer" post="who develop brain metastases have superior overall survival compared"/>
   <result pre="event requiring a specialized management approach. Women diagnosed with breast" exact="cancer" post="who develop brain metastases have superior overall survival compared"/>
   <result pre="some of the unique aspects of care for patients with" exact="breast cancer" post="metastases to the brain. Brain metastasis breast cancer gamma"/>
   <result pre="of the unique aspects of care for patients with breast" exact="cancer" post="metastases to the brain. Brain metastasis breast cancer gamma"/>
   <result pre="patients with breast cancer metastases to the brain. Brain metastasis" exact="breast cancer" post="gamma knife radiosurgery whole brain radiation INTRODUCTION Due to"/>
   <result pre="with breast cancer metastases to the brain. Brain metastasis breast" exact="cancer" post="gamma knife radiosurgery whole brain radiation INTRODUCTION Due to"/>
   <result pre="brain remains an important sanctuary site for many malignancies, including" exact="breast cancer." post="The most common cancers that metastasize to the brain"/>
   <result pre="issue. It is estimated that 10-35% of patients diagnosed with" exact="breast cancer" post="will develop metastasis to the brain.[ 2] Although patients"/>
   <result pre="It is estimated that 10-35% of patients diagnosed with breast" exact="cancer" post="will develop metastasis to the brain.[ 2] Although patients"/>
   <result pre="international guidelines for the evaluation of a new patient with" exact="breast cancer" post="recommend screening for BM only if there are suspicious"/>
   <result pre="guidelines for the evaluation of a new patient with breast" exact="cancer" post="recommend screening for BM only if there are suspicious"/>
   <result pre="ordering an MRI of the brain.[ 6] Treatment options for" exact="breast cancer" post="brain metastases (BCBM) include surgery with/without adjuvant radiotherapy (whole"/>
   <result pre="an MRI of the brain.[ 6] Treatment options for breast" exact="cancer" post="brain metastases (BCBM) include surgery with/without adjuvant radiotherapy (whole"/>
   <result pre="patients diagnosed with BM from other primary malignancies such as" exact="renal cell carcinoma" post="or melanoma.[ 10] Table 1 RPA stages for brain"/>
   <result pre="1 RPA stages for brain metastases[ 7] Among patients with" exact="breast cancer" post="in the initial GPA study, performance status was the"/>
   <result pre="RPA stages for brain metastases[ 7] Among patients with breast" exact="cancer" post="in the initial GPA study, performance status was the"/>
   <result pre="on multivariate analysis. Further analysis, using more variables revealed that" exact="breast cancer" post="subtype,[ 9] as defined by estrogen (ER), progesterone, and"/>
   <result pre="multivariate analysis. Further analysis, using more variables revealed that breast" exact="cancer" post="subtype,[ 9] as defined by estrogen (ER), progesterone, and"/>
   <result pre="have documented length of survival for patients with triple negative" exact="breast cancer" post="who develop BM between to be as short as"/>
   <result pre="documented length of survival for patients with triple negative breast" exact="cancer" post="who develop BM between to be as short as"/>
   <result pre="of diagnosis of BM (17.9 months).[ 10] Unlike triple negative" exact="breast cancer" post="patients, women with HER-2 positive disease are more likely"/>
   <result pre="diagnosis of BM (17.9 months).[ 10] Unlike triple negative breast" exact="cancer" post="patients, women with HER-2 positive disease are more likely"/>
   <result pre="opposed to more modern patient cohorts.[ 15] Table 2 Breast" exact="cancer" post="specific graded prognostic assessment[ 11] TREATMENT OPTIONS Standard treatment"/>
   <result pre="the caveat that the majority of these were patients with" exact="lung cancer," post="and not breast cancer.[ 15] Unique to breast cancer"/>
   <result pre="with lung cancer, and not breast cancer.[ 15] Unique to" exact="breast cancer" post="patients, a dural-based lesion can present a diagnostic challenge"/>
   <result pre="lung cancer, and not breast cancer.[ 15] Unique to breast" exact="cancer" post="patients, a dural-based lesion can present a diagnostic challenge"/>
   <result pre="WBRT is especially important. Possible short-term toxicities of WBRT include" exact="otitis media," post="otitis externa, dermatitis, and alopecia while long term toxicities"/>
   <result pre="especially important. Possible short-term toxicities of WBRT include otitis media," exact="otitis externa," post="dermatitis, and alopecia while long term toxicities include neurocognitive"/>
   <result pre="toxicities of WBRT include otitis media, otitis externa, dermatitis, and" exact="alopecia" post="while long term toxicities include neurocognitive decline, decrease in"/>
   <result pre="is also currently being conducted.[ 47] For patients with HER-2-positive" exact="breast cancer," post="a trial of systemic therapy alone could be considered"/>
   <result pre="with BM mixed with advanced systemic progression.[ 6] Outside of" exact="breast cancer," post="the efficacy of systemic therapy up front or targeted"/>
   <result pre="SUMMARY OF GUIDELINES For patients with a solitary BM from" exact="breast cancer," post="consideration should be given to treat with surgical resection"/>
   <result pre="and less toxic will be important. Quality of life for" exact="breast cancer" post="patients, who are expected to live longer than traditionally"/>
   <result pre="less toxic will be important. Quality of life for breast" exact="cancer" post="patients, who are expected to live longer than traditionally"/>
   <result pre="2 Lin NU Bellon JR Winer EP CNS metastases in" exact="breast cancer" post="J Clin Oncol 2004 22 3608 17 15337811 3"/>
   <result pre="Lin NU Bellon JR Winer EP CNS metastases in breast" exact="cancer" post="J Clin Oncol 2004 22 3608 17 15337811 3"/>
   <result pre="of cerebral metastases in patients treated with trastuzumab for metastatic" exact="breast cancer" post="Br J Cancer 2004 91 639 43 15266327 5"/>
   <result pre="cerebral metastases in patients treated with trastuzumab for metastatic breast" exact="cancer" post="Br J Cancer 2004 91 639 43 15266327 5"/>
   <result pre="for patients with advanced human epidermal growth factor receptor 2-positive" exact="breast cancer" post="and brain metastases: American Society of Clinical Oncology clinical"/>
   <result pre="patients with advanced human epidermal growth factor receptor 2-positive breast" exact="cancer" post="and brain metastases: American Society of Clinical Oncology clinical"/>
   <result pre="al. The accuracy of predicting survival in individual patients with" exact="cancer" post="J Neurosurg 2014 120 24 30 24160479 8 Gaspar"/>
   <result pre="to development of brain metastases and survival in patients with" exact="breast cancer" post="J Neurooncol 2013 112 467 72 23462853 12 Anders"/>
   <result pre="development of brain metastases and survival in patients with breast" exact="cancer" post="J Neurooncol 2013 112 467 72 23462853 12 Anders"/>
   <result pre="H Burrows E et al. The prognostic contribution of clinical" exact="breast cancer" post="subtype, age, and race among patients with breast cancer"/>
   <result pre="Burrows E et al. The prognostic contribution of clinical breast" exact="cancer" post="subtype, age, and race among patients with breast cancer"/>
   <result pre="clinical breast cancer subtype, age, and race among patients with" exact="breast cancer" post="brain metastases Cancer 2011 117 1602 11 21472708 13"/>
   <result pre="breast cancer subtype, age, and race among patients with breast" exact="cancer" post="brain metastases Cancer 2011 117 1602 11 21472708 13"/>
   <result pre="37 23956241 37 DeAngelis LM Delattre JY Posner JB Radiation-induced" exact="dementia" post="in patients cured of brain metastases Neurology 1989 39"/>
   <result pre="EM van der Sande JJ Response of brain metastases from" exact="breast cancer" post="to systemic chemotherapy Cancer 1992 69 972 80 1735089"/>
   <result pre="van der Sande JJ Response of brain metastases from breast" exact="cancer" post="to systemic chemotherapy Cancer 1992 69 972 80 1735089"/>
   <result pre="iniparib in combination with irinotecan to treat progressive triple negative" exact="breast cancer" post="brain metastases Breast Cancer Res and Treat 2014 146"/>
   <result pre="in combination with irinotecan to treat progressive triple negative breast" exact="cancer" post="brain metastases Breast Cancer Res and Treat 2014 146"/>
   <result pre="and PET imaging of HER2-positive lesions in patients with metastatic" exact="breast cancer" post="Clin Pharmacol Ther 2010 87 586 92 20357763 43"/>
   <result pre="PET imaging of HER2-positive lesions in patients with metastatic breast" exact="cancer" post="Clin Pharmacol Ther 2010 87 586 92 20357763 43"/>
   <result pre="control and durable prolongation of systemic extracranial disease in HER2-overexpressing" exact="breast cancer" post="patients Br J Cancer 2009 100 894 900 19240719"/>
   <result pre="and durable prolongation of systemic extracranial disease in HER2-overexpressing breast" exact="cancer" post="patients Br J Cancer 2009 100 894 900 19240719"/>
   <result pre="et al. Effect of lapatinib on the outgrowth of metastatic" exact="breast cancer" post="cells to the brain J Natl Cancer Inst 2008"/>
   <result pre="al. Effect of lapatinib on the outgrowth of metastatic breast" exact="cancer" post="cells to the brain J Natl Cancer Inst 2008"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 43 17192538"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 43 17192538"/>
   <result pre="in patients with previously untreated brain metastases from HER2-positive metastatic" exact="breast cancer" post="(LANDSCAPE): A single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="patients with previously untreated brain metastases from HER2-positive metastatic breast" exact="cancer" post="(LANDSCAPE): A single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="WBRT and SRS with temozolomide or erlotinib for non-small cell" exact="lung cancer" post="and 1 to 3 brain metastases: Radiation Therapy Oncology"/>
   <result pre="and SRS with temozolomide or erlotinib for non-small cell lung" exact="cancer" post="and 1 to 3 brain metastases: Radiation Therapy Oncology"/>
   <result pre="observation for patients with asymptomatic cerebral oligo-metastases in non-small cell" exact="lung cancer" post="(NSCLC). Oral Presentation at 2014 Annual Meeting of American"/>
   <result pre="for patients with asymptomatic cerebral oligo-metastases in non-small cell lung" exact="cancer" post="(NSCLC). Oral Presentation at 2014 Annual Meeting of American"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4479882/results/search/disease/results.xml">
   <result pre="agents, would be an effective antitumor strategy in preclinical HER2+" exact="breast cancer" post="models of trastuzumab and lapatinib resistance. We developed and"/>
   <result pre="would be an effective antitumor strategy in preclinical HER2+ breast" exact="cancer" post="models of trastuzumab and lapatinib resistance. We developed and"/>
   <result pre="FASN and HER2 pathways is effective in cells and in" exact="breast cancer" post="models refractory to anti-HER2 therapies. Funding This work was"/>
   <result pre="and HER2 pathways is effective in cells and in breast" exact="cancer" post="models refractory to anti-HER2 therapies. Funding This work was"/>
   <result pre="the first approved therapy for the treatment of HER2-positive (HER2+)" exact="breast cancer." post="Despite the considerable clinical benefit provided, a large fraction"/>
   <result pre="HER2, was found to improve time to progression in HER2" exact="breast cancer" post="patients who had progressed to tratuzumab [ 7]. Lapatinib"/>
   <result pre="was found to improve time to progression in HER2 breast" exact="cancer" post="patients who had progressed to tratuzumab [ 7]. Lapatinib"/>
   <result pre="and the toxic effects of classical FASN inhibitors, in HER2+" exact="breast cancer" post="cells and mouse models [ 19, 28, 29]. Among"/>
   <result pre="the toxic effects of classical FASN inhibitors, in HER2+ breast" exact="cancer" post="cells and mouse models [ 19, 28, 29]. Among"/>
   <result pre="effect, alone or in combination with anti-HER drugs, in HER2+" exact="breast cancer" post="cells and on breast cancer cells resistant to trastuzumab"/>
   <result pre="alone or in combination with anti-HER drugs, in HER2+ breast" exact="cancer" post="cells and on breast cancer cells resistant to trastuzumab"/>
   <result pre="with anti-HER drugs, in HER2+ breast cancer cells and on" exact="breast cancer" post="cells resistant to trastuzumab [ 29]. In this study,"/>
   <result pre="anti-HER drugs, in HER2+ breast cancer cells and on breast" exact="cancer" post="cells resistant to trastuzumab [ 29]. In this study,"/>
   <result pre="(SK LR) and trastuzumab plus lapatinib (SK TLR) resistant HER2+" exact="breast cancer" post="models. In addition, we analyzed the antitumor activity of"/>
   <result pre="LR) and trastuzumab plus lapatinib (SK TLR) resistant HER2+ breast" exact="cancer" post="models. In addition, we analyzed the antitumor activity of"/>
   <result pre="Materials and Methods Cell culture and development of long-term resistant" exact="breast cancer" post="cells SKBr3 (SK) breast carcinoma cells were obtained from"/>
   <result pre="and Methods Cell culture and development of long-term resistant breast" exact="cancer" post="cells SKBr3 (SK) breast carcinoma cells were obtained from"/>
   <result pre="breast tumor PDX (patient-derived xenografts) experiments Tumor chunks from HER2+" exact="breast cancer" post="patient and HER2+ patient who relapsed after trastuzumab and"/>
   <result pre="tumor PDX (patient-derived xenografts) experiments Tumor chunks from HER2+ breast" exact="cancer" post="patient and HER2+ patient who relapsed after trastuzumab and"/>
   <result pre="of trastuzumab (SKTR), lapatinib (SKLR) and lapatinib plus trastuzumab-resistant (SKLTR)" exact="breast cancer" post="cells As preclinical models of acquired resistance to anti-HER2"/>
   <result pre="trastuzumab (SKTR), lapatinib (SKLR) and lapatinib plus trastuzumab-resistant (SKLTR) breast" exact="cancer" post="cells As preclinical models of acquired resistance to anti-HER2"/>
   <result pre="to anti-HER2 drugs, we developed a panel of resistant HER2+" exact="breast cancer" post="cells (SK) with long-term (12 months) and high drug"/>
   <result pre="anti-HER2 drugs, we developed a panel of resistant HER2+ breast" exact="cancer" post="cells (SK) with long-term (12 months) and high drug"/>
   <result pre="resistance (combining several natural chemotherapeutic drugs) have been associated with" exact="cancer" post="invasion and metastasis [ 35, 36]. Hence, we wanted"/>
   <result pre="EGCG and G28UCM, with pertuzumab in parental and resistant HER2+" exact="breast cancer" post="cells is more active than either of the drugs"/>
   <result pre="and G28UCM, with pertuzumab in parental and resistant HER2+ breast" exact="cancer" post="cells is more active than either of the drugs"/>
   <result pre="temsirolimus could have a relevant effect in patients with HER2" exact="breast cancer," post="even those that have progressed to anti-HER2 therapies, and"/>
   <result pre="the remarkable success of anti-HER2 therapies, patients with advanced HER2-positive" exact="breast cancer" post="frequently display primary resistance and, in patients initially sensitive"/>
   <result pre="remarkable success of anti-HER2 therapies, patients with advanced HER2-positive breast" exact="cancer" post="frequently display primary resistance and, in patients initially sensitive"/>
   <result pre="has been directly related with sensitivity to anti-HER2 drugs in" exact="breast cancer" post="[ 42] whereas in prostate cancer an increase of"/>
   <result pre="been directly related with sensitivity to anti-HER2 drugs in breast" exact="cancer" post="[ 42] whereas in prostate cancer an increase of"/>
   <result pre="to anti-HER2 drugs in breast cancer [ 42] whereas in" exact="prostate cancer" post="an increase of HER4 expression has been shown to"/>
   <result pre="anti-HER2 drugs in breast cancer [ 42] whereas in prostate" exact="cancer" post="an increase of HER4 expression has been shown to"/>
   <result pre="[ 46]. Also, it is described that MAPK inhibit the" exact="tuberous sclerosis" post="complex (TSC1/TSC2), which in turn inhibits mTOR activation ["/>
   <result pre="and chemotherapy, in parental and trastuzumab- or lapatinib-resistant AU565 HER2" exact="breast cancer" post="cells [ 29]. Several studies have used mTOR inhibition"/>
   <result pre="chemotherapy, in parental and trastuzumab- or lapatinib-resistant AU565 HER2 breast" exact="cancer" post="cells [ 29]. Several studies have used mTOR inhibition"/>
   <result pre="between mTOR and FASN inhibition to induce cytotoxicity in ER/HER2-positive" exact="breast cancer" post="cell lines [ 50]. These in vitro results support"/>
   <result pre="mTOR and FASN inhibition to induce cytotoxicity in ER/HER2-positive breast" exact="cancer" post="cell lines [ 50]. These in vitro results support"/>
   <result pre="apoptosis in a resistant oropharyngeal carcinoma cell line [ 53]," exact="colorectal cancer" post="cells [ 54] and other cancers. But little, if"/>
   <result pre="in a resistant oropharyngeal carcinoma cell line [ 53], colorectal" exact="cancer" post="cells [ 54] and other cancers. But little, if"/>
   <result pre="But little, if any, apoptosis has been seen in different" exact="breast cancer" post="cell lines treated with temsirolimus [ 55]. In this"/>
   <result pre="little, if any, apoptosis has been seen in different breast" exact="cancer" post="cell lines treated with temsirolimus [ 55]. In this"/>
   <result pre="this study, we demonstrate that tumor growth inhibition in HER2" exact="breast cancer" post="PDX (non-resistant and resistant) occurs by apoptotic event in"/>
   <result pre="study, we demonstrate that tumor growth inhibition in HER2 breast" exact="cancer" post="PDX (non-resistant and resistant) occurs by apoptotic event in"/>
   <result pre="a potential combinatorial available in the clinical management of HER2-positive" exact="breast cancer" post="patients who progressed to standard treatments. In this study,"/>
   <result pre="potential combinatorial available in the clinical management of HER2-positive breast" exact="cancer" post="patients who progressed to standard treatments. In this study,"/>
   <result pre="novel mono- and dual- long term trastuzumab plus lapatinib resistant" exact="breast cancer" post="models to find out new pharmacological strategies to overcome"/>
   <result pre="mono- and dual- long term trastuzumab plus lapatinib resistant breast" exact="cancer" post="models to find out new pharmacological strategies to overcome"/>
   <result pre="of FASN activity in combination with anti-HER2 signaling agents in" exact="breast cancer" post="refractory to anti-HER2 therapies. Supporting Information S1 File Additional"/>
   <result pre="FASN activity in combination with anti-HER2 signaling agents in breast" exact="cancer" post="refractory to anti-HER2 therapies. Supporting Information S1 File Additional"/>
   <result pre="R , et al. ErbB receptors: from oncogenes to targeted" exact="cancer" post="therapies. J Clin Invest. 2007; 117( 8): 2051– 8."/>
   <result pre="T , et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med. 2006; 355( 26): 2733– 43."/>
   <result pre="of the HER2 receptor, and response to anti-HER2 therapies in" exact="breast cancer" post=". J Natl Cancer Inst. 2007; 99( 8): 628–"/>
   <result pre="the HER2 receptor, and response to anti-HER2 therapies in breast" exact="cancer" post=". J Natl Cancer Inst. 2007; 99( 8): 628–"/>
   <result pre="Mechanisms of disease: understanding resistance to HER2-targeted therapy in human" exact="breast cancer" post=". Nat Clin Pract Oncol. 2006; 3( 5): 269–"/>
   <result pre="of disease: understanding resistance to HER2-targeted therapy in human breast" exact="cancer" post=". Nat Clin Pract Oncol. 2006; 3( 5): 269–"/>
   <result pre=". Molecular predictors of response to trastuzumab and lapatinib in" exact="breast cancer." post="Nat Rev Clin Oncol. 2010; 7( 2): 98– 107."/>
   <result pre=", Porta R , et al. Fatty acid metabolism in" exact="breast cancer" post="cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and"/>
   <result pre="Porta R , et al. Fatty acid metabolism in breast" exact="cancer" post="cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and"/>
   <result pre="et al. Interaction between fatty acid synthase- and ErbB-systems in" exact="ovarian cancer" post="cells. Biochem Biophys Res Commun. 2009; 385( 3): 454–"/>
   <result pre="al. Interaction between fatty acid synthase- and ErbB-systems in ovarian" exact="cancer" post="cells. Biochem Biophys Res Commun. 2009; 385( 3): 454–"/>
   <result pre="Fatty acid synthase: a metabolic enzyme and candidate oncogene in" exact="prostate cancer." post="J Natl Cancer Inst. 2009; 101( 7): 519– 32."/>
   <result pre="novel inhibitor of fatty acid synthase shows activity against HER2+" exact="breast cancer" post="xenografts and is active in anti-HER2 drug-resistant cell lines"/>
   <result pre="inhibitor of fatty acid synthase shows activity against HER2+ breast" exact="cancer" post="xenografts and is active in anti-HER2 drug-resistant cell lines"/>
   <result pre="PubMed Central PMCID: PMCPMC3326573. 22177475 30 Trempe GL . Human" exact="breast cancer" post="in culture. Recent Results Cancer Res. 1976;( 57): 33–"/>
   <result pre="Central PMCID: PMCPMC3326573. 22177475 30 Trempe GL . Human breast" exact="cancer" post="in culture. Recent Results Cancer Res. 1976;( 57): 33–"/>
   <result pre=". In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant" exact="breast cancer" post="cells . Cancer Chemother Pharmacol. 2004; 53( 2): 186–"/>
   <result pre="In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast" exact="cancer" post="cells . Cancer Chemother Pharmacol. 2004; 53( 2): 186–"/>
   <result pre="Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+" exact="breast cancer" post=". Ann N Y Acad Sci. 2010; 1210: 86–"/>
   <result pre="anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast" exact="cancer" post=". Ann N Y Acad Sci. 2010; 1210: 86–"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer." post="Science. 1989; 244( 4905): 707– 12. . 2470152 35"/>
   <result pre="McDonnell S , Clynes M . Examining the relationship between" exact="cancer" post="invasion/metastasis and drug resistance. Curr Cancer Drug Targets. 2002;"/>
   <result pre=". EGFR over-expression and activation in high HER2, ER negative" exact="breast cancer" post="cell line induces trastuzumab resistance . Breast Cancer Res"/>
   <result pre="EGFR over-expression and activation in high HER2, ER negative breast" exact="cancer" post="cell line induces trastuzumab resistance . Breast Cancer Res"/>
   <result pre=", Dugger T , Engelman JA , et al. Human" exact="breast cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="Dugger T , Engelman JA , et al. Human breast" exact="cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive" exact="breast cancer" post=". Breast Cancer Res Treat. 2011; 125( 1): 107–"/>
   <result pre="predicts poor response to lapatinib and capecitabine in HER2-positive breast" exact="cancer" post=". Breast Cancer Res Treat. 2011; 125( 1): 107–"/>
   <result pre="associates with increased sensitivity to Herceptin in patients with metastatic" exact="breast cancer" post=". Breast Cancer Res. 2009; 11( 4): R50 doi:"/>
   <result pre="with increased sensitivity to Herceptin in patients with metastatic breast" exact="cancer" post=". Breast Cancer Res. 2009; 11( 4): R50 doi:"/>
   <result pre=", Oliveras G , Pandiella A , et al. Androgen-independent" exact="prostate cancer" post="cells circumvent EGFR inhibition by overexpression of alternative HER"/>
   <result pre="Oliveras G , Pandiella A , et al. Androgen-independent prostate" exact="cancer" post="cells circumvent EGFR inhibition by overexpression of alternative HER"/>
   <result pre="PI3K pathway as a major determinant of trastuzumab resistance in" exact="breast cancer" post=". Cancer Cell. 2007; 12( 4): 395– 402. doi:"/>
   <result pre="pathway as a major determinant of trastuzumab resistance in breast" exact="cancer" post=". Cancer Cell. 2007; 12( 4): 395– 402. doi:"/>
   <result pre=", Anjum R , Blenis J . Inactivation of the" exact="tuberous sclerosis" post="complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent"/>
   <result pre=", et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced" exact="breast cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial ."/>
   <result pre="et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast" exact="cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial ."/>
   <result pre="et al. Treatment of human epidermal growth factor receptor 2-overexpressing" exact="breast cancer" post="xenografts with multiagent HER-targeted therapy . J Natl Cancer"/>
   <result pre="al. Treatment of human epidermal growth factor receptor 2-overexpressing breast" exact="cancer" post="xenografts with multiagent HER-targeted therapy . J Natl Cancer"/>
   <result pre="HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of" exact="breast cancer" post="cells . Cancer Res. 2004; 64( 7): 2343– 6."/>
   <result pre="antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast" exact="cancer" post="cells . Cancer Res. 2004; 64( 7): 2343– 6."/>
   <result pre="Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against" exact="colorectal cancer" post="cells . J Cancer Res Clin Oncol. 2014; 140("/>
   <result pre="and chloroquine cooperatively exhibit a potent antitumor effect against colorectal" exact="cancer" post="cells . J Cancer Res Clin Oncol. 2014; 140("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4484424/results/search/disease/results.xml">
   <result pre="oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human" exact="pancreatic cancer" post="cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2"/>
   <result pre="receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic" exact="cancer" post="cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2"/>
   <result pre="of patients eligible for either gemcitabine or FOLFIRINOX treatment. ErbB2" exact="pancreatic cancer" post="gemcitabine FOLFIRINOX chemoresistance INTRODUCTION Pancreatic adenocarcinoma (PDAC) is one"/>
   <result pre="patients eligible for either gemcitabine or FOLFIRINOX treatment. ErbB2 pancreatic" exact="cancer" post="gemcitabine FOLFIRINOX chemoresistance INTRODUCTION Pancreatic adenocarcinoma (PDAC) is one"/>
   <result pre="is the main chemotherapeutic drug used in firstline in advanced" exact="pancreatic cancer" post="(PC). Despite the improvement of patient's quality of life,"/>
   <result pre="the main chemotherapeutic drug used in firstline in advanced pancreatic" exact="cancer" post="(PC). Despite the improvement of patient's quality of life,"/>
   <result pre="chemotherapeutic drug treatment is a major challenge for clinicians in" exact="pancreatic cancer" post="because it is responsible for the inefficiency of therapies."/>
   <result pre="drug treatment is a major challenge for clinicians in pancreatic" exact="cancer" post="because it is responsible for the inefficiency of therapies."/>
   <result pre="for the first time that the loss of ErbB2 sensitizes" exact="pancreatic cancer" post="cells to gemcitabine treatment. We also show that hCNT1"/>
   <result pre="the first time that the loss of ErbB2 sensitizes pancreatic" exact="cancer" post="cells to gemcitabine treatment. We also show that hCNT1"/>
   <result pre="that ErbB2 inhibition improved the cytoxic effect of gemcitabine in" exact="prostate cancer" post="cells [ 17]. We had also previously showed that"/>
   <result pre="ErbB2 inhibition improved the cytoxic effect of gemcitabine in prostate" exact="cancer" post="cells [ 17]. We had also previously showed that"/>
   <result pre="receptor ErbB2 [ 12] and that loss of MUC4 in" exact="pancreatic cancer" post="cells led to an increased sensitivity to gemcitabine and"/>
   <result pre="ErbB2 [ 12] and that loss of MUC4 in pancreatic" exact="cancer" post="cells led to an increased sensitivity to gemcitabine and"/>
   <result pre="a drug resistant phenotype. The loss of ErbB2 in CAPAN-2" exact="pancreatic cancer" post="cells induces an increase of SN-38 chemoresistance. In gastric"/>
   <result pre="drug resistant phenotype. The loss of ErbB2 in CAPAN-2 pancreatic" exact="cancer" post="cells induces an increase of SN-38 chemoresistance. In gastric"/>
   <result pre="a similar complex interplay involving ErbB2, p53 and autophagy in" exact="pancreatic cancer." post="In this report, we show that NF-κB, Erk and"/>
   <result pre="survival in response to SN-38 treatment. On the contrary, in" exact="colon cancer" post="cells, treatment with an Erk inhibitor enhanced SN-38 antitumor"/>
   <result pre="in response to SN-38 treatment. On the contrary, in colon" exact="cancer" post="cells, treatment with an Erk inhibitor enhanced SN-38 antitumor"/>
   <result pre="described as directly involved in acquired resistance to SN-38 in" exact="colon cancer" post="cells [ 30, 31]. Mohelnikova-Duchonova et al described the"/>
   <result pre="as directly involved in acquired resistance to SN-38 in colon" exact="cancer" post="cells [ 30, 31]. Mohelnikova-Duchonova et al described the"/>
   <result pre="in a variety of tumors such as gallbladder carcinoma or" exact="breast cancer" post="[ 33, 34]. MRP1 and MRP2 were previously shown"/>
   <result pre="a variety of tumors such as gallbladder carcinoma or breast" exact="cancer" post="[ 33, 34]. MRP1 and MRP2 were previously shown"/>
   <result pre="http://www.biomarkersconsortium.org)&quot; [ 36]. However, despite the discovery of thousands of" exact="cancer" post="markers over the past decades, no new major cancer"/>
   <result pre="of cancer markers over the past decades, no new major" exact="cancer" post="biomarkers have been approved for clinical use for at"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 69 90"/>
   <result pre="A Herman J Schulick R Hruban RH Goggins M Pancreatic" exact="cancer" post="Lancet 2011 378 607 620 21620466 3 Rahib L"/>
   <result pre="C Assenat E et al. FOLFIRINOX versus gemcitabine for metastatic" exact="pancreatic cancer" post="N Engl J Med 2011 364 1817 1825 21561347"/>
   <result pre="Assenat E et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic" exact="cancer" post="N Engl J Med 2011 364 1817 1825 21561347"/>
   <result pre="its signaling and transforming functions and its role in human" exact="cancer" post="pathogenesis Oncogene 2007 26 6469 6487 17471238 10 Stoecklein"/>
   <result pre="K HER2 overexpression correlates with survival after curative resection of" exact="pancreatic cancer" post="Cancer Sci 2009 100 1243 1247 19432892 12 Jonckheere"/>
   <result pre="HER2 overexpression correlates with survival after curative resection of pancreatic" exact="cancer" post="Cancer Sci 2009 100 1243 1247 19432892 12 Jonckheere"/>
   <result pre="its membrane partner ErbB2 regulate biological properties of human CAPAN-2" exact="pancreatic cancer" post="cells via different signalling pathways PLoS One 2012 7"/>
   <result pre="membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic" exact="cancer" post="cells via different signalling pathways PLoS One 2012 7"/>
   <result pre="Jonckheere N The MUC4 mucin mediates gemcitabine resistance of human" exact="pancreatic cancer" post="cells via the Concentrative Nucleoside Transporter family Oncogene 2013"/>
   <result pre="N The MUC4 mucin mediates gemcitabine resistance of human pancreatic" exact="cancer" post="cells via the Concentrative Nucleoside Transporter family Oncogene 2013"/>
   <result pre="dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric" exact="cancer" post="cells to the irinotecan active metabolite SN-38 Int J"/>
   <result pre="D Role of efflux pump activity in lapatinib/caelyx combination in" exact="breast cancer" post="cell lines Anticancer Drugs 2009 20 918 925 19752719"/>
   <result pre="Role of efflux pump activity in lapatinib/caelyx combination in breast" exact="cancer" post="cell lines Anticancer Drugs 2009 20 918 925 19752719"/>
   <result pre="Batra SK Lin MF Suppression of ErbB-2 in androgen-independent human" exact="prostate cancer" post="cells enhances cytotoxic effect by gemcitabine in an androgen-reduced"/>
   <result pre="SK Lin MF Suppression of ErbB-2 in androgen-independent human prostate" exact="cancer" post="cells enhances cytotoxic effect by gemcitabine in an androgen-reduced"/>
   <result pre="effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric" exact="cancer" post="cells depending on administration sequence Anticancer Res 2012 32"/>
   <result pre="Palmieri M Donadelli M Autophagy induced by p53-reactivating molecules protects" exact="pancreatic cancer" post="cells from apoptosis Apoptosis 2013 18 337 346 23238993"/>
   <result pre="M Donadelli M Autophagy induced by p53-reactivating molecules protects pancreatic" exact="cancer" post="cells from apoptosis Apoptosis 2013 18 337 346 23238993"/>
   <result pre="AR Signal integration by JNK and p38 MAPK pathways in" exact="cancer" post="development Nat Rev Cancer 2009 9 537 549 19629069"/>
   <result pre="Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against" exact="multiple myeloma" post="Cancer Res 2004 64 8746 8753 15574786 27 Yu"/>
   <result pre="Ludwig JA Booth-Genthe C Gottesman MM Targeting multidrug resistance in" exact="cancer" post="Nat Rev Drug Discov 2006 5 219 234 16518375"/>
   <result pre="Pau B Martineau P Del Rio M ABCG2 overexpression in" exact="colon cancer" post="cells resistant to SN38 and in irinotecan-treated metastases Int"/>
   <result pre="B Martineau P Del Rio M ABCG2 overexpression in colon" exact="cancer" post="cells resistant to SN38 and in irinotecan-treated metastases Int"/>
   <result pre="M Robert B Gongora C Sorafenib overcomes irinotecan resistance in" exact="colorectal cancer" post="by inhibiting the ABCG2 drug-efflux pump Mol Cancer Ther"/>
   <result pre="Robert B Gongora C Sorafenib overcomes irinotecan resistance in colorectal" exact="cancer" post="by inhibiting the ABCG2 drug-efflux pump Mol Cancer Ther"/>
   <result pre="JH Lee HS Cho JY Yoon YS Han HS Breast" exact="cancer" post="resistance protein expression is associated with early recurrence and"/>
   <result pre="is associated with early recurrence and decreased survival in resectable" exact="pancreatic cancer" post="patients Pathol Int 2012 62 167 175 22360504 36"/>
   <result pre="associated with early recurrence and decreased survival in resectable pancreatic" exact="cancer" post="patients Pathol Int 2012 62 167 175 22360504 36"/>
   <result pre="I Pigny P Tumour growth and resistance to gemcitabine of" exact="pancreatic cancer" post="cells are decreased by AP-2alpha overexpression Br J Cancer"/>
   <result pre="Pigny P Tumour growth and resistance to gemcitabine of pancreatic" exact="cancer" post="cells are decreased by AP-2alpha overexpression Br J Cancer"/>
   <result pre="mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal" exact="cancer" post="cells is mediated by hepatocyte nuclear factor 1alpha Biochem"/>
   <result pre="of the human mucin gene MUC5B in different phenotypes of" exact="colon cancer" post="cells Biochem J 2000 348 Pt 3 675 686"/>
   <result pre="the human mucin gene MUC5B in different phenotypes of colon" exact="cancer" post="cells Biochem J 2000 348 Pt 3 675 686"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4488128/results/search/disease/results.xml">
   <result pre="immune correlate to pathologic response following neoadjuvant therapy in HER2-positive" exact="breast cancer" post="Datta Jashodeep Jashodeep.datta@uphs.upenn.edu Berk Erik erik.berk@uphs.upenn.edu Xu Shuwen wenleiwa@mail.med.upenn.edu"/>
   <result pre="correlate to pathologic response following neoadjuvant therapy in HER2-positive breast" exact="cancer" post="Datta Jashodeep Jashodeep.datta@uphs.upenn.edu Berk Erik erik.berk@uphs.upenn.edu Xu Shuwen wenleiwa@mail.med.upenn.edu"/>
   <result pre="type 1 (Th1) immune responses is observed in HER2 pos-invasive" exact="breast cancer" post="(IBC) patients relative to healthy controls. Pathologic complete response"/>
   <result pre="1 (Th1) immune responses is observed in HER2 pos-invasive breast" exact="cancer" post="(IBC) patients relative to healthy controls. Pathologic complete response"/>
   <result pre="in healthy volunteers and patients harboring HER2 neg (0–1+) invasive" exact="breast cancer" post="(IBC). In patients with HER2 pos IBC, this anti-HER2"/>
   <result pre="healthy volunteers and patients harboring HER2 neg (0–1+) invasive breast" exact="cancer" post="(IBC). In patients with HER2 pos IBC, this anti-HER2"/>
   <result pre="(Fig. 1). pCR was defined as absence of residual invasive" exact="cancer" post="on pathologic examination of resected breast specimen(s) and sampled"/>
   <result pre="HER2 pos Human epidermal growth factor receptor overexpressing, IBC invasive" exact="breast cancer," post="T + C trastuzumab and chemotherapy, AJCC American Joint"/>
   <result pre="human epidermal growth factor receptor 2-positive ( HER2 pos )" exact="breast cancer" post="were enrolled; all tumors were histologically confirmed as invasive"/>
   <result pre="epidermal growth factor receptor 2-positive ( HER2 pos ) breast" exact="cancer" post="were enrolled; all tumors were histologically confirmed as invasive"/>
   <result pre="cancer were enrolled; all tumors were histologically confirmed as invasive" exact="breast cancer" post="( IBC) with HER2 overexpression (3+ or 2+/fluorescence in"/>
   <result pre="were enrolled; all tumors were histologically confirmed as invasive breast" exact="cancer" post="( IBC) with HER2 overexpression (3+ or 2+/fluorescence in"/>
   <result pre="stimuli Candida albicans (Allermed Laboratories, San Diego, CA, USA) and" exact="tetanus" post="toxoid (Santa Cruz Biotechnology, Dallas, TX, USA). An empiric"/>
   <result pre="T cell response variations in HER2 pos patients with invasive" exact="breast cancer" post="(IBC). IFN-γ enzyme-linked immunosorbent spot analysis of HER2 peptide-pulsed"/>
   <result pre="cell response variations in HER2 pos patients with invasive breast" exact="cancer" post="(IBC). IFN-γ enzyme-linked immunosorbent spot analysis of HER2 peptide-pulsed"/>
   <result pre="analysis (ELISPOT) are observed in patients with HER2 pos invasive" exact="breast cancer" post="achieving pCR (n = 16) following neoadjuvant trastuzumab and"/>
   <result pre="(ELISPOT) are observed in patients with HER2 pos invasive breast" exact="cancer" post="achieving pCR (n = 16) following neoadjuvant trastuzumab and"/>
   <result pre="measured by IFN-γ production to anti-CD3/anti-CD28 stimulus or recall stimuli" exact="tetanus" post="toxoid and Candida albicans – by enzyme-linked immunosorbent spot."/>
   <result pre="vivo [ 12, 18]. When employed in HER2 pos ductal" exact="carcinoma in situ" post="(DCIS) and patients with stage I HER2 pos IBC"/>
   <result pre="factor receptor 2, DC1 type 1-polarized dendritic cell, IBC invasive" exact="breast cancer," post="HLA human leukocyte antigen (A2 yes/no), ER estrogen receptor,"/>
   <result pre="SFC to anti-CD3/anti-CD28 stimulus serves as positive control. Abbreviations BC" exact="breast cancer" post="BMI body mass index DC dendritic cell DC1 type"/>
   <result pre="to anti-CD3/anti-CD28 stimulus serves as positive control. Abbreviations BC breast" exact="cancer" post="BMI body mass index DC dendritic cell DC1 type"/>
   <result pre="HER2 pos human epidermal growth factor receptor 2-positive IBC invasive" exact="breast cancer" post="iDC immature dendritic cells IFN interferon IHC immunohistochemistry IL"/>
   <result pre="pos human epidermal growth factor receptor 2-positive IBC invasive breast" exact="cancer" post="iDC immature dendritic cells IFN interferon IHC immunohistochemistry IL"/>
   <result pre="Hortobagyi GN Hunt KK HER2/neu in the management of invasive" exact="breast cancer" post="J Am Coll Surg 2002 194 4 488 501"/>
   <result pre="GN Hunt KK HER2/neu in the management of invasive breast" exact="cancer" post="J Am Coll Surg 2002 194 4 488 501"/>
   <result pre="SJ Pathological features and prognosis of different molecular subtypes of" exact="breast cancer" post="Mol Med Rep 2012 6 4 779 82 22797840"/>
   <result pre="Pathological features and prognosis of different molecular subtypes of breast" exact="cancer" post="Mol Med Rep 2012 6 4 779 82 22797840"/>
   <result pre="Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1659 72"/>
   <result pre="I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1659 72"/>
   <result pre="Swaby RF et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="RF et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced" exact="breast cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast" exact="cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="with trastuzumab predicts for improved survival in women with HER2-overexpressing" exact="breast cancer" post="Ann Oncol 2013 24 8 1999 2004 10.1093/annonc/mdt131 23562929"/>
   <result pre="trastuzumab predicts for improved survival in women with HER2-overexpressing breast" exact="cancer" post="Ann Oncol 2013 24 8 1999 2004 10.1093/annonc/mdt131 23562929"/>
   <result pre="to the HER-2/neu oncogenic protein in patients with breast and" exact="ovarian cancer" post="using a peptide-based vaccine Clin Cancer Res 1999 5"/>
   <result pre="the HER-2/neu oncogenic protein in patients with breast and ovarian" exact="cancer" post="using a peptide-based vaccine Clin Cancer Res 1999 5"/>
   <result pre="induction of durable Th1-polarized anti-HER-2/neu responses in women with early" exact="breast cancer" post="J Immunother 2012 35 1 54 65 10.1097/CJI.0b013e318235f512 22130160"/>
   <result pre="of durable Th1-polarized anti-HER-2/neu responses in women with early breast" exact="cancer" post="J Immunother 2012 35 1 54 65 10.1097/CJI.0b013e318235f512 22130160"/>
   <result pre="dendritic cell vaccine can eliminate HER-2 expression and impact ductal" exact="carcinoma in situ" post="Cancer 2012 118 17 4354 62 10.1002/cncr.26734 22252842 16."/>
   <result pre="S Roses RE et al. Optimizing dendritic cell-based approaches for" exact="cancer" post="immunotherapy Yale J Biol Med 2014 87 4 491"/>
   <result pre="as an independent predictor of response to neoadjuvant chemotherapy in" exact="breast cancer" post="J Clin Oncol 2010 28 1 105 13 10.1200/JCO.2009.23.7370"/>
   <result pre="an independent predictor of response to neoadjuvant chemotherapy in breast" exact="cancer" post="J Clin Oncol 2010 28 1 105 13 10.1200/JCO.2009.23.7370"/>
   <result pre="Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive" exact="breast cancer" post="Cancer Res 2013 73 S1 05 28. Bellati F"/>
   <result pre="infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast" exact="cancer" post="Cancer Res 2013 73 S1 05 28. Bellati F"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4491676/results/search/disease/results.xml">
   <result pre="various studies revealing that restoration of PP2A activity benefits some" exact="cancer" post="patients. However, our understanding of the mechanism of action"/>
   <result pre="are situations whereby inactivation of PP2A induces apoptosis in many" exact="cancer" post="cells. In this review we discuss this relationship and"/>
   <result pre="at altering PP2A activity. phosphatase PP2A cellular signaling tumour suppressor" exact="cancer" post="1. Introduction Reversible phosphorylation is a very important mechanism"/>
   <result pre="to altered cellular behaviour and result in many diseases including" exact="cancer" post="[ 3, 4, 5, 6, 7]. Protein Phosphatase 2A"/>
   <result pre="as this, specific mutations of PPP2R1A have been identified in" exact="lung carcinoma," post="breast carcinoma and melanoma. These mutations result in a"/>
   <result pre="expressing the E64D mutation demonstrated increased incidence of p53 dependant" exact="lung cancer" post="[ 40]. This study highlights the role of PP2A"/>
   <result pre="the E64D mutation demonstrated increased incidence of p53 dependant lung" exact="cancer" post="[ 40]. This study highlights the role of PP2A"/>
   <result pre="which is a chromosomal region that is frequently deleted in" exact="cancer" post="cells [ 41]. PPP2R1B is mutated in 15% of"/>
   <result pre="carcinomas [ 42]. One PPP2R1B mutation seen in 6% of" exact="lung cancer" post="cell lines, is defective in binding to the PP2A"/>
   <result pre="[ 42]. One PPP2R1B mutation seen in 6% of lung" exact="cancer" post="cell lines, is defective in binding to the PP2A"/>
   <result pre="[ 48]. PP2A-B55β is epigenetically inactivated by DNA hypermethylation in" exact="colorectal cancer" post="which has consequences for myc signaling [ 49]. PP2A-B55β"/>
   <result pre="48]. PP2A-B55β is epigenetically inactivated by DNA hypermethylation in colorectal" exact="cancer" post="which has consequences for myc signaling [ 49]. PP2A-B55β"/>
   <result pre="has also been shown to be mutated by hypermethylation in" exact="breast cancer" post="[ 50]. 4. Displacing the Regulatory Subunit: What We"/>
   <result pre="also been shown to be mutated by hypermethylation in breast" exact="cancer" post="[ 50]. 4. Displacing the Regulatory Subunit: What We"/>
   <result pre="PP2A activity allowing dephosphorylation of c-MYC on Ser62 which impairs" exact="cancer" post="cell survival [ 77]. Overexpression of SET, which in"/>
   <result pre="kinase pathway to promote cell proliferation [ 67]. In gastric" exact="cancer" post="cells, the EGFR positively regulates the expression of the"/>
   <result pre="regulate Akt mediated cell proliferation and survival [ 71]. In" exact="breast cancer" post="cells, PP2A associates with the scaffolding protein RACK1 in"/>
   <result pre="Akt mediated cell proliferation and survival [ 71]. In breast" exact="cancer" post="cells, PP2A associates with the scaffolding protein RACK1 in"/>
   <result pre="of therapeutic targets as they are deregulated in almost all" exact="cancer" post="types [ 7], and strategies that restore activity of"/>
   <result pre="activity of PP2A merit serious consideration as novel treatments for" exact="cancer" post="[ 86]. There are a number of compounds available"/>
   <result pre="and SET and has been shown to induce apoptosis in" exact="cancer" post="cells [ 88]. FTY720 is a sphingosine analog drug"/>
   <result pre="has been approved by the FDA as a treatment for" exact="multiple sclerosis" post="(MS) after a series of successful clinical trials ["/>
   <result pre="of FTY720 as a potential therapy for a number of" exact="cancer" post="cell types including but not limited to, neuroblastoma, bladder,"/>
   <result pre="98, 99, 100] and an in vivo study of renal" exact="cancer" post="using mouse models [ 97]. In colorectal cancer, PP2A"/>
   <result pre="study of renal cancer using mouse models [ 97]. In" exact="colorectal cancer," post="PP2A inactivation is a common occurrence and is accompanied"/>
   <result pre="of well-known PP2A inhibitors including CIP2A [ 58]. Treatment of" exact="colorectal cancer" post="cell lines with FTY720 shows reduced proliferation and an"/>
   <result pre="well-known PP2A inhibitors including CIP2A [ 58]. Treatment of colorectal" exact="cancer" post="cell lines with FTY720 shows reduced proliferation and an"/>
   <result pre="PP2A expression [ 58]. As well as this, treatment of" exact="colorectal cancer" post="cells with FTY720 enhances the effect of a number"/>
   <result pre="expression [ 58]. As well as this, treatment of colorectal" exact="cancer" post="cells with FTY720 enhances the effect of a number"/>
   <result pre="58]. One pre-clinical study showed that oestrogen receptor negative (ER−)" exact="breast cancer" post="cell lines were more sensitive to FTY720 than cells"/>
   <result pre="One pre-clinical study showed that oestrogen receptor negative (ER−) breast" exact="cancer" post="cell lines were more sensitive to FTY720 than cells"/>
   <result pre="oestrogen receptor (ER+) [ 101]. This is attributed to ER−" exact="breast cancer" post="cell lines having suppressed levels of PP2A activity in"/>
   <result pre="receptor (ER+) [ 101]. This is attributed to ER− breast" exact="cancer" post="cell lines having suppressed levels of PP2A activity in"/>
   <result pre="having suppressed levels of PP2A activity in comparison to ER+" exact="breast cancer" post="cell lines thus having a higher sensitivity to a"/>
   <result pre="suppressed levels of PP2A activity in comparison to ER+ breast" exact="cancer" post="cell lines thus having a higher sensitivity to a"/>
   <result pre="where inactivation of PP2A induces apoptosis in a number of" exact="cancer" post="cell types including cancers of the pancreas, testes, liver"/>
   <result pre="damaging DNA or disrupting components of cell replication. Conversely, in" exact="cervical cancer" post="cells, inhibition of PP2A stabilizes and activates overexpressed p53"/>
   <result pre="DNA or disrupting components of cell replication. Conversely, in cervical" exact="cancer" post="cells, inhibition of PP2A stabilizes and activates overexpressed p53"/>
   <result pre="suppressor suggesting an anti-apoptotic role for PP2A [ 116]. In" exact="osteosarcoma" post="cells, PP2A-B56γ3 interacts with p53 through an Ataxia Telangectasia"/>
   <result pre="PP2A? Overexpression of the catalytic subunit of PP2A in hepatocellular" exact="cancer" post="models and virus infected cells disrupts p53 phosphorylation and"/>
   <result pre="PP2A should be considered as a therapeutic target in some" exact="cancer" post="types. Lenalidomide is a therapeutic agent, approved by the"/>
   <result pre="in 2002 for the treatment of a specific subset of" exact="myelodysplastic syndrome" post="(MDS) patients who have an isolated deletion of chromosome"/>
   <result pre="likely prevent it from ever becoming a mainstream treatment for" exact="cancer" post="[ 128]. A less toxic demethylated analog of cantharidin,"/>
   <result pre="a promising ability to induce apoptosis in a number of" exact="cancer" post="cell types including melanoma, breast, oral and gallbladder cancers"/>
   <result pre="components of cantharidin (such as demethylcantharidin) have shown tumour growth" exact="suppression" post="(through PP2A inhibition) in both HCC cell lines and"/>
   <result pre="and were found to demonstrate similar levels of tumour growth" exact="suppression" post="compared to cisplatin sensitive mouse models. The combination of"/>
   <result pre="mechanism of drug resistance in the HER2 positive subtype of" exact="breast cancer" post="[ 138]. Lapatinib is a drug that is approved"/>
   <result pre="of drug resistance in the HER2 positive subtype of breast" exact="cancer" post="[ 138]. Lapatinib is a drug that is approved"/>
   <result pre="approved to treat patients with HER2 positive, metastatic, trastuzumab refractory" exact="breast cancer" post="when used in combination with capecitabine as it has"/>
   <result pre="to treat patients with HER2 positive, metastatic, trastuzumab refractory breast" exact="cancer" post="when used in combination with capecitabine as it has"/>
   <result pre="138]. PP2A activity was found elevated in two lapatinib resistant" exact="breast cancer" post="cell lines. Both cell lines, as expected, demonstrated increased"/>
   <result pre="PP2A activity was found elevated in two lapatinib resistant breast" exact="cancer" post="cell lines. Both cell lines, as expected, demonstrated increased"/>
   <result pre="demonstrated in this study that treatment of a lapatinib sensitive" exact="breast cancer" post="cell line with the PP2A activator FTY720, decreased its"/>
   <result pre="in this study that treatment of a lapatinib sensitive breast" exact="cancer" post="cell line with the PP2A activator FTY720, decreased its"/>
   <result pre="further investigation as a potential therapy for this type of" exact="breast cancer" post="[ 138]. 9. Summary PP2A is an indispensable enzyme"/>
   <result pre="investigation as a potential therapy for this type of breast" exact="cancer" post="[ 138]. 9. Summary PP2A is an indispensable enzyme"/>
   <result pre="being an appropriate course of treatment in particular sets of" exact="cancer" post="and PP2A has emerged as an attractive therapeutic target"/>
   <result pre="31, 32]. Inhibition of PP2A by Cantharidin promotes apoptosis in" exact="cancer" post="cells by mediating the prolonged phosphorylation of I κ"/>
   <result pre="Inhibition of PP2A using okadaic acid increases the sensitivity of" exact="breast cancer" post="cells to the drug lapatinib which has an anti-proliferative"/>
   <result pre="of PP2A using okadaic acid increases the sensitivity of breast" exact="cancer" post="cells to the drug lapatinib which has an anti-proliferative"/>
   <result pre="Creyghton M.P. Bernards R. Protein phosphatase 2A regulatory subunits and" exact="cancer" post="Biochim. Biophys. Acta 2009 1795 1 15 18588945 4."/>
   <result pre="5. Östman A. Hellberg C. Böhmer F.D. Protein-tyrosine phosphatases and" exact="cancer" post="Nat. Rev. Cancer 2006 6 307 320 10.1038/nrc1837 16557282"/>
   <result pre="Rudraraju B. Giamas G. The regulatory roles of phosphatases in" exact="cancer" post="Oncogene 2013 33 939 953 10.1038/onc.2013.80 23503460 8. Arroyo"/>
   <result pre="11. Schönthal A.H. Role of serine/threonine protein phosphatase 2A in" exact="cancer" post="Cancer Lett. 2001 170 1 13 10.1016/S0304-3835(01)00561-4 11448528 12."/>
   <result pre="Phosphatase: PP2A structural importance, regulation and its aberrant expression in" exact="cancer" post="Cancer Lett. 2013 335 9 18 10.1016/j.canlet.2013.02.036 23454242 13."/>
   <result pre="Phiel C. Functions of B56-containing PP2As in major developmental and" exact="cancer" post="signaling pathways Life Sci. 2010 87 659 666 10.1016/j.lfs.2010.10.003"/>
   <result pre="mutations in the Aα subunit of protein phosphatase 2A increase" exact="lung cancer" post="incidence in Aα knock-in and knockout mice Mol. Cell."/>
   <result pre="in the Aα subunit of protein phosphatase 2A increase lung" exact="cancer" post="incidence in Aα knock-in and knockout mice Mol. Cell."/>
   <result pre="G.A. Alterations of the PPP2R1B gene in human lung and" exact="colon cancer" post="Science 1998 282 284 287 10.1126/science.282.5387.284 9765152 43. Takagi"/>
   <result pre="Alterations of the PPP2R1B gene in human lung and colon" exact="cancer" post="Science 1998 282 284 287 10.1126/science.282.5387.284 9765152 43. Takagi"/>
   <result pre="P.H. Sheu J.C. Alterations of tumour suppressor gene PPP2R1B in" exact="hepatocellular carcinoma" post="Cancer Lett. 2007 253 138 143 10.1016/j.canlet.2007.01.016 17324501 45."/>
   <result pre="S.L. Isaacs W.B. Xu J. Evaluation of PPP2R2A as a" exact="prostate cancer" post="susceptibility gene: A comprehensive germline and somatic study Cancer"/>
   <result pre="Isaacs W.B. Xu J. Evaluation of PPP2R2A as a prostate" exact="cancer" post="susceptibility gene: A comprehensive germline and somatic study Cancer"/>
   <result pre="T308 phosphorylation of AKT and shorter complete remission duration in" exact="acute myeloid leukemia" post="patients Leukemia 2011 25 1711 1717 10.1038/leu.2011.146 21660042 49."/>
   <result pre="phosphorylation of AKT and shorter complete remission duration in acute" exact="myeloid leukemia" post="patients Leukemia 2011 25 1711 1717 10.1038/leu.2011.146 21660042 49."/>
   <result pre="of AKT and shorter complete remission duration in acute myeloid" exact="leukemia" post="patients Leukemia 2011 25 1711 1717 10.1038/leu.2011.146 21660042 49."/>
   <result pre="complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in" exact="colorectal cancer" post="Cancer Cell 2010 18 459 471 10.1016/j.ccr.2010.10.021 21075311 50."/>
   <result pre="controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal" exact="cancer" post="Cancer Cell 2010 18 459 471 10.1016/j.ccr.2010.10.021 21075311 50."/>
   <result pre="DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal" exact="carcinoma in situ" post="and early invasive breast cancer Breast Cancer Res. 2009"/>
   <result pre="and PTEN in ductal carcinoma in situ and early invasive" exact="breast cancer" post="Breast Cancer Res. 2009 12 R3 R3 20056007 51."/>
   <result pre="PTEN in ductal carcinoma in situ and early invasive breast" exact="cancer" post="Breast Cancer Res. 2009 12 R3 R3 20056007 51."/>
   <result pre="O. et al. PP2A inhibition is a common event in" exact="colorectal cancer" post="and its restoration using FTY720 shows promising therapeutic potential"/>
   <result pre="et al. PP2A inhibition is a common event in colorectal" exact="cancer" post="and its restoration using FTY720 shows promising therapeutic potential"/>
   <result pre="et al. Chk1 targeting reactivates PP2A tumor suppressor activity in" exact="cancer" post="cells Cancer Res. 2013 73 6757 6769 24072747 78."/>
   <result pre="poor outcome and contributes to protein phosphatase 2A inhibition in" exact="acute myeloid leukemia" post="Haematologica 2012 97 543 550 10.3324/haematol.2011.050542 22133779 79. Kawada"/>
   <result pre="outcome and contributes to protein phosphatase 2A inhibition in acute" exact="myeloid leukemia" post="Haematologica 2012 97 543 550 10.3324/haematol.2011.050542 22133779 79. Kawada"/>
   <result pre="and contributes to protein phosphatase 2A inhibition in acute myeloid" exact="leukemia" post="Haematologica 2012 97 543 550 10.3324/haematol.2011.050542 22133779 79. Kawada"/>
   <result pre="A specifically and potently inhibits protein phosphatase 2A and suppresses" exact="cancer" post="metastasis Cancer Sci. 2010 101 743 750 10.1111/j.1349-7006.2009.01438.x 20028386"/>
   <result pre="of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human" exact="cancer" post="cells PLoS ONE 2011 6 e17979 10.1371/journal.pone.0017979 21445343 85."/>
   <result pre="Odero M.D. PP2A impaired activity is a common event in" exact="acute myeloid leukemia" post="and its activation by forskolin has a potent anti-leukemic"/>
   <result pre="M.D. PP2A impaired activity is a common event in acute" exact="myeloid leukemia" post="and its activation by forskolin has a potent anti-leukemic"/>
   <result pre="PP2A impaired activity is a common event in acute myeloid" exact="leukemia" post="and its activation by forskolin has a potent anti-leukemic"/>
   <result pre="et al. A placebo-controlled trial of oral fingolimod in relapsing" exact="multiple sclerosis" post="N. Engl. J. Med. 2010 362 387 401 20089952"/>
   <result pre="L. collab: FTY720 D2201 Study Group Oral fingolimod (FTY720) in" exact="multiple sclerosis" post="two-year results of a phase II extension study Neurology"/>
   <result pre="G. et al. Oral fingolimod or intramuscular interferon for relapsing" exact="multiple sclerosis" post="N. Engl. J. Med. 2010 362 402 415 20089954"/>
   <result pre="(FTY720): Discovery and development of an oral drug to treat" exact="multiple sclerosis" post="Nat. Rev. Drug discov. 2010 9 883 897 10.1038/nrd3248"/>
   <result pre="T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in" exact="leukemia" post="cells Br. J. Pharmacol. 2003 138 1303 1312 10.1038/sj.bjp.0705182"/>
   <result pre="tumor growth and enhances the tumor-suppressive effect of topotecan in" exact="neuroblastoma" post="by interfering with the sphingolipid signaling pathway Pediatr. Blood"/>
   <result pre="S. Otsuki Y. Katsuoka Y. Induction of apoptosis in human" exact="bladder cancer" post="cells in vitro and in vivo caused by FTY720"/>
   <result pre="Otsuki Y. Katsuoka Y. Induction of apoptosis in human bladder" exact="cancer" post="cells in vitro and in vivo caused by FTY720"/>
   <result pre="al. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal" exact="cancer" post="cells in vitro and significantly reduced in vivo tumor"/>
   <result pre="al. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human" exact="breast cancer" post="cells in vitro Cancer Biol. Ther. 2014 15 1"/>
   <result pre="Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast" exact="cancer" post="cells in vitro Cancer Biol. Ther. 2014 15 1"/>
   <result pre="P. Combination of FTY720 with cisplatin exhibits antagonistic effects in" exact="ovarian cancer" post="cells: Role of autophagy Int. J. Oncol. 2013 42"/>
   <result pre="Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian" exact="cancer" post="cells: Role of autophagy Int. J. Oncol. 2013 42"/>
   <result pre="Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour" exact="suppression" post="via activation of PP2A-RIPK1-dependent necroptosis EMBO Mol. Med. 2013"/>
   <result pre="Deregulation of the phosphatase, PP2A is a common event in" exact="breast cancer," post="predicting sensitivity to FTY720 EPMA J. 2014 5 3"/>
   <result pre="selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of" exact="pancreatic cancer" post="cells through G2/M cell-cycle arrest and apoptosis Cancer Sci."/>
   <result pre="PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic" exact="cancer" post="cells through G2/M cell-cycle arrest and apoptosis Cancer Sci."/>
   <result pre="Lonser R. Zhuang Z. Inhibition of serine/threonine phosphatase PP2A enhances" exact="cancer" post="chemotherapy by blocking DNA damage induced defense mechanisms Proc."/>
   <result pre="Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T" exact="leukemia" post="cells is negatively regulated by PP2A-associated p38 mitogen-activated protein"/>
   <result pre="al. A critical role for phosphatase haplodeficiency in the selective" exact="suppression" post="of deletion 5q MDS by lenalidomide Proc. Natl. Acad."/>
   <result pre="A.V. Mehta A.B. Wickremasinghe R.G. Okadaic acid-induced apoptosis of HL60" exact="leukemia" post="cells is preceded by destabilization of Bcl-2 mRNA and"/>
   <result pre="mitotic spindles and lagging chromosomes resulting, in part, from the" exact="suppression" post="of PP2Aα Mol. Cancer Ther. 2006 5 2727 2736"/>
   <result pre="Yagasaki K. Zhang G. Suppression of growth of highly-metastatic human" exact="breast cancer" post="cells by norcantharidin and its mechanisms of action Cytotechnology"/>
   <result pre="K. Zhang G. Suppression of growth of highly-metastatic human breast" exact="cancer" post="cells by norcantharidin and its mechanisms of action Cytotechnology"/>
   <result pre="Hsiao M. Lin S.K. Comparisons of norcantharidin cytotoxic effects on" exact="oral cancer" post="cells and normal buccal keratinocytes Oral Oncol. 2003 39"/>
   <result pre="M. Lin S.K. Comparisons of norcantharidin cytotoxic effects on oral" exact="cancer" post="cells and normal buccal keratinocytes Oral Oncol. 2003 39"/>
   <result pre="K.K. Ho Y.-P. Au-Yeung S.C. In vitro and in vivo" exact="suppression" post="of growth of hepatocellular carcinoma cells by novel traditional"/>
   <result pre="S.C. In vitro and in vivo suppression of growth of" exact="hepatocellular carcinoma" post="cells by novel traditional Chinese medicine-platinum anti-cancer agents Anticancer"/>
   <result pre="G.R. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory" exact="breast cancer" post="cells with acquired resistance to an ErbB1/2 tyrosine kinase"/>
   <result pre="X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast" exact="cancer" post="cells with acquired resistance to an ErbB1/2 tyrosine kinase"/>
   <result pre="Kaufman B. et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N. Engl. J. Med. 2006 355 2733 2743 17192538"/>
   <result pre="B. et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N. Engl. J. Med. 2006 355 2733 2743 17192538"/>
   <result pre="inhibitor and a therapeutic strategy to prevent its onset in" exact="breast cancer" post="Proc. Natl. Acad. Sci. USA 2006 103 7795 7800"/>
   <result pre="and a therapeutic strategy to prevent its onset in breast" exact="cancer" post="Proc. Natl. Acad. Sci. USA 2006 103 7795 7800"/>
   <result pre="K.M. et al. Resistance to ErbB2 tyrosine kinase inhibitors in" exact="breast cancer" post="is mediated by calcium-dependent activation of RelA Mol. Cancer"/>
   <result pre="et al. Resistance to ErbB2 tyrosine kinase inhibitors in breast" exact="cancer" post="is mediated by calcium-dependent activation of RelA Mol. Cancer"/>
   <result pre="independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+" exact="breast cancer" post="cells Breast Cancer Res. Treat. 2012 136 683 692"/>
   <result pre="activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast" exact="cancer" post="cells Breast Cancer Res. Treat. 2012 136 683 692"/>
   <result pre="L. Sun Y. et al. PP2A inhibitors induce apoptosis in" exact="pancreatic cancer" post="cell line PANC-1 through persistent phosphorylation of IKKα and"/>
   <result pre="Sun Y. et al. PP2A inhibitors induce apoptosis in pancreatic" exact="cancer" post="cell line PANC-1 through persistent phosphorylation of IKKα and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4494590/results/search/disease/results.xml">
   <result pre="Abstract Brain metastases are the most common intracranial malignancy, and" exact="breast cancer" post="is the second most common cancer to metastasize to"/>
   <result pre="Brain metastases are the most common intracranial malignancy, and breast" exact="cancer" post="is the second most common cancer to metastasize to"/>
   <result pre="intracranial malignancy, and breast cancer is the second most common" exact="cancer" post="to metastasize to the brain. Intracranial disease is a"/>
   <result pre="to the brain. Intracranial disease is a late manifestation of" exact="breast cancer" post="with few effective treatment options, affecting 15-50% of breast"/>
   <result pre="the brain. Intracranial disease is a late manifestation of breast" exact="cancer" post="with few effective treatment options, affecting 15-50% of breast"/>
   <result pre="breast cancer with few effective treatment options, affecting 15-50% of" exact="breast cancer" post="patients, depending upon molecular subtype. In this review article,"/>
   <result pre="cancer with few effective treatment options, affecting 15-50% of breast" exact="cancer" post="patients, depending upon molecular subtype. In this review article,"/>
   <result pre="article, we describe the genetic, molecular, and metabolic changes in" exact="breast cancer" post="cells that facilitate breast to brain metastasis. We believe"/>
   <result pre="we describe the genetic, molecular, and metabolic changes in breast" exact="cancer" post="cells that facilitate breast to brain metastasis. We believe"/>
   <result pre="prospectively identify patients at increased risk for developing intracranial disease." exact="breast cancer" post="brain metastasis neurosurgery oncology her2/neu The content published in"/>
   <result pre="identify patients at increased risk for developing intracranial disease. breast" exact="cancer" post="brain metastasis neurosurgery oncology her2/neu The content published in"/>
   <result pre="Cureus. Introduction and background A significant percentage of patients with" exact="breast cancer" post="will acquire brain metastases at some point in their"/>
   <result pre="Introduction and background A significant percentage of patients with breast" exact="cancer" post="will acquire brain metastases at some point in their"/>
   <result pre="carcinoma accounts for 12-20% of brain metastases, second only to" exact="lung cancer" post="[ 2]. Autopsy studies have shown brain metastasis in"/>
   <result pre="accounts for 12-20% of brain metastases, second only to lung" exact="cancer" post="[ 2]. Autopsy studies have shown brain metastasis in"/>
   <result pre="studies have shown brain metastasis in up to 36% of" exact="breast cancer" post="patients [ 3- 5] and can involve up to"/>
   <result pre="have shown brain metastasis in up to 36% of breast" exact="cancer" post="patients [ 3- 5] and can involve up to"/>
   <result pre="up to half of patients with certain genetic markers. Breast" exact="cancer" post="subtypes include luminal A, luminal B, HER2 positive/non-luminal, and"/>
   <result pre="the most frequent cause of death [ 8- 9]. Breast" exact="cancer" post="brain metastasis is associated with young age, ER negativity"/>
   <result pre="14]. Brain metastasis is a significant cause of morbidity in" exact="breast cancer" post="patients, with cognitive impairment detected on neuropsychological testing in"/>
   <result pre="Brain metastasis is a significant cause of morbidity in breast" exact="cancer" post="patients, with cognitive impairment detected on neuropsychological testing in"/>
   <result pre="is approximately 50% [ 21]. As the treatment for systemic" exact="breast cancer" post="improves, patients survive longer and the incidence of brain"/>
   <result pre="approximately 50% [ 21]. As the treatment for systemic breast" exact="cancer" post="improves, patients survive longer and the incidence of brain"/>
   <result pre="rather a coordinated accumulation of opportunistic mutations which enable the" exact="breast cancer" post="cells to seed and flourish within the central nervous"/>
   <result pre="a coordinated accumulation of opportunistic mutations which enable the breast" exact="cancer" post="cells to seed and flourish within the central nervous"/>
   <result pre="of two to three years between surgical removal of primary" exact="breast cancer" post="and the appearance of brain metastasis [ 4], suggesting"/>
   <result pre="two to three years between surgical removal of primary breast" exact="cancer" post="and the appearance of brain metastasis [ 4], suggesting"/>
   <result pre="brain tropism. Like other carcinomas that metastasize to the brain," exact="breast cancer" post="has a predilection for brain regions with the highest"/>
   <result pre="tropism. Like other carcinomas that metastasize to the brain, breast" exact="cancer" post="has a predilection for brain regions with the highest"/>
   <result pre="and 5% occur in the brainstem [ 22]. We know" exact="breast cancer" post="within the brain is distinct from the primary site:"/>
   <result pre="5% occur in the brainstem [ 22]. We know breast" exact="cancer" post="within the brain is distinct from the primary site:"/>
   <result pre="made to understand the genetic and molecular events that predispose" exact="cancer" post="to metastasize [ 25- 30], with the goal of"/>
   <result pre="waived for all subjects present within this study. Review HER2-positive" exact="breast cancer" post="predisposes to brain metastasis HER2-positive tumors increase the likelihood"/>
   <result pre="for all subjects present within this study. Review HER2-positive breast" exact="cancer" post="predisposes to brain metastasis HER2-positive tumors increase the likelihood"/>
   <result pre="cells in brain parenchyma [ 37], general aggressiveness of HER2-positive" exact="breast cancer" post="and tendency to metastasize to other tissues [ 38],"/>
   <result pre="in brain parenchyma [ 37], general aggressiveness of HER2-positive breast" exact="cancer" post="and tendency to metastasize to other tissues [ 38],"/>
   <result pre="lapatinib (Tykerb) (GlaxoSmithKline, Middlesex, UK) [ 42]. As in primary" exact="breast cancer," post="it is hypothesized that trastuzumab functions by triggering the"/>
   <result pre="receptors [ 46]. The proportion of patients with metastatic HER2-positive" exact="breast cancer" post="who demonstrate a clinical response to trastuzumab, defined as"/>
   <result pre="[ 46]. The proportion of patients with metastatic HER2-positive breast" exact="cancer" post="who demonstrate a clinical response to trastuzumab, defined as"/>
   <result pre="enhances growth in the brain. When HER2 is overexpressed in" exact="breast cancer" post="cell lines, TGFβ production is increased, leading to activation"/>
   <result pre="growth in the brain. When HER2 is overexpressed in breast" exact="cancer" post="cell lines, TGFβ production is increased, leading to activation"/>
   <result pre="and ZEB-1. Inhibition of HER2 by cucurbitacin B leads to" exact="suppression" post="of brain metastasis in vivo [ 48]. These findings"/>
   <result pre="further contribute to trastuzumab resistance and EMT [ 53]. Breast" exact="cancer" post="is the most common solid tumor to metastasize to"/>
   <result pre="in HER2-positive tumors compared to ER-positive lobular and triple negative" exact="breast cancer" post="[ 5, 55- 56]. HER2-positive tumors remain a difficult"/>
   <result pre="HER2-positive tumors compared to ER-positive lobular and triple negative breast" exact="cancer" post="[ 5, 55- 56]. HER2-positive tumors remain a difficult"/>
   <result pre="difficult to treat brain metastasis. Brain endothelial cells interact with" exact="breast cancer" post="metastases The blood-brain barrier (BBB) poses a significant obstacle"/>
   <result pre="to treat brain metastasis. Brain endothelial cells interact with breast" exact="cancer" post="metastases The blood-brain barrier (BBB) poses a significant obstacle"/>
   <result pre="astrocyte foot processes [ 57- 58]. Real-time imaging of metastasizing" exact="cancer" post="cells in vivo has shown that brain metastasis is"/>
   <result pre="that facilitates brain metastasis [ 62]. Endothelial cells may help" exact="breast cancer" post="enter the CNS. Breast cancer cell transmigration is augmented"/>
   <result pre="facilitates brain metastasis [ 62]. Endothelial cells may help breast" exact="cancer" post="enter the CNS. Breast cancer cell transmigration is augmented"/>
   <result pre="Endothelial cells may help breast cancer enter the CNS. Breast" exact="cancer" post="cell transmigration is augmented by human brain endothelial cells"/>
   <result pre="cell expression of COX-2 induces expression of matrix metalloproteinases in" exact="cancer" post="cells [ 63]. αB-crystallin, a molecular chaperone primarily expressed"/>
   <result pre="63]. αB-crystallin, a molecular chaperone primarily expressed in triple negative" exact="breast cancer," post="is associated with poor prognosis. When overexpressed, metastatic breast"/>
   <result pre="breast cancer, is associated with poor prognosis. When overexpressed, metastatic" exact="breast cancer" post="cells exhibit enhanced adhesion to human brain microvascular endothelial"/>
   <result pre="cancer, is associated with poor prognosis. When overexpressed, metastatic breast" exact="cancer" post="cells exhibit enhanced adhesion to human brain microvascular endothelial"/>
   <result pre="is highly expressed in normal mammary epithelium, yet down-regulated in" exact="breast cancer" post="cells in the brain [ 65]. JAM-A expression positivity"/>
   <result pre="highly expressed in normal mammary epithelium, yet down-regulated in breast" exact="cancer" post="cells in the brain [ 65]. JAM-A expression positivity"/>
   <result pre="involving the injection of human estrogen receptor (ER)-negative pleural malignant" exact="breast cancer" post="cells intra-arterially in rats to select for brain tropism,"/>
   <result pre="the injection of human estrogen receptor (ER)-negative pleural malignant breast" exact="cancer" post="cells intra-arterially in rats to select for brain tropism,"/>
   <result pre="subsequent entry through the blood brain barrier [ 68]. Breast" exact="cancer" post="cells metastatic to the brain have refined a specific"/>
   <result pre="specific capacity to interact favorably with CNS endothelial cells. Breast" exact="cancer" post="adapts to the brain microenvironment Astrocytes play an important"/>
   <result pre="microenvironment Astrocytes play an important role in the survival of" exact="breast cancer" post="upon entering the brain. Once through the BBB, invading"/>
   <result pre="Astrocytes play an important role in the survival of breast" exact="cancer" post="upon entering the brain. Once through the BBB, invading"/>
   <result pre="cancer upon entering the brain. Once through the BBB, invading" exact="breast cancer" post="cells are surrounded by reactive astrocytes, quickly localizing to"/>
   <result pre="upon entering the brain. Once through the BBB, invading breast" exact="cancer" post="cells are surrounded by reactive astrocytes, quickly localizing to"/>
   <result pre="metalloproteinases (MMP), including MMP-2 and MMP-9, and that culturing metastatic" exact="breast cancer" post="cells with astrocyte-conditioned media lead to increased invasive ability"/>
   <result pre="(MMP), including MMP-2 and MMP-9, and that culturing metastatic breast" exact="cancer" post="cells with astrocyte-conditioned media lead to increased invasive ability"/>
   <result pre="cells to disperse along capillaries. To combat this onslaught, metastatic" exact="breast cancer" post="cells highly express serpins, anti-plasminogen activators, including neuroserpin and"/>
   <result pre="to disperse along capillaries. To combat this onslaught, metastatic breast" exact="cancer" post="cells highly express serpins, anti-plasminogen activators, including neuroserpin and"/>
   <result pre="tumor cell proliferation [ 59]. When co-cultured with murine astrocytes," exact="breast cancer" post="cells up-regulated survival genes, including GSTA5, BCL2L1, and TWIST1,"/>
   <result pre="cell proliferation [ 59]. When co-cultured with murine astrocytes, breast" exact="cancer" post="cells up-regulated survival genes, including GSTA5, BCL2L1, and TWIST1,"/>
   <result pre="resistance to chemotherapy [ 71]. In fact, astrocytes may protect" exact="cancer" post="cells from chemotherapeutic agents [ 72]. Breast cancer stem"/>
   <result pre="may protect cancer cells from chemotherapeutic agents [ 72]. Breast" exact="cancer" post="stem cell expression of IL-1B leads to astrocyte activation"/>
   <result pre="JAG1 in astrocytes, which leads to increased Notch signaling in" exact="cancer" post="stem cells and represents an important self-renewal pathway in"/>
   <result pre="pathway in metastatic tumor cells [ 73]. Adaptive strategies by" exact="breast cancer" post="cells and reaction of astrocytes to breast cancer cells"/>
   <result pre="in metastatic tumor cells [ 73]. Adaptive strategies by breast" exact="cancer" post="cells and reaction of astrocytes to breast cancer cells"/>
   <result pre="strategies by breast cancer cells and reaction of astrocytes to" exact="breast cancer" post="cells may facilitate breast tumor cell survival in the"/>
   <result pre="by breast cancer cells and reaction of astrocytes to breast" exact="cancer" post="cells may facilitate breast tumor cell survival in the"/>
   <result pre="in the brain. Gene expression profiling performed over time as" exact="breast cancer" post="cells underwent progressive invasion of brain tissue reveals a"/>
   <result pre="the brain. Gene expression profiling performed over time as breast" exact="cancer" post="cells underwent progressive invasion of brain tissue reveals a"/>
   <result pre="in a new microenvironment [ 74]. These experiments showed that" exact="breast cancer" post="cells co-cultured with brain tissue express many brain-specific genes,"/>
   <result pre="a new microenvironment [ 74]. These experiments showed that breast" exact="cancer" post="cells co-cultured with brain tissue express many brain-specific genes,"/>
   <result pre="[ 75]. Breast tumor metabolism within the brain niche enables" exact="cancer" post="growth and survival. Despite the high energetic demand of"/>
   <result pre="lower than blood glucose levels [ 76- 77], suggesting that" exact="breast cancer" post="cells must undergo metabolic reprogramming in order to thrive"/>
   <result pre="than blood glucose levels [ 76- 77], suggesting that breast" exact="cancer" post="cells must undergo metabolic reprogramming in order to thrive"/>
   <result pre="a five-year history of invasive ductal ER, PR, and HER2/neu-positive" exact="breast cancer" post="presented with a history of headache, nausea, and decreased"/>
   <result pre="five-year history of invasive ductal ER, PR, and HER2/neu-positive breast" exact="cancer" post="presented with a history of headache, nausea, and decreased"/>
   <result pre="Metastasis Pre- and postoperative MRI images demonstrate resection of a" exact="breast cancer" post="dural-based metastasis. Preoperative axial T2 (A) and T1 with"/>
   <result pre="Pre- and postoperative MRI images demonstrate resection of a breast" exact="cancer" post="dural-based metastasis. Preoperative axial T2 (A) and T1 with"/>
   <result pre="Conclusions Brain metastasis is a common but late complication of" exact="breast cancer" post="that contributes to significant morbidity and mortality. Patients with"/>
   <result pre="Brain metastasis is a common but late complication of breast" exact="cancer" post="that contributes to significant morbidity and mortality. Patients with"/>
   <result pre="that contributes to significant morbidity and mortality. Patients with HER2-positive" exact="breast cancer" post="are at increased risk of developing breast-to-brain metastasis, and"/>
   <result pre="contributes to significant morbidity and mortality. Patients with HER2-positive breast" exact="cancer" post="are at increased risk of developing breast-to-brain metastasis, and"/>
   <result pre="inhibition of HER2 in experimental models has led to the" exact="suppression" post="of brain metastasis. Recent work has demonstrated the genetic,"/>
   <result pre="demonstrated the genetic, molecular, and metabolic changes that occur in" exact="breast cancer" post="cells as they gain the ability to survive in"/>
   <result pre="the genetic, molecular, and metabolic changes that occur in breast" exact="cancer" post="cells as they gain the ability to survive in"/>
   <result pre="targeting of brain lesions and the ability to prospectively identify" exact="breast cancer" post="patients at highest risk of developing intracranial disease. The"/>
   <result pre="of brain lesions and the ability to prospectively identify breast" exact="cancer" post="patients at highest risk of developing intracranial disease. The"/>
   <result pre="AB DeAngelis LM 1 23 21 2003 12690643 4 Breast" exact="cancer" post="metastasis to the central nervous system Am J Pathol"/>
   <result pre="outcomes and prognostic factors for patients with brain metastases from" exact="breast cancer" post="of each subtype: A multicenter retrospective analysis Breast Cancer"/>
   <result pre="and prognostic factors for patients with brain metastases from breast" exact="cancer" post="of each subtype: A multicenter retrospective analysis Breast Cancer"/>
   <result pre="positivity for the development of brain metastasis after newly diagnosed" exact="breast cancer" post="J Clin Oncol Gabos Z Sinha R Hanson J"/>
   <result pre="for the development of brain metastasis after newly diagnosed breast" exact="cancer" post="J Clin Oncol Gabos Z Sinha R Hanson J"/>
   <result pre="protein expression and risk for brain metastases in HER-2+ advanced" exact="breast cancer" post="patients receiving trastuzumab-containing therapy Oncologist Duchnowska R Biernat W"/>
   <result pre="expression and risk for brain metastases in HER-2+ advanced breast" exact="cancer" post="patients receiving trastuzumab-containing therapy Oncologist Duchnowska R Biernat W"/>
   <result pre="23 Up-regulation of microRNA-10b is associated with the development of" exact="breast cancer" post="brain metastasis Am J Transl Res Ahmad A Sethi"/>
   <result pre="Up-regulation of microRNA-10b is associated with the development of breast" exact="cancer" post="brain metastasis Am J Transl Res Ahmad A Sethi"/>
   <result pre="in the stages of tumorigenesis correlate with hallmark capabilities of" exact="cancer" post="Genes Dev Olson P Lu J Zhang H Shai"/>
   <result pre="ER and HER2 expression are positively correlated in HER2 non-overexpressing" exact="breast cancer" post="Breast Cancer Res Pinhel I Hills M Drury S"/>
   <result pre="and HER2 expression are positively correlated in HER2 non-overexpressing breast" exact="cancer" post="Breast Cancer Res Pinhel I Hills M Drury S"/>
   <result pre="impact of tissue confirmation of metastatic disease in patients with" exact="breast cancer" post="J Clin Oncol Amir E Miller N Geddie W"/>
   <result pre="of tissue confirmation of metastatic disease in patients with breast" exact="cancer" post="J Clin Oncol Amir E Miller N Geddie W"/>
   <result pre="and clinical outcomes among patients with human epidermal growth factor-2-positive" exact="breast cancer" post="in the National Comprehensive Cancer Network: A prospective cohort"/>
   <result pre="clinical outcomes among patients with human epidermal growth factor-2-positive breast" exact="cancer" post="in the National Comprehensive Cancer Network: A prospective cohort"/>
   <result pre="37 Central nervous system metastases in a cohort of metastatic" exact="breast cancer" post="patients treated with trastuzumab Cancer Chemother Pharmacol Montagna E"/>
   <result pre="Central nervous system metastases in a cohort of metastatic breast" exact="cancer" post="patients treated with trastuzumab Cancer Chemother Pharmacol Montagna E"/>
   <result pre="increased risk of visceral metastasis and poor long-term survival in" exact="breast cancer" post="Int J Cancer Kallioniemi OP Holli K Visakorpi T"/>
   <result pre="risk of visceral metastasis and poor long-term survival in breast" exact="cancer" post="Int J Cancer Kallioniemi OP Holli K Visakorpi T"/>
   <result pre="HER2-positive breast cancer: epidemiological and clinical data from a population-based" exact="cancer" post="registry study Cancer Musolino A Ciccolallo L Panebianco M"/>
   <result pre="in the treatment of women with brain metastases from HER2-positive" exact="breast cancer" post="Cancer Treat Rev Larsen PB Kümler I Nielsen DL"/>
   <result pre="the treatment of women with brain metastases from HER2-positive breast" exact="cancer" post="Cancer Treat Rev Larsen PB Kümler I Nielsen DL"/>
   <result pre="10910043 44 Trastuzumab: Updated mechanisms of action and resistance in" exact="breast cancer" post="Front Oncol Vu T Claret FX 62 2 2012"/>
   <result pre="44 Trastuzumab: Updated mechanisms of action and resistance in breast" exact="cancer" post="Front Oncol Vu T Claret FX 62 2 2012"/>
   <result pre="as a single agent in first-line treatment of HER2-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol Vogel CL Cobleigh MA Tripathy D"/>
   <result pre="a single agent in first-line treatment of HER2-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol Vogel CL Cobleigh MA Tripathy D"/>
   <result pre="TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of" exact="breast cancer" post="Mol Oncol Gupta P Srivastava SK 1532 1547 8"/>
   <result pre="leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast" exact="cancer" post="Mol Oncol Gupta P Srivastava SK 1532 1547 8"/>
   <result pre="119 2009 19487818 50 TGF-β signaling and epithelial-mesenchymal transition in" exact="cancer" post="progression Curr Opin Oncol Katsuno Y Lamouille S Derynck"/>
   <result pre="2012 22992620 53 Epithelial-to-mesenchymal transition: What is the impact on" exact="breast cancer" post="stem cells and drug resistance Cancer Treat Rev Mallini"/>
   <result pre="22992620 53 Epithelial-to-mesenchymal transition: What is the impact on breast" exact="cancer" post="stem cells and drug resistance Cancer Treat Rev Mallini"/>
   <result pre="features, patterns of recurrence, and survival among women with triple-negative" exact="breast cancer" post="in the National Comprehensive Cancer Network Cancer Lin NU"/>
   <result pre="patterns of recurrence, and survival among women with triple-negative breast" exact="cancer" post="in the National Comprehensive Cancer Network Cancer Lin NU"/>
   <result pre="Jiang WG 779 785 9 2014 24366267 59 Serpins promote" exact="cancer" post="cell survival and vascular co-option in brain metastasis Cell"/>
   <result pre="1002 1016 156 2014 24581498 60 In vivo MRI of" exact="cancer" post="cell fate at the single-cell level in a mouse"/>
   <result pre="fate at the single-cell level in a mouse model of" exact="breast cancer" post="metastasis to the brain Magn Reson Med Heyn C"/>
   <result pre="at the single-cell level in a mouse model of breast" exact="cancer" post="metastasis to the brain Magn Reson Med Heyn C"/>
   <result pre="11905606 63 Human brain endothelial cell-derived COX-2 facilitates extravasation of" exact="breast cancer" post="cells across the blood-brain barrier Anticancer Res Lee KY"/>
   <result pre="63 Human brain endothelial cell-derived COX-2 facilitates extravasation of breast" exact="cancer" post="cells across the blood-brain barrier Anticancer Res Lee KY"/>
   <result pre="4313 31 2011 22199296 64 αB-crystallin: A novel regulator of" exact="breast cancer" post="metastasis to the brain Clin Cancer Res Malin D"/>
   <result pre="31 2011 22199296 64 αB-crystallin: A novel regulator of breast" exact="cancer" post="metastasis to the brain Clin Cancer Res Malin D"/>
   <result pre="Attenuation of junctional adhesion molecule-A is a contributing factor for" exact="breast cancer" post="cell invasion Cancer Res Naik MU Naik TU Suckow"/>
   <result pre="of junctional adhesion molecule-A is a contributing factor for breast" exact="cancer" post="cell invasion Cancer Res Naik MU Naik TU Suckow"/>
   <result pre="18381425 66 JAM-A expression positively correlates with poor prognosis in" exact="breast cancer" post="patients Int J Cancer McSherry EA McGee SF Jirstrom"/>
   <result pre="66 JAM-A expression positively correlates with poor prognosis in breast" exact="cancer" post="patients Int J Cancer McSherry EA McGee SF Jirstrom"/>
   <result pre="JA 876 888 16 2014 25086747 68 Genes that mediate" exact="breast cancer" post="metastasis to the brain Nature Bos PD Zhang XH"/>
   <result pre="876 888 16 2014 25086747 68 Genes that mediate breast" exact="cancer" post="metastasis to the brain Nature Bos PD Zhang XH"/>
   <result pre="Capturing changes in the brain microenvironment during initial steps of" exact="breast cancer" post="brain metastasis Am J Pathol Lorger M Felding-Habermann B"/>
   <result pre="changes in the brain microenvironment during initial steps of breast" exact="cancer" post="brain metastasis Am J Pathol Lorger M Felding-Habermann B"/>
   <result pre="286 298 13 2011 21390191 72 The brain microenvironment and" exact="cancer" post="metastasis Mol Cells Fidler IJ Balasubramanian K Lin Q"/>
   <result pre="2010 20799011 73 Reactive astrocytes promote the metastatic growth of" exact="breast cancer" post="stem-like cells by activating Notch signalling in brain EMBO"/>
   <result pre="20799011 73 Reactive astrocytes promote the metastatic growth of breast" exact="cancer" post="stem-like cells by activating Notch signalling in brain EMBO"/>
   <result pre="74 Effects of different tissue microenvironments on gene expression in" exact="breast cancer" post="cells PLoS One Rondeau G Abedinpour P Desai P"/>
   <result pre="Effects of different tissue microenvironments on gene expression in breast" exact="cancer" post="cells PLoS One Rondeau G Abedinpour P Desai P"/>
   <result pre="301 2011 78 Gain of glucose-independent growth upon metastasis of" exact="breast cancer" post="cells to the brain Cancer Res Chen J Lee"/>
   <result pre="2011 78 Gain of glucose-independent growth upon metastasis of breast" exact="cancer" post="cells to the brain Cancer Res Chen J Lee"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4494975/results/search/disease/results.xml">
   <result pre="and HER2 with cetuximab and trastuzumab in patients with metastatic" exact="pancreatic cancer" post="after gemcitabine failure: results of the &quot;THERAPY&quot;phase 1-2 trial"/>
   <result pre="HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic" exact="cancer" post="after gemcitabine failure: results of the &quot;THERAPY&quot;phase 1-2 trial"/>
   <result pre="preclinical results, we conducted a phase 1-2 trial in advanced" exact="pancreatic cancer" post="patients after first-line gemcitabine-based chemotherapy failure. In this single-arm,"/>
   <result pre="results, we conducted a phase 1-2 trial in advanced pancreatic" exact="cancer" post="patients after first-line gemcitabine-based chemotherapy failure. In this single-arm,"/>
   <result pre="skin toxicities were particularly detrimental because of the toxicity-response correlation." exact="pancreatic cancer" post="cetuximab trastuzumab phase 1/2 antibody combination INTRODUCTION Pancreatic cancer"/>
   <result pre="toxicities were particularly detrimental because of the toxicity-response correlation. pancreatic" exact="cancer" post="cetuximab trastuzumab phase 1/2 antibody combination INTRODUCTION Pancreatic cancer"/>
   <result pre="pancreatic cancer cetuximab trastuzumab phase 1/2 antibody combination INTRODUCTION Pancreatic" exact="cancer" post="is the tenth most common cause of cancer in"/>
   <result pre="INTRODUCTION Pancreatic cancer is the tenth most common cause of" exact="cancer" post="in the United States and the fourth leading cause"/>
   <result pre="in the United States and the fourth leading cause of" exact="cancer" post="death, with an estimated 42 000 new cases and"/>
   <result pre="gemcitabine has been the only approved first-line treatment for advanced" exact="pancreatic cancer" post="for 15 years [ 2]. Combinations of fluorouracil, irinotecan,"/>
   <result pre="has been the only approved first-line treatment for advanced pancreatic" exact="cancer" post="for 15 years [ 2]. Combinations of fluorouracil, irinotecan,"/>
   <result pre="are often administered as first-line treatment to patients with metastatic" exact="pancreatic cancer" post="and a good performance status [ 3, 4]. To"/>
   <result pre="often administered as first-line treatment to patients with metastatic pancreatic" exact="cancer" post="and a good performance status [ 3, 4]. To"/>
   <result pre="receptors (EGFR/HER1 and HER2) have been widely studied, including in" exact="pancreatic cancer" post="[ 10- 15]. Moreover, 17% to 33% of pancreatic"/>
   <result pre="(EGFR/HER1 and HER2) have been widely studied, including in pancreatic" exact="cancer" post="[ 10- 15]. Moreover, 17% to 33% of pancreatic"/>
   <result pre="showed limited therapeutic benefit in 34 patients with HER2-overexpressing metastatic" exact="pancreatic cancer" post="[ 16]. Cetuximab (CET; anti-HER1 monoclonal antibody) was also"/>
   <result pre="limited therapeutic benefit in 34 patients with HER2-overexpressing metastatic pancreatic" exact="cancer" post="[ 16]. Cetuximab (CET; anti-HER1 monoclonal antibody) was also"/>
   <result pre="a phase 2 study that included 41 patients with advanced" exact="pancreatic cancer" post="overexpressing HER1 [ 17]. However, the results of two"/>
   <result pre="phase 2 study that included 41 patients with advanced pancreatic" exact="cancer" post="overexpressing HER1 [ 17]. However, the results of two"/>
   <result pre="than the standard chemotherapy (gemcitabine) in nude mice bearing human" exact="pancreatic cancer" post="xenografts [ 20]. Finally, we demonstrated that the TRA"/>
   <result pre="the standard chemotherapy (gemcitabine) in nude mice bearing human pancreatic" exact="cancer" post="xenografts [ 20]. Finally, we demonstrated that the TRA"/>
   <result pre="+ CET combination for the treatment of patients with advanced" exact="pancreatic cancer" post="after failure of gemcitabine-based first-line chemotherapy. RESULTS Over a"/>
   <result pre="CET combination for the treatment of patients with advanced pancreatic" exact="cancer" post="after failure of gemcitabine-based first-line chemotherapy. RESULTS Over a"/>
   <result pre="Exclusion criteria brain metastases or symptomatic leptomeningeal carcinomatosis other concurrent" exact="cancer" post="(except for skin basal cell carcinoma) prior chemotherapy with"/>
   <result pre="skin basal cell carcinoma) prior chemotherapy with CET or TRA" exact="hypersensitivity" post="to CET or TRA pregnancy or lactation fertile patient"/>
   <result pre="drugs or any other anticancer therapy significant comorbidities such as:" exact="cardiovascular disease" post="(documented congestive cardiac failure, high risk unstable arrhythmia, angina"/>
   <result pre="Including all cutaneous toxicities ** Including pruritus, rash/acne, skin dryness," exact="urticaria" post="and paronychia For the survival analysis, the data of"/>
   <result pre="cutaneous toxicities ** Including pruritus, rash/acne, skin dryness, urticaria and" exact="paronychia" post="For the survival analysis, the data of all evaluable"/>
   <result pre="Including all cutaneous toxicities ** Including pruritus, rash/acne, skin dryness," exact="urticaria" post="and paronychia Concerning the ancillary experiments, KRAS status could"/>
   <result pre="cutaneous toxicities ** Including pruritus, rash/acne, skin dryness, urticaria and" exact="paronychia" post="Concerning the ancillary experiments, KRAS status could be assessed"/>
   <result pre="not efficient when administered individually with conventional chemotherapy in advanced" exact="pancreatic cancer" post="[ 9, 16, 18]. However, our survival results should"/>
   <result pre="efficient when administered individually with conventional chemotherapy in advanced pancreatic" exact="cancer" post="[ 9, 16, 18]. However, our survival results should"/>
   <result pre="acid/5-FU (OFF regimen) as second-line treatment for patients with advanced" exact="pancreatic cancer," post="OS was 4.82 months [95% CI: 4.29-5.35] in the"/>
   <result pre="gemcitabine as first- and second-line treatment for patients with metastatic" exact="pancreatic cancer" post="[ 28], PFS (from second-line start to progression) was"/>
   <result pre="as first- and second-line treatment for patients with metastatic pancreatic" exact="cancer" post="[ 28], PFS (from second-line start to progression) was"/>
   <result pre="efficacy improvement compared to the individual drugs in patients with" exact="pancreatic cancer," post="was associated with increased toxicity [ 8]. In a"/>
   <result pre="toxicity [ 8]. In a retrospective study, 168 patients with" exact="pancreatic cancer" post="and treated with combined erlotinib and gemcitabine were classified"/>
   <result pre="[ 8]. In a retrospective study, 168 patients with pancreatic" exact="cancer" post="and treated with combined erlotinib and gemcitabine were classified"/>
   <result pre="in two groups (high and low severity), based on the" exact="rash" post="intensity [ 33]. The high severity group had longer"/>
   <result pre="low severity group (both P&amp;lt;0.05); patients suffering from particularly severe" exact="rash" post="also had a lower risk of death (hazard ratio"/>
   <result pre="in a phase 2 trial that enrolled patients with metastatic" exact="pancreatic cancer" post="( n=64) treated with chemotherapy + CET, the presence"/>
   <result pre="a phase 2 trial that enrolled patients with metastatic pancreatic" exact="cancer" post="( n=64) treated with chemotherapy + CET, the presence"/>
   <result pre="n=64) treated with chemotherapy + CET, the presence of a" exact="rash" post="was significantly correlated with OS [ 34]. Moreover, as"/>
   <result pre="this efficacy-toxicity association had been described also in patients with" exact="colorectal cancer" post="(CRC), Van Cutsem et al. (34) conducted the EVEREST"/>
   <result pre="efficacy-toxicity association had been described also in patients with colorectal" exact="cancer" post="(CRC), Van Cutsem et al. (34) conducted the EVEREST"/>
   <result pre="bring the expected efficacy results for the treatment of advanced" exact="pancreatic cancer," post="one can learn from our observations. Conventional phase 1"/>
   <result pre="prophylaxis), fever or sepsis concurrent with grade 3-4 neutropenia, symptomatic" exact="thrombocytopenia" post="(hemorrhage), any grade 3 cardiotoxicity and any toxicity requiring"/>
   <result pre="SA Ma WW Saleh MN et al. Increased survival in" exact="pancreatic cancer" post="with nab-paclitaxel plus gemcitabine N Engl J Med 2013"/>
   <result pre="Ma WW Saleh MN et al. Increased survival in pancreatic" exact="cancer" post="with nab-paclitaxel plus gemcitabine N Engl J Med 2013"/>
   <result pre="and placebo as first line therapy in patients with advanced" exact="pancreatic cancer" post="Br J Cancer 2002 87 161 167 12107836 6"/>
   <result pre="placebo as first line therapy in patients with advanced pancreatic" exact="cancer" post="Br J Cancer 2002 87 161 167 12107836 6"/>
   <result pre="gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced" exact="pancreatic cancer" post="J Clin Oncol 2004 22 1430 1438 15084616 7"/>
   <result pre="plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic" exact="cancer" post="J Clin Oncol 2004 22 1430 1438 15084616 7"/>
   <result pre="in combination with gemcitabine and erlotinib in patients with metastatic" exact="pancreatic cancer" post="J Clin Oncol 2009 27 2231 2237 19307500 8"/>
   <result pre="combination with gemcitabine and erlotinib in patients with metastatic pancreatic" exact="cancer" post="J Clin Oncol 2009 27 2231 2237 19307500 8"/>
   <result pre="AL et al. Clinical and molecular characterization of HER2 amplified" exact="pancreatic cancer" post="Genome Med 2013 8 31 5 78 24004612 14"/>
   <result pre="et al. Clinical and molecular characterization of HER2 amplified pancreatic" exact="cancer" post="Genome Med 2013 8 31 5 78 24004612 14"/>
   <result pre="(NEXIRI) as second- or later-line treatment for patients with metastatic" exact="colorectal cancer" post="and KRAS-mutated tumours: a multicentre Phase I/II trial Br"/>
   <result pre="as second- or later-line treatment for patients with metastatic colorectal" exact="cancer" post="and KRAS-mutated tumours: a multicentre Phase I/II trial Br"/>
   <result pre="KRAS mutations on the clinical outcome of patients with metastatic" exact="colorectal cancer" post="treated with cetuximab plus irinotecan J Clin Oncol 2009"/>
   <result pre="mutations on the clinical outcome of patients with metastatic colorectal" exact="cancer" post="treated with cetuximab plus irinotecan J Clin Oncol 2009"/>
   <result pre="et al. Prognostic value of cetuximab-related skin toxicity in metastatic" exact="colorectal cancer" post="patients and its correlation with parameters of the epidermal"/>
   <result pre="al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal" exact="cancer" post="patients and its correlation with parameters of the epidermal"/>
   <result pre="combination of everolimus, cetuximab and capecitabine in patients with advanced" exact="pancreatic cancer" post="Invest New Drugs 2013 31 85 91 22367239"/>
   <result pre="of everolimus, cetuximab and capecitabine in patients with advanced pancreatic" exact="cancer" post="Invest New Drugs 2013 31 85 91 22367239"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4495150/results/search/disease/results.xml">
   <result pre="Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic" exact="breast cancer" post="in southern China Qin Tao 1 Yuan Zhong-Yu 1"/>
   <result pre="characteristics and prognostic factors for HER2-positive patients with metastatic breast" exact="cancer" post="in southern China Qin Tao 1 Yuan Zhong-Yu 1"/>
   <result pre="to identify prognostic factors for Chinese patients with HER2-positive metastatic" exact="breast cancer." post="Material and methods A total of 243 patients with"/>
   <result pre="and methods A total of 243 patients with HER2-positive metastatic" exact="breast cancer," post="treated during the period 2002 to 2009, were followed"/>
   <result pre="were favorable independent prognostic factors for patients with HER2-positive metastatic" exact="breast cancer." post="Conclusions These results indicated that surgical intervention, endocrine therapy,"/>
   <result pre="therapy were good for these HER2 positive patients with metastatic" exact="breast cancer," post="but ECOG performance status &amp;lt; 1 and metastasis to"/>
   <result pre="brain metastasis endocrine therapy hormone receptor status surgery Introduction Breast" exact="cancer" post="is the most common cancer among women worldwide, with"/>
   <result pre="receptor status surgery Introduction Breast cancer is the most common" exact="cancer" post="among women worldwide, with the greatest incidences in 2008"/>
   <result pre="100,000 in the United States) [ 1]. The incidence of" exact="breast cancer" post="among women is lower in Asian countries, with an"/>
   <result pre="in the United States) [ 1]. The incidence of breast" exact="cancer" post="among women is lower in Asian countries, with an"/>
   <result pre="addition to prognostic factors such as age, tumor size, and" exact="cancer" post="stage and grade, overexpression of the human epidermal growth"/>
   <result pre="identifying prognostic factors for Chinese patients with various types of" exact="breast cancer" post="have been published [ 12, 13], and some have"/>
   <result pre="prognostic factors for Chinese patients with various types of breast" exact="cancer" post="have been published [ 12, 13], and some have"/>
   <result pre="evaluated prognostic factors specifically for Chinese patients with HER2+ metastatic" exact="breast cancer." post="Identification of prognostic clinicopathologic factors among different patient populations"/>
   <result pre="and anti-HER2 therapy on OS of patients with HER2+ metastatic" exact="breast cancer" post="in southern China and to identify prognostic clinicopathologic characteristics"/>
   <result pre="anti-HER2 therapy on OS of patients with HER2+ metastatic breast" exact="cancer" post="in southern China and to identify prognostic clinicopathologic characteristics"/>
   <result pre="A total of 243 female patients with HER2 positive metastatic" exact="breast cancer," post="who received treatment at Sun Yat-sen University Cancer Center"/>
   <result pre="as follows: known performance status at first diagnosis of metastatic" exact="breast cancer," post="pathologically confirmed breast cancer, defined TNM stage, known HR"/>
   <result pre="status at first diagnosis of metastatic breast cancer, pathologically confirmed" exact="breast cancer," post="defined TNM stage, known HR status, known adjunctive or"/>
   <result pre="criteria or without complete clinical data were excluded. The primary" exact="cancer" post="was confirmed by pathologic examination. TNM staging was performed"/>
   <result pre="overexpression was assessed in well-fixed, paraffin-embedded tumor specimens containing invasive" exact="cancer" post="cells. HER2 overexpression was defined as HER2 immunohistochemical staining"/>
   <result pre="as HER2 immunohistochemical staining of 3+ (&amp;gt; 30% of invasive" exact="cancer" post="cells showing strong membrane staining) or a HER2: chromosome"/>
   <result pre="243 patients, 26 (10.7%) received a diagnosis of stage IV" exact="breast cancer" post="at first diagnosis. The remaining 217 patients were initially"/>
   <result pre="patients, 26 (10.7%) received a diagnosis of stage IV breast" exact="cancer" post="at first diagnosis. The remaining 217 patients were initially"/>
   <result pre="217 patients were initially diagnosed with stage I to III" exact="breast cancer" post="but later developed metastasis. After the diagnosis of metastasis,"/>
   <result pre="patients were initially diagnosed with stage I to III breast" exact="cancer" post="but later developed metastasis. After the diagnosis of metastasis,"/>
   <result pre="them that the best strategy for the treatment of metastatic" exact="breast cancer" post="for HER2+ patients was treatment targeting HER2. It should"/>
   <result pre="that the best strategy for the treatment of metastatic breast" exact="cancer" post="for HER2+ patients was treatment targeting HER2. It should"/>
   <result pre="were performed to identify prognostic clinicopathologic factors for HER2+ metastatic" exact="breast cancer." post="Variables with a p value &amp;lt; 0.05 in univariate"/>
   <result pre="Results Clinical characteristics of the 243 patients with HER2+ metastatic" exact="breast cancer" post="are summarized in Table I. The mean age at"/>
   <result pre="Clinical characteristics of the 243 patients with HER2+ metastatic breast" exact="cancer" post="are summarized in Table I. The mean age at"/>
   <result pre="Table I Clinical characteristics of 243 patients with HER2-positive metastatic" exact="breast cancer" post="Clinical characteristic Total ( n = 243) Age at"/>
   <result pre="I Clinical characteristics of 243 patients with HER2-positive metastatic breast" exact="cancer" post="Clinical characteristic Total ( n = 243) Age at"/>
   <result pre="Next, potential prognostic factors for 243 patients with HER2-positive metastatic" exact="breast cancer" post="were analyzed by univariate and multivariate Cox proportional hazards"/>
   <result pre="potential prognostic factors for 243 patients with HER2-positive metastatic breast" exact="cancer" post="were analyzed by univariate and multivariate Cox proportional hazards"/>
   <result pre="as unfavorable independent prognostic factors for patients with HER2-positive metastatic" exact="breast cancer." post="Table II Cox proportional hazards regression analysis of potential"/>
   <result pre="analysis of potential prognostic factors for patients with HER2-positive metastatic" exact="breast cancer" post="Variable Univariate Multivariate Hazard ratio (95% CI) Value of"/>
   <result pre="of potential prognostic factors for patients with HER2-positive metastatic breast" exact="cancer" post="Variable Univariate Multivariate Hazard ratio (95% CI) Value of"/>
   <result pre="factors that might affect prognosis for patients with HER2-positive metastatic" exact="breast cancer." post="The results of this retrospective study showed that surgical"/>
   <result pre="present study, all patients were HER2 positive and had advanced" exact="breast cancer," post="which generally has a poor prognosis. There are numerous"/>
   <result pre="by Dawood et al. [ 25] showed that among metastatic" exact="breast cancer" post="patients who were HER2+, more HR– patients benefited from"/>
   <result pre="Dawood et al. [ 25] showed that among metastatic breast" exact="cancer" post="patients who were HER2+, more HR– patients benefited from"/>
   <result pre="endocrine therapy can improve prognosis for HER2-positive patients with advanced" exact="breast cancer." post="It is not surprising to find that anti-HER2 therapy"/>
   <result pre="that anti-HER2 therapy was favorable for HER2-positive patients with metastatic" exact="breast cancer" post="in the present study. Though trastuzumab can significantly improve"/>
   <result pre="anti-HER2 therapy was favorable for HER2-positive patients with metastatic breast" exact="cancer" post="in the present study. Though trastuzumab can significantly improve"/>
   <result pre="present study. Though trastuzumab can significantly improve the OS of" exact="breast cancer" post="patients with HER2 overexpression, the incidence of brain metastasis"/>
   <result pre="study. Though trastuzumab can significantly improve the OS of breast" exact="cancer" post="patients with HER2 overexpression, the incidence of brain metastasis"/>
   <result pre="a previous study of brain metastases in Chinese patients with" exact="breast cancer," post="which indicated poor prognosis of those with HER2+ status"/>
   <result pre="lesions were not significant prognostic factors. Whereas the stage of" exact="breast cancer" post="at initial diagnosis affects the selection of adjuvant therapy,"/>
   <result pre="were not significant prognostic factors. Whereas the stage of breast" exact="cancer" post="at initial diagnosis affects the selection of adjuvant therapy,"/>
   <result pre="therapy, with the application of surgery in patients with early" exact="breast cancer" post="and the use of postoperative adjuvant therapy, the stage"/>
   <result pre="with the application of surgery in patients with early breast" exact="cancer" post="and the use of postoperative adjuvant therapy, the stage"/>
   <result pre="and the use of postoperative adjuvant therapy, the stage of" exact="breast cancer" post="now has a reduced influence on survival. With the"/>
   <result pre="the use of postoperative adjuvant therapy, the stage of breast" exact="cancer" post="now has a reduced influence on survival. With the"/>
   <result pre="site and the number of metastatic lesions failed to influence" exact="breast cancer" post="prognosis. There is evidence that in patients with controlled"/>
   <result pre="and the number of metastatic lesions failed to influence breast" exact="cancer" post="prognosis. There is evidence that in patients with controlled"/>
   <result pre="studies, indicating prognostic similarities between Chinese patients with HER2+ metastatic" exact="breast cancer" post="and other patient subsets. The findings for this specific"/>
   <result pre="indicating prognostic similarities between Chinese patients with HER2+ metastatic breast" exact="cancer" post="and other patient subsets. The findings for this specific"/>
   <result pre="subsets. The findings for this specific population with HER2+ advanced" exact="breast cancer" post="add to the overall knowledge base concerning prognostic factors"/>
   <result pre="The findings for this specific population with HER2+ advanced breast" exact="cancer" post="add to the overall knowledge base concerning prognostic factors"/>
   <result pre="add to the overall knowledge base concerning prognostic factors in" exact="breast cancer," post="and might help with the tailoring of individualized therapy"/>
   <result pre="our present results indicate that for patients with HER2+ metastatic" exact="breast cancer" post="in southern China, OS is related to biologic behaviors"/>
   <result pre="present results indicate that for patients with HER2+ metastatic breast" exact="cancer" post="in southern China, OS is related to biologic behaviors"/>
   <result pre="in southern China, OS is related to biologic behaviors of" exact="breast cancer" post="as well as the type of metastasis and the"/>
   <result pre="southern China, OS is related to biologic behaviors of breast" exact="cancer" post="as well as the type of metastasis and the"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer" post="Science 1989 244 707 12 2470152 4 Ferretti G"/>
   <result pre="Studies of the HER-2/neu proto-oncogene in human breast and ovarian" exact="cancer" post="Science 1989 244 707 12 2470152 4 Ferretti G"/>
   <result pre="associated with trastuzumab in the setting of adjuvant chemotherapy for" exact="breast cancer" post="overexpressing human epidermal growth factor receptor type 2 –"/>
   <result pre="with trastuzumab in the setting of adjuvant chemotherapy for breast" exact="cancer" post="overexpressing human epidermal growth factor receptor type 2 –"/>
   <result pre="receptor status, tumor characteristics, and prognosis: a prospective cohort of" exact="breast cancer" post="patients Breast Cancer Res 2007 9 R6 17239243 7"/>
   <result pre="status, tumor characteristics, and prognosis: a prospective cohort of breast" exact="cancer" post="patients Breast Cancer Res 2007 9 R6 17239243 7"/>
   <result pre="7 Carey LA Perou CM Livasy CA et al. Race," exact="breast cancer" post="subtypes, and survival in the Carolina Breast Cancer Study"/>
   <result pre="Carey LA Perou CM Livasy CA et al. Race, breast" exact="cancer" post="subtypes, and survival in the Carolina Breast Cancer Study"/>
   <result pre="et al. Patterns of relapse and metastatic spread in HER2-overexpressing" exact="breast cancer" post="according to estrogen receptor status Cancer Chemother Pharmacol 2010"/>
   <result pre="al. Patterns of relapse and metastatic spread in HER2-overexpressing breast" exact="cancer" post="according to estrogen receptor status Cancer Chemother Pharmacol 2010"/>
   <result pre="Prognostic effect of hormone receptor status in early HER2 positive" exact="breast cancer" post="patients Hematol Oncol Stem Cell Ther 2010 3 109"/>
   <result pre="effect of hormone receptor status in early HER2 positive breast" exact="cancer" post="patients Hematol Oncol Stem Cell Ther 2010 3 109"/>
   <result pre="M et al. Pathological complete response in younger and older" exact="breast cancer" post="patients Arch Med Sci 2012 8 310 5 22662005"/>
   <result pre="et al. Pathological complete response in younger and older breast" exact="cancer" post="patients Arch Med Sci 2012 8 310 5 22662005"/>
   <result pre="5 22662005 12 Kwong M Mang OW Wong CH Breast" exact="cancer" post="in Hong Kong, Southern China: the first population-based analysis"/>
   <result pre="analysis of epidemiological characteristics, stage-specific, cancer-specific, and disease-free survival in" exact="breast cancer" post="patients: 1997-2001 Ann Surg Oncol 2011 18 3072 8"/>
   <result pre="of epidemiological characteristics, stage-specific, cancer-specific, and disease-free survival in breast" exact="cancer" post="patients: 1997-2001 Ann Surg Oncol 2011 18 3072 8"/>
   <result pre="GL et al. A case-control study on risk factors of" exact="breast cancer" post="in China Arch Med Sci 2012 8 303 9"/>
   <result pre="et al. A case-control study on risk factors of breast" exact="cancer" post="in China Arch Med Sci 2012 8 303 9"/>
   <result pre="al. Distinct distribution and prognostic significance of molecular subtypes of" exact="breast cancer" post="in Chinese women: a population-based cohort study BMC Cancer"/>
   <result pre="Distinct distribution and prognostic significance of molecular subtypes of breast" exact="cancer" post="in Chinese women: a population-based cohort study BMC Cancer"/>
   <result pre="characteristics and prognostic factors in patients with operable HER-2 overexpressing" exact="breast cancer" post="Asian Pacific J Cancer Prev 2012 13 1197 201"/>
   <result pre="and prognostic factors in patients with operable HER-2 overexpressing breast" exact="cancer" post="Asian Pacific J Cancer Prev 2012 13 1197 201"/>
   <result pre="can predict the response and outcome of Chinese locally advanced" exact="breast cancer" post="patients treated with preoperative therapy Oncol Rep 2010 23"/>
   <result pre="predict the response and outcome of Chinese locally advanced breast" exact="cancer" post="patients treated with preoperative therapy Oncol Rep 2010 23"/>
   <result pre="therapy: results with regard to poor survival in young Chinese" exact="breast cancer" post="patients Breast Cancer Res Treat 2010 122 95 104"/>
   <result pre="results with regard to poor survival in young Chinese breast" exact="cancer" post="patients Breast Cancer Res Treat 2010 122 95 104"/>
   <result pre="ML Chang ET Kurian AW et al. Asian ethnicity and" exact="breast cancer" post="subtypes: a study from the California Cancer Registry Breast"/>
   <result pre="Chang ET Kurian AW et al. Asian ethnicity and breast" exact="cancer" post="subtypes: a study from the California Cancer Registry Breast"/>
   <result pre="8 20957431 20 Edge SB Byrd DR Compton CC AJCC" exact="cancer" post="staging manual 2009 7th ed New York (NY) Springer"/>
   <result pre="AU Hortobagyi GN Giordano SH Prognosis of women with metastatic" exact="breast cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="Hortobagyi GN Giordano SH Prognosis of women with metastatic breast" exact="cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1673 84 16236738"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1673 84 16236738"/>
   <result pre="features and survival analysis of different subtypes of patients with" exact="breast cancer" post="brain metastases Chin J Cancer 2010 29 413 9"/>
   <result pre="and survival analysis of different subtypes of patients with breast" exact="cancer" post="brain metastases Chin J Cancer 2010 29 413 9"/>
   <result pre="K Esteva FJ et al. Defining prognosis for women with" exact="breast cancer" post="and CNS metastases by HER2 status Ann Oncol 2008"/>
   <result pre="Esteva FJ et al. Defining prognosis for women with breast" exact="cancer" post="and CNS metastases by HER2 status Ann Oncol 2008"/>
   <result pre="J et al. Prognostic factors in 1,038 women with metastatic" exact="breast cancer" post="Ann Oncol 2008 19 2012 9 18641006 31 Chang"/>
   <result pre="et al. Prognostic factors in 1,038 women with metastatic breast" exact="cancer" post="Ann Oncol 2008 19 2012 9 18641006 31 Chang"/>
   <result pre="S Resch B Marpeau L Scotté M Liver resection for" exact="breast cancer" post="metastasis: does it improve survival? Surg Today 2008 38"/>
   <result pre="Resch B Marpeau L Scotté M Liver resection for breast" exact="cancer" post="metastasis: does it improve survival? Surg Today 2008 38"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4496366/results/search/disease/results.xml">
   <result pre="unison. Here we describe the identification of compounds that kill" exact="breast cancer" post="cells that overexpress EGFR or HER2. Cell death parallels"/>
   <result pre="Here we describe the identification of compounds that kill breast" exact="cancer" post="cells that overexpress EGFR or HER2. Cell death parallels"/>
   <result pre="drugs may overcome therapeutic resistance. HER2 disulfide bonds EGFR HER3" exact="breast cancer" post="INTRODUCTION The Epidermal Growth Factor Receptor (EGFR) family members"/>
   <result pre="may overcome therapeutic resistance. HER2 disulfide bonds EGFR HER3 breast" exact="cancer" post="INTRODUCTION The Epidermal Growth Factor Receptor (EGFR) family members"/>
   <result pre="in [ 1– 3]). EGFR is frequently mutationally activated in" exact="lung cancer" post="and is the target of the FDA-approved drugs Cetuximab,"/>
   <result pre="[ 1– 3]). EGFR is frequently mutationally activated in lung" exact="cancer" post="and is the target of the FDA-approved drugs Cetuximab,"/>
   <result pre="Receptor-, and HER2-negative) breast cancers [ 4]. HER2 overexpression in" exact="breast cancer" post="is associated with poor prognosis, but the production of"/>
   <result pre="and HER2-negative) breast cancers [ 4]. HER2 overexpression in breast" exact="cancer" post="is associated with poor prognosis, but the production of"/>
   <result pre="inhibitors such as Lapatinib, has revolutionized the treatment of HER2-positive" exact="breast cancer." post="Unfortunately, 66–88% of HER2-positive tumors exhibit primary resistance to"/>
   <result pre="19]. Therefore, an improved agent for the treatment of HER2-dependent" exact="breast cancer" post="would inactivate EGFR, HER2, and HER3 in parallel, be"/>
   <result pre="Therefore, an improved agent for the treatment of HER2-dependent breast" exact="cancer" post="would inactivate EGFR, HER2, and HER3 in parallel, be"/>
   <result pre="and HER3 in parallel, be effective in the treatment of" exact="cancer" post="as a single agent, and be mechanistically complementary with"/>
   <result pre="or a combination of the two compounds. F. The indicated" exact="cancer" post="cell lines were treated for 24 hours with 20"/>
   <result pre="tyrosine kinases and that this might explain the pattern of" exact="cancer" post="cell line responsiveness to these agents. Sulfinate-containing compounds kill"/>
   <result pre="cancer cell line responsiveness to these agents. Sulfinate-containing compounds kill" exact="breast cancer" post="cells that overexpress EGFR or HER2 and block Akt"/>
   <result pre="cell line responsiveness to these agents. Sulfinate-containing compounds kill breast" exact="cancer" post="cells that overexpress EGFR or HER2 and block Akt"/>
   <result pre="examined their ability to decrease the viability of various human" exact="cancer" post="cell lines. As expected, NSC624205 was lethal to MDA-MB-468"/>
   <result pre="cancer cell lines. As expected, NSC624205 was lethal to MDA-MB-468" exact="breast cancer" post="cells, but had little effect on BxPC3 pancreatic cancer"/>
   <result pre="cell lines. As expected, NSC624205 was lethal to MDA-MB-468 breast" exact="cancer" post="cells, but had little effect on BxPC3 pancreatic cancer"/>
   <result pre="MDA-MB-468 breast cancer cells, but had little effect on BxPC3" exact="pancreatic cancer" post="cells, indicating that NSC624205 is not a general cytotoxic"/>
   <result pre="breast cancer cells, but had little effect on BxPC3 pancreatic" exact="cancer" post="cells, indicating that NSC624205 is not a general cytotoxic"/>
   <result pre="HER2 respectively, but had little effect on the basal-like/triple-negative MDA-MB-231" exact="breast cancer" post="cell line, which does not overexpress either EGFR or"/>
   <result pre="respectively, but had little effect on the basal-like/triple-negative MDA-MB-231 breast" exact="cancer" post="cell line, which does not overexpress either EGFR or"/>
   <result pre="NSC624205 on cell signaling in a small panel of human" exact="cancer" post="cell lines demonstrated variable effects depending on the cell"/>
   <result pre="analyzed by immunoblot. Overexpression of EGFR is sufficient to render" exact="breast cancer" post="cells responsive to sulfinate compound-induced toxicity T47D cells are"/>
   <result pre="by immunoblot. Overexpression of EGFR is sufficient to render breast" exact="cancer" post="cells responsive to sulfinate compound-induced toxicity T47D cells are"/>
   <result pre="A summary of the compounds tested and their activity against" exact="cancer" post="cells is presented in Figure 4C. Of the RBF"/>
   <result pre="human mammary epithelial cells (HMEC-tert) and MDA-MB-468, BT474, and SKBR3" exact="breast cancer" post="cells after incubation with the indicated concentrations of RBF3"/>
   <result pre="mammary epithelial cells (HMEC-tert) and MDA-MB-468, BT474, and SKBR3 breast" exact="cancer" post="cells after incubation with the indicated concentrations of RBF3"/>
   <result pre="present in these compounds are essential for their activity against" exact="cancer" post="cells. Our interpretation of these data is that oxidation"/>
   <result pre="of RBF3 on the viability of HER2 and EGFR overexpressing" exact="breast cancer" post="cell lines, we examined whether RBF3 had activity against"/>
   <result pre="RBF3 on the viability of HER2 and EGFR overexpressing breast" exact="cancer" post="cell lines, we examined whether RBF3 had activity against"/>
   <result pre="we examined whether RBF3 had activity against xenografts of human" exact="breast cancer." post="Strikingly, 40 mg/kg RBF3 strongly suppressed the growth of"/>
   <result pre="a small fraction of these tumors was composed of viable" exact="cancer" post="cells (Figure 6C). In separate experiments, we treated tumor-bearing"/>
   <result pre="tumor tissues from RBF3-treated animals exhibited a high frequency of" exact="cancer" post="cell death. Figure 6 DDAs Suppress Tumor Growth Without"/>
   <result pre="is precedence for related approaches for other drug targets. The" exact="breast cancer" post="drug Fulvestrant functions in part by downregulating the Estrogen"/>
   <result pre="precedence for related approaches for other drug targets. The breast" exact="cancer" post="drug Fulvestrant functions in part by downregulating the Estrogen"/>
   <result pre="before toxicity was observed. Our results showing that activity against" exact="cancer" post="cells requires compounds with a sulfinate group attached to"/>
   <result pre="Kutuk O Basaga H Protein kinases as drug targets in" exact="cancer" post="Curr Cancer Drug Targets 2006 6 623 634 17100568"/>
   <result pre="High EGFR gene copy number predicts poor outcome in triple-negative" exact="breast cancer" post="Mod Pathol 2014 27 1212 1222 24406864 5 Baselga"/>
   <result pre="EGFR gene copy number predicts poor outcome in triple-negative breast" exact="cancer" post="Mod Pathol 2014 27 1212 1222 24406864 5 Baselga"/>
   <result pre="recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 1996 14 737 744 8622019 6"/>
   <result pre="humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 1996 14 737 744 8622019 6"/>
   <result pre="as a single agent in first-line treatment of HER2-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 2002 20 719 726 11821453 7"/>
   <result pre="a single agent in first-line treatment of HER2-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 2002 20 719 726 11821453 7"/>
   <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="Andersson M et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1659 1672 16236737"/>
   <result pre="M et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1659 1672 16236737"/>
   <result pre="a review of its use in the treatment of metastatic" exact="breast cancer" post="overexpressing HER2 Drugs 2002 62 209 243 11790161 10"/>
   <result pre="review of its use in the treatment of metastatic breast" exact="cancer" post="overexpressing HER2 Drugs 2002 62 209 243 11790161 10"/>
   <result pre="Claret FX Trastuzumab: updated mechanisms of action and resistance in" exact="breast cancer" post="Front Oncol 2012 2 62 22720269 11 Hutchinson L"/>
   <result pre="FX Trastuzumab: updated mechanisms of action and resistance in breast" exact="cancer" post="Front Oncol 2012 2 62 22720269 11 Hutchinson L"/>
   <result pre="R Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing" exact="breast cancer" post="cells with primary trastuzumab resistance Anticancer Agents Med Chem"/>
   <result pre="Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast" exact="cancer" post="cells with primary trastuzumab resistance Anticancer Agents Med Chem"/>
   <result pre="11 24513440 16 Gullick WJ The c-erbB3/HER3 receptor in human" exact="cancer" post="Cancer Surv 1996 27 339 349 8909809 17 Engelman"/>
   <result pre="C et al. MET amplification leads to gefitinib resistance in" exact="lung cancer" post="by activating ERBB3 signaling Science 2007 316 1039 1043"/>
   <result pre="et al. MET amplification leads to gefitinib resistance in lung" exact="cancer" post="by activating ERBB3 signaling Science 2007 316 1039 1043"/>
   <result pre="copy numbers are associated with trastuzumab failure in HER2-positive metastatic" exact="breast cancer" post="Br J Cancer 2012 107 793 799 22850551 19"/>
   <result pre="numbers are associated with trastuzumab failure in HER2-positive metastatic breast" exact="cancer" post="Br J Cancer 2012 107 793 799 22850551 19"/>
   <result pre="MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric" exact="cancer" post="cells Mol Cancer Ther 2012 11 660 669 22238368"/>
   <result pre="182, 780, but not tamoxifen, inhibits the growth of MCF-7" exact="breast cancer" post="cells refractory to long-term oestrogen deprivation through down-regulation of"/>
   <result pre="780, but not tamoxifen, inhibits the growth of MCF-7 breast" exact="cancer" post="cells refractory to long-term oestrogen deprivation through down-regulation of"/>
   <result pre="DB Donaher JL Popescu NC Hahn WC Weinberg RA Human" exact="breast cancer" post="cells generated by oncogenic transformation of primary mammary epithelial"/>
   <result pre="Donaher JL Popescu NC Hahn WC Weinberg RA Human breast" exact="cancer" post="cells generated by oncogenic transformation of primary mammary epithelial"/>
   <result pre="growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human" exact="cancer" post="cells Mol Cell Biol 2002 22 8184 8198 12417722"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4501549/results/search/disease/results.xml">
   <result pre="to treat human epidermal growth factor receptor 2 (HER-2)-positive metastatic" exact="breast cancer." post="Despite its effectiveness in most patients, some are initially"/>
   <result pre="the relationship between caveolin-1 expression and the chemosensitivity of HER-2-positive" exact="breast cancer" post="cells to T-DM1 was investigated. Samples from 32 human"/>
   <result pre="relationship between caveolin-1 expression and the chemosensitivity of HER-2-positive breast" exact="cancer" post="cells to T-DM1 was investigated. Samples from 32 human"/>
   <result pre="cancer cells to T-DM1 was investigated. Samples from 32 human" exact="breast cancer" post="biopsy and normal tissue specimens were evaluated immunohistochemically for"/>
   <result pre="cells to T-DM1 was investigated. Samples from 32 human breast" exact="cancer" post="biopsy and normal tissue specimens were evaluated immunohistochemically for"/>
   <result pre="was shown to be expressed in 68% (22/32) of the" exact="breast cancer" post="specimens. In addition, eight (72.7%, 8/11) HER-2 positive breast"/>
   <result pre="shown to be expressed in 68% (22/32) of the breast" exact="cancer" post="specimens. In addition, eight (72.7%, 8/11) HER-2 positive breast"/>
   <result pre="breast cancer specimens. In addition, eight (72.7%, 8/11) HER-2 positive" exact="breast cancer" post="specimens had a higher caveolin-1 expression than normal tissues."/>
   <result pre="cancer specimens. In addition, eight (72.7%, 8/11) HER-2 positive breast" exact="cancer" post="specimens had a higher caveolin-1 expression than normal tissues."/>
   <result pre="higher caveolin-1 expression than normal tissues. HER-2-positive BT-474 and SKBR-3" exact="breast cancer" post="cells that express low and moderate levels of caveolin-1,"/>
   <result pre="caveolin-1 expression than normal tissues. HER-2-positive BT-474 and SKBR-3 breast" exact="cancer" post="cells that express low and moderate levels of caveolin-1,"/>
   <result pre="endocytosis and promote the internalization of T-DM1 into HER-2 positive" exact="cancer" post="cells. Thus, caveolin-1 protein may be an effective predictor"/>
   <result pre="effective predictor for determining the outcome of T-DM1 treatment in" exact="breast cancer" post="patients. Funding This work was supported by a grant"/>
   <result pre="predictor for determining the outcome of T-DM1 treatment in breast" exact="cancer" post="patients. Funding This work was supported by a grant"/>
   <result pre="factor receptor 2 (HER-2) has been identified as oncoprotein in" exact="breast cancer." post="The overexpression of HER-2 mRNA and protein occurs in"/>
   <result pre="this therapeutic treatment, naked trastuzumab targeting of HER-2 expression in" exact="breast cancer" post="is rarely curative by itself, and most of the"/>
   <result pre="therapeutic treatment, naked trastuzumab targeting of HER-2 expression in breast" exact="cancer" post="is rarely curative by itself, and most of the"/>
   <result pre="drugs to reduce systemic toxicity and increase therapeutic benefits in" exact="cancer" post="patients [ 9, 10]. HER-2-based ADC targeting have been"/>
   <result pre="HER-2-based ADC targeting have been investigated for clinical application in" exact="breast cancer" post="treatment [ 11, 12] using trastuzumab emtasime (trastuzumab-DM1; T-DM1),"/>
   <result pre="ADC targeting have been investigated for clinical application in breast" exact="cancer" post="treatment [ 11, 12] using trastuzumab emtasime (trastuzumab-DM1; T-DM1),"/>
   <result pre="conjugate binds to the HER-2 receptor on the surface of" exact="cancer" post="cells allowing for the internalization of T-DM1 and its"/>
   <result pre="inhibitor lapatinib plus capecitabine in patients with HER-2 positive advanced" exact="breast cancer" post="[ 13]. The National Comprehensive Cancer Network Guidelines (NCCN)"/>
   <result pre="lapatinib plus capecitabine in patients with HER-2 positive advanced breast" exact="cancer" post="[ 13]. The National Comprehensive Cancer Network Guidelines (NCCN)"/>
   <result pre="Network Guidelines (NCCN) approved T-DM1 application in metastatic HER-2 positive" exact="breast cancer" post="in 2013. Despite the efficacy of T-DM1, most patients"/>
   <result pre="Guidelines (NCCN) approved T-DM1 application in metastatic HER-2 positive breast" exact="cancer" post="in 2013. Despite the efficacy of T-DM1, most patients"/>
   <result pre="carried out in a first line setting, 46% of metastatic" exact="breast cancer" post="patients did not respond to T-DM1 treatment [ 14]."/>
   <result pre="out in a first line setting, 46% of metastatic breast" exact="cancer" post="patients did not respond to T-DM1 treatment [ 14]."/>
   <result pre="factor is the triggering entry of the HER-2-T-DM1 conjugate into" exact="cancer" post="cells via receptor-mediated endocytosis [ 9, 10, 16, 17]."/>
   <result pre="a clathrin-independent mechanism, such as caveolin-1 for RTKs internalization in" exact="breast cancer," post="has also been demonstrated [ 20, 21]. Caveolin-1 is"/>
   <result pre="[ 24, 25], and recent studies proved that caveolin-1 inhibits" exact="breast cancer" post="cell migration and metastasis [ 26– 29]. Trastuzumab is"/>
   <result pre="24, 25], and recent studies proved that caveolin-1 inhibits breast" exact="cancer" post="cell migration and metastasis [ 26– 29]. Trastuzumab is"/>
   <result pre="recent report, trastuzumab was demonstrated to colocalize with caveolin-1 in" exact="breast cancer" post="cells [ 31]. However, whether T-DM1 uses the same"/>
   <result pre="report, trastuzumab was demonstrated to colocalize with caveolin-1 in breast" exact="cancer" post="cells [ 31]. However, whether T-DM1 uses the same"/>
   <result pre="to primary or acquired resistance in T-DM1 treatment of metastatic" exact="breast cancer" post="[ 32]. The particular trafficking route used affects the"/>
   <result pre="primary or acquired resistance in T-DM1 treatment of metastatic breast" exact="cancer" post="[ 32]. The particular trafficking route used affects the"/>
   <result pre="age 48.5 years old) who had undergone resection for localized" exact="breast cancer" post="between April 2011 and December 2013 at Cheng-Ching General"/>
   <result pre="48.5 years old) who had undergone resection for localized breast" exact="cancer" post="between April 2011 and December 2013 at Cheng-Ching General"/>
   <result pre="stage II, and 16 patients were in stage III of" exact="breast cancer." post="Tumor histology grade, specific hormone and HER-2 receptor expressions,"/>
   <result pre="epithelial tissue (tumor site and non-tumor site) of patients with" exact="breast cancer" post="were proceeded for immunohistochemistry. Five-μm-thick paraffin sections were incubated"/>
   <result pre="tissue (tumor site and non-tumor site) of patients with breast" exact="cancer" post="were proceeded for immunohistochemistry. Five-μm-thick paraffin sections were incubated"/>
   <result pre="[ 34, 35]. Fig 1 Immunohistochemical staining of caveolin-1 in" exact="breast cancer" post="tissues. (A) Negative staining; (B) weak staining; (C) moderate"/>
   <result pre="34, 35]. Fig 1 Immunohistochemical staining of caveolin-1 in breast" exact="cancer" post="tissues. (A) Negative staining; (B) weak staining; (C) moderate"/>
   <result pre="and transfection To investigate the internalization of HER-2-based antibodies, cultured" exact="breast cancer" post="cells with or without HER-2 expression were used. In"/>
   <result pre="transfection To investigate the internalization of HER-2-based antibodies, cultured breast" exact="cancer" post="cells with or without HER-2 expression were used. In"/>
   <result pre="HER-2 expression were used. In this study, the triple negative" exact="breast cancer" post="MDA-MB-231 cell line, and MCF-7 cell line were used"/>
   <result pre="expression were used. In this study, the triple negative breast" exact="cancer" post="MDA-MB-231 cell line, and MCF-7 cell line were used"/>
   <result pre="three independent experiments were performed. Results Expression of caveolin-1 in" exact="breast cancer" post="specimens In this study, the caveolin-1 expression pattern was"/>
   <result pre="independent experiments were performed. Results Expression of caveolin-1 in breast" exact="cancer" post="specimens In this study, the caveolin-1 expression pattern was"/>
   <result pre="this study, the caveolin-1 expression pattern was examined in 32" exact="breast cancer" post="patients. Imnunohistochemical staining showed that caveolin-1 was concentrated at"/>
   <result pre="study, the caveolin-1 expression pattern was examined in 32 breast" exact="cancer" post="patients. Imnunohistochemical staining showed that caveolin-1 was concentrated at"/>
   <result pre="blot protein evaluation, 8 (72.72%) of the 11 HER-2 positive" exact="breast cancer" post="patients were found to have a high expression of"/>
   <result pre="protein evaluation, 8 (72.72%) of the 11 HER-2 positive breast" exact="cancer" post="patients were found to have a high expression of"/>
   <result pre="with heterogeneous distribution in ductal epithelial. Endocytic protein expression in" exact="breast cancer" post="cell lines The expression of the two major endocytic"/>
   <result pre="heterogeneous distribution in ductal epithelial. Endocytic protein expression in breast" exact="cancer" post="cell lines The expression of the two major endocytic"/>
   <result pre="major endocytic proteins clathrin and caveolin-1 was examined in the" exact="breast cancer" post="cell lines, MDA-MB-231, MCF-7, SKBR-3, BT-474, and ZR-75-1. Western"/>
   <result pre="endocytic proteins clathrin and caveolin-1 was examined in the breast" exact="cancer" post="cell lines, MDA-MB-231, MCF-7, SKBR-3, BT-474, and ZR-75-1. Western"/>
   <result pre="demonstrated that clathrin and caveolin-1 expression levels differed in these" exact="breast cancer" post="cell lines: caveolin-1 was highly expressed in MDA-MB-231 cells."/>
   <result pre="that clathrin and caveolin-1 expression levels differed in these breast" exact="cancer" post="cell lines: caveolin-1 was highly expressed in MDA-MB-231 cells."/>
   <result pre="on drug treatment. Fig 2 Caveolin-1 and clathrin expression in" exact="breast cancer" post="cell lines. (A) Western blot analysis of cell lysates"/>
   <result pre="drug treatment. Fig 2 Caveolin-1 and clathrin expression in breast" exact="cancer" post="cell lines. (A) Western blot analysis of cell lysates"/>
   <result pre="cell lines. (A) Western blot analysis of cell lysates of" exact="breast cancer" post="cell lines, ZR-75-1,MDA-MB-231, MCF-7, SKBR-3, and BT-474 with antibodies"/>
   <result pre="lines. (A) Western blot analysis of cell lysates of breast" exact="cancer" post="cell lines, ZR-75-1,MDA-MB-231, MCF-7, SKBR-3, and BT-474 with antibodies"/>
   <result pre="colocalization of trastuzumab and T-DM1 with caveolin-1 in HER-2 positive" exact="breast cancer" post="cells MDA-MB-231, SKBR-3 and BT-474 cells were treated with"/>
   <result pre="of trastuzumab and T-DM1 with caveolin-1 in HER-2 positive breast" exact="cancer" post="cells MDA-MB-231, SKBR-3 and BT-474 cells were treated with"/>
   <result pre="a molecular strategy was applied to regulate caveolin-1 expression in" exact="breast cancer" post="cells. BT-474 and SKBR-3 cells, which express relatively lower"/>
   <result pre="molecular strategy was applied to regulate caveolin-1 expression in breast" exact="cancer" post="cells. BT-474 and SKBR-3 cells, which express relatively lower"/>
   <result pre="demonstrated to have an oncogenic or tumor suppressor role in" exact="breast cancer" post="[ 29, 39]. It has also been suggested that"/>
   <result pre="to have an oncogenic or tumor suppressor role in breast" exact="cancer" post="[ 29, 39]. It has also been suggested that"/>
   <result pre="stromal cells has a protective effect against tumor progression in" exact="breast cancer" post="and could be a good prognostic indicator [ 35,"/>
   <result pre="cells has a protective effect against tumor progression in breast" exact="cancer" post="and could be a good prognostic indicator [ 35,"/>
   <result pre="high level of caveolin-1 expression was noted in 68.8% of" exact="breast cancer" post="specimens. This incidence is similar to that of a"/>
   <result pre="level of caveolin-1 expression was noted in 68.8% of breast" exact="cancer" post="specimens. This incidence is similar to that of a"/>
   <result pre="that of a study by Park et al with 130" exact="breast cancer" post="patients [ 35]. However, their caveolin-1 expression was correlated"/>
   <result pre="of a study by Park et al with 130 breast" exact="cancer" post="patients [ 35]. However, their caveolin-1 expression was correlated"/>
   <result pre="caveolin-1 expression in tumor cells as a predictive marker for" exact="breast cancer" post="prognosis. [ 41]. However, caveolin-1 may participate in different"/>
   <result pre="expression in tumor cells as a predictive marker for breast" exact="cancer" post="prognosis. [ 41]. However, caveolin-1 may participate in different"/>
   <result pre="depending on cell type and the genetic background of the" exact="breast cancer" post="[ 42, 43]. In our study, caveolin-1 expression varied"/>
   <result pre="on cell type and the genetic background of the breast" exact="cancer" post="[ 42, 43]. In our study, caveolin-1 expression varied"/>
   <result pre="42, 43]. In our study, caveolin-1 expression varied in different" exact="breast cancer" post="cell lines: triple negative MDA-MB-231 cells showed the greatest"/>
   <result pre="43]. In our study, caveolin-1 expression varied in different breast" exact="cancer" post="cell lines: triple negative MDA-MB-231 cells showed the greatest"/>
   <result pre="progression [ 45]. The efficacies of trastuzumab and T-DM1 in" exact="breast cancer" post="cell lines have been demonstrated previously [ 11, 37]."/>
   <result pre="[ 45]. The efficacies of trastuzumab and T-DM1 in breast" exact="cancer" post="cell lines have been demonstrated previously [ 11, 37]."/>
   <result pre="revealed effective cytotoxicity of paclitaxel in the treatment of different" exact="breast cancer" post="cells which were correlated with cell apoptosis. Although the"/>
   <result pre="effective cytotoxicity of paclitaxel in the treatment of different breast" exact="cancer" post="cells which were correlated with cell apoptosis. Although the"/>
   <result pre="endocytic protein caveolin-1 in T-DM1 internalization and improved cytotoxicity in" exact="breast cancer" post="cells. The expression of caveolin-1 in HER-2 positive breast"/>
   <result pre="protein caveolin-1 in T-DM1 internalization and improved cytotoxicity in breast" exact="cancer" post="cells. The expression of caveolin-1 in HER-2 positive breast"/>
   <result pre="breast cancer cells. The expression of caveolin-1 in HER-2 positive" exact="breast cancer" post="cells could be a potential biomarker to predict the"/>
   <result pre="cancer cells. The expression of caveolin-1 in HER-2 positive breast" exact="cancer" post="cells could be a potential biomarker to predict the"/>
   <result pre="Table Expression of HER-2, ER, PR and caveolin-1 in 32" exact="breast cancer" post="patients. (DOCX) LINK Click here for additional data file."/>
   <result pre="Expression of HER-2, ER, PR and caveolin-1 in 32 breast" exact="cancer" post="patients. (DOCX) LINK Click here for additional data file."/>
   <result pre="S1 Fig Quantification of caveolin-1 and clathrin expression in different" exact="breast cancer" post="cells. Western blot analysis of cell lysates of breast"/>
   <result pre="Fig Quantification of caveolin-1 and clathrin expression in different breast" exact="cancer" post="cells. Western blot analysis of cell lysates of breast"/>
   <result pre="breast cancer cells. Western blot analysis of cell lysates of" exact="breast cancer" post="cell lines, ZR-75-1,MDA-MB-231, MCF-7, SKBR-3, and BT-474 with antibodies"/>
   <result pre="cancer cells. Western blot analysis of cell lysates of breast" exact="cancer" post="cell lines, ZR-75-1,MDA-MB-231, MCF-7, SKBR-3, and BT-474 with antibodies"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer." post="Science. 1989; 244( 4905): 707– 12. Epub 1989/05/12. ."/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="administered as first-line treatment: the M77001 study group ."/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="administered as first-line treatment: the M77001 study group ."/>
   <result pre="compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic" exact="breast cancer" post=". J Clin Oncol. 2006; 24( 18): 2786– 92."/>
   <result pre="with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast" exact="cancer" post=". J Clin Oncol. 2006; 24( 18): 2786– 92."/>
   <result pre="P , Junutula JR . Site-specific antibody drug conjugates for" exact="cancer" post="therapy. MAbs. 2014; 6( 1): 34– 45. Epub 2014/01/16."/>
   <result pre="Parsons KL , Mai E , et al. Targeting HER2-positive" exact="breast cancer" post="with trastuzumab-DM1, an antibody-cytotoxic drug conjugate . Cancer Res."/>
   <result pre="KL , Mai E , et al. Targeting HER2-positive breast" exact="cancer" post="with trastuzumab-DM1, an antibody-cytotoxic drug conjugate . Cancer Res."/>
   <result pre="conjugate in development for human epidermal growth factor receptor 2-positive" exact="cancer" post=". Clin Cancer Res. 2011; 17( 20): 6437– 47."/>
   <result pre="Baselga J , et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med. 2012; 367( 19): 1783– 91."/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post=". J Clin Oncol. 2013; 31( 9): 1157– 63."/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post=". J Clin Oncol. 2013; 31( 9): 1157– 63."/>
   <result pre="emtansine versus treatment of physician's choice for pretreated HER2-positive advanced" exact="breast cancer" post="(TH3RESA): a randomised, open-label, phase 3 trial . Lancet"/>
   <result pre="versus treatment of physician's choice for pretreated HER2-positive advanced breast" exact="cancer" post="(TH3RESA): a randomised, open-label, phase 3 trial . Lancet"/>
   <result pre="endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against" exact="cancer" post=". FEBS J. 2014; 281( 9): 2172– 89. Epub"/>
   <result pre=". Tumor cell growth inhibition by caveolin re-expression in human" exact="breast cancer" post="cells. Oncogene. 1998; 16( 11): 1391– 7. Epub 1998/04/03."/>
   <result pre="Tumor cell growth inhibition by caveolin re-expression in human breast" exact="cancer" post="cells. Oncogene. 1998; 16( 11): 1391– 7. Epub 1998/04/03."/>
   <result pre="Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human" exact="breast cancer" post="cells . Oncogene. 2002; 21( 15): 2365– 75. Epub"/>
   <result pre="inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast" exact="cancer" post="cells . Oncogene. 2002; 21( 15): 2365– 75. Epub"/>
   <result pre="T , Lisanti MP , Pestell RG . Caveolin-1 in" exact="breast cancer." post="Cancer Biol Ther. 2004; 3( 10): 931– 41. Epub"/>
   <result pre="EK , Stanley KL , Anderson RL . Caveolin-1 inhibits" exact="breast cancer" post="growth and metastasis. Oncogene. 2004; 23( 47): 7893– 7."/>
   <result pre=", Stanley KL , Anderson RL . Caveolin-1 inhibits breast" exact="cancer" post="growth and metastasis. Oncogene. 2004; 23( 47): 7893– 7."/>
   <result pre="and sorting of ErbB2 and the site of action of" exact="cancer" post="therapeutics trastuzumab and geldanamycin . Mol Biol Cell. 2004;"/>
   <result pre="potential causative factor in the generation of trastuzumab resistance in" exact="breast cancer" post="cells . J Cancer. 2013; 4( 5): 391– 401."/>
   <result pre="causative factor in the generation of trastuzumab resistance in breast" exact="cancer" post="cells . J Cancer. 2013; 4( 5): 391– 401."/>
   <result pre="Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant" exact="breast cancer" post="cells in vivo . Breast Cancer Res. 2011; 13("/>
   <result pre="causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast" exact="cancer" post="cells in vivo . Breast Cancer Res. 2011; 13("/>
   <result pre="et al. Stromal cell expression of caveolin-1 predicts outcome in" exact="breast cancer." post="Am J Pathol. 2009; 174( 6): 2035– 43. Epub"/>
   <result pre="J , Steeg PS , et al. Caveolin-1 upregulation mediates" exact="suppression" post="of primary breast tumor growth and brain metastases by"/>
   <result pre="et al. CpG island shore methylation regulates caveolin-1 expression in" exact="breast cancer." post="Oncogene. 2013; 32( 38): 4519– 28. Epub 2012/11/07. doi:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4501645/results/search/disease/results.xml">
   <result pre="AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified" exact="breast cancer" post="models CRAFTER CLAIRE 1 2 VINCENT JOHN P. 1"/>
   <result pre="inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast" exact="cancer" post="models CRAFTER CLAIRE 1 2 VINCENT JOHN P. 1"/>
   <result pre="target of rapamycin (mTOR) signalling network is frequently de-regulated in" exact="breast cancer" post="and has been shown to mediate resistance to anti-HER2"/>
   <result pre="of rapamycin (mTOR) signalling network is frequently de-regulated in breast" exact="cancer" post="and has been shown to mediate resistance to anti-HER2"/>
   <result pre="efficacy of AZD5363, a novel AKT inhibitor, a panel of" exact="breast cancer" post="cells was dosed with AZD5363 in combination with AZD8931,"/>
   <result pre="of AZD5363, a novel AKT inhibitor, a panel of breast" exact="cancer" post="cells was dosed with AZD5363 in combination with AZD8931,"/>
   <result pre="regressions. We conclude that the activity of AZD5363 in HER2-amplified" exact="breast cancer" post="cells is enhanced by the addition of AZD8931 and"/>
   <result pre="We conclude that the activity of AZD5363 in HER2-amplified breast" exact="cancer" post="cells is enhanced by the addition of AZD8931 and"/>
   <result pre="treatment option to be explored in the clinic. AZD5363 HER2-amplified" exact="breast cancer" post="PI3K/AKT/mTOR combination therapy feedback Introduction The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian"/>
   <result pre="option to be explored in the clinic. AZD5363 HER2-amplified breast" exact="cancer" post="PI3K/AKT/mTOR combination therapy feedback Introduction The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian"/>
   <result pre="cancers and activation can occur through several different mechanisms. In" exact="breast cancer" post="these include, overexpression/amplification of HER2 (ErbB2/neu), activating mutations in"/>
   <result pre="and activation can occur through several different mechanisms. In breast" exact="cancer" post="these include, overexpression/amplification of HER2 (ErbB2/neu), activating mutations in"/>
   <result pre="factors, have subsequently been identified in HER2-amplified and ER +" exact="breast cancer" post="cells ( 16– 18). Inhibition of AKT results in"/>
   <result pre="have subsequently been identified in HER2-amplified and ER + breast" exact="cancer" post="cells ( 16– 18). Inhibition of AKT results in"/>
   <result pre="have demonstrated enhanced anti-tumour efficacy in preclinical models of HER2-amplified" exact="breast cancer" post="by combining PI3K pathway inhibitors with trastuzumab or lapatinib"/>
   <result pre="demonstrated enhanced anti-tumour efficacy in preclinical models of HER2-amplified breast" exact="cancer" post="by combining PI3K pathway inhibitors with trastuzumab or lapatinib"/>
   <result pre="proliferation and enhanced cell death in a range of HER2-amplified" exact="breast cancer" post="lines in vitro and tumour regression in vivo. These"/>
   <result pre="and enhanced cell death in a range of HER2-amplified breast" exact="cancer" post="lines in vitro and tumour regression in vivo. These"/>
   <result pre="therapeutic strategy in the clinic for the treatment of HER2-amplified" exact="breast cancer." post="Materials and methods Cell lines and treatments All cell"/>
   <result pre="signalling inhibitor AZD8931, results in synergistic growth inhibition in HER2-amplified" exact="breast cancer" post="lines A panel of 23 breast cancer cell lines,"/>
   <result pre="inhibitor AZD8931, results in synergistic growth inhibition in HER2-amplified breast" exact="cancer" post="lines A panel of 23 breast cancer cell lines,"/>
   <result pre="inhibition in HER2-amplified breast cancer lines A panel of 23" exact="breast cancer" post="cell lines, representing different segments of breast cancer, was"/>
   <result pre="in HER2-amplified breast cancer lines A panel of 23 breast" exact="cancer" post="cell lines, representing different segments of breast cancer, was"/>
   <result pre="of 23 breast cancer cell lines, representing different segments of" exact="breast cancer," post="was screened to identify cell lines in which AZD8931"/>
   <result pre="synergistic interaction between AZD5363 and AZD8931. Interestingly, two triple negative" exact="breast cancer" post="lines, MDAMB468 and BT20, which are reported to have"/>
   <result pre="interaction between AZD5363 and AZD8931. Interestingly, two triple negative breast" exact="cancer" post="lines, MDAMB468 and BT20, which are reported to have"/>
   <result pre="AZD5363 and AZD8931 we selected a mini-panel of four HER2-amplified" exact="breast cancer" post="cell lines and assessed synergistic growth inhibition using the"/>
   <result pre="and AZD8931 we selected a mini-panel of four HER2-amplified breast" exact="cancer" post="cell lines and assessed synergistic growth inhibition using the"/>
   <result pre="mechanism for inhibitors of the PI3K signalling pathway and in" exact="breast cancer" post="this frequently occurs through increased expression and phosphorylation of"/>
   <result pre="for inhibitors of the PI3K signalling pathway and in breast" exact="cancer" post="this frequently occurs through increased expression and phosphorylation of"/>
   <result pre="is therefore an attractive therapeutic strategy for the treatment of" exact="breast cancer." post="In this study, we demonstrated that the activity of"/>
   <result pre="induction of phospho HER2/3 and led to a more prominent" exact="suppression" post="of the downstream markers of PI3K pathway signalling. As"/>
   <result pre="as a potential mechanism to limit its efficacy in HER2-amplified" exact="breast cancer" post="lines. Trastuzumab has had a major impact on the"/>
   <result pre="a potential mechanism to limit its efficacy in HER2-amplified breast" exact="cancer" post="lines. Trastuzumab has had a major impact on the"/>
   <result pre="had a major impact on the treatment of HER2-amplified metastatic" exact="breast cancer." post="However, not all HER2-amplified patients respond to treatment and"/>
   <result pre="Testa JR Perturbations of the AKT signaling pathway in human" exact="cancer" post="Oncogene 24 7455 7464 2005 10.1038/sj.onc.1209085 16288292 2 Bellacosa"/>
   <result pre="PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of" exact="cancer" post="cells with activating PI3K mutations Cancer Res 68 8022"/>
   <result pre="Deregulation of the PI3K and KRAS signaling pathways in human" exact="cancer" post="cells determines their response to everolimus J Clin Invest"/>
   <result pre="Negative feedback and adaptive resistance to the targeted therapy of" exact="cancer" post="Cancer Discov 2 311 319 2012 10.1158/2159-8290.CD-12-0018 22576208 13"/>
   <result pre="Majumder PK Baselga J Rosen N AKT inhibition relieves feedback" exact="suppression" post="of receptor tyrosine kinase expression and activity Cancer Cell"/>
   <result pre="JS Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached" exact="cancer" post="cells Cancer Cell 21 227 239 2012 10.1016/j.ccr.2011.12.024 22340595"/>
   <result pre="IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive" exact="breast cancer" post="cells with resistance to estrogen deprivation Breast Cancer Res"/>
   <result pre="receptor axis compensates for inhibition of AKT in ER-positive breast" exact="cancer" post="cells with resistance to estrogen deprivation Breast Cancer Res"/>
   <result pre="PI3K pathway as a major determinant of trastuzumab resistance in" exact="breast cancer" post="Cancer Cell 12 395 402 2007 10.1016/j.ccr.2007.08.030 17936563 21"/>
   <result pre="pathway as a major determinant of trastuzumab resistance in breast" exact="cancer" post="Cancer Cell 12 395 402 2007 10.1016/j.ccr.2007.08.030 17936563 21"/>
   <result pre="al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant" exact="breast cancer" post="Clin Cancer Res 18 6784 6791 2012 10.1158/1078-0432.CCR-12-1785 23092874"/>
   <result pre="Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast" exact="cancer" post="Clin Cancer Res 18 6784 6791 2012 10.1158/1078-0432.CCR-12-1785 23092874"/>
   <result pre="required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing" exact="cancer" post="cells Clin Cancer Res 15 7266 7276 2009 10.1158/1078-0432.CCR-09-1665"/>
   <result pre="in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing" exact="breast cancer" post="Oncogene 30 2547 2557 2011 10.1038/onc.2010.626 21278786 25 Chakrabarty"/>
   <result pre="enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast" exact="cancer" post="Oncogene 30 2547 2557 2011 10.1038/onc.2010.626 21278786 25 Chakrabarty"/>
   <result pre="HER2 blockade results in antitumor activity in preclinical models of" exact="breast cancer" post="resistant to anti-HER2 therapy Clin Cancer Res 18 2603"/>
   <result pre="blockade results in antitumor activity in preclinical models of breast" exact="cancer" post="resistant to anti-HER2 therapy Clin Cancer Res 18 2603"/>
   <result pre="ERBB3: A unique agent for simultaneous ERBB receptor blockade in" exact="cancer" post="Clin Cancer Res 16 1159 1169 2010 10.1158/1078-0432.CCR-09-2353 20145185"/>
   <result pre="A2A and beta-2 adrenergic receptor agonists: Novel selective and synergistic" exact="multiple myeloma" post="targets discovered through systematic combination screening Mol Cancer Ther"/>
   <result pre="al. Systematic identification of genomic markers of drug sensitivity in" exact="cancer" post="cells Nature 483 570 575 2012 10.1038/nature11005 22460902 31"/>
   <result pre="AZD8931 synergises with AZD5363 to inhibit cell growth in HER2-amplified" exact="breast cancer" post="cell lines. A panel of HER2-amplified breast cancer cell"/>
   <result pre="synergises with AZD5363 to inhibit cell growth in HER2-amplified breast" exact="cancer" post="cell lines. A panel of HER2-amplified breast cancer cell"/>
   <result pre="in HER2-amplified breast cancer cell lines. A panel of HER2-amplified" exact="breast cancer" post="cell lines was exposed to increasing concentrations of AZD5363"/>
   <result pre="HER2-amplified breast cancer cell lines. A panel of HER2-amplified breast" exact="cancer" post="cell lines was exposed to increasing concentrations of AZD5363"/>
   <result pre="the combination of AZD5363 plus AZD8931 across a panel of" exact="breast cancer" post="cell lines representing the different segments of breast cancer."/>
   <result pre="combination of AZD5363 plus AZD8931 across a panel of breast" exact="cancer" post="cell lines representing the different segments of breast cancer."/>
   <result pre="of breast cancer cell lines representing the different segments of" exact="breast cancer." post="Cell line Synergy score HER2 ER PIK3CA mutation CAMA1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4504492/results/search/disease/results.xml">
   <result pre="GSK690693 and GSK2141795 in a panel of 22 HER2 +" exact="breast cancer" post="cell lines carrying wild type or mutant PIK3CA. We"/>
   <result pre="and GSK2141795 in a panel of 22 HER2 + breast" exact="cancer" post="cell lines carrying wild type or mutant PIK3CA. We"/>
   <result pre="HER2 and AKT targeted inhibitors in 22 HER2 + human" exact="breast cancer" post="cell lines. We used reverse-phase protein arrays (RPPA) to"/>
   <result pre="and AKT targeted inhibitors in 22 HER2 + human breast" exact="cancer" post="cell lines. We used reverse-phase protein arrays (RPPA) to"/>
   <result pre="administered singly and in combination in 22 HER2 + amplified" exact="breast cancer" post="cell lines (see Table 1 for list of cell"/>
   <result pre="singly and in combination in 22 HER2 + amplified breast" exact="cancer" post="cell lines (see Table 1 for list of cell"/>
   <result pre="50 and TGI values for lapatinib in 22 HER2 positive" exact="breast cancer" post="cell lines. Cell Line Ave GI 50 (uM) St"/>
   <result pre="and TGI values for lapatinib in 22 HER2 positive breast" exact="cancer" post="cell lines. Cell Line Ave GI 50 (uM) St"/>
   <result pre="and then clustered to generate synergy heatmaps for HER2 positive" exact="breast cancer" post="cell lines treated with AKT inhibitors: A. GSK690693; B."/>
   <result pre="then clustered to generate synergy heatmaps for HER2 positive breast" exact="cancer" post="cell lines treated with AKT inhibitors: A. GSK690693; B."/>
   <result pre="in the specific context of combination treatment of HER2 +" exact="breast cancer" post="cell lines by Lapatinib and AKT i. We observed"/>
   <result pre="the specific context of combination treatment of HER2 + breast" exact="cancer" post="cell lines by Lapatinib and AKT i. We observed"/>
   <result pre="to be an effect treatment for patients with HER2 +" exact="breast cancer" post="when used in combination with chemotherapeutic agents [ 9]"/>
   <result pre="be an effect treatment for patients with HER2 + breast" exact="cancer" post="when used in combination with chemotherapeutic agents [ 9]"/>
   <result pre="up on. The recent publication of the TCGA analysis of" exact="breast cancer" post="genomic landscape indicates that there seem to be two"/>
   <result pre="on. The recent publication of the TCGA analysis of breast" exact="cancer" post="genomic landscape indicates that there seem to be two"/>
   <result pre="synergistic interaction between lapatinib and AKT inhibitors in HER2 positive" exact="breast cancer" post="cell lines when those lines also harbor PI3K pathway"/>
   <result pre="interaction between lapatinib and AKT inhibitors in HER2 positive breast" exact="cancer" post="cell lines when those lines also harbor PI3K pathway"/>
   <result pre="are twofold. First, our findings suggest that clinical trials treating" exact="breast cancer" post="with lapatinib in combination with AKT (e.g., NCT01245205) or"/>
   <result pre="twofold. First, our findings suggest that clinical trials treating breast" exact="cancer" post="with lapatinib in combination with AKT (e.g., NCT01245205) or"/>
   <result pre="for the first RPPA study of a panel of 15" exact="breast cancer" post="cell lines. (XLSX) LINK Click here for additional data"/>
   <result pre="the first RPPA study of a panel of 15 breast" exact="cancer" post="cell lines. (XLSX) LINK Click here for additional data"/>
   <result pre="in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic" exact="breast cancer" post=". J Clin Oncol. 2010; 28( 7): 1124– 30."/>
   <result pre="combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast" exact="cancer" post=". J Clin Oncol. 2010; 28( 7): 1124– 30."/>
   <result pre="Banerji U , Workman P . Combinatorial drug therapy for" exact="cancer" post="in the post-genomic era. Nature biotechnology. 2012; 30( 7):"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre="T , et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med. 2006; 355( 26): 2733– 43."/>
   <result pre="I , et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer." post="N Engl J Med. 2005; 353( 16): 1659– 72."/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post=". J Clin Oncol. 2009; 27( 33): 5538– 46."/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post=". J Clin Oncol. 2009; 27( 33): 5538– 46."/>
   <result pre="PI3K pathway as a major determinant of trastuzumab resistance in" exact="breast cancer" post=". Cancer Cell. 2007; 12( 4): 395– 402. ."/>
   <result pre="pathway as a major determinant of trastuzumab resistance in breast" exact="cancer" post=". Cancer Cell. 2007; 12( 4): 395– 402. ."/>
   <result pre=", Serra V , et al. AKT inhibition relieves feedback" exact="suppression" post="of receptor tyrosine kinase expression and activity . Cancer"/>
   <result pre="with trastuzumab response and survival in patients with HER2-positive metastatic" exact="breast cancer" post=". Am J Pathol. 2010; 177( 4): 1647– 56."/>
   <result pre="trastuzumab response and survival in patients with HER2-positive metastatic breast" exact="cancer" post=". Am J Pathol. 2010; 177( 4): 1647– 56."/>
   <result pre="and PTEN loss with efficacy of trastuzumab therapy in metastatic" exact="breast cancer" post=". Breast Cancer Res Treat. 2011; 128( 2): 447–"/>
   <result pre="PTEN loss with efficacy of trastuzumab therapy in metastatic breast" exact="cancer" post=". Breast Cancer Res Treat. 2011; 128( 2): 447–"/>
   <result pre="FL , Fevr T , et al. A collection of" exact="breast cancer" post="cell lines for the study of functionally distinct cancer"/>
   <result pre=", Fevr T , et al. A collection of breast" exact="cancer" post="cell lines for the study of functionally distinct cancer"/>
   <result pre="breast cancer cell lines for the study of functionally distinct" exact="cancer" post="subtypes . Cancer Cell. 2006; 10( 6): 515– 27."/>
   <result pre="al. Subtype and pathway specific responses to anticancer compounds in" exact="breast cancer." post="Proc Natl Acad Sci U S A. 2011 ."/>
   <result pre=", et al. A systems analysis of the chemosensitivity of" exact="breast cancer" post="cells to the polyamine analogue PG-11047 . BMC Med."/>
   <result pre="et al. A systems analysis of the chemosensitivity of breast" exact="cancer" post="cells to the polyamine analogue PG-11047 . BMC Med."/>
   <result pre="a novel proteomic technology and utility for analysis of primary" exact="leukemia" post="specimens and hematopoietic stem cells . Mol Cancer Ther."/>
   <result pre="and proteomic analysis of PIK3CA, PTEN, and AKT mutations in" exact="breast cancer" post=". Cancer Res. 2008; 68( 15): 6084– 91. doi:"/>
   <result pre="proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast" exact="cancer" post=". Cancer Res. 2008; 68( 15): 6084– 91. doi:"/>
   <result pre="and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of" exact="breast cancer" post="cells to MEK inhibition . Cancer Res. 2009; 69("/>
   <result pre="MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast" exact="cancer" post="cells to MEK inhibition . Cancer Res. 2009; 69("/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4506360/results/search/disease/results.xml">
   <result pre="investments in the development of new agents only 5% of" exact="cancer" post="drugs entering Phase I clinical trials are ultimately approved"/>
   <result pre="Phase I clinical trials are ultimately approved for routine clinical" exact="cancer" post="care. Drug repurposing strategies using novel combinations of previously"/>
   <result pre="challenges with drug repurposing strategies. Drug repurposing early phase trial" exact="cancer" post="drug development INTRODUCTION Despite the tremendous resources invested in"/>
   <result pre="development INTRODUCTION Despite the tremendous resources invested in anticancer therapy," exact="cancer" post="remains among leading causes of mortality worldwide [ 1]."/>
   <result pre="utilizing existing drugs in novel combinations and regimens for enduring" exact="cancer" post="indications. The major advantages of this &quot;drug repurposing&quot; approach"/>
   <result pre="2], and multiple studies have shown their potential benefit in" exact="cancer" post="care [ 3- 8], the design, conduct, and most"/>
   <result pre="the broader application of this approach. Drug repurposing strategies for" exact="cancer" post="therapy in early phase clinical trials Our department has"/>
   <result pre="noticed remarkable activity in several distinct tumor types, including metaplastic" exact="breast cancer" post="(MpBC) [ 8] and gynecologic malignancies [ 6]. MpBC"/>
   <result pre="remarkable activity in several distinct tumor types, including metaplastic breast" exact="cancer" post="(MpBC) [ 8] and gynecologic malignancies [ 6]. MpBC"/>
   <result pre="gynecologic malignancies [ 6]. MpBC is a rare subtype of" exact="breast cancer" post="that typically does not express estrogen/progesterone receptors or human"/>
   <result pre="malignancies [ 6]. MpBC is a rare subtype of breast" exact="cancer" post="that typically does not express estrogen/progesterone receptors or human"/>
   <result pre="2 (HER2) and thus usually is treated as a triple-negative" exact="breast cancer." post="However, MpBC patients experience more disease recurrence, and associated"/>
   <result pre="and associated poorer overall survival, than other patients with triple-negative" exact="breast cancer" post="and generally have a poor response to systemic therapy"/>
   <result pre="associated poorer overall survival, than other patients with triple-negative breast" exact="cancer" post="and generally have a poor response to systemic therapy"/>
   <result pre="after 6 cycles of DAT, and the patient has been" exact="cancer" post="free for more than 5 years and continues on"/>
   <result pre="[50%] [ 6]. The DAT regimen was effective in diverse" exact="cancer" post="types, including endometrial endometrioid carcinoma (6/15 [40%] PR), epithelial"/>
   <result pre="contrasts starkly with the rapid approval of crizotinib for anaplastic" exact="lymphoma" post="kinase gene–rearranged non-small cell lung cancer (NSCLC); crizotinib was"/>
   <result pre="approval of crizotinib for anaplastic lymphoma kinase gene–rearranged non-small cell" exact="lung cancer" post="(NSCLC); crizotinib was approved approximately 2 years after its"/>
   <result pre="of crizotinib for anaplastic lymphoma kinase gene–rearranged non-small cell lung" exact="cancer" post="(NSCLC); crizotinib was approved approximately 2 years after its"/>
   <result pre="is approved by the FDA for treatment of cutaneous T-cell" exact="lymphoma" post="and has a single-agent response rate of 4% in"/>
   <result pre="and has a single-agent response rate of 4% in Hodgkin" exact="lymphoma" post="refractory to standard therapies [ 12]. Novel HDAC inhibitors"/>
   <result pre="vorinostat. During the dose-escalation phase, we observed anticancer activity in" exact="hepatocellular carcinoma" post="and perivascular epithelioid cell tumor (data not shown) and"/>
   <result pre="in treatment-refractory Hodgkin lymphoma. The 28 patients with treatment-refractory Hodgkin" exact="lymphoma" post="enrolled in the study had received a median of"/>
   <result pre="and modifications: 15/28 [54%]). Considering that patients with refractory Hodgkin" exact="lymphoma" post="generally have a poor clinical outcome, the combination of"/>
   <result pre="trastuzumab and lapatinib with bevacizumab in patients with metastatic HER2-positive" exact="breast cancer" post="pretreated with a median of 7 regimens, including HER2-targeted"/>
   <result pre="and lapatinib with bevacizumab in patients with metastatic HER2-positive breast" exact="cancer" post="pretreated with a median of 7 regimens, including HER2-targeted"/>
   <result pre="experience has shown favorable outcomes with certain drug-repurposing strategies in" exact="cancer" post="treatment, (Figure 1) which may reduce the cost and"/>
   <result pre="RScueRX Inc. References REFERENCES 1 collab: Group UCSW United States" exact="cancer" post="statistics: 1999–2006 incidence and mortality web-based report Atlanta, GA"/>
   <result pre="combination with anti-VEGF treatment is active in heavily pretreated HER2-positive" exact="breast cancer" post="Ann Oncol 2013 24 12 3004 3011 24158411 4"/>
   <result pre="with anti-VEGF treatment is active in heavily pretreated HER2-positive breast" exact="cancer" post="Ann Oncol 2013 24 12 3004 3011 24158411 4"/>
   <result pre="anti-VEGF treatment: a phase I clinical trial in non-small cell" exact="lung cancer" post="Oncotarget 2013 4 1 118 127 23435217 5 Janku"/>
   <result pre="treatment: a phase I clinical trial in non-small cell lung" exact="cancer" post="Oncotarget 2013 4 1 118 127 23435217 5 Janku"/>
   <result pre="sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin" exact="lymphoma" post="patients American Society of Clinical Oncology Annual Meeting Chicago,"/>
   <result pre="the breast: biologic rationale and implications for stem-cell research in" exact="breast cancer" post="J Clin Oncol 2011 29 19 e572 575 21482991"/>
   <result pre="breast: biologic rationale and implications for stem-cell research in breast" exact="cancer" post="J Clin Oncol 2011 29 19 e572 575 21482991"/>
   <result pre="Shen A Engert A Panobinostat in patients with relapsed/refractory Hodgkin's" exact="lymphoma" post="after autologous stem-cell transplantation: results of a phase II"/>
   <result pre="panobinostat induces cell death and synergizes with everolimus in Hodgkin" exact="lymphoma" post="cell lines Blood 2012 119 17 4017 4025 22408261"/>
   <result pre="of panobinostat plus everolimus in patients with relapsed or refractory" exact="lymphoma" post="Clin Cancer Res 2013 19 24 6882 6890 24097867"/>
   <result pre="signaling synergizes with EGFR in tumor cells to promote epithelial" exact="cancer" post="development Cell 2010 140 2 268 279 20141840 18"/>
   <result pre="A Bachelot T et al. Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2012 366 6 520 529"/>
   <result pre="Bachelot T et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2012 366 6 520 529"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4506361/results/search/disease/results.xml">
   <result pre="genes and 47 introns of 19 genes commonly rearranged in" exact="cancer" post="was applied to ≥ 50 ng of DNA extracted"/>
   <result pre="median coverage depth of &amp;gt; 500x [ 2]. DISCUSSION Colorectal" exact="cancer" post="affects a substantial patient population, with an estimated 132,700"/>
   <result pre="annually, making this disease the second most common cause of" exact="cancer" post="death in men and women combined [ 3]. Prognosis"/>
   <result pre="[ 12, 13]. Studies of ERBB2 amplification in gastric and" exact="breast cancer" post="patients have shown a correlation between copy number alteration"/>
   <result pre="12, 13]. Studies of ERBB2 amplification in gastric and breast" exact="cancer" post="patients have shown a correlation between copy number alteration"/>
   <result pre="targeted therapy, akin to the same phenomenon in ERBB2 amplified" exact="breast cancer," post="but quantitative estimates of copy number were not available"/>
   <result pre="trastuzumab and lapatinib in this sub group of ERBB2 amplified" exact="cancer" post="as identified by FISH or IHC was without significant"/>
   <result pre="precedent one as another surrogate for biologic effect in advanced" exact="cancer" post="[ 24]. The current case of a patient treated"/>
   <result pre="The American Joint Committee on Cancer: the of the AJCC" exact="cancer" post="staging manual and the future of TNM Ann Surg"/>
   <result pre="Brennan K et al. Development and validation of a clinical" exact="cancer" post="genomic profiling test based on massively parallel DNA sequencing"/>
   <result pre="Cancer Society 2015 4 Stathopoulos GP Survival of untreated advanced" exact="colorectal cancer" post="patients Oncology Letters 2011 2 4 731 733 22848257"/>
   <result pre="Society 2015 4 Stathopoulos GP Survival of untreated advanced colorectal" exact="cancer" post="patients Oncology Letters 2011 2 4 731 733 22848257"/>
   <result pre="6 15 6 582 9 24903996 11 Ross JS Breast" exact="cancer" post="biomarkers and HER2 testing after 10 years of anti-HER2"/>
   <result pre="amplification predicts response and overall survival in HER2-positive advanced gastric" exact="cancer" post="treated with trastuzumab J Clin Oncol 2013 12 10"/>
   <result pre="trastuzumab in a patient with metastatic HER-2 gene amplified rectal" exact="cancer" post="Cancer Invest 2011 8 29 7 456 9 21696295"/>
   <result pre="Schröder CP Reyners AKL A 21-year-old patient with a HER2-positive" exact="colorectal cancer" post="Gastroenterology 2015 1 148 1 20 1 25447849 18"/>
   <result pre="CP Reyners AKL A 21-year-old patient with a HER2-positive colorectal" exact="cancer" post="Gastroenterology 2015 1 148 1 20 1 25447849 18"/>
   <result pre="Lonardi S et al. Trastuzumab and lapatinib in HER2-amplified metastatic" exact="colorectal cancer" post="patients (mCRC): The HERACLES trial J Clin Oncol 33"/>
   <result pre="S et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal" exact="cancer" post="patients (mCRC): The HERACLES trial J Clin Oncol 33"/>
   <result pre="(LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic" exact="colorectal cancer" post="(CRC) refractory to initial therapy Onkologie 2003 26 suppl3"/>
   <result pre="oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal" exact="cancer" post="(CRC) refractory to initial therapy Onkologie 2003 26 suppl3"/>
   <result pre="Chen HX Finkelstein S Low overexpression of HER-2/neu in advanced" exact="colorectal cancer" post="limits the usefulness of trastuzumab (Herceptin) and irinotecan as"/>
   <result pre="HX Finkelstein S Low overexpression of HER-2/neu in advanced colorectal" exact="cancer" post="limits the usefulness of trastuzumab (Herceptin) and irinotecan as"/>
   <result pre="Bang Y-J Kim NK Single-agent capecitabine in patients with metastatic" exact="colorectal cancer" post="refractory to 5-fluorouracil/leucovorin chemotherapy Jpn J Clin Oncol 2004"/>
   <result pre="Y-J Kim NK Single-agent capecitabine in patients with metastatic colorectal" exact="cancer" post="refractory to 5-fluorouracil/leucovorin chemotherapy Jpn J Clin Oncol 2004"/>
   <result pre="B Lindmark G Prognostic value of p53 genetic changes in" exact="colorectal cancer" post="J Clin Oncol 1999 2 17 2 593 9"/>
   <result pre="Lindmark G Prognostic value of p53 genetic changes in colorectal" exact="cancer" post="J Clin Oncol 1999 2 17 2 593 9"/>
   <result pre="versus overall survival as a first-line end point for metastatic" exact="colorectal cancer" post="in modern randomized trials: findings from the analysis and"/>
   <result pre="overall survival as a first-line end point for metastatic colorectal" exact="cancer" post="in modern randomized trials: findings from the analysis and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4511219/results/search/disease/results.xml">
   <result pre="reviewed new evidence on locoregional and systemic therapies for early" exact="breast cancer." post="This manuscript presents news and progress since the 2013"/>
   <result pre="substantial new evidence on locoregional and systemic therapies for early" exact="breast cancer." post="Further experience has supported the adequacy of tumor margins"/>
   <result pre="responsive disease, the Panel endorsed the role of ovarian function" exact="suppression" post="with either tamoxifen or exemestane for patients at higher"/>
   <result pre="chemotherapy for premenopausal women with ER-negative disease in protecting against" exact="premature ovarian failure" post="and preserving fertility. The Panel noted increasing evidence for"/>
   <result pre="unavailable in much of the world. The majority of new" exact="breast cancer" post="cases and breast cancer deaths now occur in less"/>
   <result pre="in much of the world. The majority of new breast" exact="cancer" post="cases and breast cancer deaths now occur in less"/>
   <result pre="the world. The majority of new breast cancer cases and" exact="breast cancer" post="deaths now occur in less developed regions of the"/>
   <result pre="world. The majority of new breast cancer cases and breast" exact="cancer" post="deaths now occur in less developed regions of the"/>
   <result pre="Oncology online . surgery radiation therapy systemic adjuvant therapies early" exact="breast cancer" post="St Gallen Consensus Funding CA75362 United States National Cancer"/>
   <result pre="online . surgery radiation therapy systemic adjuvant therapies early breast" exact="cancer" post="St Gallen Consensus Funding CA75362 United States National Cancer"/>
   <result pre="large part of the world has an increasing incidence of" exact="breast cancer," post="but limited resources to treat it. The majority of"/>
   <result pre="it. The majority of new cases and the majority of" exact="breast cancer" post="deaths now occur in less developed regions of the"/>
   <result pre="The majority of new cases and the majority of breast" exact="cancer" post="deaths now occur in less developed regions of the"/>
   <result pre="SOFT and TEXT trials clarifying the role of ovarian function" exact="suppression" post="with tamoxifen or exemestane in the endocrine treatment of"/>
   <result pre="the treatments differed, although there was no significant difference in" exact="breast cancer" post="mortality in trials comparing 5 years of an AI"/>
   <result pre="treatments differed, although there was no significant difference in breast" exact="cancer" post="mortality in trials comparing 5 years of an AI"/>
   <result pre="AI to the sequence of tamoxifen followed by an AI." exact="breast cancer" post="subtypes Extensive genomic analysis of breast cancers discloses four"/>
   <result pre="to the sequence of tamoxifen followed by an AI. breast" exact="cancer" post="subtypes Extensive genomic analysis of breast cancers discloses four"/>
   <result pre="the majority of women with T1 and T2 clinically node-negative" exact="breast cancer" post="[ 6]. Extent of locoregional radiotherapy Two recent radiotherapy"/>
   <result pre="majority of women with T1 and T2 clinically node-negative breast" exact="cancer" post="[ 6]. Extent of locoregional radiotherapy Two recent radiotherapy"/>
   <result pre="in two series [ 37]. Reducing the risk of chemotherapy-induced" exact="premature ovarian failure" post="In the recently reported POEMS study [ 5], OFS"/>
   <result pre="OFS with LHRH analogue during chemotherapy for patients with receptor-negative" exact="breast cancer" post="reduced the incidence of premature ovarian failure, confirming the"/>
   <result pre="with LHRH analogue during chemotherapy for patients with receptor-negative breast" exact="cancer" post="reduced the incidence of premature ovarian failure, confirming the"/>
   <result pre="for patients with receptor-negative breast cancer reduced the incidence of" exact="premature ovarian failure," post="confirming the report of Del Mastro et al. ["/>
   <result pre="of mutations and other genetic abnormalities in patients with recurrent" exact="breast cancer." post="Apart from a small number of frequently mutated genes,"/>
   <result pre="49], the distinction between these and other types of triple-negative" exact="breast cancer" post="is important for choice of chemotherapy in that carboplatin"/>
   <result pre="the distinction between these and other types of triple-negative breast" exact="cancer" post="is important for choice of chemotherapy in that carboplatin"/>
   <result pre="metastatic setting [ 50]. Further dissection of subtypes within triple-negative" exact="breast cancer" post="reveals seven distinct groupings, which differ markedly in their"/>
   <result pre="setting [ 50]. Further dissection of subtypes within triple-negative breast" exact="cancer" post="reveals seven distinct groupings, which differ markedly in their"/>
   <result pre="treatment in the PALOMA-1/TRIO-18 randomized phase II trial in metastatic" exact="breast cancer" post="[ 60]. Targeting DNA repair pathways Patients with deficient"/>
   <result pre="in the PALOMA-1/TRIO-18 randomized phase II trial in metastatic breast" exact="cancer" post="[ 60]. Targeting DNA repair pathways Patients with deficient"/>
   <result pre="study, tamoxifen was associated with a reduced risk of contralateral" exact="breast cancer" post="in patients with BRCA 1 and BRCA 2 mutations"/>
   <result pre="tamoxifen was associated with a reduced risk of contralateral breast" exact="cancer" post="in patients with BRCA 1 and BRCA 2 mutations"/>
   <result pre="with BRCA 1 and BRCA 2 mutations where the index" exact="cancer" post="was ER-positive or ER-negative [ 67]. Primary prevention Recent"/>
   <result pre="lesser extent) even without atypia as a risk factor for" exact="breast cancer" post="incidence [ 68]. ER and PgR testing A large"/>
   <result pre="extent) even without atypia as a risk factor for breast" exact="cancer" post="incidence [ 68]. ER and PgR testing A large"/>
   <result pre="76]. An improved pCR rate was also observed in triple-negative" exact="breast cancer" post="using nab-paclitaxel instead of solvent-based paclitaxel [ 50]. pCR"/>
   <result pre="An improved pCR rate was also observed in triple-negative breast" exact="cancer" post="using nab-paclitaxel instead of solvent-based paclitaxel [ 50]. pCR"/>
   <result pre="50]. pCR rates were higher in patients with lymphocyte predominant" exact="breast cancer," post="either triple-negative or HER2-positive, who were treated with carboplatin"/>
   <result pre="nodes may be associated with a survival benefit in node-positive" exact="breast cancer" post="[ 99]. Adjuvant systemic endocrine therapies in premenopausal patients"/>
   <result pre="may be associated with a survival benefit in node-positive breast" exact="cancer" post="[ 99]. Adjuvant systemic endocrine therapies in premenopausal patients"/>
   <result pre="allocation during the first 5 years [ 104]. Lifestyle and" exact="obesity" post="Obesity has been associated with poor breast cancer outcomes."/>
   <result pre="104]. Lifestyle and obesity Obesity has been associated with poor" exact="breast cancer" post="outcomes. The use of anastrozole (but not letrozole) in"/>
   <result pre="Lifestyle and obesity Obesity has been associated with poor breast" exact="cancer" post="outcomes. The use of anastrozole (but not letrozole) in"/>
   <result pre="[ 107]. A study of bone marrow neoplasms following systemic" exact="breast cancer" post="therapy showed a slightly higher incidence (0.4%–0.5% at 10"/>
   <result pre="107]. A study of bone marrow neoplasms following systemic breast" exact="cancer" post="therapy showed a slightly higher incidence (0.4%–0.5% at 10"/>
   <result pre="LHRH agonist therapy during chemotherapy proved effective to protect against" exact="premature ovarian failure" post="and preserve fertility in young women with ER-negative breast"/>
   <result pre="ovarian failure and preserve fertility in young women with ER-negative" exact="breast cancer" post="undergoing chemotherapy [ 5, 112]. A global observational trial"/>
   <result pre="failure and preserve fertility in young women with ER-negative breast" exact="cancer" post="undergoing chemotherapy [ 5, 112]. A global observational trial"/>
   <result pre="that the preferred treatment of postmenopausal women with ‘luminal A-like’" exact="breast cancer" post="not suitable for breast-conserving surgery at diagnosis was endocrine"/>
   <result pre="the preferred treatment of postmenopausal women with ‘luminal A-like’ breast" exact="cancer" post="not suitable for breast-conserving surgery at diagnosis was endocrine"/>
   <result pre="to influence locoregional and neoadjuvant treatment, but not adjuvant therapy." exact="breast cancer" post="diagnosed during pregnancy For patients whose breast cancer was"/>
   <result pre="influence locoregional and neoadjuvant treatment, but not adjuvant therapy. breast" exact="cancer" post="diagnosed during pregnancy For patients whose breast cancer was"/>
   <result pre="adjuvant therapy. breast cancer diagnosed during pregnancy For patients whose" exact="breast cancer" post="was diagnosed during pregnancy premature delivery should be avoided"/>
   <result pre="therapy. breast cancer diagnosed during pregnancy For patients whose breast" exact="cancer" post="was diagnosed during pregnancy premature delivery should be avoided"/>
   <result pre="immediate post mastectomy reconstruction could be considered. attempting pregnancy after" exact="breast cancer" post="The Panel acknowledged the possibility of interrupting endocrine therapy"/>
   <result pre="post mastectomy reconstruction could be considered. attempting pregnancy after breast" exact="cancer" post="The Panel acknowledged the possibility of interrupting endocrine therapy"/>
   <result pre="attempted pregnancy, but only in the absence of high-risk features." exact="male breast cancer" post="Recognizing that the current adjuvant treatment of males with"/>
   <result pre="pregnancy, but only in the absence of high-risk features. male" exact="breast cancer" post="Recognizing that the current adjuvant treatment of males with"/>
   <result pre="but only in the absence of high-risk features. male breast" exact="cancer" post="Recognizing that the current adjuvant treatment of males with"/>
   <result pre="cancer Recognizing that the current adjuvant treatment of males with" exact="breast cancer" post="is tamoxifen, the Panel did not support the use"/>
   <result pre="Recognizing that the current adjuvant treatment of males with breast" exact="cancer" post="is tamoxifen, the Panel did not support the use"/>
   <result pre="known BRCA mutation. Table 2. Treatment-oriented classification of subgroups of" exact="breast cancer" post="Clinical grouping Notes Triple-negative Negative ER, PgR, and HER2"/>
   <result pre="BRCA mutation. Table 2. Treatment-oriented classification of subgroups of breast" exact="cancer" post="Clinical grouping Notes Triple-negative Negative ER, PgR, and HER2"/>
   <result pre="Gallen Consensus process for the optimal treatment of women with" exact="breast cancer" post=". Breast 2015; 24 (Suppl 1): PG 0.1. 3"/>
   <result pre="Consensus process for the optimal treatment of women with breast" exact="cancer" post=". Breast 2015; 24 (Suppl 1): PG 0.1. 3"/>
   <result pre="MM , Walley BA et al. Adjuvant exemestane with ovarian" exact="suppression" post="in premenopausal breast cancer. N Engl J Med 2014;"/>
   <result pre="BA et al. Adjuvant exemestane with ovarian suppression in premenopausal" exact="breast cancer." post="N Engl J Med 2014; 371: 107– 118. 24881463"/>
   <result pre=", Regan MM , Fleming GF et al. Adjuvant ovarian" exact="suppression" post="in premenopausal breast cancer. N Engl J Med 2015;"/>
   <result pre=", Fleming GF et al. Adjuvant ovarian suppression in premenopausal" exact="breast cancer." post="N Engl J Med 2015; 372: 436– 446. 25495490"/>
   <result pre="surgery with whole-breast irradiation in stages I and II invasive" exact="breast cancer" post=". J Clin Oncol 2014; 32: 1507– 1515. 24516019"/>
   <result pre="with whole-breast irradiation in stages I and II invasive breast" exact="cancer" post=". J Clin Oncol 2014; 32: 1507– 1515. 24516019"/>
   <result pre="MA.20: an intergroup trial of regional nodal irradiation in early" exact="breast cancer" post=". In Proceedings of the American Society of Clinical"/>
   <result pre="an intergroup trial of regional nodal irradiation in early breast" exact="cancer" post=". In Proceedings of the American Society of Clinical"/>
   <result pre="al. No clear effect of postoperative radiotherapy on survival of" exact="breast cancer" post="patients with 1–3 positive nodes: a population-based study ."/>
   <result pre="No clear effect of postoperative radiotherapy on survival of breast" exact="cancer" post="patients with 1–3 positive nodes: a population-based study ."/>
   <result pre="MN et al. Long-term results of hypofractionated radiation therapy for" exact="breast cancer." post="N Engl J Med 2010; 362: 513– 520. 20147717"/>
   <result pre="RR , Rodriguez-Lescure A , Ebbert MT et al. PAM50" exact="breast cancer" post="subtyping by RT-qPCR and concordance with standard clinical molecular"/>
   <result pre=", Rodriguez-Lescure A , Ebbert MT et al. PAM50 breast" exact="cancer" post="subtyping by RT-qPCR and concordance with standard clinical molecular"/>
   <result pre="et al. Molecular subtyping predicts pathologic tumor response in early-stage" exact="breast cancer" post="treated with neoadjuvant docetaxel plus capecitabine with or without"/>
   <result pre="al. Molecular subtyping predicts pathologic tumor response in early-stage breast" exact="cancer" post="treated with neoadjuvant docetaxel plus capecitabine with or without"/>
   <result pre="impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early" exact="breast cancer" post="resulting in a risk-adapted change in chemotherapy use ."/>
   <result pre="adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast" exact="cancer" post="resulting in a risk-adapted change in chemotherapy use ."/>
   <result pre="of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A" exact="breast cancer" post=". J Clin Oncol 2013; 31: 203– 209. 23233704"/>
   <result pre="progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast" exact="cancer" post=". J Clin Oncol 2013; 31: 203– 209. 23233704"/>
   <result pre="with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive" exact="breast cancer" post=". Clin Cancer Res 2010; 16: 5222– 5232. 20837693"/>
   <result pre="immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast" exact="cancer" post=". Clin Cancer Res 2010; 16: 5222– 5232. 20837693"/>
   <result pre="expression profiles in breast cancer: toward a unified understanding of" exact="breast cancer" post="subtyping and prognosis signatures . Breast Cancer Res 2008;"/>
   <result pre="profiles in breast cancer: toward a unified understanding of breast" exact="cancer" post="subtyping and prognosis signatures . Breast Cancer Res 2008;"/>
   <result pre="to endocrine therapy in luminal B HER2 negative and node-positive" exact="breast cancer" post=". Breast 2014; 23: 69– 75. 24314620 26 Denkert"/>
   <result pre="endocrine therapy in luminal B HER2 negative and node-positive breast" exact="cancer" post=". Breast 2014; 23: 69– 75. 24314620 26 Denkert"/>
   <result pre="M et al. Evolution of sites of recurrence after early" exact="breast cancer" post="over the last 20 years: implications for patient care"/>
   <result pre="et al. Evolution of sites of recurrence after early breast" exact="cancer" post="over the last 20 years: implications for patient care"/>
   <result pre="Axillary dissection vs no axillary dissection in women with invasive" exact="breast cancer" post="and sentinel node metastasis . JAMA 2011; 305: 569–"/>
   <result pre="dissection vs no axillary dissection in women with invasive breast" exact="cancer" post="and sentinel node metastasis . JAMA 2011; 305: 569–"/>
   <result pre="surgery of the axilla after a positive sentinel node in" exact="breast cancer" post="(EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3"/>
   <result pre="of the axilla after a positive sentinel node in breast" exact="cancer" post="(EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3"/>
   <result pre="L et al. Factors predicting late recurrence for estrogen receptor-positive" exact="breast cancer." post="J Natl Cancer Inst Monogr 2013; 105: 1504– 1511."/>
   <result pre="score provides prognostic information on late distant metastases in ER+/HER2-" exact="breast cancer" post="patients . Br J Cancer 2013; 109: 2959– 2964."/>
   <result pre="provides prognostic information on late distant metastases in ER+/HER2- breast" exact="cancer" post="patients . Br J Cancer 2013; 109: 2959– 2964."/>
   <result pre="Y , Schnabel CA , Schroeder BE et al. Breast" exact="cancer" post="index identifies early-stage estrogen receptor-positive breast cancer patients at"/>
   <result pre="BE et al. Breast cancer index identifies early-stage estrogen receptor-positive" exact="breast cancer" post="patients at risk for early- and late-distant recurrence ."/>
   <result pre="et al. Breast cancer index identifies early-stage estrogen receptor-positive breast" exact="cancer" post="patients at risk for early- and late-distant recurrence ."/>
   <result pre="the occurrence of chemotherapy-induced early menopause in premenopausal women with" exact="breast cancer" post=". JAMA 2011; 306: 269– 276. 21771987 39 Gerber"/>
   <result pre="occurrence of chemotherapy-induced early menopause in premenopausal women with breast" exact="cancer" post=". JAMA 2011; 306: 269– 276. 21771987 39 Gerber"/>
   <result pre="luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant" exact="breast cancer" post="chemotherapy: the GBG 37 ZORO study . J Clin"/>
   <result pre="hormone-releasing hormone agonist on ovarian function after modern adjuvant breast" exact="cancer" post="chemotherapy: the GBG 37 ZORO study . J Clin"/>
   <result pre="surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic" exact="breast cancer" post="subtypes . Breast Cancer Res 2014; 16: R65. 24951027"/>
   <result pre="definitions of luminal A and luminal B (HER2-negative) intrinsic breast" exact="cancer" post="subtypes . Breast Cancer Res 2014; 16: R65. 24951027"/>
   <result pre="predictor identifies higher responses and improved survival outcomes in HER2-positive" exact="breast cancer" post="in the NOAH study . Clin Cancer Res 2014;"/>
   <result pre="identifies higher responses and improved survival outcomes in HER2-positive breast" exact="cancer" post="in the NOAH study . Clin Cancer Res 2014;"/>
   <result pre="MC et al. Molecular characterization of basal-like and non-basal-like triple-negative" exact="breast cancer" post=". Oncologist 2013; 18: 123– 133. 23404817 50 Loibl"/>
   <result pre="et al. Molecular characterization of basal-like and non-basal-like triple-negative breast" exact="cancer" post=". Oncologist 2013; 18: 123– 133. 23404817 50 Loibl"/>
   <result pre="et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative" exact="breast cancer" post="molecular subtypes . Clin Cancer Res 2013; 19: 5533–"/>
   <result pre="al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast" exact="cancer" post="molecular subtypes . Clin Cancer Res 2013; 19: 5533–"/>
   <result pre="JA , Chen X et al. Identification of human triple-negative" exact="breast cancer" post="subtypes and preclinical models for selection of targeted therapies"/>
   <result pre=", Chen X et al. Identification of human triple-negative breast" exact="cancer" post="subtypes and preclinical models for selection of targeted therapies"/>
   <result pre="in triple-negative breast cancers from two phase III randomized adjuvant" exact="breast cancer" post="trials: ECOG 2197 and ECOG 1199 . J Clin"/>
   <result pre="triple-negative breast cancers from two phase III randomized adjuvant breast" exact="cancer" post="trials: ECOG 2197 and ECOG 1199 . J Clin"/>
   <result pre="et al. Tumor infiltrating lymphocytes are prognostic in triple negative" exact="breast cancer" post="and predictive for trastuzumab benefit in early breast cancer:"/>
   <result pre="al. Tumor infiltrating lymphocytes are prognostic in triple negative breast" exact="cancer" post="and predictive for trastuzumab benefit in early breast cancer:"/>
   <result pre="by neutralizing IL6 antibodies, with implications for combined therapy in" exact="ovarian cancer" post=". Cancer Res 2015; 75: 1255–1264. 57 Herbst RS"/>
   <result pre="neutralizing IL6 antibodies, with implications for combined therapy in ovarian" exact="cancer" post=". Cancer Res 2015; 75: 1255–1264. 57 Herbst RS"/>
   <result pre="Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in" exact="cancer" post="patients. Nature 2014; 515: 563– 567. 25428504 58 Curigliano"/>
   <result pre="Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative" exact="breast cancer" post=". Cancer Res Suppl 2015; (Suppl): S1-09. 60 Finn"/>
   <result pre="study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast" exact="cancer" post=". Cancer Res Suppl 2015; (Suppl): S1-09. 60 Finn"/>
   <result pre="letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced" exact="breast cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study . Lancet Oncol"/>
   <result pre="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast" exact="cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study . Lancet Oncol"/>
   <result pre="and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated" exact="breast cancer" post="with assessment of a tumor-based measure of genomic instability:"/>
   <result pre="iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast" exact="cancer" post="with assessment of a tumor-based measure of genomic instability:"/>
   <result pre="in patients with germline BRCA (g BRCA) mutation and triple-negative" exact="breast cancer" post="(TNBC): results from GeparSixto . J Clin Oncol 2014;"/>
   <result pre="patients with germline BRCA (g BRCA) mutation and triple-negative breast" exact="cancer" post="(TNBC): results from GeparSixto . J Clin Oncol 2014;"/>
   <result pre="with metastatic or recurrent locally advanced triple negative or BRCA1/2" exact="breast cancer" post="CRUK/07/012) . Cancer Res Suppl 2014; 75: S3-01. 64"/>
   <result pre="metastatic or recurrent locally advanced triple negative or BRCA1/2 breast" exact="cancer" post="CRUK/07/012) . Cancer Res Suppl 2014; 75: S3-01. 64"/>
   <result pre="Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in" exact="breast cancer." post="Clin Cancer Res 2013; 19: 3693– 3702. 23658459 66"/>
   <result pre=", Rookus MA et al. Tamoxifen and risk of contralateral" exact="breast cancer" post="for BRCA1 and BRCA2 mutation carriers. J Clin Oncol"/>
   <result pre="Rookus MA et al. Tamoxifen and risk of contralateral breast" exact="cancer" post="for BRCA1 and BRCA2 mutation carriers. J Clin Oncol"/>
   <result pre="MJ et al. An epigenomic approach to therapy for tamoxifen-resistant" exact="breast cancer." post="Cell Res 2014; 24: 809– 819. 24874954 71 Denkert"/>
   <result pre="al. Ki67 levels as predictive and prognostic parameters in pretherapeutic" exact="breast cancer" post="core biopsies: a translational investigation in the neoadjuvant GeparTrio"/>
   <result pre="Ki67 levels as predictive and prognostic parameters in pretherapeutic breast" exact="cancer" post="core biopsies: a translational investigation in the neoadjuvant GeparTrio"/>
   <result pre="al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early" exact="breast cancer" post="(GeparSixto; GBG 66): a randomised phase 2 trial ."/>
   <result pre="Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast" exact="cancer" post="(GeparSixto; GBG 66): a randomised phase 2 trial ."/>
   <result pre="epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing" exact="breast cancer" post=". J Clin Oncol 2014; 32: 3212–3220. 79 Majewski"/>
   <result pre="growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast" exact="cancer" post=". J Clin Oncol 2014; 32: 3212–3220. 79 Majewski"/>
   <result pre="to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in" exact="breast cancer" post=". J Clin Oncol 2015; 33: 1334–1339. 80 Guarneri"/>
   <result pre="neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast" exact="cancer" post=". J Clin Oncol 2015; 33: 1334–1339. 80 Guarneri"/>
   <result pre="et al. Activity of neoadjuvant lapatinib plus trastuzumab for early" exact="breast cancer" post="according to PIK3CA mutations: pathological complete response (pCR) rate"/>
   <result pre="al. Activity of neoadjuvant lapatinib plus trastuzumab for early breast" exact="cancer" post="according to PIK3CA mutations: pathological complete response (pCR) rate"/>
   <result pre="long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive" exact="breast cancer" post=". Br J Cancer 2013; 108: 1587– 1592. 23579222"/>
   <result pre="neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast" exact="cancer" post=". Br J Cancer 2013; 108: 1587– 1592. 23579222"/>
   <result pre="of Ki67 expression after short-term presurgical endocrine therapy for primary" exact="breast cancer" post=". J Natl Cancer Inst 2007; 99: 167– 170."/>
   <result pre="Ki67 expression after short-term presurgical endocrine therapy for primary breast" exact="cancer" post=". J Natl Cancer Inst 2007; 99: 167– 170."/>
   <result pre="Piccart-Gebhart M et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="M et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="their combination (T+L) in the adjuvant treatment of HER2-positive early" exact="breast cancer" post="(EBC) . J Clin Oncol 2015; 32 (Suppl 15),"/>
   <result pre="combination (T+L) in the adjuvant treatment of HER2-positive early breast" exact="cancer" post="(EBC) . J Clin Oncol 2015; 32 (Suppl 15),"/>
   <result pre="neoadjuvant model is still the future for drug development in" exact="breast cancer." post="Clin Cancer Res 2015; 21: 2911– 2915. 25712686 87"/>
   <result pre="mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with" exact="breast cancer" post=". Breast Cancer Res Treat 2011; 128: 581– 583."/>
   <result pre="on mortality in BRCA1 and BRCA2 mutation carriers with breast" exact="cancer" post=". Breast Cancer Res Treat 2011; 128: 581– 583."/>
   <result pre="mortality after bilateral mastectomy compared with other surgical treatments for" exact="breast cancer" post="in California, 1998–2011 . JAMA 2014; 312: 902– 914."/>
   <result pre="after bilateral mastectomy compared with other surgical treatments for breast" exact="cancer" post="in California, 1998–2011 . JAMA 2014; 312: 902– 914."/>
   <result pre="S , Piccart-Gebhart MJ et al. Effect of age on" exact="breast cancer" post="outcomes in women with human epidermal growth factor receptor"/>
   <result pre=", Piccart-Gebhart MJ et al. Effect of age on breast" exact="cancer" post="outcomes in women with human epidermal growth factor receptor"/>
   <result pre=", Fehm T et al. Sentinel-lymph-node biopsy in patients with" exact="breast cancer" post="before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre"/>
   <result pre="Fehm T et al. Sentinel-lymph-node biopsy in patients with breast" exact="cancer" post="before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre"/>
   <result pre="affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for" exact="breast cancer" post="patients enrolled in ACOSOG Z1071 (Alliance) . Ann Surg"/>
   <result pre="sentinel lymph node identification rate after neoadjuvant chemotherapy for breast" exact="cancer" post="patients enrolled in ACOSOG Z1071 (Alliance) . Ann Surg"/>
   <result pre="25664534 95 Galimberti V Feasibility of sentinel node biopsy in" exact="breast cancer" post="after neoadjuvant treatment. Breast 2015; 24 (Suppl 1), PG"/>
   <result pre="95 Galimberti V Feasibility of sentinel node biopsy in breast" exact="cancer" post="after neoadjuvant treatment. Breast 2015; 24 (Suppl 1), PG"/>
   <result pre="on surgery and locoregional, distant and overall survival of 6,134" exact="breast cancer" post="patients treated with neoadjuvant chemotherapy . Ann Surg Oncol"/>
   <result pre="surgery and locoregional, distant and overall survival of 6,134 breast" exact="cancer" post="patients treated with neoadjuvant chemotherapy . Ann Surg Oncol"/>
   <result pre="(Suppl 1): PG 10.01. 98 Whelan T Evolving standards in" exact="breast cancer" post="radiotherapy: who should receive locoregional RT? Breast 2015; 24"/>
   <result pre="1): PG 10.01. 98 Whelan T Evolving standards in breast" exact="cancer" post="radiotherapy: who should receive locoregional RT? Breast 2015; 24"/>
   <result pre="adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function" exact="suppression" post="in premenopausal early breast cancer: final analysis of the"/>
   <result pre="Phase III comparison of tamoxifen versus tamoxifen plus ovarian function" exact="suppression" post="in premenopausal women with node-negative, hormone receptor-positive breast cancer"/>
   <result pre="ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive" exact="breast cancer" post="(E-3193, INT-0142): a trial of the Eastern Cooperative Oncology"/>
   <result pre="function suppression in premenopausal women with node-negative, hormone receptor-positive breast" exact="cancer" post="(E-3193, INT-0142): a trial of the Eastern Cooperative Oncology"/>
   <result pre="treatment with tamoxifen (T) alone versus T plus ovarian function" exact="suppression" post="(OFS) in premenopausal women with hormone receptor-positive (HR+) early"/>
   <result pre="suppression (OFS) in premenopausal women with hormone receptor-positive (HR+) early" exact="breast cancer" post="(BC) . Cancer Res Suppl 2014; S3-09. 103 Bernhard"/>
   <result pre="(OFS) in premenopausal women with hormone receptor-positive (HR+) early breast" exact="cancer" post="(BC) . Cancer Res Suppl 2014; S3-09. 103 Bernhard"/>
   <result pre="SOFT trials: adjuvant treatment with exemestane (E) plus ovarian function" exact="suppression" post="(OFS) versus tamoxifen (T) plus OFS in premenopausal women"/>
   <result pre="plus OFS in premenopausal women with hormone receptor-positive (HR+) early" exact="breast cancer" post="(BC) . J Clin Oncol 2015; 32 (Suppl 15):"/>
   <result pre="OFS in premenopausal women with hormone receptor-positive (HR+) early breast" exact="cancer" post="(BC) . J Clin Oncol 2015; 32 (Suppl 15):"/>
   <result pre="are not superior to four cycles as adjuvant chemotherapy for" exact="breast cancer" post="in women with zero to three positive axillary nodes:"/>
   <result pre="not superior to four cycles as adjuvant chemotherapy for breast" exact="cancer" post="in women with zero to three positive axillary nodes:"/>
   <result pre="Visvanathan K et al. Risk of marrow neoplasms after adjuvant" exact="breast cancer" post="therapy: The National Comprehensive Cancer Network Experience . J"/>
   <result pre="K et al. Risk of marrow neoplasms after adjuvant breast" exact="cancer" post="therapy: The National Comprehensive Cancer Network Experience . J"/>
   <result pre="Knoop A , Jensen MB et al. Persistence of docetaxel-induced" exact="neuropathy" post="and impact on quality of life among breast cancer"/>
   <result pre="of docetaxel-induced neuropathy and impact on quality of life among" exact="breast cancer" post="survivors . Eur J Cancer 2015; 51: 292– 300."/>
   <result pre="docetaxel-induced neuropathy and impact on quality of life among breast" exact="cancer" post="survivors . Eur J Cancer 2015; 51: 292– 300."/>
   <result pre="CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive" exact="breast cancer." post="N Engl J Med 2015; 372: 134– 141. 25564897"/>
   <result pre="W , Robert N et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer." post="N Engl J Med 2011; 365: 1273– 1283. 21991949"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4519046/results/search/disease/results.xml">
   <result pre="2 (HER2) interact with each other in brain trophic metastatic" exact="breast cancer" post="cells and influence their invasive phenotype. Methods Clones of"/>
   <result pre="(HER2) interact with each other in brain trophic metastatic breast" exact="cancer" post="cells and influence their invasive phenotype. Methods Clones of"/>
   <result pre="and influence their invasive phenotype. Methods Clones of MDA-MB231BR human" exact="breast cancer" post="cells with stable knock down of αv-integrin in combination"/>
   <result pre="influence their invasive phenotype. Methods Clones of MDA-MB231BR human breast" exact="cancer" post="cells with stable knock down of αv-integrin in combination"/>
   <result pre="cytoskeleton and cell morphology. HER2 co-precipitated with αv-integrin in three" exact="breast cancer" post="cell lines in vitro, suggesting they complex in cells."/>
   <result pre="and cell morphology. HER2 co-precipitated with αv-integrin in three breast" exact="cancer" post="cell lines in vitro, suggesting they complex in cells."/>
   <result pre="double deficient tumor cells. Conclusions αv-integrin interacts with HER2 in" exact="breast cancer" post="cells and may regulate HER2 localization. The combined impacts"/>
   <result pre="deficient tumor cells. Conclusions αv-integrin interacts with HER2 in breast" exact="cancer" post="cells and may regulate HER2 localization. The combined impacts"/>
   <result pre="impacts of αv-integrin and HER2 influence the invasive phenotype of" exact="breast cancer" post="cells. Targeting αv-integrin in HER2-positive breast cancer may slow"/>
   <result pre="of αv-integrin and HER2 influence the invasive phenotype of breast" exact="cancer" post="cells. Targeting αv-integrin in HER2-positive breast cancer may slow"/>
   <result pre="invasive phenotype of breast cancer cells. Targeting αv-integrin in HER2-positive" exact="breast cancer" post="may slow growth and decrease infiltration in the normal"/>
   <result pre="phenotype of breast cancer cells. Targeting αv-integrin in HER2-positive breast" exact="cancer" post="may slow growth and decrease infiltration in the normal"/>
   <result pre="within the paper and its Supporting Information files. Introduction Breast" exact="cancer" post="is the most common neoplasm in women and ranks"/>
   <result pre="Supporting Information files. Introduction Breast cancer is the most common" exact="neoplasm" post="in women and ranks as the second most common"/>
   <result pre="of the biomolecular factors and mechanisms controlling invasion of systemic" exact="cancer" post="cells into the brain, and few options available for"/>
   <result pre="be important in the survival, proliferation, migration and invasion of" exact="cancer" post="cells [ 4– 6]. Activation of αvβ 3-integrin promotes"/>
   <result pre="of these integrins with MYC decreases migration and invasion of" exact="breast cancer" post="cells in vitro and in vivo [ 12]. In"/>
   <result pre="these integrins with MYC decreases migration and invasion of breast" exact="cancer" post="cells in vitro and in vivo [ 12]. In"/>
   <result pre="ErbB2, an orphan receptor tyrosine kinase, is implicated in enhanced" exact="breast cancer" post="cell proliferation and aggressive tumorigenic behavior [ 20]. Malignancies"/>
   <result pre="an orphan receptor tyrosine kinase, is implicated in enhanced breast" exact="cancer" post="cell proliferation and aggressive tumorigenic behavior [ 20]. Malignancies"/>
   <result pre="systems have been reported in normal and pathological conditions, including" exact="cancer" post="[ 24– 26] and may alter the effect of"/>
   <result pre="Thus, understanding how integrins relate to other key drivers of" exact="cancer" post="metastasis is essential and may provide pharmacologic targets for"/>
   <result pre="evaluated the interaction of αv-integrin and HER2 using a brain-trophic" exact="breast cancer" post="cell line (MDA-MB231BR-HER2) [ 21] and two non-transformed HER2-positive"/>
   <result pre="the interaction of αv-integrin and HER2 using a brain-trophic breast" exact="cancer" post="cell line (MDA-MB231BR-HER2) [ 21] and two non-transformed HER2-positive"/>
   <result pre="cancer cell line (MDA-MB231BR-HER2) [ 21] and two non-transformed HER2-positive" exact="breast cancer" post="cell lines. Our results suggest that αv-integrin complexes with"/>
   <result pre="cell line (MDA-MB231BR-HER2) [ 21] and two non-transformed HER2-positive breast" exact="cancer" post="cell lines. Our results suggest that αv-integrin complexes with"/>
   <result pre="presence of both proteins increases the migration and invasion of" exact="breast cancer" post="cells in vitro and in the brain microenvironment. Materials"/>
   <result pre="of both proteins increases the migration and invasion of breast" exact="cancer" post="cells in vitro and in the brain microenvironment. Materials"/>
   <result pre="lines and preparation of stable knockdown clones The brain-trophic human" exact="breast cancer" post="cells transfected to express high HER2 (MDA-MB231BR-HER2, herein termed"/>
   <result pre="and preparation of stable knockdown clones The brain-trophic human breast" exact="cancer" post="cells transfected to express high HER2 (MDA-MB231BR-HER2, herein termed"/>
   <result pre="Technologies, Eugene OR). SKBR3 and HCC1954, two non-transformed high HER2" exact="breast cancer" post="cell lines, were obtained from ATCC (Manassas VA), and"/>
   <result pre="Eugene OR). SKBR3 and HCC1954, two non-transformed high HER2 breast" exact="cancer" post="cell lines, were obtained from ATCC (Manassas VA), and"/>
   <result pre="performed with Microsoft Excel and Graphpad Prism software. Results Breast" exact="cancer" post="cell clones with stable 93% and 69% knockdown of"/>
   <result pre="and 69% knockdown of αv-integrin were created in a human" exact="breast cancer" post="cell line MDA-MB231BR, herein referred to as MM2BH cells,"/>
   <result pre="69% knockdown of αv-integrin were created in a human breast" exact="cancer" post="cell line MDA-MB231BR, herein referred to as MM2BH cells,"/>
   <result pre="respectively (P&amp;lt;0.05). Fig 1 Integrin and HER2 expression in brain-trophic" exact="breast cancer" post="cell clones. MM2BH breast cancer cells, previously transfected to"/>
   <result pre="(P&amp;lt;0.05). Fig 1 Integrin and HER2 expression in brain-trophic breast" exact="cancer" post="cell clones. MM2BH breast cancer cells, previously transfected to"/>
   <result pre="and HER2 expression in brain-trophic breast cancer cell clones. MM2BH" exact="breast cancer" post="cells, previously transfected to overexpress HER2, were transduced with"/>
   <result pre="HER2 expression in brain-trophic breast cancer cell clones. MM2BH breast" exact="cancer" post="cells, previously transfected to overexpress HER2, were transduced with"/>
   <result pre="Characterization of cell morphology, actin cytoskeleton and focal adhesions in" exact="breast cancer" post="cells. MM2BH clones grown on glass coverslips were stained"/>
   <result pre="of cell morphology, actin cytoskeleton and focal adhesions in breast" exact="cancer" post="cells. MM2BH clones grown on glass coverslips were stained"/>
   <result pre="the αv+H2+ cells as well as two additional non-transformed human" exact="breast cancer" post="cell lines, HCC1954 and SKBR3. αv-integrin co-precipitated with HER2"/>
   <result pre="αv+H2+ cells as well as two additional non-transformed human breast" exact="cancer" post="cell lines, HCC1954 and SKBR3. αv-integrin co-precipitated with HER2"/>
   <result pre="3C). Fig 3 Co-immunoprecipitation of αv-integrin and HER2 proteins in" exact="breast cancer" post="cells. Lysates from the SKBR3, HCC1954, and αv+H2+ MM2BH"/>
   <result pre="Fig 3 Co-immunoprecipitation of αv-integrin and HER2 proteins in breast" exact="cancer" post="cells. Lysates from the SKBR3, HCC1954, and αv+H2+ MM2BH"/>
   <result pre="Fig 4C). Fig 4 localization of HER2 in αv-integrin knockdown" exact="breast cancer" post="cells. MM2BH cell clones grown on glass coverslips were"/>
   <result pre="4C). Fig 4 localization of HER2 in αv-integrin knockdown breast" exact="cancer" post="cells. MM2BH cell clones grown on glass coverslips were"/>
   <result pre="cells. Fig 5 In vitro cell migration and proliferation of" exact="breast cancer" post="cell clones. (A) The motility of MM2BH cell lines"/>
   <result pre="Fig 5 In vitro cell migration and proliferation of breast" exact="cancer" post="cell clones. (A) The motility of MM2BH cell lines"/>
   <result pre="HER2 protein expression levels on the proliferation and dispersal of" exact="breast cancer" post="cells in the brain microenvironment, we assessed the growth"/>
   <result pre="protein expression levels on the proliferation and dispersal of breast" exact="cancer" post="cells in the brain microenvironment, we assessed the growth"/>
   <result pre="In vivo invasive growth phenotype in αv-integrin and HER2 knockdown" exact="breast cancer" post="cells. Brain tumors of MM2BH clones were assessed by"/>
   <result pre="vivo invasive growth phenotype in αv-integrin and HER2 knockdown breast" exact="cancer" post="cells. Brain tumors of MM2BH clones were assessed by"/>
   <result pre="properties of brain-trophic tumor cells. A complete picture of how" exact="cancer" post="cells recognize, bind to, and migrate through brain vasculature,"/>
   <result pre="and HER2 and their roles in the invasive phenotype of" exact="breast cancer" post="cells. Multiple reports document direct interactions between various integrins"/>
   <result pre="HER2 and their roles in the invasive phenotype of breast" exact="cancer" post="cells. Multiple reports document direct interactions between various integrins"/>
   <result pre="be important in certain metastatic cancers [ 4, 25]. In" exact="breast cancer" post="cells, α3β1 integrin regulates dimerization of HER2 to the"/>
   <result pre="important in certain metastatic cancers [ 4, 25]. In breast" exact="cancer" post="cells, α3β1 integrin regulates dimerization of HER2 to the"/>
   <result pre="cell line for the MM2BH clones was derived from triple-negative" exact="breast cancer" post="cells (MDA-MB231) transfected to overexpress HER2 [ 21]. To"/>
   <result pre="line for the MM2BH clones was derived from triple-negative breast" exact="cancer" post="cells (MDA-MB231) transfected to overexpress HER2 [ 21]. To"/>
   <result pre="generalized phenomenon, we showed similar co-immunoprecipitation using two nontransfected human" exact="breast cancer" post="cell lines (HCC1954 and SK-BR3) with high αv-integrin and"/>
   <result pre="phenomenon, we showed similar co-immunoprecipitation using two nontransfected human breast" exact="cancer" post="cell lines (HCC1954 and SK-BR3) with high αv-integrin and"/>
   <result pre="[ 35] and influences signal transduction [ 36]. In metastasizing" exact="cancer" post="cells, where different integrin dimers are activated by ECM"/>
   <result pre="recycling regulation may influence the invasive and metastatic potential of" exact="breast cancer" post="cells co-expressing these proteins, and could have therapeutic consequences"/>
   <result pre="regulation may influence the invasive and metastatic potential of breast" exact="cancer" post="cells co-expressing these proteins, and could have therapeutic consequences"/>
   <result pre="metastatic dispersal of tumor cells [ 19]. In the xenografted" exact="breast cancer" post="brain metastasis model, the tumor infiltrative growth phenotype was"/>
   <result pre="dispersal of tumor cells [ 19]. In the xenografted breast" exact="cancer" post="brain metastasis model, the tumor infiltrative growth phenotype was"/>
   <result pre="serve as a biomarker for the prognosis of high-HER2 expressing" exact="breast cancer." post="Expression of HER2 in conjunction with αv-integrin induces infiltration"/>
   <result pre="Expression of HER2 in conjunction with αv-integrin induces infiltration of" exact="breast cancer" post="cells into brain parenchyma rather than growth as a"/>
   <result pre="of HER2 in conjunction with αv-integrin induces infiltration of breast" exact="cancer" post="cells into brain parenchyma rather than growth as a"/>
   <result pre="αv-integrin and HER2 may provide clinical advantage to the HER2-positive" exact="breast cancer" post="patients. In support of this hypothesis, targeting αvβ6 integrin"/>
   <result pre="and HER2 may provide clinical advantage to the HER2-positive breast" exact="cancer" post="patients. In support of this hypothesis, targeting αvβ6 integrin"/>
   <result pre="integrin and HER2 signaling on the plasma membrane of neoplastic" exact="breast cancer" post="cells. Assessing spacio-temportal attributes of the specific integrin-HER2 protein-protein"/>
   <result pre="and HER2 signaling on the plasma membrane of neoplastic breast" exact="cancer" post="cells. Assessing spacio-temportal attributes of the specific integrin-HER2 protein-protein"/>
   <result pre="GV ( 2015) Therapeutic approach to the management of HER2-positive" exact="breast cancer" post="metastatic to the brain . Cancer Letters 358: 93–"/>
   <result pre="( 2015) Therapeutic approach to the management of HER2-positive breast" exact="cancer" post="metastatic to the brain . Cancer Letters 358: 93–"/>
   <result pre=", Cheresh DA ( 2015) Integrins and cancer: regulators of" exact="cancer" post="stemness, metastasis, and drug resistance. Trends Cell Biol 25:"/>
   <result pre="et al. ( 2001) Integrin activation controls metastasis in human" exact="breast cancer." post="PNAS 98: 1853– 1858. 11172040 8 Sato T ,"/>
   <result pre="alpha v, c-erbB2 and DNA ploidy in lung metastases from" exact="colorectal cancer." post="Hepato-gastroenterol 50: 27– 30. 9 van den Hoogen C"/>
   <result pre="the acquisition of a metastatic stem/progenitor cell phenotype in human" exact="prostate cancer" post=". Am J Pathol 179: 2559– 2568. doi: 10.1016/j.ajpath.2011.07.011"/>
   <result pre="acquisition of a metastatic stem/progenitor cell phenotype in human prostate" exact="cancer" post=". Am J Pathol 179: 2559– 2568. doi: 10.1016/j.ajpath.2011.07.011"/>
   <result pre=", Bissell MJ , et al. ( 2012) MYC suppresses" exact="cancer" post="metastasis by direct transcriptional silencing of v and 3"/>
   <result pre="the efficacy of radiation therapy and reduces metastasis of human" exact="cancer" post="xenografts in nude rats . Cancer Res 70: 7591–"/>
   <result pre="integrins decreased metastasis and increased survival in a nude rat" exact="breast cancer" post="brain metastasis model . J Neuro-Oncol 110: 27– 36."/>
   <result pre="decreased metastasis and increased survival in a nude rat breast" exact="cancer" post="brain metastasis model . J Neuro-Oncol 110: 27– 36."/>
   <result pre="prednisone for the first-line treatment of patients with metastatic castration-resistant" exact="prostate cancer" post=". Annals Oncol 24: 329– 336. 17 O'Day S"/>
   <result pre="for the first-line treatment of patients with metastatic castration-resistant prostate" exact="cancer" post=". Annals Oncol 24: 329– 336. 17 O'Day S"/>
   <result pre="al. ( 2007) Her-2 overexpression increases the metastatic outgrowth of" exact="breast cancer" post="cells in the brain . Cancer Res 67: 4190–"/>
   <result pre="( 2007) Her-2 overexpression increases the metastatic outgrowth of breast" exact="cancer" post="cells in the brain . Cancer Res 67: 4190–"/>
   <result pre="leads to in vitro and in vivo breast tumor growth" exact="suppression" post=". Oncotarget 5: 1812– 1828. 24729020 28 Moore KM"/>
   <result pre="et al. ( 2014) Therapeutic targeting of integrin αvβ6 in" exact="breast cancer." post="J Natl Cancer Inst 106: dju169 doi: 10.1093/jnci/dju169 24974129"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4524128/results/search/disease/results.xml">
   <result pre="impacts quality of life in patients with unresectable advanced gastric" exact="cancer" post="and has the potential to be lethal. When blood"/>
   <result pre="and safety of palliative radiotherapy in patients with advanced gastric" exact="cancer" post="between January 2007 and December 2012 in Aichi Cancer"/>
   <result pre="1 week. Results During the study period, 313 advanced gastric" exact="cancer" post="patients treated in our institution. Of these 17 patients"/>
   <result pre="of death was bleeding in 1 patient (7 %) and" exact="cancer" post="progression without bleeding in 12 patients (80 %). There"/>
   <result pre="for patients with end-stage, unresectable advanced gastric cancer. Keywords Gastric" exact="cancer" post="Palliative care Radiotherapy Hemostasis Bleeding Background Adenocarcinoma of the"/>
   <result pre="000 deaths in 2012 [ 1]. Patients with early gastric" exact="cancer" post="are commonly treated surgically and with advanced locoregional disease"/>
   <result pre="or chemoradiotherapy [ 5, 6]. For patients with advanced gastric" exact="cancer" post="(AGC), quality of life is negatively impacted when the"/>
   <result pre="of Blood Banks, transfusion is recommended for hospitalized patients without" exact="cardiovascular disease" post="targeting the threshold of hemoglobin level of 7 to"/>
   <result pre="[ 7] Radiotherapy (RT) is sometimes used to treat severe" exact="anemia" post="due to gastric bleeding in patients with AGC who"/>
   <result pre="RT for bleeding has been evaluated in patients with non-small-cell" exact="lung cancer," post="cervical cancer, and bladder cancer [ 8– 11]. In"/>
   <result pre="bleeding has been evaluated in patients with non-small-cell lung cancer," exact="cervical cancer," post="and bladder cancer [ 8– 11]. In patients with"/>
   <result pre="evaluated in patients with non-small-cell lung cancer, cervical cancer, and" exact="bladder cancer" post="[ 8– 11]. In patients with AGC, between 54"/>
   <result pre="in patients with non-small-cell lung cancer, cervical cancer, and bladder" exact="cancer" post="[ 8– 11]. In patients with AGC, between 54"/>
   <result pre="bleeding, and at least one blood transfusion administered to improve" exact="anemia" post="before RT. A total of 313 patients with AGC"/>
   <result pre="death was gastric bleeding in one patient (7 %) and" exact="cancer" post="progression in 12 patients (80 %). Two patients (13"/>
   <result pre="pleural effusion were documented in two patients. Fatigue, vomiting, and" exact="diarrhea" post="were noted in one patient each. One patient required"/>
   <result pre="As a result of concurrent or subsequent chemotherapy, Grade 3/4" exact="neutropenia" post="was documented in 3 patients. Grade 4 thrombocytopenia and"/>
   <result pre="Grade 3/4 neutropenia was documented in 3 patients. Grade 4" exact="thrombocytopenia" post="and creatinine elevation developed in one patient each, findings"/>
   <result pre="0 1 2 Thrombocytopenia 2 1 0 1 Discussion Gastric" exact="cancer" post="is not adequately sensitive to RT alone; thus, multimodal"/>
   <result pre="in ten fractures is adequate to control bleeding from gastric" exact="cancer" post="[ 15]. The hemostatic rate observed in the present"/>
   <result pre="a randomized, controlled trial, for the management of patients with" exact="bladder cancer" post="who are unsuitable for curative treatment and who have"/>
   <result pre="randomized, controlled trial, for the management of patients with bladder" exact="cancer" post="who are unsuitable for curative treatment and who have"/>
   <result pre="induce more late toxicity in patients with other types of" exact="cancer" post="[ 30], so it is recommended only for patients"/>
   <result pre="the most appropriate candidates for treatment. Abbreviations AGC Advanced gastric" exact="cancer" post="RT Radiotherapy IVR Interventional radiology CT Computed tomography CTV"/>
   <result pre="A Arai K collab: ACTS-GC Group Adjuvant chemotherapy for gastric" exact="cancer" post="with S-1, an oral fluoropyrimidine N Engl J Med"/>
   <result pre="collab: CLASSIC trial investigators Adjuvant capecitabine and oxaliplatin for gastric" exact="cancer" post="after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised"/>
   <result pre="trial participants: perioperative chemotherapy versus surgery alone for resectable gastroesophageal" exact="cancer" post="N Engl J Med 2006 355 11 20 10.1056/NEJMoa055531"/>
   <result pre="A collab: CROSS Group Preoperative chemoradiotherapy for esophageal or junctional" exact="cancer" post="N Engl J Med 2012 366 2074 84 10.1056/NEJMoa1112088"/>
   <result pre="fractions or a single fraction in patients with inoperable non-small-cell" exact="lung cancer" post="(NSCLC) and poor performance status. Medical Research Council Lung"/>
   <result pre="or a single fraction in patients with inoperable non-small-cell lung" exact="cancer" post="(NSCLC) and poor performance status. Medical Research Council Lung"/>
   <result pre="role of palliative radiation therapy in symptomatic locally advanced gastric" exact="cancer" post="Int J Radiat Oncol Biol Phys 2007 67 385"/>
   <result pre="S Clinical benefit of palliative radiation therapy in advanced gastric" exact="cancer" post="Acta Oncol 2008 47 421 7 10.1080/02841860701621233 17899453 14."/>
   <result pre="Park W Ahn YC Huh SJ Radiation therapy for gastric" exact="cancer" post="bleeding Tumori 2009 95 726 30 20210237 17. Tey"/>
   <result pre="Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric" exact="cancer" post="in the modern era Medicine (Baltimore) 2014 93 e118"/>
   <result pre="Index: a scoring system for survival prediction of terminally ill" exact="cancer" post="patients Support Care Cancer 1999 7 128 33 10.1007/s005200050242"/>
   <result pre="ten Cate H The hemostatic system as a modulator of" exact="atherosclerosis" post="N Engl J Med 2011 364 1746 60 10.1056/NEJMra1011670"/>
   <result pre="pelvic irradiation for palliation and life prolongation in patients with" exact="cancer" post="of the cervix and corpus uteri Gynecol Oncol 2001"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4524286/results/search/disease/results.xml">
   <result pre="120 doi: 10.1186/s40199-015-0120-y : Research Label-free LC-MS analysis of HER2+" exact="breast cancer" post="cell line response to HER2 inhibitor treatment http://orcid.org/0000-0003-4988-6407 Di"/>
   <result pre="doi: 10.1186/s40199-015-0120-y : Research Label-free LC-MS analysis of HER2+ breast" exact="cancer" post="cell line response to HER2 inhibitor treatment http://orcid.org/0000-0003-4988-6407 Di"/>
   <result pre="ways to improve efficacy of breast-cancer treatment. Keywords Afatinib Breast" exact="cancer" post="HER2 Label-free LC-MS Proteomics Lapatinib Neratinib Background Breast cancer"/>
   <result pre="Breast cancer HER2 Label-free LC-MS Proteomics Lapatinib Neratinib Background Breast" exact="cancer" post="remains a leading cause of death among women in"/>
   <result pre="activated forms of these enzymes plays a crucial role in" exact="breast cancer" post="pathogenesis [ 2]. In spite of the efforts that"/>
   <result pre="forms of these enzymes plays a crucial role in breast" exact="cancer" post="pathogenesis [ 2]. In spite of the efforts that"/>
   <result pre="approved in combination with capecitabine for the treatment of refractory" exact="breast cancer" post="[ 6]. Although lapatinib does not cross the blood–brain"/>
   <result pre="in combination with capecitabine for the treatment of refractory breast" exact="cancer" post="[ 6]. Although lapatinib does not cross the blood–brain"/>
   <result pre="with clinical utility for the diagnosis, treatment and management of" exact="breast cancer." post="Indeed, the identification of proteins that are differentially expressed"/>
   <result pre="the proteomic profile of lapatinib, neratinib or afatinib response in" exact="breast cancer." post="To identify markers which might be useful in predicting"/>
   <result pre="proteomes of cell line models of HER2-inhibitor response in HER2-positive" exact="breast cancer" post="cell lines models, SKBR3, BT474 and HCC1954, in order"/>
   <result pre="of cell line models of HER2-inhibitor response in HER2-positive breast" exact="cancer" post="cell lines models, SKBR3, BT474 and HCC1954, in order"/>
   <result pre="to treatment response. Methods Cell culture and drug treatment HER2-overexpressing" exact="breast cancer" post="cell lines BT474, SKBR3 and HCC1954 were examined. The"/>
   <result pre="treatment response. Methods Cell culture and drug treatment HER2-overexpressing breast" exact="cancer" post="cell lines BT474, SKBR3 and HCC1954 were examined. The"/>
   <result pre="and 1 % sodium pyruvate (Sigma-Aldrich, Germany). SKBR3 and HCC1954" exact="breast cancer" post="cell lines were maintained in Roswell Park Memorial Institute"/>
   <result pre="1 % sodium pyruvate (Sigma-Aldrich, Germany). SKBR3 and HCC1954 breast" exact="cancer" post="cell lines were maintained in Roswell Park Memorial Institute"/>
   <result pre="real association with drug response. Proteomic analysis of the HER2-overexpressing" exact="breast cancer" post="cell lines Label-free proteomic analysis was performed in HER2-overexpressing"/>
   <result pre="association with drug response. Proteomic analysis of the HER2-overexpressing breast" exact="cancer" post="cell lines Label-free proteomic analysis was performed in HER2-overexpressing"/>
   <result pre="cancer cell lines Label-free proteomic analysis was performed in HER2-overexpressing" exact="breast cancer" post="cell lines to reveal the proteins that were significantly"/>
   <result pre="cell lines Label-free proteomic analysis was performed in HER2-overexpressing breast" exact="cancer" post="cell lines to reveal the proteins that were significantly"/>
   <result pre="to afatinib, neratinib or lapatinib treatments and also in the" exact="breast cancer" post="cell lines SKBR3 and HCC1954 in response to neratinib"/>
   <result pre="afatinib, neratinib or lapatinib treatments and also in the breast" exact="cancer" post="cell lines SKBR3 and HCC1954 in response to neratinib"/>
   <result pre="control Discussion Despite the improvements in diagnosis and treatment of" exact="breast cancer," post="novel and more efficient tools are needed to guide"/>
   <result pre="BT474 cell line. In addition, because of the complexity of" exact="breast cancer" post="and to get a broader perspective in multiple breast"/>
   <result pre="cell line. In addition, because of the complexity of breast" exact="cancer" post="and to get a broader perspective in multiple breast"/>
   <result pre="breast cancer and to get a broader perspective in multiple" exact="breast cancer" post="cell lines, we characterised the proteomic response to neratinib"/>
   <result pre="cancer and to get a broader perspective in multiple breast" exact="cancer" post="cell lines, we characterised the proteomic response to neratinib"/>
   <result pre="appear to be strongly involved in early treatment response. Breast" exact="cancer" post="cell lines have been widely used to investigate different"/>
   <result pre="no single cell line is truly representative of a primary" exact="breast cancer," post="however, when a panel of cell lines are used"/>
   <result pre="acid metabolism, DNA replication and glycolysis. It is known that" exact="cancer" post="cells are different from those of normal cells, showing"/>
   <result pre="and glutamine metabolism has been linked to therapeutic resistance in" exact="cancer" post="[ 23]. Several studies highlighted that targeting cellular metabolism"/>
   <result pre="highlighted that targeting cellular metabolism may improve the response to" exact="cancer" post="therapeutics and the combination of chemotherapeutic drugs with cellular"/>
   <result pre="may represent a promising strategy to overcome drug resistance in" exact="cancer" post="therapy [ 23, 24]. In the current study, an"/>
   <result pre="been published to date characterising an extensive drugs response in" exact="breast cancer." post="In a previous study from our group [ 27],"/>
   <result pre="differential abundance of trifunctional enzyme in relation to HER2-positive response" exact="breast cancer." post="This protein is a heterooctamer of four alpha- and"/>
   <result pre="that are associated with the resistance to paclitaxel in human" exact="breast cancer" post="cells, an overexpression of hnRNP C1/C2 was associated with"/>
   <result pre="are associated with the resistance to paclitaxel in human breast" exact="cancer" post="cells, an overexpression of hnRNP C1/C2 was associated with"/>
   <result pre="Several studies highlighted that this protein may be involved in" exact="cancer" post="development or may serve as useful diagnostic and prognostic"/>
   <result pre="malignant tumours, the expression of HSC70 has been reported on" exact="breast cancer" post="cells and the overexpression of HSP/HSC70 in chemoresistant cancer"/>
   <result pre="tumours, the expression of HSC70 has been reported on breast" exact="cancer" post="cells and the overexpression of HSP/HSC70 in chemoresistant cancer"/>
   <result pre="breast cancer cells and the overexpression of HSP/HSC70 in chemoresistant" exact="cancer" post="cells highlight these proteins as possible clinical markers ["/>
   <result pre="clinically relevant concentrations of different HER2-inhibitors drug treatments in HER2-overexpressing" exact="breast cancer" post="cell lines, lapatinib, neratinib or afatinib in BT474 and"/>
   <result pre="relevant concentrations of different HER2-inhibitors drug treatments in HER2-overexpressing breast" exact="cancer" post="cell lines, lapatinib, neratinib or afatinib in BT474 and"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="Arora A Scholar EM Role of tyrosine kinase inhibitors in" exact="cancer" post="therapy J Pharmacol Exp Ther 2005 315 3 971"/>
   <result pre="15 9 924 934 10.1634/theoncologist.2009-0181 20736298 7. Nancy UL Breast" exact="cancer" post="brain metastases: new directions in systemic therapy Ecancermedicalscience 2013"/>
   <result pre="DP Brennan DJ Duffy MJ Pennington SR Gallagher WM Breast" exact="cancer" post="proteomics: clinical perspectives Expert Opin Biol Ther 2007 7"/>
   <result pre="continuous afatinib (BIBW 2992) in patients with advanced non-small cell" exact="lung cancer" post="after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4) Cancer Chemother Pharmacol 2012"/>
   <result pre="afatinib (BIBW 2992) in patients with advanced non-small cell lung" exact="cancer" post="after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4) Cancer Chemother Pharmacol 2012"/>
   <result pre="Alldridge L Phosphoproteomics: a possible route to novel biomarkers of" exact="breast cancer" post="Proteomics Clin Appl 2008 2 2 181 194 10.1002/prca.200780011"/>
   <result pre="L Phosphoproteomics: a possible route to novel biomarkers of breast" exact="cancer" post="Proteomics Clin Appl 2008 2 2 181 194 10.1002/prca.200780011"/>
   <result pre="194 10.1002/prca.200780011 21136824 20. Lacroix M Leclercq G Relevance of" exact="breast cancer" post="cell lines as models for breast tumours: an update"/>
   <result pre="10.1002/prca.200780011 21136824 20. Lacroix M Leclercq G Relevance of breast" exact="cancer" post="cell lines as models for breast tumours: an update"/>
   <result pre="J Baehner FL Fevr T et al. A collection of" exact="breast cancer" post="cell lines for the study of functionally distinct cancer"/>
   <result pre="Baehner FL Fevr T et al. A collection of breast" exact="cancer" post="cell lines for the study of functionally distinct cancer"/>
   <result pre="breast cancer cell lines for the study of functionally distinct" exact="cancer" post="subtypes Cancer cell 2006 10 6 515 527 10.1016/j.ccr.2006.10.008"/>
   <result pre="Y Butler EB Tan M Targeting cellular metabolism to improve" exact="cancer" post="therapeutics Cell Death and Disease 2013 4 10.1038/cddis.2013.60 23470539"/>
   <result pre="N Smith CA et al. The role of drebrin in" exact="glioma" post="migration and invasion Exp Cell Res 2013 319 4"/>
   <result pre="that are associated with the resistance to paclitaxel in human" exact="breast cancer" post="cells Mol BioSyst 2014 10 2 294 303 10.1039/C3MB70428A"/>
   <result pre="are associated with the resistance to paclitaxel in human breast" exact="cancer" post="cells Mol BioSyst 2014 10 2 294 303 10.1039/C3MB70428A"/>
   <result pre="M Cantor A Mulshine JL Tockman MS Expression of early" exact="lung cancer" post="detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration"/>
   <result pre="Cantor A Mulshine JL Tockman MS Expression of early lung" exact="cancer" post="detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration"/>
   <result pre="hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell" exact="lung cancer" post="Lung Cancer 2001 34 3 341 350 10.1016/S0169-5002(01)00254-9 11714531"/>
   <result pre="and its relation to microsatellite alteration in non-small cell lung" exact="cancer" post="Lung Cancer 2001 34 3 341 350 10.1016/S0169-5002(01)00254-9 11714531"/>
   <result pre="Watt PJ Tzoneva G Leaner VD Deregulated LAP2α expression in" exact="cervical cancer" post="associates with aberrant E2F and p53 activities IUBMB Life"/>
   <result pre="PJ Tzoneva G Leaner VD Deregulated LAP2α expression in cervical" exact="cancer" post="associates with aberrant E2F and p53 activities IUBMB Life"/>
   <result pre="Foisner R Lamina-associated polypeptide (LAP)2α and other LEM proteins in" exact="cancer" post="biology Adv Exp Med Biol 2014 773 143 163"/>
   <result pre="Latchman DS Do heat shock proteins have a role in" exact="breast cancer?" post="Br J Cancer 1996 74 5 717 721 10.1038/bjc.1996.427"/>
   <result pre="antigen and heat shock protein 70 immuno-localization in invasive ductal" exact="breast cancer" post="not otherwise specified Breast Cancer Res Treat 1997 43"/>
   <result pre="and heat shock protein 70 immuno-localization in invasive ductal breast" exact="cancer" post="not otherwise specified Breast Cancer Res Treat 1997 43"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4525792/results/search/disease/results.xml">
   <result pre="Creative Commons CC-BY-NC 3.0 license. Abstract With the improvement in" exact="cancer" post="survival, long-term cardiotoxicity has become an area of increased"/>
   <result pre="long-term cardiotoxicity has become an area of increased interest. Various" exact="cancer" post="therapies, including chemotherapy and radiation therapy can lead to"/>
   <result pre="outcomes. The focus of this review is to summarize the" exact="cancer" post="therapy agents most often associated with cardiovascular side effects,"/>
   <result pre="heart failure cardiotoxicity chemotherapy radiation cardio-oncology Background Heart disease and" exact="cancer" post="are currently the two leading causes of death in"/>
   <result pre="when these two diseases intersect. An anticipated 1.6 million new" exact="cancer" post="cases will be diagnosed in 2015, with almost 600,000"/>
   <result pre="will be diagnosed in 2015, with almost 600,000 deaths from" exact="cancer" post="this year and nearly equivalent numbers of cardiovascular deaths."/>
   <result pre="equivalent numbers of cardiovascular deaths. 1, 2 Overall improvements in" exact="cancer" post="survival are likely due to advancements in early recognition"/>
   <result pre="Unfortunately, with the improvement in the morbidity and mortality of" exact="cancer" post="comes the increase in long-term cardiac toxicity associated with"/>
   <result pre="cancer comes the increase in long-term cardiac toxicity associated with" exact="cancer" post="treatments. Cardiovascular side effects negatively impact quality of life"/>
   <result pre="lymphomas, and leukemias as well as for adjuvant therapy in" exact="breast cancer." post="6 They are important antitumor agents with a proposed"/>
   <result pre="Patients with underlying traditional cardiac risk factors such as hypertension," exact="diabetes mellitus," post="hyperlipidemia, smoking history, and known coronary artery disease or"/>
   <result pre="gastrointestinal malignancies such as pancreatic, stomach, colorectal cancers and in" exact="breast cancer" post="through the inhibition of DNA replication. 26 There is"/>
   <result pre="malignancies such as pancreatic, stomach, colorectal cancers and in breast" exact="cancer" post="through the inhibition of DNA replication. 26 There is"/>
   <result pre="Bortezomib is a proteasome inhibitor approved for the treatment of" exact="multiple myeloma" post="and non-Hodgkin’s lymphoma, 30 while carfilzomib is used in"/>
   <result pre="carfilzomib is used in the treatment of refractory or relapsing" exact="multiple myeloma." post="31 Pro-teasome inhibitors interfere with the degradation of cell"/>
   <result pre="an alkylating agent used in the treatment of bladder and" exact="lung cancer" post="as well as sarcoma and chronic myelogenous leukemia. 17"/>
   <result pre="alkylating agent used in the treatment of bladder and lung" exact="cancer" post="as well as sarcoma and chronic myelogenous leukemia. 17"/>
   <result pre="the treatment of bladder and lung cancer as well as" exact="sarcoma" post="and chronic myelogenous leukemia. 17 Cyclophosphamide kills rapidly dividing"/>
   <result pre="is a tyrosine kinase inhibitor, approved for the treatment of" exact="renal cell carcinoma," post="colorectal cancer, chronic myeloid leukemia, and neuroendocrine tumors. 38"/>
   <result pre="kinase inhibitor, approved for the treatment of renal cell carcinoma," exact="colorectal cancer," post="chronic myeloid leukemia, and neuroendocrine tumors. 38 Cardiovascular effects"/>
   <result pre="approved for the treatment of renal cell carcinoma, colorectal cancer," exact="chronic myeloid leukemia," post="and neuroendocrine tumors. 38 Cardiovascular effects of suni-tinib include"/>
   <result pre="for the treatment of renal cell carcinoma, colorectal cancer, chronic" exact="myeloid leukemia," post="and neuroendocrine tumors. 38 Cardiovascular effects of suni-tinib include"/>
   <result pre="40 Imatinib is used in the treatment of chronic myelogenous" exact="leukemia" post="as well as acute lymphoblastic leukemia. 41 Imatinib has"/>
   <result pre="in the treatment of chronic myelogenous leukemia as well as" exact="acute lymphoblastic leukemia." post="41 Imatinib has been shown to cause reduction in"/>
   <result pre="the treatment of chronic myelogenous leukemia as well as acute" exact="lymphoblastic leukemia." post="41 Imatinib has been shown to cause reduction in"/>
   <result pre="4, 42 Sorafenib, used in the treatment of hepatocellular and" exact="renal cell carcinoma," post="38 has been shown to cause myocardial ischemia as"/>
   <result pre="cell growth and viability and is an effective treatment against" exact="cancer" post="cells, although cardiac myocytes are particularly vulnerable. 17 Mediastinal"/>
   <result pre="Cancer therapies work through a variety of mechanisms to destroy" exact="cancer" post="cells. Although there have been improvements in the development"/>
   <result pre="chemotherapy serves as an independent risk for the development of" exact="cardiovascular disease," post="and thus, these patients should be monitored accordingly. In"/>
   <result pre="the oncologist and cardiologist can facilitate the best care for" exact="cancer" post="patients. ACADEMIC EDITOR: Thomas E. Vanhecke, Editor in Chief"/>
   <result pre="Atlanta American Cancer Society 2015 2 Gaetano S Epidemiology of" exact="cardiovascular disease" post="in the 21st century: updated numbers and updated facts"/>
   <result pre="Burstein HJ Winer EP Goldhirsch A Cardiac toxicity from systemic" exact="cancer" post="therapy: a comprehensive review Prog Cardiovasc Dis 2010 53"/>
   <result pre="JJ Charniot JC Vignat N Artigou JY Cardiac side-effects of" exact="cancer" post="chemotherapy Int J Cardiol 2010 144 3 15 20399520"/>
   <result pre="A et al. Left ventricular systolic function in HER2/neu negative" exact="breast cancer" post="patients treated with anthracycline chemotherapy: a comparative analysis of"/>
   <result pre="et al. Left ventricular systolic function in HER2/neu negative breast" exact="cancer" post="patients treated with anthracycline chemotherapy: a comparative analysis of"/>
   <result pre="study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic" exact="breast cancer" post="patients treated with anthra-cycline-based chemotherapy Ann Oncol 2006 17"/>
   <result pre="of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast" exact="cancer" post="patients treated with anthra-cycline-based chemotherapy Ann Oncol 2006 17"/>
   <result pre="Mulvagh SL Kohli M Evaluation and management of patients with" exact="heart disease" post="and cancer: cardio-oncology Mayo Clin Proc 2014 89 1287"/>
   <result pre="Nielsen DL A systematic review of dual targeting in HER2-positive" exact="breast cancer" post="Cancer Treat Rev 2014 40 259 70 24080156 23"/>
   <result pre="DL A systematic review of dual targeting in HER2-positive breast" exact="cancer" post="Cancer Treat Rev 2014 40 259 70 24080156 23"/>
   <result pre="A Nearchou A Polyzos NP Lind P Cardiac toxicity in" exact="breast cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="Nearchou A Polyzos NP Lind P Cardiac toxicity in breast" exact="cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="Y et al. Congestive heart failure risk in patients with" exact="breast cancer" post="treated with bevacizumab J Clin Oncol 2011 29 632"/>
   <result pre="et al. Congestive heart failure risk in patients with breast" exact="cancer" post="treated with bevacizumab J Clin Oncol 2011 29 632"/>
   <result pre="155 66 28 Bonita R Pradhan R Cardiovascular toxicities of" exact="cancer" post="chemotherapy Semin Oncol 2013 40 156 67 23540741 29"/>
   <result pre="toxicity associated with irreversible proteasome inhibition in the treatment of" exact="multiple myeloma" post="J Card Fail 2015 21 138 44 25433360 32"/>
   <result pre="JP Roberts RR Cardiotoxicity associated with targeting kinase pathways in" exact="cancer" post="Toxicol Sci 2010 120 14 32 21177772 39 Khakoo"/>
   <result pre="Cardiac toxicity of sunitinib and sorafenib in patients with metastatic" exact="renal cell carcinoma" post="J Clin Oncol 2008 26 5204 12 18838713 41"/>
   <result pre="R Grazette L Yacobi R et al. Cardiotoxicity of the" exact="cancer" post="therapeutic agent imatinib mesylate Nat Med 2006 12 908"/>
   <result pre="6152 9 19901116 44 Heidenreich PA John RK Radiation induced" exact="heart disease" post="Heart 2009 95 252 8 19144884 45 Gaya AM"/>
   <result pre="for multimodality imaging evaluation of adult patients during and after" exact="cancer" post="therapy: a report from the American Society of Echocardiography"/>
   <result pre="JR Szalda D Ky B Asymptomatic cardiac toxicity in long-term" exact="cancer" post="survivors: defining the population and recommendations for surveillance Semin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4529453/results/search/disease/results.xml">
   <result pre="therapy. In this study, formalin-fixed paraffin-embedded tumor samples from 77" exact="breast cancer" post="patients were examined for HER2 by immunohistochemistry (IHC) and"/>
   <result pre="In this study, formalin-fixed paraffin-embedded tumor samples from 77 breast" exact="cancer" post="patients were examined for HER2 by immunohistochemistry (IHC) and"/>
   <result pre="is an improvement for pathologists and facilitates clinical decision-making for" exact="breast cancer" post="management. Keywords HER2 Breast carcinomas 4B5 SISH Gene Protein"/>
   <result pre="an improvement for pathologists and facilitates clinical decision-making for breast" exact="cancer" post="management. Keywords HER2 Breast carcinomas 4B5 SISH Gene Protein"/>
   <result pre="receptor 2 (HER2) is a protein on the surface of" exact="cancer" post="cells that stimulates tumor growth. When the HER2 gene"/>
   <result pre="protein was found in approximately 25 to 30 % of" exact="breast cancer" post="[ 5], but this rate was probably an overestimate"/>
   <result pre="was found in approximately 25 to 30 % of breast" exact="cancer" post="[ 5], but this rate was probably an overestimate"/>
   <result pre="in approximately 15 to 20 % [ 6] of primary" exact="breast cancer" post="cases, while recent data show a further decreasing trend"/>
   <result pre="approximately 15 to 20 % [ 6] of primary breast" exact="cancer" post="cases, while recent data show a further decreasing trend"/>
   <result pre="intratumor heterogeneity of HER2 gene amplification has been observed in" exact="breast cancer," post="ranging from a few [ 15] to up to"/>
   <result pre="cases [ 17] The long history of HER2 testing in" exact="breast cancer" post="is an indication of the importance of continuing efforts"/>
   <result pre="[ 17] The long history of HER2 testing in breast" exact="cancer" post="is an indication of the importance of continuing efforts"/>
   <result pre="and reliability of this new method focusing especially on borderline" exact="breast cancer" post="cases. Materials and methods Study design A new gene"/>
   <result pre="reliability of this new method focusing especially on borderline breast" exact="cancer" post="cases. Materials and methods Study design A new gene"/>
   <result pre="HER2 IHC and HER2 ISH statuses are not concordant. Although" exact="breast cancer" post="heterogeneity has been described as a major cause of"/>
   <result pre="IHC and HER2 ISH statuses are not concordant. Although breast" exact="cancer" post="heterogeneity has been described as a major cause of"/>
   <result pre="provides an elegant option for assessment of HER2 status in" exact="breast cancer." post="As a generic detection method, GP is not limited"/>
   <result pre="as a prognostic factor, and potential as a target for" exact="cancer" post="therapy Semin Cancer Biol 1993 4 1 19 26"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="J Clin Oncol 2007 25 1 118 145 10.1200/JCO.2006.09.2775"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="J Clin Oncol 2007 25 1 118 145 10.1200/JCO.2006.09.2775"/>
   <result pre="Smit VT et al. HER2 gene amplification in patients with" exact="breast cancer" post="with equivocal IHC results J Clin Pathol 2011 64"/>
   <result pre="VT et al. HER2 gene amplification in patients with breast" exact="cancer" post="with equivocal IHC results J Clin Pathol 2011 64"/>
   <result pre="of c-myc and cyclinD1 but not of c-erbB2 amplification in" exact="breast cancer" post="Lab Investig 2002 82 10 1419 1426 10.1097/01.LAB.0000032371.16521.40 12379776"/>
   <result pre="c-myc and cyclinD1 but not of c-erbB2 amplification in breast" exact="cancer" post="Lab Investig 2002 82 10 1419 1426 10.1097/01.LAB.0000032371.16521.40 12379776"/>
   <result pre="HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded" exact="breast cancer" post="tissue sections (2012) Diagnostic Pathology, 7 (1), art. no."/>
   <result pre="gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast" exact="cancer" post="tissue sections (2012) Diagnostic Pathology, 7 (1), art. no."/>
   <result pre="invasive ductal carcinoma of the breast: a new approach for" exact="cancer" post="pathobiology San Antonio Breast Cancer Symposium 2013–P4-06-12 21. Lidgren"/>
   <result pre="C Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic" exact="breast cancer" post="Acta Oncol 2008 47 6 1018 1028 10.1080/02841860801901618 18607881"/>
   <result pre="Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast" exact="cancer" post="Acta Oncol 2008 47 6 1018 1028 10.1080/02841860801901618 18607881"/>
   <result pre="potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage" exact="breast cancer" post="patients for HER2 status Cancer 2013 119 17 3113"/>
   <result pre="cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast" exact="cancer" post="patients for HER2 status Cancer 2013 119 17 3113"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4533098/results/search/disease/results.xml">
   <result pre="specificity to HER2 positive tumors. structure-based design HER2 targeted peptide" exact="breast cancer" post="MD simulation Introduction The human epidermal growth factor receptor"/>
   <result pre="to HER2 positive tumors. structure-based design HER2 targeted peptide breast" exact="cancer" post="MD simulation Introduction The human epidermal growth factor receptor"/>
   <result pre="of invasive breast cancers, which is classified as HER2 positive" exact="breast cancer" post="5, 6. Compared with HER2-normal breast cancer, HER2-positive breast"/>
   <result pre="invasive breast cancers, which is classified as HER2 positive breast" exact="cancer" post="5, 6. Compared with HER2-normal breast cancer, HER2-positive breast"/>
   <result pre="as HER2 positive breast cancer 5, 6. Compared with HER2-normal" exact="breast cancer," post="HER2-positive breast cancer is associated with worse prognosis, including"/>
   <result pre="breast cancer 5, 6. Compared with HER2-normal breast cancer, HER2-positive" exact="breast cancer" post="is associated with worse prognosis, including higher mortality in"/>
   <result pre="cancer 5, 6. Compared with HER2-normal breast cancer, HER2-positive breast" exact="cancer" post="is associated with worse prognosis, including higher mortality in"/>
   <result pre="8. Therefore, HER2 has become a validated therapeutic target in" exact="breast cancer." post="Trastuzumab (Herceptin), a recombinant humanized monoclonal antibody directed against"/>
   <result pre="of HER2, is mainly used in treating patients with HER2-positive" exact="breast cancer" post="9. However, approximately 15% of patients with HER2-positive metastatic"/>
   <result pre="HER2, is mainly used in treating patients with HER2-positive breast" exact="cancer" post="9. However, approximately 15% of patients with HER2-positive metastatic"/>
   <result pre="cancer 9. However, approximately 15% of patients with HER2-positive metastatic" exact="breast cancer" post="eventually relapse after therapy due to de novo or"/>
   <result pre="9. However, approximately 15% of patients with HER2-positive metastatic breast" exact="cancer" post="eventually relapse after therapy due to de novo or"/>
   <result pre="can have a long term effect on the treatment of" exact="breast cancer" post="and ensure disease free survival 11, 12. Affibody is"/>
   <result pre="have a long term effect on the treatment of breast" exact="cancer" post="and ensure disease free survival 11, 12. Affibody is"/>
   <result pre="as new probes in diagnosis and treatment of HER2 positive" exact="breast cancer." post="Materials and methods Prepare the initial structure Primary sequences"/>
   <result pre="the association-dissociation curves. Flow cytometry, immunocytochemistry and MTT assay Human" exact="breast cancer" post="cell lines SKBR3 (HER2 high expression), MCF-7 (HER2 medium"/>
   <result pre="association-dissociation curves. Flow cytometry, immunocytochemistry and MTT assay Human breast" exact="cancer" post="cell lines SKBR3 (HER2 high expression), MCF-7 (HER2 medium"/>
   <result pre="different peptides. The toxicity of pep27 and pep27-24M against SKBR3" exact="breast cancer" post="cells and 3T3 fibroblast cells was investigated by MTT"/>
   <result pre="peptides. The toxicity of pep27 and pep27-24M against SKBR3 breast" exact="cancer" post="cells and 3T3 fibroblast cells was investigated by MTT"/>
   <result pre="and specificity of peptides to HER2 high expression cells Human" exact="breast cancer" post="cell line SKBR3 has a high expression of HER2"/>
   <result pre="specificity of peptides to HER2 high expression cells Human breast" exact="cancer" post="cell line SKBR3 has a high expression of HER2"/>
   <result pre="HER2 positive tumors. Nude mice were inoculated with SKBR3 human" exact="breast cancer" post="cells to generate xenografted tumors of 6-8 mm in"/>
   <result pre="positive tumors. Nude mice were inoculated with SKBR3 human breast" exact="cancer" post="cells to generate xenografted tumors of 6-8 mm in"/>
   <result pre="than Z(HER2:342) may provide alternative probes to improve HER2 positive" exact="breast cancer" post="early detection, diagnosis, and targeted therapy. In addition, our"/>
   <result pre="Z(HER2:342) may provide alternative probes to improve HER2 positive breast" exact="cancer" post="early detection, diagnosis, and targeted therapy. In addition, our"/>
   <result pre="G Hynes NE The ErbB receptors and their role in" exact="cancer" post="progression Exp Cell Res 2003 284 99 110 12648469"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer" post="Science 1989 244 707 12 2470152 7 Seshadri R"/>
   <result pre="Studies of the HER-2/neu proto-oncogene in human breast and ovarian" exact="cancer" post="Science 1989 244 707 12 2470152 7 Seshadri R"/>
   <result pre="Kitchen P Clinical significance of HER-2/neu oncogene amplification in primary" exact="breast cancer." post="The South Australian Breast Cancer Study Group J Clin"/>
   <result pre="WL et al. Humanization of an anti-p185HER2 antibody for human" exact="cancer" post="therapy Proc Natl Acad Sci U S A 1992"/>
   <result pre="tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive" exact="breast cancer" post="Molecules 2014 19 15196 212 25251190 13 Nilsson B"/>
   <result pre="kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast" exact="cancer" post="Molecules 2014 19 15196 212 25251190 13 Nilsson B"/>
   <result pre="J Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3" exact="breast cancer" post="cell line Biochem Biophys Res Commun 2008 377 489"/>
   <result pre="Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast" exact="cancer" post="cell line Biochem Biophys Res Commun 2008 377 489"/>
   <result pre="A et al. Molecular imaging of HER2-expressing malignant tumors in" exact="breast cancer" post="patients using synthetic 111In- or 68Ga-labeled affibody molecules J"/>
   <result pre="et al. Molecular imaging of HER2-expressing malignant tumors in breast" exact="cancer" post="patients using synthetic 111In- or 68Ga-labeled affibody molecules J"/>
   <result pre="J Baehner FL Fevr T et al. A collection of" exact="breast cancer" post="cell lines for the study of functionally distinct cancer"/>
   <result pre="Baehner FL Fevr T et al. A collection of breast" exact="cancer" post="cell lines for the study of functionally distinct cancer"/>
   <result pre="breast cancer cell lines for the study of functionally distinct" exact="cancer" post="subtypes Cancer Cell 2006 10 515 27 17157791 47"/>
   <result pre="D serum and urine concentration in superficial and invasive transitional" exact="bladder cancer" post="as determined by surface plasmon resonance imaging Oncol Lett"/>
   <result pre="serum and urine concentration in superficial and invasive transitional bladder" exact="cancer" post="as determined by surface plasmon resonance imaging Oncol Lett"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4534500/results/search/disease/results.xml">
   <result pre="made. Abstract Opinion statement A paradigm shift towards molecular-based, personalized" exact="cancer" post="therapeutics has occurred in recent years and a number"/>
   <result pre="biliary tract cancers and potential therapeutic targets. Keywords Biliary tract" exact="cancer" post="Targeted therapy EGFR VEGF Trial Classification Biliary tract cancers"/>
   <result pre="factors for BTC include parasitic infections by liver flukes, gallstones," exact="diabetes mellitus," post="obesity, alcohol, inflammatory bowel disease, bile duct cysts, smoking,"/>
   <result pre="obesity, alcohol, inflammatory bowel disease, bile duct cysts, smoking, and" exact="hepatitis" post="B and C [ 11– 15]. The presence of"/>
   <result pre="tumor suppressor genes [ 16, 17]. The presence of gallbladder" exact="adenoma" post="has also been proposed as a risk factor ["/>
   <result pre="instability (MSI), which is well known in the pathogenesis of" exact="colon cancer," post="does not appear to play a role in BTC"/>
   <result pre="95 % CI 0.69–1.25, p = 0.611). Subgroup analysis of PFS in" exact="cholangiocarcinoma" post="(HR 0.73) and GBC/ampulla of Vater (HR 0.99) cancers"/>
   <result pre="that much of the improvement in PFS came in the" exact="cholangiocarcinoma" post="subgroup. This trial is the first phase III trial"/>
   <result pre="with mixed response, and one with stable disease. All five" exact="cholangiocarcinoma" post="patients had disease progression while on trastuzumab as part"/>
   <result pre="[ 65]. It has been shown to be effective in" exact="hepatocellular carcinoma" post="and renal cell carcinoma, but the same has not"/>
   <result pre="has been shown to be effective in hepatocellular carcinoma and" exact="renal cell carcinoma," post="but the same has not been demonstrated in advanced"/>
   <result pre="c-Kit, and rearranged during transfection (RET). It is approved for" exact="gastrointestinal stromal tumor" post="and renal cell carcinoma [ 71]. In a recent"/>
   <result pre="transfection (RET). It is approved for gastrointestinal stromal tumor and" exact="renal cell carcinoma" post="[ 71]. In a recent phase II study, Yi"/>
   <result pre="as the RET kinase. Its role in the treatment of" exact="thyroid cancer" post="has been well documented. In an Italian (VanGogh) study,"/>
   <result pre="the RET kinase. Its role in the treatment of thyroid" exact="cancer" post="has been well documented. In an Italian (VanGogh) study,"/>
   <result pre="MEK inhibitor, has been investigated in a panel of human" exact="cancer" post="cell lines and showed broad activity, particularly in cell"/>
   <result pre="targeted agents or conventional chemotherapy. mTOR is upregulated in many" exact="cancer" post="types and is currently indicated for the treatment of"/>
   <result pre="types and is currently indicated for the treatment of advanced" exact="breast cancer," post="neuroendocrine tumors of pancreatic origin, and renal cell carcinoma"/>
   <result pre="of advanced breast cancer, neuroendocrine tumors of pancreatic origin, and" exact="renal cell carcinoma" post="[ 83]. In a phase II Italian study, 39"/>
   <result pre="inhibitor was synergistic, inducing cell death in preclinical models of" exact="cholangiocarcinoma" post="[ 86]. Hedgehog pathway The Hedgehog signaling pathway is"/>
   <result pre="pathway has been shown to decrease survival and proliferation of" exact="cancer" post="cells in cholangiocarcinoma cell lines [ 90]. Notch pathway"/>
   <result pre="shown to decrease survival and proliferation of cancer cells in" exact="cholangiocarcinoma" post="cell lines [ 90]. Notch pathway The Notch pathway"/>
   <result pre="Notch pathway The Notch pathway is another attractive target in" exact="cancer" post="therapy. It is essential for tumor angiogenesis and is"/>
   <result pre="receptors 1 and 3 may play a role in the" exact="cancer" post="progression of BTC [ 93]. RO-4929097 (a notch signaling"/>
   <result pre="tumor microenvironment and also systemically. The immune system responds to" exact="cancer" post="by reacting against tumor-specific or tumor-associated antigens (TAA). Major"/>
   <result pre="have helped us discover that the immune system does recognize" exact="cancer" post="antigens. Many TAA used in cancer therapeutics have been"/>
   <result pre="immune system does recognize cancer antigens. Many TAA used in" exact="cancer" post="therapeutics have been developed in recent years. Passive immunity"/>
   <result pre="cells (DC) vaccine in the adjuvant setting in BTC or" exact="pancreatic cancer." post="The vaccine was well tolerated with no significant toxicities."/>
   <result pre="migration, proliferation, survival, and differentiation. Various mutational profiling studies in" exact="cholangiocarcinoma" post="have detected genetic alterations in the FGFR pathway, exclusively"/>
   <result pre="being evaluated in clinical trials involving solid tumors such as" exact="cholangiocarcinoma" post="that harbor these mutations [ 103, 104]. Ribonucleotide reductase"/>
   <result pre="prevalent in northern India and Chile. GBC, the most aggressive" exact="cancer" post="among all, is categorized as an orphan disease. Despite"/>
   <result pre="of patients in clinical trials and close collaboration among international" exact="cancer" post="organizations may lead to better outcomes in this aggressive"/>
   <result pre="3. Olnes MJ Erlich R A review and update on" exact="cholangiocarcinoma" post="Oncology 2004 66 3 167 79 10.1159/000077991 15218306 4."/>
   <result pre="4. Lazcano-Ponce EC et al. Epidemiology and molecular pathology of" exact="gallbladder cancer" post="CA Cancer J Clin 2001 51 6 349 64"/>
   <result pre="Lazcano-Ponce EC et al. Epidemiology and molecular pathology of gallbladder" exact="cancer" post="CA Cancer J Clin 2001 51 6 349 64"/>
   <result pre="64 10.3322/canjclin.51.6.349 11760569 5. Castro FA et al. Biliary tract" exact="cancer" post="incidence in the United States—demographic and temporal variations by"/>
   <result pre="10.4067/S0034-98872006000500004 16802048 8. Altekruse SF et al. Geographic variation of" exact="intrahepatic cholangiocarcinoma," post="extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States"/>
   <result pre="et al. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and" exact="hepatocellular carcinoma" post="in the United States PLoS One 2015 10 3"/>
   <result pre="10.1371/journal.pone.0120574 25837669 9. Shaib YH et al. Rising incidence of" exact="intrahepatic cholangiocarcinoma" post="in the United States: a true increase? J Hepatol"/>
   <result pre="25837669 9. Shaib YH et al. Rising incidence of intrahepatic" exact="cholangiocarcinoma" post="in the United States: a true increase? J Hepatol"/>
   <result pre="10.1016/j.jhep.2003.11.030 15123362 10. Shaib Y El-Serag HB The epidemiology of" exact="cholangiocarcinoma" post="Semin Liver Dis 2004 24 2 115 25 10.1055/s-2004-828889"/>
   <result pre="1 178 80 10.1038/sj.bjc.6604765 19018260 12. Parsi MA Obesity and" exact="cholangiocarcinoma" post="World J Gastroenterol 2013 19 4 457 62 10.3748/wjg.v19.i4.457"/>
   <result pre="Welzel TM et al. Risk factors for intrahepatic and extrahepatic" exact="cholangiocarcinoma" post="in the United States: a population-based case-control study Clin"/>
   <result pre="heterozygosity in patients with gallbladder stones suggest causal association with" exact="gallbladder cancer" post="Ann Surg 2014 260 6 1073 80 10.1097/SLA.0000000000000495 24827397"/>
   <result pre="in patients with gallbladder stones suggest causal association with gallbladder" exact="cancer" post="Ann Surg 2014 260 6 1073 80 10.1097/SLA.0000000000000495 24827397"/>
   <result pre="10.1097/SLA.0000000000000495 24827397 17. Roa I et al. Preneoplastic lesions in" exact="gallbladder cancer" post="J Surg Oncol 2006 93 8 615 23 10.1002/jso.20527"/>
   <result pre="24827397 17. Roa I et al. Preneoplastic lesions in gallbladder" exact="cancer" post="J Surg Oncol 2006 93 8 615 23 10.1002/jso.20527"/>
   <result pre="Valle J et al. Cisplatin plus gemcitabine versus gemcitabine for" exact="biliary tract cancer" post="N Engl J Med 2010 362 14 1273 81"/>
   <result pre="et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract" exact="cancer" post="N Engl J Med 2010 362 14 1273 81"/>
   <result pre="Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar" exact="cholangiocarcinoma" post="at 12 US centers Gastroenterology 2012 143 1 88"/>
   <result pre="survival and quality of life in advanced pancreatic and biliary" exact="cancer" post="Ann Oncol 1996 7 6 593 600 10.1093/oxfordjournals.annonc.a010676 8879373"/>
   <result pre="10.1038/ng.3030 24997986 35. Kumari N et al. Mutation profiling in" exact="gallbladder cancer" post="in Indian population Indian J Pathol Microbiol 2014 57"/>
   <result pre="24997986 35. Kumari N et al. Mutation profiling in gallbladder" exact="cancer" post="in Indian population Indian J Pathol Microbiol 2014 57"/>
   <result pre="Aberrant p53 expression and the development of gallbladder carcinoma and" exact="adenoma" post="Kaohsiung J Med Sci 2006 22 2 53 9"/>
   <result pre="N et al. Epidermal growth factor receptor (EGFR) signaling in" exact="cancer" post="Gene 2006 366 1 2 16 10.1016/j.gene.2005.10.018 16377102 39."/>
   <result pre="and prognostic significance of EGFR, VEGF, and HER2 expression in" exact="cholangiocarcinoma" post="Br J Cancer 2008 98 2 418 25 10.1038/sj.bjc.6604129"/>
   <result pre="epidermal growth factor (EGF) and its receptor (EGFR) in chronic" exact="cholecystitis" post="and gallbladder carcinoma Ai Zheng 2003 22 3 262"/>
   <result pre="Phase II study of erlotinib in patients with advanced biliary" exact="cancer" post="J Clin Oncol 2006 24 19 3069 74 10.1200/JCO.2005.05.3579"/>
   <result pre="Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract" exact="cancer" post="(BINGO): a randomised, open-label, non-comparative phase 2 trial Lancet"/>
   <result pre="and oxaliplatin alone or in combination with cetuximab in advanced" exact="biliary tract cancer" post="Ann Oncol 2015 26 5 943 9 10.1093/annonc/mdv035 25632066"/>
   <result pre="alone or in combination with cetuximab in advanced biliary tract" exact="cancer" post="Ann Oncol 2015 26 5 943 9 10.1093/annonc/mdv035 25632066"/>
   <result pre="panitumumab in KRAS wild-type unresectable or metastatic biliary tract and" exact="gallbladder cancer" post="Br J Cancer 2014 111 3 430 6 10.1038/bjc.2014.343"/>
   <result pre="in KRAS wild-type unresectable or metastatic biliary tract and gallbladder" exact="cancer" post="Br J Cancer 2014 111 3 430 6 10.1038/bjc.2014.343"/>
   <result pre="II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type" exact="biliary tract cancer" post="Ann Oncol 2012 23 9 2341 6 10.1093/annonc/mds008 22367707"/>
   <result pre="trial of panitumumab and chemotherapy in KRAS wild-type biliary tract" exact="cancer" post="Ann Oncol 2012 23 9 2341 6 10.1093/annonc/mds008 22367707"/>
   <result pre="phase II trial of gemcitabine, irinotecan and panitumumab in advanced" exact="cholangiocarcinoma" post="Ann Oncol 2013 24 12 3061 5 10.1093/annonc/mdt416 24146220"/>
   <result pre="6 11585718 55. Javle M et al. HER2/neu-directed therapy for" exact="biliary tract cancer" post="J. Hematol. Oncol 2015 8 58 10.1186/s13045-015-0155-z 26022204 56."/>
   <result pre="55. Javle M et al. HER2/neu-directed therapy for biliary tract" exact="cancer" post="J. Hematol. Oncol 2015 8 58 10.1186/s13045-015-0155-z 26022204 56."/>
   <result pre="of lapatinib in patients with advanced biliary tree and hepatocellular" exact="cancer" post="Cancer Chemother Pharmacol 2009 64 4 777 83 10.1007/s00280-009-0927-7"/>
   <result pre="growth factor protein expressions with the prognosis and metastasis of" exact="gallbladder cancer" post="J Am Coll Surg 2001 193 4 380 3"/>
   <result pre="factor protein expressions with the prognosis and metastasis of gallbladder" exact="cancer" post="J Am Coll Surg 2001 193 4 380 3"/>
   <result pre="growth factor receptor-2 tyrosine kinase inhibitor for the treatment of" exact="cancer" post="Cancer Res 2005 65 10 4389 400 10.1158/0008-5472.CAN-04-4409 15899831"/>
   <result pre="combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced" exact="biliary tract cancer" post="(ABC). J Clin Oncol, 2014. 32(15_suppl: abstr #4002). A"/>
   <result pre="cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract" exact="cancer" post="(ABC). J Clin Oncol, 2014. 32(15_suppl: abstr #4002). A"/>
   <result pre="Santoro A Sorafenib: a review of its use in advanced" exact="hepatocellular carcinoma" post="Drugs 2009 69 2 223 40 10.2165/00003495-200969020-00006 19228077 66."/>
   <result pre="sorafenib in patients with unresectable or metastatic gallbladder carcinoma and" exact="cholangiocarcinoma" post="Investig. New Drugs 2012 30 4 1646 51 10.1007/s10637-011-9719-0"/>
   <result pre="Tannapfel A et al. Mutations of the BRAF gene in" exact="cholangiocarcinoma" post="but not in hepatocellular carcinoma Gut 2003 52 5"/>
   <result pre="Mutations of the BRAF gene in cholangiocarcinoma but not in" exact="hepatocellular carcinoma" post="Gut 2003 52 5 706 12 10.1136/gut.52.5.706 12692057 78."/>
   <result pre="I study of MEK inhibitor MEK162 (ARRY-438162) in patients with" exact="biliary tract cancer." post="J Clin Oncol, 2012. 30(4_suppl: abstr #220). 80. Lowery"/>
   <result pre="(G) and cisplatin (C) patients (pts) with untreated advanced biliary" exact="cancer" post="(ABC). J Clin Oncol, 2015. 33(15_suppl: abstr #e15125). 81."/>
   <result pre="Activity and safety of RAD001 (everolimus) in patients affected by" exact="biliary tract cancer" post="progressing after prior chemotherapy: a phase II ITMO study"/>
   <result pre="safety of RAD001 (everolimus) in patients affected by biliary tract" exact="cancer" post="progressing after prior chemotherapy: a phase II ITMO study"/>
   <result pre="of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against" exact="cholangiocarcinoma" post="Oncotarget 2014 5 9 2372 89 10.18632/oncotarget.1706 24796583 87."/>
   <result pre="pathway inhibitor vismodegib in patients with advanced solid malignancies including" exact="hepatocellular carcinoma" post="with varying degrees of renal or hepatic function. clinical"/>
   <result pre="Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of" exact="cholangiocarcinoma" post="cells J Cancer Res Clin Oncol 2007 133 4"/>
   <result pre="RJ Aster JC The double-edged sword of Notch signaling in" exact="cancer" post="Semin Cell Dev Biol 2012 23 4 458 64"/>
   <result pre="et al. Clinicopathological significance of altered Notch signaling in extrahepatic" exact="cholangiocarcinoma" post="and gallbladder carcinoma World J Gastroenterol 2011 17 35"/>
   <result pre="al. MUC1 peptide vaccination in patients with advanced pancreas or" exact="biliary tract cancer" post="Anticancer Res 2005 25 5 3575 9 16101182 96."/>
   <result pre="peptide vaccination in patients with advanced pancreas or biliary tract" exact="cancer" post="Anticancer Res 2005 25 5 3575 9 16101182 96."/>
   <result pre="dendritic cell vaccine plus activated T-cell transfer in patients with" exact="intrahepatic cholangiocarcinoma" post="J. Hepatobiliary Pancreat. Sci 2012 19 2 171 8"/>
   <result pre="cell vaccine plus activated T-cell transfer in patients with intrahepatic" exact="cholangiocarcinoma" post="J. Hepatobiliary Pancreat. Sci 2012 19 2 171 8"/>
   <result pre="10.1371/journal.pone.0115383 25536104 99. Haga H Patel T Molecular diagnosis of" exact="intrahepatic cholangiocarcinoma" post="J. Hepatobiliary Pancreat. Sci 2015 22 2 114 23"/>
   <result pre="25536104 99. Haga H Patel T Molecular diagnosis of intrahepatic" exact="cholangiocarcinoma" post="J. Hepatobiliary Pancreat. Sci 2015 22 2 114 23"/>
   <result pre="2 tyrosine kinase fusions define a unique molecular subtype of" exact="cholangiocarcinoma" post="Hepatology 2014 59 4 1427 34 10.1002/hep.26890 24122810 101."/>
   <result pre="al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in" exact="cholangiocarcinoma" post="identified through broad-based tumor genotyping Oncologist 2012 17 1"/>
   <result pre="ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced" exact="biliary tract cancer" post="Cancer Chemother Pharmacol 2011 68 2 379 88 10.1007/s00280-010-1481-z"/>
   <result pre="inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract" exact="cancer" post="Cancer Chemother Pharmacol 2011 68 2 379 88 10.1007/s00280-010-1481-z"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4535951/results/search/disease/results.xml">
   <result pre="overarching goal of this project is to establish a patient-derived" exact="bladder cancer" post="xenograft (PDX) platform, annotated with deep sequencing and patient"/>
   <result pre="goal of this project is to establish a patient-derived bladder" exact="cancer" post="xenograft (PDX) platform, annotated with deep sequencing and patient"/>
   <result pre="information, to accelerate the development of new treatment options for" exact="bladder cancer" post="patients. Herein, we describe the creation, initial characterization and"/>
   <result pre="to accelerate the development of new treatment options for bladder" exact="cancer" post="patients. Herein, we describe the creation, initial characterization and"/>
   <result pre="with annotated clinical information were established from uncultured unselected clinical" exact="bladder cancer" post="specimens in immunodeficient NSG mice. The morphological fidelity was"/>
   <result pre="annotated clinical information were established from uncultured unselected clinical bladder" exact="cancer" post="specimens in immunodeficient NSG mice. The morphological fidelity was"/>
   <result pre="a patient’s response to new targeted and combination strategies for" exact="bladder cancer." post="Funding This work was supported by: Veteran Administration Career"/>
   <result pre="fig-count: table-count: page-count: Data Availability Information about all of the" exact="bladder cancer" post="PDX models are available from the JAX PDX portal"/>
   <result pre="table-count: page-count: Data Availability Information about all of the bladder" exact="cancer" post="PDX models are available from the JAX PDX portal"/>
   <result pre="the Mouse Tumor Biology (MTB) database ( http://tumor.informatics.jax.org/mtbwi/pdxSearch.do). Introduction Bladder" exact="cancer" post="is among the ten most common [ 1], yet"/>
   <result pre="major groups of bladder cancer: non-myoinvasive and advanced cancer. Non-myoinvasive" exact="bladder cancer" post="(NMIBC) accounts for 80% of cases at diagnosis. They"/>
   <result pre="groups of bladder cancer: non-myoinvasive and advanced cancer. Non-myoinvasive bladder" exact="cancer" post="(NMIBC) accounts for 80% of cases at diagnosis. They"/>
   <result pre="to advanced stages that account for the high mortality of" exact="bladder cancer." post="Highly toxic platinum-based chemotherapy is commonly used in the"/>
   <result pre="platinum-based chemotherapy is commonly used in the treatment of advanced" exact="bladder cancer" post="with a response rate of around 50% [ 6]."/>
   <result pre="chemotherapy is commonly used in the treatment of advanced bladder" exact="cancer" post="with a response rate of around 50% [ 6]."/>
   <result pre="administration of therapy. If patients are diagnosed with locally advanced" exact="bladder cancer" post="without metastasis, radical cystectomy is usually performed that is"/>
   <result pre="of therapy. If patients are diagnosed with locally advanced bladder" exact="cancer" post="without metastasis, radical cystectomy is usually performed that is"/>
   <result pre="[ 10]. Therefore, there is a critical unmet need in" exact="bladder cancer" post="to select effective first-line and salvage chemotherapy, and develop"/>
   <result pre="10]. Therefore, there is a critical unmet need in bladder" exact="cancer" post="to select effective first-line and salvage chemotherapy, and develop"/>
   <result pre="to develop patient-derived xenografts (PDXs) to improve treatment outcomes of" exact="bladder cancer." post="Many animal models are currently used in cancer research,"/>
   <result pre="of bladder cancer. Many animal models are currently used in" exact="cancer" post="research, such as mouse xenografts developed from cancer cell"/>
   <result pre="used in cancer research, such as mouse xenografts developed from" exact="cancer" post="cell lines and genetically engineered mouse models (GEMM). Even"/>
   <result pre="(GEMM). Even though these models have made tremendous contributions to" exact="cancer" post="research, they fall short in meeting the individual patient-specific"/>
   <result pre="era of precision medicine. Recent developments in and convergence of" exact="cancer" post="biology, &quot;-omics&quot; technologies, computational biology and drug development are"/>
   <result pre="are unable to robustly distinguish driver mutations (those critical for" exact="cancer" post="cell functions) from passenger mutations (those that have little"/>
   <result pre="from passenger mutations (those that have little functional consequence for" exact="cancer" post="cells). We proposed that the patient-specific PDX platform developed"/>
   <result pre="further personalized therapy and drug development. Methods Development of patient-derived" exact="bladder cancer" post="xenografts The protocol to collect clinical information and cancer"/>
   <result pre="personalized therapy and drug development. Methods Development of patient-derived bladder" exact="cancer" post="xenografts The protocol to collect clinical information and cancer"/>
   <result pre="bladder cancer xenografts The protocol to collect clinical information and" exact="cancer" post="specimens from patients was approved by the University of"/>
   <result pre="and the UC Davis IACUC (Protocol No. 17794). Fresh clinical" exact="cancer" post="specimens (3–5mm 3) were implanted subcutaneously into the flanks"/>
   <result pre="reviewed to ensure that at least 85–90% of cells were" exact="cancer" post="cells before specimen collection. Total cellular RNA was isolated"/>
   <result pre="RNA (including the small RNA fraction) was isolated from FFPE" exact="bladder cancer" post="specimens using the miRNeasy FFPE Kit (Qiagen) according to"/>
   <result pre="(including the small RNA fraction) was isolated from FFPE bladder" exact="cancer" post="specimens using the miRNeasy FFPE Kit (Qiagen) according to"/>
   <result pre="library preparation and sequencing Transcriptome profiling of P0 (passage 0)" exact="bladder cancer" post="xenograft tumors was performed by RNA-Seq analysis. RNA-Sequencing (RNA-Seq)"/>
   <result pre="preparation and sequencing Transcriptome profiling of P0 (passage 0) bladder" exact="cancer" post="xenograft tumors was performed by RNA-Seq analysis. RNA-Sequencing (RNA-Seq)"/>
   <result pre="urothelial carcinoma To date, we have established 22 PDXs from" exact="bladder cancer" post="patients, representing 41% of the tumors implanted. Among these"/>
   <result pre="carcinoma To date, we have established 22 PDXs from bladder" exact="cancer" post="patients, representing 41% of the tumors implanted. Among these"/>
   <result pre="Among these 22 PDXs, 13 PDXs were derived from advanced" exact="bladder cancer," post="and 9 PDXs from NMIBC. The clinical characteristics are"/>
   <result pre="(range: 54–83). Five of the 13 PDXs derived from advanced" exact="bladder cancer" post="received prior neoadjuvant chemotherapy before implantation while none of"/>
   <result pre="54–83). Five of the 13 PDXs derived from advanced bladder" exact="cancer" post="received prior neoadjuvant chemotherapy before implantation while none of"/>
   <result pre="patients. Twenty two PDXs were developed, including 13 from advanced" exact="bladder cancer" post="and 9 from non-myoinvasive bladder cancer. Stages Tumor ID"/>
   <result pre="Twenty two PDXs were developed, including 13 from advanced bladder" exact="cancer" post="and 9 from non-myoinvasive bladder cancer. Stages Tumor ID"/>
   <result pre="including 13 from advanced bladder cancer and 9 from non-myoinvasive" exact="bladder cancer." post="Stages Tumor ID Age (yrs) Stage Surgery Prior chemo"/>
   <result pre="Stages Tumor ID Age (yrs) Stage Surgery Prior chemo Myoinvasive" exact="bladder cancer" post="BL0269F 58 pT4 N0 Mx Cystectomy No BL0293F 77"/>
   <result pre="Tumor ID Age (yrs) Stage Surgery Prior chemo Myoinvasive bladder" exact="cancer" post="BL0269F 58 pT4 N0 Mx Cystectomy No BL0293F 77"/>
   <result pre="# BL0648 71 pT4a N2 Mx Cystectomy No. Adenocarcinoma Non-myo-invasive" exact="bladder cancer" post="BL0262F 64 pTa High TURBT No BL0364F 76 pTa"/>
   <result pre="BL0648 71 pT4a N2 Mx Cystectomy No. Adenocarcinoma Non-myo-invasive bladder" exact="cancer" post="BL0262F 64 pTa High TURBT No BL0364F 76 pTa"/>
   <result pre="( Fig 1A) . The morphology of subcutaneous and orthotopic" exact="bladder cancer" post="PDXs was also maintained ( Fig 1A right panels)"/>
   <result pre="Fig 1A) . The morphology of subcutaneous and orthotopic bladder" exact="cancer" post="PDXs was also maintained ( Fig 1A right panels)"/>
   <result pre="stained positive with an anti-human Ki67 antibody, confirming that the" exact="cancer" post="cells in PDXs were indeed of human origin. Over"/>
   <result pre="PDXs were indeed of human origin. Over 90% of PDX" exact="bladder cancer" post="cells expressed Ki67, a marker of cell proliferation ("/>
   <result pre="were indeed of human origin. Over 90% of PDX bladder" exact="cancer" post="cells expressed Ki67, a marker of cell proliferation ("/>
   <result pre="the next-generation sequencing (NGS) data ( S2 Table). Some human" exact="bladder cancer" post="cells and stromal cells in the clinical cancer specimens,"/>
   <result pre="next-generation sequencing (NGS) data ( S2 Table). Some human bladder" exact="cancer" post="cells and stromal cells in the clinical cancer specimens,"/>
   <result pre="human bladder cancer cells and stromal cells in the clinical" exact="cancer" post="specimens, as well as cancer cells in PDXs, were"/>
   <result pre="stromal cells in the clinical cancer specimens, as well as" exact="cancer" post="cells in PDXs, were stained positive for human vimentin."/>
   <result pre="with Ki67 at passage six PDX compared to the human" exact="bladder cancer" post="specimen, suggesting more cells were in cell proliferation, and"/>
   <result pre="Ki67 at passage six PDX compared to the human bladder" exact="cancer" post="specimen, suggesting more cells were in cell proliferation, and"/>
   <result pre="&amp;amp; E staining. (C) Staining of human vimentin. Some human" exact="bladder cancer" post="cells (left panel) and stromal cells (middle panel) were"/>
   <result pre="E staining. (C) Staining of human vimentin. Some human bladder" exact="cancer" post="cells (left panel) and stromal cells (middle panel) were"/>
   <result pre="In the PDX specimen at passage 0, only a few" exact="bladder cancer" post="cells were stained positive for human vimentin, suggesting that"/>
   <result pre="the PDX specimen at passage 0, only a few bladder" exact="cancer" post="cells were stained positive for human vimentin, suggesting that"/>
   <result pre="Fig 2) . In summary, the genomic variations present in" exact="bladder cancer" post="patient tumors were highly conserved in the PDXs. Fig"/>
   <result pre="2) . In summary, the genomic variations present in bladder" exact="cancer" post="patient tumors were highly conserved in the PDXs. Fig"/>
   <result pre="the PDXs. Fig 2 Conservation of genomic variants between patient" exact="bladder cancer" post="specimens and PDXs. WES analysis was performed on genomic"/>
   <result pre="PDXs. Fig 2 Conservation of genomic variants between patient bladder" exact="cancer" post="specimens and PDXs. WES analysis was performed on genomic"/>
   <result pre="KMT2C, NCF2, MTOR, PIK3CA, TSC1, and TP53; 6–10 mutations in" exact="bladder cancer" post="driver genes were found in 5 of 8 models"/>
   <result pre="NCF2, MTOR, PIK3CA, TSC1, and TP53; 6–10 mutations in bladder" exact="cancer" post="driver genes were found in 5 of 8 models"/>
   <result pre="( S5 Table) . Fig 3 Mutation status of known" exact="bladder cancer" post="functionally active genes and significantly mutated genes in PDXs."/>
   <result pre="S5 Table) . Fig 3 Mutation status of known bladder" exact="cancer" post="functionally active genes and significantly mutated genes in PDXs."/>
   <result pre="somatic mutations occurring in a consolidated list of 130 known" exact="bladder cancer" post="functionally active genes [ 27] and significantly mutated genes"/>
   <result pre="mutations occurring in a consolidated list of 130 known bladder" exact="cancer" post="functionally active genes [ 27] and significantly mutated genes"/>
   <result pre="intensities. Mutational analysis of tumor suppressor pathways Three-quarters of the" exact="bladder cancer" post="PDXs contained aberrations in one or more of the"/>
   <result pre="Mutational analysis of tumor suppressor pathways Three-quarters of the bladder" exact="cancer" post="PDXs contained aberrations in one or more of the"/>
   <result pre="of gene-level expression for the entire consolidated list of 236" exact="bladder cancer" post="functionally active and significantly mutated genes demonstrated that 85–104"/>
   <result pre="gene-level expression for the entire consolidated list of 236 bladder" exact="cancer" post="functionally active and significantly mutated genes demonstrated that 85–104"/>
   <result pre="is a dual EGFR/HER2 inhibitor approved by the FDA for" exact="breast cancer." post="NSG mice bearing PDX BL0269 or BL0440 were treated"/>
   <result pre="combination is commonly used as a first-line chemotherapy in advanced" exact="bladder cancer." post="Of the first six PDXs we screened (10–12 mice"/>
   <result pre="combination. Discussion Here we described the development and characterization of" exact="bladder cancer" post="patient-derived xenografts (PDXs) with deep sequencing characterization. These PDXs"/>
   <result pre="Discussion Here we described the development and characterization of bladder" exact="cancer" post="patient-derived xenografts (PDXs) with deep sequencing characterization. These PDXs"/>
   <result pre="cancers as determined by both morphology and genetic aberrations. Precision" exact="cancer" post="medicine represents using state-of-the-art technologies to characterize the disease"/>
   <result pre="range of response rates, from approximately 30% with trastuzumab in" exact="breast cancer" post="with HER2/Neu overexpression and/or gene amplification [ 32], 60%"/>
   <result pre="of response rates, from approximately 30% with trastuzumab in breast" exact="cancer" post="with HER2/Neu overexpression and/or gene amplification [ 32], 60%"/>
   <result pre="a BRAF mutation [ 33, 34], to over 90% in" exact="chronic myeloid leukemia" post="[ 35, 36]. Moreover, when cancers do respond to"/>
   <result pre="BRAF mutation [ 33, 34], to over 90% in chronic" exact="myeloid leukemia" post="[ 35, 36]. Moreover, when cancers do respond to"/>
   <result pre="mutation [ 33, 34], to over 90% in chronic myeloid" exact="leukemia" post="[ 35, 36]. Moreover, when cancers do respond to"/>
   <result pre="non-synonymous mutations per tumor in pediatric tumors to hundreds in" exact="colon cancer" post="with microsatellite instability [ 43], with most of these"/>
   <result pre="mutations per tumor in pediatric tumors to hundreds in colon" exact="cancer" post="with microsatellite instability [ 43], with most of these"/>
   <result pre="these genetic aberrations being passengers that are not critical for" exact="cancer" post="cell function. In the clinical setting, time (life expectancy)"/>
   <result pre="therapy during the first few attempts will be critical in" exact="cancer" post="treatment. The PDX allows populations of mice harboring the"/>
   <result pre="In this study, BL0479, BL0440 and BL0515 were established from" exact="bladder cancer" post="specimens of patients who were previously treated with chemotherapy"/>
   <result pre="this study, BL0479, BL0440 and BL0515 were established from bladder" exact="cancer" post="specimens of patients who were previously treated with chemotherapy"/>
   <result pre="molecularly guided targeted therapy. ① Patients with muscle-invasive or advanced" exact="bladder cancer" post="undergo transurethral or surgery resection. Some tumor specimens are"/>
   <result pre="guided targeted therapy. ① Patients with muscle-invasive or advanced bladder" exact="cancer" post="undergo transurethral or surgery resection. Some tumor specimens are"/>
   <result pre="④ Computational biology is used to identify genetic aberrations in" exact="cancer" post="cells. ⑤ Validation tests, such as direct sequencing, western"/>
   <result pre="to some other treatments (Drug A and D). ⑧ Upon" exact="cancer" post="relapse in human patients, biopsy can be performed to"/>
   <result pre="genetic aberrations in human cancers is used to treat relapsed" exact="cancer" post="in patients. ⑨ Drug C can potentially be used"/>
   <result pre="used while patients are in remission to cure or delay" exact="cancer" post="recurrence. The PDX platform has some unique advantages for"/>
   <result pre="for precision medicine that are not paralleled by some other" exact="cancer" post="models, such as cancer xenografts from cell lines, and"/>
   <result pre="are not paralleled by some other cancer models, such as" exact="cancer" post="xenografts from cell lines, and genetically engineered mouse model"/>
   <result pre="and harbor multiple and diversified genetic alterations. For instance, in" exact="bladder cancer," post="about two thirds of the cancers are attributed to"/>
   <result pre="As shown in Figs 3, 4 and 5 , each" exact="cancer" post="carries a unique spectrum of genetic alterations. Therefore, preclinical"/>
   <result pre="progression and short patient survival, as reported in non-small cell" exact="lung cancer" post="and pancreatic cancer (reviewed [ 49, 50]) [ 51]."/>
   <result pre="and short patient survival, as reported in non-small cell lung" exact="cancer" post="and pancreatic cancer (reviewed [ 49, 50]) [ 51]."/>
   <result pre="patient survival, as reported in non-small cell lung cancer and" exact="pancreatic cancer" post="(reviewed [ 49, 50]) [ 51]. However should the"/>
   <result pre="survival, as reported in non-small cell lung cancer and pancreatic" exact="cancer" post="(reviewed [ 49, 50]) [ 51]. However should the"/>
   <result pre="as hoped, the relatively slow rate of disease progression makes" exact="bladder cancer" post="one of the best candidate cancers in translating preclinical"/>
   <result pre="hoped, the relatively slow rate of disease progression makes bladder" exact="cancer" post="one of the best candidate cancers in translating preclinical"/>
   <result pre="will all contribute towards turning molecularly targeted therapy into precision" exact="cancer" post="medicine. In conclusion, we have developed and characterized a"/>
   <result pre="medicine. In conclusion, we have developed and characterized a patient-derived" exact="bladder cancer" post="xenograft model platform that may prove useful for screening"/>
   <result pre="In conclusion, we have developed and characterized a patient-derived bladder" exact="cancer" post="xenograft model platform that may prove useful for screening"/>
   <result pre="platform may accelerate drug discovery leading to improve treatments for" exact="bladder cancer." post="Supporting Information S1 Fig Target genes and matched targeted"/>
   <result pre="here for additional data file. S2 Fig Expression analysis of" exact="bladder cancer" post="functionally active genes and significantly mutated genes. (PPTX) LINK"/>
   <result pre="for additional data file. S2 Fig Expression analysis of bladder" exact="cancer" post="functionally active genes and significantly mutated genes. (PPTX) LINK"/>
   <result pre="Carter AJ , Nguyen CN ( 2012) A comparison of" exact="cancer" post="burden and research spending reveals discrepancies in the distribution"/>
   <result pre="WR , Whitmore WF , et al. ( 1989) Superficial" exact="bladder cancer" post="treated with bacillus Calmette-Guerin: a multivariate analysis of factors"/>
   <result pre=", Whitmore WF , et al. ( 1989) Superficial bladder" exact="cancer" post="treated with bacillus Calmette-Guerin: a multivariate analysis of factors"/>
   <result pre="et al. ( 2005) Assessing quality of life in adult" exact="cancer" post="survivors (QLACS). Qual Life Res 14: 1007– 1023. 16041897"/>
   <result pre="et al. ( 2014) Personalized medicine for patients with advanced" exact="cancer" post="in the phase I program at MD anderson: validation"/>
   <result pre="et al. ( 2011) The genomic complexity of primary human" exact="prostate cancer." post="Nature 470: 214– 220. doi: 10.1038/nature09744 21307934 14 Chapman"/>
   <result pre="et al. ( 2011) Initial genome sequencing and analysis of" exact="multiple myeloma." post="Nature 471: 467– 472. doi: 10.1038/nature09837 21430775 15 Gui"/>
   <result pre=", et al. ( 2013) Whole-genome and whole-exome sequencing of" exact="bladder cancer" post="identifies frequent alterations in genes involved in sister chromatid"/>
   <result pre="et al. ( 2013) Whole-genome and whole-exome sequencing of bladder" exact="cancer" post="identifies frequent alterations in genes involved in sister chromatid"/>
   <result pre="J , et al. ( 2013) Comprehensive identification of mutational" exact="cancer" post="driver genes across 12 tumor types. Sci Rep 3:"/>
   <result pre="et al. ( 2011) The BATTLE trial: personalizing therapy for" exact="lung cancer." post="Cancer Discov 1: 44– 53. doi: 10.1158/2159-8274.CD-10-0010 22586319 32"/>
   <result pre="as a single agent in first-line treatment of HER2-overexpressing metastatic" exact="breast cancer" post=". J Clin Oncol 20: 719– 726. 11821453 33"/>
   <result pre="a single agent in first-line treatment of HER2-overexpressing metastatic breast" exact="cancer" post=". J Clin Oncol 20: 719– 726. 11821453 33"/>
   <result pre="compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase" exact="chronic myeloid leukemia" post=". N Engl J Med 348: 994– 1004. 12637609"/>
   <result pre="with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic" exact="myeloid leukemia" post=". N Engl J Med 348: 994– 1004. 12637609"/>
   <result pre="interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid" exact="leukemia" post=". N Engl J Med 348: 994– 1004. 12637609"/>
   <result pre="et al. ( 2010) Nilotinib versus imatinib for newly diagnosed" exact="chronic myeloid leukemia." post="N Engl J Med 362: 2251– 2259. doi: 10.1056/NEJMoa0912614"/>
   <result pre="al. ( 2010) Nilotinib versus imatinib for newly diagnosed chronic" exact="myeloid leukemia." post="N Engl J Med 362: 2251– 2259. doi: 10.1056/NEJMoa0912614"/>
   <result pre="first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell" exact="lung cancer" post="(EURTAC): a multicentre, open-label, randomised phase 3 trial ."/>
   <result pre="treatment for European patients with advanced EGFR mutation-positive non-small-cell lung" exact="cancer" post="(EURTAC): a multicentre, open-label, randomised phase 3 trial ."/>
   <result pre="resource of phenotypically stable, biologically and ethnically diverse, patient-derived human" exact="breast cancer" post="xenograft models . Cancer Res 73: 4885– 4897. doi:"/>
   <result pre="of phenotypically stable, biologically and ethnically diverse, patient-derived human breast" exact="cancer" post="xenograft models . Cancer Res 73: 4885– 4897. doi:"/>
   <result pre="et al. ( 2007) A new model of patient tumor-derived" exact="breast cancer" post="xenografts for preclinical assays. Clin Cancer Res 13: 3989–"/>
   <result pre="al. ( 2007) A new model of patient tumor-derived breast" exact="cancer" post="xenografts for preclinical assays. Clin Cancer Res 13: 3989–"/>
   <result pre="et al. ( 2009) A primary xenograft model of small-cell" exact="lung cancer" post="reveals irreversible changes in gene expression imposed by culture"/>
   <result pre="al. ( 2009) A primary xenograft model of small-cell lung" exact="cancer" post="reveals irreversible changes in gene expression imposed by culture"/>
   <result pre=", Reilly KM ( 2010) Genetically engineered mouse models in" exact="cancer" post="research. Adv Cancer Res 106: 113– 164. doi: 10.1016/S0065-230X(10)06004-5"/>
   <result pre="( 2014) Patient-derived xenograft models: an emerging platform for translational" exact="cancer" post="research. Cancer Discov 4: 998– 1013. doi: 10.1158/2159-8290.CD-14-0001 25185190"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4538762/results/search/disease/results.xml">
   <result pre="26283654 1583 doi: 10.1186/s12885-015-1583-4 : Research Article Essential medicines for" exact="breast cancer" post="in low and middle income countries Bazargani Y. T."/>
   <result pre="1583 doi: 10.1186/s12885-015-1583-4 : Research Article Essential medicines for breast" exact="cancer" post="in low and middle income countries Bazargani Y. T."/>
   <result pre="available in this article, unless otherwise stated. Abstract Background Breast" exact="cancer" post="is the most common type of cancer among women"/>
   <result pre="Abstract Background Breast cancer is the most common type of" exact="cancer" post="among women worldwide. In low and middle-income countries (LMICs),"/>
   <result pre="access to treatment. We studied selection of systemic treatments for" exact="breast cancer" post="on NEMLs and assessed its alignment with treatment guidelines"/>
   <result pre="to treatment. We studied selection of systemic treatments for breast" exact="cancer" post="on NEMLs and assessed its alignment with treatment guidelines"/>
   <result pre="with treatment guidelines for different types of early and advanced" exact="breast cancer." post="Furthermore, influence of country characteristics on the selection was"/>
   <result pre="inclusion of all components of therapy in each stage of" exact="breast cancer" post="according to international consensus guidelines. The results were then"/>
   <result pre="of all components of therapy in each stage of breast" exact="cancer" post="according to international consensus guidelines. The results were then"/>
   <result pre="%). Consequently, all components of treatment for &quot;Luminal A&quot; early" exact="breast cancer" post="and non HER2 overexpressed advanced breast cancer were found"/>
   <result pre="Consequently, all components of treatment for &quot;Luminal A&quot; early breast" exact="cancer" post="and non HER2 overexpressed advanced breast cancer were found"/>
   <result pre="&quot;Luminal A&quot; early breast cancer and non HER2 overexpressed advanced" exact="breast cancer" post="were found on the NEMLs of over 70 %"/>
   <result pre="A&quot; early breast cancer and non HER2 overexpressed advanced breast" exact="cancer" post="were found on the NEMLs of over 70 %"/>
   <result pre="all the components of therapy for any type of early" exact="breast cancer" post="in their NEMLs, and adequate treatment of HER2 overexpressed"/>
   <result pre="the components of therapy for any type of early breast" exact="cancer" post="in their NEMLs, and adequate treatment of HER2 overexpressed"/>
   <result pre="cancer in their NEMLs, and adequate treatment of HER2 overexpressed" exact="breast cancer" post="was hardly possible with the current selections. Recent NEMLs"/>
   <result pre="in their NEMLs, and adequate treatment of HER2 overexpressed breast" exact="cancer" post="was hardly possible with the current selections. Recent NEMLs"/>
   <result pre="Mediterranean and African regions less frequently incorporated all components of" exact="breast cancer" post="treatment in their NEMLs. Conclusion Alignment of selection with"/>
   <result pre="and African regions less frequently incorporated all components of breast" exact="cancer" post="treatment in their NEMLs. Conclusion Alignment of selection with"/>
   <result pre="recommendations was inconsistent for different types of early and advanced" exact="breast cancer" post="in NEMLs. Regular updates and more attention to clinical"/>
   <result pre="was inconsistent for different types of early and advanced breast" exact="cancer" post="in NEMLs. Regular updates and more attention to clinical"/>
   <result pre="supplementary material, which is available to authorized users. Background Breast" exact="cancer" post="is the leading cause of death among women in"/>
   <result pre="the past decades in early detection, screening and treatment of" exact="breast cancer." post="This has resulted in 5-year survival rates of approximately"/>
   <result pre="middle and low income countries, respectively [ 2]. Comprehensive national" exact="cancer" post="control plans to fight (breast) cancer may consist of"/>
   <result pre="[ 2]. Comprehensive national cancer control plans to fight (breast)" exact="cancer" post="may consist of prevention, screening and early detection, diagnosis,"/>
   <result pre="3]. Not necessarily all the components of a comprehensive national" exact="cancer" post="control plan exist in every low or middle income"/>
   <result pre="to systemic therapy as a part of the treatment of" exact="breast cancer." post="Many international guidelines have been published including guidelines adjusted"/>
   <result pre="have been published [ 13]. Selection of appropriate medication for" exact="breast cancer" post="on national essential medicines lists (NEMLs) is an initial"/>
   <result pre="been published [ 13]. Selection of appropriate medication for breast" exact="cancer" post="on national essential medicines lists (NEMLs) is an initial"/>
   <result pre="the latter group of medicines plays a pivotal role in" exact="breast cancer" post="treatment, we thoroughly studied available NEMLs to assess diversity"/>
   <result pre="latter group of medicines plays a pivotal role in breast" exact="cancer" post="treatment, we thoroughly studied available NEMLs to assess diversity"/>
   <result pre="thoroughly studied available NEMLs to assess diversity in selection of" exact="breast cancer" post="medicines across LMICs. Besides, we aimed to assess the"/>
   <result pre="studied available NEMLs to assess diversity in selection of breast" exact="cancer" post="medicines across LMICs. Besides, we aimed to assess the"/>
   <result pre="selected essential medicines would allow treatment of different stages of" exact="breast cancer" post="according to international treatment guidelines. The influences of country"/>
   <result pre="essential medicines would allow treatment of different stages of breast" exact="cancer" post="according to international treatment guidelines. The influences of country"/>
   <result pre="Of the remaining medicines, only those which were recommended for" exact="breast cancer" post="according to international guidelines (see below) were included. Medicines"/>
   <result pre="the remaining medicines, only those which were recommended for breast" exact="cancer" post="according to international guidelines (see below) were included. Medicines"/>
   <result pre="to international guidelines (see below) were included. Medicines used for" exact="breast cancer" post="are generally categorized into three different classes, namely chemotherapeutic"/>
   <result pre="international guidelines (see below) were included. Medicines used for breast" exact="cancer" post="are generally categorized into three different classes, namely chemotherapeutic"/>
   <result pre="role in treatment of hormone receptor (estrogen and/or progesterone) positive" exact="breast cancer" post="patients [ 18]. HER2-targeted therapies are shown to increase"/>
   <result pre="in treatment of hormone receptor (estrogen and/or progesterone) positive breast" exact="cancer" post="patients [ 18]. HER2-targeted therapies are shown to increase"/>
   <result pre="of evidence based international consensus guidelines for different stages of" exact="breast cancer." post="Precedence was given to guidelines designed for LMICs when"/>
   <result pre="Cancer [ 7] and 1st International consensus guidelines for advanced" exact="breast cancer" post="(ABC 1) [ 8]). Different subtypes of early and"/>
   <result pre="[ 7] and 1st International consensus guidelines for advanced breast" exact="cancer" post="(ABC 1) [ 8]). Different subtypes of early and"/>
   <result pre="(ABC 1) [ 8]). Different subtypes of early and advanced" exact="breast cancer" post="-according to the guidelines- are described in Table 1."/>
   <result pre="1) [ 8]). Different subtypes of early and advanced breast" exact="cancer" post="-according to the guidelines- are described in Table 1."/>
   <result pre="guidelines- are described in Table 1. For each type of" exact="breast cancer," post="the necessary components of treatment regimens were identified based"/>
   <result pre="aforementioned guidelines. Full details of all components for treatment of" exact="breast cancer" post="are given in Additional file 1: Annex 2. Table"/>
   <result pre="guidelines. Full details of all components for treatment of breast" exact="cancer" post="are given in Additional file 1: Annex 2. Table"/>
   <result pre="Annex 2. Table 1 Different subtypes of early and advanced" exact="breast cancer" post="according to the selected guidelines (7, 8) Type of"/>
   <result pre="2. Table 1 Different subtypes of early and advanced breast" exact="cancer" post="according to the selected guidelines (7, 8) Type of"/>
   <result pre="cancer according to the selected guidelines (7, 8) Type of" exact="breast cancer" post="Subtypes Descriptions Early breast cancer † Luminal A HR+;HER2-;"/>
   <result pre="according to the selected guidelines (7, 8) Type of breast" exact="cancer" post="Subtypes Descriptions Early breast cancer † Luminal A HR+;HER2-;"/>
   <result pre="guidelines (7, 8) Type of breast cancer Subtypes Descriptions Early" exact="breast cancer" post="† Luminal A HR+;HER2-; Ki-67 low Luminal B HR+;HER2-;"/>
   <result pre="(7, 8) Type of breast cancer Subtypes Descriptions Early breast" exact="cancer" post="† Luminal A HR+;HER2-; Ki-67 low Luminal B HR+;HER2-;"/>
   <result pre="Special histological types HER2 absent; endocrine responsive or non-responsive Advanced" exact="breast cancer" post="†† HR +/HER2- HR+/HER2+ HR-/HER2+ HR-/HER2- HR+ = ER and/or"/>
   <result pre="histological types HER2 absent; endocrine responsive or non-responsive Advanced breast" exact="cancer" post="†† HR +/HER2- HR+/HER2+ HR-/HER2+ HR-/HER2- HR+ = ER and/or"/>
   <result pre="Ki-67 a marker of cell proliferation †Early breast cancer: Breast" exact="cancer" post="that has not spread beyond the breast or the"/>
   <result pre="the breast or the axillary lymph nodes. This includes ductal" exact="carcinoma in situ" post="and stage I, stage IIA, stage IIB, and stage"/>
   <result pre="(Reference: National Cancer Institute; http://www.cancer.gov/dictionary?cdrid=446564 ) ††Advanced breast cancer: Breast" exact="cancer" post="that has spread locally in the area of the"/>
   <result pre="and tissues (metastatic breast cancer), it includes: •Stage III: the" exact="cancer" post="has either extensively spread to lymph nodes and/or other"/>
   <result pre="not to distant sites in the body •Stage IV: the" exact="cancer" post="has spread to distant sites of the body, such"/>
   <result pre="liver, lungs, bones, brain, and/or other sites ( Reference: advanced" exact="breast cancer" post="community; http://www.advancedbreastcancercommunity.org/advanced-breast-cancer/defining-advanced-breast-cancer.html) †,††: Early breast cancer is classified based"/>
   <result pre="lungs, bones, brain, and/or other sites ( Reference: advanced breast" exact="cancer" post="community; http://www.advancedbreastcancercommunity.org/advanced-breast-cancer/defining-advanced-breast-cancer.html) †,††: Early breast cancer is classified based"/>
   <result pre="sites ( Reference: advanced breast cancer community; http://www.advancedbreastcancercommunity.org/advanced-breast-cancer/defining-advanced-breast-cancer.html) †,††: Early" exact="breast cancer" post="is classified based on clinicopathological criteria namely detection of"/>
   <result pre="( Reference: advanced breast cancer community; http://www.advancedbreastcancercommunity.org/advanced-breast-cancer/defining-advanced-breast-cancer.html) †,††: Early breast" exact="cancer" post="is classified based on clinicopathological criteria namely detection of"/>
   <result pre="and Ki-67 labeling index (a marker of cell proliferation). Advanced" exact="breast cancer" post="is classified in a similar way except for the"/>
   <result pre="Ki-67 labeling index (a marker of cell proliferation). Advanced breast" exact="cancer" post="is classified in a similar way except for the"/>
   <result pre="22, 23]. Data analysis First, the frequency of inclusion of" exact="breast cancer" post="medicines and combinations (chemotherapeutic or endocrine therapy) as recommended"/>
   <result pre="23]. Data analysis First, the frequency of inclusion of breast" exact="cancer" post="medicines and combinations (chemotherapeutic or endocrine therapy) as recommended"/>
   <result pre="inclusion of treatments in the NEMLs for various types of" exact="breast cancer" post="was compared between different clusters of countries, non-parametric tests"/>
   <result pre="of treatments in the NEMLs for various types of breast" exact="cancer" post="was compared between different clusters of countries, non-parametric tests"/>
   <result pre="manuscript is freely available. Results Selection of essential medicines for" exact="breast cancer" post="Overall, 84 % and 74 % of the studied"/>
   <result pre="is freely available. Results Selection of essential medicines for breast" exact="cancer" post="Overall, 84 % and 74 % of the studied"/>
   <result pre="had at least one chemotherapeutic and one hormonal agent for" exact="breast cancer," post="respectively. Slightly fewer than 10 % of the countries"/>
   <result pre="the main chemotherapeutic and hormonal regimens for the treatment of" exact="breast cancer" post="according to the international guidelines in the NEMLs. Tamoxifen,"/>
   <result pre="main chemotherapeutic and hormonal regimens for the treatment of breast" exact="cancer" post="according to the international guidelines in the NEMLs. Tamoxifen,"/>
   <result pre="% of the NEMLs. Selection of treatment regimens for different" exact="breast cancer" post="stages Early breast cancer In three out of four"/>
   <result pre="of the NEMLs. Selection of treatment regimens for different breast" exact="cancer" post="stages Early breast cancer In three out of four"/>
   <result pre="Selection of treatment regimens for different breast cancer stages Early" exact="breast cancer" post="In three out of four of the studied countries"/>
   <result pre="of treatment regimens for different breast cancer stages Early breast" exact="cancer" post="In three out of four of the studied countries"/>
   <result pre="studied countries all components for treatment of &quot;Luminal A&quot; type" exact="breast cancer" post="were selected as essential medicines. One third of the"/>
   <result pre="countries all components for treatment of &quot;Luminal A&quot; type breast" exact="cancer" post="were selected as essential medicines. One third of the"/>
   <result pre="including &quot;Luminal B (HER2-)&quot; and &quot;Special histological types&quot; of early" exact="breast cancer" post="in addition to the former two types. All treatment"/>
   <result pre="&quot;Luminal B (HER2-)&quot; and &quot;Special histological types&quot; of early breast" exact="cancer" post="in addition to the former two types. All treatment"/>
   <result pre="not have all therapy components for any type of early" exact="breast cancer." post="Fig. 2 a Inclusion of all components of treatment"/>
   <result pre="of all components of treatment for different types of early" exact="breast cancer" post="tumors in the NEMLs across different income levels number"/>
   <result pre="all components of treatment for different types of early breast" exact="cancer" post="tumors in the NEMLs across different income levels number"/>
   <result pre="of all components of treatment for different types of early" exact="breast cancer" post="tumors in the NEMLs across different WHO regions number"/>
   <result pre="all components of treatment for different types of early breast" exact="cancer" post="tumors in the NEMLs across different WHO regions number"/>
   <result pre="which had all treatment components for different types of early" exact="breast cancer" post="in their NEMLs (p &amp;lt; 0.001). While over 80 % of"/>
   <result pre="had all treatment components for different types of early breast" exact="cancer" post="in their NEMLs (p &amp;lt; 0.001). While over 80 % of"/>
   <result pre="countries included all therapy components for all types of early" exact="breast cancer" post="(except for HER2 overexpressed tumors), over 40 % of"/>
   <result pre="included all therapy components for all types of early breast" exact="cancer" post="(except for HER2 overexpressed tumors), over 40 % of"/>
   <result pre="any subtype (Fig. 2b). Across the different types of early" exact="breast cancer," post="newer NEMLs had more frequently incorporated all treatment components"/>
   <result pre="newer NEMLs vs. 62 % for older NEMLs, p = 0.033) Advanced" exact="breast cancer" post="All components for treatment of two types, namely HR-/"/>
   <result pre="NEMLs vs. 62 % for older NEMLs, p = 0.033) Advanced breast" exact="cancer" post="All components for treatment of two types, namely HR-/"/>
   <result pre="were selected in the NEMLs for different types of advanced" exact="breast cancer" post="was not significantly different across the 3 income level"/>
   <result pre="selected in the NEMLs for different types of advanced breast" exact="cancer" post="was not significantly different across the 3 income level"/>
   <result pre="line therapy of HR+/HER2- and HR-/ HER2- types of advanced" exact="breast cancer" post="as essential medicines (Fig. 3a). Fig. 3 a Inclusion"/>
   <result pre="therapy of HR+/HER2- and HR-/ HER2- types of advanced breast" exact="cancer" post="as essential medicines (Fig. 3a). Fig. 3 a Inclusion"/>
   <result pre="of all components of treatment for different types of advanced" exact="breast cancer" post="in the NEMLs across different income levels number of"/>
   <result pre="all components of treatment for different types of advanced breast" exact="cancer" post="in the NEMLs across different income levels number of"/>
   <result pre="of all components of treatment for different types of advanced" exact="breast cancer" post="in the NEMLs across different WHO regions number of"/>
   <result pre="all components of treatment for different types of advanced breast" exact="cancer" post="in the NEMLs across different WHO regions number of"/>
   <result pre="and South-East Asia had all components for therapies of advanced" exact="breast cancer" post="(except HER2+), while -on average- 40 % of the"/>
   <result pre="South-East Asia had all components for therapies of advanced breast" exact="cancer" post="(except HER2+), while -on average- 40 % of the"/>
   <result pre="the Western Pacific region included all treatment components for HR-/HER2-" exact="breast cancer" post="treatment less frequently than for HR+/HER2- treatment (33 %"/>
   <result pre="Western Pacific region included all treatment components for HR-/HER2- breast" exact="cancer" post="treatment less frequently than for HR+/HER2- treatment (33 %"/>
   <result pre="all components for 2nd line treatment of HR+/HER2- type advanced" exact="breast cancer" post="as essential medicines. All components for 2nd line therapy"/>
   <result pre="components for 2nd line treatment of HR+/HER2- type advanced breast" exact="cancer" post="as essential medicines. All components for 2nd line therapy"/>
   <result pre="components for 2nd line therapy for HR+/HER2+ type of advanced" exact="breast cancer" post="were not found in any of the NEMLs. The"/>
   <result pre="for 2nd line therapy for HR+/HER2+ type of advanced breast" exact="cancer" post="were not found in any of the NEMLs. The"/>
   <result pre="types. Discussion Despite substantial progress made in its treatment possibilities," exact="breast cancer" post="survival is still poor in LMICs. This might be"/>
   <result pre="Discussion Despite substantial progress made in its treatment possibilities, breast" exact="cancer" post="survival is still poor in LMICs. This might be"/>
   <result pre="possible with the selected essential medicines. Except for luminal A" exact="breast cancer," post="selection of essential medicines did not allow treatment of"/>
   <result pre="selection of essential medicines did not allow treatment of early" exact="breast cancer" post="subtypes in many LMICs. Guideline- recommended treatments were less"/>
   <result pre="of essential medicines did not allow treatment of early breast" exact="cancer" post="subtypes in many LMICs. Guideline- recommended treatments were less"/>
   <result pre="low income countries than in middle income countries. In advanced" exact="breast cancer," post="all components of therapy (except for HER2-targeted therapies) were"/>
   <result pre="the Eastern Mediterranean and African regions less frequently incorporated full" exact="breast cancer" post="treatment components for both early and advanced breast cancer."/>
   <result pre="Eastern Mediterranean and African regions less frequently incorporated full breast" exact="cancer" post="treatment components for both early and advanced breast cancer."/>
   <result pre="full breast cancer treatment components for both early and advanced" exact="breast cancer." post="Across all different breast cancer types, newer NEMLs were"/>
   <result pre="for both early and advanced breast cancer. Across all different" exact="breast cancer" post="types, newer NEMLs were more frequently aligned with clinical"/>
   <result pre="both early and advanced breast cancer. Across all different breast" exact="cancer" post="types, newer NEMLs were more frequently aligned with clinical"/>
   <result pre="more frequently aligned with clinical guidelines. Considering the fact that" exact="breast cancer" post="is the most burdensome type of cancer among women,"/>
   <result pre="frequently aligned with clinical guidelines. Considering the fact that breast" exact="cancer" post="is the most burdensome type of cancer among women,"/>
   <result pre="fact that breast cancer is the most burdensome type of" exact="cancer" post="among women, the selection of therapies for different disease"/>
   <result pre="as essential medicines compared to (several) early stages. In early" exact="breast cancer," post="treatment was mainly absent for luminal B (HER2-) in"/>
   <result pre="routine checkups and cultural barriers for educating women for self-examinations," exact="breast cancer" post="is usually diagnosed at late stages in low income"/>
   <result pre="checkups and cultural barriers for educating women for self-examinations, breast" exact="cancer" post="is usually diagnosed at late stages in low income"/>
   <result pre="whether priority should be given to additional hormonal therapies. HR+" exact="breast cancer" post="corresponds to the majority of breast cancer cases and"/>
   <result pre="priority should be given to additional hormonal therapies. HR+ breast" exact="cancer" post="corresponds to the majority of breast cancer cases and"/>
   <result pre="hormonal therapies. HR+ breast cancer corresponds to the majority of" exact="breast cancer" post="cases and thus has a crucial role in treatment."/>
   <result pre="therapies. HR+ breast cancer corresponds to the majority of breast" exact="cancer" post="cases and thus has a crucial role in treatment."/>
   <result pre="of &quot;all components&quot; of treatment for HER2 overexpressed types of" exact="breast cancer" post="(which constitute nearly one fourth of all cases ["/>
   <result pre="&quot;all components&quot; of treatment for HER2 overexpressed types of breast" exact="cancer" post="(which constitute nearly one fourth of all cases ["/>
   <result pre="when inclusion in the NEMLs will become feasible. Rank of" exact="breast cancer" post="(in terms of incidence and mortality among all cancer"/>
   <result pre="inclusion in the NEMLs will become feasible. Rank of breast" exact="cancer" post="(in terms of incidence and mortality among all cancer"/>
   <result pre="breast cancer (in terms of incidence and mortality among all" exact="cancer" post="types in women) in eastern Mediterranean and African regions"/>
   <result pre="in those health care systems might have hindered inclusion of" exact="breast cancer" post="medicines in the NEMLs in those regions. The main"/>
   <result pre="those health care systems might have hindered inclusion of breast" exact="cancer" post="medicines in the NEMLs in those regions. The main"/>
   <result pre="are lower respiratory infections, diarrheal disease, preterm birth complications and" exact="tuberculosis" post="as well as malaria and HIV/AIDS for the African"/>
   <result pre="diarrheal disease, preterm birth complications and tuberculosis as well as" exact="malaria" post="and HIV/AIDS for the African and cardiovascular disease for"/>
   <result pre="as well as malaria and HIV/AIDS for the African and" exact="cardiovascular disease" post="for the Eastern Mediterranean regions [ 40, 41]. This"/>
   <result pre="41]. This study has some limitations. While the most recent" exact="breast cancer" post="guidelines -at the time of survey -were studied, the"/>
   <result pre="This study has some limitations. While the most recent breast" exact="cancer" post="guidelines -at the time of survey -were studied, the"/>
   <result pre="addition, as previously mentioned, pharmacotherapy is only one component of" exact="breast cancer" post="care. In the entire procedure of treatment of breast"/>
   <result pre="as previously mentioned, pharmacotherapy is only one component of breast" exact="cancer" post="care. In the entire procedure of treatment of breast"/>
   <result pre="breast cancer care. In the entire procedure of treatment of" exact="breast cancer" post="a substantial degree of disparity in access and quality"/>
   <result pre="cancer care. In the entire procedure of treatment of breast" exact="cancer" post="a substantial degree of disparity in access and quality"/>
   <result pre="to explore availability of all contributing elements of care for" exact="breast cancer," post="would be a next step for further study. Although"/>
   <result pre="next step for further study. Although guidelines for management of" exact="breast cancer" post="in LMICs have been published in literature, to our"/>
   <result pre="step for further study. Although guidelines for management of breast" exact="cancer" post="in LMICs have been published in literature, to our"/>
   <result pre="to explore decisions made for selection of systemic therapy of" exact="breast cancer" post="in LMICs, which in turn may have direct implications"/>
   <result pre="explore decisions made for selection of systemic therapy of breast" exact="cancer" post="in LMICs, which in turn may have direct implications"/>
   <result pre="direct implications for the availability of medicines for treatment of" exact="breast cancer." post="Previous research showed that in general essential medicines selected"/>
   <result pre="chemotherapeutic agents and tamoxifen were selected as essential medicines for" exact="breast cancer" post="treatment on NEMLs by the vast majority of LMICs."/>
   <result pre="agents and tamoxifen were selected as essential medicines for breast" exact="cancer" post="treatment on NEMLs by the vast majority of LMICs."/>
   <result pre="medicines, which allow treatment of more types and stages of" exact="breast cancer." post="Additional file LINK Additional file 1: Annex 1. Overview"/>
   <result pre="year of NEML publication). Annex 2: International consensus guidelines for" exact="breast cancer" post="treatment. Annex 3: Frequency of inclusion of oncology medicines"/>
   <result pre="of NEML publication). Annex 2: International consensus guidelines for breast" exact="cancer" post="treatment. Annex 3: Frequency of inclusion of oncology medicines"/>
   <result pre="Annex 3: Frequency of inclusion of oncology medicines indicated for" exact="breast cancer" post="in the NEMLs studied. (PDF 449 kb) Abbreviations LMICs"/>
   <result pre="3: Frequency of inclusion of oncology medicines indicated for breast" exact="cancer" post="in the NEMLs studied. (PDF 449 kb) Abbreviations LMICs"/>
   <result pre="at: http://www.who.int/cancer/detection/breastcancer/en/index1.html. Accessed 7/25, 2013. 3. World Health Organization. National" exact="cancer" post="control programmes. 2013; Available at: http://www.who.int/cancer/nccp/en/. Accessed 7/25, 2013."/>
   <result pre="BO Carlson RW Bird PA Corbex M et al. Breast" exact="cancer" post="management in low resource countries (LRCs): consensus statement from"/>
   <result pre="Yip CH Khaled HM Otero IV et al. Optimisation of" exact="breast cancer" post="management in low-resource and middle-resource countries: executive summary of"/>
   <result pre="CH Khaled HM Otero IV et al. Optimisation of breast" exact="cancer" post="management in low-resource and middle-resource countries: executive summary of"/>
   <result pre="Fallowfield L et al. 1st International consensus guidelines for advanced" exact="breast cancer" post="(ABC 1) Breast 2012 21 3 242 252 10.1016/j.breast.2012.03.003"/>
   <result pre="L et al. 1st International consensus guidelines for advanced breast" exact="cancer" post="(ABC 1) Breast 2012 21 3 242 252 10.1016/j.breast.2012.03.003"/>
   <result pre="A Smith RA Yip CH Bese NS et al. Breast" exact="cancer" post="in limited-resource countries: an overview of the Breast Health"/>
   <result pre="BO Bright KL Caleffi M Cardoso F et al. Breast" exact="cancer" post="management in middle-resource countries (MRCs): consensus statement from the"/>
   <result pre="Strasser-Weippl K Chavarri-Guerra Y St Louis J et al. Planning" exact="cancer" post="control in Latin America and the Caribbean Lancet Oncol"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="Martin M Press M et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="M Press M et al. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="PT Yip CH Lu YS et al. Management of HER2-positive" exact="breast cancer" post="in Asia: consensus statement from the Asian Oncology Summit"/>
   <result pre="Yip CH Lu YS et al. Management of HER2-positive breast" exact="cancer" post="in Asia: consensus statement from the Asian Oncology Summit"/>
   <result pre="http://data.worldbank.org/indicator/NY.GNP.PCAP.CD. Accessed 11/23, 2012. 24. Coughlin SS Ekwueme DU Breast" exact="cancer" post="as a global health concern Cancer Epidemiol 2009 33"/>
   <result pre="10.1016/j.canep.2009.10.003 19896917 25. Brower V Developing nations face challenges as" exact="breast cancer" post="rises J Natl Cancer Inst 2011 103 24 1812"/>
   <result pre="19896917 25. Brower V Developing nations face challenges as breast" exact="cancer" post="rises J Natl Cancer Inst 2011 103 24 1812"/>
   <result pre="PE Knaul F Mohar A Finkelstein DM et al. Breast" exact="cancer" post="in Mexico: a growing challenge to health and the"/>
   <result pre="PE Barrios CH Simon SD Finkelstein DM Goss PE Breast" exact="cancer" post="in Brazil: present status and future goals Lancet Oncol"/>
   <result pre="The use of paclitaxel in the management of early stage" exact="breast cancer" post="Health Technol Assess 2009 13 Suppl 1 15 22"/>
   <result pre="use of paclitaxel in the management of early stage breast" exact="cancer" post="Health Technol Assess 2009 13 Suppl 1 15 22"/>
   <result pre="1/12, 2014. 33. Jahanzeb M Adjuvant trastuzumab therapy for HER2-positive" exact="breast cancer" post="Clin Breast Cancer 2008 8 4 324 333 10.3816/CBC.2008.n.037"/>
   <result pre="2014. 33. Jahanzeb M Adjuvant trastuzumab therapy for HER2-positive breast" exact="cancer" post="Clin Breast Cancer 2008 8 4 324 333 10.3816/CBC.2008.n.037"/>
   <result pre="Biotechnol. 2006;24(5):473. 36. Adler MJ Dimitrov DS Therapeutic antibodies against" exact="cancer" post="Hematol Oncol Clin North Am 2012 26 3 447"/>
   <result pre="43. Eng A McCormack V dos-Santos-Silva I Receptor-defined subtypes of" exact="breast cancer" post="in indigenous populations in Africa: a systematic review and"/>
   <result pre="Eng A McCormack V dos-Santos-Silva I Receptor-defined subtypes of breast" exact="cancer" post="in indigenous populations in Africa: a systematic review and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4538915/results/search/disease/results.xml">
   <result pre="made available in this article, unless otherwise stated. Abstract Breast" exact="cancer" post="is the most common cause of cancer and cancer"/>
   <result pre="stated. Abstract Breast cancer is the most common cause of" exact="cancer" post="and cancer death worldwide. Although most patients present with"/>
   <result pre="Breast cancer is the most common cause of cancer and" exact="cancer" post="death worldwide. Although most patients present with localized breast"/>
   <result pre="and cancer death worldwide. Although most patients present with localized" exact="breast cancer" post="and may be rendered disease-free with local therapy, distant"/>
   <result pre="cancer death worldwide. Although most patients present with localized breast" exact="cancer" post="and may be rendered disease-free with local therapy, distant"/>
   <result pre="widespread use of adjuvant systemic therapy has contributed to reduced" exact="breast cancer" post="mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from"/>
   <result pre="use of adjuvant systemic therapy has contributed to reduced breast" exact="cancer" post="mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from"/>
   <result pre="to benefit from adjuvant chemotherapy. Keywords Adjuvant chemotherapy Anthracyclines Breast" exact="cancer" post="Chemotherapy Early breast cancer Taxanes Background Breast cancer is"/>
   <result pre="adjuvant chemotherapy. Keywords Adjuvant chemotherapy Anthracyclines Breast cancer Chemotherapy Early" exact="breast cancer" post="Taxanes Background Breast cancer is the most frequently diagnosed"/>
   <result pre="chemotherapy. Keywords Adjuvant chemotherapy Anthracyclines Breast cancer Chemotherapy Early breast" exact="cancer" post="Taxanes Background Breast cancer is the most frequently diagnosed"/>
   <result pre="Anthracyclines Breast cancer Chemotherapy Early breast cancer Taxanes Background Breast" exact="cancer" post="is the most frequently diagnosed cancer and the leading"/>
   <result pre="cancer Taxanes Background Breast cancer is the most frequently diagnosed" exact="cancer" post="and the leading cause of cancer death among women,"/>
   <result pre="the most frequently diagnosed cancer and the leading cause of" exact="cancer" post="death among women, accounting for 25 % of the"/>
   <result pre="death among women, accounting for 25 % of the total" exact="cancer" post="cases (1.68 million) and 15 % of the cancer"/>
   <result pre="total cancer cases (1.68 million) and 15 % of the" exact="cancer" post="deaths (520,000) worldwide [ 1, 2]. In the United"/>
   <result pre="estimated that there will be 231,840 new cases of invasive" exact="breast cancer" post="and 40,290 deaths from the disease in 2015, and"/>
   <result pre="that there will be 231,840 new cases of invasive breast" exact="cancer" post="and 40,290 deaths from the disease in 2015, and"/>
   <result pre="in 2015, and that one in eight women will develop" exact="breast cancer" post="during their lifetime [ 3]. The disease is localized"/>
   <result pre="2015, and that one in eight women will develop breast" exact="cancer" post="during their lifetime [ 3]. The disease is localized"/>
   <result pre="of adjuvant systemic therapy The initial approach to therapy for" exact="breast cancer" post="was based on the premise that the disease metastasized"/>
   <result pre="adjuvant systemic therapy The initial approach to therapy for breast" exact="cancer" post="was based on the premise that the disease metastasized"/>
   <result pre="The radical mastectomy was thus the standard surgical procedure for" exact="breast cancer" post="in the early 20 th century [ 9]. Randomized"/>
   <result pre="radical mastectomy was thus the standard surgical procedure for breast" exact="cancer" post="in the early 20 th century [ 9]. Randomized"/>
   <result pre="18, 19]. Table 1 Systemic adjuvant therapy options for operable" exact="breast cancer" post="Breast cancer subtype/classification Adjuvant systemic therapy Phenotypic subtype Intrinsic"/>
   <result pre="19]. Table 1 Systemic adjuvant therapy options for operable breast" exact="cancer" post="Breast cancer subtype/classification Adjuvant systemic therapy Phenotypic subtype Intrinsic"/>
   <result pre="1 Systemic adjuvant therapy options for operable breast cancer Breast" exact="cancer" post="subtype/classification Adjuvant systemic therapy Phenotypic subtype Intrinsic subtype Endocrine"/>
   <result pre="Yes Yes The first randomized trial evaluating adjuvant chemotherapy in" exact="breast cancer" post="was the National Surgical Adjuvant Breast and Bowel Project"/>
   <result pre="Yes The first randomized trial evaluating adjuvant chemotherapy in breast" exact="cancer" post="was the National Surgical Adjuvant Breast and Bowel Project"/>
   <result pre="should be recommended to the majority of women with localized" exact="breast cancer" post="regardless of lymph node, menopausal, or hormone receptor status"/>
   <result pre="be recommended to the majority of women with localized breast" exact="cancer" post="regardless of lymph node, menopausal, or hormone receptor status"/>
   <result pre="widespread adoption of more effective systemic therapies contributed to declining" exact="breast cancer" post="mortality rates in the US and globally [ 1,"/>
   <result pre="adoption of more effective systemic therapies contributed to declining breast" exact="cancer" post="mortality rates in the US and globally [ 1,"/>
   <result pre="been shown to provide prognostic information in patients with ER-positive" exact="breast cancer" post="[ 7, 8] and also identify which patients derive"/>
   <result pre="shown to provide prognostic information in patients with ER-positive breast" exact="cancer" post="[ 7, 8] and also identify which patients derive"/>
   <result pre="Finally, in premenopausal women at high risk for recurrence, ovarian" exact="suppression" post="plus an aromatase inhibitor was shown to be more"/>
   <result pre="recurrence in patients with HER2 overexpressing node-positive or high-risk node-negative" exact="breast cancer" post="[ 40– 43]. Addition of trastuzumab to sequential anthracycline/cyclophosphamide-taxane"/>
   <result pre="in patients with HER2 overexpressing node-positive or high-risk node-negative breast" exact="cancer" post="[ 40– 43]. Addition of trastuzumab to sequential anthracycline/cyclophosphamide-taxane"/>
   <result pre="classes of cytotoxic agents for both early and advanced stage" exact="breast cancer." post="Table 2 Classification of adjuvant chemotherapy regimens Generation* Benefit"/>
   <result pre="Regimens with substantial evidence base First 35 % reduction in" exact="breast cancer" post="mortality compared with no adjuvant chemotherapy CMFx6, ACx4, FEC50x6"/>
   <result pre="with substantial evidence base First 35 % reduction in breast" exact="cancer" post="mortality compared with no adjuvant chemotherapy CMFx6, ACx4, FEC50x6"/>
   <result pre="adjuvant chemotherapy CMFx6, ACx4, FEC50x6 Second 20 % reduction in" exact="breast cancer" post="mortality compared with first generation regimen FEC100x6, CAFx6, FACx6"/>
   <result pre="chemotherapy CMFx6, ACx4, FEC50x6 Second 20 % reduction in breast" exact="cancer" post="mortality compared with first generation regimen FEC100x6, CAFx6, FACx6"/>
   <result pre="FACx6 ACx4-Tx4 (q3wks) DCx4, Ex4-CMFx4 Third 20 % reduction in" exact="breast cancer" post="mortality compared with second generation regimen FECx4-Dx3, FECx4-weekly Tx8"/>
   <result pre="ACx4-Tx4 (q3wks) DCx4, Ex4-CMFx4 Third 20 % reduction in breast" exact="cancer" post="mortality compared with second generation regimen FECx4-Dx3, FECx4-weekly Tx8"/>
   <result pre="one of the most active single cytotoxic agents in metastatic" exact="breast cancer" post="[ 54, 55], although congestive cardiomyopathy emerged as a"/>
   <result pre="of the most active single cytotoxic agents in metastatic breast" exact="cancer" post="[ 54, 55], although congestive cardiomyopathy emerged as a"/>
   <result pre="agents in metastatic breast cancer [ 54, 55], although congestive" exact="cardiomyopathy" post="emerged as a toxicity that required limiting the cumulative"/>
   <result pre="in Cremophor EL was eventually developed but was associated with" exact="hypersensitivity" post="reactions to the Cremophor EL vehicle [ 64], requiring"/>
   <result pre="States Food and Drug Administration (FDA) for treatment of metastatic" exact="breast cancer" post="in patients who had progressed after anthracycline-based combination chemotherapy"/>
   <result pre="Food and Drug Administration (FDA) for treatment of metastatic breast" exact="cancer" post="in patients who had progressed after anthracycline-based combination chemotherapy"/>
   <result pre="premedication is also required to reduce the risk of acute" exact="hypersensitivity" post="reactions and cumulative fluid retention associated with docetaxel infusions"/>
   <result pre="66]. A direct comparison of docetaxel with paclitaxel in metastatic" exact="breast cancer" post="showed greater efficacy for docetaxel but more toxicity ["/>
   <result pre="A direct comparison of docetaxel with paclitaxel in metastatic breast" exact="cancer" post="showed greater efficacy for docetaxel but more toxicity ["/>
   <result pre="upon substantial single agent activity for each agent in metastatic" exact="breast cancer" post="[ 69]. First-generation chemotherapy regimen Cyclophosphamide, methotrexate, and 5-fluorouracil"/>
   <result pre="substantial single agent activity for each agent in metastatic breast" exact="cancer" post="[ 69]. First-generation chemotherapy regimen Cyclophosphamide, methotrexate, and 5-fluorouracil"/>
   <result pre="that comparison of CMF with AC yielded similar results for" exact="breast cancer" post="mortality (HR, 0.98; P = 0.67) [ 16]. Other studies have"/>
   <result pre="comparison of CMF with AC yielded similar results for breast" exact="cancer" post="mortality (HR, 0.98; P = 0.67) [ 16]. Other studies have"/>
   <result pre="therapy with tamoxifen alone in 457 postmenopausal women with ER-positive" exact="breast cancer" post="and 1–3 positive nodes enrolled in two trials (FASG"/>
   <result pre="with tamoxifen alone in 457 postmenopausal women with ER-positive breast" exact="cancer" post="and 1–3 positive nodes enrolled in two trials (FASG"/>
   <result pre="randomized trials demonstrated a dose–response relationship for epirubicin in metastatic" exact="breast cancer" post="[ 58, 77], the FASG05 compared adjuvant fluorouracil (500"/>
   <result pre="trials demonstrated a dose–response relationship for epirubicin in metastatic breast" exact="cancer" post="[ 58, 77], the FASG05 compared adjuvant fluorouracil (500"/>
   <result pre="The SWOG-8814/INT-0100 trial randomized postmenopausal women with hormone-receptor positive, node-positive" exact="breast cancer" post="to CAF plus tamoxifen versus tamoxifen alone. DFS was"/>
   <result pre="SWOG-8814/INT-0100 trial randomized postmenopausal women with hormone-receptor positive, node-positive breast" exact="cancer" post="to CAF plus tamoxifen versus tamoxifen alone. DFS was"/>
   <result pre="(HR, 0.83; P = 0.057) [ 23]. The EBCTCG meta-analysis found that" exact="breast cancer" post="mortality rates were reduced more with FAC for six"/>
   <result pre="0.83; P = 0.057) [ 23]. The EBCTCG meta-analysis found that breast" exact="cancer" post="mortality rates were reduced more with FAC for six"/>
   <result pre="that FAC or FEC combinations were more effective in reducing" exact="breast cancer" post="mortality compared to CMF (risk ratio, 0.78; P = 0.0004) ["/>
   <result pre="FAC or FEC combinations were more effective in reducing breast" exact="cancer" post="mortality compared to CMF (risk ratio, 0.78; P = 0.0004) ["/>
   <result pre="doxorubicin, two of the most active cytotoxic agents for metastatic" exact="breast cancer," post="was associated with substantial activity, but led to prohibitive"/>
   <result pre="2 IV every 21 days) in 3,121 patients with node-positive" exact="breast cancer." post="After a median follow-up of 69 months, the addition"/>
   <result pre="to four cycles of AC in 3,060 patients with node-positive" exact="breast cancer" post="improved DFS (HR, 0.83; P = 0.006) but not OS (HR,"/>
   <result pre="four cycles of AC in 3,060 patients with node-positive breast" exact="cancer" post="improved DFS (HR, 0.83; P = 0.006) but not OS (HR,"/>
   <result pre="Oncology Research phase III trial evaluated 1,016 patients with operable" exact="breast cancer" post="who were assigned to four 3-week cycles of AC"/>
   <result pre="Research phase III trial evaluated 1,016 patients with operable breast" exact="cancer" post="who were assigned to four 3-week cycles of AC"/>
   <result pre="weeks as adjuvant treatment for 1,491 women with operable node-positive" exact="breast cancer" post="[ 89, 90]. After a median follow-up of 124"/>
   <result pre="as adjuvant treatment for 1,491 women with operable node-positive breast" exact="cancer" post="[ 89, 90]. After a median follow-up of 124"/>
   <result pre="cycles of DAC with FAC in 1,060 patients with node-negative" exact="breast cancer" post="[ 91]. After a median follow-up of 77 months,"/>
   <result pre="of DAC with FAC in 1,060 patients with node-negative breast" exact="cancer" post="[ 91]. After a median follow-up of 77 months,"/>
   <result pre="3 weeks) for three cycles in 1,999 patients with node-positive" exact="breast cancer" post="[ 92]. After a median follow-up of 93 months,"/>
   <result pre="weeks) for three cycles in 1,999 patients with node-positive breast" exact="cancer" post="[ 92]. After a median follow-up of 93 months,"/>
   <result pre="TACT study randomized 4,162 women with node-positive or high-risk node-negative" exact="breast cancer" post="to four cycles of FEC followed by four cycles"/>
   <result pre="study randomized 4,162 women with node-positive or high-risk node-negative breast" exact="cancer" post="to four cycles of FEC followed by four cycles"/>
   <result pre="94]. In the GEICAM 9906 trial, 1,246 patients with node-positive" exact="breast cancer" post="patients were randomized to six cycles of FEC (5-fluorouracil"/>
   <result pre="In the GEICAM 9906 trial, 1,246 patients with node-positive breast" exact="cancer" post="patients were randomized to six cycles of FEC (5-fluorouracil"/>
   <result pre="to a fixed anthracycline-based control regimen and extending treatment duration," exact="breast cancer" post="mortality was reduced (HR, 0.86; P = 0.0005). However, in trials"/>
   <result pre="a fixed anthracycline-based control regimen and extending treatment duration, breast" exact="cancer" post="mortality was reduced (HR, 0.86; P = 0.0005). However, in trials"/>
   <result pre="roughly doubling non-taxane dosage, there was no significant difference in" exact="breast cancer" post="mortality (HR, 0.94; P = 0.33). Although these results would suggest"/>
   <result pre="doubling non-taxane dosage, there was no significant difference in breast" exact="cancer" post="mortality (HR, 0.94; P = 0.33). Although these results would suggest"/>
   <result pre="density has been also evaluated in some adjuvant therapies for" exact="breast cancer." post="Dose density refers to administering the same therapeutic regimen"/>
   <result pre="frequent intervals, with the goal of decreasing the time for" exact="cancer" post="cells to recover in between chemotherapy cycles [ 80,"/>
   <result pre="and treatment sequence (concurrent vs sequential) in patients with operable" exact="breast cancer" post="by randomizing 2,005 patients to four different treatment arms"/>
   <result pre="treatment sequence (concurrent vs sequential) in patients with operable breast" exact="cancer" post="by randomizing 2,005 patients to four different treatment arms"/>
   <result pre="and schedule. This trial enrolled 4,954 patients with stage II–III" exact="breast cancer" post="who received standard AC followed sequentially by taxane therapy"/>
   <result pre="schedule. This trial enrolled 4,954 patients with stage II–III breast" exact="cancer" post="who received standard AC followed sequentially by taxane therapy"/>
   <result pre="0.69; P = 0.010 and HR, 0.69; P = 0.019, respectively) in triple negative" exact="breast cancer," post="no experimental arm improved OS for hormone receptor-positive, HER2"/>
   <result pre="no experimental arm improved OS for hormone receptor-positive, HER2 non-overexpressing" exact="breast cancer" post="[ 101]. Another trial found no difference in outcomes"/>
   <result pre="experimental arm improved OS for hormone receptor-positive, HER2 non-overexpressing breast" exact="cancer" post="[ 101]. Another trial found no difference in outcomes"/>
   <result pre="doxorubicin [ 103]. The study included 5,351 patients with node-positive" exact="breast cancer" post="to receive four cycles of AC followed by four"/>
   <result pre="[ 103]. The study included 5,351 patients with node-positive breast" exact="cancer" post="to receive four cycles of AC followed by four"/>
   <result pre="tumor diameter or grade, ER expression, or tamoxifen use, and" exact="breast cancer" post="mortality was reduced on average by one-third [ 16]."/>
   <result pre="diameter or grade, ER expression, or tamoxifen use, and breast" exact="cancer" post="mortality was reduced on average by one-third [ 16]."/>
   <result pre="been shown to provide prognostic information in patients with ER-positive" exact="breast cancer" post="[ 7, 8] and also identify which patients derive"/>
   <result pre="shown to provide prognostic information in patients with ER-positive breast" exact="cancer" post="[ 7, 8] and also identify which patients derive"/>
   <result pre="Likewise, in the clinical trial for treatment of endocrine responsive" exact="breast cancer" post="(RxPONDER) (NCT01272037), patients with one to three positive axillary"/>
   <result pre="in the clinical trial for treatment of endocrine responsive breast" exact="cancer" post="(RxPONDER) (NCT01272037), patients with one to three positive axillary"/>
   <result pre="a component of adjuvant therapy [ 107] for high-risk HER2-positive" exact="breast cancer" post="based on improved survival when used in metastatic HER2-postive"/>
   <result pre="component of adjuvant therapy [ 107] for high-risk HER2-positive breast" exact="cancer" post="based on improved survival when used in metastatic HER2-postive"/>
   <result pre="cancer based on improved survival when used in metastatic HER2-postive" exact="breast cancer" post="[ 108], and improved pathologic complete response when used"/>
   <result pre="based on improved survival when used in metastatic HER2-postive breast" exact="cancer" post="[ 108], and improved pathologic complete response when used"/>
   <result pre="and improved pathologic complete response when used in locally advanced" exact="breast cancer" post="[ 109]. On the other hand, other expert panels"/>
   <result pre="improved pathologic complete response when used in locally advanced breast" exact="cancer" post="[ 109]. On the other hand, other expert panels"/>
   <result pre="Pos, Positive; RS, Recurrence score. Conclusions Localized and regionally advanced" exact="breast cancer" post="is a potentially curative disease with local therapy alone,"/>
   <result pre="Positive; RS, Recurrence score. Conclusions Localized and regionally advanced breast" exact="cancer" post="is a potentially curative disease with local therapy alone,"/>
   <result pre="directed therapy substantially reduce the risk of distant recurrence and" exact="breast cancer" post="mortality. Acute reversible effects associated with chemotherapy include alopecia,"/>
   <result pre="therapy substantially reduce the risk of distant recurrence and breast" exact="cancer" post="mortality. Acute reversible effects associated with chemotherapy include alopecia,"/>
   <result pre="fatigue, and myelosuppression, whereas long-term potentially irreversible effects include cardiomyopathy," exact="acute leukemia," post="and neuropathy [ 111]. The choice of chemotherapy regimen"/>
   <result pre="whereas long-term potentially irreversible effects include cardiomyopathy, acute leukemia, and" exact="neuropathy" post="[ 111]. The choice of chemotherapy regimen may be"/>
   <result pre="patient-specific factors such as age, comorbidities, and risk tolerance. Decision" exact="aids" post="may be helpful in allowing patients and caregivers to"/>
   <result pre="clinical decision making to tailor adjuvant treatment among patients with" exact="breast cancer." post="Improvements in adjuvant cytotoxic regimens have contributed to declining"/>
   <result pre="cancer. Improvements in adjuvant cytotoxic regimens have contributed to declining" exact="breast cancer" post="mortality rates and clinical trials are underway that may"/>
   <result pre="Improvements in adjuvant cytotoxic regimens have contributed to declining breast" exact="cancer" post="mortality rates and clinical trials are underway that may"/>
   <result pre="such therapy. Box 1. Milestones in the adjuvant therapy of" exact="breast cancer" post="Chemotherapy Alkylating agents (thiotepa, L-phenylalinine mustard) given after surgery"/>
   <result pre="therapy. Box 1. Milestones in the adjuvant therapy of breast" exact="cancer" post="Chemotherapy Alkylating agents (thiotepa, L-phenylalinine mustard) given after surgery"/>
   <result pre="polychemotherapy be recommended to the majority of women with localized" exact="breast cancer" post="regardless of lymph node, menopausal, or hormone receptor status"/>
   <result pre="be recommended to the majority of women with localized breast" exact="cancer" post="regardless of lymph node, menopausal, or hormone receptor status"/>
   <result pre="or tamoxifen for up to 10 years [ 37] Ovarian" exact="suppression" post="plus an aromatase inhibitor was shown to be more"/>
   <result pre="sequentially, in patients with HER2 overexpressing node-positive or high-risk node-negative" exact="breast cancer" post="[ 43] One year of trastuzumab was more effective"/>
   <result pre="in patients with HER2 overexpressing node-positive or high-risk node-negative breast" exact="cancer" post="[ 43] One year of trastuzumab was more effective"/>
   <result pre="A Center MM DeSantis C Ward EM Global patterns of" exact="cancer" post="incidence and mortality rates and trends Cancer Epidemiol Biomarkers"/>
   <result pre="F Siegel RL Ferlay J Lortet-Tieulent J Jemal A Global" exact="cancer" post="statistics, 2012 CA Cancer J Clin. 2015 65 87"/>
   <result pre="recommendations for immunohistochemical testing of estrogen and progesterone receptors in" exact="breast cancer" post="J Clin Oncol. 2010 28 2784 95 20404251 6."/>
   <result pre="for immunohistochemical testing of estrogen and progesterone receptors in breast" exact="cancer" post="J Clin Oncol. 2010 28 2784 95 20404251 6."/>
   <result pre="M Kenny PA Clinical application of gene expression profiling in" exact="breast cancer" post="Surg Oncol Clin N Am. 2010 19 581 606"/>
   <result pre="Kenny PA Clinical application of gene expression profiling in breast" exact="cancer" post="Surg Oncol Clin N Am. 2010 19 581 606"/>
   <result pre="606 20620929 8. Sotiriou C Pusztai L Gene-expression signatures in" exact="breast cancer" post="N Engl J Med. 2009 360 790 800 19228622"/>
   <result pre="20620929 8. Sotiriou C Pusztai L Gene-expression signatures in breast" exact="cancer" post="N Engl J Med. 2009 360 790 800 19228622"/>
   <result pre="lumpectomy, and lumpectomy plus irradiation for the treatment of invasive" exact="breast cancer" post="N Engl J Med. 2002 347 1233 41 12393820"/>
   <result pre="and lumpectomy plus irradiation for the treatment of invasive breast" exact="cancer" post="N Engl J Med. 2002 347 1233 41 12393820"/>
   <result pre="adjuvant tamoxifen and of cytotoxic therapy on mortality in early" exact="breast cancer." post="An overview of 61 randomized trials among 28,896 women"/>
   <result pre="collab: Early Breast Cancer Trialists’ Collaborative Group Tamoxifen for early" exact="breast cancer" post="Cochrane Database Syst Rev 2001 1 CD000486 11279694 14."/>
   <result pre="Early Breast Cancer Trialists’ Collaborative Group Tamoxifen for early breast" exact="cancer" post="Cochrane Database Syst Rev 2001 1 CD000486 11279694 14."/>
   <result pre="Collaborative Group Effects of chemotherapy and hormonal therapy for early" exact="breast cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="Group Effects of chemotherapy and hormonal therapy for early breast" exact="cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="Gray R Clarke M Cutter D et al. Relevance of" exact="breast cancer" post="hormone receptors and other factors to the efficacy of"/>
   <result pre="R Clarke M Cutter D et al. Relevance of breast" exact="cancer" post="hormone receptors and other factors to the efficacy of"/>
   <result pre="MT Prat A Munárriz B Rowe L et al. PAM50" exact="breast cancer" post="subtyping by RT-qPCR and concordance with standard clinical molecular"/>
   <result pre="Prat A Munárriz B Rowe L et al. PAM50 breast" exact="cancer" post="subtyping by RT-qPCR and concordance with standard clinical molecular"/>
   <result pre="Voduc D Vickery T et al. Supervised risk predictor of" exact="breast cancer" post="based on intrinsic subtypes J Clin Oncol. 2009 27"/>
   <result pre="D Vickery T et al. Supervised risk predictor of breast" exact="cancer" post="based on intrinsic subtypes J Clin Oncol. 2009 27"/>
   <result pre="Slack NH Moore GE Noer RJ Surgical adjuvant chemotherapy in" exact="cancer" post="of the breast: results of a decade of cooperative"/>
   <result pre="et al. 1-Phenylalanine mustard (L-PAM) in the management of primary" exact="breast cancer." post="A report of early findings N Engl J Med"/>
   <result pre="et al. Combination chemotherapy as an adjuvant treatment in operable" exact="breast cancer" post="N Engl J Med. 1976 294 405 10 1246307"/>
   <result pre="al. Combination chemotherapy as an adjuvant treatment in operable breast" exact="cancer" post="N Engl J Med. 1976 294 405 10 1246307"/>
   <result pre="KW et al. Efficacy of adjuvant chemotherapy in high-risk node-negative" exact="breast cancer." post="An intergroup study N Engl J Med 1989 320"/>
   <result pre="et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive" exact="breast cancer" post="J Natl Cancer Inst. 1997 89 1673 82 9390536"/>
   <result pre="al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast" exact="cancer" post="J Natl Cancer Inst. 1997 89 1673 82 9390536"/>
   <result pre="Effects of screening and systemic adjuvant therapy on ER-specific US" exact="breast cancer" post="mortality J Natl Cancer Inst. 2014 106 11 29."/>
   <result pre="of screening and systemic adjuvant therapy on ER-specific US breast" exact="cancer" post="mortality J Natl Cancer Inst. 2014 106 11 29."/>
   <result pre="and benefit of chemotherapy in women with node-negative, estrogen receptor-positive" exact="breast cancer" post="J Clin Oncol. 2006 24 3726 34 16720680 30."/>
   <result pre="benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast" exact="cancer" post="J Clin Oncol. 2006 24 3726 34 16720680 30."/>
   <result pre="21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive" exact="breast cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast" exact="cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="update of recommendations for the use of tumor markers in" exact="breast cancer" post="J Clin Oncol 2007 25 5287 312 17954709 32."/>
   <result pre="of recommendations for the use of tumor markers in breast" exact="cancer" post="J Clin Oncol 2007 25 5287 312 17954709 32."/>
   <result pre="trial of tamoxifen as adjuvant agent in management of early" exact="breast cancer," post="Interim analysis at four years by Nolvadex Adjuvant Trial"/>
   <result pre="among patients treated with adjuvant tamoxifen after mastectomy for early" exact="breast cancer" post="Lancet. 1983 2 450 6135926 34. Howell A Cuzick"/>
   <result pre="patients treated with adjuvant tamoxifen after mastectomy for early breast" exact="cancer" post="Lancet. 1983 2 450 6135926 34. Howell A Cuzick"/>
   <result pre="Combination) trial after completion of 5 years’ adjuvant treatment for" exact="breast cancer" post="Lancet 2005 365 60 2 15639680 35. collab: Breast"/>
   <result pre="trial after completion of 5 years’ adjuvant treatment for breast" exact="cancer" post="Lancet 2005 365 60 2 15639680 35. collab: Breast"/>
   <result pre="comparison of letrozole and tamoxifen in postmenopausal women with early" exact="breast cancer" post="N Engl J Med 2005 353 2747 57 16382061"/>
   <result pre="of letrozole and tamoxifen in postmenopausal women with early breast" exact="cancer" post="N Engl J Med 2005 353 2747 57 16382061"/>
   <result pre="postmenopausal women after five years of tamoxifen therapy for early-stage" exact="breast cancer" post="N Engl J Med. 2003 349 1793 802 14551341"/>
   <result pre="women after five years of tamoxifen therapy for early-stage breast" exact="cancer" post="N Engl J Med. 2003 349 1793 802 14551341"/>
   <result pre="al. International Breast Cancer Study Group. Adjuvant exemestane with ovarian" exact="suppression" post="in premenopausal breast cancer N Engl J Med 2014"/>
   <result pre="Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal" exact="breast cancer" post="N Engl J Med 2014 371 107 18 24881463"/>
   <result pre="Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast" exact="cancer" post="N Engl J Med 2014 371 107 18 24881463"/>
   <result pre="SOFT Investigators; International Breast Cancer Study Group Exemestane with ovarian" exact="suppression" post="in premenopausal breast cancer N Engl J Med 2014"/>
   <result pre="Breast Cancer Study Group Exemestane with ovarian suppression in premenopausal" exact="breast cancer" post="N Engl J Med 2014 371 1358 9 25271610"/>
   <result pre="Cancer Study Group Exemestane with ovarian suppression in premenopausal breast" exact="cancer" post="N Engl J Med 2014 371 1358 9 25271610"/>
   <result pre="NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med. 2005 353 1673 84 16236738"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med. 2005 353 1673 84 16236738"/>
   <result pre="Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for" exact="breast cancer" post="N Engl J Med 2006 354 809 20 16495393"/>
   <result pre="Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast" exact="cancer" post="N Engl J Med 2006 354 809 20 16495393"/>
   <result pre="(HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1659 72 16236737"/>
   <result pre="Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1659 72 16236737"/>
   <result pre="al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 1273 83 21991949"/>
   <result pre="Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 1273 83 21991949"/>
   <result pre="PK et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive" exact="breast cancer" post="N Engl J Med. 2015 372 134 41 25564897"/>
   <result pre="et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast" exact="cancer" post="N Engl J Med. 2015 372 134 41 25564897"/>
   <result pre="12 months of adjuvant trastuzumab for patients with HER2-positive early" exact="breast cancer" post="(PHARE): a randomised phase 3 trial Lancet Oncol 2013"/>
   <result pre="months of adjuvant trastuzumab for patients with HER2-positive early breast" exact="cancer" post="(PHARE): a randomised phase 3 trial Lancet Oncol 2013"/>
   <result pre="2 years versus 1 year of adjuvant trastuzumab for HER2-positive" exact="breast cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="years versus 1 year of adjuvant trastuzumab for HER2-positive breast" exact="cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="al. Population-based validation of the prognostic model ADJUVANT! for early" exact="breast cancer" post="J Clin Oncol. 2005 23 2716 25 15837986 51."/>
   <result pre="Population-based validation of the prognostic model ADJUVANT! for early breast" exact="cancer" post="J Clin Oncol. 2005 23 2716 25 15837986 51."/>
   <result pre="et al. Calibration and discriminatory accuracy of prognosis calculation for" exact="breast cancer" post="with the online Adjuvant! program: a hospital-based retrospective cohort"/>
   <result pre="al. Calibration and discriminatory accuracy of prognosis calculation for breast" exact="cancer" post="with the online Adjuvant! program: a hospital-based retrospective cohort"/>
   <result pre="6 19801202 52. Hortobagyi GN Anthracyclines in the treatment of" exact="cancer" post="An overview. Drugs. 1997 54 1 7 9361955 53."/>
   <result pre="C Valagussa P Bonadonna G Sequential combination chemotherapy in advanced" exact="breast cancer" post="Cancer Chemother Pharmacol. 1978 1 35 9 373906 56."/>
   <result pre="Valagussa P Bonadonna G Sequential combination chemotherapy in advanced breast" exact="cancer" post="Cancer Chemother Pharmacol. 1978 1 35 9 373906 56."/>
   <result pre="Sparano JA Use of dexrazoxane and other strategies to prevent" exact="cardiomyopathy" post="associated with doxorubicin-taxane combinations Semin Oncol. 1998 25 66"/>
   <result pre="Wilke LG Tevaarwerk AJ et al. Cytotoxicity of paclitaxel in" exact="breast cancer" post="is due to chromosome missegregation on multipolar spindles Sci"/>
   <result pre="LG Tevaarwerk AJ et al. Cytotoxicity of paclitaxel in breast" exact="cancer" post="is due to chromosome missegregation on multipolar spindles Sci"/>
   <result pre="2014 6 229ra43 24670687 63. Weaver BA How taxol/paclitaxel kills" exact="cancer" post="cells Mol Biol Cell. 2014 25 2677 81 25213191"/>
   <result pre="phase III study of docetaxel compared with paclitaxel in metastatic" exact="breast cancer" post="J Clin Oncol. 2005 23 5542 51 16110015 68."/>
   <result pre="III study of docetaxel compared with paclitaxel in metastatic breast" exact="cancer" post="J Clin Oncol. 2005 23 5542 51 16110015 68."/>
   <result pre="69. Bachegowda LS Makower DF Sparano JA Taxanes: impact on" exact="breast cancer" post="therapy Anticancer Drugs. 2014 25 512 21 24552749 70."/>
   <result pre="Bachegowda LS Makower DF Sparano JA Taxanes: impact on breast" exact="cancer" post="therapy Anticancer Drugs. 2014 25 512 21 24552749 70."/>
   <result pre="with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node" exact="breast cancer" post="patients with tamoxifen-nonresponsive tumors: results from the National Surgical"/>
   <result pre="6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast" exact="cancer" post="patients with tamoxifen-nonresponsive tumors: results from the National Surgical"/>
   <result pre="doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for" exact="breast cancer" post="in women with 0 to 3 positive axillary nodes:"/>
   <result pre="and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast" exact="cancer" post="in women with 0 to 3 positive axillary nodes:"/>
   <result pre="with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal" exact="breast cancer" post="patients: results of French Adjuvant Study Group 02 and"/>
   <result pre="tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast" exact="cancer" post="patients: results of French Adjuvant Study Group 02 and"/>
   <result pre="of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive" exact="breast cancer" post="patients with poor prognostic factors: 5-year follow-up results of"/>
   <result pre="a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast" exact="cancer" post="patients with poor prognostic factors: 5-year follow-up results of"/>
   <result pre="in an adjuvant chemotherapy regimen for patients with node-positive primary" exact="breast cancer" post="J Clin Oncol. 2003 21 976 83 12637460 83."/>
   <result pre="an adjuvant chemotherapy regimen for patients with node-positive primary breast" exact="cancer" post="J Clin Oncol. 2003 21 976 83 12637460 83."/>
   <result pre="and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early" exact="breast cancer" post="N Engl J Med 2006 355 1851 62 17079759"/>
   <result pre="cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast" exact="cancer" post="N Engl J Med 2006 355 1851 62 17079759"/>
   <result pre="of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic" exact="breast cancer" post="J Clin Oncol. 2001 19 314 21 11208821 87."/>
   <result pre="docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast" exact="cancer" post="J Clin Oncol. 2001 19 314 21 11208821 87."/>
   <result pre="Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive" exact="breast cancer" post="N Engl J Med 2005 352 2302 13 15930421"/>
   <result pre="International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast" exact="cancer" post="N Engl J Med 2005 352 2302 13 15930421"/>
   <result pre="(5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive" exact="breast cancer" post="(BC) patients: interim analysis of the BCIRG 001 study"/>
   <result pre="doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast" exact="cancer" post="(BC) patients: interim analysis of the BCIRG 001 study"/>
   <result pre="et al. GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative" exact="breast cancer" post="N Engl J Med 2010 363 2200 10 21121833"/>
   <result pre="al. GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative breast" exact="cancer" post="N Engl J Med 2010 363 2200 10 21121833"/>
   <result pre="et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive" exact="breast cancer" post="patients: the FNCLCC PACS 01 Trial J Clin Oncol."/>
   <result pre="al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast" exact="cancer" post="patients: the FNCLCC PACS 01 Trial J Clin Oncol."/>
   <result pre="Group; TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early" exact="breast cancer" post="(TACT): an open-label, phase III, randomised controlled trial Lancet"/>
   <result pre="TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast" exact="cancer" post="(TACT): an open-label, phase III, randomised controlled trial Lancet"/>
   <result pre="epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early" exact="breast cancer" post="J Natl Cancer Inst 2008 100 805 14 18505968"/>
   <result pre="and cyclophosphamide alone or followed by Paclitaxel for early breast" exact="cancer" post="J Natl Cancer Inst 2008 100 805 14 18505968"/>
   <result pre="T et al. Weekly paclitaxel in the adjuvant treatment of" exact="breast cancer" post="N Engl J Med. 2008 358 1663 71 18420499"/>
   <result pre="et al. Weekly paclitaxel in the adjuvant treatment of breast" exact="cancer" post="N Engl J Med. 2008 358 1663 71 18420499"/>
   <result pre="or weekly in patients with axillary node-positive or high-risk node-negative" exact="breast cancer" post="2014 San Antonio, TX San Antonio Breast Cancer Symposium"/>
   <result pre="weekly in patients with axillary node-positive or high-risk node-negative breast" exact="cancer" post="2014 San Antonio, TX San Antonio Breast Cancer Symposium"/>
   <result pre="a phase III trial comparing chemotherapy schedules in high-risk early-stage" exact="breast cancer" post="J Clin Oncol. 2015 33 58 64 25422488 103."/>
   <result pre="phase III trial comparing chemotherapy schedules in high-risk early-stage breast" exact="cancer" post="J Clin Oncol. 2015 33 58 64 25422488 103."/>
   <result pre="et al. Longer therapy, iatrogenic amenorrhea, and survival in early" exact="breast cancer" post="N Engl J Med. 2010 362 2053 65 20519679"/>
   <result pre="al. Longer therapy, iatrogenic amenorrhea, and survival in early breast" exact="cancer" post="N Engl J Med. 2010 362 2053 65 20519679"/>
   <result pre="M et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic" exact="breast cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast" exact="cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4541732/results/search/disease/results.xml">
   <result pre="epidermal growth factor receptor 2 on circulating tumor cells of" exact="breast cancer" post="patients Kallergi Galatea +302810392783 kalergi@med.uoc.gr Agelaki Sofia agelaki@med.uoc.gr Papadaki"/>
   <result pre="growth factor receptor 2 on circulating tumor cells of breast" exact="cancer" post="patients Kallergi Galatea +302810392783 kalergi@med.uoc.gr Agelaki Sofia agelaki@med.uoc.gr Papadaki"/>
   <result pre="of p95HER2 was investigated on circulating tumor cells (CTCs) from" exact="breast cancer" post="patients. Methods Triple-staining immunofluorescent experiments were performed on peripheral"/>
   <result pre="p95HER2 was investigated on circulating tumor cells (CTCs) from breast" exact="cancer" post="patients. Methods Triple-staining immunofluorescent experiments were performed on peripheral"/>
   <result pre="( n = 24) and metastatic ( n = 37)" exact="breast cancer." post="Cells were stained with the pancytokeratin (A45-B/B3) antibody coupled"/>
   <result pre="55.6 % of early and 65.2 % of metastatic CTC-positive" exact="breast cancer" post="patients. p95HER2-positive CTCs were identified in 11.1 % of"/>
   <result pre="% of early and 65.2 % of metastatic CTC-positive breast" exact="cancer" post="patients. p95HER2-positive CTCs were identified in 11.1 % of"/>
   <result pre="in 11.1 % of early and 39.1 % of metastatic" exact="breast cancer" post="patients ( p = 0.047). In 14 patients with"/>
   <result pre="11.1 % of early and 39.1 % of metastatic breast" exact="cancer" post="patients ( p = 0.047). In 14 patients with"/>
   <result pre="( p = 0.047). In 14 patients with metastatic HER2-positive" exact="breast cancer," post="CTCs were also analyzed before and after first-line trastuzumab"/>
   <result pre="p95HER2-positive CTCs can be detected in both early and metastatic" exact="breast cancer" post="patients. Their incidence is increased in the metastatic setting"/>
   <result pre="CTCs can be detected in both early and metastatic breast" exact="cancer" post="patients. Their incidence is increased in the metastatic setting"/>
   <result pre="translation from an internal AUG codon [ 3]. In primary" exact="breast cancer," post="p95HER2 expression has been associated with node metastasis ["/>
   <result pre="was predictive of reduced 5-year survival in patients with early" exact="breast cancer" post="[ 2]. The humanized monoclonal antibody trastuzumab (Herceptin) was"/>
   <result pre="predictive of reduced 5-year survival in patients with early breast" exact="cancer" post="[ 2]. The humanized monoclonal antibody trastuzumab (Herceptin) was"/>
   <result pre="was the first HER2-directed agent approved for clinical use in" exact="breast cancer" post="patients showing marked clinical benefit for patients with early"/>
   <result pre="the first HER2-directed agent approved for clinical use in breast" exact="cancer" post="patients showing marked clinical benefit for patients with early"/>
   <result pre="trastuzumab was ineffective against in vivo tumor growth of T47D" exact="breast cancer" post="cells stably transfected with a truncated form of HER2"/>
   <result pre="was ineffective against in vivo tumor growth of T47D breast" exact="cancer" post="cells stably transfected with a truncated form of HER2"/>
   <result pre="been proposed as a powerful prognostic factor in patients with" exact="breast cancer." post="Moreover, CTCs are considered to be a &quot;real-time liquid"/>
   <result pre="that HER2 is expressed on CTCs of early and metastatic" exact="breast cancer" post="patients irrespective of the HER2 status of the primary"/>
   <result pre="HER2 is expressed on CTCs of early and metastatic breast" exact="cancer" post="patients irrespective of the HER2 status of the primary"/>
   <result pre="CTCs has been associated with poor clinical outcome in early" exact="breast cancer" post="[ 16– 18]. Finally, we have recently reported the"/>
   <result pre="has been associated with poor clinical outcome in early breast" exact="cancer" post="[ 16– 18]. Finally, we have recently reported the"/>
   <result pre="there are no data concerning the expression of p95HER2 on" exact="breast cancer" post="patients’ CTCs. In the present study, using a triple"/>
   <result pre="are no data concerning the expression of p95HER2 on breast" exact="cancer" post="patients’ CTCs. In the present study, using a triple"/>
   <result pre="presence of p95HER2-positive CTCs in patients with early and metastatic" exact="breast cancer" post="as well as the effect of trastuzumab-based chemotherapy on"/>
   <result pre="of p95HER2-positive CTCs in patients with early and metastatic breast" exact="cancer" post="as well as the effect of trastuzumab-based chemotherapy on"/>
   <result pre="results were expressed in CTCs/500,000 examined cells. Cell cultures SKBR3" exact="breast cancer" post="cells (obtained from ATCC; the American Type Culture Collection,"/>
   <result pre="were expressed in CTCs/500,000 examined cells. Cell cultures SKBR3 breast" exact="cancer" post="cells (obtained from ATCC; the American Type Culture Collection,"/>
   <result pre="EDTA (GIBCO BRL, Life Technologies, Rockville, MD, USA). HER2-positive SCOV3" exact="ovarian cancer" post="cells (obtained from the ATCC) were cultured in McCoy’s"/>
   <result pre="(GIBCO BRL, Life Technologies, Rockville, MD, USA). HER2-positive SCOV3 ovarian" exact="cancer" post="cells (obtained from the ATCC) were cultured in McCoy’s"/>
   <result pre="guidelines for the interpretation of positivity. Statistical analysis In early" exact="breast cancer" post="patients, disease-free interval (DFI), was defined as the time"/>
   <result pre="for the interpretation of positivity. Statistical analysis In early breast" exact="cancer" post="patients, disease-free interval (DFI), was defined as the time"/>
   <result pre="HER2 in SKBR3 and SKOV3 cell lines SKBR3 and SCOV3" exact="cancer" post="cell lines, which express HER2, were used for the"/>
   <result pre="of the p95HER2 receptor on CTCs in early and metastatic" exact="breast cancer" post="patients Twenty-four consecutive patients with early and 37 with"/>
   <result pre="the p95HER2 receptor on CTCs in early and metastatic breast" exact="cancer" post="patients Twenty-four consecutive patients with early and 37 with"/>
   <result pre="patients Twenty-four consecutive patients with early and 37 with metastatic" exact="breast cancer" post="were included in the study. These patients were found"/>
   <result pre="Twenty-four consecutive patients with early and 37 with metastatic breast" exact="cancer" post="were included in the study. These patients were found"/>
   <result pre="2 HER2 and truncated HER2 expression in early and metastatic" exact="breast cancer" post="patients. a Number of patients harvesting CTCs. b Number"/>
   <result pre="HER2 and truncated HER2 expression in early and metastatic breast" exact="cancer" post="patients. a Number of patients harvesting CTCs. b Number"/>
   <result pre="4 (16.6 %)   Unknown 5 (13.5 %) Histologic grade Primary" exact="breast cancer" post="  Grade 1 0 (0 %)   Adjuvant 13 (35.1 %)"/>
   <result pre="(16.6 %)   Unknown 5 (13.5 %) Histologic grade Primary breast" exact="cancer" post="  Grade 1 0 (0 %)   Adjuvant 13 (35.1 %)"/>
   <result pre="out of 23 (65.2 %) patients with early and metastatic" exact="breast cancer," post="respectively (Fig. 2b). The p95HER2 receptor was identified in"/>
   <result pre="( p = 0.047). There was no patient with early" exact="breast cancer" post="who had CTCs expressing exclusively the p95HER2 form of"/>
   <result pre="p = 0.047). There was no patient with early breast" exact="cancer" post="who had CTCs expressing exclusively the p95HER2 form of"/>
   <result pre="171 CTCs were analyzed in patients with early and metastatic" exact="breast cancer," post="respectively. The average percentage of the total examined CTCs"/>
   <result pre="ER/PR/HER2 status of the primary tumor and CTCs in CK-positive" exact="breast cancer" post="patients Early breast cancer patients HER2 primary ER primary"/>
   <result pre="status of the primary tumor and CTCs in CK-positive breast" exact="cancer" post="patients Early breast cancer patients HER2 primary ER primary"/>
   <result pre="primary tumor and CTCs in CK-positive breast cancer patients Early" exact="breast cancer" post="patients HER2 primary ER primary PR primary HER2in +"/>
   <result pre="tumor and CTCs in CK-positive breast cancer patients Early breast" exact="cancer" post="patients HER2 primary ER primary PR primary HER2in +"/>
   <result pre="1 18 + + + 1 0 0 First-line metastatic" exact="breast cancer" post="patients HER2 primary ER primary PR primary HER2in +"/>
   <result pre="18 + + + 1 0 0 First-line metastatic breast" exact="cancer" post="patients HER2 primary ER primary PR primary HER2in +"/>
   <result pre="3 HER2 full-length and truncated HER2 expression on CTCs of" exact="breast cancer" post="patients. Representative Ariol system images from one metastatic patient"/>
   <result pre="HER2 full-length and truncated HER2 expression on CTCs of breast" exact="cancer" post="patients. Representative Ariol system images from one metastatic patient"/>
   <result pre="Table 1. Four out of 18 CK-positive patients with early" exact="breast cancer" post="had HER2-positive primary tumors (22 %; Table 2). In"/>
   <result pre="1. Four out of 18 CK-positive patients with early breast" exact="cancer" post="had HER2-positive primary tumors (22 %; Table 2). In"/>
   <result pre="p95HER2 receptor before and after first-line trastuzumab-based chemotherapy in metastatic" exact="breast cancer" post="patients with HER2-positive primary tumors Fourteen patients were screened"/>
   <result pre="receptor before and after first-line trastuzumab-based chemotherapy in metastatic breast" exact="cancer" post="patients with HER2-positive primary tumors Fourteen patients were screened"/>
   <result pre="(Fig. 4a). Fig. 4 HER2 alterations on CTCs of metastatic" exact="breast cancer" post="patients ( n = 14) after trastuzumab administration. a"/>
   <result pre="4a). Fig. 4 HER2 alterations on CTCs of metastatic breast" exact="cancer" post="patients ( n = 14) after trastuzumab administration. a"/>
   <result pre="versus 51 months; p = 0.021). Statistical analysis in early" exact="breast cancer" post="patients revealed no significant differences. Discussion The presence of"/>
   <result pre="51 months; p = 0.021). Statistical analysis in early breast" exact="cancer" post="patients revealed no significant differences. Discussion The presence of"/>
   <result pre="that HER2 is expressed in CTCs of early and metastatic" exact="breast cancer" post="patients. The incidence of HER2 expression is usually higher"/>
   <result pre="HER2 is expressed in CTCs of early and metastatic breast" exact="cancer" post="patients. The incidence of HER2 expression is usually higher"/>
   <result pre="that the administration of trastuzumab, in patients with HER2-negative early" exact="breast cancer" post="who had detectable HER2-positive CTCs after the completion of"/>
   <result pre="the administration of trastuzumab, in patients with HER2-negative early breast" exact="cancer" post="who had detectable HER2-positive CTCs after the completion of"/>
   <result pre="in 55.6 % and 65.1 % of early and metastatic" exact="breast cancer" post="patients, respectively. These results are compatible with previous studies"/>
   <result pre="55.6 % and 65.1 % of early and metastatic breast" exact="cancer" post="patients, respectively. These results are compatible with previous studies"/>
   <result pre="truncated receptor is crucial for the outcome of patients with" exact="breast cancer." post="p95HER2 lacks the extracellular domain of the receptor and"/>
   <result pre="poor clinical outcome [ 2]. Moreover, in patients with metastatic" exact="breast cancer" post="increased expression of p95HER2 is associated with a significantly"/>
   <result pre="clinical outcome [ 2]. Moreover, in patients with metastatic breast" exact="cancer" post="increased expression of p95HER2 is associated with a significantly"/>
   <result pre="regimens. Furthermore, Sperinde et al. [ 34] reported that metastatic" exact="breast cancer" post="patients, with high expression of p95HER2 on the primary"/>
   <result pre="Furthermore, Sperinde et al. [ 34] reported that metastatic breast" exact="cancer" post="patients, with high expression of p95HER2 on the primary"/>
   <result pre="trastuzumab treatment. Finally, preliminary analysis of overall survival in metastatic" exact="breast cancer" post="patients revealed that the presence of CTCs expressing the"/>
   <result pre="treatment. Finally, preliminary analysis of overall survival in metastatic breast" exact="cancer" post="patients revealed that the presence of CTCs expressing the"/>
   <result pre="expressed in CTCs of patients with both early and metastatic" exact="breast cancer," post="though the incidence is higher among metastatic patients, suggesting"/>
   <result pre="for the increased clinical efficacy of this combination in HER2-positive" exact="breast cancer" post="patients. Additional file LINK Additional file 1: Figure S1."/>
   <result pre="the increased clinical efficacy of this combination in HER2-positive breast" exact="cancer" post="patients. Additional file LINK Additional file 1: Figure S1."/>
   <result pre="et al. p95HER-2 predicts worse outcome in patients with HER-2-positive" exact="breast cancer" post="Clin Cancer Res. 2006 12 424 431 10.1158/1078-0432.CCR-05-1807 16428482"/>
   <result pre="al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast" exact="cancer" post="Clin Cancer Res. 2006 12 424 431 10.1158/1078-0432.CCR-05-1807 16428482"/>
   <result pre="3. Arribas J Parra-Palau JL Pedersen K HER2 fragmentation and" exact="breast cancer" post="stratification Clin Cancer Res. 2010 16 4071 4073 10.1158/1078-0432.CCR-10-1501"/>
   <result pre="Arribas J Parra-Palau JL Pedersen K HER2 fragmentation and breast" exact="cancer" post="stratification Clin Cancer Res. 2010 16 4071 4073 10.1158/1078-0432.CCR-10-1501"/>
   <result pre="shedding of the extracellular domain and with prognostic factors in" exact="breast cancer" post="Cancer Res. 1998 58 5123 5129 9823322 5. Molina"/>
   <result pre="of the extracellular domain and with prognostic factors in breast" exact="cancer" post="Cancer Res. 1998 58 5123 5129 9823322 5. Molina"/>
   <result pre="not full-length receptor is associated with nodal metastasis in human" exact="breast cancer" post="Clin Cancer Res. 2002 8 347 353 11839648 6."/>
   <result pre="full-length receptor is associated with nodal metastasis in human breast" exact="cancer" post="Clin Cancer Res. 2002 8 347 353 11839648 6."/>
   <result pre="antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human" exact="breast cancer" post="xenografts Cancer Res. 1998 58 2825 2831 9661897 9."/>
   <result pre="activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast" exact="cancer" post="xenografts Cancer Res. 1998 58 2825 2831 9661897 9."/>
   <result pre="of the HER2 receptor, and response to anti-HER2 therapies in" exact="breast cancer" post="J Natl Cancer Inst. 2007 99 628 638 10.1093/jnci/djk134"/>
   <result pre="the HER2 receptor, and response to anti-HER2 therapies in breast" exact="cancer" post="J Natl Cancer Inst. 2007 99 628 638 10.1093/jnci/djk134"/>
   <result pre="of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic" exact="breast cancer" post="cells Mol Med. 2007 13 79 88 10.2119/2006-00083.Kallergi 17515959"/>
   <result pre="FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast" exact="cancer" post="cells Mol Med. 2007 13 79 88 10.2119/2006-00083.Kallergi 17515959"/>
   <result pre="PI3K/Akt signaling kinases are expressed in circulating tumor cells of" exact="breast cancer" post="patients Breast Cancer Res. 2008 10 R80 10.1186/bcr2149 18822183"/>
   <result pre="signaling kinases are expressed in circulating tumor cells of breast" exact="cancer" post="patients Breast Cancer Res. 2008 10 R80 10.1186/bcr2149 18822183"/>
   <result pre="assay for cytokeratin 19, mammaglobin A, and HER2 in early" exact="breast cancer" post="Clin Cancer Res. 2008 14 2593 2600 10.1158/1078-0432.CCR-07-4758 18451221"/>
   <result pre="for cytokeratin 19, mammaglobin A, and HER2 in early breast" exact="cancer" post="Clin Cancer Res. 2008 14 2593 2600 10.1158/1078-0432.CCR-07-4758 18451221"/>
   <result pre="cells indicate poor clinical outcome in stage I to III" exact="breast cancer" post="patients Clin Cancer Res. 2006 12 1715 1720 10.1158/1078-0432.CCR-05-2087"/>
   <result pre="indicate poor clinical outcome in stage I to III breast" exact="cancer" post="patients Clin Cancer Res. 2006 12 1715 1720 10.1158/1078-0432.CCR-05-2087"/>
   <result pre="decreases the incidence of clinical relapses in patients with early" exact="breast cancer" post="presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a"/>
   <result pre="the incidence of clinical relapses in patients with early breast" exact="cancer" post="presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a"/>
   <result pre="Huth JF et al. Circulating tumor cells in patients with" exact="breast cancer" post="dormancy Clin Cancer Res. 2004 10 8152 8162 10.1158/1078-0432.CCR-04-1110"/>
   <result pre="JF et al. Circulating tumor cells in patients with breast" exact="cancer" post="dormancy Clin Cancer Res. 2004 10 8152 8162 10.1158/1078-0432.CCR-04-1110"/>
   <result pre="mRNA-positive cells detected by real-time polymerase chain reaction in node-negative" exact="breast cancer" post="patients J Clin Oncol. 2006 24 3756 3762 10.1200/JCO.2005.04.5948"/>
   <result pre="cells detected by real-time polymerase chain reaction in node-negative breast" exact="cancer" post="patients J Clin Oncol. 2006 24 3756 3762 10.1200/JCO.2005.04.5948"/>
   <result pre="tumor cells: a novel prognostic factor for newly diagnosed metastatic" exact="breast cancer" post="J Clin Oncol. 2005 23 1420 1430 10.1200/JCO.2005.08.140 15735118"/>
   <result pre="cells: a novel prognostic factor for newly diagnosed metastatic breast" exact="cancer" post="J Clin Oncol. 2005 23 1420 1430 10.1200/JCO.2005.08.140 15735118"/>
   <result pre="CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic" exact="breast cancer" post="Br J Cancer. 2012 106 1917 1925 10.1038/bjc.2012.202 22669159"/>
   <result pre="tumour cells before front-line treatment in patients with metastatic breast" exact="cancer" post="Br J Cancer. 2012 106 1917 1925 10.1038/bjc.2012.202 22669159"/>
   <result pre="Q Dawsey SJ Bersano-Begey TF et al. HER2 drives luminal" exact="breast cancer" post="stem cells in the absence of HER2 amplification: implications"/>
   <result pre="Dawsey SJ Bersano-Begey TF et al. HER2 drives luminal breast" exact="cancer" post="stem cells in the absence of HER2 amplification: implications"/>
   <result pre="G Criscitiello C et al. HER2-positive circulating tumor cells in" exact="breast cancer" post="PLoS One. 2011 6 e15624 10.1371/journal.pone.0015624 21264346 29. Duchnowska"/>
   <result pre="Criscitiello C et al. HER2-positive circulating tumor cells in breast" exact="cancer" post="PLoS One. 2011 6 e15624 10.1371/journal.pone.0015624 21264346 29. Duchnowska"/>
   <result pre="al. Quantitative measurements of tumoral p95HER2 protein expression in metastatic" exact="breast cancer" post="patients treated with trastuzumab: independent validation of the p95HER2"/>
   <result pre="Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast" exact="cancer" post="patients treated with trastuzumab: independent validation of the p95HER2"/>
   <result pre="tumor cells reflects the response to neoadjuvant systemic therapy in" exact="breast cancer" post="Breast Cancer Res. 2006 8 R60 10.1186/bcr1611 17062129 32."/>
   <result pre="cells reflects the response to neoadjuvant systemic therapy in breast" exact="cancer" post="Breast Cancer Res. 2006 8 R60 10.1186/bcr1611 17062129 32."/>
   <result pre="of disseminated tumor cells in bone marrow and blood of" exact="breast cancer" post="patients by the Thomsen-Friedenreich-Antigen Clin Exp Metastasis. 2008 25"/>
   <result pre="disseminated tumor cells in bone marrow and blood of breast" exact="cancer" post="patients by the Thomsen-Friedenreich-Antigen Clin Exp Metastasis. 2008 25"/>
   <result pre="Simultaneous detection of disseminated and circulating tumor cells in primary" exact="breast cancer" post="patients. Cancer Res Treat. 2015. doi:10.4143/crt.2014.287 [Epub ahead of"/>
   <result pre="detection of disseminated and circulating tumor cells in primary breast" exact="cancer" post="patients. Cancer Res Treat. 2015. doi:10.4143/crt.2014.287 [Epub ahead of"/>
   <result pre="antibody and correlation with outcome in a cohort of trastuzumab-treated" exact="breast cancer" post="patients Clin Cancer Res. 2010 16 4226 4235 10.1158/1078-0432.CCR-10-0410"/>
   <result pre="and correlation with outcome in a cohort of trastuzumab-treated breast" exact="cancer" post="patients Clin Cancer Res. 2010 16 4226 4235 10.1158/1078-0432.CCR-10-0410"/>
   <result pre="in the peripheral blood and bone marrow of patients with" exact="breast cancer" post="Clin Cancer Res. 2004 10 8185 8194 10.1158/1078-0432.CCR-03-0094 15623593"/>
   <result pre="the peripheral blood and bone marrow of patients with breast" exact="cancer" post="Clin Cancer Res. 2004 10 8185 8194 10.1158/1078-0432.CCR-03-0094 15623593"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4542411/results/search/disease/results.xml">
   <result pre="human cancer. This may be due, in part, to hypoxic" exact="cancer" post="cells being resistant to anticancer therapy, including radiation therapy,"/>
   <result pre="expression of genes that are involved in multiple aspects of" exact="cancer" post="biology, including cell survival, proliferation, metabolism, invasion, and angiogenesis."/>
   <result pre="review multiple pathways regulated by hypoxia/hypoxia inducible factor 1 in" exact="cancer" post="cells and discuss the latest advancements in overcoming hypoxia-mediated"/>
   <result pre="in overcoming hypoxia-mediated tumor resistance. Video abstract LINK Keywords HIF-1" exact="cancer" post="chemoresistance signaling apoptosis Introduction Maintaining oxygen concentration is critical"/>
   <result pre="either apoptosis or necrosis. However, the effect of hypoxia on" exact="cancer" post="cells is multifaceted, as cancer cells are able to"/>
   <result pre="the effect of hypoxia on cancer cells is multifaceted, as" exact="cancer" post="cells are able to survive hypoxic environments and hypoxia"/>
   <result pre="has been made in understanding the effect of hypoxia on" exact="cancer" post="cells, we are just beginning to uncover the mechanisms"/>
   <result pre="this review we discuss different mechanisms of hypoxia-mediated resistance to" exact="cancer" post="therapy and potential approaches to overcome this resistance. Tumor"/>
   <result pre="resistance. Tumor hypoxia pathophysiology Hypoxia can alter multiple aspects of" exact="cancer" post="cell biology, including proliferation, survival, invasion, and metastasis, affecting"/>
   <result pre="metastasis, affecting both early and late stages of carcinogenesis. In" exact="breast cancer," post="hypoxic markers can be observed in premalignant ductal carcinoma"/>
   <result pre="breast cancer, hypoxic markers can be observed in premalignant ductal" exact="carcinoma in situ" post="lesions as cancer cells begin to form multilayers and"/>
   <result pre="be observed in premalignant ductal carcinoma in situ lesions as" exact="cancer" post="cells begin to form multilayers and move away from"/>
   <result pre="from stroma-containing blood vessels. 13 At later stages of tumorigenesis," exact="cancer" post="cells experience hypoxia due to both limited vascularization in"/>
   <result pre="shown to either promote or inhibit cell death depending on" exact="cancer" post="type and experimental setting. For example, energy deprivation and"/>
   <result pre="example, energy deprivation and ROS production induce apoptosis in human" exact="neuroblastoma" post="cells under hypoxic conditions. 21 On the other hand,"/>
   <result pre="the other hand, hypoxia was shown to inhibit apoptosis in" exact="breast cancer" post="cell lines treated with paclitaxel through activation of the"/>
   <result pre="other hand, hypoxia was shown to inhibit apoptosis in breast" exact="cancer" post="cell lines treated with paclitaxel through activation of the"/>
   <result pre="role that hypoxia/HIF-1 plays in apoptosis may be context and" exact="cancer" post="cell dependent, it is generally accepted that, in many"/>
   <result pre="in targeting hypoxic tumors. Genomic instability is a hallmark of" exact="cancer" post="that has been shown to be associated with hypoxia."/>
   <result pre="may provide a target for anticancer therapy. Indeed, hypoxia sensitizes" exact="cancer" post="cell lines to DNA damaging agents such as mitomycin"/>
   <result pre="in which it facilitates cell motility and thus contributes to" exact="cancer" post="cell invasion and metastasis. 34 Many studies have demonstrated"/>
   <result pre="invasion has also been linked to hypoxia. The ability of" exact="cancer" post="cells to modify and degrade the extracellular matrix (ECM)"/>
   <result pre="led to decreased tissue stiffness, fibrosis, and invasion in a" exact="breast cancer" post="xenograft model. 44 HIFs can also regulate the expression"/>
   <result pre="to decreased tissue stiffness, fibrosis, and invasion in a breast" exact="cancer" post="xenograft model. 44 HIFs can also regulate the expression"/>
   <result pre="and is currently in clinical trials for the treatment of" exact="pancreatic cancer." post="Finally, HIF-1 and HIF-2 can regulate the expression of"/>
   <result pre="be targeted by anticancer agents. Mechanisms of hypoxia resistance to" exact="cancer" post="therapy Clinically, the most significant feature of hypoxia is"/>
   <result pre="feature of hypoxia is its ability to promote resistance to" exact="cancer" post="therapy including radiotherapy, chemotherapy, and targeted therapy. Most of"/>
   <result pre="discuss hypoxia/HIF-1 regulated pathways that may contribute to resistance to" exact="cancer" post="therapy. Hypoxia-induced drug resistance through increased drug efflux Chemoresistance"/>
   <result pre="involved in HIF-1α-mediated doxorubicin efflux and resistance to doxorubicin in" exact="breast cancer" post="cell lines. 53 Thus, hypoxia/HIF can contribute to chemoresistance"/>
   <result pre="in HIF-1α-mediated doxorubicin efflux and resistance to doxorubicin in breast" exact="cancer" post="cell lines. 53 Thus, hypoxia/HIF can contribute to chemoresistance"/>
   <result pre="contribute to chemoresistance by increasing the drug efflux ability of" exact="cancer" post="cells. Hypoxia-induced drug resistance through inhibition of apoptotic pathways"/>
   <result pre="stability in a cell. Normally, DNA damage is recognized by" exact="ataxia telangiectasia" post="mutated/ataxia telangiectasia and Rad3-related protein kinases that promote cell-cycle"/>
   <result pre="can inhibit apoptosis and promote tumor cell survival in chemotherapy-treated" exact="cancer" post="cells. Overcoming tumor hypoxia Targeting metabolism in hypoxic tumors"/>
   <result pre="effort is being made to target metabolic pathways activated in" exact="cancer" post="cells. Since hypoxia is known to enhance glycolysis and"/>
   <result pre="with WZB117 and cisplatin or paclitaxel can synergistically kill hypoxic" exact="lung cancer" post="cells in vitro and in vivo as demonstrated with"/>
   <result pre="WZB117 and cisplatin or paclitaxel can synergistically kill hypoxic lung" exact="cancer" post="cells in vitro and in vivo as demonstrated with"/>
   <result pre="hypoxia and overcoming hypoxia-conferred drug resistance in colon, non-small cell" exact="lung carcinoma," post="and renal carcinoma cancer cell lines. 60 LDHA catalyzes"/>
   <result pre="resistance in colon, non-small cell lung carcinoma, and renal carcinoma" exact="cancer" post="cell lines. 60 LDHA catalyzes the final step in"/>
   <result pre="ability to proliferate, and reduced survival under hypoxic conditions in" exact="breast cancer" post="cell lines and in an in vivo breast cancer"/>
   <result pre="to proliferate, and reduced survival under hypoxic conditions in breast" exact="cancer" post="cell lines and in an in vivo breast cancer"/>
   <result pre="in breast cancer cell lines and in an in vivo" exact="breast cancer" post="model. 62 Inhibition of LDHA by small molecule FX11"/>
   <result pre="breast cancer cell lines and in an in vivo breast" exact="cancer" post="model. 62 Inhibition of LDHA by small molecule FX11"/>
   <result pre="levels, induces oxidative stress and inhibits tumor progression in human" exact="lymphoma" post="xenografts. 63 Importantly, combining FX11 with paclitaxel promotes tumor"/>
   <result pre="FX11 with paclitaxel promotes tumor regression in paclitaxel-resistant triple negative" exact="breast cancer" post="xenografts. 64 These results indicate that LDHA and lactate"/>
   <result pre="with paclitaxel promotes tumor regression in paclitaxel-resistant triple negative breast" exact="cancer" post="xenografts. 64 These results indicate that LDHA and lactate"/>
   <result pre="apoptosis and increased resistance to cisplatin or paclitaxel in a" exact="cervical cancer" post="cell line. 65 Knockdown of PDK3 inhibits hypoxia-induced glycolysis"/>
   <result pre="and increased resistance to cisplatin or paclitaxel in a cervical" exact="cancer" post="cell line. 65 Knockdown of PDK3 inhibits hypoxia-induced glycolysis"/>
   <result pre="of PDK3 inhibits hypoxia-induced glycolysis and increases the sensitivity of" exact="colon cancer" post="cell lines to chemotherapeutic agents such as cisplatin, paclitaxel,"/>
   <result pre="PDK3 inhibits hypoxia-induced glycolysis and increases the sensitivity of colon" exact="cancer" post="cell lines to chemotherapeutic agents such as cisplatin, paclitaxel,"/>
   <result pre="in lipid biogenesis, has been found to be upregulated in" exact="breast cancer" post="cells under hypoxia. 68 Several FAS inhibitors have shown"/>
   <result pre="lipid biogenesis, has been found to be upregulated in breast" exact="cancer" post="cells under hypoxia. 68 Several FAS inhibitors have shown"/>
   <result pre="69 Lipid synthesis and lipid droplet accumulation is essential for" exact="cancer" post="cell survival under hypoxic conditions. 70 Thus, targeting FAS"/>
   <result pre="is expressed predominantly in tumor cells and is important for" exact="cancer" post="metabolism and tumor growth. 71 PKM2 is a direct"/>
   <result pre="exhibited in vivo antitumor activity in a preclinical model of" exact="prostate cancer." post="74 Bortezomib, a proteasome inhibitor, has been shown to"/>
   <result pre="sequence 5′-CGTG-3′ and inhibit HIF-1 transcriptional activity, promoting apoptosis in" exact="glioma" post="and breast cancer cell lines. 77 However, despite its"/>
   <result pre="and inhibit HIF-1 transcriptional activity, promoting apoptosis in glioma and" exact="breast cancer" post="cell lines. 77 However, despite its efficacy in vivo"/>
   <result pre="inhibit HIF-1 transcriptional activity, promoting apoptosis in glioma and breast" exact="cancer" post="cell lines. 77 However, despite its efficacy in vivo"/>
   <result pre="increasing the rate of HIF-1α protein translation. 79 Thus, many" exact="cancer" post="cells can stabilize HIF-1α under normal oxygen tension and"/>
   <result pre="by topotecan was also shown to downregulate HIF-1 expression in" exact="glioma" post="cells in vitro and in vivo. 84 More importantly,"/>
   <result pre="is used in the clinic for treatment of small cell" exact="lung cancer" post="and ovarian cancer. An inhibitor of tubulin polymerization, 2-methoxyestradiol"/>
   <result pre="used in the clinic for treatment of small cell lung" exact="cancer" post="and ovarian cancer. An inhibitor of tubulin polymerization, 2-methoxyestradiol"/>
   <result pre="the clinic for treatment of small cell lung cancer and" exact="ovarian cancer." post="An inhibitor of tubulin polymerization, 2-methoxyestradiol (2ME2), reduces HIF-1α"/>
   <result pre="II clinical trial as a single agent for platinum-resistant epithelial" exact="ovarian cancer." post="87 The compound is currently being tested in clinical"/>
   <result pre="is currently being tested in clinical trials in patients with" exact="multiple myeloma," post="breast, prostate and ovarian cancer (NCT00028821). A few agents"/>
   <result pre="clinical trials in patients with multiple myeloma, breast, prostate and" exact="ovarian cancer" post="(NCT00028821). A few agents have been show to affect"/>
   <result pre="trials in patients with multiple myeloma, breast, prostate and ovarian" exact="cancer" post="(NCT00028821). A few agents have been show to affect"/>
   <result pre="and proteasomal degradation of HIF-1α in a VHL-independent manner in" exact="renal cell carcinoma" post="and prostate cancer cell lines. 89 An analog of"/>
   <result pre="HIF-1α in a VHL-independent manner in renal cell carcinoma and" exact="prostate cancer" post="cell lines. 89 An analog of geldanamycin, 17-AAG, has"/>
   <result pre="in a VHL-independent manner in renal cell carcinoma and prostate" exact="cancer" post="cell lines. 89 An analog of geldanamycin, 17-AAG, has"/>
   <result pre="shown efficacy in Phase II clinical trials against non-small cell" exact="lung carcinoma" post="and is currently moving to Phase III (NCT00544674). AQ4N"/>
   <result pre="98 AQ4N is currently undergoing tests in clinical trials for" exact="glioma" post="treatment (NCT00394628). Another bioreductive prodrug, E09 (apaziquone), belonging to"/>
   <result pre="selective small molecule MET inhibitor, PHA665752, demonstrated radiosensitization in gastric" exact="cancer" post="cells. 108 In addition, this compound was able to"/>
   <result pre="compound was able to abrogate hypoxia-induced invasiveness in non-small cell" exact="lung cancer" post="cell lines. 109 Another member of the MET kinase"/>
   <result pre="was able to abrogate hypoxia-induced invasiveness in non-small cell lung" exact="cancer" post="cell lines. 109 Another member of the MET kinase"/>
   <result pre="AXL kinase, was reported to participate in hypoxia-mediated resistance in" exact="prostate cancer." post="110 AXL expression and activation by its ligand, growth"/>
   <result pre="6 (GAS6), is increased under hypoxic conditions in renal cell" exact="cancer" post="cell lines. 111 Moreover, overexpression of AXL kinase interacts"/>
   <result pre="c-SRC and MET kinases, resulting in increased invasion in renal" exact="cancer" post="cell xenografts. 111 Additionally, AXL inhibition decreased tumorigenesis in"/>
   <result pre="cancer cell xenografts. 111 Additionally, AXL inhibition decreased tumorigenesis in" exact="breast cancer" post="cells in vitro and in vivo. 112 BGB324, an"/>
   <result pre="cell xenografts. 111 Additionally, AXL inhibition decreased tumorigenesis in breast" exact="cancer" post="cells in vitro and in vivo. 112 BGB324, an"/>
   <result pre="currently studied in Phase II clinical trials against non-small cell" exact="lung carcinoma" post="(NCT02424617). Macrophage-stimulating protein receptor, known as RON kinase, can"/>
   <result pre="increased RON expression. 113 Interestingly, in a panel of human" exact="breast cancer" post="cell lines, RON was reported to be transcriptionally activated"/>
   <result pre="RON expression. 113 Interestingly, in a panel of human breast" exact="cancer" post="cell lines, RON was reported to be transcriptionally activated"/>
   <result pre="and HIF-2 have been shown to increase EGFR expression in" exact="renal cell carcinoma" post="and breast cancers. 118 Thus, targeting EGFR in combination"/>
   <result pre="the ERBB family often overexpressed in breast cancers. 119 Breast" exact="cancer" post="patients with ERBB2 amplifications are currently treated with ERBB2"/>
   <result pre="endothelial growth factor (VEGF)-A is upregulated by hypoxia in many" exact="cancer" post="cells, both in vitro and in vivo. 124 Under"/>
   <result pre="targeting hypoxia/HIF-1 in immune cells or targeting T-cells against hypoxic" exact="cancer" post="cells may provide novel ways to treat therapy-resistant hypoxic"/>
   <result pre="Although the mechanisms of resistance to anticancer therapy vary from" exact="cancer" post="to cancer, some are common among different types of"/>
   <result pre="have been shown to promote resistance in different types of" exact="cancer" post="and are associated with poor prognosis. However, a better"/>
   <result pre="References 1 Brahimi-Horn MC Chiche J Pouysségur J Hypoxia and" exact="cancer" post="J Mol Med (Berl) 2007 85 12 1301 1307"/>
   <result pre="Dewhirst MW Hypoxia and radiotherapy: opportunities for improved outcomes in" exact="cancer" post="treatment Cancer Metastasis Rev 2007 26 2 241 248"/>
   <result pre="Semenza GL Defining the role of hypoxia-inducible factor 1 in" exact="cancer" post="biology and therapeutics Oncogene 2010 29 5 625 634"/>
   <result pre="19946328 10 Masson N Ratcliffe PJ Hypoxia signaling pathways in" exact="cancer" post="metabolism: the importance of co-selecting interconnected physiological pathways Cancer"/>
   <result pre="D Johnson RS Hypoxia: a key regulator of angiogenesis in" exact="cancer" post="Cancer Metastasis Rev 2007 26 2 281 290 17603752"/>
   <result pre="YL Liang XH EMT: a new vision of hypoxia promoting" exact="cancer" post="progression Cancer Biol Ther 2011 11 8 714 723"/>
   <result pre="Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal" exact="carcinoma in situ" post="of the breast Am J Pathol 2001 158 3"/>
   <result pre="Rep 2014 4 3793 24452734 16 Semenza GL Regulation of" exact="cancer" post="cell metabolism by hypoxia-inducible factor 1 Semin Cancer Biol"/>
   <result pre="16 19114105 17 Semenza GL HIF-1: upstream and downstream of" exact="cancer" post="metabolism Curr Opin Genet Dev 2010 20 1 51"/>
   <result pre="238 17785204 20 Santos CR Schulze A Lipid metabolism in" exact="cancer" post="FEBS J 2012 279 15 2610 2623 22621751 21"/>
   <result pre="Arnould T Michiels C Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231" exact="breast cancer" post="cells: role of autophagy and JNK activation Cell Death"/>
   <result pre="T Michiels C Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast" exact="cancer" post="cells: role of autophagy and JNK activation Cell Death"/>
   <result pre="al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic" exact="cancer" post="cells Mol Cell Biol 2004 24 19 8504 8518"/>
   <result pre="Vanlandewijck M Moustakas A Regulation of EMT by TGFβ in" exact="cancer" post="FEBS Lett 2012 586 14 1959 1970 22710176 37"/>
   <result pre="VM Werb Z The extracellular matrix: a dynamic niche in" exact="cancer" post="progression J Cell Biol 2012 196 4 395 406"/>
   <result pre="type I and type III collagen gene expression in human" exact="breast cancer" post="in vivo J Pathol 1998 186 3 262 268"/>
   <result pre="I and type III collagen gene expression in human breast" exact="cancer" post="in vivo J Pathol 1998 186 3 262 268"/>
   <result pre="Bajpai S et al. Collagen prolyl hydroxylases are essential for" exact="breast cancer" post="metastasis Cancer Res 2013 73 11 3285 3296 23539444"/>
   <result pre="S et al. Collagen prolyl hydroxylases are essential for breast" exact="cancer" post="metastasis Cancer Res 2013 73 11 3285 3296 23539444"/>
   <result pre="al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric" exact="cancer" post="Cancer Sci 2008 99 1 121 128 17953712 53"/>
   <result pre="55 Whelan KA Caldwell SA Shahriari KS et al. Hypoxia" exact="suppression" post="of Bim and Bmf blocks anoikis and luminal clearing"/>
   <result pre="of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell" exact="lung cancer" post="J Exp Clin Cancer Res 2009 28 29 19245702"/>
   <result pre="hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung" exact="cancer" post="J Exp Clin Cancer Res 2009 28 29 19245702"/>
   <result pre="glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits" exact="cancer" post="cell growth in vitro and in vivo Mol Cancer"/>
   <result pre="Fang L Gibbs S et al. Glucose uptake inhibitor sensitizes" exact="cancer" post="cells to daunorubicin and overcomes drug resistance in hypoxia"/>
   <result pre="16906425 61 Doherty J Cleveland J Targeting lactate metabolism for" exact="cancer" post="therapeutics J Clin Invest 2013 123 9 3685 3692"/>
   <result pre="al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant" exact="cancer" post="cells to taxol Mol Cancer 2010 9 33 20144215"/>
   <result pre="dehydrogenase kinase 3 increases drug resistance and early recurrence in" exact="colon cancer" post="Am J Pathol 2011 179 3 1405 1414 21763680"/>
   <result pre="kinase 3 increases drug resistance and early recurrence in colon" exact="cancer" post="Am J Pathol 2011 179 3 1405 1414 21763680"/>
   <result pre="Mackey JR Dichloroacetate (DCA) as a potential metabolic-targeting therapy for" exact="cancer" post="Br J Cancer 2008 99 7 989 994 18766181"/>
   <result pre="M Fatty acid synthase as a potential therapeutic target in" exact="cancer" post="Futur Oncol 2010 6 4 551 562 70 Baenke"/>
   <result pre="A Hooked on fat: the role of lipid synthesis in" exact="cancer" post="metabolism and tumour development Dis Model Mech 2013 6"/>
   <result pre="Semenza GL Emerging roles of PKM2 in cell metabolism and" exact="cancer" post="progression Trends Endocrinol Metab 2012 23 11 560 566"/>
   <result pre="2 171 174 8617582 79 Semenza GL Targeting HIF-1 for" exact="cancer" post="therapy Nat Rev Cancer 2003 3 10 721 732"/>
   <result pre="al. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant" exact="ovarian cancer" post="and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial"/>
   <result pre="Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian" exact="cancer" post="and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial"/>
   <result pre="of hypoxia-inducible factor 1alpha protein via the proteosome pathway in" exact="prostate cancer" post="cells Cancer Res 2002 62 9 2478 2482 11980636"/>
   <result pre="hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate" exact="cancer" post="cells Cancer Res 2002 62 9 2478 2482 11980636"/>
   <result pre="of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic" exact="breast cancer" post="progressing on trastuzumab Clin Cancer Res 2011 17 15"/>
   <result pre="tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast" exact="cancer" post="progressing on trastuzumab Clin Cancer Res 2011 17 15"/>
   <result pre="CP Mowday AM Ashoorzadeh A et al. Bioreductive prodrugs as" exact="cancer" post="therapeutics: targeting tumor hypoxia Chin J Cancer 2014 33"/>
   <result pre="hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of" exact="cancer" post="Clin Cancer Res 2012 18 3 758 770 22184053"/>
   <result pre="Ullrich A The discovery of receptor tyrosine kinases: targets for" exact="cancer" post="therapy Nat Rev Cancer 2004 4 5 361 370"/>
   <result pre="Arora A Scholar E Role of tyrosine kinase inhibitors in" exact="cancer" post="therapy J Pharmacol Exp 2005 315 3 971 979"/>
   <result pre="M Interplay between receptor tyrosine kinases and hypoxia signaling in" exact="cancer" post="Int J Biochem Cell Biol 2015 62 101 114"/>
   <result pre="Comoglio PM The Met tyrosine kinase receptor in development and" exact="cancer" post="Cancer Metastasis Rev 2008 27 1 85 94 18175071"/>
   <result pre="resistance and addiction to MET inhibitors in the MKN45 gastric" exact="cancer" post="cell line Invest New Drugs 2013 31 5 1158"/>
   <result pre="inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse" exact="lung cancer" post="xenografts Cancer Res 2007 67 8 3529 3534 17440059"/>
   <result pre="of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung" exact="cancer" post="xenografts Cancer Res 2007 67 8 3529 3534 17440059"/>
   <result pre="Shiozawa Y et al. Hypoxia stabilizes GAS6/Axl signaling in metastatic" exact="prostate cancer" post="Mol Cancer Res 2012 10 6 703 712 22516347"/>
   <result pre="Y et al. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate" exact="cancer" post="Mol Cancer Res 2012 10 6 703 712 22516347"/>
   <result pre="116 Yarden Y Pines G The ERBB network: at last," exact="cancer" post="therapy meets systems biology Nat Rev Cancer 2012 12"/>
   <result pre="hypoxia provides a nonmutational explanation for its overexpression in human" exact="cancer" post="Proc Natl Acad Sci U S A 2007 104"/>
   <result pre="Révillion F Bonneterre J Peyrat JP ERBB2 oncogene in human" exact="breast cancer" post="and its clinical significance Eur J Cancer 1998 34"/>
   <result pre="F Bonneterre J Peyrat JP ERBB2 oncogene in human breast" exact="cancer" post="and its clinical significance Eur J Cancer 1998 34"/>
   <result pre="Karakashev SV Reginato MJ Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive" exact="breast cancer" post="cells via regulation of DUSP2 Oncotarget 2015 6 4"/>
   <result pre="SV Reginato MJ Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast" exact="cancer" post="cells via regulation of DUSP2 Oncotarget 2015 6 4"/>
   <result pre="Carmeliet P VEGF as a key mediator of angiogenesis in" exact="cancer" post="Oncology 2005 69 Suppl 3 4 10 16301830 125"/>
   <result pre="Sleijfer S van Steenbergen S et al. Treatment of metastatic" exact="renal cell carcinoma" post="with CAIX CAR-engineered T cells: clinical evaluation and management"/>
   <result pre="and DNA repair. Figure 2 Potential strategies to target hypoxic" exact="cancer" post="cells in solid tumors. Notes: Multiple pathways may be"/>
   <result pre="inhibition of these pathways targets hypoxic cells. (4) Activation of" exact="cancer" post="signaling under hypoxia promotes proliferation, survival, and invasion. Targeting"/>
   <result pre="Hypoxia and HIF-1 can remodel the extracellular matrix (ECM) in" exact="cancer" post="cells that can also contribute to altered signaling by"/>
   <result pre="hypoxic tumors may be used to reverse hypoxia-mediated resistance to" exact="cancer" post="therapy. Abbreviations: Akt, protein kinase B; DCA, dichloroacetate; EGFR,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4546491/results/search/disease/results.xml">
   <result pre="pmcid: 4546491 pmid: 25970776 : Research Paper Cytogenomic profiling of" exact="breast cancer" post="brain metastases reveals potential for repurposing targeted therapeutics Bollig-Fischer"/>
   <result pre="4546491 pmid: 25970776 : Research Paper Cytogenomic profiling of breast" exact="cancer" post="brain metastases reveals potential for repurposing targeted therapeutics Bollig-Fischer"/>
   <result pre="provided the original author and source are credited. Abstract Breast" exact="cancer" post="brain metastases remain a significant clinical problem. Chemotherapy is"/>
   <result pre="Targeted therapeutics have proven to be highly effective in primary" exact="breast cancer," post="but lack of molecular genomic characterization of metastatic brain"/>
   <result pre="by reporting on gene copy number variation (CNV) in 10" exact="breast cancer" post="metastatic brain tumors, assayed by array comparative genomic hybridization"/>
   <result pre="reporting on gene copy number variation (CNV) in 10 breast" exact="cancer" post="metastatic brain tumors, assayed by array comparative genomic hybridization"/>
   <result pre="genomic hybridization (aCGH). Results were compared to a list of" exact="cancer" post="genes verified by others to influence cancer. Cancer gene"/>
   <result pre="the metastatic brain tumor samples (n=4) we compared patient-matched primary" exact="breast cancer" post="specimens. The results of our CGH analysis and validation"/>
   <result pre="metastatic brain tumor samples (n=4) we compared patient-matched primary breast" exact="cancer" post="specimens. The results of our CGH analysis and validation"/>
   <result pre="the use of genomic-based diagnostic tools and repurposed drug treatments." exact="breast cancer" post="brain metastases copy number variation oncogenes targeted therapy INTRODUCTION"/>
   <result pre="use of genomic-based diagnostic tools and repurposed drug treatments. breast" exact="cancer" post="brain metastases copy number variation oncogenes targeted therapy INTRODUCTION"/>
   <result pre="oncogenes targeted therapy INTRODUCTION Despite advances in the treatments for" exact="breast cancer," post="effective treatments for brain metastases remain elusive. It is"/>
   <result pre="brain metastases remain elusive. It is estimated that 30% of" exact="breast cancer" post="patients will develop a brain metastasis, and with extended"/>
   <result pre="metastases remain elusive. It is estimated that 30% of breast" exact="cancer" post="patients will develop a brain metastasis, and with extended"/>
   <result pre="of the microenvironment and the phenotype of the colonizing metastatic" exact="breast cancer" post="cells [ 3, 4]. This concept must now be"/>
   <result pre="the microenvironment and the phenotype of the colonizing metastatic breast" exact="cancer" post="cells [ 3, 4]. This concept must now be"/>
   <result pre="4]. This concept must now be reconciled with knowledge that" exact="cancer" post="is ultimately a genetic disease with pathobiology driven by"/>
   <result pre="study patients were female with an average age at primary" exact="breast cancer" post="diagnosis of 51±11 years. The average interval to the"/>
   <result pre="patients were female with an average age at primary breast" exact="cancer" post="diagnosis of 51±11 years. The average interval to the"/>
   <result pre="estrogen receptor; PR: progesterone receptor; H2N: HER-2/neu; TNBC: triple negative" exact="breast cancer;" post="AC: doxorubicin and cyclophosphamide; AC+T: doxorubicin, cyclophosphamide, and docetaxel;"/>
   <result pre="modified-radical mastectomy; RT: radiation therapy; ESRD: end-stage renal disease; DM:" exact="diabetes mellitus;" post="TH: docetaxel and trastuzumab (Herceptin); ACTH: doxorubicin and cyclophosphamide"/>
   <result pre="ACTH: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab Re-occurring" exact="cancer" post="gene amplifications in breast metastatic brain tumors Macro-colonization is"/>
   <result pre="in metastatic tumor formation, accounting for fewer than 0.1% of" exact="cancer" post="cells that enter the circulatory system [ 13– 16]."/>
   <result pre="Copy number variations detected in breast metastatic brain tumors for" exact="cancer" post="genes that are the target of existing drugs Gene"/>
   <result pre="Not a complete list. Comparing brain metastases with matched primary" exact="cancer" post="tissue The relationship between cancer driver genes in primary"/>
   <result pre="brain metastases with matched primary cancer tissue The relationship between" exact="cancer" post="driver genes in primary breast cancer and those in"/>
   <result pre="cancer tissue The relationship between cancer driver genes in primary" exact="breast cancer" post="and those in metastatic brain tumors remains incompletely understood."/>
   <result pre="tissue The relationship between cancer driver genes in primary breast" exact="cancer" post="and those in metastatic brain tumors remains incompletely understood."/>
   <result pre="frozen metastatic brain tumor tissue samples and discovered the same" exact="cancer" post="gene CNV results for the same patient specimens exposed"/>
   <result pre="either tumor in each set. Thus evidence from analysis of" exact="cancer" post="gene copy number aberrations indicates that at a gene"/>
   <result pre="brain tumors can be highly similar or divergent from the" exact="cancer" post="of origin. Figure 3 Plot of log2 ratio data"/>
   <result pre="of origin. Figure 3 Plot of log2 ratio data for" exact="cancer" post="gene aberrations discovered in matched primary and metastatic tumor"/>
   <result pre="individual results of analysis of matched primary breast and metastatic" exact="cancer" post="specimens from four patients. Representing one side of the"/>
   <result pre="outcomes spectrum, a. displays outcomes where the log2 ratios for" exact="cancer" post="gene aberrations were identical in the primary and metastatic"/>
   <result pre="no lesions were discovered in the primary tumor, but 6" exact="cancer" post="gene aberrations were observed in the metastatic tumor with"/>
   <result pre="result concurs with the clinical pathology report for the original" exact="breast cancer" post="biopsy specimen, where ERBB2 gene was not amplified according"/>
   <result pre="concurs with the clinical pathology report for the original breast" exact="cancer" post="biopsy specimen, where ERBB2 gene was not amplified according"/>
   <result pre="4b). However, the original pathology report also describes the primary" exact="breast cancer" post="specimen as being ERBB2 positive (HER2 positive score 3+)"/>
   <result pre="However, the original pathology report also describes the primary breast" exact="cancer" post="specimen as being ERBB2 positive (HER2 positive score 3+)"/>
   <result pre="b. The result of FISH analysis of the original biopsied" exact="breast cancer" post="specimen concluded that there was normal diploid copy number"/>
   <result pre="The result of FISH analysis of the original biopsied breast" exact="cancer" post="specimen concluded that there was normal diploid copy number"/>
   <result pre="negative for ERBB2 amplification. c. IHC analysis of the primary" exact="breast cancer" post="specimen indicates that although not DNA amplified, ERBB2 is"/>
   <result pre="for ERBB2 amplification. c. IHC analysis of the primary breast" exact="cancer" post="specimen indicates that although not DNA amplified, ERBB2 is"/>
   <result pre="of patient (13-19) with right temporal brain metastasis from primary" exact="breast cancer." post="e. IHC of the metastatic brain lesion shows relatively"/>
   <result pre="50 μM and also applies to panel c. DISCUSSION Breast" exact="cancer" post="patients who suffer metastatic brain tumors are in dire"/>
   <result pre="of improved treatment options. There is mounting evidence that metastatic" exact="cancer" post="patients will one day benefit from informed molecularly-targeted therapies"/>
   <result pre="profile. There is growing literature on the molecular underpinnings of" exact="breast cancer" post="metastatic brain tumor growth [ 5, 17– 27], but"/>
   <result pre="There is growing literature on the molecular underpinnings of breast" exact="cancer" post="metastatic brain tumor growth [ 5, 17– 27], but"/>
   <result pre="metastatic specimens and a subset of 4 available matched primary" exact="cancer" post="specimens to appreciate the gene copy number lesions that"/>
   <result pre="analyzed. This contributes genomic evidence to reinforce the importance of" exact="cancer" post="stem-like cells in promoting metastatic brain tumors. Cancer stem-like"/>
   <result pre="to the Karmanos Cancer Institute after having had their primary" exact="cancer" post="diagnosed and treated elsewhere. However, based on our analyses"/>
   <result pre="diagnosed and treated elsewhere. However, based on our analyses of" exact="cancer" post="gene CNV in 4 matched primary breast and metastatic"/>
   <result pre="observed. One primary and metastatic tumor set showed nearly identical" exact="cancer" post="gene aberration profiles (Figure 3a). For this pair CCND1"/>
   <result pre="pair CCND1 specifically demonstrated a high amplification in the primary" exact="cancer" post="(1.32 log2 ratio amplification spanning 1.5Mb sequence and 13"/>
   <result pre="but that CCND1 likely has a role in the primary" exact="breast cancer" post="that is reinforced in the metastatic cancer. Two paired"/>
   <result pre="that CCND1 likely has a role in the primary breast" exact="cancer" post="that is reinforced in the metastatic cancer. Two paired"/>
   <result pre="Two paired primary-metastatic tumor sets demonstrated a set of conserved" exact="cancer" post="gene aberrations, though one set showed additional cancer gene"/>
   <result pre="of conserved cancer gene aberrations, though one set showed additional" exact="cancer" post="gene lesions in the primary cancer specimen and the"/>
   <result pre="one set showed additional cancer gene lesions in the primary" exact="cancer" post="specimen and the other had gains in the metastasis."/>
   <result pre="upwards of 100 genes; Figure 3b). Here the trend holds," exact="cancer" post="gene amplifications at relatively lower log2 ratios were associated"/>
   <result pre="35]. The fourth and final matched tumor set showed no" exact="cancer" post="gene aberrations in the primary specimen according to aCGH"/>
   <result pre="leads to a conclusion that the dependence of this patient's" exact="cancer" post="on ERBB2 was sustained in both the primary and"/>
   <result pre="Of note, in the course of treatment for this primary" exact="breast cancer," post="the patient did receive anti-ERBB2 therapy as part of"/>
   <result pre="gene analysis such as by FISH, all efforts to analyze" exact="cancer" post="specimen DNA genomic methods or by FISH can result"/>
   <result pre="are known to drive transcription and upregulation of ERBB2 in" exact="breast cancer" post="absent any copy number gain [ 37]. To conclude,"/>
   <result pre="known to drive transcription and upregulation of ERBB2 in breast" exact="cancer" post="absent any copy number gain [ 37]. To conclude,"/>
   <result pre="bolstering the expectation that continued molecular genomic study of primary" exact="breast cancer" post="and metastatic brain tumors will lead to improved targeted,"/>
   <result pre="the expectation that continued molecular genomic study of primary breast" exact="cancer" post="and metastatic brain tumors will lead to improved targeted,"/>
   <result pre="resection as part of the standard-of-care for the treatment of" exact="breast cancer" post="brain metastases. The study procurement period was 2009-2013. Fresh"/>
   <result pre="as part of the standard-of-care for the treatment of breast" exact="cancer" post="brain metastases. The study procurement period was 2009-2013. Fresh"/>
   <result pre="included: date of birth, gender, age at diagnosis of primary" exact="breast cancer" post="and metastatic brain tumor, and histopathological features of primary"/>
   <result pre="date of birth, gender, age at diagnosis of primary breast" exact="cancer" post="and metastatic brain tumor, and histopathological features of primary"/>
   <result pre="well-characterized roles in cancer, gene-level data were compared to a" exact="cancer" post="gene list comprising known cancer promoting genes, oncogenes or"/>
   <result pre="data were compared to a cancer gene list comprising known" exact="cancer" post="promoting genes, oncogenes or tumor suppressor genes ( Supplementary"/>
   <result pre="listed genes were compiled from the Cancer Gene Census (a" exact="cancer" post="atlas project supported by the Wellcome Trust Sanger Institute,"/>
   <result pre="least 20 non-overlapping cells in two separate areas of invasive" exact="cancer" post="were scored following the American Society of Clinical Oncology"/>
   <result pre="242 15735152 2 Niwinska A Murawska M Pogoda K Breast" exact="cancer" post="subtypes and response to systemic treatment after whole-brain radiotherapy"/>
   <result pre="20549816 3 Paget S The distribution of secondary growths in" exact="cancer" post="of the breast. 1889 Cancer metastasis reviews 1989 8"/>
   <result pre="Settleman J Oncogene addiction: setting the stage for molecularly targeted" exact="cancer" post="therapy Genes Dev 2007 21 3214 3231 18079171 7"/>
   <result pre="with the oral, specific, EGFR-tyrosine kinase inhibitor ZD139 (iressa) Clinical" exact="cancer" post="research : an official journal of the American Association"/>
   <result pre="Rubin SD et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 2743 17192538"/>
   <result pre="SD et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 2743 17192538"/>
   <result pre="study of lapatinib in patients with brain metastases from HER2-positive" exact="breast cancer" post="Clinical cancer research : an official journal of the"/>
   <result pre="of lapatinib in patients with brain metastases from HER2-positive breast" exact="cancer" post="Clinical cancer research : an official journal of the"/>
   <result pre="in patients with brain metastases from HER2-positive breast cancer Clinical" exact="cancer" post="research : an official journal of the American Association"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="DA Toner M Isolation of rare circulating tumour cells in" exact="cancer" post="patients by microchip technology Nature 2007 450 1235 1239"/>
   <result pre="TA Thomassen M Clonal expansion and linear genome evolution through" exact="breast cancer" post="progression from pre-invasive stages to asynchronous metastasis Oncotarget 2015"/>
   <result pre="Thomassen M Clonal expansion and linear genome evolution through breast" exact="cancer" post="progression from pre-invasive stages to asynchronous metastasis Oncotarget 2015"/>
   <result pre="breast carcinoma to distant metastasis: Few copy number changes of" exact="breast cancer" post="related genes Cancer letters 2014 344 138 146 24184827"/>
   <result pre="carcinoma to distant metastasis: Few copy number changes of breast" exact="cancer" post="related genes Cancer letters 2014 344 138 146 24184827"/>
   <result pre="H Kalicki J et al. Genome remodelling in a basal-like" exact="breast cancer" post="metastasis and xenograft Nature 2010 464 999 1005 20393555"/>
   <result pre="Kalicki J et al. Genome remodelling in a basal-like breast" exact="cancer" post="metastasis and xenograft Nature 2010 464 999 1005 20393555"/>
   <result pre="downstream pathways are involved in colonization of brain metastases from" exact="breast cancer" post="Breast cancer research : BCR 2010 12 R46 20604919"/>
   <result pre="pathways are involved in colonization of brain metastases from breast" exact="cancer" post="Breast cancer research : BCR 2010 12 R46 20604919"/>
   <result pre="involved in colonization of brain metastases from breast cancer Breast" exact="cancer" post="research : BCR 2010 12 R46 20604919 22 Wikman"/>
   <result pre="K Relevance of PTEN loss in brain metastasis formation in" exact="breast cancer" post="patients Breast cancer research : BCR 2012 14 R49"/>
   <result pre="Relevance of PTEN loss in brain metastasis formation in breast" exact="cancer" post="patients Breast cancer research : BCR 2012 14 R49"/>
   <result pre="loss in brain metastasis formation in breast cancer patients Breast" exact="cancer" post="research : BCR 2012 14 R49 22429330 23 Hohensee"/>
   <result pre="H Frequent genetic alterations in EGFR- and HER2-driven pathways in" exact="breast cancer" post="brain metastases The American journal of pathology 2013 183"/>
   <result pre="Frequent genetic alterations in EGFR- and HER2-driven pathways in breast" exact="cancer" post="brain metastases The American journal of pathology 2013 183"/>
   <result pre="70-gene prognosis signature are preserved throughout the metastatic process of" exact="breast cancer" post="Cancer research 2005 65 9155 9158 16230372 26 Salhia"/>
   <result pre="prognosis signature are preserved throughout the metastatic process of breast" exact="cancer" post="Cancer research 2005 65 9155 9158 16230372 26 Salhia"/>
   <result pre="Ryken T et al. Integrated genomic and epigenomic analysis of" exact="breast cancer" post="brain metastasis PloS one 2014 9 e85448 24489661 27"/>
   <result pre="T et al. Integrated genomic and epigenomic analysis of breast" exact="cancer" post="brain metastasis PloS one 2014 9 e85448 24489661 27"/>
   <result pre="Reva B Goldberg AP Sander C Schultz N The cBio" exact="cancer" post="genomics portal: an open platform for exploring multidimensional cancer"/>
   <result pre="cBio cancer genomics portal: an open platform for exploring multidimensional" exact="cancer" post="genomics data Cancer discovery 2012 2 401 404 22588877"/>
   <result pre="Cerami E Sander C Schultz N Integrative analysis of complex" exact="cancer" post="genomics and clinical profiles using the cBioPortal Science signaling"/>
   <result pre="amplification predicts response and overall survival in HER2-positive advanced gastric" exact="cancer" post="treated with trastuzumab Journal of clinical oncology : official"/>
   <result pre="Z Pekkolay Z Isikdogan A Brain metastases in HER2-positive metastatic" exact="breast cancer" post="patients who received chemotherapy with or without trastuzumab Breast"/>
   <result pre="Pekkolay Z Isikdogan A Brain metastases in HER2-positive metastatic breast" exact="cancer" post="patients who received chemotherapy with or without trastuzumab Breast"/>
   <result pre="cancer patients who received chemotherapy with or without trastuzumab Breast" exact="cancer" post="2014 37 Ithimakin S Day KC Malik F Zen"/>
   <result pre="N Luther TK Clouthier SG et al. HER2 drives luminal" exact="breast cancer" post="stem cells in the absence of HER2 amplification: implications"/>
   <result pre="Luther TK Clouthier SG et al. HER2 drives luminal breast" exact="cancer" post="stem cells in the absence of HER2 amplification: implications"/>
   <result pre="SB Lander ES Getz G Discovery and saturation analysis of" exact="cancer" post="genes across 21 tumour types Nature 2014 505 495"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4548203/results/search/disease/results.xml">
   <result pre="with these terms. Abstract Peripheral arterial disease (PAD) results from" exact="atherosclerosis" post="that leads to blocked arteries and reduced blood flow,"/>
   <result pre="arterial disease computational drug repositioning inflammation angiogenesis drug-target network bioinformatics" exact="cardiovascular disease" post="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Recent pharmaceutical"/>
   <result pre="(approximately 50% of all PAD subjects) to patients who have" exact="intermittent claudication" post="manifested as leg pain with walking/exercise that is relieved"/>
   <result pre="including myocardial infarction, heart failure, coronary artery disease (CAD), and" exact="stroke" post="(Frostegård, 2013). Atherosclerosis is a chronic inflammatory condition. Potential"/>
   <result pre="Atherosclerosis is a chronic inflammatory condition. Potential anti-inflammatory treatments in" exact="atherosclerosis" post="are reviewed in Frostegård ( 2013). The interplay between"/>
   <result pre="Chemokine (C-C motif) ligand 2 Mimosine, danazol Potential indicator of" exact="atherosclerosis" post="in PAD (Rull et al., 2011) NPPB Natriuretic peptide"/>
   <result pre="Intravenous immunoglobulin C3 level in serum associated with ABI and" exact="atherosclerosis" post="in PAD patients (Fehervari et al., 2014) CCR5 Chemokine"/>
   <result pre="Ginseng Phase III clinical trial targeting IL-6 by tocilizumab in" exact="cardiovascular disease" post="(Ridker and Lüscher, 2014) LTA Lymphotoxin alpha Etanercept Implicated"/>
   <result pre="Lüscher, 2014) LTA Lymphotoxin alpha Etanercept Implicated in predisposition for" exact="heart attack" post="by genome-wide association studies (GWAS) (Topol et al., 2006)"/>
   <result pre="inhibition improves inflammation and endothelial dysfunction in PAD patients with" exact="intermittent claudication" post="(IC) (Flórez et al., 2009) S100A12 S100 calcium binding"/>
   <result pre="et al., 2006), and PRKCA (protein kinase C, alpha) in" exact="atherosclerosis" post="(Konopatskaya and Poole, 2010). Many of the anti-inflammatory genes"/>
   <result pre="use PubMed search Alteplase SERPINE1 14 Plasminogen activator Acute ischemic" exact="stroke" post="Lapchak and Araujo, 2007; Hacke et al., 2008 Danazol"/>
   <result pre="use PubMed search Lapatinib EGFR 137 Tyrosine kinase inhibitor Breast" exact="cancer" post="Hall et al., 2009 Lidocaine EGFR 137 Stopping nerves"/>
   <result pre="al., 2012 Chloroquine TNF, TLR9 22, 22 4-aminoquinoline drug Malaria," exact="rheumatoid arthritis" post="Yang et al., 2013 Clenbuterol TNF 22 Angiotensin-converting enzyme"/>
   <result pre="2012 Chloroquine TNF, TLR9 22, 22 4-aminoquinoline drug Malaria, rheumatoid" exact="arthritis" post="Yang et al., 2013 Clenbuterol TNF 22 Angiotensin-converting enzyme"/>
   <result pre="TNF 22 Chimeric monoclonal antibody against TNF alpha Rheumatoid arthritis," exact="psoriatic arthritis," post="ankylosing spondylitis Hirono et al., 2009 Alteplase SERPINE1 18"/>
   <result pre="Chimeric monoclonal antibody against TNF alpha Rheumatoid arthritis, psoriatic arthritis," exact="ankylosing spondylitis" post="Hirono et al., 2009 Alteplase SERPINE1 18 Plasminogen activator"/>
   <result pre="monoclonal antibody against TNF alpha Rheumatoid arthritis, psoriatic arthritis, ankylosing" exact="spondylitis" post="Hirono et al., 2009 Alteplase SERPINE1 18 Plasminogen activator"/>
   <result pre="et al., 2009 Alteplase SERPINE1 18 Plasminogen activator Acute ischemic" exact="stroke" post="Lapchak and Araujo, 2007; Hacke et al., 2008 Intravenous"/>
   <result pre="FCGR2A, TNF 13, 11, 22 Monoclonal antibody against TNF-alpha Arthritis," exact="ankylosing spondylitis" post="Jiang et al., 2013 Lenalidomide TNFSF11 15 Immunomodulatory and"/>
   <result pre="TNF 13, 11, 22 Monoclonal antibody against TNF-alpha Arthritis, ankylosing" exact="spondylitis" post="Jiang et al., 2013 Lenalidomide TNFSF11 15 Immunomodulatory and"/>
   <result pre="2013 Lenalidomide TNFSF11 15 Immunomodulatory and antiangiogenic agent Anemia and" exact="multiple myeloma" post="Rozovski et al., 2013 Thalidomide PTGS2, TNF 7, 22"/>
   <result pre="2013 Thalidomide PTGS2, TNF 7, 22 Immunomodulatory drug Certain cancers," exact="leprosy" post="Keifer et al., 2001 Etanercept FCGR1A, FCGR2A, LTA, TNF"/>
   <result pre="11, 7, 22 Tumor necrosis factor (TNF) inhibitor Rheumatoid arthritis," exact="psoriatic arthritis," post="ankylosing spondylitis, and plaque psoriasis Cao et al., 2015"/>
   <result pre="22 Tumor necrosis factor (TNF) inhibitor Rheumatoid arthritis, psoriatic arthritis," exact="ankylosing spondylitis," post="and plaque psoriasis Cao et al., 2015 Abciximab FCGR1A,"/>
   <result pre="(TNF) inhibitor Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque" exact="psoriasis" post="Cao et al., 2015 Abciximab FCGR1A, FCGR2A 13, 11"/>
   <result pre="11 Immune suppressant Control of inflammation in moderate to severe" exact="psoriasis" post="Kraan et al., 2002; Chamian et al., 2005 Alemtuzumab"/>
   <result pre="present on the surface of mature lymphocytes Chronic lymphocytic leukemia," exact="multiple sclerosis" post="Heilman et al., 2013 Daclizumab FCGR1A, FCGR2A 13, 11"/>
   <result pre="IL-2 receptor of T cells Prevents rejection in organ transplantation," exact="multiple sclerosis" post="Papaliodis et al., 2003 Efalizumab FCGR1A, FCGR2A 13, 11"/>
   <result pre="FCGR2A 13, 11 Monoclonal antibody against the protein CD20 Rheumatoid" exact="arthritis" post="Baslund et al., 2012 Canakinumab IL1B 10 Monoclonal antibody"/>
   <result pre="in the body to mesalamine and reducing bowel inflammation Ulcerative" exact="colitis" post="Pardi et al., 2002 Acetaminophen PTGS2 7 Analgesics (pain"/>
   <result pre="anti-inflammatory drug (NSAID) Pain and swelling of the eye after" exact="cataract" post="surgery Rajpal et al., 2014 Etodolac PTGS2 7 Non-steroidal"/>
   <result pre="PTGS2 7 Non-steroidal anti-inflammatory drug (NSAID) Treats pain caused by" exact="arthritis" post="Costa et al., 2008 Etoricoxib PTGS2 7 COX-2 selective"/>
   <result pre="al., 2008 Etoricoxib PTGS2 7 COX-2 selective inhibitor Rheumatoid arthritis," exact="psoriatic arthritis," post="osteoarthritis Moraes et al., 2007 Gamma-homolinolenic acid PTGS2 7"/>
   <result pre="Etoricoxib PTGS2 7 COX-2 selective inhibitor Rheumatoid arthritis, psoriatic arthritis," exact="osteoarthritis" post="Moraes et al., 2007 Gamma-homolinolenic acid PTGS2 7 Omega-6"/>
   <result pre="Reduces inflammation by inhibition of COX-2 Pain and inflammation from" exact="arthritis" post="Fox and Johnston, 1997 Celecoxib PTGS2 7 COX-2 selective"/>
   <result pre="COX-2 selective non-steroidal anti-inflammatory drug (NSAID) Treats pain caused by" exact="arthritis" post="Chen et al., 2008 Ibuprofen PTGS2 7 Non-steroidal anti-inflammatory"/>
   <result pre="7 Non-steroidal anti-inflammatory drugs (NSAIDs) Pain and inflammation caused by" exact="arthritis" post="Donnenfeld et al., 2011 Lornoxicam PTGS2 7 Non-steroidal anti-inflammatory"/>
   <result pre="Mesalazine PTGS2 7 5-amino-2-hydroxybenzoic acid Inflammatory bowel disease, such as" exact="ulcerative colitis" post="Nabumetone PTGS2 7 Non-steroidal anti-inflammatory drug (NSAID) Relief of"/>
   <result pre="PTGS2 7 5-amino-2-hydroxybenzoic acid Inflammatory bowel disease, such as ulcerative" exact="colitis" post="Nabumetone PTGS2 7 Non-steroidal anti-inflammatory drug (NSAID) Relief of"/>
   <result pre="Non-steroidal anti-inflammatory drug (NSAID) Relief of pain and inflammation in" exact="arthritis" post="Naproxen PTGS2 7 Non-steroidal anti-inflammatory drugs (NSAIDs) Relief of"/>
   <result pre="7 Non-steroidal anti-inflammatory drugs (NSAIDs) Eye pain and swelling after" exact="cataract" post="surgery Nardi et al., 2007 Niflumic acid PTGS2 7"/>
   <result pre="2003 Piroxicam PTGS2 7 Non-steroidal anti-inflammatory drugs (NSAIDs) Pain, including" exact="arthritis" post="pain Salsalate PTGS2 7 Non-steroidal anti-inflammatory drugs (NSAIDs) Rheumatoid"/>
   <result pre="arthritis pain Salsalate PTGS2 7 Non-steroidal anti-inflammatory drugs (NSAIDs) Rheumatoid" exact="arthritis" post="Goldfine et al., 2008 Sulindac PTGS2 7 Non-steroidal anti-inflammatory"/>
   <result pre="Non-steroidal anti-inflammatory drug (NSAID) Relieve inflammation and pain associated with" exact="rheumatoid arthritis" post="Indomethacin PTGS2, PLA2G2A 7, 6 Non-steroidal anti-inflammatory drugs (NSAIDs)"/>
   <result pre="anti-inflammatory drug (NSAID) Relieve inflammation and pain associated with rheumatoid" exact="arthritis" post="Indomethacin PTGS2, PLA2G2A 7, 6 Non-steroidal anti-inflammatory drugs (NSAIDs)"/>
   <result pre="Rossetti et al., 1995 Pentoxifylline PDE5A 2 Phosphodiesterase inhibiton Treating" exact="intermittent claudication" post="resulting from peripheral artery disease Abdel-Salam et al., 2003;"/>
   <result pre="Pentoxifylline PDE5A 2 Phosphodiesterase inhibiton Treating intermittent claudication resulting from" exact="peripheral artery disease" post="Abdel-Salam et al., 2003; Fernandes et al., 2008 Perindopril"/>
   <result pre="2012 Theophylline PDE5A, ADORA2B 2, 2 Methylxanthine drug Asthma and" exact="respiratory disease" post="Cosio et al., 2009 Vardenafil PDE5A 2 PDE5 inhibitor"/>
   <result pre="and showed that endothelin levels were increased in patients with" exact="intermittent claudication" post="compared to non-PAD controls. Just as importantly patients with"/>
   <result pre="an elevation of endothelin is specific to the pathophysiology of" exact="intermittent claudication" post="and not all forms of PAD. The original indication"/>
   <result pre="reuse of an endothelin receptor antagonists in PAD patients with" exact="intermittent claudication" post="is now in a Phase II clinical trial; the"/>
   <result pre="NPPB Carvedilol has anti-inflammatory and pro-angiogenic effects in chronic ischemic" exact="cardiomyopathy" post="(Le et al., 2013). Carvedilol showed improvement of myocardial"/>
   <result pre="but not directly affects the angiogenesis pathway in triple negative" exact="breast cancer" post="cell lines (Lee et al., 2014). Currently there are"/>
   <result pre="not directly affects the angiogenesis pathway in triple negative breast" exact="cancer" post="cell lines (Lee et al., 2014). Currently there are"/>
   <result pre="of adhesion related molecules in synovial tissues of patients with" exact="rheumatoid arthritis" post=". Xi Bao Yu Fen Zi Mian Yi Xue"/>
   <result pre="adhesion related molecules in synovial tissues of patients with rheumatoid" exact="arthritis" post=". Xi Bao Yu Fen Zi Mian Yi Xue"/>
   <result pre="infiltrating T cells, activated dendritic cells, and inflammatory genes in" exact="psoriasis" post="vulgaris . Proc. Natl. Acad. Sci. U.S.A. 102, 2075–"/>
   <result pre="drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for" exact="osteoarthritis" post="and rheumatoid arthritis: a systematic review and economic evaluation"/>
   <result pre="inflammatory biomarkers in induced sputum: implications for clinical trials in" exact="cystic fibrosis" post=". J. Cyst. Fibros. [Epub ahead of print]. 10.1016/j.jcf.2015.03.007"/>
   <result pre="2015). Inhibition of PKC-induced COX-2 and IL-8 expression in human" exact="breast cancer" post="cells by glucosamine . J. Cell. Physiol. 230, 2240–"/>
   <result pre="Inhibition of PKC-induced COX-2 and IL-8 expression in human breast" exact="cancer" post="cells by glucosamine . J. Cell. Physiol. 230, 2240–"/>
   <result pre="W. et al. . ( 2005). Enalapril attenuates angiotensin II-induced" exact="atherosclerosis" post="and vascular inflammation. Atherosclerosis 178, 9– 17. 10.1016/j.atherosclerosis.2004.08.023 15585195"/>
   <result pre="preservative-free ketorolac 0.45% for treatment of inflammation and pain after" exact="cataract" post="surgery . Am. J. Ophthalmol. 151, 420.e1– 426.e1. 10.1016/j.ajo.2010.09.003"/>
   <result pre="303– 311. 10.1093/bib/bbr013 21690101 Eby G. ( 2005). Elimination of" exact="arthritis" post="pain and inflammation for over 2 years with a"/>
   <result pre="level of complement C3 is associated with the severity of" exact="atherosclerosis" post="but not with arterial calcification in peripheral artery disease"/>
   <result pre="the severity of atherosclerosis but not with arterial calcification in" exact="peripheral artery disease" post=". Int. Angiol. 33, 35– 41. 24452084 Fernandes J."/>
   <result pre="reduces endothelial dysfunction and improves inflammatory status in patients with" exact="intermittent claudication" post=". Rev. Esp. Cardiol. 62, 851– 857. 10.1016/s1885-5857(09)72649-0 19706240"/>
   <result pre="46, 466– 470. 10.3109/00365548.2014.898332 24738757 Frostegård J. ( 2013). Immunity," exact="atherosclerosis" post="and cardiovascular disease. BMC Med. 11: 117 10.1186/1741-7015-11-117 23635324"/>
   <result pre="470. 10.3109/00365548.2014.898332 24738757 Frostegård J. ( 2013). Immunity, atherosclerosis and" exact="cardiovascular disease." post="BMC Med. 11: 117 10.1186/1741-7015-11-117 23635324 Frumkin L. R."/>
   <result pre="vascular endothelial growth factor A and inflammation in patients with" exact="peripheral artery disease" post=". Angiology 65, 683– 690. 10.1177/0003319713501376 24006146 Glaser K."/>
   <result pre="A. Wu J. C. ( 2011). Endothelial progenitor cells in" exact="cardiovascular disease" post="and chronic inflammation: from biomarker to therapeutic agent ."/>
   <result pre="Hanby A. Cameron D. A. ( 2009). Lapatinib for inflammatory" exact="breast cancer." post="Lancet Oncol. 10, 538– 539. 10.1016/S1470-2045(09)70120-2 19482243 Hazarika S."/>
   <result pre="Effects of omalizumab on markers of inflammation in patients with" exact="allergic asthma." post="Allergy 64, 1728– 1736. 10.1111/j.1398-9995.2009.02201.x 19839977 Hong Y. J."/>
   <result pre="Jr. Lowe D. K. ( 2013). Angiotensin-converting enzyme inhibitors for" exact="intermittent claudication" post="associated with peripheral arterial disease . Ann. Pharmacother. 47,"/>
   <result pre="( 2001). Inhibition of NF-kappa B activity by thalidomide through" exact="suppression" post="of IkappaB kinase activity . J. Biol. Chem. 276,"/>
   <result pre="synovial tissue is associated with improvement of clinical signs of" exact="arthritis" post=". Arthritis Rheum. 46, 2776– 2784. 10.1002/art.10543 12384938 Lapchak"/>
   <result pre="P. A. Araujo D. M. ( 2007). Advances in ischemic" exact="stroke" post="treatment: neuroprotective and combination therapies. Expert Opin. Emerg. Drugs"/>
   <result pre="S. Pandey N. B. Popel A. S. ( 2014). Breast" exact="cancer" post="cells condition lymphatic endothelial cells within pre-metastatic niches to"/>
   <result pre="2012). Immunomodulatory activity of vardenafil on induced lung inflammation in" exact="cystic fibrosis" post="mice . J. Cyst. Fibros. 11, 266– 273. 10.1016/j.jcf.2012.03.003"/>
   <result pre="et al. . ( 2013). Sulindac activates NF-kappaB signaling in" exact="colon cancer" post="cells. Cell Commun. Signal. 11: 73. 10.1186/1478-811X-11-73 24083678 Moraes"/>
   <result pre="al. . ( 2013). Sulindac activates NF-kappaB signaling in colon" exact="cancer" post="cells. Cell Commun. Signal. 11: 73. 10.1186/1478-811X-11-73 24083678 Moraes"/>
   <result pre="2013). Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental" exact="colitis" post="in rats . Toxicol. Appl. Pharmacol. 271, 106– 113."/>
   <result pre="( 2007). Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for" exact="cataract" post="surgery. Clin. Ophthalmol. 1, 527– 533. 19668532 Nimmerjahn F."/>
   <result pre="P. M. Lüscher T. F. ( 2014). Anti-inflammatory therapies for" exact="cardiovascular disease." post="Eur. Heart J. 35, 1782– 1791. 10.1093/eurheartj/ehu203 24864079 Ridker"/>
   <result pre="M. J. Estrov Z. ( 2013). Targeting inflammatory pathways in" exact="chronic lymphocytic leukemia." post="Crit. Rev. Oncol. Hematol. 88, 655– 666. 10.1016/j.critrevonc.2013.07.011 23941728"/>
   <result pre="walking ability and ankle brachial pressure index in patients with" exact="intermittent claudication" post=". Atherosclerosis 231, 283– 290. 10.1016/j.atherosclerosis.2013.09.037 24267241 Shameer K."/>
   <result pre="( 2014). Evaluation of selected angiogenic and inflammatory markers in" exact="endometriosis" post="before and after danazol treatment . Reprod. Fertil. Dev."/>
   <result pre="Dai S. et al. . ( 2010). Heart disease and" exact="stroke" post="statistics–2010 update: a report from the American Heart Association"/>
   <result pre="et al. . ( 2014). Uncoupling angiogenesis and inflammation in" exact="peripheral artery disease" post="with therapeutic peptide-loaded microgels . Biomaterials 35, 9635– 9648."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4550185/results/search/disease/results.xml">
   <result pre="ages, the proportion of elderly patients (aged ≥65 years) with" exact="breast cancer" post="also increases. Studies have shown that elderly patients with"/>
   <result pre="the proportion of elderly patients (aged ≥65 years) with breast" exact="cancer" post="also increases. Studies have shown that elderly patients with"/>
   <result pre="increases. Studies have shown that elderly patients with hormone receptor–positive" exact="breast cancer" post="can derive as much benefit from treatment as do"/>
   <result pre="Studies have shown that elderly patients with hormone receptor–positive breast" exact="cancer" post="can derive as much benefit from treatment as do"/>
   <result pre="symptoms. Resistance to therapy remains a problem in the advanced" exact="breast cancer" post="setting, with most patients eventually becoming resistant to additional"/>
   <result pre="Resistance to therapy remains a problem in the advanced breast" exact="cancer" post="setting, with most patients eventually becoming resistant to additional"/>
   <result pre="and quality of life are considered. hormone receptor positive advanced" exact="breast cancer" post="targeted therapy Introduction The incidence of breast cancer increases"/>
   <result pre="quality of life are considered. hormone receptor positive advanced breast" exact="cancer" post="targeted therapy Introduction The incidence of breast cancer increases"/>
   <result pre="positive advanced breast cancer targeted therapy Introduction The incidence of" exact="breast cancer" post="increases with age, 1 and as the overall mean"/>
   <result pre="advanced breast cancer targeted therapy Introduction The incidence of breast" exact="cancer" post="increases with age, 1 and as the overall mean"/>
   <result pre="mean population ages, the proportion of elderly (aged &amp;gt;65 years)" exact="breast cancer" post="patients will increase. 2– 4 The median age for"/>
   <result pre="population ages, the proportion of elderly (aged &amp;gt;65 years) breast" exact="cancer" post="patients will increase. 2– 4 The median age for"/>
   <result pre="cancer patients will increase. 2– 4 The median age for" exact="breast cancer" post="diagnosis is 61 years (Surveillance, Epidemiology, and End Results"/>
   <result pre="patients will increase. 2– 4 The median age for breast" exact="cancer" post="diagnosis is 61 years (Surveillance, Epidemiology, and End Results"/>
   <result pre="and approximately 10% are older than 80 years. 6 Breast" exact="cancer" post="can be classified into the following subtypes based on"/>
   <result pre="7 Compared with younger patients, a larger proportion of elderly" exact="breast cancer" post="patients have hormone receptor–positive (HR+) disease, which is defined"/>
   <result pre="Compared with younger patients, a larger proportion of elderly breast" exact="cancer" post="patients have hormone receptor–positive (HR+) disease, which is defined"/>
   <result pre="years, disease-related deaths have not declined as much in elderly" exact="breast cancer" post="patients compared with younger patients. 3, 11– 13 Elderly"/>
   <result pre="disease-related deaths have not declined as much in elderly breast" exact="cancer" post="patients compared with younger patients. 3, 11– 13 Elderly"/>
   <result pre="3, 11– 13 Elderly patients are generally underrepresented in many" exact="breast cancer" post="trials compared with the general cancer population, 11– 14"/>
   <result pre="11– 13 Elderly patients are generally underrepresented in many breast" exact="cancer" post="trials compared with the general cancer population, 11– 14"/>
   <result pre="underrepresented in many breast cancer trials compared with the general" exact="cancer" post="population, 11– 14 and this may contribute to the"/>
   <result pre="relative lack of progress seen in reducing mortality in older" exact="breast cancer" post="patients compared with younger patients. A post hoc analysis"/>
   <result pre="lack of progress seen in reducing mortality in older breast" exact="cancer" post="patients compared with younger patients. A post hoc analysis"/>
   <result pre="A post hoc analysis of older postmenopausal patients with HR+" exact="breast cancer" post="showed that older age was associated with higher disease-specific"/>
   <result pre="post hoc analysis of older postmenopausal patients with HR+ breast" exact="cancer" post="showed that older age was associated with higher disease-specific"/>
   <result pre="studies. The relatively low enrollment numbers of elderly women in" exact="breast cancer" post="clinical trials may reflect toxicity issues (physician perceived or"/>
   <result pre="The relatively low enrollment numbers of elderly women in breast" exact="cancer" post="clinical trials may reflect toxicity issues (physician perceived or"/>
   <result pre="and life expectancy. 4, 14, 19– 24 Although many older" exact="cancer" post="survivors can function well, they are more likely to"/>
   <result pre="factors that may not be as relevant to treating younger" exact="cancer" post="patients, such as poorer overall physiologic functioning and, in"/>
   <result pre="physiologic functioning should be undertaken before deciding on an appropriate" exact="breast cancer" post="treatment regimen, using a comprehensive geriatric assessment tool that"/>
   <result pre="functioning should be undertaken before deciding on an appropriate breast" exact="cancer" post="treatment regimen, using a comprehensive geriatric assessment tool that"/>
   <result pre="adversely affect survival. 32 When deciding how to treat elderly" exact="breast cancer" post="patients, oncologists need to balance the risk posed by"/>
   <result pre="affect survival. 32 When deciding how to treat elderly breast" exact="cancer" post="patients, oncologists need to balance the risk posed by"/>
   <result pre="patients, oncologists need to balance the risk posed by the" exact="cancer" post="versus the risk from other major comorbidities, such as"/>
   <result pre="cancer versus the risk from other major comorbidities, such as" exact="cardiovascular disease," post="that could be worsened by cancer therapy. 14, 33,"/>
   <result pre="comorbidities, such as cardiovascular disease, that could be worsened by" exact="cancer" post="therapy. 14, 33, 34 The role of chemotherapy needs"/>
   <result pre="may be at greater risk of not complying with their" exact="cancer" post="therapy regimen due to increased prevalence of chronic illnesses"/>
   <result pre="chronic illnesses and concomitant medications. 35 In patients with HR+" exact="breast cancer," post="the likelihood of discontinuing hormone therapy has been shown"/>
   <result pre="hormone therapy has been shown to increase with age in" exact="breast cancer" post="trials, 37, 38 particularly in patients experiencing AEs from"/>
   <result pre="therapy has been shown to increase with age in breast" exact="cancer" post="trials, 37, 38 particularly in patients experiencing AEs from"/>
   <result pre="Breast Cancer Current treatment options for elderly patients with HR+" exact="breast cancer" post="are similar to those for younger patients. 24, 40,"/>
   <result pre="Cancer Current treatment options for elderly patients with HR+ breast" exact="cancer" post="are similar to those for younger patients. 24, 40,"/>
   <result pre="have issued recommendations for the management of older individuals with" exact="breast cancer." post="42 These recommendations state that the management of elderly"/>
   <result pre="cancer. 42 These recommendations state that the management of elderly" exact="breast cancer" post="patients should not be driven by chronologic age alone;"/>
   <result pre="42 These recommendations state that the management of elderly breast" exact="cancer" post="patients should not be driven by chronologic age alone;"/>
   <result pre="data from large, randomized, controlled trials about outcomes for elderly" exact="breast cancer" post="patients, prospectively defined subgroup analyses and observational studies may"/>
   <result pre="from large, randomized, controlled trials about outcomes for elderly breast" exact="cancer" post="patients, prospectively defined subgroup analyses and observational studies may"/>
   <result pre="summarizes the current recommendations for the use of individual pharmacological" exact="breast cancer" post="therapies in elderly patients. 44– 49 First-line therapy In"/>
   <result pre="the current recommendations for the use of individual pharmacological breast" exact="cancer" post="therapies in elderly patients. 44– 49 First-line therapy In"/>
   <result pre="elderly patients. 44– 49 First-line therapy In contrast to early" exact="breast cancer," post="wherein the goal for treatment is cure, 20 for"/>
   <result pre="treatment is cure, 20 for patients with advanced or metastatic" exact="breast cancer," post="the emphasis of treatment is to palliate symptoms and"/>
   <result pre="Current first-line treatment for postmenopausal patients diagnosed with HR+ advanced" exact="breast cancer" post="depends on previous treatment. For women who are naive"/>
   <result pre="first-line treatment for postmenopausal patients diagnosed with HR+ advanced breast" exact="cancer" post="depends on previous treatment. For women who are naive"/>
   <result pre="same treatment is recommended for elderly patients diagnosed with HR+" exact="breast cancer," post="40, 50, 55 including those with diminished functional status."/>
   <result pre="59, 61 For patients with both HR+ and HER2+ metastatic" exact="breast cancer," post="lapatinib (a dual HER2 and epidermal growth factor receptor"/>
   <result pre="and progression-free survival (PFS) in postmenopausal women with HR+/HER2+ metastatic" exact="breast cancer," post="but not in patients with HR+/human epidermal growth factor"/>
   <result pre="a phase III trial in postmenopausal patients with HR+/HER2+ metastatic" exact="breast cancer," post="some of whom had previous exposure to endocrine therapy."/>
   <result pre="with trastuzumab to letrozole alone in patients with HR+/HER2+ metastatic" exact="breast cancer," post="in which approximately 40% of patients had received previous"/>
   <result pre="in breast tissue. 67 For many women with HR+ advanced" exact="breast cancer," post="sequential use of endocrine therapies at each disease progression"/>
   <result pre="effect. 47, 79 Fulvestrant is currently approved for treating HR+" exact="breast cancer" post="in postmenopausal women only after progression 47; however, in"/>
   <result pre="47, 79 Fulvestrant is currently approved for treating HR+ breast" exact="cancer" post="in postmenopausal women only after progression 47; however, in"/>
   <result pre="second-line setting in postmenopausal women with locally advanced or metastatic" exact="breast cancer" post="and disease progression during previous endocrine therapy found fulvestrant"/>
   <result pre="setting in postmenopausal women with locally advanced or metastatic breast" exact="cancer" post="and disease progression during previous endocrine therapy found fulvestrant"/>
   <result pre="comparable efficacy and tolerability versus exemestane in patients with advanced" exact="breast cancer" post="after nonsteroidal AI failure. 85 In a phase III"/>
   <result pre="efficacy and tolerability versus exemestane in patients with advanced breast" exact="cancer" post="after nonsteroidal AI failure. 85 In a phase III"/>
   <result pre="500 mg versus 250 mg in postmenopausal patients with advanced" exact="breast cancer" post="who had disease recurrence on or after endocrine therapy"/>
   <result pre="mg versus 250 mg in postmenopausal patients with advanced breast" exact="cancer" post="who had disease recurrence on or after endocrine therapy"/>
   <result pre="pathway has been shown to be another mechanism by which" exact="breast cancer" post="cells bypass estrogen blockade, resulting in endocrine resistance, 91"/>
   <result pre="has been shown to be another mechanism by which breast" exact="cancer" post="cells bypass estrogen blockade, resulting in endocrine resistance, 91"/>
   <result pre="development ( Fig. 1). 92 For patients with advanced HR+" exact="breast cancer" post="who have progressed after treatment with endocrine therapy, one"/>
   <result pre="( Fig. 1). 92 For patients with advanced HR+ breast" exact="cancer" post="who have progressed after treatment with endocrine therapy, one"/>
   <result pre="approved for the treatment of postmenopausal women with advanced HR+/HER2−" exact="breast cancer" post="after failure of anastrozole or letrozole therapy, 45 based"/>
   <result pre="for the treatment of postmenopausal women with advanced HR+/HER2− breast" exact="cancer" post="after failure of anastrozole or letrozole therapy, 45 based"/>
   <result pre="of clinically meaningful benefit in the pivotal phase III Breast" exact="cancer" post="trials of OraL EveROlimus-2 (BOLERO-2) trial. 91, 93, 94"/>
   <result pre="population in the BOLERO-2 study, the most common AEs were" exact="stomatitis" post="(49%), fatigue (38%), decreased appetite (36%), and diarrhea (36%)."/>
   <result pre="AEs were stomatitis (49%), fatigue (38%), decreased appetite (36%), and" exact="diarrhea" post="(36%). 95 The incidence of special-interest AEs was similar"/>
   <result pre="those aged &amp;lt;70 years, including pneumonitis (14% vs 17%, respectively)," exact="hyperglycemia" post="(12% vs 15%), and hypercholesterolemia (7% vs 11%). 95"/>
   <result pre="to patients aged ≥70 years and/or frail patients with metastatic" exact="breast cancer," post="weekly dosing was shown to be well tolerated, retaining"/>
   <result pre="been specifically assessed in patients aged ≥70 years with metastatic" exact="breast cancer" post="at a dose of 40 mg/m 2 every 28"/>
   <result pre="specifically assessed in patients aged ≥70 years with metastatic breast" exact="cancer" post="at a dose of 40 mg/m 2 every 28"/>
   <result pre="assessed for overcoming resistance to therapy in patients with HR+" exact="breast cancer." post="On the basis of the success observed with the"/>
   <result pre="with other endocrine therapies to overcome endocrine resistance in advanced" exact="breast cancer" post="continues to be explored in several ongoing phase II"/>
   <result pre="other endocrine therapies to overcome endocrine resistance in advanced breast" exact="cancer" post="continues to be explored in several ongoing phase II"/>
   <result pre="also demonstrated some efficacy. In postmenopausal women with HR+ advanced" exact="breast cancer" post="in whom previous tamoxifen and/or AI therapy was ineffective,"/>
   <result pre="demonstrated some efficacy. In postmenopausal women with HR+ advanced breast" exact="cancer" post="in whom previous tamoxifen and/or AI therapy was ineffective,"/>
   <result pre="trial in postmenopausal women with AI-naïve locally advanced or metastatic" exact="breast cancer" post="in the first-line setting. 106 In this study, 41%"/>
   <result pre="in postmenopausal women with AI-naïve locally advanced or metastatic breast" exact="cancer" post="in the first-line setting. 106 In this study, 41%"/>
   <result pre="the PI3K pathway are also being investigated for ER+ relapsed" exact="breast cancer" post="that is resistant to AIs. 107 In early studies,"/>
   <result pre="PI3K pathway are also being investigated for ER+ relapsed breast" exact="cancer" post="that is resistant to AIs. 107 In early studies,"/>
   <result pre="in patients with HR+/HER2− mTOR inhibitor–naïve locally advanced or metastatic" exact="breast cancer" post="refractory to AIs in the Buparlisib brEast cancer cLinicaL"/>
   <result pre="patients with HR+/HER2− mTOR inhibitor–naïve locally advanced or metastatic breast" exact="cancer" post="refractory to AIs in the Buparlisib brEast cancer cLinicaL"/>
   <result pre="metastatic breast cancer refractory to AIs in the Buparlisib brEast" exact="cancer" post="cLinicaL Evaluation-2 (BELLE-2) (NCT01610284) trial. 109 The BELLE-3 trial"/>
   <result pre="in postmenopausal women with HR+ HER2− locally advanced or metastatic" exact="breast cancer" post="who were treated with an AI and are refractory"/>
   <result pre="postmenopausal women with HR+ HER2− locally advanced or metastatic breast" exact="cancer" post="who were treated with an AI and are refractory"/>
   <result pre="novel pan-PI3K/mTOR inhibitor) in combination with letrozole in HR+ metastatic" exact="breast cancer" post="(NCT01248494). 111 Also in development for HR+ breast cancer"/>
   <result pre="pan-PI3K/mTOR inhibitor) in combination with letrozole in HR+ metastatic breast" exact="cancer" post="(NCT01248494). 111 Also in development for HR+ breast cancer"/>
   <result pre="metastatic breast cancer (NCT01248494). 111 Also in development for HR+" exact="breast cancer" post="are agents targeting histone deacetylase (HDAC) and cyclin-dependent kinase"/>
   <result pre="breast cancer (NCT01248494). 111 Also in development for HR+ breast" exact="cancer" post="are agents targeting histone deacetylase (HDAC) and cyclin-dependent kinase"/>
   <result pre="inhibitor) in combination with exemestane in patients with HR+ metastatic" exact="breast cancer" post="that progressed while using a nonsteroidal AI. 114 In"/>
   <result pre="in combination with exemestane in patients with HR+ metastatic breast" exact="cancer" post="that progressed while using a nonsteroidal AI. 114 In"/>
   <result pre="good efficacy in early studies in women with HR+ endocrine-refractory" exact="breast cancer." post="115 In the PALbociclib: Ongoing trials in the Management"/>
   <result pre="use in combination with letrozole in women with postmenopausal HR+" exact="breast cancer" post="who have metastatic disease. Several other studies with palbociclib"/>
   <result pre="in combination with letrozole in women with postmenopausal HR+ breast" exact="cancer" post="who have metastatic disease. Several other studies with palbociclib"/>
   <result pre="as first-line treatment in combination with letrozole for HR+ advanced" exact="breast cancer" post="(phases I/II, NCT00721409 120; phase II, NCT01709370 121; phase"/>
   <result pre="first-line treatment in combination with letrozole for HR+ advanced breast" exact="cancer" post="(phases I/II, NCT00721409 120; phase II, NCT01709370 121; phase"/>
   <result pre="is also in development for the treatment of HER2− advanced" exact="breast cancer," post="in combination with letrozole (phases I/II, NCT01872260 123; phase"/>
   <result pre="the antiangiogenic antibody bevacizumab, in combination with paclitaxel, in metastatic" exact="breast cancer" post="was revoked by the FDA because of additional clinical"/>
   <result pre="antiangiogenic antibody bevacizumab, in combination with paclitaxel, in metastatic breast" exact="cancer" post="was revoked by the FDA because of additional clinical"/>
   <result pre="21 In the recently reported Avastin THErapy for advaNced breAst" exact="cancer" post="(ATHENA) trial, bevacizumab plus chemotherapy for first-line clinical use"/>
   <result pre="Elderly women are an increasingly large proportion of the HR+" exact="breast cancer" post="population, yet they are often underrepresented in clinical trials."/>
   <result pre="women are an increasingly large proportion of the HR+ breast" exact="cancer" post="population, yet they are often underrepresented in clinical trials."/>
   <result pre="Atlanta GA American Cancer Society 2013 3 Audisio RA Breast" exact="cancer" post="in the elderly: different treatment modalities Eur J Cancer"/>
   <result pre="Jones E Muss HB Challenges in the treatment of older" exact="breast cancer" post="patients Hematol Oncol Clin North Am 2013 27 4"/>
   <result pre="E Muss HB Challenges in the treatment of older breast" exact="cancer" post="patients Hematol Oncol Clin North Am 2013 27 4"/>
   <result pre="6 Vetter M Huang DJ Bosshard G Guth U Breast" exact="cancer" post="in women 80 years of age and older: a"/>
   <result pre="Gallen international expert consensus on the primary therapy of early" exact="breast cancer" post="2013 Ann Oncol 2013 24 9 2206 23 23917950"/>
   <result pre="international expert consensus on the primary therapy of early breast" exact="cancer" post="2013 Ann Oncol 2013 24 9 2206 23 23917950"/>
   <result pre="GM Tumor characteristics and clinical outcome of elderly women with" exact="breast cancer" post="J Natl Cancer Inst 2000 92 7 550 6"/>
   <result pre="Tumor characteristics and clinical outcome of elderly women with breast" exact="cancer" post="J Natl Cancer Inst 2000 92 7 550 6"/>
   <result pre="Buchholz TA The impact of age on outcome in early-stage" exact="breast cancer" post="Semin Radiat Oncol 2011 21 1 26 34 21134651"/>
   <result pre="TA The impact of age on outcome in early-stage breast" exact="cancer" post="Semin Radiat Oncol 2011 21 1 26 34 21134651"/>
   <result pre="L et al. International Society of Geriatric Oncology. Management of" exact="breast cancer" post="in elderly individuals: recommendations of the international society of"/>
   <result pre="et al. International Society of Geriatric Oncology. Management of breast" exact="cancer" post="in elderly individuals: recommendations of the international society of"/>
   <result pre="11 Daidone MG Coradini D Martelli G Veneroni S Primary" exact="breast cancer" post="in elderly women: biological profile and relation with clinical"/>
   <result pre="Daidone MG Coradini D Martelli G Veneroni S Primary breast" exact="cancer" post="in elderly women: biological profile and relation with clinical"/>
   <result pre="3 313 25 12633842 12 Downey LB Adjuvant treatment of" exact="breast cancer" post="in the elderly. Understanding and addressing the challenges Oncology"/>
   <result pre="313 25 12633842 12 Downey LB Adjuvant treatment of breast" exact="cancer" post="in the elderly. Understanding and addressing the challenges Oncology"/>
   <result pre="JW et al. Slow accrual of elderly patients with metastatic" exact="breast cancer" post="in the Dutch multicentre OMEGA study Breast 2013 22"/>
   <result pre="et al. Slow accrual of elderly patients with metastatic breast" exact="cancer" post="in the Dutch multicentre OMEGA study Breast 2013 22"/>
   <result pre="C van de Water W van de Velde CJ Breast" exact="cancer" post="in the elderly: reducing the losses Future Oncol 2013"/>
   <result pre="diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive" exact="breast cancer" post="JAMA 2012 307 6 590 7 22318280 16 Debled"/>
   <result pre="and disease-specific mortality among postmenopausal women with hormone receptor-positive breast" exact="cancer" post="JAMA 2012 307 6 590 7 22318280 16 Debled"/>
   <result pre="al. Barriers to clinical trial participation by older women with" exact="breast cancer" post="J Clin Oncol 2003 21 12 2268 75 12805325"/>
   <result pre="Barriers to clinical trial participation by older women with breast" exact="cancer" post="J Clin Oncol 2003 21 12 2268 75 12805325"/>
   <result pre="50 22541668 19 Tran P Fentiman IS Better treatment for" exact="breast cancer" post="in older patients Expert Rev Anticancer Ther 2009 9"/>
   <result pre="22541668 19 Tran P Fentiman IS Better treatment for breast" exact="cancer" post="in older patients Expert Rev Anticancer Ther 2009 9"/>
   <result pre="8 1081 90 19671028 20 Gandhi S Verma S Early" exact="breast cancer" post="in the older woman Oncologist 2011 16 4 479"/>
   <result pre="1081 90 19671028 20 Gandhi S Verma S Early breast" exact="cancer" post="in the older woman Oncologist 2011 16 4 479"/>
   <result pre="Puglisi F Bevacizumab in older patients with advanced colorectal or" exact="breast cancer" post="Crit Rev Oncol Hematol 2013 87 1 41 54"/>
   <result pre="F Bevacizumab in older patients with advanced colorectal or breast" exact="cancer" post="Crit Rev Oncol Hematol 2013 87 1 41 54"/>
   <result pre="assessment for patient care in acutely hospitalized older patients with" exact="cancer" post="Oncologist 2011 16 10 1403 12 21914699 23 Kartal"/>
   <result pre="Canda T Diagnosis, treatment characteristics, and survival of women with" exact="breast cancer" post="aged 65 and above: a hospital-based retrospective study BMC"/>
   <result pre="T Diagnosis, treatment characteristics, and survival of women with breast" exact="cancer" post="aged 65 and above: a hospital-based retrospective study BMC"/>
   <result pre="S Crivellari D Bedard P et al. Therapeutic management of" exact="breast cancer" post="in the elderly Expert Opin Pharmacother 2011 12 6"/>
   <result pre="Crivellari D Bedard P et al. Therapeutic management of breast" exact="cancer" post="in the elderly Expert Opin Pharmacother 2011 12 6"/>
   <result pre="SL Clark JC Stein KD The effect of aging and" exact="cancer" post="on the symptom experience and physical function of elderly"/>
   <result pre="cancer on the symptom experience and physical function of elderly" exact="breast cancer" post="survivors Cancer 2012 118 24 6171 8 22674036 26"/>
   <result pre="on the symptom experience and physical function of elderly breast" exact="cancer" post="survivors Cancer 2012 118 24 6171 8 22674036 26"/>
   <result pre="T Gerber B Quality-of-life considerations in the treatment of early-stage" exact="breast cancer" post="in the elderly Drugs Aging 2010 27 10 791"/>
   <result pre="Gerber B Quality-of-life considerations in the treatment of early-stage breast" exact="cancer" post="in the elderly Drugs Aging 2010 27 10 791"/>
   <result pre="Moench S Hurria A et al. NCCN task force report:" exact="breast cancer" post="in the older woman J Natl Compr Canc Netw"/>
   <result pre="S Hurria A et al. NCCN task force report: breast" exact="cancer" post="in the older woman J Natl Compr Canc Netw"/>
   <result pre="Dittus K Muss HB Management of the frail elderly with" exact="breast cancer" post="Oncology (Williston Park) 2007 21 14 1727 34 18247018"/>
   <result pre="K Muss HB Management of the frail elderly with breast" exact="cancer" post="Oncology (Williston Park) 2007 21 14 1727 34 18247018"/>
   <result pre="Khan AJ Haffty BG Issues in the curative therapy of" exact="breast cancer" post="in elderly women Semin Radiat Oncol 2012 22 4"/>
   <result pre="AJ Haffty BG Issues in the curative therapy of breast" exact="cancer" post="in elderly women Semin Radiat Oncol 2012 22 4"/>
   <result pre="PO Dabakuyo TS Marilier S et al. Population-based study of" exact="breast cancer" post="in older women: prognostic factors of relative survival and"/>
   <result pre="Dabakuyo TS Marilier S et al. Population-based study of breast" exact="cancer" post="in older women: prognostic factors of relative survival and"/>
   <result pre="Bardia A Arieas ET Zhang Z et al. Comparison of" exact="breast cancer" post="recurrence risk and cardiovascular disease incidence risk among postmenopausal"/>
   <result pre="A Arieas ET Zhang Z et al. Comparison of breast" exact="cancer" post="recurrence risk and cardiovascular disease incidence risk among postmenopausal"/>
   <result pre="Z et al. Comparison of breast cancer recurrence risk and" exact="cardiovascular disease" post="incidence risk among postmenopausal women with breast cancer Breast"/>
   <result pre="risk and cardiovascular disease incidence risk among postmenopausal women with" exact="breast cancer" post="Breast Cancer Res Treat 2012 131 3 907 14"/>
   <result pre="and cardiovascular disease incidence risk among postmenopausal women with breast" exact="cancer" post="Breast Cancer Res Treat 2012 131 3 907 14"/>
   <result pre="C Brain EG et al. Anthracycline cardiotoxicity in the elderly" exact="cancer" post="patient: a SIOG expert position paper Ann Oncol 2011"/>
   <result pre="Yoon J Malin JL Tao ML et al. Symptoms after" exact="breast cancer" post="treatment: are they influenced by patient characteristics? Breast Cancer"/>
   <result pre="J Malin JL Tao ML et al. Symptoms after breast" exact="cancer" post="treatment: are they influenced by patient characteristics? Breast Cancer"/>
   <result pre="Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive" exact="breast cancer" post="J Clin Oncol 2008 26 4 549 55 18071188"/>
   <result pre="of tamoxifen discontinuation among older women with estrogen receptor-positive breast" exact="cancer" post="J Clin Oncol 2008 26 4 549 55 18071188"/>
   <result pre="S Jirillo A Basso U Management of primary and advanced" exact="breast cancer" post="in older unfit patients (medical treatment) Cancer Treat Rev"/>
   <result pre="Jirillo A Basso U Management of primary and advanced breast" exact="cancer" post="in older unfit patients (medical treatment) Cancer Treat Rev"/>
   <result pre="international society of geriatric oncology (SIOG) and European society of" exact="breast cancer" post="specialists (EUSOMA) Lancet Oncol 2012 13 4 e148 60"/>
   <result pre="society of geriatric oncology (SIOG) and European society of breast" exact="cancer" post="specialists (EUSOMA) Lancet Oncol 2012 13 4 e148 60"/>
   <result pre="60 22469125 43 Malik MK Tartter PI Belfer R Undertreated" exact="breast cancer" post="in the elderly J Cancer Epidemiol 2013 2013 893104"/>
   <result pre="22469125 43 Malik MK Tartter PI Belfer R Undertreated breast" exact="cancer" post="in the elderly J Cancer Epidemiol 2013 2013 893104"/>
   <result pre="T Williams GR Jones E Muss HB Treatment of metastatic" exact="breast cancer" post="in women aged 65 years and older Womens Health"/>
   <result pre="Williams GR Jones E Muss HB Treatment of metastatic breast" exact="cancer" post="in women aged 65 years and older Womens Health"/>
   <result pre="2009 update on the treatment of patients with hormone receptor-positive" exact="breast cancer" post="Clin Breast Cancer 2009 9 suppl 1 S6 17"/>
   <result pre="update on the treatment of patients with hormone receptor-positive breast" exact="cancer" post="Clin Breast Cancer 2009 9 suppl 1 S6 17"/>
   <result pre="17 19561006 53 Johnston SR New strategies in estrogen receptor-positive" exact="breast cancer" post="Clin Cancer Res 2010 16 7 1979 87 20332324"/>
   <result pre="19561006 53 Johnston SR New strategies in estrogen receptor-positive breast" exact="cancer" post="Clin Cancer Res 2010 16 7 1979 87 20332324"/>
   <result pre="R Endocrine therapy for the treatment of postmenopausal women with" exact="breast cancer" post="Expert Rev Anticancer Ther 2009 9 2 187 98"/>
   <result pre="Endocrine therapy for the treatment of postmenopausal women with breast" exact="cancer" post="Expert Rev Anticancer Ther 2009 9 2 187 98"/>
   <result pre="as a function of age in postmenopausal women with advanced" exact="breast cancer" post="Oncologist 2004 9 5 497 506 15477634 56 Riley"/>
   <result pre="a function of age in postmenopausal women with advanced breast" exact="cancer" post="Oncologist 2004 9 5 497 506 15477634 56 Riley"/>
   <result pre="LC Blackwell SA Endocrine therapy use among elderly hormone receptor-positive" exact="breast cancer" post="patients enrolled in medicare part D Medicare Medicaid Res"/>
   <result pre="Blackwell SA Endocrine therapy use among elderly hormone receptor-positive breast" exact="cancer" post="patients enrolled in medicare part D Medicare Medicaid Res"/>
   <result pre="Aromatase inhibitors in the treatment of elderly women with metastatic" exact="breast cancer" post="Breast 2013 22 2 142 9 23321585 58 Cardoso"/>
   <result pre="inhibitors in the treatment of elderly women with metastatic breast" exact="cancer" post="Breast 2013 22 2 142 9 23321585 58 Cardoso"/>
   <result pre="Norton L et al. 1st international consensus guidelines for advanced" exact="breast cancer" post="(ABC 1) Breast 2012 21 3 242 52 22425534"/>
   <result pre="L et al. 1st international consensus guidelines for advanced breast" exact="cancer" post="(ABC 1) Breast 2012 21 3 242 52 22425534"/>
   <result pre="Dawson C Bliss J Aromatase inhibitors for treatment of advanced" exact="breast cancer" post="in postmenopausal women Cochrane Database Syst Rev 2009 4"/>
   <result pre="C Bliss J Aromatase inhibitors for treatment of advanced breast" exact="cancer" post="in postmenopausal women Cochrane Database Syst Rev 2009 4"/>
   <result pre="in the first-line treatment for hormone sensitive advanced or metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2010 123 1 9 24"/>
   <result pre="the first-line treatment for hormone sensitive advanced or metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2010 123 1 9 24"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 33 5538 46 19786658"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 33 5538 46 19786658"/>
   <result pre="monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic" exact="breast cancer" post="– results of the eLEcTRA trial Breast 2012 21"/>
   <result pre="as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast" exact="cancer" post="– results of the eLEcTRA trial Breast 2012 21"/>
   <result pre="67 Osborne CK Schiff R Mechanisms of endocrine resistance in" exact="breast cancer" post="Annu Rev Med 2011 62 233 47 20887199 68"/>
   <result pre="Osborne CK Schiff R Mechanisms of endocrine resistance in breast" exact="cancer" post="Annu Rev Med 2011 62 233 47 20887199 68"/>
   <result pre="68 Burstein HJ Novel agents and future directions for refractory" exact="breast cancer" post="Semin Oncol 2011 38 suppl 2 S17 24 21600381"/>
   <result pre="Burstein HJ Novel agents and future directions for refractory breast" exact="cancer" post="Semin Oncol 2011 38 suppl 2 S17 24 21600381"/>
   <result pre="Mansky PJ Straus SE St. John’s wort: more implications for" exact="cancer" post="patients J Natl Cancer Inst 2002 94 16 1187"/>
   <result pre="Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced" exact="breast cancer" post="Clin Invest 2014 4 1 19 33 72 Johnston"/>
   <result pre="to overcome endocrine therapy resistance in hormone receptor-positive advanced breast" exact="cancer" post="Clin Invest 2014 4 1 19 33 72 Johnston"/>
   <result pre="estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human" exact="breast cancer" post="Cancer Res 1995 55 15 3331 8 7614468 73"/>
   <result pre="receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast" exact="cancer" post="Cancer Res 1995 55 15 3331 8 7614468 73"/>
   <result pre="an extra step in the treatment sequence for ER-positive advanced" exact="breast cancer" post="Br J Cancer 2008 99 12 1984 90 19018261"/>
   <result pre="extra step in the treatment sequence for ER-positive advanced breast" exact="cancer" post="Br J Cancer 2008 99 12 1984 90 19018261"/>
   <result pre="E Murray R et al. Activity of exemestane in metastatic" exact="breast cancer" post="after failure of nonsteroidal aromatase inhibitors: a phase II"/>
   <result pre="Murray R et al. Activity of exemestane in metastatic breast" exact="cancer" post="after failure of nonsteroidal aromatase inhibitors: a phase II"/>
   <result pre="Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced" exact="breast cancer" post="Oncology 2005 69 6 471 7 16410685 77 Beresford"/>
   <result pre="treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast" exact="cancer" post="Oncology 2005 69 6 471 7 16410685 77 Beresford"/>
   <result pre="for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic" exact="breast cancer" post="Clin Oncol 2011 23 3 209 15 78 Cruz"/>
   <result pre="non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast" exact="cancer" post="Clin Oncol 2011 23 3 209 15 78 Cruz"/>
   <result pre="AP Garcia MJ et al. Management of patients with metastatic" exact="breast cancer" post="Adv Ther 2011 28 suppl 6 50 65 21922395"/>
   <result pre="Garcia MJ et al. Management of patients with metastatic breast" exact="cancer" post="Adv Ther 2011 28 suppl 6 50 65 21922395"/>
   <result pre="Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive" exact="breast cancer" post="Future Oncol 2011 7 2 173 86 21345137 80"/>
   <result pre="in the management of postmenopausal women with advanced, endocrine-responsive breast" exact="cancer" post="Future Oncol 2011 7 2 173 86 21345137 80"/>
   <result pre="Comparison of fulvestrant versus tamoxifen for the treatment of advanced" exact="breast cancer" post="in postmenopausal women previously untreated with endocrine therapy: a"/>
   <result pre="of fulvestrant versus tamoxifen for the treatment of advanced breast" exact="cancer" post="in postmenopausal women previously untreated with endocrine therapy: a"/>
   <result pre="tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced" exact="breast cancer" post="progressing on prior endocrine therapy: results of a North"/>
   <result pre="of fulvestrant versus anastrozole in postmenopausal women with advanced breast" exact="cancer" post="progressing on prior endocrine therapy: results of a North"/>
   <result pre="is as effective as anastrozole in postmenopausal women with advanced" exact="breast cancer" post="progressing after prior endocrine treatment J Clin Oncol 2002"/>
   <result pre="as effective as anastrozole in postmenopausal women with advanced breast" exact="cancer" post="progressing after prior endocrine treatment J Clin Oncol 2002"/>
   <result pre="JA Fulvestrant for systemic therapy of locally advanced or metastatic" exact="breast cancer" post="in postmenopausal women: a systematic review Breast Cancer Res"/>
   <result pre="Fulvestrant for systemic therapy of locally advanced or metastatic breast" exact="cancer" post="in postmenopausal women: a systematic review Breast Cancer Res"/>
   <result pre="fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced" exact="breast cancer" post="J Clin Oncol 2010 28 30 4594 600 20855825"/>
   <result pre="500 mg in postmenopausal women with estrogen receptor-positive advanced breast" exact="cancer" post="J Clin Oncol 2010 28 30 4594 600 20855825"/>
   <result pre="Albain KS et al. Combination anastrozole and fulvestrant in metastatic" exact="breast cancer" post="N Engl J Med 2012 367 5 435 44"/>
   <result pre="KS et al. Combination anastrozole and fulvestrant in metastatic breast" exact="cancer" post="N Engl J Med 2012 367 5 435 44"/>
   <result pre="anastro-zole alone as first-line therapy for patients with receptor-positive postmenopausal" exact="breast cancer" post="J Clin Oncol 2012 30 16 1919 25 22370325"/>
   <result pre="alone as first-line therapy for patients with receptor-positive postmenopausal breast" exact="cancer" post="J Clin Oncol 2012 30 16 1919 25 22370325"/>
   <result pre="inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic" exact="breast cancer" post="(SoFEA): a composite, multicentre, phase 3 randomised trial Lancet"/>
   <result pre="in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast" exact="cancer" post="(SoFEA): a composite, multicentre, phase 3 randomised trial Lancet"/>
   <result pre="Piccart M et al. Everolimus in postmenopausal hormone receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2012 366 6 520 9"/>
   <result pre="M et al. Everolimus in postmenopausal hormone receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2012 366 6 520 9"/>
   <result pre="R Aqil F Gupta RC Promising molecular targeted therapies in" exact="breast cancer" post="Indian J Pharmacol 2011 43 3 236 45 21713084"/>
   <result pre="Aqil F Gupta RC Promising molecular targeted therapies in breast" exact="cancer" post="Indian J Pharmacol 2011 43 3 236 45 21713084"/>
   <result pre="vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive" exact="breast cancer" post="in BOLERO−2 Clin Breast Cancer 2013 13 6 421"/>
   <result pre="exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast" exact="cancer" post="in BOLERO−2 Clin Breast Cancer 2013 13 6 421"/>
   <result pre="bevacizumab (B) as first-line therapy for locally recurrent or metastatic" exact="breast cancer" post="Presented at the American Society of Clinical Oncology Annual"/>
   <result pre="(B) as first-line therapy for locally recurrent or metastatic breast" exact="cancer" post="Presented at the American Society of Clinical Oncology Annual"/>
   <result pre="on pegy-lated liposomal doxorubicin tolerance and efficacy in elderly metastatic" exact="breast cancer" post="patients: final results of the DOGMES multicentre GINECO trial"/>
   <result pre="pegy-lated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast" exact="cancer" post="patients: final results of the DOGMES multicentre GINECO trial"/>
   <result pre="Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive" exact="breast cancer" post="who are NOT suitable for a &quot;standard chemotherapy regimen&quot;:"/>
   <result pre="pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast" exact="cancer" post="who are NOT suitable for a &quot;standard chemotherapy regimen&quot;:"/>
   <result pre="in postmenopausal women with ER+, HER2− metastatic or locally advanced" exact="breast cancer" post="(Bolero-4) ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine"/>
   <result pre="postmenopausal women with ER+, HER2− metastatic or locally advanced breast" exact="cancer" post="(Bolero-4) ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine"/>
   <result pre="addition of everolimus in postmenopausal women with advanced endocrine resistant" exact="breast cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="of everolimus in postmenopausal women with advanced endocrine resistant breast" exact="cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="collab: Novartis Study of combined fulvestrant and everolimus in advanced/metastatic" exact="breast cancer" post="after aromatase inhibitor failure (BRE-43) ClinicalTrials.gov [Internet] Bethesda, MD"/>
   <result pre="Novartis Study of combined fulvestrant and everolimus in advanced/metastatic breast" exact="cancer" post="after aromatase inhibitor failure (BRE-43) ClinicalTrials.gov [Internet] Bethesda, MD"/>
   <result pre="(hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic" exact="breast cancer" post="Presented at 2011 European Multidisciplinary Cancer Congress September 23–27,"/>
   <result pre="resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast" exact="cancer" post="Presented at 2011 European Multidisciplinary Cancer Congress September 23–27,"/>
   <result pre="endocrine therapy in postmenopausal women with locally advanced or metastatic" exact="breast cancer" post="J Clin Oncol 2013 31 2 195 202 23233719"/>
   <result pre="therapy in postmenopausal women with locally advanced or metastatic breast" exact="cancer" post="J Clin Oncol 2013 31 2 195 202 23233719"/>
   <result pre="of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive" exact="breast cancer" post="Breast Cancer Res 2011 13 2 R21 21362200 108"/>
   <result pre="combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast" exact="cancer" post="Breast Cancer Res 2011 13 2 R21 21362200 108"/>
   <result pre="with hormone receptor positive HER2− negative locally advanced or metastatic" exact="breast cancer" post="refractory to aromatase inhibitor (BELLE-2) ClinicalTrials.gov [Internet] Bethesda, MD"/>
   <result pre="hormone receptor positive HER2− negative locally advanced or metastatic breast" exact="cancer" post="refractory to aromatase inhibitor (BELLE-2) ClinicalTrials.gov [Internet] Bethesda, MD"/>
   <result pre="in patients with HR+,HER2−, AI treated, locally advanced or metastatic" exact="breast cancer" post="who progressed on or after mTORi (BELLE-3) ClinicalTrials.gov [Internet]"/>
   <result pre="patients with HR+,HER2−, AI treated, locally advanced or metastatic breast" exact="cancer" post="who progressed on or after mTORi (BELLE-3) ClinicalTrials.gov [Internet]"/>
   <result pre="BEZ235+endocrine treatment in post-menopausal patients with hormone receptor + metastatic" exact="breast cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="treatment in post-menopausal patients with hormone receptor + metastatic breast" exact="cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="G Warsch S Gluck S Avancha K Montero AJ Treating" exact="breast cancer" post="in the 21st century: emerging biological therapies J Cancer"/>
   <result pre="Warsch S Gluck S Avancha K Montero AJ Treating breast" exact="cancer" post="in the 21st century: emerging biological therapies J Cancer"/>
   <result pre="second messenger: targeting loss of cell cycle control in endocrine-resistant" exact="breast cancer" post="Endocr Relat Cancer 2011 18 4 C19 24 21613412"/>
   <result pre="messenger: targeting loss of cell cycle control in endocrine-resistant breast" exact="cancer" post="Endocr Relat Cancer 2011 18 4 C19 24 21613412"/>
   <result pre="in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive" exact="breast cancer" post="progressing on treatment with a nonsteroidal aromatase inhibitor J"/>
   <result pre="postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast" exact="cancer" post="progressing on treatment with a nonsteroidal aromatase inhibitor J"/>
   <result pre="(palbociclib) + goserelin in women with hormone receptor-positive, HER2-negative metastatic" exact="breast cancer" post="whose disease progressed after prior endocrine therapy Presented at"/>
   <result pre="+ goserelin in women with hormone receptor-positive, HER2-negative metastatic breast" exact="cancer" post="whose disease progressed after prior endocrine therapy Presented at"/>
   <result pre="letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced" exact="breast cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2014"/>
   <result pre="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast" exact="cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2014"/>
   <result pre="(CDK 4/6 inhibitor) for ER positive, HER2− negative post-menopausal advanced" exact="breast cancer" post="patients recurring after hormonal therapy (to reverse endocrine resistance-TREnd"/>
   <result pre="4/6 inhibitor) for ER positive, HER2− negative post-menopausal advanced breast" exact="cancer" post="patients recurring after hormonal therapy (to reverse endocrine resistance-TREnd"/>
   <result pre="stage 2 or 3 estrogen receptor positive and HER2 negative" exact="breast cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="2 or 3 estrogen receptor positive and HER2 negative breast" exact="cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic" exact="breast cancer" post="(MBC) patients with resistance to non-steroidal aromatase inhibitors (PEARL)"/>
   <result pre="chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast" exact="cancer" post="(MBC) patients with resistance to non-steroidal aromatase inhibitors (PEARL)"/>
   <result pre="Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-receptor positive advanced" exact="breast cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="(PD-0332991) For The First-Line Treatment Of Hormone-receptor positive advanced breast" exact="cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="Letrozole and CDK 4/6 inhibitor for ER positive, HER2 negative" exact="breast cancer" post="in postmenopausal women ClinicalTrials.gov [Internet] Bethesda, MD National Library"/>
   <result pre="and CDK 4/6 inhibitor for ER positive, HER2 negative breast" exact="cancer" post="in postmenopausal women ClinicalTrials.gov [Internet] Bethesda, MD National Library"/>
   <result pre="for 1st line treatment of postmenopausal women with ER+/HER2− advanced" exact="breast cancer" post="(PALOMA-2) ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine"/>
   <result pre="1st line treatment of postmenopausal women with ER+/HER2− advanced breast" exact="cancer" post="(PALOMA-2) ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine"/>
   <result pre="Pharmaceuticals Study of LEE011, BYL719 and letrozole in advanced ER+" exact="breast cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="Study of LEE011, BYL719 and letrozole in advanced ER+ breast" exact="cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="efficacy and safety of LEE011 in postmenopausal women with advanced" exact="breast cancer" post="(MONALEESA-2) ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine"/>
   <result pre="and safety of LEE011 in postmenopausal women with advanced breast" exact="cancer" post="(MONALEESA-2) ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine"/>
   <result pre="(RAD001) and exemestane in the treatment of ER+ Her2− advanced" exact="breast cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="and exemestane in the treatment of ER+ Her2− advanced breast" exact="cancer" post="ClinicalTrials.gov [Internet] Bethesda, MD National Library of Medicine (US)"/>
   <result pre="3 595 802 20819780 Figure 1 Key targeted agents against" exact="breast cancer" post="under clinical development. Adapted from: Munagala R et al."/>
   <result pre="595 802 20819780 Figure 1 Key targeted agents against breast" exact="cancer" post="under clinical development. Adapted from: Munagala R et al."/>
   <result pre="from: Munagala R et al. Promising molecular targeted therapies in" exact="breast cancer." post="Indian J Pharmacol. 2011;43(3):236–245. 92 Abbreviations: EGF, epidermal growth"/>
   <result pre="growth factor-I; IGF-1R, IGF-1 receptor; PI3K, phosphatidylinositol 3-kinase; Ras, rat" exact="sarcoma" post="subfamily of genes; AKT, protein kinase B; PDK1, pyruvate"/>
   <result pre="VEGFR, VEGF receptor; BRAF, B-type RAF kinase; src, v-Src (Rous" exact="sarcoma" post="virus) tyrosine kinase; BCR-ABL, Philadelphia chromosome; JAK/STAT, Janus kinases/signal"/>
   <result pre="regarding pharmacological therapy use in elderly patients with hormone receptor–positive" exact="breast cancer." post="RECOMMENDATIONS FOR USE IN THE ELDERLY Anastrozole 44 •"/>
   <result pre="FOR USE IN THE ELDERLY Anastrozole 44 • In advanced" exact="breast cancer" post="studies, efficacy findings were not affected by age •"/>
   <result pre="USE IN THE ELDERLY Anastrozole 44 • In advanced breast" exact="cancer" post="studies, efficacy findings were not affected by age •"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4552740/results/search/disease/results.xml">
   <result pre="in vitro cell models have identified genes, which override growth" exact="suppression" post="induced by anti-estrogenic drugs like tamoxifen. Using that approach,"/>
   <result pre="high level of expression and function of BCAR4 in human" exact="breast cancer." post="Methods BCAR4 mRNA expression was evaluated by (q)RT-PCR in"/>
   <result pre="in IPH-926, a cell line derived from an endocrine-resistant lobular" exact="breast cancer." post="Moderate BCAR4 expression was evident in MDA-MB-134 and MDA-MB-453"/>
   <result pre="cancer. Moderate BCAR4 expression was evident in MDA-MB-134 and MDA-MB-453" exact="breast cancer" post="cells. BCAR4 protein was detected in breast cancer cells"/>
   <result pre="Moderate BCAR4 expression was evident in MDA-MB-134 and MDA-MB-453 breast" exact="cancer" post="cells. BCAR4 protein was detected in breast cancer cells"/>
   <result pre="and MDA-MB-453 breast cancer cells. BCAR4 protein was detected in" exact="breast cancer" post="cells with ectopic (ZR-75-1- BCAR4) and endogenous (IPH-926, MDA-MB-453)"/>
   <result pre="MDA-MB-453 breast cancer cells. BCAR4 protein was detected in breast" exact="cancer" post="cells with ectopic (ZR-75-1- BCAR4) and endogenous (IPH-926, MDA-MB-453)"/>
   <result pre="BCAR4 encodes a functional protein, which drives proliferation of endocrine-resistant" exact="breast cancer" post="cells. Lapatinib, a clinically approved EGFR/ERBB2 inhibitor, counteracts BCAR4-driven"/>
   <result pre="encodes a functional protein, which drives proliferation of endocrine-resistant breast" exact="cancer" post="cells. Lapatinib, a clinically approved EGFR/ERBB2 inhibitor, counteracts BCAR4-driven"/>
   <result pre="receptor (ER)-positive mammary carcinomas account for the vast majority of" exact="breast cancer" post="(BC) cases. They depend on estrogenic growth stimulation. Anti-hormone"/>
   <result pre="(ER)-positive mammary carcinomas account for the vast majority of breast" exact="cancer" post="(BC) cases. They depend on estrogenic growth stimulation. Anti-hormone"/>
   <result pre="4 ( BCAR4), a gene that can override tamoxifen-induced growth" exact="suppression" post="in vitro [ 8– 11]. In brief, BCAR4 was"/>
   <result pre="and error bars represent SEM. Discussion The vast majority of" exact="breast cancer" post="cases are ER-positive and hormone-dependent. Anti-hormone therapy has thus"/>
   <result pre="error bars represent SEM. Discussion The vast majority of breast" exact="cancer" post="cases are ER-positive and hormone-dependent. Anti-hormone therapy has thus"/>
   <result pre="gene as factor, whose ectopic overexpression can override tamoxifen-induced growth" exact="suppression" post="in vitro [ 8]. Follow-up studies revealed that BCAR4"/>
   <result pre="Together, these data firmly establish the role of BCAR4 in" exact="breast cancer" post="biology. However, this work does not only provide new"/>
   <result pre="these data firmly establish the role of BCAR4 in breast" exact="cancer" post="biology. However, this work does not only provide new"/>
   <result pre="disease-free survival in women with resected node-positive or high-risk node-negative" exact="breast cancer" post="which is reported as HER2-low by all HER2 testing"/>
   <result pre="survival in women with resected node-positive or high-risk node-negative breast" exact="cancer" post="which is reported as HER2-low by all HER2 testing"/>
   <result pre="of estrogen receptor alpha and progesterone receptor conversion in distant" exact="breast cancer" post="metastases . Cancer. 2012; 118( 20): 4929– 35. doi:"/>
   <result pre="estrogen receptor alpha and progesterone receptor conversion in distant breast" exact="cancer" post="metastases . Cancer. 2012; 118( 20): 4929– 35. doi:"/>
   <result pre=", Sutherland RL . Biological determinants of endocrine resistance in" exact="breast cancer." post="Nat Rev Cancer. 2009; 9( 9): 631– 43. doi:"/>
   <result pre=", Smid M , Veldscholte J et al. Relevance of" exact="breast cancer" post="antiestrogen resistance genes in human breast cancer progression and"/>
   <result pre="Smid M , Veldscholte J et al. Relevance of breast" exact="cancer" post="antiestrogen resistance genes in human breast cancer progression and"/>
   <result pre="al. Relevance of breast cancer antiestrogen resistance genes in human" exact="breast cancer" post="progression and tamoxifen resistance . J Clin Oncol. 2009;"/>
   <result pre="Relevance of breast cancer antiestrogen resistance genes in human breast" exact="cancer" post="progression and tamoxifen resistance . J Clin Oncol. 2009;"/>
   <result pre="Functional screen for genes responsible for tamoxifen resistance in human" exact="breast cancer" post="cells . Mol Cancer Res. 2006; 4( 6): 379–"/>
   <result pre="screen for genes responsible for tamoxifen resistance in human breast" exact="cancer" post="cells . Mol Cancer Res. 2006; 4( 6): 379–"/>
   <result pre="of BCAR4 in tamoxifen resistance and tumour aggressiveness of human" exact="breast cancer" post=". Br J Cancer. 2010; 103( 8): 1284– 91."/>
   <result pre="BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast" exact="cancer" post=". Br J Cancer. 2010; 103( 8): 1284– 91."/>
   <result pre="of BCAR4, a novel oncogene causing endocrine resistance in human" exact="breast cancer" post="cells . J Cell Physiol. 2011; 226: 1741– 49."/>
   <result pre="BCAR4, a novel oncogene causing endocrine resistance in human breast" exact="cancer" post="cells . J Cell Physiol. 2011; 226: 1741– 49."/>
   <result pre="activation mapping reveals molecular networks associated with antiestrogen resistance in" exact="breast cancer" post="cell lines . Int J Cancer. 2012; 131( 9):"/>
   <result pre="mapping reveals molecular networks associated with antiestrogen resistance in breast" exact="cancer" post="cell lines . Int J Cancer. 2012; 131( 9):"/>
   <result pre="IPH-926: a novel CDH1-null tumour cell line from human lobular" exact="breast cancer" post=". J Pathol. 2009; 217( 5): 620– 32. doi:"/>
   <result pre="a novel CDH1-null tumour cell line from human lobular breast" exact="cancer" post=". J Pathol. 2009; 217( 5): 620– 32. doi:"/>
   <result pre=", Christgen H , Geffers R et al. IPH-926 lobular" exact="breast cancer" post="cells harbor a p53 mutant with temperature-sensitive functional activity"/>
   <result pre="Christgen H , Geffers R et al. IPH-926 lobular breast" exact="cancer" post="cells harbor a p53 mutant with temperature-sensitive functional activity"/>
   <result pre="contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular" exact="breast cancer" post="cells . Cancer Lett. 2012; 315: 153– 60. doi:"/>
   <result pre="to the anticancer drug-resistant phenotype of IPH-926 human lobular breast" exact="cancer" post="cells . Cancer Lett. 2012; 315: 153– 60. doi:"/>
   <result pre="R , Kreipe H , Lehmann U . IPH-926 lobular" exact="breast cancer" post="cells are triple-negative but their microarray profile uncovers a"/>
   <result pre=", Kreipe H , Lehmann U . IPH-926 lobular breast" exact="cancer" post="cells are triple-negative but their microarray profile uncovers a"/>
   <result pre="of estrogen receptor-mediated gene repression and downregulated in primary human" exact="breast cancer" post=". Int J Cancer. 2008; 123( 10): 2239– 46."/>
   <result pre="estrogen receptor-mediated gene repression and downregulated in primary human breast" exact="cancer" post=". Int J Cancer. 2008; 123( 10): 2239– 46."/>
   <result pre=", Krech T et al. Oncogenic PIK3CA mutations in lobular" exact="breast cancer" post="progression. Genes Chromosomes Cancer. 2013; 52: 69– 80. doi:"/>
   <result pre="Krech T et al. Oncogenic PIK3CA mutations in lobular breast" exact="cancer" post="progression. Genes Chromosomes Cancer. 2013; 52: 69– 80. doi:"/>
   <result pre="index, HER2 status, and prognosis of patients with luminal B" exact="breast cancer." post="J Natl Cancer Inst. 2009; 101( 10): 736– 50."/>
   <result pre="S , McKinney S , Chia SK et al. Basal-like" exact="breast cancer" post="defined by five biomarkers has superior prognostic value than"/>
   <result pre=", McKinney S , Chia SK et al. Basal-like breast" exact="cancer" post="defined by five biomarkers has superior prognostic value than"/>
   <result pre="Foekens JA et al. BCAR4 induces antioestrogen resistance but sensitises" exact="breast cancer" post="to lapatinib. Br J Cancer. 2012; 107( 6): 947–"/>
   <result pre="JA et al. BCAR4 induces antioestrogen resistance but sensitises breast" exact="cancer" post="to lapatinib. Br J Cancer. 2012; 107( 6): 947–"/>
   <result pre="et al. Distinct gene mutation profiles among luminal-type and basal-type" exact="breast cancer" post="cell lines . Breast Cancer Res Treat. 2010; 121("/>
   <result pre="al. Distinct gene mutation profiles among luminal-type and basal-type breast" exact="cancer" post="cell lines . Breast Cancer Res Treat. 2010; 121("/>
   <result pre="oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional" exact="breast cancer" post="cohort . Breast Cancer Res Treat. 2011; 126( 3):"/>
   <result pre="DX recurrence scores on chemotherapy utilization in a multi-institutional breast" exact="cancer" post="cohort . Breast Cancer Res Treat. 2011; 126( 3):"/>
   <result pre="Downing SR et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular" exact="breast cancer" post="shows a high frequency of HER2 (ERBB2) gene mutations"/>
   <result pre="SR et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast" exact="cancer" post="shows a high frequency of HER2 (ERBB2) gene mutations"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4553016/results/search/disease/results.xml">
   <result pre="article, unless otherwise stated. Abstract Background Treatment for patients with" exact="breast cancer" post="(BC) is guided by human epidermal growth factor receptor"/>
   <result pre="unless otherwise stated. Abstract Background Treatment for patients with breast" exact="cancer" post="(BC) is guided by human epidermal growth factor receptor"/>
   <result pre="test results have far-reaching clinical and economic consequences. Background Breast" exact="cancer" post="is the most commonly diagnosed malignancy in women worldwide"/>
   <result pre="diagnosed malignancy in women worldwide and the leading cause of" exact="cancer" post="death in developed and developing countries [ 1]. Breast"/>
   <result pre="cancer death in developed and developing countries [ 1]. Breast" exact="cancer" post="accounted for an estimated 1.67 million new cancer cases"/>
   <result pre="1]. Breast cancer accounted for an estimated 1.67 million new" exact="cancer" post="cases worldwide and 522 000 of all cancer deaths"/>
   <result pre="million new cancer cases worldwide and 522 000 of all" exact="cancer" post="deaths in 2012 [ 2]. The management of patients"/>
   <result pre="deaths in 2012 [ 2]. The management of patients with" exact="breast cancer" post="is complex and depends on a combination of factors."/>
   <result pre="in 2012 [ 2]. The management of patients with breast" exact="cancer" post="is complex and depends on a combination of factors."/>
   <result pre="expression status [ 3]. Approximately 15–20 % of women with" exact="breast cancer" post="have tumours that overexpress HER2 [ 4]. HER2 positivity"/>
   <result pre="status [ 3]. Approximately 15–20 % of women with breast" exact="cancer" post="have tumours that overexpress HER2 [ 4]. HER2 positivity"/>
   <result pre="is the key to optimal treatment selection for patients with" exact="breast cancer." post="Tumour classification is based on morphological features and molecular"/>
   <result pre="ISH to assess tumour HER2 status for all patients with" exact="breast cancer." post="Both tests are used, in case an equivocal result"/>
   <result pre="inaccurate HER2 test results and subsequent treatment for patients with" exact="breast cancer." post="Methods Data sources HER2 IHC testing data were collected"/>
   <result pre="organisation. These data were used in an economic model of" exact="breast cancer" post="that was developed at Ventana Medical Systems, Inc./Roche. NordiQC"/>
   <result pre="These data were used in an economic model of breast" exact="cancer" post="that was developed at Ventana Medical Systems, Inc./Roche. NordiQC"/>
   <result pre="year, each of which contains a 5-core microarray slide of" exact="breast cancer" post="cores with varying predefined HER2 expression (0/1+/2+/3+) and amplification"/>
   <result pre="each of which contains a 5-core microarray slide of breast" exact="cancer" post="cores with varying predefined HER2 expression (0/1+/2+/3+) and amplification"/>
   <result pre="(0/1+/2+/3+) and amplification levels (both amplified and unamplified for 2+" exact="cancer" post="cores) as verified by using two IHC FDA/CE-IVD approved"/>
   <result pre="life and loss of productivity in patients with early stage" exact="breast cancer" post="(EBC; stage II and III disease) and receiving systemic"/>
   <result pre="and loss of productivity in patients with early stage breast" exact="cancer" post="(EBC; stage II and III disease) and receiving systemic"/>
   <result pre="receiving systemic treatment, as well as in those with metastatic" exact="breast cancer" post="(MBC; stage IV disease) as detailed below. When considering"/>
   <result pre="systemic treatment, as well as in those with metastatic breast" exact="cancer" post="(MBC; stage IV disease) as detailed below. When considering"/>
   <result pre="to the estimated numbers of patients receiving systemic treatment for" exact="breast cancer" post="in the US to correspond with the use of"/>
   <result pre="the estimated numbers of patients receiving systemic treatment for breast" exact="cancer" post="in the US to correspond with the use of"/>
   <result pre="were based on the estimated 232 340 patients with invasive" exact="breast cancer" post="in the USA in 2013 [ 20], 132 433"/>
   <result pre="based on the estimated 232 340 patients with invasive breast" exact="cancer" post="in the USA in 2013 [ 20], 132 433"/>
   <result pre="years for the laboratory-developed IVD tests. Extrapolation to the US" exact="breast cancer" post="population over a 1-year time horizon would give a"/>
   <result pre="for the laboratory-developed IVD tests. Extrapolation to the US breast" exact="cancer" post="population over a 1-year time horizon would give a"/>
   <result pre="and c QALYs missed in patients with early and metastatic" exact="breast cancer" post="based on US patient numbers and NordiQC FN and"/>
   <result pre="c QALYs missed in patients with early and metastatic breast" exact="cancer" post="based on US patient numbers and NordiQC FN and"/>
   <result pre="estimated prevalence of IHC 2+ cases (20 %). EBC, early" exact="breast cancer;" post="FN, false negative; FP, false positive; IHC, immunohistochemistry; IVD,"/>
   <result pre="false positive; IHC, immunohistochemistry; IVD, in vitro diagnostic; MBC, metastatic" exact="breast cancer;" post="QALY, quality-adjusted life-year The estimated effect of an FN"/>
   <result pre="IVD tests of 15 QALYs when applied to the US" exact="breast cancer" post="population (Fig. 3c). Economic cost of inaccurate results As"/>
   <result pre="tests of 15 QALYs when applied to the US breast" exact="cancer" post="population (Fig. 3c). Economic cost of inaccurate results As"/>
   <result pre="according to the estimated prevalence of immunohistochemistry scores Early stage" exact="breast cancer" post="Cost, US $ Approved IVD Laboratory-developed IVD Difference Direct"/>
   <result pre="to the estimated prevalence of immunohistochemistry scores Early stage breast" exact="cancer" post="Cost, US $ Approved IVD Laboratory-developed IVD Difference Direct"/>
   <result pre="data; weighted according to the estimated prevalence of immunohistochemistry Metastatic" exact="breast cancer" post="Outcome, US $ Approved IVD Laboratory-developed IVD Difference Direct"/>
   <result pre="weighted according to the estimated prevalence of immunohistochemistry Metastatic breast" exact="cancer" post="Outcome, US $ Approved IVD Laboratory-developed IVD Difference Direct"/>
   <result pre="the NordiQC laboratories, reagents for the primary testing of US" exact="breast cancer" post="patients with an approved IVD could potentially cost approximately"/>
   <result pre="NordiQC laboratories, reagents for the primary testing of US breast" exact="cancer" post="patients with an approved IVD could potentially cost approximately"/>
   <result pre="million) is therefore estimated at 2.5:1. Discussion HER2 expression in" exact="breast cancer" post="tissue is indicative of an aggressive pathology. HER2 expression"/>
   <result pre="is therefore estimated at 2.5:1. Discussion HER2 expression in breast" exact="cancer" post="tissue is indicative of an aggressive pathology. HER2 expression"/>
   <result pre="determination is fundamental to the success, safety and cost-effectiveness of" exact="breast cancer" post="treatment programmes. Analysis of HER2 status may be requested"/>
   <result pre="is fundamental to the success, safety and cost-effectiveness of breast" exact="cancer" post="treatment programmes. Analysis of HER2 status may be requested"/>
   <result pre="IVD tests [ 13]. In a German ring study of" exact="breast cancer" post="testing procedures, discordant results with a high percentage of"/>
   <result pre="tests [ 13]. In a German ring study of breast" exact="cancer" post="testing procedures, discordant results with a high percentage of"/>
   <result pre="in additional costs. Extrapolation of these results to the EU" exact="breast cancer" post="population, where the numbers of patients with EBC and"/>
   <result pre="additional costs. Extrapolation of these results to the EU breast" exact="cancer" post="population, where the numbers of patients with EBC and"/>
   <result pre="treatment advances made in recent years. Abbreviations EBC Early stage" exact="breast cancer" post="ER Oestrogen receptor FISH Fluorescence in situ hybridisation FN"/>
   <result pre="advances made in recent years. Abbreviations EBC Early stage breast" exact="cancer" post="ER Oestrogen receptor FISH Fluorescence in situ hybridisation FN"/>
   <result pre="ISH In situ hybridization IVD In vitro diagnostic MBC Metastatic" exact="breast cancer" post="NEQAS National External Quality Assessment Service NordiQC Nordic Immunohistochemistry"/>
   <result pre="In situ hybridization IVD In vitro diagnostic MBC Metastatic breast" exact="cancer" post="NEQAS National External Quality Assessment Service NordiQC Nordic Immunohistochemistry"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 69 90"/>
   <result pre="69 90 10.3322/caac.20107 21296855 2. Globocan Cancer Fact Sheet. Breast" exact="cancer" post="incidence, mortality and prevalence worldwide in 2012. [Cited 25"/>
   <result pre="receptor status, tumor characteristics, and prognosis: a prospective cohort of" exact="breast cancer" post="patients Breast Cancer Res 2007 9 R6 10.1186/bcr1639 17239243"/>
   <result pre="status, tumor characteristics, and prognosis: a prospective cohort of breast" exact="cancer" post="patients Breast Cancer Res 2007 9 R6 10.1186/bcr1639 17239243"/>
   <result pre="6. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast" exact="cancer" post="subtypes based on ER/PR and HER2 expression: comparison of"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2. N Engl J Med. 2001;344:783–92. 8."/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2. N Engl J Med. 2001;344:783–92. 8."/>
   <result pre="Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer." post="N Engl J Med. 2005;353:1659–772. 9. Slamon D, Eiermann"/>
   <result pre="Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer." post="N Engl J Med. 2011;365:1273–83. 10. ASCO–CAP HER2 test"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer." post="J Clin Oncol. 2007;25:118–45. 12. Wolff AC, Hammond ME,"/>
   <result pre="NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer." post="N Engl J Med. 2005;353:1673–84. 17. Koopmanschap M Burdorf"/>
   <result pre="A Kreipe H Proficiency testing of immunohistochemical biomarker assays in" exact="breast cancer" post="Virchows Arch 2008 453 537 543 10.1007/s00428-008-0688-4 18958494 22."/>
   <result pre="Kreipe H Proficiency testing of immunohistochemical biomarker assays in breast" exact="cancer" post="Virchows Arch 2008 453 537 543 10.1007/s00428-008-0688-4 18958494 22."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558113/results/search/disease/results.xml">
   <result pre="AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in" exact="breast cancer" post="Jhaveri Teraneh Z. 1 Woo Juhyung 1 Shang Xiaobin"/>
   <result pre="kinase (AMPK) regulates activity of HER2 and EGFR in breast" exact="cancer" post="Jhaveri Teraneh Z. 1 Woo Juhyung 1 Shang Xiaobin"/>
   <result pre="many types of cancers. Investigating effects of AMPK activation on" exact="breast cancer" post="cell signaling and survival, we found that breast cancer"/>
   <result pre="types of cancers. Investigating effects of AMPK activation on breast" exact="cancer" post="cell signaling and survival, we found that breast cancer"/>
   <result pre="on breast cancer cell signaling and survival, we found that" exact="breast cancer" post="cell lines with amplification and over-expression of HER2 or"/>
   <result pre="breast cancer cell signaling and survival, we found that breast" exact="cancer" post="cell lines with amplification and over-expression of HER2 or"/>
   <result pre="effects of AICAR, a canonical pharmacological activator of AMPK, than" exact="breast cancer" post="cell lines lacking HER2 or EGFR overexpression. Paralleling effects"/>
   <result pre="of AICAR, a canonical pharmacological activator of AMPK, than breast" exact="cancer" post="cell lines lacking HER2 or EGFR overexpression. Paralleling effects"/>
   <result pre="dose- and time-dependent inhibition of HER2 and EGFR in HER2-amplified" exact="breast cancer" post="cells, with activation of AMPK and suppression of HER2/EGFR"/>
   <result pre="and time-dependent inhibition of HER2 and EGFR in HER2-amplified breast" exact="cancer" post="cells, with activation of AMPK and suppression of HER2/EGFR"/>
   <result pre="in HER2-amplified breast cancer cells, with activation of AMPK and" exact="suppression" post="of HER2/EGFR activity preceding commitment to cell death. Transfection"/>
   <result pre="signaling associated with these receptor tyrosine kinases (RTKs), and reduced" exact="breast cancer" post="cell growth, confirming effects of AMPK activity on HER2/EGFR."/>
   <result pre="associated with these receptor tyrosine kinases (RTKs), and reduced breast" exact="cancer" post="cell growth, confirming effects of AMPK activity on HER2/EGFR."/>
   <result pre="postulate that AMPK regulates HER2 and EGFR activity in HER2-amplified" exact="breast cancer" post="cells and thus activation of AMPK might provide therapeutic"/>
   <result pre="that AMPK regulates HER2 and EGFR activity in HER2-amplified breast" exact="cancer" post="cells and thus activation of AMPK might provide therapeutic"/>
   <result pre="benefit in such cancers. AMP-activated protein kinase (AMPK) HER2 EGFR" exact="cancer" post="cell metabolism cancer therapy INTRODUCTION As the critical sensor"/>
   <result pre="cancers. AMP-activated protein kinase (AMPK) HER2 EGFR cancer cell metabolism" exact="cancer" post="therapy INTRODUCTION As the critical sensor of cellular energy,"/>
   <result pre="While AMPK has been proposed as a therapeutic target in" exact="breast cancer" post="and is recognized to inhibit many of the pathways"/>
   <result pre="AMPK has been proposed as a therapeutic target in breast" exact="cancer" post="and is recognized to inhibit many of the pathways"/>
   <result pre="RESULTS AMPK activation preferentially inhibits growth of HER2 and/or EGFR" exact="breast cancer" post="To determine how AMPK activation affects proliferation and survival"/>
   <result pre="AMPK activation preferentially inhibits growth of HER2 and/or EGFR breast" exact="cancer" post="To determine how AMPK activation affects proliferation and survival"/>
   <result pre="To determine how AMPK activation affects proliferation and survival of" exact="breast cancer" post="cells, we first screened a series of breast cancer"/>
   <result pre="determine how AMPK activation affects proliferation and survival of breast" exact="cancer" post="cells, we first screened a series of breast cancer"/>
   <result pre="of breast cancer cells, we first screened a series of" exact="breast cancer" post="cell lines for sensitivity to AICAR, the canonical activator"/>
   <result pre="breast cancer cells, we first screened a series of breast" exact="cancer" post="cell lines for sensitivity to AICAR, the canonical activator"/>
   <result pre="and 1B, we observed considerable variability in the sensitivity of" exact="breast cancer" post="cell lines to AICAR treatment, with breast cancer cell"/>
   <result pre="1B, we observed considerable variability in the sensitivity of breast" exact="cancer" post="cell lines to AICAR treatment, with breast cancer cell"/>
   <result pre="sensitivity of breast cancer cell lines to AICAR treatment, with" exact="breast cancer" post="cell lines known to have high expression of HER2"/>
   <result pre="of breast cancer cell lines to AICAR treatment, with breast" exact="cancer" post="cell lines known to have high expression of HER2"/>
   <result pre="inhibits the growth and reduces survival of EGFR- and HER2-activated" exact="breast cancer" post="cell lines A. MTT assay of breast cancer cell"/>
   <result pre="the growth and reduces survival of EGFR- and HER2-activated breast" exact="cancer" post="cell lines A. MTT assay of breast cancer cell"/>
   <result pre="and HER2-activated breast cancer cell lines A. MTT assay of" exact="breast cancer" post="cell line viability after 1mM AICAR treatment for 24"/>
   <result pre="HER2-activated breast cancer cell lines A. MTT assay of breast" exact="cancer" post="cell line viability after 1mM AICAR treatment for 24"/>
   <result pre="triplicate. C. Immunoblots measuring HER2 and EGFR levels in selected" exact="breast cancer" post="cell lines. Note that cell lines sensitive to AICAR"/>
   <result pre="C. Immunoblots measuring HER2 and EGFR levels in selected breast" exact="cancer" post="cell lines. Note that cell lines sensitive to AICAR"/>
   <result pre="to AICAR. G. EGF treatment rescues AICAR-mediated growth inhibition of" exact="breast cancer" post="cell lines in HCC1419 and BT474 cell lines. Representative"/>
   <result pre="AICAR. G. EGF treatment rescues AICAR-mediated growth inhibition of breast" exact="cancer" post="cell lines in HCC1419 and BT474 cell lines. Representative"/>
   <result pre="activation of EGFR signaling by exogenous ligand can protect HER2-amplified" exact="breast cancer" post="cells from AICAR-induced toxicity. As shown in Figure 1G,"/>
   <result pre="of EGFR signaling by exogenous ligand can protect HER2-amplified breast" exact="cancer" post="cells from AICAR-induced toxicity. As shown in Figure 1G,"/>
   <result pre="AICAR-induced toxicity. As shown in Figure 1G, co-treatment of HER2-positive" exact="breast cancer" post="cells with both EGF and AICAR resulted in significantly"/>
   <result pre="toxicity. As shown in Figure 1G, co-treatment of HER2-positive breast" exact="cancer" post="cells with both EGF and AICAR resulted in significantly"/>
   <result pre="Given the correlation between high HER2 or EGFR expression in" exact="breast cancer" post="cells and sensitivity to AMPK activation, we next sought"/>
   <result pre="the correlation between high HER2 or EGFR expression in breast" exact="cancer" post="cells and sensitivity to AMPK activation, we next sought"/>
   <result pre="cells (Figure 2C). Figure 2 AICAR treatment activates AMPK in" exact="breast cancer" post="cell lines A., B. Immunoblots show AICAR-dependent activation of"/>
   <result pre="(Figure 2C). Figure 2 AICAR treatment activates AMPK in breast" exact="cancer" post="cell lines A., B. Immunoblots show AICAR-dependent activation of"/>
   <result pre="phosphorylation of HER2 and EGFR at auto-phosphorylation activation sites in" exact="breast cancer" post="cells. Immunoblots show decreased levels of phosphorylated HER2 and"/>
   <result pre="of HER2 and EGFR at auto-phosphorylation activation sites in breast" exact="cancer" post="cells. Immunoblots show decreased levels of phosphorylated HER2 and"/>
   <result pre="mechanism to explain heightened sensitivity of HER2 and EGFR overexpressing" exact="breast cancer" post="cell lines to the AMPK activating agent, AICAR. Inhibition"/>
   <result pre="to explain heightened sensitivity of HER2 and EGFR overexpressing breast" exact="cancer" post="cell lines to the AMPK activating agent, AICAR. Inhibition"/>
   <result pre="in decreased HER2 activity and inhibition of growth of HER2-dependent" exact="breast cancer" post="cells. DISCUSSION In summary, we show evidence that activated"/>
   <result pre="decreased HER2 activity and inhibition of growth of HER2-dependent breast" exact="cancer" post="cells. DISCUSSION In summary, we show evidence that activated"/>
   <result pre="regulatory sites, leading to inhibition of growth and survival of" exact="breast cancer" post="cells that are dependent on these pathways. Our results"/>
   <result pre="sites, leading to inhibition of growth and survival of breast" exact="cancer" post="cells that are dependent on these pathways. Our results"/>
   <result pre="these protein kinases. Both HER2 and EGFR have importance in" exact="cancer" post="biology, however. For example, HER2 is amplified and overexpressed"/>
   <result pre="protein kinases implicated in driving human carcinogenesis. Key players in" exact="cancer" post="development and growth, HER2 and EGFR have emerged as"/>
   <result pre="surface HER2, is widely used in the treatment of HER2-overexpressing" exact="breast cancer" post="[ 31, 33- 35]. Lapatinib, a small molecule dual"/>
   <result pre="HER2, is widely used in the treatment of HER2-overexpressing breast" exact="cancer" post="[ 31, 33- 35]. Lapatinib, a small molecule dual"/>
   <result pre="of EGFR and HER2, is another therapeutic option for HER2-positive" exact="breast cancer" post="patients [ 36- 38], although it offers only a"/>
   <result pre="EGFR and HER2, is another therapeutic option for HER2-positive breast" exact="cancer" post="patients [ 36- 38], although it offers only a"/>
   <result pre="offers only a 4.3% response rate in patients with HER2-positive" exact="breast cancer" post="when used as monotherapy [ 39- 41]. While these"/>
   <result pre="only a 4.3% response rate in patients with HER2-positive breast" exact="cancer" post="when used as monotherapy [ 39- 41]. While these"/>
   <result pre="agents have shown efficacy in the treatment of HER2 overexpressing" exact="breast cancer," post="not all HER2- positive cancers respond even initially to"/>
   <result pre="augment trastuzumab's effectiveness and/or overcome trastuzumab resistance in HER2 positive" exact="breast cancer." post="Many breast cancers, particularly those that do not express"/>
   <result pre="progesterone receptor, or high levels of HER2 (i.e., triple negative" exact="breast cancer" post="(TNBC)) have high levels of expression of EGFR ["/>
   <result pre="receptor, or high levels of HER2 (i.e., triple negative breast" exact="cancer" post="(TNBC)) have high levels of expression of EGFR ["/>
   <result pre="RNAiMax (Invitrogen) according to the manufacturer's recommendation. Cell culture Human" exact="cancer" post="cell lines HCC1937, DU4475, BT549, HCC1806, HCC1954, MDA231, HCC1419,"/>
   <result pre="(Sigma). Incorporation of radioisotope was measured by scintillation counting. Breast" exact="cancer" post="xenografts For xenograft experiments, SKBR3 cells at ~50% confluence"/>
   <result pre="E AMPK and cell proliferation—AMPK as a therapeutic target for" exact="atherosclerosis" post="and cancer J Physiol 2006 574 63 71 16613876"/>
   <result pre="and cell proliferation—AMPK as a therapeutic target for atherosclerosis and" exact="cancer" post="J Physiol 2006 574 63 71 16613876 7 Carling"/>
   <result pre="AR Logsdon MN Blenis J Cantley LC Identification of the" exact="tuberous sclerosis" post="complex-2 tumor suppressor gene product tuberin as a target"/>
   <result pre="RJ The LKB1-AMPK pathway: metabolism and growth control in tumour" exact="suppression" post="Nat Rev Cancer 2009 9 563 75 19629071 15"/>
   <result pre="Fan C McNamara K Kozlowski P et al. LKB1 modulates" exact="lung cancer" post="differentiation and metastasis Nature 2007 448 807 10 17676035"/>
   <result pre="C McNamara K Kozlowski P et al. LKB1 modulates lung" exact="cancer" post="differentiation and metastasis Nature 2007 448 807 10 17676035"/>
   <result pre="G et al. Histological evaluation of AMPK signalling in primary" exact="breast cancer" post="BMC cancer 2009 9 307 19723334 18 Hadad SM"/>
   <result pre="et al. Histological evaluation of AMPK signalling in primary breast" exact="cancer" post="BMC cancer 2009 9 307 19723334 18 Hadad SM"/>
   <result pre="Histological evaluation of AMPK signalling in primary breast cancer BMC" exact="cancer" post="2009 9 307 19723334 18 Hadad SM Fleming S"/>
   <result pre="S Thompson AM Targeting AMPK: a new therapeutic opportunity in" exact="breast cancer" post="Crit Rev Oncol Hematol 2008 67 1 7 18343152"/>
   <result pre="Thompson AM Targeting AMPK: a new therapeutic opportunity in breast" exact="cancer" post="Crit Rev Oncol Hematol 2008 67 1 7 18343152"/>
   <result pre="phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for" exact="breast cancer" post="patients with hormone receptor-positive tumors Breast Cancer Res 2009"/>
   <result pre="at tyrosine 1221/1222 improves prediction of poor survival for breast" exact="cancer" post="patients with hormone receptor-positive tumors Breast Cancer Res 2009"/>
   <result pre="Roskoski R Jr The ErbB/HER family of protein-tyrosine kinases and" exact="cancer" post="Pharm Res 2014 79 34 74 30 Gravalos C"/>
   <result pre="Hortobagyi GN Hunt KK HER2/neu in the management of invasive" exact="breast cancer" post="J Am Col Surg 2002 194 488 501 32"/>
   <result pre="GN Hunt KK HER2/neu in the management of invasive breast" exact="cancer" post="J Am Col Surg 2002 194 488 501 32"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="factor receptor in relation to tumor development: EGFR gene and" exact="cancer" post="FEBS Journal 2010 277 301 08 19922469 34 Slamon"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="growth factor receptor 2 blockade for the treatment of HER2-positive" exact="breast cancer" post="Breast Cancer 2013 20 103 10 23377763 40 Bender"/>
   <result pre="factor receptor 2 blockade for the treatment of HER2-positive breast" exact="cancer" post="Breast Cancer 2013 20 103 10 23377763 40 Bender"/>
   <result pre="LM Nahta R Her2 cross talk and therapeutic resistance in" exact="breast cancer" post="Frontiers Biosci 2008 13 3906 12 41 Cameron D"/>
   <result pre="Nahta R Her2 cross talk and therapeutic resistance in breast" exact="cancer" post="Frontiers Biosci 2008 13 3906 12 41 Cameron D"/>
   <result pre="lapatinib plus capecitabine versus capecitabine alone in women with advanced" exact="breast cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="plus capecitabine versus capecitabine alone in women with advanced breast" exact="cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="Mechanisms of disease: understanding resistance to HER2-targeted therapy in human" exact="breast cancer" post="Nature Clin Prac Oncol 2006 3 269 80 44"/>
   <result pre="of disease: understanding resistance to HER2-targeted therapy in human breast" exact="cancer" post="Nature Clin Prac Oncol 2006 3 269 80 44"/>
   <result pre="A Cazet A et al. Therapeutic targets in triple negative" exact="breast cancer" post="J Clin Path 2013 66 530 42 23436929 45"/>
   <result pre="Cazet A et al. Therapeutic targets in triple negative breast" exact="cancer" post="J Clin Path 2013 66 530 42 23436929 45"/>
   <result pre="34 17671126 46 Foulkes WD Smith IE Reis-Filho JS Triple-negative" exact="breast cancer" post="N Engl J Med 2010 363 1938 48 21067385"/>
   <result pre="17671126 46 Foulkes WD Smith IE Reis-Filho JS Triple-negative breast" exact="cancer" post="N Engl J Med 2010 363 1938 48 21067385"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558136/results/search/disease/results.xml">
   <result pre="HER-2 and HER-3 expression in liver metastases of patients with" exact="colorectal cancer" post="Styczen Hanna 1 Nagelmeier Iris 2 Beissbarth Tim 3"/>
   <result pre="and HER-3 expression in liver metastases of patients with colorectal" exact="cancer" post="Styczen Hanna 1 Nagelmeier Iris 2 Beissbarth Tim 3"/>
   <result pre="HER-2 and HER-3 expression in liver metastases from patients with" exact="colorectal cancer" post="(CRLM). We analyzed the potential of HER-2 and HER-3"/>
   <result pre="and HER-3 expression in liver metastases from patients with colorectal" exact="cancer" post="(CRLM). We analyzed the potential of HER-2 and HER-3"/>
   <result pre="as novel targets to be addressed within multimodal treatment approaches." exact="colorectal cancer" post="HER-2 HER-3 targeted therapy liver metastases INTRODUCTION Colorectal cancer"/>
   <result pre="novel targets to be addressed within multimodal treatment approaches. colorectal" exact="cancer" post="HER-2 HER-3 targeted therapy liver metastases INTRODUCTION Colorectal cancer"/>
   <result pre="colorectal cancer HER-2 HER-3 targeted therapy liver metastases INTRODUCTION Colorectal" exact="cancer" post="(CRC) is the third most common cancer in the"/>
   <result pre="metastases INTRODUCTION Colorectal cancer (CRC) is the third most common" exact="cancer" post="in the United States and also the third leading"/>
   <result pre="the United States and also the third leading cause of" exact="cancer" post="related deaths [ 1]. High incidence rates of CRC"/>
   <result pre="in various solid tumors (for more than a decade in" exact="breast cancer" post="[ 18][ 19], more recently for gastric cancer ["/>
   <result pre="various solid tumors (for more than a decade in breast" exact="cancer" post="[ 18][ 19], more recently for gastric cancer ["/>
   <result pre="in breast cancer [ 18][ 19], more recently for gastric" exact="cancer" post="[ 20], esophageal adenocarcinoma [ 21], pancreatic [ 22]"/>
   <result pre="20], esophageal adenocarcinoma [ 21], pancreatic [ 22] and rectal" exact="cancer" post="[ 23]) and even more importantly as a potential"/>
   <result pre="a HER-2 positivity of 22.1% [ 20][ 24] in gastric" exact="cancer" post="and adenocarcinoma of the gastro-esophageal junction (overall n ="/>
   <result pre="a specific modified immunohistochemistry (IHC) scoring algorithm in comparison to" exact="breast cancer" post="[ 20][ 25]. Patients with overexpression of HER-2 (IHC"/>
   <result pre="specific modified immunohistochemistry (IHC) scoring algorithm in comparison to breast" exact="cancer" post="[ 20][ 25]. Patients with overexpression of HER-2 (IHC"/>
   <result pre="of 27% in resection specimens of patients with cUICC-II/-III rectal" exact="cancer" post="[ 21][ 23]. Both studies demonstrated the correlation of"/>
   <result pre="correlation of a high HER-2 expression with better survival in" exact="gastrointestinal cancer." post="On the contrary, in breast cancer HER-2 positivity seems"/>
   <result pre="with better survival in gastrointestinal cancer. On the contrary, in" exact="breast cancer" post="HER-2 positivity seems to be associated with a higher"/>
   <result pre="better survival in gastrointestinal cancer. On the contrary, in breast" exact="cancer" post="HER-2 positivity seems to be associated with a higher"/>
   <result pre="revealed heterogeneous or focal expression (≤ 30% of HER-2 positive" exact="cancer" post="cells) of HER-2. Positivity of HER-2 status was found"/>
   <result pre="HER-2 was in trend more often overexpressed in metastases of" exact="colon cancer" post="( n = 8; 12.1%) compared to metastases of"/>
   <result pre="was in trend more often overexpressed in metastases of colon" exact="cancer" post="( n = 8; 12.1%) compared to metastases of"/>
   <result pre="64 125 (93.3%) 9 (6.7%) 36 (26.9%) 98 (73.1%) No" exact="cancer" post="related death 14 7 14 (100%) 0 NS 3"/>
   <result pre="14 (63.6%) Within the 22 matched paired samples, 4 primary" exact="cancer" post="samples and 2 CRLM samples showed HER-2 overexpression but"/>
   <result pre="metastases ( n = 72; 80%) and in metastases of" exact="colon cancer" post="( n = 52; 78.8%). Correlation of HER-2 and"/>
   <result pre="( n = 72; 80%) and in metastases of colon" exact="cancer" post="( n = 52; 78.8%). Correlation of HER-2 and"/>
   <result pre="expression (75% of tissue specimens had ≤30% of HER-2/HER-3 positive" exact="cancer" post="cells) as observed in previously published studies in gastrointestinal"/>
   <result pre="positive cancer cells) as observed in previously published studies in" exact="gastrointestinal cancer" post="[ 20][ 23]. The frequency of exclusive membrane staining"/>
   <result pre="cancer cells) as observed in previously published studies in gastrointestinal" exact="cancer" post="[ 20][ 23]. The frequency of exclusive membrane staining"/>
   <result pre="et al. [ 29] ( n = 236) and in" exact="colon cancer" post="patients by Beji et al. [ 34] ( n"/>
   <result pre="al. [ 29] ( n = 236) and in colon" exact="cancer" post="patients by Beji et al. [ 34] ( n"/>
   <result pre="HER-2 expression was found mainly in primary tumors in rectal" exact="cancer" post="patients ( n = 4; 18.2%). The rate of"/>
   <result pre="HER-2 might be induced by multimodal treatment, as described for" exact="breast cancer" post="[ 47][ 48] or is an effect of metastatic"/>
   <result pre="might be induced by multimodal treatment, as described for breast" exact="cancer" post="[ 47][ 48] or is an effect of metastatic"/>
   <result pre="that 22 matched pairs of CRLM samples and corresponding primary" exact="cancer" post="resection specimens were available for further analyses. HER-2 immunostaining"/>
   <result pre="HER-3 according to the magnification rule as adopted from gastric" exact="cancer" post="scoring for HER-2. *in ≥10% tumor cells in resection"/>
   <result pre="was defined as time from surgery of the metastasis and" exact="cancer" post="related death. The p-value was set to p &amp;lt;"/>
   <result pre="808 11009523 4 Wilmink AB Overview of the epidemiology of" exact="colorectal cancer" post="Dis Colon Rectum 1997 40 483 493 9106701 5"/>
   <result pre="11009523 4 Wilmink AB Overview of the epidemiology of colorectal" exact="cancer" post="Dis Colon Rectum 1997 40 483 493 9106701 5"/>
   <result pre="fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal" exact="cancer" post="after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2,"/>
   <result pre="Schmidberger H Raab R Preoperative versus postoperative chemoradiotherapy for rectal" exact="cancer" post="N Engl J Med 2004 351 1731 40 15496622"/>
   <result pre="MacFarlane JK Ryall RD Heald RJ Mesorectal excision for rectal" exact="cancer" post="Lancet 1993 341 457 60 8094488 9 Homayounfar K"/>
   <result pre="Mochizuki H Yamamoto J Therapeutic results for hepatic metastasis of" exact="colorectal cancer" post="with special reference to effectiveness of hepatectomy: analysis of"/>
   <result pre="H Yamamoto J Therapeutic results for hepatic metastasis of colorectal" exact="cancer" post="with special reference to effectiveness of hepatectomy: analysis of"/>
   <result pre="sequential and combination chemotherapy for patients with poor prognosis advanced" exact="colorectal cancer" post="(MRC FOCUS): a randomised controlled trial Lancet 2007 370"/>
   <result pre="and combination chemotherapy for patients with poor prognosis advanced colorectal" exact="cancer" post="(MRC FOCUS): a randomised controlled trial Lancet 2007 370"/>
   <result pre="versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced" exact="colorectal cancer" post="(CAIRO): a phase III randomised controlled trial Lancet 2007"/>
   <result pre="combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal" exact="cancer" post="(CAIRO): a phase III randomised controlled trial Lancet 2007"/>
   <result pre="Barrios CH et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1659 72 16236737"/>
   <result pre="CH et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1659 72 16236737"/>
   <result pre="L et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1673 84 16236738"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1673 84 16236738"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="K HER2 overexpression correlates with survival after curative resection of" exact="pancreatic cancer" post="Cancer Sci 2009 100 1243 7 19432892 23 Conradi"/>
   <result pre="HER2 overexpression correlates with survival after curative resection of pancreatic" exact="cancer" post="Cancer Sci 2009 100 1243 7 19432892 23 Conradi"/>
   <result pre="Middel P et al. Frequency of HER-2 positivity in rectal" exact="cancer" post="and prognosis Am J Surg Pathol 2013 37 522"/>
   <result pre="data from ToGA: targeting HER2 in gastric and gastroesophageal junction" exact="cancer" post="Gastric Cancer 2014 [Epub ahead of print] 25 Hofmann"/>
   <result pre="Öhrling K Edler D HER3 expression in patients with primary" exact="colorectal cancer" post="and corresponding lymph node metastases related to clinical outcome"/>
   <result pre="K Edler D HER3 expression in patients with primary colorectal" exact="cancer" post="and corresponding lymph node metastases related to clinical outcome"/>
   <result pre="mRNA expression levels predict distant metastases in locally advanced rectal" exact="cancer" post="Int J Cancer 2011 128 2938 46 20824716 31"/>
   <result pre="value of coexpressed erbB family members for the survival of" exact="colorectal cancer" post="patients after curative surgery Eur J Cancer 2002 38"/>
   <result pre="of coexpressed erbB family members for the survival of colorectal" exact="cancer" post="patients after curative surgery Eur J Cancer 2002 38"/>
   <result pre="human epidermal growth factor receptor 2-positive locally advanced or metastatic" exact="breast cancer" post="Cancer 2014 120 642 651 24222194 38 Alba E"/>
   <result pre="epidermal growth factor receptor 2-positive locally advanced or metastatic breast" exact="cancer" post="Cancer 2014 120 642 651 24222194 38 Alba E"/>
   <result pre="HER-3 expression in the prediction of clinical outcome for advanced" exact="colorectal cancer" post="patients receiving irinotecan and cetuximab Oncologist 2011 16 53"/>
   <result pre="expression in the prediction of clinical outcome for advanced colorectal" exact="cancer" post="patients receiving irinotecan and cetuximab Oncologist 2011 16 53"/>
   <result pre="GC Ferreira FO Nakagawa WT ErbB family immunohistochemical expression in" exact="colorectal cancer" post="patients with higher risk of recurrence after radical surgery"/>
   <result pre="Ferreira FO Nakagawa WT ErbB family immunohistochemical expression in colorectal" exact="cancer" post="patients with higher risk of recurrence after radical surgery"/>
   <result pre="GD Sinicrope FA HER-2 receptor expression, localization, and activation in" exact="colorectal cancer" post="cell lines and human tumors Int J Cancer 2004"/>
   <result pre="Sinicrope FA HER-2 receptor expression, localization, and activation in colorectal" exact="cancer" post="cell lines and human tumors Int J Cancer 2004"/>
   <result pre="in ER, PR, and HER2 receptors after neoadjuvant chemotherapy in" exact="breast cancer" post="Cancer Treat Rev 2011 37 422 30 21177040 48"/>
   <result pre="ER, PR, and HER2 receptors after neoadjuvant chemotherapy in breast" exact="cancer" post="Cancer Treat Rev 2011 37 422 30 21177040 48"/>
   <result pre="results of the phase II DUX study in chemotherapy-refractory, advanced" exact="colorectal cancer" post="J Clin Oncol 2012 30 1505 12 22412142 51"/>
   <result pre="of the phase II DUX study in chemotherapy-refractory, advanced colorectal" exact="cancer" post="J Clin Oncol 2012 30 1505 12 22412142 51"/>
   <result pre="Marsoni S Therapeutic dual inhibition of HER2 pathway for metastatic" exact="colorectal cancer" post="(mCRC): The HERACLES trial J Clin Oncol 33 2015"/>
   <result pre="S Therapeutic dual inhibition of HER2 pathway for metastatic colorectal" exact="cancer" post="(mCRC): The HERACLES trial J Clin Oncol 33 2015"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558503/results/search/disease/results.xml">
   <result pre="Phosphorylation of the PTK6 substrates focal adhesion kinase (FAK) and" exact="breast cancer" post="anti-estrogen resistance 1 (BCAR1; p130CAS) was decreased in Ptk6"/>
   <result pre="of the PTK6 substrates focal adhesion kinase (FAK) and breast" exact="cancer" post="anti-estrogen resistance 1 (BCAR1; p130CAS) was decreased in Ptk6"/>
   <result pre="STAT3, FAK, and BCAR1 as physiologically relevant PTK6 substrates in" exact="breast cancer." post="Including PTK6 inhibitors as part of a treatment regimen"/>
   <result pre="regimen could have distinct benefits in ERBB2/HER2-positive breast cancers. Breast" exact="cancer" post="remains the second leading cause of death for women"/>
   <result pre="growth factor receptor family tyrosine kinase ERBB2 (HER2, Neu) in" exact="breast cancer" post="2, 3 has made it a prominent therapeutic target."/>
   <result pre="factor receptor family tyrosine kinase ERBB2 (HER2, Neu) in breast" exact="cancer" post="2, 3 has made it a prominent therapeutic target."/>
   <result pre="3 (STAT3), 15, 16 focal adhesion kinase (FAK), 17 and" exact="breast cancer" post="anti-estrogen resistance 1 (BCAR1 also known as p130CAS). 18"/>
   <result pre="(STAT3), 15, 16 focal adhesion kinase (FAK), 17 and breast" exact="cancer" post="anti-estrogen resistance 1 (BCAR1 also known as p130CAS). 18"/>
   <result pre="tumor initiation and metastasis in the MMTV-ERBB2 mouse model of" exact="breast cancer." post="We previously showed that PTK6 expression is induced in"/>
   <result pre="negative regulation of calpain, a calcium-dependent, non-lysosomal cysteine protease, in" exact="breast cancer" post="cell lines. 25 PTK6 expression is also regulated at"/>
   <result pre="regulation of calpain, a calcium-dependent, non-lysosomal cysteine protease, in breast" exact="cancer" post="cell lines. 25 PTK6 expression is also regulated at"/>
   <result pre="STAT3 activation and tumorigenesis in mouse models of colon and" exact="skin cancer." post="19 , 22 We show that mammary tumor latency"/>
   <result pre="34 and activation of STAT3 has been detected in human" exact="breast cancer" post="stem cell models. 35 We found that disruption of"/>
   <result pre="and activation of STAT3 has been detected in human breast" exact="cancer" post="stem cell models. 35 We found that disruption of"/>
   <result pre="transgenic mice led to delayed and reduced tumor formation and" exact="suppression" post="of tumor progression. 39 We detected impaired phosphorylation of"/>
   <result pre="PTK6, and that BCAR1 was important for oncogenic signaling in" exact="prostate cancer" post="cells. 18 Several studies with human tumor cell lines"/>
   <result pre="and that BCAR1 was important for oncogenic signaling in prostate" exact="cancer" post="cells. 18 Several studies with human tumor cell lines"/>
   <result pre="human tumor cell lines have suggested PTK6 contributes to ERBB2-induced" exact="breast cancer." post="A recent study showed that siRNA mediated knockdown of"/>
   <result pre="siRNA mediated knockdown of both PTK6 and ERBB2 in human" exact="breast cancer" post="cell lines additively impairs xenograft tumor growth. 45 Recently,"/>
   <result pre="mediated knockdown of both PTK6 and ERBB2 in human breast" exact="cancer" post="cell lines additively impairs xenograft tumor growth. 45 Recently,"/>
   <result pre="identified as a kinase that is differentially regulated in ERBB2-positive" exact="breast cancer" post="cells that develop resistance to lapatinib, 46 and shRNA"/>
   <result pre="as a kinase that is differentially regulated in ERBB2-positive breast" exact="cancer" post="cells that develop resistance to lapatinib, 46 and shRNA"/>
   <result pre="of PTK6 reduced growth and promoted apoptosis of lapatinib-resistant ERBB2-positive" exact="breast cancer" post="cell lines. 47 For the first time, we have"/>
   <result pre="PTK6 reduced growth and promoted apoptosis of lapatinib-resistant ERBB2-positive breast" exact="cancer" post="cell lines. 47 For the first time, we have"/>
   <result pre="and metastasis in vivo in a mouse model of ERBB2-induced" exact="breast cancer." post="We have determined that PTK6 promotes tumor initiation and"/>
   <result pre="and activator of transcription 3 FAK focal adhesion kinase BCAR1" exact="breast cancer" post="anti-estrogen resistance 1 B2; Ptk6 +/+ MMTV-ERBB2 transgenic mouse"/>
   <result pre="activator of transcription 3 FAK focal adhesion kinase BCAR1 breast" exact="cancer" post="anti-estrogen resistance 1 B2; Ptk6 +/+ MMTV-ERBB2 transgenic mouse"/>
   <result pre="between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary" exact="breast cancer" post="J Natl Cancer Inst 2003 95 142 153 12529347"/>
   <result pre="HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast" exact="cancer" post="J Natl Cancer Inst 2003 95 142 153 12529347"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer" post="Science 1989 244 707 712 2470152 Jones KL Buzdar"/>
   <result pre="Studies of the HER-2/neu proto-oncogene in human breast and ovarian" exact="cancer" post="Science 1989 244 707 712 2470152 Jones KL Buzdar"/>
   <result pre="Pohlmann PR Mayer IA Mernaugh R Resistance to trastuzumab in" exact="breast cancer" post="Clin Cancer Res 2009 15 7479 7491 Brauer PM"/>
   <result pre="PR Mayer IA Mernaugh R Resistance to trastuzumab in breast" exact="cancer" post="Clin Cancer Res 2009 15 7479 7491 Brauer PM"/>
   <result pre="regulates heregulin-induced activation of ERK5 and p38 MAP kinases in" exact="breast cancer" post="cells Cancer Res 2007 67 4199 4209 17483331 Xiang"/>
   <result pre="heregulin-induced activation of ERK5 and p38 MAP kinases in breast" exact="cancer" post="cells Cancer Res 2007 67 4199 4209 17483331 Xiang"/>
   <result pre="al. Brk is coamplified with ErbB2 to promote proliferation in" exact="breast cancer" post="Proc Natl Acad Sci USA 2008 105 12463 12468"/>
   <result pre="Brk is coamplified with ErbB2 to promote proliferation in breast" exact="cancer" post="Proc Natl Acad Sci USA 2008 105 12463 12468"/>
   <result pre="(PTK6) on human epidermal growth factor receptor (HER) signalling in" exact="breast cancer" post="Mol Biosyst 2011 7 1603 1612 21380407 Ludyga N"/>
   <result pre="on human epidermal growth factor receptor (HER) signalling in breast" exact="cancer" post="Mol Biosyst 2011 7 1603 1612 21380407 Ludyga N"/>
   <result pre="HER2 and PTK6 on malignancy and tumor progression in human" exact="breast cancer" post="cells Mol Cancer Res 2013 11 381 392 23364537"/>
   <result pre="and PTK6 on malignancy and tumor progression in human breast" exact="cancer" post="cells Mol Cancer Res 2013 11 381 392 23364537"/>
   <result pre="Fan Z Brk/PTK6 cooperates with HER2 and Src in regulating" exact="breast cancer" post="cell survival and epithelial-to-mesenchymal transition Cancer Biol Ther 2013"/>
   <result pre="Z Brk/PTK6 cooperates with HER2 and Src in regulating breast" exact="cancer" post="cell survival and epithelial-to-mesenchymal transition Cancer Biol Ther 2013"/>
   <result pre="al. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated" exact="breast cancer" post="progression Cancer Res 2013 73 5810 5820 23928995 Pires"/>
   <result pre="Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast" exact="cancer" post="progression Cancer Res 2013 73 5810 5820 23928995 Pires"/>
   <result pre="M The unholy trinity: inflammation, cytokines, and STAT3 shape the" exact="cancer" post="microenvironment Cancer Cell 2011 19 429 431 21481782 Grivennikov"/>
   <result pre="M Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in" exact="cancer" post="Cytokine Growth Factor Rev 2010 21 11 19 20018552"/>
   <result pre="A Bromberg J Stat3 is required for the development of" exact="skin cancer" post="J Clin Invest 2004 114 619 622 15343379 Ranger"/>
   <result pre="Bromberg J Stat3 is required for the development of skin" exact="cancer" post="J Clin Invest 2004 114 619 622 15343379 Ranger"/>
   <result pre="activated preferentially in tumor-initiating cells in claudin-low models of human" exact="breast cancer" post="Stem Cells 2014 32 2571 2582 24891218 Sulzmaier FJ"/>
   <result pre="preferentially in tumor-initiating cells in claudin-low models of human breast" exact="cancer" post="Stem Cells 2014 32 2571 2582 24891218 Sulzmaier FJ"/>
   <result pre="homologue of the adapter protein p130Cas, and antiestrogen resistance in" exact="breast cancer" post="cells J Natl Cancer Inst 2000 92 112 120"/>
   <result pre="of the adapter protein p130Cas, and antiestrogen resistance in breast" exact="cancer" post="cells J Natl Cancer Inst 2000 92 112 120"/>
   <result pre="domain signaling promotes migration, invasion, and survival of estrogen receptor-negative" exact="breast cancer" post="cells Breast Cancer (Lond) 2009 1 39 52 Meenderink"/>
   <result pre="signaling promotes migration, invasion, and survival of estrogen receptor-negative breast" exact="cancer" post="cells Breast Cancer (Lond) 2009 1 39 52 Meenderink"/>
   <result pre="HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced" exact="breast cancer" post="progression in vivo Mol Oncol 2015 9 282 294"/>
   <result pre="on interactions with HER3 or IGF-1R leads to reduced breast" exact="cancer" post="progression in vivo Mol Oncol 2015 9 282 294"/>
   <result pre="JS et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive" exact="breast cancer" post="by targeting BET family bromodomains Cell Rep 2015 11"/>
   <result pre="et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast" exact="cancer" post="by targeting BET family bromodomains Cell Rep 2015 11"/>
   <result pre="G Irie HY PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2" exact="breast cancer" post="cells by inducing Bim Breast Cancer Res 2015 17"/>
   <result pre="Irie HY PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2 breast" exact="cancer" post="cells by inducing Bim Breast Cancer Res 2015 17"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558517/results/search/disease/results.xml">
   <result pre="Original Article Activation of RAR α induces autophagy in SKBR3" exact="breast cancer" post="cells and depletion of key autophagy genes enhances ATRA"/>
   <result pre="Article Activation of RAR α induces autophagy in SKBR3 breast" exact="cancer" post="cells and depletion of key autophagy genes enhances ATRA"/>
   <result pre="of key autophagy genes enhances ATRA toxicity Retinoid-induced autophagy in" exact="breast cancer" post="cells Brigger D 1 2 4 Schläfli A M"/>
   <result pre="key autophagy genes enhances ATRA toxicity Retinoid-induced autophagy in breast" exact="cancer" post="cells Brigger D 1 2 4 Schläfli A M"/>
   <result pre="preclinical studies have shown promising anticancer effects of ATRA in" exact="breast cancer;" post="on the other hand, resistances occurred. Autophagy is a"/>
   <result pre="induces autophagic flux in ATRA-sensitive but not in ATRA-resistant human" exact="breast cancer" post="cells. Moreover, using different RAR agonists as well as"/>
   <result pre="autophagic flux in ATRA-sensitive but not in ATRA-resistant human breast" exact="cancer" post="cells. Moreover, using different RAR agonists as well as"/>
   <result pre="Moreover, using different RAR agonists as well as RAR α-knockdown" exact="breast cancer" post="cells, we demonstrate that autophagy is dependent on RAR"/>
   <result pre="using different RAR agonists as well as RAR α-knockdown breast" exact="cancer" post="cells, we demonstrate that autophagy is dependent on RAR"/>
   <result pre="dependent on RAR α activation. Interestingly, inhibition of autophagy in" exact="breast cancer" post="cells by either genetic or pharmacological approaches resulted in"/>
   <result pre="on RAR α activation. Interestingly, inhibition of autophagy in breast" exact="cancer" post="cells by either genetic or pharmacological approaches resulted in"/>
   <result pre="demonstrate that ATRA-induced autophagy is mediated by RAR α in" exact="breast cancer" post="cells. Furthermore, inhibition of autophagy results in enhanced apoptosis."/>
   <result pre="that ATRA-induced autophagy is mediated by RAR α in breast" exact="cancer" post="cells. Furthermore, inhibition of autophagy results in enhanced apoptosis."/>
   <result pre="a potential novel treatment strategy for a selected group of" exact="breast cancer" post="patients where ATRA and autophagy inhibitors are applied simultaneously."/>
   <result pre="potential novel treatment strategy for a selected group of breast" exact="cancer" post="patients where ATRA and autophagy inhibitors are applied simultaneously."/>
   <result pre="erythrocyte, lymphocyte or adipocyte differentiation. 3 In the context of" exact="cancer" post="and cancer therapy, autophagy is a double-edged sword. Owing"/>
   <result pre="or adipocyte differentiation. 3 In the context of cancer and" exact="cancer" post="therapy, autophagy is a double-edged sword. Owing to its"/>
   <result pre="suggested to be tumor suppressive under normal conditions. 4 In" exact="cancer" post="cells, however, autophagy can be oncogenic, enabling survival under"/>
   <result pre="pathophysiology. 8 ATRA is successfully used in the treatment of" exact="acute promyelocytic leukemia" post="(APL), where it induces granulocytic differentiation of the blast"/>
   <result pre="ATRA is successfully used in the treatment of acute promyelocytic" exact="leukemia" post="(APL), where it induces granulocytic differentiation of the blast"/>
   <result pre="RAR α, RAR β and RAR γ. 13, 14 In" exact="breast cancer," post="preclinical studies have shown that retinoids are promising therapeutic"/>
   <result pre="possibly as a consequence of the study designs. 15 Breast" exact="cancer" post="is a highly heterogeneous disease represented as a collection"/>
   <result pre="receptor) and HER2 (human epidermal growth factor receptor-2) receptors. ER-positive" exact="breast cancer" post="patients are eligible for hormonal therapies, whereas HER2 oncogenic"/>
   <result pre="and HER2 (human epidermal growth factor receptor-2) receptors. ER-positive breast" exact="cancer" post="patients are eligible for hormonal therapies, whereas HER2 oncogenic"/>
   <result pre="NB4 9, 10, 11 and retinoids have clinical relevance in" exact="breast cancer." post="Thus, we investigated whether and how autophagy is induced"/>
   <result pre="Thus, we investigated whether and how autophagy is induced in" exact="breast cancer" post="cells. In addition, we evaluated whether autophagy modulation represents"/>
   <result pre="we investigated whether and how autophagy is induced in breast" exact="cancer" post="cells. In addition, we evaluated whether autophagy modulation represents"/>
   <result pre="represents a potential therapeutic strategy for potentiating ATRA cytotoxicity in" exact="breast cancer" post="cells. Results ATRA initiates a dose- and time-dependent autophagic"/>
   <result pre="a potential therapeutic strategy for potentiating ATRA cytotoxicity in breast" exact="cancer" post="cells. Results ATRA initiates a dose- and time-dependent autophagic"/>
   <result pre="in SKBR3 cells To determine whether ATRA modulates autophagy in" exact="breast cancer" post="cells, we first measured steady-state levels of the autophagy"/>
   <result pre="SKBR3 cells To determine whether ATRA modulates autophagy in breast" exact="cancer" post="cells, we first measured steady-state levels of the autophagy"/>
   <result pre="the autophagy marker LC3B-II in the two luminal, HER2-positive ER-negative" exact="breast cancer" post="cell lines, SKBR3 (HER2/RAR α coamplification) and MDA-MB453 (HER2"/>
   <result pre="autophagy marker LC3B-II in the two luminal, HER2-positive ER-negative breast" exact="cancer" post="cell lines, SKBR3 (HER2/RAR α coamplification) and MDA-MB453 (HER2"/>
   <result pre="as BafA, indicating that retinoids preferentially induce macroautophagy in retinoid-sensitive" exact="breast cancer" post="cells ( Figure 1g). As a third assay to"/>
   <result pre="BafA, indicating that retinoids preferentially induce macroautophagy in retinoid-sensitive breast" exact="cancer" post="cells ( Figure 1g). As a third assay to"/>
   <result pre="As a third assay to assess autophagic flux in our" exact="breast cancer" post="cells, we took advantage of a Cherry-GFP-LC3B tandem construct."/>
   <result pre="a third assay to assess autophagic flux in our breast" exact="cancer" post="cells, we took advantage of a Cherry-GFP-LC3B tandem construct."/>
   <result pre="we report that ATRA induces autophagic flux in retinoid-sensitive SKBR3" exact="breast cancer" post="cells via RAR α. In contrast, autophagy activation is"/>
   <result pre="report that ATRA induces autophagic flux in retinoid-sensitive SKBR3 breast" exact="cancer" post="cells via RAR α. In contrast, autophagy activation is"/>
   <result pre="to directly link macroautophagy induction to RAR α activation in" exact="breast cancer" post="cell lines. We hypothesize that ATRA induces autophagy only"/>
   <result pre="directly link macroautophagy induction to RAR α activation in breast" exact="cancer" post="cell lines. We hypothesize that ATRA induces autophagy only"/>
   <result pre="cell lines. We hypothesize that ATRA induces autophagy only in" exact="breast cancer" post="cells that are not terminally differentiated and can be"/>
   <result pre="lines. We hypothesize that ATRA induces autophagy only in breast" exact="cancer" post="cells that are not terminally differentiated and can be"/>
   <result pre="depleting RAR α induced 3-MA-sensitive autophagy, our results in differentiation-competent" exact="breast cancer" post="cells show that RAR α depletion abrogates 3-MA-sensitive proteolysis."/>
   <result pre="RAR α induced 3-MA-sensitive autophagy, our results in differentiation-competent breast" exact="cancer" post="cells show that RAR α depletion abrogates 3-MA-sensitive proteolysis."/>
   <result pre="induction in non-terminally differentiated cells. A novel treatment strategy for" exact="breast cancer" post="may involve combinations of retinoids and autophagy inhibitors with"/>
   <result pre="in non-terminally differentiated cells. A novel treatment strategy for breast" exact="cancer" post="may involve combinations of retinoids and autophagy inhibitors with"/>
   <result pre="autophagy inhibitors with the aim of shortening the survival of" exact="breast cancer" post="cells. Several groups identified a role for autophagy in"/>
   <result pre="inhibitors with the aim of shortening the survival of breast" exact="cancer" post="cells. Several groups identified a role for autophagy in"/>
   <result pre="autophagy, which in turn delays apoptotic cell death in noninvasive" exact="breast cancer." post="26 Somewhat conflicting data exist on the role of"/>
   <result pre="Furthermore, inhibition of epirubicin-triggered autophagy enhances therapeutic efficiency in MDA-MB-231" exact="breast cancer" post="cells. 29 Given the possible role for autophagy as"/>
   <result pre="inhibition of epirubicin-triggered autophagy enhances therapeutic efficiency in MDA-MB-231 breast" exact="cancer" post="cells. 29 Given the possible role for autophagy as"/>
   <result pre="the tumor response to autophagy individually for each type of" exact="cancer" post="and therapy condition. Our results clearly support a model"/>
   <result pre="mechanism how blocking autophagy contributes to cell death in ATRA-sensitive" exact="breast cancer" post="cells remains to be elucidated. Autophagy and cellular differentiation"/>
   <result pre="how blocking autophagy contributes to cell death in ATRA-sensitive breast" exact="cancer" post="cells remains to be elucidated. Autophagy and cellular differentiation"/>
   <result pre="have great therapeutic potential. 38 For example, CD44 inhibition in" exact="breast cancer" post="stem cells results in differentiation and enhanced drug sensitivity."/>
   <result pre="great therapeutic potential. 38 For example, CD44 inhibition in breast" exact="cancer" post="stem cells results in differentiation and enhanced drug sensitivity."/>
   <result pre="differentiation and enhanced drug sensitivity. 39 Similarly, ATRA-dependent differentiation of" exact="cancer" post="stem cells reduces the formation of mammospheres and the"/>
   <result pre="the formation of mammospheres and the tumor-initiating potential of certain" exact="breast cancer" post="cell lines. 40 We now show that autophagy once"/>
   <result pre="formation of mammospheres and the tumor-initiating potential of certain breast" exact="cancer" post="cell lines. 40 We now show that autophagy once"/>
   <result pre="(Huston, TX, USA), respectively. Cell lines and culture conditions Human" exact="breast cancer" post="lines MDA-MB-453 and SKBR3 were cultured in DMEM/F12 supplemented"/>
   <result pre="TX, USA), respectively. Cell lines and culture conditions Human breast" exact="cancer" post="lines MDA-MB-453 and SKBR3 were cultured in DMEM/F12 supplemented"/>
   <result pre="PBS-T. Fluorescence microscopy of GFP-Cherry-LC3B expressing SKBR3 and MDA-MB-453 human" exact="breast cancer" post="cell lines was performed as described in Brigger et"/>
   <result pre="Fluorescence microscopy of GFP-Cherry-LC3B expressing SKBR3 and MDA-MB-453 human breast" exact="cancer" post="cell lines was performed as described in Brigger et"/>
   <result pre="December 2013 in memory of Simone Riedo, who died from" exact="breast cancer" post="in 2008. ATRA all- trans retinoic acid RAR retinoic"/>
   <result pre="2013 in memory of Simone Riedo, who died from breast" exact="cancer" post="in 2008. ATRA all- trans retinoic acid RAR retinoic"/>
   <result pre="ATRA all- trans retinoic acid RAR retinoic acid receptor APL" exact="acute promyelocytic leukemia" post="HER2 human epidermal growth factor receptor-2 LC3 (MAP1LC3) microtubule-associated"/>
   <result pre="trans retinoic acid RAR retinoic acid receptor APL acute promyelocytic" exact="leukemia" post="HER2 human epidermal growth factor receptor-2 LC3 (MAP1LC3) microtubule-associated"/>
   <result pre="830 20811354 Chen H-Y White E Role of autophagy in" exact="cancer" post="prevention Cancer Prev Res (Phila) 2011 4 973 983"/>
   <result pre="119 21255998 Thorburn A Thamm DH Gustafson DL Autophagy and" exact="cancer" post="therapy Mol Pharmacol 2014 85 830 838 24574520 Tang"/>
   <result pre="24574520 Tang X-H Gudas LJ Retinoids, retinoic acid receptors, and" exact="cancer" post="Annu Rev Pathol 2011 6 345 364 21073338 Gudas"/>
   <result pre="T Tschan MP WIPI-dependent autophagy during neutrophil differentiation of NB4" exact="acute promyelocytic leukemia" post="cells Cell Death Dis 2014 5 e1315 24991767 Brigger"/>
   <result pre="MP WIPI-dependent autophagy during neutrophil differentiation of NB4 acute promyelocytic" exact="leukemia" post="cells Cell Death Dis 2014 5 e1315 24991767 Brigger"/>
   <result pre="Expression of the HER1-4 family of receptor tyrosine kinases in" exact="breast cancer" post="J Pathol 2003 200 290 297 12845624 Hudis CA"/>
   <result pre="of the HER1-4 family of receptor tyrosine kinases in breast" exact="cancer" post="J Pathol 2003 200 290 297 12845624 Hudis CA"/>
   <result pre="GN Molecular predictors of response to trastuzumab and lapatinib in" exact="breast cancer" post="Nat Rev Clin Oncol 2010 7 98 107 20027191"/>
   <result pre="Molecular predictors of response to trastuzumab and lapatinib in breast" exact="cancer" post="Nat Rev Clin Oncol 2010 7 98 107 20027191"/>
   <result pre="activity of lapatinib and retinoids on a novel subtype of" exact="breast cancer" post="with coamplification of ERBB2 and RARA Oncogene 2011 31"/>
   <result pre="of lapatinib and retinoids on a novel subtype of breast" exact="cancer" post="with coamplification of ERBB2 and RARA Oncogene 2011 31"/>
   <result pre="MA Lehmann U Kelekar A Autophagy delays apoptotic death in" exact="breast cancer" post="cells following DNA damage Cell Death Differ 2007 14"/>
   <result pre="Lehmann U Kelekar A Autophagy delays apoptotic death in breast" exact="cancer" post="cells following DNA damage Cell Death Differ 2007 14"/>
   <result pre="effects of epirubicin treatment in anthracycline-sensitive and resistant triple negative" exact="breast cancer" post="Clin Cancer Res 2014 20 3159 3173 24721646 Tschan"/>
   <result pre="of epirubicin treatment in anthracycline-sensitive and resistant triple negative breast" exact="cancer" post="Clin Cancer Res 2014 20 3159 3173 24721646 Tschan"/>
   <result pre="erythroid cells leads to defective removal of mitochondria and severe" exact="anemia" post="in vivo Proc Natl Acad Sci USA 2010 107"/>
   <result pre="Truong NH Duong TT Le DV et al. Differentiation of" exact="breast cancer" post="stem cells by knockdown of CD44: promising differentiation therapy"/>
   <result pre="NH Duong TT Le DV et al. Differentiation of breast" exact="cancer" post="stem cells by knockdown of CD44: promising differentiation therapy"/>
   <result pre="F Finetti P Bertucci F et al. Retinoid signaling regulates" exact="breast cancer" post="stem cell differentiation Cell Cycle 2009 8 3297 3302"/>
   <result pre="Finetti P Bertucci F et al. Retinoid signaling regulates breast" exact="cancer" post="stem cell differentiation Cell Cycle 2009 8 3297 3302"/>
   <result pre="induces autophagy in SKBR3 cells. ( a) SKBR3 and MDA-MB-453" exact="breast cancer" post="cells were treated either with 0.1 or 1  μM"/>
   <result pre="autophagy in SKBR3 cells. ( a) SKBR3 and MDA-MB-453 breast" exact="cancer" post="cells were treated either with 0.1 or 1  μM"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4567019/results/search/disease/results.xml">
   <result pre="of glycoprotein nonmetastatic B and its association with HER2 in" exact="breast cancer" post="Kanematsu Masako 1 Futamura Manabu 2 Takata Masafumi 3"/>
   <result pre="glycoprotein nonmetastatic B and its association with HER2 in breast" exact="cancer" post="Kanematsu Masako 1 Futamura Manabu 2 Takata Masafumi 3"/>
   <result pre="a potential oncogene that is particularly expressed in melanoma and" exact="breast cancer" post="(BC). To clarify its clinical significance in BC, we"/>
   <result pre="potential oncogene that is particularly expressed in melanoma and breast" exact="cancer" post="(BC). To clarify its clinical significance in BC, we"/>
   <result pre="of six colorectal cell lines, and two of four gastric" exact="cancer" post="(GC) cell lines. We established a GPNMB quantification system"/>
   <result pre="in 162 consecutive BC patients and in 88 controls (50" exact="colorectal cancer" post="[CC] and 38 GC patients). The GPNMB concentration in"/>
   <result pre="162 consecutive BC patients and in 88 controls (50 colorectal" exact="cancer" post="[CC] and 38 GC patients). The GPNMB concentration in"/>
   <result pre="therefore emerge as an important player in anti-HER2 therapy. Biomarker" exact="breast cancer" post="cross talk GPNMB HER2 Introduction Breast cancer (BC) is"/>
   <result pre="emerge as an important player in anti-HER2 therapy. Biomarker breast" exact="cancer" post="cross talk GPNMB HER2 Introduction Breast cancer (BC) is"/>
   <result pre="therapy. Biomarker breast cancer cross talk GPNMB HER2 Introduction Breast" exact="cancer" post="(BC) is the most globally prevalent cancer that affects"/>
   <result pre="HER2 Introduction Breast cancer (BC) is the most globally prevalent" exact="cancer" post="that affects the female population. Despite recent progress in"/>
   <result pre="GPNMB plays an important role in neuroprotection, leading to the" exact="suppression" post="of motor neuron degeneration such as amyotrophic lateral sclerosis"/>
   <result pre="leading to the suppression of motor neuron degeneration such as" exact="amyotrophic lateral sclerosis" post="(ALS) 13. Furthermore, GPNMB has been reported to be"/>
   <result pre="be overexpressed in several cancers, including melanoma, breast, and gastric" exact="cancer" post="14– 16. Recently emerging data has generated a more"/>
   <result pre="complex picture related to metastasis with respect to GPNMB in" exact="cancer" post="progression 17– 19. It was reported that the ECD"/>
   <result pre="21 proposed GPNMB as a prognostic indicator in small cell" exact="lung cancer." post="These novel discoveries prompted us to measure the serum"/>
   <result pre="MDA-MB-231, and MDA-MB-157), an immortalized normal breast cell line (MCF10)," exact="colon cancer" post="(CC) cell lines (SW48, HCT116, LS174T, SW1417, Lovo, and"/>
   <result pre="and MDA-MB-157), an immortalized normal breast cell line (MCF10), colon" exact="cancer" post="(CC) cell lines (SW48, HCT116, LS174T, SW1417, Lovo, and"/>
   <result pre="HER2-positive (including Luminal/HER2), 20 as TN, and nine as Ductal" exact="carcinoma in situ" post="(DCIS) 2. All patients gave informed consent to provide"/>
   <result pre="was from EMD Millipore (Billerica, MA), and the v-akt murine" exact="thymoma" post="viral oncogene homolog (Akt) inhibitor MK-2206 from Merck Oncology"/>
   <result pre="a P &amp;lt; 0.05. Results Expression of GPNMB in various" exact="cancer" post="cell lines First, the expression levels of GPNMB were"/>
   <result pre="levels of GPNMB (Fig. S1). Figure 1 GPNMB expression in" exact="cancer" post="cell lines. (A) Expression levels of various receptors in"/>
   <result pre="Expression levels of various receptors in breast, colon, and gastric" exact="cancer" post="cell lines assessed by RT-PCR; GAPDH was used as"/>
   <result pre="an internal control. (B) Expression levels of GPNMB in several" exact="cancer" post="cell lines analyzed by western blot; β-actin was used"/>
   <result pre="(CC: n = 50), or gastric (GC: n = 38)" exact="cancer" post="are indicated, respectively. (C) GPNMBs in four subgroups of"/>
   <result pre="the combination of Tra with DTX enhanced the cell growth" exact="suppression" post="beyond that obtained with Tra monotherapy (Fig. 5B) ("/>
   <result pre="(* P &amp;lt; 0.0001). Discussion The role of GPNMB in" exact="cancer" post="was first discussed based on expression analyses demonstrating that"/>
   <result pre="to be determined, because it may originate not only from" exact="cancer" post="cells but also from noncancerous tissue such as bone,"/>
   <result pre="GPNMB. We also measured GPNMB for 16 patients with benign" exact="breast disease," post="including patients with fibroadenoma and mastopathy, and cancer-free patients,"/>
   <result pre="for 16 patients with benign breast disease, including patients with" exact="fibroadenoma" post="and mastopathy, and cancer-free patients, whose GPNMB level was"/>
   <result pre="reported that GPNMB is a prognostic factor for non-small cell" exact="lung cancer" post="based on ELISA. A direct comparison between these findings"/>
   <result pre="that GPNMB is a prognostic factor for non-small cell lung" exact="cancer" post="based on ELISA. A direct comparison between these findings"/>
   <result pre="results is difficult, because GPNMB expression is as low in" exact="lung cancer" post="cells as it is in colon, ovary, and renal"/>
   <result pre="is difficult, because GPNMB expression is as low in lung" exact="cancer" post="cells as it is in colon, ovary, and renal"/>
   <result pre="cancer cells as it is in colon, ovary, and renal" exact="cancer" post="cells 10, 11, 14, and a different measuring system"/>
   <result pre="Tra treatment led induced a stronger effect on HER2-positive tumor" exact="suppression" post="than Tra treatment alone. Additional chemotherapy (DTX) further enhanced"/>
   <result pre="than Tra treatment alone. Additional chemotherapy (DTX) further enhanced tumor" exact="suppression" post="in vitro. Recent studies have shown that Tra induces"/>
   <result pre="AU Hortobagyi GN Giordano SH Prognosis of women with metastatic" exact="breast cancer" post="by HER2 status and trastuzumab Treatment: an institutional-based review"/>
   <result pre="Hortobagyi GN Giordano SH Prognosis of women with metastatic breast" exact="cancer" post="by HER2 status and trastuzumab Treatment: an institutional-based review"/>
   <result pre="and progression-free survival to trastuzumab-based treatment in patients with metastatic" exact="breast cancer" post="Clin. Cancer Res 2004 10 1618 1624 15014012 Lüftner"/>
   <result pre="progression-free survival to trastuzumab-based treatment in patients with metastatic breast" exact="cancer" post="Clin. Cancer Res 2004 10 1618 1624 15014012 Lüftner"/>
   <result pre="ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic" exact="breast cancer" post="Int. J. Biol. Markers 2004 19 175 182 15503818"/>
   <result pre="Centaur HER-2/neu shows value in monitoring patients with metastatic breast" exact="cancer" post="Int. J. Biol. Markers 2004 19 175 182 15503818"/>
   <result pre="et al. Evaluation of serum HER2 extracellular domain in early" exact="breast cancer" post="patients: correlation with clinicopathological parameters and survival Ann. Oncol"/>
   <result pre="al. Evaluation of serum HER2 extracellular domain in early breast" exact="cancer" post="patients: correlation with clinicopathological parameters and survival Ann. Oncol"/>
   <result pre="HER2 levels determined by two methods in patients with metastatic" exact="breast cancer" post="Int. J. Clin. Oncol 2012 17 55 62 21607830"/>
   <result pre="levels determined by two methods in patients with metastatic breast" exact="cancer" post="Int. J. Clin. Oncol 2012 17 55 62 21607830"/>
   <result pre="al. The potential of GPNMB as novel neuroprotective factor in" exact="amyotrophic lateral sclerosis" post="Sci. Rep 2012 2 573 583 22891158 Qian X"/>
   <result pre="prognostic indicator of recurrence and a novel therapeutic target in" exact="breast cancer" post="Clin. Cancer Res 2010 16 2147 2156 20215530 Rho"/>
   <result pre="indicator of recurrence and a novel therapeutic target in breast" exact="cancer" post="Clin. Cancer Res 2010 16 2147 2156 20215530 Rho"/>
   <result pre="of valid reference genes for gene expression studies of human" exact="stomach cancer" post="by reverse transcription-qPCR BMC Cancer 2010 10 240 252"/>
   <result pre="valid reference genes for gene expression studies of human stomach" exact="cancer" post="by reverse transcription-qPCR BMC Cancer 2010 10 240 252"/>
   <result pre="C Abou Khalil JE Hallett M Siegel PM Osteoactivin promotes" exact="breast cancer" post="metastasis to bone Mol. Cancer Res 2007 5 1001"/>
   <result pre="Abou Khalil JE Hallett M Siegel PM Osteoactivin promotes breast" exact="cancer" post="metastasis to bone Mol. Cancer Res 2007 5 1001"/>
   <result pre="protein B, a potential molecular therapeutic target in patients with" exact="glioblastoma multiforme" post="Clin. Cancer Res 2006 12 1970 1982 16609006 Maric"/>
   <result pre="b (GPNMB): a metastatic mediator and emerging therapeutic target in" exact="cancer" post="Onco Targets Ther 2013 6 839 852 23874106 Rose"/>
   <result pre="Glycoprotein nonmetastatic B as a prognostic indicator in small cell" exact="lung cancer" post="APMIS 2014 122 140 146 23656629 Futamura M Kamino"/>
   <result pre="nonmetastatic B as a prognostic indicator in small cell lung" exact="cancer" post="APMIS 2014 122 140 146 23656629 Futamura M Kamino"/>
   <result pre="candidate tumor suppressor gene at 3p21.3, in p53-regulated tumor angiogenesis" exact="suppression" post="Cancer Res 2007 67 1451 1460 17308083 Ohnishi S"/>
   <result pre="of trastuzumab with chemotherapeutic drugs used in the treatment of" exact="breast cancer" post="J. Natl. Cancer Inst 2004 96 739 749 15150302"/>
   <result pre="trastuzumab with chemotherapeutic drugs used in the treatment of breast" exact="cancer" post="J. Natl. Cancer Inst 2004 96 739 749 15150302"/>
   <result pre="conjugate glembatumumab vedotin in patients with locally advanced or metastatic" exact="breast cancer" post="J. Clin. Oncol 2014 32 3619 3625 25267761 Dowsett"/>
   <result pre="glembatumumab vedotin in patients with locally advanced or metastatic breast" exact="cancer" post="J. Clin. Oncol 2014 32 3619 3625 25267761 Dowsett"/>
   <result pre="S113 S137 16113087 Johnston SR New strategies in estrogen receptor-positive" exact="breast cancer" post="Clin. Cancer Res 2010 16 1979 1987 20332324 Gijsen"/>
   <result pre="S137 16113087 Johnston SR New strategies in estrogen receptor-positive breast" exact="cancer" post="Clin. Cancer Res 2010 16 1979 1987 20332324 Gijsen"/>
   <result pre="PKB negative feedback loop in response to anti-HER2 Herceptin in" exact="breast cancer" post="PLoS One 2010 12 e1000563 Scaltriti M Verma C"/>
   <result pre="negative feedback loop in response to anti-HER2 Herceptin in breast" exact="cancer" post="PLoS One 2010 12 e1000563 Scaltriti M Verma C"/>
   <result pre="PKB negative feedback loop in response to anti-HER2 herceptin in" exact="breast cancer" post="PLoS Biol 2010 8 e1000563 21203579 Lavaud P Andre"/>
   <result pre="negative feedback loop in response to anti-HER2 herceptin in breast" exact="cancer" post="PLoS Biol 2010 8 e1000563 21203579 Lavaud P Andre"/>
   <result pre="YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N. Engl. J. Med 2012 366 109 119 22149875"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N. Engl. J. Med 2012 366 109 119 22149875"/>
   <result pre="the relative quantification (RQ) was determined. Figure S2. Immunohistochemistry of" exact="breast cancer" post="samples of the HER2-rich subtype. Representative cases of immunohistochemistry"/>
   <result pre="relative quantification (RQ) was determined. Figure S2. Immunohistochemistry of breast" exact="cancer" post="samples of the HER2-rich subtype. Representative cases of immunohistochemistry"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4570757/results/search/disease/results.xml">
   <result pre="trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+" exact="breast cancer" post="patient Lu Nu T. nlu@mednet.ucla.edu Raizer Jeffrey jraizer@nmff.org Gabor"/>
   <result pre="immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast" exact="cancer" post="patient Lu Nu T. nlu@mednet.ucla.edu Raizer Jeffrey jraizer@nmff.org Gabor"/>
   <result pre="clinical and therapeutic course of a 51-year-old woman with HER-2+" exact="breast cancer" post="who developed leptomeningeal (LM) and spinal cord metastases after"/>
   <result pre="and therapeutic course of a 51-year-old woman with HER-2+ breast" exact="cancer" post="who developed leptomeningeal (LM) and spinal cord metastases after"/>
   <result pre="which has revolutionized the outcome of patients with HER-2 overexpressing" exact="breast cancer." post="Traditionally, HER-2 overexpressing tumors have been associated with more"/>
   <result pre="shorter survival [ 1, 2]. However, trastuzumab has transformed HER-2+" exact="breast cancer" post="into one of the most treatable types of cancer."/>
   <result pre="survival [ 1, 2]. However, trastuzumab has transformed HER-2+ breast" exact="cancer" post="into one of the most treatable types of cancer."/>
   <result pre="mechanism [ 3]. Trastuzumab’s control of systemic disease in HER-2+" exact="breast cancer" post="patients has led to a higher incidence of CNS"/>
   <result pre="[ 3]. Trastuzumab’s control of systemic disease in HER-2+ breast" exact="cancer" post="patients has led to a higher incidence of CNS"/>
   <result pre="to treat. As trastuzumab is highly effective against systemic HER-2+" exact="breast cancer," post="a logical strategy is to investigate its ability to"/>
   <result pre="CNS metastases. As a single-agent first line therapy for HER-2+" exact="breast cancer," post="trastuzumab achieved a response rate of 25 –35 % ["/>
   <result pre="rate of 25 –35 % [ 5]. Among women with metastatic" exact="breast cancer" post="who progressed after standard chemotherapy, trastuzumab yielded response rates"/>
   <result pre="of 25 –35 % [ 5]. Among women with metastatic breast" exact="cancer" post="who progressed after standard chemotherapy, trastuzumab yielded response rates"/>
   <result pre="these patients. Trastuzumab benefits women at any stage of HER-2+" exact="breast cancer" post="and is currently part of the standard of care."/>
   <result pre="patients. Trastuzumab benefits women at any stage of HER-2+ breast" exact="cancer" post="and is currently part of the standard of care."/>
   <result pre="is underutilized as a treatment modality for HER-2+ LM from" exact="breast cancer." post="Our challenge remains: To implement an effective dose schedule"/>
   <result pre="April 2003, a 41-year-old woman was diagnosed with stage II" exact="breast cancer" post="(T1N1M0, ER/PR-, HER-2/ 3+ by immunohistochemistry). She was treated"/>
   <result pre="2003, a 41-year-old woman was diagnosed with stage II breast" exact="cancer" post="(T1N1M0, ER/PR-, HER-2/ 3+ by immunohistochemistry). She was treated"/>
   <result pre="Treatment Serum CA 27.29 (U/mL) April-2003 Diagnosed with stage II" exact="breast cancer" post="Surgery and adjuvant chemotherapy (adriamysin/cytoxan, and weekly docataxel) na"/>
   <result pre="Serum CA 27.29 (U/mL) April-2003 Diagnosed with stage II breast" exact="cancer" post="Surgery and adjuvant chemotherapy (adriamysin/cytoxan, and weekly docataxel) na"/>
   <result pre="activity of thoracic and lumbar lesions 59 June-2013 Diagnosed with" exact="meningitis" post="Extended antibiotic treatment for two plus months (vancomycin) 58"/>
   <result pre="trastuzumab was generally well tolerated, except for an episode of" exact="meningitis" post="in June 2013, which required removal of the ommaya"/>
   <result pre="parenting of two adolescent children. Eleven years after her HER-2+" exact="breast cancer" post="was diagnosed, she expired from respiratory compromise due to"/>
   <result pre="of two adolescent children. Eleven years after her HER-2+ breast" exact="cancer" post="was diagnosed, she expired from respiratory compromise due to"/>
   <result pre="lesion at C1-C2 with associated cord edema Discussion Pervasive HER-2+" exact="breast cancer" post="cells can travel long distances and break virtually any"/>
   <result pre="at C1-C2 with associated cord edema Discussion Pervasive HER-2+ breast" exact="cancer" post="cells can travel long distances and break virtually any"/>
   <result pre="compared to a median life expectancy of 3–4 months for" exact="breast cancer" post="patients following the diagnosis of LM without treatment ["/>
   <result pre="to a median life expectancy of 3–4 months for breast" exact="cancer" post="patients following the diagnosis of LM without treatment ["/>
   <result pre="with severe side effects including meningoencephalopathy, leukoencephalopathy, stomatitis, and marrow" exact="suppression" post="[ 19]. Furthermore, dose escalation of IT trastuzumab enabled"/>
   <result pre="median overall survival of approximately 2–7 months in those with" exact="breast cancer" post="following the diagnosis of LM with standard IT chemotherapy"/>
   <result pre="overall survival of approximately 2–7 months in those with breast" exact="cancer" post="following the diagnosis of LM with standard IT chemotherapy"/>
   <result pre="impact the prognosis of patients with LM metastases from HER-2+" exact="breast cancer." post="While its activity on extramedullary lesions is apparent, IT"/>
   <result pre="has displayed clinical activity against brain metastases from HER-2 overexpressing" exact="breast cancer" post="[ 23]. Stereotactic radiosurgery can control CNS parenchymal disease"/>
   <result pre="displayed clinical activity against brain metastases from HER-2 overexpressing breast" exact="cancer" post="[ 23]. Stereotactic radiosurgery can control CNS parenchymal disease"/>
   <result pre="In particular, trastuzumab (Herceptin) has paved the way for HER-2+" exact="breast cancer" post="patients to fight their disease. Due to the incidence"/>
   <result pre="particular, trastuzumab (Herceptin) has paved the way for HER-2+ breast" exact="cancer" post="patients to fight their disease. Due to the incidence"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer." post="Science. 1989;244(4905):707-12. 2. Ravdin PM Chamness GC The c-erbB-2"/>
   <result pre="Claret FX Trastuzumab: updated mechanisms of action and resistance in" exact="breast cancer" post="Front Oncol 2012 2 62 10.3389/fonc.2012.00062 22720269 4. Bendell"/>
   <result pre="FX Trastuzumab: updated mechanisms of action and resistance in breast" exact="cancer" post="Front Oncol 2012 2 62 10.3389/fonc.2012.00062 22720269 4. Bendell"/>
   <result pre="as a single agent in first-line treatment of HER2-overexpressing metastatic" exact="breast cancer." post="Journal of clinical oncology: official journal of the American"/>
   <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease. Journal"/>
   <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease. Journal"/>
   <result pre="NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer." post="The New England journal of medicine. 2005;353(16):1673-84. 8. Smith"/>
   <result pre="compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic" exact="breast cancer." post="Journal of clinical oncology: official journal of the American"/>
   <result pre="and their combination plus paclitaxel in women with HER2-positive primary" exact="breast cancer" post="Cancer Res 2010 70 82s 11. Gianni L, Eiermann"/>
   <result pre="their combination plus paclitaxel in women with HER2-positive primary breast" exact="cancer" post="Cancer Res 2010 70 82s 11. Gianni L, Eiermann"/>
   <result pre="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced" exact="breast cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast" exact="cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="(Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic" exact="breast cancer." post="Oncology reports. 2006;15(5):1373-7. 13. Stemmler HJ, Mengele K, Schmitt"/>
   <result pre="14. Platini C Long J Walter S Meningeal carcinomatosis from" exact="breast cancer" post="treated with intrathecal trastuzumab Lancet Oncol 2006 7 9"/>
   <result pre="Platini C Long J Walter S Meningeal carcinomatosis from breast" exact="cancer" post="treated with intrathecal trastuzumab Lancet Oncol 2006 7 9"/>
   <result pre="KF Use of intrathecal trastuzumab in a patient with carcinomatous" exact="meningitis" post="Clin Breast Cancer 2001 2 3 235 10.1016/S1526-8209(11)70419-0 11899418"/>
   <result pre="High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing" exact="breast cancer." post="Annals of oncology: official journal of the European Society"/>
   <result pre="20. Lin NU Bellon JR Winer EP CNS metastases in" exact="breast cancer" post="J Clin Oncol 2004 22 17 3608 17 10.1200/JCO.2004.01.175"/>
   <result pre="Lin NU Bellon JR Winer EP CNS metastases in breast" exact="cancer" post="J Clin Oncol 2004 22 17 3608 17 10.1200/JCO.2004.01.175"/>
   <result pre="10.1200/JCO.2004.01.175 15337811 21. Scott BJ Kesari S Leptomeningeal metastases in" exact="breast cancer" post="Am J Cancer Res 2013 3 2 117 26"/>
   <result pre="15337811 21. Scott BJ Kesari S Leptomeningeal metastases in breast" exact="cancer" post="Am J Cancer Res 2013 3 2 117 26"/>
   <result pre="in patients with previously untreated brain metastases from HER2-positive metastatic" exact="breast cancer" post="(LANDSCAPE): a single-group phase 2 study. The lancet oncology."/>
   <result pre="patients with previously untreated brain metastases from HER2-positive metastatic breast" exact="cancer" post="(LANDSCAPE): a single-group phase 2 study. The lancet oncology."/>
   <result pre="in patients with advanced human epidermal growth factor receptor 2-positive" exact="breast cancer." post="Journal of clinical oncology: official journal of the American"/>
   <result pre="of a HER2/neu (E75) vaccine to prevent recurrence in high-risk" exact="breast cancer" post="patients. Journal of clinical oncology: official journal of the"/>
   <result pre="a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast" exact="cancer" post="patients. Journal of clinical oncology: official journal of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4574060/results/search/disease/results.xml">
   <result pre="lapatinib vs. continuing trastuzumab beyond progression (TBP) in HER2-positive metastatic" exact="breast cancer" post="(MBC) patients, who progressed on first-line trastuzumab, is still"/>
   <result pre="vs. continuing trastuzumab beyond progression (TBP) in HER2-positive metastatic breast" exact="cancer" post="(MBC) patients, who progressed on first-line trastuzumab, is still"/>
   <result pre="within the paper and its Supporting Information files. Introduction Metastatic" exact="breast cancer" post="(MBC) is the leading cause of death from cancer"/>
   <result pre="the paper and its Supporting Information files. Introduction Metastatic breast" exact="cancer" post="(MBC) is the leading cause of death from cancer"/>
   <result pre="breast cancer (MBC) is the leading cause of death from" exact="cancer" post="among women worldwide. Approximately 15% to 20% of patients"/>
   <result pre="among women worldwide. Approximately 15% to 20% of patients with" exact="breast cancer" post="have tumors that over-express the human epidermal growth factor"/>
   <result pre="women worldwide. Approximately 15% to 20% of patients with breast" exact="cancer" post="have tumors that over-express the human epidermal growth factor"/>
   <result pre="(HER2) protein. Prior to the era of HER2-targeted therapy, HER2-positive" exact="breast cancer" post="was characterized by poor prognosis [ 1, 2]. Treatment"/>
   <result pre="protein. Prior to the era of HER2-targeted therapy, HER2-positive breast" exact="cancer" post="was characterized by poor prognosis [ 1, 2]. Treatment"/>
   <result pre="from CHS' databases: age, Charlson co-morbidity index [ 10, 11]" exact="cancer" post="diagnosis, all reimbursed anti-cancer drugs provided (in the early"/>
   <result pre="tamoxifen and aromatase inhibitors are fully reimbursed in Israel for" exact="cancer" post="patients, use of hormonal treatment at any disease stage"/>
   <result pre="less preferable outcomes with lapatinib compared to trastuzumab in various" exact="breast cancer" post="settings. Recently, Gelmon et al. [ 17] have reported"/>
   <result pre="preferable outcomes with lapatinib compared to trastuzumab in various breast" exact="cancer" post="settings. Recently, Gelmon et al. [ 17] have reported"/>
   <result pre=", et al. High risk of recurrence for patients with" exact="breast cancer" post="who have human epidermal growth factor receptor 2-positive, node-negative"/>
   <result pre="et al. High risk of recurrence for patients with breast" exact="cancer" post="who have human epidermal growth factor receptor 2-positive, node-negative"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre="Mortimer JE , et al. Safety of treatment of metastatic" exact="breast cancer" post="with trastuzumab beyond disease progression. J Clin Oncol. 2004;"/>
   <result pre="JE , et al. Safety of treatment of metastatic breast" exact="cancer" post="with trastuzumab beyond disease progression. J Clin Oncol. 2004;"/>
   <result pre=", Papaldo P , et al. Do HER-2 positive metastatic" exact="breast cancer" post="patients benefit from the use of trastuzumab beyond disease"/>
   <result pre="Papaldo P , et al. Do HER-2 positive metastatic breast" exact="cancer" post="patients benefit from the use of trastuzumab beyond disease"/>
   <result pre="Summary: Lapatinib in combination with capecitabine for previously treated metastatic" exact="breast cancer" post="that overexpresses HER-2 . The Oncologist. 2008; 13: 1114–"/>
   <result pre="Lapatinib in combination with capecitabine for previously treated metastatic breast" exact="cancer" post="that overexpresses HER-2 . The Oncologist. 2008; 13: 1114–"/>
   <result pre="of lapatinib in patients with brain metastases from HER2- positive" exact="breast cancer" post=". Clin Cancer Res. 2009; 15: 1452– 1459. doi:"/>
   <result pre="lapatinib in patients with brain metastases from HER2- positive breast" exact="cancer" post=". Clin Cancer Res. 2009; 15: 1452– 1459. doi:"/>
   <result pre="T , et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med. 2006; 355: 2733– 2743. 17192538"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post=". J Clin Oncol. 2015; 33: 1564– 1573. doi:"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post=". J Clin Oncol. 2015; 33: 1564– 1573. doi:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4578850/results/search/disease/results.xml">
   <result pre="available in this article, unless otherwise stated. Abstract Background Neoadjuvant" exact="breast cancer" post="trials are important for speeding up the introduction of"/>
   <result pre="in this article, unless otherwise stated. Abstract Background Neoadjuvant breast" exact="cancer" post="trials are important for speeding up the introduction of"/>
   <result pre="up the introduction of new treatments for patients with early" exact="breast cancer" post="and for the highly productive translational research which they"/>
   <result pre="the introduction of new treatments for patients with early breast" exact="cancer" post="and for the highly productive translational research which they"/>
   <result pre="methods for pathological response at surgery; subtype and prognosis of" exact="breast cancer" post="at diagnosis; number of patients recruited; adjuvant treatments; the"/>
   <result pre="for pathological response at surgery; subtype and prognosis of breast" exact="cancer" post="at diagnosis; number of patients recruited; adjuvant treatments; the"/>
   <result pre="trial designs with additional neo/adjuvant treatments. Future developments of neoadjuvant" exact="breast cancer" post="trials are discussed. With so many factors influencing the"/>
   <result pre="designs with additional neo/adjuvant treatments. Future developments of neoadjuvant breast" exact="cancer" post="trials are discussed. With so many factors influencing the"/>
   <result pre="should remain the primary endpoint of pathological response. Summary Neoadjuvant" exact="breast cancer" post="trials are very important investigational studies that will continue"/>
   <result pre="remain the primary endpoint of pathological response. Summary Neoadjuvant breast" exact="cancer" post="trials are very important investigational studies that will continue"/>
   <result pre="rapid introduction of new treatments for women with high-risk early" exact="breast cancer." post="In the future, we are likely to see both"/>
   <result pre="positive correlation between pathological response and longer-term outcomes. Keywords Early" exact="breast cancer" post="Longer-term outcomes Neoadjuvant trials Pathological response Background Neoadjuvant treatment"/>
   <result pre="correlation between pathological response and longer-term outcomes. Keywords Early breast" exact="cancer" post="Longer-term outcomes Neoadjuvant trials Pathological response Background Neoadjuvant treatment"/>
   <result pre="outcomes Neoadjuvant trials Pathological response Background Neoadjuvant treatment of early" exact="breast cancer" post="has many advantages both for patients and for the"/>
   <result pre="Neoadjuvant trials Pathological response Background Neoadjuvant treatment of early breast" exact="cancer" post="has many advantages both for patients and for the"/>
   <result pre="between pathological response and longer-term outcome in women with early" exact="breast cancer" post="receiving neoadjuvant systemic therapy is highly complex and its'"/>
   <result pre="pathological response and longer-term outcome in women with early breast" exact="cancer" post="receiving neoadjuvant systemic therapy is highly complex and its'"/>
   <result pre="the relationship between the two. A recent meta-analysis of neoadjuvant" exact="breast cancer" post="trials [ 5] and a meta-regression of trials data"/>
   <result pre="relationship between the two. A recent meta-analysis of neoadjuvant breast" exact="cancer" post="trials [ 5] and a meta-regression of trials data"/>
   <result pre="at the forefront of research and treatment for high-risk early" exact="breast cancer." post="Fig. 1 Associations between pathological complete response and event-free"/>
   <result pre="of pathological complete response was used (i.e. absence of invasive" exact="cancer" post="in the breast and axillary nodes, irrespective of ductal"/>
   <result pre="disease in the breast, irrespective of the presence of ductal" exact="carcinoma in situ" post="(DCIS) or nodal involvement (ypT0/is ypNx). Some later trials"/>
   <result pre="and similar in the remaining two groups without residual invasive" exact="cancer" post="in breast and lymph nodes regardless of the presence"/>
   <result pre="approval for agents in the neoadjuvant treatment of aggressive early" exact="breast cancer" post="[ 11, 12]. Fig. 2 Associations between three definitions"/>
   <result pre="for agents in the neoadjuvant treatment of aggressive early breast" exact="cancer" post="[ 11, 12]. Fig. 2 Associations between three definitions"/>
   <result pre="response according to more than one definition. ypT0ypN0 = absence of invasive" exact="cancer" post="and in situ cancer in breast and axillary nodes."/>
   <result pre="than one definition. ypT0ypN0 = absence of invasive cancer and in situ" exact="cancer" post="in breast and axillary nodes. ypT0/is ypN0 = absence of invasive"/>
   <result pre="cancer in breast and axillary nodes. ypT0/is ypN0 = absence of invasive" exact="cancer" post="in breast and axillary nodes, irrespective of ductal carcinoma"/>
   <result pre="axillary nodes, irrespective of ductal carcinoma in-situ. ypT0/is = absence of invasive" exact="cancer" post="in breast, irrespective of ductal carcinoma in-situ or nodal"/>
   <result pre="quantification of residual disease important? The likelihood of pCR in" exact="breast cancer" post="is heavily influenced by the biological subtype. Breast cancers"/>
   <result pre="of residual disease important? The likelihood of pCR in breast" exact="cancer" post="is heavily influenced by the biological subtype. Breast cancers"/>
   <result pre="better standardisation of specimen handling and histological reporting of neoadjuvant" exact="breast cancer" post="specimens. The BIG-NABCG Residual Disease Working Group has recently"/>
   <result pre="standardisation of specimen handling and histological reporting of neoadjuvant breast" exact="cancer" post="specimens. The BIG-NABCG Residual Disease Working Group has recently"/>
   <result pre="recommendations for the standardised pathological evaluation and reporting of neoadjuvant" exact="breast cancer" post="specimens, which will hopefully facilitate accurate comparison of treatment"/>
   <result pre="for the standardised pathological evaluation and reporting of neoadjuvant breast" exact="cancer" post="specimens, which will hopefully facilitate accurate comparison of treatment"/>
   <result pre="disease. Table 1 Classification systems of pathological response to neoadjuvant" exact="breast cancer" post="treatment Classification system Comment American Joint Committee on Cancer/Union"/>
   <result pre="Table 1 Classification systems of pathological response to neoadjuvant breast" exact="cancer" post="treatment Classification system Comment American Joint Committee on Cancer/Union"/>
   <result pre="with survival outcomes over long term follow up DCIS ducal" exact="carcinoma in situ," post="pCR complete pathological response The Residual Cancer Burden score"/>
   <result pre="score is derived from the size of the residual invasive" exact="cancer" post="measured in two dimensions, residual tumour cellularity and proportion"/>
   <result pre="influences the relationship between pCR and longer-term outcomes in neoadjuvant" exact="breast cancer?" post="Definition of pCR and review How the definition of"/>
   <result pre="are not completely harmonised in each trial report. Type of" exact="breast cancer" post="and prognostic and predictive factors The biology of the"/>
   <result pre="not completely harmonised in each trial report. Type of breast" exact="cancer" post="and prognostic and predictive factors The biology of the"/>
   <result pre="prognostic and predictive factors The biology of the type of" exact="breast cancer" post="(e.g. ER-positive HER2-positive) will influence the pCR rate and"/>
   <result pre="and predictive factors The biology of the type of breast" exact="cancer" post="(e.g. ER-positive HER2-positive) will influence the pCR rate and"/>
   <result pre="breast conservation. Length of follow-up and interaction with type of" exact="breast cancer" post="and prognosis Length of follow-up in neo/adjuvant early breast"/>
   <result pre="conservation. Length of follow-up and interaction with type of breast" exact="cancer" post="and prognosis Length of follow-up in neo/adjuvant early breast"/>
   <result pre="breast cancer and prognosis Length of follow-up in neo/adjuvant early" exact="breast cancer" post="trials is a further factor influencing longer-term results. This"/>
   <result pre="cancer and prognosis Length of follow-up in neo/adjuvant early breast" exact="cancer" post="trials is a further factor influencing longer-term results. This"/>
   <result pre="factor influencing longer-term results. This has been reviewed for adjuvant" exact="breast cancer" post="trial reporting [ 30], and the same arguments would"/>
   <result pre="influencing longer-term results. This has been reviewed for adjuvant breast" exact="cancer" post="trial reporting [ 30], and the same arguments would"/>
   <result pre="distant metastases free survival (DMFS), i.e. recurrence pertinent to the" exact="breast cancer" post="we have treated. In terms of mortality indicators, breast"/>
   <result pre="metastases free survival (DMFS), i.e. recurrence pertinent to the breast" exact="cancer" post="we have treated. In terms of mortality indicators, breast"/>
   <result pre="mortality indicators, breast cancer-specific survival (BCSS), i.e. death caused by" exact="breast cancer" post="metastases, is more relevant than OS. In neoadjuvant trials,"/>
   <result pre="indicators, breast cancer-specific survival (BCSS), i.e. death caused by breast" exact="cancer" post="metastases, is more relevant than OS. In neoadjuvant trials,"/>
   <result pre="analysis of nearly 2,000 patients included in the intrinsic cluster" exact="breast cancer" post="subtypes [ 31]. The longer the follow-up, the more"/>
   <result pre="of nearly 2,000 patients included in the intrinsic cluster breast" exact="cancer" post="subtypes [ 31]. The longer the follow-up, the more"/>
   <result pre="outcomes of lower-risk patients who do not die because of" exact="cancer" post="and are relatively more exposed to these competing risks."/>
   <result pre="angiogenesis inhibition Reports of neo/adjuvant use of bevacizumab in early" exact="breast cancer" post="have produced added complexity when examining the correlation between"/>
   <result pre="inhibition Reports of neo/adjuvant use of bevacizumab in early breast" exact="cancer" post="have produced added complexity when examining the correlation between"/>
   <result pre="and agreed by the FDA for licensing purposes, that neoadjuvant" exact="breast cancer" post="trials will have most applicability in subtypes of breast"/>
   <result pre="agreed by the FDA for licensing purposes, that neoadjuvant breast" exact="cancer" post="trials will have most applicability in subtypes of breast"/>
   <result pre="breast cancer trials will have most applicability in subtypes of" exact="breast cancer" post="that have aggressive tumour biology and respond well to"/>
   <result pre="cancer trials will have most applicability in subtypes of breast" exact="cancer" post="that have aggressive tumour biology and respond well to"/>
   <result pre="treatments. At present, the neoadjuvant literature has clearly identified triple-negative" exact="breast cancer" post="and HER2-positive disease as fitting these criteria. In our"/>
   <result pre="At present, the neoadjuvant literature has clearly identified triple-negative breast" exact="cancer" post="and HER2-positive disease as fitting these criteria. In our"/>
   <result pre="supporting the continued use of neoadjuvant trials in high-risk HER2-positive" exact="breast cancer." post="Theirs is an important generic review of the evidence"/>
   <result pre="that the vast majority of future neoadjuvant trials in high-risk" exact="breast cancer" post="will be asking questions about the benefit of new"/>
   <result pre="the vast majority of future neoadjuvant trials in high-risk breast" exact="cancer" post="will be asking questions about the benefit of new"/>
   <result pre="to improve their long-term outcomes? In neoadjuvant trials of high-risk" exact="breast cancer," post="although pCR rates are relatively high, there will still"/>
   <result pre="most important outcome from a neoadjuvant trial in high-risk early" exact="breast cancer" post="is the primary endpoint of pathological response and that"/>
   <result pre="important outcome from a neoadjuvant trial in high-risk early breast" exact="cancer" post="is the primary endpoint of pathological response and that"/>
   <result pre="with correlation of pathological response and longer-term outcomes. Summary Neoadjuvant" exact="breast cancer" post="trials have a great future but, in our opinion,"/>
   <result pre="correlation of pathological response and longer-term outcomes. Summary Neoadjuvant breast" exact="cancer" post="trials have a great future but, in our opinion,"/>
   <result pre="the development and implementation of adaptive Bayesian designs in neoadjuvant" exact="breast cancer" post="[ 45]. This group has now moved two novel"/>
   <result pre="development and implementation of adaptive Bayesian designs in neoadjuvant breast" exact="cancer" post="[ 45]. This group has now moved two novel"/>
   <result pre="up the introduction of new therapies for patients with early" exact="breast cancer." post="Our own group is developing Bayesian adaptive randomised designs"/>
   <result pre="NR Pusztai L Chagpar AB et al. Neoadjuvant chemotherapy for" exact="breast cancer" post="increases the rate of breast conservation: results from the"/>
   <result pre="Pusztai L Chagpar AB et al. Neoadjuvant chemotherapy for breast" exact="cancer" post="increases the rate of breast conservation: results from the"/>
   <result pre="fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early" exact="breast cancer" post="(ARTemis): an open-label randomised phase 3 trial Lancet Oncol"/>
   <result pre="epirubicin and cyclophosphamide, for women with HER2 negative early breast" exact="cancer" post="(ARTemis): an open-label randomised phase 3 trial Lancet Oncol"/>
   <result pre="a potential surrogate for the clinical outcome in patients with" exact="breast cancer" post="after neoadjuvant therapy: a meta-regression of 29 randomized prospective"/>
   <result pre="potential surrogate for the clinical outcome in patients with breast" exact="cancer" post="after neoadjuvant therapy: a meta-regression of 29 randomized prospective"/>
   <result pre="sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early" exact="breast cancer" post="(Neo-tAnGo): an open-label, 2 x 2 factorial randomised phase"/>
   <result pre="epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast" exact="cancer" post="(Neo-tAnGo): an open-label, 2 x 2 factorial randomised phase"/>
   <result pre="chemotherapy with or without bevacizumab or everolimus for HER2-negative primary" exact="breast cancer" post="(GBG 44-GeparQuinto) Ann Oncol 2014 25 2363 72 10.1093/annonc/mdu455"/>
   <result pre="with or without bevacizumab or everolimus for HER2-negative primary breast" exact="cancer" post="(GBG 44-GeparQuinto) Ann Oncol 2014 25 2363 72 10.1093/annonc/mdu455"/>
   <result pre="Robidoux A, et al. Neoadjuvant plus adjuvant bevacizumab in early" exact="breast cancer" post="(NSABP B-40 [NRG Oncology]): secondary outcomes of a phase"/>
   <result pre="A, et al. Neoadjuvant plus adjuvant bevacizumab in early breast" exact="cancer" post="(NSABP B-40 [NRG Oncology]): secondary outcomes of a phase"/>
   <result pre="Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced" exact="breast cancer" post="(NOAH): follow-up of a randomised controlled superiority trial with"/>
   <result pre="and adjuvant trastuzumab in patients with HER2-positive locally advanced breast" exact="cancer" post="(NOAH): follow-up of a randomised controlled superiority trial with"/>
   <result pre="Perspective: pathological complete response and accelerated drug approval in early" exact="breast cancer" post="N Engl J Med 2012 366 2438 41 10.1056/NEJMp1205737"/>
   <result pre="pathological complete response and accelerated drug approval in early breast" exact="cancer" post="N Engl J Med 2012 366 2438 41 10.1056/NEJMp1205737"/>
   <result pre="prognostic significance of complete axillary downstaging after primary chemotherapy in" exact="breast cancer" post="patients with T1 to T3 tumors and cytologically proven"/>
   <result pre="significance of complete axillary downstaging after primary chemotherapy in breast" exact="cancer" post="patients with T1 to T3 tumors and cytologically proven"/>
   <result pre="of lymph node metastases after preoperative chemotherapy for locally advanced" exact="breast cancer" post="Arch Surg 1989 124 21 5 10.1001/archsurg.1989.01410010027005 2910244 15."/>
   <result pre="lymph node metastases after preoperative chemotherapy for locally advanced breast" exact="cancer" post="Arch Surg 1989 124 21 5 10.1001/archsurg.1989.01410010027005 2910244 15."/>
   <result pre="et al. Outcome after pathologic complete eradication of cytologically proven" exact="breast cancer" post="axillary node metastases following primary chemotherapy J Clin Oncol"/>
   <result pre="al. Outcome after pathologic complete eradication of cytologically proven breast" exact="cancer" post="axillary node metastases following primary chemotherapy J Clin Oncol"/>
   <result pre="Pinder SE Pathological controversies in breast cancer: classification of ductal" exact="carcinoma in situ," post="sentinel lymph nodes and low volume metastatic disease and"/>
   <result pre="Andre F Gonzalez-Angulo AM Symmans WF et al. Residual ductal" exact="carcinoma in situ" post="in patients with complete eradication of invasive breast cancer"/>
   <result pre="carcinoma in situ in patients with complete eradication of invasive" exact="breast cancer" post="after neoadjuvant chemotherapy does not adversely affect patient outcome"/>
   <result pre="in situ in patients with complete eradication of invasive breast" exact="cancer" post="after neoadjuvant chemotherapy does not adversely affect patient outcome"/>
   <result pre="complete response on prognosis after neoadjuvant chemotherapy in various intrinsic" exact="breast cancer" post="subtypes J Clin Oncol 2012 30 1796 804 10.1200/JCO.2011.38.8595"/>
   <result pre="response on prognosis after neoadjuvant chemotherapy in various intrinsic breast" exact="cancer" post="subtypes J Clin Oncol 2012 30 1796 804 10.1200/JCO.2011.38.8595"/>
   <result pre="A et al. A central review of histopathology reports after" exact="breast cancer" post="neoadjuvant chemotherapy in the Neo-tAnGo trial Br J Cancer"/>
   <result pre="et al. A central review of histopathology reports after breast" exact="cancer" post="neoadjuvant chemotherapy in the Neo-tAnGo trial Br J Cancer"/>
   <result pre="B Roche H Olivier JP Chollet P Hurteloup P Inflammatory" exact="breast cancer." post="Pilot study of intensive induction chemotherapy (FEC-HD) results in"/>
   <result pre="R Kuerer H Valero V et al. Measurement of residual" exact="breast cancer" post="burden to predict survival after neoadjuvant chemotherapy J Clin"/>
   <result pre="Kuerer H Valero V et al. Measurement of residual breast" exact="cancer" post="burden to predict survival after neoadjuvant chemotherapy J Clin"/>
   <result pre="L Symmans WF Residual specimen cellularity after neoadjuvant chemotherapy for" exact="breast cancer" post="Br J Surg 2008 95 433 7 10.1002/bjs.6044 18161887"/>
   <result pre="Symmans WF Residual specimen cellularity after neoadjuvant chemotherapy for breast" exact="cancer" post="Br J Surg 2008 95 433 7 10.1002/bjs.6044 18161887"/>
   <result pre="433 7 10.1002/bjs.6044 18161887 30. Earl HM Reporting of adjuvant" exact="breast cancer" post="trials – when is the right time? J Clin"/>
   <result pre="7 10.1002/bjs.6044 18161887 30. Earl HM Reporting of adjuvant breast" exact="cancer" post="trials – when is the right time? J Clin"/>
   <result pre="Aparicio S Caldas C A new genome-driven integrated classification of" exact="breast cancer" post="and its implications EMBO J 2013 32 617 28"/>
   <result pre="S Caldas C A new genome-driven integrated classification of breast" exact="cancer" post="and its implications EMBO J 2013 32 617 28"/>
   <result pre="et al. Analysis of circulating tumor DNA to monitor metastatic" exact="breast cancer" post="N Engl J Med 2013 368 1199 209 10.1056/NEJMoa1213261"/>
   <result pre="al. Analysis of circulating tumor DNA to monitor metastatic breast" exact="cancer" post="N Engl J Med 2013 368 1199 209 10.1056/NEJMoa1213261"/>
   <result pre="Eggemann H et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative" exact="breast cancer" post="N Engl J Med 2012 366 299 309 10.1056/NEJMoa1111065"/>
   <result pre="H et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast" exact="cancer" post="N Engl J Med 2012 366 299 309 10.1056/NEJMoa1111065"/>
   <result pre="Atkins JN et al. Bevacizumab added to neoadjuvant chemotherapy for" exact="breast cancer" post="N Engl J Med 2012 366 310 20 10.1056/NEJMoa1111097"/>
   <result pre="JN et al. Bevacizumab added to neoadjuvant chemotherapy for breast" exact="cancer" post="N Engl J Med 2012 366 310 20 10.1056/NEJMoa1111097"/>
   <result pre="J Pivot X et al. Adjuvant bevacizumab-containing therapy in triple-negative" exact="breast cancer" post="(BEATRICE): primary results of a randomised, phase 3 trial"/>
   <result pre="Pivot X et al. Adjuvant bevacizumab-containing therapy in triple-negative breast" exact="cancer" post="(BEATRICE): primary results of a randomised, phase 3 trial"/>
   <result pre="Aura C et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="C et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="their combinations (T + L) in the adjuvant treatment of HER2-positive early" exact="breast cancer" post="(EBC) [abstract] J Clin Oncol 2014 32 Suppl 5"/>
   <result pre="combinations (T + L) in the adjuvant treatment of HER2-positive early breast" exact="cancer" post="(EBC) [abstract] J Clin Oncol 2014 32 Suppl 5"/>
   <result pre="neoadjuvant model is still the future for drug development in" exact="breast cancer" post="Clin Cancer Res 2015 21 2911 5 10.1158/1078-0432.CCR-14-1760 25712686"/>
   <result pre="model is still the future for drug development in breast" exact="cancer" post="Clin Cancer Res 2015 21 2911 5 10.1158/1078-0432.CCR-14-1760 25712686"/>
   <result pre="improvements in pathologic response rate to neoadjuvant chemotherapy in different" exact="breast cancer" post="subtypes. San Antonio Breast Cancer Symposium Cancer Res 2013"/>
   <result pre="in pathologic response rate to neoadjuvant chemotherapy in different breast" exact="cancer" post="subtypes. San Antonio Breast Cancer Symposium Cancer Res 2013"/>
   <result pre="NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1673 84 10.1056/NEJMoa052122"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1673 84 10.1056/NEJMoa052122"/>
   <result pre="Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1659 72 10.1056/NEJMoa052306"/>
   <result pre="I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1659 72 10.1056/NEJMoa052306"/>
   <result pre="al. Pathologic complete response predicts recurrence-free survival more effectively by" exact="cancer" post="subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4586465/results/search/disease/results.xml">
   <result pre="therapies, there remains an urgent need for effective treatment for" exact="esophageal cancer" post="(EC) and triple-negative breast cancer (TNBC). Current FDA-approved drugs"/>
   <result pre="there remains an urgent need for effective treatment for esophageal" exact="cancer" post="(EC) and triple-negative breast cancer (TNBC). Current FDA-approved drugs"/>
   <result pre="need for effective treatment for esophageal cancer (EC) and triple-negative" exact="breast cancer" post="(TNBC). Current FDA-approved drugs have significant problems of toxicity,"/>
   <result pre="for effective treatment for esophageal cancer (EC) and triple-negative breast" exact="cancer" post="(TNBC). Current FDA-approved drugs have significant problems of toxicity,"/>
   <result pre="elucidates the mechanisms of HER-1/IGF-1R and HER-1/HER-2 signaling in these" exact="cancer" post="cell lines, and the promising results support the rationale"/>
   <result pre="and gastroesophageal cancers remain the sixth most common cause of" exact="cancer" post="deaths worldwide [ 1, 2] with an increasingly high"/>
   <result pre="remain elusive [ 3]. Adenocarcinoma remains the leading type of" exact="esophageal cancer" post="(EC) and increased rates of these cancers are seen"/>
   <result pre="elusive [ 3]. Adenocarcinoma remains the leading type of esophageal" exact="cancer" post="(EC) and increased rates of these cancers are seen"/>
   <result pre="typically less than one year with therapy [ 6]. Triple-negative" exact="breast cancer" post="(TNBC) accounts for 12%–24% of all breast cancer cases"/>
   <result pre="less than one year with therapy [ 6]. Triple-negative breast" exact="cancer" post="(TNBC) accounts for 12%–24% of all breast cancer cases"/>
   <result pre="6]. Triple-negative breast cancer (TNBC) accounts for 12%–24% of all" exact="breast cancer" post="cases and is one of the most aggressive subtypes"/>
   <result pre="Triple-negative breast cancer (TNBC) accounts for 12%–24% of all breast" exact="cancer" post="cases and is one of the most aggressive subtypes"/>
   <result pre="advances in our understanding of the signaling networks that drive" exact="cancer" post="progression have ushered in a new era of cancer"/>
   <result pre="drive cancer progression have ushered in a new era of" exact="cancer" post="therapeutics. These new agents inhibit specific growth stimulatory pathways,"/>
   <result pre="pertuzumab has had significant clinical success in the treatment of" exact="breast cancer" post="when combined with trastuzumab [ 36]; similar dual-targeting clinical"/>
   <result pre="has had significant clinical success in the treatment of breast" exact="cancer" post="when combined with trastuzumab [ 36]; similar dual-targeting clinical"/>
   <result pre="50, 51]. HER-1-targeting with hmAb cetuximab performed poorly in metastatic" exact="breast cancer." post="However, further trials combining cetuximab with cisplatin showed significant"/>
   <result pre="that co-inhibition of HER-1 and IGF-IR sensitized HER-1/IGF-1R expressing human" exact="breast cancer" post="cells to radiation [ 59]. FDA-approved drugs targeting HER-1"/>
   <result pre="co-inhibition of HER-1 and IGF-IR sensitized HER-1/IGF-1R expressing human breast" exact="cancer" post="cells to radiation [ 59]. FDA-approved drugs targeting HER-1"/>
   <result pre="(AG1024) respectively show synergistic therapeutic advantage in in vitro human" exact="breast cancer" post="cells, further highlighting the importance of pursuing combination therapies"/>
   <result pre="respectively show synergistic therapeutic advantage in in vitro human breast" exact="cancer" post="cells, further highlighting the importance of pursuing combination therapies"/>
   <result pre="cells, further highlighting the importance of pursuing combination therapies in" exact="cancer" post="treatment [ 60]. Combination therapy has also demonstrated clinical"/>
   <result pre="failed to show a synergistic effect in patients with metastatic" exact="breast cancer" post="[ 66]. Further, the combination of the HER-1 kinase"/>
   <result pre="to show a synergistic effect in patients with metastatic breast" exact="cancer" post="[ 66]. Further, the combination of the HER-1 kinase"/>
   <result pre="hmAb bevacizumab showed promising synergy in preliminary data obtained in" exact="colorectal cancer" post="[ 67]. Clearly, an urgent need exists for novel"/>
   <result pre="bevacizumab showed promising synergy in preliminary data obtained in colorectal" exact="cancer" post="[ 67]. Clearly, an urgent need exists for novel"/>
   <result pre="approach using peptide mimics and peptide vaccine antibodies significantly inhibited" exact="cancer" post="signaling pathways in vitro. Combination treatment with HER-1 and"/>
   <result pre="binding domains of the receptors and block ligand-induced signaling in" exact="cancer" post="cells that express these receptors. The two HER-2 peptide"/>
   <result pre="synthesized with a promiscuous Th cell epitope derived from the" exact="measles" post="virus fusion protein (MVF; residues 288–302) using a four"/>
   <result pre="on its (i) overall in vitro antitumor properties: inhibition of" exact="cancer" post="cell growth, prevention of HER-1-specific phosphorylation, down regulation of"/>
   <result pre="&amp;lt; 0.005) delayed tumor growth in the FVB/n Met-1 transplantable" exact="breast cancer" post="model. Additionally, there were significant reductions in the number"/>
   <result pre="0.005) delayed tumor growth in the FVB/n Met-1 transplantable breast" exact="cancer" post="model. Additionally, there were significant reductions in the number"/>
   <result pre="inhibited tumor growth in the transplantable BxPC-3 pancreatic and JIMT-1" exact="breast cancer" post="models. We found additive antitumor effects for the combination"/>
   <result pre="tumor growth in the transplantable BxPC-3 pancreatic and JIMT-1 breast" exact="cancer" post="models. We found additive antitumor effects for the combination"/>
   <result pre="interventions would decrease in vitro proliferation of OE19 and MDA-MB-231" exact="cancer" post="cell lines. We treated the cells with different combinations"/>
   <result pre="vaccines engineered with the &quot;promiscuous&quot; T cell epitope of the" exact="measles" post="virus fusion protein (MVF; italics). The flexible linker sequence"/>
   <result pre="vaccine antibodies down-regulate phosphorylation of HER-1 and HER-2 in OE19" exact="cancer" post="cells in vitro. Specifically, in EC cells (OE19), single"/>
   <result pre="induction of apoptosis in EC or TNBC. OE19 or MDA-MB-231" exact="cancer" post="cells were plated in 96-well plates and treated with"/>
   <result pre="synergistic inhibition of tumor growth and suppress metastasis of multiple" exact="cancer" post="types. In the present study, we focused on two"/>
   <result pre="are augmented, supporting the importance of combination therapies in novel" exact="cancer" post="treatment. Co-treatment with trastuzumab and cetuximab has shown promising"/>
   <result pre="anti proliferative effects in vitro in a human non-small cell" exact="lung carcinoma" post="cell line (A549) [ 81]. In our in vitro"/>
   <result pre="and apoptosis than single treatment, exhibiting indirect methods of tumor" exact="suppression" post="as well. Interestingly, depending on the mechanisms being measured,"/>
   <result pre="insulin-like growth factor-1 receptor (IGF-1R) as a major target in" exact="cancer" post="drug discovery and its role in the development of"/>
   <result pre="HER-1/IGF-1R and HER-1/HER-2 signaling influences complex biological processes in these" exact="cancer" post="cell lines, and the promising results support the rationale"/>
   <result pre="1. Parkin D.M. Bray F. Ferlay J. Pisani P. Global" exact="cancer" post="statistics, 2002 CA Cancer J. Clin. 2005 55 74"/>
   <result pre="Z. Tang P. Li L. Wang G. The strategy for" exact="esophageal cancer" post="control in high-risk areas of China Jpn. J. Clin."/>
   <result pre="Tang P. Li L. Wang G. The strategy for esophageal" exact="cancer" post="control in high-risk areas of China Jpn. J. Clin."/>
   <result pre="Oates J. Norman A.R. Capecitabine and oxaliplatin for advanced esophagogastric" exact="cancer" post="N. Engl. J. Med. 2008 358 36 46 10.1056/NEJMoa073149"/>
   <result pre="al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative" exact="breast cancer" post="Clin. Cancer Res. 2013 19 2723 2733 10.1158/1078-0432.CCR-12-2986 23549873"/>
   <result pre="Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast" exact="cancer" post="Clin. Cancer Res. 2013 19 2723 2733 10.1158/1078-0432.CCR-12-2986 23549873"/>
   <result pre="and emerging trends in epidermal growth factor receptor targeting in" exact="cancer" post="J. Clin. Oncol. 2005 23 2445 2459 10.1200/JCO.2005.11.890 15753456"/>
   <result pre="Lessons from phase III clinical trials on anti-VEGF therapy for" exact="cancer" post="Nat. Clin. Pract. Oncol. 2006 3 24 40 10.1038/ncponc0403"/>
   <result pre="phase I/II dose-escalation trial of bevacizumab in previously treated metastatic" exact="breast cancer" post="Sem. Oncol. 2003 30 117 124 10.1053/j.seminoncol.2003.08.013 16. Hynes"/>
   <result pre="I/II dose-escalation trial of bevacizumab in previously treated metastatic breast" exact="cancer" post="Sem. Oncol. 2003 30 117 124 10.1053/j.seminoncol.2003.08.013 16. Hynes"/>
   <result pre="A. Recognizing and managing toxicities of molecular targeted therapies for" exact="colorectal cancer" post="Oncology (Williston Park) 2006 20 21 28 17354514 30."/>
   <result pre="Recognizing and managing toxicities of molecular targeted therapies for colorectal" exact="cancer" post="Oncology (Williston Park) 2006 20 21 28 17354514 30."/>
   <result pre="option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="Ther. Adv. Gastroenterol. 2012 5 301 318 10.1177/1756283X12450246 22973416"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): A phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="A. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic" exact="breast cancer" post="(cleopatra study): Overall survival results from a randomised, double-blind,"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast" exact="cancer" post="(cleopatra study): Overall survival results from a randomised, double-blind,"/>
   <result pre="Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell" exact="cancer" post="of the esophagus N. Engl. J. Med. 1997 337"/>
   <result pre="Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of" exact="barrett's esophagus" post="to adenocarcinoma World J. Gastroenterol. 2006 12 928 934"/>
   <result pre="C. et al. HER-2 amplification is highly homogenous in gastric" exact="cancer" post="Hum. Pathol. 2009 40 769 777 10.1016/j.humpath.2008.11.014 19269014 44."/>
   <result pre="Sharma N. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric" exact="cancer" post="Anticancer Res. 2013 33 4139 4155 24122977 45. Gluz"/>
   <result pre="High EGFR gene copy number predicts poor outcome in triple-negative" exact="breast cancer" post="Mod. Pathol. 2014 27 1212 1222 10.1038/modpathol.2013.251 24406864 49."/>
   <result pre="EGFR gene copy number predicts poor outcome in triple-negative breast" exact="cancer" post="Mod. Pathol. 2014 27 1212 1222 10.1038/modpathol.2013.251 24406864 49."/>
   <result pre="markers as potential therapeutic targets in saudi women with triple-negative" exact="breast cancer" post="Tumori 2013 99 545 554 24326846 50. Carey L.A."/>
   <result pre="as potential therapeutic targets in saudi women with triple-negative breast" exact="cancer" post="Tumori 2013 99 545 554 24326846 50. Carey L.A."/>
   <result pre="of cetuximab in combination with carboplatin in stage iv triple-negative" exact="breast cancer" post="J. Clin. Oncol. 2012 30 2615 2623 10.1200/JCO.2010.34.5579 22665533"/>
   <result pre="cetuximab in combination with carboplatin in stage iv triple-negative breast" exact="cancer" post="J. Clin. Oncol. 2012 30 2615 2623 10.1200/JCO.2010.34.5579 22665533"/>
   <result pre="with cisplatin versus cisplatin alone in patients with metastatic triple-negative" exact="breast cancer" post="J. Clin. Oncol. 2013 31 2586 2592 10.1200/JCO.2012.46.2408 23733761"/>
   <result pre="cisplatin versus cisplatin alone in patients with metastatic triple-negative breast" exact="cancer" post="J. Clin. Oncol. 2013 31 2586 2592 10.1200/JCO.2012.46.2408 23733761"/>
   <result pre="May F.E. Insulin-like growth factor-dependent proliferation and survival of triple-negative" exact="breast cancer" post="cells: Implications for therapy Neoplasia 2011 13 504 515"/>
   <result pre="F.E. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast" exact="cancer" post="cells: Implications for therapy Neoplasia 2011 13 504 515"/>
   <result pre="F. Chang J.C. et al. High igf-ir activity in triple-negative" exact="breast cancer" post="cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR"/>
   <result pre="Chang J.C. et al. High igf-ir activity in triple-negative breast" exact="cancer" post="cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR"/>
   <result pre="et al. Acquired resistance to EGFR tyrosine kinase inhibitors in" exact="cancer" post="cells is mediated by loss of IGF-binding proteins J."/>
   <result pre="and insulin-like growth factor receptor 1 enhances radiosensitivity in human" exact="breast cancer" post="cells BMC Cancer 2013 10.1186/1471-2407-13-297 23777562 60. Camirand A."/>
   <result pre="insulin-like growth factor receptor 1 enhances radiosensitivity in human breast" exact="cancer" post="cells BMC Cancer 2013 10.1186/1471-2407-13-297 23777562 60. Camirand A."/>
   <result pre="enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human" exact="breast cancer" post="cells Breast Cancer Res. 2005 7 R570 R579 10.1186/bcr1028"/>
   <result pre="growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast" exact="cancer" post="cells Breast Cancer Res. 2005 7 R570 R579 10.1186/bcr1028"/>
   <result pre="in the management of trastuzumab resistant or refractory HER-2(+) metastatic" exact="breast cancer" post="Oncologist 2011 16 1535 1546 10.1634/theoncologist.2011-0165 22020213 63. Gerlinger"/>
   <result pre="the management of trastuzumab resistant or refractory HER-2(+) metastatic breast" exact="cancer" post="Oncologist 2011 16 1535 1546 10.1634/theoncologist.2011-0165 22020213 63. Gerlinger"/>
   <result pre="for human epidermal growth factor receptor (HER) 2 in gastric" exact="cancer" post="specimens Cell Biochem. Biophys. 2012 62 221 228 10.1007/s12013-011-9286-1"/>
   <result pre="I/II trial of trastuzumab and gefitinib in patients with metastatic" exact="breast cancer" post="that overexpresses HER2/neu (ErbB-2) Clin. Breast Cancer 2003 4"/>
   <result pre="trial of trastuzumab and gefitinib in patients with metastatic breast" exact="cancer" post="that overexpresses HER2/neu (ErbB-2) Clin. Breast Cancer 2003 4"/>
   <result pre="vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit" exact="cancer" post="cell growth in vitro and in vivo J. Immunol."/>
   <result pre="antineoplastic effects in transplantable and transgenic mouse models of human" exact="breast cancer" post="Oncoimmunology 2012 1 1004 1016 10.4161/onci.21057 23170249 72. Taylor"/>
   <result pre="effects in transplantable and transgenic mouse models of human breast" exact="cancer" post="Oncoimmunology 2012 1 1004 1016 10.4161/onci.21057 23170249 72. Taylor"/>
   <result pre="and HER-1 peptides induces synergistic antitumor effects against breast and" exact="pancreatic cancer" post="cells Oncoimmunology 2014 3 e956012 10.4161/21624011.2014.956012 25941588 76. Foy"/>
   <result pre="HER-1 peptides induces synergistic antitumor effects against breast and pancreatic" exact="cancer" post="cells Oncoimmunology 2014 3 e956012 10.4161/21624011.2014.956012 25941588 76. Foy"/>
   <result pre="IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1" exact="cancer" post="cells and exhibit synergistic antitumor effects with HER-1 and"/>
   <result pre="cetuximab (erbitux ®) in a model of human non-small cell" exact="lung cancer" post="expressing EGFR and HER2 Clin. Exp. Med. 2015 10.1007/s10238-015-0343-8"/>
   <result pre="(erbitux ®) in a model of human non-small cell lung" exact="cancer" post="expressing EGFR and HER2 Clin. Exp. Med. 2015 10.1007/s10238-015-0343-8"/>
   <result pre="Harari D. Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in" exact="breast cancer" post="Oncogene 2000 19 6102 6114 10.1038/sj.onc.1203973 11156523 83. Balana"/>
   <result pre="D. Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast" exact="cancer" post="Oncogene 2000 19 6102 6114 10.1038/sj.onc.1203973 11156523 83. Balana"/>
   <result pre="growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing" exact="breast cancer" post="cells Med. Sci. Monit. 2002 8 BR521 526 12503030"/>
   <result pre="factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast" exact="cancer" post="cells Med. Sci. Monit. 2002 8 BR521 526 12503030"/>
   <result pre="growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of" exact="breast cancer" post="cells Cancer Res. 2005 65 11118 11128 10.1158/0008-5472.CAN-04-3841 16322262"/>
   <result pre="factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast" exact="cancer" post="cells Cancer Res. 2005 65 11118 11128 10.1158/0008-5472.CAN-04-3841 16322262"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4586793/results/search/disease/results.xml">
   <result pre="tissue origins. Therefore, these signaling pathways became prime targets for" exact="cancer" post="therapy. This review aims to provide an overview about"/>
   <result pre="aberrant functions. RTK MAP kinase PI3K AKT small molecule inhibitors" exact="cancer" post="1. Introduction Receptor tyrosine kinases (RTKs) are a family"/>
   <result pre="remains a challenge for scientists and clinicians working in the" exact="cancer" post="field. Several small molecule inhibitors and antibodies are being"/>
   <result pre="tissue origins. This chapter discusses the role of RTKs in" exact="cancer" post="and the therapeutic strategies developed to target them ("/>
   <result pre="representation of the mode of action of RTKs inhibitors. In" exact="cancer" post="therapy, RTKs are targeted using monoclonal antibodies that prevent"/>
   <result pre="transduction. cancers-07-00860-t001_Table 1 Table 1 Examples of RTK targeted molecular" exact="cancer" post="therapies being used clinically or subjected to clinical trials."/>
   <result pre="Target Compound Cancer References EGFR family HER2 Trastuzumab (Herceptin) HER2-positive" exact="breast cancer" post="[ 7, 8, 9] EGFR Cetuximab (Erbitux) Metastatic colorectal"/>
   <result pre="Compound Cancer References EGFR family HER2 Trastuzumab (Herceptin) HER2-positive breast" exact="cancer" post="[ 7, 8, 9] EGFR Cetuximab (Erbitux) Metastatic colorectal"/>
   <result pre="breast cancer [ 7, 8, 9] EGFR Cetuximab (Erbitux) Metastatic" exact="colorectal cancer" post="(RAS wild type) Metastatic non-small-cell lung cancer [ 10]"/>
   <result pre="cancer [ 7, 8, 9] EGFR Cetuximab (Erbitux) Metastatic colorectal" exact="cancer" post="(RAS wild type) Metastatic non-small-cell lung cancer [ 10]"/>
   <result pre="Cetuximab (Erbitux) Metastatic colorectal cancer (RAS wild type) Metastatic non-small-cell" exact="lung cancer" post="[ 10] Panitumumab (Vectibix) [ 10, 11, 12] Gefitinib"/>
   <result pre="(Erbitux) Metastatic colorectal cancer (RAS wild type) Metastatic non-small-cell lung" exact="cancer" post="[ 10] Panitumumab (Vectibix) [ 10, 11, 12] Gefitinib"/>
   <result pre="(Tarceva) [ 13, 16] EGFR and HER2 Lapatinib (Tykerb HER2-positive" exact="breast cancer" post="(Trastuzumab-resistant) [ 14, 17] Afatinib NSCLC HER2-positive breast cancer"/>
   <result pre="[ 13, 16] EGFR and HER2 Lapatinib (Tykerb HER2-positive breast" exact="cancer" post="(Trastuzumab-resistant) [ 14, 17] Afatinib NSCLC HER2-positive breast cancer"/>
   <result pre="HER2-positive breast cancer (Trastuzumab-resistant) [ 14, 17] Afatinib NSCLC HER2-positive" exact="breast cancer" post="[ 18, 19, 20, 21] VEGFR Sorafenib (Nexavar) Renal,"/>
   <result pre="breast cancer (Trastuzumab-resistant) [ 14, 17] Afatinib NSCLC HER2-positive breast" exact="cancer" post="[ 18, 19, 20, 21] VEGFR Sorafenib (Nexavar) Renal,"/>
   <result pre="18, 19, 20, 21] VEGFR Sorafenib (Nexavar) Renal, liver and" exact="thyroid cancer" post="[ 22, 23, 24] Sunitinib (Sutent) Renal cell cancer"/>
   <result pre="19, 20, 21] VEGFR Sorafenib (Nexavar) Renal, liver and thyroid" exact="cancer" post="[ 22, 23, 24] Sunitinib (Sutent) Renal cell cancer"/>
   <result pre="thyroid cancer [ 22, 23, 24] Sunitinib (Sutent) Renal cell" exact="cancer" post="Gastrointestinal stromal tumor (GIST) [ 25, 26] Bevacizumab (Avastin)"/>
   <result pre="32] Soratinib Pazopanib Nilotinib FGFR and VEGFR Brivanib (BMS-540215) Human" exact="hepatocellular carcinoma" post="model [ 33] VEGFR, PDGFR, FLT-3, c-KIT and FGFR"/>
   <result pre="members have been associated with several cancers [ 40]. In" exact="breast cancer," post="overexpression of HER2 (ERBB2) is found in approximately 10%–30%"/>
   <result pre="overexpression in 30%–50% of glioblastomas [ 42, 43], 25%–82% in" exact="colorectal cancer" post="[ 44, 45, 46, 47] and 5%–20% in non-small-cell"/>
   <result pre="in 30%–50% of glioblastomas [ 42, 43], 25%–82% in colorectal" exact="cancer" post="[ 44, 45, 46, 47] and 5%–20% in non-small-cell"/>
   <result pre="cancer [ 44, 45, 46, 47] and 5%–20% in non-small-cell" exact="lung cancer" post="[ 13, 48]. Therefore, molecular targeted therapeutics were developed"/>
   <result pre="[ 44, 45, 46, 47] and 5%–20% in non-small-cell lung" exact="cancer" post="[ 13, 48]. Therefore, molecular targeted therapeutics were developed"/>
   <result pre="target the extracellular domain of the HER2 protein in HER2-positive" exact="breast cancer" post="patients and has been shown to increase survival at"/>
   <result pre="the extracellular domain of the HER2 protein in HER2-positive breast" exact="cancer" post="patients and has been shown to increase survival at"/>
   <result pre="shown to increase survival at early and late stages of" exact="breast cancer" post="[ 7]. Cetuximab (Erbitux) and Panitumumab (Vectibix) are two"/>
   <result pre="to increase survival at early and late stages of breast" exact="cancer" post="[ 7]. Cetuximab (Erbitux) and Panitumumab (Vectibix) are two"/>
   <result pre="the EGFR-ligand binding in the treatment of patients with metastatic" exact="colorectal cancer" post="[ 11, 12]. The benefit of cetuximab and Panitumumab"/>
   <result pre="EGFR-ligand binding in the treatment of patients with metastatic colorectal" exact="cancer" post="[ 11, 12]. The benefit of cetuximab and Panitumumab"/>
   <result pre="and has been used as an alternative treatment of HER2-positive" exact="breast cancer" post="patients that developed resistance to Trastuzumab [ 8, 9]."/>
   <result pre="has been used as an alternative treatment of HER2-positive breast" exact="cancer" post="patients that developed resistance to Trastuzumab [ 8, 9]."/>
   <result pre="the risk of disease progression in women with advanced HER2-positive" exact="breast cancer" post="who had received multiple previous treatments [ 17]. More"/>
   <result pre="risk of disease progression in women with advanced HER2-positive breast" exact="cancer" post="who had received multiple previous treatments [ 17]. More"/>
   <result pre="treat postmenopausal women with Hormone receptor (HR) positive, HER2-positive metastatic" exact="breast cancer." post="This combination resulted in increased progression free survival in"/>
   <result pre="have been used in treatment of patients with metastatic non-small-cell" exact="lung cancer." post="These drugs have been used in combination with chemotherapy"/>
   <result pre="to extend progression free survival of patients with non-small cell" exact="lung carcinoma" post="(NSCLC). However, this effect appears to be more beneficial"/>
   <result pre="investigated for use in other HER2-positive cancers such as HER2-positive" exact="breast cancer" post="[ 21]. 2.1.2. VEGFR-Targeted Therapy This family of receptors,"/>
   <result pre="for use in other HER2-positive cancers such as HER2-positive breast" exact="cancer" post="[ 21]. 2.1.2. VEGFR-Targeted Therapy This family of receptors,"/>
   <result pre="with the aim of reducing angiogenesis and lymphangiogenesis associated with" exact="cancer" post="progression [ 49]. Sorafenib (Nexavar), a small molecule inhibitor"/>
   <result pre="Sorafenib treatment was reported in patients with advanced renal cell" exact="cancer" post="and nonresponsive thyroid cancer [ 22, 23]. In patients"/>
   <result pre="reported in patients with advanced renal cell cancer and nonresponsive" exact="thyroid cancer" post="[ 22, 23]. In patients with liver cancer, an"/>
   <result pre="in patients with advanced renal cell cancer and nonresponsive thyroid" exact="cancer" post="[ 22, 23]. In patients with liver cancer, an"/>
   <result pre="and nonresponsive thyroid cancer [ 22, 23]. In patients with" exact="liver cancer," post="an improvement of median overall survival was reported ["/>
   <result pre="shown to improve overall survival of patients with renal cell" exact="cancer" post="and gastrointestinal stromal tumor [ 25, 26]. Besides the"/>
   <result pre="improve overall survival of patients with renal cell cancer and" exact="gastrointestinal stromal tumor" post="[ 25, 26]. Besides the use of small molecule"/>
   <result pre="PDGFRα gene have been found in 5% of gastrointestinal stromal" exact="cancer" post="(GIST). These mutations affect tyrosine kinase domains and juxtamembrane"/>
   <result pre="In addition, amplifications of PDGFRα were reported in 5%–10% of" exact="glioblastoma multiforme," post="in oligodendrocytoma, esophageal squamous cell carcinoma and artery intimal"/>
   <result pre="of the oncogenic Bcr-abl fusion protein responsible for chronic myelogenous" exact="leukemia" post="(CML), has been used to target PDGFR in gastrointestinal"/>
   <result pre="61]. Amplifications of FGFR1 and 2 have been found in" exact="breast cancer" post="[ 62, 63, 64, 65, 66, 67, 68, 69,"/>
   <result pre="Amplifications of FGFR1 and 2 have been found in breast" exact="cancer" post="[ 62, 63, 64, 65, 66, 67, 68, 69,"/>
   <result pre="64, 65, 66, 67, 68, 69, 70] and in gastric" exact="cancer" post="where these mutations were associated with poor prognosis ["/>
   <result pre="poor prognosis [ 71, 72]. FGFR1 amplifications were found in" exact="bladder cancer," post="oral squamous carcinoma and ovarian cancer [ 73, 74,"/>
   <result pre="amplifications were found in bladder cancer, oral squamous carcinoma and" exact="ovarian cancer" post="[ 73, 74, 75]. Point mutations that affect FGFR1,"/>
   <result pre="were found in bladder cancer, oral squamous carcinoma and ovarian" exact="cancer" post="[ 73, 74, 75]. Point mutations that affect FGFR1,"/>
   <result pre="increase of receptors or constitutive activations and were observed in" exact="cancer" post="of the prostate, bladder, breast, brain, lung, uterus, stomach,"/>
   <result pre="shown to affect tumor growth in mouse models of human" exact="hepatocellular carcinoma" post="(HCC) [ 33]. CHIR-258 (TKI-258), a multiple target inhibitor"/>
   <result pre="that has been shown to inhibit the growth of the" exact="breast cancer" post="cell line MDA-MB-231, the prostate cancer cell line PC3,"/>
   <result pre="has been shown to inhibit the growth of the breast" exact="cancer" post="cell line MDA-MB-231, the prostate cancer cell line PC3,"/>
   <result pre="the growth of the breast cancer cell line MDA-MB-231, the" exact="prostate cancer" post="cell line PC3, the colon cancer cell line HT29"/>
   <result pre="growth of the breast cancer cell line MDA-MB-231, the prostate" exact="cancer" post="cell line PC3, the colon cancer cell line HT29"/>
   <result pre="cell line MDA-MB-231, the prostate cancer cell line PC3, the" exact="colon cancer" post="cell line HT29 and the pancreatic cancer cell line"/>
   <result pre="line MDA-MB-231, the prostate cancer cell line PC3, the colon" exact="cancer" post="cell line HT29 and the pancreatic cancer cell line"/>
   <result pre="line PC3, the colon cancer cell line HT29 and the" exact="pancreatic cancer" post="cell line PaCa2 [ 116, 117]. Other inhibitors have"/>
   <result pre="PC3, the colon cancer cell line HT29 and the pancreatic" exact="cancer" post="cell line PaCa2 [ 116, 117]. Other inhibitors have"/>
   <result pre="cell cycle [ 124]. Similar results were observed in other" exact="cancer" post="cell lines, re-enforcing its role as a regulator of"/>
   <result pre="ERK5 using siRNA, triggered apoptosis and reduced chemo-resistance of HL-60" exact="acute myeloid leukemia" post="cells [ 126]. ERK5 also appears to play a"/>
   <result pre="using siRNA, triggered apoptosis and reduced chemo-resistance of HL-60 acute" exact="myeloid leukemia" post="cells [ 126]. ERK5 also appears to play a"/>
   <result pre="siRNA, triggered apoptosis and reduced chemo-resistance of HL-60 acute myeloid" exact="leukemia" post="cells [ 126]. ERK5 also appears to play a"/>
   <result pre="[ 126]. ERK5 also appears to play a role in" exact="prostate cancer" post="invasion and metastasis. High levels of expression of ERK5"/>
   <result pre="126]. ERK5 also appears to play a role in prostate" exact="cancer" post="invasion and metastasis. High levels of expression of ERK5"/>
   <result pre="presence of bony metastases and less favourable disease-specific survival in" exact="prostate cancer" post="patients. This expression was associated with increased expression of"/>
   <result pre="of bony metastases and less favourable disease-specific survival in prostate" exact="cancer" post="patients. This expression was associated with increased expression of"/>
   <result pre="in xenograft tumour models of B16F10 melanoma and LL/2 Lewis" exact="lung cancer" post="and which resulted in reduced mass and vascular density"/>
   <result pre="xenograft tumour models of B16F10 melanoma and LL/2 Lewis lung" exact="cancer" post="and which resulted in reduced mass and vascular density"/>
   <result pre="In a similar manner, JNK2 but not JNK1 knockout, prevented" exact="skin cancer" post="formation that was induced by DMBA (7,12-dimethylbenz[ a]anthracene) and"/>
   <result pre="a similar manner, JNK2 but not JNK1 knockout, prevented skin" exact="cancer" post="formation that was induced by DMBA (7,12-dimethylbenz[ a]anthracene) and"/>
   <result pre="two JNK MAP kinase activators, have been associated with high-grade" exact="prostate cancer" post="[ 132]. The p38 family comprises four isoforms (p38α,"/>
   <result pre="JNK MAP kinase activators, have been associated with high-grade prostate" exact="cancer" post="[ 132]. The p38 family comprises four isoforms (p38α,"/>
   <result pre="important event in tumor migration and spreading, as it allows" exact="cancer" post="cells to survive following a loss of contact with"/>
   <result pre="cancers and in this regard constitutes a potential target for" exact="cancer" post="therapies. Targeting the RAS/MAP Kinase Pathway in Cancer Most"/>
   <result pre="therapies. Targeting the RAS/MAP Kinase Pathway in Cancer Most of" exact="cancer" post="associated mutations affecting the MAP kinase signaling pathway involve"/>
   <result pre="inhibitors are mainly developed for treatment of diseases such as" exact="rheumatoid arthritis" post="and Crohn’s disease, however, the inhibitor LY2228820 dimesylate produced"/>
   <result pre="are mainly developed for treatment of diseases such as rheumatoid" exact="arthritis" post="and Crohn’s disease, however, the inhibitor LY2228820 dimesylate produced"/>
   <result pre="of MAP kinase and PI3K/AKT pathways’ factors targeted by molecular" exact="cancer" post="therapies being used clinically or that are subject to"/>
   <result pre="146] PLX4720 PLX4032 GSK2118436 C-RAF LErafAON (NeoPharm) Ovarian and Breast" exact="cancer" post="[ 143, 144, 145, 146] ISIS 5132 MEK CI-1040"/>
   <result pre="reported in human breast, colorectal, ovarian cancers and squamous cell" exact="lung carcinoma" post="[ 168, 169]. This mutation activates Akt1 by promoting"/>
   <result pre="amplifications in the PIK3CA gene were found in squamous cell" exact="lung carcinoma," post="head and neck, cervical, gastric, and oesophageal cancers ["/>
   <result pre="175]. Amplifications in the AKT1 gene were associated with gastric" exact="cancer" post="and in AKT2 gene with head and neck, pancreatic,"/>
   <result pre="this regard, an important obstacle remains in the capacity of" exact="cancer" post="cells to adapt to these inhibitors by developing resistance"/>
   <result pre="Raf inhibitors) or PI3K/AKT may have a better effect in" exact="cancer" post="patients’ treatment. Finally, cancers have heterogeneous populations of cells"/>
   <result pre="those inhibitors and might play a role in chemo-resistance and" exact="cancer" post="initiation and progression following chemotherapeutic treatments. Cancer stem cells"/>
   <result pre="a well-known example of chemo-resistance that leads to relapse in" exact="cancer" post="patients. For instance, malignant melanoma stem cells express the"/>
   <result pre="may attenuate the therapeutic efficiency of the inhibitors used in" exact="cancer" post="therapy [ 180]. Therefore, a better understanding of tumor"/>
   <result pre="J.E. Murphy M. Stewart S.J. Safety of treatment of metastatic" exact="breast cancer" post="with trastuzumab beyond disease progression J. Clin. Oncol. 2004"/>
   <result pre="Murphy M. Stewart S.J. Safety of treatment of metastatic breast" exact="cancer" post="with trastuzumab beyond disease progression J. Clin. Oncol. 2004"/>
   <result pre="Venturini M. et al. Outcome of patients with HER2-positive advanced" exact="breast cancer" post="progressing during trastuzumab-based therapy Oncologist 2006 11 318 324"/>
   <result pre="M. et al. Outcome of patients with HER2-positive advanced breast" exact="cancer" post="progressing during trastuzumab-based therapy Oncologist 2006 11 318 324"/>
   <result pre="cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic" exact="colorectal cancer" post="(ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study"/>
   <result pre="in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal" exact="cancer" post="(ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study"/>
   <result pre="10.1016/S1470-2045(14)70118-4 24739896 11. Messersmith W.A. Ahnen D.J. Targeting EGFR in" exact="colorectal cancer" post="N. Engl. J. Med. 2008 359 1834 1836 10.1056/NEJMe0806778"/>
   <result pre="24739896 11. Messersmith W.A. Ahnen D.J. Targeting EGFR in colorectal" exact="cancer" post="N. Engl. J. Med. 2008 359 1834 1836 10.1056/NEJMe0806778"/>
   <result pre="Jassem J. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in" exact="colorectal cancer" post="N. Engl. J. Med. 2013 369 1023 1034 10.1056/NEJMoa1305275"/>
   <result pre="J. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal" exact="cancer" post="N. Engl. J. Med. 2013 369 1023 1034 10.1056/NEJMoa1305275"/>
   <result pre="M. Miller V.A. Clinical course of patients with non-small cell" exact="lung cancer" post="and epidermal growth factor receptor exon 19 and exon"/>
   <result pre="Miller V.A. Clinical course of patients with non-small cell lung" exact="cancer" post="and epidermal growth factor receptor exon 19 and exon"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="J. Clin. Oncol. 2009 20 5538 5546 10.1200/JCO.2009.23.3734 19786658"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="J. Clin. Oncol. 2009 20 5538 5546 10.1200/JCO.2009.23.3734 19786658"/>
   <result pre="as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell" exact="lung cancer" post="(OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study"/>
   <result pre="first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung" exact="cancer" post="(OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study"/>
   <result pre="Kaufman B. et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N. Engl. J. Med. 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="B. et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N. Engl. J. Med. 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical" exact="lung cancer" post="models Oncogene 2008 27 4702 4711 10.1038/onc.2008.109 18408761 19."/>
   <result pre="BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung" exact="cancer" post="models Oncogene 2008 27 4702 4711 10.1038/onc.2008.109 18408761 19."/>
   <result pre="an irreversible ErbB family blocker, in patients with HER2-positive metastatic" exact="breast cancer" post="progressing after trastuzumab Breast Cancer Res. Treat. 2012 133"/>
   <result pre="irreversible ErbB family blocker, in patients with HER2-positive metastatic breast" exact="cancer" post="progressing after trastuzumab Breast Cancer Res. Treat. 2012 133"/>
   <result pre="A. Raoul J.-L. Forner A. et al. Sorafenib in advanced" exact="hepatocellular carcinoma" post="N. Engl. J. Med. 2008 359 378 390 10.1056/NEJMoa0708857"/>
   <result pre="for sunitinib compared with interferon alfa in patients with metastatic" exact="renal cell carcinoma" post="J. Clin. Oncol. 2009 27 3584 3590 10.1200/JCO.2008.20.1293 19487381"/>
   <result pre="et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic" exact="colorectal cancer" post="N. Engl. J. Med. 2004 350 2335 2342 10.1056/NEJMoa032691"/>
   <result pre="al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal" exact="cancer" post="N. Engl. J. Med. 2004 350 2335 2342 10.1056/NEJMoa032691"/>
   <result pre="receptor and platelet-derived growth factor receptor, in patients with metastatic" exact="renal cell carcinoma" post="J. Clin. Oncol. 2006 24 16 24 10.1200/JCO.2005.02.2574 16330672"/>
   <result pre="Staddon A.P. Beppu Y. et al. Pazopanib for metastatic soft-tissue" exact="sarcoma" post="(PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial Lancet"/>
   <result pre="V.R. Leggas M. Sunitinib malate for the treatment of metastatic" exact="renal cell carcinoma" post="and gastrointestinal stromal tumors Clin. Ther. 2007 29 1338"/>
   <result pre="tyrosine kinases, induces growth inhibition in mouse models of human" exact="hepatocellular carcinoma" post="Clin. Cancer Res. 2008 14 6146 6153 10.1158/1078-0432.CCR-08-0509 18829493"/>
   <result pre="kinase inhibitor for the potential treatment of t (4; 14)" exact="multiple myeloma" post="Blood 2008 105 2941 2948 10.1182/blood-2004-10-3913 15598814 36. Buchanan"/>
   <result pre="39. Ashman L.K. Griffith R. Therapeutic targeting of c-KIT in" exact="cancer" post="Expert Opin. Investig. Drugs 2013 22 103 115 10.1517/13543784.2013.740010"/>
   <result pre="40. Takeuchi K. Ito F. Receptor tyrosine kinases and targeted" exact="cancer" post="therapeutics Biol. Pharm. Bull. 2011 34 1774 1780 10.1248/bpb.34.1774"/>
   <result pre="receptor immunohistochemical reactivity in patients with American Joint Committee on" exact="cancer" post="stage IV colon adenocarcinoma Cancer 2001 92 1331 1346"/>
   <result pre="C. Ponder B.A. Allele-specific up-regulation of FGFR2 increases susceptibility to" exact="breast cancer" post="PLoS Biol. 2008 6 e108 10.1371/journal.pbio.0060108 18462018 64. Chin"/>
   <result pre="Ponder B.A. Allele-specific up-regulation of FGFR2 increases susceptibility to breast" exact="cancer" post="PLoS Biol. 2008 6 e108 10.1371/journal.pbio.0060108 18462018 64. Chin"/>
   <result pre="Ryder T. et al. Genomic and transcriptional aberrations linked to" exact="breast cancer" post="pathophysiologies Cancer Cell 2006 10 529 541 10.1016/j.ccr.2006.10.009 17157792"/>
   <result pre="T. et al. Genomic and transcriptional aberrations linked to breast" exact="cancer" post="pathophysiologies Cancer Cell 2006 10 529 541 10.1016/j.ccr.2006.10.009 17157792"/>
   <result pre="Monville F. et al. Comprehensive profiling of 8p11-12 amplification in" exact="breast cancer" post="Mol. Cancer Res. 2005 3 655 667 10.1158/1541-7786.MCR-05-0128 16380503"/>
   <result pre="F. et al. Comprehensive profiling of 8p11-12 amplification in breast" exact="cancer" post="Mol. Cancer Res. 2005 3 655 667 10.1158/1541-7786.MCR-05-0128 16380503"/>
   <result pre="PPAPDC1B, a phosphatase protein, as a new therapeutic target in" exact="breast cancer" post="Cancer Res. 2008 68 7165 7175 10.1158/0008-5472.CAN-08-1360 18757432 68."/>
   <result pre="a phosphatase protein, as a new therapeutic target in breast" exact="cancer" post="Cancer Res. 2008 68 7165 7175 10.1158/0008-5472.CAN-08-1360 18757432 68."/>
   <result pre="et al. A 1 Mb minimal amplicon at 8p11-12 in" exact="breast cancer" post="identifies new candidate oncogenes Oncogene 2005 24 5235 5245"/>
   <result pre="al. A 1 Mb minimal amplicon at 8p11-12 in breast" exact="cancer" post="identifies new candidate oncogenes Oncogene 2005 24 5235 5245"/>
   <result pre="identifies alleles in FGFR2 associated with risk of sporadic postmenopausal" exact="breast cancer" post="Nat. Genet. 2007 39 870 874 10.1038/ng2075 17529973 71."/>
   <result pre="alleles in FGFR2 associated with risk of sporadic postmenopausal breast" exact="cancer" post="Nat. Genet. 2007 39 870 874 10.1038/ng2075 17529973 71."/>
   <result pre="M. di Bacco A. Elbi C. Lutterbach B. FGFR2-amplified gastric" exact="cancer" post="cell lines require FGFR2 and Erbb3 signaling for growth"/>
   <result pre="Campbell I.G. High-resolution single nucleotide polymorphism array analysis of epithelial" exact="ovarian cancer" post="reveals numerous microdeletions and amplifications Clin. Cancer Res. 2007"/>
   <result pre="I.G. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian" exact="cancer" post="reveals numerous microdeletions and amplifications Clin. Cancer Res. 2007"/>
   <result pre="F. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in" exact="bladder cancer" post="previously identified in non-lethal skeletal disorders Eur. J. Hum."/>
   <result pre="Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder" exact="cancer" post="previously identified in non-lethal skeletal disorders Eur. J. Hum."/>
   <result pre="Stevens C. et al. Patterns of somatic mutation in human" exact="cancer" post="genomes Nature 2007 446 153 158 10.1038/nature05610 17344846 79."/>
   <result pre="3 is an oncogene that contributes to tumor progression in" exact="multiple myeloma" post="Blood 2001 97 729 736 10.1182/blood.V97.3.729 11157491 82. Chou"/>
   <result pre="novel fibroblast growth factor receptor 3 gene mutations in actinic" exact="cheilitis" post="and squamous cell carcinoma of the lip Oral Surg."/>
   <result pre="Somatic mutations of the protein kinase gene family in human" exact="lung cancer" post="Cancer Res. 2005 65 7591 7595 16140923 84. Pollock"/>
   <result pre="mutations of the protein kinase gene family in human lung" exact="cancer" post="Cancer Res. 2005 65 7591 7595 16140923 84. Pollock"/>
   <result pre="FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with" exact="craniosynostosis" post="and skeletal dysplasia syndromes Oncogene 2007 26 7158 7162"/>
   <result pre="ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell" exact="lymphoma" post="with at (4; 12)(p16; p13) chromosomal translocation Cancer Res."/>
   <result pre="F. Cross N.C. van Etten R.A. Distinct stem cell myeloproliferative/T" exact="lymphoma" post="syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from"/>
   <result pre="G. Rodwell R. et al. The t (8; 22) in" exact="chronic myeloid leukemia" post="fuses BCR to FGFR1: Transforming activity and specific inhibition"/>
   <result pre="Rodwell R. et al. The t (8; 22) in chronic" exact="myeloid leukemia" post="fuses BCR to FGFR1: Transforming activity and specific inhibition"/>
   <result pre="R. et al. The t (8; 22) in chronic myeloid" exact="leukemia" post="fuses BCR to FGFR1: Transforming activity and specific inhibition"/>
   <result pre="J.K. Genetic fingerprinting of the development and progression of T-cell" exact="lymphoma" post="in a murine model of atypical myeloproliferative disorder initiated"/>
   <result pre="V. Cook S.J. De-regulated FGF receptors as therapeutic targets in" exact="cancer" post="Pharmacol. Ther. 2010 125 105 117 10.1016/j.pharmthera.2009.10.001 19874848 94."/>
   <result pre="growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell" exact="lung cancer" post="cells Mol. Pharmacol. 2009 75 196 207 10.1124/mol.108.049544 18849352"/>
   <result pre="factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung" exact="cancer" post="cells Mol. Pharmacol. 2009 75 196 207 10.1124/mol.108.049544 18849352"/>
   <result pre="Peruzzi B. Bottaro D.P. Targeting the c-Met signaling pathway in" exact="cancer" post="Clin. Cancer Res. 2006 12 3657 3660 10.1158/1078-0432.CCR-06-0818 16778093"/>
   <result pre="amplification of the met/HGF receptor gene during the progression of" exact="colorectal cancer" post="Clin. Cancer Res. 1995 1 147 154 9815967 106."/>
   <result pre="of the met/HGF receptor gene during the progression of colorectal" exact="cancer" post="Clin. Cancer Res. 1995 1 147 154 9815967 106."/>
   <result pre="significance of chromosomal aberrations in cancer: Methodology and application to" exact="glioma" post="Proc. Natl. Acad. Sci. USA 2007 104 20007 20012"/>
   <result pre="Kaneda R. et al. A genomic analysis of adult T-cell" exact="leukemia" post="Oncogene 2007 26 1245 1255 10.1038/sj.onc.1209898 16909099 111. Kang"/>
   <result pre="growth factor activator inhibitor 1 in the progression of node-negative" exact="breast cancer" post="Cancer Res. 2003 63 1101 1105 12615728 112. Lengyel"/>
   <result pre="factor activator inhibitor 1 in the progression of node-negative breast" exact="cancer" post="Cancer Res. 2003 63 1101 1105 12615728 112. Lengyel"/>
   <result pre="B. Vande Woude G.F. et al. C-Met overexpression in node-positive" exact="breast cancer" post="identifies patients with poor clinical outcome independent of Her2/neu"/>
   <result pre="Vande Woude G.F. et al. C-Met overexpression in node-positive breast" exact="cancer" post="identifies patients with poor clinical outcome independent of Her2/neu"/>
   <result pre="P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in" exact="cancer" post="Clin. Cancer Res. 2009 15 2207 2214 10.1158/1078-0432.CCR-08-1306 19318488"/>
   <result pre="Neal D.E. Leung H.Y. MEK5 overexpression is associated with metastatic" exact="prostate cancer," post="and stimulates proliferation, MMP-9expression and invasion Oncogene 2003 22"/>
   <result pre="A.R. Signal integration by JNK and p38 MAPK pathways in" exact="cancer" post="development Nat. Rev. Cancer 2009 9 537 549 10.1038/nrc2694"/>
   <result pre="activation is associated with altered histone H3 methylations in human" exact="liver cancer" post="J. Hepatol. 2009 50 323 333 19041150 137. Cuenda"/>
   <result pre="is associated with altered histone H3 methylations in human liver" exact="cancer" post="J. Hepatol. 2009 50 323 333 19041150 137. Cuenda"/>
   <result pre="S. Rath O. Kolch W. MAP kinase signalling pathways in" exact="cancer" post="Oncogene 2007 26 3279 3290 10.1038/sj.onc.1210421 17496922 140. Koul"/>
   <result pre="kinase/MAP kinase phosphatase regulation: Roles in cell growth, death, and" exact="cancer" post="Pharmacol. Rev. 2008 60 261 310 10.1124/pr.107.00106 18922965 144."/>
   <result pre="Lippman S.M. El-Naggar A.K. Targeting the MAPK-RAS-RAF signaling pathway in" exact="cancer" post="therapy Expert Opin. Ther. Targets 2012 16 103 119"/>
   <result pre="W. et al. Mutations of the BRAF gene in human" exact="cancer" post="Nature 2002 417 949 954 10.1038/nature00766 12068308 146. Poulikakos"/>
   <result pre="Y.Y. Valentino J.D. Gulhati P. Evers B.M. mTOR inhibitors in" exact="cancer" post="therapy Cancer Lett. 2012 319 1 7 10.1016/j.canlet.2012.01.005 22261336"/>
   <result pre="The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of" exact="cancer" post="cell motility and growth in three-dimensional cultures Mol. Cancer"/>
   <result pre="GDC-0941 combines with existing clinical regimens for superior activity in" exact="multiple myeloma" post="Oncogene 2014 33 316 325 10.1038/onc.2012.594 23318440 158. Bendell"/>
   <result pre="inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in" exact="chronic lymphocytic leukemia" post="Blood 2011 118 3603 3612 10.1182/blood-2011-05-352492 21803855 160. Richardson"/>
   <result pre="inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic" exact="leukemia" post="Blood 2011 118 3603 3612 10.1182/blood-2011-05-352492 21803855 160. Richardson"/>
   <result pre="and cell death by modulation of AIF and Ezrin in" exact="colorectal cancer" post="BMC Cancer 2014 14 145 10.1186/1471-2407-14-145 24581231 163. Bhagwat"/>
   <result pre="cell death by modulation of AIF and Ezrin in colorectal" exact="cancer" post="BMC Cancer 2014 14 145 10.1186/1471-2407-14-145 24581231 163. Bhagwat"/>
   <result pre="transforming mutation in the pleckstrin homology domain of AKT1 in" exact="cancer" post="Nature 2007 448 439 444 10.1038/nature05933 17611497 168. Kim"/>
   <result pre="D. et al. Genomic copy number analysis of non-small cell" exact="lung cancer" post="using array comparative genomic hybridization implications of the phosphatidylinositol"/>
   <result pre="et al. Genomic copy number analysis of non-small cell lung" exact="cancer" post="using array comparative genomic hybridization implications of the phosphatidylinositol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4588449/results/search/disease/results.xml">
   <result pre="vaccination involving a truncated HER2 sequence in patients with HER2-expressing" exact="breast cancer" post="Gene therapy using HER2 vaccine in breast cancer Kim"/>
   <result pre="involving a truncated HER2 sequence in patients with HER2-expressing breast" exact="cancer" post="Gene therapy using HER2 vaccine in breast cancer Kim"/>
   <result pre="with HER2-expressing breast cancer Gene therapy using HER2 vaccine in" exact="breast cancer" post="Kim Sung-Bae 1 * Ahn Jin-Hee 1 Kim Jeongeun"/>
   <result pre="HER2-expressing breast cancer Gene therapy using HER2 vaccine in breast" exact="cancer" post="Kim Sung-Bae 1 * Ahn Jin-Hee 1 Kim Jeongeun"/>
   <result pre="modified HER2 sequence only), in patients with stage III–IV metastatic" exact="breast cancer" post="expressing HER2. Nine eligible subjects were divided into three"/>
   <result pre="HER2 sequence only), in patients with stage III–IV metastatic breast" exact="cancer" post="expressing HER2. Nine eligible subjects were divided into three"/>
   <result pre="bladder, and ovarian cancers. 1–4 Overexpression of HER2 in human" exact="cancer" post="correlates with poor prognosis and the severity of the"/>
   <result pre="inhibit tumor growth and extend progression-free survival, only 15–20% of" exact="breast cancer" post="patients overexpressing HER2 are known to respond to this"/>
   <result pre="tumor growth and extend progression-free survival, only 15–20% of breast" exact="cancer" post="patients overexpressing HER2 are known to respond to this"/>
   <result pre="and peptide combination strategy, the possibility of using DNA-based therapeutic" exact="cancer" post="vaccines has been explored in various clinical trials, which"/>
   <result pre="therapeutic vaccination involving pHM-GM-CSF and Ad-HM in patients with HER2-expressing" exact="breast cancer" post="and to determine the appropriate dose. Results Study design"/>
   <result pre="vaccination involving pHM-GM-CSF and Ad-HM in patients with HER2-expressing breast" exact="cancer" post="and to determine the appropriate dose. Results Study design"/>
   <result pre="(pHM-GM-CSF) and an adenoviral vector (Ad-HM), in patients with HER2-expressing" exact="breast cancer" post="(including 1+, 2+, and 3+ as measured by IHC)."/>
   <result pre="and an adenoviral vector (Ad-HM), in patients with HER2-expressing breast" exact="cancer" post="(including 1+, 2+, and 3+ as measured by IHC)."/>
   <result pre="Subjects were followed up for 24 weeks. Sixteen subjects with" exact="breast cancer" post="who provided informed consent form were screened for eligibility."/>
   <result pre="were followed up for 24 weeks. Sixteen subjects with breast" exact="cancer" post="who provided informed consent form were screened for eligibility."/>
   <result pre="subject death was reported during the follow-up phase due to" exact="pneumonia" post="sepsis after chemotherapy. Clinical tumor response All the subjects"/>
   <result pre="In this phase 1 clinical study involving patients with HER2-expressing" exact="breast cancer," post="we showed that vaccination with pHM-GM-CSF priming followed by"/>
   <result pre="have produced highly positive results as vaccinated subjects with late-stage" exact="breast cancer" post="had failed in multiple lines of prior chemotherapies ("/>
   <result pre="produced highly positive results as vaccinated subjects with late-stage breast" exact="cancer" post="had failed in multiple lines of prior chemotherapies ("/>
   <result pre="observed in 13 of 29 subjects (45%) with prostate-specific antigen–expressing" exact="prostate cancer." post="Five of 29 subjects showed greater than a sixfold"/>
   <result pre="of HER2-specific cellular and humoral responses in subjects with metastatic" exact="breast cancer" post="expressing HER2. Although the clinical outcomes of VM206RY could"/>
   <result pre="HER2-specific cellular and humoral responses in subjects with metastatic breast" exact="cancer" post="expressing HER2. Although the clinical outcomes of VM206RY could"/>
   <result pre="older than 20 years of age who had HER2-expressing metastatic" exact="breast cancer," post="measurable lesion(s) in the breast or metastasized sites, an"/>
   <result pre="normal. Exclusion criteria included uncontrolled cardiac disease, coronary artery disease," exact="autoimmune disease," post="and immune deficiency disease. In addition, patients were excluded"/>
   <result pre="defined as the percentage of subjects with advanced or metastatic" exact="cancer" post="who have achieved CR or PR. The disease control"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial ."/>
   <result pre="( 2010). Use of monoclonal antibodies in the treatment of" exact="ovarian cancer." post="Curr Opin Obstet Gynecol 22: 3–8. 19770762 Tomasello, G,"/>
   <result pre="1989). Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer." post="Science 244: 707–712. 2470152 Cobleigh, MA, Vogel, CL, Tripathy,"/>
   <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease ."/>
   <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease ."/>
   <result pre="associated with trastuzumab (Herceptin) therapy in the treatment of metastatic" exact="breast cancer" post=". Breast 13: 173–183. 15177418 Lin, YZ and Clinton,"/>
   <result pre="with trastuzumab (Herceptin) therapy in the treatment of metastatic breast" exact="cancer" post=". Breast 13: 173–183. 15177418 Lin, YZ and Clinton,"/>
   <result pre="trial of a PSA DNA vaccine in patients with hormone-refractory" exact="prostate cancer" post=". J Immunother 28: 389–395. 16000958 Tokuda, Y, Watanabe,"/>
   <result pre="of a PSA DNA vaccine in patients with hormone-refractory prostate" exact="cancer" post=". J Immunother 28: 389–395. 16000958 Tokuda, Y, Watanabe,"/>
   <result pre="a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic" exact="breast cancer" post=". Br J Cancer 81: 1419–1425. 10604742 Walter, J,"/>
   <result pre="humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast" exact="cancer" post=". Br J Cancer 81: 1419–1425. 10604742 Walter, J,"/>
   <result pre="and immunogenicity of a DNA vaccine encoding carcinoemvryonic antigen and" exact="hepatitis" post="B surface antigen in colorectal carcinoma patients . Clin"/>
   <result pre="receptor 2 in combination with gemcitabine for patients with advanced" exact="pancreatic cancer" post=". Cancer Sci 101: 433–439. 19930156 Ko, HJ, Kim,"/>
   <result pre="2 in combination with gemcitabine for patients with advanced pancreatic" exact="cancer" post=". Cancer Sci 101: 433–439. 19930156 Ko, HJ, Kim,"/>
   <result pre="(0.0) 0 (0.0) 0  Blood and lymphatic system disorders   Febrile" exact="neutropenia" post="0 (0.0) 0 1 (33.3) 1 0 (0.0) 0"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4589126/results/search/disease/results.xml">
   <result pre="btt-9-093 : Review Clinical utility of ramucirumab in advanced gastric" exact="cancer" post="Chan Matthew MK 1 2 Sjoquist Katrin M 1"/>
   <result pre="Press Limited, provided the work is properly attributed. Abstract Gastric" exact="cancer" post="is currently the third most common cause of cancer"/>
   <result pre="Gastric cancer is currently the third most common cause of" exact="cancer" post="deaths worldwide. Prognosis remains poor with most patients presenting"/>
   <result pre="of ramucirumab in advanced gastric cancer. Keywords ramucirumab IMC-1121B gastric" exact="cancer" post="vascular endothelial growth factor receptor-2 angiogenesis targeted therapy Introduction"/>
   <result pre="vascular endothelial growth factor receptor-2 angiogenesis targeted therapy Introduction Gastric" exact="cancer" post="is currently the fifth most common cancer and the"/>
   <result pre="therapy Introduction Gastric cancer is currently the fifth most common" exact="cancer" post="and the third most common cause of cancer deaths"/>
   <result pre="most common cancer and the third most common cause of" exact="cancer" post="deaths worldwide, accounting for almost 9% of all deaths"/>
   <result pre="over many years, the prognosis of patients with advanced gastric" exact="cancer" post="remains poor, and until recently, little progress has been"/>
   <result pre="growth factor receptor-2 (VEGFR-2), in advanced gastric cancer. Advanced gastric" exact="cancer" post="Prognosis The prognosis of patients with advanced or metastatic"/>
   <result pre="Prognosis The prognosis of patients with advanced or metastatic gastric" exact="cancer" post="is poor with a median survival of approximately 3–4"/>
   <result pre="of molecularly targeted therapies have been tested in advanced gastric" exact="cancer" post="including epidermal growth factor receptor (EGFR) inhibitors, cetuximab (Erbitux;"/>
   <result pre="VEGF in tumor and serum has been shown in gastric" exact="cancer" post="which is associated with poor prognosis and more aggressive"/>
   <result pre="suggests that angiogenesis may be an important target for gastric" exact="cancer" post="and that inhibitors of the VEGF pathway may be"/>
   <result pre="for anti-VEGF monoclonal antibodies such as bevacizumab in advanced gastric" exact="cancer" post="outside of clinical trials. Angiogenic receptor tyrosine kinases (sunitinib,"/>
   <result pre="inhibitor that targets VEGFR-2. Phase II studies of advanced gastric" exact="cancer" post="in chemotherapy refractory patients showed promising activity with improvements"/>
   <result pre="improve OS and PFS in Phase III trials of non-small-cell" exact="lung cancer" post="(NSCLC) and colorectal cancer but not of breast cancer"/>
   <result pre="OS and PFS in Phase III trials of non-small-cell lung" exact="cancer" post="(NSCLC) and colorectal cancer but not of breast cancer"/>
   <result pre="in Phase III trials of non-small-cell lung cancer (NSCLC) and" exact="colorectal cancer" post="but not of breast cancer or hepatocellular carcinoma (HCC)"/>
   <result pre="Phase III trials of non-small-cell lung cancer (NSCLC) and colorectal" exact="cancer" post="but not of breast cancer or hepatocellular carcinoma (HCC)"/>
   <result pre="non-small-cell lung cancer (NSCLC) and colorectal cancer but not of" exact="breast cancer" post="or hepatocellular carcinoma (HCC) ( Table 2). 48– 51"/>
   <result pre="lung cancer (NSCLC) and colorectal cancer but not of breast" exact="cancer" post="or hepatocellular carcinoma (HCC) ( Table 2). 48– 51"/>
   <result pre="(NSCLC) and colorectal cancer but not of breast cancer or" exact="hepatocellular carcinoma" post="(HCC) ( Table 2). 48– 51 Pharmacology Ramucirumab is"/>
   <result pre="37 patients with advanced solid malignancies including patients with gastric" exact="cancer" post="who were refractory to treatment and did not have"/>
   <result pre="lasting at least 12 weeks including one patient with gastric" exact="cancer" post="and 23 patients who had stable disease as their"/>
   <result pre="in combination with paclitaxel and docetaxel in patients with gastric" exact="cancer" post="have been published in abstract form. 59, 60 These"/>
   <result pre="mFOLFOX6 plus placebo in first-line treatment of advanced gastric and" exact="esophageal cancer" post="accrued 168 patients and showed a median PFS of"/>
   <result pre="plus placebo in first-line treatment of advanced gastric and esophageal" exact="cancer" post="accrued 168 patients and showed a median PFS of"/>
   <result pre="III trial as first-line treatment for patients with advanced gastric" exact="cancer" post="only. Efficacy studies, including any combinational studies Phase III"/>
   <result pre="III trials of ramucirumab completed to date including studies in" exact="breast cancer," post="hepatocellular cancer, colorectal cancer, NSCLC, as well as two"/>
   <result pre="completed to date including studies in breast cancer, hepatocellular cancer," exact="colorectal cancer," post="NSCLC, as well as two in advanced gastric cancer"/>
   <result pre="colorectal cancer, NSCLC, as well as two in advanced gastric" exact="cancer" post="( Table 2). The landmark REGARD trial (NCT00917384) of"/>
   <result pre="evaluate the efficacy of second-line ramucirumab monotherapy for advanced gastric" exact="cancer" post="( Table 3). Patients who were ECOG PS 0–1"/>
   <result pre="authors concluded that VEGFR-2 is an important target in gastric" exact="cancer" post="given the benefits in OS seen in patients with"/>
   <result pre="the benefits in OS seen in patients with advanced gastric" exact="cancer" post="who have progressed after first-line treatment with platinum or"/>
   <result pre="trial is the largest trial of second-line therapy in gastric" exact="cancer" post="to date. Although the median OS of patients treated"/>
   <result pre="capecitabine with, or without, ramucirumab as first-line treatment for gastric" exact="cancer" post="(NCT02314117). A summary of Phase III trials of ramucirumab"/>
   <result pre="Table 2. A survival benefit was demonstrated for NSCLC and" exact="colon cancer" post="but not for HCC or breast cancer. 48– 51"/>
   <result pre="2. A survival benefit was demonstrated for NSCLC and colon" exact="cancer" post="but not for HCC or breast cancer. 48– 51"/>
   <result pre="for NSCLC and colon cancer but not for HCC or" exact="breast cancer." post="48– 51 Interestingly, the subset of patients with elevated"/>
   <result pre="absence of a survival benefit seen in HER-2 negative metastatic" exact="breast cancer," post="when ramucirumab was added to first-line docetaxel chemotherapy, is"/>
   <result pre="10%), decreased appetite (3% vs 3%), vomiting (3% vs 4%)," exact="anemia" post="(6% vs 8%), bleeding (3% vs 3%), venous thrombosis"/>
   <result pre="8%), bleeding (3% vs 3%), venous thrombosis (1% vs 4%)," exact="proteinuria" post="(&amp;lt;1% vs 0%), gastrointestinal perforation (&amp;lt;1% vs &amp;lt;1%), fistula"/>
   <result pre="the most frequent grade 3 or above adverse events were" exact="neutropenia" post="(41% vs 19%), leucopenia (17% vs 7%), hypertension (14%"/>
   <result pre="4%), and fatigue (12% vs 5%). The rate of febrile" exact="neutropenia" post="was similar between the two treatment groups (3% vs"/>
   <result pre="declining clinical status are common in patients with advanced gastric" exact="cancer" post="and that all patients included in the trials were"/>
   <result pre="for patients with good ECOG PS who have advanced gastric" exact="cancer" post="where ramucirumab is not available. 18– 20 There is"/>
   <result pre="preclinical and clinical research. The AVAGAST trial in advanced gastric" exact="cancer" post="showed that baseline plasma VEGF-A and tumor expression of"/>
   <result pre="the modest improvement in survival. Given the increasing costs of" exact="cancer" post="care, cost-effectiveness analysis should be incorporated into future clinical"/>
   <result pre="et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal" exact="cancer" post="N Engl J Med 2006 355 11 20 16822992"/>
   <result pre="Yang HK et al. Adjuvant capecitabine and oxaliplatin for gastric" exact="cancer" post="after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised"/>
   <result pre="S-1 versus surgery alone in stage II or III gastric" exact="cancer" post="J Clin Oncol 2011 29 4387 4393 22010012 5"/>
   <result pre="Unverzagt S Grothe W et al. Chemotherapy for advanced gastric" exact="cancer" post="Cochrane Database Syst Rev 2010 CD004064 20238327 8 Cunningham"/>
   <result pre="Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric" exact="cancer" post="N Engl J Med 2008 358 36 46 18172173"/>
   <result pre="cisplatin versus S-1 alone for first-line treatment of advanced gastric" exact="cancer" post="(SPIRITS trial): a phase III trial Lancet Oncol 2008"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="Kim HJ Kim SY et al. Second-line chemotherapy versus supportive" exact="cancer" post="treatment in advanced gastric cancer: a meta-analysis Ann Oncol"/>
   <result pre="study comparing irinotecan with paclitaxel in patients with advanced gastric" exact="cancer" post="without severe peritoneal metastasis after failure of prior combination"/>
   <result pre="or without cetuximab for patients with previously untreated advanced gastric" exact="cancer" post="(EXPAND): a randomised, open-label phase 3 trial Lancet Oncol"/>
   <result pre="or without panitumumab for patients with previously untreated advanced oesophagogastric" exact="cancer" post="(REAL3): a randomised, open-label phase 3 trial Lancet Oncol"/>
   <result pre="paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric" exact="cancer" post="in Asian populations: TyTAN – A randomized, phase III"/>
   <result pre="Ongaro E et al. Critical appraisal of ramucirumab (IMC-1121B) for" exact="cancer" post="treatment: from benchside to clinical use Drugs 2013 73"/>
   <result pre="is an independent prognostic indicator of worse outcome in gastric" exact="cancer" post="patients Ann Surg Oncol 2008 15 69 79 17896140"/>
   <result pre="trial of docetaxel and sunitinib in patients with metastatic gastric" exact="cancer" post="who were previously treated with fluoropyrimidine and platinum Br"/>
   <result pre="II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric" exact="cancer" post="(AOGC) – A study by the Australasian Gastrointestinal Trials"/>
   <result pre="placebo plus docetaxel for second-line treatment of stage IV non-small-cell" exact="lung cancer" post="after disease progression on platinum-based therapy (REVEL): a multicentre,"/>
   <result pre="plus docetaxel for second-line treatment of stage IV non-small-cell lung" exact="cancer" post="after disease progression on platinum-based therapy (REVEL): a multicentre,"/>
   <result pre="the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic" exact="breast cancer" post="J Clin Oncol 2015 33 141 148 25185099 50"/>
   <result pre="addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast" exact="cancer" post="J Clin Oncol 2015 33 141 148 25185099 50"/>
   <result pre="Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced" exact="hepatocellular carcinoma" post="(hcc) following first-line therapy with sorafenib: results from the"/>
   <result pre="of Phase III trials investigating second-line chemotherapy for advanced gastric" exact="cancer" post="Trial reference Country n Regimens Results ORR (%) DCR"/>
   <result pre="Abbreviations: BSC, best supportive care; FOLFIRI, fluorouracil and irinotecan; HCC," exact="hepatocellular carcinoma;" post="NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression"/>
   <result pre="care; FOLFIRI, fluorouracil and irinotecan; HCC, hepatocellular carcinoma; NSCLC, non-small-cell" exact="lung cancer;" post="OS, overall survival; PFS, progression free survival. Table 3"/>
   <result pre="Table 3 Summary of trials investigating ramucirumab for advanced gastric" exact="cancer" post="Trial ID Phase Line Indication n Regimens Results ORR"/>
   <result pre="Table 4 Ongoing clinical trials investigating ramucirumab for advanced gastric" exact="cancer" post="Trial ID Phase Line Intervention and schedule Recruitment Projected"/>
   <result pre="haematoma, haemorrhage, and upper gastrointestinal haemorrhage. # Includes angina pectoris," exact="cardiac arrest," post="cerebral ischaemia, cerebrovascular accident, myocardial infarction, and myocardial ischaemia."/>
   <result pre="ischaemia, cerebrovascular accident, myocardial infarction, and myocardial ischaemia. ** Includes" exact="pulmonary embolism," post="deep vein thrombosis, thrombosis and venous thrombosis in a"/>
   <result pre="CJ, et al, Ramucirumab monotherapy for previously treated advanced gastric" exact="cancer" post="or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multi-centre,"/>
   <result pre="4 (1%) 0 0 20 (6%) 0 0 0  Malignant" exact="neoplasm" post="progression 5 (2%) 16 (5%) 4 (1%) 27 (8%)"/>
   <result pre="34 Table 7 Ongoing studies of targeted therapies in gastric" exact="cancer" post="Trial ID Clinical trial Phase Line Intervention and schedule"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4589954/results/search/disease/results.xml">
   <result pre="the addition of trastuzumab to chemotherapy in stage I–III HER2-positive" exact="breast cancer." post="For two of the arms of the trial, doxorubicin"/>
   <result pre="added to chemoendocrine therapy not only for centrally assessed HER2-positive" exact="breast cancer" post="but also for centrally assessed HER2-negative breast cancer ["/>
   <result pre="to chemoendocrine therapy not only for centrally assessed HER2-positive breast" exact="cancer" post="but also for centrally assessed HER2-negative breast cancer ["/>
   <result pre="assessed HER2-positive breast cancer but also for centrally assessed HER2-negative" exact="breast cancer" post="[ 12, 13, 17, 18]. The reasons for the"/>
   <result pre="HER2-positive breast cancer but also for centrally assessed HER2-negative breast" exact="cancer" post="[ 12, 13, 17, 18]. The reasons for the"/>
   <result pre="The reasons for the observed benefit in centrally assessed HER2-negative" exact="breast cancer" post="may be due to a wide range of FISH"/>
   <result pre="reasons for the observed benefit in centrally assessed HER2-negative breast" exact="cancer" post="may be due to a wide range of FISH"/>
   <result pre="survival (DFS) in women with resected node-positive or high-risk node-negative" exact="breast cancer" post="which is reported as HER2-low by all HER2 testing"/>
   <result pre="(DFS) in women with resected node-positive or high-risk node-negative breast" exact="cancer" post="which is reported as HER2-low by all HER2 testing"/>
   <result pre="assay. Invasive carcinoma cells (and not benign epithelial or ductal" exact="carcinoma in situ" post="cells) were used for the assessment of HER2 status"/>
   <result pre="Food and Drug Administration-approved test for HER2 gene alterations in" exact="breast cancer" post="(BC). A specimen with an HER2/CEP17 ratio ≥2.0 in"/>
   <result pre="and Drug Administration-approved test for HER2 gene alterations in breast" exact="cancer" post="(BC). A specimen with an HER2/CEP17 ratio ≥2.0 in"/>
   <result pre="for HER2. HER2 mRNA testing methods The Onco type DX" exact="breast cancer" post="assay was performed as previously described for all available"/>
   <result pre="HER2. HER2 mRNA testing methods The Onco type DX breast" exact="cancer" post="assay was performed as previously described for all available"/>
   <result pre="time from randomization to local, regional or distant recurrence, contralateral" exact="breast cancer" post="including ductal carcinoma in situ, other second primary cancers,"/>
   <result pre="from randomization to local, regional or distant recurrence, contralateral breast" exact="cancer" post="including ductal carcinoma in situ, other second primary cancers,"/>
   <result pre="local, regional or distant recurrence, contralateral breast cancer including ductal" exact="carcinoma in situ," post="other second primary cancers, or death from any cause."/>
   <result pre="improves outcome in women with resected node-positive or high-risk node-negative" exact="breast cancer" post="which is reported as HER2-low by all HER2 testing"/>
   <result pre="outcome in women with resected node-positive or high-risk node-negative breast" exact="cancer" post="which is reported as HER2-low by all HER2 testing"/>
   <result pre="large landmark N9831 randomized trial population of patients with HER2-positive" exact="breast cancer," post="randomized to chemotherapy ± trastuzumab treatment, using high-quality central and reference"/>
   <result pre="ASCO/CAP American Society of Clinical Oncology/College of American Pathologists BC" exact="breast cancer" post="CEP17 centromere enumerator probe for chromosome 17 CLIA Clinical"/>
   <result pre="American Society of Clinical Oncology/College of American Pathologists BC breast" exact="cancer" post="CEP17 centromere enumerator probe for chromosome 17 CLIA Clinical"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med. 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med. 2001 344"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med. 2006 355 2733 43 10.1056/NEJMoa064320"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med. 2006 355 2733 43 10.1056/NEJMoa064320"/>
   <result pre="Diagn Pathol. 2010 5 50 20670419 9. Ross JS Breast" exact="cancer" post="biomarkers and HER2 testing after 10 years of anti-HER2"/>
   <result pre="Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in" exact="breast cancer" post="Hum Pathol. 2010 41 103 6 10.1016/j.humpath.2009.07.001 19762065 12."/>
   <result pre="of American Pathologists guideline recommendations on HER2 interpretation in breast" exact="cancer" post="Hum Pathol. 2010 41 103 6 10.1016/j.humpath.2009.07.001 19762065 12."/>
   <result pre="and protein expression, and lapatinib efficacy in women with metastatic" exact="breast cancer" post="Clin Cancer Res. 2008 14 7861 70 10.1158/1078-0432.CCR-08-1056 19047115"/>
   <result pre="protein expression, and lapatinib efficacy in women with metastatic breast" exact="cancer" post="Clin Cancer Res. 2008 14 7861 70 10.1158/1078-0432.CCR-08-1056 19047115"/>
   <result pre="frequently used assay methods in a molecularly characterized cohort of" exact="breast cancer" post="specimens J Clin Oncol. 2002 20 3095 105 12118023"/>
   <result pre="used assay methods in a molecularly characterized cohort of breast" exact="cancer" post="specimens J Clin Oncol. 2002 20 3095 105 12118023"/>
   <result pre="Wolmark N HER2 status and benefit from adjuvant trastuzumab in" exact="breast cancer" post="N Engl J Med. 2008 358 1409 11 10.1056/NEJMc0801440"/>
   <result pre="N HER2 status and benefit from adjuvant trastuzumab in breast" exact="cancer" post="N Engl J Med. 2008 358 1409 11 10.1056/NEJMc0801440"/>
   <result pre="recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive" exact="breast cancer" post="Clin Chem. 2007 53 1084 91 10.1373/clinchem.2006.076497 17463177 22."/>
   <result pre="prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast" exact="cancer" post="Clin Chem. 2007 53 1084 91 10.1373/clinchem.2006.076497 17463177 22."/>
   <result pre="factor receptor 2 classification by Oncotype DX in patients with" exact="breast cancer" post="J Clin Oncol. 2012 30 3313 4 10.1200/JCO.2012.42.1990 22649153"/>
   <result pre="receptor 2 classification by Oncotype DX in patients with breast" exact="cancer" post="J Clin Oncol. 2012 30 3313 4 10.1200/JCO.2012.42.1990 22649153"/>
   <result pre="RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded" exact="breast cancer" post="tissues Int J Clin Exp Pathol. 2014 7 6752"/>
   <result pre="assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast" exact="cancer" post="tissues Int J Clin Exp Pathol. 2014 7 6752"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="J Clin Oncol. 2007 25 118 45 10.1200/JCO.2006.09.2775 17159189"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="J Clin Oncol. 2007 25 118 45 10.1200/JCO.2006.09.2775 17159189"/>
   <result pre="et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for" exact="breast cancer" post="J Clin Oncol. 2011 29 4491 7 10.1200/JCO.2011.36.7045 22042958"/>
   <result pre="al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast" exact="cancer" post="J Clin Oncol. 2011 29 4491 7 10.1200/JCO.2011.36.7045 22042958"/>
   <result pre="3, and 10 on patient response to trastuzumab in metastatic" exact="breast cancer" post="Genes Chromosomes Cancer. 2007 46 397 405 10.1002/gcc.20419 17243161"/>
   <result pre="and 10 on patient response to trastuzumab in metastatic breast" exact="cancer" post="Genes Chromosomes Cancer. 2007 46 397 405 10.1002/gcc.20419 17243161"/>
   <result pre="DW Lingle WL Schroeder MJ Perez EA et al. Breast" exact="cancer" post="and aneusomy 17: implications for carcinogenesis and therapeutic response"/>
   <result pre="W et al. Gene copy numbers of HER family in" exact="breast cancer" post="J Cancer Res Clin Oncol. 2008 134 271 9"/>
   <result pre="et al. Gene copy numbers of HER family in breast" exact="cancer" post="J Cancer Res Clin Oncol. 2008 134 271 9"/>
   <result pre="al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative" exact="breast cancer" post="N Engl J Med. 2004 351 2817 26 10.1056/NEJMoa041588"/>
   <result pre="A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast" exact="cancer" post="N Engl J Med. 2004 351 2817 26 10.1056/NEJMoa041588"/>
   <result pre="15591335 40. Elston CW Ellis IO Pathological prognostic factors in" exact="breast cancer." post="I. The value of histological grade in breast cancer:"/>
   <result pre="Liu ML et al. Tumor gene expression and prognosis in" exact="breast cancer" post="patients with 10 or more positive lymph nodes Clin"/>
   <result pre="ML et al. Tumor gene expression and prognosis in breast" exact="cancer" post="patients with 10 or more positive lymph nodes Clin"/>
   <result pre="of a multigene reverse transcriptase-PCR assay in patients with node-negative" exact="breast cancer" post="not receiving adjuvant systemic therapy Clin Cancer Res. 2005"/>
   <result pre="a multigene reverse transcriptase-PCR assay in patients with node-negative breast" exact="cancer" post="not receiving adjuvant systemic therapy Clin Cancer Res. 2005"/>
   <result pre="patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in" exact="breast cancer" post="patients Breast Cancer Res Treat. 2008 108 233 40"/>
   <result pre="in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast" exact="cancer" post="patients Breast Cancer Res Treat. 2008 108 233 40"/>
   <result pre="between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary" exact="breast cancer" post="J Natl Cancer Inst. 2003 95 142 53 10.1093/jnci/95.2.142"/>
   <result pre="HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast" exact="cancer" post="J Natl Cancer Inst. 2003 95 142 53 10.1093/jnci/95.2.142"/>
   <result pre="expression profiles in breast cancer: toward a unified understanding of" exact="breast cancer" post="subtyping and prognosis signatures Breast Cancer Res. 2008 10"/>
   <result pre="profiles in breast cancer: toward a unified understanding of breast" exact="cancer" post="subtyping and prognosis signatures Breast Cancer Res. 2008 10"/>
   <result pre="and fluorescence in situ hybridization testing for HER2 status in" exact="breast cancer" post="requires a normalized IHC scoring system Mod Pathol. 2008"/>
   <result pre="fluorescence in situ hybridization testing for HER2 status in breast" exact="cancer" post="requires a normalized IHC scoring system Mod Pathol. 2008"/>
   <result pre="HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative" exact="cancer" post="biopsies Int J Oncol. 2004 25 1551 7 15547690"/>
   <result pre="PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for" exact="breast cancer" post="treatment Breast J. 2014 20 37 45 10.1111/tbj.12223 24261318"/>
   <result pre="immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast" exact="cancer" post="treatment Breast J. 2014 20 37 45 10.1111/tbj.12223 24261318"/>
   <result pre="R Hwang H Ellis GK et al. HER-2 testing in" exact="breast cancer" post="using parallel tissue-based methods JAMA. 2004 291 1972 7"/>
   <result pre="Hwang H Ellis GK et al. HER-2 testing in breast" exact="cancer" post="using parallel tissue-based methods JAMA. 2004 291 1972 7"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4590321/results/search/disease/results.xml">
   <result pre="HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive" exact="breast cancer" post="Advani Pooja 1 Cornell Lauren 2 Chumsri Saranya 1"/>
   <result pre="blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast" exact="cancer" post="Advani Pooja 1 Cornell Lauren 2 Chumsri Saranya 1"/>
   <result pre="in combination with standard chemotherapy in both early and advanced" exact="breast cancer." post="However, resistance to trastuzumab may pose a major problem"/>
   <result pre="pose a major problem in the effective treatment of HER2-positive" exact="breast cancer." post="Dual HER2 blockade, using agents that work in a"/>
   <result pre="currently approved in the metastatic and neoadjuvant treatment of HER2-positive" exact="breast cancer." post="Various biomarkers have also been investigated to identify subsets"/>
   <result pre="trials have been discussed. Keywords HER2 dual blockade neoadjuvant adjuvant" exact="breast cancer" post="trastuzumab Introduction Human epidermal growth factor receptor 2 (HER2)"/>
   <result pre="have been discussed. Keywords HER2 dual blockade neoadjuvant adjuvant breast" exact="cancer" post="trastuzumab Introduction Human epidermal growth factor receptor 2 (HER2)"/>
   <result pre="1998 has been a milestone in the treatment of HER2-positive" exact="breast cancer" post="(BC). It has been shown to consistently improve disease-free"/>
   <result pre="has been a milestone in the treatment of HER2-positive breast" exact="cancer" post="(BC). It has been shown to consistently improve disease-free"/>
   <result pre="study’s primary endpoint of pCR, defined as absence of invasive" exact="cancer" post="in the breast at the time of surgery, was"/>
   <result pre="and docetaxel may have contributed to the higher number of" exact="diarrhea" post="and neutropenia cases seen in the lapatinib arm. However,"/>
   <result pre="may have contributed to the higher number of diarrhea and" exact="neutropenia" post="cases seen in the lapatinib arm. However, no major"/>
   <result pre="and one patient in the combination group developing class III" exact="congestive heart failure" post="(CHF); the LVEF patients recovered after therapy was stopped."/>
   <result pre="chemotherapy. The majority of patients (78.8%) who received lapatinib developed" exact="diarrhea" post="(28% grade 3–4), 61.8% developed skin rash (6.8% grade"/>
   <result pre="received lapatinib developed diarrhea (28% grade 3–4), 61.8% developed skin" exact="rash" post="(6.8% grade 3–4), and 41.2% developed hepatic toxicities (36%"/>
   <result pre="3–4), and 41.2% developed hepatic toxicities (36% grade 3–4). Both" exact="rash" post="and diarrhea mainly developed during the first 2–3 weeks"/>
   <result pre="41.2% developed hepatic toxicities (36% grade 3–4). Both rash and" exact="diarrhea" post="mainly developed during the first 2–3 weeks of lapatinib;"/>
   <result pre="patients (&amp;lt;50 years of age) had significantly higher rates of" exact="rash" post="development compared to older patients (&amp;gt;50 years of age;"/>
   <result pre="years of age; 74.4% vs 47.9%; P&amp;lt;0.0001). Early onset of" exact="rash" post="(within 6 weeks of starting therapy) was associated with"/>
   <result pre="in those ≤50 years of age. 42 This association between" exact="rash" post="and clinical response has also been demonstrated in non-small-cell"/>
   <result pre="rash and clinical response has also been demonstrated in non-small-cell" exact="lung carcinoma" post="and head and neck cancers treated with other EGFR"/>
   <result pre="were more common in the two groups with lapatinib, with" exact="diarrhea" post="being the most common AE (27% in combination vs"/>
   <result pre="arm in the CHER-LOB study. 33 The high occurrence of" exact="diarrhea" post="necessitated a protocol amendment to reduce the starting dose"/>
   <result pre="expected, grade 3+ toxicity was higher among lapatinib-containing arms, including" exact="neutropenia" post="(12% docetaxel–lapatinib [DL], 7% docetaxel–trastuzumab–lapatinib [DTL], 2% docetaxel–trastuzumab [DT]),"/>
   <result pre="neutropenia (12% docetaxel–lapatinib [DL], 7% docetaxel–trastuzumab–lapatinib [DTL], 2% docetaxel–trastuzumab [DT])," exact="rash" post="(15% DL, 14% DTL, 2% DT), and diarrhea (20%"/>
   <result pre="docetaxel–trastuzumab [DT]), rash (15% DL, 14% DTL, 2% DT), and" exact="diarrhea" post="(20% DL, 20% DTL, 2% DT). 35 The most"/>
   <result pre="not receive chemotherapy, the rate of neutropenia, febrile neutropenia, and" exact="leukopenia" post="was significantly lower (4% vs 10%–17% in all other"/>
   <result pre="of the Adjuvant Pertuzumab and Herceptin in Initial Therapy of" exact="breast cancer" post="(APHINITY) trial, a randomized, double-blind, placebo-controlled, two-arm study evaluating"/>
   <result pre="the Adjuvant Pertuzumab and Herceptin in Initial Therapy of breast" exact="cancer" post="(APHINITY) trial, a randomized, double-blind, placebo-controlled, two-arm study evaluating"/>
   <result pre="&amp;gt;90% received trastuzumab as planned. As expected, AEs such as" exact="diarrhea" post="(75% vs 50% vs 20%, respectively), rash (55% vs"/>
   <result pre="AEs such as diarrhea (75% vs 50% vs 20%, respectively)," exact="rash" post="(55% vs 49% vs 20%, respectively), and hepatobiliary toxicity"/>
   <result pre="3 or unacceptable grade 2 or less diarrhea, despite active" exact="diarrhea" post="management, and 43% had reductions in lapatinib dose, necessitating"/>
   <result pre="trastuzumab and lapatinib. In regards to overall toxicity, grade 3–4" exact="diarrhea" post="was observed in 41% and 2.7% of patients, respectively,"/>
   <result pre="management of diarrhea, resulting in a decrease of grade 3" exact="diarrhea" post="to 31% and no additional grade 4 events. The"/>
   <result pre="trial optimizing risk assessment and therapy response prediction in early" exact="breast cancer" post="(WSG AM06 trial, Fofmann et al, Trials 2013). 78"/>
   <result pre="optimizing risk assessment and therapy response prediction in early breast" exact="cancer" post="(WSG AM06 trial, Fofmann et al, Trials 2013). 78"/>
   <result pre="MJ Crown J O’Donovan N HER-2 signaling and inhibition in" exact="breast cancer" post="Curr Cancer Drug Targets 2009 9 3 419 438"/>
   <result pre="Crown J O’Donovan N HER-2 signaling and inhibition in breast" exact="cancer" post="Curr Cancer Drug Targets 2009 9 3 419 438"/>
   <result pre="collab: Breast Cancer International Research Group Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="Breast Cancer International Research Group Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="2 years versus 1 year of adjuvant trastuzumab for HER2-positive" exact="breast cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="years versus 1 year of adjuvant trastuzumab for HER2-positive breast" exact="cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="of the HER2 receptor, and response to anti-HER2 therapies in" exact="breast cancer" post="J Natl Cancer Inst 2007 99 8 628 638"/>
   <result pre="the HER2 receptor, and response to anti-HER2 therapies in breast" exact="cancer" post="J Natl Cancer Inst 2007 99 8 628 638"/>
   <result pre="lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic" exact="breast cancer" post="Ann Oncol 2008 19 6 1068 1074 18283035 15"/>
   <result pre="monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast" exact="cancer" post="Ann Oncol 2008 19 6 1068 1074 18283035 15"/>
   <result pre="al. collab: EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="collab: EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive" exact="breast cancer" post="J Clin Oncol 2010 28 8 1301 1307 20142587"/>
   <result pre="receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast" exact="cancer" post="J Clin Oncol 2010 28 8 1301 1307 20142587"/>
   <result pre="tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing" exact="breast cancer" post="cells Oncogene 2005 24 41 6213 6221 16091755 20"/>
   <result pre="kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast" exact="cancer" post="cells Oncogene 2005 24 41 6213 6221 16091755 20"/>
   <result pre="the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated" exact="breast cancer" post="cells Cancer Res 2006 66 3 1630 1639 16452222"/>
   <result pre="dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast" exact="cancer" post="cells Cancer Res 2006 66 3 1630 1639 16452222"/>
   <result pre="et al. Treatment of human epidermal growth factor receptor 2-overexpressing" exact="breast cancer" post="xenografts with multiagent HER-targeted therapy J Natl Cancer Inst"/>
   <result pre="al. Treatment of human epidermal growth factor receptor 2-overexpressing breast" exact="cancer" post="xenografts with multiagent HER-targeted therapy J Natl Cancer Inst"/>
   <result pre="in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic" exact="breast cancer" post="J Clin Oncol 2010 28 7 1124 1130 20124187"/>
   <result pre="combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast" exact="cancer" post="J Clin Oncol 2010 28 7 1124 1130 20124187"/>
   <result pre="CLEOPATRA Study Group Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic" exact="breast cancer" post="N Engl J Med 2015 372 8 724 734"/>
   <result pre="Study Group Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast" exact="cancer" post="N Engl J Med 2015 372 8 724 734"/>
   <result pre="van de Velde CJ Preoperative chemotherapy for women with operable" exact="breast cancer" post="[review] Cochrane Database Syst Rev 2007 2 CD005002 17443564"/>
   <result pre="de Velde CJ Preoperative chemotherapy for women with operable breast" exact="cancer" post="[review] Cochrane Database Syst Rev 2007 2 CD005002 17443564"/>
   <result pre="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced" exact="breast cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast" exact="cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="collab: NeoALTTO Study Team Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="NeoALTTO Study Team Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="Piccart-Gebhart M et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="M et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="Lapatinib as a component of neoadjuvant therapy for HER2-positive operable" exact="breast cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="as a component of neoadjuvant therapy for HER2-positive operable breast" exact="cancer" post="(NSABP protocol B-41): an open-label, randomised phase 3 trial"/>
   <result pre="weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive" exact="breast cancer" post="J Clin Oncol 2013 31 15 Suppl 500 36"/>
   <result pre="paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast" exact="cancer" post="J Clin Oncol 2013 31 15 Suppl 500 36"/>
   <result pre="(T + L) in the adjuvant treatment of HER2-positive early" exact="breast cancer" post="(EBC) J Clin Oncol 2014 32 15 Suppl Abstract"/>
   <result pre="+ L) in the adjuvant treatment of HER2-positive early breast" exact="cancer" post="(EBC) J Clin Oncol 2014 32 15 Suppl Abstract"/>
   <result pre="carboplatin with trastuzumab and/or lapatinib in patients with HER2 +" exact="breast cancer" post="(TRIO-US B07) Cancer Res 2013 73 24 Suppl Abstract"/>
   <result pre="with trastuzumab and/or lapatinib in patients with HER2 + breast" exact="cancer" post="(TRIO-US B07) Cancer Res 2013 73 24 Suppl Abstract"/>
   <result pre="preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant" exact="breast cancer" post="chemotherapy J Clin Oncol 2011 29 15 Suppl 506"/>
   <result pre="lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast" exact="cancer" post="chemotherapy J Clin Oncol 2011 29 15 Suppl 506"/>
   <result pre="43 Liu H Wu Y Lv T et al. Skin" exact="rash" post="could predict the response to EGFR tyrosine kinase inhibitor"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="2 TRIAL: neoadjuvant and personalized adaptive novel agents to treat" exact="breast cancer" post="Bethesda, MD US National Institutes of Health 2009 Available"/>
   <result pre="TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast" exact="cancer" post="Bethesda, MD US National Institutes of Health 2009 Available"/>
   <result pre="weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive" exact="breast cancer" post="(BrCa) J Clin Oncol 2014 32 15 Suppl 506"/>
   <result pre="paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast" exact="cancer" post="(BrCa) J Clin Oncol 2014 32 15 Suppl 506"/>
   <result pre="protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and" exact="breast cancer" post="tissue Diagn Mol Pathol 2009 18 1 11 21"/>
   <result pre="expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast" exact="cancer" post="tissue Diagn Mol Pathol 2009 18 1 11 21"/>
   <result pre="Arribas J Baselga J Pedersen K Parra-Palau JL p95HER2 and" exact="breast cancer" post="Cancer Res 2011 71 5 1515 1519 21343397 56"/>
   <result pre="J Baselga J Pedersen K Parra-Palau JL p95HER2 and breast" exact="cancer" post="Cancer Res 2011 71 5 1515 1519 21343397 56"/>
   <result pre="to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in" exact="breast cancer" post="J Clin Oncol 2015 33 12 1334 1339 25559818"/>
   <result pre="neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast" exact="cancer" post="J Clin Oncol 2015 33 12 1334 1339 25559818"/>
   <result pre="Activity of neoadjuvant lapatinib (L) plus trastuzumab (T) for early" exact="breast cancer" post="(EBC) according to PIK3CA mutations: pathological complete response (pCR)"/>
   <result pre="of neoadjuvant lapatinib (L) plus trastuzumab (T) for early breast" exact="cancer" post="(EBC) according to PIK3CA mutations: pathological complete response (pCR)"/>
   <result pre="adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive" exact="breast cancer" post="in the North Central Cancer Treatment Group N9831 trial"/>
   <result pre="trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast" exact="cancer" post="in the North Central Cancer Treatment Group N9831 trial"/>
   <result pre="al. Circulating tumor cells, disease progression, and survival in metastatic" exact="breast cancer" post="N Engl J Med 2004 351 8 781 791"/>
   <result pre="Circulating tumor cells, disease progression, and survival in metastatic breast" exact="cancer" post="N Engl J Med 2004 351 8 781 791"/>
   <result pre="and HER2 expression of circulating tumor cells: prospective monitoring in" exact="breast cancer" post="patients treated in the neoadjuvant GeparQuattro trial Clin Cancer"/>
   <result pre="HER2 expression of circulating tumor cells: prospective monitoring in breast" exact="cancer" post="patients treated in the neoadjuvant GeparQuattro trial Clin Cancer"/>
   <result pre="herceptin (trastuzumab) as adjuvant therapy in patients with HER2-positive primary" exact="breast cancer" post="Bethesda, MD US National Institutes of Health 2011 Available"/>
   <result pre="(trastuzumab) as adjuvant therapy in patients with HER2-positive primary breast" exact="cancer" post="Bethesda, MD US National Institutes of Health 2011 Available"/>
   <result pre="followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified" exact="breast cancer" post="is not feasible because of excessive diarrhea J Clin"/>
   <result pre="by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast" exact="cancer" post="is not feasible because of excessive diarrhea J Clin"/>
   <result pre="in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive" exact="diarrhea" post="J Clin Oncol 2010 28 18 2982 2988 20479410"/>
   <result pre="trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive" exact="breast cancer" post="Breast Cancer Res Treat 2013 138 2 427 435"/>
   <result pre="and lapatinib as adjuvant therapy for early stage HER2-positive breast" exact="cancer" post="Breast Cancer Res Treat 2013 138 2 427 435"/>
   <result pre="435 23479422 69 collab: Perjetacom [database on the Internet] Neoadjuvant" exact="breast cancer" post="treatment: Tryphaena trial overview Basel, Switzerland Hoffman-La Roche Ltd"/>
   <result pre="23479422 69 collab: Perjetacom [database on the Internet] Neoadjuvant breast" exact="cancer" post="treatment: Tryphaena trial overview Basel, Switzerland Hoffman-La Roche Ltd"/>
   <result pre="Baselga J Pooled analysis of cardiac safety in patients with" exact="cancer" post="treated with pertuzumab Ann Oncol 2012 23 3 791"/>
   <result pre="A Nearchou A Polyzos NP Lind P Cardiac toxicity in" exact="breast cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="Nearchou A Polyzos NP Lind P Cardiac toxicity in breast" exact="cancer" post="patients treated with dual HER2 blockade Int J Cancer"/>
   <result pre="complete response on prognosis after neoadjuvant chemotherapy in various intrinsic" exact="breast cancer" post="subtypes J Clin Oncol 2012 30 15 1796 1804"/>
   <result pre="response on prognosis after neoadjuvant chemotherapy in various intrinsic breast" exact="cancer" post="subtypes J Clin Oncol 2012 30 15 1796 1804"/>
   <result pre="R Pathological complete response and accelerated drug approval in early" exact="breast cancer" post="N Engl J Med 2012 366 26 2438 2441"/>
   <result pre="Pathological complete response and accelerated drug approval in early breast" exact="cancer" post="N Engl J Med 2012 366 26 2438 2441"/>
   <result pre="76 Gradishar WJ Anderson BO Balassanian R et al. Breast" exact="cancer" post="version 2. 2015 J Natl Compr Canc Netw 2015"/>
   <result pre="trastuzumab plus lapatinib in the neoadjuvant setting for HER2 positive" exact="breast cancer" post="Study/phase Therapy Patients enrolled pCR rate (breast only) pCR"/>
   <result pre="plus lapatinib in the neoadjuvant setting for HER2 positive breast" exact="cancer" post="Study/phase Therapy Patients enrolled pCR rate (breast only) pCR"/>
   <result pre="trastuzumab plus pertuzumab in the neoadjuvant setting for HER2 positive" exact="breast cancer" post="Study/phase Therapy Patients enrolled pCR (breast only) pCR (breast"/>
   <result pre="plus pertuzumab in the neoadjuvant setting for HER2 positive breast" exact="cancer" post="Study/phase Therapy Patients enrolled pCR (breast only) pCR (breast"/>
   <result pre="surgery → FEC ×3 + T Stage II/III, including inflammatory" exact="cancer" post="417 patients ( A: 107, B: 107, C: 107,"/>
   <result pre="→ T + P + docetaxel Stage II/III, including inflammatory" exact="cancer" post="225 patients ( A: 77, B: 75, C: 73)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4591587/results/search/disease/results.xml">
   <result pre="evaluation of trends in survival among patients with HER2-positive advanced" exact="breast cancer" post="Korner Eli J. korner.eli@gene.com Morris Anne morris.anne@gene.com Allen Isabel"/>
   <result pre="of trends in survival among patients with HER2-positive advanced breast" exact="cancer" post="Korner Eli J. korner.eli@gene.com Morris Anne morris.anne@gene.com Allen Isabel"/>
   <result pre="Abstract Background Human epidermal growth factor receptor 2 (HER2)-positive metastatic" exact="breast cancer" post="(MBC) is an aggressive form of breast cancer and"/>
   <result pre="Background Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast" exact="cancer" post="(MBC) is an aggressive form of breast cancer and"/>
   <result pre="(HER2)-positive metastatic breast cancer (MBC) is an aggressive form of" exact="breast cancer" post="and is historically associated with poor outcomes compared with"/>
   <result pre="metastatic breast cancer (MBC) is an aggressive form of breast" exact="cancer" post="and is historically associated with poor outcomes compared with"/>
   <result pre="of HER2-positive MBC. Additional advances in patient care—such as improved" exact="breast cancer" post="screening, HER2 testing, and supportive care—have also occurred. The"/>
   <result pre="HER2-positive MBC. Additional advances in patient care—such as improved breast" exact="cancer" post="screening, HER2 testing, and supportive care—have also occurred. The"/>
   <result pre="change in survival over time in patients with HER2-positive advanced" exact="breast cancer" post="based on results from interventional clinical trials (ICTs) and"/>
   <result pre="in survival over time in patients with HER2-positive advanced breast" exact="cancer" post="based on results from interventional clinical trials (ICTs) and"/>
   <result pre="ICTs and observational studies that include patients with HER2-positive advanced" exact="breast cancer" post="from 1987 onwards will be considered. The primary outcome"/>
   <result pre="and observational studies that include patients with HER2-positive advanced breast" exact="cancer" post="from 1987 onwards will be considered. The primary outcome"/>
   <result pre="current and evolving trends in survival associated with HER2-positive advanced" exact="breast cancer" post="over nearly 30 years and will build upon prior,"/>
   <result pre="and evolving trends in survival associated with HER2-positive advanced breast" exact="cancer" post="over nearly 30 years and will build upon prior,"/>
   <result pre="supplementary material, which is available to authorized users. Keywords Advanced" exact="breast cancer" post="HER2-positive breast cancer Interventional controlled trials Locally advanced breast"/>
   <result pre="material, which is available to authorized users. Keywords Advanced breast" exact="cancer" post="HER2-positive breast cancer Interventional controlled trials Locally advanced breast"/>
   <result pre="is available to authorized users. Keywords Advanced breast cancer HER2-positive" exact="breast cancer" post="Interventional controlled trials Locally advanced breast cancer Meta-analysis Metastatic"/>
   <result pre="available to authorized users. Keywords Advanced breast cancer HER2-positive breast" exact="cancer" post="Interventional controlled trials Locally advanced breast cancer Meta-analysis Metastatic"/>
   <result pre="breast cancer HER2-positive breast cancer Interventional controlled trials Locally advanced" exact="breast cancer" post="Meta-analysis Metastatic breast cancer Observational study Randomized clinical trial"/>
   <result pre="cancer HER2-positive breast cancer Interventional controlled trials Locally advanced breast" exact="cancer" post="Meta-analysis Metastatic breast cancer Observational study Randomized clinical trial"/>
   <result pre="cancer Interventional controlled trials Locally advanced breast cancer Meta-analysis Metastatic" exact="breast cancer" post="Observational study Randomized clinical trial Survival Systematic review Background"/>
   <result pre="Interventional controlled trials Locally advanced breast cancer Meta-analysis Metastatic breast" exact="cancer" post="Observational study Randomized clinical trial Survival Systematic review Background"/>
   <result pre="Observational study Randomized clinical trial Survival Systematic review Background Breast" exact="cancer" post="is the most common cancer among women worldwide. Globally,"/>
   <result pre="Survival Systematic review Background Breast cancer is the most common" exact="cancer" post="among women worldwide. Globally, there were an estimated 1.67"/>
   <result pre="women worldwide. Globally, there were an estimated 1.67 million new" exact="breast cancer" post="diagnoses and 522,000 breast cancer-related deaths in 2012 ["/>
   <result pre="worldwide. Globally, there were an estimated 1.67 million new breast" exact="cancer" post="diagnoses and 522,000 breast cancer-related deaths in 2012 ["/>
   <result pre="prior to the availability of HER2-targeted therapy, patients with HER2-positive" exact="breast cancer" post="experienced significantly shorter disease-free survival [ 5, 6, 9]"/>
   <result pre="to the availability of HER2-targeted therapy, patients with HER2-positive breast" exact="cancer" post="experienced significantly shorter disease-free survival [ 5, 6, 9]"/>
   <result pre="[ 5, 6, 9] and an approximately twofold increase in" exact="breast cancer" post="mortality [ 10– 12] relative to patients with HER2-normal"/>
   <result pre="5, 6, 9] and an approximately twofold increase in breast" exact="cancer" post="mortality [ 10– 12] relative to patients with HER2-normal"/>
   <result pre="cancer mortality [ 10– 12] relative to patients with HER2-normal" exact="breast cancer." post="The first HER2-targeted therapy, the humanized monoclonal antibody trastuzumab,"/>
   <result pre="trastuzumab, was approved for the treatment of patients with metastatic" exact="breast cancer" post="(MBC) in 1998. Since then, three additional HER2-targeted agents"/>
   <result pre="was approved for the treatment of patients with metastatic breast" exact="cancer" post="(MBC) in 1998. Since then, three additional HER2-targeted agents"/>
   <result pre="advances in the care of patients identified with HER2-positive advanced" exact="breast cancer" post="(i.e., MBC or locally advanced breast cancer [LABC]) have"/>
   <result pre="in the care of patients identified with HER2-positive advanced breast" exact="cancer" post="(i.e., MBC or locally advanced breast cancer [LABC]) have"/>
   <result pre="with HER2-positive advanced breast cancer (i.e., MBC or locally advanced" exact="breast cancer" post="[LABC]) have occurred, such as improvements in breast cancer"/>
   <result pre="HER2-positive advanced breast cancer (i.e., MBC or locally advanced breast" exact="cancer" post="[LABC]) have occurred, such as improvements in breast cancer"/>
   <result pre="advanced breast cancer [LABC]) have occurred, such as improvements in" exact="breast cancer" post="screening, advances in reliable identification of HER2-positive disease, refinement"/>
   <result pre="breast cancer [LABC]) have occurred, such as improvements in breast" exact="cancer" post="screening, advances in reliable identification of HER2-positive disease, refinement"/>
   <result pre="trials, systematic reviews, and meta-analyses of patients with HER2-positive advanced" exact="breast cancer" post="published through October 2012 [ 13]. The analysis found"/>
   <result pre="systematic reviews, and meta-analyses of patients with HER2-positive advanced breast" exact="cancer" post="published through October 2012 [ 13]. The analysis found"/>
   <result pre="over time, including in studies of patients with HER2-positive advanced" exact="breast cancer," post="this systematic review included only studies that assessed trastuzumab-based"/>
   <result pre="2010 [ 16]. The study included patients with HER2-positive advanced" exact="breast cancer" post="(IHC 3+ or amplification ratio ≥2.0 by fluorescence in"/>
   <result pre="[ 16]. The study included patients with HER2-positive advanced breast" exact="cancer" post="(IHC 3+ or amplification ratio ≥2.0 by fluorescence in"/>
   <result pre="on the collective effect of interventions to manage HER2-positive advanced" exact="breast cancer" post="on outcomes in patients in real-world settings, and none"/>
   <result pre="the collective effect of interventions to manage HER2-positive advanced breast" exact="cancer" post="on outcomes in patients in real-world settings, and none"/>
   <result pre="included 6268 patients with MBC and 118,817 patients with early-stage" exact="breast cancer," post="found 3-year survival rates of 47.6 % for patients"/>
   <result pre="stand in contrast with the negative prognosis associated with HER2-positive" exact="breast cancer" post="that existed prior to the availability of HER2-directed therapy"/>
   <result pre="in contrast with the negative prognosis associated with HER2-positive breast" exact="cancer" post="that existed prior to the availability of HER2-directed therapy"/>
   <result pre="data—as well as clinical experience—suggests that patients with HER2-positive advanced" exact="breast cancer" post="have experienced improved survival outcomes over time. However, to"/>
   <result pre="well as clinical experience—suggests that patients with HER2-positive advanced breast" exact="cancer" post="have experienced improved survival outcomes over time. However, to"/>
   <result pre="sources. To examine survival outcomes in patients with HER2-positive advanced" exact="breast cancer" post="in a comprehensive way, we will conduct a systematic"/>
   <result pre="To examine survival outcomes in patients with HER2-positive advanced breast" exact="cancer" post="in a comprehensive way, we will conduct a systematic"/>
   <result pre="studies that reported survival outcomes in patients with HER2-positive advanced" exact="breast cancer" post="from 1987, when HER2-overexpressing breast cancer was identified as"/>
   <result pre="that reported survival outcomes in patients with HER2-positive advanced breast" exact="cancer" post="from 1987, when HER2-overexpressing breast cancer was identified as"/>
   <result pre="patients with HER2-positive advanced breast cancer from 1987, when HER2-overexpressing" exact="breast cancer" post="was identified as a distinct phenotype, to the present."/>
   <result pre="with HER2-positive advanced breast cancer from 1987, when HER2-overexpressing breast" exact="cancer" post="was identified as a distinct phenotype, to the present."/>
   <result pre="evaluate clinical outcomes over time in patients with HER2-positive advanced" exact="breast cancer" post="from both interventional clinical trials and observational studies and"/>
   <result pre="clinical outcomes over time in patients with HER2-positive advanced breast" exact="cancer" post="from both interventional clinical trials and observational studies and"/>
   <result pre="will meet the following criteria: Population: Adults with HER2-positive advanced" exact="breast cancer" post="(i.e., HER2-positive MBC or LABC) identified prior to receipt"/>
   <result pre="meet the following criteria: Population: Adults with HER2-positive advanced breast" exact="cancer" post="(i.e., HER2-positive MBC or LABC) identified prior to receipt"/>
   <result pre="receipt of the first targeted or chemotherapeutic agent for advanced" exact="breast cancer." post="HER2-positive status is defined by each publication. Mixed populations"/>
   <result pre="those studies with at least 15 patients with HER2-positive advanced" exact="breast cancer" post="will be used for the final analysis. Intervention/comparator: Any"/>
   <result pre="studies with at least 15 patients with HER2-positive advanced breast" exact="cancer" post="will be used for the final analysis. Intervention/comparator: Any"/>
   <result pre="advanced setting or as the time from diagnosis of advanced" exact="breast cancer" post="until death from any cause. o Eligible interventional controlled"/>
   <result pre="setting or as the time from diagnosis of advanced breast" exact="cancer" post="until death from any cause. o Eligible interventional controlled"/>
   <result pre="from the initiation of first-line treatment or diagnosis of advanced" exact="breast cancer" post="until objective tumor progression or death. Time of follow-up:"/>
   <result pre="the initiation of first-line treatment or diagnosis of advanced breast" exact="cancer" post="until objective tumor progression or death. Time of follow-up:"/>
   <result pre="outcome of interest is OS in patients with HER2-positive advanced" exact="breast cancer," post="which will be evaluated both overall and separately for"/>
   <result pre="in survival outcomes over time in patients with HER2-positive advanced" exact="breast cancer" post="will serve several purposes. First, this research may identify"/>
   <result pre="survival outcomes over time in patients with HER2-positive advanced breast" exact="cancer" post="will serve several purposes. First, this research may identify"/>
   <result pre="state of research knowledge about the characterization of HER2-positive advanced" exact="breast cancer" post="over time by providing important historical and clinical context"/>
   <result pre="of research knowledge about the characterization of HER2-positive advanced breast" exact="cancer" post="over time by providing important historical and clinical context"/>
   <result pre="OS and PFS over time among patients with HER2-positive advanced" exact="breast cancer" post="may also provide insight into potential differences observed in"/>
   <result pre="and PFS over time among patients with HER2-positive advanced breast" exact="cancer" post="may also provide insight into potential differences observed in"/>
   <result pre="comprehensive systematic review of outcomes in patients with HER2-positive advanced" exact="breast cancer" post="that evaluates nearly 30 years of published data and"/>
   <result pre="systematic review of outcomes in patients with HER2-positive advanced breast" exact="cancer" post="that evaluates nearly 30 years of published data and"/>
   <result pre="more diagnostic and therapeutic interventions for patients with HER2-positive advanced" exact="breast cancer," post="it is important to patients, healthcare providers, and researchers"/>
   <result pre="(TNM) classification for defining subgroups of patients with locally advanced" exact="breast cancer" post="and metastatic breast cancer. This table provides TNM classifications"/>
   <result pre="classification for defining subgroups of patients with locally advanced breast" exact="cancer" post="and metastatic breast cancer. This table provides TNM classifications"/>
   <result pre="subgroups of patients with locally advanced breast cancer and metastatic" exact="breast cancer." post="This table provides TNM classifications used in this study."/>
   <result pre="epidermal growth factor receptor 2 IHC immunohistochemistry LABC locally advanced" exact="breast cancer" post="MBC metastatic breast cancer OS overall survival PFS progression-free"/>
   <result pre="growth factor receptor 2 IHC immunohistochemistry LABC locally advanced breast" exact="cancer" post="MBC metastatic breast cancer OS overall survival PFS progression-free"/>
   <result pre="2 IHC immunohistochemistry LABC locally advanced breast cancer MBC metastatic" exact="breast cancer" post="OS overall survival PFS progression-free survival MOOSE Meta-analysis of"/>
   <result pre="IHC immunohistochemistry LABC locally advanced breast cancer MBC metastatic breast" exact="cancer" post="OS overall survival PFS progression-free survival MOOSE Meta-analysis of"/>
   <result pre="Inc. References References 1. World Health Organization. GLOBOCAN 2012: estimated" exact="cancer" post="incidence, mortality, and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx#. Accessed"/>
   <result pre="AU Hortobagyi GN Giordano SH Prognosis of women with metastatic" exact="breast cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="Hortobagyi GN Giordano SH Prognosis of women with metastatic breast" exact="cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="Kitchen P Clinical significance of HER-2/neu oncogene amplification in primary" exact="breast cancer." post="The South Australian Breast Cancer Study Group J Clin"/>
   <result pre="Ayers M et al. The Her-2/neu gene and protein in" exact="breast cancer" post="2003: biomarker and target of therapy Oncologist 2003 8"/>
   <result pre="M et al. The Her-2/neu gene and protein in breast" exact="cancer" post="2003: biomarker and target of therapy Oncologist 2003 8"/>
   <result pre="Expression of the HER1-4 family of receptor tyrosine kinases in" exact="breast cancer" post="J Pathol 2003 200 290 7 10.1002/path.1370 12845624 9."/>
   <result pre="of the HER1-4 family of receptor tyrosine kinases in breast" exact="cancer" post="J Pathol 2003 200 290 7 10.1002/path.1370 12845624 9."/>
   <result pre="positivity for the development of brain metastases after newly diagnosed" exact="breast cancer" post="J Clin Oncol 2006 24 5658 63 10.1200/JCO.2006.07.0250 17102066"/>
   <result pre="for the development of brain metastases after newly diagnosed breast" exact="cancer" post="J Clin Oncol 2006 24 5658 63 10.1200/JCO.2006.07.0250 17102066"/>
   <result pre="Bowel Project: prognostic significance of erbB-2 protein overexpression in primary" exact="breast cancer" post="J Clin Oncol 1990 8 103 12 1967301 11."/>
   <result pre="Project: prognostic significance of erbB-2 protein overexpression in primary breast" exact="cancer" post="J Clin Oncol 1990 8 103 12 1967301 11."/>
   <result pre="increased risk of visceral metastasis and poor long-term survival in" exact="breast cancer" post="Int J Cancer 1991 49 650 5 10.1002/ijc.2910490504 1682277"/>
   <result pre="risk of visceral metastasis and poor long-term survival in breast" exact="cancer" post="Int J Cancer 1991 49 650 5 10.1002/ijc.2910490504 1682277"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 109 19 10.1056/NEJMoa1113216"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 109 19 10.1056/NEJMoa1113216"/>
   <result pre="M et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic" exact="breast cancer" post="N Engl J Med 2015 372 724 34 10.1056/NEJMoa1413513"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast" exact="cancer" post="N Engl J Med 2015 372 724 34 10.1056/NEJMoa1413513"/>
   <result pre="L, Moy L, Yang J, Wang L, et al. Breast" exact="cancer" post="subtype and survival in a population-based cohort of patients"/>
   <result pre="Guidance for industry clinical trial endpoints for the approval of" exact="cancer" post="drugs and biologics. http://www.fda.gov/downloads/Drugs/%E2%80%A6/%20Guidances/ucm071590.pdf. Accessed 25 Mar 2015. 24."/>
   <result pre="Mar 2015. 24. Balduzzi S Cochrane review—Trastuzumab-containing regimens for metastatic" exact="breast cancer" post="J Evid Based Med 2014 7 229 10.1111/jebm.12119 25."/>
   <result pre="2015. 24. Balduzzi S Cochrane review—Trastuzumab-containing regimens for metastatic breast" exact="cancer" post="J Evid Based Med 2014 7 229 10.1111/jebm.12119 25."/>
   <result pre="Kumar A et al. Survival of patients with non-small cell" exact="lung cancer" post="without treatment: a systematic review and meta-analysis Syst Rev"/>
   <result pre="A et al. Survival of patients with non-small cell lung" exact="cancer" post="without treatment: a systematic review and meta-analysis Syst Rev"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4593385/results/search/disease/results.xml">
   <result pre="drug-resistant issue has also emerged to limit their benefits to" exact="cancer" post="patients. In this regard, we aim to improve targeted"/>
   <result pre="regarding the drug resistance mechanisms and alternative approaches to re-sensitize" exact="cancer" post="cells/tissues therapeutically. Keywords Targeted therapy Drug resistance Re-sensitization Background"/>
   <result pre="ago, the rise of hormonal therapy, such as tamoxifen for" exact="breast cancer," post="has remarkably enhanced tissue selectivity and thereby diminished adverse"/>
   <result pre="showed an impressive response to treatment initially, the majority of" exact="cancer" post="patients relapsed because small cohorts of tumor cells can"/>
   <result pre="Regorafenib [ 7, 8] EGFR Gefitinib Erlotinib Cetuximab NSCLC Colorectal" exact="cancer" post="1. Secondary mutations in EGFR such as T790 M"/>
   <result pre="ALK rearrangement Ceritinib Alertinib [ 14, 15] HER2 Trastuzumab Breast" exact="cancer" post="Gastric cancer 1. Lack of the extracellular domain of"/>
   <result pre="Ceritinib Alertinib [ 14, 15] HER2 Trastuzumab Breast cancer Gastric" exact="cancer" post="1. Lack of the extracellular domain of HER2 2."/>
   <result pre="Ramucirumab Sorafenib Sunitinib Aflibercept Pazopanib Vandetanib Vatalanib Cediranib Axitinib Renal" exact="cancer" post="Colorectal cancer Small cell lung cancer Thyroid cancer Sarcoma"/>
   <result pre="Sunitinib Aflibercept Pazopanib Vandetanib Vatalanib Cediranib Axitinib Renal cancer Colorectal" exact="cancer" post="Small cell lung cancer Thyroid cancer Sarcoma 1. Alternative"/>
   <result pre="Vandetanib Vatalanib Cediranib Axitinib Renal cancer Colorectal cancer Small cell" exact="lung cancer" post="Thyroid cancer Sarcoma 1. Alternative angiogenic signaling 2. Increased"/>
   <result pre="Vatalanib Cediranib Axitinib Renal cancer Colorectal cancer Small cell lung" exact="cancer" post="Thyroid cancer Sarcoma 1. Alternative angiogenic signaling 2. Increased"/>
   <result pre="Axitinib Renal cancer Colorectal cancer Small cell lung cancer Thyroid" exact="cancer" post="Sarcoma 1. Alternative angiogenic signaling 2. Increased HIF1, MDSCs,"/>
   <result pre="antibodies [ 22– 24] BCR- ABL breakpoint cluster region-Abelson, CML" exact="chronic myeloid leukemia," post="KIT kit receptor tyrosine kinase, GIST gastrointestinal stromal tumor,"/>
   <result pre="[ 22– 24] BCR- ABL breakpoint cluster region-Abelson, CML chronic" exact="myeloid leukemia," post="KIT kit receptor tyrosine kinase, GIST gastrointestinal stromal tumor,"/>
   <result pre="CML chronic myeloid leukemia, KIT kit receptor tyrosine kinase, GIST" exact="gastrointestinal stromal tumor," post="PDGFRA platelet-derived growth factor receptor A, EGFR epidermal growth"/>
   <result pre="receptor A, EGFR epidermal growth factor receptor, NSCLC non–small cell" exact="lung cancer," post="ALK anaplastic lymphoma kinase, HER2 human EGFR2, VEGF(R) vascular"/>
   <result pre="growth factor receptor, NSCLC non–small cell lung cancer, ALK anaplastic" exact="lymphoma" post="kinase, HER2 human EGFR2, VEGF(R) vascular endothelial cell growth"/>
   <result pre="(receptor), HIF1 hypoxia-inducible factor 1, MDSC myeloid-derived suppressor cell, CSC" exact="cancer" post="stem cell, BRAF raf murine sarcoma viral oncogene homolog"/>
   <result pre="myeloid-derived suppressor cell, CSC cancer stem cell, BRAF raf murine" exact="sarcoma" post="viral oncogene homolog B, MAPK mitogen-activated protein kinase, PD-"/>
   <result pre="inhibitor Imatinib (Gleevec, Novartis, Basel, Switzerland) revolutionized therapeutic strategies for" exact="chronic myeloid leukemia" post="(CML) through targeting the BCR-ABL fusion protein, which drives"/>
   <result pre="Imatinib (Gleevec, Novartis, Basel, Switzerland) revolutionized therapeutic strategies for chronic" exact="myeloid leukemia" post="(CML) through targeting the BCR-ABL fusion protein, which drives"/>
   <result pre="(Gleevec, Novartis, Basel, Switzerland) revolutionized therapeutic strategies for chronic myeloid" exact="leukemia" post="(CML) through targeting the BCR-ABL fusion protein, which drives"/>
   <result pre="8]. Inhibitors of epidermal growth factor receptor (EGFR) and anaplastic" exact="lymphoma" post="kinase (ALK) EGFR represents a member of the cell"/>
   <result pre="EGFR addiction). In addition, cetuximab in combination with radiation in" exact="head and neck cancer" post="has delivered more impressive benefits, increasing the 2-year OS"/>
   <result pre="addition, cetuximab in combination with radiation in head and neck" exact="cancer" post="has delivered more impressive benefits, increasing the 2-year OS"/>
   <result pre="13]. Additionally, cetuximab was approved for treating metastatic and chemotherapy-resistant" exact="colorectal cancer" post="due to its clinical efficacy with improved PFS and"/>
   <result pre="Additionally, cetuximab was approved for treating metastatic and chemotherapy-resistant colorectal" exact="cancer" post="due to its clinical efficacy with improved PFS and"/>
   <result pre="mechanism of primary and acquired resistance to EGFR inhibitor in" exact="lung cancer" post="is the T790 M &quot;gatekeeper&quot; mutation, for which a"/>
   <result pre="of primary and acquired resistance to EGFR inhibitor in lung" exact="cancer" post="is the T790 M &quot;gatekeeper&quot; mutation, for which a"/>
   <result pre="combining cetuximab with afatinid. However, an EGFR mutation S492R in" exact="colorectal cancer" post="leads to resistance to cetuximab, which can be overcome"/>
   <result pre="cetuximab with afatinid. However, an EGFR mutation S492R in colorectal" exact="cancer" post="leads to resistance to cetuximab, which can be overcome"/>
   <result pre="ALK activation has been identified in 3–5% of non–small cell" exact="lung cancer" post="(NSCLC) patients, and is clinically linked to a more"/>
   <result pre="activation has been identified in 3–5% of non–small cell lung" exact="cancer" post="(NSCLC) patients, and is clinically linked to a more"/>
   <result pre="clinically linked to a more aggressive phenotype. This subset of" exact="lung cancer" post="is addicted to high ALK activity for malignant growth,"/>
   <result pre="linked to a more aggressive phenotype. This subset of lung" exact="cancer" post="is addicted to high ALK activity for malignant growth,"/>
   <result pre="shown encouraging efficacy [ 15]. Human EGFR2 (HER2) antibody Breast" exact="cancer" post="consists of a heterogeneous mass of pathologic conditions which,"/>
   <result pre="Strategies targeting the estrogen receptor (ER) and HER2 to treat" exact="breast cancer" post="have come up with some of the most successful"/>
   <result pre="targeting the estrogen receptor (ER) and HER2 to treat breast" exact="cancer" post="have come up with some of the most successful"/>
   <result pre="successful drugs in oncology. HER2 is overexpressed in 25–30% of" exact="breast cancer" post="patients, predicting a poor clinical outcome in the absence"/>
   <result pre="drugs in oncology. HER2 is overexpressed in 25–30% of breast" exact="cancer" post="patients, predicting a poor clinical outcome in the absence"/>
   <result pre="been accepted as the standard first-line treatment for HER2-positive metastatic" exact="breast cancer" post="(MBC). Application of trastuzumab was revealed to confer extra-clinical"/>
   <result pre="accepted as the standard first-line treatment for HER2-positive metastatic breast" exact="cancer" post="(MBC). Application of trastuzumab was revealed to confer extra-clinical"/>
   <result pre="relapse compared with conventional therapy [ 29]. Even if the" exact="cancer" post="progresses on trastuzumab, the anti-cancer drug is still recommended"/>
   <result pre="slowing tumor growth [ 29, 30]. The majority of HER2-positive" exact="breast cancer" post="patients would not respond to trastuzumab without simultaneous cytotoxic"/>
   <result pre="tumor growth [ 29, 30]. The majority of HER2-positive breast" exact="cancer" post="patients would not respond to trastuzumab without simultaneous cytotoxic"/>
   <result pre="kDa receptor (p95HER2), expressed in a minor portion of HER2-positive" exact="breast cancer" post="patients, leads to an aggressive trastuzumab-resistant phenotype due to"/>
   <result pre="receptor (p95HER2), expressed in a minor portion of HER2-positive breast" exact="cancer" post="patients, leads to an aggressive trastuzumab-resistant phenotype due to"/>
   <result pre="of EGFR and HER2, has been approved to treat HER2-positive" exact="breast cancer" post="upon trastuzumab failure [ 28]. Vascular endothelial growth factor"/>
   <result pre="EGFR and HER2, has been approved to treat HER2-positive breast" exact="cancer" post="upon trastuzumab failure [ 28]. Vascular endothelial growth factor"/>
   <result pre="improvements in PFS, RR, and OS in patients with certain" exact="cancer" post="types in the clinic [ 18, 19]. Even though"/>
   <result pre="inducible factor 1 α (HIF1α), myeloid-derived suppressor cells (MDSCs), and" exact="cancer" post="stem cells (CSCs). As a transcription factor, HIF1α up-regulates"/>
   <result pre="associated with cell survival and anaerobic metabolism [ 20]. Meanwhile," exact="cancer" post="and stromal cells secrete granulocyte colony-stimulating factor (GCSF) and"/>
   <result pre="also contribute to drug resistance via suppressing immune activity against" exact="cancer" post="in the tumor microenvironment. Recently, CSCs have been recognized"/>
   <result pre="Recently, CSCs have been recognized as a particular subpopulation of" exact="cancer" post="cells that are responsible for metastasis and therapeutic resistance"/>
   <result pre="reversed by combining with certain therapeutic means accordingly. Raf murine" exact="sarcoma" post="viral oncogene homolog B (BRAF) inhibitor The serine/threonine kinase"/>
   <result pre="serine/threonine kinase BRAF serves as a crucial mediator in rat" exact="sarcoma" post="(RAS) mitogen-activated protein kinase (MAPK) signaling cascade which represents"/>
   <result pre="many types of tumors, and are highly frequent in melanoma," exact="colorectal cancer," post="and papillary thyroid cancer. Over 50% of melanomas bear"/>
   <result pre="and are highly frequent in melanoma, colorectal cancer, and papillary" exact="thyroid cancer." post="Over 50% of melanomas bear BRAF mutations at the"/>
   <result pre="most targeted therapies are limited, extending PFS or OS of" exact="cancer" post="patients by only a few months, and resistance is"/>
   <result pre="each individual patient which is regarded as personalized medicine. Furthermore," exact="cancer" post="genome monitoring and microRNA profiling [ 38] are being"/>
   <result pre="clinical outcomes [ 21, 33]. In addition, the renaissance of" exact="cancer" post="immunology in recent years has dramatically inspired oncology with"/>
   <result pre="BA Roberts TG Jr Timeline: chemotherapy and the war on" exact="cancer" post="Nat Rev Cancer 2005 5 65 72 10.1038/nrc1529 15630416"/>
   <result pre="clinical indications, and resistance mechanisms in molecular targeted therapies in" exact="cancer" post="Pharmacol Rev 2013 65 1351 1395 10.1124/pr.113.007807 24092887 3."/>
   <result pre="24092887 3. Schiavon G Smith IE Endocrine therapy for advanced/metastatic" exact="breast cancer" post="Hematol Oncol Clin North Am 2013 27 715 736"/>
   <result pre="3. Schiavon G Smith IE Endocrine therapy for advanced/metastatic breast" exact="cancer" post="Hematol Oncol Clin North Am 2013 27 715 736"/>
   <result pre="10.1016/j.hoc.2013.05.004 23915741 4. Zhang J Yang PL Cray NS Targeting" exact="cancer" post="with small molecule kinase inhibitors Nat Rev Cancer 2009"/>
   <result pre="the biological and clinical activity of sunitinib in imatinib resistant" exact="gastrointestinal stromal tumor" post="J Clin Oncol 2008 26 5352 5359 10.1200/JCO.2007.15.7461 18955458"/>
   <result pre="growth factor receptor antagonists in the biology and treatment of" exact="cancer" post="J Clin Oncol 2003 21 2787 2799 10.1200/JCO.2003.01.504 12860957"/>
   <result pre="PA The quest to overcome resistance to EGFR-targeted therapies in" exact="cancer" post="Nat Med 2013 19 1389 1400 10.1038/nm.3388 24202392 12."/>
   <result pre="K Xu Y Management of tyrosine kinase inhibitor resistance in" exact="lung cancer" post="with EGFR mutation World J Clin Oncol 2014 5"/>
   <result pre="Xu Y Management of tyrosine kinase inhibitor resistance in lung" exact="cancer" post="with EGFR mutation World J Clin Oncol 2014 5"/>
   <result pre="T Takashima J Nakajima T et al. EML4-ALK mutations in" exact="lung cancer" post="that confer resistance to ALK inhibitors N Engl J"/>
   <result pre="Takashima J Nakajima T et al. EML4-ALK mutations in lung" exact="cancer" post="that confer resistance to ALK inhibitors N Engl J"/>
   <result pre="of the HER2 receptor, and response to anti-HER2 therapies in" exact="breast cancer" post="J Natl Cancer Inst 2007 99 628 638 10.1093/jnci/djk134"/>
   <result pre="the HER2 receptor, and response to anti-HER2 therapies in breast" exact="cancer" post="J Natl Cancer Inst 2007 99 628 638 10.1093/jnci/djk134"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="B Korkaya H Heath AN et al. Antiangiogenic agents increase" exact="breast cancer" post="stem cells via the generation of tumor hypoxia Proc"/>
   <result pre="Korkaya H Heath AN et al. Antiangiogenic agents increase breast" exact="cancer" post="stem cells via the generation of tumor hypoxia Proc"/>
   <result pre="old drugs as emerging approaches to selectively target human glioblastoma" exact="cancer" post="stem cells Biomed Res Int. 2014 2014 126586 10.1155/2014/126586"/>
   <result pre="S et al. Mutations of the BRAF gene in human" exact="cancer" post="Nature 2002 417 949 954 10.1038/nature00766 12068308 23. Jarkowski"/>
   <result pre="BJ Perspectives on development of imatinib and the future of" exact="cancer" post="Nat Med 2009 15 1149 1152 10.1038/nm1009-1149 19812576 26."/>
   <result pre="2009 15 1149 1152 10.1038/nm1009-1149 19812576 26. Lydon N Attacking" exact="cancer" post="at its foundation Nat Med 2009 15 1153 1157"/>
   <result pre="ERBB receptors: from oncogene discovery to basic science to mechanism-based" exact="cancer" post="therapeutics Cancer Cell 2014 25 282 303 10.1016/j.ccr.2014.02.025 24651011"/>
   <result pre="24651011 28. Gradishar WJ Emerging approaches for treating HER2-positive metastatic" exact="breast cancer" post="beyond trastuzumab Ann Oncol 2013 24 2492 2500 10.1093/annonc/mdt217"/>
   <result pre="28. Gradishar WJ Emerging approaches for treating HER2-positive metastatic breast" exact="cancer" post="beyond trastuzumab Ann Oncol 2013 24 2492 2500 10.1093/annonc/mdt217"/>
   <result pre="NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122"/>
   <result pre="Martin M Press M et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 1273 1283 10.1056/NEJMoa0910383"/>
   <result pre="M Press M et al. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 1273 1283 10.1056/NEJMoa0910383"/>
   <result pre="Novotny W Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for" exact="cancer" post="therapy Biochem Biophys Res Commun. 2005 333 328 335"/>
   <result pre="ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to" exact="cancer" post="stem-like cells and metastasis in breast cancer Cancer Res"/>
   <result pre="connects collagen signaling to cancer stem-like cells and metastasis in" exact="breast cancer" post="Cancer Res 2013 73 5821 5833 10.1158/0008-5472.CAN-13-1080 23832666 34."/>
   <result pre="collagen signaling to cancer stem-like cells and metastasis in breast" exact="cancer" post="Cancer Res 2013 73 5821 5833 10.1158/0008-5472.CAN-13-1080 23832666 34."/>
   <result pre="et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in" exact="renal cell carcinoma" post="Cancer Res 2010 70 1063 1071 10.1158/0008-5472.CAN-09-3965 20103651 38."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4600684/results/search/disease/results.xml">
   <result pre="medium, provided the original work is properly cited. Abstract Breast" exact="cancer" post="generally develops in older women and its incidence is"/>
   <result pre="increasing age of the population. The pathology and biology of" exact="breast cancer" post="seem to be different in the elderly, often resulting"/>
   <result pre="age of the population. The pathology and biology of breast" exact="cancer" post="seem to be different in the elderly, often resulting"/>
   <result pre="describe the differences in the biology and treatment of early" exact="breast cancer" post="in the elderly as well as the use of"/>
   <result pre="the differences in the biology and treatment of early breast" exact="cancer" post="in the elderly as well as the use of"/>
   <result pre="and demonstrate an aggressive tumor profile. Although the prognosis of" exact="breast cancer" post="patients has generally improved during the last few decades,"/>
   <result pre="demonstrate an aggressive tumor profile. Although the prognosis of breast" exact="cancer" post="patients has generally improved during the last few decades,"/>
   <result pre="older patients. Aged Breast Disease management Neoplasms Therapeutics INTRODUCTION Breast" exact="cancer" post="(BC) is the prevailing malignancy of women in industrialized"/>
   <result pre="spread beyond the breast or axillary lymph nodes, including ductal" exact="carcinoma in situ," post="stages I, IIA, IIB, and IIIA) are not managed"/>
   <result pre="p53 mutations [ 13], and the overexpression of the B-cell" exact="lymphoma" post="2 (Bcl-2) protein [ 9]. In terms of ER/PR"/>
   <result pre="the lowest annual local recurrence and the lowest second ipsilateral" exact="cancer" post="rates (0.58 and 0.22, respectively). Additionally, in a large"/>
   <result pre="the administration of AIs poses a lower risk of developing" exact="endometrial cancer," post="thromboembolism, vaginal hemorrhage and hot flushes than that of"/>
   <result pre="KJ McCarthy NJ Critical review of the management of early-stage" exact="breast cancer" post="in elderly women Intern Med J 2007 37 181"/>
   <result pre="McCarthy NJ Critical review of the management of early-stage breast" exact="cancer" post="in elderly women Intern Med J 2007 37 181"/>
   <result pre="2 Jemal A Ward E Thun MJ Recent trends in" exact="breast cancer" post="incidence rates by age and tumor characteristics among U.S."/>
   <result pre="Jemal A Ward E Thun MJ Recent trends in breast" exact="cancer" post="incidence rates by age and tumor characteristics among U.S."/>
   <result pre="Breast Cancer Group Differences in management of older women influence" exact="breast cancer" post="survival: results from a population-based database in Sweden PLoS"/>
   <result pre="Cancer Group Differences in management of older women influence breast" exact="cancer" post="survival: results from a population-based database in Sweden PLoS"/>
   <result pre="16409108 4 Balducci L Extermann M Carreca I Management of" exact="breast cancer" post="in the older woman Cancer Control 2001 8 431"/>
   <result pre="4 Balducci L Extermann M Carreca I Management of breast" exact="cancer" post="in the older woman Cancer Control 2001 8 431"/>
   <result pre="Mink PJ Carroll L Devesa SS Probabilities of death from" exact="breast cancer" post="and other causes among female breast cancer patients J"/>
   <result pre="PJ Carroll L Devesa SS Probabilities of death from breast" exact="cancer" post="and other causes among female breast cancer patients J"/>
   <result pre="of death from breast cancer and other causes among female" exact="breast cancer" post="patients J Natl Cancer Inst 2004 96 1311 1321"/>
   <result pre="death from breast cancer and other causes among female breast" exact="cancer" post="patients J Natl Cancer Inst 2004 96 1311 1321"/>
   <result pre="CK Anderson KE Lazovich D Folsom AR Risk factors for" exact="breast cancer" post="in elderly women Am J Epidemiol 2004 160 868"/>
   <result pre="Anderson KE Lazovich D Folsom AR Risk factors for breast" exact="cancer" post="in elderly women Am J Epidemiol 2004 160 868"/>
   <result pre="J Dinur I Sella A Stahl-Kent V et al. Breast" exact="cancer" post="in the elderly: histological, hormonal and surgical characteristics Breast"/>
   <result pre="D Garibaldi J Morgan L et al. Biology of primary" exact="breast cancer" post="in older women treated by surgery: with correlation with"/>
   <result pre="Garibaldi J Morgan L et al. Biology of primary breast" exact="cancer" post="in older women treated by surgery: with correlation with"/>
   <result pre="1042 1051 23462719 11 Wedding U Höffken K Care of" exact="breast cancer" post="in the elderly woman: what does comprehensive geriatric assessment"/>
   <result pre="1051 23462719 11 Wedding U Höffken K Care of breast" exact="cancer" post="in the elderly woman: what does comprehensive geriatric assessment"/>
   <result pre="11 769 774 14523632 12 Gennari R Audisio RA Breast" exact="cancer" post="in elderly women: optimizing the treatment Breast Cancer Res"/>
   <result pre="P Fallai C Cerrotta AM Lozza L Badii D Breast" exact="cancer" post="in the elderly: the role of adjuvant radiation therapy"/>
   <result pre="14607380 14 Holmes CE Muss HB Diagnosis and treatment of" exact="breast cancer" post="in the elderly CA Cancer J Clin 2003 53"/>
   <result pre="14 Holmes CE Muss HB Diagnosis and treatment of breast" exact="cancer" post="in the elderly CA Cancer J Clin 2003 53"/>
   <result pre="von Minckwitz G Brain E Goldhirsch A et al. Breast" exact="cancer" post="in the elderly J Clin Oncol 2007 25 1882"/>
   <result pre="16 Daidone MG Coradini D Martelli G Veneroni S Primary" exact="breast cancer" post="in elderly women: biological profile and relation with clinical"/>
   <result pre="Daidone MG Coradini D Martelli G Veneroni S Primary breast" exact="cancer" post="in elderly women: biological profile and relation with clinical"/>
   <result pre="Gray R Clarke M Cutter D et al. Relevance of" exact="breast cancer" post="hormone receptors and other factors to the efficacy of"/>
   <result pre="R Clarke M Cutter D et al. Relevance of breast" exact="cancer" post="hormone receptors and other factors to the efficacy of"/>
   <result pre="and clinical characteristics, and surgical management, of elderly women with" exact="breast cancer" post="Crit Rev Oncol Hematol 2006 59 226 233 16533603"/>
   <result pre="clinical characteristics, and surgical management, of elderly women with breast" exact="cancer" post="Crit Rev Oncol Hematol 2006 59 226 233 16533603"/>
   <result pre="RH Nieuwenhuijzen GA Coebergh JW Voogd AC Clinical epidemiology of" exact="breast cancer" post="in the elderly Eur J Cancer 2007 43 2242"/>
   <result pre="Nieuwenhuijzen GA Coebergh JW Voogd AC Clinical epidemiology of breast" exact="cancer" post="in the elderly Eur J Cancer 2007 43 2242"/>
   <result pre="NM Ye W Herlong T Giuliano AE Surgical management of" exact="breast cancer" post="in the elderly patient Am J Surg 2001 182"/>
   <result pre="Ye W Herlong T Giuliano AE Surgical management of breast" exact="cancer" post="in the elderly patient Am J Surg 2001 182"/>
   <result pre="A Howell A Bundred N Campbell M Non-standard management of" exact="breast cancer" post="increases with age in the UK: a population based"/>
   <result pre="Howell A Bundred N Campbell M Non-standard management of breast" exact="cancer" post="increases with age in the UK: a population based"/>
   <result pre="1203 17387342 22 Malik MK Tartter PI Belfer R Undertreated" exact="breast cancer" post="in the elderly J Cancer Epidemiol 2013 2013 893104"/>
   <result pre="17387342 22 Malik MK Tartter PI Belfer R Undertreated breast" exact="cancer" post="in the elderly J Cancer Epidemiol 2013 2013 893104"/>
   <result pre="Rapiti E Blagojevic S Vlastos AT Vlastos G Older female" exact="cancer" post="patients: importance, causes, and consequences of undertreatment J Clin"/>
   <result pre="BK Yates JW Effect of age and comorbidity in postmenopausal" exact="breast cancer" post="patients aged 55 years and older JAMA 2001 285"/>
   <result pre="Yates JW Effect of age and comorbidity in postmenopausal breast" exact="cancer" post="patients aged 55 years and older JAMA 2001 285"/>
   <result pre="of comorbidities on overall survival among older women diagnosed with" exact="breast cancer" post="J Natl Cancer Inst 2011 103 1101 1111 21719777"/>
   <result pre="comorbidities on overall survival among older women diagnosed with breast" exact="cancer" post="J Natl Cancer Inst 2011 103 1101 1111 21719777"/>
   <result pre="21719777 27 Seah MD Chan PM Rethinking undertreatment in elderly" exact="breast cancer" post="patients Asian J Surg 2009 32 71 75 19423451"/>
   <result pre="27 Seah MD Chan PM Rethinking undertreatment in elderly breast" exact="cancer" post="patients Asian J Surg 2009 32 71 75 19423451"/>
   <result pre="highlights: international expert consensus on the primary therapy of early" exact="breast cancer" post="2005 Ann Oncol 2005 16 1569 1583 16148022 29"/>
   <result pre="international expert consensus on the primary therapy of early breast" exact="cancer" post="2005 Ann Oncol 2005 16 1569 1583 16148022 29"/>
   <result pre="HB Update in medical oncology for older patients: focus on" exact="breast cancer." post="Management of early breast cancer Cancer J 2005 11"/>
   <result pre="for older patients: focus on breast cancer. Management of early" exact="breast cancer" post="Cancer J 2005 11 506 517 16393485 30 Taira"/>
   <result pre="older patients: focus on breast cancer. Management of early breast" exact="cancer" post="Cancer J 2005 11 506 517 16393485 30 Taira"/>
   <result pre="M Shimozuma K Ohashi Y Comprehensive geriatric assessment in elderly" exact="breast cancer" post="patients Breast Cancer 2010 17 183 189 19756923 31"/>
   <result pre="Shimozuma K Ohashi Y Comprehensive geriatric assessment in elderly breast" exact="cancer" post="patients Breast Cancer 2010 17 183 189 19756923 31"/>
   <result pre="38 85 103 23503518 32 Albrand G Terret C Early" exact="breast cancer" post="in the elderly: assessment and management considerations Drugs Aging"/>
   <result pre="85 103 23503518 32 Albrand G Terret C Early breast" exact="cancer" post="in the elderly: assessment and management considerations Drugs Aging"/>
   <result pre="25 35 45 18184027 33 Blamey RW Management of primary" exact="breast cancer" post="in the elderly patient Eur J Cancer 2003 39"/>
   <result pre="35 45 18184027 33 Blamey RW Management of primary breast" exact="cancer" post="in the elderly patient Eur J Cancer 2003 39"/>
   <result pre="34 Downey L Livingston R Stopeck A Diagnosing and treating" exact="breast cancer" post="in elderly women: a call for improved understanding J"/>
   <result pre="Downey L Livingston R Stopeck A Diagnosing and treating breast" exact="cancer" post="in elderly women: a call for improved understanding J"/>
   <result pre="role of surgery in the management of older women with" exact="breast cancer" post="Eur J Cancer 2007 43 2253 2263 17904836 36"/>
   <result pre="of surgery in the management of older women with breast" exact="cancer" post="Eur J Cancer 2007 43 2253 2263 17904836 36"/>
   <result pre="S Engel J et al. Surgical treatment of early stage" exact="breast cancer" post="in elderly: an international comparison Breast Cancer Res Treat"/>
   <result pre="Engel J et al. Surgical treatment of early stage breast" exact="cancer" post="in elderly: an international comparison Breast Cancer Res Treat"/>
   <result pre="al. Omission of surgery in elderly patients with early stage" exact="breast cancer" post="Eur J Cancer 2013 49 545 552 22959185 39"/>
   <result pre="Omission of surgery in elderly patients with early stage breast" exact="cancer" post="Eur J Cancer 2013 49 545 552 22959185 39"/>
   <result pre="Muss H Wildiers H et al. The treatment of early" exact="breast cancer" post="in women over the age of 70 Br J"/>
   <result pre="H Wildiers H et al. The treatment of early breast" exact="cancer" post="in women over the age of 70 Br J"/>
   <result pre="Impact of axillary lymph node dissection on the therapy of" exact="breast cancer" post="patients J Clin Oncol 1993 11 1536 1544 8336192"/>
   <result pre="of axillary lymph node dissection on the therapy of breast" exact="cancer" post="patients J Clin Oncol 1993 11 1536 1544 8336192"/>
   <result pre="K Necessity of axillary dissection in elderly women with early" exact="breast cancer" post="World J Surg 2002 26 1239 1242 12209229 42"/>
   <result pre="Necessity of axillary dissection in elderly women with early breast" exact="cancer" post="World J Surg 2002 26 1239 1242 12209229 42"/>
   <result pre="Axillary dissection vs no axillary dissection in women with invasive" exact="breast cancer" post="and sentinel node metastasis: a randomized clinical trial JAMA"/>
   <result pre="dissection vs no axillary dissection in women with invasive breast" exact="cancer" post="and sentinel node metastasis: a randomized clinical trial JAMA"/>
   <result pre="versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly" exact="breast cancer" post="patients: 6-year follow-up results of the French Adjuvant Study"/>
   <result pre="tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast" exact="cancer" post="patients: 6-year follow-up results of the French Adjuvant Study"/>
   <result pre="sentinel node in the administration of adjuvant therapy in early" exact="breast cancer" post="J Clin Oncol 2010 28 731 737 20038733 49"/>
   <result pre="node in the administration of adjuvant therapy in early breast" exact="cancer" post="J Clin Oncol 2010 28 731 737 20038733 49"/>
   <result pre="surgery of the axilla after a positive sentinel node in" exact="breast cancer" post="(EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3"/>
   <result pre="of the axilla after a positive sentinel node in breast" exact="cancer" post="(EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3"/>
   <result pre="lumpectomy, and lumpectomy plus irradiation for the treatment of invasive" exact="breast cancer" post="N Engl J Med 2002 347 1233 1241 12393820"/>
   <result pre="and lumpectomy plus irradiation for the treatment of invasive breast" exact="cancer" post="N Engl J Med 2002 347 1233 1241 12393820"/>
   <result pre="BG Effectiveness of radiation therapy for older women with early" exact="breast cancer" post="J Natl Cancer Inst 2006 98 681 690 16705122"/>
   <result pre="Effectiveness of radiation therapy for older women with early breast" exact="cancer" post="J Natl Cancer Inst 2006 98 681 690 16705122"/>
   <result pre="of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year" exact="breast cancer" post="death: meta-analysis of individual patient data for 10,801 women"/>
   <result pre="radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast" exact="cancer" post="death: meta-analysis of individual patient data for 10,801 women"/>
   <result pre="Gross CP Postmastectomy radiation and survival in older women with" exact="breast cancer" post="J Clin Oncol 2006 24 4901 4907 17050874 54"/>
   <result pre="CP Postmastectomy radiation and survival in older women with breast" exact="cancer" post="J Clin Oncol 2006 24 4901 4907 17050874 54"/>
   <result pre="in women 70 years of age or older with early" exact="breast cancer" post="N Engl J Med 2004 351 971 977 15342805"/>
   <result pre="women 70 years of age or older with early breast" exact="cancer" post="N Engl J Med 2004 351 971 977 15342805"/>
   <result pre="in women 50 years of age or older with early" exact="breast cancer" post="N Engl J Med 2004 351 963 970 15342804"/>
   <result pre="women 50 years of age or older with early breast" exact="cancer" post="N Engl J Med 2004 351 963 970 15342804"/>
   <result pre="ER Li D Silliman RA Ngo L McCarthy EP Breast" exact="cancer" post="among the oldest old: tumor characteristics, treatment choices, and"/>
   <result pre="Khan AJ Haffty BG Issues in the curative therapy of" exact="breast cancer" post="in elderly women Semin Radiat Oncol 2012 22 295"/>
   <result pre="AJ Haffty BG Issues in the curative therapy of breast" exact="cancer" post="in elderly women Semin Radiat Oncol 2012 22 295"/>
   <result pre="whole breast irradiation in women ≥ 65 years with early" exact="breast cancer" post="managed by breast conservation Cancer Res 2013 73 24"/>
   <result pre="breast irradiation in women ≥ 65 years with early breast" exact="cancer" post="managed by breast conservation Cancer Res 2013 73 24"/>
   <result pre="radiotherapy fraction size on tumour control in patients with early-stage" exact="breast cancer" post="after local tumour excision: long-term results of a randomised"/>
   <result pre="fraction size on tumour control in patients with early-stage breast" exact="cancer" post="after local tumour excision: long-term results of a randomised"/>
   <result pre="breast irradiation schedules after lumpectomy for women with lymph node-negative" exact="breast cancer" post="J Natl Cancer Inst 2002 94 1143 1150 12165639"/>
   <result pre="irradiation schedules after lumpectomy for women with lymph node-negative breast" exact="cancer" post="J Natl Cancer Inst 2002 94 1143 1150 12165639"/>
   <result pre="R Courdi A Long-term results of adjuvant hypofractionated radiotherapy for" exact="breast cancer" post="in elderly patients Int J Radiat Oncol Biol Phys"/>
   <result pre="Courdi A Long-term results of adjuvant hypofractionated radiotherapy for breast" exact="cancer" post="in elderly patients Int J Radiat Oncol Biol Phys"/>
   <result pre="Radiotherapy as sole adjuvant treatment for older patients with low-risk" exact="breast cancer" post="Breast 2012 21 629 634 22763240 69 Sautter-Bihl ML"/>
   <result pre="as sole adjuvant treatment for older patients with low-risk breast" exact="cancer" post="Breast 2012 21 629 634 22763240 69 Sautter-Bihl ML"/>
   <result pre="Gerber B Adjuvant therapy for women over age 65 with" exact="breast cancer" post="Dtsch Arztebl Int 2011 108 365 371 21691560 70"/>
   <result pre="B Adjuvant therapy for women over age 65 with breast" exact="cancer" post="Dtsch Arztebl Int 2011 108 365 371 21691560 70"/>
   <result pre="et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for" exact="breast cancer" post="(TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3"/>
   <result pre="al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast" exact="cancer" post="(TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3"/>
   <result pre="prediction refinement to personalize the treatment of patients with early" exact="breast cancer" post="Ecancermedicalscience 2015 9 518 25932042 76 Fentiman IS Christiaens"/>
   <result pre="refinement to personalize the treatment of patients with early breast" exact="cancer" post="Ecancermedicalscience 2015 9 518 25932042 76 Fentiman IS Christiaens"/>
   <result pre="A Rutgers E Berner J et al. Treatment of operable" exact="breast cancer" post="in the elderly: a randomised clinical trial EORTC 10851"/>
   <result pre="Rutgers E Berner J et al. Treatment of operable breast" exact="cancer" post="in the elderly: a randomised clinical trial EORTC 10851"/>
   <result pre="Reed MW Surgery versus primary endocrine therapy for operable primary" exact="breast cancer" post="in elderly women (70 years plus) Cochrane Database Syst"/>
   <result pre="MW Surgery versus primary endocrine therapy for operable primary breast" exact="cancer" post="in elderly women (70 years plus) Cochrane Database Syst"/>
   <result pre="M Winer EP Harris JR Local therapy and survival in" exact="breast cancer" post="N Engl J Med 2007 356 2399 2405 17554121"/>
   <result pre="Winer EP Harris JR Local therapy and survival in breast" exact="cancer" post="N Engl J Med 2007 356 2399 2405 17554121"/>
   <result pre="Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early" exact="breast cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="(EBCTCG) Effects of chemotherapy and hormonal therapy for early breast" exact="cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="Lænkholm AV et al. Mortality rates among early-stage hormone receptor-positive" exact="breast cancer" post="patients: a population-based cohort study in Denmark J Natl"/>
   <result pre="AV et al. Mortality rates among early-stage hormone receptor-positive breast" exact="cancer" post="patients: a population-based cohort study in Denmark J Natl"/>
   <result pre="postmenopausal women after five years of tamoxifen therapy for early-stage" exact="breast cancer" post="N Engl J Med 2003 349 1793 1802 14551341"/>
   <result pre="women after five years of tamoxifen therapy for early-stage breast" exact="cancer" post="N Engl J Med 2003 349 1793 1802 14551341"/>
   <result pre="three years of tamoxifen therapy in postmenopausal women with primary" exact="breast cancer" post="N Engl J Med 2004 350 1081 1092 15014181"/>
   <result pre="years of tamoxifen therapy in postmenopausal women with primary breast" exact="cancer" post="N Engl J Med 2004 350 1081 1092 15014181"/>
   <result pre="comparison of letrozole and tamoxifen in postmenopausal women with early" exact="breast cancer" post="N Engl J Med 2005 353 2747 2757 16382061"/>
   <result pre="of letrozole and tamoxifen in postmenopausal women with early breast" exact="cancer" post="N Engl J Med 2005 353 2747 2757 16382061"/>
   <result pre="Fratino L Scalone S Veronesi A Hormone therapy in elderly" exact="breast cancer" post="patients with comorbidities Crit Rev Oncol Hematol 2010 73"/>
   <result pre="L Scalone S Veronesi A Hormone therapy in elderly breast" exact="cancer" post="patients with comorbidities Crit Rev Oncol Hematol 2010 73"/>
   <result pre="Coates A Forbes J Bliss J et al. Meta-analysis of" exact="breast cancer" post="outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen"/>
   <result pre="A Forbes J Bliss J et al. Meta-analysis of breast" exact="cancer" post="outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen"/>
   <result pre="RJ Clinical review: effect of endocrine therapies on bone in" exact="breast cancer" post="patients J Clin Endocrinol Metab 2011 96 308 319"/>
   <result pre="Clinical review: effect of endocrine therapies on bone in breast" exact="cancer" post="patients J Clin Endocrinol Metab 2011 96 308 319"/>
   <result pre="adjuvant hormonal therapy among a population-based cohort of older female" exact="breast cancer" post="patients Osteoporos Int 2011 22 2847 2855 21170643 100"/>
   <result pre="hormonal therapy among a population-based cohort of older female breast" exact="cancer" post="patients Osteoporos Int 2011 22 2847 2855 21170643 100"/>
   <result pre="al. Efficacy of zoledronic acid in postmenopausal women with early" exact="breast cancer" post="receiving adjuvant letrozole: 36-month results of the ZO-FAST Study"/>
   <result pre="Efficacy of zoledronic acid in postmenopausal women with early breast" exact="cancer" post="receiving adjuvant letrozole: 36-month results of the ZO-FAST Study"/>
   <result pre="Combination) trial after completion of 5 years' adjuvant treatment for" exact="breast cancer" post="Lancet 2005 365 60 62 15639680 103 Baum M"/>
   <result pre="trial after completion of 5 years' adjuvant treatment for breast" exact="cancer" post="Lancet 2005 365 60 62 15639680 103 Baum M"/>
   <result pre="update on adjuvant endocrine therapy for women with hormone receptor-positive" exact="breast cancer" post="J Clin Oncol 2010 28 3784 3796 20625130 106"/>
   <result pre="on adjuvant endocrine therapy for women with hormone receptor-positive breast" exact="cancer" post="J Clin Oncol 2010 28 3784 3796 20625130 106"/>
   <result pre="Winterbottom L Morgan DA et al. Pathological features of primary" exact="breast cancer" post="in the elderly based on needle core biopsies: a"/>
   <result pre="L Morgan DA et al. Pathological features of primary breast" exact="cancer" post="in the elderly based on needle core biopsies: a"/>
   <result pre="Use and outcomes of adjuvant chemotherapy in older women with" exact="breast cancer" post="J Clin Oncol 2006 24 2750 2756 16782915 109"/>
   <result pre="and outcomes of adjuvant chemotherapy in older women with breast" exact="cancer" post="J Clin Oncol 2006 24 2750 2756 16782915 109"/>
   <result pre="AB et al. Adjuvant chemotherapy in older women with early-stage" exact="breast cancer" post="N Engl J Med 2009 360 2055 2065 19439741"/>
   <result pre="et al. Adjuvant chemotherapy in older women with early-stage breast" exact="cancer" post="N Engl J Med 2009 360 2055 2065 19439741"/>
   <result pre="status and outcomes of modern chemotherapy for patients with node-positive" exact="breast cancer" post="JAMA 2006 295 1658 1667 16609087 112 Albain KS"/>
   <result pre="and outcomes of modern chemotherapy for patients with node-positive breast" exact="cancer" post="JAMA 2006 295 1658 1667 16609087 112 Albain KS"/>
   <result pre="21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive" exact="breast cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast" exact="cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="113 Jones EL Leak A Muss HB Adjuvant therapy of" exact="breast cancer" post="in women 70 years of age and older: tough"/>
   <result pre="Jones EL Leak A Muss HB Adjuvant therapy of breast" exact="cancer" post="in women 70 years of age and older: tough"/>
   <result pre="Lichtman SM Skirvin JA Pharmacology of antineoplastic agents in older" exact="cancer" post="patients Oncology (Williston Park) 2000 14 1743 1755 11204376"/>
   <result pre="14 1743 1755 11204376 117 Kimmick G Adjuvant chemotherapy for" exact="breast cancer" post="in older women: emerging evidence to aid in decision"/>
   <result pre="1743 1755 11204376 117 Kimmick G Adjuvant chemotherapy for breast" exact="cancer" post="in older women: emerging evidence to aid in decision"/>
   <result pre="Matteis A Di Costanzo F Floriani I et al. Breast" exact="cancer" post="in elderly women: a different reality? Results from the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4602505/results/search/disease/results.xml">
   <result pre="Abstract Abstract Misdiagnosis in the evaluation of HER2 status in" exact="breast cancer" post="may have consequent negative impact on clinical decision-making. Therefore,"/>
   <result pre="Abstract Misdiagnosis in the evaluation of HER2 status in breast" exact="cancer" post="may have consequent negative impact on clinical decision-making. Therefore,"/>
   <result pre="of HER2 status. INTRODUCTION It is widely known that HER2-positive" exact="breast cancer" post="(BC) significantly differs from HER2-negative tumor both in terms"/>
   <result pre="HER2 status. INTRODUCTION It is widely known that HER2-positive breast" exact="cancer" post="(BC) significantly differs from HER2-negative tumor both in terms"/>
   <result pre="allows to properly plan the treatment of patients affected by" exact="breast cancer?" post="In fact, concordance analyses performed between results sent by"/>
   <result pre="American Society of Clinical Oncology/College of American Pathologists, BC =" exact="breast cancer," post="CI = confidence interval, DAB = diaminobenzidine, DDISH ="/>
   <result pre="Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med 2006; 355: 2733– 2743. 17192538"/>
   <result pre="CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post=". N Engl J Med 2012; 366: 109– 119."/>
   <result pre="Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post=". N Engl J Med 2012; 366: 109– 119."/>
   <result pre="al. collab: EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med 2012; 367: 1783– 1791. 23020162"/>
   <result pre="Iorfida M Dellapasqua S Bagnardi V et al. HER2-negative (1+)" exact="breast cancer" post="with unfavorable prognostic features: to FISH or not to"/>
   <result pre="M Dellapasqua S Bagnardi V et al. HER2-negative (1+) breast" exact="cancer" post="with unfavorable prognostic features: to FISH or not to"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post=". J Clin Oncol 2007; 25: 118– 145. 17159189"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post=". J Clin Oncol 2007; 25: 118– 145. 17159189"/>
   <result pre="situ hybridization (BDISH) for frontline assessment of HER2 status in" exact="breast cancer" post="samples in a community setting: influence of poor tissue"/>
   <result pre="hybridization (BDISH) for frontline assessment of HER2 status in breast" exact="cancer" post="samples in a community setting: influence of poor tissue"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4609140/results/search/disease/results.xml">
   <result pre="(ADCC) [ 6]. The treatment of HER2-overexpressing breast or gastric" exact="cancer" post="patients with trastuzumab in combination with chemotherapeutic agents is"/>
   <result pre="amplification of HER2 in PDAs were generally lower than in" exact="breast cancer" post="[ 14, 15]. Trastuzumab emtansine (T-DM1) is a recently"/>
   <result pre="of HER2 in PDAs were generally lower than in breast" exact="cancer" post="[ 14, 15]. Trastuzumab emtansine (T-DM1) is a recently"/>
   <result pre="studies, the cytotoxic activity of T-DM1 in breast and gastric" exact="cancer" post="cells was stronger than that of trastuzumab, even if"/>
   <result pre="those of lapatinib and docetaxel in patients with HER2-positive advanced" exact="breast cancer" post="that was resistant to trastuzumab and taxanes [ 20]."/>
   <result pre="of lapatinib and docetaxel in patients with HER2-positive advanced breast" exact="cancer" post="that was resistant to trastuzumab and taxanes [ 20]."/>
   <result pre="it took to disappear from the blood when used in" exact="cancer" post="chemotherapy. Treatment with 40 μg/ml of five-fluorouracil (5-FU) enhanced"/>
   <result pre="a micro RNA regulates HER2 expression [ 26, 27]. In" exact="breast cancer," post="miR-205 down regulates HER2 [ 27]. If GEM suppresses"/>
   <result pre="conjugate of trastuzumab and emtansine, has shown promising results in" exact="breast cancer" post="therapy [ 20]. It has been reported that the"/>
   <result pre="of trastuzumab and emtansine, has shown promising results in breast" exact="cancer" post="therapy [ 20]. It has been reported that the"/>
   <result pre="resulting binding of T-DM1 to HER2 in breast and gastric" exact="cancer" post="cells [ 18, 19]. Induction of HER2 up-regulation in"/>
   <result pre="treatment might be a promising modality for patients with cancerous" exact="peritonitis" post="caused by advanced PDA. The prognosis of PDA patients"/>
   <result pre="by advanced PDA. The prognosis of PDA patients with cancerous" exact="peritonitis" post="is extremely poor, and no effective treatment is currently"/>
   <result pre="GEM [ 30– 32]. The procedure for treatment against cancerous" exact="peritonitis" post="might be as follows. First, HER2 expression in PDA"/>
   <result pre="and T-DM1 treatment might help improve the prognosis of cancerous" exact="peritonitis" post="caused by advanced PDA. Conclusions In this study, we"/>
   <result pre="H Okusaka T Nakao A Hatori T et al. Japan" exact="pancreatic cancer" post="registry; 30th year anniversary: Japan pancreas society Pancreas 2012"/>
   <result pre="Okusaka T Nakao A Hatori T et al. Japan pancreatic" exact="cancer" post="registry; 30th year anniversary: Japan pancreas society Pancreas 2012"/>
   <result pre="its signaling and transforming functions and its role in human" exact="cancer" post="pathogenesis Oncogene 2007 26 6469 87 10.1038/sj.onc.1210477 17471238 6."/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="W Vaitkevicius VK Crissman JD et al. Relationship of family" exact="cancer" post="history to the expression of p53, p21WAF-1, HER-2/neu, and"/>
   <result pre="B Juda L Prognostic significance of c-erbB-2 gene expression in" exact="pancreatic cancer" post="patients Neoplasma 2001 48 188 91 11583287 14. Safran"/>
   <result pre="Juda L Prognostic significance of c-erbB-2 gene expression in pancreatic" exact="cancer" post="patients Neoplasma 2001 48 188 91 11583287 14. Safran"/>
   <result pre="of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic" exact="pancreatic cancer" post="Br J Cancer 2012 106 1033 8 10.1038/bjc.2012.18 22374460"/>
   <result pre="trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic" exact="cancer" post="Br J Cancer 2012 106 1033 8 10.1038/bjc.2012.18 22374460"/>
   <result pre="GD Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+" exact="breast cancer" post="Clin Breast Cancer 2011 11 275 82 10.1016/j.clbc.2011.03.018 21729661"/>
   <result pre="Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast" exact="cancer" post="Clin Breast Cancer 2011 11 275 82 10.1016/j.clbc.2011.03.018 21729661"/>
   <result pre="conjugate in development for human epidermal growth factor receptor 2-positive" exact="cancer" post="Clin Cancer Res 2011 17 6437 47 10.1158/1078-0432.CCR-11-0762 22003071"/>
   <result pre="Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant" exact="breast cancer" post="cells in vivo Breast Cancer Res 2011 13 R46"/>
   <result pre="causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast" exact="cancer" post="cells in vivo Breast Cancer Res 2011 13 R46"/>
   <result pre="Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric" exact="cancer" post="Cancer Lett 2011 306 171 9 10.1016/j.canlet.2011.03.002 21458915 20."/>
   <result pre="IE Welslau M Baselga J Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 1783 91 10.1056/NEJMoa1209124"/>
   <result pre="Welslau M Baselga J Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 1783 91 10.1056/NEJMoa1209124"/>
   <result pre="Török V Löhr M Klöppel G A comprehensive characterization of" exact="pancreatic ductal carcinoma" post="cell lines: towards the establishment of an in vitro"/>
   <result pre="Kitano S Kobayashi M Immunohistochemical study of c-erbB-2 protein in" exact="colorectal cancer" post="and the correlation with patient survival Oncology 1998 55"/>
   <result pre="S Kobayashi M Immunohistochemical study of c-erbB-2 protein in colorectal" exact="cancer" post="and the correlation with patient survival Oncology 1998 55"/>
   <result pre="13 9196156 26. Wang SE Lin RJ MicroRNA and HER2-overexpressing" exact="cancer" post="Microrna 2013 2 137 47 10.2174/22115366113029990011 25070783 27. Scott"/>
   <result pre="A Bhaumik D Berger CE Sullivan CS Benz CC Coordinate" exact="suppression" post="of ERBB2 and ERBB3 by enforced expression of micro-RNA"/>
   <result pre="B et al. Proteasome-regulated ERBB2 and estrogen receptor pathways in" exact="breast cancer" post="Mol Pharmacol 2007 71 1525 34 10.1124/mol.107.034090 17392524 29."/>
   <result pre="et al. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast" exact="cancer" post="Mol Pharmacol 2007 71 1525 34 10.1124/mol.107.034090 17392524 29."/>
   <result pre="Suzuki E Yoshino M Prognostic factors in patients with gemcitabine-refractory" exact="pancreatic cancer" post="Jpn J Clin Oncol 2007 37 114 20 10.1093/jjco/hyl144"/>
   <result pre="E Yoshino M Prognostic factors in patients with gemcitabine-refractory pancreatic" exact="cancer" post="Jpn J Clin Oncol 2007 37 114 20 10.1093/jjco/hyl144"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4612451/results/search/disease/results.xml">
   <result pre="Centre hospitalier de l’Université de Montréal (CRCHUM) and Institut du" exact="cancer" post="de Montréal Canada [3], Division de gynéco-oncologie; Université de"/>
   <result pre="combination with anthracyclines or platinum drugs to treat breast and" exact="ovarian cancer," post="respectively. Taxanes target microtubules in cancer cells and modifiers"/>
   <result pre="treat breast and ovarian cancer, respectively. Taxanes target microtubules in" exact="cancer" post="cells and modifiers of taxane sensitivity have been identified"/>
   <result pre="gene amplification is associated with benefit from taxane therapy in" exact="breast cancer" post="yet high HER2 expression also correlates with poor survival"/>
   <result pre="amplification is associated with benefit from taxane therapy in breast" exact="cancer" post="yet high HER2 expression also correlates with poor survival"/>
   <result pre="expression also correlates with poor survival in both breast and" exact="ovarian cancer." post="The pre-mRNA splicing factor 4 kinase PRP4K (PRPF4B), which"/>
   <result pre="correlation between PRP4K expression and HER2 status in breast and" exact="ovarian cancer" post="patient tumors, which we determined was a direct result"/>
   <result pre="between PRP4K expression and HER2 status in breast and ovarian" exact="cancer" post="patient tumors, which we determined was a direct result"/>
   <result pre="Knock-down of PRP4K expression reduced the sensitivity of breast and" exact="ovarian cancer" post="cell lines to taxanes, and low PRP4K levels correlated"/>
   <result pre="of PRP4K expression reduced the sensitivity of breast and ovarian" exact="cancer" post="cell lines to taxanes, and low PRP4K levels correlated"/>
   <result pre="in vitro-derived and patient acquired taxane resistance in breast and" exact="ovarian cancer." post="Patients with high-grade serous ovarian cancer and high HER2"/>
   <result pre="resistance in breast and ovarian cancer. Patients with high-grade serous" exact="ovarian cancer" post="and high HER2 levels had poor overall survival; however,"/>
   <result pre="in breast and ovarian cancer. Patients with high-grade serous ovarian" exact="cancer" post="and high HER2 levels had poor overall survival; however,"/>
   <result pre="value as a marker of better overall survival in taxane-treated" exact="ovarian cancer" post="patients. Keywords breast cancer HER2 ovarian cancer PRP4K taxane"/>
   <result pre="as a marker of better overall survival in taxane-treated ovarian" exact="cancer" post="patients. Keywords breast cancer HER2 ovarian cancer PRP4K taxane"/>
   <result pre="of better overall survival in taxane-treated ovarian cancer patients. Keywords" exact="breast cancer" post="HER2 ovarian cancer PRP4K taxane sensitivity fig-count: table-count: ref-count:"/>
   <result pre="better overall survival in taxane-treated ovarian cancer patients. Keywords breast" exact="cancer" post="HER2 ovarian cancer PRP4K taxane sensitivity fig-count: table-count: ref-count:"/>
   <result pre="survival in taxane-treated ovarian cancer patients. Keywords breast cancer HER2" exact="ovarian cancer" post="PRP4K taxane sensitivity fig-count: table-count: ref-count: page-count: Abbreviations HER2"/>
   <result pre="in taxane-treated ovarian cancer patients. Keywords breast cancer HER2 ovarian" exact="cancer" post="PRP4K taxane sensitivity fig-count: table-count: ref-count: page-count: Abbreviations HER2"/>
   <result pre="used as first-line therapies for many malignancies, including breast and" exact="ovarian cancer," post="2,3 the emergence of clinical drug resistance remains the"/>
   <result pre="had limited success clinically as markers of taxane response. In" exact="breast cancer," post="the amplification/overexpression of the HER2/ERBB2 gene has been widely"/>
   <result pre="has been shown to increase cellular resistance to taxanes in" exact="breast cancer" post="cells, 16 while a number of clinical studies have"/>
   <result pre="been shown to increase cellular resistance to taxanes in breast" exact="cancer" post="cells, 16 while a number of clinical studies have"/>
   <result pre="kinase (PRP4K) as a novel HER2-regulated gene in breast and" exact="ovarian cancer." post="In interphase cells, we previously identified PRP4K, also known"/>
   <result pre="resistance in a large scale RNAi screen conducted in HCT-116" exact="colon cancer" post="cells. 26 In this study we demonstrate that decreased"/>
   <result pre="in a large scale RNAi screen conducted in HCT-116 colon" exact="cancer" post="cells. 26 In this study we demonstrate that decreased"/>
   <result pre="results in reduced sensitivity to paclitaxel in both breast and" exact="ovarian cancer" post="cell lines, and that in vitro-derived and patient acquired"/>
   <result pre="in reduced sensitivity to paclitaxel in both breast and ovarian" exact="cancer" post="cell lines, and that in vitro-derived and patient acquired"/>
   <result pre="expression. In addition, PRP4K protein expression in the biopsies of" exact="ovarian cancer" post="patients with low HER2-expressing tumors correlates with better overall"/>
   <result pre="In addition, PRP4K protein expression in the biopsies of ovarian" exact="cancer" post="patients with low HER2-expressing tumors correlates with better overall"/>
   <result pre="PRP4K may be oncogenic and a possible molecular target in" exact="cancer" post="27,28 or may be a predictive biomarker of treatment"/>
   <result pre="controversial. To better evaluate the possible role of PRP4K in" exact="cancer" post="we performed immunohistochemistry analysis of PRP4K expression in breast"/>
   <result pre="of commonly used prognostic and therapeutic markers of breast and" exact="ovarian cancer" post="( Fig. 1A ). A positive correlation was observed"/>
   <result pre="commonly used prognostic and therapeutic markers of breast and ovarian" exact="cancer" post="( Fig. 1A ). A positive correlation was observed"/>
   <result pre="expression in breast and ovarian tumors. ( A) Breast and" exact="ovarian cancer" post="tissue microarrays were used to correlate PRP4K protein levels"/>
   <result pre="in breast and ovarian tumors. ( A) Breast and ovarian" exact="cancer" post="tissue microarrays were used to correlate PRP4K protein levels"/>
   <result pre="HER2 expression was knocked down in 2 respective ovarian and" exact="breast cancer" post="cell lines, IGROV-1 and SK-BR-3. As shown in Figure"/>
   <result pre="expression was knocked down in 2 respective ovarian and breast" exact="cancer" post="cell lines, IGROV-1 and SK-BR-3. As shown in Figure"/>
   <result pre="level ( Fig. 2B ). Conversely, when the HER2 negative" exact="breast cancer" post="cell line MCF-7 was transfected with constitutively active HER2,"/>
   <result pre="( Fig. 2B ). Conversely, when the HER2 negative breast" exact="cancer" post="cell line MCF-7 was transfected with constitutively active HER2,"/>
   <result pre="= 10 microns. Knockdown of PRP4K decreases the sensitivity of" exact="cancer" post="cells to paclitaxel HER2 amplification has received a lot"/>
   <result pre="cell lines isolated from a patient diagnosed with high-grade serous" exact="ovarian cancer" post="that had received paclitaxel as part of their treatment"/>
   <result pre="lines isolated from a patient diagnosed with high-grade serous ovarian" exact="cancer" post="that had received paclitaxel as part of their treatment"/>
   <result pre="have an acquired resistance to taxanes. ( A) MCF-7 human" exact="breast cancer" post="cells were exposed to a sub-lethal concentration of paclitaxel"/>
   <result pre="an acquired resistance to taxanes. ( A) MCF-7 human breast" exact="cancer" post="cells were exposed to a sub-lethal concentration of paclitaxel"/>
   <result pre="B) TOV1369 and OV1369(R2) cell lines were isolated from an" exact="ovarian cancer" post="patient pre-taxane treatment, and post-relapse, respectively. Whole cell lysates"/>
   <result pre="TOV1369 and OV1369(R2) cell lines were isolated from an ovarian" exact="cancer" post="patient pre-taxane treatment, and post-relapse, respectively. Whole cell lysates"/>
   <result pre="as ratios. PRP4K expression correlates with better overall survival in" exact="ovarian cancer" post="patients treated with taxanes with low HER2-expressing tumors Given"/>
   <result pre="ratios. PRP4K expression correlates with better overall survival in ovarian" exact="cancer" post="patients treated with taxanes with low HER2-expressing tumors Given"/>
   <result pre="more direct biomarker for taxane response among high-grade serous epithelial" exact="ovarian cancer" post="patients receiving taxanes as first-line therapy. The taxane treated"/>
   <result pre="direct biomarker for taxane response among high-grade serous epithelial ovarian" exact="cancer" post="patients receiving taxanes as first-line therapy. The taxane treated"/>
   <result pre="), although this was not statistically significant. In breast and" exact="ovarian cancer," post="HER2/ ERBB2 gene amplification is generally associated with poor"/>
   <result pre="low (0-1) patients within our cohort of high-grade serous epithelial" exact="ovarian cancer" post="patients, the HER2 high patients display a significantly worse"/>
   <result pre="(0-1) patients within our cohort of high-grade serous epithelial ovarian" exact="cancer" post="patients, the HER2 high patients display a significantly worse"/>
   <result pre="expression, PRP4K is a positive prognostic biomarker for high-grade serous" exact="ovarian cancer" post="patients treated with platinum/taxane-based therapies. The same analysis could"/>
   <result pre="PRP4K is a positive prognostic biomarker for high-grade serous ovarian" exact="cancer" post="patients treated with platinum/taxane-based therapies. The same analysis could"/>
   <result pre="therapies. The same analysis could not be done for the" exact="breast cancer" post="TMA as those patients did not receive taxanes as"/>
   <result pre="The same analysis could not be done for the breast" exact="cancer" post="TMA as those patients did not receive taxanes as"/>
   <result pre="PRP4K as a biomarker of platinum/taxane response in high-grade serous" exact="ovarian cancer." post="( A) Kaplan Meier curves of overall disease free"/>
   <result pre="(left) and overall survival (right) in a cohort of 130" exact="ovarian cancer" post="patients treated with platinum/taxane chemotherapy. ( B) Kaplan Meier"/>
   <result pre="and overall survival (right) in a cohort of 130 ovarian" exact="cancer" post="patients treated with platinum/taxane chemotherapy. ( B) Kaplan Meier"/>
   <result pre="survival (left) and overall survival (right) in 103 platinum/taxane treated" exact="ovarian cancer" post="patients with either low (0–1), or high (2-3), expression"/>
   <result pre="(left) and overall survival (right) in 103 platinum/taxane treated ovarian" exact="cancer" post="patients with either low (0–1), or high (2-3), expression"/>
   <result pre="for a range of human malignancies, including breast, lung and" exact="ovarian cancer." post="Biomarkers which can accurately predict taxane response are needed"/>
   <result pre="response to taxanes. Immunostaining for PRP4K in human breast and" exact="ovarian cancer" post="TMAs revealed a significant correlation between PRP4K and HER2"/>
   <result pre="to taxanes. Immunostaining for PRP4K in human breast and ovarian" exact="cancer" post="TMAs revealed a significant correlation between PRP4K and HER2"/>
   <result pre="link between HER2 expression and positive response to taxanes in" exact="breast cancer." post="17-22 However, due to the discrepancies between in vitro"/>
   <result pre="the observed HER2 mediated taxane sensitivity, we generated breast and" exact="ovarian cancer" post="cell lines stably expressing a doxycycline inducible hairpin targeting"/>
   <result pre="observed HER2 mediated taxane sensitivity, we generated breast and ovarian" exact="cancer" post="cell lines stably expressing a doxycycline inducible hairpin targeting"/>
   <result pre="taxane response in part by modulating PRP4K gene expression. In" exact="breast cancer," post="HER2-based therapies target this receptor tyrosine kinase either by"/>
   <result pre="evaluated PRP4K as a potential prognostic biomarker for outcome in" exact="ovarian cancer" post="patients treated with taxane-containing therapies. Although we had PRP4K"/>
   <result pre="PRP4K as a potential prognostic biomarker for outcome in ovarian" exact="cancer" post="patients treated with taxane-containing therapies. Although we had PRP4K"/>
   <result pre="5A ). In interpreting these results, we noted that although" exact="breast cancer" post="patients with tumors harboring a HER2 amplification have better"/>
   <result pre="). In interpreting these results, we noted that although breast" exact="cancer" post="patients with tumors harboring a HER2 amplification have better"/>
   <result pre="amplification is associated with poor prognosis in breast 15 and" exact="ovarian cancer." post="35,42 Given the strong correlation between HER2 expression and"/>
   <result pre="and as a potential prognostic marker for better survival in" exact="ovarian cancer" post="patients treated with taxanes that harbour low HER2 expressing"/>
   <result pre="as a potential prognostic marker for better survival in ovarian" exact="cancer" post="patients treated with taxanes that harbour low HER2 expressing"/>
   <result pre="addition to being a positive prognostic marker for survival in" exact="ovarian cancer" post="patients with low or HER2-negative tumors at diagnosis, PRP4K"/>
   <result pre="to being a positive prognostic marker for survival in ovarian" exact="cancer" post="patients with low or HER2-negative tumors at diagnosis, PRP4K"/>
   <result pre="was defined as the time from surgery to death from" exact="ovarian cancer." post="Patients known to be alive at the time of"/>
   <result pre="the study were as follows: no pre-operative chemotherapeutic treatment for" exact="ovarian cancer;" post="platinum-based post-operative chemotherapy treatment, high grade tumors, serous histopathology"/>
   <result pre="(Pathology Devices Inc.). The tissue array contained samples from 260" exact="ovarian cancer" post="patients, and each patient is represented by 2 cores."/>
   <result pre="Devices Inc.). The tissue array contained samples from 260 ovarian" exact="cancer" post="patients, and each patient is represented by 2 cores."/>
   <result pre="observers. Correlation was &amp;gt;80%. The average of all cores with" exact="cancer" post="from the same patient was used for the final"/>
   <result pre="et de données of the Réseau de recherche sur le" exact="cancer" post="of the Fonds de la recherche en santé du"/>
   <result pre="Carney DN , McCann A . Taxanes, microtubules and chemoresistant" exact="breast cancer." post="Biochim Biophys Acta 2008; 1785: 96- 132; PMID:18068131 18068131"/>
   <result pre="al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in" exact="breast cancer." post="Proc Natl Acad Sci U S A 2005; 102:"/>
   <result pre="and new understanding of traditional markers in personalized therapy for" exact="breast cancer" post=". Clin Cancer Res 2008; 14: 8019- 26; PMID:19088018;"/>
   <result pre="new understanding of traditional markers in personalized therapy for breast" exact="cancer" post=". Clin Cancer Res 2008; 14: 8019- 26; PMID:19088018;"/>
   <result pre="Wang SS , Hung MC . Overexpression of c-erbB-2/neu in" exact="breast cancer" post="cells confers increased resistance to Taxol via mdr-1-independent mechanisms"/>
   <result pre="SS , Hung MC . Overexpression of c-erbB-2/neu in breast" exact="cancer" post="cells confers increased resistance to Taxol via mdr-1-independent mechanisms"/>
   <result pre="HER-2/neu as a predictive marker in a population of advanced" exact="breast cancer" post="patients randomly treated either with single-agent doxorubicin or single-agent"/>
   <result pre="as a predictive marker in a population of advanced breast" exact="cancer" post="patients randomly treated either with single-agent doxorubicin or single-agent"/>
   <result pre="gene amplification and response to paclitaxel in patients with metastatic" exact="breast cancer" post=". J Natl Cancer Inst 2004; 96: 1141- 51;"/>
   <result pre="amplification and response to paclitaxel in patients with metastatic breast" exact="cancer" post=". J Natl Cancer Inst 2004; 96: 1141- 51;"/>
   <result pre=", Juhos E , et al. Adjuvant docetaxel for node-positive" exact="breast cancer." post="N Engl J Med 2005; 352: 2302- 13; PMID:15930421;"/>
   <result pre=", et al. HER2 and response to paclitaxel in node-positive" exact="breast cancer." post="N Engl J Med 2007; 357: 1496- 506; PMID:17928597;"/>
   <result pre="expression in predicting response to docetaxel-based first-line chemotherapy in advanced" exact="breast cancer" post=". J Exp Clin Cancer Res 2011; 30: 38;"/>
   <result pre="in predicting response to docetaxel-based first-line chemotherapy in advanced breast" exact="cancer" post=". J Exp Clin Cancer Res 2011; 30: 38;"/>
   <result pre="identifies PRP-4 as a new regulator of chemoresistance in human" exact="ovarian cancer" post=". Mol Cancer Ther 2008; 7: 2377- 85; PMID:18687998;"/>
   <result pre="PRP-4 as a new regulator of chemoresistance in human ovarian" exact="cancer" post=". Mol Cancer Ther 2008; 7: 2377- 85; PMID:18687998;"/>
   <result pre="Wang A , Wiederschain D , et al. Evaluation of" exact="cancer" post="dependence and druggability of PRP4 kinase using cellular, biochemical,"/>
   <result pre="BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial" exact="ovarian cancer." post="Cancer Epidemiol Biomarkers Prev 2008; 17: 913- 20; PMID:8398031UND;"/>
   <result pre="Schrump DS . Potentiation of paclitaxel cytotoxicity in lung and" exact="esophageal cancer" post="cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase"/>
   <result pre="DS . Potentiation of paclitaxel cytotoxicity in lung and esophageal" exact="cancer" post="cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase"/>
   <result pre="KE , Taylor SS . How do anti-mitotic drugs kill" exact="cancer" post="cells? J Cell Sci 2009; 122: 2579- 85; PMID:19625502;"/>
   <result pre="characterization of matched cell lines from primary and recurrent serous" exact="ovarian cancer" post=". BMC Cancer 2012; 12: 379; PMID:22931248; http://dx.doi.org/ 10.1186/1471-2407-12-379"/>
   <result pre="of matched cell lines from primary and recurrent serous ovarian" exact="cancer" post=". BMC Cancer 2012; 12: 379; PMID:22931248; http://dx.doi.org/ 10.1186/1471-2407-12-379"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 . N Engl J Med 2001;"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 . N Engl J Med 2001;"/>
   <result pre=", et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer." post="N Engl J Med 2005; 353: 1673- 84; PMID:16236738;"/>
   <result pre="of HER-2/neu is associated with poor survival in advanced epithelial" exact="ovarian cancer" post=". Cancer research 1990; 50: 4087- 91; PMID:1972347 1972347"/>
   <result pre="HER-2/neu is associated with poor survival in advanced epithelial ovarian" exact="cancer" post=". Cancer research 1990; 50: 4087- 91; PMID:1972347 1972347"/>
   <result pre=", Provencher DM , et al. BTN3A2 expression in epithelial" exact="ovarian cancer" post="is associated with higher tumor infiltrating T cells and"/>
   <result pre="Provencher DM , et al. BTN3A2 expression in epithelial ovarian" exact="cancer" post="is associated with higher tumor infiltrating T cells and"/>
   <result pre="I and T modification detected in serum from patients with" exact="acute myocardial infarction" post=". Circulation 2000; 102: 1221- 6; PMID:10982534; http://dx.doi.org/ 10.1161/01.CIR.102.11.1221"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4612553/results/search/disease/results.xml">
   <result pre=": Original Paper Risk factors for disease progression in HER2-positive" exact="breast cancer" post="patients based on the location of metastases Huszno Joanna"/>
   <result pre="Original Paper Risk factors for disease progression in HER2-positive breast" exact="cancer" post="patients based on the location of metastases Huszno Joanna"/>
   <result pre="therapy significantly improves progression-free and overall survival in HER2-positive [HER2(+)]" exact="breast cancer" post="(BC) patients. However, in most patients with HER2(+) metastatic"/>
   <result pre="significantly improves progression-free and overall survival in HER2-positive [HER2(+)] breast" exact="cancer" post="(BC) patients. However, in most patients with HER2(+) metastatic"/>
   <result pre="to evaluate the clinicopathological risk factors for progression in HER2-positive" exact="breast cancer" post="patients during trastuzumab therapy. Material and methods The analysis"/>
   <result pre="evaluate the clinicopathological risk factors for progression in HER2-positive breast" exact="cancer" post="patients during trastuzumab therapy. Material and methods The analysis"/>
   <result pre="with lung metastases significantly more often had a history of" exact="cancer" post="in the family than women with other metastasis sites"/>
   <result pre="positive steroid receptor status ( p = 0.019) and second" exact="neoplasm" post="in history ( p = 0.06). Conclusions Risk factors"/>
   <result pre="receptor status (liver, lymph nodes and bone metastases), history of" exact="cancer" post="in the family (lung metastases) and history of cigarette"/>
   <result pre="(lung metastases) and history of cigarette smoking (liver metastases). metastatic" exact="breast cancer" post="HER2 overexpression trastuzumab risk factors metastasis location Introduction The"/>
   <result pre="metastases) and history of cigarette smoking (liver metastases). metastatic breast" exact="cancer" post="HER2 overexpression trastuzumab risk factors metastasis location Introduction The"/>
   <result pre="improves progression-free and overall survival among patients with HER2-positive [HER2(+)]" exact="breast cancer" post="(BC). However, in most patients with HER2(+) metastatic BC,"/>
   <result pre="progression-free and overall survival among patients with HER2-positive [HER2(+)] breast" exact="cancer" post="(BC). However, in most patients with HER2(+) metastatic BC,"/>
   <result pre="BC confirmed with a microscopic examination. The study group comprised" exact="breast cancer" post="patients with HER2 receptor overexpression or HER2 gene amplification."/>
   <result pre="confirmed with a microscopic examination. The study group comprised breast" exact="cancer" post="patients with HER2 receptor overexpression or HER2 gene amplification."/>
   <result pre="medical history without serious comorbid conditions such as unstable ischemic" exact="heart disease," post="valvular heart disease, chronic hypertension with cardiovascular problems or"/>
   <result pre="without serious comorbid conditions such as unstable ischemic heart disease," exact="valvular heart disease," post="chronic hypertension with cardiovascular problems or uncontrolled diabetes (uncontrolled"/>
   <result pre="serious comorbid conditions such as unstable ischemic heart disease, valvular" exact="heart disease," post="chronic hypertension with cardiovascular problems or uncontrolled diabetes (uncontrolled"/>
   <result pre="histology, estrogen and progesterone receptor status, HER2 status and contralateral" exact="breast cancer" post="were gathered from hospital records and pathology reports. Echocardiography"/>
   <result pre="estrogen and progesterone receptor status, HER2 status and contralateral breast" exact="cancer" post="were gathered from hospital records and pathology reports. Echocardiography"/>
   <result pre="the premenopausal status 8/11 (32% vs. 28%, p = 0.784)," exact="obesity" post="(BMI &amp;gt; 25) 15/25 (60% vs. 64%, p ="/>
   <result pre="with lung metastases significantly more often had a history of" exact="cancer" post="in the family than women with other metastasis sites"/>
   <result pre="0/5 (0 vs. 5%), hypertension 1/6 (13% vs. 11%) or" exact="cardiovascular disease" post="0/2 (0% vs. 4%) and CNS metastases. Dissemination to"/>
   <result pre="presence of liver metastases in patients without any history of" exact="breast cancer" post="in the family in comparison with other metastasis location"/>
   <result pre="of liver metastases in patients without any history of breast" exact="cancer" post="in the family in comparison with other metastasis location"/>
   <result pre="Women with liver metastases had also less frequently the second" exact="neoplasm" post="in history 1/17 (13% vs. 33%, p = 0.225)."/>
   <result pre="None of the patients with skin metastases had history of" exact="breast cancer" post="in the family 0/7 (0 vs. 13%). There was"/>
   <result pre="of the patients with skin metastases had history of breast" exact="cancer" post="in the family 0/7 (0 vs. 13%). There was"/>
   <result pre="as the menopausal status, steroid receptor status and history of" exact="cancer" post="in the family may be predictive factors for disease"/>
   <result pre="most papers concern risk factors for brain relapse in metastatic" exact="breast cancer" post="patients. Metastases to CNS occur in 10-16% of patients"/>
   <result pre="papers concern risk factors for brain relapse in metastatic breast" exact="cancer" post="patients. Metastases to CNS occur in 10-16% of patients"/>
   <result pre="patients [ 3, 4]. Although trastuzumab improves survival in metastatic" exact="breast cancer" post="patients with HER2 overexpression, 40% of them develop brain"/>
   <result pre="[ 3, 4]. Although trastuzumab improves survival in metastatic breast" exact="cancer" post="patients with HER2 overexpression, 40% of them develop brain"/>
   <result pre="associated with metastasis to the liver [ 12]. History of" exact="breast cancer" post="in the family, history of cigarette smoking and a"/>
   <result pre="with metastasis to the liver [ 12]. History of breast" exact="cancer" post="in the family, history of cigarette smoking and a"/>
   <result pre="factors were age under 65 years and a history of" exact="cancer" post="in the family. The remaining clinicopathological factors did not"/>
   <result pre="patients with a positive steroid receptor status. However, ER positive" exact="breast cancer" post="may be predictive factor for a higher incidence of"/>
   <result pre="with a positive steroid receptor status. However, ER positive breast" exact="cancer" post="may be predictive factor for a higher incidence of"/>
   <result pre="receptor status (liver, lymph nodes and bone metastases), history of" exact="cancer" post="in the family (lung metastases) and history of cigarette"/>
   <result pre="al. Trastuzmab treatment beyond brain progression in HER2 positive metastatic" exact="breast cancer" post="Ann Oncol 2009 20 56 62 18664558 2 Pestalozzi"/>
   <result pre="Trastuzmab treatment beyond brain progression in HER2 positive metastatic breast" exact="cancer" post="Ann Oncol 2009 20 56 62 18664558 2 Pestalozzi"/>
   <result pre="62 18664558 2 Pestalozzi BC Brain metastases and subtypes of" exact="breast cancer" post="Ann Oncol 2009 20 803 805 19403934 3 Lin"/>
   <result pre="18664558 2 Pestalozzi BC Brain metastases and subtypes of breast" exact="cancer" post="Ann Oncol 2009 20 803 805 19403934 3 Lin"/>
   <result pre="3 Lin NU Bellon JR Winter EP CNS metastases in" exact="breast cancer" post="J Clin Oncol 2004 22 3608 3617 15337811 4"/>
   <result pre="Lin NU Bellon JR Winter EP CNS metastases in breast" exact="cancer" post="J Clin Oncol 2004 22 3608 3617 15337811 4"/>
   <result pre="4 Weil RJ Palmieri DC Bronder JL et al. Breast" exact="cancer" post="metastasis to the central nervous system Am J Pathol"/>
   <result pre="system (CNS) relapse related to adjuvant taxane treatment in node-positive" exact="breast cancer?" post="Results of the CNS substudy in the intergroup phase"/>
   <result pre="6 Pestalozzi BC Zahrieh D Price KN et al. Identifying" exact="breast cancer" post="patients at risk for central nervous system (CNS) metastases"/>
   <result pre="Pestalozzi BC Zahrieh D Price KN et al. Identifying breast" exact="cancer" post="patients at risk for central nervous system (CNS) metastases"/>
   <result pre="7 Tham YL Sexton K Kramer R et al. Primary" exact="breast cancer" post="phenotypes associated with propensity for central nervous system metastases"/>
   <result pre="Tham YL Sexton K Kramer R et al. Primary breast" exact="cancer" post="phenotypes associated with propensity for central nervous system metastases"/>
   <result pre="al. Risk factors for brain relapse in patients with metastatic" exact="breast cancer" post="Ann Oncol 2004 15 1640 1644 15520065 9 Crivellari"/>
   <result pre="Risk factors for brain relapse in patients with metastatic breast" exact="cancer" post="Ann Oncol 2004 15 1640 1644 15520065 9 Crivellari"/>
   <result pre="central nervous system involvement inpatients with metastatic or locally advanced" exact="breast cancer" post="treated with epirubicin and docetaxel Ann Oncol 2001 12"/>
   <result pre="nervous system involvement inpatients with metastatic or locally advanced breast" exact="cancer" post="treated with epirubicin and docetaxel Ann Oncol 2001 12"/>
   <result pre="et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic" exact="breast cancer" post="patients with central nervous system metastasis Cancer 2007 110"/>
   <result pre="al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast" exact="cancer" post="patients with central nervous system metastasis Cancer 2007 110"/>
   <result pre="al. Risk factors for brain relapse in patients with metastatic" exact="breast cancer" post="Ann Oncol 2004 15 1640 1644 15520065 14 Coleman"/>
   <result pre="Risk factors for brain relapse in patients with metastatic breast" exact="cancer" post="Ann Oncol 2004 15 1640 1644 15520065 14 Coleman"/>
   <result pre="1640 1644 15520065 14 Coleman RE Clinical features of metastatic" exact="bone disease" post="and risk of skeletal morbidity Clin Cancer Res 2006"/>
   <result pre="D et al. Analysis of trastuzumab and chemotherapy in advanced" exact="breast cancer" post="after the failure of at least one earlier combination:"/>
   <result pre="et al. Analysis of trastuzumab and chemotherapy in advanced breast" exact="cancer" post="after the failure of at least one earlier combination:"/>
   <result pre="trastuzumab beyond disease progression: outcomes analysis in patients with metastatic" exact="breast cancer" post="Breast Cancer Res 2008 10 R60 18631394"/>
   <result pre="beyond disease progression: outcomes analysis in patients with metastatic breast" exact="cancer" post="Breast Cancer Res 2008 10 R60 18631394"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4619560/results/search/disease/results.xml">
   <result pre="postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced" exact="breast cancer" post="in Europe Jerusalem Guy g.jerusalem@chu.ulg.ac.be Neven Patrick patrick.neven@uz.kuleuven.ac.be Marinsek"/>
   <result pre="women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast" exact="cancer" post="in Europe Jerusalem Guy g.jerusalem@chu.ulg.ac.be Neven Patrick patrick.neven@uz.kuleuven.ac.be Marinsek"/>
   <result pre="article, unless otherwise stated. Abstract Background Healthcare resource utilization in" exact="breast cancer" post="varies by disease characteristics and treatment choices. However, lack"/>
   <result pre="unless otherwise stated. Abstract Background Healthcare resource utilization in breast" exact="cancer" post="varies by disease characteristics and treatment choices. However, lack"/>
   <result pre="with hormone-receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced" exact="breast cancer" post="across 5 European countries (France, Germany, The Netherlands, Belgium,"/>
   <result pre="hormone-receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast" exact="cancer" post="across 5 European countries (France, Germany, The Netherlands, Belgium,"/>
   <result pre="of working patients) versus hormone therapy in HR+, HER2– advanced" exact="breast cancer." post="Electronic supplementary material The online version of this article"/>
   <result pre="supplementary material, which is available to authorized users. Keywords Advanced" exact="breast cancer" post="Direct costs Europe Resource utilization Work productivity Background Breast"/>
   <result pre="material, which is available to authorized users. Keywords Advanced breast" exact="cancer" post="Direct costs Europe Resource utilization Work productivity Background Breast"/>
   <result pre="cancer Direct costs Europe Resource utilization Work productivity Background Breast" exact="cancer" post="is one of the most commonly diagnosed cancers in"/>
   <result pre="of this disease is also high; across the European Union," exact="breast cancer" post="generated the highest estimated healthcare costs (6 billion Euros/year)"/>
   <result pre="this disease is also high; across the European Union, breast" exact="cancer" post="generated the highest estimated healthcare costs (6 billion Euros/year)"/>
   <result pre="accounted for 13 % of the total healthcare costs for" exact="cancer" post="[ 2, 3]. However, healthcare resource utilization in breast"/>
   <result pre="for cancer [ 2, 3]. However, healthcare resource utilization in" exact="breast cancer" post="varies by disease stage and treatment choice [ 4]."/>
   <result pre="cancer [ 2, 3]. However, healthcare resource utilization in breast" exact="cancer" post="varies by disease stage and treatment choice [ 4]."/>
   <result pre="by disease stage and treatment choice [ 4]. In advanced" exact="breast cancer" post="(ABC), hormone therapy and chemotherapy are treatment options that"/>
   <result pre="disease stage and treatment choice [ 4]. In advanced breast" exact="cancer" post="(ABC), hormone therapy and chemotherapy are treatment options that"/>
   <result pre="treating patients (≥60 %), and the number of patients with" exact="breast cancer" post="for whom they were responsible for systemic treatment decisions"/>
   <result pre="patients (≥60 %), and the number of patients with breast" exact="cancer" post="for whom they were responsible for systemic treatment decisions"/>
   <result pre="assess their interest in participation (based on a database of" exact="breast cancer" post="oncologists and record of previous participation in such research),"/>
   <result pre="their interest in participation (based on a database of breast" exact="cancer" post="oncologists and record of previous participation in such research),"/>
   <result pre="+, HER2 − ABC, defined as metastatic or locally advanced" exact="breast cancer" post="not amenable to curative treatment by surgery or radiotherapy;"/>
   <result pre="HER2 − ABC, defined as metastatic or locally advanced breast" exact="cancer" post="not amenable to curative treatment by surgery or radiotherapy;"/>
   <result pre="more likely to have a family history of breast and/or" exact="ovarian cancer" post="and to present with liver and brain metastases at"/>
   <result pre="likely to have a family history of breast and/or ovarian" exact="cancer" post="and to present with liver and brain metastases at"/>
   <result pre="of resource utilization in the three cohorts. Abbreviations: ABC, advanced" exact="breast cancer;" post="HT, hormone therapy; TT, targeted therapy Table 3 Patient"/>
   <result pre="duration of 3 therapy lines, months 20.9 22.9 19.7 Breast" exact="cancer" post="history at ABC diagnosis, n (%)  Recurring during adjuvant"/>
   <result pre="(8)  None 149 (68) 0 73 (66) Abbreviation: ABC advanced" exact="breast cancer," post="CT chemotherapy, HT hormone therapy, Trx treatment Table 4"/>
   <result pre="Group, PgR progesterone receptor aMay reflect baseline characteristics before advanced" exact="breast cancer" post="(ABC) diagnosis when biopsy was not conducted at ABC"/>
   <result pre="PgR progesterone receptor aMay reflect baseline characteristics before advanced breast" exact="cancer" post="(ABC) diagnosis when biopsy was not conducted at ABC"/>
   <result pre="adjuvant endocrine therapy or who presented with de novo advanced" exact="breast cancer" post="(hormone therapy-eligible). Table 5 Cost differences between chemotherapy-based and"/>
   <result pre="endocrine therapy or who presented with de novo advanced breast" exact="cancer" post="(hormone therapy-eligible). Table 5 Cost differences between chemotherapy-based and"/>
   <result pre="line CTx €8201 (~€1700/mo) NA €8550 (~€1700/mo) Abbreviations: ABC advanced" exact="breast cancer," post="CTx chemotherapy, HT hormone therapy, mo month, NA not"/>
   <result pre="(7) 1 (4) 14 (52) 2 (7) Abbreviation: ABC advanced" exact="breast cancer" post="aThe percentages of patients do not add to 100"/>
   <result pre="1 (4) 14 (52) 2 (7) Abbreviation: ABC advanced breast" exact="cancer" post="aThe percentages of patients do not add to 100"/>
   <result pre="example, a Swedish study stratified the total cost of all" exact="breast cancer" post="cases in 2002 and reported higher indirect costs in"/>
   <result pre="a Swedish study stratified the total cost of all breast" exact="cancer" post="cases in 2002 and reported higher indirect costs in"/>
   <result pre="cancer cases in 2002 and reported higher indirect costs in" exact="breast cancer" post="from sick leave, early retirement, and premature mortality (70"/>
   <result pre="cases in 2002 and reported higher indirect costs in breast" exact="cancer" post="from sick leave, early retirement, and premature mortality (70"/>
   <result pre="costs dominated the total cost was because most of these" exact="breast cancer" post="cases were in patients &amp;lt;65 years of age who"/>
   <result pre="dominated the total cost was because most of these breast" exact="cancer" post="cases were in patients &amp;lt;65 years of age who"/>
   <result pre="in making the decision to initiate chemotherapy in patients with" exact="breast cancer" post="and will also include a cost analysis [ 23]."/>
   <result pre="making the decision to initiate chemotherapy in patients with breast" exact="cancer" post="and will also include a cost analysis [ 23]."/>
   <result pre="Medical Oncology. ESMO 2012 press release: the true costs of" exact="cancer" post="in Europe revealed. http://www.esmo.org/Conferences/Past-Conferences/ESMO-2012-Congress/News-Press-Releases/ESMO-2012-Press-Releases/The-true-costs-of-cancer-in-Europe-revealed. (2012). Accessed 26 Mar 2014."/>
   <result pre="Simou E Maniadakis N Pharmacoeconomic considerations in the treatment of" exact="breast cancer" post="Clinicoecon Outcomes Res 2010 2 47 61 21935314 5."/>
   <result pre="E Maniadakis N Pharmacoeconomic considerations in the treatment of breast" exact="cancer" post="Clinicoecon Outcomes Res 2010 2 47 61 21935314 5."/>
   <result pre="F et al. ESO-ESMO 2nd international consensus guidelines for advanced" exact="breast cancer" post="(ABC2) [published simultaneously in Ann Oncol] Breast 2014 23"/>
   <result pre="et al. ESO-ESMO 2nd international consensus guidelines for advanced breast" exact="cancer" post="(ABC2) [published simultaneously in Ann Oncol] Breast 2014 23"/>
   <result pre="F et al. ESO-ESMO 2nd international consensus guidelines for advanced" exact="breast cancer" post="(ABC2) [published simultaneously in Breast] Ann Oncol 2014 25"/>
   <result pre="et al. ESO-ESMO 2nd international consensus guidelines for advanced breast" exact="cancer" post="(ABC2) [published simultaneously in Breast] Ann Oncol 2014 25"/>
   <result pre="S et al. Adjuvant chemotherapy in hormone-receptor positive HER2-negative early" exact="breast cancer" post="Clin Ter 2009 160 6 481 8 20198292 12."/>
   <result pre="et al. Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast" exact="cancer" post="Clin Ter 2009 160 6 481 8 20198292 12."/>
   <result pre="Fallowfield L et al. 1st International consensus guidelines for advanced" exact="breast cancer" post="(ABC 1) Breast 2012 21 3 242 52 10.1016/j.breast.2012.03.003"/>
   <result pre="L et al. 1st International consensus guidelines for advanced breast" exact="cancer" post="(ABC 1) Breast 2012 21 3 242 52 10.1016/j.breast.2012.03.003"/>
   <result pre="Gao S Healthcare costs in postmenopausal women with hormone-positive metastatic" exact="breast cancer" post="J Med Econ 2010 13 4 691 7 10.3111/13696998.2010.531829"/>
   <result pre="S Healthcare costs in postmenopausal women with hormone-positive metastatic breast" exact="cancer" post="J Med Econ 2010 13 4 691 7 10.3111/13696998.2010.531829"/>
   <result pre="21070099 15. Campbell JD Ramsey SD The costs of treating" exact="breast cancer" post="in the US: a synthesis of published evidence Pharmacoeconomics"/>
   <result pre="15. Campbell JD Ramsey SD The costs of treating breast" exact="cancer" post="in the US: a synthesis of published evidence Pharmacoeconomics"/>
   <result pre="Qin A et al. Healthcare costs in women with metastatic" exact="breast cancer" post="receiving chemotherapy as their principal treatment modality BMC Cancer"/>
   <result pre="A et al. Healthcare costs in women with metastatic breast" exact="cancer" post="receiving chemotherapy as their principal treatment modality BMC Cancer"/>
   <result pre="21676243 20. Lidgren M Wilking N Jonsson B Cost of" exact="breast cancer" post="in Sweden in 2002 Eur J Health Econ 2007"/>
   <result pre="20. Lidgren M Wilking N Jonsson B Cost of breast" exact="cancer" post="in Sweden in 2002 Eur J Health Econ 2007"/>
   <result pre="D Martin M et al. Incidence-based cost-of-illness model for metastatic" exact="breast cancer" post="in the United States Int J Technol Assess Health"/>
   <result pre="Martin M et al. Incidence-based cost-of-illness model for metastatic breast" exact="cancer" post="in the United States Int J Technol Assess Health"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 33 5538 46 10.1200/JCO.2009.23.3734"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 33 5538 46 10.1200/JCO.2009.23.3734"/>
   <result pre="A Cameron D Donovan J Dunn J et al. Selecting" exact="breast cancer" post="patients for chemotherapy: the opening of the UK OPTIMA"/>
   <result pre="Cameron D Donovan J Dunn J et al. Selecting breast" exact="cancer" post="patients for chemotherapy: the opening of the UK OPTIMA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4621756/results/search/disease/results.xml">
   <result pre="Approximately 20 drugs have been approved by the FDA for" exact="breast cancer" post="treatment, yet predictive biomarkers are known for only a"/>
   <result pre="20 drugs have been approved by the FDA for breast" exact="cancer" post="treatment, yet predictive biomarkers are known for only a"/>
   <result pre="biomarkers would be useful both for drugs currently approved for" exact="breast cancer" post="treatment and for new drug development. Using glycoprotein expression"/>
   <result pre="would be useful both for drugs currently approved for breast" exact="cancer" post="treatment and for new drug development. Using glycoprotein expression"/>
   <result pre="net or lasso regression, we modeled quantitatively the responses of" exact="breast cancer" post="cell lines to ~90 drugs. Lasso and elastic net"/>
   <result pre="or lasso regression, we modeled quantitatively the responses of breast" exact="cancer" post="cell lines to ~90 drugs. Lasso and elastic net"/>
   <result pre="when the nominal target is not in the dataset. Breast" exact="cancer" post="cell lines Chemotherapy Targeted agents Mass spectrometry Statistical modeling"/>
   <result pre="and Drug Administration has approved roughly two dozen drugs for" exact="breast cancer" post="treatment, but only a few predictive biomarkers are currently"/>
   <result pre="Drug Administration has approved roughly two dozen drugs for breast" exact="cancer" post="treatment, but only a few predictive biomarkers are currently"/>
   <result pre="of tumors to drugs already approved for clinical use in" exact="breast cancer," post="as well as for new drug development [ 1,"/>
   <result pre="on solving the simplified problem of predicting the responses of" exact="cancer" post="cell lines, rather than of tumors [ 3– 8]."/>
   <result pre="source of predictors of drug response in several types of" exact="cancer" post="[ 16, 17]. To date these attempts have not"/>
   <result pre="of the estrogen receptor, progesterone receptor and HER2 proteins in" exact="breast cancer," post="suggesting that protein expression data may be more useful"/>
   <result pre="research group has assembled a database of glycoproteins from 26" exact="breast cancer" post="cell lines [ 18, 19]; for 22 of these"/>
   <result pre="group has assembled a database of glycoproteins from 26 breast" exact="cancer" post="cell lines [ 18, 19]; for 22 of these"/>
   <result pre="describing the effects of various drugs on the growth of" exact="cancer" post="cell lines have recently been generated for the purpose"/>
   <result pre="these datasets describes the effects of 90 drugs on 70" exact="breast cancer" post="cell lines, and is the largest of the datasets"/>
   <result pre="datasets describes the effects of 90 drugs on 70 breast" exact="cancer" post="cell lines, and is the largest of the datasets"/>
   <result pre="the datasets with respect to the number of drugs and" exact="breast cancer" post="cell lines [ 4]. Those authors measured the concentration"/>
   <result pre="datasets with respect to the number of drugs and breast" exact="cancer" post="cell lines [ 4]. Those authors measured the concentration"/>
   <result pre="Methods Our glycoprotein dataset includes 185 glycoproteins obtained from 22" exact="breast cancer" post="cell lines. Glycoproteins were collected using a protocol in"/>
   <result pre="Our glycoprotein dataset includes 185 glycoproteins obtained from 22 breast" exact="cancer" post="cell lines. Glycoproteins were collected using a protocol in"/>
   <result pre="more useful than mRNA data for predicting the responses of" exact="breast cancer" post="cell lines to drugs. In this study we evaluated"/>
   <result pre="useful than mRNA data for predicting the responses of breast" exact="cancer" post="cell lines to drugs. In this study we evaluated"/>
   <result pre="significance. Rapamycin illustrates the differences between the two methods. The" exact="breast cancer" post="cell lines in our sample vary in their sensitivity"/>
   <result pre="Rapamycin illustrates the differences between the two methods. The breast" exact="cancer" post="cell lines in our sample vary in their sensitivity"/>
   <result pre="predictors. Both have been identified independently in the context of" exact="breast cancer." post="SLC7A is one of five proteins in the Mammastrat"/>
   <result pre="to develop multiple reaction monitoring (MRM) assays for proteins in" exact="breast cancer" post="cell lines [ 21]. In the RPPA dataset, the"/>
   <result pre="develop multiple reaction monitoring (MRM) assays for proteins in breast" exact="cancer" post="cell lines [ 21]. In the RPPA dataset, the"/>
   <result pre="dataset, targeted assays were devised for 317 proteins in 30" exact="breast cancer" post="cell lines, of which 27 lines overlap with the"/>
   <result pre="targeted assays were devised for 317 proteins in 30 breast" exact="cancer" post="cell lines, of which 27 lines overlap with the"/>
   <result pre="Everolimus is approved for use in patients with ER+, HER2-" exact="breast cancer," post="in combination with exemestane [ 27]. The cell line"/>
   <result pre="here. Palbociclib, another CDK inhibitor, has been analyzed elsewhere on" exact="breast cancer" post="cell lines [ 28]. For all these drugs except"/>
   <result pre="Palbociclib, another CDK inhibitor, has been analyzed elsewhere on breast" exact="cancer" post="cell lines [ 28]. For all these drugs except"/>
   <result pre="to provide predictors for regression modeling of drug sensitivities in" exact="breast cancer" post="cell lines. We used two criteria for evaluating performance:"/>
   <result pre="provide predictors for regression modeling of drug sensitivities in breast" exact="cancer" post="cell lines. We used two criteria for evaluating performance:"/>
   <result pre="show that it is possible to predict the responses of" exact="breast cancer" post="cell lines to drugs, particularly when mass spectrometry has"/>
   <result pre="that it is possible to predict the responses of breast" exact="cancer" post="cell lines to drugs, particularly when mass spectrometry has"/>
   <result pre="that predict patient response for many more drugs used in" exact="breast cancer." post="Supplementary Material Supplementary file LINK Support for this work"/>
   <result pre="Castro D Clarke PA Al-Lazikani B Workman P 2013 Personalized" exact="cancer" post="medicine: molecular diagnostics, predictive biomarkers, and drug resistance Clin"/>
   <result pre="NJ Enache OM et al. 2013 Modeling precision treatment of" exact="breast cancer" post="Genome Biol 14 R110 24176112 5 Garnett MJ Edelman"/>
   <result pre="Enache OM et al. 2013 Modeling precision treatment of breast" exact="cancer" post="Genome Biol 14 R110 24176112 5 Garnett MJ Edelman"/>
   <result pre="2012 Systematic identification of genomic markers of drug sensitivity in" exact="cancer" post="cells Nature 483 570 575 22460902 6 Greshock J"/>
   <result pre="2012 Subtype and pathway specific responses to anticancer compounds in" exact="breast cancer" post="Proc Natl Acad Sci U S A 109 2724"/>
   <result pre="Subtype and pathway specific responses to anticancer compounds in breast" exact="cancer" post="Proc Natl Acad Sci U S A 109 2724"/>
   <result pre="define prognosis and predict pathologic complete response in patients with" exact="breast cancer" post="Clinical Proteomics 8 11 21906370 10 Niepel M Hafner"/>
   <result pre="prognosis and predict pathologic complete response in patients with breast" exact="cancer" post="Clinical Proteomics 8 11 21906370 10 Niepel M Hafner"/>
   <result pre="Basal and stimulated receptor signaling networks predict drug response in" exact="breast cancer" post="lines Sci Signal 6 ra84 24065145 11 Costello JC"/>
   <result pre="and stimulated receptor signaling networks predict drug response in breast" exact="cancer" post="lines Sci Signal 6 ra84 24065145 11 Costello JC"/>
   <result pre="Systematic assessment of analytical methods for drug sensitivity prediction from" exact="cancer" post="cell line data Pac Symp Biocomput 13 Menden MP"/>
   <result pre="U Benes CH et al. 2013 Machine learning prediction of" exact="cancer" post="cell sensitivity to drugs based on genomic and chemical"/>
   <result pre="Wessels L 2010 Do predictive signatures really predict response to" exact="cancer" post="chemotherapy? Cell Cycle 9 4836 4840 21150277 17 Reis-Filho"/>
   <result pre="Systemic alteration of cell-surface and secreted glycoprotein expression in malignant" exact="breast cancer" post="cell lines Glycobiology 23 1240 1249 23918816 19 Yen"/>
   <result pre="alteration of cell-surface and secreted glycoprotein expression in malignant breast" exact="cancer" post="cell lines Glycobiology 23 1240 1249 23918816 19 Yen"/>
   <result pre="22106898 20 Rebucci M Michiels C 2013 Molecular aspects of" exact="cancer" post="cell resistance to chemotherapy Biochem Pharmacol 85 1219 1226"/>
   <result pre="BZ et al. 2010 Mammostrat as a tool to stratify" exact="breast cancer" post="patients at risk of recurrence during endocrine therapy Breast"/>
   <result pre="et al. 2010 Mammostrat as a tool to stratify breast" exact="cancer" post="patients at risk of recurrence during endocrine therapy Breast"/>
   <result pre="et al. 2014 Bone marrow stromal antigen 2 expressed in" exact="cancer" post="cells promotes mammary tumor growth and metastasis Breast Cancer"/>
   <result pre="4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human" exact="breast cancer" post="cell lines in vitro Breast Cancer Res 11 R77"/>
   <result pre="inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast" exact="cancer" post="cell lines in vitro Breast Cancer Res 11 R77"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4624825/results/search/disease/results.xml">
   <result pre="license, and indicate if changes were made. Abstract Cancer and" exact="cardiovascular disease" post="(CVD) are two major causes of mortality in older"/>
   <result pre="mortality in older adults. With improved survival and outcomes from" exact="cancer" post="and CVD, the role of the geriatrician is evolving."/>
   <result pre="patient-centered and value-based care in the growing older population of" exact="cancer" post="patients (and survivors). Cancer treatment in older adults is"/>
   <result pre="adults is particularly injurious with respect to complications stemming from" exact="cancer" post="therapy and as well as to CVD related to"/>
   <result pre="cancer therapy and as well as to CVD related to" exact="cancer" post="therapy in the context of physiologic aging. To best"/>
   <result pre="on geriatric principles. Keywords Geriatric cardiology Geriatric oncology Cardio-oncology Chemotherapy-induced" exact="cardiomyopathy" post="Introduction Cancer and heart disease are the leading cause"/>
   <result pre="Geriatric cardiology Geriatric oncology Cardio-oncology Chemotherapy-induced cardiomyopathy Introduction Cancer and" exact="heart disease" post="are the leading cause of death in patients older"/>
   <result pre="patients older than 60 years of age [ 1]. While" exact="cancer" post="is the number one cause of mortality in patients"/>
   <result pre="cause of mortality in patients between 60 and 79 years," exact="heart disease" post="is most common in people aged 80 and older"/>
   <result pre="geriatric oncology have long been respective partners because advances in" exact="cancer" post="and cardiovascular (CV) care have increased life expectancy. With"/>
   <result pre="the field of &quot;cardio-oncology&quot; or &quot;onco-cardiology&quot; faces renewed interest. Because" exact="cancer" post="and heart disease are pathology related to the aging"/>
   <result pre="of &quot;cardio-oncology&quot; or &quot;onco-cardiology&quot; faces renewed interest. Because cancer and" exact="heart disease" post="are pathology related to the aging process, a close"/>
   <result pre="Caucasian female with a history of chronic anemia, hypertension, and" exact="dyslipidemia" post="was admitted for hip fracture following a mechanical fall."/>
   <result pre="During the evaluation of her fall, she was diagnosed with" exact="multiple myeloma" post="as the underlying etiology of her fracture. With daily"/>
   <result pre="and low-dose dexamethasone. Subsequently, she was admitted with new onset" exact="shortness" post="of breath and leg swelling and found to have"/>
   <result pre="breath and leg swelling and found to have new onset" exact="congestive heart failure" post="(CHF) and extensive right iliac vein thrombosis. Echocardiography showed"/>
   <result pre="coronary artery disease (CAD), and she was started on a" exact="cardiomyopathy" post="regimen. Potential placement of an implantable cardioverter defibrillator (ICD)"/>
   <result pre="2] and lenalidomide [ 3], respectively. Although the development of" exact="cardiomyopathy" post="might have been unavoidable, how might we approach her"/>
   <result pre="is foundational in deciding whether or not to proceed with" exact="cancer" post="therapy. A spectrum of chemotherapy and/or radiation-induced CV complications"/>
   <result pre="A spectrum of chemotherapy and/or radiation-induced CV complications exists: arrhythmias," exact="cardiomyopathy" post="and left ventricular dysfunction (LVD), valvular and pericardial disease,"/>
   <result pre="ischemic disease, as well as vascular disease. However, LVD and" exact="cardiomyopathy" post="have received significant attention in recent years due to"/>
   <result pre="global or more severe in the septum, (2) symptoms of" exact="congestive heart failure," post="(3) signs of CHF (S3 gallop, tachycardia, or both),"/>
   <result pre="Yearly focused clinical exam searching for signs and symptoms of" exact="cardiovascular disease," post="screen for modifiable risk factors and treat  • Diagnostic"/>
   <result pre="risk factors and treat  • Diagnostic evaluation if signs/symptoms of" exact="cardiovascular disease" post=" • Asymptomatic   Screening echo at 5 years for high"/>
   <result pre="for others   Functional non-invasive stress test for detection of ischemic" exact="heart disease" post="5 to 10 years after exposure in high risk"/>
   <result pre="malignancies [ 22, 23] such as sarcomas, lymphomas, leukemias, and" exact="breast cancer." post="However, their use is limited by potential LVD and"/>
   <result pre="existing CV disease, elevation of cardiac biomarker during and after" exact="cancer" post="treatment, as well as time since completion of cancer"/>
   <result pre="after cancer treatment, as well as time since completion of" exact="cancer" post="therapy. Nonspecific electrocardiographic changes such as ST-T wave abnormalities"/>
   <result pre="of anthracycline •ECG monitoring •Continuous infusion with infusion monitoring for" exact="hypersensitivity" post="reaction Targeted agents (monoclonal antibody-based TK and small TKIs)"/>
   <result pre="agents; termination if QTc &amp;gt;470 ms Cetuximab Hypotension Anaphylaxis and" exact="hypersensitivity" post="reaction Electrolytes imbalance  Rituximab Hypotension, angioedema, arrhythmias Anaphylaxis and"/>
   <result pre="hypersensitivity reaction Electrolytes imbalance  Rituximab Hypotension, angioedema, arrhythmias Anaphylaxis and" exact="hypersensitivity" post="reaction  Trastuzumab CHF, LV Dysfunction anti-Erb2 (transmembrane receptors)  Imatinib"/>
   <result pre="anthracycline, CAD coronary artery disease, CCB calcium channel blocker, CHF" exact="congestive heart failure," post="DVT deep venous thrombosis, ER endoplasmic reticulum, HTN hypertension,"/>
   <result pre="HTN hypertension, LV left ventricular dysfunction, NO nitric oxide, PH" exact="pulmonary hypertension," post="TK tyrosine kinase, TKI tyrosine kinase inhibitors, VEGF vascular"/>
   <result pre="factors for CAD or known CAD. For older men with" exact="prostate cancer" post="undergoing treatment with androgen deprivation therapy (ADT), the verdict"/>
   <result pre="for CAD or known CAD. For older men with prostate" exact="cancer" post="undergoing treatment with androgen deprivation therapy (ADT), the verdict"/>
   <result pre="inconsistent. Although there are reports of an increased risk of" exact="heart disease" post="including CAD, acute ischemia, and sudden cardiac death ["/>
   <result pre="that is most affected by radiotherapy-induced CV injury is adult" exact="cancer" post="survivors treated with radiotherapy at a relatively young age"/>
   <result pre="effects. These typically include those with Hodgkin’s lymphoma, early stage" exact="breast cancer," post="lung, and esophageal cancer. Mediastinal radiotherapy may lead to"/>
   <result pre="those with Hodgkin’s lymphoma, early stage breast cancer, lung, and" exact="esophageal cancer." post="Mediastinal radiotherapy may lead to disease of the coronaries,"/>
   <result pre="events is 2–7 years post-radiotherapy, while for those with left-sided" exact="breast cancer," post="the range is 1.0–2.2 years [ 5••]. Device Therapy"/>
   <result pre="effect. If LVD remains ≤35 % after treatment with optimal" exact="cardiomyopathy" post="medications and if there is greater than one year"/>
   <result pre="pacemaker therapy. In discussing device therapy, particularly in the older" exact="cancer" post="patient, it is important to stress that ICD therapy"/>
   <result pre="a rapid progression of symptoms such as fatigue, dizziness, or" exact="shortness" post="of breath [ 65]. In deciding which patients are"/>
   <result pre="from advanced device therapy, one must consider the patient’s overall" exact="cancer" post="prognosis, social support risk of complications such as bleeding"/>
   <result pre="have also released publications on the care of the older" exact="cancer" post="patient—both of which cover CV complications and management. NCCN"/>
   <result pre="Dale et al. in their article on the interface of" exact="cancer" post="and aging research [ 67] outlined selected clinical trials"/>
   <result pre="67] outlined selected clinical trials which enrolled older patients with" exact="cancer" post="(12 in total—two trials in breast cancer, two lung"/>
   <result pre="enrolled older patients with cancer (12 in total—two trials in" exact="breast cancer," post="two lung cancer, two colorectal cancer, two acute myeloid"/>
   <result pre="with cancer (12 in total—two trials in breast cancer, two" exact="lung cancer," post="two colorectal cancer, two acute myeloid leukemia, three prostate"/>
   <result pre="in total—two trials in breast cancer, two lung cancer, two" exact="colorectal cancer," post="two acute myeloid leukemia, three prostate cancer, and two"/>
   <result pre="in breast cancer, two lung cancer, two colorectal cancer, two" exact="acute myeloid leukemia," post="three prostate cancer, and two ovarian cancer). They noted"/>
   <result pre="breast cancer, two lung cancer, two colorectal cancer, two acute" exact="myeloid leukemia," post="three prostate cancer, and two ovarian cancer). They noted"/>
   <result pre="lung cancer, two colorectal cancer, two acute myeloid leukemia, three" exact="prostate cancer," post="and two ovarian cancer). They noted several themes: (1)"/>
   <result pre="subclinical cardiac disease that may manifest during the course of" exact="cancer" post="therapy or be exacerbated by the treatment. Chronologic vs"/>
   <result pre="adverse events involve a combination of underlying comorbidities (renal insufficiency," exact="lung disease," post="hearing or visual loss, gastrointestinal disease, neuropathy, osteoporosis, diabetes,"/>
   <result pre="underlying comorbidities (renal insufficiency, lung disease, hearing or visual loss," exact="gastrointestinal disease," post="neuropathy, osteoporosis, diabetes, anemia, known CHF), geriatric syndromes (functional"/>
   <result pre="called upon to assess an older patient’s &quot;fitness&quot; to undergo" exact="cancer" post="therapy, particularly if the patient has known ischemic heart"/>
   <result pre="undergo cancer therapy, particularly if the patient has known ischemic" exact="heart disease" post="or LVD. Predictive models such as Chemotherapy Risk Assessment"/>
   <result pre="diagnosis [ 72]. The oncologist approaches the patient from a" exact="cancer" post="perspective and proceeds with therapy accepting the risk of"/>
   <result pre="perspective and proceeds with therapy accepting the risk of later" exact="cardiomyopathy" post="diagnosis, while the cardiologist identifies the ischemic heart disease,"/>
   <result pre="of later cardiomyopathy diagnosis, while the cardiologist identifies the ischemic" exact="heart disease," post="proceeds with appropriate therapy, and later finds cancer from"/>
   <result pre="ischemic heart disease, proceeds with appropriate therapy, and later finds" exact="cancer" post="from symptomatic bleeding secondary to anti-platelet therapy. From Albini"/>
   <result pre="increased implementation of durable power of attorney assignment (DPOA) by" exact="cancer" post="patients between 2010 and 2012, but this was not"/>
   <result pre="require constant ongoing negotiations, particularly in cases of patients with" exact="cancer" post="and heart disease whereby treatment of one carries significant"/>
   <result pre="ongoing negotiations, particularly in cases of patients with cancer and" exact="heart disease" post="whereby treatment of one carries significant complications for other"/>
   <result pre="other comorbidities. Within the GOC discussion, dialogue on outcomes following" exact="cardiac arrest" post="and cardiopulmonary resuscitation (CPR) merits specific attention. Although recent"/>
   <result pre="years or older were alive at one year following in-hospital" exact="cardiac arrest" post="and that the 3-year survival rate is similar to"/>
   <result pre="centered on the finding that among older survivors of in-hospital" exact="cardiac arrest," post="less than 10 % are alive at one year"/>
   <result pre="survive to discharge [ 81]. In older patients with out-of-hospital" exact="cardiac arrest" post="(OHCA), there is a 25 % survival to discharge"/>
   <result pre="This suggestion may prove more crucial in older adults with" exact="cancer" post="and heart disease. Having at minimum, an annual appointment"/>
   <result pre="may prove more crucial in older adults with cancer and" exact="heart disease." post="Having at minimum, an annual appointment dedicated solely to"/>
   <result pre="available to the entire medical team. While the treatment of" exact="cancer" post="may not result in death, treatment complications may result"/>
   <result pre="result in death, treatment complications may result in progression of" exact="heart disease," post="which may significantly alter the quality of life. Few"/>
   <result pre="the older patient’s preferences and values. Conclusion With advances in" exact="cancer" post="and CV treatment, survival will improve and life expectancy"/>
   <result pre="with treating unintended consequences of these therapies. CV complications from" exact="cancer" post="therapy, high burden of underlying CV disease, and age-related"/>
   <result pre="and safety of lenalidomide and dexamethasone in patients with relapsed/refractory" exact="multiple myeloma" post="who were treated according to the standard clinical practice:"/>
   <result pre="Burstein HJ Winer EP Goldhirsch A Cardiac toxicity from systemic" exact="cancer" post="therapy: a comprehensive review Prog Cardiovasc Dis 2010 53"/>
   <result pre="23522920 8. Sheppard RJ Berger J Sebag IA Cardiotoxicity of" exact="cancer" post="therapeutics: current issues in screening, prevention, and therapy Front"/>
   <result pre="10.3389/fphar.2013.00019 23487556 9. Yeh ETH Bickford CL Cardiovascular complications of" exact="cancer" post="therapy J Am Coll Cardiol 2009 53 2231 47"/>
   <result pre="SM Therapy insight: therapeutic challenges in the treatment of elderly" exact="cancer" post="patients Nat Clin Pract Oncol 2006 3 86 93"/>
   <result pre="Sehl M Naeim A Physiologic aspects of aging: impact on" exact="cancer" post="management and decision making, part I Cancer J 2005"/>
   <result pre="Sawhney R Naeim A Physiologic aspects of aging: impact on" exact="cancer" post="management and decision making, part II Cancer J 2005"/>
   <result pre="AM Herrmann J et al. Cardiovascular health of patients with" exact="cancer" post="and cancer survivors: a roadmap to the next level"/>
   <result pre="J et al. Cardiovascular health of patients with cancer and" exact="cancer" post="survivors: a roadmap to the next level J Am"/>
   <result pre="for multimodality imaging evaluation of adult patients during and after" exact="cancer" post="therapy: a report from the American Society of Echocardiography"/>
   <result pre="LL Keefe D Einzig AI et al. Cardiovascular toxicity with" exact="cancer" post="chemotherapy Curr Probl Cancer 1997 21 301 60 10.1016/S0147-0272(97)80001-3"/>
   <result pre="F Krzemieniecki K et al. Anthracycline cardiotoxicity in the elderly" exact="cancer" post="patient: a SIOG expert position paper Ann Oncol 2011"/>
   <result pre="Elting L et al. Trastuzumab-related cardiotoxicity among older patients with" exact="breast cancer" post="J Clin Oncol 2013 31 4222 8 10.1200/JCO.2013.48.7884 24127446"/>
   <result pre="L et al. Trastuzumab-related cardiotoxicity among older patients with breast" exact="cancer" post="J Clin Oncol 2013 31 4222 8 10.1200/JCO.2013.48.7884 24127446"/>
   <result pre="21 10.1159/000055397 11694783 32. Mellstedt H Monoclonal antibodies in human" exact="cancer" post="Drugs Today 2003 39 Suppl C 1 16 14988743"/>
   <result pre="McDonald DM Mechanisms of adverse effects of anti-VEGF therapy for" exact="cancer" post="Br J Cancer 2007 96 1788 95 10.1038/sj.bjc.6603813 17519900"/>
   <result pre="toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for" exact="testicular cancer" post="Eur Heart J 1988 9 552 6 2456930 40."/>
   <result pre="after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular" exact="cancer" post="Eur Heart J 1988 9 552 6 2456930 40."/>
   <result pre="et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic" exact="colorectal cancer" post="N Engl J Med 2004 350 2335 42 10.1056/NEJMoa032691"/>
   <result pre="al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal" exact="cancer" post="N Engl J Med 2004 350 2335 42 10.1056/NEJMoa032691"/>
   <result pre="Keating NL O’Malley A Freedland SJ Smith MR Diabetes and" exact="cardiovascular disease" post="during androgen deprivation therapy: observational study of veterans with"/>
   <result pre="disease during androgen deprivation therapy: observational study of veterans with" exact="prostate cancer" post="J Natl Cancer Inst 2012 104 1518 23 10.1093/jnci/djs376"/>
   <result pre="during androgen deprivation therapy: observational study of veterans with prostate" exact="cancer" post="J Natl Cancer Inst 2012 104 1518 23 10.1093/jnci/djs376"/>
   <result pre="DE et al. Coronary revascularization and mortality in men with" exact="congestive heart failure" post="or prior myocardial infarction who receive androgen deprivation Cancer"/>
   <result pre="Rodriguez LA Androgen deprivation therapy and the risk of coronary" exact="heart disease" post="and heart failure in patients with prostate cancer: a"/>
   <result pre="therapy: defining the problem and promoting health among men with" exact="prostate cancer" post="J Natl Compr Canc Netw 2010 8 211 23"/>
   <result pre="defining the problem and promoting health among men with prostate" exact="cancer" post="J Natl Compr Canc Netw 2010 8 211 23"/>
   <result pre="J Stattin P Van Hemelrijck M Risk and timing of" exact="cardiovascular disease" post="after androgen-deprivation therapy in men with prostate cancer J"/>
   <result pre="timing of cardiovascular disease after androgen-deprivation therapy in men with" exact="prostate cancer" post="J Clin Oncol 2015 33 1243 51 10.1200/JCO.2014.59.1792 25732167"/>
   <result pre="of cardiovascular disease after androgen-deprivation therapy in men with prostate" exact="cancer" post="J Clin Oncol 2015 33 1243 51 10.1200/JCO.2014.59.1792 25732167"/>
   <result pre="25732167 55. Keating NL O’Malley AJ Smith MR Diabetes and" exact="cardiovascular disease" post="during androgen deprivation therapy for prostate cancer J Clin"/>
   <result pre="MR Diabetes and cardiovascular disease during androgen deprivation therapy for" exact="prostate cancer" post="J Clin Oncol 2006 24 4448 56 10.1200/JCO.2006.06.2497 16983113"/>
   <result pre="Diabetes and cardiovascular disease during androgen deprivation therapy for prostate" exact="cancer" post="J Clin Oncol 2006 24 4448 56 10.1200/JCO.2006.06.2497 16983113"/>
   <result pre="Cheung AM et al. Impact of androgen deprivation therapy on" exact="cardiovascular disease" post="and diabetes J Clin Oncol 2009 27 3452 8"/>
   <result pre="PA Kapoor JR Radiation induced heart disease: systemic disorders in" exact="heart disease" post="Heart 2009 95 252 8 10.1136/hrt.2008.149088 19144884 59.•• Lancellotti"/>
   <result pre="al. Biological, clinical, and psychosocial correlates at the interface of" exact="cancer" post="and aging research JNCI J Nat Cancer Inst 2012"/>
   <result pre="M Hurria A Comprehensive geriatric assessment for older patients with" exact="cancer" post="J Clin Oncol 2007 25 1824 31 10.1200/JCO.2007.10.6559 17488980"/>
   <result pre="gaps in the advance care planning process of patients with" exact="cancer" post="JAMA Oncol 2015 1 5 610 10.1001/jamaoncol.2015.2088 26181351 75."/>
   <result pre="BG et al. Long-term outcomes in elderly survivors of in-hospital" exact="cardiac arrest" post="N Engl J Med 2013 368 1019 26 10.1056/NEJMoa1200657"/>
   <result pre="Yee P Newman J Long-term outcomes in elderly survivors of" exact="cardiac arrest" post="N Engl J Med 2013 368 2438 23782194 79.•"/>
   <result pre="Y Krumholz HM Chan PS Trends in survival after in-hospital" exact="cardiac arrest" post="N Engl J Med 2012 367 1912 20 10.1056/NEJMoa1109148"/>
   <result pre="Glavan BJ Ehlenbach WJ Long-term outcomes in elderly survivors of" exact="cardiac arrest" post="N Engl J Med 2013 368 2437 8 10.1056/NEJMc1305198"/>
   <result pre="A Nordberg P Hollenberg J Albertsson P et al. Out-of-hospital" exact="cardiac arrest" post="in the elderly: a large-scale population-based study Resuscitation 2015"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627342/results/search/disease/results.xml">
   <result pre="capecitabine or paclitaxel to treat patients with progressive HER2-overexpressing metastatic" exact="breast cancer" post="(MBC). Unfortunately, an increased incidence of hepatotoxicity had been"/>
   <result pre="or paclitaxel to treat patients with progressive HER2-overexpressing metastatic breast" exact="cancer" post="(MBC). Unfortunately, an increased incidence of hepatotoxicity had been"/>
   <result pre="shown to increase the accumulation of doxorubicin in ABCB1-overexpressing hepatocellular" exact="cancer" post="cells and normal liver tissues without altering the protein"/>
   <result pre="[ 2]. P-glycoprotein (ABCB1/MDR1), multidrug resistance-associated protein 1 (ABCC1/MRP1) and" exact="breast cancer" post="resistance protein (ABCG2/MXR) are three major ABC transporters associated"/>
   <result pre="2]. P-glycoprotein (ABCB1/MDR1), multidrug resistance-associated protein 1 (ABCC1/MRP1) and breast" exact="cancer" post="resistance protein (ABCG2/MXR) are three major ABC transporters associated"/>
   <result pre="have been found overexpressed in many chemotherapeutic-resistant tumors such as" exact="colon cancer," post="liver cancer and kidney cancer [ 3]. With a"/>
   <result pre="found overexpressed in many chemotherapeutic-resistant tumors such as colon cancer," exact="liver cancer" post="and kidney cancer [ 3]. With a crucial protective"/>
   <result pre="overexpressed in many chemotherapeutic-resistant tumors such as colon cancer, liver" exact="cancer" post="and kidney cancer [ 3]. With a crucial protective"/>
   <result pre="many chemotherapeutic-resistant tumors such as colon cancer, liver cancer and" exact="kidney cancer" post="[ 3]. With a crucial protective role, these ABC"/>
   <result pre="chemotherapeutic-resistant tumors such as colon cancer, liver cancer and kidney" exact="cancer" post="[ 3]. With a crucial protective role, these ABC"/>
   <result pre="enhanced the anticancer activity of chemotherapeutic agents in ABC transporter-overexpressing" exact="cancer" post="cells [ 7, 8]. In liver, ABCB1 is expressed"/>
   <result pre="in patients with progressive human epidermal receptor 2 (HER2)-overexpressing metastatic" exact="breast cancer" post="[ 13- 15]. A phase III study demonstrated that"/>
   <result pre="patients with progressive human epidermal receptor 2 (HER2)-overexpressing metastatic breast" exact="cancer" post="[ 13- 15]. A phase III study demonstrated that"/>
   <result pre="alone From a cohort of 39 patients with HER2-overexpressing metastatic" exact="breast cancer," post="we analyzed the adverse events in hepatobiliary system from"/>
   <result pre="those in paclitaxel alone. Lapatinib increased doxorubicin accumulation in ABCB1-overexpressing" exact="hepatocellular carcinoma" post="cells in vitro We hypothesized that the increased hepatotoxicity"/>
   <result pre="effect of lapatinib on increasing drug accumulation in a sensitive" exact="hepatocellular carcinoma" post="cells HepG2 and its ABCB1-overexpressing resistant HepG2/Adr subline. The"/>
   <result pre="accumulation in normal liver tissues obtained from Swiss mice and" exact="cancer" post="patients. We first detected the expression levels of ABCB1"/>
   <result pre="of ABCB1 substrate chemotherapeutical agents not only in ABCB1 overexpressing" exact="cancer" post="cells but also in normal liver cells. Figure 3"/>
   <result pre="is an effective first-line therapy in patients with HER2-positive metastatic" exact="breast cancer" post="[ 21, 22]. However, it has been reported that"/>
   <result pre="an effective first-line therapy in patients with HER2-positive metastatic breast" exact="cancer" post="[ 21, 22]. However, it has been reported that"/>
   <result pre="increased the accumulation of doxorubicin and rhodamine 123 in ABCB1-overexpressing" exact="hepatocellular carcinoma" post="cells and normal liver tissues in concentration-dependent manners. However,"/>
   <result pre="drugs. Doxorubicin and paclitaxel, which are commonly used in treating" exact="breast cancer," post="are all ABCB1 substrates. Possible drug-drug interactions with lapatinib"/>
   <result pre="[ 28]. In a phase III trial of HER2-positive metastatic" exact="breast cancer" post="patients whose cancers had not responded to trastuzumab or"/>
   <result pre="28]. In a phase III trial of HER2-positive metastatic breast" exact="cancer" post="patients whose cancers had not responded to trastuzumab or"/>
   <result pre="cell proliferation and restore tamoxifen sensitivity in ER-positive and tamoxifen-resistant" exact="breast cancer" post="[ 30]. While lapatinib was also shown to provide"/>
   <result pre="proliferation and restore tamoxifen sensitivity in ER-positive and tamoxifen-resistant breast" exact="cancer" post="[ 30]. While lapatinib was also shown to provide"/>
   <result pre="combination with other anticancer drugs in patients with brain metastasis" exact="breast cancer" post="by promoting drug penetration through the blood brain barrier"/>
   <result pre="with other anticancer drugs in patients with brain metastasis breast" exact="cancer" post="by promoting drug penetration through the blood brain barrier"/>
   <result pre="sources (Guangzhou, China). Cell lines and cell culture The human" exact="hepatocellular carcinoma" post="cell line HepG2 was obtained from American Type Culture"/>
   <result pre="(Guangzhou, China) for analysis. All patients were diagnosed with invasive" exact="breast cancer" post="by histological examination. The HER2 overexpression was confirmed by"/>
   <result pre="China) for analysis. All patients were diagnosed with invasive breast" exact="cancer" post="by histological examination. The HER2 overexpression was confirmed by"/>
   <result pre="liver tissues The fresh normal liver tissue adjacent to the" exact="hepatocellular carcinoma" post="retrieved from Sun Yat-sen university cancer center was used"/>
   <result pre="adjacent to the hepatocellular carcinoma retrieved from Sun Yat-sen university" exact="cancer" post="center was used for the drug accumulation assay ex"/>
   <result pre="A Kumar P Chen ZS Role of ABC transporters in" exact="cancer" post="chemotherapy Chinese journal of cancer 2012 31 51 57"/>
   <result pre="Role of ABC transporters in cancer chemotherapy Chinese journal of" exact="cancer" post="2012 31 51 57 22257384 2 Ambudkar SV Kimchi-Sarfaty"/>
   <result pre="Scheper RJ Schellens JH Subcellular localization and distribution of the" exact="breast cancer" post="resistance protein transporter in normal human tissues Cancer research"/>
   <result pre="RJ Schellens JH Subcellular localization and distribution of the breast" exact="cancer" post="resistance protein transporter in normal human tissues Cancer research"/>
   <result pre="ZS Fu LW Lapatinib (Tykerb, GW572016) reverses multidrug resistance in" exact="cancer" post="cells by inhibiting the activity of ATP-binding cassette subfamily"/>
   <result pre="MW Absolute immunoquantification of the expression of ABC transporters P-glycoprotein," exact="breast cancer" post="resistance protein and multidrug resistance-associated protein 2 in human"/>
   <result pre="Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast" exact="cancer" post="resistance protein and multidrug resistance-associated protein 2 in human"/>
   <result pre="and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity Clinical" exact="cancer" post="research : an official journal of the American Association"/>
   <result pre="activation and resistance of EGFR-tyrosine kinase inhibitors American journal of" exact="cancer" post="research 2014 4 608 628 25520855 14 Cetin B"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="Journal of clinical oncology : official journal of the"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="Journal of clinical oncology : official journal of the"/>
   <result pre="5546 19786658 16 Wang H Lapatinib for the treatment of" exact="breast cancer" post="in the People's Republic of China OncoTargets and therapy"/>
   <result pre="19786658 16 Wang H Lapatinib for the treatment of breast" exact="cancer" post="in the People's Republic of China OncoTargets and therapy"/>
   <result pre="D. Goss P. E. Hepatobiliary abnormalities in patients with metastatic" exact="cancer" post="treated with lapatinib Journal of clinical oncology : official"/>
   <result pre="insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in" exact="cancer" post="therapy Nature clinical practice Oncology 2008 5 268 278"/>
   <result pre="of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic" exact="breast cancer" post="Oncology 2010 79 129 135 21088439 22 Di Leo"/>
   <result pre="first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast" exact="cancer" post="Oncology 2010 79 129 135 21088439 22 Di Leo"/>
   <result pre="paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic" exact="breast cancer" post="Journal of clinical oncology : official journal of the"/>
   <result pre="with placebo plus paclitaxel as first-line treatment for metastatic breast" exact="cancer" post="Journal of clinical oncology : official journal of the"/>
   <result pre="safety, and biomarker results from Chinese patients Chinese journal of" exact="cancer" post="2011 30 327 335 21527065 24 Ostapowicz G Fontana"/>
   <result pre="Rubin SD et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="The New England journal of medicine 2006 355 2733"/>
   <result pre="SD et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="The New England journal of medicine 2006 355 2733"/>
   <result pre="inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant" exact="breast cancer" post="Cancer research 2005 65 18 25 15665275 31 Moy"/>
   <result pre="both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast" exact="cancer" post="Cancer research 2005 65 18 25 15665275 31 Moy"/>
   <result pre="B Goss PE Lapatinib: current status and future directions in" exact="breast cancer" post="The oncologist 2006 11 1047 1057 17110623 32 Mir"/>
   <result pre="Goss PE Lapatinib: current status and future directions in breast" exact="cancer" post="The oncologist 2006 11 1047 1057 17110623 32 Mir"/>
   <result pre="Pons G Treluyer JM Goldwasser F Emerging therapeutic options for" exact="breast cancer" post="chemotherapy during pregnancy Annals of oncology : official journal"/>
   <result pre="G Treluyer JM Goldwasser F Emerging therapeutic options for breast" exact="cancer" post="chemotherapy during pregnancy Annals of oncology : official journal"/>
   <result pre="Hait WN Pharmacology of drugs that alter multidrug resistance in" exact="cancer" post="Pharmacological reviews 1990 42 155 199 2217530 43 Chen"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627999/results/search/disease/results.xml">
   <result pre="Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic" exact="breast cancer" post="in the real world: a single institutional review Watanabe"/>
   <result pre="monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast" exact="cancer" post="in the real world: a single institutional review Watanabe"/>
   <result pre="of eribulin in clinical settings for the treatment of metastatic" exact="breast cancer" post="(MBC) are limited. This retrospective observational study investigated the"/>
   <result pre="eribulin in clinical settings for the treatment of metastatic breast" exact="cancer" post="(MBC) are limited. This retrospective observational study investigated the"/>
   <result pre="factor receptor 2 (HER2)-negative (ER+/HER2−) MBC, including unresectable locally advanced" exact="breast cancer," post="treated at a single institution were included in this"/>
   <result pre="therapy due to AEs. In the eribulin arm, grade 4" exact="neutropenia" post="and grade 3 febrile neutropenia were observed in 8"/>
   <result pre="the eribulin arm, grade 4 neutropenia and grade 3 febrile" exact="neutropenia" post="were observed in 8 (12.1 %) and 4 (6.1"/>
   <result pre="therapy for ER+/HER2− MBC. Keywords Chemotherapy Eribulin mesylate Japanese Metastatic" exact="breast cancer" post="Background The treatment of metastatic breast cancer (MBC) remains"/>
   <result pre="for ER+/HER2− MBC. Keywords Chemotherapy Eribulin mesylate Japanese Metastatic breast" exact="cancer" post="Background The treatment of metastatic breast cancer (MBC) remains"/>
   <result pre="mesylate Japanese Metastatic breast cancer Background The treatment of metastatic" exact="breast cancer" post="(MBC) remains a challenge, with approximately 6–10 % of"/>
   <result pre="Japanese Metastatic breast cancer Background The treatment of metastatic breast" exact="cancer" post="(MBC) remains a challenge, with approximately 6–10 % of"/>
   <result pre="(MBC) remains a challenge, with approximately 6–10 % of new" exact="breast cancer" post="cases being initially diagnosed as stage IV or metastatic"/>
   <result pre="remains a challenge, with approximately 6–10 % of new breast" exact="cancer" post="cases being initially diagnosed as stage IV or metastatic"/>
   <result pre="systemic neo-adjuvant/adjuvant chemotherapy may reduce mortality risks in those with" exact="breast cancer" post="(Berry et al. 2005), the choice of chemotherapy regimen"/>
   <result pre="neo-adjuvant/adjuvant chemotherapy may reduce mortality risks in those with breast" exact="cancer" post="(Berry et al. 2005), the choice of chemotherapy regimen"/>
   <result pre="National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology" exact="breast cancer," post="version 2 2015). Recently, eribulin, a nontaxane microtubule dynamics"/>
   <result pre="approved for the treatment of patients with inoperable or recurrent" exact="breast cancer" post="but not limited to those who have been previously"/>
   <result pre="for the treatment of patients with inoperable or recurrent breast" exact="cancer" post="but not limited to those who have been previously"/>
   <result pre="1 Baseline demographics and clinical characteristics at diagnosis of metastatic" exact="breast cancer" post="Variables Overall Eribulin Noneribulin P value Fisher’s exact test"/>
   <result pre="Baseline demographics and clinical characteristics at diagnosis of metastatic breast" exact="cancer" post="Variables Overall Eribulin Noneribulin P value Fisher’s exact test"/>
   <result pre="(13.7) 40 (60.6) – CNS central nervous system, EBC early" exact="breast cancer," post="MBC metastatic breast cancer Efficacy outcomes A total of"/>
   <result pre="CNS central nervous system, EBC early breast cancer, MBC metastatic" exact="breast cancer" post="Efficacy outcomes A total of 214 (73.0 %) patients"/>
   <result pre="central nervous system, EBC early breast cancer, MBC metastatic breast" exact="cancer" post="Efficacy outcomes A total of 214 (73.0 %) patients"/>
   <result pre="which was calculated as the time from diagnosis of metastatic" exact="breast cancer" post="until death from any cause. HR denotes hazard ratio"/>
   <result pre="was calculated as the time from diagnosis of metastatic breast" exact="cancer" post="until death from any cause. HR denotes hazard ratio"/>
   <result pre="0.03* CI confidence interval, CNS central nervous system, EBC early" exact="breast cancer," post="HR hazard ratio, MBC metastatic breast cancer Safety outcomes"/>
   <result pre="system, EBC early breast cancer, HR hazard ratio, MBC metastatic" exact="breast cancer" post="Safety outcomes No patient discontinued eribulin therapy due to"/>
   <result pre="EBC early breast cancer, HR hazard ratio, MBC metastatic breast" exact="cancer" post="Safety outcomes No patient discontinued eribulin therapy due to"/>
   <result pre="therapy due to adverse events. No grade 3 or 4" exact="neuropathy" post="was documented. Grade 4 neutropenia was observed in 8"/>
   <result pre="No grade 3 or 4 neuropathy was documented. Grade 4" exact="neutropenia" post="was observed in 8 (12.1 %) patients, and grade"/>
   <result pre="observed in 8 (12.1 %) patients, and grade 3 febrile" exact="neutropenia" post="was observed in 4 (6.1 %) patients. None of"/>
   <result pre="eribulin has been approved for patients with inoperable or recurrent" exact="breast cancer," post="irrespective of their previous treatment history. The present study"/>
   <result pre="role in the development and progression of certain types of" exact="breast cancer," post="several novel anti-HER2 therapeutic agents, including trastuzumab, lapatinib, pertuzumab,"/>
   <result pre="eribulin had an acceptable safety profile. Grade 3 and 4" exact="neutropenia" post="were observed in 6.1 and 12.1 % patients, respectively,"/>
   <result pre="3/4 hematological or non-hematological toxicity was documented. Notably, grade 3/4" exact="peripheral neuropathy," post="the most common adverse event leading to discontinuation of"/>
   <result pre="study included Japanese women with MBC, including unresectable locally advanced" exact="breast cancer" post="(LABC), who were treated at the Shizuoka Cancer Center"/>
   <result pre="included Japanese women with MBC, including unresectable locally advanced breast" exact="cancer" post="(LABC), who were treated at the Shizuoka Cancer Center"/>
   <result pre="(National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology" exact="breast cancer," post="version 2 2015) (e.g., TS-1 monotherapy and capecitabine +"/>
   <result pre="factor receptor 2 (HER2)-negative HR hazard ratio LABC locally advanced" exact="breast cancer" post="MBC metastatic breast cancer OS overall survival Acknowledgements The"/>
   <result pre="receptor 2 (HER2)-negative HR hazard ratio LABC locally advanced breast" exact="cancer" post="MBC metastatic breast cancer OS overall survival Acknowledgements The"/>
   <result pre="HR hazard ratio LABC locally advanced breast cancer MBC metastatic" exact="breast cancer" post="OS overall survival Acknowledgements The author would like to"/>
   <result pre="hazard ratio LABC locally advanced breast cancer MBC metastatic breast" exact="cancer" post="OS overall survival Acknowledgements The author would like to"/>
   <result pre="study of eribulin in Japanese patients with heavily pretreated metastatic" exact="breast cancer" post="Ann Oncol 2012 23 1441 1448 10.1093/annonc/mdr444 21989327 Berry"/>
   <result pre="of eribulin in Japanese patients with heavily pretreated metastatic breast" exact="cancer" post="Ann Oncol 2012 23 1441 1448 10.1093/annonc/mdr444 21989327 Berry"/>
   <result pre="EJ Effect of screening and adjuvant therapy on mortality from" exact="breast cancer" post="N Engl J Med 2005 353 1784 1792 10.1056/NEJMoa050518"/>
   <result pre="Effect of screening and adjuvant therapy on mortality from breast" exact="cancer" post="N Engl J Med 2005 353 1784 1792 10.1056/NEJMoa050518"/>
   <result pre="B Winer E ESO-ESMO 2nd international consensus guidelines for advanced" exact="breast cancer" post="(ABC2) Ann Oncol 2014 25 1871 1888 10.1093/annonc/mdu385 25234545"/>
   <result pre="Winer E ESO-ESMO 2nd international consensus guidelines for advanced breast" exact="cancer" post="(ABC2) Ann Oncol 2014 25 1871 1888 10.1093/annonc/mdu385 25234545"/>
   <result pre="analog eribulin mesylate in patients with locally advanced or metastatic" exact="breast cancer" post="previously treated with an anthracycline, a taxane, and capecitabine"/>
   <result pre="eribulin mesylate in patients with locally advanced or metastatic breast" exact="cancer" post="previously treated with an anthracycline, a taxane, and capecitabine"/>
   <result pre="monotherapy versus treatment of physician’s choice in patients with metastatic" exact="breast cancer" post="(EMBRACE): a phase 3 open-label randomised study Lancet 2011"/>
   <result pre="versus treatment of physician’s choice in patients with metastatic breast" exact="cancer" post="(EMBRACE): a phase 3 open-label randomised study Lancet 2011"/>
   <result pre="Moscetti L Marchetti P Vici P Eribulin mesylate in pretreated" exact="breast cancer" post="patients: a multicenter retrospective observational study J Cancer 2014"/>
   <result pre="L Marchetti P Vici P Eribulin mesylate in pretreated breast" exact="cancer" post="patients: a multicenter retrospective observational study J Cancer 2014"/>
   <result pre="VW Clarke CA Ries LA Cronin KA US incidence of" exact="breast cancer" post="subtypes defined by joint hormone receptor and HER2 status"/>
   <result pre="Clarke CA Ries LA Cronin KA US incidence of breast" exact="cancer" post="subtypes defined by joint hormone receptor and HER2 status"/>
   <result pre="mesylate versus capecitabine in patients with locally advanced or metastatic" exact="breast cancer" post="previously treated with an anthracycline and a taxane J"/>
   <result pre="versus capecitabine in patients with locally advanced or metastatic breast" exact="cancer" post="previously treated with an anthracycline and a taxane J"/>
   <result pre="National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology" exact="breast cancer," post="version 2. 2015. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 01 Apr 2015 Poletti"/>
   <result pre="Caremoli E Tondini C Eribulin mesylate in heavily pretreated metastatic" exact="breast cancer" post="patients: current practice in an Italian community hospital Future"/>
   <result pre="E Tondini C Eribulin mesylate in heavily pretreated metastatic breast" exact="cancer" post="patients: current practice in an Italian community hospital Future"/>
   <result pre="eribulin mesylate, a halichondrin B analog, in patients with metastatic" exact="breast cancer" post="previously treated with an anthracycline and a taxane J"/>
   <result pre="mesylate, a halichondrin B analog, in patients with metastatic breast" exact="cancer" post="previously treated with an anthracycline and a taxane J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4631578/results/search/disease/results.xml">
   <result pre="properly cited. Abstract Approximately 35% of patients with confirmed HER2" exact="breast cancer" post="progress to metastases of the central nervous system (CNS)."/>
   <result pre="cited. Abstract Approximately 35% of patients with confirmed HER2 breast" exact="cancer" post="progress to metastases of the central nervous system (CNS)."/>
   <result pre="article, we report the case of a patient with HER2-positive" exact="breast cancer" post="who showed isolated progression of the illness in the"/>
   <result pre="we report the case of a patient with HER2-positive breast" exact="cancer" post="who showed isolated progression of the illness in the"/>
   <result pre="with T-DM1 for the treatment of cerebral metastases in HER2-positive" exact="breast cancer," post="we describe the efficacy and tolerance of the concomitant"/>
   <result pre="efficacy and tolerance of the concomitant application of these treatments." exact="breast cancer" post="HER2-positive TDM1 radiotherapy Introduction Breast cancer is one of"/>
   <result pre="and tolerance of the concomitant application of these treatments. breast" exact="cancer" post="HER2-positive TDM1 radiotherapy Introduction Breast cancer is one of"/>
   <result pre="of these treatments. breast cancer HER2-positive TDM1 radiotherapy Introduction Breast" exact="cancer" post="is one of the most common neoplasia in Western"/>
   <result pre="20% are HER2 positive [ 2]. Generally, among patients with" exact="breast cancer," post="approximately 25% progress to metastases of the central nervous"/>
   <result pre="and tolerance of the treatment of a patient with HER2-positive" exact="breast cancer" post="with metastases of the CNS subjected to total cerebral"/>
   <result pre="tolerance of the treatment of a patient with HER2-positive breast" exact="cancer" post="with metastases of the CNS subjected to total cerebral"/>
   <result pre="other treatments in patients with HER2-positive metastatic or locally advanced/recurrent" exact="breast cancer." post="The patients in question were randomised into the group"/>
   <result pre="up to 25% of all patients with advanced cancer. In" exact="breast cancer," post="the incidence is approximately 25%, and it is the"/>
   <result pre="as a risk factor for cerebral metastases in patients with" exact="breast cancer," post="increasing the incidence of these metastases to 37.3% ["/>
   <result pre="an increase in the number of cases of metastases from" exact="breast cancer" post="has been observed. The principal sites for breast cancer"/>
   <result pre="increase in the number of cases of metastases from breast" exact="cancer" post="has been observed. The principal sites for breast cancer"/>
   <result pre="from breast cancer has been observed. The principal sites for" exact="breast cancer" post="metastases are the CNS, with the parenchyma being the"/>
   <result pre="breast cancer has been observed. The principal sites for breast" exact="cancer" post="metastases are the CNS, with the parenchyma being the"/>
   <result pre="metastases and a decrease in the survival of patients with" exact="breast cancer" post="without anti-HER2 treatment, while there is an increase in"/>
   <result pre="and a decrease in the survival of patients with breast" exact="cancer" post="without anti-HER2 treatment, while there is an increase in"/>
   <result pre="of patients taking trastuzumab exclusively as a treatment for metastatic" exact="breast cancer" post="develop isolated involvement of the CNS [ 6]. Multiple"/>
   <result pre="patients taking trastuzumab exclusively as a treatment for metastatic breast" exact="cancer" post="develop isolated involvement of the CNS [ 6]. Multiple"/>
   <result pre="involvement of the CNS [ 6]. Multiple cerebral metastases of" exact="breast cancer" post="exist in two-thirds of patients at the time of"/>
   <result pre="of the CNS [ 6]. Multiple cerebral metastases of breast" exact="cancer" post="exist in two-thirds of patients at the time of"/>
   <result pre="[ 8] Treatment options for patients with cerebral metastases of" exact="breast cancer" post="are the use of systemic chemotherapy, total or localised"/>
   <result pre="8] Treatment options for patients with cerebral metastases of breast" exact="cancer" post="are the use of systemic chemotherapy, total or localised"/>
   <result pre="with multiple cerebral metastases, which correspond to most cases of" exact="breast cancer," post="the best option is total or localised cerebral radiotherapy."/>
   <result pre="than 3 Gy/fraction achieves a good response in patients with" exact="breast cancer" post="that is sensitive to radiotherapy and those with a"/>
   <result pre="3 Gy/fraction achieves a good response in patients with breast" exact="cancer" post="that is sensitive to radiotherapy and those with a"/>
   <result pre="11]. The use of chemotherapy in the treatment of advanced" exact="breast cancer" post="depends on multiple factors. In addition to a good"/>
   <result pre="The use of chemotherapy in the treatment of advanced breast" exact="cancer" post="depends on multiple factors. In addition to a good"/>
   <result pre="characteristics of the patient and his or her type of" exact="cancer" post="are important to the decision on what drug should"/>
   <result pre="on what drug should be used. The greatest difficulty in" exact="cancer" post="management is in establishing the best time for the"/>
   <result pre="use of lapatinib plus capecitabine in patients with advanced HER2-positive" exact="breast cancer" post="in prior treatment with trastuzumab and taxanes [ 13,"/>
   <result pre="of lapatinib plus capecitabine in patients with advanced HER2-positive breast" exact="cancer" post="in prior treatment with trastuzumab and taxanes [ 13,"/>
   <result pre="(64.5), nausea (48.4%), headache (30.4%), fever (28.4%), nosebleeds (28.9%), and" exact="constipation" post="(28.6). These events were classified with grade 1 or"/>
   <result pre="grade 3 or higher, of which the main effects were" exact="thrombocytopenia" post="(7.7%), hypocalcaemia (4%), increased fatigue (4%), increased AST (3.3%),"/>
   <result pre="thrombocytopenia (7.7%), hypocalcaemia (4%), increased fatigue (4%), increased AST (3.3%)," exact="shortness" post="of breath (2.9%), anaemia (2.6%), cellulite (2.6%), hyperglycaemia (2.2%),"/>
   <result pre="to the efficacy of treatment with isolated trastuzumab in advanced" exact="breast cancer" post="with cerebral metastasis. What has been discussed is that"/>
   <result pre="the efficacy of treatment with isolated trastuzumab in advanced breast" exact="cancer" post="with cerebral metastasis. What has been discussed is that"/>
   <result pre="D Levivier M Hilderbrand J Treatment of brain metastases from" exact="breast cancer" post="Breast Cancer Mol Med 2006 505 523 10.1007/978-3-540-28266-2 8."/>
   <result pre="Levivier M Hilderbrand J Treatment of brain metastases from breast" exact="cancer" post="Breast Cancer Mol Med 2006 505 523 10.1007/978-3-540-28266-2 8."/>
   <result pre="Aandahl G Dalhaug A A case of brain metastases from" exact="breast cancer" post="treated with whole-brain radiotherapy and eribulin mesylate Case Rep"/>
   <result pre="G Dalhaug A A case of brain metastases from breast" exact="cancer" post="treated with whole-brain radiotherapy and eribulin mesylate Case Rep"/>
   <result pre="outcomes after brain radiotherapy in patients with brain metastases from" exact="breast cancer" post="in the pre-traztuzumab and trastuzumab eras Radiat Oncol 2013"/>
   <result pre="after brain radiotherapy in patients with brain metastases from breast" exact="cancer" post="in the pre-traztuzumab and trastuzumab eras Radiat Oncol 2013"/>
   <result pre="conjugate, given every three weeks to patients with HER2-positive metastatic" exact="breast cancer" post="J Clin Oncol 2010 28 2698 2704 10.1200/JCO.2009.26.2071 20421541"/>
   <result pre="given every three weeks to patients with HER2-positive metastatic breast" exact="cancer" post="J Clin Oncol 2010 28 2698 2704 10.1200/JCO.2009.26.2071 20421541"/>
   <result pre="D Gianni L et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Eng J Med 2012 367 1783 1791 10.1056/NEJMoa1209124"/>
   <result pre="Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Eng J Med 2012 367 1783 1791 10.1056/NEJMoa1209124"/>
   <result pre="S Activity of T-DM1 in HER-2 positive central nervous system" exact="breast cancer" post="metastases BMJ Case Rep 2014 14 2014"/>
   <result pre="Activity of T-DM1 in HER-2 positive central nervous system breast" exact="cancer" post="metastases BMJ Case Rep 2014 14 2014"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4632920/results/search/disease/results.xml">
   <result pre="(ER) signaling compensatory activation in acquired resistance to lapatinib in" exact="breast cancer" post="cells BT474 and the related mechanism. Methods Acquired resistant"/>
   <result pre="signaling compensatory activation in acquired resistance to lapatinib in breast" exact="cancer" post="cells BT474 and the related mechanism. Methods Acquired resistant"/>
   <result pre="human epidermal growth factor receptor (HER)2 and ER pathways in" exact="breast cancer" post="cell BT474 after treatment with lapatinib and the distinction"/>
   <result pre="epidermal growth factor receptor (HER)2 and ER pathways in breast" exact="cancer" post="cell BT474 after treatment with lapatinib and the distinction"/>
   <result pre="activation may partly contribute to lapatinib acquired resistance in HER2-overexpressing/ERα-positive" exact="breast cancer" post="cells, which might be related to PI3K/AKT inhibition and"/>
   <result pre="may partly contribute to lapatinib acquired resistance in HER2-overexpressing/ERα-positive breast" exact="cancer" post="cells, which might be related to PI3K/AKT inhibition and"/>
   <result pre="related to PI3K/AKT inhibition and MAPK pathway activation. Acquired resistance" exact="breast cancer" post="ER HER2 Lapatinib Introduction Lapatinib (Tykerb, GlaxoSmithKline, Middlesex, UK)"/>
   <result pre="to PI3K/AKT inhibition and MAPK pathway activation. Acquired resistance breast" exact="cancer" post="ER HER2 Lapatinib Introduction Lapatinib (Tykerb, GlaxoSmithKline, Middlesex, UK)"/>
   <result pre="targeting drug for treating human epidermal growth factor receptor (HER)2-positive" exact="breast cancer," post="and is the second HER2 inhibitor to be approved"/>
   <result pre="that lapatinib can reduce the risk of brain metastases in" exact="breast cancer" post="patients with trastuzumab resistance. 2 Moreover, lapatinib has weak"/>
   <result pre="lapatinib can reduce the risk of brain metastases in breast" exact="cancer" post="patients with trastuzumab resistance. 2 Moreover, lapatinib has weak"/>
   <result pre="in vitro. Materials and methods Cell line and reagents Breast" exact="cancer" post="cell line BT474 was purchased from Type Culture Collection"/>
   <result pre="observe the impact of lapatinib on the ERα pathway in" exact="breast cancer" post="cells, HER2 overexpression and ERα(+) breast cancer cell line"/>
   <result pre="the impact of lapatinib on the ERα pathway in breast" exact="cancer" post="cells, HER2 overexpression and ERα(+) breast cancer cell line"/>
   <result pre="ERα pathway in breast cancer cells, HER2 overexpression and ERα(+)" exact="breast cancer" post="cell line BT474 were chosen for this study. Real-time"/>
   <result pre="pathway in breast cancer cells, HER2 overexpression and ERα(+) breast" exact="cancer" post="cell line BT474 were chosen for this study. Real-time"/>
   <result pre="both lapatinib and fulvestrant had a remarkably synergistic inhibition on" exact="breast cancer" post="cells BT474 and rBT474, and enhanced the sensitivity to"/>
   <result pre="lapatinib and fulvestrant had a remarkably synergistic inhibition on breast" exact="cancer" post="cells BT474 and rBT474, and enhanced the sensitivity to"/>
   <result pre="growth factor receptor 2 is highly expressed in 25% of" exact="breast cancer" post="cases, and HER2(+) breast cancer is highly malignant, invasive,"/>
   <result pre="factor receptor 2 is highly expressed in 25% of breast" exact="cancer" post="cases, and HER2(+) breast cancer is highly malignant, invasive,"/>
   <result pre="highly expressed in 25% of breast cancer cases, and HER2(+)" exact="breast cancer" post="is highly malignant, invasive, and has a poor prognosis."/>
   <result pre="expressed in 25% of breast cancer cases, and HER2(+) breast" exact="cancer" post="is highly malignant, invasive, and has a poor prognosis."/>
   <result pre="HER1 and HER2, indicating that it is efficient for trastuzumab-resistant" exact="breast cancer" post="cells. The molecular weight of lapatinib is small; therefore"/>
   <result pre="and HER2, indicating that it is efficient for trastuzumab-resistant breast" exact="cancer" post="cells. The molecular weight of lapatinib is small; therefore"/>
   <result pre="the activation of other compensatory channels. As a result the" exact="cancer" post="cells no longer depend only upon the HER2 pathway;"/>
   <result pre="drug-resistant strains. In this study, we built HER2(+) and ER(+)" exact="breast cancer" post="cells, BT474, as models to detect the influence of"/>
   <result pre="strains. In this study, we built HER2(+) and ER(+) breast" exact="cancer" post="cells, BT474, as models to detect the influence of"/>
   <result pre="positive correlation with the level of activated FOXO3a in the" exact="breast cancer" post="cell line, and heterologous FOXO3a elicits the level of"/>
   <result pre="correlation with the level of activated FOXO3a in the breast" exact="cancer" post="cell line, and heterologous FOXO3a elicits the level of"/>
   <result pre="in the interaction between HER2 and ER in mammogenesis and" exact="breast cancer." post="23, 25– 28 In ER(+) breast cancer cells, the"/>
   <result pre="in mammogenesis and breast cancer. 23, 25– 28 In ER(+)" exact="breast cancer" post="cells, the MAPK pathway induced by Src phosphorylation can"/>
   <result pre="mammogenesis and breast cancer. 23, 25– 28 In ER(+) breast" exact="cancer" post="cells, the MAPK pathway induced by Src phosphorylation can"/>
   <result pre="therapeutic strategy to prevent and/or overcome lapatinib resistance in HER2-overexpressing" exact="breast cancer." post="Further in vivo or clinical studies are warranted. This"/>
   <result pre="References Higa GM Abraham J Lapatinib in the treatment of" exact="breast cancer" post="Expert Rev Anticancer Ther 2007 7 1183 1192 17892419"/>
   <result pre="Higa GM Abraham J Lapatinib in the treatment of breast" exact="cancer" post="Expert Rev Anticancer Ther 2007 7 1183 1192 17892419"/>
   <result pre="Chan A Lapatinib - Overview and current role in metastatic" exact="breast cancer" post="Cancer Res Treat 2006 38 198 200 19771242 Campone"/>
   <result pre="A Lapatinib - Overview and current role in metastatic breast" exact="cancer" post="Cancer Res Treat 2006 38 198 200 19771242 Campone"/>
   <result pre="et al. Characterizing the HER2/neu status and metastatic potential of" exact="breast cancer" post="stem/progenitor cells Ann Surg Oncol 2010 17 613 623"/>
   <result pre="al. Characterizing the HER2/neu status and metastatic potential of breast" exact="cancer" post="stem/progenitor cells Ann Surg Oncol 2010 17 613 623"/>
   <result pre="lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic" exact="breast cancer" post="J Clin Oncol 2008 26 2999 3005 18458039 Esteva"/>
   <result pre="as first-line therapy for ErbB2-amplified locally advanced or metastatic breast" exact="cancer" post="J Clin Oncol 2008 26 2999 3005 18458039 Esteva"/>
   <result pre="GN Molecular predictors of response to trastuzumab and lapatinib in" exact="breast cancer" post="Nat Rev Clin Oncol 2010 7 98 107 20027191"/>
   <result pre="Molecular predictors of response to trastuzumab and lapatinib in breast" exact="cancer" post="Nat Rev Clin Oncol 2010 7 98 107 20027191"/>
   <result pre="al. Brk is coamplified with ErbB2 to promote proliferation in" exact="breast cancer" post="Proc Natl Acad Sci U S A 2008 105"/>
   <result pre="Brk is coamplified with ErbB2 to promote proliferation in breast" exact="cancer" post="Proc Natl Acad Sci U S A 2008 105"/>
   <result pre="inhibitor and a therapeutic strategy to prevent its onset in" exact="breast cancer" post="Proc Natl Acad Sci U S A 2006 103"/>
   <result pre="and a therapeutic strategy to prevent its onset in breast" exact="cancer" post="Proc Natl Acad Sci U S A 2006 103"/>
   <result pre="D Heinemann V Lapatinib in the treatment of hormone receptor-positive/ErbB2-positive" exact="breast cancer" post="Breast Care (Basel) 2010 5 Suppl. 1 13 15"/>
   <result pre="Heinemann V Lapatinib in the treatment of hormone receptor-positive/ErbB2-positive breast" exact="cancer" post="Breast Care (Basel) 2010 5 Suppl. 1 13 15"/>
   <result pre="20847831 Ritter CA Perez-Torres M Rinehart C et al. Human" exact="breast cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="Ritter CA Perez-Torres M Rinehart C et al. Human breast" exact="cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="of the PI-3K and MEK pathways in Ras-mediated chemoresistance in" exact="breast cancer" post="cells Br J Cancer 2003 89 185 191 12838322"/>
   <result pre="the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast" exact="cancer" post="cells Br J Cancer 2003 89 185 191 12838322"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4637019/results/search/disease/results.xml">
   <result pre="markers of cardiac dysfunction that can predict this form of" exact="cardiomyopathy" post="before ejection fraction (EF) is reduced are becoming increasingly"/>
   <result pre="the attempt of protecting cardiooncologic patients from the development of" exact="congestive heart failure." post="1. Introduction The prognosis of cancer has dramatically improved"/>
   <result pre="development of congestive heart failure. 1. Introduction The prognosis of" exact="cancer" post="has dramatically improved in the last decades: several types"/>
   <result pre="increases, the higher is the likelihood that cardiovascular consequences of" exact="cancer" post="therapies become the major health problem after tumor elimination"/>
   <result pre="about 2100 for the past few years (2001 Heart and" exact="stroke" post="statistical update. Dallas: American Heart Association, 2000). Here we"/>
   <result pre="are currently the cornerstone of treatment of many malignancies, including" exact="breast cancer," post="lymphomas, and sarcomas. It has been estimated that approximately"/>
   <result pre="functional reserve [ 18, 19]. The probability of developing anthracycline" exact="cardiomyopathy" post="is primarily dose dependent [ 20]. Additional risk factors"/>
   <result pre="young or old age, female gender, intravenous bolus infusion, hypertension," exact="diabetes mellitus," post="preexisting cardiac disease, previous or concurrent mediastinal radiation therapy,"/>
   <result pre="least in part secondary to the activity of IL-1 β," exact="suppression" post="of the latter might blunt some of the adverse"/>
   <result pre="Instead, sunitinib and sorafenib, which are used in metastatic renal" exact="cancer" post="and in imatinib-resistant gastrointestinal stromal tumors [ 72, 80],"/>
   <result pre="the work of Scartozzi and colleagues [ 99] on metastatic" exact="colorectal cancer" post="patients, 20% of patients developed grade 2-3 hypertension. A"/>
   <result pre="work of Scartozzi and colleagues [ 99] on metastatic colorectal" exact="cancer" post="patients, 20% of patients developed grade 2-3 hypertension. A"/>
   <result pre="are tyrosine kinase inhibitors used for treatment of chronic myelogenous" exact="leukemia" post="and gastrointestinal stromal tumors. These two drugs were initially"/>
   <result pre="reversible cardiotoxicity and may mislead physicians to stop potentially lifesaving" exact="cancer" post="therapies. Cardiovascular side effects such as myocardial ischaemia, arterial"/>
   <result pre="MUGA (Multiple Gated Acquisition) scans are now commonly used in" exact="cancer" post="patients [ 1, 45, 57, 104, 105]. These methods"/>
   <result pre="cardiac function. It should be noted that patients with advanced" exact="cancer" post="may already have cardiovascular abnormalities such as fatigue, dyspnea,"/>
   <result pre="to severe arrhythmia. Distinguishing these from side effects attributable to" exact="cancer" post="therapies requires a specific expertise. One important and very"/>
   <result pre="the limitations of cardiac imaging to stratify the risk in" exact="cancer" post="patients with cardiac dysfunction. Cardiac biomarkers such as troponins"/>
   <result pre="cardiac biomarkers is not being performed routinely in patients undergoing" exact="cancer" post="treatment, and multicentre trials to evaluate the role of"/>
   <result pre="TnI to be associated with LV dysfunction in patients with" exact="breast cancer" post="undergoing sequential therapy with doxorubicin and trastuzumab, also showed"/>
   <result pre="to be associated with LV dysfunction in patients with breast" exact="cancer" post="undergoing sequential therapy with doxorubicin and trastuzumab, also showed"/>
   <result pre="as myeloperoxidase (MPO) could be mechanistically relevant to cardiotoxicity with" exact="cancer" post="therapy [ 133]. All things said, there is no"/>
   <result pre="preoncologic treatments evaluation and follow-up of patients during and after" exact="cancer" post="therapies. Nevertheless, we need to avoid that patients who"/>
   <result pre="therapies. Nevertheless, we need to avoid that patients who survive" exact="cancer" post="today develop cardiac dysfunction tomorrow. Therefore such patients should"/>
   <result pre="and treat cardiovascular risk factors (hypertension, diabetes, current and previous" exact="cardiovascular disease," post="subclinical organ damage previously documented by ECG or echocardiography"/>
   <result pre="subclinical renal disease, age, smoking, dyslipidemia, family history of premature" exact="cardiovascular disease," post="and abdominal obesity) in order to allow long-term continuous"/>
   <result pre="type 2 cardiotoxicity [ 1]. Interestingly, anthracyclines are used for" exact="cancer" post="in children, too, and both elderly patients and children"/>
   <result pre="Study showed that, 30 years after anthracyclines, 73% of pediatric" exact="cancer" post="survivors would develop at least 1 chronic condition, while"/>
   <result pre="monitoring of cardiac function is necessary. At the end of" exact="cancer" post="treatments, EF should be monitored to check for late"/>
   <result pre="patients at high risk of developing HF, but without structural" exact="heart disease" post="or symptoms of HF yet. On such basis, patients"/>
   <result pre="been performed mostly on anthracyclines and, in the case of" exact="breast cancer," post="on anthracyclines + trastuzumab [ 30, 146] and have"/>
   <result pre="as not to impede a patient's ability to benefit from" exact="cancer" post="treatment. In a patient with metastatic disease, risk of"/>
   <result pre="are at increased risk for developing cardiac dysfunction associated with" exact="cancer" post="treatments. The major mechanisms of left ventricular dysfunction are"/>
   <result pre="failure patients and improve longevity and quality of life for" exact="cancer" post="patients. Currently, about 20% of all the investments on"/>
   <result pre="kinase inhibitors, the majority of which (about 80%) being in" exact="cancer" post="(with little component in inflammatory and other diseases) ["/>
   <result pre="T. Moslehi J. J. Emerging paradigms in cardiomyopathies associated with" exact="cancer" post="therapies Circulation Research 2013 113 6 754 764 10.1161/circresaha.113.300218"/>
   <result pre="H. Force T. Molecular mechanisms of cardiovascular toxicity of targeted" exact="cancer" post="therapeutics Circulation Research 2010 106 1 21 34 10.1161/circresaha.109.206920"/>
   <result pre="T. Ewer M. S. et al. Cardiovascular side effects of" exact="cancer" post="therapies: a position statement from the Heart Failure Association"/>
   <result pre="chemotherapy is associated with early noninvasive imaging evidence of subclinical" exact="cardiovascular disease" post="JACC: Cardiovascular Imaging 2013 6 8 877 885 10.1016/j.jcmg.2012.11.017"/>
   <result pre="et al. Myocardial injury revealed by plasma troponin I in" exact="breast cancer" post="treated with high-dose chemotherapy Annals of Oncology 2002 13"/>
   <result pre="al. Myocardial injury revealed by plasma troponin I in breast" exact="cancer" post="treated with high-dose chemotherapy Annals of Oncology 2002 13"/>
   <result pre="M. W. Basa P. et al. Risk factors for doxorubicin-induced" exact="congestive heart failure" post="Annals of Internal Medicine 1979 91 5 710 717"/>
   <result pre="factors for late cardiotoxic effects of doxorubicin therapy for childhood" exact="cancer" post="The New England Journal of Medicine 1995 332 26"/>
   <result pre="Menna P. Cantalupo E. et al. The concomitant management of" exact="cancer" post="therapy and cardiac therapy Biochimica et Biophysica Acta 2015"/>
   <result pre="and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's" exact="lymphoma" post="Journal of Clinical Oncology 2008 26 19 3159 3165"/>
   <result pre="al. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced" exact="cardiomyopathy" post="in the pig Journal of Heart and Lung Transplantation"/>
   <result pre="al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for" exact="testicular cancer" post="Annals of Oncology 2011 22 10 2286 2293 10.1093/annonc/mdr408"/>
   <result pre="Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular" exact="cancer" post="Annals of Oncology 2011 22 10 2286 2293 10.1093/annonc/mdr408"/>
   <result pre="Eiermann W. Robert N. et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="The New England Journal of Medicine 2011 365 14"/>
   <result pre="W. Robert N. et al. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="The New England Journal of Medicine 2011 365 14"/>
   <result pre="48 Yeh E. T. Bickford C. L. Cardiovascular complications of" exact="cancer" post="therapy: incidence, pathogenesis, diagnosis, and management Journal of the"/>
   <result pre="of chemotherapy plus a monoclonal antibody against her2 for metastatic" exact="breast cancer" post="that overexpresses HER2 The New England Journal of Medicine"/>
   <result pre="chemotherapy plus a monoclonal antibody against her2 for metastatic breast" exact="cancer" post="that overexpresses HER2 The New England Journal of Medicine"/>
   <result pre="et al. ErbB2 is essential in the prevention of dilated" exact="cardiomyopathy" post="Nature Medicine 2002 8 5 459 465 10.1038/nm0502-459 62"/>
   <result pre="Cardiac toxicity of sunitinib and sorafenib in patients with metastatic" exact="renal cell carcinoma" post="Journal of Clinical Oncology 2008 26 32 5204 5212"/>
   <result pre="P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in" exact="cancer" post="The Journal of Clinical Investigation 2013 123 8 3190"/>
   <result pre="et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic" exact="colorectal cancer" post="The New England Journal of Medicine 2004 350 23"/>
   <result pre="al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal" exact="cancer" post="The New England Journal of Medicine 2004 350 23"/>
   <result pre="C. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell" exact="lung cancer" post="The New England Journal of Medicine 2006 355 24"/>
   <result pre="et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung" exact="cancer" post="The New England Journal of Medicine 2006 355 24"/>
   <result pre="with bevacizumab plus capecitabine in patients with previously treated metastatic" exact="breast cancer" post="Journal of Clinical Oncology 2005 23 4 792 799"/>
   <result pre="bevacizumab plus capecitabine in patients with previously treated metastatic breast" exact="cancer" post="Journal of Clinical Oncology 2005 23 4 792 799"/>
   <result pre="M. Fisher G. A. Srinivas S. Cardiotoxicity associated with the" exact="cancer" post="therapeutic agent sunitinib malate Annals of Oncology 2008 19"/>
   <result pre="Schutz F. A. B. et al. Incidence and risk of" exact="congestive heart failure" post="in patients with renal and nonrenal cell carcinoma treated"/>
   <result pre="al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell" exact="lung cancer" post="receiving chemotherapy with or without the vascular endothelial growth"/>
   <result pre="Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung" exact="cancer" post="receiving chemotherapy with or without the vascular endothelial growth"/>
   <result pre="S. et al. Arterial hypertension correlates with clinical outcome in" exact="colorectal cancer" post="patients treated with first-line bevacizumab Annals of Oncology 2009"/>
   <result pre="et al. Arterial hypertension correlates with clinical outcome in colorectal" exact="cancer" post="patients treated with first-line bevacizumab Annals of Oncology 2009"/>
   <result pre="R. Grazette L. Yacobi R. et al. Cardiotoxicity of the" exact="cancer" post="therapeutic agent imatinib mesylate Nature Medicine 2006 12 8"/>
   <result pre="Donal E. et al. EACVI/HFA Cardiac Oncology Toxicity Registry in" exact="breast cancer" post="patients: rationale, study design, and methodology (EACVI/HFA COT Registry)—EURObservational"/>
   <result pre="E. et al. EACVI/HFA Cardiac Oncology Toxicity Registry in breast" exact="cancer" post="patients: rationale, study design, and methodology (EACVI/HFA COT Registry)—EURObservational"/>
   <result pre="the early detection of cardiotoxicity in patients during and after" exact="cancer" post="chemotherapy: a systematic review Journal of the American College"/>
   <result pre="dysfunction in patients with human epidermal growth factor receptor II-positive" exact="breast cancer" post="treated with adjuvant trastuzumab therapy Journal of the American"/>
   <result pre="in patients with human epidermal growth factor receptor II-positive breast" exact="cancer" post="treated with adjuvant trastuzumab therapy Journal of the American"/>
   <result pre="imaging in the early detection of trastuzumab and anthracycline mediated" exact="cardiomyopathy" post="Journal of the American Society of Echocardiography 2009 22"/>
   <result pre="detect preclinical myocardial dysfunction before conventional measures in patients undergoing" exact="breast cancer" post="treatment with trastuzumab American Heart Journal 2009 158 2"/>
   <result pre="preclinical myocardial dysfunction before conventional measures in patients undergoing breast" exact="cancer" post="treatment with trastuzumab American Heart Journal 2009 158 2"/>
   <result pre="anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic" exact="breast cancer" post="survivors: a speckle tracking echocardiographic study Heart 2010 96"/>
   <result pre="and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast" exact="cancer" post="survivors: a speckle tracking echocardiographic study Heart 2010 96"/>
   <result pre="reveals subclinical cardiac dysfunction in young adult survivors of childhood" exact="acute lymphoblastic leukemia" post="Pediatric Blood and Cancer 2007 49 6 835 840"/>
   <result pre="subclinical cardiac dysfunction in young adult survivors of childhood acute" exact="lymphoblastic leukemia" post="Pediatric Blood and Cancer 2007 49 6 835 840"/>
   <result pre="cardiac dysfunction in young adult survivors of childhood acute lymphoblastic" exact="leukemia" post="Pediatric Blood and Cancer 2007 49 6 835 840"/>
   <result pre="N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced" exact="cardiomyopathy" post="with iodine-125-metaiodobenzylguanidine Journal of Nuclear Medicine 1992 33 2"/>
   <result pre="T. M. Behe M. Wormann B. et al. Trastuzumab and" exact="breast cancer" post="The New England Journal of Medicine 2001 345 995"/>
   <result pre="M. Behe M. Wormann B. et al. Trastuzumab and breast" exact="cancer" post="The New England Journal of Medicine 2001 345 995"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="Journal of Clinical Oncology 2006 24 15 2276 2282"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="Journal of Clinical Oncology 2006 24 15 2276 2282"/>
   <result pre="Prognostic value of troponin I in cardiac risk stratification of" exact="cancer" post="patients undergoing high-dose chemotherapy Circulation 2004 109 22 2749"/>
   <result pre="increases in multiple biomarkers predict subsequent cardiotoxicity in patients with" exact="breast cancer" post="treated with doxorubicin, taxanes, and trastuzumab Journal of the"/>
   <result pre="in multiple biomarkers predict subsequent cardiotoxicity in patients with breast" exact="cancer" post="treated with doxorubicin, taxanes, and trastuzumab Journal of the"/>
   <result pre="et al. Chronic health conditions in adult survivors of childhood" exact="cancer" post="The New England Journal of Medicine 2006 355 15"/>
   <result pre="L. Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced" exact="cardiomyopathy" post="American Journal of Cardiology 2010 105 4 522 526"/>
   <result pre="Witteles R. M. Left ventricular dysfunction in patients receiving cardiotoxic" exact="cancer" post="therapies: are clinicians responding optimally? Journal of the American"/>
   <result pre="prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early" exact="breast cancer" post="using cardiac MRI BMC Cancer 2011 11, article 318"/>
   <result pre="trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast" exact="cancer" post="using cardiac MRI BMC Cancer 2011 11, article 318"/>
   <result pre="N. Dickinson H. O. Kremer L. C. Cardioprotective interventions for" exact="cancer" post="patients receiving anthracyclines Cochrane Database of Systematic Reviews 2011"/>
   <result pre="et al. Efficiency of atorvastatin in the protection of anthracycline-induced" exact="cardiomyopathy" post="Journal of the American College of Cardiology 2011 58"/>
   <result pre="on the risk for incident heart failure in patients with" exact="breast cancer" post="receiving anthracycline chemotherapy: an observational clinical cohort study Journal"/>
   <result pre="the risk for incident heart failure in patients with breast" exact="cancer" post="receiving anthracycline chemotherapy: an observational clinical cohort study Journal"/>
   <result pre="T. H. Cardioprotective effect of β-adrenoceptor blockade in patients with" exact="breast cancer" post="undergoing chemotherapy: follow-up study of heart failure Circulation: Heart"/>
   <result pre="H. Cardioprotective effect of β-adrenoceptor blockade in patients with breast" exact="cancer" post="undergoing chemotherapy: follow-up study of heart failure Circulation: Heart"/>
   <result pre="Ozdogru I. et al. Protective effects of carvedilol against anthracycline-induced" exact="cardiomyopathy" post="Journal of the American College of Cardiology 2006 48"/>
   <result pre="of β-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin" exact="cardiomyopathy" post="Journal of Molecular and Cellular Cardiology 2006 40 3"/>
   <result pre="21756913 155 Fonarow G. C. Role of carvedilol controlled-release in" exact="cardiovascular disease" post="Expert Review of Cardiovascular Therapy 2009 7 5 483"/>
   <result pre="Xi L. Kukreja R. C. PDE5 inhibitors as therapeutics for" exact="heart disease," post="diabetes and cancer Pharmacology &amp;amp; Therapeutics 2015 147 12"/>
   <result pre="C. PDE5 inhibitors as therapeutics for heart disease, diabetes and" exact="cancer" post="Pharmacology &amp;amp; Therapeutics 2015 147 12 21 10.1016/j.pharmthera.2014.10.003 25444755"/>
   <result pre="growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic" exact="cardiomyopathy" post="in mice PLoS ONE 2012 7 8 10.1371/journal.pone.0042805 168"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648606/results/search/disease/results.xml">
   <result pre="the clinical outcome of human epidermal growth factor 2-positive metastatic" exact="breast cancer" post="patients receiving trastuzumab therapy: a multicenter retrospective study Wang"/>
   <result pre="clinical outcome of human epidermal growth factor 2-positive metastatic breast" exact="cancer" post="patients receiving trastuzumab therapy: a multicenter retrospective study Wang"/>
   <result pre="receptor 2 (HER2), dramatically improves the clinical outcomes of HER2-positive" exact="breast cancer." post="Emerging evidence implied that the clinical behavior and sensitivity"/>
   <result pre="the clinical behavior and sensitivity to targeted agents in HER2-positive" exact="breast cancer" post="differed by hormone receptor (HR) status. The objective of"/>
   <result pre="clinical behavior and sensitivity to targeted agents in HER2-positive breast" exact="cancer" post="differed by hormone receptor (HR) status. The objective of"/>
   <result pre="of the HR status on survival benefit of HER2-positive metastatic" exact="breast cancer" post="when treated with anti-HER2-targeted therapy in People’s Republic of"/>
   <result pre="the HR status on survival benefit of HER2-positive metastatic breast" exact="cancer" post="when treated with anti-HER2-targeted therapy in People’s Republic of"/>
   <result pre="with anti-HER2-targeted therapy in People’s Republic of China. Methods Metastatic" exact="breast cancer" post="patients with HER2-positive diseases across six cancer centers in"/>
   <result pre="anti-HER2-targeted therapy in People’s Republic of China. Methods Metastatic breast" exact="cancer" post="patients with HER2-positive diseases across six cancer centers in"/>
   <result pre="Methods Metastatic breast cancer patients with HER2-positive diseases across six" exact="cancer" post="centers in People’s Republic of China were retrospectively analyzed"/>
   <result pre="is an independent predictor of overall survival in HER2-positive metastatic" exact="breast cancer" post="patients and patients with HER2+/HR− subtype might be associated"/>
   <result pre="an independent predictor of overall survival in HER2-positive metastatic breast" exact="cancer" post="patients and patients with HER2+/HR− subtype might be associated"/>
   <result pre="survival benefits when treated with trastuzumab-based regimens. Keywords HER2-positive metastatic" exact="breast cancer" post="hormone receptor status Background Human epidermal growth factor receptor"/>
   <result pre="benefits when treated with trastuzumab-based regimens. Keywords HER2-positive metastatic breast" exact="cancer" post="hormone receptor status Background Human epidermal growth factor receptor"/>
   <result pre="that binds HER2, dramatically improves the clinical outcomes of HER2-positive" exact="breast cancer." post="6– 11 Patients with HER2-positive breast cancer are more"/>
   <result pre="outcomes of HER2-positive breast cancer. 6– 11 Patients with HER2-positive" exact="breast cancer" post="are more likely to develop metastases compared with HER2-negative"/>
   <result pre="of HER2-positive breast cancer. 6– 11 Patients with HER2-positive breast" exact="cancer" post="are more likely to develop metastases compared with HER2-negative"/>
   <result pre="cancer are more likely to develop metastases compared with HER2-negative" exact="breast cancer" post="patients, and anti-HER2 agents such as trastuzumab in combination"/>
   <result pre="are more likely to develop metastases compared with HER2-negative breast" exact="cancer" post="patients, and anti-HER2 agents such as trastuzumab in combination"/>
   <result pre="settings also indicate that HR-positive and HR-negative tumors among HER2-positive" exact="breast cancer" post="patients exhibit different response rates to treatment 20 and"/>
   <result pre="also indicate that HR-positive and HR-negative tumors among HER2-positive breast" exact="cancer" post="patients exhibit different response rates to treatment 20 and"/>
   <result pre="affected trastuzumab responses and survival in patients with HER2-positive metastatic" exact="breast cancer" post="(MBC). 25 Assessment of HR status helps to direct"/>
   <result pre="trastuzumab responses and survival in patients with HER2-positive metastatic breast" exact="cancer" post="(MBC). 25 Assessment of HR status helps to direct"/>
   <result pre="25 Assessment of HR status helps to direct therapy for" exact="breast cancer" post="patients. Before the HR testing guidelines were published, the"/>
   <result pre="Assessment of HR status helps to direct therapy for breast" exact="cancer" post="patients. Before the HR testing guidelines were published, the"/>
   <result pre="its effect on outcomes of patients with MBC across multiple" exact="cancer" post="centers in People’s Republic of China. Patients and methods"/>
   <result pre="and methods Patients This retrospective study was conducted at six" exact="cancer" post="centers across People’s Republic of China, which included Beijing"/>
   <result pre="of trastuzumab and chemotherapy gained different clinical outcomes in HER2-positive" exact="breast cancer" post="according to HR status, and the pCR rates were"/>
   <result pre="trastuzumab and chemotherapy gained different clinical outcomes in HER2-positive breast" exact="cancer" post="according to HR status, and the pCR rates were"/>
   <result pre="39 These results suggest that the treatment strategy for HER2-positive" exact="breast cancer" post="may be stratified by HR status. Contrary to the"/>
   <result pre="These results suggest that the treatment strategy for HER2-positive breast" exact="cancer" post="may be stratified by HR status. Contrary to the"/>
   <result pre="stratified by HR status. Contrary to the situation in early" exact="breast cancer," post="data on the influence of HR status on trastuzumab"/>
   <result pre="of HR status on trastuzumab treatment benefits in advanced HER2-positive" exact="breast cancer" post="are limited. In our study, we evaluated the impact"/>
   <result pre="HR status on trastuzumab treatment benefits in advanced HER2-positive breast" exact="cancer" post="are limited. In our study, we evaluated the impact"/>
   <result pre="partly support the clinical benefits of trastuzumab therapy in HER2+/HR−" exact="breast cancer" post="patients and imply that dual inhibition of both HER2"/>
   <result pre="support the clinical benefits of trastuzumab therapy in HER2+/HR− breast" exact="cancer" post="patients and imply that dual inhibition of both HER2"/>
   <result pre="of both HER2 and ER achieves better responsiveness in HER2+/HR+" exact="breast cancer" post="patients. The systematic treatment of HER2-positive patients enrolled in"/>
   <result pre="both HER2 and ER achieves better responsiveness in HER2+/HR+ breast" exact="cancer" post="patients. The systematic treatment of HER2-positive patients enrolled in"/>
   <result pre="People’s Republic of China, a significant percentage of the HER2-positive" exact="breast cancer" post="patients do not receive trastuzumab therapy because of drug"/>
   <result pre="Republic of China, a significant percentage of the HER2-positive breast" exact="cancer" post="patients do not receive trastuzumab therapy because of drug"/>
   <result pre="53 On the other hand, the patients with metastatic HER2+/HR−" exact="breast cancer" post="should be more strongly recommended to consider trastuzumab-based therapy"/>
   <result pre="On the other hand, the patients with metastatic HER2+/HR− breast" exact="cancer" post="should be more strongly recommended to consider trastuzumab-based therapy"/>
   <result pre="2 Qin T Yuan Z Peng R et al. HER2-positive" exact="breast cancer" post="receiving trastuzumab treatment obtain prognosis comparable with that of"/>
   <result pre="Qin T Yuan Z Peng R et al. HER2-positive breast" exact="cancer" post="receiving trastuzumab treatment obtain prognosis comparable with that of"/>
   <result pre="receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative" exact="breast cancer" post="patients Onco Targets Ther 2013 6 341 347 23630425"/>
   <result pre="trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast" exact="cancer" post="patients Onco Targets Ther 2013 6 341 347 23630425"/>
   <result pre="4 Brufsky AM Current approaches and emerging directions in HER2-resistant" exact="breast cancer" post="Breast Cancer (Auckl) 2014 8 109 118 25125981 5"/>
   <result pre="Brufsky AM Current approaches and emerging directions in HER2-resistant breast" exact="cancer" post="Breast Cancer (Auckl) 2014 8 109 118 25125981 5"/>
   <result pre="S Mu Y Lu J Targeted therapy for HER2 positive" exact="breast cancer" post="J Hematol Oncol 2013 6 38 23731980 7 Romond"/>
   <result pre="Mu Y Lu J Targeted therapy for HER2 positive breast" exact="cancer" post="J Hematol Oncol 2013 6 38 23731980 7 Romond"/>
   <result pre="J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1659 1672"/>
   <result pre="B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1659 1672"/>
   <result pre="Eiermann W Robert N et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="W Robert N et al. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="2 Years versus 1 year of adjuvant trastuzumab for HER2-positive" exact="breast cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="Years versus 1 year of adjuvant trastuzumab for HER2-positive breast" exact="cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="Saura C Bellet M et al. HER2 and hormone receptor-positive" exact="breast cancer" post="– blocking the right target Nat Rev Clin Oncol"/>
   <result pre="C Bellet M et al. HER2 and hormone receptor-positive breast" exact="cancer" post="– blocking the right target Nat Rev Clin Oncol"/>
   <result pre="Gallen International Expert Consensus on the primary therapy of early" exact="breast cancer" post="2009 Ann Oncol 2009 20 8 1319 1329 19535820"/>
   <result pre="International Expert Consensus on the primary therapy of early breast" exact="cancer" post="2009 Ann Oncol 2009 20 8 1319 1329 19535820"/>
   <result pre="between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary" exact="breast cancer" post="J Natl Cancer Inst 2003 95 18 142 153"/>
   <result pre="HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast" exact="cancer" post="J Natl Cancer Inst 2003 95 18 142 153"/>
   <result pre="19 10869 10874 11553815 18 Morrow M Personalizing extent of" exact="breast cancer" post="surgery according to molecular subtypes Breast 2013 22 Suppl"/>
   <result pre="10869 10874 11553815 18 Morrow M Personalizing extent of breast" exact="cancer" post="surgery according to molecular subtypes Breast 2013 22 Suppl"/>
   <result pre="19 Sihto H Lundin J Lundin M et al. Breast" exact="cancer" post="biological subtypes and protein expression predict for the preferential"/>
   <result pre="et al. Patterns of relapse and metastatic spread in HER2-overexpressing" exact="breast cancer" post="according to estrogen receptor status Cancer Chemother Pharmacol 2010"/>
   <result pre="al. Patterns of relapse and metastatic spread in HER2-overexpressing breast" exact="cancer" post="according to estrogen receptor status Cancer Chemother Pharmacol 2010"/>
   <result pre="Effect of HER2 status on distant recurrence in early stage" exact="breast cancer" post="Breast Cancer Res Treat 2013 137 2 449 455"/>
   <result pre="of HER2 status on distant recurrence in early stage breast" exact="cancer" post="Breast Cancer Res Treat 2013 137 2 449 455"/>
   <result pre="different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive" exact="breast cancer" post="Breast Cancer Res Treat 2014 145 3 615 623"/>
   <result pre="diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast" exact="cancer" post="Breast Cancer Res Treat 2014 145 3 615 623"/>
   <result pre="affects trastuzumab responses and survival in patients with HER2-positive metastatic" exact="breast cancer" post="Am J Clin Pathol 2014 142 6 755 766"/>
   <result pre="trastuzumab responses and survival in patients with HER2-positive metastatic breast" exact="cancer" post="Am J Clin Pathol 2014 142 6 755 766"/>
   <result pre="Task Force Report: estrogen receptor and progesterone receptor testing in" exact="breast cancer" post="by immunohistochemistry J Natl Compr Canc Netw 2009 7"/>
   <result pre="Force Report: estrogen receptor and progesterone receptor testing in breast" exact="cancer" post="by immunohistochemistry J Natl Compr Canc Netw 2009 7"/>
   <result pre="recommendations for immunohistochemical testing of estrogen and progesterone receptors in" exact="breast cancer" post="J Oncol Pract 2010 6 4 195 197 21037871"/>
   <result pre="for immunohistochemical testing of estrogen and progesterone receptors in breast" exact="cancer" post="J Oncol Pract 2010 6 4 195 197 21037871"/>
   <result pre="S et al. Systematic review on hormone receptor testing in" exact="breast cancer" post="Appl Immunohistochem Mol Morphol 2012 20 3 214 263"/>
   <result pre="et al. Systematic review on hormone receptor testing in breast" exact="cancer" post="Appl Immunohistochem Mol Morphol 2012 20 3 214 263"/>
   <result pre="recommendations for human epidermal growth factor receptor 2 testing in" exact="breast cancer" post="J Clin Oncol 2007 25 1 118 145 17159189"/>
   <result pre="for human epidermal growth factor receptor 2 testing in breast" exact="cancer" post="J Clin Oncol 2007 25 1 118 145 17159189"/>
   <result pre="Joint Committee on Cancer: the 7th edition of the AJCC" exact="cancer" post="staging manual and the future of TNM Ann Surg"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomized multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomized multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="H et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="predictor identifies higher responses and improved survival outcomes in HER2-positive" exact="breast cancer" post="in the NOAH study Clin Cancer Res 2014 20"/>
   <result pre="identifies higher responses and improved survival outcomes in HER2-positive breast" exact="cancer" post="in the NOAH study Clin Cancer Res 2014 20"/>
   <result pre="FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive" exact="breast cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast" exact="cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="et al. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing" exact="breast cancer" post="according to hormonal receptor status Breast 2014 23 4"/>
   <result pre="al. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast" exact="cancer" post="according to hormonal receptor status Breast 2014 23 4"/>
   <result pre="expression and activity of trastuzumab with chemotherapy in HER2-positive advanced" exact="breast cancer" post="patients Cancer 2012 118 1 17 26 21598238 40"/>
   <result pre="and activity of trastuzumab with chemotherapy in HER2-positive advanced breast" exact="cancer" post="patients Cancer 2012 118 1 17 26 21598238 40"/>
   <result pre="al. Distinct distribution and prognostic significance of molecular subtypes of" exact="breast cancer" post="in Chinese women: a population-based cohort study BMC Cancer"/>
   <result pre="Distinct distribution and prognostic significance of molecular subtypes of breast" exact="cancer" post="in Chinese women: a population-based cohort study BMC Cancer"/>
   <result pre="the clinical benefit of trastuzumab therapy for patients with metastatic" exact="breast cancer" post="Clin Breast Cancer 2005 6 3 247 252 16137436"/>
   <result pre="clinical benefit of trastuzumab therapy for patients with metastatic breast" exact="cancer" post="Clin Breast Cancer 2005 6 3 247 252 16137436"/>
   <result pre="et al. Growth factor receptor/steroid receptor cross talk in trastuzumab-treated" exact="breast cancer" post="Oncogene 2015 34 4 525 530 24469058 46 Takada"/>
   <result pre="al. Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast" exact="cancer" post="Oncogene 2015 34 4 525 530 24469058 46 Takada"/>
   <result pre="in human epidermal growth factor receptor 2-positive and hormone receptor-positive" exact="breast cancer" post="patients treated with trastuzumab containing neoadjuvant chemotherapy BMC Cancer"/>
   <result pre="human epidermal growth factor receptor 2-positive and hormone receptor-positive breast" exact="cancer" post="patients treated with trastuzumab containing neoadjuvant chemotherapy BMC Cancer"/>
   <result pre="MJ van Slooten HJ et al. Receptor conversion in distant" exact="breast cancer" post="metastases Breast Cancer Res 2010 12 5 R75 20863372"/>
   <result pre="van Slooten HJ et al. Receptor conversion in distant breast" exact="cancer" post="metastases Breast Cancer Res 2010 12 5 R75 20863372"/>
   <result pre="epidermal growth factor receptor 2 and hormone receptor expression in" exact="breast cancer" post="metastases to the brain Breast Cancer Res 2012 14"/>
   <result pre="growth factor receptor 2 and hormone receptor expression in breast" exact="cancer" post="metastases to the brain Breast Cancer Res 2012 14"/>
   <result pre="impact of tissue confirmation of metastatic disease in patients with" exact="breast cancer" post="J Clin Oncol 2012 30 6 587 592 22124102"/>
   <result pre="of tissue confirmation of metastatic disease in patients with breast" exact="cancer" post="J Clin Oncol 2012 30 6 587 592 22124102"/>
   <result pre="L et al. ESO-ESMO 2nd international consensus guidelines for advanced" exact="breast cancer" post="(ABC2) Breast 2014 23 5 489 502 25244983 52"/>
   <result pre="et al. ESO-ESMO 2nd international consensus guidelines for advanced breast" exact="cancer" post="(ABC2) Breast 2014 23 5 489 502 25244983 52"/>
   <result pre="Purdie CA et al. Tissue confirmation of disease recurrence in" exact="breast cancer" post="patients: pooled analysis of multi-center, multi-disciplinary prospective studies Cancer"/>
   <result pre="CA et al. Tissue confirmation of disease recurrence in breast" exact="cancer" post="patients: pooled analysis of multi-center, multi-disciplinary prospective studies Cancer"/>
   <result pre="CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive" exact="breast cancer" post="N Engl J Med 2015 372 2 134 141"/>
   <result pre="et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast" exact="cancer" post="N Engl J Med 2015 372 2 134 141"/>
   <result pre="HER, human epidermal growth receptor; HR, hormone receptor; MBC, metastatic" exact="breast cancer;" post="T, trastuzumab. Figure 2 Median overall survival (OS) regarding"/>
   <result pre="IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MBC, metastatic" exact="breast cancer;" post="TNM, tumor-node-metastasis. Table 3 Multivariate analysis of prognostic factors"/>
   <result pre="epidermal growth factor receptor 2; HR, hormone receptor; MBC, metastatic" exact="breast cancer;" post="OS, overall survival; TNM, tumor-node-metastasis. Table 4 Multivariate analysis"/>
   <result pre="epidermal growth factor receptor 2; HR, hormone receptor; MBC, metastatic" exact="breast cancer;" post="OS, overall survival; TNM, tumor-node-metastasis. Table 5 Multivariate analysis"/>
   <result pre="hormone receptor; HER2, human epidermal growth factor 2; MBC, metastatic" exact="breast cancer;" post="PFS, progression-free survival. Table 6 Multivariate analysis of prognostic"/>
   <result pre="hormone receptor; HER2, human epidermal growth factor 2; MBC, metastatic" exact="breast cancer;" post="PFS, progression-free survival."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648969/results/search/disease/results.xml">
   <result pre="of lapatinib in combination with gemcitabine in patients with advanced" exact="breast cancer" post="van der Noll R. Smit W. M. Wymenga A."/>
   <result pre="lapatinib in combination with gemcitabine in patients with advanced breast" exact="cancer" post="van der Noll R. Smit W. M. Wymenga A."/>
   <result pre="monotherapy and in combination with capecitabine in patients with metastatic" exact="breast cancer" post="(MBC) overexpressing HER2 and/or EGFR. Gemcitabine also has anti-tumor"/>
   <result pre="and in combination with capecitabine in patients with metastatic breast" exact="cancer" post="(MBC) overexpressing HER2 and/or EGFR. Gemcitabine also has anti-tumor"/>
   <result pre="Most common toxicities were fatigue (73 %), nausea (70 %)," exact="diarrhea" post="(58 %), increases in ALAT and ASAT (55 and"/>
   <result pre="in ALAT and ASAT (55 and 52 %, respectively) and" exact="rash" post="(46 %). The maximum tolerated dose was lapatinib 1250"/>
   <result pre="while showing signs of anti-tumor activity. Keywords Lapatinib Gemcitabine Advanced" exact="breast cancer" post="Phase I trial Introduction Globally, breast cancer is the"/>
   <result pre="showing signs of anti-tumor activity. Keywords Lapatinib Gemcitabine Advanced breast" exact="cancer" post="Phase I trial Introduction Globally, breast cancer is the"/>
   <result pre="Lapatinib Gemcitabine Advanced breast cancer Phase I trial Introduction Globally," exact="breast cancer" post="is the most frequently diagnosed cancer and the leading"/>
   <result pre="Gemcitabine Advanced breast cancer Phase I trial Introduction Globally, breast" exact="cancer" post="is the most frequently diagnosed cancer and the leading"/>
   <result pre="trial Introduction Globally, breast cancer is the most frequently diagnosed" exact="cancer" post="and the leading cause of cancer death in both"/>
   <result pre="the most frequently diagnosed cancer and the leading cause of" exact="cancer" post="death in both economically developed and developing countries. It"/>
   <result pre="and developing countries. It accounts for 23 % of new" exact="cancer" post="cases and 14 % of cancer deaths worldwide (data"/>
   <result pre="23 % of new cancer cases and 14 % of" exact="cancer" post="deaths worldwide (data from 2008) [ 1]. In the"/>
   <result pre="improve survival in the adjuvant setting in patients with HER2-overexpressing" exact="breast cancer" post="[ 7]. Unfortunately, the majority of the patients treated"/>
   <result pre="survival in the adjuvant setting in patients with HER2-overexpressing breast" exact="cancer" post="[ 7]. Unfortunately, the majority of the patients treated"/>
   <result pre="relatively mild toxicity profile with main adverse events consisting of" exact="diarrhea" post="and rash [ 10– 12]. Importantly, it has shown"/>
   <result pre="toxicity profile with main adverse events consisting of diarrhea and" exact="rash" post="[ 10– 12]. Importantly, it has shown anti-tumor activity"/>
   <result pre="lapatinib in combination with capecitabine for previously treated, metastatic, HER2-overexpressing" exact="breast cancer" post="[ 14, 15]. Toxicities observed with this combination in"/>
   <result pre="in combination with capecitabine for previously treated, metastatic, HER2-overexpressing breast" exact="cancer" post="[ 14, 15]. Toxicities observed with this combination in"/>
   <result pre="in the phase III and registration study only showed increased" exact="diarrhea" post="and rash when compared to capecitabine alone, as was"/>
   <result pre="phase III and registration study only showed increased diarrhea and" exact="rash" post="when compared to capecitabine alone, as was expected ["/>
   <result pre="first approval for gemcitabine was as a treatment modality for" exact="pancreatic cancer" post="[ 18– 20]. Due to its favourable toxicity profile,"/>
   <result pre="approval for gemcitabine was as a treatment modality for pancreatic" exact="cancer" post="[ 18– 20]. Due to its favourable toxicity profile,"/>
   <result pre="instance led to its use in patients with non-small cell" exact="lung cancer" post="(NSCLC) and bladder cancer in combination with cisplatin ["/>
   <result pre="led to its use in patients with non-small cell lung" exact="cancer" post="(NSCLC) and bladder cancer in combination with cisplatin ["/>
   <result pre="use in patients with non-small cell lung cancer (NSCLC) and" exact="bladder cancer" post="in combination with cisplatin [ 21, 22]. Since gemcitabine"/>
   <result pre="in patients with non-small cell lung cancer (NSCLC) and bladder" exact="cancer" post="in combination with cisplatin [ 21, 22]. Since gemcitabine"/>
   <result pre="22]. Since gemcitabine has shown activity in patients with metastatic" exact="breast cancer" post="[ 23, 24], this study intended to investigate whether"/>
   <result pre="Since gemcitabine has shown activity in patients with metastatic breast" exact="cancer" post="[ 23, 24], this study intended to investigate whether"/>
   <result pre="could be a feasible treatment option for women with advanced" exact="breast cancer." post="In order to explore the anti-tumor activity of this"/>
   <result pre="Enschede, the Netherlands. It was conducted in women with advanced" exact="breast cancer" post="who had previously been treated with an anthracycline and"/>
   <result pre="the Netherlands. It was conducted in women with advanced breast" exact="cancer" post="who had previously been treated with an anthracycline and"/>
   <result pre="(left ventricular ejection fraction (LVEF) of ≤ 50 %) or unstable ischemic" exact="heart disease" post="including a myocardial infarction (&amp;lt;3 months of study entry)"/>
   <result pre="the first cycle: grade ≥ 3 non-hematological toxicities; grade ≥ 3 nausea, vomiting or" exact="diarrhea" post="in the presence of maximal support; grade 4 thrombocytopenia;"/>
   <result pre="the presence of maximal support; grade 4 thrombocytopenia; grade 4" exact="neutropenia" post="for &amp;gt; 7 consecutive days; or grade 3 febrile neutropenia. The"/>
   <result pre="Tumors (RECIST) version 1.0 [ 29]. Furthermore, the tumor markers" exact="cancer" post="antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) were measured"/>
   <result pre="Results Patient characteristics In total, 33 female patients with advanced" exact="breast cancer" post="were included in this study, between November 2007 and"/>
   <result pre="Patient characteristics In total, 33 female patients with advanced breast" exact="cancer" post="were included in this study, between November 2007 and"/>
   <result pre="110 (11–770) Patient characteristics. LVEF left ventricular ejection fraction, CA" exact="cancer" post="antigen Four patients had to be replaced per protocol"/>
   <result pre="lapatinib with 250 mg. Additionally, one DLT of grade 3" exact="diarrhea" post="was observed at the highest dose-level explored, despite maximal"/>
   <result pre="or definitely TRAEs were fatigue (73 %), nausea (70 %)," exact="diarrhea" post="(58 %), increases in ALAT and ASAT (55 and"/>
   <result pre="increases in ALAT and ASAT (55 and 52 %, respectively)," exact="rash" post="(46 %) and neutropenia (39 %). Adverse events that"/>
   <result pre="ASAT (55 and 52 %, respectively), rash (46 %) and" exact="neutropenia" post="(39 %). Adverse events that were grade 3 or"/>
   <result pre="events that were grade 3 or higher mostly consisted of" exact="neutropenia" post="(39 %), elevated ALAT and ASAT (18 and 15"/>
   <result pre="elevated ALAT and ASAT (18 and 15 %, respectively) and" exact="diarrhea" post="(9 %). Interrupting lapatinib dosing and omitting gemcitabine infusion"/>
   <result pre="to recovery of hematological and biochemical laboratory values. Nausea and" exact="diarrhea" post="were mostly mild (grade 1–2), but in some cases"/>
   <result pre="study drug, except for the patient who experienced grade 3" exact="diarrhea" post="despite maximal support with loperamide and ciprofloxacin. This patient"/>
   <result pre="persisting toxicity. The most common adverse events seen with lapatinib," exact="diarrhea" post="and rash (42 and 31 %, respectively, in the"/>
   <result pre="The most common adverse events seen with lapatinib, diarrhea and" exact="rash" post="(42 and 31 %, respectively, in the lapatinib monotherapy"/>
   <result pre="increased frequency (58 and 46 %, respectively). In all cases," exact="rash" post="was mild (grade 1–2) and appeared to respond to"/>
   <result pre="and appeared to respond to local or systemic treatment. The" exact="diarrhea" post="was also mostly mild and manageable with concomitant treatment"/>
   <result pre="concomitant treatment of loperamide. Hematological and biochemical toxicities, such as" exact="neutropenia" post="and elevated ALAT and ASAT, were also increased in"/>
   <result pre="mg/m 2 respectively, with only 1 DLT of grade 3" exact="diarrhea" post="[ 32]. A subsequent phase II study of lapatinib/gemcitabine"/>
   <result pre="II study of lapatinib/gemcitabine was performed in patients with metastatic" exact="pancreatic cancer." post="Toxicities were mostly hematologic (30 % experienced grade 3"/>
   <result pre="investigate whether these drugs showed synergistic or antagonistic effects in" exact="pancreatic cancer" post="cell lines. There was no clear effect observed and"/>
   <result pre="whether these drugs showed synergistic or antagonistic effects in pancreatic" exact="cancer" post="cell lines. There was no clear effect observed and"/>
   <result pre="lapatinib may not enhance the anti-tumor effects of gemcitabine in" exact="pancreatic cancer" post="[ 34]. In contrast and consistent with our study,"/>
   <result pre="may not enhance the anti-tumor effects of gemcitabine in pancreatic" exact="cancer" post="[ 34]. In contrast and consistent with our study,"/>
   <result pre="in a case report of a female with metastatic, HER2-overexpressing" exact="breast cancer" post="who developed a complete clinical response for 1 year"/>
   <result pre="a case report of a female with metastatic, HER2-overexpressing breast" exact="cancer" post="who developed a complete clinical response for 1 year"/>
   <result pre="to be a safe treatment regimen for patients with advanced" exact="breast cancer," post="while showing preliminary signs of anti-tumor activity. Combining these"/>
   <result pre="F, Center MM, Ferlay J, Ward E, Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 69 90"/>
   <result pre="its signaling and transforming functions and its role in human" exact="cancer" post="pathogenesis Oncogene 2007 26 6469 6487 10.1038/sj.onc.1210477 17471238 5."/>
   <result pre="monoclonal antibody, a novel agent for the treatment of metastatic" exact="breast cancer" post="Clin Ther 1999 21 309 318 10.1016/S0149-2918(00)88288-0 10211534 6."/>
   <result pre="antibody, a novel agent for the treatment of metastatic breast" exact="cancer" post="Clin Ther 1999 21 309 318 10.1016/S0149-2918(00)88288-0 10211534 6."/>
   <result pre="Martin M Press M et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 1273 1283 10.1056/NEJMoa0910383"/>
   <result pre="M Press M et al. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 1273 1283 10.1056/NEJMoa0910383"/>
   <result pre="Leary A Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for" exact="cancer" post="Drugs Today 2006 42 441 453 10.1358/dot.2006.42.7.985637 16894399 10."/>
   <result pre="lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic" exact="breast cancer" post="Ann Oncol 2008 19 1068 1074 10.1093/annonc/mdm601 18283035 12."/>
   <result pre="monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast" exact="cancer" post="Ann Oncol 2008 19 1068 1074 10.1093/annonc/mdm601 18283035 12."/>
   <result pre="JD et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic" exact="breast cancer" post="that progressed on first- or second-line trastuzumab-containing regimens Ann"/>
   <result pre="et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast" exact="cancer" post="that progressed on first- or second-line trastuzumab-containing regimens Ann"/>
   <result pre="summary: lapatinib in combination with capecitabine for previously treated metastatic" exact="breast cancer" post="that overexpresses HER-2 Oncologist 2008 13 1114 1119 10.1634/theoncologist.2008-0816"/>
   <result pre="lapatinib in combination with capecitabine for previously treated metastatic breast" exact="cancer" post="that overexpresses HER-2 Oncologist 2008 13 1114 1119 10.1634/theoncologist.2008-0816"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell" exact="lung cancer" post="J Clin Oncol 1999 17 12 18 10458212 22."/>
   <result pre="in the treatment of locally advanced or metastatic non-small-cell lung" exact="cancer" post="J Clin Oncol 1999 17 12 18 10458212 22."/>
   <result pre="cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with" exact="bladder cancer" post="J Clin Oncol 2005 23 4602 4608 10.1200/JCO.2005.07.757 16034041"/>
   <result pre="with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder" exact="cancer" post="J Clin Oncol 2005 23 4602 4608 10.1200/JCO.2005.07.757 16034041"/>
   <result pre="al. Single-agent gemcitabine as second- and third-line treatment in metastatic" exact="breast cancer" post="Breast 2000 9 338 342 10.1054/brst.2000.0170 14965758 24. Blackstein"/>
   <result pre="Single-agent gemcitabine as second- and third-line treatment in metastatic breast" exact="cancer" post="Breast 2000 9 338 342 10.1054/brst.2000.0170 14965758 24. Blackstein"/>
   <result pre="of a comprehensive grading system for the adverse effects of" exact="cancer" post="treatment Semin Radiat Oncol 2003 13 176 181 10.1016/S1053-4296(03)00031-6"/>
   <result pre="and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell" exact="lung cancer" post="J Clin Oncol 1999 17 2190 2197 10561275 32."/>
   <result pre="paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung" exact="cancer" post="J Clin Oncol 1999 17 2190 2197 10561275 32."/>
   <result pre="Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary" exact="cancer" post="Am J Clin Oncol 2008 31 140 144 10.1097/COC.0b013e318145b9a5"/>
   <result pre="CD Sun W et al. Lapatinib and gemcitabine for metastatic" exact="pancreatic cancer" post="Am J Clin Oncol 2011 34 50 52 10.1097/COC.0b013e3181d26b01"/>
   <result pre="Sun W et al. Lapatinib and gemcitabine for metastatic pancreatic" exact="cancer" post="Am J Clin Oncol 2011 34 50 52 10.1097/COC.0b013e3181d26b01"/>
   <result pre="et al. In vitro effects of lapatinib with gemcitabine for" exact="pancreatic cancer" post="cells Hepatogastroenterology 2013 60 1484 1487 23933942 35. Gasent"/>
   <result pre="al. In vitro effects of lapatinib with gemcitabine for pancreatic" exact="cancer" post="cells Hepatogastroenterology 2013 60 1484 1487 23933942 35. Gasent"/>
   <result pre="VA One year of complete clinical response in a metastatic" exact="breast cancer" post="patient treated with a combination of lapatinib and gemcitabine"/>
   <result pre="One year of complete clinical response in a metastatic breast" exact="cancer" post="patient treated with a combination of lapatinib and gemcitabine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650737/results/search/disease/results.xml">
   <result pre="26181203 : Original Article miR-205-5p-mediated downregulation of ErbB/HER receptors in" exact="breast cancer" post="stem cells results in targeted therapy resistance miR-205-5p targets"/>
   <result pre=": Original Article miR-205-5p-mediated downregulation of ErbB/HER receptors in breast" exact="cancer" post="stem cells results in targeted therapy resistance miR-205-5p targets"/>
   <result pre="results in targeted therapy resistance miR-205-5p targets ERBB receptors in" exact="breast cancer" post="stem cells De Cola A 1 Volpe S 2"/>
   <result pre="in targeted therapy resistance miR-205-5p targets ERBB receptors in breast" exact="cancer" post="stem cells De Cola A 1 Volpe S 2"/>
   <result pre="tumors. Various drugs targeting these receptors have been approved for" exact="cancer" post="treatment. Particularly, in breast cancer, anti-Her2/EGFR molecules represent the"/>
   <result pre="these receptors have been approved for cancer treatment. Particularly, in" exact="breast cancer," post="anti-Her2/EGFR molecules represent the standard therapy for Her2-positive malignancies."/>
   <result pre="the tumor relapses or progresses thus suggesting that not all" exact="cancer" post="cells have been targeted. One possibility is that a"/>
   <result pre="subset of cells capable of regenerating the tumor, such as" exact="cancer" post="stem cells (CSCs), may not respond to these therapeutic"/>
   <result pre="involved in the EGFR expression suggesting a miR-205/p63/EGFR regulation. Breast" exact="cancer" post="is the most frequent type of cancer in women"/>
   <result pre="miR-205/p63/EGFR regulation. Breast cancer is the most frequent type of" exact="cancer" post="in women and despite the great improvement in diagnosis"/>
   <result pre="site, 2010). Recent studies have provided strong support for the" exact="cancer" post="stem cell (CSC) hypothesis which holds that breast cancers"/>
   <result pre="relapse. It is therefore possible that relapses observed in ErbB2-positive" exact="breast cancer" post="patients receiving adjuvant Trastuzumab (humanized antibody anti-Her2-Herceptin) or Lapatinib"/>
   <result pre="It is therefore possible that relapses observed in ErbB2-positive breast" exact="cancer" post="patients receiving adjuvant Trastuzumab (humanized antibody anti-Her2-Herceptin) or Lapatinib"/>
   <result pre="target mRNAs. 7, 8 MiRNA deregulation is widely described in" exact="cancer" post="and has an important role in tumorigenesis. 9, 10"/>
   <result pre="12 It has been shown that miR-205-5p is downregulated in" exact="breast cancer" post="and can specifically suppress ErbB3 expression. 13 Moreover, miR-205-5p"/>
   <result pre="It has been shown that miR-205-5p is downregulated in breast" exact="cancer" post="and can specifically suppress ErbB3 expression. 13 Moreover, miR-205-5p"/>
   <result pre="of the p63/miR-205 axis enhances cell migration and metastasis in" exact="prostate cancer" post="cells. 19 The TP63 gene contains two promoters that"/>
   <result pre="the p63/miR-205 axis enhances cell migration and metastasis in prostate" exact="cancer" post="cells. 19 The TP63 gene contains two promoters that"/>
   <result pre="have a role in both normal mammary development and in" exact="breast cancer." post="MiR-205 has also been shown to be highly expressed"/>
   <result pre="( Figure 3d). Interestingly, p63 levels increase in more differentiated" exact="cancer" post="cells as compared with cells grown as spheroids in"/>
   <result pre="mis-regulation could be translated in maintaining the CSC phenotype. In" exact="breast cancer," post="miR-205-5p was found to be either up- or downregulated"/>
   <result pre="of these cells to agents such as Lapatinib used in" exact="breast cancer" post="therapy. Survival of these cells could then lead to"/>
   <result pre="these cells to agents such as Lapatinib used in breast" exact="cancer" post="therapy. Survival of these cells could then lead to"/>
   <result pre="an important target to improve outcome of patients with Her2-overexpressing" exact="breast cancer." post="In conclusion, we want to point out that we"/>
   <result pre="Methods BCSC isolation and culture BCSCs were isolated from human" exact="breast cancer" post="tissues obtained from patients as previously described 34 and"/>
   <result pre="BCSC isolation and culture BCSCs were isolated from human breast" exact="cancer" post="tissues obtained from patients as previously described 34 and"/>
   <result pre="of Research and University FIRB project RBAP11BYNP_002 to MN. BCSC" exact="breast cancer" post="stem cells CSC cancer stem cells HT hercept test"/>
   <result pre="Research and University FIRB project RBAP11BYNP_002 to MN. BCSC breast" exact="cancer" post="stem cells CSC cancer stem cells HT hercept test"/>
   <result pre="project RBAP11BYNP_002 to MN. BCSC breast cancer stem cells CSC" exact="cancer" post="stem cells HT hercept test SDAC sphere-derived adherent cells"/>
   <result pre="SG, Wicha MS. Role of microRNAs in the regulation of" exact="breast cancer" post="stem cells. J Mammary Gland Biol Neoplasia 2012; 17:"/>
   <result pre="Wicha MS. Role of microRNAs in the regulation of breast" exact="cancer" post="stem cells. J Mammary Gland Biol Neoplasia 2012; 17:"/>
   <result pre="Y-Y. Suppression of cell growth and invasion by miR-205 in" exact="breast cancer." post="Cell Res 2009; 19: 439–448. 19238171 14Gregory PA, Bert"/>
   <result pre="WO. miR-205 expression promotes cell proliferation and migration of human" exact="cervical cancer" post="cells . PLoS One 2012; 7: e46990. 23056551 17Gandellini"/>
   <result pre="miR-205 expression promotes cell proliferation and migration of human cervical" exact="cancer" post="cells . PLoS One 2012; 7: e46990. 23056551 17Gandellini"/>
   <result pre="The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human" exact="bladder cancer" post="cells: role of MIR-205 . J Biol Chem 2013;"/>
   <result pre="p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder" exact="cancer" post="cells: role of MIR-205 . J Biol Chem 2013;"/>
   <result pre="microRNA-205 target results in enhanced cell migration and metastasis in" exact="prostate cancer" post=". Proc Natl Acad Sci USA 2012; 109: 15312–15317."/>
   <result pre="target results in enhanced cell migration and metastasis in prostate" exact="cancer" post=". Proc Natl Acad Sci USA 2012; 109: 15312–15317."/>
   <result pre="22326462 21Graziano V, De Laurenzi V. Role of p63 in" exact="cancer" post="development. Biochim Biophys Acta 2011; 1816: 57–66. 21515338 22D'Aguanno"/>
   <result pre="D, Cortese C et al. P63 isoforms regulate metabolism of" exact="cancer" post="stem cells. J Proteome Res 2014; 13: 2120–2136. 24597989"/>
   <result pre="the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated" exact="breast cancer" post="cells . Cancer Res 2006; 66: 1630–1639. 16452222 24Lowery"/>
   <result pre="dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast" exact="cancer" post="cells . Cancer Res 2006; 66: 1630–1639. 16452222 24Lowery"/>
   <result pre="MicroRNAs as prognostic indicators and therapeutic targets: potential effect on" exact="breast cancer" post="management . Clin cancer Res 2008; 14: 360–365. 18223209"/>
   <result pre="as prognostic indicators and therapeutic targets: potential effect on breast" exact="cancer" post="management . Clin cancer Res 2008; 14: 360–365. 18223209"/>
   <result pre="therapeutic targets: potential effect on breast cancer management . Clin" exact="cancer" post="Res 2008; 14: 360–365. 18223209 25Wiemer EAC. The role"/>
   <result pre="Altered MicroRNA expression confined to specific epithelial cell subpopulations in" exact="breast cancer" post=". Cancer Res 2007; 67: 11612–11620. 18089790 28Ibarra I,"/>
   <result pre="MicroRNA expression confined to specific epithelial cell subpopulations in breast" exact="cancer" post=". Cancer Res 2007; 67: 11612–11620. 18089790 28Ibarra I,"/>
   <result pre="identifying th eroles of miR-205 in mammary gland development and" exact="breast cancer" post=". RNA Biol 2011; 7: 300–304. 30Danilov AV, Neupane"/>
   <result pre="th eroles of miR-205 in mammary gland development and breast" exact="cancer" post=". RNA Biol 2011; 7: 300–304. 30Danilov AV, Neupane"/>
   <result pre="et al. DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes" exact="pancreatic cancer" post="cell growth and chemoresistance . PLoS One 2011; 6:"/>
   <result pre="al. DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic" exact="cancer" post="cell growth and chemoresistance . PLoS One 2011; 6:"/>
   <result pre="A, Triulzi T et al. microRNA-205 regulates HER3 in human" exact="breast cancer." post="Cancer Res 2009; 69: 2195–2200. 19276373 33Wang D, Zhang"/>
   <result pre="AB, Cammareri P, Vermeulen L, Iovino F et al. Colon" exact="cancer" post="stem cells dictate tumor growth and resist cell death"/>
   <result pre="Ellisen LW. p63 mediates survival in squamous cell carcinoma by" exact="suppression" post="of p73-dependent apoptosis. Cancer Cell 2006; 9: 45–56. 16413471"/>
   <result pre="index, HER2 status, and prognosis of patients with luminal B" exact="breast cancer." post="J Natl Cancer Inst 2009; 101: 736–750. 19436038 Supplementary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650834/results/search/disease/results.xml">
   <result pre="HER2-targeted therapies on overall survival of patients with metastatic HER2-positive" exact="breast cancer" post="– a systematic review Mendes Diogo +351 239 480"/>
   <result pre="therapies on overall survival of patients with metastatic HER2-positive breast" exact="cancer" post="– a systematic review Mendes Diogo +351 239 480"/>
   <result pre="growth factor receptor 2 (HER2)-directed therapies in patients with metastatic" exact="breast cancer" post="(mBC). Methods A bibliographic search was conducted in PubMed"/>
   <result pre="factor receptor 2 (HER2)-directed therapies in patients with metastatic breast" exact="cancer" post="(mBC). Methods A bibliographic search was conducted in PubMed"/>
   <result pre="supplementary material, which is available to authorized users. Introduction Breast" exact="cancer" post="(BC) is the second most common cancer worldwide and,"/>
   <result pre="users. Introduction Breast cancer (BC) is the second most common" exact="cancer" post="worldwide and, by far, the most frequent among women"/>
   <result pre="[ 6]). BC is the fifth cause of death from" exact="cancer" post="overall (522,000 deaths) and it is the most frequent"/>
   <result pre="(522,000 deaths) and it is the most frequent cause of" exact="cancer" post="death in women in less developed regions (324,000 deaths,"/>
   <result pre="In the developed countries, it is the second cause of" exact="cancer" post="death (198,000 deaths, 15.4 %), after lung cancer (Ferlay"/>
   <result pre="second cause of cancer death (198,000 deaths, 15.4 %), after" exact="lung cancer" post="(Ferlay et al. [ 6]). In developed countries between"/>
   <result pre="cause of cancer death (198,000 deaths, 15.4 %), after lung" exact="cancer" post="(Ferlay et al. [ 6]). In developed countries between"/>
   <result pre="HER2+ human epidermal growth factor receptor 2 positive, mBC metastatic" exact="breast cancer," post="RCTs randomized controlled trials First-line metastatic BC Twelve phase"/>
   <result pre="therapies for the treatment of patients diagnosed with HER2-positive metastatic" exact="breast cancer" post="Clinical trial Reference Year Target population T1 T2 Primary"/>
   <result pre="for the treatment of patients diagnosed with HER2-positive metastatic breast" exact="cancer" post="Clinical trial Reference Year Target population T1 T2 Primary"/>
   <result pre="histologically confirmed stage IIIB/IIIC or IV ER-positive and/or PgR–positive invasive" exact="breast cancer;" post="LVEF within the range of normal; ECOG-PS 0–1. No"/>
   <result pre="(≥18 years old) with locally assessed HER2-positive, locally recurrent invasive" exact="breast cancer" post="unamenable to resection with curative intent or metastatic disease,"/>
   <result pre="years old) with locally assessed HER2-positive, locally recurrent invasive breast" exact="cancer" post="unamenable to resection with curative intent or metastatic disease,"/>
   <result pre="growth factor receptor 2, HR hazard ratio, LACB locally advanced" exact="breast cancer," post="LVEF left ventricular ejection fraction, mBC metastatic breast cancer,"/>
   <result pre="advanced breast cancer, LVEF left ventricular ejection fraction, mBC metastatic" exact="breast cancer," post="NA not available, NPLD nonpegylated liposomal doxorubicin, ORR overall"/>
   <result pre="and progression-free survival ( red) of patients diagnosed with metastatic" exact="breast cancer" post="receiving first-line treatment, according to the most effective treatment"/>
   <result pre="progression-free survival ( red) of patients diagnosed with metastatic breast" exact="cancer" post="receiving first-line treatment, according to the most effective treatment"/>
   <result pre="therapies for the treatment of patients diagnosed with HER2-positive metastatic" exact="breast cancer" post="Clinical trial Reference Year Target population T1 T2 Primary"/>
   <result pre="for the treatment of patients diagnosed with HER2-positive metastatic breast" exact="cancer" post="Clinical trial Reference Year Target population T1 T2 Primary"/>
   <result pre="25] 2006 Women with progressive, HER2-positive, locally advanced or metastatic" exact="breast cancer" post="who had previously been treated with a minimum of"/>
   <result pre="2006 Women with progressive, HER2-positive, locally advanced or metastatic breast" exact="cancer" post="who had previously been treated with a minimum of"/>
   <result pre="2009 Women with pathologically confirmed, HER-2–positive, locally advanced or metastatic" exact="breast cancer" post="Capecitabine 2500 mg/m2 (1250 mg/m2 twice daily) on days"/>
   <result pre="Women with pathologically confirmed, HER-2–positive, locally advanced or metastatic breast" exact="cancer" post="Capecitabine 2500 mg/m2 (1250 mg/m2 twice daily) on days"/>
   <result pre="(T-DM1) EMILIA Verma et al. [ 4] 2012 HER2-positive advanced" exact="breast cancer" post="previously treated with trastuzumab and a taxane T-DM1 3.6"/>
   <result pre="EMILIA Verma et al. [ 4] 2012 HER2-positive advanced breast" exact="cancer" post="previously treated with trastuzumab and a taxane T-DM1 3.6"/>
   <result pre="(≥18 years, LVEF ≥ 50 %, ECOG-PS 0–2) with progressive HER2-positive advanced" exact="breast cancer" post="who had received two or more HER2-directed regimens in"/>
   <result pre="years, LVEF ≥ 50 %, ECOG-PS 0–2) with progressive HER2-positive advanced breast" exact="cancer" post="who had received two or more HER2-directed regimens in"/>
   <result pre="HR hazard ratio, LVEF left ventricular ejection fraction mBC metastatic" exact="breast cancer," post="NA not available, NYR not yet reached, OS overall"/>
   <result pre="and progression-free survival ( red) of patients diagnosed with metastatic" exact="breast cancer" post="receiving second-line treatment, according to the most effective treatment"/>
   <result pre="progression-free survival ( red) of patients diagnosed with metastatic breast" exact="cancer" post="receiving second-line treatment, according to the most effective treatment"/>
   <result pre="a lack of accurate data for this condition since most" exact="cancer" post="registries do not capture relapses (Cardoso et al. ["/>
   <result pre="(both combined with taxanes) as first-line treatments for HER2+ metastatic" exact="breast cancer" post="(Gelmon et al. [ 31]). Compared to trastuzumab, lapatinib"/>
   <result pre="combined with taxanes) as first-line treatments for HER2+ metastatic breast" exact="cancer" post="(Gelmon et al. [ 31]). Compared to trastuzumab, lapatinib"/>
   <result pre="profile, with increased diarrhea, appetite loss, social functioning, and skin" exact="rash" post="(Gelmon et al. [ 31]). These results support the"/>
   <result pre="of trastuzumab over lapatinib in patients with treatment-naïve HER2+ metastatic" exact="breast cancer," post="and have implications for clinical practice (Gelmon et al."/>
   <result pre="not extend OS and was associated with increased rates of" exact="neutropenia" post="and thrombocytopenia (Robert et al. [ 19]; Valero et"/>
   <result pre="OS and was associated with increased rates of neutropenia and" exact="thrombocytopenia" post="(Robert et al. [ 19]; Valero et al. ["/>
   <result pre="in an improvement of PFS in patients with HER2+ advanced" exact="breast cancer" post="(Hurwitz et al. [ 32]); a clinically important prolongation"/>
   <result pre="an improvement of PFS in patients with HER2+ advanced breast" exact="cancer" post="(Hurwitz et al. [ 32]); a clinically important prolongation"/>
   <result pre="risk of cardiotoxicity, mainly asymptomatic left ventricular systolic dysfunction or" exact="congestive heart failure" post="(Slamon et al. [ 1]; Seidman et al. ["/>
   <result pre="(Updated, 6 October 2015). (DOCX 12 kb) Abbreviations BC Breast" exact="cancer" post="HER2+ Human epidermal growth factor receptor 2 positive ITT"/>
   <result pre="epidermal growth factor receptor 2 positive ITT intention-to-treat mBC Metastatic" exact="breast cancer" post="OS Overall survival PFS Progression-free survival RCTs Randomized controlled"/>
   <result pre="growth factor receptor 2 positive ITT intention-to-treat mBC Metastatic breast" exact="cancer" post="OS Overall survival PFS Progression-free survival RCTs Randomized controlled"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="M et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic" exact="breast cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast" exact="cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="lapatinib plus capecitabine versus capecitabine alone in women with advanced" exact="breast cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="plus capecitabine versus capecitabine alone in women with advanced breast" exact="cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="M Baselga J et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 1783 91 10.1056/NEJMoa1209124"/>
   <result pre="Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 1783 91 10.1056/NEJMoa1209124"/>
   <result pre="AU Hortobagyi GN Giordano SH Prognosis of women with metastatic" exact="breast cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="Hortobagyi GN Giordano SH Prognosis of women with metastatic breast" exact="cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="F et al. ESO-ESMO 2nd international consensus guidelines for advanced" exact="breast cancer" post="(ABC2)† Ann Oncol 2014 25 1871 88 10.1093/annonc/mdu385 25234545"/>
   <result pre="et al. ESO-ESMO 2nd international consensus guidelines for advanced breast" exact="cancer" post="(ABC2)† Ann Oncol 2014 25 1871 88 10.1093/annonc/mdu385 25234545"/>
   <result pre="Ullrich A McGuire WL HER-2/neu oncogene protein and prognosis in" exact="breast cancer" post="J Clin Oncol 1989 7 1120 8 2569032 10."/>
   <result pre="A McGuire WL HER-2/neu oncogene protein and prognosis in breast" exact="cancer" post="J Clin Oncol 1989 7 1120 8 2569032 10."/>
   <result pre="YH et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 109 19 10.1056/NEJMoa1113216"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 109 19 10.1056/NEJMoa1113216"/>
   <result pre="doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic" exact="breast cancer" post="Ann Oncol 2014 25 592 8 10.1093/annonc/mdt543 24401928 15."/>
   <result pre="in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast" exact="cancer" post="Ann Oncol 2014 25 592 8 10.1093/annonc/mdt543 24401928 15."/>
   <result pre="the treatment of human epidermal growth factor receptor 2-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 2013 31 1947 53 10.1200/JCO.2011.40.5241 23509322"/>
   <result pre="treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 2013 31 1947 53 10.1200/JCO.2011.40.5241 23509322"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 5538 46 10.1200/JCO.2009.23.3734 19786658"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 5538 46 10.1200/JCO.2009.23.3734 19786658"/>
   <result pre="compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 2006 24 2786 92 10.1200/JCO.2005.04.1764 16782917"/>
   <result pre="with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 2006 24 2786 92 10.1200/JCO.2005.04.1764 16782917"/>
   <result pre="plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic" exact="breast cancer" post="Oncologist 2010 15 122 9 10.1634/theoncologist.2009-0240 20156908 21. Swain"/>
   <result pre="letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast" exact="cancer" post="Oncologist 2010 15 122 9 10.1634/theoncologist.2009-0240 20156908 21. Swain"/>
   <result pre="M et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic" exact="breast cancer" post="N Engl J Med 2015 372 724 34 10.1056/NEJMoa1413513"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast" exact="cancer" post="N Engl J Med 2015 372 724 34 10.1056/NEJMoa1413513"/>
   <result pre="and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic" exact="breast cancer" post="(BCIRG 007 study): two highly active therapeutic regimens J"/>
   <result pre="trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast" exact="cancer" post="(BCIRG 007 study): two highly active therapeutic regimens J"/>
   <result pre="G et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced" exact="breast cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Lancet"/>
   <result pre="et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast" exact="cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Lancet"/>
   <result pre="in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic" exact="breast cancer" post="J Clin Oncol 2010 28 1124 30 10.1200/JCO.2008.21.4437 20124187"/>
   <result pre="combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast" exact="cancer" post="J Clin Oncol 2010 28 1124 30 10.1200/JCO.2008.21.4437 20124187"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 43 10.1056/NEJMoa064320"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 43 10.1056/NEJMoa064320"/>
   <result pre="emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced" exact="breast cancer" post="(TH3RESA): a randomised, open-label, phase 3 trial Lancet Oncol"/>
   <result pre="versus treatment of physician’s choice for pretreated HER2-positive advanced breast" exact="cancer" post="(TH3RESA): a randomised, open-label, phase 3 trial Lancet Oncol"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="J Clin Oncol 2015 33 1564 73 10.1200/JCO.2014.57.1794 25605838"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="J Clin Oncol 2015 33 1564 73 10.1200/JCO.2014.57.1794 25605838"/>
   <result pre="of the GBG 26/BIG 3–05 phase III study in HER2-positive" exact="breast cancer" post="Eur J Cancer 2011 47 2273 81 10.1016/j.ejca.2011.06.021 21741829"/>
   <result pre="the GBG 26/BIG 3–05 phase III study in HER2-positive breast" exact="cancer" post="Eur J Cancer 2011 47 2273 81 10.1016/j.ejca.2011.06.021 21741829"/>
   <result pre="plus paclitaxel as first-line treatment for patients with HER2-positive advanced" exact="breast cancer" post="(BOLERO-1): a phase 3, randomised, double-blind, multicentre trial Lancet"/>
   <result pre="paclitaxel as first-line treatment for patients with HER2-positive advanced breast" exact="cancer" post="(BOLERO-1): a phase 3, randomised, double-blind, multicentre trial Lancet"/>
   <result pre="on survival in a population-based cohort of women with metastatic" exact="breast cancer" post="Cancer 2007 110 973 9 10.1002/cncr.22867 17647245 34. Seidman"/>
   <result pre="survival in a population-based cohort of women with metastatic breast" exact="cancer" post="Cancer 2007 110 973 9 10.1002/cncr.22867 17647245 34. Seidman"/>
   <result pre="35. Morris PG Hudis CA Optimizing dose-dense regimens for early-stage" exact="breast cancer" post="Nat Rev Clin Oncol 2010 7 678 9 10.1038/nrclinonc.2010.188"/>
   <result pre="Morris PG Hudis CA Optimizing dose-dense regimens for early-stage breast" exact="cancer" post="Nat Rev Clin Oncol 2010 7 678 9 10.1038/nrclinonc.2010.188"/>
   <result pre="Lu J Trastuzumab in the adjuvant treatment of HER2-positive early" exact="breast cancer" post="patients: a meta-analysis of published randomized controlled trials PLoS"/>
   <result pre="J Trastuzumab in the adjuvant treatment of HER2-positive early breast" exact="cancer" post="patients: a meta-analysis of published randomized controlled trials PLoS"/>
   <result pre="SB Kim TY et al. Brain metastases in Asian HER2-positive" exact="breast cancer" post="patients: anti-HER2 treatments and their impact on survival Br"/>
   <result pre="Kim TY et al. Brain metastases in Asian HER2-positive breast" exact="cancer" post="patients: anti-HER2 treatments and their impact on survival Br"/>
   <result pre="SW Islam R et al. Defining prognosis for women with" exact="breast cancer" post="and CNS metastases by HER2 status Ann Oncol 2008"/>
   <result pre="Islam R et al. Defining prognosis for women with breast" exact="cancer" post="and CNS metastases by HER2 status Ann Oncol 2008"/>
   <result pre="of trastuzumab with chemotherapeutic drugs used in the treatment of" exact="breast cancer" post="J Natl Cancer Inst 2004 96 739 49 10.1093/jnci/djh131"/>
   <result pre="trastuzumab with chemotherapeutic drugs used in the treatment of breast" exact="cancer" post="J Natl Cancer Inst 2004 96 739 49 10.1093/jnci/djh131"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650980/results/search/disease/results.xml">
   <result pre="329 received: 2015-9-7 accepted: 2015-9-9 (C) , 2015 Abstract Gastroesophageal" exact="cancer" post="is a significant global problem that frequently presents at"/>
   <result pre="review will examine the epidemiology and molecular biology of gastroesophageal" exact="cancer" post="and will focus on the key deregulated signaling pathways"/>
   <result pre="EGFR and MET pathways have been evaluated extensively in gastroesophageal" exact="cancer" post="but have repeatedly failed to show benefit. An increased"/>
   <result pre="should subdivide this heterogeneous disease entity to allow individualization of" exact="cancer" post="therapy based on integrated and global identification of deregulated"/>
   <result pre="approaches should further improve the treatment of this deadly disease." exact="esophageal cancer" post="gastric cancer targeted therapy molecular oncology page-count: Introduction The"/>
   <result pre="should further improve the treatment of this deadly disease. esophageal" exact="cancer" post="gastric cancer targeted therapy molecular oncology page-count: Introduction The"/>
   <result pre="improve the treatment of this deadly disease. esophageal cancer gastric" exact="cancer" post="targeted therapy molecular oncology page-count: Introduction The treatment of"/>
   <result pre="the future. Epidemiology and molecular biology of gastroesophageal cancers Esophageal" exact="cancer" post="The incidence of esophageal cancer has been rising in"/>
   <result pre="molecular biology of gastroesophageal cancers Esophageal cancer The incidence of" exact="esophageal cancer" post="has been rising in Western populations over the past"/>
   <result pre="biology of gastroesophageal cancers Esophageal cancer The incidence of esophageal" exact="cancer" post="has been rising in Western populations over the past"/>
   <result pre="few decades. It is estimated that 16 980 new cases of" exact="esophageal cancer" post="will be diagnosed in the United States in the"/>
   <result pre="decades. It is estimated that 16 980 new cases of esophageal" exact="cancer" post="will be diagnosed in the United States in the"/>
   <result pre="deaths being expected [ 1]. Worldwide, an estimated 455 800 new" exact="esophageal cancer" post="cases and 400 200 deaths occurred in 2012 [ 2,"/>
   <result pre="being expected [ 1]. Worldwide, an estimated 455 800 new esophageal" exact="cancer" post="cases and 400 200 deaths occurred in 2012 [ 2,"/>
   <result pre="there has been a substantial shift in the histology of" exact="esophageal cancer" post="in the Western countries. Since approximately the 1970s, the"/>
   <result pre="has been a substantial shift in the histology of esophageal" exact="cancer" post="in the Western countries. Since approximately the 1970s, the"/>
   <result pre="countries. Since approximately the 1970s, the most common type of" exact="esophageal cancer" post="in the United States has shifted from SCC to"/>
   <result pre="Since approximately the 1970s, the most common type of esophageal" exact="cancer" post="in the United States has shifted from SCC to"/>
   <result pre="in part due to increases in known risk factors including" exact="obesity" post="as well as Barrett’s esophagus, gastroesophageal reflux disease (GERD),"/>
   <result pre="to non-Western populations, the markedly increased incidence of predominantly SCC" exact="esophageal cancer" post="worldwide suggests that additional unidentified risk factors also exist."/>
   <result pre="non-Western populations, the markedly increased incidence of predominantly SCC esophageal" exact="cancer" post="worldwide suggests that additional unidentified risk factors also exist."/>
   <result pre="is significant disparity in the mutation spectrum of the two" exact="cancer" post="types. Notably, there are more insertions/deletions (indels) and C:G&amp;gt;G:C"/>
   <result pre="and therapies benefiting specific histologic subtypes remain poorly defined. Gastric" exact="cancer" post="Although it is relatively uncommon in Western populations, gastric"/>
   <result pre="cancer Although it is relatively uncommon in Western populations, gastric" exact="cancer" post="was the leading cause of cancer deaths globally until"/>
   <result pre="in Western populations, gastric cancer was the leading cause of" exact="cancer" post="deaths globally until the 1980s [ 8] and remains"/>
   <result pre="9]. It is estimated that 24 590 new cases of gastric" exact="cancer" post="will be diagnosed in the United States in the"/>
   <result pre="2015, with 10 720 deaths expected [ 1]. In 2012, gastric" exact="cancer" post="developed in approximately 930 000 individuals and accounted for 10%"/>
   <result pre="cancer-related deaths [ 2]. The incidence and mortality of gastric" exact="cancer" post="have declined since World War II [ 10], although"/>
   <result pre="factors may have a greater influence than genetics on gastric" exact="cancer" post="incidence and mortality [ 11]. The use of screening"/>
   <result pre="remains poor at 8–10 months [ 12, 13]. Histologically, gastric" exact="cancer" post="is generally divided into intestinal and diffuse (infiltrative) subtypes."/>
   <result pre="relevance than the anatomical classifications described above. However, as in" exact="esophageal cancer," post="clinical trials have not focused on treatment by histology"/>
   <result pre="[ 18]. Aberrant EGFR signaling leads to several hallmarks of" exact="cancer" post="including increased proliferation, angiogenesis, metastasis and resistance to apoptosis"/>
   <result pre="[ 19]. EGFR is an attractive target in GE-Ca. In" exact="esophageal cancer," post="the overexpression of EGFR as assessed by immunohistochemistry (IHC)"/>
   <result pre="was observed in a smaller subset of patients with gastric" exact="cancer" post="(27% by IHC) but was similarly associated with an"/>
   <result pre="EGFR pathway The EGFR pathway is an established target in" exact="colorectal cancer," post="SCC of the head and neck and lung cancer."/>
   <result pre="in colorectal cancer, SCC of the head and neck and" exact="lung cancer." post="EGFR is overexpressed in GE-Ca and is a rational"/>
   <result pre="trials testing EGFR-targeted therapies in GE-Ca. Biomarkers relevant to other" exact="cancer" post="types do not appear to be relevant in GE-Ca,"/>
   <result pre="are currently approved as therapy for multiple cancers including RAS-wildtype" exact="colorectal cancer" post="in which they appear to be interchangeable in terms"/>
   <result pre="currently approved as therapy for multiple cancers including RAS-wildtype colorectal" exact="cancer" post="in which they appear to be interchangeable in terms"/>
   <result pre="the addition of cetuximab. Toxicity was similar except for increased" exact="rash" post="in the cetuximab group. The REAL-3 trial randomized 503"/>
   <result pre="was increased with panitumumab, with increased incidence of grade 3–4" exact="diarrhea" post="and rash. As has been seen in previous trials,"/>
   <result pre="diarrhea and rash. As has been seen in previous trials," exact="rash" post="appeared predictive of response to treatment. Other biomarkers were"/>
   <result pre="tumorigenesis [ 52]. The unprecedented success of HER2 targeting in" exact="breast cancer" post="supports the critical importance of HER2 in the control"/>
   <result pre="[ 52]. The unprecedented success of HER2 targeting in breast" exact="cancer" post="supports the critical importance of HER2 in the control"/>
   <result pre="supports the critical importance of HER2 in the control of" exact="cancer" post="growth and survival [ 53]. Approximately 30% of gastroesophageal"/>
   <result pre="adenocarcinomas overexpress HER2, which is comparable to the rates in" exact="breast cancer" post="[ 54]. HER2 positivity rates were higher in GEJ"/>
   <result pre="overexpress HER2, which is comparable to the rates in breast" exact="cancer" post="[ 54]. HER2 positivity rates were higher in GEJ"/>
   <result pre="cancer [ 54]. HER2 positivity rates were higher in GEJ" exact="cancer" post="than in gastric cancer (33.2% vs 20.9%) and higher"/>
   <result pre="positivity rates were higher in GEJ cancer than in gastric" exact="cancer" post="(33.2% vs 20.9%) and higher in intestinal cancer than"/>
   <result pre="than in gastric cancer (33.2% vs 20.9%) and higher in" exact="intestinal cancer" post="than in diffuse or mixed pathologic subtypes (32.2% vs"/>
   <result pre="in gastric cancer (33.2% vs 20.9%) and higher in intestinal" exact="cancer" post="than in diffuse or mixed pathologic subtypes (32.2% vs"/>
   <result pre="the eligibility of anti-HER2 therapy differ from those used in" exact="breast cancer" post="[ 57]. GE-Cas that are IHC 3+ or FISH-positive"/>
   <result pre="eligibility of anti-HER2 therapy differ from those used in breast" exact="cancer" post="[ 57]. GE-Cas that are IHC 3+ or FISH-positive"/>
   <result pre="with the established adverse prognostic role of HER2 overexpression in" exact="breast cancer." post="For example, six trials of first-line chemotherapy that involved"/>
   <result pre="Pathway HER-targeted agents are well established for the treatment of" exact="breast cancer," post="where four agents are currently approved: the mAbs trastuzumab,"/>
   <result pre="(ToGA) trial, patients with unresectable or metastatic gastric or GEJ" exact="cancer" post="were screened for HER2 overexpression using a combination of"/>
   <result pre="compare favorably to data from ToGA. Cross-trial comparison shows that" exact="peripheral neuropathy" post="was the only side effect which was increased by"/>
   <result pre="favorably to data from ToGA. Cross-trial comparison shows that peripheral" exact="neuropathy" post="was the only side effect which was increased by"/>
   <result pre="There is theoretical concern that differences in trastuzumab metabolism between" exact="breast cancer" post="and GE-Ca patients may mean that currently used regimens"/>
   <result pre="is theoretical concern that differences in trastuzumab metabolism between breast" exact="cancer" post="and GE-Ca patients may mean that currently used regimens"/>
   <result pre="evaluating trastuzumab in combination with chemoradiation for patients with resectable" exact="esophageal cancer" post="[ 73]. The regimen was tolerable, and it appeared"/>
   <result pre="trastuzumab in combination with chemoradiation for patients with resectable esophageal" exact="cancer" post="[ 73]. The regimen was tolerable, and it appeared"/>
   <result pre="microtubule polymerization inhibitor emtansine, which has been approved for HER2-positive" exact="breast cancer" post="patients [ 63]. It is currently being tested in"/>
   <result pre="polymerization inhibitor emtansine, which has been approved for HER2-positive breast" exact="cancer" post="patients [ 63]. It is currently being tested in"/>
   <result pre="than trastuzumab, and studies both in preclinical models of gastric" exact="cancer" post="and in patients with breast cancer show that combining"/>
   <result pre="in preclinical models of gastric cancer and in patients with" exact="breast cancer" post="show that combining the two HER2-targeted antibodies increases activity"/>
   <result pre="preclinical models of gastric cancer and in patients with breast" exact="cancer" post="show that combining the two HER2-targeted antibodies increases activity"/>
   <result pre="is a HER2-specific TKI that has been approved for HER2-positive" exact="breast cancer" post="but has been less successful in GE-Ca [ 63]."/>
   <result pre="a HER2-specific TKI that has been approved for HER2-positive breast" exact="cancer" post="but has been less successful in GE-Ca [ 63]."/>
   <result pre="HER4 [ 83]. It is currently approved for use in" exact="lung cancer" post="patients but is being actively studied in other cancers"/>
   <result pre="[ 83]. It is currently approved for use in lung" exact="cancer" post="patients but is being actively studied in other cancers"/>
   <result pre="improvements in survival and cure that parallel those seen in" exact="breast cancer" post="patients. The VEGF pathway Vascular endothelial growth factors (VEGFs)"/>
   <result pre="in survival and cure that parallel those seen in breast" exact="cancer" post="patients. The VEGF pathway Vascular endothelial growth factors (VEGFs)"/>
   <result pre="the most important interaction in the process of angiogenesis and" exact="cancer" post="is the binding of the ligand VEGF-A to the"/>
   <result pre="and with worse clinical outcomes, as have been found in" exact="colorectal cancer" post="[ 89–91]. Clinical results of agents targeting VEGF pathways"/>
   <result pre="with worse clinical outcomes, as have been found in colorectal" exact="cancer" post="[ 89–91]. Clinical results of agents targeting VEGF pathways"/>
   <result pre="with GE-Ca appeared to have more benefit than those with" exact="stomach cancer." post="Furthermore, Asian patients did not appear to benefit from"/>
   <result pre="half of the 168 patients treated on this trial had" exact="esophageal cancer," post="but analyzing the results by tumor site did not"/>
   <result pre="study led to ziv-aflibercept being approved for the treatment of" exact="colorectal cancer" post="[ 105]. There is an ongoing phase II randomized"/>
   <result pre="led to ziv-aflibercept being approved for the treatment of colorectal" exact="cancer" post="[ 105]. There is an ongoing phase II randomized"/>
   <result pre="sorafenib, have been found to have clinical activity in multiple" exact="cancer" post="subtypes. Sunitinib is currently FDA approved for treatment of"/>
   <result pre="cancer subtypes. Sunitinib is currently FDA approved for treatment of" exact="gastrointestinal stromal tumor" post="(GIST), pancreatic neuroendocrine tumor (NET) and kidney cancer, while"/>
   <result pre="FDA approved for treatment of gastrointestinal stromal tumor (GIST), pancreatic" exact="neuroendocrine tumor" post="(NET) and kidney cancer, while sorafenib is approved for"/>
   <result pre="of gastrointestinal stromal tumor (GIST), pancreatic neuroendocrine tumor (NET) and" exact="kidney cancer," post="while sorafenib is approved for thyroid, liver and kidney"/>
   <result pre="a single agent in end-line therapy for patients with metastatic" exact="colorectal cancer" post="and GIST, where it provides modest benefit but significant"/>
   <result pre="single agent in end-line therapy for patients with metastatic colorectal" exact="cancer" post="and GIST, where it provides modest benefit but significant"/>
   <result pre="define the role of regorafenib in GE-Ca but, as in" exact="colorectal cancer," post="current studies have yet to show a clinically meaningful"/>
   <result pre="based on available negative results seen in both GE-Ca and" exact="lung cancer." post="Some have raised concerns that IHC is not optimal"/>
   <result pre="multitargeted TKI that is approved for the treatment of ALK-positive" exact="lung cancer;" post="this agent also inhibits the MET tyrosine kinase. Preclinical"/>
   <result pre="shown that crizotinib can inhibit the growth of MET-overexpressing gastric" exact="cancer" post="cell lines and in vivo tumor models [ 139,"/>
   <result pre="pilot study testing crizotinib as third-line therapy for MET-positive gastric" exact="cancer" post="in Korea, and NCT02034981, which will test crizotinib across"/>
   <result pre="results can be augmented by ongoing and significant advances in" exact="cancer" post="immunotherapy. Most cancers including GE-Ca exploit multiple mechanisms in"/>
   <result pre="2 Torre LA Bray F Siegel RL et al. Global" exact="cancer" post="statistics, 2012. CA Cancer J Clin 2015; 65 :"/>
   <result pre="9 Jemal A Bray F Center MM et al. Global" exact="cancer" post="statistics. CA Cancer J Clin 2011 ; 61: 69–"/>
   <result pre="69– 90. 21296855 10 Zhu AL Sonnenberg A Is gastric" exact="cancer" post="again rising? J Clin Gastroenterol 2012; 46 : 804"/>
   <result pre="11 Haenszel W Kurihara M Segi M et al. Stomach" exact="cancer" post="among Japanese in Hawaii. J Natl Cancer Inst 1972;"/>
   <result pre="20 Tew WP Kelsen DP Ilson DH Targeted therapies for" exact="esophageal cancer." post="Oncologist 2005; 10 : 590– 601. 16177283 21 Nicholson"/>
   <result pre="16177283 21 Nicholson RI Gee JM Harper ME EGFR and" exact="cancer" post="prognosis. Eur J Cancer 2001 ; 37 ( Suppl"/>
   <result pre="growth factor (EGF) radioreceptor analysis on long-term survival of gastric" exact="cancer" post="patients . Anticancer Res 2002; 22 : 1161 –"/>
   <result pre="analysis of cetuximab combined with modified FOLFOX6 in advanced gastric" exact="cancer" post=". Br J Cancer 2009; 100 : 298 –"/>
   <result pre="and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric" exact="cancer" post=". Invest New Drugs 2011; 29 : 366 –"/>
   <result pre="or without cetuximab for patients with previously untreated advanced gastric" exact="cancer" post="(EXPAND): a randomised, open-label phase 3 trial . Lancet"/>
   <result pre="or without panitumumab for patients with previously untreated advanced oesophagogastric" exact="cancer" post="(REAL3): a randomised, open-label phase 3 trial . Lancet"/>
   <result pre="al. Chemoradiotherapy with or without cetuximab in patients with oesophageal" exact="cancer" post="(SCOPE1): a multicentre, phase 2/3 randomised trial . Lancet"/>
   <result pre="irinotecan, cisplatin, and radiation therapy for patients with locally advanced" exact="esophageal cancer" post=". Oncologist 2013; 18 : 281 – 7. 23429739"/>
   <result pre="cisplatin, and radiation therapy for patients with locally advanced esophageal" exact="cancer" post=". Oncologist 2013; 18 : 281 – 7. 23429739"/>
   <result pre="phase II study of gefitinib in second-line treatment of advanced" exact="esophageal cancer" post="patients . J Clin Oncol 2006; 24 : 1612"/>
   <result pre="II study of gefitinib in second-line treatment of advanced esophageal" exact="cancer" post="patients . J Clin Oncol 2006; 24 : 1612"/>
   <result pre="copy number gain (EGFR CNG) and response to gefitinib in" exact="esophageal cancer" post="(EC): Results of a biomarker analysis of a phase"/>
   <result pre="number gain (EGFR CNG) and response to gefitinib in esophageal" exact="cancer" post="(EC): Results of a biomarker analysis of a phase"/>
   <result pre="H Xu J et al. Pathological features of advanced gastric" exact="cancer" post="(GC): Relationship to human epidermal growth factor receptor 2"/>
   <result pre="K Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric" exact="cancer" post="based on the randomised ToGA trial . Br J"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial ."/>
   <result pre="C et al. Prognosis of metastatic gastric and gastroesophageal junction" exact="cancer" post="by HER2 status: a European and USA International collaborative"/>
   <result pre="to tumor HER2 status and EGFR expression in advanced gastric" exact="cancer" post="patients from the EXPAND study . J Clin Oncol"/>
   <result pre="21468131 63 Gradishar WJ Emerging approaches for treating HER2-positive metastatic" exact="breast cancer" post="beyond trastuzumab. Ann Oncol 2013; 24 : 2492 –"/>
   <result pre="63 Gradishar WJ Emerging approaches for treating HER2-positive metastatic breast" exact="cancer" post="beyond trastuzumab. Ann Oncol 2013; 24 : 2492 –"/>
   <result pre="trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric" exact="cancer" post=". Eur J Cancer 2015; 51 : 482 –"/>
   <result pre="The modulated oral fluoropyrimidine prodrug S-1, and its use in" exact="gastrointestinal cancer" post="and other solid tumors . Anticancer Drugs 2004; 15"/>
   <result pre="modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal" exact="cancer" post="and other solid tumors . Anticancer Drugs 2004; 15"/>
   <result pre="S-1 alone in elderly patients with HER-2 positive advanced gastric" exact="cancer" post="(JACCRO GC-06) . J Clin Oncol 2015; 33 ("/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel in HER2- positive metastatic" exact="breast cancer." post=". N Engl J Med 2015; 372 : 724"/>
   <result pre="trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric" exact="cancer" post="xenograft models . Clin Cancer Res 2011; 17 :"/>
   <result pre="trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric" exact="cancer" post=". Br J Cancer 2014; 111 : 660 –"/>
   <result pre="paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric" exact="cancer" post="in Asian populations: TyTAN–a randomized, phase III study ."/>
   <result pre="human epidermal growth factor receptor (HER2)-positive trastuzumab- refractory esophagogastric (EG)" exact="cancer" post=". J Clin Oncol 2014; 32 ( Suppl 3"/>
   <result pre="human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG)" exact="cancer" post=". J Clin Oncol 2015; 33 ( Suppl 3"/>
   <result pre="Zetter BR The scientific contributions of M. Judah Folkman to" exact="cancer" post="research. Nat Rev Cancer 2008; 8 : 647 –"/>
   <result pre="of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric" exact="cancer" post=". Gut Liver 2009; 3 : 88 – 94."/>
   <result pre="is an independent prognostic indicator of worse outcome in gastric" exact="cancer" post="patients . Ann Surg Oncol 2008; 15 : 69"/>
   <result pre="al. Microvessel density and VEGF expression are prognostic factors in" exact="colorectal cancer." post="Meta-analysis of the literature. Br J Cancer 2006; 94"/>
   <result pre="in a phase III randomized trial in patients with metastatic" exact="colorectal cancer" post="previously treated with an oxaliplatin-based regimen . J Clin"/>
   <result pre="a phase III randomized trial in patients with metastatic colorectal" exact="cancer" post="previously treated with an oxaliplatin-based regimen . J Clin"/>
   <result pre="F Qing Z et al. Risk of gastrointestinal perforation in" exact="cancer" post="patients treated with aflibercept: a systematic review and meta-analysis"/>
   <result pre="II trial of sunitinib for patients with chemo-refractory advanced gastric" exact="cancer" post=". Eur J Cancer 2011; 47 : 1511 –"/>
   <result pre="trial of docetaxel and sunitinib in patients with metastatic gastric" exact="cancer" post="who were previously treated with fluoropyrimidine and platinum ."/>
   <result pre="treatment in patients with unresectable locally advanced or metastatic gastric" exact="cancer" post=". Chin J Cancer Res 2015; 27 : 239"/>
   <result pre="cisplatin as a first-line treatment in patients with advanced gastric" exact="cancer" post=". Invest New Drugs 2012; 30 : 306 –"/>
   <result pre="combination with S-1 plus cisplatin in patients with advanced gastric" exact="cancer" post=". Gastric Cancer 2014; 17 : 161 – 72."/>
   <result pre="Sobrero A et al. Regorafenib monotherapy for previously treated metastatic" exact="colorectal cancer" post="(CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial"/>
   <result pre="A et al. Regorafenib monotherapy for previously treated metastatic colorectal" exact="cancer" post="(CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial"/>
   <result pre="best supportive care in Asian patients with previously treated metastatic" exact="colorectal cancer" post="(CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial ."/>
   <result pre="supportive care in Asian patients with previously treated metastatic colorectal" exact="cancer" post="(CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial ."/>
   <result pre="double- blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric" exact="cancer" post="(AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG),"/>
   <result pre="Rabe DC Bottaro DP Targeting the HGF/Met signaling pathway in" exact="cancer" post="therapy. Expert Opin Ther Targets 2012; 16 : 553"/>
   <result pre="130 Appleman LJ MET signaling pathway: a rational target for" exact="cancer" post="therapy. J Clin Oncol 2011; 29 : 4837 –"/>
   <result pre="with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E)" exact="cancer" post=". J Clin Oncol 2015; 33 ( Suppl 3"/>
   <result pre="of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric" exact="cancer" post="positive for MET amplification . Mol Cancer Ther 2012;"/>
   <result pre="A de Bono JS Development of therapeutic combinations targeting major" exact="cancer" post="signaling pathways. J Clin Oncol 2013; 31 : 1592"/>
   <result pre="Postow MA Callahan MK Wolchok JD Immune checkpoint blockade in" exact="cancer" post="therapy. J Clin Oncol 2015; 33 : 1974 –"/>
   <result pre="expression and clinical outcomes in patients (Pts) with advanced gastric" exact="cancer" post="treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4656949/results/search/disease/results.xml">
   <result pre="anti-tumor necrosis factor-α microantibody, are effective in the treatment of" exact="corneal neovascularization." post="corneal neovascularization vascular endothelial growth factor anti VEGF therapy"/>
   <result pre="factor-α microantibody, are effective in the treatment of corneal neovascularization." exact="corneal neovascularization" post="vascular endothelial growth factor anti VEGF therapy Introduction A"/>
   <result pre="factor, angiostatin and endostatin [ 2 ]. Current treatments for" exact="corneal neovascularization" post="include topical corticosteroid and non-steroid anti-inflammatory medications, photodynamic therapy,"/>
   <result pre="role in vasculogenesis and the pathologic neovascularization (NV) associated with" exact="eye disease." post="Although anti-VEGF therapy for ocular disease has been principally"/>
   <result pre="of VEGF-A was observed in tumor cell proliferation, similarly to" exact="corneal neovascularization" post="formation. VEGF-A sustains several steps of angiogenesis including proteolytic"/>
   <result pre="6 ]. Anti VEGF antibody One possible strategy for treating" exact="corneal neovascularization" post="is to inhibit VEGF activity by competitively binding VEGF"/>
   <result pre="specific neutralizing anti-VEGFantibody. Anti-VEGF agents have demonstrated efficacy in reducing" exact="corneal neovascularization" post="in both animal models and clinical trials. VEGF inhibitors"/>
   <result pre="the treatment of various retinal diseases such as neovascular age-related" exact="macular degeneration" post="[ 16 ]. Bevacizumab is a full-length, humanized murine"/>
   <result pre="]. In addition, studies have exhibited a partial reduction of" exact="corneal neovascularization" post="through topical, subconjunctival, and intraocular application of bevacizumab and"/>
   <result pre="also used in a topical preparation in the treatment of" exact="atopic dermatitis" post="(eczema), severe refractory uveitis after bone marrow transplants. Comparative"/>
   <result pre="used in a topical preparation in the treatment of atopic" exact="dermatitis" post="(eczema), severe refractory uveitis after bone marrow transplants. Comparative"/>
   <result pre="preparation in the treatment of atopic dermatitis (eczema), severe refractory" exact="uveitis" post="after bone marrow transplants. Comparative studies between bevacizumab and"/>
   <result pre="both bevacizumab and sunitinib (anti VEGF and anti PDGF) inhibits" exact="corneal neovascularization" post="in rabbits. But vascular endothelial growth factor (VEGF) pathway"/>
   <result pre="in the pathogenesis of many diseases, such as autoimmune diseases," exact="multiple myeloma" post="and prostate cancer. An antiangiogenic effect was observed after"/>
   <result pre="of many diseases, such as autoimmune diseases, multiple myeloma and" exact="prostate cancer." post="An antiangiogenic effect was observed after subconjunctival injection of"/>
   <result pre="subconjunctival application of tocilizumab is effective for the inhibition of" exact="corneal neovascularization" post="[ 22 ]. Ranibizumab is a recombinant humanized monoclonal"/>
   <result pre="that early subconjunctival administration of ranibizumab may successfully inhibit alkali-induced" exact="corneal neovascularization." post="Subconjunctival ranibizumab reduces VEGF levels significantly not only in"/>
   <result pre="18 ]. A comparative study of ranibizumab and bevacizumab on" exact="corneal neovascularization" post="in rabbits indicated that subconjunctival administrations of both substances"/>
   <result pre="in clinical trials in treating choroidal neovascularization associated with age-related" exact="macular degeneration." post="Therefore, Pegaptanib has the notable distinction of being the"/>
   <result pre="and pegaptanib sodium is effective with no epitheliopathy in controlling" exact="corneal neovascularization" post="after corneal burn in rats. In addition, bevacizumab is"/>
   <result pre="form of lapatinib ditosylate, is an orally active drug for" exact="breast cancer" post="and other solid tumours. It is a dual tyrosine"/>
   <result pre="of lapatinib ditosylate, is an orally active drug for breast" exact="cancer" post="and other solid tumours. It is a dual tyrosine"/>
   <result pre="studies, both substances were compared for the treatment of experimental" exact="corneal neovascularization" post="and suggested that systemically administered lapatinib is more effective"/>
   <result pre="lapatinib is more effective than systemically administered trastuzumab in preventing" exact="corneal neovascularization" post="[ 31 ]. Antibody based biologics with specificity for"/>
   <result pre="factor-alpha (TNFα) are also currently examined for efficacy in modulating" exact="corneal disease" post="in experimental animals. Topical infilximab has been shown to"/>
   <result pre="one of the major factors involved in the pathogenesis of" exact="corneal neovascularization." post="VEGF-A is believed to be the most important member"/>
   <result pre="the treatment just after the chemical cauterization might cause less" exact="corneal neovascularization" post="and the affinity of anti-VEGF agents for VEGF in"/>
   <result pre="agents have generated an enormous hope for the treatment of" exact="corneal neovascularization." post="Large, randomized, controlled clinical trials are essential for the"/>
   <result pre="H Nejabat M A potential therapeutic strategy for inhibition of" exact="corneal neovascularization" post="with new anti-VEGF agents Med Hypotheses 2007 68 4"/>
   <result pre="Campos-Mollo E Lledó-Riquelme M Javaloy J Alió JL Inhibition of" exact="corneal neovascularization" post="by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF)"/>
   <result pre="Kremer I Effect of subconjunctival and intraocular bevacizumab injections on" exact="corneal neovascularization" post="in a mouse model Curr Eye Res 2010 2"/>
   <result pre="P Racca L Berra A Anti-VEGF monoclonal antibody-induced regression of" exact="corneal neovascularization" post="and inflammation in a rabbit model of herpetic stromal"/>
   <result pre="neovascularization and inflammation in a rabbit model of herpetic stromal" exact="keratitis" post="Graefes Arch Clin Exp Ophthalmol 2009 10 247 10"/>
   <result pre="SJ Chung SK Comparative study of ranibizumab and bevacizumab on" exact="corneal neovascularization" post="in rabbits Cornea 2014 1 33 1 60 64"/>
   <result pre="Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on" exact="corneal neovascularization" post="Int J Ophthalmol 2014 4 18 7 2 220"/>
   <result pre="(avastin) on the inhibition of early but not late formed" exact="corneal neovascularization" post="PLoS One 2014 4 8 9 4 e94205 24714670"/>
   <result pre="effects of early and late bevacizumab (Avastin) injection on inhibiting" exact="corneal neovascularization" post="and conjunctivalization in rabbit limbal insufficiency Invest Ophthalmol Vis"/>
   <result pre="of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of" exact="corneal neovascularization" post="in a rat model Int J Ophthalmol 2013 4"/>
   <result pre="lapatinib and trastuzumab on vascular endothelial growth factor in experimental" exact="corneal neovascularization" post="Clin Experiment Ophthalmol 2015 2 2 doi: 10.1111/ceo.12500 32"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4657380/results/search/disease/results.xml">
   <result pre="Central London pmcid: 4657380 28 doi: 10.1186/s40164-015-0028-8 : Review Breast" exact="cancer" post="brain metastases: the last frontier Leone José Pablo 319-356-7839"/>
   <result pre="made available in this article, unless otherwise stated. Abstract Breast" exact="cancer" post="is a common cause of brain metastases, with metastases"/>
   <result pre="10–16 % of patients. Longer survival of patients with metastatic" exact="breast cancer" post="and the use of better imaging techniques are associated"/>
   <result pre="% of patients. Longer survival of patients with metastatic breast" exact="cancer" post="and the use of better imaging techniques are associated"/>
   <result pre="therapies, future approaches and ongoing clinical trials for patients with" exact="breast cancer" post="brain metastases. Keywords Breast cancer Brain metastasis Metastatic breast"/>
   <result pre="future approaches and ongoing clinical trials for patients with breast" exact="cancer" post="brain metastases. Keywords Breast cancer Brain metastasis Metastatic breast"/>
   <result pre="trials for patients with breast cancer brain metastases. Keywords Breast" exact="cancer" post="Brain metastasis Metastatic breast cancer Background Breast cancer represents"/>
   <result pre="breast cancer brain metastases. Keywords Breast cancer Brain metastasis Metastatic" exact="breast cancer" post="Background Breast cancer represents the second most frequent cause"/>
   <result pre="cancer brain metastases. Keywords Breast cancer Brain metastasis Metastatic breast" exact="cancer" post="Background Breast cancer represents the second most frequent cause"/>
   <result pre="Keywords Breast cancer Brain metastasis Metastatic breast cancer Background Breast" exact="cancer" post="represents the second most frequent cause of brain metastases"/>
   <result pre="represents the second most frequent cause of brain metastases after" exact="lung cancer," post="with metastases occurring in 10–16 % of patients ["/>
   <result pre="metastases is a complex process, requiring invasion of the primary" exact="breast cancer" post="cells into surrounding tissue and vessels, traffic through the"/>
   <result pre="is a complex process, requiring invasion of the primary breast" exact="cancer" post="cells into surrounding tissue and vessels, traffic through the"/>
   <result pre="and growth in the brain parenchyma [ 3, 4]. In" exact="breast cancer," post="this process takes a median of 32 months from"/>
   <result pre="process takes a median of 32 months from the initial" exact="cancer" post="diagnosis [ 5]; which shows that the breast cancer"/>
   <result pre="the initial cancer diagnosis [ 5]; which shows that the" exact="breast cancer" post="tumor cells, unlike other cancer cells, need more time"/>
   <result pre="initial cancer diagnosis [ 5]; which shows that the breast" exact="cancer" post="tumor cells, unlike other cancer cells, need more time"/>
   <result pre="which shows that the breast cancer tumor cells, unlike other" exact="cancer" post="cells, need more time to develop the ability to"/>
   <result pre="with triple-negative and human epidermal growth factor receptor 2 (HER2)-positive" exact="breast cancer" post="as having an increased risk for the development of"/>
   <result pre="triple-negative and human epidermal growth factor receptor 2 (HER2)-positive breast" exact="cancer" post="as having an increased risk for the development of"/>
   <result pre="9], with up to half of patients with HER2-positive metastatic" exact="breast cancer" post="experiencing brain metastases over time [ 10]. Tumor subtypes"/>
   <result pre="with up to half of patients with HER2-positive metastatic breast" exact="cancer" post="experiencing brain metastases over time [ 10]. Tumor subtypes"/>
   <result pre="estrogen receptor (ER) positive tumors [ 11]. Brain metastases in" exact="breast cancer" post="patients represent a catastrophic event that portends a poor"/>
   <result pre="receptor (ER) positive tumors [ 11]. Brain metastases in breast" exact="cancer" post="patients represent a catastrophic event that portends a poor"/>
   <result pre="16]. In contrast, it is common for patients with triple-negative" exact="breast cancer" post="to develop brain metastases with concurrent extracranial disease progression"/>
   <result pre="In contrast, it is common for patients with triple-negative breast" exact="cancer" post="to develop brain metastases with concurrent extracranial disease progression"/>
   <result pre="extracranial disease progression [ 17]. Treatment options for patients with" exact="breast cancer" post="brain metastases are limited and include surgical resection, whole-brain"/>
   <result pre="disease progression [ 17]. Treatment options for patients with breast" exact="cancer" post="brain metastases are limited and include surgical resection, whole-brain"/>
   <result pre="on novel therapies and ongoing clinical trials for patients with" exact="breast cancer" post="brain metastases. Prognostic factors The prognosis of patients with"/>
   <result pre="novel therapies and ongoing clinical trials for patients with breast" exact="cancer" post="brain metastases. Prognostic factors The prognosis of patients with"/>
   <result pre="cancer brain metastases. Prognostic factors The prognosis of patients with" exact="breast cancer" post="who develop brain metastases is affected by several factors."/>
   <result pre="brain metastases. Prognostic factors The prognosis of patients with breast" exact="cancer" post="who develop brain metastases is affected by several factors."/>
   <result pre="for overall survival in brain metastases [ 20, 21]. Triple-negative" exact="breast cancer" post="patients have the shortest survival ranging from 3 to"/>
   <result pre="overall survival in brain metastases [ 20, 21]. Triple-negative breast" exact="cancer" post="patients have the shortest survival ranging from 3 to"/>
   <result pre="also affect prognosis. Older age at the time of initial" exact="breast cancer" post="diagnosis has been associated with shorter overall survival and"/>
   <result pre="affect prognosis. Older age at the time of initial breast" exact="cancer" post="diagnosis has been associated with shorter overall survival and"/>
   <result pre="&amp;lt; 0.005). A subsequent study randomized 63 patients with systemic" exact="cancer" post="and a single brain metastasis to surgical resection plus"/>
   <result pre="Therefore, delaying or avoiding the administration of WBRT in metastatic" exact="breast cancer" post="after surgical resection or SRS through the careful use"/>
   <result pre="delaying or avoiding the administration of WBRT in metastatic breast" exact="cancer" post="after surgical resection or SRS through the careful use"/>
   <result pre="of WBRT. Systemic therapies The mainstay of systemic treatment for" exact="breast cancer" post="brain metastases is cytotoxic chemotherapy; however, there are currently"/>
   <result pre="WBRT. Systemic therapies The mainstay of systemic treatment for breast" exact="cancer" post="brain metastases is cytotoxic chemotherapy; however, there are currently"/>
   <result pre="with the addition of systemic therapy in patients with luminal" exact="breast cancer" post="[ 20]. A similar result was seen in another"/>
   <result pre="the addition of systemic therapy in patients with luminal breast" exact="cancer" post="[ 20]. A similar result was seen in another"/>
   <result pre="study where the median overall survival of patients with luminal" exact="breast cancer" post="was improved from 7.1 to 14.3 months with chemotherapy"/>
   <result pre="where the median overall survival of patients with luminal breast" exact="cancer" post="was improved from 7.1 to 14.3 months with chemotherapy"/>
   <result pre="data support the hypothesis that in patients with metastatic ER-positive" exact="breast cancer" post="who have asymptomatic systemic disease and locally treated brain"/>
   <result pre="support the hypothesis that in patients with metastatic ER-positive breast" exact="cancer" post="who have asymptomatic systemic disease and locally treated brain"/>
   <result pre="this approach should be conducted. HER2-positive Patients with HER2-positive metastatic" exact="breast cancer" post="have experienced a dramatic improvement in overall survival with"/>
   <result pre="approach should be conducted. HER2-positive Patients with HER2-positive metastatic breast" exact="cancer" post="have experienced a dramatic improvement in overall survival with"/>
   <result pre="periods of time has exposed the ability of the HER2-positive" exact="breast cancer" post="cells to seed the brain parenchyma and develop brain"/>
   <result pre="of time has exposed the ability of the HER2-positive breast" exact="cancer" post="cells to seed the brain parenchyma and develop brain"/>
   <result pre="tested in the CEREBEL trial, where patients with HER2-positive metastatic" exact="breast cancer" post="without CNS metastases were randomized to lapatinib or trastuzumab"/>
   <result pre="in the CEREBEL trial, where patients with HER2-positive metastatic breast" exact="cancer" post="without CNS metastases were randomized to lapatinib or trastuzumab"/>
   <result pre="lapatinib plus capecitabine in patients with previously treated HER2-positive metastatic" exact="breast cancer" post="[ 81]. A recent retrospective, exploratory analysis of this"/>
   <result pre="plus capecitabine in patients with previously treated HER2-positive metastatic breast" exact="cancer" post="[ 81]. A recent retrospective, exploratory analysis of this"/>
   <result pre="the CLEOPATRA trial, where patients with HER2-positive first line metastatic" exact="breast cancer" post="experienced significant improvements in progression-free and overall survival with"/>
   <result pre="CLEOPATRA trial, where patients with HER2-positive first line metastatic breast" exact="cancer" post="experienced significant improvements in progression-free and overall survival with"/>
   <result pre="and impact that brain metastases cause in patients with HER2-positive" exact="breast cancer," post="the American Society of Clinical Oncology (ASCO) published in"/>
   <result pre="therapy according to the algorithms for treatment of HER2-positive metastatic" exact="breast cancer" post="[ 85]. Triple-negative Patients with brain metastases from triple-negative"/>
   <result pre="according to the algorithms for treatment of HER2-positive metastatic breast" exact="cancer" post="[ 85]. Triple-negative Patients with brain metastases from triple-negative"/>
   <result pre="cancer [ 85]. Triple-negative Patients with brain metastases from triple-negative" exact="breast cancer" post="unfortunately lack targeted therapies and chemotherapy is currently their"/>
   <result pre="[ 85]. Triple-negative Patients with brain metastases from triple-negative breast" exact="cancer" post="unfortunately lack targeted therapies and chemotherapy is currently their"/>
   <result pre="they tend to occur late in the natural history of" exact="breast cancer" post="and by that point many times the breast cancer"/>
   <result pre="tend to occur late in the natural history of breast" exact="cancer" post="and by that point many times the breast cancer"/>
   <result pre="of breast cancer and by that point many times the" exact="breast cancer" post="is already chemotherapy-resistant. Suggested treatment approach Based on the"/>
   <result pre="breast cancer and by that point many times the breast" exact="cancer" post="is already chemotherapy-resistant. Suggested treatment approach Based on the"/>
   <result pre="Given the paucity of effective treatment options for patients with" exact="breast cancer" post="brain metastases, this currently represents an area of great"/>
   <result pre="the paucity of effective treatment options for patients with breast" exact="cancer" post="brain metastases, this currently represents an area of great"/>
   <result pre="overall survival benefit with the use of bevacizumab in metastatic" exact="breast cancer," post="which resulted in the US Food and Drug Administration"/>
   <result pre="Another approach that is currently under study in patients with" exact="breast cancer" post="brain metastases is targeting the phosphatidylinositol 3-kinase (PI3K)—mammalian target"/>
   <result pre="approach that is currently under study in patients with breast" exact="cancer" post="brain metastases is targeting the phosphatidylinositol 3-kinase (PI3K)—mammalian target"/>
   <result pre="of the most commonly altered pathways not only in metastatic" exact="breast cancer" post="but also in brain metastases [ 97]. Everolimus is"/>
   <result pre="the most commonly altered pathways not only in metastatic breast" exact="cancer" post="but also in brain metastases [ 97]. Everolimus is"/>
   <result pre="of brain metastases, particularly for patients with HER2-positive and triple-negative" exact="breast cancer," post="there have been efforts to develop strategies for prevention"/>
   <result pre="of using prophylactic cranial irradiation (PCI) in patients with these" exact="breast cancer" post="subtypes, similar to what is currently done for patients"/>
   <result pre="using prophylactic cranial irradiation (PCI) in patients with these breast" exact="cancer" post="subtypes, similar to what is currently done for patients"/>
   <result pre="to what is currently done for patients with small cell" exact="lung cancer." post="However, as mentioned earlier in this article, the timing"/>
   <result pre="development of brain metastases in patients with HER2-positive and triple-negative" exact="breast cancer" post="is not the same, nor is the same their"/>
   <result pre="of brain metastases in patients with HER2-positive and triple-negative breast" exact="cancer" post="is not the same, nor is the same their"/>
   <result pre="summary of currently ongoing studies evaluating different treatment strategies in" exact="breast cancer" post="brain metastases. Table 1 Ongoing clinical trials in breast"/>
   <result pre="of currently ongoing studies evaluating different treatment strategies in breast" exact="cancer" post="brain metastases. Table 1 Ongoing clinical trials in breast"/>
   <result pre="breast cancer brain metastases. Table 1 Ongoing clinical trials in" exact="breast cancer" post="brain metastases Tumor subtype Treatment/target Experimental arm Control arm"/>
   <result pre="cancer brain metastases. Table 1 Ongoing clinical trials in breast" exact="cancer" post="brain metastases Tumor subtype Treatment/target Experimental arm Control arm"/>
   <result pre="radiation therapy Conclusions Brain metastases are an increasing problem in" exact="breast cancer." post="They represent an unmet need for which more efficacious"/>
   <result pre="1. Lin NU Bellon JR Winer EP CNS metastases in" exact="breast cancer" post="J Clin Oncol Off J Am Soc Clin Oncol"/>
   <result pre="Lin NU Bellon JR Winer EP CNS metastases in breast" exact="cancer" post="J Clin Oncol Off J Am Soc Clin Oncol"/>
   <result pre="RJ Palmieri DC Bronder JL Stark AM Steeg PS Breast" exact="cancer" post="metastasis to the central nervous system Am J Pathol"/>
   <result pre="Prognostic factors and survival of patients with brain metastasis from" exact="breast cancer" post="who underwent craniotomy Cancer Med. 2015 4 7 989"/>
   <result pre="factors and survival of patients with brain metastasis from breast" exact="cancer" post="who underwent craniotomy Cancer Med. 2015 4 7 989"/>
   <result pre="positivity for the development of brain metastasis after newly diagnosed" exact="breast cancer" post="J Clin Oncol Off J Am Soc Clin Oncol"/>
   <result pre="for the development of brain metastasis after newly diagnosed breast" exact="cancer" post="J Clin Oncol Off J Am Soc Clin Oncol"/>
   <result pre="YL Sexton K Kramer R Hilsenbeck S Elledge R Primary" exact="breast cancer" post="phenotypes associated with propensity for central nervous system metastases"/>
   <result pre="Sexton K Kramer R Hilsenbeck S Elledge R Primary breast" exact="cancer" post="phenotypes associated with propensity for central nervous system metastases"/>
   <result pre="KN Holmberg SB Lindtner J Collins J et al. Identifying" exact="breast cancer" post="patients at risk for central nervous system (CNS) metastases"/>
   <result pre="Holmberg SB Lindtner J Collins J et al. Identifying breast" exact="cancer" post="patients at risk for central nervous system (CNS) metastases"/>
   <result pre="HS Kwon Y Lee KS Kim TH et al. Breast" exact="cancer" post="subtypes and survival in patients with brain metastases Breast"/>
   <result pre="E Martinello R Milani A Redana S et al. Metastatic" exact="breast cancer" post="subtypes and central nervous system metastases Breast. 2014 23"/>
   <result pre="Martinello R Milani A Redana S et al. Metastatic breast" exact="cancer" post="subtypes and central nervous system metastases Breast. 2014 23"/>
   <result pre="to development of brain metastases and survival in patients with" exact="breast cancer" post="J Neuro-Oncol 2013 112 3 467 472 10.1007/s11060-013-1083-9 12."/>
   <result pre="development of brain metastases and survival in patients with breast" exact="cancer" post="J Neuro-Oncol 2013 112 3 467 472 10.1007/s11060-013-1083-9 12."/>
   <result pre="Y et al. Treatment and prognosis of brain metastases from" exact="breast cancer" post="J Neuro-Oncol 2008 86 2 231 238 10.1007/s11060-007-9469-1 14."/>
   <result pre="et al. Treatment and prognosis of brain metastases from breast" exact="cancer" post="J Neuro-Oncol 2008 86 2 231 238 10.1007/s11060-007-9469-1 14."/>
   <result pre="on survival and the graded prognostic assessment for patients with" exact="breast cancer" post="and brain metastases Int J Radiat Oncol Biol Phys."/>
   <result pre="survival and the graded prognostic assessment for patients with breast" exact="cancer" post="and brain metastases Int J Radiat Oncol Biol Phys."/>
   <result pre="SW Islam R et al. Defining prognosis for women with" exact="breast cancer" post="and CNS metastases by HER2 status Ann Oncol Off"/>
   <result pre="Islam R et al. Defining prognosis for women with breast" exact="cancer" post="and CNS metastases by HER2 status Ann Oncol Off"/>
   <result pre="Conesa G Del Barco S Gonzalez-Jimenez S et al. Breast" exact="cancer" post="brain metastases: a review of the literature and a"/>
   <result pre="Murawska M Niwinski P Factors influencing survival in patients with" exact="breast cancer" post="and single or solitary brain metastasis Eur J Surg"/>
   <result pre="M Niwinski P Factors influencing survival in patients with breast" exact="cancer" post="and single or solitary brain metastasis Eur J Surg"/>
   <result pre="635 642 20. Niwinska A Murawska M Pogoda K Breast" exact="cancer" post="brain metastases: differences in survival depending on biological subtype,"/>
   <result pre="outcomes and prognostic factors for patients with brain metastases from" exact="breast cancer" post="of each subtype: a multicenter retrospective analysis Breast Cancer"/>
   <result pre="and prognostic factors for patients with brain metastases from breast" exact="cancer" post="of each subtype: a multicenter retrospective analysis Breast Cancer"/>
   <result pre="H Burrows E et al. The prognostic contribution of clinical" exact="breast cancer" post="subtype, age, and race among patients with breast cancer"/>
   <result pre="Burrows E et al. The prognostic contribution of clinical breast" exact="cancer" post="subtype, age, and race among patients with breast cancer"/>
   <result pre="clinical breast cancer subtype, age, and race among patients with" exact="breast cancer" post="brain metastases Cancer. 2011 117 8 1602 1611 10.1002/cncr.25746"/>
   <result pre="breast cancer subtype, age, and race among patients with breast" exact="cancer" post="brain metastases Cancer. 2011 117 8 1602 1611 10.1002/cncr.25746"/>
   <result pre="subtype on the risk and timing of brain metastasis in" exact="breast cancer" post="patients PloS One. 2014 9 2 e89389 10.1371/journal.pone.0089389 24586742"/>
   <result pre="on the risk and timing of brain metastasis in breast" exact="cancer" post="patients PloS One. 2014 9 2 e89389 10.1371/journal.pone.0089389 24586742"/>
   <result pre="Astner ST Molls M Prognostic scores in brain metastases from" exact="breast cancer" post="BMC Cancer. 2009 9 105 10.1186/1471-2407-9-105 19351389 27. Sperduto"/>
   <result pre="ST Molls M Prognostic scores in brain metastases from breast" exact="cancer" post="BMC Cancer. 2009 9 105 10.1186/1471-2407-9-105 19351389 27. Sperduto"/>
   <result pre="prognostic assessment as a tool for survival in patients with" exact="breast cancer" post="and brain metastases J Clin Oncol Off J Am"/>
   <result pre="assessment as a tool for survival in patients with breast" exact="cancer" post="and brain metastases J Clin Oncol Off J Am"/>
   <result pre="et al. A European Organisation for research and treatment of" exact="cancer" post="phase III trial of adjuvant whole-brain radiotherapy versus observation"/>
   <result pre="Yildiz R et al. Biological subtypes and survival outcomes in" exact="breast cancer" post="patients with brain metastases (study of the Anatolian Society"/>
   <result pre="R et al. Biological subtypes and survival outcomes in breast" exact="cancer" post="patients with brain metastases (study of the Anatolian Society"/>
   <result pre="JM Boada M Rubio D Salvador L Brain metastases from" exact="breast cancer" post="may respond to endocrine therapy Breast Cancer Res Treat."/>
   <result pre="Boada M Rubio D Salvador L Brain metastases from breast" exact="cancer" post="may respond to endocrine therapy Breast Cancer Res Treat."/>
   <result pre="58. Stewart DJ Dahrouge S Response of brain metastases from" exact="breast cancer" post="to megestrol acetate: a case report J Neuro-oncol 1995"/>
   <result pre="Stewart DJ Dahrouge S Response of brain metastases from breast" exact="cancer" post="to megestrol acetate: a case report J Neuro-oncol 1995"/>
   <result pre="Rath GK. Excellent response to letrozole in brain metastases from" exact="breast cancer." post="Acta Neurochir. 2008;150(6):613–4 (discussion 4-5). doi:10.1007/s00701-008-1576-z. 61. Ito K"/>
   <result pre="Kanai T et al. A case of brain metastases from" exact="breast cancer" post="that responded to anastrozole monotherapy Breast J 2009 15"/>
   <result pre="T et al. A case of brain metastases from breast" exact="cancer" post="that responded to anastrozole monotherapy Breast J 2009 15"/>
   <result pre="tamoxifen and metabolites into brain tissue and brain metastases in" exact="breast cancer" post="patients Br J Cancer. 1991 63 4 641 645"/>
   <result pre="and metabolites into brain tissue and brain metastases in breast" exact="cancer" post="patients Br J Cancer. 1991 63 4 641 645"/>
   <result pre="M et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic" exact="breast cancer" post="N Engl J Med. 2015 372 8 724 734"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast" exact="cancer" post="N Engl J Med. 2015 372 8 724 734"/>
   <result pre="and PET imaging of HER2-positive lesions in patients with metastatic" exact="breast cancer" post="Clin Pharmacol Ther 2010 87 5 586 592 10.1038/clpt.2010.12"/>
   <result pre="PET imaging of HER2-positive lesions in patients with metastatic breast" exact="cancer" post="Clin Pharmacol Ther 2010 87 5 586 592 10.1038/clpt.2010.12"/>
   <result pre="Y et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive" exact="breast cancer" post="J Nucl Med Off Publ Soc Nucl Med. 2013"/>
   <result pre="et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast" exact="cancer" post="J Nucl Med Off Publ Soc Nucl Med. 2013"/>
   <result pre="overall survival in patients with brain metastases from Her2 positive" exact="breast cancer" post="J Neuro-oncol 2007 85 3 311 317 10.1007/s11060-007-9420-5 69."/>
   <result pre="survival in patients with brain metastases from Her2 positive breast" exact="cancer" post="J Neuro-oncol 2007 85 3 311 317 10.1007/s11060-007-9420-5 69."/>
   <result pre="SB Kim TY et al. Brain metastases in Asian HER2-positive" exact="breast cancer" post="patients: anti-HER2 treatments and their impact on survival Br"/>
   <result pre="Kim TY et al. Brain metastases in Asian HER2-positive breast" exact="cancer" post="patients: anti-HER2 treatments and their impact on survival Br"/>
   <result pre="control and durable prolongation of systemic extracranial disease in HER2-overexpressing" exact="breast cancer" post="patients Br J Cancer. 2009 100 6 894 900"/>
   <result pre="and durable prolongation of systemic extracranial disease in HER2-overexpressing breast" exact="cancer" post="patients Br J Cancer. 2009 100 6 894 900"/>
   <result pre="metastases in patients with human epidermal growth factor receptor 2-positive" exact="breast cancer" post="J Clin Oncol Off J Am Soc Clin Oncol"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive breast" exact="cancer" post="J Clin Oncol Off J Am Soc Clin Oncol"/>
   <result pre="study of lapatinib in patients with brain metastases from HER2-positive" exact="breast cancer" post="Clin Cancer Res Off J Am Assoc Cancer Res."/>
   <result pre="of lapatinib in patients with brain metastases from HER2-positive breast" exact="cancer" post="Clin Cancer Res Off J Am Assoc Cancer Res."/>
   <result pre="Wardley A Davidson N et al. Treatment of HER2-positive metastatic" exact="breast cancer" post="with lapatinib and capecitabine in the lapatinib expanded access"/>
   <result pre="A Davidson N et al. Treatment of HER2-positive metastatic breast" exact="cancer" post="with lapatinib and capecitabine in the lapatinib expanded access"/>
   <result pre="al. Clinical outcome of patients with brain metastases from HER2-positive" exact="breast cancer" post="treated with lapatinib and capecitabine Ann Oncol Off J"/>
   <result pre="Clinical outcome of patients with brain metastases from HER2-positive breast" exact="cancer" post="treated with lapatinib and capecitabine Ann Oncol Off J"/>
   <result pre="study of lapatinib for brain metastases in patients with HER2-overexpressing" exact="breast cancer" post="following trastuzumab based systemic therapy and cranial radiotherapy: subset"/>
   <result pre="of lapatinib for brain metastases in patients with HER2-overexpressing breast" exact="cancer" post="following trastuzumab based systemic therapy and cranial radiotherapy: subset"/>
   <result pre="YH Rha SY et al. Clinical outcomes of HER2-positive metastatic" exact="breast cancer" post="patients with brain metastasis treated with lapatinib and capecitabine:"/>
   <result pre="Rha SY et al. Clinical outcomes of HER2-positive metastatic breast" exact="cancer" post="patients with brain metastasis treated with lapatinib and capecitabine:"/>
   <result pre="in patients with previously untreated brain metastases from HER2-positive metastatic" exact="breast cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol. 2013"/>
   <result pre="patients with previously untreated brain metastases from HER2-positive metastatic breast" exact="cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol. 2013"/>
   <result pre="lapatinib plus capecitabine versus capecitabine alone in women with advanced" exact="breast cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="plus capecitabine versus capecitabine alone in women with advanced breast" exact="cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="J Clin Oncol Off J Am Soc Clin Oncol"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="J Clin Oncol Off J Am Soc Clin Oncol"/>
   <result pre="M Baselga J et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med. 2012 367 19 1783 1791"/>
   <result pre="Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med. 2012 367 19 1783 1791"/>
   <result pre="(T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic" exact="breast cancer" post="and central nervous system metastases: a retrospective, exploratory analysis"/>
   <result pre="versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast" exact="cancer" post="and central nervous system metastases: a retrospective, exploratory analysis"/>
   <result pre="of central nervous system metastases in patients with HER2-positive metastatic" exact="breast cancer" post="treated with pertuzumab, trastuzumab, and docetaxel: results from the"/>
   <result pre="central nervous system metastases in patients with HER2-positive metastatic breast" exact="cancer" post="treated with pertuzumab, trastuzumab, and docetaxel: results from the"/>
   <result pre="for patients with advanced human epidermal growth factor receptor 2-positive" exact="breast cancer" post="and brain metastases: american Society of Clinical Oncology clinical"/>
   <result pre="patients with advanced human epidermal growth factor receptor 2-positive breast" exact="cancer" post="and brain metastases: american Society of Clinical Oncology clinical"/>
   <result pre="EM van der Sande JJ Response of brain metastases from" exact="breast cancer" post="to systemic chemotherapy Cancer. 1992 69 4 972 980"/>
   <result pre="van der Sande JJ Response of brain metastases from breast" exact="cancer" post="to systemic chemotherapy Cancer. 1992 69 4 972 980"/>
   <result pre="for patients with brain metastases from breast carcinoma, nonsmall cell" exact="lung carcinoma," post="or malignant melanoma: a prospective study Cancer. 1999 85"/>
   <result pre="L Bordeleau L Matthews S et al. Temozolomide in metastatic" exact="breast cancer" post="(MBC): a phase II trial of the National Cancer"/>
   <result pre="Bordeleau L Matthews S et al. Temozolomide in metastatic breast" exact="cancer" post="(MBC): a phase II trial of the National Cancer"/>
   <result pre="Abrey LE Capecitabine therapy of central nervous system metastases from" exact="breast cancer" post="J Neuro-oncol. 2007 85 2 223 227 10.1007/s11060-007-9409-0 94."/>
   <result pre="LE Capecitabine therapy of central nervous system metastases from breast" exact="cancer" post="J Neuro-oncol. 2007 85 2 223 227 10.1007/s11060-007-9409-0 94."/>
   <result pre="of carboplatin (C) and bevacizumab (BEV) in patients (pts) with" exact="breast cancer" post="brain metastases (BCBM). J Clin Oncol Off J Am"/>
   <result pre="carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast" exact="cancer" post="brain metastases (BCBM). J Clin Oncol Off J Am"/>
   <result pre="al. Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of" exact="breast cancer" post="progressing from radiotherapy: Results of the first stage of"/>
   <result pre="Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast" exact="cancer" post="progressing from radiotherapy: Results of the first stage of"/>
   <result pre="AV Brufsky AM Expression of high affinity folate receptor in" exact="breast cancer" post="brain metastasis Oncotarget. 2015 6 30 30327 30333 26160847"/>
   <result pre="Brufsky AM Expression of high affinity folate receptor in breast" exact="cancer" post="brain metastasis Oncotarget. 2015 6 30 30327 30333 26160847"/>
   <result pre="E Blackwell KL et al. Phosphatidylinositol 3-kinase pathway activation in" exact="breast cancer" post="brain metastases Breast Cancer Res BCR. 2011 13 6"/>
   <result pre="Blackwell KL et al. Phosphatidylinositol 3-kinase pathway activation in breast" exact="cancer" post="brain metastases Breast Cancer Res BCR. 2011 13 6"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4657385/results/search/disease/results.xml">
   <result pre="has been found to be amplified in gliomas and non-small-cell" exact="lung carcinoma" post="while ErbB2 amplifications are seen in breast, ovarian, bladder,"/>
   <result pre="while ErbB2 amplifications are seen in breast, ovarian, bladder, non-small-cell" exact="lung carcinoma," post="as well as several other tumor types. Several data"/>
   <result pre="anti-cancer therapy to inhibit ErbB family receptor activation. ErbB receptors" exact="cancer" post="epithelial-mesenchymal transition migration cell signaling Funding Centre National de"/>
   <result pre="receptors in epithelial-mesenchymal transition (EMT), migration, and tumor invasion of" exact="cancer" post="cells. Role of ErbB Receptors in Cancer and New"/>
   <result pre="Developed in Anti-Cancer Therapy ErbB receptors were linked to human" exact="cancer" post="pathogenesis by about three decades ago. For example, EGFR"/>
   <result pre="clinical studies suggest that they play an important role in" exact="cancer" post="development and progression. These receptors have been largely studied,"/>
   <result pre="metastasize, resistance to therapy, and possibly the generation of stem-like" exact="cancer" post="cells ( Mallini et al., 2014). Members of the"/>
   <result pre="motility and invasiveness of tumor cells, and EGFR inhibitors block" exact="cancer" post="cell migration in vitro. Cellular migration and invasion is"/>
   <result pre="a crucial role for EGFR inhibitors in the control of" exact="cancer" post="metastasis ( Yue et al., 2012; Liu et al.,"/>
   <result pre="induction of fibronectin expression, a major component of ECM, in" exact="breast cancer" post="cells that triggers cell adhesion and cell invasion. Several"/>
   <result pre="of fibronectin expression, a major component of ECM, in breast" exact="cancer" post="cells that triggers cell adhesion and cell invasion. Several"/>
   <result pre="is expressed in circulating tumors cells of early and metastatic" exact="breast cancer" post="patients. The consequences of HER2 expression are usually more"/>
   <result pre="expressed in circulating tumors cells of early and metastatic breast" exact="cancer" post="patients. The consequences of HER2 expression are usually more"/>
   <result pre="et al., 2010). Indeed, circulating tumor cells and metastases of" exact="breast cancer" post="present a dynamic in vivo pattern of EMT ("/>
   <result pre="al., 2010). Indeed, circulating tumor cells and metastases of breast" exact="cancer" post="present a dynamic in vivo pattern of EMT ("/>
   <result pre="Morel et al., 2008; Creighton et al., 2009). EMT in" exact="breast cancer" post="stem cells could play an important role in the"/>
   <result pre="et al., 2008; Creighton et al., 2009). EMT in breast" exact="cancer" post="stem cells could play an important role in the"/>
   <result pre="Bedard et al., 2009) and that HER2 overexpression in multiple" exact="breast cancer" post="cell lines results in an increase of ALDH1 +"/>
   <result pre="et al., 2009) and that HER2 overexpression in multiple breast" exact="cancer" post="cell lines results in an increase of ALDH1 +"/>
   <result pre="carcinomas rearranges the actin cytoskeleton, induces focal adhesions, and limits" exact="esophageal cancer" post="cell migration by rapid inhibition of ERK1/2, Akt, STAT3,"/>
   <result pre="rearranges the actin cytoskeleton, induces focal adhesions, and limits esophageal" exact="cancer" post="cell migration by rapid inhibition of ERK1/2, Akt, STAT3,"/>
   <result pre="can both act on endothelial cells and activate EGFR in" exact="cancer" post="cells are produced by bone marrow stromal cells ("/>
   <result pre="a better understanding of the biology of ErbB signaling in" exact="cancer" post="have led to the development of many therapeutic agents"/>
   <result pre="directed against EGFR First approval by FDA in 2006 Metastatic" exact="colorectal cancer" post="Erlotinib (Tarceva) Roche/Genentech/OSI EGFR Inhibitor of EGFR signaling First"/>
   <result pre="against EGFR First approval by FDA in 2006 Metastatic colorectal" exact="cancer" post="Erlotinib (Tarceva) Roche/Genentech/OSI EGFR Inhibitor of EGFR signaling First"/>
   <result pre="EGFR signaling First approval by FDA in 2004 Non-small cell" exact="lung cancer," post="pancreatic cancer Gefitinib (Iressa) AstraZeneca EGFR Inhibitor of EGFR"/>
   <result pre="First approval by FDA in 2004 Non-small cell lung cancer," exact="pancreatic cancer" post="Gefitinib (Iressa) AstraZeneca EGFR Inhibitor of EGFR signaling First"/>
   <result pre="approval by FDA in 2004 Non-small cell lung cancer, pancreatic" exact="cancer" post="Gefitinib (Iressa) AstraZeneca EGFR Inhibitor of EGFR signaling First"/>
   <result pre="EGFR signaling First approval by FDA in 2003 Non-small cell" exact="lung cancer," post="esophageal cancer Lapatinib (Tykerb/Tyverb) GlaxoSmithKline EGFR/HER2 Inhibitor of EGFR/HER2"/>
   <result pre="First approval by FDA in 2003 Non-small cell lung cancer," exact="esophageal cancer" post="Lapatinib (Tykerb/Tyverb) GlaxoSmithKline EGFR/HER2 Inhibitor of EGFR/HER2 signaling First"/>
   <result pre="approval by FDA in 2003 Non-small cell lung cancer, esophageal" exact="cancer" post="Lapatinib (Tykerb/Tyverb) GlaxoSmithKline EGFR/HER2 Inhibitor of EGFR/HER2 signaling First"/>
   <result pre="of EGFR/HER2 signaling First approval by FDA in 2007 Metastatic" exact="breast cancer" post="Dacomitinib Pfizer EGFR/HER2/HER4 Pan-inhibitor of ErbB receptors signaling Phase"/>
   <result pre="EGFR/HER2 signaling First approval by FDA in 2007 Metastatic breast" exact="cancer" post="Dacomitinib Pfizer EGFR/HER2/HER4 Pan-inhibitor of ErbB receptors signaling Phase"/>
   <result pre="EGFR/HER2/HER4 Pan-inhibitor of ErbB receptors signaling Phase III Non-small cell" exact="lung cancer" post="Trastuzumab (Herceptin) Genentech HER2 mAb directed against HER2 First"/>
   <result pre="Pan-inhibitor of ErbB receptors signaling Phase III Non-small cell lung" exact="cancer" post="Trastuzumab (Herceptin) Genentech HER2 mAb directed against HER2 First"/>
   <result pre="directed against HER2 First approval by FDA in 1998 HER2-positive" exact="breast cancer" post="HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma Pertuzumab (Perjeta)"/>
   <result pre="against HER2 First approval by FDA in 1998 HER2-positive breast" exact="cancer" post="HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma Pertuzumab (Perjeta)"/>
   <result pre="directed against HER2 First approval by FDA in 2012 Breast" exact="cancer" post="Margetuximab (MGAH22) MacroGenics HER2 mAb directed against HER2 Phase"/>
   <result pre="Amgen HER3 mAb directed against HER3 Phase I–II Non-small cell" exact="lung cancer" post="mAb, monoclonal antibody. Cetuximab and Panitumumab are mAbs that"/>
   <result pre="HER3 mAb directed against HER3 Phase I–II Non-small cell lung" exact="cancer" post="mAb, monoclonal antibody. Cetuximab and Panitumumab are mAbs that"/>
   <result pre="Activity of Panitumumab has been demonstrated against variety of advanced" exact="cancer" post="patients, including renal carcinomas and metastatic colorectal cancer in"/>
   <result pre="variety of advanced cancer patients, including renal carcinomas and metastatic" exact="colorectal cancer" post="in clinical trials ( Douillard et al., 2010). Another"/>
   <result pre="of advanced cancer patients, including renal carcinomas and metastatic colorectal" exact="cancer" post="in clinical trials ( Douillard et al., 2010). Another"/>
   <result pre="Trastuzumab is predominantly used in the treatment of the ErbB2-positive" exact="breast cancer" post="subtype where its combination with conventional chemotherapy, had a"/>
   <result pre="is predominantly used in the treatment of the ErbB2-positive breast" exact="cancer" post="subtype where its combination with conventional chemotherapy, had a"/>
   <result pre="on disease free survival of patients with early stage ErbB2+" exact="breast cancer" post="( Hudis, 2007). Currently, small molecule inhibitors under clinical"/>
   <result pre="disease free survival of patients with early stage ErbB2+ breast" exact="cancer" post="( Hudis, 2007). Currently, small molecule inhibitors under clinical"/>
   <result pre="specific and selective TKIs have been approved by authorities for" exact="cancer" post="treatment. Several approaches have been developed: TKI that targets"/>
   <result pre="and are approved first-line therapies for patients with non-small cell" exact="lung cancer" post="(NSCLC) presenting activating EGFR mutations. Unfortunately, despite these agents"/>
   <result pre="are approved first-line therapies for patients with non-small cell lung" exact="cancer" post="(NSCLC) presenting activating EGFR mutations. Unfortunately, despite these agents"/>
   <result pre="2007, Lapatinib was approved by the FDA for patients with" exact="breast cancer" post="as second-line treatment. Lapatinib, in combination with an aromatase"/>
   <result pre="Lapatinib was approved by the FDA for patients with breast" exact="cancer" post="as second-line treatment. Lapatinib, in combination with an aromatase"/>
   <result pre="first-line therapy for treatment of postmenopausal women with estrogen/HER2 receptor-positive" exact="breast cancer." post="Another inhibitor, Dacomitinib (PF-00299804, PF299), is currently under development."/>
   <result pre="multivalent agents that combine several modes of EGFR or other" exact="cancer" post="target inhibition. Affibody molecules are derived from the B-domain"/>
   <result pre="corresponding HER2-negative cells, and induce a rapid shrinkage of BT-474" exact="breast cancer" post="xenograft tumors. This study demonstrates that HER2-affitoxin is an"/>
   <result pre="HER2-negative cells, and induce a rapid shrinkage of BT-474 breast" exact="cancer" post="xenograft tumors. This study demonstrates that HER2-affitoxin is an"/>
   <result pre="and cell signaling induced by EGF and ErbB2 receptors in" exact="cancer" post="cells ( Bennasroune et al., 2004a). More recently, it"/>
   <result pre="tumor growth and metastasis in genetically engineered mouse model of" exact="breast cancer" post="( Arpel et al., 2014). Conclusion Even if the"/>
   <result pre="growth and metastasis in genetically engineered mouse model of breast" exact="cancer" post="( Arpel et al., 2014). Conclusion Even if the"/>
   <result pre="cell proliferation and migration are not widely understood. Moreover, the" exact="cancer" post="progression is accompanied by an extensive remodeling of ECM"/>
   <result pre="be used both as diagnostic markers and as targets in" exact="cancer" post="therapy. Indeed, studying the role of ECM components and"/>
   <result pre="2015). ErbB polymorphisms: insights and implications for response to targeted" exact="cancer" post="therapeutics. Front. Genet. 6: 17 10.3389/fgene.2015.00017 Al Moustafa A."/>
   <result pre="P. ( 2004b). Tyrosine kinase receptors as attractive targets of" exact="cancer" post="therapy. Crit. Rev. Oncol. Hematol. 50 23– 38. 10.1016/j.critrevonc.2003.08.004"/>
   <result pre="Jr. Nakshatri H. ( 2013). Identification of FDA-approved drugs targeting" exact="breast cancer" post="stem cells along with biomarkers of sensitivity. Sci. Rep."/>
   <result pre="Nakshatri H. ( 2013). Identification of FDA-approved drugs targeting breast" exact="cancer" post="stem cells along with biomarkers of sensitivity. Sci. Rep."/>
   <result pre="of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of" exact="breast cancer." post="Oncogene 31 3741– 3753. 10.1038/onc.2011.540 22120722 Bouyain S. Longo"/>
   <result pre="print] Fidler I. J. ( 2002). The organ microenvironment and" exact="cancer" post="metastasis. Differentiation 70 498– 505. 10.1046/j.1432-0436.2002.700904.x 12492492 Friedl P."/>
   <result pre="2009). Quantitative multiplexed analysis of ErbB family coexpression for primary" exact="breast cancer" post="prognosis in a large retrospective cohort. Cancer 115 2400–"/>
   <result pre="Quantitative multiplexed analysis of ErbB family coexpression for primary breast" exact="cancer" post="prognosis in a large retrospective cohort. Cancer 115 2400–"/>
   <result pre="P. H. ( 2011). Targeting the HER/EGFR/ErbB family to prevent" exact="breast cancer." post="Cancer Prev. Res. (Phila) 4 1149– 1157. 10.1158/1940-6207.CAPR-11-0334 21816844"/>
   <result pre="of fibronectin by HER2 overexpression triggers adhesion and invasion of" exact="breast cancer" post="cells. Exp. Cell Res. 333 116– 126. 10.1016/j.yexcr.2015.02.019 25743092"/>
   <result pre="fibronectin by HER2 overexpression triggers adhesion and invasion of breast" exact="cancer" post="cells. Exp. Cell Res. 333 116– 126. 10.1016/j.yexcr.2015.02.019 25743092"/>
   <result pre="PI3K/Akt signaling kinases are expressed in circulating tumor cells of" exact="breast cancer" post="patients. Breast Cancer Res. 10 R80 10.1186/bcr2149 Kedrin D."/>
   <result pre="signaling kinases are expressed in circulating tumor cells of breast" exact="cancer" post="patients. Breast Cancer Res. 10 R80 10.1186/bcr2149 Kedrin D."/>
   <result pre="of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+" exact="breast cancer" post="by expanding the cancer stem cell population. Mol. Cell."/>
   <result pre="an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast" exact="cancer" post="by expanding the cancer stem cell population. Mol. Cell."/>
   <result pre="mediates trastuzumab resistance in HER2+ breast cancer by expanding the" exact="cancer" post="stem cell population. Mol. Cell. 47 570– 584. 10.1016/j.molcel.2012.06.014"/>
   <result pre="G. ( 2014). Emerging protein kinase inhibitors for non-small cell" exact="lung cancer." post="Expert Opin. Emerg. Drugs 19 51– 65. 10.1517/14728214.2014.873403 24354593"/>
   <result pre="A. ( 2014). Epithelial-to-mesenchymal transition: what is the impact on" exact="breast cancer" post="stem cells and drug resistance. Cancer Treat. Rev. 40"/>
   <result pre="( 2014). Epithelial-to-mesenchymal transition: what is the impact on breast" exact="cancer" post="stem cells and drug resistance. Cancer Treat. Rev. 40"/>
   <result pre="monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in" exact="breast cancer" post="cells. Cancer Res. 61 4744– 4749. 11406546 Morel A."/>
   <result pre="antibody, inhibits basal and activated Her2 ectodomain cleavage in breast" exact="cancer" post="cells. Cancer Res. 61 4744– 4749. 11406546 Morel A."/>
   <result pre="Hinkal G. Ansieau S. Puisieux A. ( 2008). Generation of" exact="breast cancer" post="stem cells through epithelial-mesenchymal transition. PLoS ONE 3: e2888"/>
   <result pre="G. Ansieau S. Puisieux A. ( 2008). Generation of breast" exact="cancer" post="stem cells through epithelial-mesenchymal transition. PLoS ONE 3: e2888"/>
   <result pre="of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for" exact="cancer" post="therapy. Crit. Rev. Oncol. Hematol. 38 17– 23. 10.1016/S1040-8428(00)00134-7"/>
   <result pre="Y. Pines G. ( 2012). The ERBB network: at last," exact="cancer" post="therapy meets systems biology. Nat. Rev. Cancer 12 553–"/>
   <result pre="signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant" exact="ovarian cancer" post="cells. Oncogene 31 2309– 2322. 10.1038/onc.2011.409 21909139 Zhan L."/>
   <result pre="promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian" exact="cancer" post="cells. Oncogene 31 2309– 2322. 10.1038/onc.2011.409 21909139 Zhan L."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4659935/results/search/disease/results.xml">
   <result pre="characterized using circulating tumour DNA in a case of metastatic" exact="breast cancer" post="Murtaza Muhammed 1 2 3 4 * http://orcid.org/0000-0001-7557-2861 Dawson"/>
   <result pre="using circulating tumour DNA in a case of metastatic breast" exact="cancer" post="Murtaza Muhammed 1 2 3 4 * http://orcid.org/0000-0001-7557-2861 Dawson"/>
   <result pre="analysis can be used to track tumour burden and analyse" exact="cancer" post="genomes non-invasively but the extent to which it represents"/>
   <result pre="Here we follow a patient with metastatic ER-positive and HER2-positive" exact="breast cancer" post="receiving two lines of targeted therapy over 3 years."/>
   <result pre="we follow a patient with metastatic ER-positive and HER2-positive breast" exact="cancer" post="receiving two lines of targeted therapy over 3 years."/>
   <result pre="biopsy and plasma samples in a single patient with metastatic" exact="breast cancer" post="shows that circulating tumour DNA can allow real-time sampling"/>
   <result pre="and plasma samples in a single patient with metastatic breast" exact="cancer" post="shows that circulating tumour DNA can allow real-time sampling"/>
   <result pre="multiple tumour and plasma samples over 3 years from a" exact="breast cancer" post="patient and show mutations detected in the plasma samples"/>
   <result pre="tumour and plasma samples over 3 years from a breast" exact="cancer" post="patient and show mutations detected in the plasma samples"/>
   <result pre="efficacy and duration of response to targeted treatments in metastatic" exact="cancer" post="1 2 3. Evaluating heterogeneity to guide choice and"/>
   <result pre="receptor-positive (ER+) human epidermal growth factor receptor 2-positive (HER2+) metastatic" exact="breast cancer" post="treated with sequential targeted therapies (tamoxifen and trastuzumab, followed"/>
   <result pre="(ER+) human epidermal growth factor receptor 2-positive (HER2+) metastatic breast" exact="cancer" post="treated with sequential targeted therapies (tamoxifen and trastuzumab, followed"/>
   <result pre="on imaging. These results, from a single patient with metastatic" exact="breast cancer," post="suggest that ctDNA reflects clonal tumour hierarchy and captures"/>
   <result pre="and hepatomegaly. Core biopsies from the breast lump showed ductal" exact="carcinoma in situ" post="(sample labelled P1.1; Supplementary Fig. 1 and Supplementary Table"/>
   <result pre="clusters 3–8). The most parsimonious pathway of evolution in this" exact="cancer" post="together with mutation clustering results is presented in Fig."/>
   <result pre="comparison of biopsy and plasma samples collected from a metastatic" exact="breast cancer" post="patient over a 3-year clinical course. Our results show"/>
   <result pre="of biopsy and plasma samples collected from a metastatic breast" exact="cancer" post="patient over a 3-year clinical course. Our results show"/>
   <result pre="treated with targeted therapies heralds a new era for precision" exact="cancer" post="medicine. Methods Sample collection and exome sequencing Informed consent"/>
   <result pre="cellular frequencies shown in the figures represent the proportion of" exact="cancer" post="cells containing each set of clonal mutations (hence stem"/>
   <result pre="characterized using circulating tumour DNA in a case of metastatic" exact="breast cancer." post="Nat. Commun. 6:8760 doi: 10.1038/ncomms9760 (2015). Supplementary Material Supplementary"/>
   <result pre="the DETECT study, all medical and ancillary staff in the" exact="breast cancer" post="clinic and the patient for consenting to participate. We"/>
   <result pre="DETECT study, all medical and ancillary staff in the breast" exact="cancer" post="clinic and the patient for consenting to participate. We"/>
   <result pre="&amp;amp; Caldas C. The implications of clonal genome evolution for" exact="cancer" post="medicine. N. Engl. J. Med. 368, 842– 851 ("/>
   <result pre="Murtaza M. et al. Non-invasive analysis of acquired resistance to" exact="cancer" post="therapy by sequencing of plasma DNA . Nature 497,"/>
   <result pre="et al. Analysis of circulating tumour DNA to monitor metastatic" exact="breast cancer." post="N. Engl. J. Med. 368, 1199– 1209 ( 2013)."/>
   <result pre="23780408 Forshew T. et al. Noninvasive identification and monitoring of" exact="cancer" post="mutations by targeted deep sequencing of plasma DNA ."/>
   <result pre="Tumor-associated copy number changes in the circulation of patients with" exact="prostate cancer" post="identified through whole-genome sequencing . Genome Med. 5, 30"/>
   <result pre="copy number changes in the circulation of patients with prostate" exact="cancer" post="identified through whole-genome sequencing . Genome Med. 5, 30"/>
   <result pre="25009010 Eirew P. et al. Dynamics of genomic clones in" exact="breast cancer" post="patient xenografts at single-cell resolution. Nature 518, 422– 426"/>
   <result pre="Eirew P. et al. Dynamics of genomic clones in breast" exact="cancer" post="patient xenografts at single-cell resolution. Nature 518, 422– 426"/>
   <result pre="tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in" exact="breast cancer" post="cells . Cell Cycle 14, 648– 655 ( 2015)."/>
   <result pre="kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast" exact="cancer" post="cells . Cell Cycle 14, 648– 655 ( 2015)."/>
   <result pre="PI3K pathway as a major determinant of trastuzumab resistance in" exact="breast cancer" post=". Cancer Cell 12, 395– 402 ( 2007). 17936563"/>
   <result pre="pathway as a major determinant of trastuzumab resistance in breast" exact="cancer" post=". Cancer Cell 12, 395– 402 ( 2007). 17936563"/>
   <result pre="al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant" exact="breast cancer" post=". Clin. Cancer Res. 18, 6784– 6791 ( 2012)."/>
   <result pre="Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast" exact="cancer" post=". Clin. Cancer Res. 18, 6784– 6791 ( 2012)."/>
   <result pre="the manuscript. N.R. and D.G. are co-founders of Inivata, a" exact="cancer" post="genomics company focused on ctDNA analysis. D.T. is a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4664841/results/search/disease/results.xml">
   <result pre="the treatment of refractory brain metastases in patients with HER2–neu-positive" exact="breast cancer" post="Sengupta S. 1 Rojas R. 2 Mahadevan A. 3"/>
   <result pre="treatment of refractory brain metastases in patients with HER2–neu-positive breast" exact="cancer" post="Sengupta S. 1 Rojas R. 2 Mahadevan A. 3"/>
   <result pre="omv01001_thumb.gif Abstract Nervous system relapse of patients with advanced HER2–neu-positive" exact="breast cancer" post="is an increasing problem, with one-third of women developing"/>
   <result pre="Abstract Nervous system relapse of patients with advanced HER2–neu-positive breast" exact="cancer" post="is an increasing problem, with one-third of women developing"/>
   <result pre="cross the blood–brain barrier, as combination therapy to treat HER2–neu-positive" exact="breast cancer" post="with brain metastases. page-count: INTRODUCTION Patients with breast cancer"/>
   <result pre="the blood–brain barrier, as combination therapy to treat HER2–neu-positive breast" exact="cancer" post="with brain metastases. page-count: INTRODUCTION Patients with breast cancer"/>
   <result pre="HER2–neu-positive breast cancer with brain metastases. page-count: INTRODUCTION Patients with" exact="breast cancer" post="that overexpress HER2/neu have a poor prognosis, shorter relapse"/>
   <result pre="breast cancer with brain metastases. page-count: INTRODUCTION Patients with breast" exact="cancer" post="that overexpress HER2/neu have a poor prognosis, shorter relapse"/>
   <result pre="low survival rate. Before the introduction of HER2-targeted therapy, HER2-positive" exact="breast cancer" post="was treated with protocols similar to those employed for"/>
   <result pre="survival rate. Before the introduction of HER2-targeted therapy, HER2-positive breast" exact="cancer" post="was treated with protocols similar to those employed for"/>
   <result pre="combination with systemic chemotherapy for the treatment of HER2-positive metastatic" exact="breast cancer." post="Nervous system relapse of patients with advanced HER2–neu-positive breast"/>
   <result pre="breast cancer. Nervous system relapse of patients with advanced HER2–neu-positive" exact="breast cancer" post="is an increasing problem, with one-third of women developing"/>
   <result pre="cancer. Nervous system relapse of patients with advanced HER2–neu-positive breast" exact="cancer" post="is an increasing problem, with one-third of women developing"/>
   <result pre="of women developing brain metastases. However, once patients with HER2/neu" exact="breast cancer" post="have brain metastases, they tend to fail all the"/>
   <result pre="women developing brain metastases. However, once patients with HER2/neu breast" exact="cancer" post="have brain metastases, they tend to fail all the"/>
   <result pre="namely CPT-11 and avastin, in this group of HER2/neu metastatic" exact="breast cancer" post="patients. CASE REPORT Women who had had failed other"/>
   <result pre="CPT-11 and avastin, in this group of HER2/neu metastatic breast" exact="cancer" post="patients. CASE REPORT Women who had had failed other"/>
   <result pre="Women who had had failed other treatments for HER2–neu-positive metastatic" exact="breast cancer" post="were selected. There were four women (Patients 1–4, Table"/>
   <result pre="who had had failed other treatments for HER2–neu-positive metastatic breast" exact="cancer" post="were selected. There were four women (Patients 1–4, Table"/>
   <result pre="1: Characteristics of the four patients Patient and type of" exact="breast cancer" post="Radiation dose Chemotherapy Number of brain metastases Surgery Patient"/>
   <result pre="Characteristics of the four patients Patient and type of breast" exact="cancer" post="Radiation dose Chemotherapy Number of brain metastases Surgery Patient"/>
   <result pre="of brain metastases Surgery Patient 1 HER-2-/neu-positive stage IIA infiltrating" exact="breast cancer" post="ER/PR negative After her right frontal metastasis was resected,"/>
   <result pre="brain metastases Surgery Patient 1 HER-2-/neu-positive stage IIA infiltrating breast" exact="cancer" post="ER/PR negative After her right frontal metastasis was resected,"/>
   <result pre="cerebellar mass Resected Patient 4 HER-2-/neu- positive Grade 2 invasive" exact="breast cancer" post="with lympho vascular invasion She had radiosurgery to left"/>
   <result pre="mass Resected Patient 4 HER-2-/neu- positive Grade 2 invasive breast" exact="cancer" post="with lympho vascular invasion She had radiosurgery to left"/>
   <result pre="estrogen receptor; PR, partial response; SRS, stereotactic radio-surgery; DCIS, ductal" exact="carcinoma in situ;" post="WBRT, whole-brain radiation. Table 2: Patient outcomes on the"/>
   <result pre="lymphopenia (2/4). Treatment-related non-hematologic grade 3/4 toxicities were: fatigue (2/4)," exact="alopecia" post="(1/4) and diarrhea (1/4). Figure 1: Patient 1: MRI"/>
   <result pre="non-hematologic grade 3/4 toxicities were: fatigue (2/4), alopecia (1/4) and" exact="diarrhea" post="(1/4). Figure 1: Patient 1: MRI scans post contrast"/>
   <result pre="were taken ∼5 months apart. DISCUSSION In terms of cancers," exact="lung cancer" post="and then breast cancer are the main causes of"/>
   <result pre="taken ∼5 months apart. DISCUSSION In terms of cancers, lung" exact="cancer" post="and then breast cancer are the main causes of"/>
   <result pre="apart. DISCUSSION In terms of cancers, lung cancer and then" exact="breast cancer" post="are the main causes of death in women. According"/>
   <result pre="DISCUSSION In terms of cancers, lung cancer and then breast" exact="cancer" post="are the main causes of death in women. According"/>
   <result pre="the American Cancer Society, ∼1.3 million women are diagnosed with" exact="breast cancer" post="per year globally, and ∼465 000 will die from"/>
   <result pre="American Cancer Society, ∼1.3 million women are diagnosed with breast" exact="cancer" post="per year globally, and ∼465 000 will die from"/>
   <result pre="globally, and ∼465 000 will die from this cancer. Breast" exact="cancer" post="has become a chronic disease, and metastasis to the"/>
   <result pre="HER2/neu, and this is found in ∼30% of patients with" exact="breast cancer." post="This in turn leads to poor survival and more"/>
   <result pre="the usual chemotherapeutic regimens used in the treatment of metastatic" exact="breast cancer" post="[ 4, 5]. Experimental models indicate that neutralizing antibodies"/>
   <result pre="usual chemotherapeutic regimens used in the treatment of metastatic breast" exact="cancer" post="[ 4, 5]. Experimental models indicate that neutralizing antibodies"/>
   <result pre="cause decreased angiogenesis secondary to vascular endothelial growth factor gene" exact="suppression" post="[ 6]. On 22 February 2008, the US Food"/>
   <result pre="Genentech) plus paclitaxel as first-line therapy in patients with metastatic" exact="breast cancer" post="[ 7]. A multicenter phase III randomized trial of"/>
   <result pre="plus paclitaxel as first-line therapy in patients with metastatic breast" exact="cancer" post="[ 7]. A multicenter phase III randomized trial of"/>
   <result pre="adjuvant therapy for patients with HER2-positive node-positive or high-risk node-negative" exact="breast cancer" post="comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus"/>
   <result pre="therapy for patients with HER2-positive node-positive or high-risk node-negative breast" exact="cancer" post="comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus"/>
   <result pre="was tried in four women as outlined above with metastatic" exact="breast cancer" post="to the brain, who had failed various treatment options."/>
   <result pre="tried in four women as outlined above with metastatic breast" exact="cancer" post="to the brain, who had failed various treatment options."/>
   <result pre="response for the treatment of refractory brain metastases from HER2–neu-positive" exact="breast cancer." post="The regimen was well tolerated with improvement of time"/>
   <result pre="A simple survival score for patients with brain metastases from" exact="breast cancer." post="Strahlenther Onkol 2013; 189: 664– 7. 23740157 2 Yamamoto"/>
   <result pre="Revillion F Bonneterre J Peyrat JP ERBB2 oncogene in human" exact="breast cancer" post="and its clinical significance. Eur J Cancer 1998; 34:"/>
   <result pre="F Bonneterre J Peyrat JP ERBB2 oncogene in human breast" exact="cancer" post="and its clinical significance. Eur J Cancer 1998; 34:"/>
   <result pre="Alvarez RH Valero V Hortobagyi GN Emerging targeted therapies for" exact="breast cancer." post="Clin Oncol 2010; 28: 3366– 79. 8 Chen W"/>
   <result pre="JA Rich JN et al. Bevacizumab plus irinotecan in recurrent" exact="glioblastoma multiforme." post="J Clin Oncol 2007; 25: 4722– 29. 17947719"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4665969/results/search/disease/results.xml">
   <result pre="treatment of patients with human epidermal growth factor receptor 2-positive" exact="breast cancer" post="in Japan OSAKO TOMOFUMI NISHIMURA REIKI NISHIYAMA YASUYUKI FUJISUE"/>
   <result pre="of patients with human epidermal growth factor receptor 2-positive breast" exact="cancer" post="in Japan OSAKO TOMOFUMI NISHIMURA REIKI NISHIYAMA YASUYUKI FUJISUE"/>
   <result pre="factor receptor 2 (HER2) agent, is effective for metastatic HER2-positive" exact="breast cancer" post="when used in combination with taxane and trastuzumab. The"/>
   <result pre="receptor 2 (HER2) agent, is effective for metastatic HER2-positive breast" exact="cancer" post="when used in combination with taxane and trastuzumab. The"/>
   <result pre="A phase I clinical trial of pertuzumab for HER2-positive metastatic" exact="breast cancer" post="was first conducted in the United States in 2001"/>
   <result pre="phase I clinical trial of pertuzumab for HER2-positive metastatic breast" exact="cancer" post="was first conducted in the United States in 2001"/>
   <result pre="not enrolled in a global phase II trial for metastatic" exact="breast cancer" post="(study ID no. BO17929) and no phase II trial"/>
   <result pre="enrolled in a global phase II trial for metastatic breast" exact="cancer" post="(study ID no. BO17929) and no phase II trial"/>
   <result pre="been conducted. A phase III trial on pertuzumab for metastatic" exact="breast cancer" post="(CLEOPATRA study), which included 53 Japanese patients, revealed that"/>
   <result pre="conducted. A phase III trial on pertuzumab for metastatic breast" exact="cancer" post="(CLEOPATRA study), which included 53 Japanese patients, revealed that"/>
   <result pre="a postmarketing clinical trial for Japanese patients with HER2-positive metastatic" exact="breast cancer" post="(COMACHI study) was initiated in November, 2013, to investigate"/>
   <result pre="postmarketing clinical trial for Japanese patients with HER2-positive metastatic breast" exact="cancer" post="(COMACHI study) was initiated in November, 2013, to investigate"/>
   <result pre="are currently ongoing. These trials included Japanese patients with HER2-positive" exact="breast cancer." post="Pertuzumab was approved in Japan in August, 2013 due"/>
   <result pre="of pertuzumab as second- or later-line treatment for HER2-positive metastatic" exact="breast cancer," post="as well as first-line treatment. Furthermore, pertuzumab may be"/>
   <result pre="other countries. pertuzumab trastuzumab human epidermal growth factor receptor 2" exact="breast cancer" post="clinical trial Japan Introduction Human epidermal growth factor receptor"/>
   <result pre="countries. pertuzumab trastuzumab human epidermal growth factor receptor 2 breast" exact="cancer" post="clinical trial Japan Introduction Human epidermal growth factor receptor"/>
   <result pre="growth factor receptor 2 (HER2) is a biomarker expressed on" exact="cancer" post="cell membranes and is overexpressed in 15–20% of breast"/>
   <result pre="the first anti-HER2 agent, improved the clinical outcome of HER2-positive" exact="breast cancer" post="when used in the metastatic and adjuvant settings ("/>
   <result pre="first anti-HER2 agent, improved the clinical outcome of HER2-positive breast" exact="cancer" post="when used in the metastatic and adjuvant settings ("/>
   <result pre="expected to improve the clinical outcomes of patients with HER2-positive" exact="breast cancer." post="Several ongoing clinical trials on these anti-HER2 agents are"/>
   <result pre="are conducted to establish the optimal treatment strategy for HER2-positive" exact="breast cancer." post="Pertuzumab blocks the domain of the HER2 protein associated"/>
   <result pre="pathway of HER2, which controls the existence and growth of" exact="cancer" post="cells ( 11, 13– 15). Similar to trastuzumab, pertuzumab"/>
   <result pre="13, 16). In a phase III trial for HER2-positive metastatic" exact="breast cancer" post="(CLEOPATRA study), the patients received placebo plus trastuzumab plus"/>
   <result pre="16). In a phase III trial for HER2-positive metastatic breast" exact="cancer" post="(CLEOPATRA study), the patients received placebo plus trastuzumab plus"/>
   <result pre="and docetaxel for the treatment of patients with HER2-positive metastatic" exact="breast cancer" post="under the condition that they did not receive any"/>
   <result pre="docetaxel for the treatment of patients with HER2-positive metastatic breast" exact="cancer" post="under the condition that they did not receive any"/>
   <result pre="was approved in August, 2013 for patients with HER2-positive metastatic" exact="breast cancer," post="although for reasons different than those indicated by the"/>
   <result pre="tumor marker level decrease were observed in 1 patient with" exact="ovarian cancer" post="and 1 patient with non-small-cell lung cancer, respectively. Pertuzumab"/>
   <result pre="marker level decrease were observed in 1 patient with ovarian" exact="cancer" post="and 1 patient with non-small-cell lung cancer, respectively. Pertuzumab"/>
   <result pre="1 patient with ovarian cancer and 1 patient with non-small-cell" exact="lung cancer," post="respectively. Pertuzumab was well tolerated up to 25 mg/kg."/>
   <result pre="trial of pertuzumab and trastuzumab in patients with HER2-positive metastatic" exact="breast cancer" post="(study ID no. BO17929) was conducted in the United"/>
   <result pre="of pertuzumab and trastuzumab in patients with HER2-positive metastatic breast" exact="cancer" post="(study ID no. BO17929) was conducted in the United"/>
   <result pre="and safety profile of this combination in patients with HER2-positive" exact="breast cancer" post="whose disease had progressed during prior trastuzumab-based therapy. The"/>
   <result pre="safety profile of this combination in patients with HER2-positive breast" exact="cancer" post="whose disease had progressed during prior trastuzumab-based therapy. The"/>
   <result pre="was effective and well tolerated in patients with HER2-positive metastatic" exact="breast cancer" post="who experienced progression during prior trastuzumab-based therapy. Phase III"/>
   <result pre="effective and well tolerated in patients with HER2-positive metastatic breast" exact="cancer" post="who experienced progression during prior trastuzumab-based therapy. Phase III"/>
   <result pre="Pertuzumab and Trastuzumab; CLEOPATRA study) was conducted for HER2-positive metastatic" exact="breast cancer" post="as first-line treatment ( Table I) ( 13). In"/>
   <result pre="and Trastuzumab; CLEOPATRA study) was conducted for HER2-positive metastatic breast" exact="cancer" post="as first-line treatment ( Table I) ( 13). In"/>
   <result pre="( 13). In that study, 808 patients with HER2-positive metastatic" exact="breast cancer" post="were randomly assigned to receive placebo plus trastuzumab plus"/>
   <result pre="13). In that study, 808 patients with HER2-positive metastatic breast" exact="cancer" post="were randomly assigned to receive placebo plus trastuzumab plus"/>
   <result pre="with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic" exact="breast cancer" post="compared with the control group (placebo, trastuzumab and docetaxel)."/>
   <result pre="pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast" exact="cancer" post="compared with the control group (placebo, trastuzumab and docetaxel)."/>
   <result pre="selection for the trastuzumab plus pertuzumab-based regimen in HER2-positive metastatic" exact="breast cancer," post="and that HER2, HER3 and PIK3CA were relevant prognostic"/>
   <result pre="first-line treatment in Japanese patients with HER2-positive inoperable or recurrent" exact="breast cancer" post="(details described below) ( 24). Neoadjuvant setting NEOSPHERE study"/>
   <result pre="treatment in Japanese patients with HER2-positive inoperable or recurrent breast" exact="cancer" post="(details described below) ( 24). Neoadjuvant setting NEOSPHERE study"/>
   <result pre="patients with newly diagnosed HER2-positive, locally advanced, inflammatory or early-stage" exact="breast cancer" post="( 25). Japanese patients were not enrolled in that"/>
   <result pre="with newly diagnosed HER2-positive, locally advanced, inflammatory or early-stage breast" exact="cancer" post="( 25). Japanese patients were not enrolled in that"/>
   <result pre="study The tolerability of pertuzumab, trastuzumab and anthracyclines in neoadjuvant" exact="breast cancer" post="treatment (TRYPHAENA) is a randomized, multicenter phase II study"/>
   <result pre="The tolerability of pertuzumab, trastuzumab and anthracyclines in neoadjuvant breast" exact="cancer" post="treatment (TRYPHAENA) is a randomized, multicenter phase II study"/>
   <result pre="on 225 patients with HER2-positive, locally advanced, inflammatory, or early-stage" exact="breast cancer," post="with tumors sized &amp;gt;2 cm ( 26). Japanese patients"/>
   <result pre="pertuzumab/pertuzumab-placebo vs. trastuzumab plus a taxane in patients with metastatic" exact="breast cancer" post="(MARIANNE, NCT01120184) is a randomized, three-arm, multicenter, phase III"/>
   <result pre="vs. trastuzumab plus a taxane in patients with metastatic breast" exact="cancer" post="(MARIANNE, NCT01120184) is a randomized, three-arm, multicenter, phase III"/>
   <result pre="HER2-positive progressive or recurrent locally advanced or previously untreated metastatic" exact="breast cancer" post="( Table I) ( 27). The primary endpoints were"/>
   <result pre="progressive or recurrent locally advanced or previously untreated metastatic breast" exact="cancer" post="( Table I) ( 27). The primary endpoints were"/>
   <result pre="a taxane as first-line treatment in patients with HER2-positive advanced" exact="breast cancer" post="(PERUSE study ID no. NCT01572038) is a multicenter, open-label,"/>
   <result pre="taxane as first-line treatment in patients with HER2-positive advanced breast" exact="cancer" post="(PERUSE study ID no. NCT01572038) is a multicenter, open-label,"/>
   <result pre="first-line treatment in patients with metastatic or locally recurrent HER2-positive" exact="breast cancer" post="( 29). The patients are scheduled to receive pertuzumab"/>
   <result pre="treatment in patients with metastatic or locally recurrent HER2-positive breast" exact="cancer" post="( 29). The patients are scheduled to receive pertuzumab"/>
   <result pre="first-line treatment in patients with metastatic or locally advanced HER2-positive" exact="breast cancer" post="(VELVET study ID no. NCT01565083) is a two-cohort, open-label,"/>
   <result pre="treatment in patients with metastatic or locally advanced HER2-positive breast" exact="cancer" post="(VELVET study ID no. NCT01565083) is a two-cohort, open-label,"/>
   <result pre="first-line treatment in patients with metastatic or locally advanced HER2-positive" exact="breast cancer" post="( 30). The patients are scheduled to receive 840"/>
   <result pre="treatment in patients with metastatic or locally advanced HER2-positive breast" exact="cancer" post="( 30). The patients are scheduled to receive 840"/>
   <result pre="capecitabine with or without pertuzumab in patients with HER2-positive metastatic" exact="breast cancer" post="(PHEREXA study ID no. NCT01026142) is a randomized, open-label,"/>
   <result pre="with or without pertuzumab in patients with HER2-positive metastatic breast" exact="cancer" post="(PHEREXA study ID no. NCT01026142) is a randomized, open-label,"/>
   <result pre="capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic" exact="breast cancer" post="( Table I) ( 31). Eligibility requires progression during"/>
   <result pre="with or without pertuzumab, in patients with HER2-positive metastatic breast" exact="cancer" post="( Table I) ( 31). Eligibility requires progression during"/>
   <result pre="an aromatase inhibitor in patients with hormone receptor-positive HER2-positive metastatic" exact="breast cancer" post="(PERTAIN study ID no. NCT01491737) is a randomized, open-label,"/>
   <result pre="aromatase inhibitor in patients with hormone receptor-positive HER2-positive metastatic breast" exact="cancer" post="(PERTAIN study ID no. NCT01491737) is a randomized, open-label,"/>
   <result pre="first-line treatment of patients with HER2-positive and hormone receptor-positive advanced" exact="breast cancer" post="( 32). The patients will be randomized to one"/>
   <result pre="treatment of patients with HER2-positive and hormone receptor-positive advanced breast" exact="cancer" post="( 32). The patients will be randomized to one"/>
   <result pre="combination with trastuzumab and pertuzumab for advanced or recurrent HER2-positive" exact="breast cancer" post="(JBCRG-M03 and UMIN000012232) is a multicenter, single-arm, phase II"/>
   <result pre="with trastuzumab and pertuzumab for advanced or recurrent HER2-positive breast" exact="cancer" post="(JBCRG-M03 and UMIN000012232) is a multicenter, single-arm, phase II"/>
   <result pre="or second-line therapy for patients with advanced or recurrent HER2-positive" exact="breast cancer" post="( Table II) ( 33). The first endpoint is"/>
   <result pre="second-line therapy for patients with advanced or recurrent HER2-positive breast" exact="cancer" post="( Table II) ( 33). The first endpoint is"/>
   <result pre="and trastuzumab as adjuvant therapy in patients with HER2-positive primary" exact="breast cancer" post="(APHINITY study ID no. NCT01358877) is a randomized, double-blind,"/>
   <result pre="trastuzumab as adjuvant therapy in patients with HER2-positive primary breast" exact="cancer" post="(APHINITY study ID no. NCT01358877) is a randomized, double-blind,"/>
   <result pre="trastuzumab as adjuvant therapy in patients with operable HER2-positive primary" exact="breast cancer" post="( Table I) ( 35). The patients will be"/>
   <result pre="as adjuvant therapy in patients with operable HER2-positive primary breast" exact="cancer" post="( Table I) ( 35). The patients will be"/>
   <result pre="anthracyclines as adjuvant therapy in patients with operable HER2-positive primary" exact="breast cancer" post="(KAITLIN study ID no. NCT01966471) is a two-arm, randomized,"/>
   <result pre="as adjuvant therapy in patients with operable HER2-positive primary breast" exact="cancer" post="(KAITLIN study ID no. NCT01966471) is a two-arm, randomized,"/>
   <result pre="taxane as adjuvant therapy in patients with HER2-positive primary invasive" exact="breast cancer" post="( Table I) ( 36). Following surgery and anthracycline-based"/>
   <result pre="as adjuvant therapy in patients with HER2-positive primary invasive breast" exact="cancer" post="( Table I) ( 36). Following surgery and anthracycline-based"/>
   <result pre="defined as the time from randomization to occurrence of ipsilateral" exact="breast cancer" post="recurrence, second primary invasive breast cancer, distant recurrence, or"/>
   <result pre="as the time from randomization to occurrence of ipsilateral breast" exact="cancer" post="recurrence, second primary invasive breast cancer, distant recurrence, or"/>
   <result pre="to occurrence of ipsilateral breast cancer recurrence, second primary invasive" exact="breast cancer," post="distant recurrence, or death by any cause. The secondary"/>
   <result pre="plus second primary non-breast cancer, excluding non-melanoma skin cancers and" exact="carcinoma in situ" post="of any site, DFS (time between randomization and first"/>
   <result pre="between randomization and first occurrence of IDFS, second primary non-breast" exact="cancer" post="and contralateral or ipsilateral ductal carcinoma in situ), distant"/>
   <result pre="recurrence-free interval (time between randomization and first occurrence of distant" exact="breast cancer" post="recurrence), OS and incidence of adverse events. This study"/>
   <result pre="interval (time between randomization and first occurrence of distant breast" exact="cancer" post="recurrence), OS and incidence of adverse events. This study"/>
   <result pre="as second- or later-line treatment for patients with HER2-positive metastatic" exact="breast cancer." post="Moreover, Japanese physicians may use pertuzumab for patients who"/>
   <result pre="combination with trastuzumab and pertuzumab for advanced or recurrent HER2-positive" exact="breast cancer" post="(JBCRG-M03 study) has been initiated at several institutions in"/>
   <result pre="with trastuzumab and pertuzumab for advanced or recurrent HER2-positive breast" exact="cancer" post="(JBCRG-M03 study) has been initiated at several institutions in"/>
   <result pre="the PMDA, disrupted the treatment of patients with HER2-positive metastatic" exact="breast cancer" post="in Japan. Similar to pertuzumab, the PMDA allowed the"/>
   <result pre="PMDA, disrupted the treatment of patients with HER2-positive metastatic breast" exact="cancer" post="in Japan. Similar to pertuzumab, the PMDA allowed the"/>
   <result pre="of T-DM1 for all-line treatment of patients with HER2-positive metastatic" exact="breast cancer," post="although the Japanese T-DM1 package insert indicated that T-DM1"/>
   <result pre="may be used in Japan for patients with HER2-positive metastatic" exact="breast cancer" post="irrespective of the treatment history, and chemotherapeutic agents other"/>
   <result pre="be used in Japan for patients with HER2-positive metastatic breast" exact="cancer" post="irrespective of the treatment history, and chemotherapeutic agents other"/>
   <result pre="be some confusion in the treatment strategy of HER2-positive metastatic" exact="breast cancer." post="Hereafter, new treatment strategies must be developed for HER2-positive"/>
   <result pre="cancer. Hereafter, new treatment strategies must be developed for HER2-positive" exact="breast cancer" post="patients through clinical trials or through comprehensive data collection"/>
   <result pre="Hereafter, new treatment strategies must be developed for HER2-positive breast" exact="cancer" post="patients through clinical trials or through comprehensive data collection"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer" post="Science 244 707 712 1989 10.1126/science.2470152 2470152 3 Gusterson"/>
   <result pre="Studies of the HER-2/neu proto-oncogene in human breast and ovarian" exact="cancer" post="Science 244 707 712 1989 10.1126/science.2470152 2470152 3 Gusterson"/>
   <result pre="Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in" exact="breast cancer" post="J Clin Oncol 10 1049 1056 1992 1351538 4"/>
   <result pre="Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast" exact="cancer" post="J Clin Oncol 10 1049 1056 1992 1351538 4"/>
   <result pre="Study Group: Clinical significance of HER-2/neu oncogene amplification in primary" exact="breast cancer" post="J Clin Oncol 11 1936 1942 1993 8105035 5"/>
   <result pre="Group: Clinical significance of HER-2/neu oncogene amplification in primary breast" exact="cancer" post="J Clin Oncol 11 1936 1942 1993 8105035 5"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 344 783"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 344 783"/>
   <result pre="(HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 353 1659 1672 2005 10.1056/NEJMoa052306"/>
   <result pre="Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 353 1659 1672 2005 10.1056/NEJMoa052306"/>
   <result pre="2 years versus 1 year of adjuvant trastuzumab for HER2-positive" exact="breast cancer" post="(HERA): An open-label, randomised controlled trial Lancet 382 1021"/>
   <result pre="years versus 1 year of adjuvant trastuzumab for HER2-positive breast" exact="cancer" post="(HERA): An open-label, randomised controlled trial Lancet 382 1021"/>
   <result pre="CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 366 109 119 2012 10.1056/NEJMoa1113216"/>
   <result pre="Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 366 109 119 2012 10.1056/NEJMoa1113216"/>
   <result pre="pertuzumab, a novel HER dimerization inhibitor, in patients with advanced" exact="cancer" post="J Clin Oncol 23 2534 2543 2005 10.1200/JCO.2005.03.184 15699478"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="A et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic" exact="breast cancer" post="(CLEOPATRA study): Overall survival results from a randomised, double-blind,"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast" exact="cancer" post="(CLEOPATRA study): Overall survival results from a randomised, double-blind,"/>
   <result pre="pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic" exact="breast cancer" post="J Clin Oncol 32 3753 3761 2014 10.1200/JCO.2013.54.5384 25332247"/>
   <result pre="in human epidermal growth factor receptor 2-positive, first-line metastatic breast" exact="cancer" post="J Clin Oncol 32 3753 3761 2014 10.1200/JCO.2013.54.5384 25332247"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): A randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): A randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="versus trastuzumab [Herceptin] plus a taxane in patients with metastatic" exact="breast cancer" post="(MARIANNE) https://clinicaltrials.gov/ct2/show/NCT01120184 Accessed 4 2 2015 28 F. Hoffmann-La,"/>
   <result pre="trastuzumab [Herceptin] plus a taxane in patients with metastatic breast" exact="cancer" post="(MARIANNE) https://clinicaltrials.gov/ct2/show/NCT01120184 Accessed 4 2 2015 28 F. Hoffmann-La,"/>
   <result pre="III MARIANNE study in people with previously untreated advanced HER2-positive" exact="breast cancer" post="(media release, Basel, 19 December 2014) http://www.roche.com/media/store/releases/med-cor-2014-12-19.htm Accessed 4"/>
   <result pre="MARIANNE study in people with previously untreated advanced HER2-positive breast" exact="cancer" post="(media release, Basel, 19 December 2014) http://www.roche.com/media/store/releases/med-cor-2014-12-19.htm Accessed 4"/>
   <result pre="a taxane in first-line treatment in patients with HER2-positive advanced" exact="breast cancer" post="(PERUSE) https://clinicaltrials.gov/ct2/show/NCT01572038 Accessed 4 2 2015 30 ClinicalTrials.gov A"/>
   <result pre="taxane in first-line treatment in patients with HER2-positive advanced breast" exact="cancer" post="(PERUSE) https://clinicaltrials.gov/ct2/show/NCT01572038 Accessed 4 2 2015 30 ClinicalTrials.gov A"/>
   <result pre="first line in patients with metastatic or locally advanced HER2-positive" exact="breast cancer" post="https://clinicaltrials.gov/ct2/show/NCT01565083 Accessed 4 2 2015 31 ClinicalTrials.gov A study"/>
   <result pre="line in patients with metastatic or locally advanced HER2-positive breast" exact="cancer" post="https://clinicaltrials.gov/ct2/show/NCT01565083 Accessed 4 2 2015 31 ClinicalTrials.gov A study"/>
   <result pre="capecitabine with or without pertuzumab in patients with HER2-positive metastatic" exact="breast cancer" post="(PHEREXA) https://clinicaltrials.gov/ct2/show/NCT01026142 Accessed 4 2 2015 32 ClinicalTrials.gov A"/>
   <result pre="with or without pertuzumab in patients with HER2-positive metastatic breast" exact="cancer" post="(PHEREXA) https://clinicaltrials.gov/ct2/show/NCT01026142 Accessed 4 2 2015 32 ClinicalTrials.gov A"/>
   <result pre="an aromatase inhibitor in patients with hormone receptor-positive, metastatic HER2-positive" exact="breast cancer" post="https://www.clinicaltrials.gov/ct2/show/NCT01491737 Accessed 4 2 2015 33 Japan Breast Cancer"/>
   <result pre="aromatase inhibitor in patients with hormone receptor-positive, metastatic HER2-positive breast" exact="cancer" post="https://www.clinicaltrials.gov/ct2/show/NCT01491737 Accessed 4 2 2015 33 Japan Breast Cancer"/>
   <result pre="advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive" exact="breast cancer" post="(JBCRG-M03) http://www.jbcrg.jp/en/clinicaltrials/detail.php?id=32 Accessed 4 2 2015 34 Japan Pharmaceutical"/>
   <result pre="or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast" exact="cancer" post="(JBCRG-M03) http://www.jbcrg.jp/en/clinicaltrials/detail.php?id=32 Accessed 4 2 2015 34 Japan Pharmaceutical"/>
   <result pre="as first line treatment in HER2- positive inoperable or recurrent" exact="breast cancer" post="http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132321 Accessed 4 2 2015 35 ClinicalTrials.gov A study"/>
   <result pre="first line treatment in HER2- positive inoperable or recurrent breast" exact="cancer" post="http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132321 Accessed 4 2 2015 35 ClinicalTrials.gov A study"/>
   <result pre="Herceptin (trastuzumab) as adjuvant therapy in patients with HER2-positive primary" exact="breast cancer" post="https://www.clinicaltrials.gov/ct2/show/study/NCT01358877 Accessed 4 2 2015 36 ClinicalTrials.gov A Study"/>
   <result pre="(trastuzumab) as adjuvant therapy in patients with HER2-positive primary breast" exact="cancer" post="https://www.clinicaltrials.gov/ct2/show/study/NCT01358877 Accessed 4 2 2015 36 ClinicalTrials.gov A Study"/>
   <result pre="anthracyclines as adjuvant therapy in patients with operable HER2-positive primary" exact="breast cancer" post="https://clinicaltrials.gov/ct2/show/study/NCT01966471 Accessed 4 2 2015 37 Verma S Miles"/>
   <result pre="as adjuvant therapy in patients with operable HER2-positive primary breast" exact="cancer" post="https://clinicaltrials.gov/ct2/show/study/NCT01966471 Accessed 4 2 2015 37 Verma S Miles"/>
   <result pre="et al. EMILIA Study Group: Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 367 1783 1791 2012 10.1056/NEJMoa1209124"/>
   <result pre="al. EMILIA Study Group: Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 367 1783 1791 2012 10.1056/NEJMoa1209124"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4666271/results/search/disease/results.xml">
   <result pre="lapatinib as first-line therapy for Japanese women with HER2-positive metastatic" exact="breast cancer" post="Inoue Kenichi +81-48-722-1111 ino@cancer-c.pref.saitama.jp Kuroi Katsumasa Shimizu Satoru Rai"/>
   <result pre="as first-line therapy for Japanese women with HER2-positive metastatic breast" exact="cancer" post="Inoue Kenichi +81-48-722-1111 ino@cancer-c.pref.saitama.jp Kuroi Katsumasa Shimizu Satoru Rai"/>
   <result pre="receptor 2 (HER2) targeting agent approved globally for HER2-positive metastatic" exact="breast cancer" post="(MBC). The efficacy, safety and pharmacokinetics (PK) of lapatinib"/>
   <result pre="2 (HER2) targeting agent approved globally for HER2-positive metastatic breast" exact="cancer" post="(MBC). The efficacy, safety and pharmacokinetics (PK) of lapatinib"/>
   <result pre="cycles. Results The only dose-limiting toxicity reported was Grade 3" exact="diarrhea" post="in one patient. The systemic exposure to maximum plasma"/>
   <result pre="adverse events (AEs) related to the study treatment were alopecia," exact="diarrhea" post="and decreased hemoglobin. The majority of drug-related AEs were"/>
   <result pre="from those in non-Japanese patients. Keywords Lapatinib Paclitaxel HER2 Metastatic" exact="breast cancer" post="Introduction Overexpression or gene amplification of human epidermal growth"/>
   <result pre="those in non-Japanese patients. Keywords Lapatinib Paclitaxel HER2 Metastatic breast" exact="cancer" post="Introduction Overexpression or gene amplification of human epidermal growth"/>
   <result pre="factor receptor 2 (HER2) occurs in approximately 20 % of" exact="breast cancer" post="cases. It is known to be an independent prognostic"/>
   <result pre="receptor 2 (HER2) occurs in approximately 20 % of breast" exact="cancer" post="cases. It is known to be an independent prognostic"/>
   <result pre="trastuzumab-containing regimens, which have significantly improved the prognosis for HER2-positive" exact="breast cancer" post="[ 3, 4]. One of the key combination regimens"/>
   <result pre="regimens, which have significantly improved the prognosis for HER2-positive breast" exact="cancer" post="[ 3, 4]. One of the key combination regimens"/>
   <result pre="USA in 2006 in combination with capecitabine for HER2-positive metastatic" exact="breast cancer" post="(MBC) which persisted or recurred after anthracycline, taxane and"/>
   <result pre="in 2006 in combination with capecitabine for HER2-positive metastatic breast" exact="cancer" post="(MBC) which persisted or recurred after anthracycline, taxane and"/>
   <result pre="study, in which 579 HER2-negative or unknown, advanced or recurrent" exact="breast cancer" post="patients were enrolled [ 15]. Of 579 patients enrolled,"/>
   <result pre="in which 579 HER2-negative or unknown, advanced or recurrent breast" exact="cancer" post="patients were enrolled [ 15]. Of 579 patients enrolled,"/>
   <result pre="with investigational drug and/or anticancer treatment; uncontrolled infection; ≥Grade 2" exact="peripheral neuropathy" post="according to National Cancer Institute Common Terminology Criteria for"/>
   <result pre="investigational drug and/or anticancer treatment; uncontrolled infection; ≥Grade 2 peripheral" exact="neuropathy" post="according to National Cancer Institute Common Terminology Criteria for"/>
   <result pre="Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0;" exact="malabsorption" post="syndrome or other conditions that would prevent the efficacy"/>
   <result pre="treatment and applicable to any of the following: Grade 4" exact="neutropenia" post="sustained for ≥7 days, Grade 4 thrombocytopenia, ≥Grade 3"/>
   <result pre="had received prior trastuzumab. Six patients had estrogen receptor (ER)-positive" exact="breast cancer" post="as assessed by a local laboratory, of whom 4"/>
   <result pre="received prior trastuzumab. Six patients had estrogen receptor (ER)-positive breast" exact="cancer" post="as assessed by a local laboratory, of whom 4"/>
   <result pre="common AEs reported were alopecia, neutropenia, diarrhea, decreased hemoglobin and" exact="rash" post="(Table 2). Grade 3 treatment-related AEs found in more"/>
   <result pre="3 treatment-related AEs found in more than 2 patients were:" exact="neutropenia" post="( n = 7), leukopenia ( n = 5),"/>
   <result pre="more than 2 patients were: neutropenia ( n = 7)," exact="leukopenia" post="( n = 5), diarrhea ( n = 3),"/>
   <result pre="neutropenia ( n = 7), leukopenia ( n = 5)," exact="diarrhea" post="( n = 3), increased ALT ( n ="/>
   <result pre="Fatigue 8 (67) 0 0 0 8 (67) Peripheral sensory" exact="neuropathy" post="6 (50) 2 (17) 0 0 8 (67) Leukopenia"/>
   <result pre="6 (50) ALT alanine aminotransferase, AST aspartate aminotransferase Rash and" exact="diarrhea" post="were the special interest AEs for lapatinib. No ≥Grade"/>
   <result pre="special interest AEs for lapatinib. No ≥Grade 3 or serious" exact="rash" post="was reported. One Grade 2 rash event led to"/>
   <result pre="≥Grade 3 or serious rash was reported. One Grade 2" exact="rash" post="event led to withdrawal from study treatment in one"/>
   <result pre="and on the back of both hands. Although Grade 3" exact="diarrhea" post="events occurred in 3 patients, no diarrhea was reported"/>
   <result pre="Although Grade 3 diarrhea events occurred in 3 patients, no" exact="diarrhea" post="was reported as ≥Grade 4 or serious, and there"/>
   <result pre="history of prior anthracycline treatment for other past malignancy, and" exact="pneumonia" post="in a patient who was diagnosed by X-ray imaging."/>
   <result pre="pilot part of the Asian Phase III study targeting gastric" exact="cancer" post="patients showed a similar tolerability of this regimen ["/>
   <result pre="was found, as the AUC and C max of Japanese" exact="breast cancer" post="patients given the combination were affected. A similar trend"/>
   <result pre="found, as the AUC and C max of Japanese breast" exact="cancer" post="patients given the combination were affected. A similar trend"/>
   <result pre="profiles of lapatinib and paclitaxel is consistent regardless of the" exact="cancer" post="type, and such interaction was considered to be the"/>
   <result pre="paclitaxel given as monotherapy [ 14– 17]. The grade of" exact="diarrhea" post="was slightly worsened compared with lapatinib monotherapy, which means"/>
   <result pre="patients with MBC. Nevertheless, paclitaxel remains a key drug in" exact="breast cancer" post="therapies and many multiple-agent regimens with paclitaxel have been"/>
   <result pre="with MBC. Nevertheless, paclitaxel remains a key drug in breast" exact="cancer" post="therapies and many multiple-agent regimens with paclitaxel have been"/>
   <result pre="previously reported in other ethnicities, as well as in different" exact="cancer" post="types, was found. We thank all the patients who"/>
   <result pre="Burstein HJ Winer EP The distinctive nature of HER2 positive" exact="breast cancer" post="N Engl J Med 2005 353 1652 1654 10.1056/NEJMp058197"/>
   <result pre="HJ Winer EP The distinctive nature of HER2 positive breast" exact="cancer" post="N Engl J Med 2005 353 1652 1654 10.1056/NEJMp058197"/>
   <result pre="Oncol 2014 32 2078 2099 10.1200/JCO.2013.54.0948 24799465 4. National comprehensive" exact="cancer" post="network (2014) Clinical practice guidelines in oncology. Breast cancer."/>
   <result pre="Version 3 5. Japanese Breast Cancer Society (2013) Evidence based" exact="breast cancer" post="diagnostic guideline. Japanese Breast Cancer Society, editors. 1 Medicinal"/>
   <result pre="3 5. Japanese Breast Cancer Society (2013) Evidence based breast" exact="cancer" post="diagnostic guideline. Japanese Breast Cancer Society, editors. 1 Medicinal"/>
   <result pre="of cerebral metastases in patients treated with trastuzumab for metastatic" exact="breast cancer" post="Br J Cancer 2004 91 639 643 15266327 8."/>
   <result pre="cerebral metastases in patients treated with trastuzumab for metastatic breast" exact="cancer" post="Br J Cancer 2004 91 639 643 15266327 8."/>
   <result pre="patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic" exact="breast cancer" post="Breast 2006 15 219 225 10.1016/j.breast.2005.04.017 16026983 10. Yau"/>
   <result pre="with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast" exact="cancer" post="Breast 2006 15 219 225 10.1016/j.breast.2005.04.017 16026983 10. Yau"/>
   <result pre="pattern and timing of brain metastases among patients with advanced" exact="breast cancer" post="treated with trastuzumab Acta Oncol 2006 45 196 201"/>
   <result pre="and timing of brain metastases among patients with advanced breast" exact="cancer" post="treated with trastuzumab Acta Oncol 2006 45 196 201"/>
   <result pre="Palshof AE et al. Efficacy of HER2-targeted therapy in metastatic" exact="breast cancer." post="Monoclonal antibodies and tyrosine kinase inhibitors Breast 2013 22"/>
   <result pre="Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="D et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 2743 10.1056/NEJMoa064320"/>
   <result pre="metastases in patients with human epidermal growth factor receptor 2–positive" exact="breast cancer" post="J Clin Oncol 2008 26 1993 1999 10.1200/JCO.2007.12.3588 18421051"/>
   <result pre="in patients with human epidermal growth factor receptor 2–positive breast" exact="cancer" post="J Clin Oncol 2008 26 1993 1999 10.1200/JCO.2007.12.3588 18421051"/>
   <result pre="paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic" exact="breast cancer" post="J Clin Oncol 2008 26 5544 5552 10.1200/JCO.2008.16.2578 18955454"/>
   <result pre="with placebo plus paclitaxel as first-line treatment for metastatic breast" exact="cancer" post="J Clin Oncol 2008 26 5544 5552 10.1200/JCO.2008.16.2578 18955454"/>
   <result pre="the treatment of human epidermal growth factor receptor 2–overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 2013 31 1947 1953 10.1200/JCO.2011.40.5241 23509322"/>
   <result pre="treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 2013 31 1947 1953 10.1200/JCO.2011.40.5241 23509322"/>
   <result pre="paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric" exact="cancer" post="in Asian populations: TyTAN–a randomized, phase III study J"/>
   <result pre="SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 109 119 10.1056/NEJMoa1113216"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 109 119 10.1056/NEJMoa1113216"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4669075/results/search/disease/results.xml">
   <result pre="published under the Creative Commons CC-BY-NC 3.0 license. Abstract Breast" exact="cancer" post="(BC) is the most common cause of cancer-related death"/>
   <result pre="single genomic locus. Aberrant alternative splicing is very common in" exact="cancer" post="where emerging tumor cells take advantage of this flexibility"/>
   <result pre="the prognosis, and choose specific therapies for BC. alternative splicing" exact="breast cancer" post="tumorigenesis metastasis estrogen receptor HER2 CD44 signal transduction stem"/>
   <result pre="prognosis, and choose specific therapies for BC. alternative splicing breast" exact="cancer" post="tumorigenesis metastasis estrogen receptor HER2 CD44 signal transduction stem"/>
   <result pre="of stem cell pluripotency. 7, 8 A common signature of" exact="cancer" post="cells is a general loss of splicing fidelity with"/>
   <result pre="isoforms usually expressed in other cell types to bestow incipient" exact="cancer" post="cells a growth advantage; thus, specific splicing errors are"/>
   <result pre="advantage; thus, specific splicing errors are detectable in fully developed" exact="cancer" post="cells than pathologically normal-looking tissues. Indeed, genome-wide studies have"/>
   <result pre="The ability to regulate AS could be beneficial to emerging" exact="cancer" post="cells at their early stage of development if splice"/>
   <result pre="death (Bcl-x, Fas1, caspase 2 9), angiogenesis (VEGF-A 9), tumor" exact="suppression" post="(p53, p63, p73, DMP1 14, 21), and invasion and"/>
   <result pre="and metastasis (ASF/SF2, SRp20, hTra2β1, YB-1, MDM2 9– 13). Breast" exact="cancer" post="(BC) is the most common malignance in women in"/>
   <result pre="HER2, leading to cell proliferation and might be involved in" exact="cancer" post="development and progression. Another factor that affects the ERα66/ERα36"/>
   <result pre="on the estradiol concentration. 57 SNCG is highly expressed in" exact="cancer" post="cells but not in normal epithelium. Shi et al"/>
   <result pre="associated with better survival in patients with HER2-positive and triple-negative" exact="breast cancer" post="(TNBC) with a good response to TAM. Generally, ERβ1"/>
   <result pre="with better survival in patients with HER2-positive and triple-negative breast" exact="cancer" post="(TNBC) with a good response to TAM. Generally, ERβ1"/>
   <result pre="expression was inversely correlated with Ki67, particularly in high-grade ductal" exact="carcinoma in situ." post="84 Although there is no correlation between loss of"/>
   <result pre="phosphorylation of AKT-heat shock factor 1 (HSF1)-SLUG, eventually leading to" exact="cancer" post="metastasis. 131 Splicing in HER2 is supposed to trigger"/>
   <result pre="with MCF-7/Δ16HER2 cells, they found that Δ16HER2 caused a fivefold" exact="suppression" post="of the miR-7 tumor suppressor. Re-expression of miR-7 in"/>
   <result pre="well as malignant human mammary stem cells. 142, 143 These" exact="cancer" post="stem cells (CSCs) have enhanced invasiveness, 144 resistance to"/>
   <result pre="via CD44v3-bound hepatocyte growth factor (HGF), which is important in" exact="colorectal cancer" post="tumorigenesis. 151 CD44v6 also initiates MET activation through HGF"/>
   <result pre="CD44v3-bound hepatocyte growth factor (HGF), which is important in colorectal" exact="cancer" post="tumorigenesis. 151 CD44v6 also initiates MET activation through HGF"/>
   <result pre="cells, indicating the significant role of the CD44–MMP–TGFβ axis in" exact="cancer" post="invasion and metastasis. CD44 also interacts with multidrug resistance"/>
   <result pre="165 CD44 as a marker for CSCs—role of EMT in" exact="cancer" post="metastasis Normal stem cells renew themselves through asymmetrical cell"/>
   <result pre="and execute tissue-specific functions. 166, 167 More recently, studies of" exact="cancer" post="cells have provided evidence of self-renewing, stem-like cells within"/>
   <result pre="tumor metastasis is often enabled by EMT, 177, 178 where" exact="cancer" post="cells require self-renewal capability. This raises the possibility that"/>
   <result pre="This raises the possibility that the EMT process, which enables" exact="cancer" post="cell dissemination, may also bestow a self-renewal capacity to"/>
   <result pre="cell dissemination, may also bestow a self-renewal capacity to the" exact="cancer" post="cells. EMT is transcriptionally regulated by a family of"/>
   <result pre="by microRNAs (reviewed in Refs. 179– 184). Successful colonization of" exact="cancer" post="cells in secondary sites requires the ability of the"/>
   <result pre="results in efficient lung metastasis accompanied by expansion of stem-like" exact="cancer" post="cells proving the role of the variant isoform in"/>
   <result pre="cancer cells proving the role of the variant isoform in" exact="cancer" post="metastasis. 185 Other studies support the finding of the"/>
   <result pre="of the Yae study concluding that some CD44v isoforms mediate" exact="cancer" post="metastasis. 186, 187 In good contrast to these studies,"/>
   <result pre="groups demonstrated the importance of CD44s rather than CD44v in" exact="cancer" post="progression. Brown et al 188 demonstrated the role of"/>
   <result pre="for CD44 constitutes a critical mechanism in controlling EMT and" exact="cancer" post="progression. 188 Xu et al 189 showed that the"/>
   <result pre="or basal cell subtypes that are often metastatic. Inhibition of" exact="cancer" post="progression by CD44 Although the majority of in vitro"/>
   <result pre="vitro researches described earlier suggest the role of CD44 in" exact="cancer" post="progression, other reports have shown that CD44 can respond"/>
   <result pre="(HMW, &amp;gt;500 kDa) HA, to inhibit growth and invasion in" exact="cancer" post="cells ( Fig. 4, right). Consistent with the tumor-suppressive"/>
   <result pre="loss of CD44 has been reported in Burkitt’s lymphoma, neuroblastoma," exact="prostate cancer," post="and BC. 192 CD44 binding to merlin acts as"/>
   <result pre="plays a role in contact inhibition, which is lost in" exact="cancer" post="cells. 192 Similarly, Louderbough et al 193, 194 showed"/>
   <result pre="vivo. Possible mechanisms for the dual roles of CD44 in" exact="cancer" post="Research findings described earlier indicate that CD44 has dual"/>
   <result pre="has dual roles, that is, it either promotes or inhibits" exact="cancer" post="progression dependent on the experimental conditions used. 194 In"/>
   <result pre="of CD44 in cell growth. Contradictory roles of CD44 in" exact="cancer" post="progression can also be attributed to the expression of"/>
   <result pre="HER2 status, and basal-like subtype in BCs. 191 In advanced" exact="ovarian cancer," post="CD44v6 was associated with peritoneal dissemination and poor prognosis."/>
   <result pre="third possibility to explain the dual roles of CD44 in" exact="cancer" post="is its crosstalk with the TGFβ pathway since TGFβ"/>
   <result pre="cascades that regulate ERα36/66 ratio will have significant impacts on" exact="cancer" post="therapy. It will also be needed to characterize the"/>
   <result pre="therapy. The molecular mechanisms for the role of CD44 in" exact="cancer" post="development look very complicated since CD44 has multiple isoforms"/>
   <result pre="same laboratory later reported that the absence of CD44 prevented" exact="sarcoma" post="metastasis using the more physiological min mutation model for"/>
   <result pre="sarcoma metastasis using the more physiological min mutation model for" exact="colon cancer," post="demonstrating the pro-metastatic potential for CD44. 201 There has"/>
   <result pre="mice to elucidate the role of each CD44 isoform in" exact="cancer" post="development or prevention. Acknowledgments We thank all members of"/>
   <result pre="Biamonti G Ghigna C Oncogenic alternative splicing switches: role in" exact="cancer" post="progression and prospects for therapy Int J Cell Biol"/>
   <result pre="M Gautrey H Tyson-Capper A Deregulation of splicing factors and" exact="breast cancer" post="development J Mol Cell Biol 2015 7 388 401"/>
   <result pre="Gautrey H Tyson-Capper A Deregulation of splicing factors and breast" exact="cancer" post="development J Mol Cell Biol 2015 7 388 401"/>
   <result pre="K Fry EA Aberrant expression of cyclin D1 in human" exact="cancer" post="Sign Transduct Insights 2015 4 1 13 10.4137/STI.S30306 19"/>
   <result pre="the tumor suppressor DMP1 locus, induces proliferation and progression of" exact="breast cancer" post="J Pathol 2015 236 90 102 25537728 22 Siegel"/>
   <result pre="tumor suppressor DMP1 locus, induces proliferation and progression of breast" exact="cancer" post="J Pathol 2015 236 90 102 25537728 22 Siegel"/>
   <result pre="EA et al. Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in" exact="breast cancer" post="Oncogene 2013 32 4120 4129 23045280 30 Taneja P"/>
   <result pre="et al. Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast" exact="cancer" post="Oncogene 2013 32 4120 4129 23045280 30 Taneja P"/>
   <result pre="et al. Classical and novel molecular prognostic markers for human" exact="breast cancer" post="and their clinical significance Clin Med Insights Oncol 2010"/>
   <result pre="al. Classical and novel molecular prognostic markers for human breast" exact="cancer" post="and their clinical significance Clin Med Insights Oncol 2010"/>
   <result pre="C Gustafsson JÅ Estrogen receptor mutations and functional consequences for" exact="breast cancer" post="Trends Endocrinol Metab 2015 26 467 476 26183887 34"/>
   <result pre="Gustafsson JÅ Estrogen receptor mutations and functional consequences for breast" exact="cancer" post="Trends Endocrinol Metab 2015 26 467 476 26183887 34"/>
   <result pre="receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen" exact="hypersensitivity" post="Endocrinology 2013 154 1990 1998 23546601 41 Su X"/>
   <result pre="L ER-α36: a novel biomarker and potential therapeutic target in" exact="breast cancer" post="Onco Targets Ther 2014 7 1525 1533 25210466 42"/>
   <result pre="ER-α36: a novel biomarker and potential therapeutic target in breast" exact="cancer" post="Onco Targets Ther 2014 7 1525 1533 25210466 42"/>
   <result pre="isoform hERα46 antagonizes the proliferative influence of hERα66 in MCF7" exact="breast cancer" post="cells Endocrinology 2005 146 5474 5484 16150902 43 Li"/>
   <result pre="hERα46 antagonizes the proliferative influence of hERα66 in MCF7 breast" exact="cancer" post="cells Endocrinology 2005 146 5474 5484 16150902 43 Li"/>
   <result pre="al. Estrogen receptor alpha 46 is reduced in tamoxifen resistant" exact="breast cancer" post="cells and re-expression inhibits cell proliferation and estrogen receptor"/>
   <result pre="Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast" exact="cancer" post="cells and re-expression inhibits cell proliferation and estrogen receptor"/>
   <result pre="L Estrogen receptor alpha-36 (ER-α36): a new player in human" exact="breast cancer" post="Mol Cell Endocrinol 2015 4 24 pii: S0303-7207(15)00208-7 10.1016/j.mce.2015.04.017"/>
   <result pre="Estrogen receptor alpha-36 (ER-α36): a new player in human breast" exact="cancer" post="Mol Cell Endocrinol 2015 4 24 pii: S0303-7207(15)00208-7 10.1016/j.mce.2015.04.017"/>
   <result pre="new marker for the detection of minimal residual disease in" exact="acute leukemia" post="Blood 1994 84 3071 3079 7949179 51 Inoue K"/>
   <result pre="marker for the detection of minimal residual disease in acute" exact="leukemia" post="Blood 1994 84 3071 3079 7949179 51 Inoue K"/>
   <result pre="Aberrant overexpression of the Wilms tumor gene (WT1) in human" exact="leukemia" post="Blood 1997 89 1405 1412 9028964 52 Oji Y"/>
   <result pre="isoforms with HER2 and ER-α and its oncogenic role in" exact="breast cancer" post="Anticancer Res 2014 34 1333 1342 24596380 57 Shi"/>
   <result pre="with HER2 and ER-α and its oncogenic role in breast" exact="cancer" post="Anticancer Res 2014 34 1333 1342 24596380 57 Shi"/>
   <result pre="59 Georgakis GV Younes A Heat-shock protein 90 inhibitors in" exact="cancer" post="therapy: 17AAG and beyond Future Oncol 2005 1 273"/>
   <result pre="Kong X Shah T et al. The HOXB7 protein renders" exact="breast cancer" post="cells resistant to tamoxifen through activation of the EGFR"/>
   <result pre="X Shah T et al. The HOXB7 protein renders breast" exact="cancer" post="cells resistant to tamoxifen through activation of the EGFR"/>
   <result pre="FH Functional role of miR-10b in tamoxifen resistance of ER-positive" exact="breast cancer" post="cells through down-regulation of HDAC4 BMC Cancer 2015 15"/>
   <result pre="Functional role of miR-10b in tamoxifen resistance of ER-positive breast" exact="cancer" post="cells through down-regulation of HDAC4 BMC Cancer 2015 15"/>
   <result pre="ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in" exact="breast cancer" post="cells Oncogene 2015 34 3895 3907 25531331 66 Jeselsohn"/>
   <result pre="transcriptional activity and tamoxifen resistance via targeting CDK3 in breast" exact="cancer" post="cells Oncogene 2015 34 3895 3907 25531331 66 Jeselsohn"/>
   <result pre="Schiff R ESR1 mutations-a mechanism for acquired endocrine resistance in" exact="breast cancer" post="Nat Rev Clin Oncol 2015 12 10 573 583"/>
   <result pre="R ESR1 mutations-a mechanism for acquired endocrine resistance in breast" exact="cancer" post="Nat Rev Clin Oncol 2015 12 10 573 583"/>
   <result pre="is associated with activation of AKT and tamoxifen resistance in" exact="breast cancer" post="Breast Cancer Res Treat 2015 153 31 40 26208487"/>
   <result pre="associated with activation of AKT and tamoxifen resistance in breast" exact="cancer" post="Breast Cancer Res Treat 2015 153 31 40 26208487"/>
   <result pre="of microRNAs as predictors of response to tamoxifen treatment in" exact="breast cancer" post="patients Int J Mol Sci 2015 16 24243 24275"/>
   <result pre="microRNAs as predictors of response to tamoxifen treatment in breast" exact="cancer" post="patients Int J Mol Sci 2015 16 24243 24275"/>
   <result pre="Leygue E Watson PH Murphy LC Estrogen receptor alpha negative" exact="breast cancer" post="patients: estrogen receptor beta as a therapeutic target J"/>
   <result pre="E Watson PH Murphy LC Estrogen receptor alpha negative breast" exact="cancer" post="patients: estrogen receptor beta as a therapeutic target J"/>
   <result pre="Gustafsson JA Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the" exact="breast cancer" post="cell line T47D Proc Natl Acad Sci U S"/>
   <result pre="JA Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast" exact="cancer" post="cell line T47D Proc Natl Acad Sci U S"/>
   <result pre="C Vignon F ER beta inhibits proliferation and invasion of" exact="breast cancer" post="cells Endocrinology 2001 142 4120 4130 11517191 76 Paruthiyil"/>
   <result pre="Vignon F ER beta inhibits proliferation and invasion of breast" exact="cancer" post="cells Endocrinology 2001 142 4120 4130 11517191 76 Paruthiyil"/>
   <result pre="GR Firestone GL Leitman DC Estrogen receptor beta inhibits human" exact="breast cancer" post="cell proliferation and tumor formation by causing a G2"/>
   <result pre="Firestone GL Leitman DC Estrogen receptor beta inhibits human breast" exact="cancer" post="cell proliferation and tumor formation by causing a G2"/>
   <result pre="T et al. Clinical importance of estrogen receptor-beta evaluation in" exact="breast cancer" post="patients treated with adjuvant tamoxifen therapy J Clin Oncol"/>
   <result pre="et al. Clinical importance of estrogen receptor-beta evaluation in breast" exact="cancer" post="patients treated with adjuvant tamoxifen therapy J Clin Oncol"/>
   <result pre="favourable prognostic value of oestrogen receptor beta immunohistochemical expression in" exact="breast cancer" post="J Clin Pathol 2004 57 523 528 15113861 79"/>
   <result pre="prognostic value of oestrogen receptor beta immunohistochemical expression in breast" exact="cancer" post="J Clin Pathol 2004 57 523 528 15113861 79"/>
   <result pre="significance of high expression of ER-beta in surgically treated ER-positive" exact="breast cancer" post="following endocrine therapy J Breast Cancer 2012 15 79"/>
   <result pre="of high expression of ER-beta in surgically treated ER-positive breast" exact="cancer" post="following endocrine therapy J Breast Cancer 2012 15 79"/>
   <result pre="J Oestrogen receptors β1 and βcx have divergent roles in" exact="breast cancer" post="survival and lymph node metastasis Br J Cancer 2014"/>
   <result pre="Oestrogen receptors β1 and βcx have divergent roles in breast" exact="cancer" post="survival and lymph node metastasis Br J Cancer 2014"/>
   <result pre="et al. Reduced expression of oestrogen receptor beta in invasive" exact="breast cancer" post="and its re-expression using DNA methyl transferase inhibitors in"/>
   <result pre="al. Reduced expression of oestrogen receptor beta in invasive breast" exact="cancer" post="and its re-expression using DNA methyl transferase inhibitors in"/>
   <result pre="SM et al. Regulation of estrogen receptor β1 expression in" exact="breast cancer" post="by epigenetic modification of the 5′ regulatory region Int"/>
   <result pre="et al. Regulation of estrogen receptor β1 expression in breast" exact="cancer" post="by epigenetic modification of the 5′ regulatory region Int"/>
   <result pre="V Estrogen receptor β: putting a positive into triple negative" exact="breast cancer?" post="Horm Mol Biol Clin Investig 2013 16 117 123"/>
   <result pre="with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative" exact="breast cancer" post="Breast Cancer Res Treat 2015 152 255 269 26070269"/>
   <result pre="PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast" exact="cancer" post="Breast Cancer Res Treat 2015 152 255 269 26070269"/>
   <result pre="al. Estrogen receptors and proliferation markers in primary and recurrent" exact="breast cancer" post="Proc Natl Acad Sci U S A 2001 98"/>
   <result pre="Estrogen receptors and proliferation markers in primary and recurrent breast" exact="cancer" post="Proc Natl Acad Sci U S A 2001 98"/>
   <result pre="negatively regulates the transactivation of estrogen receptor alpha in human" exact="breast cancer" post="cells Cancer Res 2007 67 3955 3962 17440111 94"/>
   <result pre="regulates the transactivation of estrogen receptor alpha in human breast" exact="cancer" post="cells Cancer Res 2007 67 3955 3962 17440111 94"/>
   <result pre="M Differential expression of estrogen receptor beta isoforms in human" exact="breast cancer" post="tissue Anticancer Res 2003 23 211 216 12680215 95"/>
   <result pre="Differential expression of estrogen receptor beta isoforms in human breast" exact="cancer" post="tissue Anticancer Res 2003 23 211 216 12680215 95"/>
   <result pre="estrogen receptor α, β1, and β2 in lobular and ductal" exact="breast cancer" post="Proc Natl Acad Sci U S A 2014 111"/>
   <result pre="receptor α, β1, and β2 in lobular and ductal breast" exact="cancer" post="Proc Natl Acad Sci U S A 2014 111"/>
   <result pre="of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for" exact="breast cancer" post="patients Clin Cancer Res 2008 14 5228 5235 18698041"/>
   <result pre="ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast" exact="cancer" post="patients Clin Cancer Res 2008 14 5228 5235 18698041"/>
   <result pre="Jung SS The potential role of estrogen receptor β2 in" exact="breast cancer" post="Int J Surg 2015 14 17 22 25450264 101"/>
   <result pre="SS The potential role of estrogen receptor β2 in breast" exact="cancer" post="Int J Surg 2015 14 17 22 25450264 101"/>
   <result pre="Pupa SM delta16HER2 splice variant and its role in HER2-overexpressing" exact="breast cancer" post="Atlas Genet Cytogenet Oncol Haematol 2014 18 526 531"/>
   <result pre="SM delta16HER2 splice variant and its role in HER2-overexpressing breast" exact="cancer" post="Atlas Genet Cytogenet Oncol Haematol 2014 18 526 531"/>
   <result pre="models and the diagnostic values of MMTV-like sequences in human" exact="breast cancer" post="Expert Rev Mol Diagn 2009 9 423 440 19580428"/>
   <result pre="and the diagnostic values of MMTV-like sequences in human breast" exact="cancer" post="Expert Rev Mol Diagn 2009 9 423 440 19580428"/>
   <result pre="DH Rehg JE Sherr CJ Dmp1 is haplo-insufficient for tumor" exact="suppression" post="and modifies the frequencies of Arf and p53 mutations"/>
   <result pre="et al. Mutually exclusive inactivation of DMP1 and ARF/p53 in" exact="lung cancer" post="Cancer Cell 2007 12 381 394 17936562 119 Frazier"/>
   <result pre="al. Mutually exclusive inactivation of DMP1 and ARF/p53 in lung" exact="cancer" post="Cancer Cell 2007 12 381 394 17936562 119 Frazier"/>
   <result pre="120 Inoue K Mallakin A Frazier DP Dmp1 and tumor" exact="suppression" post="Oncogene 2007 26 4329 4335 17237816 121 Inoue K"/>
   <result pre="induction of mammary tumors in transgenic mice: implications for human" exact="breast cancer" post="EMBO J 1999 18 2149 2164 10205169 124 Castiglioni"/>
   <result pre="of mammary tumors in transgenic mice: implications for human breast" exact="cancer" post="EMBO J 1999 18 2149 2164 10205169 124 Castiglioni"/>
   <result pre="leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing" exact="breast cancer" post="cells Oncogene 2015 34 546 557 24469056 132 Druillennec"/>
   <result pre="to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast" exact="cancer" post="cells Oncogene 2015 34 546 557 24469056 132 Druillennec"/>
   <result pre="A Alternative splicing in oncogenic kinases: from physiological functions to" exact="cancer" post="J Nucleic Acids 2012 2012 639062 22007291 133 Zhang"/>
   <result pre="Arribas J Baselga J Pedersen K Parra-Palau JL p95HER2 and" exact="breast cancer" post="Cancer Res 2011 71 1515 1519 21343397 138 Gajria"/>
   <result pre="J Baselga J Pedersen K Parra-Palau JL p95HER2 and breast" exact="cancer" post="Cancer Res 2011 71 1515 1519 21343397 138 Gajria"/>
   <result pre="275 21342044 139 Miller LD Liu ET Expression genomics in" exact="breast cancer" post="research: microarrays at the crossroads of biology and medicine"/>
   <result pre="21342044 139 Miller LD Liu ET Expression genomics in breast" exact="cancer" post="research: microarrays at the crossroads of biology and medicine"/>
   <result pre="et al. Intratumor heterogeneity and precision of microarray-based predictors of" exact="breast cancer" post="biology and clinical outcome J Clin Oncol 2010 28"/>
   <result pre="al. Intratumor heterogeneity and precision of microarray-based predictors of breast" exact="cancer" post="biology and clinical outcome J Clin Oncol 2010 28"/>
   <result pre="Benito-Hernandez A Morrison SJ Clarke MF Prospective identification of tumorigenic" exact="breast cancer" post="cells Proc Natl Acad Sci U S A 2003"/>
   <result pre="A Morrison SJ Clarke MF Prospective identification of tumorigenic breast" exact="cancer" post="cells Proc Natl Acad Sci U S A 2003"/>
   <result pre="143 Ricardo S Vieira AF Gerhard R et al. Breast" exact="cancer" post="stem cell markers CD44, CD24 and ALDH1: expression distribution"/>
   <result pre="Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative" exact="breast cancer" post="(TNBC) Cancer Lett 2014 353 153 159 25130168 145"/>
   <result pre="CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast" exact="cancer" post="(TNBC) Cancer Lett 2014 353 153 159 25130168 145"/>
   <result pre="Lewis MT Huang J et al. Intrinsic resistance of tumorigenic" exact="breast cancer" post="cells to chemotherapy J Natl Cancer Inst 2008 100"/>
   <result pre="MT Huang J et al. Intrinsic resistance of tumorigenic breast" exact="cancer" post="cells to chemotherapy J Natl Cancer Inst 2008 100"/>
   <result pre="J et al. Cancer stem cells and their implication in" exact="breast cancer" post="Eur J Clin Invest 2014 44 678 687 24766664"/>
   <result pre="et al. Cancer stem cells and their implication in breast" exact="cancer" post="Eur J Clin Invest 2014 44 678 687 24766664"/>
   <result pre="In vivo evidence for the role of CD44s in promoting" exact="breast cancer" post="metastasis to the liver Am J Pathol 2007 171"/>
   <result pre="vivo evidence for the role of CD44s in promoting breast" exact="cancer" post="metastasis to the liver Am J Pathol 2007 171"/>
   <result pre="Gupta I et al. TGF-β2: a novel target of CD44-promoted" exact="breast cancer" post="invasion J Cancer 2013 4 566 572 23983821 165"/>
   <result pre="I et al. TGF-β2: a novel target of CD44-promoted breast" exact="cancer" post="invasion J Cancer 2013 4 566 572 23983821 165"/>
   <result pre="Morrison SJ Clarke MF Weissman IL Stem cells, cancer, and" exact="cancer" post="stem cells Nature 2001 414 105 111 11689955 167"/>
   <result pre="and its CD44 receptor in the stemness and survival of" exact="cancer" post="stem cells Front Oncol 2015 5 180 26322272 169"/>
   <result pre="5 180 26322272 169 Rycaj K Tang DG Cell-of-origin of" exact="cancer" post="versus cancer stem cells: assays and interpretations Cancer Res"/>
   <result pre="26322272 169 Rycaj K Tang DG Cell-of-origin of cancer versus" exact="cancer" post="stem cells: assays and interpretations Cancer Res 2015 75"/>
   <result pre="X Wei D Concise review: emerging role of CD44 in" exact="cancer" post="stem cells: a promising biomarker and therapeutic target Stem"/>
   <result pre="4 1033 1043 26136504 171 Bonnet D Dick JE Human" exact="acute myeloid leukemia" post="is organized as a hierarchy that originates from a"/>
   <result pre="1033 1043 26136504 171 Bonnet D Dick JE Human acute" exact="myeloid leukemia" post="is organized as a hierarchy that originates from a"/>
   <result pre="1043 26136504 171 Bonnet D Dick JE Human acute myeloid" exact="leukemia" post="is organized as a hierarchy that originates from a"/>
   <result pre="737 9212098 172 Horton SJ Huntly BJ Recent advances in" exact="acute myeloid leukemia" post="stem cell biology Haematologica 2012 97 966 974 22511496"/>
   <result pre="9212098 172 Horton SJ Huntly BJ Recent advances in acute" exact="myeloid leukemia" post="stem cell biology Haematologica 2012 97 966 974 22511496"/>
   <result pre="172 Horton SJ Huntly BJ Recent advances in acute myeloid" exact="leukemia" post="stem cell biology Haematologica 2012 97 966 974 22511496"/>
   <result pre="173 Filipova A Seifrtova M Mokry J et al. Breast" exact="cancer" post="and cancer stem cells: a mini-review Tumori 2014 100"/>
   <result pre="A Seifrtova M Mokry J et al. Breast cancer and" exact="cancer" post="stem cells: a mini-review Tumori 2014 100 363 369"/>
   <result pre="O’Brien CA Pollett A Gallinger S Dick JE A human" exact="colon cancer" post="cell capable of initiating tumour growth in immunodeficient mice"/>
   <result pre="CA Pollett A Gallinger S Dick JE A human colon" exact="cancer" post="cell capable of initiating tumour growth in immunodeficient mice"/>
   <result pre="178 Bill R Christofori G The relevance of EMT in" exact="breast cancer" post="metastasis: correlation or causality? FEBS Lett 2015 589 1577"/>
   <result pre="Bill R Christofori G The relevance of EMT in breast" exact="cancer" post="metastasis: correlation or causality? FEBS Lett 2015 589 1577"/>
   <result pre="Peter ME The miR-200 family determines the epithelial phenotype of" exact="cancer" post="cells by targeting the E-cadherin repressors ZEB1 and ZEB2"/>
   <result pre="Kim EJ et al. MicroRNA-9 is associated with epithelial-mesenchymal transition," exact="breast cancer" post="stem cell phenotype, and tumor progression in breast cancer"/>
   <result pre="EJ et al. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast" exact="cancer" post="stem cell phenotype, and tumor progression in breast cancer"/>
   <result pre="transition, breast cancer stem cell phenotype, and tumor progression in" exact="breast cancer" post="Breast Cancer Res Treat 2014 147 39 49 25086633"/>
   <result pre="breast cancer stem cell phenotype, and tumor progression in breast" exact="cancer" post="Breast Cancer Res Treat 2014 147 39 49 25086633"/>
   <result pre="WX et al. Role of miR-155 in drug resistance of" exact="breast cancer" post="Tumour Biol 2015 36 1395 1401 25744731 185 Yae"/>
   <result pre="et al. Role of miR-155 in drug resistance of breast" exact="cancer" post="Tumour Biol 2015 36 1395 1401 25744731 185 Yae"/>
   <result pre="of CD44 mRNA by ESRP1 enhances lung colonization of metastatic" exact="cancer" post="cell Nat Commun 2012 3 883 22673910 186 Zhang"/>
   <result pre="peritoneal dissemination and poor prognosis in patients with advanced epithelial" exact="ovarian cancer" post="Cancer Sci 2015 106 10 1421 1428 26250934 188"/>
   <result pre="dissemination and poor prognosis in patients with advanced epithelial ovarian" exact="cancer" post="Cancer Sci 2015 106 10 1421 1428 26250934 188"/>
   <result pre="human and mouse epithelium is essential for epithelial-mesenchymal transition and" exact="breast cancer" post="progression J Clin Invest 2011 121 1064 1074 21393860"/>
   <result pre="and mouse epithelium is essential for epithelial-mesenchymal transition and breast" exact="cancer" post="progression J Clin Invest 2011 121 1064 1074 21393860"/>
   <result pre="Lee JH et al. Cell type-restricted activity of hnRNPM promotes" exact="breast cancer" post="metastasis via regulating alternative splicing Genes Dev 2014 28"/>
   <result pre="JH et al. Cell type-restricted activity of hnRNPM promotes breast" exact="cancer" post="metastasis via regulating alternative splicing Genes Dev 2014 28"/>
   <result pre="self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in" exact="cancer" post="cells Int J Cancer 2015 137 11 2566 2577"/>
   <result pre="Bendahl PO et al. CD44 isoforms are heterogeneously expressed in" exact="breast cancer" post="and correlate with tumor subtypes and cancer stem cell"/>
   <result pre="PO et al. CD44 isoforms are heterogeneously expressed in breast" exact="cancer" post="and correlate with tumor subtypes and cancer stem cell"/>
   <result pre="expressed in breast cancer and correlate with tumor subtypes and" exact="cancer" post="stem cell markers BMC Cancer 2011 11 418 21957977"/>
   <result pre="JM Schroeder JA Understanding the dual nature of CD44 in" exact="breast cancer" post="progression Mol Cancer Res 2011 9 1573 1586 21970856"/>
   <result pre="Schroeder JA Understanding the dual nature of CD44 in breast" exact="cancer" post="progression Mol Cancer Res 2011 9 1573 1586 21970856"/>
   <result pre="BJ McDonald J Schroeder JA CD44 attenuates metastatic invasion during" exact="breast cancer" post="progression Cancer Res 2005 65 6755 6763 16061657 198"/>
   <result pre="McDonald J Schroeder JA CD44 attenuates metastatic invasion during breast" exact="cancer" post="progression Cancer Res 2005 65 6755 6763 16061657 198"/>
   <result pre="promotes epithelial mammary gland development and exhibits altered localization during" exact="cancer" post="progression Genes Cancer 2011 2 771 781 22393462 199"/>
   <result pre="199 Leivonen SK Kähäri VM Transforming growth factor-beta signaling in" exact="cancer" post="invasion and metastasis Int J Cancer 2007 121 2119"/>
   <result pre="2124 17849476 200 Zarzynska JM Two faces of TGF-beta1 in" exact="breast cancer" post="Mediators Inflamm 2014 2014 141747 24891760 201 Weber GF"/>
   <result pre="17849476 200 Zarzynska JM Two faces of TGF-beta1 in breast" exact="cancer" post="Mediators Inflamm 2014 2014 141747 24891760 201 Weber GF"/>
   <result pre="Schmits R Mak TW Absence of the CD44 gene prevents" exact="sarcoma" post="metastasis Cancer Res 2002 62 2281 2286 11956084 202"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4678619/results/search/disease/results.xml">
   <result pre="otherwise stated. Abstract Advances in surgical and medical treatments for" exact="ovarian cancer" post="have improved prognoses. Platinum drugs in particular are pivotal"/>
   <result pre="stated. Abstract Advances in surgical and medical treatments for ovarian" exact="cancer" post="have improved prognoses. Platinum drugs in particular are pivotal"/>
   <result pre="drugs in particular are pivotal for the medical treatment of" exact="ovarian cancer." post="However, previous studies have revealed that some histological subtypes,"/>
   <result pre="factor-1β, ZNF217. We also review targeted molecular therapeutics for epithelial" exact="ovarian cancer" post="and discuss their role in clear cell carcinoma treatment."/>
   <result pre="ZNF217. We also review targeted molecular therapeutics for epithelial ovarian" exact="cancer" post="and discuss their role in clear cell carcinoma treatment."/>
   <result pre="Clear cell carcinoma Platinum resistance Annexin A4 Target-based therapies Ovarian" exact="cancer" post="Background Ovarian cancer has the highest mortality among gynecological"/>
   <result pre="Platinum resistance Annexin A4 Target-based therapies Ovarian cancer Background Ovarian" exact="cancer" post="has the highest mortality among gynecological cancers and is"/>
   <result pre="CCC is the second most common histological subtype of epithelial" exact="ovarian cancer" post="(EOC) in Japan [ 2, 3]. Over the past"/>
   <result pre="is the second most common histological subtype of epithelial ovarian" exact="cancer" post="(EOC) in Japan [ 2, 3]. Over the past"/>
   <result pre="standard intravenous regimens administered to women requiring first-line chemotherapy for" exact="ovarian cancer" post="[ 4], and high response rates (60–80 %) have"/>
   <result pre="intravenous regimens administered to women requiring first-line chemotherapy for ovarian" exact="cancer" post="[ 4], and high response rates (60–80 %) have"/>
   <result pre="them. Although these chemotherapies have improved PFS and OS in" exact="ovarian cancer," post="some histological subtypes have shown low response rates. Moreover,"/>
   <result pre="CCC is considered a highly malignant and chemoresistant type of" exact="ovarian cancer," post="and conventional chemotherapy is not regarded as an effective"/>
   <result pre="into three classes: multi-drug resistance proteins, sulfonylurea receptors, and the" exact="cystic fibrosis" post="transmembrane conductance regulator [ 15]. ABCC3 transports monovalent bile"/>
   <result pre="glycocholate) and sulfated bile salts(i.e., taurochenodeoxycholate-3-sulfate, taurolithocholate-3-sulfate) [ 15] In" exact="cancer" post="tissues Overexpression of ABCC3, which transports chemotherapeutic agents, has"/>
   <result pre="transports chemotherapeutic agents, has been associated with paclitaxel resistance in" exact="breast cancer" post="cell lines [ 16, 17] and cisplatin resistance in"/>
   <result pre="chemotherapeutic agents, has been associated with paclitaxel resistance in breast" exact="cancer" post="cell lines [ 16, 17] and cisplatin resistance in"/>
   <result pre="cancer cell lines [ 16, 17] and cisplatin resistance in" exact="ovarian cancer" post="cell lines [ 18] In CCC One study reported"/>
   <result pre="cell lines [ 16, 17] and cisplatin resistance in ovarian" exact="cancer" post="cell lines [ 18] In CCC One study reported"/>
   <result pre="and regulation of epithelial Cl − secretion [ 20] In" exact="cancer" post="tissues Studies indicate that Anx A4 up-regulation promotes tumor"/>
   <result pre="that Anx A4 up-regulation promotes tumor progression and chemoresistance in" exact="colorectal cancer," post="esophageal squamous cell carcinoma, endometrial carcinoma, gastric cancer, chemoresistant"/>
   <result pre="cancer, esophageal squamous cell carcinoma, endometrial carcinoma, gastric cancer, chemoresistant" exact="lung cancer," post="malignant mesothelioma, renal cell carcinoma, ovarian clear cell carcinoma"/>
   <result pre="carcinoma, endometrial carcinoma, gastric cancer, chemoresistant lung cancer, malignant mesothelioma," exact="renal cell carcinoma," post="ovarian clear cell carcinoma (CCC), cholangiocarcinoma, hepatocellular carcinoma, breast"/>
   <result pre="mesothelioma, renal cell carcinoma, ovarian clear cell carcinoma (CCC), cholangiocarcinoma," exact="hepatocellular carcinoma," post="breast cancer, and laryngeal cancer [ 21] In CCC"/>
   <result pre="cell carcinoma, ovarian clear cell carcinoma (CCC), cholangiocarcinoma, hepatocellular carcinoma," exact="breast cancer," post="and laryngeal cancer [ 21] In CCC Enhanced Anx"/>
   <result pre="cell carcinoma (CCC), cholangiocarcinoma, hepatocellular carcinoma, breast cancer, and laryngeal" exact="cancer" post="[ 21] In CCC Enhanced Anx A4 expression was"/>
   <result pre="for nearly all GPx activities in plasma [ 26] In" exact="cancer" post="tissues GPx3 expression has been reported in hepatocellular carcinoma,"/>
   <result pre="26] In cancer tissues GPx3 expression has been reported in" exact="hepatocellular carcinoma," post="gastric cancer, acute myeloid leukemia, and clear cell renal"/>
   <result pre="GPx3 expression has been reported in hepatocellular carcinoma, gastric cancer," exact="acute myeloid leukemia," post="and clear cell renal cell carcinoma [ 27]. One"/>
   <result pre="expression has been reported in hepatocellular carcinoma, gastric cancer, acute" exact="myeloid leukemia," post="and clear cell renal cell carcinoma [ 27]. One"/>
   <result pre="hepatocellular carcinoma, gastric cancer, acute myeloid leukemia, and clear cell" exact="renal cell carcinoma" post="[ 27]. One study reported a correlation between GPx3"/>
   <result pre="study reported a correlation between GPx3 methylation and chemoresistance in" exact="head and neck cancer" post="(HNC), which may serve as a potential prognostic indicator"/>
   <result pre="correlation between GPx3 methylation and chemoresistance in head and neck" exact="cancer" post="(HNC), which may serve as a potential prognostic indicator"/>
   <result pre="be highly expressed in CCC by DNA microarray analysis. GPx3" exact="suppression" post="by RNA interference increased cisplatin sensitivity by approximately 4-fold"/>
   <result pre="sensitivity by approximately 4-fold in CCC cell lines. Since GPx3" exact="suppression" post="increased cisplatin sensitivity of CCC cells, GPx3 may be"/>
   <result pre="excision repair, and in telomere length regulation [ 30] In" exact="cancer" post="tissues ERCC1 is perhaps one of the most important"/>
   <result pre="levels in CCC specimens than other histological types of epithelial" exact="ovarian cancer" post="[ 35]. Because ERCC1 was found to play an"/>
   <result pre="in CCC specimens than other histological types of epithelial ovarian" exact="cancer" post="[ 35]. Because ERCC1 was found to play an"/>
   <result pre="proliferation, and apoptosis, as well as angiogenesis [ 36] In" exact="cancer" post="tissues Galectin 3 has been implicated in many aspects"/>
   <result pre="tissues Galectin 3 has been implicated in many aspects of" exact="cancer" post="progression, such as tumor cell adhesion, proliferation, differentiation, and"/>
   <result pre="such as cell survival, proliferation, and motility [ 43] In" exact="cancer" post="tissues EGFR overexpression has been associated with advanced disease"/>
   <result pre="EGFR is reportedly associated with platinum resistance in lung and" exact="ovarian cancer" post="[ 14, 43, 45] In CCC A previous study"/>
   <result pre="is reportedly associated with platinum resistance in lung and ovarian" exact="cancer" post="[ 14, 43, 45] In CCC A previous study"/>
   <result pre="or other members of the EGFR family [ 48] In" exact="cancer" post="tissues Amplification or overexpression of HER2 occurs in approximately"/>
   <result pre="[ 49]. The association between HER2 and platinum resistance in" exact="breast cancer" post="cells [ 50] and the data of a systematic"/>
   <result pre="49]. The association between HER2 and platinum resistance in breast" exact="cancer" post="cells [ 50] and the data of a systematic"/>
   <result pre="and the data of a systematic review suggest that triple-negative" exact="breast cancer" post="have increased sensitivity to platinum-based chemotherapy [ 51] In"/>
   <result pre="the data of a systematic review suggest that triple-negative breast" exact="cancer" post="have increased sensitivity to platinum-based chemotherapy [ 51] In"/>
   <result pre="CCC Pre-target mechanisms include at least two mechanisms using which" exact="cancer" post="cells elude the cytotoxic potential of cisplatin before binding"/>
   <result pre="this mechanism, galectin-3 is associated with CCC platinum resistance, and" exact="suppression" post="of galectin-3 reportedly leads to cis-diamminedichloroplatinum-induced apoptosis via decreases"/>
   <result pre="in comparison with other major histological subtypes of EOC. In" exact="ovarian cancer," post="the HER2 protein was overexpressed as a consequence of"/>
   <result pre="for this is unknown, although CCC has been associated with" exact="endometriosis" post="and endometriosis-associated ovarian cancers in 22–70 % of younger"/>
   <result pre="Previous studies showed that ovarian endometrioma increases the risk for" exact="ovarian cancer," post="and 0.72 % of all cases of ovarian endometrioma"/>
   <result pre="62, 85] Clear cell carcinoma has a strong association with" exact="endometriosis" post="PIK3CA is mutated in 33 % of CCC patients"/>
   <result pre="52] ARID1A AT-rich interactive domain 1A (SWI-like) gene, BRCA 1/2" exact="breast cancer" post="susceptibility gene 1/2, EGFR epidermal growth factor receptor, HER2"/>
   <result pre="ARID1A AT-rich interactive domain 1A (SWI-like) gene, BRCA 1/2 breast" exact="cancer" post="susceptibility gene 1/2, EGFR epidermal growth factor receptor, HER2"/>
   <result pre="pathways are being developed to improve the outcomes of chemotherapy-resistant" exact="ovarian cancer." post="Moreover, studies of chemotherapy-resistant ovarian cancer therapy indicate that"/>
   <result pre="the outcomes of chemotherapy-resistant ovarian cancer. Moreover, studies of chemotherapy-resistant" exact="ovarian cancer" post="therapy indicate that effective treatments for CCC are available."/>
   <result pre="outcomes of chemotherapy-resistant ovarian cancer. Moreover, studies of chemotherapy-resistant ovarian" exact="cancer" post="therapy indicate that effective treatments for CCC are available."/>
   <result pre="clinical features of CCC. Table 3 Examples of targeted molecular" exact="cancer" post="therapeutics for epithelial ovarian cancer Category Target molecule Agent(s)"/>
   <result pre="Table 3 Examples of targeted molecular cancer therapeutics for epithelial" exact="ovarian cancer" post="Category Target molecule Agent(s) References Angiogenesis Vascular endothelial growth"/>
   <result pre="3 Examples of targeted molecular cancer therapeutics for epithelial ovarian" exact="cancer" post="Category Target molecule Agent(s) References Angiogenesis Vascular endothelial growth"/>
   <result pre="bevacizumab addition to standard chemotherapy treatment in newly diagnosed advanced" exact="ovarian cancer" post="demonstrated its efficacy. Bevacizumab monotherapy is effective in the"/>
   <result pre="addition to standard chemotherapy treatment in newly diagnosed advanced ovarian" exact="cancer" post="demonstrated its efficacy. Bevacizumab monotherapy is effective in the"/>
   <result pre="effective in the treatment of persistent, resistant, or recurrent epithelial" exact="ovarian cancer" post="(EOC). However, it remains unknown whether bevacizumab is effective"/>
   <result pre="in the treatment of persistent, resistant, or recurrent epithelial ovarian" exact="cancer" post="(EOC). However, it remains unknown whether bevacizumab is effective"/>
   <result pre="inhibitors. Promising single-agent activity was demonstrated in patients with recurrent" exact="ovarian cancer." post="Phase II and III trials indicate that pazopanib may"/>
   <result pre="associated with transmembrane cell surface receptors on both normal and" exact="cancer" post="cells, including the epidermal growth factor receptor (EGFR) assoicated"/>
   <result pre="Efficacy HER-2 gene and protein overexpression have been reported in" exact="breast cancer" post="and are associated with an aggressive clinical course and"/>
   <result pre="HER-2 gene and protein overexpression have been reported in breast" exact="cancer" post="and are associated with an aggressive clinical course and"/>
   <result pre="HER 2 overexpression has no predictive or prognostic value in" exact="ovarian cancer." post="Although trastuzumab is not useful for ovarian cancer, no"/>
   <result pre="value in ovarian cancer. Although trastuzumab is not useful for" exact="ovarian cancer," post="no studies have investigated its use in the treatment"/>
   <result pre="demonstrated modest single-agent activity in unselected patients with platinum-sensitive recurrent" exact="ovarian cancer." post="To our knowledge, two clinical trails have been completed,"/>
   <result pre="Oregovomab is a monoclonal antibody that binds to the antigen" exact="cancer" post="antigen (CA 125) Efficacy A phase III clinical trial"/>
   <result pre="of Src tyrosine kinase is suggested to be linked to" exact="cancer" post="progression through the promotion of other signals. Dasatinib is"/>
   <result pre="combination with iniparib in patients with platinum-sensitive or -resistant recurrent" exact="ovarian cancer." post="Phase III clinical trial of olaparib was initiated for"/>
   <result pre="trial of olaparib was initiated for patients with BRCA mutant" exact="ovarian cancer." post="However, low frequency of BRCA1/2 mutations in CCC were"/>
   <result pre="reported ABL Abelson murine leukemia, BCR breakpoint cluster region, CA125" exact="cancer" post="antigen 125, EGFR epidermal growth factor receptor, EPHA2 ephrin"/>
   <result pre="of bevacizumab addition to standard chemotherapy in newly diagnosed advanced" exact="ovarian cancer" post="both reported significant improvements in PFS. The ICON7 trial"/>
   <result pre="bevacizumab addition to standard chemotherapy in newly diagnosed advanced ovarian" exact="cancer" post="both reported significant improvements in PFS. The ICON7 trial"/>
   <result pre="not been performed. Sunitinib is another possible therapeutic option for" exact="renal cell carcinoma" post="treatment and acts as an oral, small-molecule, multitargeted receptor"/>
   <result pre="have shown that AnxA4 induces drug resistance [ 20], and" exact="suppression" post="of AnxA4 expression improved platinum sensitivity of CCC in"/>
   <result pre="64]. Recent studies have reported specific expression of HNF-1β in" exact="endometriosis" post="and CCC and suggest that early differentiation into the"/>
   <result pre="that early differentiation into the clear cell lineage occurs in" exact="endometriosis" post="[ 64, 74]. However, the role of HNF-1β expression"/>
   <result pre="role of HNF-1β expression in ovarian clear cell tumors and" exact="endometriosis" post="remains uncertain. Nonetheless, RNA interference has been used to"/>
   <result pre="irinotecan plus cisplatin EGFR epidermal growth factor receptor EOC epithelial" exact="ovarian cancer" post="EZH2 enhancer of zeste homolog 2 GOG Gynecologic Oncology"/>
   <result pre="plus cisplatin EGFR epidermal growth factor receptor EOC epithelial ovarian" exact="cancer" post="EZH2 enhancer of zeste homolog 2 GOG Gynecologic Oncology"/>
   <result pre="identifies ABCC3 as a mediator of taxane resistance in HER2-amplified" exact="breast cancer" post="Cancer Res 2008 68 5380 5389 10.1158/0008-5472.CAN-08-0234 18593940 18."/>
   <result pre="ABCC3 as a mediator of taxane resistance in HER2-amplified breast" exact="cancer" post="Cancer Res 2008 68 5380 5389 10.1158/0008-5472.CAN-08-0234 18593940 18."/>
   <result pre="et al. Midkine as a potential diagnostic marker in epithelial" exact="ovarian cancer" post="for cisplatin/paclitaxel combination clinical therapy Am J Cancer Res."/>
   <result pre="al. Midkine as a potential diagnostic marker in epithelial ovarian" exact="cancer" post="for cisplatin/paclitaxel combination clinical therapy Am J Cancer Res."/>
   <result pre="B Guo C Liu S Sun MZ Annexin A4 and" exact="cancer" post="Clin Chim Acta 2015 447 72 78 10.1016/j.cca.2015.05.016 26048190"/>
   <result pre="GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3" exact="acute myeloid leukemia" post="Am J Cancer Res. 2015 5 2047 2055 26269763"/>
   <result pre="hypermethylation serves as an independent prognostic biomarker in non-M3 acute" exact="myeloid leukemia" post="Am J Cancer Res. 2015 5 2047 2055 26269763"/>
   <result pre="serves as an independent prognostic biomarker in non-M3 acute myeloid" exact="leukemia" post="Am J Cancer Res. 2015 5 2047 2055 26269763"/>
   <result pre="significance and therapeutic value of glutathione peroxidase 3 (GPx3) in" exact="hepatocellular carcinoma" post="Oncotarget. 2014 5 11103 11120 10.18632/oncotarget.2549 25333265 28. Chen"/>
   <result pre="Z GPx3 promoter hypermethylation is a frequent event in human" exact="cancer" post="and is associated with tumorigenesis and chemotherapy response Cancer"/>
   <result pre="MP The role of DNA repair pathways in cisplatin resistant" exact="lung cancer" post="Cancer Treat Rev 2014 40 1161 1170 10.1016/j.ctrv.2014.10.003 25458603"/>
   <result pre="The role of DNA repair pathways in cisplatin resistant lung" exact="cancer" post="Cancer Treat Rev 2014 40 1161 1170 10.1016/j.ctrv.2014.10.003 25458603"/>
   <result pre="TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in" exact="colorectal cancer" post="Anticancer Res 2011 31 3843 3849 22110208 33. Liu"/>
   <result pre="and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal" exact="cancer" post="Anticancer Res 2011 31 3843 3849 22110208 33. Liu"/>
   <result pre="effects of ERCC1 expression levels on the chemosensitivity of gastric" exact="cancer" post="cells to platinum agents and survival in gastric cancer"/>
   <result pre="gastric cancer cells to platinum agents and survival in gastric" exact="cancer" post="patients treated with oxaliplatin-based adjuvant chemotherapy Oncol Lett. 2013"/>
   <result pre="in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial" exact="ovarian cancer" post="Gynecol Oncol 2013 130 377 382 10.1016/j.ygyno.2013.04.054 23632208 35."/>
   <result pre="predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian" exact="cancer" post="Gynecol Oncol 2013 130 377 382 10.1016/j.ygyno.2013.04.054 23632208 35."/>
   <result pre="of ERCC1 and XPB than other histological types of epithelial" exact="ovarian cancer" post="Clin Cancer Res 2003 9 5299 5305 14614013 36."/>
   <result pre="ERCC1 and XPB than other histological types of epithelial ovarian" exact="cancer" post="Clin Cancer Res 2003 9 5299 5305 14614013 36."/>
   <result pre="T Kanayama HO Raz A The role of galectin-3 in" exact="cancer" post="drug resistance Drug Resist Updat. 2007 10 101 108"/>
   <result pre="Sullivan DM Nuclear export of proteins and drug resistance in" exact="cancer" post="Biochem Pharmacol 2012 83 1021 1032 10.1016/j.bcp.2011.12.016 22209898 38."/>
   <result pre="inhibition suppresses drug resistance, motility, invasion and angiogenic potential in" exact="ovarian cancer" post="Gynecol Oncol 2014 135 573 579 10.1016/j.ygyno.2014.09.021 25284038 39."/>
   <result pre="suppresses drug resistance, motility, invasion and angiogenic potential in ovarian" exact="cancer" post="Gynecol Oncol 2014 135 573 579 10.1016/j.ygyno.2014.09.021 25284038 39."/>
   <result pre="al. Galectin-3 as a marker and potential therapeutic target in" exact="breast cancer" post="PLoS One 2014 9 e103482 10.1371/journal.pone.0103482 25254965 40. Kobayashi"/>
   <result pre="Galectin-3 as a marker and potential therapeutic target in breast" exact="cancer" post="PLoS One 2014 9 e103482 10.1371/journal.pone.0103482 25254965 40. Kobayashi"/>
   <result pre="stability and antiapoptotic function in response to anticancer drug in" exact="prostate cancer" post="Cancer Res 2006 66 3114 3119 10.1158/0008-5472.CAN-05-3750 16540661 42."/>
   <result pre="and antiapoptotic function in response to anticancer drug in prostate" exact="cancer" post="Cancer Res 2006 66 3114 3119 10.1158/0008-5472.CAN-05-3750 16540661 42."/>
   <result pre="growth factor receptor enhances invasiveness and cisplatin resistance in epithelial" exact="ovarian cancer" post="Carcinogenesis 2013 34 2639 2646 10.1093/carcin/bgt216 23764753 44. Lynch"/>
   <result pre="factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian" exact="cancer" post="Carcinogenesis 2013 34 2639 2646 10.1093/carcin/bgt216 23764753 44. Lynch"/>
   <result pre="in the epidermal growth factor receptor underlying responsiveness of non-small-cell" exact="lung cancer" post="to gefitinib N Engl J Med 2004 350 2129"/>
   <result pre="the epidermal growth factor receptor underlying responsiveness of non-small-cell lung" exact="cancer" post="to gefitinib N Engl J Med 2004 350 2129"/>
   <result pre="et al. Gefitinib (ZD1839) increases the efficacy of cisplatin in" exact="ovarian cancer" post="cells Cancer Biol Ther 2012 13 408 416 10.4161/cbt.19292"/>
   <result pre="al. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian" exact="cancer" post="cells Cancer Biol Ther 2012 13 408 416 10.4161/cbt.19292"/>
   <result pre="amphiregulin as a key factor for cisplatin resistance of human" exact="breast cancer" post="cells J Biol Chem 2008 283 739 750 10.1074/jbc.M706287200"/>
   <result pre="as a key factor for cisplatin resistance of human breast" exact="cancer" post="cells J Biol Chem 2008 283 739 750 10.1074/jbc.M706287200"/>
   <result pre="R Michailidis G Taylor JM et al. Gene expression in" exact="ovarian cancer" post="reflects both morphology and biological behavior, distinguishing clear cell"/>
   <result pre="Michailidis G Taylor JM et al. Gene expression in ovarian" exact="cancer" post="reflects both morphology and biological behavior, distinguishing clear cell"/>
   <result pre="Mori S Li J et al. Histotype-specific copy-number alterations in" exact="ovarian cancer" post="BMC Med Genom 2012 5 47 10.1186/1755-8794-5-47 60. Okamoto"/>
   <result pre="S Li J et al. Histotype-specific copy-number alterations in ovarian" exact="cancer" post="BMC Med Genom 2012 5 47 10.1186/1755-8794-5-47 60. Okamoto"/>
   <result pre="et al. Somatic copy number alterations associated with Japanese or" exact="endometriosis" post="in ovarian clear cell adenocarcinoma PLoS One 2015 10"/>
   <result pre="of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and" exact="endometriosis" post="of the ovary Mod Pathol 2006 19 83 89"/>
   <result pre="epidermal growth factor receptor as a therapeutic target in epithelial" exact="ovarian cancer" post="Cancer Epidemiol. 2012 36 490 496 10.1016/j.canep.2012.06.005 22818908 79."/>
   <result pre="growth factor receptor as a therapeutic target in epithelial ovarian" exact="cancer" post="Cancer Epidemiol. 2012 36 490 496 10.1016/j.canep.2012.06.005 22818908 79."/>
   <result pre="antibody, trastuzumab, in patients with recurrent or refractory ovarian or" exact="primary peritoneal carcinoma" post="with overexpression of HER2: a phase II trial of"/>
   <result pre="receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive" exact="ovarian cancer." post="J Clin Oncol. 2013;31(suppl; abstr 5515). 81. Bell-McGuinn KM"/>
   <result pre="in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal" exact="cancer" post="Gynecol Oncol 2011 121 273 279 10.1016/j.ygyno.2010.12.362 21276608 82."/>
   <result pre="83. Wilkinson-Ryan I Mutch D A review of iniparib in" exact="ovarian cancer" post="Expert Opin Investig Drugs 2013 22 399 405 10.1517/13543784.2013.772135"/>
   <result pre="Wilkinson-Ryan I Mutch D A review of iniparib in ovarian" exact="cancer" post="Expert Opin Investig Drugs 2013 22 399 405 10.1517/13543784.2013.772135"/>
   <result pre="Jayson GC Angiogenesis as a target for the treatment of" exact="ovarian cancer" post="Curr Opin Oncol 2013 25 558 565 10.1097/CCO.0b013e328363e0da 23942301"/>
   <result pre="GC Angiogenesis as a target for the treatment of ovarian" exact="cancer" post="Curr Opin Oncol 2013 25 558 565 10.1097/CCO.0b013e328363e0da 23942301"/>
   <result pre="factor ZNF217 is a prognostic biomarker and therapeutic target during" exact="breast cancer" post="progression Cancer Discov. 2012 2 638 651 10.1158/2159-8290.CD-12-0093 22728437"/>
   <result pre="ZNF217 is a prognostic biomarker and therapeutic target during breast" exact="cancer" post="progression Cancer Discov. 2012 2 638 651 10.1158/2159-8290.CD-12-0093 22728437"/>
   <result pre="et al. ZNF217 is a marker of poor prognosis in" exact="breast cancer" post="that drives epithelial-mesenchymal transition and invasion Cancer Res 2012"/>
   <result pre="al. ZNF217 is a marker of poor prognosis in breast" exact="cancer" post="that drives epithelial-mesenchymal transition and invasion Cancer Res 2012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4679405/results/search/disease/results.xml">
   <result pre="(T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic" exact="breast cancer" post="and central nervous system metastases: a retrospective, exploratory analysis"/>
   <result pre="versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast" exact="cancer" post="and central nervous system metastases: a retrospective, exploratory analysis"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="and central nervous system metastases: results from a retrospective"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="and central nervous system metastases: results from a retrospective"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="was similar for trastuzumab emtansine (T-DM1) and for capecitabine–lapatinib."/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="was similar for trastuzumab emtansine (T-DM1) and for capecitabine–lapatinib."/>
   <result pre="patients with human epidermal growth factor receptor 2 (HER2)-positive advanced" exact="breast cancer" post="previously treated with trastuzumab and a taxane were randomized"/>
   <result pre="with human epidermal growth factor receptor 2 (HER2)-positive advanced breast" exact="cancer" post="previously treated with trastuzumab and a taxane were randomized"/>
   <result pre="the rate of CNS progression in patients with HER2-positive advanced" exact="breast cancer" post="was similar for T-DM1 and for XL, and higher"/>
   <result pre="rate of CNS progression in patients with HER2-positive advanced breast" exact="cancer" post="was similar for T-DM1 and for XL, and higher"/>
   <result pre="significantly improved OS compared with XL. ado-trastuzumab emtansine T-DM1 metastatic" exact="breast cancer" post="central nervous system metastasis introduction The central nervous system"/>
   <result pre="improved OS compared with XL. ado-trastuzumab emtansine T-DM1 metastatic breast" exact="cancer" post="central nervous system metastasis introduction The central nervous system"/>
   <result pre="The central nervous system (CNS) is a common site of" exact="breast cancer" post="metastasis [ 1, 2]. The development of CNS disease"/>
   <result pre="central nervous system (CNS) is a common site of breast" exact="cancer" post="metastasis [ 1, 2]. The development of CNS disease"/>
   <result pre="Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic" exact="breast cancer" post="(MBC) are at increased risk for developing CNS metastases,"/>
   <result pre="with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast" exact="cancer" post="(MBC) are at increased risk for developing CNS metastases,"/>
   <result pre="radiosurgery, are indicated for the treatment of CNS metastases across" exact="breast cancer" post="subtypes, but are associated with high rates of intracranial"/>
   <result pre="are indicated for the treatment of CNS metastases across breast" exact="cancer" post="subtypes, but are associated with high rates of intracranial"/>
   <result pre="with XL in patients with previously treated HER2-positive locally advanced" exact="breast cancer" post="(LABC) or MBC [ 25]. Here, we present the"/>
   <result pre="XL in patients with previously treated HER2-positive locally advanced breast" exact="cancer" post="(LABC) or MBC [ 25]. Here, we present the"/>
   <result pre="26.5%), AEs leading to treatment discontinuation (2.3% versus 12.2%), any-grade" exact="diarrhea" post="(18.6% versus 79.6%), and any-grade hand-foot syndrome (2.3% versus"/>
   <result pre="a higher incidence of any-grade hepatotoxicity (25.6% versus 14.3%), any-grade" exact="thrombocytopenia" post="(32.6% versus 4.1%), and any-grade hemorrhage (27.9% versus 12.2%)"/>
   <result pre="1 Lin NU Bellon JR Winer EP CNS metastases in" exact="breast cancer" post="J Clin Oncol 2004 22 3608 3617 15337811 2"/>
   <result pre="Lin NU Bellon JR Winer EP CNS metastases in breast" exact="cancer" post="J Clin Oncol 2004 22 3608 3617 15337811 2"/>
   <result pre="H Yerushalmi R Woods R et al. Metastatic behavior of" exact="breast cancer" post="subtypes J Clin Oncol 2010 28 3271 3277 20498394"/>
   <result pre="Yerushalmi R Woods R et al. Metastatic behavior of breast" exact="cancer" post="subtypes J Clin Oncol 2010 28 3271 3277 20498394"/>
   <result pre="3 Weil RJ Palmieri DC Bronder JL et al. Breast" exact="cancer" post="metastasis to the central nervous system Am J Pathol"/>
   <result pre="outcomes and treatment practice patterns of patients with HER2-positive metastatic" exact="breast cancer" post="in the post-trastuzumab era Breast 2013 22 525 531"/>
   <result pre="and treatment practice patterns of patients with HER2-positive metastatic breast" exact="cancer" post="in the post-trastuzumab era Breast 2013 22 525 531"/>
   <result pre="E et al. CNS relapses in patients with HER2-positive early" exact="breast cancer" post="who have and have not received adjuvant trastuzumab: a"/>
   <result pre="et al. CNS relapses in patients with HER2-positive early breast" exact="cancer" post="who have and have not received adjuvant trastuzumab: a"/>
   <result pre="disease status and tumor subtype for patients undergoing radiosurgery for" exact="breast cancer" post="brain metastases Int J Radiat Oncol Biol Phys 2012"/>
   <result pre="status and tumor subtype for patients undergoing radiosurgery for breast" exact="cancer" post="brain metastases Int J Radiat Oncol Biol Phys 2012"/>
   <result pre="study of lapatinib in patients with brain metastases from HER2-positive" exact="breast cancer" post="Clin Cancer Res 2009 15 1452 1459 19228746 16"/>
   <result pre="of lapatinib in patients with brain metastases from HER2-positive breast" exact="cancer" post="Clin Cancer Res 2009 15 1452 1459 19228746 16"/>
   <result pre="in patients with previously untreated brain metastases from HER2-positive metastatic" exact="breast cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="patients with previously untreated brain metastases from HER2-positive metastatic breast" exact="cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="in patients with human epidermal growth factor receptor 2 (HER2)-positive" exact="breast cancer" post="brain metastases Breast Cancer Res Treat 2013 142 405"/>
   <result pre="patients with human epidermal growth factor receptor 2 (HER2)-positive breast" exact="cancer" post="brain metastases Breast Cancer Res Treat 2013 142 405"/>
   <result pre="al. Clinical outcome of patients with brain metastases from HER2-positive" exact="breast cancer" post="treated with lapatinib and capecitabine Ann Oncol 2011 22"/>
   <result pre="Clinical outcome of patients with brain metastases from HER2-positive breast" exact="cancer" post="treated with lapatinib and capecitabine Ann Oncol 2011 22"/>
   <result pre="CJ Mathews CS et al. Survival after brain metastases from" exact="breast cancer" post="in the trastuzumab era J Clin Oncol 2005 23"/>
   <result pre="Mathews CS et al. Survival after brain metastases from breast" exact="cancer" post="in the trastuzumab era J Clin Oncol 2005 23"/>
   <result pre="K Esteva FJ et al. Defining prognosis for women with" exact="breast cancer" post="and CNS metastases by HER2 status Ann Oncol 2008"/>
   <result pre="Esteva FJ et al. Defining prognosis for women with breast" exact="cancer" post="and CNS metastases by HER2 status Ann Oncol 2008"/>
   <result pre="after whole brain radiotherapy and re-irradiation in patients with metastatic" exact="breast cancer" post="in the trastuzumab era Radiat Oncol 2011 6 181"/>
   <result pre="whole brain radiotherapy and re-irradiation in patients with metastatic breast" exact="cancer" post="in the trastuzumab era Radiat Oncol 2011 6 181"/>
   <result pre="and PET imaging of HER2-positive lesions in patients with metastatic" exact="breast cancer" post="Clin Pharmacol Ther 2010 87 586 592 20357763 23"/>
   <result pre="PET imaging of HER2-positive lesions in patients with metastatic breast" exact="cancer" post="Clin Pharmacol Ther 2010 87 586 592 20357763 23"/>
   <result pre="Phillips GD Li G Dugger DL et al. Targeting HER2-positive" exact="breast cancer" post="with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 2008"/>
   <result pre="GD Li G Dugger DL et al. Targeting HER2-positive breast" exact="cancer" post="with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 2008"/>
   <result pre="action of trastuzumab and efficiently inhibits growth of lapatinib insensitive" exact="breast cancer" post="Breast Cancer Res Treat 2011 128 347 356 20730488"/>
   <result pre="of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast" exact="cancer" post="Breast Cancer Res Treat 2011 128 347 356 20730488"/>
   <result pre="al. collab: EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 1783 1791 Erratum"/>
   <result pre="collab: EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 1783 1791 Erratum"/>
   <result pre="incidence of CNS metastases in patients (pts) with HER2+ metastatic" exact="breast cancer" post="(MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab"/>
   <result pre="of CNS metastases in patients (pts) with HER2+ metastatic breast" exact="cancer" post="(MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab"/>
   <result pre="lapatinib plus capecitabine versus capecitabine alone in women with advanced" exact="breast cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="plus capecitabine versus capecitabine alone in women with advanced breast" exact="cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="control and durable prolongation of systemic extracranial disease in HER2-overexpressing" exact="breast cancer" post="patients Br J Cancer 2009 100 894 900 19240719"/>
   <result pre="and durable prolongation of systemic extracranial disease in HER2-overexpressing breast" exact="cancer" post="patients Br J Cancer 2009 100 894 900 19240719"/>
   <result pre="HER2-positive breast cancer: epidemiological and clinical data from a population-based" exact="cancer" post="registry study Cancer 2011 117 1837 1846 21509760 30"/>
   <result pre="barrier permeability determines drug efficacy in experimental brain metastases of" exact="breast cancer" post="Clin Cancer Res 2010 16 5664 5678 20829328 31"/>
   <result pre="permeability determines drug efficacy in experimental brain metastases of breast" exact="cancer" post="Clin Cancer Res 2010 16 5664 5678 20829328 31"/>
   <result pre="5678 20829328 31 Bartsch R Berghoff AS Preusser M Breast" exact="cancer" post="brain metastases responding to primary systemic therapy with T-DM1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4682234/results/search/disease/results.xml">
   <result pre="Research Article Effect of the molecular targeted drug, erlotinib, against" exact="endometrial cancer" post="expressing high levels of epidermal growth factor receptor Nishimura"/>
   <result pre="Article Effect of the molecular targeted drug, erlotinib, against endometrial" exact="cancer" post="expressing high levels of epidermal growth factor receptor Nishimura"/>
   <result pre="erlotinib or trastuzumab. Results At our institution, 20.9 % of" exact="endometrial cancer" post="patients with low grade endometrioid histology have been diagnosed"/>
   <result pre="or trastuzumab. Results At our institution, 20.9 % of endometrial" exact="cancer" post="patients with low grade endometrioid histology have been diagnosed"/>
   <result pre="the EGFR expression levels. Keywords Molecular targeted drug Erlotinib Endometrial" exact="cancer" post="EGFR Background Endometrial carcinoma (EC) is one of the"/>
   <result pre="from 33 to 57 % [ 8, 10– 14]. Cytotoxic" exact="cancer" post="therapy induces apoptosis in cancer cells by inhibiting microtubule"/>
   <result pre="[ 8, 10– 14]. Cytotoxic cancer therapy induces apoptosis in" exact="cancer" post="cells by inhibiting microtubule function, protein function, or DNA"/>
   <result pre="therapy is designed to interfere with specific molecules involved in" exact="cancer" post="cell proliferation and metastasis. Recently, a better understanding of"/>
   <result pre="research that targets angiogenesis and cellular signaling pathways involved in" exact="cancer" post="development and progression. Epidermal growth factor receptor (EGFR) has"/>
   <result pre="EC, by accurately assessing the expression levels of EGFR in" exact="cancer" post="cells. Methods Reagents Erlotinib (Abcam, Tokyo, Japan) was dissolved"/>
   <result pre="RNA isolation and quantitative RT-PCR RNA was extracted from the" exact="endometrial cancer" post="cell lines and primary resected endometrioid adenocarcinoma tissue samples."/>
   <result pre="isolation and quantitative RT-PCR RNA was extracted from the endometrial" exact="cancer" post="cell lines and primary resected endometrioid adenocarcinoma tissue samples."/>
   <result pre="statistics 21 software. Results Expression of EGFR and HER-2 in" exact="endometrial cancer" post="Fifty-one surgically resected endometrioid carcinoma samples, classified as: well"/>
   <result pre="21 software. Results Expression of EGFR and HER-2 in endometrial" exact="cancer" post="Fifty-one surgically resected endometrioid carcinoma samples, classified as: well"/>
   <result pre="(Table 1). In our institution, 20.9 % of patients with" exact="endometrial cancer" post="with low-grade endometrioid histology were diagnosed as stage III"/>
   <result pre="1). In our institution, 20.9 % of patients with endometrial" exact="cancer" post="with low-grade endometrioid histology were diagnosed as stage III"/>
   <result pre="expression between the three grades. Table 1 Characteristics of surgical" exact="cancer" post="patients Well differentiated Mediate differentiated Poorly differentiated P value"/>
   <result pre="EGFR and HER-2 proteins in endometrial adenocarcinoma (surgically resected endometrioid" exact="cancer" post="sample). a We used tissue samples of well differentiated"/>
   <result pre="the significance of EGFR and HER-2 in the proliferation of" exact="endometrial cancer" post="cells, all cells were transfected with siRNA to knock"/>
   <result pre="significance of EGFR and HER-2 in the proliferation of endometrial" exact="cancer" post="cells, all cells were transfected with siRNA to knock"/>
   <result pre="3, 4]. In fact, in our institution, 20.9 % of" exact="endometrial cancer" post="patients with low-grade endometrioid histology have been diagnosed as"/>
   <result pre="4]. In fact, in our institution, 20.9 % of endometrial" exact="cancer" post="patients with low-grade endometrioid histology have been diagnosed as"/>
   <result pre="across a variety of disease types. For HER2-positive patients with" exact="breast cancer," post="trastuzumab has significantly reduced the rate of recurrence ["/>
   <result pre="and HER2 expression has been found in patients with non-small-cell" exact="lung cancer" post="with poor prognosis [ 38], erlotinib was beneficial in"/>
   <result pre="HER2 expression has been found in patients with non-small-cell lung" exact="cancer" post="with poor prognosis [ 38], erlotinib was beneficial in"/>
   <result pre="EGFR expression plays an important role in MAPK pathway in" exact="endometrial cancer" post="cell (Fig. 3), suggesting that endometrial cancer with highly"/>
   <result pre="expression plays an important role in MAPK pathway in endometrial" exact="cancer" post="cell (Fig. 3), suggesting that endometrial cancer with highly"/>
   <result pre="MAPK pathway in endometrial cancer cell (Fig. 3), suggesting that" exact="endometrial cancer" post="with highly expressed EGFR is strongly effected by anti-EGFR"/>
   <result pre="pathway in endometrial cancer cell (Fig. 3), suggesting that endometrial" exact="cancer" post="with highly expressed EGFR is strongly effected by anti-EGFR"/>
   <result pre="in the molecular targeted therapy against pathogenic tyrosine kinases in" exact="endometrial cancer," post="and suggest that EGFR inhibitors may be clinically useful"/>
   <result pre="EGFR inhibitors may be clinically useful for well-defined subgroups of" exact="endometrial cancer" post="patients with highly-expressed EGFR. A phase II study (NCIC"/>
   <result pre="inhibitors may be clinically useful for well-defined subgroups of endometrial" exact="cancer" post="patients with highly-expressed EGFR. A phase II study (NCIC"/>
   <result pre="for systemic chemotherapy, although it is not unanimously accepted. Basic" exact="cancer" post="research is conducted to identify the markers that determine"/>
   <result pre="transforming growth factor alpha is frequent in resectable non-small cell" exact="lung cancer" post="but does not predict tumor progression Clin Cancer Res"/>
   <result pre="growth factor alpha is frequent in resectable non-small cell lung" exact="cancer" post="but does not predict tumor progression Clin Cancer Res"/>
   <result pre="growth factor receptor and HER2-neu mRNA expression in non-small cell" exact="lung cancer" post="Is correlated with survival Clin Cancer Res 2001 7"/>
   <result pre="factor receptor and HER2-neu mRNA expression in non-small cell lung" exact="cancer" post="Is correlated with survival Clin Cancer Res 2001 7"/>
   <result pre="urinary epidermal growth factor and its receptor expression in human" exact="bladder cancer" post="Anticancer Res 1997 17 2B 1293 1296 9137488 20."/>
   <result pre="epidermal growth factor and its receptor expression in human bladder" exact="cancer" post="Anticancer Res 1997 17 2B 1293 1296 9137488 20."/>
   <result pre="Significance of epidermal growth factor receptor expression in primary human" exact="endometrial cancer" post="Int J Cancer 1994 56 1 26 30 10.1002/ijc.2910560106"/>
   <result pre="of epidermal growth factor receptor expression in primary human endometrial" exact="cancer" post="Int J Cancer 1994 56 1 26 30 10.1002/ijc.2910560106"/>
   <result pre="O Expression of the epidermal growth factor system in endometrioid" exact="endometrial cancer" post="Gynecol Oncol 2007 104 1 158 167 10.1016/j.ygyno.2006.07.015 16962163"/>
   <result pre="Expression of the epidermal growth factor system in endometrioid endometrial" exact="cancer" post="Gynecol Oncol 2007 104 1 158 167 10.1016/j.ygyno.2006.07.015 16962163"/>
   <result pre="Expression of HER-2 affects patient survival and paclitaxel sensitivity in" exact="endometrial cancer" post="Br J Cancer 2010 103 6 889 898 10.1038/sj.bjc.6605805"/>
   <result pre="of HER-2 affects patient survival and paclitaxel sensitivity in endometrial" exact="cancer" post="Br J Cancer 2010 103 6 889 898 10.1038/sj.bjc.6605805"/>
   <result pre="a novel HER2 and EGFR dual kinase inhibitor in human" exact="endometrial cancer" post="cells Br J Cancer 2008 98 6 1076 1084"/>
   <result pre="novel HER2 and EGFR dual kinase inhibitor in human endometrial" exact="cancer" post="cells Br J Cancer 2008 98 6 1076 1084"/>
   <result pre="large cohort of surgically staged patients with nonendometrioid (type II)" exact="endometrial cancer" post="Br J Cancer 2009 100 1 89 95 10.1038/sj.bjc.6604814"/>
   <result pre="cohort of surgically staged patients with nonendometrioid (type II) endometrial" exact="cancer" post="Br J Cancer 2009 100 1 89 95 10.1038/sj.bjc.6604814"/>
   <result pre="NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated" exact="breast cancer" post="cells Cancer Res 2006 66 3 1630 1639 10.1158/0008-5472.CAN-05-1182"/>
   <result pre="dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast" exact="cancer" post="cells Cancer Res 2006 66 3 1630 1639 10.1158/0008-5472.CAN-05-1182"/>
   <result pre="V Thongprasert S et al. Erlotinib in previously treated non-small-cell" exact="lung cancer" post="N Engl J Med 2005 353 2 123 132"/>
   <result pre="Thongprasert S et al. Erlotinib in previously treated non-small-cell lung" exact="cancer" post="N Engl J Med 2005 353 2 123 132"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4687700/results/search/disease/results.xml">
   <result pre="JCMM12662 : Review: Reviews Analysis of different HER‐2 mutations in" exact="breast cancer" post="progression and drug resistance Sun Zijia 1 Shi Yaqin"/>
   <result pre=": Review: Reviews Analysis of different HER‐2 mutations in breast" exact="cancer" post="progression and drug resistance Sun Zijia 1 Shi Yaqin"/>
   <result pre="carcinogenesis and prognosis in a variety of solid tumours, especially" exact="breast cancer." post="Lots of painstaking efforts were invested on the HER‐2"/>
   <result pre="drug resistance, but also have a potential association with the" exact="cancer" post="risk. In this review, we summarize the possible mutations"/>
   <result pre="the possible mutations and focus on HER‐2 variants’ role in" exact="breast cancer" post="tumourigenesis. Additionally, the alteration of HER‐2, as a potential"/>
   <result pre="possible mutations and focus on HER‐2 variants’ role in breast" exact="cancer" post="tumourigenesis. Additionally, the alteration of HER‐2, as a potential"/>
   <result pre="broader range of patients than previously classified as HER‐2 overexpressed." exact="breast cancer" post="HER‐2 HER‐2 mutation variants cancer risk resistance Funding National"/>
   <result pre="range of patients than previously classified as HER‐2 overexpressed. breast" exact="cancer" post="HER‐2 HER‐2 mutation variants cancer risk resistance Funding National"/>
   <result pre="classified as HER‐2 overexpressed. breast cancer HER‐2 HER‐2 mutation variants" exact="cancer" post="risk resistance Funding National Natural Science Foundation of China"/>
   <result pre="existing data, the probability of HER‐2 mutations is 1.67% in" exact="breast cancer," post="1–4% in lung cancer and 2.9% in colorectal 6,"/>
   <result pre="of HER‐2 mutations is 1.67% in breast cancer, 1–4% in" exact="lung cancer" post="and 2.9% in colorectal 6, 7, 8, 9, 10,"/>
   <result pre="HER‐2 mutations is 1.67% in breast cancer, 1–4% in lung" exact="cancer" post="and 2.9% in colorectal 6, 7, 8, 9, 10,"/>
   <result pre="18–23 25. HER‐2 kinase domain mutations have been described in" exact="lung carcinoma" post="and breast cancer albeit at a lower frequency 26,"/>
   <result pre="kinase domain mutations have been described in lung carcinoma and" exact="breast cancer" post="albeit at a lower frequency 26, 27, 28, 29."/>
   <result pre="domain mutations have been described in lung carcinoma and breast" exact="cancer" post="albeit at a lower frequency 26, 27, 28, 29."/>
   <result pre="gene amplification or protein overexpression has been extensively studied in" exact="breast cancer" post="37, 38, 39, 40, much less is known about"/>
   <result pre="amplification or protein overexpression has been extensively studied in breast" exact="cancer" post="37, 38, 39, 40, much less is known about"/>
   <result pre="might have an impact on the risk or therapy of" exact="breast cancer." post="It may be more challenged to successfully target HER‐2"/>
   <result pre="has been identified as a mechanism of HER‐2 activation in" exact="breast cancer" post="1. However, HER‐2 activating mutations, another novel modus to"/>
   <result pre="been identified as a mechanism of HER‐2 activation in breast" exact="cancer" post="1. However, HER‐2 activating mutations, another novel modus to"/>
   <result pre="Bose and his colleagues identified 16 HER‐2 somatic mutations though" exact="cancer" post="genome sequencing in HER‐2 gene amplification‐negative breast cancer patients."/>
   <result pre="somatic mutations though cancer genome sequencing in HER‐2 gene amplification‐negative" exact="breast cancer" post="patients. Seven of these HER‐2 kinase domain mutations are"/>
   <result pre="mutations though cancer genome sequencing in HER‐2 gene amplification‐negative breast" exact="cancer" post="patients. Seven of these HER‐2 kinase domain mutations are"/>
   <result pre="found at low frequency in several other carcinomas, such as" exact="bladder cancer" post="and lung cancer 23, 31, 43. Human epidermal growth"/>
   <result pre="at low frequency in several other carcinomas, such as bladder" exact="cancer" post="and lung cancer 23, 31, 43. Human epidermal growth"/>
   <result pre="frequency in several other carcinomas, such as bladder cancer and" exact="lung cancer" post="23, 31, 43. Human epidermal growth factor receptor‐2 gene"/>
   <result pre="in several other carcinomas, such as bladder cancer and lung" exact="cancer" post="23, 31, 43. Human epidermal growth factor receptor‐2 gene"/>
   <result pre="TK domain, recurring HER‐2 extracellular domain mutations in breast and" exact="lung cancer" post="were also identified ( e.g. S310F/Y, G309A/E, S335C) 23,"/>
   <result pre="domain, recurring HER‐2 extracellular domain mutations in breast and lung" exact="cancer" post="were also identified ( e.g. S310F/Y, G309A/E, S335C) 23,"/>
   <result pre="than wild‐type genes, both can act as driver mutations in" exact="lung cancer," post="and have the capacity to activate Akt. Simultaneously, p38"/>
   <result pre="I655V in the transmembrane domain was reported to increase the" exact="breast cancer" post="risk. The HER‐2 variants These variants, different from the"/>
   <result pre="in the transmembrane domain was reported to increase the breast" exact="cancer" post="risk. The HER‐2 variants These variants, different from the"/>
   <result pre="other resistant HER‐2 alterations have also been identified in HER‐2‐positive" exact="breast cancer," post="such as Δ16HER‐2 (a HER‐2 splice variant lacking exon"/>
   <result pre="transforming cells 62. Another study found that 44% of Δ16HER‐2‐expressing" exact="breast cancer" post="showed the activated Src kinase, heralding the potential clinical"/>
   <result pre="cells 62. Another study found that 44% of Δ16HER‐2‐expressing breast" exact="cancer" post="showed the activated Src kinase, heralding the potential clinical"/>
   <result pre="hyperactive and has been demonstrated to play a role in" exact="cancer" post="progression, increased metastasis, poor prognosis and disease‐free survival when"/>
   <result pre="and HER‐2/EGFR) 56. Herein, considering of the less association with" exact="breast cancer" post="risk or drug resistance, we will not focus on"/>
   <result pre="HER‐2/EGFR) 56. Herein, considering of the less association with breast" exact="cancer" post="risk or drug resistance, we will not focus on"/>
   <result pre="two subsets of variants more. The HER‐2 mutations associated with" exact="breast cancer" post="risk A breadth of literature describes the link between"/>
   <result pre="subsets of variants more. The HER‐2 mutations associated with breast" exact="cancer" post="risk A breadth of literature describes the link between"/>
   <result pre="breadth of literature describes the link between genetic variations and" exact="breast cancer" post="risk. Single nucleotide polymorphisms (SNPs) are the commonest sources"/>
   <result pre="of literature describes the link between genetic variations and breast" exact="cancer" post="risk. Single nucleotide polymorphisms (SNPs) are the commonest sources"/>
   <result pre="rs1136201) has been extensively investigated as a risk factor for" exact="breast cancer" post="73. Since the initial case –control study on 700"/>
   <result pre="has been extensively investigated as a risk factor for breast" exact="cancer" post="73. Since the initial case –control study on 700"/>
   <result pre="between the HER‐2 655V polymorphism and an increased risk of" exact="breast cancer" post="31. However, the results are inconsistent. Several meta‐analyses have"/>
   <result pre="the HER‐2 655V polymorphism and an increased risk of breast" exact="cancer" post="31. However, the results are inconsistent. Several meta‐analyses have"/>
   <result pre="been performed to investigate the association between the polymorphism and" exact="breast cancer." post="Due to the differential including studies and methodological issues,"/>
   <result pre="demonstrate any significant associations between HER‐2 codon 655 polymorphism and" exact="breast cancer" post="susceptibility, either at the overall or the ethnicity analyses"/>
   <result pre="any significant associations between HER‐2 codon 655 polymorphism and breast" exact="cancer" post="susceptibility, either at the overall or the ethnicity analyses"/>
   <result pre="updated meta‐analysis suggests that this polymorphism is marginally associated with" exact="breast cancer" post="in worldwide populations with additive and dominant models, but"/>
   <result pre="meta‐analysis suggests that this polymorphism is marginally associated with breast" exact="cancer" post="in worldwide populations with additive and dominant models, but"/>
   <result pre="associations could be identified between the polymorphism and an increased" exact="breast cancer" post="risk among different ethnicities. A stronger association was revealed"/>
   <result pre="could be identified between the polymorphism and an increased breast" exact="cancer" post="risk among different ethnicities. A stronger association was revealed"/>
   <result pre="the HER‐2 valine allele might predominantly affect pre‐ or peri‐menopausal" exact="breast cancer" post="78. Consistent with the above investigations, another study also"/>
   <result pre="HER‐2 valine allele might predominantly affect pre‐ or peri‐menopausal breast" exact="cancer" post="78. Consistent with the above investigations, another study also"/>
   <result pre="years of age and reported a positive family history of" exact="breast cancer" post="(OR = 2.3, 95% CI = 1–5.3) 79. However,"/>
   <result pre="of age and reported a positive family history of breast" exact="cancer" post="(OR = 2.3, 95% CI = 1–5.3) 79. However,"/>
   <result pre="revealing that HER‐2 I655V polymorphism may be a biomarker for" exact="breast cancer" post="susceptibility among older women 80. Furthermore, a rare HER‐2"/>
   <result pre="that HER‐2 I655V polymorphism may be a biomarker for breast" exact="cancer" post="susceptibility among older women 80. Furthermore, a rare HER‐2"/>
   <result pre="HER‐2 variant Ile654Val is also associated with an increased familial" exact="breast cancer" post="risk, which revealed an oncogenic role for carriers of"/>
   <result pre="variant Ile654Val is also associated with an increased familial breast" exact="cancer" post="risk, which revealed an oncogenic role for carriers of"/>
   <result pre="growth factors signalling appear to have the stronger influence on" exact="breast cancer" post="risk via combining with other variant gene, including variant"/>
   <result pre="factors signalling appear to have the stronger influence on breast" exact="cancer" post="risk via combining with other variant gene, including variant"/>
   <result pre="human epidermal growth factor receptor ( HER)‐2 oncogenic activities in" exact="breast cancer" post="development and progression. The HER‐2 mutations associated with breast"/>
   <result pre="epidermal growth factor receptor ( HER)‐2 oncogenic activities in breast" exact="cancer" post="development and progression. The HER‐2 mutations associated with breast"/>
   <result pre="breast cancer development and progression. The HER‐2 mutations associated with" exact="breast cancer" post="resistance In 1987, HER‐2 amplification and overexpression were first"/>
   <result pre="cancer development and progression. The HER‐2 mutations associated with breast" exact="cancer" post="resistance In 1987, HER‐2 amplification and overexpression were first"/>
   <result pre="These molecular alterations could be found in approximately 20–30% of" exact="breast cancer" post="90. Since then, HER‐2 was considered as a significant"/>
   <result pre="molecular alterations could be found in approximately 20–30% of breast" exact="cancer" post="90. Since then, HER‐2 was considered as a significant"/>
   <result pre="1). Table 1 The HER‐2 mutations and variations associated with" exact="breast cancer" post="resistance Mutations Primary tumour Number of patients screened TNM"/>
   <result pre="Table 1 The HER‐2 mutations and variations associated with breast" exact="cancer" post="resistance Mutations Primary tumour Number of patients screened TNM"/>
   <result pre="NA NA Trastuzumab 62 NA: not available; TNBC: triple negative" exact="breast cancer;" post="HER: human epidermal growth factor receptor. (C) John Wiley"/>
   <result pre="that a 52‐year‐old man diagnosed with stage IV non‐small cell" exact="lung cancer" post="(NSCLC), was detected to overexpress HER‐2 and harbour an"/>
   <result pre="a 52‐year‐old man diagnosed with stage IV non‐small cell lung" exact="cancer" post="(NSCLC), was detected to overexpress HER‐2 and harbour an"/>
   <result pre="is still unknown. Another study revealed that the HER‐2 gene‐amplified" exact="breast cancer" post="cells, which harbour the T798M mutant alleles, acquired a"/>
   <result pre="still unknown. Another study revealed that the HER‐2 gene‐amplified breast" exact="cancer" post="cells, which harbour the T798M mutant alleles, acquired a"/>
   <result pre="mutation was the most common subtype of mutant HER‐2 in" exact="breast cancer." post="In his study, six of total 27 patients with"/>
   <result pre="growth factor receptor TKI, primarily for NSCLC, also respond to" exact="breast cancer" post="with positive HER‐2. A subset of breast cancer cell"/>
   <result pre="factor receptor TKI, primarily for NSCLC, also respond to breast" exact="cancer" post="with positive HER‐2. A subset of breast cancer cell"/>
   <result pre="respond to breast cancer with positive HER‐2. A subset of" exact="breast cancer" post="cell lines overexpressing the activated HER‐2 was treated with"/>
   <result pre="to breast cancer with positive HER‐2. A subset of breast" exact="cancer" post="cell lines overexpressing the activated HER‐2 was treated with"/>
   <result pre="of patients with the expressed Δ16HER‐2 were locally disseminated node‐positive" exact="breast cancer," post="indicating that more attention should be put on this"/>
   <result pre="binding region. It has been demonstrated to be associated with" exact="cancer" post="progression, metastasis, poor prognosis and disease‐free survival when compared"/>
   <result pre="expressing the wild full‐length HER‐2 65, 68. Additionally, patients with" exact="breast cancer" post="harbouring the expression of p95HER‐2 exhibit less response to"/>
   <result pre="the wild full‐length HER‐2 65, 68. Additionally, patients with breast" exact="cancer" post="harbouring the expression of p95HER‐2 exhibit less response to"/>
   <result pre="Similar outcome of HER‐2‐targeted therapy has also been achieved in" exact="breast cancer" post="patients with HER‐2‐mutantions 103, 110. Notably, in Bose's research,"/>
   <result pre="outcome of HER‐2‐targeted therapy has also been achieved in breast" exact="cancer" post="patients with HER‐2‐mutantions 103, 110. Notably, in Bose's research,"/>
   <result pre="clinical trial is being launched to screen patients with metastatic" exact="breast cancer" post="for HER‐2 mutation and investigate the clinical outcome of"/>
   <result pre="trial is being launched to screen patients with metastatic breast" exact="cancer" post="for HER‐2 mutation and investigate the clinical outcome of"/>
   <result pre="HER‐2, has significantly improved the outcome and prognosis of HER‐2‐overexpressing" exact="breast cancer." post="However, despite the clinical success, the resistance of HER‐2"/>
   <result pre="secondary mutations were detected to play a critical role in" exact="breast cancer" post="progression and drug resistance, revealing a sophisticated challenge for"/>
   <result pre="mutations were detected to play a critical role in breast" exact="cancer" post="progression and drug resistance, revealing a sophisticated challenge for"/>
   <result pre=", et al EGFR and erbB2 mutation status in Japanese" exact="lung cancer" post="patients. Int J Cancer. 2006; 118: 180– 4. 16003726"/>
   <result pre="et al EGFR and erbB2 mutation status in Japanese lung" exact="cancer" post="patients. Int J Cancer. 2006; 118: 180– 4. 16003726"/>
   <result pre="alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open‐label, randomised controlled trial ."/>
   <result pre="amplification and novel mutations in the HER2 protein‐overexpressed mucinous epithelial" exact="ovarian cancer" post=". Ann Surg Oncol. 2011; 18: 2388– 94. 21347793"/>
   <result pre="and novel mutations in the HER2 protein‐overexpressed mucinous epithelial ovarian" exact="cancer" post=". Ann Surg Oncol. 2011; 18: 2388– 94. 21347793"/>
   <result pre="novel mutation in the tyrosine kinase domain of ERBB2 in" exact="hepatocellular carcinoma." post="BMC Cancer. 2006; 6: 278. 17150109 19 Tschui J"/>
   <result pre="et al Morphological and molecular characteristics of HER2 amplified urothelial" exact="bladder cancer." post="Virchows Arch. 2015; 466: 1– 8. 25527271 20 Kubo"/>
   <result pre="the human tyrosine kinase gene family in poorly differentiated gastric" exact="cancer" post=". Carcinogenesis. 2009; 30: bgp206. 21 Cohen EE ,"/>
   <result pre="et al Activating HER2 mutations in HER2 gene amplification negative" exact="breast cancer." post="Cancer Discov. 2013; 3: 224– 37. 23220880 24 Matthew"/>
   <result pre="Carter CA , Giaccone G . HER2 mutations in non–small‐cell" exact="lung cancer" post="can be continually targeted. J Clin Oncol. 2012; 30:"/>
   <result pre="CA , Giaccone G . HER2 mutations in non–small‐cell lung" exact="cancer" post="can be continually targeted. J Clin Oncol. 2012; 30:"/>
   <result pre=", Ji H , Minami Y , et al Non‐small‐cell" exact="lung cancer" post="and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation"/>
   <result pre="Ji H , Minami Y , et al Non‐small‐cell lung" exact="cancer" post="and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation"/>
   <result pre="in the epidermal growth factor receptor underlying responsiveness of non–small‐cell" exact="lung cancer" post="to gefitinib . N Engl J Med. 2004; 350:"/>
   <result pre="the epidermal growth factor receptor underlying responsiveness of non–small‐cell lung" exact="cancer" post="to gefitinib . N Engl J Med. 2004; 350:"/>
   <result pre="al Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell" exact="lung cancer" post="harbouring mutations of the epidermal growth factor receptor (WJTOG3405):"/>
   <result pre="Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung" exact="cancer" post="harbouring mutations of the epidermal growth factor receptor (WJTOG3405):"/>
   <result pre="al Detection and quantitation of HER‐2/neu gene amplification in human" exact="breast cancer" post="archival material using fluorescence in situ hybridization . Oncogene."/>
   <result pre="Detection and quantitation of HER‐2/neu gene amplification in human breast" exact="cancer" post="archival material using fluorescence in situ hybridization . Oncogene."/>
   <result pre="8700555 36 Kamoshida S . Challenges of immunohistochemistry for individualized" exact="cancer" post="chemotherapy. Rinsho Byori. 2014; 62: 710– 8. 25669042 37"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre=", et al Trastuzumab plus adjuvant chemotherapy for operable HER2‐positive" exact="breast cancer." post="N Engl J Med. 2005; 353: 1673– 84. 16236738"/>
   <result pre="pertuzumab in human epidermal growth factor receptor 2–positive, first‐line metastatic" exact="breast cancer" post=". J Clin Oncol. 2014; 32: 3753– 61. 25332247"/>
   <result pre="in human epidermal growth factor receptor 2–positive, first‐line metastatic breast" exact="cancer" post=". J Clin Oncol. 2014; 32: 3753– 61. 25332247"/>
   <result pre="tumor progression and can predict response to treatment in human" exact="breast cancer" post=". Mol Oncol. 2014; 9: 586– 600. 25435280 43"/>
   <result pre="progression and can predict response to treatment in human breast" exact="cancer" post=". Mol Oncol. 2014; 9: 586– 600. 25435280 43"/>
   <result pre=", et al Somatic mutations of the HER2 in metastatic" exact="breast cancer." post="Tumour Biol. 2014; 35: 11851– 4. 25326805 46 Herter‐Sprie"/>
   <result pre="et al Functional analysis of receptor tyrosine kinase mutations in" exact="lung cancer" post="identifies oncogenic extracellular domain mutations of ERBB2 . Proc"/>
   <result pre="al Functional analysis of receptor tyrosine kinase mutations in lung" exact="cancer" post="identifies oncogenic extracellular domain mutations of ERBB2 . Proc"/>
   <result pre="al An oncogenic isoform of HER2 associated with locally disseminated" exact="breast cancer" post="and trastuzumab resistance . Mol Cancer Ther. 2009; 8:"/>
   <result pre="An oncogenic isoform of HER2 associated with locally disseminated breast" exact="cancer" post="and trastuzumab resistance . Mol Cancer Ther. 2009; 8:"/>
   <result pre="Sirotković‐Skerlev M , et al Circulating her‐2/neu extracellular domain in" exact="breast cancer" post="patients‐correlation with prognosis and clinicopathological parameters including steroid receptor,"/>
   <result pre="M , et al Circulating her‐2/neu extracellular domain in breast" exact="cancer" post="patients‐correlation with prognosis and clinicopathological parameters including steroid receptor,"/>
   <result pre=", et al Clinical significance of HER‐2 splice variants in" exact="breast cancer" post="progression and drug resistance . Int J Cell Biol."/>
   <result pre="et al Clinical significance of HER‐2 splice variants in breast" exact="cancer" post="progression and drug resistance . Int J Cell Biol."/>
   <result pre=". Mechanisms and strategies to overcome chemotherapy resistance in metastatic" exact="breast cancer" post=". Cancer Treat Rev. 2008; 34: 378– 90. 18367336"/>
   <result pre="Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast" exact="cancer" post=". Cancer Treat Rev. 2008; 34: 378– 90. 18367336"/>
   <result pre=". Advances in first‐line treatment for patients with HER‐2+ metastatic" exact="breast cancer." post="Oncologist. 2012; 17: 631– 44. 22523199 60 Thery J‐C"/>
   <result pre="antibody and correlation with outcome in a cohort of trastuzumab‐treated" exact="breast cancer" post="patients . Clin Cancer Res. 2010; 16: 4226– 35."/>
   <result pre="and correlation with outcome in a cohort of trastuzumab‐treated breast" exact="cancer" post="patients . Clin Cancer Res. 2010; 16: 4226– 35."/>
   <result pre="Baselga J , Pedersen K , et al p95HER2 and" exact="breast cancer." post="Cancer Res. 2011; 71: 1515– 9. 21343397 66 Tural"/>
   <result pre=", Mutlu H , et al P95 HER2 fragments and" exact="breast cancer" post="outcome. Expert Rev Anticancer Ther. 2014; 14: 1089– 96."/>
   <result pre="Mutlu H , et al P95 HER2 fragments and breast" exact="cancer" post="outcome. Expert Rev Anticancer Ther. 2014; 14: 1089– 96."/>
   <result pre="et al p95HER‐2 predicts worse outcome in patients with HER‐2‐positive" exact="breast cancer." post="Clin Cancer Res. 2006; 12: 424– 31. 16428482 69"/>
   <result pre="al Quantitative measurements of tumoral p95HER2 protein expression in metastatic" exact="breast cancer" post="patients treated with trastuzumab: independent validation of the p95HER2"/>
   <result pre="Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast" exact="cancer" post="patients treated with trastuzumab: independent validation of the p95HER2"/>
   <result pre="R497K and HER2 I655V polymorphisms are linked to development of" exact="breast cancer." post="Dis Markers. 2013; 34: 407– 17. 23594562 73 Millikan"/>
   <result pre="et al Population‐based, case‐control study of HER2 genetic polymorphism and" exact="breast cancer" post="risk . J Natl Cancer Inst. 2000; 92: 412–"/>
   <result pre="al Population‐based, case‐control study of HER2 genetic polymorphism and breast" exact="cancer" post="risk . J Natl Cancer Inst. 2000; 92: 412–"/>
   <result pre="Liu H , et al HER2 Ile655Val polymorphism contributes to" exact="breast cancer" post="risk: evidence from 27 case‐control studies . Breast Cancer"/>
   <result pre="H , et al HER2 Ile655Val polymorphism contributes to breast" exact="cancer" post="risk: evidence from 27 case‐control studies . Breast Cancer"/>
   <result pre="al Lack of association between HER2 codon 655 polymorphism and" exact="breast cancer" post="susceptibility: meta‐analysis of 22 studies involving 19,341 subjects ."/>
   <result pre="Lack of association between HER2 codon 655 polymorphism and breast" exact="cancer" post="susceptibility: meta‐analysis of 22 studies involving 19,341 subjects ."/>
   <result pre="Wacholder S , et al The HER2 I655V polymorphism and" exact="breast cancer" post="risk in ashkenazim. Epidemiology. 2003; 14: 694– 700. 14569185"/>
   <result pre="S , et al The HER2 I655V polymorphism and breast" exact="cancer" post="risk in ashkenazim. Epidemiology. 2003; 14: 694– 700. 14569185"/>
   <result pre=", et al HER2 codon 655 polymorphism and risk of" exact="breast cancer" post="in African Americans and whites. Breast Cancer Res Treat."/>
   <result pre="et al HER2 codon 655 polymorphism and risk of breast" exact="cancer" post="in African Americans and whites. Breast Cancer Res Treat."/>
   <result pre="rare ERBB2 variant Ile654Val is associated with an increased familial" exact="breast cancer" post="risk . Carcinogenesis. 2005; 26: 643– 7. 15550452 82"/>
   <result pre="ERBB2 variant Ile654Val is associated with an increased familial breast" exact="cancer" post="risk . Carcinogenesis. 2005; 26: 643– 7. 15550452 82"/>
   <result pre="R , Cheng K . The role of HER2 in" exact="cancer" post="therapy and targeted drug delivery. J Controlled Release. 2010;"/>
   <result pre="DL . A systematic review of dual targeting in HER2‐positive" exact="breast cancer." post="Cancer Treat Rev. 2014; 40: 259– 70. 24080156 84"/>
   <result pre="factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with" exact="breast cancer" post="risk and survival: the Breast Cancer Health Disparities Study"/>
   <result pre="genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast" exact="cancer" post="risk and survival: the Breast Cancer Health Disparities Study"/>
   <result pre=", Clark GM , Wong SG , et al Human‐breast" exact="cancer" post="‐ correlation of relapse and survival with amplification of"/>
   <result pre=", Andersson M , Kamby C . HER2‐targeted therapy in" exact="breast cancer." post="Monoclonal antibodies and tyrosine kinase inhibitors . Cancer Treat"/>
   <result pre="behind trastuzumab therapy for human epidermal growth factor receptor 2–positive" exact="breast cancer" post=". J Clin Oncol. 2009; 27: 5838– 47. 19884552"/>
   <result pre="trastuzumab therapy for human epidermal growth factor receptor 2–positive breast" exact="cancer" post=". J Clin Oncol. 2009; 27: 5838– 47. 19884552"/>
   <result pre="factor receptor mutations of unknown clinical significance in non‐small cell" exact="lung cancer" post=". Clin Cancer Res. 2011; 17: 3812– 21. 21531810"/>
   <result pre="receptor mutations of unknown clinical significance in non‐small cell lung" exact="cancer" post=". Clin Cancer Res. 2011; 17: 3812– 21. 21531810"/>
   <result pre=", Ghosh R , Narasanna A , et al Human" exact="breast cancer" post="cells harboring a gatekeeper T798M mutation in HER2 overexpress"/>
   <result pre="Ghosh R , Narasanna A , et al Human breast" exact="cancer" post="cells harboring a gatekeeper T798M mutation in HER2 overexpress"/>
   <result pre="kinase inhibitor imatinib (STI571) in chronic phase and blast crisis" exact="chronic myeloid leukemia" post=". Cancer Cell. 2002; 2: 117– 25. 12204532 100"/>
   <result pre="inhibitor imatinib (STI571) in chronic phase and blast crisis chronic" exact="myeloid leukemia" post=". Cancer Cell. 2002; 2: 117– 25. 12204532 100"/>
   <result pre="imatinib (STI571) in chronic phase and blast crisis chronic myeloid" exact="leukemia" post=". Cancer Cell. 2002; 2: 117– 25. 12204532 100"/>
   <result pre="Guo TH , et al Acquired resistance to imatinib in" exact="gastrointestinal stromal tumor" post="occurs through secondary gene mutation . Clin Cancer Res."/>
   <result pre=", Yoo GH , Dibbley SK , et al Breast" exact="cancer" post="expressing the activated HER2/neu is sensitive to gefitinib in"/>
   <result pre=", Janku F , Tsao AS , et al Non‐small‐cell" exact="lung cancer" post="with HER2 exon 20 mutation regression with dual HER2"/>
   <result pre="Janku F , Tsao AS , et al Non‐small‐cell lung" exact="cancer" post="with HER2 exon 20 mutation regression with dual HER2"/>
   <result pre=", Peters S , Lepage B , et al Lung" exact="cancer" post="that harbors an HER2 mutation: epidemiologic characteristics and therapeutic"/>
   <result pre=". HER2 mutation and response to trastuzumab therapy in non‐small‐cell" exact="lung cancer." post="N Engl J Med. 2006; 354: 2619– 21. 16775247"/>
   <result pre="N , et al HER2 mutation status in Japanese HER2‐negative" exact="breast cancer" post="patients. Jpn J Clin Oncol. 2014; 44: 619– 23."/>
   <result pre=", et al HER2 mutation status in Japanese HER2‐negative breast" exact="cancer" post="patients. Jpn J Clin Oncol. 2014; 44: 619– 23."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4687715/results/search/disease/results.xml">
   <result pre="in sarcoplasmic reticulum. Also, mitochondrial dysfunction was involved in stress-induced" exact="cardiomyopathy" post="[ 40]. Thus, following chemotherapy treatment, similar pathophysiological mechanism"/>
   <result pre="troponin: recent advances in the development of alternative biomarkers for" exact="cardiovascular disease" post=". Expert Rev Mol Diagn. 2015 4; 15( 4):"/>
   <result pre="Blomberg C , Hoffner E , Yan X . Anti-HER2" exact="cancer" post="therapy and cardiotoxicity. Curr Pharm Des. 2014; 20( 30):"/>
   <result pre=", Clark RA . The prevention, detection and management of" exact="cancer" post="treatment-induced cardiotoxicity: a meta-review . BMC Cancer. 2015; 15("/>
   <result pre="liver enzymes with biomarkers of subclinical myocardial damage and structural" exact="heart disease" post=". J Hepatol. 2015 4; 62( 4): 841– 7."/>
   <result pre="and trastuzumab with and without lapatinib in patients with early" exact="breast cancer" post=". Cancer. 2013 11 15; 119( 22): 3943– 51."/>
   <result pre="trastuzumab with and without lapatinib in patients with early breast" exact="cancer" post=". Cancer. 2013 11 15; 119( 22): 3943– 51."/>
   <result pre="et al. Myocardial injury revealed by plasma troponin I in" exact="breast cancer" post="treated with high-dose chemotherapy . Ann Oncol. 2002 5;"/>
   <result pre="al. Myocardial injury revealed by plasma troponin I in breast" exact="cancer" post="treated with high-dose chemotherapy . Ann Oncol. 2002 5;"/>
   <result pre="I and C-reactive protein are commonly detected in patients with" exact="breast cancer" post="treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib ."/>
   <result pre="and C-reactive protein are commonly detected in patients with breast" exact="cancer" post="treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib ."/>
   <result pre="detection of cardiac toxicity after chemotherapy and radiation therapy in" exact="breast cancer" post="patients . Front Oncol. 2014; 4: 277 doi: 10.3389/fonc.2014.00277"/>
   <result pre="of cardiac toxicity after chemotherapy and radiation therapy in breast" exact="cancer" post="patients . Front Oncol. 2014; 4: 277 doi: 10.3389/fonc.2014.00277"/>
   <result pre=". S100 protein family in human cancer. American journal of" exact="cancer" post="research. 2014; 4( 2): 89 24660101 38 Ji YF"/>
   <result pre="MB . S100 family signaling network and related proteins in" exact="pancreatic cancer" post="(Review). International journal of molecular medicine. 2014 4; 33("/>
   <result pre=". S100 family signaling network and related proteins in pancreatic" exact="cancer" post="(Review). International journal of molecular medicine. 2014 4; 33("/>
   <result pre="underlie cardiac dysfunction in a rat model of post-acute isoproterenol-induced" exact="cardiomyopathy" post=". Am J Physiol Heart Circ Physiol. 2014 3"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4689767/results/search/disease/results.xml">
   <result pre=": Clinical Guides in Oncology SEOM clinical guidelines in early-stage" exact="breast cancer" post="2015 Garcia-Saenz J. A. +34-91-330-3546 jagsaenz@yahoo.com Bermejo B. Estevez"/>
   <result pre="Clinical Guides in Oncology SEOM clinical guidelines in early-stage breast" exact="cancer" post="2015 Garcia-Saenz J. A. +34-91-330-3546 jagsaenz@yahoo.com Bermejo B. Estevez"/>
   <result pre="Commons license, and indicate if changes were made. Abstract Breast" exact="cancer" post="is a major public health problem. Despite remarkable advances"/>
   <result pre="we summarize current evidence for the medical management of early-stage" exact="breast cancer." post="Keywords Early-stage breast cancer Clinical guidelines Adjuvant Neoadjuvant Genomic"/>
   <result pre="for the medical management of early-stage breast cancer. Keywords Early-stage" exact="breast cancer" post="Clinical guidelines Adjuvant Neoadjuvant Genomic platforms Introduction Breast cancer"/>
   <result pre="the medical management of early-stage breast cancer. Keywords Early-stage breast" exact="cancer" post="Clinical guidelines Adjuvant Neoadjuvant Genomic platforms Introduction Breast cancer"/>
   <result pre="breast cancer Clinical guidelines Adjuvant Neoadjuvant Genomic platforms Introduction Breast" exact="cancer" post="is a major public health problem due to its"/>
   <result pre="prevalence, and mortality. It is by far the most common" exact="cancer" post="among women in Spain (2012), accounting for 29 %"/>
   <result pre="(2012), accounting for 29 % of all new cases of" exact="cancer" post="in females. Moreover, it is the first cause of"/>
   <result pre="in the female population, accounting for 15.5 % of female" exact="cancer" post="deaths, and the 5-year prevalence is 31.4 % ["/>
   <result pre="and the 5-year prevalence is 31.4 % [ 1]. Breast" exact="cancer" post="is a heterogeneous disease with multiple intrinsic tumor subtypes"/>
   <result pre="metastases during the disease depending on lymph node involvement and" exact="breast cancer" post="subtype, despite remarkable progress in early diagnosis and treatment"/>
   <result pre="during the disease depending on lymph node involvement and breast" exact="cancer" post="subtype, despite remarkable progress in early diagnosis and treatment"/>
   <result pre="predictive factors is allowing to individualize the treatment of early-stage" exact="breast cancer" post="patients. The aim of these guidelines is to summarize"/>
   <result pre="factors is allowing to individualize the treatment of early-stage breast" exact="cancer" post="patients. The aim of these guidelines is to summarize"/>
   <result pre="SEOM Guidelines have been developed with the consensus of ten" exact="breast cancer" post="oncologists from the cooperative groups GEICAM (Spanish Breast Cancer"/>
   <result pre="Guidelines have been developed with the consensus of ten breast" exact="cancer" post="oncologists from the cooperative groups GEICAM (Spanish Breast Cancer"/>
   <result pre="present) [I, B] [ 6]. Principles of surgery in early-stage" exact="breast cancer" post="Breast-conserving surgery based on lumpectomy is equivalent to mastectomy"/>
   <result pre="[I, B] [ 6]. Principles of surgery in early-stage breast" exact="cancer" post="Breast-conserving surgery based on lumpectomy is equivalent to mastectomy"/>
   <result pre="adjuvant treatment Systemic adjuvant treatment is commonly used in early" exact="breast cancer" post="with the intention to reduce the rate of locoregional"/>
   <result pre="treatment Systemic adjuvant treatment is commonly used in early breast" exact="cancer" post="with the intention to reduce the rate of locoregional"/>
   <result pre="factors that can help in making treatment decisions in ER-positive" exact="breast cancer." post="All of these tests have been validated for prognosis"/>
   <result pre="for predicting risk of distance recurrence to 10 years in" exact="breast cancer" post="patients treated with hormone therapy. Oncotype has also proved"/>
   <result pre="predicting risk of distance recurrence to 10 years in breast" exact="cancer" post="patients treated with hormone therapy. Oncotype has also proved"/>
   <result pre="benefit of chemotherapy [ 29]. Systemic treatment for Luminal-type early-stage" exact="breast cancer" post="Adjuvant endocrine therapy for early-stage breast cancer There is"/>
   <result pre="of chemotherapy [ 29]. Systemic treatment for Luminal-type early-stage breast" exact="cancer" post="Adjuvant endocrine therapy for early-stage breast cancer There is"/>
   <result pre="for Luminal-type early-stage breast cancer Adjuvant endocrine therapy for early-stage" exact="breast cancer" post="There is robust evidence that endocrine therapy improves survival"/>
   <result pre="Luminal-type early-stage breast cancer Adjuvant endocrine therapy for early-stage breast" exact="cancer" post="There is robust evidence that endocrine therapy improves survival"/>
   <result pre="robust evidence that endocrine therapy improves survival of early-stage luminal" exact="breast cancer." post="Therefore, adjuvant hormonotherapy should be offered to any of"/>
   <result pre="cost of greater toxicity [I, B]. Adjuvant exemestane with ovarian" exact="suppression" post="as compared with tamoxifen plus ovarian suppression significantly reduced"/>
   <result pre="exemestane with ovarian suppression as compared with tamoxifen plus ovarian" exact="suppression" post="significantly reduced recurrence but did not improve overall survival"/>
   <result pre="but did not improve overall survival in high-risk adjuvant-chemotherapy-treated premenopausal" exact="breast cancer" post="patients [ 33]. This combination is an alternative to"/>
   <result pre="did not improve overall survival in high-risk adjuvant-chemotherapy-treated premenopausal breast" exact="cancer" post="patients [ 33]. This combination is an alternative to"/>
   <result pre="tamoxifen. Primary/neoadjuvant therapy for hormone receptor-positive disease In locally advanced" exact="cancer" post="and large tumors, primary systemic treatment is indicated (I,"/>
   <result pre="hormonal treatment in premenopausal patients. Systemic therapy for early-stage triple-negative" exact="breast cancer" post="Adjuvant treatment for triple-negative disease Triple-negative breast cancer (TNBC)"/>
   <result pre="treatment in premenopausal patients. Systemic therapy for early-stage triple-negative breast" exact="cancer" post="Adjuvant treatment for triple-negative disease Triple-negative breast cancer (TNBC)"/>
   <result pre="early-stage triple-negative breast cancer Adjuvant treatment for triple-negative disease Triple-negative" exact="breast cancer" post="(TNBC) is a heterogeneous disease comprising approximately 15 %"/>
   <result pre="triple-negative breast cancer Adjuvant treatment for triple-negative disease Triple-negative breast" exact="cancer" post="(TNBC) is a heterogeneous disease comprising approximately 15 %"/>
   <result pre="is currently being evaluated. Neoadjuvant cisplatin monotherapy in BRCA1 mutation-breast" exact="cancer" post="patients is highly effective with pCR rates of 72–83"/>
   <result pre="with both a BRCA1/2 and family history of breast or" exact="ovarian cancer" post="had the largest improvement in pCR. In the CALGB"/>
   <result pre="both a BRCA1/2 and family history of breast or ovarian" exact="cancer" post="had the largest improvement in pCR. In the CALGB"/>
   <result pre="mutation carriers or patients with a strong family history of" exact="breast cancer" post="[I, A]. Systemic treatment for early-stage HER2-positive breast cancer"/>
   <result pre="carriers or patients with a strong family history of breast" exact="cancer" post="[I, A]. Systemic treatment for early-stage HER2-positive breast cancer"/>
   <result pre="of breast cancer [I, A]. Systemic treatment for early-stage HER2-positive" exact="breast cancer" post="Adjuvant treatment for HER2-positive disease HER2 receptor is a"/>
   <result pre="breast cancer [I, A]. Systemic treatment for early-stage HER2-positive breast" exact="cancer" post="Adjuvant treatment for HER2-positive disease HER2 receptor is a"/>
   <result pre="relevant in decreasing the risk of local recurrence and improving" exact="breast cancer" post="mortality. Despite these recommendations, it is important to note"/>
   <result pre="in decreasing the risk of local recurrence and improving breast" exact="cancer" post="mortality. Despite these recommendations, it is important to note"/>
   <result pre="lumpectomy, and lumpectomy plus irradiation for the treatment of invasive" exact="breast cancer" post="N Engl J Med 2002 347 1233 1241 10.1056/NEJMoa022152"/>
   <result pre="and lumpectomy plus irradiation for the treatment of invasive breast" exact="cancer" post="N Engl J Med 2002 347 1233 1241 10.1056/NEJMoa022152"/>
   <result pre="randomized study comparing breast-conserving surgery with radical mastectomy for early" exact="breast cancer" post="N Engl J Med 2002 347 1227 1232 10.1056/NEJMoa020989"/>
   <result pre="study comparing breast-conserving surgery with radical mastectomy for early breast" exact="cancer" post="N Engl J Med 2002 347 1227 1232 10.1056/NEJMoa020989"/>
   <result pre="Population-based study of contralateral prophylactic mastectomy and survival outcomes of" exact="breast cancer" post="patients J Natl Cancer Inst 2010 102 401 409"/>
   <result pre="study of contralateral prophylactic mastectomy and survival outcomes of breast" exact="cancer" post="patients J Natl Cancer Inst 2010 102 401 409"/>
   <result pre="M Helms G et al. Sentinel-lymph-node biopsy in patients with" exact="breast cancer" post="before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre"/>
   <result pre="Helms G et al. Sentinel-lymph-node biopsy in patients with breast" exact="cancer" post="before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre"/>
   <result pre="al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative" exact="breast cancer" post="N Engl J Med 2004 351 2817 2826 10.1056/NEJMoa041588"/>
   <result pre="A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast" exact="cancer" post="N Engl J Med 2004 351 2817 2826 10.1056/NEJMoa041588"/>
   <result pre="and benefit of chemotherapy in women with node-negative, estrogen receptor-positive" exact="breast cancer" post="J Clin Oncol 2006 24 3726 3734 10.1200/JCO.2005.04.7985 16720680"/>
   <result pre="benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast" exact="cancer" post="J Clin Oncol 2006 24 3726 3734 10.1200/JCO.2005.04.7985 16720680"/>
   <result pre="21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive" exact="breast cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast" exact="cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="impact of discordance between different risk assessment tools in early" exact="breast cancer" post="(Recurrence Score, Central Grade, Ki67): early outcome analysis from"/>
   <result pre="of discordance between different risk assessment tools in early breast" exact="cancer" post="(Recurrence Score, Central Grade, Ki67): early outcome analysis from"/>
   <result pre="et al. Prospective validation of a 21-gene expression assay in" exact="breast cancer." post="N England J Med. 2015. 19. Parker JS Mullins"/>
   <result pre="Voduc D Vickery T et al. Supervised risk predictor of" exact="breast cancer" post="based on intrinsic subtypes J Clin Oncol 2009 27"/>
   <result pre="D Vickery T et al. Supervised risk predictor of breast" exact="cancer" post="based on intrinsic subtypes J Clin Oncol 2009 27"/>
   <result pre="with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive" exact="breast cancer" post="Clin Cancer Res 2010 16 5222 5232 10.1158/1078-0432.CCR-10-1282 20837693"/>
   <result pre="immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast" exact="cancer" post="Clin Cancer Res 2010 16 5222 5232 10.1158/1078-0432.CCR-10-1282 20837693"/>
   <result pre="M Bago-Horvath Z et al. Predicting distant recurrence in receptor-positive" exact="breast cancer" post="patients with limited clinicopathological risk: using the PAM50 Risk"/>
   <result pre="Bago-Horvath Z et al. Predicting distant recurrence in receptor-positive breast" exact="cancer" post="patients with limited clinicopathological risk: using the PAM50 Risk"/>
   <result pre="a randomized controlled trial in postmenopausal patients with endocrine-responsive early" exact="breast cancer" post="from the Austrian Breast and Colorectal Cancer Study Group"/>
   <result pre="randomized controlled trial in postmenopausal patients with endocrine-responsive early breast" exact="cancer" post="from the Austrian Breast and Colorectal Cancer Study Group"/>
   <result pre="al. A gene-expression signature as a predictor of survival in" exact="breast cancer" post="N Engl J Med 2002 347 1999 2009 10.1056/NEJMoa021967"/>
   <result pre="A gene-expression signature as a predictor of survival in breast" exact="cancer" post="N Engl J Med 2002 347 1999 2009 10.1056/NEJMoa021967"/>
   <result pre="utility of a 70-gene prognostic signature for women with node-negative" exact="breast cancer" post="J Natl Cancer Inst. 2006 98 1183 1192 10.1093/jnci/djj329"/>
   <result pre="of a 70-gene prognostic signature for women with node-negative breast" exact="cancer" post="J Natl Cancer Inst. 2006 98 1183 1192 10.1093/jnci/djj329"/>
   <result pre="A new molecular predictor of distant recurrence in ER-positive, HER2-negative" exact="breast cancer" post="adds independent information to conventional clinical risk factors Clin"/>
   <result pre="new molecular predictor of distant recurrence in ER-positive, HER2-negative breast" exact="cancer" post="adds independent information to conventional clinical risk factors Clin"/>
   <result pre="classification derived from common clinical guidelines in ER-positive, HER2-negative early" exact="breast cancer" post="Ann Oncol 2012 24 640 647 10.1093/annonc/mds334 23035151 29."/>
   <result pre="derived from common clinical guidelines in ER-positive, HER2-negative early breast" exact="cancer" post="Ann Oncol 2012 24 640 647 10.1093/annonc/mds334 23035151 29."/>
   <result pre="Hayes DF Indications for prognostic gene expression profiling in early" exact="breast cancer" post="Curr Treat Options Oncol 2015 16 23 10.1007/s11864-015-0340-x 25929335"/>
   <result pre="DF Indications for prognostic gene expression profiling in early breast" exact="cancer" post="Curr Treat Options Oncol 2015 16 23 10.1007/s11864-015-0340-x 25929335"/>
   <result pre="Clarke M Cutter D Darby S et al. Relevance of" exact="breast cancer" post="hormone receptors and other factors to the efficacy of"/>
   <result pre="M Cutter D Darby S et al. Relevance of breast" exact="cancer" post="hormone receptors and other factors to the efficacy of"/>
   <result pre="versus stopping at 5 years in 6,953 women with early" exact="breast cancer." post="J Clin Oncol. 2013;31s (a:5). 33. Pagani O Regan"/>
   <result pre="Colleoni M Láng I et al. Adjuvant exemestane with ovarian" exact="suppression" post="in premenopausal breast cancer N Engl J Med 2014"/>
   <result pre="I et al. Adjuvant exemestane with ovarian suppression in premenopausal" exact="breast cancer" post="N Engl J Med 2014 371 107 10.1056/NEJMoa1404037 24881463"/>
   <result pre="et al. Adjuvant exemestane with ovarian suppression in premenopausal breast" exact="cancer" post="N Engl J Med 2014 371 107 10.1056/NEJMoa1404037 24881463"/>
   <result pre="et al. Impact of treatment characteristics on response of different" exact="breast cancer" post="phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials"/>
   <result pre="al. Impact of treatment characteristics on response of different breast" exact="cancer" post="phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials"/>
   <result pre="Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal" exact="breast cancer" post="patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II"/>
   <result pre="(CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast" exact="cancer" post="patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II"/>
   <result pre="Skene A Blohmer JU et al. Neoadjuvant treatment of postmenopausal" exact="breast cancer" post="with anastrozole, tamoxifen, or both in combination: the immediate"/>
   <result pre="A Blohmer JU et al. Neoadjuvant treatment of postmenopausal breast" exact="cancer" post="with anastrozole, tamoxifen, or both in combination: the immediate"/>
   <result pre="Eremin J Vinholes J et al. Preoperative treatment of postmenopausal" exact="breast cancer" post="patients with letrozole: a randomized double blind multicenter study"/>
   <result pre="J Vinholes J et al. Preoperative treatment of postmenopausal breast" exact="cancer" post="patients with letrozole: a randomized double blind multicenter study"/>
   <result pre="al. Neoadjuvant carboplatin in patients with triple-negative and Her2-positive early" exact="breast cancer" post="(GeparSixto; GBG 66): a randomised phase 2 trial Lancet"/>
   <result pre="Neoadjuvant carboplatin in patients with triple-negative and Her2-positive early breast" exact="cancer" post="(GeparSixto; GBG 66): a randomised phase 2 trial Lancet"/>
   <result pre="paclitaxel as part of neoadjuvant chemotherapy for patients with early" exact="breast cancer" post="GBG 69—GeparSept0, San Antonio Breast Cancer Symposium; 2014. 45."/>
   <result pre="as part of neoadjuvant chemotherapy for patients with early breast" exact="cancer" post="GBG 69—GeparSept0, San Antonio Breast Cancer Symposium; 2014. 45."/>
   <result pre="F et al. High risk of recurrence for patients with" exact="breast cancer" post="who have human epidermal growth factor receptors 2-positive, node"/>
   <result pre="et al. High risk of recurrence for patients with breast" exact="cancer" post="who have human epidermal growth factor receptors 2-positive, node"/>
   <result pre="2 years versus 1 year of adjuvant trastuzumab for HER2-positive" exact="breast cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="years versus 1 year of adjuvant trastuzumab for HER2-positive breast" exact="cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="Martin M Press M et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 1273 1283 10.1056/NEJMoa0910383"/>
   <result pre="M Press M et al. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 1273 1283 10.1056/NEJMoa0910383"/>
   <result pre="PK et al. Adjuvant paclitaxel and trastuzumab for node-negative HER2-positive" exact="breast cancer" post="N Engl Med 2015 372 134 141 10.1056/NEJMoa1406281 51."/>
   <result pre="et al. Adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast" exact="cancer" post="N Engl Med 2015 372 134 141 10.1056/NEJMoa1406281 51."/>
   <result pre="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced" exact="breast cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast" exact="cancer" post="(the NOAH trial): a randomised controlled superiority trial with"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="Aura C et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="C et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="(T + L) in the adjuvant treatment of HER2-positive early" exact="breast cancer" post="(EBC). J Clin Oncol. 2014;32s (LBA4). 55. collab: EBCTCG"/>
   <result pre="+ L) in the adjuvant treatment of HER2-positive early breast" exact="cancer" post="(EBC). J Clin Oncol. 2014;32s (LBA4). 55. collab: EBCTCG"/>
   <result pre="after mastectomy and axillary surgery on 10-year recurrence and 20-year" exact="breast cancer" post="mortality: meta-analysis of individual patient data for 8135 women"/>
   <result pre="mastectomy and axillary surgery on 10-year recurrence and 20-year breast" exact="cancer" post="mortality: meta-analysis of individual patient data for 8135 women"/>
   <result pre="F et al. Postoperative radiotherapy in high-risk premenopausal women with" exact="breast cancer" post="who receive adjuvant chemotherapy N Engl J Med 1997"/>
   <result pre="et al. Postoperative radiotherapy in high-risk premenopausal women with breast" exact="cancer" post="who receive adjuvant chemotherapy N Engl J Med 1997"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4689775/results/search/disease/results.xml">
   <result pre=": Clinical Guides in Oncology SEOM clinical guidelines in metastatic" exact="breast cancer" post="2015 Gavilá J. jogagre@hotmail.com Lopez-Tarruella S. Saura C. Muñoz"/>
   <result pre="Clinical Guides in Oncology SEOM clinical guidelines in metastatic breast" exact="cancer" post="2015 Gavilá J. jogagre@hotmail.com Lopez-Tarruella S. Saura C. Muñoz"/>
   <result pre="Commons license, and indicate if changes were made. Abstract Metastatic" exact="breast cancer" post="is essentially an incurable disease. However, recent advances have"/>
   <result pre="license, and indicate if changes were made. Abstract Metastatic breast" exact="cancer" post="is essentially an incurable disease. However, recent advances have"/>
   <result pre="make evidence-based recommendations on how to manage patients with metastatic" exact="breast cancer" post="to achieve the best patient outcomes based on a"/>
   <result pre="evidence-based recommendations on how to manage patients with metastatic breast" exact="cancer" post="to achieve the best patient outcomes based on a"/>
   <result pre="Task Force guidelines methodology was selected as reference. Keywords Metastatic" exact="breast cancer" post="Clinical guidelines Chemotherapy Hormonal therapy Anti-HER2 therapy Introduction Metastatic"/>
   <result pre="Force guidelines methodology was selected as reference. Keywords Metastatic breast" exact="cancer" post="Clinical guidelines Chemotherapy Hormonal therapy Anti-HER2 therapy Introduction Metastatic"/>
   <result pre="cancer Clinical guidelines Chemotherapy Hormonal therapy Anti-HER2 therapy Introduction Metastatic" exact="breast cancer" post="is essentially an incurable disease. However, recent advances in"/>
   <result pre="Clinical guidelines Chemotherapy Hormonal therapy Anti-HER2 therapy Introduction Metastatic breast" exact="cancer" post="is essentially an incurable disease. However, recent advances in"/>
   <result pre="make evidence-based recommendations on how to manage patients with metastatic" exact="breast cancer" post="to achieve the best patient outcomes by means of"/>
   <result pre="evidence-based recommendations on how to manage patients with metastatic breast" exact="cancer" post="to achieve the best patient outcomes by means of"/>
   <result pre="SEOM Guidelines have been developed with the consensus of ten" exact="breast cancer" post="oncologists from the cooperative groups GEICAM (Spanish Breast Cancer"/>
   <result pre="Guidelines have been developed with the consensus of ten breast" exact="cancer" post="oncologists from the cooperative groups GEICAM (Spanish Breast Cancer"/>
   <result pre="of effects on health outcomes Goal of the treatment Metastatic" exact="breast cancer" post="(MBC) is a treatable but virtually incurable disease ["/>
   <result pre="effects on health outcomes Goal of the treatment Metastatic breast" exact="cancer" post="(MBC) is a treatable but virtually incurable disease ["/>
   <result pre="The routine use of tumoral markers in the follow-up of" exact="breast cancer" post="is controversial (level of certainty: low; strength of recommendation:"/>
   <result pre="routine use of tumoral markers in the follow-up of breast" exact="cancer" post="is controversial (level of certainty: low; strength of recommendation:"/>
   <result pre="of recommendation: A). Evaluation of response to therapy in advanced" exact="breast cancer" post="The evaluation of response to therapy should be done"/>
   <result pre="recommendation: A). Evaluation of response to therapy in advanced breast" exact="cancer" post="The evaluation of response to therapy should be done"/>
   <result pre="conventional imaging, the utility of PET/CT in the monitoring of" exact="breast cancer" post="metastasis is controversial [ 13] (level of certainty: low;"/>
   <result pre="imaging, the utility of PET/CT in the monitoring of breast" exact="cancer" post="metastasis is controversial [ 13] (level of certainty: low;"/>
   <result pre="as soon as possible to all patients with metastatic HER2-positive" exact="breast cancer" post="(level of certainty: high; strength of recommendation: A). First-line"/>
   <result pre="soon as possible to all patients with metastatic HER2-positive breast" exact="cancer" post="(level of certainty: high; strength of recommendation: A). First-line"/>
   <result pre="recommendation: B). Third-line and further therapy Patients with advanced HER2-positive" exact="breast cancer," post="who have been treated with two or more lines"/>
   <result pre="new standard for the treatment of patients with advanced HER2-positive" exact="breast cancer" post="previously treated with anti-HER2 therapy (including trastuzumab, lapatinib and"/>
   <result pre="standard for the treatment of patients with advanced HER2-positive breast" exact="cancer" post="previously treated with anti-HER2 therapy (including trastuzumab, lapatinib and"/>
   <result pre="The optimal number of lines of anti-HER2 therapy for metastatic" exact="breast cancer" post="is currently unknown, although available data suggest benefits are"/>
   <result pre="optimal number of lines of anti-HER2 therapy for metastatic breast" exact="cancer" post="is currently unknown, although available data suggest benefits are"/>
   <result pre="1 shows an algorithm for the treatment of HER2-positive metastatic" exact="breast cancer," post="in accordance with the prior recommendations. Fig. 1 Therapeutic"/>
   <result pre="the prior recommendations. Fig. 1 Therapeutic algorithm for HER2-positive metastatic" exact="breast cancer" post="Treatment of hormone-sensitive HER2-negative MBC Endocrine therapy (ET) is"/>
   <result pre="prior recommendations. Fig. 1 Therapeutic algorithm for HER2-positive metastatic breast" exact="cancer" post="Treatment of hormone-sensitive HER2-negative MBC Endocrine therapy (ET) is"/>
   <result pre="downregulation SERD Fulvestrant Estrogen deprivation Ovarian ablation Surgery, radiation Ovarian" exact="suppression" post="with GnRH Goserelin, triptorelin, leuprolide Aromatase inhibition NSAI Anastrozole,"/>
   <result pre="and patient co-morbidities. Premenopausal women First-line treatment: Ovarian ablation or" exact="suppression" post="(OA) or tamoxifen has similar results, the combination of"/>
   <result pre="high; strength of recommendation: A). Treatment of triple-negative MBC Triple-negative" exact="breast cancer" post="(TNBC) is a somewhat heterogeneous entity, although at least"/>
   <result pre="strength of recommendation: A). Treatment of triple-negative MBC Triple-negative breast" exact="cancer" post="(TNBC) is a somewhat heterogeneous entity, although at least"/>
   <result pre="patients are of the basal-like subtype by PAM50 subtyping. Basal-like" exact="breast cancer" post="is characterized by high proliferation (as measured by Ki67)"/>
   <result pre="are of the basal-like subtype by PAM50 subtyping. Basal-like breast" exact="cancer" post="is characterized by high proliferation (as measured by Ki67)"/>
   <result pre="shortest survival compared with other sites of metastatic disease in" exact="breast cancer" post="[ 42]. A modified breast-graded prognostic assessment (GPA) index"/>
   <result pre="survival compared with other sites of metastatic disease in breast" exact="cancer" post="[ 42]. A modified breast-graded prognostic assessment (GPA) index"/>
   <result pre="1.5 2.0 Karnofsky score ≤50 60 70–80 90–100 – Breast" exact="cancer" post="subtype Triple negative Hormone receptor positive/HER2 negative Hormone receptor"/>
   <result pre="routine breast surgery cannot be recommended in de novo metastatic" exact="breast cancer" post="(level of certainty: moderate; strength of recommendation: I statement)."/>
   <result pre="breast surgery cannot be recommended in de novo metastatic breast" exact="cancer" post="(level of certainty: moderate; strength of recommendation: I statement)."/>
   <result pre="to be effective in delaying complications of bone metastases from" exact="breast cancer" post="and should be added to anti-tumor therapy in patients"/>
   <result pre="be effective in delaying complications of bone metastases from breast" exact="cancer" post="and should be added to anti-tumor therapy in patients"/>
   <result pre="and should be added to anti-tumor therapy in patients with" exact="breast cancer" post="and bone metastases [ 51] (level of certainly high;"/>
   <result pre="should be added to anti-tumor therapy in patients with breast" exact="cancer" post="and bone metastases [ 51] (level of certainly high;"/>
   <result pre="with anti-tumor therapy, for the management of bone metastases from" exact="breast cancer" post="[ 52] (level of certainly high; strength of recommendation:"/>
   <result pre="anti-tumor therapy, for the management of bone metastases from breast" exact="cancer" post="[ 52] (level of certainly high; strength of recommendation:"/>
   <result pre="The most appropriate duration of anti-resorptive therapy (bisphosphonates, denosumab) in" exact="breast cancer" post="patients with bone metastases is unknown. The experience with"/>
   <result pre="most appropriate duration of anti-resorptive therapy (bisphosphonates, denosumab) in breast" exact="cancer" post="patients with bone metastases is unknown. The experience with"/>
   <result pre="V et al. Prognostic factors in 1038 women with metastatic" exact="breast cancer" post="Ann Oncol 2008 19 12 2012 2019 10.1093/annonc/mdn424 18641006"/>
   <result pre="et al. Prognostic factors in 1038 women with metastatic breast" exact="cancer" post="Ann Oncol 2008 19 12 2012 2019 10.1093/annonc/mdn424 18641006"/>
   <result pre="F, et al. ESO-ESMO 2nd international consensus guidelines for advanced" exact="breast cancer" post="(ABC2). Ann Oncol. 2014;mdu385. 4. Bernsdorf M Graff J"/>
   <result pre="et al. ESO-ESMO 2nd international consensus guidelines for advanced breast" exact="cancer" post="(ABC2). Ann Oncol. 2014;mdu385. 4. Bernsdorf M Graff J"/>
   <result pre="Clinical application of 18F-fluoro-2-deoxy- d-glucose positron emission tomography/computed tomography in" exact="breast cancer" post="Clin Physiol Funct Imaging 2014 34 6 426 433"/>
   <result pre="application of 18F-fluoro-2-deoxy- d-glucose positron emission tomography/computed tomography in breast" exact="cancer" post="Clin Physiol Funct Imaging 2014 34 6 426 433"/>
   <result pre="and positron emission tomography/computed tomography (PET/CT) for the diagnosis of" exact="breast cancer" post="recurrence. Health Technol Assess. 2010;14(50). http://www.journalslibrary.nihr.ac.uk/hta/volume-14/issue-50. Accessed 10 November"/>
   <result pre="positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast" exact="cancer" post="recurrence. Health Technol Assess. 2010;14(50). http://www.journalslibrary.nihr.ac.uk/hta/volume-14/issue-50. Accessed 10 November"/>
   <result pre="Meta-analysis of the prognostic value of circulating tumor cells in" exact="breast cancer" post="Clin Cancer Res Off J Am Assoc Cancer Res."/>
   <result pre="of the prognostic value of circulating tumor cells in breast" exact="cancer" post="Clin Cancer Res Off J Am Assoc Cancer Res."/>
   <result pre="of the conversion rate in the receptor status between primary" exact="breast cancer" post="and metastasis: results from the GEICAM 2009–03 ConvertHER study"/>
   <result pre="the conversion rate in the receptor status between primary breast" exact="cancer" post="and metastasis: results from the GEICAM 2009–03 ConvertHER study"/>
   <result pre="to order a biopsy to characterise a metastatic relapse in" exact="breast cancer" post="Ann Oncol Off J Eur Soc Med Oncol ESMO."/>
   <result pre="order a biopsy to characterise a metastatic relapse in breast" exact="cancer" post="Ann Oncol Off J Eur Soc Med Oncol ESMO."/>
   <result pre="Balleine RL Bilous M Pegram MD HER2 discordance between primary" exact="breast cancer" post="and its paired metastasis: tumor biology or test artefact?"/>
   <result pre="RL Bilous M Pegram MD HER2 discordance between primary breast" exact="cancer" post="and its paired metastasis: tumor biology or test artefact?"/>
   <result pre="guidelines for the use of tumor markers in breast and" exact="colorectal cancer." post="Adopted on 17 May 1996 by the American Society"/>
   <result pre="al. Heterogeneity of metabolic response to systemic therapy in metastatic" exact="breast cancer" post="patients Clin Oncol R Coll Radiol G B. 2010"/>
   <result pre="Heterogeneity of metabolic response to systemic therapy in metastatic breast" exact="cancer" post="patients Clin Oncol R Coll Radiol G B. 2010"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 33 5538 5546 10.1200/JCO.2009.23.3734"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 33 5538 5546 10.1200/JCO.2009.23.3734"/>
   <result pre="M et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic" exact="breast cancer" post="N Engl J Med 2015 372 8 724 734"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast" exact="cancer" post="N Engl J Med 2015 372 8 724 734"/>
   <result pre="treatment of patients (pts) with HER2-positive locally advanced or metastatic" exact="breast cancer" post="(MBC). Ann Oncol. 2014;25(suppl 4):iv120–iv120. 20. Geyer CE Forster"/>
   <result pre="of patients (pts) with HER2-positive locally advanced or metastatic breast" exact="cancer" post="(MBC). Ann Oncol. 2014;25(suppl 4):iv120–iv120. 20. Geyer CE Forster"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="M Baselga J et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced" exact="breast cancer" post="(TH3RESA): a randomised, open-label, phase 3 trial Lancet Oncol."/>
   <result pre="versus treatment of physician’s choice for pretreated HER2-positive advanced breast" exact="cancer" post="(TH3RESA): a randomised, open-label, phase 3 trial Lancet Oncol."/>
   <result pre="Verma S Iwata H et al. Palbociclib in hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2015 373 3 209 219"/>
   <result pre="S Iwata H et al. Palbociclib in hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2015 373 3 209 219"/>
   <result pre="Wilcken N. Combination versus sequential single agent chemotherapy for metastatic" exact="breast cancer." post="Cochrane Database Syst. Rev. (Wiley). 2013. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008792.pub2/abstract. Accessed 11"/>
   <result pre="first-line treatment of human epidermal growth factor receptor 2-negative metastatic" exact="breast cancer" post="J Clin Oncol 2010 28 20 3239 3247 10.1200/JCO.2008.21.6457"/>
   <result pre="treatment of human epidermal growth factor receptor 2-negative metastatic breast" exact="cancer" post="J Clin Oncol 2010 28 20 3239 3247 10.1200/JCO.2008.21.6457"/>
   <result pre="et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic" exact="breast cancer" post="N Engl J Med 2007 357 26 2666 2676"/>
   <result pre="al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast" exact="cancer" post="N Engl J Med 2007 357 26 2666 2676"/>
   <result pre="human epidermal growth factor receptor 2-negative, locally recurrent or metastatic" exact="breast cancer" post="J Clin Oncol 2011 29 10 1252 1260 10.1200/JCO.2010.28.0982"/>
   <result pre="epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast" exact="cancer" post="J Clin Oncol 2011 29 10 1252 1260 10.1200/JCO.2010.28.0982"/>
   <result pre="F-C A systematic review of vinorelbine for the treatment of" exact="breast cancer" post="Breast J. 2013 19 2 180 188 10.1111/tbj.12071 23320984"/>
   <result pre="A systematic review of vinorelbine for the treatment of breast" exact="cancer" post="Breast J. 2013 19 2 180 188 10.1111/tbj.12071 23320984"/>
   <result pre="33. Chan A Verrill M Capecitabine and vinorelbine in metastatic" exact="breast cancer" post="Eur J Cancer 2009 45 13 2253 2265 10.1016/j.ejca.2009.04.031"/>
   <result pre="Chan A Verrill M Capecitabine and vinorelbine in metastatic breast" exact="cancer" post="Eur J Cancer 2009 45 13 2253 2265 10.1016/j.ejca.2009.04.031"/>
   <result pre="monotherapy versus treatment of physician’s choice in patients with metastatic" exact="breast cancer" post="(EMBRACE): a phase 3 open-label randomised study Lancet. 2011"/>
   <result pre="versus treatment of physician’s choice in patients with metastatic breast" exact="cancer" post="(EMBRACE): a phase 3 open-label randomised study Lancet. 2011"/>
   <result pre="mesylate versus capecitabine in patients with locally advanced or metastatic" exact="breast cancer" post="previously treated with an anthracycline and a taxane. J"/>
   <result pre="versus capecitabine in patients with locally advanced or metastatic breast" exact="cancer" post="previously treated with an anthracycline and a taxane. J"/>
   <result pre="doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic" exact="breast cancer" post="J Clin Oncol 2001 19 5 1444 1454 11230490"/>
   <result pre="and cyclophosphamide in a randomized, multicenter trial of metastatic breast" exact="cancer" post="J Clin Oncol 2001 19 5 1444 1454 11230490"/>
   <result pre="profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced" exact="breast cancer" post="Anticancer Drugs 2014 25 2 219 224 10.1097/CAD.0000000000000037 24247203"/>
   <result pre="of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast" exact="cancer" post="Anticancer Drugs 2014 25 2 219 224 10.1097/CAD.0000000000000037 24247203"/>
   <result pre="carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative" exact="breast cancer." post="J Clin Oncol. 2014;JCO.2014.55.2984. 41. Tutt A, Ellis P,"/>
   <result pre="with metastatic or recurrent locally advanced triple negative or BRCA1/2" exact="breast cancer" post="(CRUK/07/012). Cancer Res. 2014;75(S9):S3-01. 42. Kennecke H Yerushalmi R"/>
   <result pre="metastatic or recurrent locally advanced triple negative or BRCA1/2 breast" exact="cancer" post="(CRUK/07/012). Cancer Res. 2014;75(S9):S3-01. 42. Kennecke H Yerushalmi R"/>
   <result pre="MCU Voduc D Speers CH et al. Metastatic behavior of" exact="breast cancer" post="subtypes J Clin Oncol 2010 28 20 3271 3277"/>
   <result pre="Voduc D Speers CH et al. Metastatic behavior of breast" exact="cancer" post="subtypes J Clin Oncol 2010 28 20 3271 3277"/>
   <result pre="500 10.1056/NEJM199002223220802 2405271 44. Hofer S Pestalozzi BC Treatment of" exact="breast cancer" post="brain metastases Eur J Pharmacol 2013 717 1–3 84"/>
   <result pre="10.1056/NEJM199002223220802 2405271 44. Hofer S Pestalozzi BC Treatment of breast" exact="cancer" post="brain metastases Eur J Pharmacol 2013 717 1–3 84"/>
   <result pre="Conesa G del Barco S González-Jimenez S et al. Breast" exact="cancer" post="brain metastases: a review of the literature and a"/>
   <result pre="breast tumor in women presenting with de novo stage IV" exact="breast cancer;" post="Turkish study (protocol MF07-01) Cancer Res 2013 73 24"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694793/results/search/disease/results.xml">
   <result pre="provided the original author and source are credited. Abstract Gastric" exact="cancer" post="(GC) is the third leading cause of cancer mortality"/>
   <result pre="Abstract Gastric cancer (GC) is the third leading cause of" exact="cancer" post="mortality worldwide. Although surgical resection is a potentially curative"/>
   <result pre="improve the efficacy, safety, and cost-effectiveness for GC treatments. gastric" exact="cancer" post="chemotherapy molecular classification signaling pathway cancer stem cells INTRODUCTION"/>
   <result pre="for GC treatments. gastric cancer chemotherapy molecular classification signaling pathway" exact="cancer" post="stem cells INTRODUCTION Gastric cancer (GC) is an important"/>
   <result pre="chemotherapy molecular classification signaling pathway cancer stem cells INTRODUCTION Gastric" exact="cancer" post="(GC) is an important public health problem worldwide due"/>
   <result pre="frequently diagnosed cancer, and it is the third most lethal" exact="cancer" post="worldwide. Each year, almost one million new cases of"/>
   <result pre="this disease, thereby representing ~10% of the deaths due to" exact="cancer" post="worldwide [ 1]. This high mortality rate is associated"/>
   <result pre="stages of GC, the lack of validated screening programs, and" exact="cancer" post="health care in developing countries, which can be economically"/>
   <result pre="CRT, and radiotherapy helped only in patients with resected gastric" exact="cancer" post="with high-risk loco-regional failure [ 10]. In contrast to"/>
   <result pre="alone. Finally, in a capecitabine and oxaliplatin adjuvant study for" exact="stomach cancer" post="(CLASSIC), a phase III randomized controlled trial involving 37"/>
   <result pre="Finally, in a capecitabine and oxaliplatin adjuvant study for stomach" exact="cancer" post="(CLASSIC), a phase III randomized controlled trial involving 37"/>
   <result pre="FL 3 years 31 41 0.005 Resectable GC or GEJ" exact="cancer" post="FL/RT 48 50 ARTIST trial Lee et al. (2012)"/>
   <result pre="alone 5 years 18 26 0.009 Resectable GC or GEJ" exact="cancer" post="Perioperative ECF + surgery 32 36.3 Asian ACTS-GC trial"/>
   <result pre="DCF 37 5.6 9.2 0.02 Advanced stage GC and GEJ" exact="cancer" post="FP4w 25 3.7 8.6 ML17032 Kang et al. (2009)"/>
   <result pre="220 FLO 35 5.8 10.7 0.08 Metastatic GC and GEJ" exact="cancer" post="FLP 25 3.9 8.8 REAL 2 trial Cunningham et"/>
   <result pre="ECF 41 6.2 9.9 0.06 Advanced stage GC and GEJ" exact="cancer" post="ECX 46 6.7 9.9 EOF 42 6.5 9.3 EOX"/>
   <result pre="the clinic as a first-line therapy for patients with metastatic" exact="cancer" post="of the stomach or gastroesophageal junction (GEJ) positive for"/>
   <result pre="chemotherapy alone [ 27]. Patients that are diagnosed with metastatic" exact="stomach cancer" post="must be evaluated for ERBB2 overexpression or amplification by"/>
   <result pre="alone [ 27]. Patients that are diagnosed with metastatic stomach" exact="cancer" post="must be evaluated for ERBB2 overexpression or amplification by"/>
   <result pre="(90%); while the remaining 10% of patients are diagnosed with" exact="lymphoma" post="or gastrointestinal stromal tumors. In general, there are two"/>
   <result pre="injury and further augment the risk for developing dismal gastric" exact="cancer" post="[ 34]. In contrast, diffuse-type adenocarcinoma has a poorer"/>
   <result pre="stomach [ 4, 42]. EBV is the etiologic agent of" exact="infectious mononucleosis" post="and is responsible for certain cancers, including nasopharyngeal carcinoma"/>
   <result pre="of infectious mononucleosis and is responsible for certain cancers, including" exact="nasopharyngeal carcinoma" post="and some types of lymphoma [ 43– 45]. In"/>
   <result pre="for certain cancers, including nasopharyngeal carcinoma and some types of" exact="lymphoma" post="[ 43– 45]. In a recent meta-analysis, EBV-associated GC"/>
   <result pre="PIK3CA is the second most commonly mutated gene across many" exact="cancer" post="types, and was detected in more than 10% of"/>
   <result pre="types, and was detected in more than 10% of the" exact="cancer" post="cases examined by the TCGA [ 48]. Mutations in"/>
   <result pre="differentiation and apoptosis and has been intensely investigates in gastric" exact="cancer" post="[ 50] and increased expression of PD-L1 has been"/>
   <result pre="poor prognosis in the GC cases, potentially contributing to immune" exact="suppression" post="and evasion [ 51, 52]. Correspondingly, PI3K inhibitors, JAK2"/>
   <result pre="125] and 79.6% [ 109] of GC cases Early gastric" exact="cancer" post="[ 124] p-P70S6K Overexpressed in 59.5% [ 258] and"/>
   <result pre="35 5.5 11.1 0.0046 ERBB2-positive advanced stage GC or GEJ" exact="cancer" post="X(FU)P-T 47 6.7 13.8 EXPAND trial Lordick et al."/>
   <result pre="Advanced stage unresectable (M0) or metastatic (M1) GC or GEJ" exact="cancer" post="XP-Cet 30 5.6 21 REAL3 trial Wadell et al."/>
   <result pre="7.4 11.3 0.013 Untreated, metastatic or locally advanced stage GEJ" exact="cancer" post="EOX-Pan 46 6.0 8.8 TyTAN-Asian trial Satoh et al"/>
   <result pre="545 XELOX 40 5.4 10.5 0.35 ERBB2-positive advanced or metastatic" exact="cancer" post="and GEJ cancer XELOX-Lap 53 6.0 12.2 HERBIS-1 trial"/>
   <result pre="5.4 10.5 0.35 ERBB2-positive advanced or metastatic cancer and GEJ" exact="cancer" post="XELOX-Lap 53 6.0 12.2 HERBIS-1 trial Kurokawa et al."/>
   <result pre="1.3 3.8 0.047 Previously treated advanced stage GC and GEJ" exact="cancer" post="X(FU)P Ram 49 2.1 5.2 RAINBOW trial Wilke et"/>
   <result pre="2.9 7.4 0.017 Previously treated advanced stage GC and GEJ" exact="cancer" post="Paclitaxel-Ram 28 4.4 9.6 Li J et al. (2013)"/>
   <result pre="Placebo 0 1.4 2.5 0.01 Chemotherapy-refractory advanced stage metastatic gastric" exact="cancer" post="Apatinib 10 3.7 4.8 PI3K/AKT/mTOR Pathway GRANITE -1 trial"/>
   <result pre="ECX 4.2 Unresectable advanced stage or metastatic GC or GEJ" exact="cancer" post="Ril (15mg/kg) 5.1 Ril (7.5 mg/kg) 6.8 ECX-Ril 5.7"/>
   <result pre="and/or HER2), which share overlapping signaling pathways [ 86]. In" exact="colon cancer" post="studies, RAS mutations ( KRAS and NRAS) have been"/>
   <result pre="HER2), which share overlapping signaling pathways [ 86]. In colon" exact="cancer" post="studies, RAS mutations ( KRAS and NRAS) have been"/>
   <result pre="in patients with untreated ERBB2-positive advanced gastric or gastroesophageal junction" exact="cancer" post="[ 31]. In a recent phase III trial that"/>
   <result pre="therapies has been correlated with serious adverse effects such as" exact="diarrhea" post="and skin toxicity [ 93, 94]. Currently, a phase"/>
   <result pre="in patients with metastatic or advanced stage GC and GEJ" exact="cancer" post="[ 106]. Based on these results, additional studies of"/>
   <result pre="GDC0068). The allosteric inhibitors of AKT, have been effective against" exact="breast cancer" post="cell lines carrying PI3KCA mutations and ERBB2 ampliﬁcations ["/>
   <result pre="The allosteric inhibitors of AKT, have been effective against breast" exact="cancer" post="cell lines carrying PI3KCA mutations and ERBB2 ampliﬁcations ["/>
   <result pre="[ 120]. Similarly, GDC0068 has exhibited anti-tumor activity in human" exact="cancer" post="cell lines and xenograft models [ 121], and is"/>
   <result pre="in a multicenter phase II trial of gastric and GEJ" exact="cancer" post="patients with locally advanced or metastatic disease (NCT01896531) ["/>
   <result pre="(mTORC1) inhibitor, everolimus, has been used to successfully treat several" exact="cancer" post="types [ 122, 123]. For GC, everolimus has been"/>
   <result pre="et al. [ 130] observed that 78% of patients with" exact="colorectal cancer" post="with the PIK3CA mutation also had simultaneous KRAS mutation"/>
   <result pre="al. [ 130] observed that 78% of patients with colorectal" exact="cancer" post="with the PIK3CA mutation also had simultaneous KRAS mutation"/>
   <result pre="not respond to PI3K/AKT/mTOR axis therapy. By contrast, patients with" exact="ovarian cancer" post="and simultaneously occurring KRAS or BRAF mutations achieved a"/>
   <result pre="respond to PI3K/AKT/mTOR axis therapy. By contrast, patients with ovarian" exact="cancer" post="and simultaneously occurring KRAS or BRAF mutations achieved a"/>
   <result pre="manner in GC cell lines [ 134, 136] and other" exact="cancer" post="models [ 121], especially those characterized by PTEN loss"/>
   <result pre="metastasis, thereby leading to the activation of MAPK, PI3K-AKT, v-src" exact="sarcoma" post="viral oncogene homolog, and signal transducer and activator of"/>
   <result pre="has also highlighted the additional roles for the MET in" exact="cancer" post="via crosstalk with other receptors and cell surface proteins,"/>
   <result pre="50% response rate in patients with MET-amplified advanced gastric and" exact="esophageal cancer" post="(NCT01472016) [ 160]. Interestingly, the MET amplification appears to"/>
   <result pre="response rate in patients with MET-amplified advanced gastric and esophageal" exact="cancer" post="(NCT01472016) [ 160]. Interestingly, the MET amplification appears to"/>
   <result pre="bevacizumab for the treatment of patients with GEJ and gastric" exact="cancer" post="(NCT01611857, NCT01468922 and NCT01749384) [ 92]. The novel AMG"/>
   <result pre="approved cabozantinib for the treatment of patients with metastatic medullary" exact="thyroid cancer," post="and a phase II clinical trial for the treatment"/>
   <result pre="golvatinib in combination with gefitinib was used to treat EGFR-mutated" exact="lung cancer" post="cell lines, the MET/Gab1/PI3K/AKT pathway was blocked [ 169]."/>
   <result pre="in combination with gefitinib was used to treat EGFR-mutated lung" exact="cancer" post="cell lines, the MET/Gab1/PI3K/AKT pathway was blocked [ 169]."/>
   <result pre="are consistent with the hypothesis that diffuse-type GC is a" exact="neoplasm" post="whose initial existence relies more on the inherent characteristics"/>
   <result pre="and Y16 represent newly developed Rho-specific inhibitors that potently suppress" exact="breast cancer" post="cell proliferation, migration, and invasion in vitro [ 172]."/>
   <result pre="Y16 represent newly developed Rho-specific inhibitors that potently suppress breast" exact="cancer" post="cell proliferation, migration, and invasion in vitro [ 172]."/>
   <result pre="approved in Japan in September 2014 for the treatment of" exact="glaucoma" post="and ocular hypertension [ 173]. Accordingly, it is predicted"/>
   <result pre="Japan in September 2014 for the treatment of glaucoma and" exact="ocular hypertension" post="[ 173]. Accordingly, it is predicted that current and"/>
   <result pre="of JAK2 has been applied to myeloproliferative disorders such as" exact="polycythemia" post="vera, essential thrombocythemia, and primary myelofibrosis [ 177]. For"/>
   <result pre="myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and primary" exact="myelofibrosis" post="[ 177]. For multiple myeloma patients, inhibition of JAK2"/>
   <result pre="polycythemia vera, essential thrombocythemia, and primary myelofibrosis [ 177]. For" exact="multiple myeloma" post="patients, inhibition of JAK2 led to a significant reduction"/>
   <result pre="STEM CELL PATHWAYS PROVIDE NOVEL GASTRIC CANCER THERAPY TARGETS Gastric" exact="cancer" post="stem cells (GCSCs) have been identified in GC cell"/>
   <result pre="strategies targeting self-renewal pathways leading to the direct elimination of" exact="cancer" post="stem cells (CSCs). Stemness-related signaling pathways include Hedgehog (Hh),"/>
   <result pre="in a phase II clinical trial of patients with metastatic" exact="colorectal cancer," post="treatment with vismodegib exhibited no incremental benefit in combination"/>
   <result pre="To date, mutated NOTCH1 has only been detected in T-cell" exact="acute lymphoblastic leukemia," post="and not in other common human cancers, including GC"/>
   <result pre="date, mutated NOTCH1 has only been detected in T-cell acute" exact="lymphoblastic leukemia," post="and not in other common human cancers, including GC"/>
   <result pre="I clinical trials. RO4929097 is being evaluated in patients with" exact="breast cancer," post="pancreatic cancer, leukemia, sarcoma, melanoma, or other solid tumors"/>
   <result pre="trials. RO4929097 is being evaluated in patients with breast cancer," exact="pancreatic cancer," post="leukemia, sarcoma, melanoma, or other solid tumors (NCT01131234), whereas"/>
   <result pre="(NCT01131234), whereas PF-03084014 is being tested in patients with advances" exact="cancer" post="and leukemia (NCT00878189) [ 92]. THE HIPPO SIGNALING PATHWAY"/>
   <result pre="PF-03084014 is being tested in patients with advances cancer and" exact="leukemia" post="(NCT00878189) [ 92]. THE HIPPO SIGNALING PATHWAY In mammals,"/>
   <result pre="VP photodynamic therapy for the treatment of locally advanced stage" exact="pancreatic cancer" post="was demonstrated [ 254]. However, despite these promising data,"/>
   <result pre="photodynamic therapy for the treatment of locally advanced stage pancreatic" exact="cancer" post="was demonstrated [ 254]. However, despite these promising data,"/>
   <result pre="rates of recurrence. New strategies should seek to intervene in" exact="cancer" post="or tissue-specific targets, enabling the protection of normal cells"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 2 69"/>
   <result pre="LD Ford JM Molecular profiling of gastric cancer: toward personalized" exact="cancer" post="medicine J Clin Oncol 2013 31 7 838 839"/>
   <result pre="Kim WH Protein expression profiling and molecular classification of gastric" exact="cancer" post="by the tissue array method Clin Cancer Res 2007"/>
   <result pre="25113841 6 Stock M Otto F Gene deregulation in gastric" exact="cancer" post="Gene 2005 360 1 1 19 16154715 7 Rivera"/>
   <result pre="plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric" exact="cancer" post="with D2 lymph node dissection: the ARTIST trial J"/>
   <result pre="Participants MT Perioperative chemotherapy versus surgery alone for resectable gastroesophageal" exact="cancer" post="N Engl J Med 2006 355 1 11 20"/>
   <result pre="Kurita A Arai K Group A-G Adjuvant chemotherapy for gastric" exact="cancer" post="with S-1, an oral fluoropyrimidine N Engl J Med"/>
   <result pre="Ji J et al. Adjuvant capecitabine plus oxaliplatin for gastric" exact="cancer" post="after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label,"/>
   <result pre="Grothey A Haerting J Fleig WE Chemotherapy for advanced gastric" exact="cancer" post="Cochrane Database Syst Rev 2010 3 CD004064 17 Garrido"/>
   <result pre="in first line chemotherapy and targeted therapy in advanced gastric" exact="cancer" post="Expert Rev Anticancer Ther 2014 14 8 887 900"/>
   <result pre="cisplatin versus S-1 alone for first-line treatment of advanced gastric" exact="cancer" post="(SPIRITS trial): a phase III trial Lancet Oncol 2008"/>
   <result pre="with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric" exact="cancer" post="Ann Oncol 2015 26 1 141 148 25316259 21"/>
   <result pre="of the United K Capecitabine and oxaliplatin for advanced esophagogastric" exact="cancer" post="N Engl J Med 2008 358 1 36 46"/>
   <result pre="in a phase III trial of advanced gastric or gastroesophageal" exact="cancer" post="adenocarcinoma: the V-325 Study Group J Clin Oncol 2007"/>
   <result pre="study comparing irinotecan with paclitaxel in patients with advanced gastric" exact="cancer" post="without severe peritoneal metastasis after failure of prior combination"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="YJ The prognostic significance of HER2 positivity for advanced gastric" exact="cancer" post="patients undergoing first-line modified FOLFOX-6 regimen Anticancer Res 2012"/>
   <result pre="receptors EGFR and ERBB2 on survival in stage II/III gastric" exact="cancer" post="Clin Cancer Res 2012 18 21 5992 6000 22977193"/>
   <result pre="therapy in patients with HER2-positive advanced gastric or gastroesophageal junction" exact="cancer" post="Clin Transl Oncol 2011 13 3 179 184 21421462"/>
   <result pre="37 Tahara E Genetic pathways of two types of gastric" exact="cancer" post="IARC Sci Publ 2004 157 327 349 15055305 38"/>
   <result pre="Natsugoe S Liao LM et al. Improved survival of gastric" exact="cancer" post="with tumour Epstein-Barr virus positivity: an international pooled analysis"/>
   <result pre="Kandoth C Akbani R et al. Multiplatform analysis of 12" exact="cancer" post="types reveals molecular classification within and across tissues of"/>
   <result pre="JS et al. Mutational landscape and significance across 12 major" exact="cancer" post="types Nature 2013 502 7471 333 339 24132290 50"/>
   <result pre="Shu Y Liu P MiR-135a targets JAK2 and inhibits gastric" exact="cancer" post="cell proliferation Cancer Biol Ther 2012 13 5 281"/>
   <result pre="McDermott D Atkins M PD-1 as a potential target in" exact="cancer" post="therapy Cancer Med 2013 2 5 662 673 24403232"/>
   <result pre="F Mariani-Costantini R Nesi G Palli D Ottini L Gastric" exact="cancer" post="with high-level microsatellite instability: target gene mutations, clinicopathologic features,"/>
   <result pre="Yamamoto H Sawai H Perucho M Frameshift somatic mutations in" exact="gastrointestinal cancer" post="of the microsatellite mutator phenotype Cancer Res 1997 57"/>
   <result pre="H Sawai H Perucho M Frameshift somatic mutations in gastrointestinal" exact="cancer" post="of the microsatellite mutator phenotype Cancer Res 1997 57"/>
   <result pre="SM Allelic imbalance of 8p indicates poor survival in gastric" exact="cancer" post="J Mol Diagn 2004 6 3 243 252 15269302"/>
   <result pre="252 15269302 60 McLean MH El-Omar EM Genetics of gastric" exact="cancer" post="Nat Rev Gastroenterol Hepatol 2014 11 11 664 674"/>
   <result pre="and comprehensive molecular profiling identify new driver mutations in gastric" exact="cancer" post="Nat Genet 2014 46 6 573 582 24816253 62"/>
   <result pre="Chen S-T Jeng Y-M Kuo M-L IL-6 induces AGS gastric" exact="cancer" post="cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway"/>
   <result pre="activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric" exact="cancer" post="Br J Cancer 2008 99 8 1322 1329 18827818"/>
   <result pre="et al. A comprehensive survey of genomic alterations in gastric" exact="cancer" post="reveals systematic patterns of molecular exclusivity and co-occurrence among"/>
   <result pre="J Kim KM Jang J Sohn I Kang WK Gastric" exact="cancer" post="(GC) patients with hedgehog pathway activation: PTCH1 and GLI2"/>
   <result pre="Roskoski R Jr The ErbB/HER family of protein-tyrosine kinases and" exact="cancer" post="Pharmacol Res 2014 79 34 74 24269963 71 Dragovich"/>
   <result pre="phase II study of gefitinib in second-line treatment of advanced" exact="esophageal cancer" post="patients J Clin Oncol 2006 24 10 1612 1619"/>
   <result pre="II study of gefitinib in second-line treatment of advanced esophageal" exact="cancer" post="patients J Clin Oncol 2006 24 10 1612 1619"/>
   <result pre="analysis of cetuximab combined with modified FOLFOX6 in advanced gastric" exact="cancer" post="Br J Cancer 2009 100 2 298 304 19127259"/>
   <result pre="and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric" exact="cancer" post="Invest New Drugs 2011 29 2 366 373 19997960"/>
   <result pre="or without cetuximab for patients with previously untreated advanced gastric" exact="cancer" post="(EXPAND): a randomised, open-label phase 3 trial Lancet Oncol"/>
   <result pre="of amplification of HER2, EGFR, CCND1 and MYC in gastric" exact="cancer" post="BMC Gastroenterol 2015 15 7 25649416 84 Blagosklonny MV"/>
   <result pre="2 268 277 85 Yamada Y Molecular therapy for gastric" exact="cancer" post="Chin Clin Oncol 2013 2 1 5 25841446 86"/>
   <result pre="of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric" exact="cancer" post="BMC Res Notes 2014 7 271 24774510 87 Smyth"/>
   <result pre="24774510 87 Smyth EC Cunningham D Targeted therapy for gastric" exact="cancer" post="Curr Treat Options Oncol 2012 13 3 377 389"/>
   <result pre="Claret FX Trastuzumab: updated mechanisms of action and resistance in" exact="breast cancer" post="Front Oncol 2012 2 62 22720269 89 Hudis CA"/>
   <result pre="FX Trastuzumab: updated mechanisms of action and resistance in breast" exact="cancer" post="Front Oncol 2012 2 62 22720269 89 Hudis CA"/>
   <result pre="trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric" exact="cancer" post="(HERBIS-1) Br J Cancer 2014 110 5 1163 1168"/>
   <result pre="paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric" exact="cancer" post="in Asian populations: TyTAN--a randomized, phase III study J"/>
   <result pre="L Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric" exact="cancer" post="Tumour Biol 2010 31 6 549 558 20563765 96"/>
   <result pre="of galectin-1 and vascular endothelial growth factor expression in gastric" exact="cancer" post="World J Gastroenterol 2013 19 13 2073 2079 23599627"/>
   <result pre="(VEGF-A) and VEGF-C expression with survival in patients with gastric" exact="cancer" post="Cancer Res Treat 2009 41 4 218 223 20057967"/>
   <result pre="factors C and D and chemokine receptor CCR7 in gastric" exact="cancer" post="Anticancer Res 2010 30 6 2361 2366 20651394 99"/>
   <result pre="P Roa J The PI3K/AKT/mTOR pathway is activated in gastric" exact="cancer" post="with potential prognostic and predictive significance Virchows Archiv 2014"/>
   <result pre="Zhou D Li Z Expression of PI3K/AKT pathway in gastric" exact="cancer" post="and its blockade suppresses tumor growth and metastasis Int"/>
   <result pre="P Activated Akt as an indicator of prognosis in gastric" exact="cancer" post="Virchows Archiv 2008 453 5 449 455 18841391 111"/>
   <result pre="I Siu L Clinical development of phosphatidylinositol 3-kinase inhibitors for" exact="cancer" post="treatment BMC Med 2012 10 1 161 23232172 114"/>
   <result pre="target of rapamycin inhibition and 5-Fluorouracil in PIK3CA mutant gastric" exact="cancer" post="cells Cancer Biol Ther 2012 13 1 34 42"/>
   <result pre="in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric" exact="cancer" post="xenograft model with PTEN loss to Taxotere J Transl"/>
   <result pre="G Mammalian target of rapamycin is activated in human gastric" exact="cancer" post="and serves as a target for therapy in an"/>
   <result pre="signalling potentiates the effects of trichostatin A in human gastric" exact="cancer" post="cell lines by promoting histone acetylation Cell Biol Int"/>
   <result pre="of everolimus with biomarker exploration in patients with advanced gastric" exact="cancer" post="refractory to chemotherapy including fluoropyrimidine and platinum Br J"/>
   <result pre="MAPK pathway activation through a PI3K-dependent feedback loop in human" exact="cancer" post="J Clin Invest 2008 118 3065 3074 18725988 128"/>
   <result pre="BY Kang YK Successful control of heavily pretreated metastatic gastric" exact="cancer" post="with the mTOR inhibitor everolimus (RAD001) in a patient"/>
   <result pre="with LOH of PTEN and leads to chemoresistance for gastric" exact="cancer" post="Int J Cancer 2005 117 376 380 15900596 133"/>
   <result pre="resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric" exact="cancer" post="cells BMC Cancer 2010 10 1 425 20704765 134"/>
   <result pre="Impact of PTEN/AKT/PI3K signal pathway on the chemotherapy for gastric" exact="cancer" post="J Clin Oncol 2006 24 18 4034 135 Yu"/>
   <result pre="3-kinase/Akt pathway plays an important role in chemoresistance of gastric" exact="cancer" post="cells against etoposide and doxorubicin induced cell death Int"/>
   <result pre="M-S c-MET as a potential therapeutic target and biomarker in" exact="cancer" post="Ther Adv Med Oncol 2011 3 1 Suppl S21"/>
   <result pre="Y MET amplification as a potential therapeutic target in gastric" exact="cancer" post="Oncotarget 2013 4 1 9 17 23327903 153 Hack"/>
   <result pre="an anti-c-Met antibody, in patients (pts) with advanced gastric or" exact="esophageal cancer" post="(GEC) J Clin Oncol 33 2015 suppl 3 abstr"/>
   <result pre="anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal" exact="cancer" post="(GEC) J Clin Oncol 33 2015 suppl 3 abstr"/>
   <result pre="second- or third-line therapy in the patients with metastatic gastric" exact="cancer" post="Invest New Drugs 2014 32 2 355 361 24337769"/>
   <result pre="with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E)" exact="cancer" post="J Clin Oncol 33 2015 suppl 3 abstr 1"/>
   <result pre="multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric" exact="cancer" post="cell lines by blocking inter-receptor tyrosine kinase networks Invest"/>
   <result pre="6284 6294 25278451 170 Sahai E Marshall CJ RHO-GTPases and" exact="cancer" post="Nat Rev Cancer 2002 2 2 133 142 12635176"/>
   <result pre="et al. Activating mutation in the tyrosine kinase JAK2 in" exact="polycythemia" post="vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer"/>
   <result pre="JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with" exact="myelofibrosis" post="Cancer Cell 2005 7 4 387 397 15837627 177"/>
   <result pre="Involvement of nuclear JAK2 signaling in AG490-induced apoptosis of gastric" exact="cancer" post="cells Anat Rec 2013 296 12 1865 1873 181"/>
   <result pre="W Giraud AS Inhibition of the JAK2/STAT3 pathway reduces gastric" exact="cancer" post="growth in vitro and in vivo PLoS One 2014"/>
   <result pre="Xu H Hu J Mo X Identification and expansion of" exact="cancer" post="stem cells in tumor tissues and peripheral blood derived"/>
   <result pre="Y Nie Y Wong BC Pang R Identification of CD44+" exact="cancer" post="stem cells in human gastric cancer Hepatogastroenterology 2013 60"/>
   <result pre="R Identification of CD44+ cancer stem cells in human gastric" exact="cancer" post="Hepatogastroenterology 2013 60 124 949 954 23478146 184 Liu"/>
   <result pre="R Zhou Y Spheroid body-forming cells in the human gastric" exact="cancer" post="cell line MKN-45 possess cancer stem cell properties Int"/>
   <result pre="cells in the human gastric cancer cell line MKN-45 possess" exact="cancer" post="stem cell properties Int J Oncol 2013 42 2"/>
   <result pre="Zhou W Zhang YY Wang DL Wu XL CD44 gastric" exact="cancer" post="cells with stemness properties are chemoradioresistant and highly invasive"/>
   <result pre="M Su X Cancer stem cells: the ‘heartbeat’ of gastric" exact="cancer" post="J Gastroenterol 2013 48 7 781 797 23184096 187"/>
   <result pre="Stem cell-like circulating tumor cells indicate poor prognosis in gastric" exact="cancer" post="Biomed Res Int 2014 2014 981261 24963492 188 Li"/>
   <result pre="981261 24963492 188 Li K Dan Z Nie YQ Gastric" exact="cancer" post="stem cells in gastric carcinogenesis, progression, prevention and treatment"/>
   <result pre="S Krstic M Ristic-Petrovic A Stefanovic V Hattori T Gastric" exact="cancer" post="stem cells: therapeutic targets Gastric Cancer 2014 17 1"/>
   <result pre="Chen L Sonic hedgehog pathway is essential for maintenance of" exact="cancer" post="stem-like cells in human gastric cancer PLoS One 2011"/>
   <result pre="essential for maintenance of cancer stem-like cells in human gastric" exact="cancer" post="PLoS One 2011 6 3 e17687 21394208 193 Tanaka"/>
   <result pre="S Takebe N Lorusso P Targeting the Hedgehog pathway in" exact="cancer" post="Ther Adv Med Oncol 2010 2 4 237 250"/>
   <result pre="HS Jin CJ Choi KW Sonic hedgehog expression in gastric" exact="cancer" post="and gastric adenoma Oncol Rep 2007 17 5 1051"/>
   <result pre="Choi KW Sonic hedgehog expression in gastric cancer and gastric" exact="adenoma" post="Oncol Rep 2007 17 5 1051 1055 17390043 196"/>
   <result pre="Role of Sonic Hedgehog signaling during progression from inflammation to" exact="cancer" post="in the stomach World J Gastrointest Pathophysiol 2011 2"/>
   <result pre="pylori infection on the sonic hedgehog signaling pathway in gastric" exact="cancer" post="cells Oncol Rep 2010 23 6 1523 1528 20428805"/>
   <result pre="Contrasting activity of Hedgehog and Wnt pathways according to gastric" exact="cancer" post="cell differentiation: relevance of crosstalk mechanisms Cancer Sci 2010"/>
   <result pre="Katano M Crosstalk of hedgehog and Wnt pathways in gastric" exact="cancer" post="Cancer Lett 2008 263 1 145 156 18243529 200"/>
   <result pre="hedgehog signaling by the mitogen-activated protein kinase cascade in gastric" exact="cancer" post="Mol Carcinog 2009 48 8 703 712 19142899 201"/>
   <result pre="SC Prognostic value of sonic hedgehog protein expression in gastric" exact="cancer" post="Jpn J Clin Oncol 2012 42 11 1054 1059"/>
   <result pre="via activation of Akt, EMT, and MMP-9 pathway in gastric" exact="cancer" post="Cancer Res 2011 71 22 7061 7070 21975935 203"/>
   <result pre="hedgehog pathway and its prognostic impact in patients with gastric" exact="cancer" post="Dig Surg 2012 29 2 115 123 22456124 204"/>
   <result pre="prognostic significance of sonic hedgehog protein overexpression in human gastric" exact="cancer" post="Int J Clin Exp Pathol 2014 7 8 5144"/>
   <result pre="and migration by blocking the Hedgehog signaling pathway in gastric" exact="cancer" post="cells Cell Oncol (Dordr) 2013 36 5 421 435"/>
   <result pre="Wang Y Cui H Sonic hedgehog pathway contributes to gastric" exact="cancer" post="cell growth and proliferation Biores Open Access 2014 3"/>
   <result pre="DJ Yoon SS CD44 expression denotes a subpopulation of gastric" exact="cancer" post="cells in which Hedgehog signaling promotes chemotherapy resistance Clin"/>
   <result pre="or FOLFIRI and bevacizumab in patients with previously untreated metastatic" exact="colorectal cancer" post="Clin Cancer Res 2013 19 1 258 267 23082002"/>
   <result pre="FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal" exact="cancer" post="Clin Cancer Res 2013 19 1 258 267 23082002"/>
   <result pre="other signaling pathways as a basis for combination therapies in" exact="cancer" post="Cancer Treat Rev 2014 40 6 750 759 24613036"/>
   <result pre="214 Schepers A Clevers H Wnt signaling, stem cells, and" exact="cancer" post="of the gastrointestinal tract Cold Spring Harb Perspect Biol"/>
   <result pre="F Kahn M Targeting Wnt signaling: can we safely eradicate" exact="cancer" post="stem cells? Clin Cancer Res 2010 16 12 3153"/>
   <result pre="JN Moon RT WNT signalling pathways as therapeutic targets in" exact="cancer" post="Nat Rev Cancer 2013 13 1 11 26 23258168"/>
   <result pre="et al. Oncogenic pathway combinations predict clinical prognosis in gastric" exact="cancer" post="PLoS Genet 2009 5 10 e1000676 19798449 218 Mao"/>
   <result pre="B Li L Roles of Wnt/beta-catenin signaling in the gastric" exact="cancer" post="stem cells proliferation and salinomycin treatment Cell Death Dis"/>
   <result pre="specific intracellular pathways and targetable genes associated with advanced gastric" exact="cancer" post="Int J Cancer 2014 134 4 755 764 23907728"/>
   <result pre="Lorenzi MV Drug discovery approaches to target Wnt signaling in" exact="cancer" post="stem cells Oncotarget 2010 1 7 552 566 21317452"/>
   <result pre="552 566 21317452 221 Lenz HJ Kahn M Safely targeting" exact="cancer" post="stem cells via selective catenin coactivator antagonism Cancer Sci"/>
   <result pre="A Garratt AN Birchmeier W Wnt signaling in stem and" exact="cancer" post="stem cells Curr Opin Cell Biol 2013 25 2"/>
   <result pre="2013 25 2 254 264 23347562 223 Singh SR Gastric" exact="cancer" post="stem cells: a novel therapeutic target Cancer Lett 2013"/>
   <result pre="R Gordon SA Shimada Y Wang TC Identification of gastric" exact="cancer" post="stem cells using the cell surface marker CD44 Stem"/>
   <result pre="He F Cai Y Yang H Identification of CD44+CD24+ gastric" exact="cancer" post="stem cells J Cancer Res Clin Oncol 2011 137"/>
   <result pre="F Guo ZJ Qian C Cui YH Bian XW Gastric" exact="cancer" post="stem-like cells possess higher capability of invasion and metastasis"/>
   <result pre="Kim BS Kang CD Oh SO Cancer spheres from gastric" exact="cancer" post="patients provide an ideal model system for cancer stem"/>
   <result pre="from gastric cancer patients provide an ideal model system for" exact="cancer" post="stem cell research Cell Mol Life Sci 2011 68"/>
   <result pre="Vermeulen L Richel D Medema JP Targeting Wnt signaling in" exact="colon cancer" post="stem cells Clin Cancer Res 2011 17 4 647"/>
   <result pre="L Richel D Medema JP Targeting Wnt signaling in colon" exact="cancer" post="stem cells Clin Cancer Res 2011 17 4 647"/>
   <result pre="K Richel DJ Stassi G Medema JP Wnt activity defines" exact="colon cancer" post="stem cells and is regulated by the microenvironment Nat"/>
   <result pre="Richel DJ Stassi G Medema JP Wnt activity defines colon" exact="cancer" post="stem cells and is regulated by the microenvironment Nat"/>
   <result pre="Landberg G Sims AH Clarke RB Wnt pathway activity in" exact="breast cancer" post="sub-types and stem-like cells PLoS One 2013 8 7"/>
   <result pre="G Sims AH Clarke RB Wnt pathway activity in breast" exact="cancer" post="sub-types and stem-like cells PLoS One 2013 8 7"/>
   <result pre="7 e67811 23861811 231 Kwon MJ Shin YK Regulation of" exact="ovarian cancer" post="stem cells or tumor-initiating cells Int J Mol Sci"/>
   <result pre="e67811 23861811 231 Kwon MJ Shin YK Regulation of ovarian" exact="cancer" post="stem cells or tumor-initiating cells Int J Mol Sci"/>
   <result pre="Xie K Role of Wnt/beta-catenin signaling in drug resistance of" exact="pancreatic cancer" post="Curr Pharm Des 2012 18 17 2464 2471 22372504"/>
   <result pre="K Role of Wnt/beta-catenin signaling in drug resistance of pancreatic" exact="cancer" post="Curr Pharm Des 2012 18 17 2464 2471 22372504"/>
   <result pre="Y Wang X Wang Y Ma D Wnt/beta-catenin signaling regulates" exact="cancer" post="stem cells in lung cancer A549 cells Biochem Biophys"/>
   <result pre="Y Ma D Wnt/beta-catenin signaling regulates cancer stem cells in" exact="lung cancer" post="A549 cells Biochem Biophys Res Commun 2010 392 3"/>
   <result pre="Ma D Wnt/beta-catenin signaling regulates cancer stem cells in lung" exact="cancer" post="A549 cells Biochem Biophys Res Commun 2010 392 3"/>
   <result pre="Ahn D Kim G Notch3 and Jagged2 contribute to gastric" exact="cancer" post="development and to glandular differentiation associated with MUC2 and"/>
   <result pre="M Wojnicz R Role of Notch signaling pathway in gastric" exact="cancer" post="pathogenesis Contemp Oncol (Pozn) 2013 17 1 1 5"/>
   <result pre="C The activated Notch1 signal pathway is associated with gastric" exact="cancer" post="progression through cyclooxygenase-2 Cancer Res 2009 69 12 5039"/>
   <result pre="Osborne B Miele L Rational targeting of Notch signaling in" exact="cancer" post="Oncogene 2008 27 38 5124 5131 18758481 244 Wang"/>
   <result pre="FH Targeting Notch signaling pathway to overcome drug resistance for" exact="cancer" post="therapy Biochim Biophys Acta 2010 1806 2 258 267"/>
   <result pre="of Hippo: targeting the Hippo pathway for regenerative medicine and" exact="cancer" post="treatment Nat Rev Drug Discov 2014 13 1 63"/>
   <result pre="1 overexpression and its relationship to tumor biomarkers in gastric" exact="cancer" post="Int J Immunopathol Pharmacol 2012 25 4 977 987"/>
   <result pre="protein 1 correlates with poor prognosis in intestinal type gastric" exact="cancer" post="Anticancer Res 2012 32 9 3827 3834 22993325 250"/>
   <result pre="Wang XY A breakdown of the Hippo pathway in gastric" exact="cancer" post="Hepatogastroenterology 2011 58 110-111 1611 1617 21940329 251 Liu-Chittenden"/>
   <result pre="Phase I/II study of verteporfin photodynamic therapy in locally advanced" exact="pancreatic cancer" post="Br J Cancer 2014 110 7 1698 1704 24569464"/>
   <result pre="I/II study of verteporfin photodynamic therapy in locally advanced pancreatic" exact="cancer" post="Br J Cancer 2014 110 7 1698 1704 24569464"/>
   <result pre="or without panitumumab for patients with previously untreated advanced oesophagogastric" exact="cancer" post="(REAL3): a randomised, open-label phase 3 trial Lancet Oncol"/>
   <result pre="hybridization and HER2 protein expression assessed by immunohistochemistry in gastric" exact="cancer" post="Oncol Rep 2006 15 1 65 71 16328035 257"/>
   <result pre="HER-2 expression in immunohistochemistry has no prognostic significance in gastric" exact="cancer" post="patients Scientific World Journal 2012 2012 941259 22645475 258"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694855/results/search/disease/results.xml">
   <result pre="and BRAF mutations [ 16]. Interestingly, salivary duct carcinomas resemble" exact="breast cancer" post="histologically, and about 20 to 80% of salivary duct"/>
   <result pre="BRAF mutations [ 16]. Interestingly, salivary duct carcinomas resemble breast" exact="cancer" post="histologically, and about 20 to 80% of salivary duct"/>
   <result pre="was adenocarcinoma, not otherwise specified (NOS) (39.3% [46/117]) followed by" exact="acinic cell carcinoma" post="(6.0% [7/117]), mucoepidermoid carcinoma (4.3% [5/117]), salivary duct carcinoma"/>
   <result pre="No. 3808, 4033, 4051 and 5681 [first three cases with" exact="acinic cell carcinoma" post="and last past patient had adenocarcinoma, not otherwise specified];"/>
   <result pre="DISCUSSION Malignant salivary gland tumors are an uncommon type of" exact="cancer" post="of the head and neck [ 1, 2]. In"/>
   <result pre="most common histology was adenocarcinoma, NOS (39.3% [46/117]) followed by" exact="acinic cell carcinoma" post="(6.0% [7/117]) and mucoepidermoid carcinoma (4.3% [5/117]) (Table 1)."/>
   <result pre="and aberrations in the cyclin pathway will likely lead to" exact="suppression" post="of TP53 ( TP53 is negatively regulated by MDM2)"/>
   <result pre="results are similar to those that we reported in metastatic" exact="breast cancer," post="where we recently described 131 distinct aberrations in 57"/>
   <result pre="47 introns from 19 genes often rearranged or altered in" exact="cancer" post="to an average depth-of-coverage of greater than 250X ("/>
   <result pre="Domont J et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="J et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="D Palbociclib (PD 0332991): targeting the cell cycle machinery in" exact="breast cancer" post="Expert Opin Pharmacother 2014 15 407 420 24369047 34"/>
   <result pre="Palbociclib (PD 0332991): targeting the cell cycle machinery in breast" exact="cancer" post="Expert Opin Pharmacother 2014 15 407 420 24369047 34"/>
   <result pre="25596748 36 Shapiro GI Cyclin-dependent kinase pathways as targets for" exact="cancer" post="treatment J Clin Oncol 2006 24 11 1770 1783"/>
   <result pre="A Nunes FD Ribeiro KC Araujo VC Immunohistochemical expression of" exact="retinoblastoma" post="pathway proteins in normal salivary glands and in salivary"/>
   <result pre="MDM2 and CDKN2A appear independent in diffuse large B cell" exact="lymphoma" post="Leukemia 1999 13 453 459 10086736 40 Polager S"/>
   <result pre="and response to everolimus and letrozole in estrogen receptor positive" exact="breast cancer" post="PLoS One 2013 8 e53292 23301057 45 Janku F"/>
   <result pre="response to everolimus and letrozole in estrogen receptor positive breast" exact="cancer" post="PLoS One 2013 8 e53292 23301057 45 Janku F"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694868/results/search/disease/results.xml">
   <result pre="estrogen receptor target gene and a predictor of survival in" exact="breast cancer" post="patients Chan Hei Jason 1 Li Haiqing 2 Liu"/>
   <result pre="receptor target gene and a predictor of survival in breast" exact="cancer" post="patients Chan Hei Jason 1 Li Haiqing 2 Liu"/>
   <result pre="the original author and source are credited. Abstract Of all" exact="breast cancer" post="patients, about 70% are ER+ and 10% are ER+/HER2+."/>
   <result pre="original author and source are credited. Abstract Of all breast" exact="cancer" post="patients, about 70% are ER+ and 10% are ER+/HER2+."/>
   <result pre="These genes were correlated to survival outcome using publicly available" exact="breast cancer" post="patient cohorts. We found the expression of the gene"/>
   <result pre="genes were correlated to survival outcome using publicly available breast" exact="cancer" post="patient cohorts. We found the expression of the gene"/>
   <result pre="better clinical outcome of ER+ and ER+/HER2+ patients. estrogen receptor" exact="breast cancer" post="endocrine resistance SERPINA1 survival analysis INTRODUCTION The estrogen receptor"/>
   <result pre="clinical outcome of ER+ and ER+/HER2+ patients. estrogen receptor breast" exact="cancer" post="endocrine resistance SERPINA1 survival analysis INTRODUCTION The estrogen receptor"/>
   <result pre="that is required for cell proliferation in the majority of" exact="breast cancer" post="cases, which accounts for about 70% of all breast"/>
   <result pre="is required for cell proliferation in the majority of breast" exact="cancer" post="cases, which accounts for about 70% of all breast"/>
   <result pre="70% of all breast cancers. A major treatment of ER+" exact="breast cancer" post="is endocrine therapy using anti-estrogens like tamoxifen or aromatase"/>
   <result pre="of all breast cancers. A major treatment of ER+ breast" exact="cancer" post="is endocrine therapy using anti-estrogens like tamoxifen or aromatase"/>
   <result pre="is required for growth in both endocrine (therapy)-responsive and endocrine-resistant" exact="breast cancer" post="cells, but only endocrine-responsive cells require estrogen for the"/>
   <result pre="required for growth in both endocrine (therapy)-responsive and endocrine-resistant breast" exact="cancer" post="cells, but only endocrine-responsive cells require estrogen for the"/>
   <result pre="binding profile of ER has been well documented in endocrine-responsive" exact="breast cancer" post="cells but not in endocrine-resistant cells [ 2]. To"/>
   <result pre="profile of ER has been well documented in endocrine-responsive breast" exact="cancer" post="cells but not in endocrine-resistant cells [ 2]. To"/>
   <result pre="project, we used MCF-7aro cells as a model for endocrine-responsive" exact="breast cancer," post="and Long Term Estrogen Deprived (LTEDaro) cells as a"/>
   <result pre="Term Estrogen Deprived (LTEDaro) cells as a model for endocrine-resistant" exact="breast cancer" post="[ 4]. In the endocrine-responsive breast cancer cells, 17β-estradiol"/>
   <result pre="Estrogen Deprived (LTEDaro) cells as a model for endocrine-resistant breast" exact="cancer" post="[ 4]. In the endocrine-responsive breast cancer cells, 17β-estradiol"/>
   <result pre="model for endocrine-resistant breast cancer [ 4]. In the endocrine-responsive" exact="breast cancer" post="cells, 17β-estradiol (E2) acts as a ligand and binds"/>
   <result pre="for endocrine-resistant breast cancer [ 4]. In the endocrine-responsive breast" exact="cancer" post="cells, 17β-estradiol (E2) acts as a ligand and binds"/>
   <result pre="of ER is thought to play key roles in endocrine-resistant" exact="breast cancer" post="because the ER degrader, fulvestrant (ICI 182, 780), is"/>
   <result pre="ER is thought to play key roles in endocrine-resistant breast" exact="cancer" post="because the ER degrader, fulvestrant (ICI 182, 780), is"/>
   <result pre="that acts as a biomarker associated with endocrine response of" exact="breast cancer," post="which would be valuable for the prediction of the"/>
   <result pre="available large panel of The Cancer Genome Atlas (TCGA) 779" exact="breast cancer" post="patient cohort [ 6] with clincopathological information, we further"/>
   <result pre="large panel of The Cancer Genome Atlas (TCGA) 779 breast" exact="cancer" post="patient cohort [ 6] with clincopathological information, we further"/>
   <result pre="and has significant association with better survival outcome for ER+/HER2+" exact="breast cancer." post="SERPINA1, also known as α1-AntiTrypsin (AAT), is a protease"/>
   <result pre="[ 10], NSCLC [ 11], papillary thyroid carcinoma [ 12]" exact="lung cancer" post="[ 13] and breast carcinoma [ 14– 16]. Unexpectedly,"/>
   <result pre="10], NSCLC [ 11], papillary thyroid carcinoma [ 12] lung" exact="cancer" post="[ 13] and breast carcinoma [ 14– 16]. Unexpectedly,"/>
   <result pre="is a significant predictor of survival in ER+ and ER+/HER2+" exact="breast cancer" post="patients. Patients with ER+/HER2+ breast cancer generally have a"/>
   <result pre="a significant predictor of survival in ER+ and ER+/HER2+ breast" exact="cancer" post="patients. Patients with ER+/HER2+ breast cancer generally have a"/>
   <result pre="in ER+ and ER+/HER2+ breast cancer patients. Patients with ER+/HER2+" exact="breast cancer" post="generally have a worse outcome compared to ER+/HER2- patients"/>
   <result pre="ER+ and ER+/HER2+ breast cancer patients. Patients with ER+/HER2+ breast" exact="cancer" post="generally have a worse outcome compared to ER+/HER2- patients"/>
   <result pre="SERPINA1 to predict the survival of this intrinsic subtype of" exact="breast cancer" post="patients is valuable. RESULTS Bioinformatics analysis of ER ChIP-seq"/>
   <result pre="to predict the survival of this intrinsic subtype of breast" exact="cancer" post="patients is valuable. RESULTS Bioinformatics analysis of ER ChIP-seq"/>
   <result pre="LTEDaro, as detected by ChIP-seq. Survival analysis using publicly available" exact="breast cancer" post="patient cohorts To determine the physiological significance of ER-binding"/>
   <result pre="as detected by ChIP-seq. Survival analysis using publicly available breast" exact="cancer" post="patient cohorts To determine the physiological significance of ER-binding"/>
   <result pre="for the ability to predict patient survival using the TCGA" exact="breast cancer" post="patient cohort. 2-means clustering was adopted to cluster patients"/>
   <result pre="the ability to predict patient survival using the TCGA breast" exact="cancer" post="patient cohort. 2-means clustering was adopted to cluster patients"/>
   <result pre="it has been reported to be an ER-regulated gene in" exact="breast cancer" post="cells [ 29]. In our analysis, SERPINA1 has a"/>
   <result pre="has been reported to be an ER-regulated gene in breast" exact="cancer" post="cells [ 29]. In our analysis, SERPINA1 has a"/>
   <result pre="that SERPINA1 is a known marker for good prognosis in" exact="cancer" post="[ 12, 14]. As indicated by a negative Cox"/>
   <result pre="large patient cohort, and validated using the Curtis and Bild" exact="breast cancer" post="patient cohorts. These results will be discussed in more"/>
   <result pre="patient cohort, and validated using the Curtis and Bild breast" exact="cancer" post="patient cohorts. These results will be discussed in more"/>
   <result pre="is known to be activated through ER-HER2 crosstalk in ER+/HER2+" exact="breast cancer" post="cells, we performed experiments to determine whether the expression"/>
   <result pre="known to be activated through ER-HER2 crosstalk in ER+/HER2+ breast" exact="cancer" post="cells, we performed experiments to determine whether the expression"/>
   <result pre="are reduced. Significance of SERPINA1 expression in ER+ and ER+/HER2+" exact="breast cancer" post="Based on our findings that the expression of SERPINA1"/>
   <result pre="reduced. Significance of SERPINA1 expression in ER+ and ER+/HER2+ breast" exact="cancer" post="Based on our findings that the expression of SERPINA1"/>
   <result pre="5 SERPINA1 expression level is a predictive marker for ER+" exact="breast cancer" post="patient survival A. The survival analysis in TCGA breast"/>
   <result pre="SERPINA1 expression level is a predictive marker for ER+ breast" exact="cancer" post="patient survival A. The survival analysis in TCGA breast"/>
   <result pre="breast cancer patient survival A. The survival analysis in TCGA" exact="breast cancer" post="cohort of ER+ and ER- patients shows that SERPINA1"/>
   <result pre="cancer patient survival A. The survival analysis in TCGA breast" exact="cancer" post="cohort of ER+ and ER- patients shows that SERPINA1"/>
   <result pre="B. Validation with ER+ and ER- patients in the Curtis" exact="breast cancer" post="cohort confirms that SERPINA1 has a significant predictive value"/>
   <result pre="Validation with ER+ and ER- patients in the Curtis breast" exact="cancer" post="cohort confirms that SERPINA1 has a significant predictive value"/>
   <result pre="(ER- data not shown). For validation we used the Bild" exact="breast cancer" post="patient cohort with 61 ER+/HER2+ patients [ 24]. The"/>
   <result pre="data not shown). For validation we used the Bild breast" exact="cancer" post="patient cohort with 61 ER+/HER2+ patients [ 24]. The"/>
   <result pre="Figure 6 Survival analysis of SERPINA1 in TCGA and Bild" exact="breast cancer" post="patient cohorts with ER+/HER2+ status A. SERPINA1 has a"/>
   <result pre="6 Survival analysis of SERPINA1 in TCGA and Bild breast" exact="cancer" post="patient cohorts with ER+/HER2+ status A. SERPINA1 has a"/>
   <result pre="DISCUSSION ER is a key player in estrogen (or hormone)-dependent" exact="breast cancer," post="and its action can be modified through many mechanisms"/>
   <result pre="changes in ER binding is associated with clinical outcome in" exact="breast cancer." post="There have been extensive studies of ER binding in"/>
   <result pre="role in the phosphorylation of ER, as in luminal B" exact="breast cancer" post="[ 41]. In our laboratory, we generated an MCF-7"/>
   <result pre="in the phosphorylation of ER, as in luminal B breast" exact="cancer" post="[ 41]. In our laboratory, we generated an MCF-7"/>
   <result pre="outcome information for more meaningful prediction. Since the majority of" exact="breast cancer" post="patients are ER+, our finding that SERPINA1 can predict"/>
   <result pre="information for more meaningful prediction. Since the majority of breast" exact="cancer" post="patients are ER+, our finding that SERPINA1 can predict"/>
   <result pre="predictive value of SERPINA1 transcript expression levels in the ER+/HER2+" exact="breast cancer," post="since these patients have relatively poor prognosis. As two"/>
   <result pre="when they co-exist [ 42, 43]. Approximately 10 percent of" exact="breast cancer" post="patients are ER+ and HER2+, and these patients have"/>
   <result pre="they co-exist [ 42, 43]. Approximately 10 percent of breast" exact="cancer" post="patients are ER+ and HER2+, and these patients have"/>
   <result pre="worse survival compared to ER+/HER2- patients [ 44]. The ER+/HER2+" exact="breast cancer" post="is an important subtype of luminal B breast cancer"/>
   <result pre="survival compared to ER+/HER2- patients [ 44]. The ER+/HER2+ breast" exact="cancer" post="is an important subtype of luminal B breast cancer"/>
   <result pre="ER+/HER2+ breast cancer is an important subtype of luminal B" exact="breast cancer" post="[ 41]. It has been also observed that a"/>
   <result pre="breast cancer is an important subtype of luminal B breast" exact="cancer" post="[ 41]. It has been also observed that a"/>
   <result pre="that a significant number of recurring tumors from luminal A" exact="cancer" post="are converted to luminal B HER2+ [ 41]. Overexpression"/>
   <result pre="luminal B HER2+ [ 41]. Overexpression of HER2 in ER+" exact="breast cancer" post="is well recognized to reduce the effectiveness of endocrine"/>
   <result pre="B HER2+ [ 41]. Overexpression of HER2 in ER+ breast" exact="cancer" post="is well recognized to reduce the effectiveness of endocrine"/>
   <result pre="survival in ER and HER2 positive luminal B subtype of" exact="breast cancer." post="To explain our findings, we hypothesize that a high"/>
   <result pre="with survival outcome based on our analysis. In early stage" exact="breast cancer," post="women with ER+/HER2+ cancers are treated with adjuvant trastuzumab."/>
   <result pre="are made to translate results from ER ChIP-seq analysis to" exact="breast cancer" post="patient outcome information. Ross-Innes et al. [ 35] have"/>
   <result pre="made to translate results from ER ChIP-seq analysis to breast" exact="cancer" post="patient outcome information. Ross-Innes et al. [ 35] have"/>
   <result pre="precedence that differential ER-binding is associated with clinical outcome in" exact="breast cancer." post="Based on our findings, we propose that the expression"/>
   <result pre="gene, is linked to the outcome of ER+ and ER+/HER2+" exact="breast cancer." post="MATERIALS AND METHODS Cell lines The MCF-7aro cell line"/>
   <result pre="22], resulting in a list of 35 genes. Using TCGA" exact="breast cancer" post="patient cohort as the training set [ 6], we"/>
   <result pre="resulting in a list of 35 genes. Using TCGA breast" exact="cancer" post="patient cohort as the training set [ 6], we"/>
   <result pre="J Levitz M alpha 1-Antitrypsin- and anchorage-independent growth of MCF-7" exact="breast cancer" post="cells Endocrinology 1993 133 996 1002 8365378 8 Farshchian"/>
   <result pre="Levitz M alpha 1-Antitrypsin- and anchorage-independent growth of MCF-7 breast" exact="cancer" post="cells Endocrinology 1993 133 996 1002 8365378 8 Farshchian"/>
   <result pre="Z Chen F Alpha-1 antitrypsin is a potential biomarker for" exact="hepatitis" post="B Virology journal 2011 8 274 21639939 10 de"/>
   <result pre="alpha1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell" exact="lung cancer" post="treated with epidermal growth factor receptor tyrosine kinase inhibitors"/>
   <result pre="as a potential prognostic biomarker for advanced nonsmall cell lung" exact="cancer" post="treated with epidermal growth factor receptor tyrosine kinase inhibitors"/>
   <result pre="D Alpha-1-antitrypsin phenotypes and neutrophil elastase gene promoter polymorphisms in" exact="lung cancer" post="Pathology oncology research : POR 2011 17 75 80"/>
   <result pre="Alpha-1-antitrypsin phenotypes and neutrophil elastase gene promoter polymorphisms in lung" exact="cancer" post="Pathology oncology research : POR 2011 17 75 80"/>
   <result pre="1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage" exact="breast cancer" post="Electrophoresis 2012 33 2130 2137 22821488 17 Dawood S"/>
   <result pre="a novel tumor-associated antigen identified in patients with early-stage breast" exact="cancer" post="Electrophoresis 2012 33 2130 2137 22821488 17 Dawood S"/>
   <result pre="AU Hortobagyi GN Giordano SH Prognosis of women with metastatic" exact="breast cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="Hortobagyi GN Giordano SH Prognosis of women with metastatic breast" exact="cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="of proliferation and HER2 expression in the luminal class of" exact="breast cancer" post="Breast Cancer Res Treat 2014 145 317 30 24744091"/>
   <result pre="proliferation and HER2 expression in the luminal class of breast" exact="cancer" post="Breast Cancer Res Treat 2014 145 317 30 24744091"/>
   <result pre="from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic" exact="breast cancer" post="Clin Cancer Res 2014 20 736 743 24198242 20"/>
   <result pre="lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast" exact="cancer" post="Clin Cancer Res 2014 20 736 743 24198242 20"/>
   <result pre="Meng Z et al. Genomic and transcriptional aberrations linked to" exact="breast cancer" post="pathophysiologies Cancer cell 2006 10 529 541 17157792 26"/>
   <result pre="Z et al. Genomic and transcriptional aberrations linked to breast" exact="cancer" post="pathophysiologies Cancer cell 2006 10 529 541 17157792 26"/>
   <result pre="Strong time dependence of the 76-gene prognostic signature for node-negative" exact="breast cancer" post="patients in the TRANSBIG multicenter independent validation series Clin"/>
   <result pre="time dependence of the 76-gene prognostic signature for node-negative breast" exact="cancer" post="patients in the TRANSBIG multicenter independent validation series Clin"/>
   <result pre="K Shaw PM et al. Gene expression profiling spares early" exact="breast cancer" post="patients from adjuvant therapy: derived and validated in two"/>
   <result pre="Shaw PM et al. Gene expression profiling spares early breast" exact="cancer" post="patients from adjuvant therapy: derived and validated in two"/>
   <result pre="adjuvant therapy: derived and validated in two population-based cohorts Breast" exact="cancer" post="research : BCR 2005 7 R953 964 16280042 28"/>
   <result pre="A Martiat P Fox SB Harris AL Liu ET Breast" exact="cancer" post="classification and prognosis based on gene expression profiles from"/>
   <result pre="occupancy of estrogen receptor alpha by the cochaperone p23 in" exact="breast cancer" post="cells Mol Endocrinol 2012 26 194 202 22074947 30"/>
   <result pre="of estrogen receptor alpha by the cochaperone p23 in breast" exact="cancer" post="cells Mol Endocrinol 2012 26 194 202 22074947 30"/>
   <result pre="K Kimber I Orphanides G Anti-proliferative effect of estrogen in" exact="breast cancer" post="cells that re-express ERalpha is mediated by aberrant regulation"/>
   <result pre="Kimber I Orphanides G Anti-proliferative effect of estrogen in breast" exact="cancer" post="cells that re-express ERalpha is mediated by aberrant regulation"/>
   <result pre="D Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive" exact="breast cancer" post="cells in vitro induces an in vivo molecular phenotype"/>
   <result pre="Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast" exact="cancer" post="cells in vitro induces an in vivo molecular phenotype"/>
   <result pre="aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive" exact="breast cancer" post="Breast Cancer Res Treat 2015 152 29 39 26026468"/>
   <result pre="inhibitor resistance and a poor prognosis in estrogen receptor-positive breast" exact="cancer" post="Breast Cancer Res Treat 2015 152 29 39 26026468"/>
   <result pre="Differential oestrogen receptor binding is associated with clinical outcome in" exact="breast cancer" post="Nature 2012 481 389 393 22217937 36 Carroll JS"/>
   <result pre="oestrogen receptor binding is associated with clinical outcome in breast" exact="cancer" post="Nature 2012 481 389 393 22217937 36 Carroll JS"/>
   <result pre="Wong C Chen S The development, application and limitations of" exact="breast cancer" post="cell lines to study tamoxifen and aromatase inhibitor resistance"/>
   <result pre="C Chen S The development, application and limitations of breast" exact="cancer" post="cell lines to study tamoxifen and aromatase inhibitor resistance"/>
   <result pre="tumours, synchronous lymph node metastases and asynchronous relapses in primary" exact="breast cancer" post="patients with 10 years' follow-up Breast Cancer Res Treat"/>
   <result pre="synchronous lymph node metastases and asynchronous relapses in primary breast" exact="cancer" post="patients with 10 years' follow-up Breast Cancer Res Treat"/>
   <result pre="in human epidermal growth factor receptor 2-positive and hormone receptor-positive" exact="breast cancer" post="patients treated with trastuzumab-containing neoadjuvant chemotherapy BMC Cancer 2013"/>
   <result pre="human epidermal growth factor receptor 2-positive and hormone receptor-positive breast" exact="cancer" post="patients treated with trastuzumab-containing neoadjuvant chemotherapy BMC Cancer 2013"/>
   <result pre="LC Schnitt SJ HER2 protein overexpression in estrogen receptor-positive ductal" exact="carcinoma in situ" post="of the breast: frequency and implications for tamoxifen therapy"/>
   <result pre="Young LS Growth factor receptor/steroid receptor cross talk in trastuzumab-treated" exact="breast cancer" post="Oncogene 2015 34 525 30 24469058 47 Denkert C"/>
   <result pre="LS Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast" exact="cancer" post="Oncogene 2015 34 525 30 24469058 47 Denkert C"/>
   <result pre="response to neoadjuvant trastuzumab plus chemotherapy in patients with primary" exact="breast cancer" post="Breast cancer research : BCR 2013 15 R11 23391338"/>
   <result pre="to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast" exact="cancer" post="Breast cancer research : BCR 2013 15 R11 23391338"/>
   <result pre="trastuzumab plus chemotherapy in patients with primary breast cancer Breast" exact="cancer" post="research : BCR 2013 15 R11 23391338 48 Pogue-Geile"/>
   <result pre="A Trastuzumab reverses letrozole resistance and amplifies the sensitivity of" exact="breast cancer" post="cells to estrogen Cancer Res 2009 69 1416 1428"/>
   <result pre="Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast" exact="cancer" post="cells to estrogen Cancer Res 2009 69 1416 1428"/>
   <result pre="Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant" exact="breast cancer" post="cells J Mol Endocrinol 2008 41 367 377 18768663"/>
   <result pre="of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast" exact="cancer" post="cells J Mol Endocrinol 2008 41 367 377 18768663"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4695049/results/search/disease/results.xml">
   <result pre="signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in" exact="breast cancer" post="cells Brusgard Jessica L. 1 3 Choe Moran 3"/>
   <result pre="pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast" exact="cancer" post="cells Brusgard Jessica L. 1 3 Choe Moran 3"/>
   <result pre="source are credited. Abstract Intratumoral heterogeneity and treatment resistance drive" exact="breast cancer" post="(BC) metastasis and recurrence. The RUNX2 transcription factor is"/>
   <result pre="are credited. Abstract Intratumoral heterogeneity and treatment resistance drive breast" exact="cancer" post="(BC) metastasis and recurrence. The RUNX2 transcription factor is"/>
   <result pre="the discovery of new therapeutic modalities to treat BC patients." exact="breast cancer" post="transcription factors tumorspheres therapeutics INTRODUCTION Breast cancer (BC) is"/>
   <result pre="discovery of new therapeutic modalities to treat BC patients. breast" exact="cancer" post="transcription factors tumorspheres therapeutics INTRODUCTION Breast cancer (BC) is"/>
   <result pre="BC patients. breast cancer transcription factors tumorspheres therapeutics INTRODUCTION Breast" exact="cancer" post="(BC) is a heterogeneous disease [ 1, 2] and"/>
   <result pre="for terminal end bud differentiation [ 7, 8]. In basal-type" exact="breast cancer" post="cell lines RUNX2 promotes an osteomimetic phenotype and metastasis"/>
   <result pre="terminal end bud differentiation [ 7, 8]. In basal-type breast" exact="cancer" post="cell lines RUNX2 promotes an osteomimetic phenotype and metastasis"/>
   <result pre="of BC patients [ 28] and is expressed in many" exact="breast cancer" post="cell lines [ 26] where it has been shown"/>
   <result pre="BC patients [ 28] and is expressed in many breast" exact="cancer" post="cell lines [ 26] where it has been shown"/>
   <result pre="mediate migration, invasion, and proliferation while maintaining epithelial morphology in" exact="cancer" post="cells [ 35– 40]. The proteolytic processing of E-Cadherin"/>
   <result pre="the cell surface. sE-Cad is an established biomarker for metastatic" exact="prostate cancer" post="[ 37, 39] and has been found in the"/>
   <result pre="cell surface. sE-Cad is an established biomarker for metastatic prostate" exact="cancer" post="[ 37, 39] and has been found in the"/>
   <result pre="and has been found in the conditioned media of DU145" exact="prostate cancer" post="cells where it promotes tumorigenesis and mediates invasion ["/>
   <result pre="has been found in the conditioned media of DU145 prostate" exact="cancer" post="cells where it promotes tumorigenesis and mediates invasion ["/>
   <result pre="each bar as &quot; n&quot;. DISCUSSION Luminal BCs include ductal" exact="carcinoma in situ" post="(DCIS), which is the most commonly diagnosed BC that"/>
   <result pre="There are many possible approaches to target transcription factors for" exact="cancer" post="therapy [ 65]. Using a new RUNX2-targeting agent that"/>
   <result pre="doxycycline for 3 days. RUNX2 transiently transfected T47D or HCC1428" exact="breast cancer" post="cells were grown in media that was then replaced"/>
   <result pre="for 3 days. RUNX2 transiently transfected T47D or HCC1428 breast" exact="cancer" post="cells were grown in media that was then replaced"/>
   <result pre="W Kareddula A Nienhuis H Miles G Reiss M Luminal" exact="breast cancer" post="metastasis is dependent on estrogen signaling Clin Exp Metastasis"/>
   <result pre="Kareddula A Nienhuis H Miles G Reiss M Luminal breast" exact="cancer" post="metastasis is dependent on estrogen signaling Clin Exp Metastasis"/>
   <result pre="CL Palanisamy N Heath AN et al. HER2 drives luminal" exact="breast cancer" post="stem cells in the absence of HER2 amplification: implications"/>
   <result pre="Palanisamy N Heath AN et al. HER2 drives luminal breast" exact="cancer" post="stem cells in the absence of HER2 amplification: implications"/>
   <result pre="Cameron ER Blyth K RUNX2 in mammary gland development and" exact="breast cancer" post="J Cell Physiol 2013 228 1137 1142 23169547 8"/>
   <result pre="ER Blyth K RUNX2 in mammary gland development and breast" exact="cancer" post="J Cell Physiol 2013 228 1137 1142 23169547 8"/>
   <result pre="Morris JS Cameron ER et al. RUNX2 correlates with subtype-specific" exact="breast cancer" post="in a human tissue microarray, and ectopic expression of"/>
   <result pre="JS Cameron ER et al. RUNX2 correlates with subtype-specific breast" exact="cancer" post="in a human tissue microarray, and ectopic expression of"/>
   <result pre="JB Stein GS Gerstenfeld LC Fidelity of Runx2 activity in" exact="breast cancer" post="cells is required for the generation of metastases-associated osteolytic"/>
   <result pre="Stein GS Gerstenfeld LC Fidelity of Runx2 activity in breast" exact="cancer" post="cells is required for the generation of metastases-associated osteolytic"/>
   <result pre="osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic" exact="cancer" post="cells and controls cell invasion Mol Cell Biol 2005"/>
   <result pre="Stein GS Regulatory roles of Runx2 in metastatic tumor and" exact="cancer" post="cell interactions with bone Cancer Metastasis Rev 2006 25"/>
   <result pre="and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human" exact="breast cancer" post="cells J Biol Chem 2004 279 27764 27773 15084595"/>
   <result pre="Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast" exact="cancer" post="cells J Biol Chem 2004 279 27764 27773 15084595"/>
   <result pre="and oestrogen-progesterone receptor gene expression characterises a biological subtype of" exact="breast cancer" post="Eur J Cancer 2009 45 2239 2248 19632824 19"/>
   <result pre="oestrogen-progesterone receptor gene expression characterises a biological subtype of breast" exact="cancer" post="Eur J Cancer 2009 45 2239 2248 19632824 19"/>
   <result pre="H Runx2 in human breast carcinoma: its potential roles in" exact="cancer" post="progression Cancer Sci 2010 101 2670 2675 20946121 20"/>
   <result pre="Borresen-Dale AL Ronnov-Jessen et al. Tumor initiating but differentiated luminal-like" exact="breast cancer" post="cells are highly invasive in the absence of basal-like"/>
   <result pre="AL Ronnov-Jessen et al. Tumor initiating but differentiated luminal-like breast" exact="cancer" post="cells are highly invasive in the absence of basal-like"/>
   <result pre="S Basso G et al. The Hippo transducer TAZ confers" exact="cancer" post="stem cell-related traits on breast cancer cells Cell 2011"/>
   <result pre="The Hippo transducer TAZ confers cancer stem cell-related traits on" exact="breast cancer" post="cells Cell 2011 147 759 772 22078877 26 Hiemer"/>
   <result pre="Hippo transducer TAZ confers cancer stem cell-related traits on breast" exact="cancer" post="cells Cell 2011 147 759 772 22078877 26 Hiemer"/>
   <result pre="and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in" exact="breast cancer" post="cells J Biol Chem 2014 289 13461 13474 24648515"/>
   <result pre="YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast" exact="cancer" post="cells J Biol Chem 2014 289 13461 13474 24648515"/>
   <result pre="A role for TAZ in migration, invasion, and tumorigenesis of" exact="breast cancer" post="cells Cancer Res 2008 68 2592 2598 18413727 29"/>
   <result pre="role for TAZ in migration, invasion, and tumorigenesis of breast" exact="cancer" post="cells Cancer Res 2008 68 2592 2598 18413727 29"/>
   <result pre="Perrucchini G Bendinelli P Desiderio MA Bone metastatic process of" exact="breast cancer" post="involves methylation state affecting E-cadherin expression through TAZ and"/>
   <result pre="G Bendinelli P Desiderio MA Bone metastatic process of breast" exact="cancer" post="involves methylation state affecting E-cadherin expression through TAZ and"/>
   <result pre="not a necessity for epithelial to mesenchymal transition in human" exact="breast cancer" post="Breast Cancer Res Treat 2013 138 47 57 23338761"/>
   <result pre="a necessity for epithelial to mesenchymal transition in human breast" exact="cancer" post="Breast Cancer Res Treat 2013 138 47 57 23338761"/>
   <result pre="Heidger PM Jr Hendrix MJ Dual roles of E-cadherin in" exact="prostate cancer" post="invasion J Cell Biochem 2004 91 649 661 14991757"/>
   <result pre="PM Jr Hendrix MJ Dual roles of E-cadherin in prostate" exact="cancer" post="invasion J Cell Biochem 2004 91 649 661 14991757"/>
   <result pre="80 kDa fragment of E-cadherin in the metastatic progression of" exact="prostate cancer" post="Clin Cancer Res 2003 9 6447 6452 14695147 40"/>
   <result pre="kDa fragment of E-cadherin in the metastatic progression of prostate" exact="cancer" post="Clin Cancer Res 2003 9 6447 6452 14695147 40"/>
   <result pre="WG Mason MD Matrilysin mediates extracellular cleavage of E-cadherin from" exact="prostate cancer" post="cells: a key mechanism in hepatocyte growth factor/scatter factor-induced"/>
   <result pre="Mason MD Matrilysin mediates extracellular cleavage of E-cadherin from prostate" exact="cancer" post="cells: a key mechanism in hepatocyte growth factor/scatter factor-induced"/>
   <result pre="al. The predictive value of serum soluble E-cadherin levels in" exact="breast cancer" post="patients undergoing preoperative systemic chemotherapy Clin Biochem 2013 46"/>
   <result pre="The predictive value of serum soluble E-cadherin levels in breast" exact="cancer" post="patients undergoing preoperative systemic chemotherapy Clin Biochem 2013 46"/>
   <result pre="of e-cadherin as a serum biomarker with predictive value for" exact="prostate cancer" post="Br J Cancer 2005 92 2018 2023 15870707 50"/>
   <result pre="e-cadherin as a serum biomarker with predictive value for prostate" exact="cancer" post="Br J Cancer 2005 92 2018 2023 15870707 50"/>
   <result pre="2023 15870707 50 Turner C Kohandel M Quantitative approaches to" exact="cancer" post="stem cells and epithelial-mesenchymal transition Semin Cancer Biol 2012"/>
   <result pre="Chen YB Kahn M Tripathy D et al. Regulation of" exact="breast cancer" post="metastasis by Runx2 and estrogen signaling: the role of"/>
   <result pre="YB Kahn M Tripathy D et al. Regulation of breast" exact="cancer" post="metastasis by Runx2 and estrogen signaling: the role of"/>
   <result pre="Rak JW Florenes VA Slingerland JM Kerbel RS E-Cadherin-dependent growth" exact="suppression" post="is mediated by the cyclin-dependent kinase inhibitor p27(KIP1) J"/>
   <result pre="Mechanisms of disease: understanding resistance to HER2-targeted therapy in human" exact="breast cancer" post="Nat Clin Pract Oncol 2006 3 269 280 16683005"/>
   <result pre="of disease: understanding resistance to HER2-targeted therapy in human breast" exact="cancer" post="Nat Clin Pract Oncol 2006 3 269 280 16683005"/>
   <result pre="MJ Frenkel B Opposing effects of Runx2 and estradiol on" exact="breast cancer" post="cell proliferation: in vitro identification of reciprocally regulated gene"/>
   <result pre="Frenkel B Opposing effects of Runx2 and estradiol on breast" exact="cancer" post="cell proliferation: in vitro identification of reciprocally regulated gene"/>
   <result pre="PA Frank DA Targeting transcription factors: promising new strategies for" exact="cancer" post="therapy Curr Opin Oncol 2013 25 652 658 24048019"/>
   <result pre="Yoneda T Cellular and molecular basis of preferential metastasis of" exact="breast cancer" post="to bone J Orthop Sci 2000 5 75 81"/>
   <result pre="T Cellular and molecular basis of preferential metastasis of breast" exact="cancer" post="to bone J Orthop Sci 2000 5 75 81"/>
   <result pre="DNMT1 and maintains DNA methylation of the E-cadherin promoter in" exact="breast cancer" post="cells Cancer Med 2015 4 125 135 25315069 70"/>
   <result pre="and maintains DNA methylation of the E-cadherin promoter in breast" exact="cancer" post="cells Cancer Med 2015 4 125 135 25315069 70"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4696215/results/search/disease/results.xml">
   <result pre="and safety of nab ®-paclitaxel for the treatment of metastatic" exact="breast cancer" post="in the United States: results from health insurance claims"/>
   <result pre="safety of nab ®-paclitaxel for the treatment of metastatic breast" exact="cancer" post="in the United States: results from health insurance claims"/>
   <result pre="albumin-bound formulation of paclitaxel approved for the treatment of metastatic" exact="breast cancer" post="(MBC). This analysis was designed to characterize the treatment"/>
   <result pre="formulation of paclitaxel approved for the treatment of metastatic breast" exact="cancer" post="(MBC). This analysis was designed to characterize the treatment"/>
   <result pre="appear consistent with those from clinical trial data. Keywords Metastatic" exact="breast cancer" post="nab-Paclitaxel Claims analysis Background Taxanes are some of the"/>
   <result pre="consistent with those from clinical trial data. Keywords Metastatic breast" exact="cancer" post="nab-Paclitaxel Claims analysis Background Taxanes are some of the"/>
   <result pre="of the most active chemotherapeutic agents in the treatment of" exact="breast cancer" post="[ 1– 3]. However, sensory neuropathy, neutropenia, and significant"/>
   <result pre="the most active chemotherapeutic agents in the treatment of breast" exact="cancer" post="[ 1– 3]. However, sensory neuropathy, neutropenia, and significant"/>
   <result pre="3]. However, sensory neuropathy, neutropenia, and significant toxicities—such as severe" exact="hypersensitivity" post="reactions, which require substantial premedication with high doses of"/>
   <result pre="and Drug Administration in January 2005 for the treatment of" exact="breast cancer" post="after failure of combination chemotherapy, including anthracyclines, for metastatic"/>
   <result pre="Drug Administration in January 2005 for the treatment of breast" exact="cancer" post="after failure of combination chemotherapy, including anthracyclines, for metastatic"/>
   <result pre="been well established in clinical trials of patients with metastatic" exact="breast cancer" post="(MBC) (Table 1) [ 10– 13]. In a phase"/>
   <result pre="well established in clinical trials of patients with metastatic breast" exact="cancer" post="(MBC) (Table 1) [ 10– 13]. In a phase"/>
   <result pre="(5.3 vs 3.9 months; P = 0.006). The incidence of grade 4" exact="neutropenia" post="was significantly lower with nab-paclitaxel compared with sb-paclitaxel. Although"/>
   <result pre="compared with sb-paclitaxel. Although the incidence of grade 3 sensory" exact="neuropathy" post="was significantly higher with nab-paclitaxel compared with sb-paclitaxel, it"/>
   <result pre="arms compared with docetaxel. The incidence of grade 3 sensory" exact="neuropathy" post="was higher for the 300 mg/m 2 q3w and"/>
   <result pre="2/week) [ 13]. The median time to improvement of sensory" exact="neuropathy" post="to ≤ grade 2 was 20 to 22 days for nab-paclitaxel"/>
   <result pre="13]. Table 1 Select clinical trials of nab-P in metastatic" exact="breast cancer" post="Trial Phase Patient population Regimen Efficacy Select a Grade ≥ 3"/>
   <result pre="Table 1 Select clinical trials of nab-P in metastatic breast" exact="cancer" post="Trial Phase Patient population Regimen Efficacy Select a Grade ≥ 3"/>
   <result pre="weekly for the first 3 of 4 weeks aNeutropenia and" exact="neuropathy" post="are common grade ≥ 3 toxicities associated with nab-P treatment bNo"/>
   <result pre="the known safety profile of nab-paclitaxel: neutropenia, anemia, thrombocytopenia, infections," exact="peripheral neuropathy," post="asthenia, nausea, vomiting, diarrhea, fluid retention, myalgia/arthralgia, and alopecia."/>
   <result pre="by line of therapy. The background characteristics, including demographics and" exact="breast cancer" post="risk factors, were ascertained during the 6-month baseline period."/>
   <result pre="line of therapy. The background characteristics, including demographics and breast" exact="cancer" post="risk factors, were ascertained during the 6-month baseline period."/>
   <result pre="sparse data recorded in the claims for family history of" exact="breast cancer," post="oral contraceptive use, hormone replacement therapy, alcohol use, obesity,"/>
   <result pre="baseline period. Anemia (26.3 %), nausea and vomiting (24.5 %)," exact="neutropenia" post="(17.5 %), and asthenia (15.6 %) were the most"/>
   <result pre="study also found that 14.5 % of claims were for" exact="peripheral neuropathy." post="These events were more frequently recorded in patients with"/>
   <result pre="184 25 13.6 242 27 11.2 578 84 14.5 Peripheral" exact="neuropathy" post="129 20 15.5 155 19 12.3 200 31 15.5"/>
   <result pre="of the subjects survived during the study period Discussion Breast" exact="cancer" post="is a heterogeneous disease with various clinical and biological"/>
   <result pre="6.7 months, respectively). In 2011, bevacizumab for the treatment of" exact="breast cancer" post="was revoked by the US Food and Drug Administration"/>
   <result pre="months, respectively). In 2011, bevacizumab for the treatment of breast" exact="cancer" post="was revoked by the US Food and Drug Administration"/>
   <result pre="study. The occurrence of select known nab-paclitaxel toxicities (eg, neutropenia," exact="peripheral neuropathy," post="anemia, infections, and nausea and vomiting) ranged from 15"/>
   <result pre="1) [ 10– 19]. In particular, the frequency of reported" exact="neuropathy" post="was relatively low (&amp;lt;15 %) compared with that reported"/>
   <result pre="for incorrect reporting of diagnosis codes, mixing patients with early-stage" exact="breast cancer" post="with patients with MBC, missing information on hormone receptor"/>
   <result pre="incorrect reporting of diagnosis codes, mixing patients with early-stage breast" exact="cancer" post="with patients with MBC, missing information on hormone receptor"/>
   <result pre="International Classification of Diseases, Ninth Revision, Clinical Modification MBC Metastatic" exact="breast cancer" post="OS Overall survival PFS Progression-free survival q2w Every 2"/>
   <result pre="Classification of Diseases, Ninth Revision, Clinical Modification MBC Metastatic breast" exact="cancer" post="OS Overall survival PFS Progression-free survival q2w Every 2"/>
   <result pre="paclitaxel compared with polyethylated castor oil-based paclitaxel in women with" exact="breast cancer" post="J Clin Oncol 2005 23 31 7794 803 10.1200/JCO.2005.04.937"/>
   <result pre="compared with polyethylated castor oil-based paclitaxel in women with breast" exact="cancer" post="J Clin Oncol 2005 23 31 7794 803 10.1200/JCO.2005.04.937"/>
   <result pre="trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic" exact="breast cancer" post="J Clin Oncol 2005 23 25 6019 26 10.1200/JCO.2005.11.013"/>
   <result pre="of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast" exact="cancer" post="J Clin Oncol 2005 23 25 6019 26 10.1200/JCO.2005.11.013"/>
   <result pre="with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 22 3611 19 10.1200/JCO.2008.18.5397"/>
   <result pre="nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 22 3611 19 10.1200/JCO.2008.18.5397"/>
   <result pre="(nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic" exact="breast cancer" post="(N0531) Ann Oncol 2009 20 3 449 53 10.1093/annonc/mdn661"/>
   <result pre="(Abraxane) in combination with gemcitabine in patients with metastatic breast" exact="cancer" post="(N0531) Ann Oncol 2009 20 3 449 53 10.1093/annonc/mdn661"/>
   <result pre="paclitaxel and capecitabine in first-line treatment of patients with metastatic" exact="breast cancer" post="Clin Breast Cancer 2012 12 2 87 93 10.1016/j.clbc.2011.10.004"/>
   <result pre="and capecitabine in first-line treatment of patients with metastatic breast" exact="cancer" post="Clin Breast Cancer 2012 12 2 87 93 10.1016/j.clbc.2011.10.004"/>
   <result pre="nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic" exact="breast cancer" post="Clin Breast Cancer 2013 13 4 239 46.e1 10.1016/j.clbc.2013.02.008"/>
   <result pre="albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast" exact="cancer" post="Clin Breast Cancer 2013 13 4 239 46.e1 10.1016/j.clbc.2013.02.008"/>
   <result pre="weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic" exact="breast cancer" post="Clin Breast Cancer 2011 11 2 121 8 10.1016/j.clbc.2011.03.007"/>
   <result pre="nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast" exact="cancer" post="Clin Breast Cancer 2011 11 2 121 8 10.1016/j.clbc.2011.03.007"/>
   <result pre="study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic" exact="breast cancer" post="patients who have received no more than one prior"/>
   <result pre="evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast" exact="cancer" post="patients who have received no more than one prior"/>
   <result pre="64 10.1007/s10549-012-2341-9 23224144 20. Chirgwin J Chua SL Management of" exact="breast cancer" post="with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review"/>
   <result pre="10.1007/s10549-012-2341-9 23224144 20. Chirgwin J Chua SL Management of breast" exact="cancer" post="with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review"/>
   <result pre="22. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast" exact="cancer" post="subtypes based on ER/PR and Her2 expression: comparison of"/>
   <result pre="WF Ibrahim N Cristofanilli M Anderson K et al. Breast" exact="cancer" post="molecular subtypes respond differently to preoperative chemotherapy Clin Cancer"/>
   <result pre="al. Pathologic complete response predicts recurrence-free survival more effectively by" exact="cancer" post="subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN"/>
   <result pre="Iglesias J. nab-Paclitaxel for first-line treatment of patients with metastatic" exact="breast cancer" post="and poor prognostic factors: a retrospective analysis. Breast Cancer"/>
   <result pre="J. nab-Paclitaxel for first-line treatment of patients with metastatic breast" exact="cancer" post="and poor prognostic factors: a retrospective analysis. Breast Cancer"/>
   <result pre="or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic" exact="breast cancer." post="Chicago, IL: Poster presented at: American Society of Clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4700735/results/search/disease/results.xml">
   <result pre=": Review Molecular targeted therapy for the treatment of gastric" exact="cancer" post="Xu Wenting Yang Zhen zyang@ncu.edu.cn Lu Nonghua lunonghua@ncu.edu.cn [],"/>
   <result pre="chemotherapy is the preferred treatment for recurrent and advanced gastric" exact="cancer" post="patients who are not candidates for reoperation. The short"/>
   <result pre="underlie molecular targeted therapies will provide new insights into gastric" exact="cancer" post="treatment. Keywords Molecular targeted therapy Gastric cancer Monoclonal antibody"/>
   <result pre="insights into gastric cancer treatment. Keywords Molecular targeted therapy Gastric" exact="cancer" post="Monoclonal antibody Tyrosine kinase inhibitor Funding the National Natural"/>
   <result pre="Foundation of Jiangxi Province, China YC2015-B021 Xu Wenting Background Gastric" exact="cancer" post="is a common malignancy of the digestive system and"/>
   <result pre="[ 2]. Although surgery is the primary method for gastric" exact="cancer" post="treatment, the majority of patients exhibit advanced disease at"/>
   <result pre="ignored. Table 1 Characteristic of molecular targeted agents for gastric" exact="cancer" post="treatment Agent Type Target(s) Current prospects for gastric cancer"/>
   <result pre="gastric cancer treatment Agent Type Target(s) Current prospects for gastric" exact="cancer" post="therapy Trastuzumab Recombinant humanized mAb HER-2 Approved by FDA"/>
   <result pre="cyclin-dependent kinase Table 2 Evaluation of combination chemotherapy for gastric" exact="cancer" post="treatment As a result of the rapid advancements in"/>
   <result pre="approved by the FDA for different cancers. Abbreviations: CML, Ph + chronic" exact="myeloid leukemia;" post="ALL, lymphoblastic leukemia; NSCLC, non-small cell lung cancer; CLL,"/>
   <result pre="FDA for different cancers. Abbreviations: CML, Ph + chronic myeloid leukemia; ALL," exact="lymphoblastic leukemia;" post="NSCLC, non-small cell lung cancer; CLL, chronic lymphocytic leukemia"/>
   <result pre="CML, Ph + chronic myeloid leukemia; ALL, lymphoblastic leukemia; NSCLC, non-small cell" exact="lung cancer;" post="CLL, chronic lymphocytic leukemia Agents that target epidermal growth"/>
   <result pre="leukemia; ALL, lymphoblastic leukemia; NSCLC, non-small cell lung cancer; CLL," exact="chronic lymphocytic leukemia" post="Agents that target epidermal growth factor receptor (EGFR) EGFR"/>
   <result pre="lymphoblastic leukemia; NSCLC, non-small cell lung cancer; CLL, chronic lymphocytic" exact="leukemia" post="Agents that target epidermal growth factor receptor (EGFR) EGFR"/>
   <result pre="expression of EGFR and HER-2 has been identified in gastric" exact="cancer" post="cells, colorectal cancer cells and esophageal squamous cell carcinoma"/>
   <result pre="EGFR and HER-2 has been identified in gastric cancer cells," exact="colorectal cancer" post="cells and esophageal squamous cell carcinoma cells [ 6–"/>
   <result pre="and HER-2 has been identified in gastric cancer cells, colorectal" exact="cancer" post="cells and esophageal squamous cell carcinoma cells [ 6–"/>
   <result pre="HER-2 are expected to improve the therapeutic efficacy of gastric" exact="cancer" post="treatments. Fig. 2 Mechanism of molecular targeted therapy in"/>
   <result pre="Cetuximab in combination with capecitabine and cisplatin in advanced esophagogastric" exact="cancer" post="(EXPAND), a phase III clinical trial, evaluated the efficacy"/>
   <result pre="capecitabine and cisplatin as a first-line treatment for advanced gastric" exact="cancer" post="[ 17]. However, no significant difference in the median"/>
   <result pre="group. Multivariate analysis indicated that mutations in the Kirsten rat" exact="sarcoma" post="viral oncogene homolog (KRAS) and PIK3CA were poor prognostic"/>
   <result pre="oncogene homolog (KRAS) and PIK3CA were poor prognostic factors. In" exact="colon cancer," post="the efficacy of cetuximab was increased in patients who"/>
   <result pre="the relationship between KRAS expression and treatment efficacy in gastric" exact="cancer" post="patients has not been established. In contrast to cetuximab,"/>
   <result pre="is a completely humanized monoclonal antibody. Panitumumab is beneficial for" exact="colorectal cancer" post="patients who have failed FOLFOX treatment. In REAL3, a"/>
   <result pre="a completely humanized monoclonal antibody. Panitumumab is beneficial for colorectal" exact="cancer" post="patients who have failed FOLFOX treatment. In REAL3, a"/>
   <result pre="the condition of patients with esophageal, gastroesophageal junction or gastric" exact="cancer" post="or with undifferentiated carcinoma [ 18]. The median OS"/>
   <result pre="have been a result of inadequate chemotherapy drug doses, accelerated" exact="cancer" post="progression after drug withdrawal or an inability to continue"/>
   <result pre="with trastuzumab improves the survival rate of HER-2-positive advanced gastric" exact="cancer" post="patients. The study defines the standard for HER-2 positive"/>
   <result pre="the quality of life of the patients with advanced gastric" exact="cancer" post="was greatly improved. These findings highlight the advantages of"/>
   <result pre="either capecitabine or 5-FU and DDP to treat metastatic gastric" exact="cancer" post="or gastroesophageal junction cancer in 2010. Furthermore, the HELOISE"/>
   <result pre="and DDP to treat metastatic gastric cancer or gastroesophageal junction" exact="cancer" post="in 2010. Furthermore, the HELOISE trial is investigating the"/>
   <result pre="with trastuzumab enhanced the anticancer effect in an HER2-positive gastric" exact="cancer" post="xenograft model [ 22]. A double-blind, placebo-controlled, randomized clinical"/>
   <result pre="trastuzumab and cisplatin and 5-FU/capecitabine treatment in HER2-positive metastatic gastric" exact="cancer" post="or gastroesophageal junction cancer [ 23]. The study is"/>
   <result pre="5-FU/capecitabine treatment in HER2-positive metastatic gastric cancer or gastroesophageal junction" exact="cancer" post="[ 23]. The study is expected to include 780"/>
   <result pre="[ 27]. Therefore, gefitinib is not primarily recommended for gastric" exact="cancer" post="treatment. Erlotinib (Tarceva) is another small-molecule tyrosinase inhibitor. The"/>
   <result pre="experimental group compared with the control group, the incidence of" exact="diarrhea" post="and skin toxicity was substantially higher in the former"/>
   <result pre="combined with paclitaxel as a second-line regimen for advanced gastric" exact="cancer" post="in patients who exhibited amplification of HER-2 (FISH-positive) did"/>
   <result pre="specific to HER-2-positive patients. The efficacy of lapatinib for gastric" exact="cancer" post="may not be as beneficial as trastuzumab. This discrepancy"/>
   <result pre="additional prospective studies of Asian patients with HER-2-positive advanced gastric" exact="cancer" post="are warranted. Agents that target vascular endothelial growth factor"/>
   <result pre="that target tumor angiogenesis have become a primary strategy for" exact="cancer" post="therapy. VEGF is one of the most important cytokines"/>
   <result pre="increasing vascular permeability. VEGF expression is commonly high in gastric" exact="cancer" post="tissues and is related to the invasiveness, clinical stage"/>
   <result pre="related to the invasiveness, clinical stage and prognosis of gastric" exact="cancer" post="[ 35]. Anti-VEGF antibodies and VEGF inhibitors are expected"/>
   <result pre="to VEGF, was the first FDA-approved anti-VEGF monoclonal antibody for" exact="cancer" post="treatment. It has been acknowledged for clinical use to"/>
   <result pre="treatment. It has been acknowledged for clinical use to treat" exact="colorectal cancer," post="non-small cell lung cancer (NSCLC), breast cancer, renal cell"/>
   <result pre="acknowledged for clinical use to treat colorectal cancer, non-small cell" exact="lung cancer" post="(NSCLC), breast cancer, renal cell carcinoma, ovarian cancer and"/>
   <result pre="for clinical use to treat colorectal cancer, non-small cell lung" exact="cancer" post="(NSCLC), breast cancer, renal cell carcinoma, ovarian cancer and"/>
   <result pre="use to treat colorectal cancer, non-small cell lung cancer (NSCLC)," exact="breast cancer," post="renal cell carcinoma, ovarian cancer and glioblastoma [ 36–"/>
   <result pre="treat colorectal cancer, non-small cell lung cancer (NSCLC), breast cancer," exact="renal cell carcinoma," post="ovarian cancer and glioblastoma [ 36– 44]. To assess"/>
   <result pre="non-small cell lung cancer (NSCLC), breast cancer, renal cell carcinoma," exact="ovarian cancer" post="and glioblastoma [ 36– 44]. To assess its value"/>
   <result pre="cell lung cancer (NSCLC), breast cancer, renal cell carcinoma, ovarian" exact="cancer" post="and glioblastoma [ 36– 44]. To assess its value"/>
   <result pre="Neuropilin-1 expression. These findings suggest that the future development of" exact="gastrointestinal cancer" post="treatments must include the identification of appropriate biomarkers for"/>
   <result pre="expression. These findings suggest that the future development of gastrointestinal" exact="cancer" post="treatments must include the identification of appropriate biomarkers for"/>
   <result pre="against VEGFR. A randomized phase III study of advanced gastric" exact="cancer" post="patients who had failed first-line treatment demonstrated that best"/>
   <result pre="the OS, PFS and disease control rate for advanced gastric" exact="cancer" post="[ 49]. Therefore, based on the results of these"/>
   <result pre="(41.1 vs 14.3 %, respectively) in patients with metastatic gastric" exact="cancer" post="compared with docetaxel alone [ 50]. Various phase І"/>
   <result pre="Sorafenib is beneficial for more than 20 types of malignant" exact="cancer" post="and is associated with few side effects. A phase"/>
   <result pre="II clinical trial that included 44 patients with advanced gastric" exact="cancer" post="indicated that sorafenib combined with docetaxel and cisplatin was"/>
   <result pre="and CTLA-4 will be developed for the treatment of gastric" exact="cancer" post="[ 54]. Agents that act on the tumor cell"/>
   <result pre="However, flavopiridol failed to exert the desired effect on gastric" exact="cancer" post="as a result of low efficacy and serious adverse"/>
   <result pre="Consequently, the promotion of apoptosis is an important topic in" exact="cancer" post="therapy. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces"/>
   <result pre="induces the apoptosis of multiple types of tumor cells. Gastric" exact="cancer" post="cells often exhibit resistance to TRAIL-induced apoptosis; however, various"/>
   <result pre="apoptosis; however, various chemotherapeutic agents enhance the sensitivity of gastric" exact="cancer" post="cells to TRAIL [ 58]. Therefore, there is a"/>
   <result pre="correlates with the degree of malignancy and negatively correlates with" exact="cancer" post="prognosis. Bortezomib, a proteasome inhibitor, specifically inhibits the chymotrypsin"/>
   <result pre="which suggests that bortezomib is a feasible option for relapsed/refractory" exact="cancer" post="[ 59]. Progress in other related fields Matrix metalloproteinase"/>
   <result pre="is associated with the progression and poor prognosis of gastric" exact="cancer" post="[ 60– 63]. The MMP inhibitor marimastat (BB-2516, TA-2516)"/>
   <result pre="(BB-2516, TA-2516) exhibits anti-tumor activity in gastric cancer. Advanced gastric" exact="cancer" post="patients also benefit from marimastat because of its low"/>
   <result pre="toxicity, which confirms the clinical value of marimastat for gastric" exact="cancer" post="patients [ 64]. c-Met signaling pathway inhibitors c-Met is"/>
   <result pre="pathways [ 67]. c-Met overexpression has been observed in gastric" exact="cancer" post="patients [ 68]. A phase II clinical trial demonstrated"/>
   <result pre="the efficacy of rilotumumab has been demonstrated for c-Met-positive gastric" exact="cancer" post="or esophagogastric junction cancer in RILOMET-1, a phase III"/>
   <result pre="has been demonstrated for c-Met-positive gastric cancer or esophagogastric junction" exact="cancer" post="in RILOMET-1, a phase III clinical study [ 70]."/>
   <result pre="expression of phosphorylated mTOR is a prognostic factor for gastric" exact="cancer" post="that negatively correlates with cancer prognosis [ 73]. Everolimus"/>
   <result pre="a prognostic factor for gastric cancer that negatively correlates with" exact="cancer" post="prognosis [ 73]. Everolimus prevents the phosphorylation of p70S6K"/>
   <result pre="a phase III clinical study of everolimus in advanced gastric" exact="cancer" post="patients who failed previous chemotherapy treatment demonstrated that there"/>
   <result pre="that there was no significant efficacy of everolimus in gastric" exact="cancer" post="[ 75]. Cyclooxygenase-2 (COX-2) inhibitors COX is an important"/>
   <result pre="expressed in gastric cancer. COX-2 is involved in tumorigenesis and" exact="cancer" post="development via the promotion of cell proliferation, suppression of"/>
   <result pre="tumorigenesis and cancer development via the promotion of cell proliferation," exact="suppression" post="of apoptosis, and induction of tumor angiogenesis. COX-2 inhibitors"/>
   <result pre="inhibitors have been demonstrated to exert anti-cancer effects on gastric" exact="cancer" post="cells; however, precise clinical trial data are lacking ["/>
   <result pre="clinical studies have confirmed the efficacy of figitumumab on Ewing’s" exact="sarcoma" post="and NSCLC; however, a phase Ш clinical study of"/>
   <result pre="endpoint [ 77– 79]. Studies of this agent in gastric" exact="cancer" post="treatment are in the clinical research stage. Conclusions and"/>
   <result pre="or in combination with chemotherapy in the field of gastric" exact="cancer" post="(Tables 1 and 2), its application in gastric cancer"/>
   <result pre="gastric cancer (Tables 1 and 2), its application in gastric" exact="cancer" post="remains in its infancy compared with its successful use"/>
   <result pre="in colon, lung, and breast cancers. Targeted therapy for gastric" exact="cancer" post="continues to face enormous challenges (Fig. 3) (1). Numerous"/>
   <result pre="single molecule has limited use for the treatment of gastric" exact="cancer" post="because of the complex pathogenesis of the disease. Consequently,"/>
   <result pre="difficult to target the entire tumor because subclones of gastric" exact="cancer" post="cells exhibit different biological behaviors. This is only one"/>
   <result pre="surgery, radiotherapy and chemotherapy may result in new opportunities for" exact="cancer" post="treatment. (3) Individual differences create challenges; not all patients"/>
   <result pre="Evolution of molecular targeted agents for the treatment of gastric" exact="cancer" post="Abbreviations ALL lymphoblastic leukemia CDK cyclin-dependent kinase CLL chronic"/>
   <result pre="targeted agents for the treatment of gastric cancer Abbreviations ALL" exact="lymphoblastic leukemia" post="CDK cyclin-dependent kinase CLL chronic lymphocytic leukemia CML Ph + chronic"/>
   <result pre="agents for the treatment of gastric cancer Abbreviations ALL lymphoblastic" exact="leukemia" post="CDK cyclin-dependent kinase CLL chronic lymphocytic leukemia CML Ph + chronic"/>
   <result pre="gastric cancer Abbreviations ALL lymphoblastic leukemia CDK cyclin-dependent kinase CLL" exact="chronic lymphocytic leukemia" post="CML Ph + chronic myeloid leukemia EGF epidermal growth factor EGFR"/>
   <result pre="Abbreviations ALL lymphoblastic leukemia CDK cyclin-dependent kinase CLL chronic lymphocytic" exact="leukemia" post="CML Ph + chronic myeloid leukemia EGF epidermal growth factor EGFR"/>
   <result pre="leukemia CDK cyclin-dependent kinase CLL chronic lymphocytic leukemia CML Ph + chronic" exact="myeloid leukemia" post="EGF epidermal growth factor EGFR epidermal growth factor receptor"/>
   <result pre="CDK cyclin-dependent kinase CLL chronic lymphocytic leukemia CML Ph + chronic myeloid" exact="leukemia" post="EGF epidermal growth factor EGFR epidermal growth factor receptor"/>
   <result pre="insulin-like growth factor 1 receptor IHC immunohistochemistry KRAS Kirsten rat" exact="sarcoma" post="viral oncogene homolog mAb monoclonal antibody MMP matrix metalloproteinase"/>
   <result pre="homolog mAb monoclonal antibody MMP matrix metalloproteinase NSCLC non-small cell" exact="lung cancer" post="OS overall survival PDGFR platelet-derived growth factor receptor PFS"/>
   <result pre="mAb monoclonal antibody MMP matrix metalloproteinase NSCLC non-small cell lung" exact="cancer" post="OS overall survival PDGFR platelet-derived growth factor receptor PFS"/>
   <result pre="Province, China. References References 1. Guggenheim DE Shah MA Gastric" exact="cancer" post="epidemiology and risk factors J Surg Oncol 2013 107"/>
   <result pre="2. Rahman R Asombang AW Ibdah JA Characteristics of gastric" exact="cancer" post="in Asia World J Gastroenterol 2014 20 4483 90"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 69 90"/>
   <result pre="predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced" exact="breast cancer" post="patients treated with anthracycline-based neoadjuvant chemotherapy World J Surg"/>
   <result pre="value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast" exact="cancer" post="patients treated with anthracycline-based neoadjuvant chemotherapy World J Surg"/>
   <result pre="may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic" exact="colorectal cancer" post="patients Br J Cancer 2013 108 668 75 10.1038/bjc.2013.4"/>
   <result pre="influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal" exact="cancer" post="patients Br J Cancer 2013 108 668 75 10.1038/bjc.2013.4"/>
   <result pre="al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic" exact="colorectal cancer" post="N Engl J Med 2004 351 337 45 10.1056/NEJMoa033025"/>
   <result pre="Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal" exact="cancer" post="N Engl J Med 2004 351 337 45 10.1056/NEJMoa033025"/>
   <result pre="and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric" exact="cancer" post="Invest New Drugs 2011 29 366 73 10.1007/s10637-009-9363-0 19997960"/>
   <result pre="Pastorelli D Bergamo F Lombardi G Zagonel V Advanced gastric" exact="cancer" post="(GC) and cancer of the gastro-oesophageal junction (GEJ): focus"/>
   <result pre="F Lombardi G Zagonel V Advanced gastric cancer (GC) and" exact="cancer" post="of the gastro-oesophageal junction (GEJ): focus on targeted therapies"/>
   <result pre="or without cetuximab for patients with previously untreated advanced gastric" exact="cancer" post="(EXPAND): a randomised, open-label phase 3 trial Lancet Oncol"/>
   <result pre="or without panitumumab for patients with previously untreated advanced oesophagogastric" exact="cancer" post="(REAL3): a randomised, open-label phase 3 trial Lancet Oncol"/>
   <result pre="D et al. Trastuzumab inhibits the growth of human gastric" exact="cancer" post="cell lines with HER2 amplification synergistically with cisplatin Int"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric" exact="cancer" post="xenograft models Clin Cancer Res 2011 17 5060 70"/>
   <result pre="A phase II trial of gefitinib for recurrent or metastatic" exact="cancer" post="of the esophagus or gastroesophageal junction Invest New Drugs"/>
   <result pre="EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric" exact="cancer" post="cells and is synergistic with trastuzumab in vitro and"/>
   <result pre="paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric" exact="cancer" post="in Asian populations: TyTAN--a randomized, phase III study J"/>
   <result pre="MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric" exact="cancer" post="cells Mol Cancer Ther 2012 11 660 9 10.1158/1535-7163.MCT-11-0754"/>
   <result pre="predictive biomarker of resistance to HER2-targeted therapy in advanced gastric" exact="cancer" post="Oncology 2015 88 76 85 10.1159/000366426 25300346 35. Grigore"/>
   <result pre="the adjuvant treatment of subjects with node-positive or high-risk node-negative" exact="breast cancer" post="Springerplus 2014 3 244 10.1186/2193-1801-3-244 24860718 40. Cuppone F"/>
   <result pre="adjuvant treatment of subjects with node-positive or high-risk node-negative breast" exact="cancer" post="Springerplus 2014 3 244 10.1186/2193-1801-3-244 24860718 40. Cuppone F"/>
   <result pre="benefits of the addition of Bevacizumab to chemotherapy for advanced" exact="breast cancer" post="patients: meta-regression analysis of randomized trials J Exp Clin"/>
   <result pre="of the addition of Bevacizumab to chemotherapy for advanced breast" exact="cancer" post="patients: meta-regression analysis of randomized trials J Exp Clin"/>
   <result pre="Ueda Y Naka T Enomoto T Therapeutic strategies in epithelial" exact="ovarian cancer" post="J Exp Clin Cancer Res 2012 31 14 10.1186/1756-9966-31-14"/>
   <result pre="Y Naka T Enomoto T Therapeutic strategies in epithelial ovarian" exact="cancer" post="J Exp Clin Cancer Res 2012 31 14 10.1186/1756-9966-31-14"/>
   <result pre="meta-analysis of fatal adverse events caused by bevacizumab therapy in" exact="cancer" post="patients PLoS One 2014 9 10.1371/journal.pone.0089960 24599121 47. Van"/>
   <result pre="trial of docetaxel and sunitinib in patients with metastatic gastric" exact="cancer" post="who were previously treated with fluoropyrimidine and platinum Br"/>
   <result pre="combined with cisplatin and 5-fluorouracil in patients with advanced gastric" exact="cancer" post="Invest New Drugs 2013 31 390 8 10.1007/s10637-012-9830-x 22615059"/>
   <result pre="study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric" exact="cancer" post="Invest New Drugs 2013 31 1547 58 10.1007/s10637-013-0032-y 24091982"/>
   <result pre="and alvocidib in patients with relapsed, refractory, or poor prognosis" exact="acute leukemia," post="or refractory anemia with excess blasts-2 Clin Cancer Res"/>
   <result pre="with relapsed, refractory, or poor prognosis acute leukemia, or refractory" exact="anemia" post="with excess blasts-2 Clin Cancer Res 2013 19 1873"/>
   <result pre="Qu J et al. Epirubicin enhances TRAIL-induced apoptosis in gastric" exact="cancer" post="cells by promoting death receptor clustering in lipid rafts"/>
   <result pre="a single agent in patients with previously untreated or relapsed/refractory" exact="acute myeloid leukemia" post="ineligible for intensive therapy Leuk Res Treatment 2013 2013"/>
   <result pre="single agent in patients with previously untreated or relapsed/refractory acute" exact="myeloid leukemia" post="ineligible for intensive therapy Leuk Res Treatment 2013 2013"/>
   <result pre="agent in patients with previously untreated or relapsed/refractory acute myeloid" exact="leukemia" post="ineligible for intensive therapy Leuk Res Treatment 2013 2013"/>
   <result pre="T VEGF and metalloproteinase 2 (MMP 2) expression in gastric" exact="cancer" post="tissue Med Sci Monit 2012 18 BR130 4 10.12659/MSM.882614"/>
   <result pre="is associated with poor overall survival of patients with gastric" exact="cancer" post="Med Oncol 2013 30 323 10.1007/s12032-012-0323-8 23275114 62. He"/>
   <result pre="metalloproteinase-14 is a negative prognostic marker for patients with gastric" exact="cancer" post="Dig Dis Sci 2013 58 1264 70 10.1007/s10620-012-2513-9 23314917"/>
   <result pre="S He S Andreoli M et al. HGF/c-Met axis drives" exact="cancer" post="aggressiveness in the neo-adjuvant setting of ovarian cancer Oncotarget"/>
   <result pre="HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of" exact="ovarian cancer" post="Oncotarget 2014 5 4855 67 10.18632/oncotarget.2049 24952592 66. Hasenauer"/>
   <result pre="axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian" exact="cancer" post="Oncotarget 2014 5 4855 67 10.18632/oncotarget.2049 24952592 66. Hasenauer"/>
   <result pre="second- or third-line therapy in the patients with metastatic gastric" exact="cancer" post="Invest New Drugs 2014 32 355 61 10.1007/s10637-013-0057-2 24337769"/>
   <result pre="lymph node metastasis and prognosis of chinese patients with gastric" exact="cancer" post="Clin Cancer Res 2009 15 1821 9 10.1158/1078-0432.CCR-08-2138 19223493"/>
   <result pre="Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in" exact="colorectal cancer" post="cells World J Surg Oncol 2012 10 200 10.1186/1477-7819-10-200"/>
   <result pre="shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal" exact="cancer" post="cells World J Surg Oncol 2012 10 200 10.1186/1477-7819-10-200"/>
   <result pre="type 1 receptor antibody figitumumab in patients with refractory Ewing" exact="sarcoma" post="J Clin Oncol 2011 29 4534 40 10.1200/JCO.2010.33.0670 22025154"/>
   <result pre="and paclitaxel in treatment-naive Japanese patients with advanced non-small cell" exact="lung cancer" post="Invest New Drugs 2012 30 1548 56 10.1007/s10637-011-9715-4 21748299"/>
   <result pre="paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung" exact="cancer" post="Invest New Drugs 2012 30 1548 56 10.1007/s10637-011-9715-4 21748299"/>
   <result pre="versus paclitaxel and carboplatin alone in patients with advanced non-small-cell" exact="lung cancer" post="J Clin Oncol 2014 32 2059 66 10.1200/JCO.2013.54.4932 24888810"/>
   <result pre="paclitaxel and carboplatin alone in patients with advanced non-small-cell lung" exact="cancer" post="J Clin Oncol 2014 32 2059 66 10.1200/JCO.2013.54.4932 24888810"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4703392/results/search/disease/results.xml">
   <result pre="abrogates cell growth in both HER-TKI-sensitive as well as -resistant" exact="breast cancer" post="cells, respectively. Conclusion We have shown that HER-TKIs exert"/>
   <result pre="cell growth in both HER-TKI-sensitive as well as -resistant breast" exact="cancer" post="cells, respectively. Conclusion We have shown that HER-TKIs exert"/>
   <result pre="shown that HER-TKIs exert a HER2 expression-dependent anti-cancer effect in" exact="breast cancer" post="cell lines. This involves blockade of JNK and STAT5A/B"/>
   <result pre="that HER-TKIs exert a HER2 expression-dependent anti-cancer effect in breast" exact="cancer" post="cell lines. This involves blockade of JNK and STAT5A/B"/>
   <result pre="tyrosine kinase family are known to be key modulators of" exact="breast cancer" post="cell growth. They act mainly by promoting tumor cell"/>
   <result pre="kinase family are known to be key modulators of breast" exact="cancer" post="cell growth. They act mainly by promoting tumor cell"/>
   <result pre="trastuzumab has profoundly improved treatment outcome in HER2 overexpressing human" exact="breast cancer" post="[ 3]. Nevertheless, a substantial fraction of patients with"/>
   <result pre="has profoundly improved treatment outcome in HER2 overexpressing human breast" exact="cancer" post="[ 3]. Nevertheless, a substantial fraction of patients with"/>
   <result pre="suggesting a HER2-independent effect on HER family members and on" exact="cancer" post="cell growth [ 6– 10]. A better understanding of"/>
   <result pre="essential for the improvement of the therapy of HER2 overexpressing" exact="breast cancer." post="In principle, HER-dependent signaling acts on cell proliferation and"/>
   <result pre="early-phase trials of advanced solid tumors and HER2 positive metastatic" exact="breast cancer" post="[ 7, 18– 21]. Afatinib (BIBW 2992) is another"/>
   <result pre="trials of advanced solid tumors and HER2 positive metastatic breast" exact="cancer" post="[ 7, 18– 21]. Afatinib (BIBW 2992) is another"/>
   <result pre="in early-phase trials of advanced solid tumors and trastuzumab-refractory HER2-positive" exact="breast cancer" post="[ 22]. In order to account for potential differences"/>
   <result pre="early-phase trials of advanced solid tumors and trastuzumab-refractory HER2-positive breast" exact="cancer" post="[ 22]. In order to account for potential differences"/>
   <result pre="lines The HER2-overexpressing SKBR3 and the HER2-moderately expressing T47D human" exact="breast cancer" post="cell lines were purchased from the American Tissue Type"/>
   <result pre="The HER2-overexpressing SKBR3 and the HER2-moderately expressing T47D human breast" exact="cancer" post="cell lines were purchased from the American Tissue Type"/>
   <result pre="and T47D cells ( Fig 4b). These results indicate that" exact="breast cancer" post="cells require activation of JNK and STAT5A/B for growth"/>
   <result pre="T47D cells ( Fig 4b). These results indicate that breast" exact="cancer" post="cells require activation of JNK and STAT5A/B for growth"/>
   <result pre="STAT5A/B for growth and that this activity is lost in" exact="breast cancer" post="cells that are sensitive to HER-TKIs. The data therefore"/>
   <result pre="for growth and that this activity is lost in breast" exact="cancer" post="cells that are sensitive to HER-TKIs. The data therefore"/>
   <result pre="levels may be used as predictors for HER-TKI sensitivity of" exact="breast cancer" post="cells. Fig 4 Dose-dependent growth inhibition in response to"/>
   <result pre="may be used as predictors for HER-TKI sensitivity of breast" exact="cancer" post="cells. Fig 4 Dose-dependent growth inhibition in response to"/>
   <result pre="STAT5 Inhibitor II IQDMA (b) on SKBR3 and T47D human" exact="breast cancer" post="cells. Means ± SD. Pan-HER-TKIs promote apoptosis in HER2"/>
   <result pre="Inhibitor II IQDMA (b) on SKBR3 and T47D human breast" exact="cancer" post="cells. Means ± SD. Pan-HER-TKIs promote apoptosis in HER2"/>
   <result pre="receptor tyrosine kinases have been implicated in several aspects of" exact="breast cancer" post="development and tumor progression. Among them, HER2 has gained"/>
   <result pre="tyrosine kinases have been implicated in several aspects of breast" exact="cancer" post="development and tumor progression. Among them, HER2 has gained"/>
   <result pre="because HER2 overexpression is present in approximately 20% of invasive" exact="breast cancer" post="cases and renders these tumors responsive to treatment with"/>
   <result pre="HER2 overexpression is present in approximately 20% of invasive breast" exact="cancer" post="cases and renders these tumors responsive to treatment with"/>
   <result pre="has also shown promising activity in triple-negative xenograft models of" exact="breast cancer." post="However, a recently conducted phase II trial in HER2"/>
   <result pre="However, a recently conducted phase II trial in HER2 negative" exact="breast cancer" post="indicated only limited activity, which supports our clinical finding"/>
   <result pre="a recently conducted phase II trial in HER2 negative breast" exact="cancer" post="indicated only limited activity, which supports our clinical finding"/>
   <result pre="heavily pretreated patients with HER2 +, ++, and +++ metastatic" exact="breast cancer." post="Not surprisingly, single-agent canertinib did not show clinically meaningful"/>
   <result pre="proliferative signaling and activate apoptosis, although no comparison to HER2-overexpressing" exact="breast cancer" post="cells has been provided. Despite considerable differences in pharmacokinetics,"/>
   <result pre="signaling and activate apoptosis, although no comparison to HER2-overexpressing breast" exact="cancer" post="cells has been provided. Despite considerable differences in pharmacokinetics,"/>
   <result pre="STAT3 and CREB were inhibited in both sensitive and resistant" exact="breast cancer" post="cell lines, whereas JNK and STAT5A/B were only inhibited"/>
   <result pre="and CREB were inhibited in both sensitive and resistant breast" exact="cancer" post="cell lines, whereas JNK and STAT5A/B were only inhibited"/>
   <result pre="two parameters also contribute to the development of resistance of" exact="breast cancer" post="cells against HER-TKIs. This hypothesis is supported by studies"/>
   <result pre="parameters also contribute to the development of resistance of breast" exact="cancer" post="cells against HER-TKIs. This hypothesis is supported by studies"/>
   <result pre="HER-TKIs. This hypothesis is supported by studies in pancreatic and" exact="prostate cancer," post="which also suggest a role for JNK activation in"/>
   <result pre="the HER-TKIs, which directly correlated with the sensitivity of the" exact="breast cancer" post="cells against these TKIs. Thus, silencing of JNK and"/>
   <result pre="HER-TKIs, which directly correlated with the sensitivity of the breast" exact="cancer" post="cells against these TKIs. Thus, silencing of JNK and"/>
   <result pre="could therefore potentially serve as biological indicator for sensitivity of" exact="breast cancer" post="cells against HER-TKIs. References References 1 Mendelsohn J ."/>
   <result pre="therefore potentially serve as biological indicator for sensitivity of breast" exact="cancer" post="cells against HER-TKIs. References References 1 Mendelsohn J ."/>
   <result pre="Mendelsohn J . Targeting the epidermal growth factor receptor for" exact="cancer" post="therapy. J Clin Oncol. 2009; 20: 1– 13. 2"/>
   <result pre="kinase inhibitor lapatinib (GW572016) on Her2 overexpressing and trastuzumab- treated" exact="breast cancer" post="cells . Cancer Res. 2006; 66: 1630– 1639. 16452222"/>
   <result pre="inhibitor lapatinib (GW572016) on Her2 overexpressing and trastuzumab- treated breast" exact="cancer" post="cells . Cancer Res. 2006; 66: 1630– 1639. 16452222"/>
   <result pre="Napolitano M , et al. AZD3409 inhibits the growth of" exact="breast cancer" post="cells with intrinsic resistance to the EGFR tyrosine kinase"/>
   <result pre="M , et al. AZD3409 inhibits the growth of breast" exact="cancer" post="cells with intrinsic resistance to the EGFR tyrosine kinase"/>
   <result pre="receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing" exact="breast cancer" post="cells in vitro and in vivo . Cancer Res."/>
   <result pre="(HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast" exact="cancer" post="cells in vitro and in vivo . Cancer Res."/>
   <result pre="epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell" exact="lung cancer" post=". The Oncologist 2007; 12: 325– 330. 17405897 20"/>
   <result pre="growth factor receptor tyrosine kinase inhibitors in non-small cell lung" exact="cancer" post=". The Oncologist 2007; 12: 325– 330. 17405897 20"/>
   <result pre="pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic" exact="breast cancer" post=". Cancer Chemother Pharmacol. 2009; 64: 1139– 1148. doi:"/>
   <result pre="receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast" exact="cancer" post=". Cancer Chemother Pharmacol. 2009; 64: 1139– 1148. doi:"/>
   <result pre="An EGF receptor inhibitor induces RAR-beta expression in breast and" exact="ovarian cancer" post="cells . Biochem Biophys Res Commun. 2005; 329: 1253–"/>
   <result pre="EGF receptor inhibitor induces RAR-beta expression in breast and ovarian" exact="cancer" post="cells . Biochem Biophys Res Commun. 2005; 329: 1253–"/>
   <result pre="kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell" exact="leukemia" post="(Jurkat) cells . Biochem Biophys Res Commun. 2011; 410:"/>
   <result pre="safety of afatinib in extensively pretreated patients with HER2-negative metastatic" exact="breast cancer" post=". Breast Cancer Res Treat. 2012; 134: 1149– 1159."/>
   <result pre="of afatinib in extensively pretreated patients with HER2-negative metastatic breast" exact="cancer" post=". Breast Cancer Res Treat. 2012; 134: 1149– 1159."/>
   <result pre="an irreversible ErbB family blocker, in patients with HER2-positive metastatic" exact="breast cancer" post="progressing after trastuzumab . Breast Cancer Res Treat. 2012;"/>
   <result pre="irreversible ErbB family blocker, in patients with HER2-positive metastatic breast" exact="cancer" post="progressing after trastuzumab . Breast Cancer Res Treat. 2012;"/>
   <result pre="kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in" exact="breast cancer" post="cells . Breast Cancer Res Treat. 2011; 129: 387–"/>
   <result pre="blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast" exact="cancer" post="cells . Breast Cancer Res Treat. 2011; 129: 387–"/>
   <result pre=", et al. Expression and differential signaling of heregulins in" exact="pancreatic cancer" post="cells. Int J Cancer 2007; 120: 514– 523. 17096356"/>
   <result pre="et al. Expression and differential signaling of heregulins in pancreatic" exact="cancer" post="cells. Int J Cancer 2007; 120: 514– 523. 17096356"/>
   <result pre="Kung HJ . ErbB kinases and NDF signaling in human" exact="prostate cancer" post="cells. Oncogene 1997; 15: 2705– 2716. 9400997 32 Olayioye"/>
   <result pre="HJ . ErbB kinases and NDF signaling in human prostate" exact="cancer" post="cells. Oncogene 1997; 15: 2705– 2716. 9400997 32 Olayioye"/>
   <result pre=", Steinberg SL , et al. Mapping ErbB receptors on" exact="breast cancer" post="cell membranes during signal transduction. J Cell Sci. 2007;"/>
   <result pre="Steinberg SL , et al. Mapping ErbB receptors on breast" exact="cancer" post="cell membranes during signal transduction. J Cell Sci. 2007;"/>
   <result pre="of Erbb4: selective loss-of-function phenotype affecting signal transduction pathways in" exact="cancer" post=". J Biol Chem. 2009; 284: 5582– 5591. doi:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706127/results/search/disease/results.xml">
   <result pre="panitumumab as first-line treatment in patients with wild-type KRAS metastatic" exact="colorectal cancer" post="Patel Shiven B * Gill David * Garrido-Laguna Ignacio"/>
   <result pre="as first-line treatment in patients with wild-type KRAS metastatic colorectal" exact="cancer" post="Patel Shiven B * Gill David * Garrido-Laguna Ignacio"/>
   <result pre="factor receptor have expanded treatment options for patients with metastatic" exact="colorectal cancer" post="(mCRC). Unfortunately, biomarkers to identify patients that are most"/>
   <result pre="receptor have expanded treatment options for patients with metastatic colorectal" exact="cancer" post="(mCRC). Unfortunately, biomarkers to identify patients that are most"/>
   <result pre="reserved for patients with RAS wild-type mCRC. Keywords panitumumab metastatic" exact="colorectal cancer" post="first-line RAS Introduction Colorectal cancer (CRC) is the second"/>
   <result pre="for patients with RAS wild-type mCRC. Keywords panitumumab metastatic colorectal" exact="cancer" post="first-line RAS Introduction Colorectal cancer (CRC) is the second"/>
   <result pre="mCRC. Keywords panitumumab metastatic colorectal cancer first-line RAS Introduction Colorectal" exact="cancer" post="(CRC) is the second most common cause of cancer"/>
   <result pre="Colorectal cancer (CRC) is the second most common cause of" exact="cancer" post="death in the United States and Europe, 1, 2"/>
   <result pre="is the backbone of treatment for patients with unresectable metastatic" exact="colorectal cancer" post="(mCRC). In these patients, 5-fluorouracil or its derivatives have"/>
   <result pre="the backbone of treatment for patients with unresectable metastatic colorectal" exact="cancer" post="(mCRC). In these patients, 5-fluorouracil or its derivatives have"/>
   <result pre="signaling pathways including MAPK or the PI3K/mTOR pathway, leading to" exact="cancer" post="cell proliferation, angiogenesis, migration, and survival. 16 The EGFR"/>
   <result pre="2.5 mg/kg weekly) were evaluated in 88 patients with advanced" exact="kidney cancer." post="33 Panitumumab was well tolerated in these patients. The"/>
   <result pre="mg/kg weekly dose, 100% of patients developed skin toxicity. The" exact="rash" post="was typically distributed in the facial, periorificial regions, and"/>
   <result pre="facial, periorificial regions, and the upper trunk. For most patients," exact="rash" post="intensity decreased despite treatment continuation. Responses were rare, but"/>
   <result pre="Treatment was well tolerated. The most common treatment-related AEs were" exact="rash" post="(60%) and dry skin (19%). Most skin-related toxicities were"/>
   <result pre="study (Panitumumab Randomized trial In combination with chemotherapy for Metastatic" exact="colorectal cancer" post="to determine Efficacy) showed improved PFS when panitumumab was"/>
   <result pre="(Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal" exact="cancer" post="to determine Efficacy) showed improved PFS when panitumumab was"/>
   <result pre="all patients in the IFL arm, 58% had grade 3–4" exact="diarrhea" post="vs 25% in the FOLFIRI arm. No differences were"/>
   <result pre="KRAS status. The most common AE with panitumumab was acneiform" exact="rash" post="(37% and 31% for KRAS wild-type and KRAS mutant,"/>
   <result pre="the KRAS wild-type group, patients who developed grade 2–4 skin" exact="rash" post="had improved clinical outcomes measured by RR, PFS, and"/>
   <result pre="rash. Thirty percent of patients had a delayed onset of" exact="rash" post="with similarly improved clinical outcomes as did those with"/>
   <result pre="antibiotic treatment with doxycycline decreases the incidence of grade ≥2" exact="rash" post="secondary to panitumumab from 62% to 29%. 78 Similarly,"/>
   <result pre="the addition of panitumumab increased the incidence of grade 3–4" exact="diarrhea" post="(18% vs 9%), hypokalemia (10% vs 5%), and fatigue"/>
   <result pre="increased the incidence of grade 3–4 diarrhea (18% vs 9%)," exact="hypokalemia" post="(10% vs 5%), and fatigue (10% vs 3%). In"/>
   <result pre="3–4 AEs that were increased in the panitumumab arm included" exact="hypokalemia" post="(11% vs 5%) and hypomagnesemia (7% vs 0%). Conclusion"/>
   <result pre="3 Rahib L Smith BD Aizenberg R et al. Projecting" exact="cancer" post="incidence and deaths to 2030: the unexpected burden of"/>
   <result pre="versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced" exact="colorectal cancer" post="(CAIRO): a phase III randomised controlled trial Lancet 2007"/>
   <result pre="combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal" exact="cancer" post="(CAIRO): a phase III randomised controlled trial Lancet 2007"/>
   <result pre="FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic" exact="colorectal cancer" post="(FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol"/>
   <result pre="plus bevacizumab as first-line treatment for patients with metastatic colorectal" exact="cancer" post="(FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol"/>
   <result pre="Ullrich A The discovery of receptor tyrosine kinases: targets for" exact="cancer" post="therapy Nat Rev Cancer 2004 4 361 370 15122207"/>
   <result pre="Shia J Kemeny NE et al. Cetuximab shows activity in" exact="colorectal cancer" post="patients with tumors that do not express the epidermal"/>
   <result pre="J Kemeny NE et al. Cetuximab shows activity in colorectal" exact="cancer" post="patients with tumors that do not express the epidermal"/>
   <result pre="KRAS is required for panitumumab efficacy in patients with metastatic" exact="colorectal cancer" post="J Clin Oncol 2008 26 1626 1634 18316791 23"/>
   <result pre="is required for panitumumab efficacy in patients with metastatic colorectal" exact="cancer" post="J Clin Oncol 2008 26 1626 1634 18316791 23"/>
   <result pre="of EGFR gene copy number as a predictive marker in" exact="colorectal cancer" post="patients treated with cetuximab: a fluorescent in situ hybridization"/>
   <result pre="EGFR gene copy number as a predictive marker in colorectal" exact="cancer" post="patients treated with cetuximab: a fluorescent in situ hybridization"/>
   <result pre="FISH assay predicts for response to cetuximab in chemotherapy refractory" exact="colorectal cancer" post="patients Ann Oncol 2008 19 717 723 17974556 26"/>
   <result pre="assay predicts for response to cetuximab in chemotherapy refractory colorectal" exact="cancer" post="patients Ann Oncol 2008 19 717 723 17974556 26"/>
   <result pre="factor receptor gene copy number and clinical outcome of metastatic" exact="colorectal cancer" post="treated with panitumumab J Clin Oncol 2007 25 3238"/>
   <result pre="receptor gene copy number and clinical outcome of metastatic colorectal" exact="cancer" post="treated with panitumumab J Clin Oncol 2007 25 3238"/>
   <result pre="of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for" exact="cancer" post="therapy Crit Rev Oncol Hematol 2001 38 17 23"/>
   <result pre="factor receptor monoclonal antibody in patients with metastatic renal cell" exact="cancer" post="J Clin Oncol 2004 22 3003 3015 15210739 34"/>
   <result pre="study of panitumumab with FOLFOX4 for first-line treatment of metastatic" exact="colorectal cancer" post="Ann Oncol 2014 25 1346 1355 24718886 37 Schwartzberg"/>
   <result pre="of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal" exact="cancer" post="Ann Oncol 2014 25 1346 1355 24718886 37 Schwartzberg"/>
   <result pre="patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic" exact="colorectal cancer" post="J Clin Oncol 2014 32 2240 2247 24687833 38"/>
   <result pre="with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal" exact="cancer" post="J Clin Oncol 2014 32 2240 2247 24687833 38"/>
   <result pre="assessing safety and efficacy of panitumumab in patients with metastatic" exact="colorectal cancer" post="refractory to standard chemotherapy Ann Oncol 2008 19 1"/>
   <result pre="safety and efficacy of panitumumab in patients with metastatic colorectal" exact="cancer" post="refractory to standard chemotherapy Ann Oncol 2008 19 1"/>
   <result pre="al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic" exact="colorectal cancer" post="J Cancer Res Clin Oncol 2012 138 65 72"/>
   <result pre="First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal" exact="cancer" post="J Cancer Res Clin Oncol 2012 138 65 72"/>
   <result pre="and panitumumab compared with chemotherapy and bevacizumab alone for metastatic" exact="colorectal cancer" post="J Clin Oncol 2009 27 672 680 19114685 42"/>
   <result pre="panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal" exact="cancer" post="J Clin Oncol 2009 27 672 680 19114685 42"/>
   <result pre="Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic" exact="colorectal cancer" post="N Engl J Med 2009 360 563 572 19196673"/>
   <result pre="A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal" exact="cancer" post="N Engl J Med 2009 360 563 572 19196673"/>
   <result pre="al. Pragmatic issues in biomarker evaluation for targeted therapies in" exact="cancer" post="Nat Rev Clin Oncol 2015 12 197 212 25421275"/>
   <result pre="CJ Karapetis CS et al. Cetuximab for the treatment of" exact="colorectal cancer" post="N Engl J Med 2007 357 2040 2048 18003960"/>
   <result pre="Karapetis CS et al. Cetuximab for the treatment of colorectal" exact="cancer" post="N Engl J Med 2007 357 2040 2048 18003960"/>
   <result pre="et al. K-ras mutations and benefit from cetuximab in advanced" exact="colorectal cancer" post="N Engl J Med 2008 359 1757 1765 18946061"/>
   <result pre="al. K-ras mutations and benefit from cetuximab in advanced colorectal" exact="cancer" post="N Engl J Med 2008 359 1757 1765 18946061"/>
   <result pre="KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic" exact="colorectal cancer" post="treated with cetuximab JAMA 2010 304 1812 1820 20978259"/>
   <result pre="p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal" exact="cancer" post="treated with cetuximab JAMA 2010 304 1812 1820 20978259"/>
   <result pre="of KRAS mutations and acquired resistance to anti-EGFR therapy in" exact="colorectal cancer" post="Nature 2012 486 532 536 22722830 48 Segelov E"/>
   <result pre="KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal" exact="cancer" post="Nature 2012 486 532 536 22722830 48 Segelov E"/>
   <result pre="Mutation – analysis of outcomes in patients with refractory metastatic" exact="colorectal cancer" post="harbouring the KRAS G13D mutation Paper presented at: European"/>
   <result pre="– analysis of outcomes in patients with refractory metastatic colorectal" exact="cancer" post="harbouring the KRAS G13D mutation Paper presented at: European"/>
   <result pre="Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in" exact="colorectal cancer" post="N Engl J Med 2013 369 1023 1034 24024839"/>
   <result pre="S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal" exact="cancer" post="N Engl J Med 2013 369 1023 1034 24024839"/>
   <result pre="al. Predictive role of BRAF mutations in patients with advanced" exact="colorectal cancer" post="receiving cetuximab and panitumumab: a meta-analysis Eur J Cancer"/>
   <result pre="Predictive role of BRAF mutations in patients with advanced colorectal" exact="cancer" post="receiving cetuximab and panitumumab: a meta-analysis Eur J Cancer"/>
   <result pre="Prahallad A Sun C Huang S et al. Unresponsiveness of" exact="colon cancer" post="to BRAF(V600E) inhibition through feedback activation of EGFR Nature"/>
   <result pre="A Sun C Huang S et al. Unresponsiveness of colon" exact="cancer" post="to BRAF(V600E) inhibition through feedback activation of EGFR Nature"/>
   <result pre="and cetuximab with or without vemurafenib in BRAF mutant metastatic" exact="colorectal cancer" post="Available from: https://www.clinicaltrials.gov/ct2/show/NCT02164916. NLM identifier: NCT02164916 Accessed October 28,"/>
   <result pre="cetuximab with or without vemurafenib in BRAF mutant metastatic colorectal" exact="cancer" post="Available from: https://www.clinicaltrials.gov/ct2/show/NCT02164916. NLM identifier: NCT02164916 Accessed October 28,"/>
   <result pre="cetuximab or LGX818, BYL719, and cetuximab in BRAF mutant metastatic" exact="colorectal cancer" post="Available from: https://www.clinicaltrials.gov/ct2/show/NCT01719380. NLM identifier: NCT01719380 Accessed October 28,"/>
   <result pre="or LGX818, BYL719, and cetuximab in BRAF mutant metastatic colorectal" exact="cancer" post="Available from: https://www.clinicaltrials.gov/ct2/show/NCT01719380. NLM identifier: NCT01719380 Accessed October 28,"/>
   <result pre="α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant" exact="colorectal cancer" post="Paper presented at: AACR 106th Annual Meeting April 18–22,"/>
   <result pre="PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal" exact="cancer" post="Paper presented at: AACR 106th Annual Meeting April 18–22,"/>
   <result pre="and irinotecan plus cetuximab treatment and RAS mutations in col-orectal" exact="cancer" post="J Clin Oncol 2015 33 692 700 25605843 60"/>
   <result pre="al. Mutant PIK3CA promotes cell growth and invasion of human" exact="cancer" post="cells Cancer Cell 2005 7 561 573 15950905 63"/>
   <result pre="Atlas Network Comprehensive molecular characterization of human colon and rectal" exact="cancer" post="Nature 2012 487 330 337 22810696 64 De Roock"/>
   <result pre="status and benefit from cetuximab in the treatment of advanced" exact="colorectal cancer" post="– results from NCIC CTG/AGITG CO.17 Clin Cancer Res"/>
   <result pre="and benefit from cetuximab in the treatment of advanced colorectal" exact="cancer" post="– results from NCIC CTG/AGITG CO.17 Clin Cancer Res"/>
   <result pre="of the MET receptor drives resistance to anti-EGFR therapies in" exact="colorectal cancer" post="Cancer Discov 2013 3 658 673 23729478 68 Price"/>
   <result pre="the MET receptor drives resistance to anti-EGFR therapies in colorectal" exact="cancer" post="Cancer Discov 2013 3 658 673 23729478 68 Price"/>
   <result pre="cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic" exact="colorectal cancer" post="(ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study"/>
   <result pre="in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal" exact="cancer" post="(ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study"/>
   <result pre="Abrams TA et al. Panitumumab in patients with KRAS wild-type" exact="colorectal cancer" post="after progression on cetuximab Oncologist 2012 17 14 22210091"/>
   <result pre="TA et al. Panitumumab in patients with KRAS wild-type colorectal" exact="cancer" post="after progression on cetuximab Oncologist 2012 17 14 22210091"/>
   <result pre="of the epidermal growth factor receptor conferring cetuximab resistance in" exact="colorectal cancer" post="Nat Med 2012 18 221 223 22270724 71 Arena"/>
   <result pre="the epidermal growth factor receptor conferring cetuximab resistance in colorectal" exact="cancer" post="Nat Med 2012 18 221 223 22270724 71 Arena"/>
   <result pre="Emergence of multiple EGFR extracellular mutations during cetuximab treatment in" exact="colorectal cancer" post="Clin Cancer Res 2015 21 9 2157 2166 25623215"/>
   <result pre="of multiple EGFR extracellular mutations during cetuximab treatment in colorectal" exact="cancer" post="Clin Cancer Res 2015 21 9 2157 2166 25623215"/>
   <result pre="(cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic" exact="colorectal cancer" post="(mCRC) J Clin Oncol 2015 33 Suppl abstr e14623."/>
   <result pre="in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal" exact="cancer" post="(mCRC) J Clin Oncol 2015 33 Suppl abstr e14623."/>
   <result pre="F et al. TP53 mutations predict disease control in metastatic" exact="colorectal cancer" post="treated with cetuximab-based chemotherapy Br J Cancer 2009 100"/>
   <result pre="et al. TP53 mutations predict disease control in metastatic colorectal" exact="cancer" post="treated with cetuximab-based chemotherapy Br J Cancer 2009 100"/>
   <result pre="to panitumumab in a random-ized phase III study of metastatic" exact="colorectal cancer" post="Clin Cancer Res 2013 19 1902 1912 23325582 76"/>
   <result pre="panitumumab in a random-ized phase III study of metastatic colorectal" exact="cancer" post="Clin Cancer Res 2013 19 1902 1912 23325582 76"/>
   <result pre="Galimi F et al. HER2 activating mutations are targets for" exact="colorectal cancer" post="treatment Cancer Discov 2015 5 832 841 26243863 77"/>
   <result pre="F et al. HER2 activating mutations are targets for colorectal" exact="cancer" post="treatment Cancer Discov 2015 5 832 841 26243863 77"/>
   <result pre="al. The genomic landscape of response to EGFR blockade in" exact="colorectal cancer" post="Nature 2015 526 263 267 26416732 78 Lacouture ME"/>
   <result pre="The genomic landscape of response to EGFR blockade in colorectal" exact="cancer" post="Nature 2015 526 263 267 26416732 78 Lacouture ME"/>
   <result pre="skin toxicities and quality of life in patients with metastatic" exact="colorectal cancer" post="J Clin Oncol 2010 28 1351 1357 20142600 79"/>
   <result pre="toxicities and quality of life in patients with metastatic colorectal" exact="cancer" post="J Clin Oncol 2010 28 1351 1357 20142600 79"/>
   <result pre="and NRAS mutations on treatment outcomes in patients with metastatic" exact="colorectal cancer" post="(mCRC) treated first-line with cetuximab plus FOLFOX4: new results"/>
   <result pre="NRAS mutations on treatment outcomes in patients with metastatic colorectal" exact="cancer" post="(mCRC) treated first-line with cetuximab plus FOLFOX4: new results"/>
   <result pre="of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary" exact="colorectal cancer" post="and matched metastases Sci Rep 2015 5 8065 25639985"/>
   <result pre="KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal" exact="cancer" post="and matched metastases Sci Rep 2015 5 8065 25639985"/>
   <result pre="Terrasi A Bellomo SE et al. Stromal contribution to the" exact="colorectal cancer" post="transcriptome Nat Genet 2015 47 312 319 25706627 Figure"/>
   <result pre="A Bellomo SE et al. Stromal contribution to the colorectal" exact="cancer" post="transcriptome Nat Genet 2015 47 312 319 25706627 Figure"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706528/results/search/disease/results.xml">
   <result pre="4706528 cbm-12-04-342 doi: 10.7497/j.issn.2095-3941.2015.0089 : Review Article PI3K/Akt/mTOR inhibitors in" exact="breast cancer" post="Lee Joycelyn JX Loh Kiley Yap Yoon-Sim [], Singapore"/>
   <result pre="cbm-12-04-342 doi: 10.7497/j.issn.2095-3941.2015.0089 : Review Article PI3K/Akt/mTOR inhibitors in breast" exact="cancer" post="Lee Joycelyn JX Loh Kiley Yap Yoon-Sim [], Singapore"/>
   <result pre="kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in" exact="breast cancer." post="There is preclinical data to support inhibition of the"/>
   <result pre="have been or are being conducted in solid tumors and" exact="breast cancer." post="Everolimus, an mTOR inhibitor, is currently approved for the"/>
   <result pre="hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative" exact="breast cancer." post="In this review, we summarise the efficacy and toxicity"/>
   <result pre="benefit from inhibition of the PI3K/Akt/mTOR (PAM) pathway. KEYWORDS Breast" exact="cancer" post="phosphoinositide 3 kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR)"/>
   <result pre="target of rapamycin (mTOR) (PAM) pathway is frequently activated in" exact="breast cancer," post="with PIK3CA being the most commonly mutated gene of"/>
   <result pre="commonly mutated gene of significance in estrogen receptor (ER) positive" exact="breast cancer" post="1 . Activation of the pathway has been associated"/>
   <result pre="mutated gene of significance in estrogen receptor (ER) positive breast" exact="cancer" post="1 . Activation of the pathway has been associated"/>
   <result pre="growth factor receptor 2 (HER2)-directed therapy and cytotoxic therapy in" exact="breast cancer." post="Several inhibitors of this pathway have been in preclinical"/>
   <result pre="being approved for treatment of hormone receptor (HR)-positive, HER2-negative advanced" exact="breast cancer." post="Other PAM pathway inhibitors which show promise include the"/>
   <result pre="the literature on the relevance of the PAM pathway in" exact="breast cancer," post="the advances in targeting this pathway including potential biomarkers"/>
   <result pre="management of mTOR inhibition. PAM pathway and its relevance in" exact="breast cancer" post="The PAM pathway PAM is a major signalling pathway"/>
   <result pre="of mTOR inhibition. PAM pathway and its relevance in breast" exact="cancer" post="The PAM pathway PAM is a major signalling pathway"/>
   <result pre="Figure 1 ). Table 1 Common PAM pathway alterations in" exact="breast cancer" post="Gene Type of alteration Effect on signaling Frequency (%)"/>
   <result pre="1 ). Table 1 Common PAM pathway alterations in breast" exact="cancer" post="Gene Type of alteration Effect on signaling Frequency (%)"/>
   <result pre="and tensin homologue deleted on chromosome ten; AKT, akt murine" exact="thymoma" post="viral oncogene; PDK1, phosphoinositide-dependent kinase 1; INPP4B, inositol polyphosphate"/>
   <result pre="4-phosphatase II; LKB, liver kinase B; ERBB2, erb-B2 avian erythroblastic" exact="leukemia" post="viral oncogene homologue (also known as HER2, human epidermal"/>
   <result pre="tested in phase I-III clinical trials on solid tumors and/or" exact="breast cancer." post="PI3K, phosphoinositide 3 kinase; PTEN, phosphatase and tensin homologue"/>
   <result pre="and tensin homologue deleted on chromosome ten; AKT, akt murine" exact="thymoma" post="viral oncogene; mTORC, mammalian target of rapamycin complex; INPP4B,"/>
   <result pre="INPP4B, inositol polyphosphate 4-phosphatase II; 4EBP1, 4E-binding protein 1; TSC," exact="tuberous sclerosis;" post="RAS, rat sarcoma; RAF, rapidly accelerated fibrosarcoma; MEK, mitogen-activated"/>
   <result pre="cell growth by activating mTOR via effects on the intermediary" exact="tuberous sclerosis" post="1/2 complex (TSC1/2) 11 , 12 . Phosphatase and"/>
   <result pre="also been associated with other cancers such as non-small cell" exact="lung cancer" post="23 - 25 and hematologic malignancies 26 . Preclinical"/>
   <result pre="been associated with other cancers such as non-small cell lung" exact="cancer" post="23 - 25 and hematologic malignancies 26 . Preclinical"/>
   <result pre="PAM pathway has been implicated in endocrine resistance in preclinical" exact="breast cancer" post="models 27 . Preclinical studies have shown that Akt"/>
   <result pre="pathway has been implicated in endocrine resistance in preclinical breast" exact="cancer" post="models 27 . Preclinical studies have shown that Akt"/>
   <result pre="in resistant cells 31 - 34 . In triple negative" exact="breast cancer" post="(TNBC), preclinical studies including array comparative genomic hybridisation studies"/>
   <result pre="resistant cells 31 - 34 . In triple negative breast" exact="cancer" post="(TNBC), preclinical studies including array comparative genomic hybridisation studies"/>
   <result pre="pathway activation. Everolimus has also been shown to sensitise basal-like" exact="breast cancer" post="cells to DNA damaging agents, including cisplatin 38 ,"/>
   <result pre="activation. Everolimus has also been shown to sensitise basal-like breast" exact="cancer" post="cells to DNA damaging agents, including cisplatin 38 ,"/>
   <result pre="Summary of completed randomised trials of mTOR inhibitors in metastatic" exact="breast cancer" post="Study name Comparison arms Study description Key findings References"/>
   <result pre="of completed randomised trials of mTOR inhibitors in metastatic breast" exact="cancer" post="Study name Comparison arms Study description Key findings References"/>
   <result pre="subpopulation: 20.3 vs. 13.1 months ( P=0.0049) 46 ABC, advanced" exact="breast cancer;" post="PFS, progression-free survival; NSAI, non-steroidal aromatase inhibitor; AI, aromatase"/>
   <result pre="was subsequently developed and is approved for the treatment of" exact="renal cell carcinoma." post="Everolimus is an oral mTOR inhibitor which has been"/>
   <result pre="has been approved for use in post-menopausal women with HR-positive" exact="breast cancer;" post="it is also approved for used in other cancers"/>
   <result pre="it is also approved for used in other cancers including" exact="renal cell carcinoma," post="neuroendocrine tumors of the pancreas and subependymal giant cell"/>
   <result pre="randomised trial evaluating the use of an mTOR inhibitor in" exact="breast cancer." post="The trial compared the combination of temsirolimus plus letrozole"/>
   <result pre="letrozole, in the first-line setting in patients with HR+ advanced" exact="breast cancer." post="The study was terminated after an interim analysis showed"/>
   <result pre="BOLERO-2 trial was another randomised phase III trial in advanced" exact="breast cancer" post="evaluating an mTOR inhibitor and aromatase inhibitor (AI) combination."/>
   <result pre="trial was another randomised phase III trial in advanced breast" exact="cancer" post="evaluating an mTOR inhibitor and aromatase inhibitor (AI) combination."/>
   <result pre="(AI) combination. It randomised 724 postmenopausal women with HR-positive advanced" exact="breast cancer" post="who had relapsed or progressed on nonsteroidal AI in"/>
   <result pre="combination. It randomised 724 postmenopausal women with HR-positive advanced breast" exact="cancer" post="who had relapsed or progressed on nonsteroidal AI in"/>
   <result pre="exemestane in the treatment of postmenopausal women with HR+HER2− advanced" exact="breast cancer" post="after failure of treatment with letrozole or anastrozole. The"/>
   <result pre="in the treatment of postmenopausal women with HR+HER2− advanced breast" exact="cancer" post="after failure of treatment with letrozole or anastrozole. The"/>
   <result pre="in a phase II randomised study among HR+/HER2−, AI-resistant metastatic" exact="breast cancer" post="patients. Addition of everolimus significantly improved the clinical benefit"/>
   <result pre="a phase II randomised study among HR+/HER2−, AI-resistant metastatic breast" exact="cancer" post="patients. Addition of everolimus significantly improved the clinical benefit"/>
   <result pre="study and the BOLERO-2 study suggest that patients with endocrine-resistant" exact="cancer" post="may benefit more from the addition of an mTOR"/>
   <result pre="not ER is inhibited. The role of everolimus in HER2+" exact="breast cancer" post="however remains unclear, especially with the approved indications for"/>
   <result pre="ER is inhibited. The role of everolimus in HER2+ breast" exact="cancer" post="however remains unclear, especially with the approved indications for"/>
   <result pre="mg in combination with paclitaxel and trastuzumab in HER2+ advanced" exact="breast cancer" post="in the first-line setting, testing the potential for everolimus"/>
   <result pre="in combination with paclitaxel and trastuzumab in HER2+ advanced breast" exact="cancer" post="in the first-line setting, testing the potential for everolimus"/>
   <result pre="population, with PFS in the subset of patients with HR-negative" exact="breast cancer" post="added as a co-primary endpoint following the findings of"/>
   <result pre="with PFS in the subset of patients with HR-negative breast" exact="cancer" post="added as a co-primary endpoint following the findings of"/>
   <result pre="was consistent with results previously reported and included stomatitis, diarrhoea," exact="neutropenia" post="and anaemia. There was also a higher rate of"/>
   <result pre="of everolimus concurrently with weekly paclitaxel and trastuzumab. Triple negative" exact="breast cancer" post="(TNBC) Following the encouraging preclinical data in TNBC, there"/>
   <result pre="everolimus concurrently with weekly paclitaxel and trastuzumab. Triple negative breast" exact="cancer" post="(TNBC) Following the encouraging preclinical data in TNBC, there"/>
   <result pre="in a phase III study, where 403 patients with HER2-" exact="breast cancer" post="showing no response after four cycles of neoadjuvant epirubicin"/>
   <result pre="a phase III study, where 403 patients with HER2- breast" exact="cancer" post="showing no response after four cycles of neoadjuvant epirubicin"/>
   <result pre="making this a negative study 49 . HER-2 negative metastatic" exact="breast cancer" post="In the metastatic setting, a randomised phase II trial"/>
   <result pre="this a negative study 49 . HER-2 negative metastatic breast" exact="cancer" post="In the metastatic setting, a randomised phase II trial"/>
   <result pre="or without everolimus in 112 women with untreated metastatic HER2-negative" exact="breast cancer." post="In a preliminary report, although response rates and median"/>
   <result pre="BOLERO-1 and BOLERO-3 trials were presented recently. Exons of 282" exact="cancer" post="related genes were analysed by NGS and PTEN levels"/>
   <result pre="to fulvestrant. A total of 168 women with ER+ advanced" exact="breast cancer" post="who had progressed on prior AI use were randomised"/>
   <result pre="fulvestrant. A total of 168 women with ER+ advanced breast" exact="cancer" post="who had progressed on prior AI use were randomised"/>
   <result pre="III trial which randomised 1,148 postmenopausal women with HR+/HER2- advanced" exact="breast cancer" post="after progression on AI to fulvestrant and buparlisib or"/>
   <result pre="trial which randomised 1,148 postmenopausal women with HR+/HER2- advanced breast" exact="cancer" post="after progression on AI to fulvestrant and buparlisib or"/>
   <result pre="been tested in a phase I trial with 26 metastatic" exact="breast cancer" post="patients 65 . Stable disease was the best response"/>
   <result pre="tested in a phase I trial with 26 metastatic breast" exact="cancer" post="patients 65 . Stable disease was the best response"/>
   <result pre="and BYL719 or BKM120 in postmenopausal women with advanced HR+" exact="breast cancer" post="(Clinicaltrials.gov no: NCT02088684), and another study is looking at"/>
   <result pre="BYL719 or BKM120 in postmenopausal women with advanced HR+ breast" exact="cancer" post="(Clinicaltrials.gov no: NCT02088684), and another study is looking at"/>
   <result pre="liver panel, fasting glucose, lipid panel; screen baseline virologies for" exact="hepatitis" post="B and other opportunistic infections as clinically indicated; Screen"/>
   <result pre="adverse events including pneumonitis (cough, breathlessness), infections (fever, localising symptoms)," exact="hypersensitivity" post="(breathlessness, flushing, rash, swelling), oral ulceration, and hyperglycemia (and"/>
   <result pre="localising symptoms), hypersensitivity (breathlessness, flushing, rash, swelling), oral ulceration, and" exact="hyperglycemia" post="(and reinforce need for monitoring if patient is already"/>
   <result pre="management, everolimus may be continued in some patients who experience" exact="stomatitis" post="70 . Table 4 Management of common side effects"/>
   <result pre="(partly adapted from www.global.afinitor.com) Grading Description Suggested management Management of" exact="stomatitis" post="Grade 1 Minimal symptoms, normal diet; erythema of mucosa"/>
   <result pre="spontaneous bleeding Discontinue treatment; supportive treatment as above Management of" exact="rash" post="Grade 1 Macular or papular eruption or erythema; asymptomatic"/>
   <result pre="or eruption/desquamation covering &amp;gt;50% BSA As above for management of" exact="rash" post="+ systemic steroids ± antibiotics; interrupt treatment until resolution"/>
   <result pre="grade 3 recurrence Grade 4 Generalised exfoliative, ulcerative or bullous" exact="dermatitis" post="As above for management of rash; discontinue treatment Management"/>
   <result pre="hypercholesterolemia; HTG, hypertriglyceridemia. Everolimus is also associated with an acneiform" exact="rash" post="that may require topical corticosteroids, with or without topical"/>
   <result pre="interruption, reduction or discontinuation. Metabolic effects mTOR inhibitors may cause" exact="hyperglycemia" post="and hyperlipidemia, with elevations in both low density lipoprotein"/>
   <result pre="bacterial, fungal and viral infections, as well as reactivation of" exact="hepatitis" post="B virus. Baseline screening for hepatitis B, and other"/>
   <result pre="well as reactivation of hepatitis B virus. Baseline screening for" exact="hepatitis" post="B, and other infections such as hepatitis C, HIV"/>
   <result pre="Baseline screening for hepatitis B, and other infections such as" exact="hepatitis" post="C, HIV and tuberculosis should be considered before drug"/>
   <result pre="B, and other infections such as hepatitis C, HIV and" exact="tuberculosis" post="should be considered before drug initiation for patients at"/>
   <result pre="adversely affected. Conclusion The PAM pathway is frequently activated in" exact="breast cancer," post="and inhibitors targeting this pathway are currently available or"/>
   <result pre="of clinical efficacy is mainly in the setting of HR+/HER2−" exact="breast cancer" post="at this present moment, with everolimus approved for use"/>
   <result pre="clinical efficacy is mainly in the setting of HR+/HER2− breast" exact="cancer" post="at this present moment, with everolimus approved for use"/>
   <result pre="1 Ellis MJ Perou CM . The genomic landscape of" exact="breast cancer" post="as a therapeutic roadmap. Cancer Discov 2013; 3: 27-"/>
   <result pre="Ellis MJ Perou CM . The genomic landscape of breast" exact="cancer" post="as a therapeutic roadmap. Cancer Discov 2013; 3: 27-"/>
   <result pre="Ciruelos EM . The phosphatidyl inositol 3-kinase/AKT signaling pathway in" exact="breast cancer." post="Cancer Metastasis Rev 2010; 29: 751- 759. 20922461 5"/>
   <result pre="S Lee JS et al. Characterization of a naturally occurring" exact="breast cancer" post="subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics."/>
   <result pre="Lee JS et al. Characterization of a naturally occurring breast" exact="cancer" post="subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics."/>
   <result pre="J Sahin F et al. LKB1 protein expression in human" exact="breast cancer." post="Appl Immunohistochem Mol Morphol 2006; 14: 146- 153. 16785781"/>
   <result pre="3-kinase pathway: role in tumor progression and therapeutic implications in" exact="breast cancer." post="Breast Cancer Res 2011; 13: 224. 22114931 9 Courtney"/>
   <result pre="and proteomic analysis of PIK3CA, PTEN, and AKT mutations in" exact="breast cancer." post="Cancer Res 2008; 68: 6084- 6091. 18676830 11 Cantley"/>
   <result pre="12 Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in" exact="breast cancer." post="Oncologist 2011; 16 Suppl 1: 12- 19. 21278436 13"/>
   <result pre="Activated mammalian target of rapamycin pathway in the pathogenesis of" exact="tuberous sclerosis" post="complex renal tumors. Cancer Res 2002; 62: 5645- 5650."/>
   <result pre="S6 kinase 1 regulates estrogen receptor alpha in control of" exact="breast cancer" post="cell proliferation. J Biol Chem 2009; 284: 6361- 6369."/>
   <result pre="kinase 1 regulates estrogen receptor alpha in control of breast" exact="cancer" post="cell proliferation. J Biol Chem 2009; 284: 6361- 6369."/>
   <result pre="central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated" exact="breast cancer." post="Cancer Metab 2013; 1: 18. 24280377 23 Fernandez P"/>
   <result pre="Liu L Li MX . LKB1/AMPK/mTOR signaling pathway in non-small-cell" exact="lung cancer." post="Asian Pac J Cancer Prev 2013; 14: 4033- 4039."/>
   <result pre=". LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to" exact="cancer" post="cell biology. Cell Cycle 2011; 10: 2115- 2120. 21572254"/>
   <result pre="receptor signaling in vitro induces cell death in models of" exact="breast cancer." post="Clin Cancer Res 2005; 11: 5319- 5328. 16033851 28"/>
   <result pre="kinase promotes escape from hormone dependence in estrogen receptor-positive human" exact="breast cancer." post="J Clin Invest 2010; 120: 2406- 2413. 20530877 29"/>
   <result pre="synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive" exact="breast cancer." post="Cancer Res 2009; 69: 3955- 3962. 19366795 30 Nagata"/>
   <result pre="kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in" exact="breast cancer" post="cells. Breast Cancer Res Treat 2011; 129: 387- 400."/>
   <result pre="blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast" exact="cancer" post="cells. Breast Cancer Res Treat 2011; 129: 387- 400."/>
   <result pre="HER2 blockade results in antitumor activity in preclinical models of" exact="breast cancer" post="resistant to anti-HER2 therapy. Clin Cancer Res 2012; 18:"/>
   <result pre="blockade results in antitumor activity in preclinical models of breast" exact="cancer" post="resistant to anti-HER2 therapy. Clin Cancer Res 2012; 18:"/>
   <result pre="A Michiels S Liedtke C et al. Molecular characterization of" exact="breast cancer" post="with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer"/>
   <result pre="Michiels S Liedtke C et al. Molecular characterization of breast" exact="cancer" post="with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer"/>
   <result pre="PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like" exact="breast cancer" post="cells. Breast Cancer Res 2008; 10: R101. 19055754 37"/>
   <result pre="genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast" exact="cancer" post="cells. Breast Cancer Res 2008; 10: R101. 19055754 37"/>
   <result pre="Lim JY et al. Rapamycin synergizes cisplatin sensitivity in basal-like" exact="breast cancer" post="cells through up-regulation of p73. Breast Cancer Res Treat"/>
   <result pre="JY et al. Rapamycin synergizes cisplatin sensitivity in basal-like breast" exact="cancer" post="cells through up-regulation of p73. Breast Cancer Res Treat"/>
   <result pre="Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in" exact="breast cancer" post="cells. Clin Cancer Res 2004; 10: 7031- 7042. 15501983"/>
   <result pre="mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast" exact="cancer" post="cells. Clin Cancer Res 2004; 10: 7031- 7042. 15501983"/>
   <result pre="endocrine therapy in postmenopausal women with locally advanced or metastatic" exact="breast cancer." post="J Clin Oncol 2013; 31: 195- 202. 23233719 42"/>
   <result pre="HS Sahmoud T et al. Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer." post="N Engl J Med 2012; 366: 520- 529. 22149876"/>
   <result pre="with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic" exact="breast cancer" post="with prior exposure to aromatase inhibitors: a GINECO study."/>
   <result pre="hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast" exact="cancer" post="with prior exposure to aromatase inhibitors: a GINECO study."/>
   <result pre="G et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced" exact="breast cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet"/>
   <result pre="et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast" exact="cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet"/>
   <result pre="plus paclitaxel as first-line treatment for patients with HER2-positive advanced" exact="breast cancer" post="(BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet"/>
   <result pre="paclitaxel as first-line treatment for patients with HER2-positive advanced breast" exact="cancer" post="(BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet"/>
   <result pre="K et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in" exact="breast cancer" post="patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab"/>
   <result pre="et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast" exact="cancer" post="patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab"/>
   <result pre="with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic" exact="breast cancer" post="(MBC): A randomized, double-blind, placebo-controlled phase II trial of"/>
   <result pre="paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast" exact="cancer" post="(MBC): A randomized, double-blind, placebo-controlled phase II trial of"/>
   <result pre="marker as a predictive factor for everolimus efficacy in advanced" exact="breast cancer." post="Ann Oncol 2015; 26: 120- 125. 25361980 53 Slamon"/>
   <result pre="in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic" exact="breast cancer" post="– Part I results. Presented at San Antonio Breast"/>
   <result pre="patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast" exact="cancer" post="– Part I results. Presented at San Antonio Breast"/>
   <result pre="fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic" exact="breast cancer" post="(BC) after aromatase inhibitor (AI; BELLE-2) or AI and"/>
   <result pre="in postmenopausal women with HR+/HER2– locally advanced or metastatic breast" exact="cancer" post="(BC) after aromatase inhibitor (AI; BELLE-2) or AI and"/>
   <result pre="trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic" exact="breast cancer." post="J Clin Oncol 2012;30:abstr 508. 63 Shimizu T Tolcher"/>
   <result pre="antibody cixutumumab in combination with temsirolimus in patients with metastatic" exact="breast cancer." post="Breast Cancer Res Treat 2013; 139: 145- 153. 23605083"/>
   <result pre="Costa C et al. CDK 4/6 inhibitors sensitize PIK3CA mutant" exact="breast cancer" post="to PI3K inhibitors. Cancer Cell 2014; 26: 136- 149."/>
   <result pre="C et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast" exact="cancer" post="to PI3K inhibitors. Cancer Cell 2014; 26: 136- 149."/>
   <result pre="of inhibitors of the pi3k/Akt/mtor pathway for the treatment of" exact="breast cancer." post="Curr Oncol 2015; 22: 33- 48. 25684987 70 Rugo"/>
   <result pre="Pavel ME, Franz DN, Ravaud A, et al. Meta-analysis of" exact="stomatitis" post="incidence in everolimus (EVE) clinical studies and its relationship"/>
   <result pre=". Management of adverse events in patients with hormone receptor-positive" exact="breast cancer" post="treated with everolimus: observations from a phase III clinical"/>
   <result pre="Management of adverse events in patients with hormone receptor-positive breast" exact="cancer" post="treated with everolimus: observations from a phase III clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706584/results/search/disease/results.xml">
   <result pre="&quot;manual syringe&quot; injection or intravenously in women with HER2-positive early" exact="breast cancer" post="Quartino Angelica L. Hillenbach Carina Li Jing Li Hanbin"/>
   <result pre="syringe&quot; injection or intravenously in women with HER2-positive early breast" exact="cancer" post="Quartino Angelica L. Hillenbach Carina Li Jing Li Hanbin"/>
   <result pre="(PKs) of subcutaneous (SC) and intravenous (IV) trastuzumab in early" exact="breast cancer" post="(EBC), assess the impact of covariates on trastuzumab PK,"/>
   <result pre="of subcutaneous (SC) and intravenous (IV) trastuzumab in early breast" exact="cancer" post="(EBC), assess the impact of covariates on trastuzumab PK,"/>
   <result pre="supplementary material, which is available to authorized users. Keywords Early" exact="breast cancer" post="Fixed dose HER2 NONMEM Population pharmacokinetics modeling Trastuzumab Funding"/>
   <result pre="material, which is available to authorized users. Keywords Early breast" exact="cancer" post="Fixed dose HER2 NONMEM Population pharmacokinetics modeling Trastuzumab Funding"/>
   <result pre="in the USA/EU for treatment of patients with HER2-positive early" exact="breast cancer" post="(EBC) (in combination with neoadjuvant and/or adjuvant chemotherapy), HER2-positive"/>
   <result pre="the USA/EU for treatment of patients with HER2-positive early breast" exact="cancer" post="(EBC) (in combination with neoadjuvant and/or adjuvant chemotherapy), HER2-positive"/>
   <result pre="(EBC) (in combination with neoadjuvant and/or adjuvant chemotherapy), HER2-positive metastatic" exact="breast cancer" post="(MBC) (as monotherapy or in combination with pertuzumab plus"/>
   <result pre="(in combination with neoadjuvant and/or adjuvant chemotherapy), HER2-positive metastatic breast" exact="cancer" post="(MBC) (as monotherapy or in combination with pertuzumab plus"/>
   <result pre="paclitaxel, docetaxel, or an aromatase inhibitor), and HER2-positive metastatic gastric" exact="cancer" post="(in combination with capecitabine or 5-fluorouracil and cisplatin) ["/>
   <result pre="cisplatin) [ 3, 4]. The approved intravenous (IV) regimens for" exact="breast cancer" post="include an 8 mg/kg loading dose followed by 6"/>
   <result pre="[ 3, 4]. The approved intravenous (IV) regimens for breast" exact="cancer" post="include an 8 mg/kg loading dose followed by 6"/>
   <result pre="[ 13]. Patients with HER2-positive, operable, locally advanced, or inflammatory" exact="breast cancer" post="were randomized 1:1 to receive eight cycles of neoadjuvant"/>
   <result pre="13]. Patients with HER2-positive, operable, locally advanced, or inflammatory breast" exact="cancer" post="were randomized 1:1 to receive eight cycles of neoadjuvant"/>
   <result pre="the appropriateness of a fixed 600 mg SC dose across" exact="breast cancer" post="indications. Electronic supplementary material LINK Supplementary material 1 (DOCX"/>
   <result pre="appropriateness of a fixed 600 mg SC dose across breast" exact="cancer" post="indications. Electronic supplementary material LINK Supplementary material 1 (DOCX"/>
   <result pre="I/Ib trial in healthy male volunteers and patients with HER2-positive" exact="breast cancer" post="J Clin Pharmacol 2013 53 192 201 10.1177/0091270012436560 23436264"/>
   <result pre="trial in healthy male volunteers and patients with HER2-positive breast" exact="cancer" post="J Clin Pharmacol 2013 53 192 201 10.1177/0091270012436560 23436264"/>
   <result pre="P Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic" exact="breast cancer" post="Cancer Chemother Pharmacol 2005 56 361 369 10.1007/s00280-005-1026-z 15868146"/>
   <result pre="Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast" exact="cancer" post="Cancer Chemother Pharmacol 2005 56 361 369 10.1007/s00280-005-1026-z 15868146"/>
   <result pre="of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III" exact="breast cancer" post="(HannaH study): a phase 3, open-label, multicentre, randomised trial"/>
   <result pre="(neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast" exact="cancer" post="(HannaH study): a phase 3, open-label, multicentre, randomised trial"/>
   <result pre="humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic" exact="breast cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast" exact="cancer" post="that has progressed after chemotherapy for metastatic disease J"/>
   <result pre="factor of infliximab pharmacokinetics and clinical response in patients with" exact="ulcerative colitis" post="Int J Clin Pharmacol Ther 2010 48 297 308"/>
   <result pre="of infliximab pharmacokinetics and clinical response in patients with ulcerative" exact="colitis" post="Int J Clin Pharmacol Ther 2010 48 297 308"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4707213/results/search/disease/results.xml">
   <result pre="doi: 10.3857/roj.2015.33.4.301 : Original Article: Clinical Investigation Prognostic factors in" exact="breast cancer" post="with extracranial oligometastases and the appropriate role of radiation"/>
   <result pre="10.3857/roj.2015.33.4.301 : Original Article: Clinical Investigation Prognostic factors in breast" exact="cancer" post="with extracranial oligometastases and the appropriate role of radiation"/>
   <result pre="for disease progression and survival of patients with extracranial oligometastatic" exact="breast cancer" post="(EOMBC), and to investigate the role of radiation therapy"/>
   <result pre="disease progression and survival of patients with extracranial oligometastatic breast" exact="cancer" post="(EOMBC), and to investigate the role of radiation therapy"/>
   <result pre="had been diagnosed with EOMBC following standard treatment for primary" exact="breast cancer" post="initially, and received RT for metastatic lesions, with or"/>
   <result pre="been diagnosed with EOMBC following standard treatment for primary breast" exact="cancer" post="initially, and received RT for metastatic lesions, with or"/>
   <result pre="between January 2004 and December 2008. EOMBC was defined as" exact="breast cancer" post="with five or less metastases involving any organs except"/>
   <result pre="January 2004 and December 2008. EOMBC was defined as breast" exact="cancer" post="with five or less metastases involving any organs except"/>
   <result pre="of patients with EOMBC. Oligometastasis Radiotherapy Breast neoplasms Introduction Metastatic" exact="breast cancer" post="(MBC) is generally considered an incurable disease. Advances in"/>
   <result pre="patients with EOMBC. Oligometastasis Radiotherapy Breast neoplasms Introduction Metastatic breast" exact="cancer" post="(MBC) is generally considered an incurable disease. Advances in"/>
   <result pre="Weichselbaum [ 5] suggested a new clinically significant state of" exact="cancer" post="spread referred to as oligometastases (OM). Oligometastatic states were"/>
   <result pre="renal cell cancer, in addition to hepatic resections for metastatic" exact="colorectal cancer" post="[ 6 7]. Since the concept of OM was"/>
   <result pre="cell cancer, in addition to hepatic resections for metastatic colorectal" exact="cancer" post="[ 6 7]. Since the concept of OM was"/>
   <result pre="(RT) and radiofrequency ablation for metastases [ 8]. Like metastatic" exact="colorectal cancer" post="and sarcomas, surgical resection for metastases in patients with"/>
   <result pre="and radiofrequency ablation for metastases [ 8]. Like metastatic colorectal" exact="cancer" post="and sarcomas, surgical resection for metastases in patients with"/>
   <result pre="the role of RT in treating patients with extracranial oligometastatic" exact="breast cancer" post="(EOMBC) by analyzing potential prognostic factors. The aims of"/>
   <result pre="role of RT in treating patients with extracranial oligometastatic breast" exact="cancer" post="(EOMBC) by analyzing potential prognostic factors. The aims of"/>
   <result pre="treatments including surgery with neoadjuvant or adjuvant therapies for primary" exact="breast cancer" post="and thereafter were diagnosed as MBC and received RT"/>
   <result pre="including surgery with neoadjuvant or adjuvant therapies for primary breast" exact="cancer" post="and thereafter were diagnosed as MBC and received RT"/>
   <result pre="non-MBC initially, but did not receive standard treatment for primary" exact="breast cancer" post="before metastasis. After application of these criteria, the final"/>
   <result pre="initially, but did not receive standard treatment for primary breast" exact="cancer" post="before metastasis. After application of these criteria, the final"/>
   <result pre="the time interval from the beginning of treatment for primary" exact="breast cancer" post="to the first diagnosis of distant metastasis. We defined"/>
   <result pre="time interval from the beginning of treatment for primary breast" exact="cancer" post="to the first diagnosis of distant metastasis. We defined"/>
   <result pre="patients were female and one patient was male. For primary" exact="breast cancer," post="four patients received neoadjuvant chemotherapy and 44 patients underwent"/>
   <result pre="therapies were considered to be enough to control the primary" exact="breast cancer." post="Twenty-seven patients were treated with an adriamycin-based regimen and"/>
   <result pre="HR-positive status, 35 patients received adjuvant endocrinologic therapy for primary" exact="breast cancer." post="Human epidermal growth factor receptor 2 (HER2) status was"/>
   <result pre="of SABR for patients with metastatic cancer, including patients with" exact="breast cancer." post="They reported LC rates at 1 and 2 years"/>
   <result pre="however, is now currently used to treat patients with HER2-positive" exact="breast cancer." post="Therefore, further studies are needed to investigate the outcomes"/>
   <result pre="on survival in a population-based cohort of women with metastatic" exact="breast cancer" post="Cancer 2007 110 973 979 17647245 2 O'Shaughnessy J"/>
   <result pre="survival in a population-based cohort of women with metastatic breast" exact="cancer" post="Cancer 2007 110 973 979 17647245 2 O'Shaughnessy J"/>
   <result pre="17647245 2 O'Shaughnessy J Extending survival with chemotherapy in metastatic" exact="breast cancer" post="Oncologist 2005 10 Suppl 3 20 29 16368868 3"/>
   <result pre="2 O'Shaughnessy J Extending survival with chemotherapy in metastatic breast" exact="cancer" post="Oncologist 2005 10 Suppl 3 20 29 16368868 3"/>
   <result pre="International guidelines for management of metastatic breast cancer: can metastatic" exact="breast cancer" post="be cured? J Natl Cancer Inst 2010 102 456"/>
   <result pre="guidelines for management of metastatic breast cancer: can metastatic breast" exact="cancer" post="be cured? J Natl Cancer Inst 2010 102 456"/>
   <result pre="of pulmonary metastases in adult patients with extremity soft tissue" exact="sarcoma" post="Ann Surg 1993 218 705 712 8257219 8 Corbin"/>
   <result pre="MT Zhang H Metcalfe SK Muhs AG Okunieff P Oligometastatic" exact="breast cancer" post="treated with curative-intent stereotactic body radiation therapy Breast Cancer"/>
   <result pre="Zhang H Metcalfe SK Muhs AG Okunieff P Oligometastatic breast" exact="cancer" post="treated with curative-intent stereotactic body radiation therapy Breast Cancer"/>
   <result pre="in metastatic patients? The concept of local therapy in oligometastatic" exact="breast cancer" post="Breast Care (Basel) 2011 6 363 368 22619646 12"/>
   <result pre="metastatic patients? The concept of local therapy in oligometastatic breast" exact="cancer" post="Breast Care (Basel) 2011 6 363 368 22619646 12"/>
   <result pre="metastatic breast cancer: lessons from our 30-year experience with oligometastatic" exact="breast cancer" post="patients and literature review Breast Cancer 2012 19 218"/>
   <result pre="breast cancer: lessons from our 30-year experience with oligometastatic breast" exact="cancer" post="patients and literature review Breast Cancer 2012 19 218"/>
   <result pre="A Systemic therapy for treating locoregional recurrence in women with" exact="breast cancer" post="Cochrane Database Syst Rev 2001 4 CD002195 11687148 22"/>
   <result pre="Systemic therapy for treating locoregional recurrence in women with breast" exact="cancer" post="Cochrane Database Syst Rev 2001 4 CD002195 11687148 22"/>
   <result pre="Siegel PM Shu W et al. A multigenic program mediating" exact="breast cancer" post="metastasis to bone Cancer Cell 2003 3 537 549"/>
   <result pre="PM Shu W et al. A multigenic program mediating breast" exact="cancer" post="metastasis to bone Cancer Cell 2003 3 537 549"/>
   <result pre="AJ Gupta GP Siegel PM et al. Genes that mediate" exact="breast cancer" post="metastasis to lung Nature 2005 436 518 524 16049480"/>
   <result pre="Gupta GP Siegel PM et al. Genes that mediate breast" exact="cancer" post="metastasis to lung Nature 2005 436 518 524 16049480"/>
   <result pre="M Hanaoka N et al. Surgery for pulmonary nodules in" exact="breast cancer" post="patients Ann Thorac Surg 2005 79 1711 1714 15854960"/>
   <result pre="Hanaoka N et al. Surgery for pulmonary nodules in breast" exact="cancer" post="patients Ann Thorac Surg 2005 79 1711 1714 15854960"/>
   <result pre="of surgery in the management of solitary pulmonary nodule in" exact="breast cancer" post="patients Eur J Surg Oncol 2007 33 546 550"/>
   <result pre="surgery in the management of solitary pulmonary nodule in breast" exact="cancer" post="patients Eur J Surg Oncol 2007 33 546 550"/>
   <result pre="Long-term survival after an aggressive surgical approach in patients with" exact="breast cancer" post="hepatic metastases Ann Surg Oncol 2004 11 869 874"/>
   <result pre="survival after an aggressive surgical approach in patients with breast" exact="cancer" post="hepatic metastases Ann Surg Oncol 2004 11 869 874"/>
   <result pre="J et al. Prognostic factors in 1,038 women with metastatic" exact="breast cancer" post="Ann Oncol 2008 19 2012 2019 18641006 30 Ahn"/>
   <result pre="et al. Prognostic factors in 1,038 women with metastatic breast" exact="cancer" post="Ann Oncol 2008 19 2012 2019 18641006 30 Ahn"/>
   <result pre="et al. Prognostic factors for patients with bone-only metastasis in" exact="breast cancer" post="Yonsei Med J 2013 54 1168 1177 23918566 31"/>
   <result pre="al. Prognostic factors for patients with bone-only metastasis in breast" exact="cancer" post="Yonsei Med J 2013 54 1168 1177 23918566 31"/>
   <result pre="E Comparison between solitary and multiple skeletal metastatic lesions of" exact="breast cancer" post="patients Ann Oncol 2003 14 1234 1240 12881385 33"/>
   <result pre="Comparison between solitary and multiple skeletal metastatic lesions of breast" exact="cancer" post="patients Ann Oncol 2003 14 1234 1240 12881385 33"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4708008/results/search/disease/results.xml">
   <result pre="and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474" exact="breast cancer" post="cells Apigenin induced apoptosis in HER2-overexpressing breast cancer cells"/>
   <result pre="activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast" exact="cancer" post="cells Apigenin induced apoptosis in HER2-overexpressing breast cancer cells"/>
   <result pre="HER2-overexpressing BT-474 breast cancer cells Apigenin induced apoptosis in HER2-overexpressing" exact="breast cancer" post="cells H.-S. Seo and others Seo Hye-Sook * 1"/>
   <result pre="BT-474 breast cancer cells Apigenin induced apoptosis in HER2-overexpressing breast" exact="cancer" post="cells H.-S. Seo and others Seo Hye-Sook * 1"/>
   <result pre="apoptosis through inhibition of STAT3 signaling in HER2 overexpressing BT-474" exact="breast cancer" post="cells. Abstract Phytoestrogen intake is known to be beneficial"/>
   <result pre="through inhibition of STAT3 signaling in HER2 overexpressing BT-474 breast" exact="cancer" post="cells. Abstract Phytoestrogen intake is known to be beneficial"/>
   <result pre="Abstract Phytoestrogen intake is known to be beneficial to decrease" exact="breast cancer" post="incidence and progression. But its molecular mechanisms of action"/>
   <result pre="Phytoestrogen intake is known to be beneficial to decrease breast" exact="cancer" post="incidence and progression. But its molecular mechanisms of action"/>
   <result pre="the effect of apigenin on proliferation and apoptosis in HER2-expressing" exact="breast cancer" post="cells. In our experiments, apigenin inhibited the proliferation of"/>
   <result pre="effect of apigenin on proliferation and apoptosis in HER2-expressing breast" exact="cancer" post="cells. In our experiments, apigenin inhibited the proliferation of"/>
   <result pre="decrease mitochondrial membrane potential without affecting the levels of B-cell" exact="lymphoma" post="2 (Bcl-2) and Bcl-2-associated X protein (BAX). Apigenin reduced"/>
   <result pre="serve as a useful compound to prevent or treat HER2-overexpressing" exact="breast cancer." post="apigenin apoptosis breast cancer HER2 p53 STAT3 fig-count: table-count:"/>
   <result pre="compound to prevent or treat HER2-overexpressing breast cancer. apigenin apoptosis" exact="breast cancer" post="HER2 p53 STAT3 fig-count: table-count: ref-count: page-count: INTRODUCTION Phytoestrogens"/>
   <result pre="to prevent or treat HER2-overexpressing breast cancer. apigenin apoptosis breast" exact="cancer" post="HER2 p53 STAT3 fig-count: table-count: ref-count: page-count: INTRODUCTION Phytoestrogens"/>
   <result pre="models, apigenin-induced growth inhibition and apoptosis in a variety of" exact="cancer" post="cell lines including breast [ 15], lung [ 16],"/>
   <result pre="neurodegenerative diseases, ischemic damage, autoimmune disorders and many types of" exact="cancer" post="[ 22]. Two core pathways exist to induce apoptosis,"/>
   <result pre="protein overexpression are called HER2-positive [ 29]. Approximately 20% of" exact="breast cancer" post="cases are HER2-positive [ 29]. HER2-positive breast cancers tend"/>
   <result pre="overexpression are called HER2-positive [ 29]. Approximately 20% of breast" exact="cancer" post="cases are HER2-positive [ 29]. HER2-positive breast cancers tend"/>
   <result pre="cancers tend to be more aggressive than other types of" exact="breast cancer" post="[ 30]. They are also less responsive to hormone"/>
   <result pre="tend to be more aggressive than other types of breast" exact="cancer" post="[ 30]. They are also less responsive to hormone"/>
   <result pre="kinase activity associated with HER2 [ 35]. Lapatinib decreases tumour-causing" exact="breast cancer" post="stem cells [ 36]. Lapatinib inhibits receptor signal processes"/>
   <result pre="activity associated with HER2 [ 35]. Lapatinib decreases tumour-causing breast" exact="cancer" post="stem cells [ 36]. Lapatinib inhibits receptor signal processes"/>
   <result pre="efforts to find other compounds which could effectively treat HER2-overexpressing" exact="breast cancer." post="In the present study, we investigated whether apigenin displays"/>
   <result pre="study, we investigated whether apigenin displays growth-suppressive activity on HER2-overexpressing" exact="breast cancer" post="cells. For this purpose, we tested the effects of"/>
   <result pre="we investigated whether apigenin displays growth-suppressive activity on HER2-overexpressing breast" exact="cancer" post="cells. For this purpose, we tested the effects of"/>
   <result pre="and FACS analysis to evaluate the cytotoxicity of apigenin in" exact="breast cancer" post="cells. We also investigated the mechanism by which apigenin"/>
   <result pre="FACS analysis to evaluate the cytotoxicity of apigenin in breast" exact="cancer" post="cells. We also investigated the mechanism by which apigenin"/>
   <result pre="activator of transcription 3 (STAT3) signalling pathway, leading to growth" exact="suppression" post="of HER2-expressing breast cancer cells. Since we report here"/>
   <result pre="3 (STAT3) signalling pathway, leading to growth suppression of HER2-expressing" exact="breast cancer" post="cells. Since we report here that apigenin may suppress"/>
   <result pre="(STAT3) signalling pathway, leading to growth suppression of HER2-expressing breast" exact="cancer" post="cells. Since we report here that apigenin may suppress"/>
   <result pre="cells. Since we report here that apigenin may suppress HER2-positive" exact="breast cancer," post="the present study advances human health. MATERIALS AND METHODS"/>
   <result pre="cell growth rate compared with 0% DMSO (no treatment) in" exact="breast cancer" post="cells (data not shown). JC-1 was obtained from Molecular"/>
   <result pre="growth rate compared with 0% DMSO (no treatment) in breast" exact="cancer" post="cells (data not shown). JC-1 was obtained from Molecular"/>
   <result pre="was purchased from Daeillab Service Co. Cell cultures BT-474 human" exact="breast cancer" post="cells (A.T.C.C.) were cultured in RPMI 1640 medium containing"/>
   <result pre="purchased from Daeillab Service Co. Cell cultures BT-474 human breast" exact="cancer" post="cells (A.T.C.C.) were cultured in RPMI 1640 medium containing"/>
   <result pre="from Cell Signaling Technology, Inc. Primary antibodies directed against B-cell" exact="lymphoma" post="2 (Bcl-2), Bcl-2-associated X protein (BAX), p53, phospho-p53 (Ser"/>
   <result pre="and MMP-9. These results also suggest that apigenin suppresses HER2-positive" exact="breast cancer" post="cell growth rate by inhibiting the JAK-STAT3-VEGF signalling pathway."/>
   <result pre="MMP-9. These results also suggest that apigenin suppresses HER2-positive breast" exact="cancer" post="cell growth rate by inhibiting the JAK-STAT3-VEGF signalling pathway."/>
   <result pre="the mechanism by which apigenin suppresses the growth of HER2-overexpressing" exact="breast cancer" post="cells. The purpose of the present study is whether"/>
   <result pre="mechanism by which apigenin suppresses the growth of HER2-overexpressing breast" exact="cancer" post="cells. The purpose of the present study is whether"/>
   <result pre="serve as a useful compound to prevent or treat HER2-overexpressing" exact="breast cancer." post="Apigenin suppressed the growth of BT-474 cells in a"/>
   <result pre="[ 39]. Dysregulation of caspases results in human diseases including" exact="cancer" post="and inflammatory disorders [ 39]. Hence, the investigation of"/>
   <result pre="the caspase-dependent apoptotic pathway is important to prevent or treat" exact="breast cancer." post="Apigenin increased the expression of active p53 (p-p53) suggesting"/>
   <result pre="of active p53 (p-p53) suggesting that this compound suppresses HER2-overexpressing" exact="breast cancer" post="cell growth via a p53-dependent manner. In agreement with"/>
   <result pre="active p53 (p-p53) suggesting that this compound suppresses HER2-overexpressing breast" exact="cancer" post="cell growth via a p53-dependent manner. In agreement with"/>
   <result pre="apigenin significantly inhibited the growth and induced apoptosis in HER2-overexpressing" exact="breast cancer" post="cells. This indicates that apigenin could be a useful"/>
   <result pre="significantly inhibited the growth and induced apoptosis in HER2-overexpressing breast" exact="cancer" post="cells. This indicates that apigenin could be a useful"/>
   <result pre="apigenin could be a useful natural therapy that inhibits HER2-overexpressing" exact="breast cancer." post="Apigenin could be a promising target for the treatment"/>
   <result pre="a promising target for the treatment and prevention of HER2-overexpressing" exact="breast cancer." post="The major questions remain about our study are whether"/>
   <result pre="whether apigenin overcomes drug resistance in the treatment of HER2-overexpressing" exact="breast cancer." post="This leads to further investigation. AUTHOR CONTRIBUTION Hye-Sook Seo"/>
   <result pre="numbers HI12C1889 and HI11C2110]. Abbreviations AIF apoptosis-inducing factor Bcl-2 B-cell" exact="lymphoma" post="2 BAX Bcl-2-associated X protein ER oestrogen receptor HRP"/>
   <result pre="C. Perez K. Partridge A. Implications of phytoestrogen intake for" exact="breast cancer" post="CA Cancer J. Clin. 2007 57 260 277 10.3322/CA.57.5.260"/>
   <result pre="Perez K. Partridge A. Implications of phytoestrogen intake for breast" exact="cancer" post="CA Cancer J. Clin. 2007 57 260 277 10.3322/CA.57.5.260"/>
   <result pre="Kim N.D. Kim G.Y. Gossypol suppresses telomerase activity in human" exact="leukemia" post="cells via regulating hTERT FEBS Lett. 2008 582 367"/>
   <result pre="6 Shukla S. Gupta S. Apigenin: a promising molecule for" exact="cancer" post="prevention Pharm. Res. 2010 27 962 978 10.1007/s11095-010-0089-7 20306120"/>
   <result pre="Pukkala E. Aromaa A. Dietary flavonoids and the risk of" exact="lung cancer" post="and other malignant neoplasms Am. J. Epidemiol. 1997 146"/>
   <result pre="E. Aromaa A. Dietary flavonoids and the risk of lung" exact="cancer" post="and other malignant neoplasms Am. J. Epidemiol. 1997 146"/>
   <result pre="E.J. Hollman P.C. Katan M.B. Kromhout D. Dietary flavonoids and" exact="cancer" post="risk in the Zutphen Elderly Study Nutr. Cancer 1994"/>
   <result pre="L. Montella M. Franceschi S. La Vecchia C. Flavonoids and" exact="ovarian cancer" post="risk: a case-control study in Italy Int. J. Cancer"/>
   <result pre="Montella M. Franceschi S. La Vecchia C. Flavonoids and ovarian" exact="cancer" post="risk: a case-control study in Italy Int. J. Cancer"/>
   <result pre="Montella M. Peterson J. Dwyer J. et al. Flavonoids and" exact="breast cancer" post="risk in Italy Cancer Epidemiol. Biomarkers Prev. 2005 14"/>
   <result pre="M. Peterson J. Dwyer J. et al. Flavonoids and breast" exact="cancer" post="risk in Italy Cancer Epidemiol. Biomarkers Prev. 2005 14"/>
   <result pre="Babcook M.A. Fu P. Maclennan G.T. Gupta S. Apigenin inhibits" exact="prostate cancer" post="progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway Carcinogenesis"/>
   <result pre="M.A. Fu P. Maclennan G.T. Gupta S. Apigenin inhibits prostate" exact="cancer" post="progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway Carcinogenesis"/>
   <result pre="G. Luo J. Shi X. Apigenin induces apoptosis in human" exact="leukemia" post="cells and exhibits anti-leukemic activity in vivo Mol. Cancer"/>
   <result pre="expression of vascular endothelial growth factor and angiogenesis in human" exact="lung cancer" post="cells: implication of chemoprevention of lung cancer Mol. Pharmacol."/>
   <result pre="of vascular endothelial growth factor and angiogenesis in human lung" exact="cancer" post="cells: implication of chemoprevention of lung cancer Mol. Pharmacol."/>
   <result pre="angiogenesis in human lung cancer cells: implication of chemoprevention of" exact="lung cancer" post="Mol. Pharmacol. 2005 68 635 643 15947208 15 Seo"/>
   <result pre="in human lung cancer cells: implication of chemoprevention of lung" exact="cancer" post="Mol. Pharmacol. 2005 68 635 643 15947208 15 Seo"/>
   <result pre="Ip S.W. Chung J.G. Apigenin induces caspase-dependent apoptosis in human" exact="lung cancer" post="A549 cells through Bax- and Bcl-2-triggered mitochondrial pathway Int."/>
   <result pre="S.W. Chung J.G. Apigenin induces caspase-dependent apoptosis in human lung" exact="cancer" post="A549 cells through Bax- and Bcl-2-triggered mitochondrial pathway Int."/>
   <result pre="the flavonoid apigenin on apoptotic pathway gene expression on the" exact="colon cancer" post="cell line (HT29) J. Med. Food 2011 14 1107"/>
   <result pre="flavonoid apigenin on apoptotic pathway gene expression on the colon" exact="cancer" post="cell line (HT29) J. Med. Food 2011 14 1107"/>
   <result pre="Ferreira C.V. Aoyama H. Peppelenbosch M.P. Cytotoxicity of apigenin on" exact="leukemia" post="cell lines: implications for prevention and therapy Cell Death"/>
   <result pre="M.S. Bell R.H. Jr Iwamura T. Adrian T.E. Apigenin inhibits" exact="pancreatic cancer" post="cell proliferation through G2/M cell cycle arrest Mol. Cancer"/>
   <result pre="Bell R.H. Jr Iwamura T. Adrian T.E. Apigenin inhibits pancreatic" exact="cancer" post="cell proliferation through G2/M cell cycle arrest Mol. Cancer"/>
   <result pre="Nielsen D.L. A systematic review of dual targeting in HER2-positive" exact="breast cancer" post="Cancer Treat. Rev. 2014 40 259 270 10.1016/j.ctrv.2013.09.002 24080156"/>
   <result pre="D.L. A systematic review of dual targeting in HER2-positive breast" exact="cancer" post="Cancer Treat. Rev. 2014 40 259 270 10.1016/j.ctrv.2013.09.002 24080156"/>
   <result pre="M. Tagliabue E. Biologic and therapeutic role of HER2 in" exact="cancer" post="Oncogene 2003 22 6570 6578 10.1038/sj.onc.1206779 14528282 31 Lipton"/>
   <result pre="her-2/neu level predicts decreased response to hormone therapy in metastatic" exact="breast cancer" post="J. Clin. Oncol. 2002 20 1467 1472 10.1200/JCO.20.6.1467 11896093"/>
   <result pre="level predicts decreased response to hormone therapy in metastatic breast" exact="cancer" post="J. Clin. Oncol. 2002 20 1467 1472 10.1200/JCO.20.6.1467 11896093"/>
   <result pre="K. Mitchell T. Vaughn J.P. Development of Herceptin resistance in" exact="breast cancer" post="cells Cytometry A 2004 57 86 93 10.1002/cyto.a.10095 14750129"/>
   <result pre="Mitchell T. Vaughn J.P. Development of Herceptin resistance in breast" exact="cancer" post="cells Cytometry A 2004 57 86 93 10.1002/cyto.a.10095 14750129"/>
   <result pre="6652 6659 10.1158/0008-5472.CAN-04-1168 15374980 36 Liu S. Wicha M.S. Targeting" exact="breast cancer" post="stem cells J. Clin. Oncol. 2010 28 4006 4012"/>
   <result pre="6659 10.1158/0008-5472.CAN-04-1168 15374980 36 Liu S. Wicha M.S. Targeting breast" exact="cancer" post="stem cells J. Clin. Oncol. 2010 28 4006 4012"/>
   <result pre="Molecular targets for apigenin-induced cell cycle arrest and apoptosis in" exact="prostate cancer" post="cell xenograft Mol. Cancer Ther. 2006 5 843 852"/>
   <result pre="targets for apigenin-induced cell cycle arrest and apoptosis in prostate" exact="cancer" post="cell xenograft Mol. Cancer Ther. 2006 5 843 852"/>
   <result pre="S. Pandey V.N. Barton B.E. STAT3 inhibition in prostate and" exact="pancreatic cancer" post="lines by STAT3 binding sequence oligonucleotides: differential activity between"/>
   <result pre="Pandey V.N. Barton B.E. STAT3 inhibition in prostate and pancreatic" exact="cancer" post="lines by STAT3 binding sequence oligonucleotides: differential activity between"/>
   <result pre="57 Tolaney S.M. Krop I.E. Mechanisms of trastuzumab resistance in" exact="breast cancer" post="Anticancer Agents Med. Chem. 2009 9 348 355 10.2174/1871520610909030348"/>
   <result pre="Tolaney S.M. Krop I.E. Mechanisms of trastuzumab resistance in breast" exact="cancer" post="Anticancer Agents Med. Chem. 2009 9 348 355 10.2174/1871520610909030348"/>
   <result pre="of biologic therapy and chemotherapy in hormone receptor- and HER2-positive" exact="breast cancer" post="Ann. Oncol. 2009 20 993 999 10.1093/annonc/mdn739 19150946"/>
   <result pre="biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast" exact="cancer" post="Ann. Oncol. 2009 20 993 999 10.1093/annonc/mdn739 19150946"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4708174/results/search/disease/results.xml">
   <result pre="4708174 doi: 10.2147/OTT.S89967 ott-9-203 : Review PI3K inhibitors as new" exact="cancer" post="therapeutics: implications for clinical trial design Massacesi Cristian 1"/>
   <result pre="However, a number of unanswered questions regarding PI3K inhibition in" exact="cancer" post="remain, including: what is the best approach for different"/>
   <result pre="trials that are utilizing these approaches in a range of" exact="cancer" post="types, including breast cancer, head and neck squamous cell"/>
   <result pre="utilizing these approaches in a range of cancer types, including" exact="breast cancer," post="head and neck squamous cell carcinoma, non-small cell lung"/>
   <result pre="breast cancer, head and neck squamous cell carcinoma, non-small cell" exact="lung carcinoma," post="lymphoma, and glioblastoma multiforme, is also described. Keywords PI3K–AKT–mTOR"/>
   <result pre="neck squamous cell carcinoma, non-small cell lung carcinoma, lymphoma, and" exact="glioblastoma multiforme," post="is also described. Keywords PI3K–AKT–mTOR pathway patient selection biomarkers"/>
   <result pre="trial design Introduction The PI3K–AKT–mTOR pathway is frequently activated in" exact="cancer" post="( Figure 1). 1 Mechanisms of PI3K–AKT–mTOR pathway activation"/>
   <result pre="node of this pathway, PI3K is an attractive target for" exact="cancer" post="therapy. A number of PI3K inhibitors are under clinical"/>
   <result pre="now approved in the USA for various hematologic malignancies, including" exact="chronic lymphocytic leukemia," post="relapsed follicular B-cell non-Hodgkin’s lymphoma (NHL), and relapsed small"/>
   <result pre="hematologic malignancies, including chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin’s" exact="lymphoma" post="(NHL), and relapsed small lymphocytic lymphoma, and was the"/>
   <result pre="unanswered questions remain regarding the role of PI3K inhibition in" exact="cancer" post="treatment. First, what is the best treatment strategy for"/>
   <result pre="help to fully realize the potential of PI3K inhibitors in" exact="cancer" post="treatment. Approaches for PI3K inhibitors in clinical development Buparlisib"/>
   <result pre="use by Novartis Oncology in the following tumor types. Breast" exact="cancer" post="PI3K–AKT–mTOR is the most frequently activated signaling pathway in"/>
   <result pre="cancer PI3K–AKT–mTOR is the most frequently activated signaling pathway in" exact="breast cancer," post="9 and has been validated as a therapeutic target"/>
   <result pre="paper. 10, 11 Buparlisib and alpelisib are under investigation in" exact="breast cancer," post="with various strategies applied according to the setting. Hormone"/>
   <result pre="with various strategies applied according to the setting. Hormone receptor-positive" exact="breast cancer" post="The Phase III trial of everolimus in combination with"/>
   <result pre="various strategies applied according to the setting. Hormone receptor-positive breast" exact="cancer" post="The Phase III trial of everolimus in combination with"/>
   <result pre="of everolimus in combination with exemestane in ER-positive, HER2-negative advanced" exact="breast cancer" post="(BOLERO-2; NCT00863655) demonstrated the value of PI3K–AKT–mTOR pathway inhibition"/>
   <result pre="everolimus in combination with exemestane in ER-positive, HER2-negative advanced breast" exact="cancer" post="(BOLERO-2; NCT00863655) demonstrated the value of PI3K–AKT–mTOR pathway inhibition"/>
   <result pre="demonstrated the value of PI3K–AKT–mTOR pathway inhibition in HR-positive advanced" exact="breast cancer." post="11 However, retrospective molecular analyses of the BOLERO-2 study"/>
   <result pre="PI3K inhibitor with letrozole in patients with ER-positive, HER2-negative metastatic" exact="breast cancer" post="refractory to endocrine therapy. 13 Of the 46 patients"/>
   <result pre="inhibitor with letrozole in patients with ER-positive, HER2-negative metastatic breast" exact="cancer" post="refractory to endocrine therapy. 13 Of the 46 patients"/>
   <result pre="(a selective ER downregulator) in patients with HR-positive, HER2-negative advanced" exact="breast cancer" post="that has progressed on/after aromatase inhibitor therapy, patient selection"/>
   <result pre="selective ER downregulator) in patients with HR-positive, HER2-negative advanced breast" exact="cancer" post="that has progressed on/after aromatase inhibitor therapy, patient selection"/>
   <result pre="patients with HR-positive, HER2-negative, aromatase inhibitor-treated, locally advanced or metastatic" exact="breast cancer" post="that has progressed on mTOR inhibitor therapy (NCT01633060). Due"/>
   <result pre="with HR-positive, HER2-negative, aromatase inhibitor-treated, locally advanced or metastatic breast" exact="cancer" post="that has progressed on mTOR inhibitor therapy (NCT01633060). Due"/>
   <result pre="PI3K pathway activation status. Preclinical studies have also shown that" exact="breast cancer" post="cell lines are sensitive to the PI3Kα inhibitor alpelisib"/>
   <result pre="pathway activation status. Preclinical studies have also shown that breast" exact="cancer" post="cell lines are sensitive to the PI3Kα inhibitor alpelisib"/>
   <result pre="multiple isoforms. As such, alpelisib is being investigated in several" exact="breast cancer" post="studies using targeted enrollment. The first-in-human Phase I study"/>
   <result pre="isoforms. As such, alpelisib is being investigated in several breast" exact="cancer" post="studies using targeted enrollment. The first-in-human Phase I study"/>
   <result pre="a subsequent study in combination with fulvestrant in ER-positive metastatic" exact="breast cancer" post="( PIK3CA-altered and PIK3CA wild-type tumors), used patient selection"/>
   <result pre="subsequent study in combination with fulvestrant in ER-positive metastatic breast" exact="cancer" post="( PIK3CA-altered and PIK3CA wild-type tumors), used patient selection"/>
   <result pre="trial in postmenopausal women, or men, with HR-positive, HER2-negative advanced" exact="breast cancer" post="that progressed after aromatase inhibitor treatment (SOLAR-1; NCT02437318). Patients"/>
   <result pre="in postmenopausal women, or men, with HR-positive, HER2-negative advanced breast" exact="cancer" post="that progressed after aromatase inhibitor treatment (SOLAR-1; NCT02437318). Patients"/>
   <result pre="with letrozole or exemestane in HR-positive, locally advanced, and/or metastatic" exact="breast cancer" post="(NCT01791478, NCT01870505). The nonselective, mandatory tissue collection approach is"/>
   <result pre="letrozole or exemestane in HR-positive, locally advanced, and/or metastatic breast" exact="cancer" post="(NCT01791478, NCT01870505). The nonselective, mandatory tissue collection approach is"/>
   <result pre="alpelisib plus paclitaxel in locally advanced or metastatic, chemotherapy-naïve, HER2-negative" exact="breast cancer" post="and recurrent, metastatic head and neck squamous cell carcinoma"/>
   <result pre="plus paclitaxel in locally advanced or metastatic, chemotherapy-naïve, HER2-negative breast" exact="cancer" post="and recurrent, metastatic head and neck squamous cell carcinoma"/>
   <result pre="the triplet combination of alpelisib, everolimus, and exemestane in advanced" exact="breast cancer" post="(NCT02077933). Enrollment for both studies is based on the"/>
   <result pre="triplet combination of alpelisib, everolimus, and exemestane in advanced breast" exact="cancer" post="(NCT02077933). Enrollment for both studies is based on the"/>
   <result pre="letrozole with or without buparlisib or alpelisib in HR-positive, HER2-negative" exact="breast cancer" post="is employing targeted enrollment (NCT01923168). Two cohorts are being"/>
   <result pre="with or without buparlisib or alpelisib in HR-positive, HER2-negative breast" exact="cancer" post="is employing targeted enrollment (NCT01923168). Two cohorts are being"/>
   <result pre="other mechanisms, such as alteration of PTEN or INPP4B. HER2-positive" exact="breast cancer" post="The PI3K–AKT–mTOR pathway is frequently activated in HER2-positive breast"/>
   <result pre="mechanisms, such as alteration of PTEN or INPP4B. HER2-positive breast" exact="cancer" post="The PI3K–AKT–mTOR pathway is frequently activated in HER2-positive breast"/>
   <result pre="breast cancer The PI3K–AKT–mTOR pathway is frequently activated in HER2-positive" exact="breast cancer." post="9 The Phase III trial of combined trastuzumab and"/>
   <result pre="and paclitaxel treatment with or without everolimus in HER2-positive advanced" exact="breast cancer" post="(BOLERO-1; NCT00876395), showed no improvement in progression-free survival (PFS)"/>
   <result pre="paclitaxel treatment with or without everolimus in HER2-positive advanced breast" exact="cancer" post="(BOLERO-1; NCT00876395), showed no improvement in progression-free survival (PFS)"/>
   <result pre="everolimus to trastuzumab and vinorelbine in women with HER2-positive metastatic" exact="breast cancer" post="in the Phase III BOLERO-3 trial (NCT01007942) achieved an"/>
   <result pre="to trastuzumab and vinorelbine in women with HER2-positive metastatic breast" exact="cancer" post="in the Phase III BOLERO-3 trial (NCT01007942) achieved an"/>
   <result pre="CLEOPATRA study of pertuzumab, trastuzumab, and docetaxel in first-line metastatic" exact="breast cancer" post="(NCT00567190) established PIK3CA mutation as a negative prognostic factor"/>
   <result pre="study of pertuzumab, trastuzumab, and docetaxel in first-line metastatic breast" exact="cancer" post="(NCT00567190) established PIK3CA mutation as a negative prognostic factor"/>
   <result pre="established PIK3CA mutation as a negative prognostic factor in HER2-positive" exact="breast cancer;" post="patients with tumors harboring PIK3CA mutations had a significantly"/>
   <result pre="neoadjuvant buparlisib in combination with trastuzumab and paclitaxel in HER2-positive" exact="breast cancer" post="with or without PIK3CA mutations (NeoPHOEBE; NCT01816594) to establish"/>
   <result pre="buparlisib in combination with trastuzumab and paclitaxel in HER2-positive breast" exact="cancer" post="with or without PIK3CA mutations (NeoPHOEBE; NCT01816594) to establish"/>
   <result pre="IB/II study has investigated buparlisib and trastuzumab in relapsed HER2-positive" exact="breast cancer" post="that has previously failed on trastuzumab, with no selective"/>
   <result pre="study has investigated buparlisib and trastuzumab in relapsed HER2-positive breast" exact="cancer" post="that has previously failed on trastuzumab, with no selective"/>
   <result pre="also being studied in a Phase IB/II trial in HER2-positive" exact="breast cancer" post="that has failed following trastuzumab therapy, again using the"/>
   <result pre="being studied in a Phase IB/II trial in HER2-positive breast" exact="cancer" post="that has failed following trastuzumab therapy, again using the"/>
   <result pre="antitumor activity in patients with recurrent HNSCC. 26 Non-small cell" exact="lung carcinoma" post="PI3K pathway alterations occur in a clinically significant proportion"/>
   <result pre="in a clinically significant proportion of patients with non-small cell" exact="lung carcinoma" post="(NSCLC). 27 In a large data set of patients"/>
   <result pre="NSCLC. Preclinical data suggest that PI3K–AKT–mTOR pathway inhibition can sensitize" exact="cancer" post="cells to chemotherapy, 29, 30 providing a rationale for"/>
   <result pre="which was approved in the USA for the treatment of" exact="chronic lymphocytic leukemia," post="relapsed follicular B-cell NHL, and relapsed small lymphocytic leukemia,"/>
   <result pre="NHL (NCT01719250) and relapsed or refractory diffuse large B-cell lymphoma," exact="mantle cell lymphoma," post="or follicular lymphoma (NCT01693614). In particular, the DCR was"/>
   <result pre="or refractory diffuse large B-cell lymphoma, mantle cell lymphoma, or" exact="follicular lymphoma" post="(NCT01693614). In particular, the DCR was 88% in patients"/>
   <result pre="refractory diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular" exact="lymphoma" post="(NCT01693614). In particular, the DCR was 88% in patients"/>
   <result pre="(NCT01693614). In particular, the DCR was 88% in patients with" exact="follicular lymphoma" post="treated with buparlisib monotherapy. 34 Glioblastoma multiforme The PI3K–AKT–mTOR"/>
   <result pre="In particular, the DCR was 88% in patients with follicular" exact="lymphoma" post="treated with buparlisib monotherapy. 34 Glioblastoma multiforme The PI3K–AKT–mTOR"/>
   <result pre="The PI3K–AKT–mTOR pathway is frequently activated by PTEN loss in" exact="glioblastoma multiforme" post="(GBM). 35 Buparlisib holds promise for the treatment of"/>
   <result pre="patient populations, and mechanisms of resistance in a variety of" exact="cancer" post="types. In addition, optimization of the platforms used to"/>
   <result pre="inhibitors as anticancer agents, and will shape the future of" exact="cancer" post="care. Disclosure All authors are employees of Novartis Pharmaceuticals"/>
   <result pre="3-kinase pathway: role in tumor progression and therapeutic implications in" exact="breast cancer" post="Breast Cancer Res 2011 13 6 224 22114931 10"/>
   <result pre="pathway: role in tumor progression and therapeutic implications in breast" exact="cancer" post="Breast Cancer Res 2011 13 6 224 22114931 10"/>
   <result pre="M et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced" exact="breast cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Lancet"/>
   <result pre="et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast" exact="cancer" post="(BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Lancet"/>
   <result pre="M Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2012 366 6 520 529"/>
   <result pre="Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2012 366 6 520 529"/>
   <result pre="IA Abramson VG Isakoff SJ et al. Stand up to" exact="cancer" post="phase IB study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole"/>
   <result pre="letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic" exact="breast cancer" post="J Clin Oncol 2014 32 12 1202 1209 24663045"/>
   <result pre="in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast" exact="cancer" post="J Clin Oncol 2014 32 12 1202 1209 24663045"/>
   <result pre="I Siu LL Clinical development of phosphatidylinositol 3-kinase inhibitors for" exact="cancer" post="treatment BMC Med 2012 10 161 23232172 15 Juric"/>
   <result pre="and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic" exact="breast cancer" post="(MBC) Cancer Res 2012 72 P6-10-07 17 Hurvitz SA"/>
   <result pre="safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast" exact="cancer" post="(MBC) Cancer Res 2012 72 P6-10-07 17 Hurvitz SA"/>
   <result pre="plus paclitaxel as first-line treatment for patients with HER2-positive advanced" exact="breast cancer" post="(BOLERO-1): a phase 3, randomised, double-blind, multicentre trial Lancet"/>
   <result pre="paclitaxel as first-line treatment for patients with HER2-positive advanced breast" exact="cancer" post="(BOLERO-1): a phase 3, randomised, double-blind, multicentre trial Lancet"/>
   <result pre="phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic" exact="breast cancer" post="(MBC) Poster presented at: 35th Annual San Antonio Breast"/>
   <result pre="III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast" exact="cancer" post="(MBC) Poster presented at: 35th Annual San Antonio Breast"/>
   <result pre="buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic" exact="breast cancer" post="that has progressed on trastuzumab-based therapy Clin Cancer Res"/>
   <result pre="plus trastuzumab in patients with HER2-positive advanced or metastatic breast" exact="cancer" post="that has progressed on trastuzumab-based therapy Clin Cancer Res"/>
   <result pre="H et al. Frequent mutation of the PI3K pathway in" exact="head and neck cancer" post="defines predictive biomarkers Cancer Discov 2013 3 7 761"/>
   <result pre="Frequent mutation of the PI3K pathway in head and neck" exact="cancer" post="defines predictive biomarkers Cancer Discov 2013 3 7 761"/>
   <result pre="Single agent activity of PIK3CA inhibitor BYL719 in a broad" exact="cancer" post="cell line panel Cancer Res 2012 72 3749 24"/>
   <result pre="R Targeting HER3 and PI3K in head and neck squamous" exact="cancer" post="cells Cancer Res 2013 73 4261 25 Mao C"/>
   <result pre="inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell" exact="cancer" post="of the head and neck (SCCHN) J Clin Oncol"/>
   <result pre="of PI3K pathway alterations in patients with metastatic non-small cell" exact="lung cancer" post="(NSCLC): findings from the international BASALT-1 study Poster presented"/>
   <result pre="PI3K pathway alterations in patients with metastatic non-small cell lung" exact="cancer" post="(NSCLC): findings from the international BASALT-1 study Poster presented"/>
   <result pre="of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell" exact="lung cancer" post="(NSCLC): results from the phase II BASALT-1 study J"/>
   <result pre="buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung" exact="cancer" post="(NSCLC): results from the phase II BASALT-1 study J"/>
   <result pre="K Asselin E AKT involvement in cisplatin chemoresistance of human" exact="uterine cancer" post="cells Gynecol Oncol 2004 94 3 785 795 15350374"/>
   <result pre="Asselin E AKT involvement in cisplatin chemoresistance of human uterine" exact="cancer" post="cells Gynecol Oncol 2004 94 3 785 795 15350374"/>
   <result pre="and PIK3CA mRNA amplification contributes to cisplatin resistance in an" exact="ovarian cancer" post="cell line Gynecol Oncol 2005 97 1 26 34"/>
   <result pre="PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian" exact="cancer" post="cell line Gynecol Oncol 2005 97 1 26 34"/>
   <result pre="blocks proliferation and induces cell death in diffuse large B-cell" exact="lymphoma" post="Leuk Lymphoma 2014 55 2 425 434 23721513 34"/>
   <result pre="in patients with relapsed and refractory diffuse large B-cell lymphoma," exact="mantle cell lymphoma" post="or follicular lymphoma Poster presented at: 56th ASH Annual"/>
   <result pre="with relapsed and refractory diffuse large B-cell lymphoma, mantle cell" exact="lymphoma" post="or follicular lymphoma Poster presented at: 56th ASH Annual"/>
   <result pre="and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or" exact="follicular lymphoma" post="Poster presented at: 56th ASH Annual Meeting and Exposition"/>
   <result pre="refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular" exact="lymphoma" post="Poster presented at: 56th ASH Annual Meeting and Exposition"/>
   <result pre="to overcome challenges in PI3K inhibitor development. Abbreviations: NSCLC, non-small-cell" exact="lung carcinoma;" post="GBM, glioblastoma multiforme."/>
   <result pre="in PI3K inhibitor development. Abbreviations: NSCLC, non-small-cell lung carcinoma; GBM," exact="glioblastoma multiforme." post=""/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4709394/results/search/disease/results.xml">
   <result pre="its license. Abstract In general, strategies for the treatment of" exact="cancer" post="in pregnancy should not differ significantly from the treatment"/>
   <result pre="targeted therapies currently used in selected cancers diagnosed during pregnancy:" exact="breast cancer," post="cervical cancer, Hodgkin's disease, melanoma, thyroid cancer, ovarian cancer,"/>
   <result pre="currently used in selected cancers diagnosed during pregnancy: breast cancer," exact="cervical cancer," post="Hodgkin's disease, melanoma, thyroid cancer, ovarian cancer, and colorectal"/>
   <result pre="diagnosed during pregnancy: breast cancer, cervical cancer, Hodgkin's disease, melanoma," exact="thyroid cancer," post="ovarian cancer, and colorectal cancer. cancer pregnant pregnancy-associated breast"/>
   <result pre="pregnancy: breast cancer, cervical cancer, Hodgkin's disease, melanoma, thyroid cancer," exact="ovarian cancer," post="and colorectal cancer. cancer pregnant pregnancy-associated breast cancer melanoma"/>
   <result pre="cervical cancer, Hodgkin's disease, melanoma, thyroid cancer, ovarian cancer, and" exact="colorectal cancer." post="cancer pregnant pregnancy-associated breast cancer melanoma lymphoma thyroid ovarian"/>
   <result pre="Hodgkin's disease, melanoma, thyroid cancer, ovarian cancer, and colorectal cancer." exact="cancer" post="pregnant pregnancy-associated breast cancer melanoma lymphoma thyroid ovarian colorectal"/>
   <result pre="thyroid cancer, ovarian cancer, and colorectal cancer. cancer pregnant pregnancy-associated" exact="breast cancer" post="melanoma lymphoma thyroid ovarian colorectal cancer Introduction Malignancies in"/>
   <result pre="cancer, ovarian cancer, and colorectal cancer. cancer pregnant pregnancy-associated breast" exact="cancer" post="melanoma lymphoma thyroid ovarian colorectal cancer Introduction Malignancies in"/>
   <result pre="cancer, and colorectal cancer. cancer pregnant pregnancy-associated breast cancer melanoma" exact="lymphoma" post="thyroid ovarian colorectal cancer Introduction Malignancies in pregnant women"/>
   <result pre="cancer. cancer pregnant pregnancy-associated breast cancer melanoma lymphoma thyroid ovarian" exact="colorectal cancer" post="Introduction Malignancies in pregnant women account for 0.05–0.1% of"/>
   <result pre="cancer pregnant pregnancy-associated breast cancer melanoma lymphoma thyroid ovarian colorectal" exact="cancer" post="Introduction Malignancies in pregnant women account for 0.05–0.1% of"/>
   <result pre="one in 1000–1500 pregnancies is complicated by the presence of" exact="cancer" post="in the mother [ 1, 2]. There is some"/>
   <result pre="reliable scientific data. In general, strategies for the treatment of" exact="cancer" post="in pregnancy should not differ significantly from the treatment"/>
   <result pre="the exposure to drugs and radiation. Following a diagnosis of" exact="cancer" post="in pregnancy, the decision about how to proceed should"/>
   <result pre="targeted therapies currently used in selected cancers diagnosed during pregnancy:" exact="breast cancer," post="cervical cancer, Hodgkin's disease, melanoma, and thyroid cancer. Therapeutic"/>
   <result pre="currently used in selected cancers diagnosed during pregnancy: breast cancer," exact="cervical cancer," post="Hodgkin's disease, melanoma, and thyroid cancer. Therapeutic options in"/>
   <result pre="during pregnancy: breast cancer, cervical cancer, Hodgkin's disease, melanoma, and" exact="thyroid cancer." post="Therapeutic options in pregnant patients with cancer Surgery Surgery"/>
   <result pre="melanoma, and thyroid cancer. Therapeutic options in pregnant patients with" exact="cancer" post="Surgery Surgery is the mainstay of treatment of solid"/>
   <result pre="Preterm births usually occur in cases of abdominal surgeries and" exact="peritonitis" post="[ 5, 6]. Since pain can also induce premature"/>
   <result pre="regard low birth weight, and about 33% of which regard" exact="pancytopenia" post="[ 9]. The most adverse antimetabolites are aminopterin, methotrexate,"/>
   <result pre="the foetus and may cause hearing deficiency. Etoposide can cause" exact="pancytopenia" post="in foetuses and newborns, and a higher risk of"/>
   <result pre="and third trimester of pregnancy in pregnant women treated for" exact="breast cancer" post="and ovarian cancer. If the use of chemotherapeutics during"/>
   <result pre="third trimester of pregnancy in pregnant women treated for breast" exact="cancer" post="and ovarian cancer. If the use of chemotherapeutics during"/>
   <result pre="of pregnancy in pregnant women treated for breast cancer and" exact="ovarian cancer." post="If the use of chemotherapeutics during pregnancy is necessary,"/>
   <result pre="doxorubicin, daunorubicin, adriamycin, idarubicin, epirubicin, dactinomycine, bleomycin, mitoxantrone Mid-trimester miscarriage," exact="transient neonatal neutropenia," post="and sepsis, IUGR [ 69]. Transient myelosuppression [ 70]."/>
   <result pre="chlorambucil, carmustine, dacarbazine Absent toes, eye abnormalities, low-set ears, and" exact="cleft palate" post="[ 71]. Oesophageal atresia, abnormal inferior vena cava ["/>
   <result pre="Oesophageal atresia, abnormal inferior vena cava [ 72]. Pyloric stenosis," exact="renal agenesis," post="and liver calcifications [ 73]. Antimetabolites: Methotrexate, 5-fluorouracil, aminopterin,"/>
   <result pre="weeks 1 to 8 mental retardation, multiorgan malformation, growth retardation," exact="microcephaly" post="weeks 8 to 15 mental retardation, microcephaly, possible skeletal"/>
   <result pre="structural abnormalities, growth retardation still possible, major risks are increased" exact="cancer" post="risk and potential effect on fertility Treatment of tumours"/>
   <result pre="effect on fertility Treatment of tumours occurring during pregnancy Breast" exact="cancer" post="Pregnancy-associated breast cancer (PABC) is defined as breast cancer"/>
   <result pre="fertility Treatment of tumours occurring during pregnancy Breast cancer Pregnancy-associated" exact="breast cancer" post="(PABC) is defined as breast cancer occurring at any"/>
   <result pre="Treatment of tumours occurring during pregnancy Breast cancer Pregnancy-associated breast" exact="cancer" post="(PABC) is defined as breast cancer occurring at any"/>
   <result pre="pregnancy Breast cancer Pregnancy-associated breast cancer (PABC) is defined as" exact="breast cancer" post="occurring at any time during pregnancy, lactation, or within"/>
   <result pre="Breast cancer Pregnancy-associated breast cancer (PABC) is defined as breast" exact="cancer" post="occurring at any time during pregnancy, lactation, or within"/>
   <result pre="during pregnancy contribute to the delay in the diagnosis of" exact="breast cancer" post="in pregnant women, amounting to an average of 5–7"/>
   <result pre="pregnancy contribute to the delay in the diagnosis of breast" exact="cancer" post="in pregnant women, amounting to an average of 5–7"/>
   <result pre="safe throughout pregnancy. Surgery is the primary treatment for early" exact="breast cancer." post="Modified radical mastectomy is the standard treatment in the"/>
   <result pre="prospective study [ 22, 23] involving 12 pregnant patients with" exact="breast cancer" post="who underwent the removal of lymph nodes with a"/>
   <result pre="study [ 22, 23] involving 12 pregnant patients with breast" exact="cancer" post="who underwent the removal of lymph nodes with a"/>
   <result pre="mental retardation, growth retardation, haematological disorders, and can induce childhood" exact="cancer" post="[ 26, 27]. An alternative to external beam radiotherapy"/>
   <result pre="tamoxifen [ 31]. In women with locally advanced or metastatic" exact="breast cancer" post="with overexpression of HER2, after failure of at least"/>
   <result pre="[ 31]. In women with locally advanced or metastatic breast" exact="cancer" post="with overexpression of HER2, after failure of at least"/>
   <result pre="cases have been described. Treatment with trastuzumab is associated with" exact="oligohydramnios" post="(sometimes severe), lung aplasia, dysplastic kidney, and death shortly"/>
   <result pre="data on breast reconstructive surgery in pregnancy are available. Cervical" exact="cancer" post="Cervical cancer is the most frequent gynaecological tumour diagnosed"/>
   <result pre="breast reconstructive surgery in pregnancy are available. Cervical cancer Cervical" exact="cancer" post="is the most frequent gynaecological tumour diagnosed in pregnant"/>
   <result pre="pregnant women. As many as 1% of women diagnosed with" exact="cervical cancer" post="are pregnant. The role of pregnancy in the carcinogenesis"/>
   <result pre="women. As many as 1% of women diagnosed with cervical" exact="cancer" post="are pregnant. The role of pregnancy in the carcinogenesis"/>
   <result pre="are pregnant. The role of pregnancy in the carcinogenesis of" exact="cervical cancer," post="as well as in the treatment and prognosis, is"/>
   <result pre="The survival rates of pregnant and non-pregnant women with invasive" exact="cervical cancer" post="are similar [ 35]. Treatment during pregnancy can be"/>
   <result pre="survival rates of pregnant and non-pregnant women with invasive cervical" exact="cancer" post="are similar [ 35]. Treatment during pregnancy can be"/>
   <result pre="following circumstances: intention to maintain the pregnancy, gestational age, and" exact="cancer" post="stage. During pregnancy, surgical interventions in the pelvic area"/>
   <result pre="from an oncological perspective [ 36]. In the case of" exact="cervical cancer" post="diagnosed after the 20 th week of pregnancy, the"/>
   <result pre="an oncological perspective [ 36]. In the case of cervical" exact="cancer" post="diagnosed after the 20 th week of pregnancy, the"/>
   <result pre="of the impact of this delay on the results of" exact="cancer" post="treatment. However, possible threats related with cancer treatment should"/>
   <result pre="the results of cancer treatment. However, possible threats related with" exact="cancer" post="treatment should be discussed with the patient. If a"/>
   <result pre="be discussed with the patient. If a woman diagnosed with" exact="cervical cancer" post="in the first trimester of pregnancy wishes to maintain"/>
   <result pre="discussed with the patient. If a woman diagnosed with cervical" exact="cancer" post="in the first trimester of pregnancy wishes to maintain"/>
   <result pre="10–15 fractions of RT [ 14]. In pregnant women with" exact="cervical cancer" post="at stage IA2–IB1, lymph node biopsy should be performed"/>
   <result pre="fractions of RT [ 14]. In pregnant women with cervical" exact="cancer" post="at stage IA2–IB1, lymph node biopsy should be performed"/>
   <result pre="of pregnancy was normal [ 39]. In the case of" exact="cervical cancer" post="diagnosed in the first trimester of pregnancy, the treatment"/>
   <result pre="pregnancy was normal [ 39]. In the case of cervical" exact="cancer" post="diagnosed in the first trimester of pregnancy, the treatment"/>
   <result pre="postponed to the second trimester. Treatment used in patients with" exact="cervical cancer" post="diagnosed in the second trimester of pregnancy depends on"/>
   <result pre="to the second trimester. Treatment used in patients with cervical" exact="cancer" post="diagnosed in the second trimester of pregnancy depends on"/>
   <result pre="the second trimester of pregnancy depends on tumour stage. Cervical" exact="cancer" post="diagnosed in the third trimester is an indication for"/>
   <result pre="foetal maturity, followed by standard therapy [ 42]. Lymphomas Hodgkin's" exact="lymphoma" post="is the most common haematological malignancy reported during pregnancy."/>
   <result pre="metastases requires close observation of children for the development of" exact="cancer" post="[ 46]. Primary treatment is based on a surgery"/>
   <result pre="of no practical use in such cases [ 49]. Thyroid" exact="cancer" post="Thyroid cancer has a reported incidence of 14 cases"/>
   <result pre="practical use in such cases [ 49]. Thyroid cancer Thyroid" exact="cancer" post="has a reported incidence of 14 cases per 100,000"/>
   <result pre="second trimester of pregnancy. Patients with early-stage follicular and papillary" exact="thyroid cancer" post="are candidates for delaying the surgery because the lesions"/>
   <result pre="trimester of pregnancy. Patients with early-stage follicular and papillary thyroid" exact="cancer" post="are candidates for delaying the surgery because the lesions"/>
   <result pre="or decreased survival have been reported in pregnant patients with" exact="thyroid cancer," post="as compared with non-pregnant patients [ 52]. Ovarian cancer"/>
   <result pre="thyroid cancer, as compared with non-pregnant patients [ 52]. Ovarian" exact="cancer" post="Ovarian cancer in pregnancy is rare and has occurred"/>
   <result pre="as compared with non-pregnant patients [ 52]. Ovarian cancer Ovarian" exact="cancer" post="in pregnancy is rare and has occurred in 1"/>
   <result pre="the other ovary is intact. However, in the case of" exact="ovarian cancer," post="cytoreductive surgery should only be considered at stage IA/IB"/>
   <result pre="be considered at stage IA/IB [ 53]. Advanced stages of" exact="ovarian cancer" post="can be treated using various methods, including basic cytoreductive"/>
   <result pre="considered at stage IA/IB [ 53]. Advanced stages of ovarian" exact="cancer" post="can be treated using various methods, including basic cytoreductive"/>
   <result pre="[ 54– 56]. Maintaining the pregnancy is very difficult if" exact="cancer" post="has been diagnosed before the 20 th week. After"/>
   <result pre="carboplatin + paclitaxel until foetal maturity [ 57, 58]. Colorectal" exact="cancer" post="Colorectal cancer in pregnancy is rare, and has occurred"/>
   <result pre="paclitaxel until foetal maturity [ 57, 58]. Colorectal cancer Colorectal" exact="cancer" post="in pregnancy is rare, and has occurred in 1"/>
   <result pre="59]. The treatment and the prognosis in pregnant patients with" exact="colorectal cancer" post="do not differ from those in the general population."/>
   <result pre="The treatment and the prognosis in pregnant patients with colorectal" exact="cancer" post="do not differ from those in the general population."/>
   <result pre="or due to the pregnancy, and the patient's decision. Unfortunately," exact="colorectal cancer" post="is often diagnosed during pregnancy at an advanced stage,"/>
   <result pre="due to the pregnancy, and the patient's decision. Unfortunately, colorectal" exact="cancer" post="is often diagnosed during pregnancy at an advanced stage,"/>
   <result pre="week of pregnancy [ 61]. It has been proposed that" exact="colorectal cancer" post="surgery be conducted immediately after uncomplicated Caesarean section ["/>
   <result pre="of pregnancy [ 61]. It has been proposed that colorectal" exact="cancer" post="surgery be conducted immediately after uncomplicated Caesarean section ["/>
   <result pre="5-fluorouracil (5-FU) used as standard treatment at stage III of" exact="colorectal cancer" post="causes a high risk of teratogenic effect [ 60]."/>
   <result pre="(5-FU) used as standard treatment at stage III of colorectal" exact="cancer" post="causes a high risk of teratogenic effect [ 60]."/>
   <result pre="its derivative chemotherapeutics are also used in the treatment of" exact="colorectal cancer," post="but they are not recommended during breastfeeding or pregnancy."/>
   <result pre="Zahir N Farquharson M Conflicting priorities in surgical intervention for" exact="cancer" post="in pregnancy Lancet Oncol 2007 8 536 44 17540305"/>
   <result pre="S Kanz L Marini P Mayer F Pregnancy after successful" exact="cancer" post="treatment: what needs to be considered Onkologie 2012 35"/>
   <result pre="Amant F Loibl S Neven P Van Calsteren K Breast" exact="cancer" post="in pregnancy Lancet 2012 379 570 9 22325662 12"/>
   <result pre="16 Martin DD Review of radiation therapy in the pregnant" exact="cancer" post="patient Clin Obstet Gynecol 2011 54 591 601 22031249"/>
   <result pre="54 591 601 22031249 17 Litton JK Theriault RL Breast" exact="cancer" post="and pregnancy: current concepts in diagnosis and treatment Oncologist"/>
   <result pre="McGuire WL Estrogen receptor, progesterone receptor, and HER2/neu protein in" exact="breast cancer" post="from pregnant patients Cancer 1993 71 2499 506 8095853"/>
   <result pre="WL Estrogen receptor, progesterone receptor, and HER2/neu protein in breast" exact="cancer" post="from pregnant patients Cancer 1993 71 2499 506 8095853"/>
   <result pre="20 Pirvulescu C Mau C Schultz H et al. Breast" exact="cancer" post="during pregnancy: an interdisciplinary approach in our institution Breast"/>
   <result pre="E Merlot B Poncelet E Collinet P Vinatier D Breast" exact="cancer" post="during pregnancy Eur J Obstet Gynecol Reprod Biol 2009"/>
   <result pre="al. Safety of sentinel node biopsy in pregnant patients with" exact="breast cancer" post="Ann Oncol 2004 15 1348 51 15319240 23 Gentilini"/>
   <result pre="Safety of sentinel node biopsy in pregnant patients with breast" exact="cancer" post="Ann Oncol 2004 15 1348 51 15319240 23 Gentilini"/>
   <result pre="et al. Sentinel lymph node biopsy in pregnant patients with" exact="breast cancer" post="Eur J Nucl Med Mol Imaging 2010 37 78"/>
   <result pre="al. Sentinel lymph node biopsy in pregnant patients with breast" exact="cancer" post="Eur J Nucl Med Mol Imaging 2010 37 78"/>
   <result pre="TL Meyers MP Dupont EL Berman CG Cox CE Pregnancy-associated" exact="breast cancer" post="patients can safely undergo lymphatic mapping Breast J 2008"/>
   <result pre="Meyers MP Dupont EL Berman CG Cox CE Pregnancy-associated breast" exact="cancer" post="patients can safely undergo lymphatic mapping Breast J 2008"/>
   <result pre="Kruper L Sentinel lymph node biopsy indications and controversies in" exact="breast cancer" post="Maturitas 2011 69 7 10 21411254 26 Amant F"/>
   <result pre="L Sentinel lymph node biopsy indications and controversies in breast" exact="cancer" post="Maturitas 2011 69 7 10 21411254 26 Amant F"/>
   <result pre="Amant F Deckers S Van Calsteren K et al. Breast" exact="cancer" post="in pregnancy: recommendations of an international consensus meeting Eur"/>
   <result pre="Jr Del Mastro L Scarfone G Peccatori FA Treatment of" exact="breast cancer" post="during pregnancy: regimen selection, pregnancy monitoring and more Breast"/>
   <result pre="Del Mastro L Scarfone G Peccatori FA Treatment of breast" exact="cancer" post="during pregnancy: regimen selection, pregnancy monitoring and more Breast"/>
   <result pre="beam intraoperative radiotherapy (ELIOT) safe in pregnant women with early" exact="breast cancer?" post="In vivo dosimetry to assess fetal dose Ann Surg"/>
   <result pre="29 Martin DD Review of radiation therapy in the pregnant" exact="cancer" post="patient Clin Obstet Gynecol 2011 54 591 601 22031249"/>
   <result pre="N Paesmans M et al. Prognostic impact of pregnancy after" exact="breast cancer" post="according to estrogen receptor status: a multicenter retrospective study"/>
   <result pre="Paesmans M et al. Prognostic impact of pregnancy after breast" exact="cancer" post="according to estrogen receptor status: a multicenter retrospective study"/>
   <result pre="SJ Herceptin (trastuzumab) therapy in a twin pregnancy with associated" exact="oligohydramnios" post="Am J Obstet Gynecol 2009 201 13 14 33"/>
   <result pre="F Brepoels L Halaska MJ Gziri MM Calsteren KV Gynaecologic" exact="cancer" post="complicating pregnancy: an overview Best Pract Res Clin Obstet"/>
   <result pre="et al. Neoadjuvant chemotherapy followed by radical hysterectomy for invasive" exact="cervical cancer" post="diagnosed during pregnancy: report of a case and review"/>
   <result pre="al. Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical" exact="cancer" post="diagnosed during pregnancy: report of a case and review"/>
   <result pre="N Holschneider CH Neoadjuvant cisplatin and radical cesarean hysterectomy for" exact="cervical cancer" post="in pregnancy Nat Clin Pract Oncol 2007 4 375"/>
   <result pre="Holschneider CH Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical" exact="cancer" post="in pregnancy Nat Clin Pract Oncol 2007 4 375"/>
   <result pre="22325663 44 Cohen JB Blum KA Evaluation and management of" exact="lymphoma" post="and leukemia in pregnancy Clin Obstet Gynecol 2011 54"/>
   <result pre="Cohen JB Blum KA Evaluation and management of lymphoma and" exact="leukemia" post="in pregnancy Clin Obstet Gynecol 2011 54 556 66"/>
   <result pre="about the management with systemic treatment of pregnant women with" exact="cancer" post="Eur J Cancer 2011 47 348 52 50 Smith"/>
   <result pre="associated with obstetric delivery: results of linkage with the California" exact="cancer" post="registry Am J Obstet Gynecol 2003 189 1128 35"/>
   <result pre="175 85 52 Moosa M Mazzaferri EL Outcome of differentiated" exact="thyroid cancer" post="diagnosed in pregnant women J Clin Endocrinol Metab 1997"/>
   <result pre="85 52 Moosa M Mazzaferri EL Outcome of differentiated thyroid" exact="cancer" post="diagnosed in pregnant women J Clin Endocrinol Metab 1997"/>
   <result pre="Behnamfar F Preservation of pregnancy in a patient with advanced" exact="ovarian cancer" post="at 20 weeks of gestation: case report and literature"/>
   <result pre="F Preservation of pregnancy in a patient with advanced ovarian" exact="cancer" post="at 20 weeks of gestation: case report and literature"/>
   <result pre="Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial" exact="ovarian cancer" post="Obstet Gynecol 2003 102 1200 2 14607056 57 Picone"/>
   <result pre="and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian" exact="cancer" post="Obstet Gynecol 2003 102 1200 2 14607056 57 Picone"/>
   <result pre="J Perez A Sanchez R Parrilla JJ Abad L Ovarian" exact="cancer" post="during pregnancy: analysis of 15 cases Gynecol Oncol 2007"/>
   <result pre="73 16105538 62 Schirmer B Kouretas PC Cameron JL Gallstone" exact="pancreatitis" post="Current surgical therapy 2001 7th ed Philadelphia, PA Mosby"/>
   <result pre="Jones A Shannon C Galani E Ellis PA Chemotherapy for" exact="breast cancer" post="during pregnancy: an 18-year experience from five London teaching"/>
   <result pre="A Shannon C Galani E Ellis PA Chemotherapy for breast" exact="cancer" post="during pregnancy: an 18-year experience from five London teaching"/>
   <result pre="Schüler-Faccini L Assessment of fetal risk associated with exposure to" exact="cancer" post="chemotherapy during pregnancy: a multicenter study Braz J Med"/>
   <result pre="S Han SN von Minckwitz G et al. Treatment of" exact="breast cancer" post="during pregnancy: an observational study Lancet Oncol 2012 13"/>
   <result pre="Han SN von Minckwitz G et al. Treatment of breast" exact="cancer" post="during pregnancy: an observational study Lancet Oncol 2012 13"/>
   <result pre="KM Johnson PH Gordon N et al. Treatment of pregnant" exact="breast cancer" post="patients and outcomes of children exposed to chemotherapy in"/>
   <result pre="Johnson PH Gordon N et al. Treatment of pregnant breast" exact="cancer" post="patients and outcomes of children exposed to chemotherapy in"/>
   <result pre="SJ Herceptin (trastuzumab) therapy in a twin pregnancy with associated" exact="oligohydramnios" post="Am J Obstet Gynecol 2009 201 e13 e14 19398090"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4717619/results/search/disease/results.xml">
   <result pre="Central London pmcid: 4717619 665 doi: 10.1186/s13058-015-0665-1 : Review Breast" exact="cancer" post="brain metastases: biology and new clinical perspectives Witzel Isabell"/>
   <result pre="Because of improvements in the treatment of patients with metastatic" exact="breast cancer," post="the development of brain metastases (BM) has become a"/>
   <result pre="limitation of life expectancy and quality of life for many" exact="breast cancer" post="patients. The improvement of management strategies for BM is"/>
   <result pre="of life expectancy and quality of life for many breast" exact="cancer" post="patients. The improvement of management strategies for BM is"/>
   <result pre="to metastasize. In this review, we summarize the biology of" exact="breast cancer" post="that has spread into the brain and discuss the"/>
   <result pre="metastasize. In this review, we summarize the biology of breast" exact="cancer" post="that has spread into the brain and discuss the"/>
   <result pre="Because of improvements in the treatment of patients with metastatic" exact="breast cancer," post="long-term survival can be achieved. Nevertheless, 15–30 % of"/>
   <result pre="can be achieved. Nevertheless, 15–30 % of patients with metastatic" exact="breast cancer" post="will develop brain metastases (BM) during the course of"/>
   <result pre="be achieved. Nevertheless, 15–30 % of patients with metastatic breast" exact="cancer" post="will develop brain metastases (BM) during the course of"/>
   <result pre="TGF transforming growth factor, VEGF vascular endothelial growth factor Breast" exact="cancer" post="is the second most common cause for the development"/>
   <result pre="second most common cause for the development of BM after" exact="lung cancer." post="Lung and breast cancer BM are more commonly diagnosed"/>
   <result pre="for the development of BM after lung cancer. Lung and" exact="breast cancer" post="BM are more commonly diagnosed than primary brain tumors."/>
   <result pre="the development of BM after lung cancer. Lung and breast" exact="cancer" post="BM are more commonly diagnosed than primary brain tumors."/>
   <result pre="diagnosed than primary brain tumors. The incidence of BM in" exact="breast cancer" post="patients is rising, probably because many patients survive longer"/>
   <result pre="than primary brain tumors. The incidence of BM in breast" exact="cancer" post="patients is rising, probably because many patients survive longer"/>
   <result pre="(Table 1). Table 1 Frequency of site-specific metastasis among metastatic" exact="breast cancer" post="patients Site of relapse Brain (%) Bone (%) Lung"/>
   <result pre="1). Table 1 Frequency of site-specific metastasis among metastatic breast" exact="cancer" post="patients Site of relapse Brain (%) Bone (%) Lung"/>
   <result pre="12, 14] HER human epidermal growth factor receptor, TNBC triple-negative" exact="breast cancer" post="Distant metastasis formation is a multistep process and is"/>
   <result pre="14] HER human epidermal growth factor receptor, TNBC triple-negative breast" exact="cancer" post="Distant metastasis formation is a multistep process and is"/>
   <result pre="an increased risk of BM have been identified in a" exact="breast cancer" post="scenario. Younger patients, poorly differentiated tumors (high grade), hormone"/>
   <result pre="increased risk of BM have been identified in a breast" exact="cancer" post="scenario. Younger patients, poorly differentiated tumors (high grade), hormone"/>
   <result pre="[ 1]. Human epidermal growth factor receptor (HER)2-positive and triple-negative" exact="breast cancer" post="(TNBC) patients also have a higher risk of BM"/>
   <result pre="1]. Human epidermal growth factor receptor (HER)2-positive and triple-negative breast" exact="cancer" post="(TNBC) patients also have a higher risk of BM"/>
   <result pre="also have a higher risk of BM compared with luminal" exact="cancer" post="patients [ 4, 5]. In HER2-positive and TNBC patients,"/>
   <result pre="only 4.9 months (95 % CI: 3.9–5.9). Site-specific metastasis and" exact="breast cancer" post="subtypes Steven Paget [ 8] proposed the so-called &quot;seed"/>
   <result pre="4.9 months (95 % CI: 3.9–5.9). Site-specific metastasis and breast" exact="cancer" post="subtypes Steven Paget [ 8] proposed the so-called &quot;seed"/>
   <result pre="cells appear to have a propensity towards the brain, whereas" exact="prostate cancer" post="rarely metastasizes to the brain [ 10]. Interestingly, although"/>
   <result pre="appear to have a propensity towards the brain, whereas prostate" exact="cancer" post="rarely metastasizes to the brain [ 10]. Interestingly, although"/>
   <result pre="to the brain [ 10]. Interestingly, although lung adenocarcinomas and" exact="breast cancer" post="share similar organ tropism (metastatic patterns), they have strikingly"/>
   <result pre="the brain [ 10]. Interestingly, although lung adenocarcinomas and breast" exact="cancer" post="share similar organ tropism (metastatic patterns), they have strikingly"/>
   <result pre="patterns), they have strikingly different metastatic rates [ 1]. In" exact="lung cancer" post="BM occur usually within 2 years after the primary"/>
   <result pre="they have strikingly different metastatic rates [ 1]. In lung" exact="cancer" post="BM occur usually within 2 years after the primary"/>
   <result pre="usually within 2 years after the primary diagnosis, whereas in" exact="breast cancer" post="BM are usually associated with the metastatic stage of"/>
   <result pre="within 2 years after the primary diagnosis, whereas in breast" exact="cancer" post="BM are usually associated with the metastatic stage of"/>
   <result pre="detected rather early in the course of the disease. Different" exact="breast cancer" post="subtypes have a very different likelihood of metastasizing to"/>
   <result pre="rather early in the course of the disease. Different breast" exact="cancer" post="subtypes have a very different likelihood of metastasizing to"/>
   <result pre="al. [ 12] investigated the metastatic patterns in 3726 early-stage" exact="breast cancer" post="patients diagnosed between 1986 and 1992. The luminal tumors"/>
   <result pre="[ 12] investigated the metastatic patterns in 3726 early-stage breast" exact="cancer" post="patients diagnosed between 1986 and 1992. The luminal tumors"/>
   <result pre="whereas BM were most commonly found among HER2 and basal-like" exact="breast cancer." post="The gene expression profiling of these primary tumors showed"/>
   <result pre="basal-like tumors as well as brain metastatic tissue (irrespective of" exact="breast cancer" post="subtype) showed upregulation of WNT signaling and upregulation of"/>
   <result pre="tumors as well as brain metastatic tissue (irrespective of breast" exact="cancer" post="subtype) showed upregulation of WNT signaling and upregulation of"/>
   <result pre="2 Reported frequencies for the first site of metastasis among" exact="breast cancer" post="patients Site of metastasis Brain (%) Bone (%) Lung"/>
   <result pre="Reported frequencies for the first site of metastasis among breast" exact="cancer" post="patients Site of metastasis Brain (%) Bone (%) Lung"/>
   <result pre="human epidermal growth factor receptor, ND not determined, TNBC triple-negative" exact="breast cancer" post="A large study by Sihto et al. [ 13]"/>
   <result pre="epidermal growth factor receptor, ND not determined, TNBC triple-negative breast" exact="cancer" post="A large study by Sihto et al. [ 13]"/>
   <result pre="(CD133). Interestingly, both nestin and CD133 are considered to be" exact="cancer" post="stem cell (CSC) markers for glioblastoma [ 15]. Similarly,"/>
   <result pre="future therapeutic strategies. Local and systemic treatment of BM Historically," exact="breast cancer" post="BM were treated with whole-brain radiation therapy (WBRT) or"/>
   <result pre="therapeutic strategies. Local and systemic treatment of BM Historically, breast" exact="cancer" post="BM were treated with whole-brain radiation therapy (WBRT) or"/>
   <result pre="criterion for nearly all clinical trials on treatment in metastatic" exact="breast cancer." post="Studies examining chemotherapy regimens usually included various solid tumors"/>
   <result pre="ideal treatment strategy. Although trastuzumab is effective for treating HER2-positive" exact="breast cancer," post="it is not clear whether it also acts in"/>
   <result pre="concentration approach that of systemic metastases [ 23]. In HER2-positive" exact="breast cancer" post="patients who progressed after WBRT, lapatinib monotherapy showed minor"/>
   <result pre="approach that of systemic metastases [ 23]. In HER2-positive breast" exact="cancer" post="patients who progressed after WBRT, lapatinib monotherapy showed minor"/>
   <result pre="efficacy in a phase I trial including 13 patients with" exact="breast cancer" post="BM [ 32]. Some agents show moderate activity in"/>
   <result pre="in a phase I trial including 13 patients with breast" exact="cancer" post="BM [ 32]. Some agents show moderate activity in"/>
   <result pre="would be of high interest to understand the nature of" exact="breast cancer" post="tumor cells that outgrow in the brain in an"/>
   <result pre="be of high interest to understand the nature of breast" exact="cancer" post="tumor cells that outgrow in the brain in an"/>
   <result pre="an effort to prevent this process. Signaling pathways involved in" exact="breast cancer" post="brain metastasis Among the different pathways associated with breast"/>
   <result pre="effort to prevent this process. Signaling pathways involved in breast" exact="cancer" post="brain metastasis Among the different pathways associated with breast"/>
   <result pre="breast cancer brain metastasis Among the different pathways associated with" exact="breast cancer" post="BM formation, we will briefly discuss two stem cell"/>
   <result pre="cancer brain metastasis Among the different pathways associated with breast" exact="cancer" post="BM formation, we will briefly discuss two stem cell"/>
   <result pre="the expression profiles of different metastatic variants of the MDA-MB-435" exact="breast cancer" post="cell line. The cell line with enhanced BM properties"/>
   <result pre="expression profiles of different metastatic variants of the MDA-MB-435 breast" exact="cancer" post="cell line. The cell line with enhanced BM properties"/>
   <result pre="HER3) and their downstream mediators (PTEN, PIK3CA, AKT, mTOR) in" exact="breast cancer" post="BM [ 37– 40]. We performed a genome-wide screening"/>
   <result pre="and their downstream mediators (PTEN, PIK3CA, AKT, mTOR) in breast" exact="cancer" post="BM [ 37– 40]. We performed a genome-wide screening"/>
   <result pre="of the genomic and transcriptional aberration patterns in BM from" exact="breast cancer" post="patients and showed that BM, in general, display similar"/>
   <result pre="the genomic and transcriptional aberration patterns in BM from breast" exact="cancer" post="patients and showed that BM, in general, display similar"/>
   <result pre="44]. Additionally, HER3 overexpression has been associated with BM in" exact="breast cancer" post="patients [ 45]. In contrast to EGFR and HER2,"/>
   <result pre="Additionally, HER3 overexpression has been associated with BM in breast" exact="cancer" post="patients [ 45]. In contrast to EGFR and HER2,"/>
   <result pre="has been shown to induce the transendothelial migration of HER2/HER3-positive" exact="breast cancer" post="cell lines across a tight barrier of primary brain"/>
   <result pre="been shown to induce the transendothelial migration of HER2/HER3-positive breast" exact="cancer" post="cell lines across a tight barrier of primary brain"/>
   <result pre="expression of RECK, a gene found to be downregulated in" exact="breast cancer" post="BM [ 48]. Breast cancer patients with BM show"/>
   <result pre="of RECK, a gene found to be downregulated in breast" exact="cancer" post="BM [ 48]. Breast cancer patients with BM show"/>
   <result pre="to be downregulated in breast cancer BM [ 48]. Breast" exact="cancer" post="patients with BM show less circulating tumor cells (CTCs)"/>
   <result pre="tumor cells (CTCs) when detected via epithelial-like properties compared with" exact="breast cancer" post="patients with other metastases [ 49]. Zhang et al."/>
   <result pre="cells (CTCs) when detected via epithelial-like properties compared with breast" exact="cancer" post="patients with other metastases [ 49]. Zhang et al."/>
   <result pre="intensive bidirectional crosstalk between the ERBB and notch pathways in" exact="breast cancer," post="indicating that the simultaneous inhibition of both ERBB and"/>
   <result pre="and notch pathways may be an interesting option in treating" exact="breast cancer" post="BM patients. Brain microenvironment and breast cancer BBB and"/>
   <result pre="notch pathways may be an interesting option in treating breast" exact="cancer" post="BM patients. Brain microenvironment and breast cancer BBB and"/>
   <result pre="option in treating breast cancer BM patients. Brain microenvironment and" exact="breast cancer" post="BBB and blood–tumor barrier The controversial concept of the"/>
   <result pre="in treating breast cancer BM patients. Brain microenvironment and breast" exact="cancer" post="BBB and blood–tumor barrier The controversial concept of the"/>
   <result pre="detected CTCs in the blood of approximately 20 % of" exact="glioma" post="patients at primary diagnosis [ 54, 55]. Thus, it"/>
   <result pre="the BBB actually shields the brain from the periphery in" exact="cancer" post="patients. Notably, glioma data may not be equated directly"/>
   <result pre="shields the brain from the periphery in cancer patients. Notably," exact="glioma" post="data may not be equated directly with brain metastasis"/>
   <result pre="described as a key mediator of the transendothelial migration of" exact="breast cancer" post="cells. Here, glycosaminoglycan hyaluronan binds to its receptor CD44"/>
   <result pre="as a key mediator of the transendothelial migration of breast" exact="cancer" post="cells. Here, glycosaminoglycan hyaluronan binds to its receptor CD44"/>
   <result pre="with activated CD44 receptors expressed on the endothelium, suggesting that" exact="cancer" post="cells with elevated hyaluronic acid synthase activity and high"/>
   <result pre="EGFR ligand HBEGF, and the α2,6-sialyltransferase ST6GALNAC5 as mediators of" exact="cancer" post="cell passage through the BBB [ 62]. Blood–tumor barrier"/>
   <result pre="BBB breakdown and efficient drug delivery in a scenario of" exact="breast cancer" post="BM. In a preclinical study using two different models"/>
   <result pre="breakdown and efficient drug delivery in a scenario of breast" exact="cancer" post="BM. In a preclinical study using two different models"/>
   <result pre="BM. In a preclinical study using two different models of" exact="breast cancer" post="BM, most metastases exhibited some increased BTB permeability; however,"/>
   <result pre="In a preclinical study using two different models of breast" exact="cancer" post="BM, most metastases exhibited some increased BTB permeability; however,"/>
   <result pre="the cell adhesion molecule L1CAM mediates the metastatic spread of" exact="breast cancer" post="cells on the vasculature as well as interactions between"/>
   <result pre="cell adhesion molecule L1CAM mediates the metastatic spread of breast" exact="cancer" post="cells on the vasculature as well as interactions between"/>
   <result pre="cancer cells on the vasculature as well as interactions between" exact="cancer" post="cells [ 69]. Once tumor cells have infiltrated the"/>
   <result pre="persistent vessel cooption (melanoma model) [ 52]. In a mouse" exact="breast cancer" post="BM model, the authors observed two different phenotypes of"/>
   <result pre="vessel cooption (melanoma model) [ 52]. In a mouse breast" exact="cancer" post="BM model, the authors observed two different phenotypes of"/>
   <result pre="neuronal [ 67]. Here, the vascular-induced adhesion and invasion of" exact="breast cancer" post="cells may be sufficient for tumor growth prior to"/>
   <result pre="[ 67]. Here, the vascular-induced adhesion and invasion of breast" exact="cancer" post="cells may be sufficient for tumor growth prior to"/>
   <result pre="for angiogenesis in the formation and development of BM in" exact="breast cancer." post="The authors of that study showed a significant increase"/>
   <result pre="showed a significant increase in VEGF-A production in a BM" exact="breast cancer" post="cell line (MDA-MB-231-BR) compared with the parental cell line"/>
   <result pre="a significant increase in VEGF-A production in a BM breast" exact="cancer" post="cell line (MDA-MB-231-BR) compared with the parental cell line"/>
   <result pre="local activation of astrocytes including reactive gliosis [ 75]. In" exact="breast cancer" post="patients, the activated astrocytes accumulate both around and inside"/>
   <result pre="activation of astrocytes including reactive gliosis [ 75]. In breast" exact="cancer" post="patients, the activated astrocytes accumulate both around and inside"/>
   <result pre="by the astrocytes induce both the migration and invasion of" exact="breast cancer" post="cells [ 79]. Wang et al. [ 79] identified"/>
   <result pre="the astrocytes induce both the migration and invasion of breast" exact="cancer" post="cells [ 79]. Wang et al. [ 79] identified"/>
   <result pre="of the mediators for astrocyte-induced tumor cell invasion. Furthermore, when" exact="breast cancer" post="cells are cocultured with astrocytes, the tumor cells become"/>
   <result pre="the mediators for astrocyte-induced tumor cell invasion. Furthermore, when breast" exact="cancer" post="cells are cocultured with astrocytes, the tumor cells become"/>
   <result pre="of cancer, and the role of differentially activated macrophages in" exact="cancer" post="progression is widely investigated. In a manner similar to"/>
   <result pre="to enhance the invasion and colonization of brain tissue by" exact="breast cancer" post="cells. This invasion was shown to be dependent on"/>
   <result pre="enhance the invasion and colonization of brain tissue by breast" exact="cancer" post="cells. This invasion was shown to be dependent on"/>
   <result pre="In recent decades, a substantial improvement in the treatment of" exact="breast cancer" post="patients, including those in the metastatic situation, has been"/>
   <result pre="recent decades, a substantial improvement in the treatment of breast" exact="cancer" post="patients, including those in the metastatic situation, has been"/>
   <result pre="patients is unclear. To obtain further knowledge about outcomes in" exact="breast cancer" post="patients, we established a national clinical data registry and"/>
   <result pre="is unclear. To obtain further knowledge about outcomes in breast" exact="cancer" post="patients, we established a national clinical data registry and"/>
   <result pre="and transporter systems or nanotherapy, may also be appropriate for" exact="breast cancer" post="BM. Abbreviations BBB blood–brain barrier BM brain metastases BTB"/>
   <result pre="transporter systems or nanotherapy, may also be appropriate for breast" exact="cancer" post="BM. Abbreviations BBB blood–brain barrier BM brain metastases BTB"/>
   <result pre="blood–tumor barrier CI confidence interval CNS central nervous system CSC" exact="cancer" post="stem cell CTC circulating tumor cell EGFR epidermal growth"/>
   <result pre="OS overall survival T-DM1 trastuzumab-DM1 TJ tight junction TNBC triple-negative" exact="breast cancer" post="VEGF vascular endothelial growth factor WBRT whole-brain radiation therapy"/>
   <result pre="overall survival T-DM1 trastuzumab-DM1 TJ tight junction TNBC triple-negative breast" exact="cancer" post="VEGF vascular endothelial growth factor WBRT whole-brain radiation therapy"/>
   <result pre="B Bhatia S Karlovits S The shifting landscape of metastatic" exact="breast cancer" post="to the CNS Neurosurg Rev 2013 36 377 82"/>
   <result pre="Bhatia S Karlovits S The shifting landscape of metastatic breast" exact="cancer" post="to the CNS Neurosurg Rev 2013 36 377 82"/>
   <result pre="pattern and timing of brain metastases among patients with advanced" exact="breast cancer" post="treated with trastuzumab Acta Oncol 2006 45 196 201"/>
   <result pre="and timing of brain metastases among patients with advanced breast" exact="cancer" post="treated with trastuzumab Acta Oncol 2006 45 196 201"/>
   <result pre="of patients with brain metastases receiving trastuzumab treatment for metastatic" exact="breast cancer" post="Onkologie 2011 34 304 8 10.1159/000328679 21625183 6. Kaplan"/>
   <result pre="patients with brain metastases receiving trastuzumab treatment for metastatic breast" exact="cancer" post="Onkologie 2011 34 304 8 10.1159/000328679 21625183 6. Kaplan"/>
   <result pre="Yildiz R et al. Biological subtypes and survival outcomes in" exact="breast cancer" post="patients with brain metastases (study of the Anatolian Society"/>
   <result pre="R et al. Biological subtypes and survival outcomes in breast" exact="cancer" post="patients with brain metastases (study of the Anatolian Society"/>
   <result pre="outcomes and prognostic factors for patients with brain metastases from" exact="breast cancer" post="of each subtype: a multicenter retrospective analysis Breast Cancer"/>
   <result pre="and prognostic factors for patients with brain metastases from breast" exact="cancer" post="of each subtype: a multicenter retrospective analysis Breast Cancer"/>
   <result pre="25106661 8. Paget S The distribution of secondary growths in" exact="cancer" post="of the breast Lancet 1889 133 571 3 10.1016/S0140-6736(00)49915-0"/>
   <result pre="O Chanda D Morgan CJ Siegal GP et al. Breast" exact="cancer" post="subtypes predispose the site of distant metastases Am J"/>
   <result pre="MC Voduc D Speers CH et al. Metastatic behavior of" exact="breast cancer" post="subtypes J Clin Oncol 2010 28 3271 7 10.1200/JCO.2009.25.9820"/>
   <result pre="Voduc D Speers CH et al. Metastatic behavior of breast" exact="cancer" post="subtypes J Clin Oncol 2010 28 3271 7 10.1200/JCO.2009.25.9820"/>
   <result pre="M Lehtimaki T Ristimaki A Holli K et al. Breast" exact="cancer" post="biological subtypes and protein expression predict for the preferential"/>
   <result pre="Sieuwerts AM Yu J Klijn JG et al. Subtypes of" exact="breast cancer" post="show preferential site of relapse Cancer Res 2008 68"/>
   <result pre="AM Yu J Klijn JG et al. Subtypes of breast" exact="cancer" post="show preferential site of relapse Cancer Res 2008 68"/>
   <result pre="Lee JS Marchetti D et al. Selection of brain metastasis-initiating" exact="breast cancer" post="cells determined by growth on hard agar Am J"/>
   <result pre="JS Marchetti D et al. Selection of brain metastasis-initiating breast" exact="cancer" post="cells determined by growth on hard agar Am J"/>
   <result pre="10.1200/JCO.2010.33.3294 21135269 19. Niwinska A Murawska M Pogoda K Breast" exact="cancer" post="subtypes and response to systemic treatment after whole-brain radiotherapy"/>
   <result pre="Zagonel V Tabouret E Systemic treatments for brain metastases from" exact="breast cancer," post="non-small cell lung cancer, melanoma and renal cell carcinoma:"/>
   <result pre="Systemic treatments for brain metastases from breast cancer, non-small cell" exact="lung cancer," post="melanoma and renal cell carcinoma: an overview of the"/>
   <result pre="levels in serum and cerebrospinal fluid is altered in HER2-positive" exact="breast cancer" post="patients with brain metastases and impairment of blood–brain barrier"/>
   <result pre="in serum and cerebrospinal fluid is altered in HER2-positive breast" exact="cancer" post="patients with brain metastases and impairment of blood–brain barrier"/>
   <result pre="metastases as site of first recurrence in patients with HER2-positive" exact="breast cancer" post="treated with adjuvant trastuzumab Ann Oncol 2013 24 1526"/>
   <result pre="as site of first recurrence in patients with HER2-positive breast" exact="cancer" post="treated with adjuvant trastuzumab Ann Oncol 2013 24 1526"/>
   <result pre="al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of" exact="breast cancer" post="Pharm Res 2012 29 770 81 10.1007/s11095-011-0601-8 22011930 24."/>
   <result pre="Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast" exact="cancer" post="Pharm Res 2012 29 770 81 10.1007/s11095-011-0601-8 22011930 24."/>
   <result pre="Reactive glia are recruited by highly proliferative brain metastases of" exact="breast cancer" post="and promote tumor cell colonization Clin Exp Metastasis 2008"/>
   <result pre="glia are recruited by highly proliferative brain metastases of breast" exact="cancer" post="and promote tumor cell colonization Clin Exp Metastasis 2008"/>
   <result pre="in patients with previously untreated brain metastases from HER2-positive metastatic" exact="breast cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="patients with previously untreated brain metastases from HER2-positive metastatic breast" exact="cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="and lapatinib uptake in surgically resected brain metastases from metastatic" exact="breast cancer" post="patients: a prospective study Neuro Oncol 2015 17 289"/>
   <result pre="lapatinib uptake in surgically resected brain metastases from metastatic breast" exact="cancer" post="patients: a prospective study Neuro Oncol 2015 17 289"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="J Clin Oncol 2015 33 1564 73 10.1200/JCO.2014.57.1794 25605838"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="J Clin Oncol 2015 33 1564 73 10.1200/JCO.2014.57.1794 25605838"/>
   <result pre="10.1200/JCO.2014.57.1794 25605838 28. Bartsch R Berghoff AS Preusser M Breast" exact="cancer" post="brain metastases responding to primary systemic therapy with T-DM1"/>
   <result pre="(T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic" exact="breast cancer" post="and central nervous system metastases: a retrospective, exploratory analysis"/>
   <result pre="versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast" exact="cancer" post="and central nervous system metastases: a retrospective, exploratory analysis"/>
   <result pre="Baker AT Zlobin A Osipo C Notch-EGFR/HER2 bidirectional crosstalk in" exact="breast cancer" post="Front Oncol 2014 4 360 10.3389/fonc.2014.00360 25566499 32. Levy"/>
   <result pre="AT Zlobin A Osipo C Notch-EGFR/HER2 bidirectional crosstalk in breast" exact="cancer" post="Front Oncol 2014 4 360 10.3389/fonc.2014.00360 25566499 32. Levy"/>
   <result pre="R Xing F Watabe K Miele L Notch signaling: targeting" exact="cancer" post="stem cells and epithelial-to-mesenchymal transition Onco Targets Ther 2013"/>
   <result pre="PR et al. Reactive astrocytes promote the metastatic growth of" exact="breast cancer" post="stem-like cells by activating Notch signalling in brain EMBO"/>
   <result pre="et al. Reactive astrocytes promote the metastatic growth of breast" exact="cancer" post="stem-like cells by activating Notch signalling in brain EMBO"/>
   <result pre="CD44hi/CD24lo population and reduces the formation of brain metastases from" exact="breast cancer" post="Mol Cancer Res 2011 9 834 44 10.1158/1541-7786.MCR-10-0457 21665937"/>
   <result pre="population and reduces the formation of brain metastases from breast" exact="cancer" post="Mol Cancer Res 2011 9 834 44 10.1158/1541-7786.MCR-10-0457 21665937"/>
   <result pre="the basal type and HER-2/neu type in brain metastasis from" exact="breast cancer" post="Mod Pathol 2007 20 864 70 10.1038/modpathol.3800830 17541441 38."/>
   <result pre="basal type and HER-2/neu type in brain metastasis from breast" exact="cancer" post="Mod Pathol 2007 20 864 70 10.1038/modpathol.3800830 17541441 38."/>
   <result pre="E Blackwell KL et al. Phosphatidylinositol 3-kinase pathway activation in" exact="breast cancer" post="brain metastases Breast Cancer Res 2011 13 R125 10.1186/bcr3071"/>
   <result pre="Blackwell KL et al. Phosphatidylinositol 3-kinase pathway activation in breast" exact="cancer" post="brain metastases Breast Cancer Res 2011 13 R125 10.1186/bcr3071"/>
   <result pre="Kleinschmidt-DeMasters BK Singh M Epidermal growth factor receptor status in" exact="breast cancer" post="metastases to the central nervous system. Comparison with HER-2/neu"/>
   <result pre="BK Singh M Epidermal growth factor receptor status in breast" exact="cancer" post="metastases to the central nervous system. Comparison with HER-2/neu"/>
   <result pre="al. Frequent genetic alterations in EGFR- and HER2-driven pathways in" exact="breast cancer" post="brain metastases Am J Pathol 2013 183 83 95"/>
   <result pre="Frequent genetic alterations in EGFR- and HER2-driven pathways in breast" exact="cancer" post="brain metastases Am J Pathol 2013 183 83 95"/>
   <result pre="of epidermal growth factor receptor overexpression in the promotion of" exact="breast cancer" post="brain metastasis Cancer 2012 118 5198 209 10.1002/cncr.27553 22510844"/>
   <result pre="epidermal growth factor receptor overexpression in the promotion of breast" exact="cancer" post="brain metastasis Cancer 2012 118 5198 209 10.1002/cncr.27553 22510844"/>
   <result pre="AM et al. Her-2 overexpression increases the metastatic outgrowth of" exact="breast cancer" post="cells in the brain Cancer Res 2007 67 4190"/>
   <result pre="et al. Her-2 overexpression increases the metastatic outgrowth of breast" exact="cancer" post="cells in the brain Cancer Res 2007 67 4190"/>
   <result pre="Co-overexpression of HER2/HER3 is a predictor of impaired survival in" exact="breast cancer" post="patients Breast 2014 23 637 43 10.1016/j.breast.2014.06.011 25017122 46."/>
   <result pre="of HER2/HER3 is a predictor of impaired survival in breast" exact="cancer" post="patients Breast 2014 23 637 43 10.1016/j.breast.2014.06.011 25017122 46."/>
   <result pre="downstream pathways are involved in colonization of brain metastases from" exact="breast cancer" post="Breast Cancer Res 2010 12 4 R46 10.1186/bcr2603 20604919"/>
   <result pre="pathways are involved in colonization of brain metastases from breast" exact="cancer" post="Breast Cancer Res 2010 12 4 R46 10.1186/bcr2603 20604919"/>
   <result pre="Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood–brain-barrier transendothelial migration of human" exact="breast cancer" post="cell lines Oncotarget 2015 6 3932 46 10.18632/oncotarget.2846 25668816"/>
   <result pre="signaling promotes matrix metalloproteinase-dependent blood–brain-barrier transendothelial migration of human breast" exact="cancer" post="cell lines Oncotarget 2015 6 3932 46 10.18632/oncotarget.2846 25668816"/>
   <result pre="expression is associated with poor prognosis and brain metastasis in" exact="breast cancer" post="patients Oncotarget 2014 5 3076 87 10.18632/oncotarget.1832 24833255 49."/>
   <result pre="is associated with poor prognosis and brain metastasis in breast" exact="cancer" post="patients Oncotarget 2014 5 3076 87 10.18632/oncotarget.1832 24833255 49."/>
   <result pre="X Valero V Andreopoulou E et al. Characterization of metastatic" exact="breast cancer" post="patients with nondetectable circulating tumor cells Int J Cancer"/>
   <result pre="Valero V Andreopoulou E et al. Characterization of metastatic breast" exact="cancer" post="patients with nondetectable circulating tumor cells Int J Cancer"/>
   <result pre="W Kumar D et al. The identification and characterization of" exact="breast cancer" post="CTCs competent for brain metastasis Sci Transl Med 2013"/>
   <result pre="Kumar D et al. The identification and characterization of breast" exact="cancer" post="CTCs competent for brain metastasis Sci Transl Med 2013"/>
   <result pre="E Lamszus K Schulte A et al. Hematogenous dissemination of" exact="glioblastoma multiforme" post="Sci Transl Med 2014 6 247ra101 10.1126/scitranslmed.3009095 25080476 55."/>
   <result pre="Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231" exact="breast cancer" post="cells through regulation of brain microvascular endothelial cell permeability"/>
   <result pre="endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast" exact="cancer" post="cells through regulation of brain microvascular endothelial cell permeability"/>
   <result pre="Yasuda M et al. Hepatocyte growth factor enhances adhesion of" exact="breast cancer" post="cells to endothelial cells in vitro through up-regulation of"/>
   <result pre="M et al. Hepatocyte growth factor enhances adhesion of breast" exact="cancer" post="cells to endothelial cells in vitro through up-regulation of"/>
   <result pre="Waugh DJ CD44 potentiates the adherence of metastatic prostate and" exact="breast cancer" post="cells to bone marrow endothelial cells Cancer Res 2004"/>
   <result pre="DJ CD44 potentiates the adherence of metastatic prostate and breast" exact="cancer" post="cells to bone marrow endothelial cells Cancer Res 2004"/>
   <result pre="S Angiopoietin-2 mediates blood–brain barrier impairment and colonization of triple-negative" exact="breast cancer" post="cells in brain J Pathol 2014 232 369 81"/>
   <result pre="Angiopoietin-2 mediates blood–brain barrier impairment and colonization of triple-negative breast" exact="cancer" post="cells in brain J Pathol 2014 232 369 81"/>
   <result pre="receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in" exact="breast cancer" post="cell migration through human brain microvascular endothelial cells Mol"/>
   <result pre="CXCR4 and its ligand stromal cell-derived factor 1alpha in breast" exact="cancer" post="cell migration through human brain microvascular endothelial cells Mol"/>
   <result pre="W Gomis RR Nguyen DX et al. Genes that mediate" exact="breast cancer" post="metastasis to the brain Nature 2009 459 1005 9"/>
   <result pre="Gomis RR Nguyen DX et al. Genes that mediate breast" exact="cancer" post="metastasis to the brain Nature 2009 459 1005 9"/>
   <result pre="63. Lin NU Bellon JR Winer EP CNS metastases in" exact="breast cancer" post="J Clin Oncol 2004 22 3608 17 10.1200/JCO.2004.01.175 15337811"/>
   <result pre="Lin NU Bellon JR Winer EP CNS metastases in breast" exact="cancer" post="J Clin Oncol 2004 22 3608 17 10.1200/JCO.2004.01.175 15337811"/>
   <result pre="blood brain barrier by brain metastases of triple-negative and basal-type" exact="breast cancer" post="but not HER2/neu-positive breast cancer Cancer 2010 116 302"/>
   <result pre="brain barrier by brain metastases of triple-negative and basal-type breast" exact="cancer" post="but not HER2/neu-positive breast cancer Cancer 2010 116 302"/>
   <result pre="metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive" exact="breast cancer" post="Cancer 2010 116 302 8 10.1002/cncr.24735 19937674 66. Lockman"/>
   <result pre="of triple-negative and basal-type breast cancer but not HER2/neu-positive breast" exact="cancer" post="Cancer 2010 116 302 8 10.1002/cncr.24735 19937674 66. Lockman"/>
   <result pre="barrier permeability determines drug efficacy in experimental brain metastases of" exact="breast cancer" post="Clin Cancer Res 2010 16 5664 78 10.1158/1078-0432.CCR-10-1564 20829328"/>
   <result pre="permeability determines drug efficacy in experimental brain metastases of breast" exact="cancer" post="Clin Cancer Res 2010 16 5664 78 10.1158/1078-0432.CCR-10-1564 20829328"/>
   <result pre="Capturing changes in the brain microenvironment during initial steps of" exact="breast cancer" post="brain metastasis Am J Pathol 2010 176 2958 71"/>
   <result pre="changes in the brain microenvironment during initial steps of breast" exact="cancer" post="brain metastasis Am J Pathol 2010 176 2958 71"/>
   <result pre="Chen Q Zhang XH Lee DJ et al. Serpins promote" exact="cancer" post="cell survival and vascular co-option in brain metastasis Cell"/>
   <result pre="JE Vascular endothelial growth factor expression promotes the growth of" exact="breast cancer" post="brain metastases in nude mice Clin Exp Metastasis 2004"/>
   <result pre="Vascular endothelial growth factor expression promotes the growth of breast" exact="cancer" post="brain metastases in nude mice Clin Exp Metastasis 2004"/>
   <result pre="drug clinical efficacies using models of early or late stage" exact="breast cancer" post="metastatis Breast 2013 22 Suppl 2 S57 65 10.1016/j.breast.2013.07.011"/>
   <result pre="clinical efficacies using models of early or late stage breast" exact="cancer" post="metastatis Breast 2013 22 Suppl 2 S57 65 10.1016/j.breast.2013.07.011"/>
   <result pre="and cisplatin is highly effective in treating brain metastases of" exact="breast cancer" post="progressing from whole-brain radiotherapy Clin Cancer Res 2015 21"/>
   <result pre="cisplatin is highly effective in treating brain metastases of breast" exact="cancer" post="progressing from whole-brain radiotherapy Clin Cancer Res 2015 21"/>
   <result pre="Jandial R Role of the neural niche in brain metastatic" exact="cancer" post="Cancer Res 2014 74 4011 5 10.1158/0008-5472.CAN-14-1226 25035392 76."/>
   <result pre="S Vaidehi N Choy C Kowolik CM et al. Human" exact="breast cancer" post="metastases to the brain display GABAergic properties in the"/>
   <result pre="Vaidehi N Choy C Kowolik CM et al. Human breast" exact="cancer" post="metastases to the brain display GABAergic properties in the"/>
   <result pre="A Astrocyte-derived cytokines contribute to the metastatic brain specificity of" exact="breast cancer" post="cells Lab Invest 1997 77 357 68 9354770 79."/>
   <result pre="Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast" exact="cancer" post="cells Lab Invest 1997 77 357 68 9354770 79."/>
   <result pre="S et al. Microglia promote colonization of brain tissue by" exact="breast cancer" post="cells in a Wnt-dependent way Glia 2010 58 1477"/>
   <result pre="et al. Microglia promote colonization of brain tissue by breast" exact="cancer" post="cells in a Wnt-dependent way Glia 2010 58 1477"/>
   <result pre="Incidence and patterns of distant metastases for patients with early-stage" exact="breast cancer" post="after breast conservation treatment Clin Breast Cancer 2013 13"/>
   <result pre="and patterns of distant metastases for patients with early-stage breast" exact="cancer" post="after breast conservation treatment Clin Breast Cancer 2013 13"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4717845/results/search/disease/results.xml">
   <result pre="Melanoma Metabolism Glutaminolysis 1 Introduction One of the hallmarks of" exact="cancer" post="is metabolic reprogramming, which provides the nutrients and redox"/>
   <result pre="metabolic rewiring can also contribute to resistance. For example, lapatinib/trastuzumab-resistant" exact="breast cancer" post="cells display a dependency on glucose metabolism and the"/>
   <result pre="rewiring can also contribute to resistance. For example, lapatinib/trastuzumab-resistant breast" exact="cancer" post="cells display a dependency on glucose metabolism and the"/>
   <result pre="( Corazao-Rozas et al., 2013), suggesting that these drugs place" exact="cancer" post="cells under selective pressure to restore oxidative metabolism and"/>
   <result pre="provide other advantages. It was recently reported that highly invasive" exact="ovarian cancer" post="cells are more dependent on glutamine for survival than"/>
   <result pre="other advantages. It was recently reported that highly invasive ovarian" exact="cancer" post="cells are more dependent on glutamine for survival than"/>
   <result pre="sustain proliferation; it may also contribute to other hallmarks of" exact="cancer" post="such as invasion and metastasis. Our findings are consistent"/>
   <result pre="and metastasis. Our findings are consistent with studies showing that" exact="cancer" post="cells, including melanoma, display metabolic flexibility and can adapt"/>
   <result pre="glutaminolysis. Inhibition of glutaminolysis can suppress the growth of Burkitt's" exact="lymphoma" post="and other cancers driven by MYC ( Le et"/>
   <result pre="resistant tumors. PGC1α is important for glutamine metabolism in ERBB2-positive" exact="breast cancer" post="( McGuirk et al., 2013) and glutamine transporters are"/>
   <result pre="tumors. PGC1α is important for glutamine metabolism in ERBB2-positive breast" exact="cancer" post="( McGuirk et al., 2013) and glutamine transporters are"/>
   <result pre="M.R. Futreal P.A. Mutations of the BRAF gene in human" exact="cancer" post="Nature 417 2002 949 954 12068308 Dhomen N. Marais"/>
   <result pre="P.T. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive" exact="breast cancer" post="cells Mol. Syst. Biol. 8 2012 596 22864381 Le"/>
   <result pre="The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast" exact="cancer" post="cells Mol. Syst. Biol. 8 2012 596 22864381 Le"/>
   <result pre="R.G. Giguere V. St-Pierre J. PGC-1alpha supports glutamine metabolism in" exact="breast cancer" post="Cancer Metab. 1 2013 22 24304688 Menzies A.M. Long"/>
   <result pre="Giguere V. St-Pierre J. PGC-1alpha supports glutamine metabolism in breast" exact="cancer" post="Cancer Metab. 1 2013 22 24304688 Menzies A.M. Long"/>
   <result pre="1060 1071 24531984 Ward P.S. Thompson C.B. Metabolic reprogramming: a" exact="cancer" post="hallmark even Warburg did not anticipate Cancer Cell 21"/>
   <result pre="shifts toward glutamine regulate tumor growth, invasion and bioenergetics in" exact="ovarian cancer" post="Mol. Syst. Biol. 10 2014 728 24799285 Ying H."/>
   <result pre="toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian" exact="cancer" post="Mol. Syst. Biol. 10 2014 728 24799285 Ying H."/>
   <result pre="Wu Y. Price J.E. Tan M. Overcoming trastuzumab resistance in" exact="breast cancer" post="by targeting dysregulated glucose metabolism Cancer Res. 71 2011"/>
   <result pre="Y. Price J.E. Tan M. Overcoming trastuzumab resistance in breast" exact="cancer" post="by targeting dysregulated glucose metabolism Cancer Res. 71 2011"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4718910/results/search/disease/results.xml">
   <result pre="added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic" exact="breast cancer" post="progressing on letrozole Gunzer Katharina +33-231455002 k.gunzer@baclesse.unicancer.fr Joly Florence"/>
   <result pre="to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast" exact="cancer" post="progressing on letrozole Gunzer Katharina +33-231455002 k.gunzer@baclesse.unicancer.fr Joly Florence"/>
   <result pre="family blocker afatinib combined with letrozole in estrogen receptor-positive metastatic" exact="breast cancer" post="(MBC) patients who had progressed on letrozole monotherapy. Adult"/>
   <result pre="blocker afatinib combined with letrozole in estrogen receptor-positive metastatic breast" exact="cancer" post="(MBC) patients who had progressed on letrozole monotherapy. Adult"/>
   <result pre="NCT00708214 Keywords Phase II Afatinib ErbB Family Blocker Letrozole Metastatic" exact="breast cancer" post="Pharmacokinetics Background Abnormally activated ErbB Family receptors (EGFR [ErbB1],"/>
   <result pre="Keywords Phase II Afatinib ErbB Family Blocker Letrozole Metastatic breast" exact="cancer" post="Pharmacokinetics Background Abnormally activated ErbB Family receptors (EGFR [ErbB1],"/>
   <result pre="and ErbB4) and estrogen receptors (ER) are frequently implicated in" exact="breast cancer," post="making these potential therapeutic targets (Hurvitz and Pietras 2008;"/>
   <result pre="modulators have proven effective in the treatment of hormone receptor-positive" exact="breast cancer;" post="however, a major clinical problem limiting the usefulness of"/>
   <result pre="in the management of patients with primary or acquired hormone-resistant" exact="breast cancer" post="(Osborne et al. 2005). Furthermore, restoration of hormone sensitivity"/>
   <result pre="the management of patients with primary or acquired hormone-resistant breast" exact="cancer" post="(Osborne et al. 2005). Furthermore, restoration of hormone sensitivity"/>
   <result pre="demonstrated clinical activity in heavily pre-treated patients with HER2-positive metastatic" exact="breast cancer" post="(MBC) who had progressed following trastuzumab treatment, with a"/>
   <result pre="clinical activity in heavily pre-treated patients with HER2-positive metastatic breast" exact="cancer" post="(MBC) who had progressed following trastuzumab treatment, with a"/>
   <result pre="of prior chemotherapy for MBC were permitted. Patients with HER2-positive" exact="breast cancer" post="could have received prior trastuzumab in the adjuvant and"/>
   <result pre="prior chemotherapy for MBC were permitted. Patients with HER2-positive breast" exact="cancer" post="could have received prior trastuzumab in the adjuvant and"/>
   <result pre="Patients were excluded from the study if they had: chronic" exact="diarrhea" post="or gastrointestinal (GI) disorders that could interfere with absorption"/>
   <result pre="could interfere with absorption of study treatment; brain metastases; significant" exact="cardiovascular disease" post="(i.e., uncontrolled hypertension, unstable angina pectoris, history of infarction,"/>
   <result pre="study treatment; brain metastases; significant cardiovascular disease (i.e., uncontrolled hypertension," exact="unstable angina" post="pectoris, history of infarction, congestive heart failure of New"/>
   <result pre="disease (i.e., uncontrolled hypertension, unstable angina pectoris, history of infarction," exact="congestive heart failure" post="of New York Heart Association grade &amp;gt;2) within the"/>
   <result pre="investigator (Table 3). The most frequently reported treatment-related AEs were" exact="diarrhea" post="(26 patients; 93 %), asthenia and rash (both 16"/>
   <result pre="treatment-related AEs were diarrhea (26 patients; 93 %), asthenia and" exact="rash" post="(both 16 patients; 57 %), mucosal inflammation (11 patients;"/>
   <result pre="%). The most frequently occurring grade ≥3 treatment-related AEs were" exact="diarrhea" post="(six patients; 22 %), asthenia and rash (five patients"/>
   <result pre="treatment-related AEs were diarrhea (six patients; 22 %), asthenia and" exact="rash" post="(five patients each; 18 %) (Table 3). No treatment-related"/>
   <result pre="treatment-emergent AEs. The most frequent AEs necessitating treatment discontinuation were" exact="diarrhea" post="(eight patients; 29 %), asthenia (four patients; 14 %),"/>
   <result pre="diarrhea (eight patients; 29 %), asthenia (four patients; 14 %)," exact="rash" post="and mucosal inflammation (three patients each; 11 %); some"/>
   <result pre="rate of grade 3 GI and skin-related AEs (rash, acne," exact="dermatitis" post="acneiform and palmar–plantar erythrodysesthesia) was observed at the 50"/>
   <result pre="interruption or discontinuation. Further analyses suggested dose-related trends for both" exact="rash" post="and diarrhea. Among the 16 patients (57 %) who"/>
   <result pre="doses of afatinib were more likely to experience grade 3" exact="rash" post="and have a faster onset of symptoms (7 days"/>
   <result pre="There was a small decrease in the incidence of drug-related" exact="diarrhea" post="with decreasing dose. The first onset of treatment-related diarrhea"/>
   <result pre="drug-related diarrhea with decreasing dose. The first onset of treatment-related" exact="diarrhea" post="usually occurred within 7 days after the start of"/>
   <result pre="were deemed non-measurable by RECIST version 1.0. Patients with ER-positive" exact="breast cancer" post="frequently have bone metastases. Upon PD during trial treatment,"/>
   <result pre="deemed non-measurable by RECIST version 1.0. Patients with ER-positive breast" exact="cancer" post="frequently have bone metastases. Upon PD during trial treatment,"/>
   <result pre="reversible EGFR TKIs, in combination with an AI in ER-positive" exact="breast cancer" post="patients have demonstrated varying levels of clinical benefit, including"/>
   <result pre="EGFR TKIs, in combination with an AI in ER-positive breast" exact="cancer" post="patients have demonstrated varying levels of clinical benefit, including"/>
   <result pre="5 Clinical trials co-targeting growth factor receptors in hormone-positive metastatic" exact="breast cancer" post="patients Study/phase Patients Prior hormone therapy experience N Regimen"/>
   <result pre="Clinical trials co-targeting growth factor receptors in hormone-positive metastatic breast" exact="cancer" post="patients Study/phase Patients Prior hormone therapy experience N Regimen"/>
   <result pre="clinical benefit (1 CR, 4 PR and 6 SD) Hypermagnesemia," exact="hypokalemia" post="and scalp infection in 1 patient Phase II (Mita"/>
   <result pre="42 % BOLER0-2/phase III (Baselga et al. 2012) ER/PgR-positive advanced" exact="breast cancer" post="Aromatase inhibitor-resistant 724 Exemestane + everolimus 6.9 Stomatitis 8"/>
   <result pre="% BOLER0-2/phase III (Baselga et al. 2012) ER/PgR-positive advanced breast" exact="cancer" post="Aromatase inhibitor-resistant 724 Exemestane + everolimus 6.9 Stomatitis 8"/>
   <result pre="receptor, HER2 human epidermal growth factor receptor 2, MBC metastatic" exact="breast cancer," post="mTOR mammalian target of rapamycin, PFS progression-free survival, PgR"/>
   <result pre="stopping adjuvant tamoxifen cPatients with centrally confirmed hormone receptor-positive, HER2-negative" exact="cancer" post="(952 patients) had no improvement in PFS One limitation"/>
   <result pre="40 mg daily. The occurrence of significant skin-associated AEs and" exact="diarrhea" post="within the 40 mg dose cohort also led to"/>
   <result pre="Despite the significant achievements of endocrine therapy in patients with" exact="breast cancer," post="only 50 % of all ER-positive tumors are initially"/>
   <result pre="letrozole versus letrozole alone in first-line advanced ER-positive, HER2-negative postmenopausal" exact="breast cancer" post="with low ER expression. Conclusions In this small exploratory"/>
   <result pre="versus letrozole alone in first-line advanced ER-positive, HER2-negative postmenopausal breast" exact="cancer" post="with low ER expression. Conclusions In this small exploratory"/>
   <result pre="to treatment continuation of letrozole in estrogen receptor (ER)-positive metastatic" exact="breast cancer" post="progressing on letrozole. Poster presentation at 32nd Annual San"/>
   <result pre="treatment continuation of letrozole in estrogen receptor (ER)-positive metastatic breast" exact="cancer" post="progressing on letrozole. Poster presentation at 32nd Annual San"/>
   <result pre="EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic" exact="breast cancer" post="(mBC) progressing on letrozole monotherapy. Poster presentation at 46th"/>
   <result pre="and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast" exact="cancer" post="(mBC) progressing on letrozole monotherapy. Poster presentation at 46th"/>
   <result pre="with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic" exact="breast cancer" post="with prior exposure to aromatase inhibitors: a GINECO study"/>
   <result pre="hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast" exact="cancer" post="with prior exposure to aromatase inhibitors: a GINECO study"/>
   <result pre="HS Sahmoud T et al. Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2012 366 520 529 10.1056/NEJMoa1109653"/>
   <result pre="Sahmoud T et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2012 366 520 529 10.1056/NEJMoa1109653"/>
   <result pre="16 10.1186/1756-8722-1-16 18828924 Ciardiello F Tortora G EGFR antagonists in" exact="cancer" post="treatment N Engl J Med 2008 358 1160 1174"/>
   <result pre="gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic" exact="breast cancer" post="Clin Cancer Res 2010 16 1904 1914 10.1158/1078-0432.CCR-09-2282 20215537"/>
   <result pre="or placebo in postmenopausal women with hormone receptor-positive metastatic breast" exact="cancer" post="Clin Cancer Res 2010 16 1904 1914 10.1158/1078-0432.CCR-09-2282 20215537"/>
   <result pre="Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic" exact="breast cancer" post="(MBC) with the addition of lapatinib to letrozole: Biomarker"/>
   <result pre="survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast" exact="cancer" post="(MBC) with the addition of lapatinib to letrozole: Biomarker"/>
   <result pre="and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic" exact="breast cancer" post="J Clin Oncol 2009 27 5538 5546 10.1200/JCO.2009.23.3734 19786658"/>
   <result pre="placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast" exact="cancer" post="J Clin Oncol 2009 27 5538 5546 10.1200/JCO.2009.23.3734 19786658"/>
   <result pre="al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical" exact="lung cancer" post="models Oncogene 2008 27 4211 4702 Lin NU Winer"/>
   <result pre="BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung" exact="cancer" post="models Oncogene 2008 27 4211 4702 Lin NU Winer"/>
   <result pre="an irreversible ErbB family blocker, in patients with HER2-positive metastatic" exact="breast cancer" post="progressing after trastuzumab Breast Cancer Res Treat 2012 133"/>
   <result pre="irreversible ErbB family blocker, in patients with HER2-positive metastatic breast" exact="cancer" post="progressing after trastuzumab Breast Cancer Res Treat 2012 133"/>
   <result pre="al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell" exact="lung cancer" post="harbouring mutations of the epidermal growth factor receptor (WJTOG3405):"/>
   <result pre="Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung" exact="cancer" post="harbouring mutations of the epidermal growth factor receptor (WJTOG3405):"/>
   <result pre="Brodie AH Smith IE Challenges in the endocrine management of" exact="breast cancer" post="Breast 2003 12 Suppl 2 S2 S19 10.1016/S0960-9776(03)80158-3 14659138"/>
   <result pre="AH Smith IE Challenges in the endocrine management of breast" exact="cancer" post="Breast 2003 12 Suppl 2 S2 S19 10.1016/S0960-9776(03)80158-3 14659138"/>
   <result pre="10.1016/S0960-9776(03)80158-3 14659138 Nicholson RI Gee JM Harper ME EGFR and" exact="cancer" post="prognosis Eur J Cancer 2001 37 Suppl 4 S9"/>
   <result pre="S15 10.1016/S0959-8049(01)00231-3 11597399 Osborne CK Tamoxifen in the treatment of" exact="breast cancer" post="N Engl J Med 1998 339 1609 1618 10.1056/NEJM199811263392207"/>
   <result pre="10.1016/S0959-8049(01)00231-3 11597399 Osborne CK Tamoxifen in the treatment of breast" exact="cancer" post="N Engl J Med 1998 339 1609 1618 10.1056/NEJM199811263392207"/>
   <result pre="receptor pathways as a cause for endocrine therapy resistance in" exact="breast cancer" post="Clin Cancer Res 2005 11 865s 870s 15701879 Osborne"/>
   <result pre="pathways as a cause for endocrine therapy resistance in breast" exact="cancer" post="Clin Cancer Res 2005 11 865s 870s 15701879 Osborne"/>
   <result pre="and single versus multiple dose pharmacokinetics of letrozole (Femara) in" exact="breast cancer" post="patients Biopharm Drug Dispos 2001 22 191 197 10.1002/bdd.273"/>
   <result pre="single versus multiple dose pharmacokinetics of letrozole (Femara) in breast" exact="cancer" post="patients Biopharm Drug Dispos 2001 22 191 197 10.1002/bdd.273"/>
   <result pre="first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell" exact="lung cancer" post="(EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet"/>
   <result pre="treatment for European patients with advanced EGFR mutation-positive non-small-cell lung" exact="cancer" post="(EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet"/>
   <result pre="kinase inhibitor, for the treatment of patients with HER2-negative metastatic" exact="breast cancer" post="after failure of no more than two prior chemotherapies."/>
   <result pre="inhibitor, for the treatment of patients with HER2-negative metastatic breast" exact="cancer" post="after failure of no more than two prior chemotherapies."/>
   <result pre="plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic" exact="breast cancer" post="Oncologist 2010 15 122 129 10.1634/theoncologist.2009-0240 20156908 Smith IE"/>
   <result pre="letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast" exact="cancer" post="Oncologist 2010 15 122 129 10.1634/theoncologist.2009-0240 20156908 Smith IE"/>
   <result pre="trial of neoadjuvant anastrozole alone or with gefitinib in early" exact="breast cancer" post="J Clin Oncol 2007 25 3816 3822 10.1200/JCO.2006.09.6578 17679728"/>
   <result pre="of neoadjuvant anastrozole alone or with gefitinib in early breast" exact="cancer" post="J Clin Oncol 2007 25 3816 3822 10.1200/JCO.2006.09.6578 17679728"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4720061/results/search/disease/results.xml">
   <result pre="analyze their clinical implications. Materials and Methods We included consecutive" exact="breast cancer" post="patients who received NAC at the National Cancer Center,"/>
   <result pre="their clinical implications. Materials and Methods We included consecutive breast" exact="cancer" post="patients who received NAC at the National Cancer Center,"/>
   <result pre="Tumor subtyping should be repeated after NAC in patients with" exact="breast cancer." post="Breast neoplasms Molecular subtype Receptor status Neoadjuvant chemotherapy Introduction"/>
   <result pre="widely accepted as the standard of care for locally advanced" exact="breast cancer." post="Studies have confirmed that NAC can be used to"/>
   <result pre="results after breast conserving surgery, without compromising long-term outcomes of" exact="breast cancer" post="treatment [ 1- 3]. Accordingly, the rate of NAC"/>
   <result pre="after breast conserving surgery, without compromising long-term outcomes of breast" exact="cancer" post="treatment [ 1- 3]. Accordingly, the rate of NAC"/>
   <result pre="cancers, and those who had received any previous treatment for" exact="breast cancer" post="were excluded. 2. HR and HER2 status determination and"/>
   <result pre="and those who had received any previous treatment for breast" exact="cancer" post="were excluded. 2. HR and HER2 status determination and"/>
   <result pre="Patient characteristics Of 4,460 patients who underwent surgery for invasive" exact="breast cancer" post="at our institution during the study period, 449 consecutive"/>
   <result pre="characteristics Of 4,460 patients who underwent surgery for invasive breast" exact="cancer" post="at our institution during the study period, 449 consecutive"/>
   <result pre="some limitations. First, it was retrospective in nature, although our" exact="breast cancer" post="database is prospectively maintained. Therefore, it was not possible"/>
   <result pre="limitations. First, it was retrospective in nature, although our breast" exact="cancer" post="database is prospectively maintained. Therefore, it was not possible"/>
   <result pre="molecular subtype could provide important predictive and prognostic information, as" exact="breast cancer" post="management becomes more individualized. Conflict of interest relevant to"/>
   <result pre="subtype could provide important predictive and prognostic information, as breast" exact="cancer" post="management becomes more individualized. Conflict of interest relevant to"/>
   <result pre="al. Impact of chemotherapy sequencing on local-regional failure risk in" exact="breast cancer" post="patients undergoing breast-conserving therapy Ann Surg 2013 257 173"/>
   <result pre="Impact of chemotherapy sequencing on local-regional failure risk in breast" exact="cancer" post="patients undergoing breast-conserving therapy Ann Surg 2013 257 173"/>
   <result pre="BG Yang Q et al. The hormonal receptor status in" exact="breast cancer" post="can be altered by neoadjuvant chemotherapy: a meta-analysis Cancer"/>
   <result pre="Yang Q et al. The hormonal receptor status in breast" exact="cancer" post="can be altered by neoadjuvant chemotherapy: a meta-analysis Cancer"/>
   <result pre="in ER, PR and HER2 receptors after neoadjuvant chemotherapy in" exact="breast cancer" post="Cancer Treat Rev 2011 37 422 30 21177040 6"/>
   <result pre="ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast" exact="cancer" post="Cancer Treat Rev 2011 37 422 30 21177040 6"/>
   <result pre="value of hormone receptor status in a series of operable" exact="breast cancer" post="patients treated with neoadjuvant chemotherapy Oncologist 2007 12 636"/>
   <result pre="of hormone receptor status in a series of operable breast" exact="cancer" post="patients treated with neoadjuvant chemotherapy Oncologist 2007 12 636"/>
   <result pre="its impact on the long-term outcome in patients with primary" exact="breast cancer" post="Br J Cancer 2009 101 1529 36 19809429 8"/>
   <result pre="impact on the long-term outcome in patients with primary breast" exact="cancer" post="Br J Cancer 2009 101 1529 36 19809429 8"/>
   <result pre="WF Ibrahim N Cristofanilli M Anderson K et al. Breast" exact="cancer" post="molecular subtypes respond differently to preoperative chemotherapy Clin Cancer"/>
   <result pre="CA Dressler LG Cowan D Conway K et al. Race," exact="breast cancer" post="subtypes, and survival in the Carolina Breast Cancer Study"/>
   <result pre="Dressler LG Cowan D Conway K et al. Race, breast" exact="cancer" post="subtypes, and survival in the Carolina Breast Cancer Study"/>
   <result pre="14 Onitilo AA Engel JM Greenlee RT Mukesh BN Breast" exact="cancer" post="subtypes based on ER/PR and Her2 expression: comparison of"/>
   <result pre="surgery after preoperative chemotherapy in korean women with locally advanced" exact="breast cancer" post="J Breast Cancer 2011 14 289 95 22323915 16"/>
   <result pre="after preoperative chemotherapy in korean women with locally advanced breast" exact="cancer" post="J Breast Cancer 2011 14 289 95 22323915 16"/>
   <result pre="and gemcitabine combination therapy in women with HER2 positive early" exact="breast cancer" post="Invest New Drugs 2012 30 1972 7 22006161 19"/>
   <result pre="gemcitabine combination therapy in women with HER2 positive early breast" exact="cancer" post="Invest New Drugs 2012 30 1972 7 22006161 19"/>
   <result pre="receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive" exact="breast cancer" post="Ann Surg Oncol 2012 19 3002 11 22437200 22"/>
   <result pre="status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast" exact="cancer" post="Ann Surg Oncol 2012 19 3002 11 22437200 22"/>
   <result pre="MC Tyldesley S Gelmon K Nielsen TO Kennecke H Breast" exact="cancer" post="subtypes and the risk of local and regional relapse"/>
   <result pre="G Marinovich ML Mamounas E Meta-analysis of the association of" exact="breast cancer" post="subtype and pathologic complete response to neoadjuvant chemotherapy Eur"/>
   <result pre="Marinovich ML Mamounas E Meta-analysis of the association of breast" exact="cancer" post="subtype and pathologic complete response to neoadjuvant chemotherapy Eur"/>
   <result pre="significance of pathological complete response following neoadjuvant chemotherapy for operable" exact="breast cancer" post="Oncol Lett 2014 7 663 8 24527070 Fig. 1."/>
   <result pre="of pathological complete response following neoadjuvant chemotherapy for operable breast" exact="cancer" post="Oncol Lett 2014 7 663 8 24527070 Fig. 1."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4720106/results/search/disease/results.xml">
   <result pre="Abstract Brain metastasis affects one third of patients with HER2-positive" exact="breast cancer" post="after treatment with trastuzumab. Surgical resection and radiation therapy"/>
   <result pre="Brain metastasis affects one third of patients with HER2-positive breast" exact="cancer" post="after treatment with trastuzumab. Surgical resection and radiation therapy"/>
   <result pre="blood-brain barrier, and exhibits clinical activities for treatment of HER2-positive" exact="breast cancer." post="A 43-year-old woman was treated for early breast carcinoma"/>
   <result pre="the end of adjuvant trastuzumab therapy, she was diagnosed with" exact="panhypopituitarism" post="due to pituitary metastasis. Surgical removal and whole brain"/>
   <result pre="began to shrink. Trastuzumab may have controlled the micro-metastasis of" exact="breast cancer," post="but it was unable to control its progression to"/>
   <result pre="nervous system. Lapatinib is a possible option for HER2-positive metastatic" exact="breast cancer" post="patients with brain metastasis. Breast neoplasms Neoplasm metastasis Hypopituitarism"/>
   <result pre="system. Lapatinib is a possible option for HER2-positive metastatic breast" exact="cancer" post="patients with brain metastasis. Breast neoplasms Neoplasm metastasis Hypopituitarism"/>
   <result pre="factor receptor 2 (HER2) results in an aggressive form of" exact="breast cancer" post="[ 1]; however, the introduction of trastuzumab has significantly"/>
   <result pre="receptor 2 (HER2) results in an aggressive form of breast" exact="cancer" post="[ 1]; however, the introduction of trastuzumab has significantly"/>
   <result pre="trastuzumab-based regimens are associated with improved control of HER2-positive metastatic" exact="breast cancer," post="one third of trastuzumab-treated patients still develop brain metastasis"/>
   <result pre="barrier [ 5]. Pituitary metastasis is an unusual event of" exact="cancer" post="progression, representing only 1% of pituitary lesions [ 6]."/>
   <result pre="6]. Approximately 30% of pituitary metastasis cases are from primary" exact="breast cancer," post="and less than 10% are symptomatic. Most common signs"/>
   <result pre="10% are symptomatic. Most common signs of pituitary metastasis are" exact="diabetes insipidus," post="hypopituitarism, visual difficulty, and headache [ 6, 7]. There"/>
   <result pre="activity in combination with capecitabine for treatment of HER2-positive metastatic" exact="breast cancer" post="that progresses after treatment with trastuzumab-containing regimens [ 10-"/>
   <result pre="in combination with capecitabine for treatment of HER2-positive metastatic breast" exact="cancer" post="that progresses after treatment with trastuzumab-containing regimens [ 10-"/>
   <result pre="report on the case of a patient with HER2-positive early" exact="breast cancer," post="who developed solitary pituitary metastasis after treatment with trastuzumab."/>
   <result pre="in September, 2012. She was diagnosed with a stage II" exact="breast cancer" post="in April, 2011; a pathology report based on samples"/>
   <result pre="September, 2012. She was diagnosed with a stage II breast" exact="cancer" post="in April, 2011; a pathology report based on samples"/>
   <result pre="hemianopsia was noted after her physical examination. No organomegaly or" exact="lymphadenopathy" post="was found. As shown in Table 1, laboratory investigations"/>
   <result pre="serum sodium level changed rapidly despite treatment with desmopressin as" exact="panhypopituitarism" post="originated from the metastatic brain lesion ( Fig. 3)."/>
   <result pre="score. Discussion This is a case involving early recurrence of" exact="breast cancer" post="manifested with panhypopituitarism due to metastasis to the pituitary,"/>
   <result pre="Discussion This is a case involving early recurrence of breast" exact="cancer" post="manifested with panhypopituitarism due to metastasis to the pituitary,"/>
   <result pre="a case involving early recurrence of breast cancer manifested with" exact="panhypopituitarism" post="due to metastasis to the pituitary, pituitary stalk, and"/>
   <result pre="clinical history of the patient shows a rare pattern of" exact="breast cancer" post="metastasis. Brain metastasis developed despite previous treatment with trastuzumab"/>
   <result pre="history of the patient shows a rare pattern of breast" exact="cancer" post="metastasis. Brain metastasis developed despite previous treatment with trastuzumab"/>
   <result pre="metastasis developed despite previous treatment with trastuzumab in early stage" exact="breast cancer." post="Recent studies have suggested that trastuzumab may not be"/>
   <result pre="sanctuary site for disease progression in trastuzumab-treated patients with HER2-positive" exact="breast cancer." post="According to previous reports regarding pituitary metastasis from breast"/>
   <result pre="breast cancer. According to previous reports regarding pituitary metastasis from" exact="breast cancer," post="most patients are elderly, and have clinical and/or radiologic"/>
   <result pre="In this case, trastuzumab may have controlled the micro-metastasis of" exact="breast cancer" post="after the initial total mastectomy and lymph-node dissection, however,"/>
   <result pre="this case, trastuzumab may have controlled the micro-metastasis of breast" exact="cancer" post="after the initial total mastectomy and lymph-node dissection, however,"/>
   <result pre="radiation could not completely control the pituitary metastasis of the" exact="breast cancer." post="Metastatic pituitary lesions tend to be firm, diffuse, invasive,"/>
   <result pre="as active as first-line treatment of brain metastasis from HER2-positive" exact="breast cancer" post="in combination with capecitabine [ 12]. It has low"/>
   <result pre="active as first-line treatment of brain metastasis from HER2-positive breast" exact="cancer" post="in combination with capecitabine [ 12]. It has low"/>
   <result pre="associated with grade 3 and grade 4 toxicity (most commonly," exact="diarrhea" post="and hand-foot syndrome) [ 12], however, adjustment of regimen"/>
   <result pre="these issues. Widespread use of trastuzumab for treatment of HER2-positive" exact="breast cancer" post="leaves patients with an increased risk of brain metastasis"/>
   <result pre="issues. Widespread use of trastuzumab for treatment of HER2-positive breast" exact="cancer" post="leaves patients with an increased risk of brain metastasis"/>
   <result pre="metastasis. Pituitary metastasis is an uncommon but serious event of" exact="cancer" post="progression because it can lead to pituitary insufficiency. Life-long"/>
   <result pre="an effective alternative therapy for managing brain metastasis of HER2-positive" exact="breast cancer," post="in cases that cannot be completely controlled by surgery"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic" exact="breast cancer" post="Breast 2006 15 219 25 16026983 5 Pestalozzi BC"/>
   <result pre="with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast" exact="cancer" post="Breast 2006 15 219 25 16026983 5 Pestalozzi BC"/>
   <result pre="of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for" exact="cancer" post="Cancer Res 2001 61 7196 203 11585755 10 Geyer"/>
   <result pre="Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 2733 43 17192538"/>
   <result pre="T et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 2733 43 17192538"/>
   <result pre="lapatinib plus capecitabine versus capecitabine alone in women with advanced" exact="breast cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="plus capecitabine versus capecitabine alone in women with advanced breast" exact="cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="in patients with previously untreated brain metastases from HER2-positive metastatic" exact="breast cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="patients with previously untreated brain metastases from HER2-positive metastatic breast" exact="cancer" post="(LANDSCAPE): a single-group phase 2 study Lancet Oncol 2013"/>
   <result pre="Max MB Deck MD Rottenberg DA Pituitary metastasis: incidence in" exact="cancer" post="patients and clinical differentiation from pituitary adenoma Neurology 1981"/>
   <result pre="Pituitary metastasis: incidence in cancer patients and clinical differentiation from" exact="pituitary adenoma" post="Neurology 1981 31 998 1002 7196526 15 Taskar KS"/>
   <result pre="metastasis: incidence in cancer patients and clinical differentiation from pituitary" exact="adenoma" post="Neurology 1981 31 998 1002 7196526 15 Taskar KS"/>
   <result pre="al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of" exact="breast cancer" post="Pharm Res 2012 29 770 81 22011930 Fig. 1."/>
   <result pre="Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast" exact="cancer" post="Pharm Res 2012 29 770 81 22011930 Fig. 1."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4722889/results/search/disease/results.xml">
   <result pre="trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant" exact="mesothelioma" post="cells OKITA RIKI SHIMIZU KATSUHIKO NOJIMA YUJI YUKAWA TAKURO"/>
   <result pre="the clinical benefit of using EGFR/HER2-targeting drugs in patients with" exact="malignant pleural mesothelioma" post="(MPM). It was reported that the tyrosine kinase inhibitor"/>
   <result pre="benefit of using EGFR/HER2-targeting drugs in patients with malignant pleural" exact="mesothelioma" post="(MPM). It was reported that the tyrosine kinase inhibitor"/>
   <result pre="(TKI) lapatinib enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) in HER2-positive" exact="breast cancer," post="suggesting that this combination is a promising strategy for"/>
   <result pre="and trastuzumab may be a promising strategy for MPM treatment." exact="malignant pleural mesothelioma" post="antibody-dependent cellular cytotoxicity lapatinib trastuzumab cetuximab Introduction Malignant pleural"/>
   <result pre="may be a promising strategy for MPM treatment. malignant pleural" exact="mesothelioma" post="antibody-dependent cellular cytotoxicity lapatinib trastuzumab cetuximab Introduction Malignant pleural"/>
   <result pre="mesothelioma antibody-dependent cellular cytotoxicity lapatinib trastuzumab cetuximab Introduction Malignant pleural" exact="mesothelioma" post="(MPM) is an aggressive thoracic malignancy. Most patients are"/>
   <result pre="expression in breast ( 6), esophageal ( 7) and gastric" exact="cancer" post="( 8) cell lines. In the present study, we"/>
   <result pre="is a powerful tool for EGFR driver mutation-positive non-small cell" exact="lung cancer" post="(NSCLC) but invalid for NSCLC with an EGFR gatekeeper"/>
   <result pre="a powerful tool for EGFR driver mutation-positive non-small cell lung" exact="cancer" post="(NSCLC) but invalid for NSCLC with an EGFR gatekeeper"/>
   <result pre="is a dual EGFR/HER2-TKI with clinical benefit for HER2 over-expressing" exact="breast cancer" post="( 12) but resistance to T790M ( 13). Five"/>
   <result pre="a dual EGFR/HER2-TKI with clinical benefit for HER2 over-expressing breast" exact="cancer" post="( 12) but resistance to T790M ( 13). Five"/>
   <result pre="potential of the anti-HER2 antibody drug trastuzumab in HER2 overexpressing" exact="breast cancer" post="cells is ADCC ( 14), which is also a"/>
   <result pre="of the anti-HER2 antibody drug trastuzumab in HER2 overexpressing breast" exact="cancer" post="cells is ADCC ( 14), which is also a"/>
   <result pre="the recent studies showing that lapatinib enhanced trastuzumab-mediated ADCC in" exact="breast cancer" post="or gastrointestinal cancers ( 6– 8), we believe that"/>
   <result pre="recent studies showing that lapatinib enhanced trastuzumab-mediated ADCC in breast" exact="cancer" post="or gastrointestinal cancers ( 6– 8), we believe that"/>
   <result pre="al showed that afatinib monotherapy decreased the HER2 dimer in" exact="breast cancer" post="tissue collected from patients ( 17). It was also"/>
   <result pre="showed that afatinib monotherapy decreased the HER2 dimer in breast" exact="cancer" post="tissue collected from patients ( 17). It was also"/>
   <result pre="inactive HER2 homo- and heterodimers in the plasma membrane of" exact="breast cancer" post="cells ( 6). Based on these reported findings, the"/>
   <result pre="HER2 homo- and heterodimers in the plasma membrane of breast" exact="cancer" post="cells ( 6). Based on these reported findings, the"/>
   <result pre="Education, Culture, Sport, Science and Technology (to M.N.). Abbreviations MPM" exact="malignant pleural mesothelioma" post="TKI tyrosine kinase inhibitor ADCC antibody-dependent cellular cytotoxicity DMSO"/>
   <result pre="Sport, Science and Technology (to M.N.). Abbreviations MPM malignant pleural" exact="mesothelioma" post="TKI tyrosine kinase inhibitor ADCC antibody-dependent cellular cytotoxicity DMSO"/>
   <result pre="p- phosphorylated PBMC peripheral blood mononuclear cell NSCLC non-small cell" exact="lung cancer" post="E:T ratio effector/target ratio References References 1 Rusch VW"/>
   <result pre="phosphorylated PBMC peripheral blood mononuclear cell NSCLC non-small cell lung" exact="cancer" post="E:T ratio effector/target ratio References References 1 Rusch VW"/>
   <result pre="Rusch VW Venkatraman ES Important prognostic factors in patients with" exact="malignant pleural mesothelioma," post="managed surgically Ann Thorac Surg 68 1799 1804 1999"/>
   <result pre="in combination with cisplatin versus cisplatin alone in patients with" exact="malignant pleural mesothelioma" post="J Clin Oncol 21 2636 2644 2003 10.1200/JCO.2003.11.136 12860938"/>
   <result pre="with cisplatin versus cisplatin alone in patients with malignant pleural" exact="mesothelioma" post="J Clin Oncol 21 2636 2644 2003 10.1200/JCO.2003.11.136 12860938"/>
   <result pre="N Vaira V Alloisio M et al. EGFR overexpression in" exact="malignant pleural mesothelioma." post="An immunohistochemical and molecular study with clinico-pathological correlations Lung"/>
   <result pre="cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR-and HER2-overexpressing" exact="esophageal cancer" post="cell lines Int J Cancer 129 2408 2416 2011"/>
   <result pre="growth and enhances antibody-dependent cellular cytotoxicity of EGFR-and HER2-overexpressing esophageal" exact="cancer" post="cell lines Int J Cancer 129 2408 2416 2011"/>
   <result pre="Inoue M Fujii H et al. Lapatinib acts on gastric" exact="cancer" post="through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent"/>
   <result pre="K Sekido Y et al. Establishment and characterization of four" exact="malignant pleural mesothelioma" post="cell lines from Japanese patients Cancer Sci 97 387"/>
   <result pre="Y et al. Establishment and characterization of four malignant pleural" exact="mesothelioma" post="cell lines from Japanese patients Cancer Sci 97 387"/>
   <result pre="al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical" exact="lung cancer" post="models Oncogene 27 4702 4711 2008 10.1038/onc.2008.109 18408761 12"/>
   <result pre="BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung" exact="cancer" post="models Oncogene 27 4702 4711 2008 10.1038/onc.2008.109 18408761 12"/>
   <result pre="Kaufman B et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 355 2733 2743 2006 10.1056/NEJMoa064320"/>
   <result pre="B et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 355 2733 2743 2006 10.1056/NEJMoa064320"/>
   <result pre="M et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against" exact="lung cancer" post="cell lines Clin Cancer Res 13 1552 1561 2007"/>
   <result pre="et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung" exact="cancer" post="cell lines Clin Cancer Res 13 1552 1561 2007"/>
   <result pre="antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against" exact="malignant pleural mesothelioma" post="Int J Oncol 41 1610 1618 2012 22922885 17"/>
   <result pre="of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural" exact="mesothelioma" post="Int J Oncol 41 1610 1618 2012 22922885 17"/>
   <result pre="versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive" exact="breast cancer" post="Clin Breast Cancer 15 101 109 2015 10.1016/j.clbc.2014.11.004 25537159"/>
   <result pre="trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast" exact="cancer" post="Clin Breast Cancer 15 101 109 2015 10.1016/j.clbc.2014.11.004 25537159"/>
   <result pre="Figure 1 The expression of EGFR, HER2 and HER3 in" exact="malignant pleural mesothelioma" post="cells. The basal expression of each cell surface molecule"/>
   <result pre="The expression of EGFR, HER2 and HER3 in malignant pleural" exact="mesothelioma" post="cells. The basal expression of each cell surface molecule"/>
   <result pre="line). Figure 2 Tyrosine kinase inhibitors inhibited cell proliferation in" exact="malignant pleural mesothelioma" post="cells. Five malignant pleural mesothelioma (MPM) cell lines and"/>
   <result pre="2 Tyrosine kinase inhibitors inhibited cell proliferation in malignant pleural" exact="mesothelioma" post="cells. Five malignant pleural mesothelioma (MPM) cell lines and"/>
   <result pre="inhibitors inhibited cell proliferation in malignant pleural mesothelioma cells. Five" exact="malignant pleural mesothelioma" post="(MPM) cell lines and tumor cells from a patient"/>
   <result pre="cell proliferation in malignant pleural mesothelioma cells. Five malignant pleural" exact="mesothelioma" post="(MPM) cell lines and tumor cells from a patient"/>
   <result pre="inhibitors on the expression of EGFR, HER2 and HER3 in" exact="malignant pleural mesothelioma" post="cells. Five malignant pleural mesothelioma (MPM) cell lines and"/>
   <result pre="the expression of EGFR, HER2 and HER3 in malignant pleural" exact="mesothelioma" post="cells. Five malignant pleural mesothelioma (MPM) cell lines and"/>
   <result pre="EGFR, HER2 and HER3 in malignant pleural mesothelioma cells. Five" exact="malignant pleural mesothelioma" post="(MPM) cell lines and a patient-derived MPM cells were"/>
   <result pre="and HER3 in malignant pleural mesothelioma cells. Five malignant pleural" exact="mesothelioma" post="(MPM) cell lines and a patient-derived MPM cells were"/>
   <result pre="of tyrosine kinase inhibitor on EGFR and HER2 signaling in" exact="malignant pleural mesothelioma" post="cells. Western blot analysis showing total EGFR and HER2,"/>
   <result pre="kinase inhibitor on EGFR and HER2 signaling in malignant pleural" exact="mesothelioma" post="cells. Western blot analysis showing total EGFR and HER2,"/>
   <result pre="upregulated HER2 expression and enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity in" exact="malignant pleural mesothelioma" post="cell lines. (A) NCI-H28 and (B) NCI-H2052 cells were"/>
   <result pre="expression and enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity in malignant pleural" exact="mesothelioma" post="cell lines. (A) NCI-H28 and (B) NCI-H2052 cells were"/>
   <result pre="cellular cytotoxicity via upregulations of EGFR and HER2 in patient-derived" exact="malignant pleural mesothelioma" post="cells. Patient-derived MPM-p3 cells were treated with DMSO or"/>
   <result pre="via upregulations of EGFR and HER2 in patient-derived malignant pleural" exact="mesothelioma" post="cells. Patient-derived MPM-p3 cells were treated with DMSO or"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4728453/results/search/disease/results.xml">
   <result pre="on the PK of anticancer agents frequently administered to elderly" exact="breast cancer" post="patients. Methods: A literature search was performed using the"/>
   <result pre="the PK of anticancer agents frequently administered to elderly breast" exact="cancer" post="patients. Methods: A literature search was performed using the"/>
   <result pre="that describe age-related PK profiles of selected anticancer drugs against" exact="breast cancer," post="excluding endocrine compounds, were selected and included. Results: This"/>
   <result pre="PK of selected anticancer drugs used for the treatment of" exact="breast cancer." post="Conclusions: Selected published data revealed differences in the effect"/>
   <result pre="Score or geriatric functional assessment. pharmacology pharmacokinetics anticancer drugs elderly" exact="breast cancer" post="1. Introduction The majority of patients diagnosed with cancer"/>
   <result pre="or geriatric functional assessment. pharmacology pharmacokinetics anticancer drugs elderly breast" exact="cancer" post="1. Introduction The majority of patients diagnosed with cancer"/>
   <result pre="breast cancer 1. Introduction The majority of patients diagnosed with" exact="cancer" post="are aged 65 years and older, and it is"/>
   <result pre="it is predicted that in the period from 2010–2030, the" exact="cancer" post="incidence in the elderly will increase by 67% ["/>
   <result pre="the underrepresentation of older patients has been substantial, even in" exact="cancer" post="types that predominantly occur in the elderly [ 5,"/>
   <result pre="safety and effectiveness in clinical practice. In daily practice, elderly" exact="breast cancer" post="patients have a higher risk of death from breast"/>
   <result pre="and effectiveness in clinical practice. In daily practice, elderly breast" exact="cancer" post="patients have a higher risk of death from breast"/>
   <result pre="breast cancer patients have a higher risk of death from" exact="breast cancer" post="compared to their younger peers [ 10]. This may"/>
   <result pre="cancer patients have a higher risk of death from breast" exact="cancer" post="compared to their younger peers [ 10]. This may"/>
   <result pre="potential dose adjustments of anticancer agents frequently administered to elderly" exact="breast cancer" post="patients. 2. Influence of Aging on Drug Pharmacokinetics With"/>
   <result pre="dose adjustments of anticancer agents frequently administered to elderly breast" exact="cancer" post="patients. 2. Influence of Aging on Drug Pharmacokinetics With"/>
   <result pre="the PK profile of a specific drug administered to elderly" exact="breast cancer" post="patients. Besides these physiological changes, multiple other factors contribute"/>
   <result pre="PK profile of a specific drug administered to elderly breast" exact="cancer" post="patients. Besides these physiological changes, multiple other factors contribute"/>
   <result pre="anticancer treatment [ 12, 15, 16]. For instance, patients with" exact="diabetes mellitus" post="encountered more chemotherapy-related toxicities when receiving adjuvant chemotherapy for"/>
   <result pre="mellitus encountered more chemotherapy-related toxicities when receiving adjuvant chemotherapy for" exact="breast cancer" post="compared to the non-diabetic control group [ 17]. While"/>
   <result pre="encountered more chemotherapy-related toxicities when receiving adjuvant chemotherapy for breast" exact="cancer" post="compared to the non-diabetic control group [ 17]. While"/>
   <result pre="non-geriatric patients. Because the proportion and absolute number of elderly" exact="cancer" post="patients is steadily increasing, and with it the detrimental"/>
   <result pre="steadily increasing, and with it the detrimental impact of suboptimal" exact="cancer" post="treatment, it is important to have adequate evidence-based anticancer"/>
   <result pre="anticancer drug regimens that are tailored to use in elderly" exact="breast cancer" post="patients. 3. Methodology A literature search was performed using"/>
   <result pre="drug regimens that are tailored to use in elderly breast" exact="cancer" post="patients. 3. Methodology A literature search was performed using"/>
   <result pre="data on anticancer drugs that were frequently administered to elderly" exact="breast cancer" post="patients, excluding endocrine compounds. The following keywords were used:"/>
   <result pre="on anticancer drugs that were frequently administered to elderly breast" exact="cancer" post="patients, excluding endocrine compounds. The following keywords were used:"/>
   <result pre="evaluation of pivotal trial data has been conducted for elderly" exact="breast cancer" post="patients [ 20]. Four different studies found no significant"/>
   <result pre="of pivotal trial data has been conducted for elderly breast" exact="cancer" post="patients [ 20]. Four different studies found no significant"/>
   <result pre="NA NS Wade 1992 Epirubicin 25–100 mg/m 2 MC, lymphoma," exact="sarcoma" post="36 NA (20–73) ≥70 y; n = 1 SIG"/>
   <result pre="= 57 Denham 1999 5-FU–cisplatin 5-FU: 800 mg/m 2 Esophageal" exact="cancer" post="44 72 (42–91) NA 5FU: SIG Cisplatin: 80 mg/m"/>
   <result pre="Vss = volume of distribution at steady-state conditions; CRC =" exact="colorectal cancer;" post="D &amp;gt;0.1 μM = duration drug concentration above 0.1"/>
   <result pre="MRT = mean residence time (h); NSCLC = non-small cell" exact="lung cancer;" post="PK = pharmacokinetics; po = per os; RCC ="/>
   <result pre="cancer; PK = pharmacokinetics; po = per os; RCC =" exact="renal cell carcinoma;" post="SD = standard deviation; T ½ = terminal half-life"/>
   <result pre="or longer interval between cycles in elderly women with metastatic" exact="breast cancer," post="without providing support or references [ 45]. Relatively small"/>
   <result pre="in two different study populations ( n = 37 with" exact="breast cancer," post="lymphoma or other tumors and n = 26 with"/>
   <result pre="different study populations ( n = 37 with breast cancer," exact="lymphoma" post="or other tumors and n = 26 with solid"/>
   <result pre="49]. These findings were supported by a study including 65" exact="breast cancer" post="patients, showing a significant 9% decrease in doxorubicin clearance"/>
   <result pre="These findings were supported by a study including 65 breast" exact="cancer" post="patients, showing a significant 9% decrease in doxorubicin clearance"/>
   <result pre="in the bile [ 51]. In one study, including 78" exact="breast cancer" post="patients, no relevant age-related differences in PK of epirubicin"/>
   <result pre="the bile [ 51]. In one study, including 78 breast" exact="cancer" post="patients, no relevant age-related differences in PK of epirubicin"/>
   <result pre="53]. This finding was supported by a study including 66" exact="breast cancer" post="patients, showing an increased epirubicin maximum serum concentration with"/>
   <result pre="This finding was supported by a study including 66 breast" exact="cancer" post="patients, showing an increased epirubicin maximum serum concentration with"/>
   <result pre="as independent predictors of dose reductions in elderly patients with" exact="colon cancer" post="[ 87]. Twelves et al. showed that patients aged"/>
   <result pre="independent predictors of dose reductions in elderly patients with colon" exact="cancer" post="[ 87]. Twelves et al. showed that patients aged"/>
   <result pre="extracellular HER-2 receptor that is overexpressed in roughly 25% of" exact="breast cancer" post="patients. After intravenous administration, trastuzumab undergoes target-directed distribution and"/>
   <result pre="HER-2 receptor that is overexpressed in roughly 25% of breast" exact="cancer" post="patients. After intravenous administration, trastuzumab undergoes target-directed distribution and"/>
   <result pre="of 3–4 weeks. Trastuzumab is approved in patients with HER2-positive" exact="breast cancer" post="in the early or advanced stage. While trastuzumab is"/>
   <result pre="3–4 weeks. Trastuzumab is approved in patients with HER2-positive breast" exact="cancer" post="in the early or advanced stage. While trastuzumab is"/>
   <result pre="trastuzumab is given as a three-weekly intravenous infusion in early-stage" exact="breast cancer" post="[ 118], it is usually given as a weekly"/>
   <result pre="is given as a three-weekly intravenous infusion in early-stage breast" exact="cancer" post="[ 118], it is usually given as a weekly"/>
   <result pre="usually given as a weekly infusion in patients with metastatic" exact="breast cancer" post="[ 119]. In a large pooled dataset of 164"/>
   <result pre="given as a weekly infusion in patients with metastatic breast" exact="cancer" post="[ 119]. In a large pooled dataset of 164"/>
   <result pre="of 164 patients with early-stage and 76 patients with metastatic" exact="breast cancer," post="the authors performed a population PK-PD analysis to assess"/>
   <result pre="to keep a favorable benefit-risk profile also in the elderly" exact="breast cancer" post="patient. This is also in agreement with data as"/>
   <result pre="keep a favorable benefit-risk profile also in the elderly breast" exact="cancer" post="patient. This is also in agreement with data as"/>
   <result pre="and EMA approval for the treatment of locally-advanced or metastatic" exact="breast cancer" post="refractory to both anthracyclines and taxanes. According to the"/>
   <result pre="EMA approval for the treatment of locally-advanced or metastatic breast" exact="cancer" post="refractory to both anthracyclines and taxanes. According to the"/>
   <result pre="the PK of anticancer drugs used for the treatment of" exact="breast cancer" post="(excluding endocrine drugs). Although PK results published on many"/>
   <result pre="PK of anticancer drugs used for the treatment of breast" exact="cancer" post="(excluding endocrine drugs). Although PK results published on many"/>
   <result pre="recommendations per anticancer drug for elderly women in the current" exact="breast cancer" post="guidelines [ 143, 144, 145, 146, 147]. Some published"/>
   <result pre="per anticancer drug for elderly women in the current breast" exact="cancer" post="guidelines [ 143, 144, 145, 146, 147]. Some published"/>
   <result pre="the American Association of Clinical Oncology (ASCO) on advanced HER2-positive" exact="breast cancer" post="however support the need for high quality data in"/>
   <result pre="American Association of Clinical Oncology (ASCO) on advanced HER2-positive breast" exact="cancer" post="however support the need for high quality data in"/>
   <result pre="advice for the elderly population [ 143]. The respective European" exact="breast cancer" post="guidelines state that treatment decisions should not be age"/>
   <result pre="for the elderly population [ 143]. The respective European breast" exact="cancer" post="guidelines state that treatment decisions should not be age"/>
   <result pre="While combination chemotherapy is clearly more effective in the adjuvant" exact="breast cancer" post="setting, single-agent sequential chemotherapy is advised to be the"/>
   <result pre="combination chemotherapy is clearly more effective in the adjuvant breast" exact="cancer" post="setting, single-agent sequential chemotherapy is advised to be the"/>
   <result pre="dose adaptations or dose reductions are considered in an elderly" exact="breast cancer" post="patient, clinicians should consider the following issues: (1) potential"/>
   <result pre="adaptations or dose reductions are considered in an elderly breast" exact="cancer" post="patient, clinicians should consider the following issues: (1) potential"/>
   <result pre="regulatory agencies; and (4) a holistic approach for the older" exact="cancer" post="patient including international geriatric assessments, such as the Comprehensive"/>
   <result pre="Smith G.L. Hurria A. Hortobagyi G.N. Buchholz T.A. Future of" exact="cancer" post="incidence in the United States: Burdens upon an aging,"/>
   <result pre="21286840 5. Murthy V.H. Krumholz H.M. Gross C.P. Participation in" exact="cancer" post="clinical trials: Race-, sex, and aged-based disparities Prim. Care"/>
   <result pre="Participation of patients 65 years of age or older in" exact="cancer" post="clinical trials J. Clin. Oncol. 2003 21 1383 1389"/>
   <result pre="M.L.G. Dekkers O.M. van de Velde C.J.H. et al. Breast" exact="cancer" post="in elderly compared to younger patients in the Netherlands:"/>
   <result pre="C.J.H. Liefers G.J. Impact of comorbidity on outcome of older" exact="breast cancer" post="patients: A FOCUS cohort study Breast Cancer Res. Treat."/>
   <result pre="Liefers G.J. Impact of comorbidity on outcome of older breast" exact="cancer" post="patients: A FOCUS cohort study Breast Cancer Res. Treat."/>
   <result pre="L. Potential drug interactions and chemotoxicity in older patients with" exact="cancer" post="receiving chemotherapy J. Geriatr. Oncol. 2015 5 307 314"/>
   <result pre="Srokowski T.P. Fang S. Hortobagyi G.N. Giordano S.H. Impact of" exact="diabetes mellitus" post="on complications and outcomes of adjuvant chemotherapy in older"/>
   <result pre="complications and outcomes of adjuvant chemotherapy in older patients with" exact="breast cancer" post="J. Clin. Oncol. 2009 27 2170 2176 10.1200/JCO.2008.17.5935 19307509"/>
   <result pre="and outcomes of adjuvant chemotherapy in older patients with breast" exact="cancer" post="J. Clin. Oncol. 2009 27 2170 2176 10.1200/JCO.2008.17.5935 19307509"/>
   <result pre="effect of comorbidity on 3-year survival of women with primary" exact="breast cancer" post="Ann. Intern. Med. 1994 120 104 110 10.7326/0003-4819-120-2-199401150-00002 8256968"/>
   <result pre="of comorbidity on 3-year survival of women with primary breast" exact="cancer" post="Ann. Intern. Med. 1994 120 104 110 10.7326/0003-4819-120-2-199401150-00002 8256968"/>
   <result pre="B.K. Yates J.W. Effect of age and comorbidity in postmenopausal" exact="breast cancer" post="patients aged 55 years and older JAMA 2001 285"/>
   <result pre="Yates J.W. Effect of age and comorbidity in postmenopausal breast" exact="cancer" post="patients aged 55 years and older JAMA 2001 285"/>
   <result pre="L.P. Population pharmacokinetics of weekly docetaxel in patients with advanced" exact="cancer" post="Br. J. Clin. Pharmacol. 2004 57 44 53 10.1046/j.1365-2125.2003.01956.x"/>
   <result pre="impact of co-morbidity in elderly patients with advanced non-small cell" exact="lung cancer" post="treated with chemotherapy. A phase II study of weekly"/>
   <result pre="of co-morbidity in elderly patients with advanced non-small cell lung" exact="cancer" post="treated with chemotherapy. A phase II study of weekly"/>
   <result pre="Altered clearance of unbound paclitaxel in elderly patients with metastatic" exact="breast cancer" post="Eur. J. Cancer 2003 39 196 202 10.1016/S0959-8049(02)00611-1 12509952"/>
   <result pre="clearance of unbound paclitaxel in elderly patients with metastatic breast" exact="cancer" post="Eur. J. Cancer 2003 39 196 202 10.1016/S0959-8049(02)00611-1 12509952"/>
   <result pre="in a dose-escalating and dose-sequencing study in patients with non-small-cell" exact="lung cancer." post="The European Cancer Centre J. Clin. Oncol. 1997 15"/>
   <result pre="evaluation of age-related toxicity of adjuvant chemotherapy in women with" exact="breast cancer" post="Cancer Investig. 2000 18 521 529 10.3109/07357900009012191 10923100 48."/>
   <result pre="of age-related toxicity of adjuvant chemotherapy in women with breast" exact="cancer" post="Cancer Investig. 2000 18 521 529 10.3109/07357900009012191 10923100 48."/>
   <result pre="al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in" exact="breast cancer" post="patients: A study by the EORTC-PAMM-NDDG Clin. Pharmacokinet. 2007"/>
   <result pre="Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast" exact="cancer" post="patients: A study by the EORTC-PAMM-NDDG Clin. Pharmacokinet. 2007"/>
   <result pre="at four different dose levels: Studies in patients with metastatic" exact="breast cancer" post="Cancer Chemother. Pharmacol. 1991 28 63 68 10.1007/BF00684959 2040035"/>
   <result pre="four different dose levels: Studies in patients with metastatic breast" exact="cancer" post="Cancer Chemother. Pharmacol. 1991 28 63 68 10.1007/BF00684959 2040035"/>
   <result pre="Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic" exact="breast cancer" post="Eur. J. Cancer 1997 33 301 303 10.1016/S0959-8049(96)00426-1 9135505"/>
   <result pre="and tolerance of vinorelbine in elderly patients with metastatic breast" exact="cancer" post="Eur. J. Cancer 1997 33 301 303 10.1016/S0959-8049(96)00426-1 9135505"/>
   <result pre="al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with" exact="cancer" post="J. Clin. Oncol. 2006 24 2448 2455 10.1200/JCO.2005.02.1295 16651648"/>
   <result pre="of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic" exact="cancer" post="Clin. Cancer Res. 2000 6 2690 2695 10914711 67."/>
   <result pre="pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic" exact="cancer" post="Anticancer Drugs 2002 13 473 480 10.1097/00001813-200206000-00005 12045458 68."/>
   <result pre="Salvador J. Albanell J. Isla D. et al. Treatment of" exact="cancer" post="with oral drugs: A position statement by the Spanish"/>
   <result pre="in DPYD and toxicity and efficacy of capecitabine in advanced" exact="colorectal cancer" post="Clin. Cancer Res. 2011 17 3455 3468 10.1158/1078-0432.CCR-10-2209 21498394"/>
   <result pre="DPYD and toxicity and efficacy of capecitabine in advanced colorectal" exact="cancer" post="Clin. Cancer Res. 2011 17 3455 3468 10.1158/1078-0432.CCR-10-2209 21498394"/>
   <result pre="for increased myelosuppression with increasing age in patients with oesophageal" exact="cancer" post="treated by chemoradiotherapy Eur. J. Cancer 1999 35 921"/>
   <result pre="approach: Comparative study in elderly and non-elderly patients with metastatic" exact="colorectal cancer" post="J. Chemother. 2010 22 179 185 10.1179/joc.2010.22.3.179 20566423 84."/>
   <result pre="Comparative study in elderly and non-elderly patients with metastatic colorectal" exact="cancer" post="J. Chemother. 2010 22 179 185 10.1179/joc.2010.22.3.179 20566423 84."/>
   <result pre="R.E. Chemotherapy options in elderly and frail patients with metastatic" exact="colorectal cancer" post="(MRC FOCUS2): An open-label, randomised factorial trial Lancet 2011"/>
   <result pre="Chemotherapy options in elderly and frail patients with metastatic colorectal" exact="cancer" post="(MRC FOCUS2): An open-label, randomised factorial trial Lancet 2011"/>
   <result pre="Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced" exact="pancreatic cancer" post="Radiat. Oncol. 2013 8 160 10.1186/1748-717X-8-160 23822606 87. Chang"/>
   <result pre="of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic" exact="cancer" post="Radiat. Oncol. 2013 8 160 10.1186/1748-717X-8-160 23822606 87. Chang"/>
   <result pre="capecitabine chemotherapy using a tailored-dose strategy in elderly patients with" exact="colon cancer" post="Ann. Oncol. 2012 23 911 918 10.1093/annonc/mdr329 21821549 88."/>
   <result pre="chemotherapy using a tailored-dose strategy in elderly patients with colon" exact="cancer" post="Ann. Oncol. 2012 23 911 918 10.1093/annonc/mdr329 21821549 88."/>
   <result pre="two different doses of capecitabine in the treatment of advanced" exact="breast cancer" post="in older women J. Clin. Oncol. 2005 23 2155"/>
   <result pre="different doses of capecitabine in the treatment of advanced breast" exact="cancer" post="in older women J. Clin. Oncol. 2005 23 2155"/>
   <result pre="versus capecitabine alone in elderly patients with previously untreated metastatic" exact="colorectal cancer" post="(AVEX): An open-label, randomised phase 3 trial Lancet Oncol."/>
   <result pre="capecitabine alone in elderly patients with previously untreated metastatic colorectal" exact="cancer" post="(AVEX): An open-label, randomised phase 3 trial Lancet Oncol."/>
   <result pre="V. et al. Capecitabine as adjuvant treatment for stage III" exact="colon cancer" post="N. Engl. J. Med. 2005 352 2696 2704 10.1056/NEJMoa043116"/>
   <result pre="et al. Capecitabine as adjuvant treatment for stage III colon" exact="cancer" post="N. Engl. J. Med. 2005 352 2696 2704 10.1056/NEJMoa043116"/>
   <result pre="evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic" exact="breast cancer" post="Eur. J. Cancer 2004 40 536 542 10.1016/j.ejca.2003.11.007 14962720"/>
   <result pre="capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast" exact="cancer" post="Eur. J. Cancer 2004 40 536 542 10.1016/j.ejca.2003.11.007 14962720"/>
   <result pre="Qiu M. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III" exact="colorectal cancer" post="patients (LC-ACEC): Study protocol for a randomized controlled trial"/>
   <result pre="M. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal" exact="cancer" post="patients (LC-ACEC): Study protocol for a randomized controlled trial"/>
   <result pre="J.L. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in" exact="colorectal cancer" post="patients Br. J. Clin. Pharmacol. 2003 55 252 263"/>
   <result pre="Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal" exact="cancer" post="patients Br. J. Clin. Pharmacol. 2003 55 252 263"/>
   <result pre="area, and creatinine clearance as factors influencing systemic exposure in" exact="cancer" post="patients Cancer Chemother. Pharmacol. 1999 44 453 460 10.1007/s002800051118"/>
   <result pre="exposure-effect relationships of capecitabine in elderly patients with breast or" exact="colorectal cancer" post="Cancer Chemother. Pharmacol. 2014 73 1285 1293 10.1007/s00280-014-2466-0 24801171"/>
   <result pre="relationships of capecitabine in elderly patients with breast or colorectal" exact="cancer" post="Cancer Chemother. Pharmacol. 2014 73 1285 1293 10.1007/s00280-014-2466-0 24801171"/>
   <result pre="Blanke C.D. Higher capecitabine AUC in elderly patients with advanced" exact="colorectal cancer" post="(SWOGS0030) Br. J. Cancer 2013 109 1744 1749 10.1038/bjc.2013.517"/>
   <result pre="C.D. Higher capecitabine AUC in elderly patients with advanced colorectal" exact="cancer" post="(SWOGS0030) Br. J. Cancer 2013 109 1744 1749 10.1038/bjc.2013.517"/>
   <result pre="exposure and haematological toxicity of carboplatin in advanced non-small cell" exact="lung cancer" post="patients Basic Clin. Pharmacol. Toxicol. 2011 109 457 464"/>
   <result pre="and haematological toxicity of carboplatin in advanced non-small cell lung" exact="cancer" post="patients Basic Clin. Pharmacol. Toxicol. 2011 109 457 464"/>
   <result pre="Creatinine clearance as a predictor of ultrafilterable platinum disposition in" exact="cancer" post="patients treated with cisplatin: Relationship between peak ultrafilterable platinum"/>
   <result pre="Katsumata N. The influence of ageing on cisplatin pharmacokinetics in" exact="lung cancer" post="patients with normal organ function Cancer Chemother. Pharmacol. 1995"/>
   <result pre="N. The influence of ageing on cisplatin pharmacokinetics in lung" exact="cancer" post="patients with normal organ function Cancer Chemother. Pharmacol. 1995"/>
   <result pre="Jackisch C. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N. Engl. J. Med. 2005 353 1659 1672 10.1056/NEJMoa052306"/>
   <result pre="C. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N. Engl. J. Med. 2005 353 1659 1672 10.1056/NEJMoa052306"/>
   <result pre="III trial of weekly compared with every-3-weeks paclitaxel for metastatic" exact="breast cancer," post="with trastuzumab for all HER-2 overexpressors and random assignment"/>
   <result pre="to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic" exact="breast cancer" post="Clin. Pharmacokinet. 2013 52 657 672 10.1007/s40262-013-0060-y 23553425 125."/>
   <result pre="evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast" exact="cancer" post="Clin. Pharmacokinet. 2013 52 657 672 10.1007/s40262-013-0060-y 23553425 125."/>
   <result pre="M. Gambassi G. Assessment and treatment of elderly patients with" exact="cancer" post="Surg. Oncol. 2010 19 117 123 10.1016/j.suronc.2009.11.008 20006489 150."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4729711/results/search/disease/results.xml">
   <result pre="are the three major classes of drugs used to treat" exact="breast cancer." post="Imaging modalities such as computed tomography (CT), magnetic resonance"/>
   <result pre="article is to elucidate the various systemic therapies used in" exact="breast cancer," post="with an emphasis on the role of imaging in"/>
   <result pre="CT is the workhorse for assessment of treatment response in" exact="breast cancer" post="metastases. • Alternate treatment response criteria can help in"/>
   <result pre="is the workhorse for assessment of treatment response in breast" exact="cancer" post="metastases. • Alternate treatment response criteria can help in"/>
   <result pre="chemotherapy and with endocrine and HER2-targeted therapies . Keywords Breast" exact="cancer" post="Hormonal therapy Molecular-targeted therapy CT MRI Funding http://dx.doi.org/10.13039/100005625 RSNA"/>
   <result pre="few decades in the systemic (non-surgical and non-radiation) treatment of" exact="breast cancer," post="with treatment regimens evolving from single-agent chemotherapy to those"/>
   <result pre="attributed to a better understanding of the molecular complexity of" exact="breast cancer." post="Recent studies have revealed that there are several molecular"/>
   <result pre="studies have revealed that there are several molecular phenotypes of" exact="breast cancer," post="based on receptor expression [ 2]. The major subtypes"/>
   <result pre="these include luminal A, luminal B, HER2-positive and triple-negative (TN)" exact="breast cancer" post="[ 2]. The risk of recurrence, disease management and"/>
   <result pre="include luminal A, luminal B, HER2-positive and triple-negative (TN) breast" exact="cancer" post="[ 2]. The risk of recurrence, disease management and"/>
   <result pre="MTTs have also changed the course of treatment in triple-negative" exact="breast cancer" post="(TNBC). The increased use of these drugs in clinical"/>
   <result pre="have also changed the course of treatment in triple-negative breast" exact="cancer" post="(TNBC). The increased use of these drugs in clinical"/>
   <result pre="of the various cytotoxic, hormonal and biologic agents used in" exact="breast cancer" post="in neoadjuvant, adjuvant and metastatic settings, with an emphasis"/>
   <result pre="the various cytotoxic, hormonal and biologic agents used in breast" exact="cancer" post="in neoadjuvant, adjuvant and metastatic settings, with an emphasis"/>
   <result pre="Systemic treatment in breast cancer: an overview Systemic treatment in" exact="breast cancer" post="includes cytotoxic chemotherapy, hormonal therapy, molecular-targeted therapy or a"/>
   <result pre="treatment in breast cancer: an overview Systemic treatment in breast" exact="cancer" post="includes cytotoxic chemotherapy, hormonal therapy, molecular-targeted therapy or a"/>
   <result pre="irrespective of other tumour characteristics. Table 1 Systemic treatment in" exact="breast cancer" post="Drugs Mechanism of action Side effects Chemotherapy Anthracycline (doxorubicin"/>
   <result pre="of other tumour characteristics. Table 1 Systemic treatment in breast" exact="cancer" post="Drugs Mechanism of action Side effects Chemotherapy Anthracycline (doxorubicin"/>
   <result pre="epirubicin) Inhibits DNA and RNA synthesis Cardiotoxicity, typhlitis, bone marrow" exact="suppression" post="Taxanes (paclitaxel and docetaxel) Inhibits mitosis by stabilization of"/>
   <result pre="enters the cell and releases the cytotoxic agent emtansine Hepatotoxicity," exact="thrombocytopenia" post="The commonly used cytotoxic drugs are taxanes (paclitaxel and"/>
   <result pre="Taxanes and anthracyclines are the mainstay in first-line treatment of" exact="breast cancer" post="in the adjuvant, neoadjuvant and metastatic settings, and are"/>
   <result pre="and anthracyclines are the mainstay in first-line treatment of breast" exact="cancer" post="in the adjuvant, neoadjuvant and metastatic settings, and are"/>
   <result pre="settings, and are often used with HER2-targeted therapies in HER2-positive" exact="breast cancer" post="and with hormonal therapy in HR-positive breast cancer. Anthracycline-based"/>
   <result pre="and are often used with HER2-targeted therapies in HER2-positive breast" exact="cancer" post="and with hormonal therapy in HR-positive breast cancer. Anthracycline-based"/>
   <result pre="in HER2-positive breast cancer and with hormonal therapy in HR-positive" exact="breast cancer." post="Anthracycline-based regimens have shown greater efficacy than non-anthracycline based"/>
   <result pre="regimens. Hormonal therapy is recommended for most women with HR-positive" exact="breast cancer." post="Tamoxifen, a selective oestrogen receptor modulator (SERM), acts as"/>
   <result pre="equivalent to superior response compared to neoadjuvant chemotherapy in HR-positive" exact="breast cancer." post="Studies have demonstrated greater rates of breast-conserving surgery in"/>
   <result pre="demonstrated greater rates of breast-conserving surgery in postmenopausal oestrogen receptor-positive" exact="breast cancer" post="patients on neoadjuvant hormonal therapy versus neoadjuvant chemotherapy ["/>
   <result pre="greater rates of breast-conserving surgery in postmenopausal oestrogen receptor-positive breast" exact="cancer" post="patients on neoadjuvant hormonal therapy versus neoadjuvant chemotherapy ["/>
   <result pre="approved for second-line use in postmenopausal women with HR-positive metastatic" exact="breast cancer" post="with disease progression following treatment with an anti-oestrogen ["/>
   <result pre="for second-line use in postmenopausal women with HR-positive metastatic breast" exact="cancer" post="with disease progression following treatment with an anti-oestrogen ["/>
   <result pre="hormonal therapies used in the adjuvant and metastatic setting in" exact="breast cancer" post="[ 1]. Trastuzumab (Herceptin) is a monoclonal antibody that"/>
   <result pre="therapies used in the adjuvant and metastatic setting in breast" exact="cancer" post="[ 1]. Trastuzumab (Herceptin) is a monoclonal antibody that"/>
   <result pre="[ 1]. Trastuzumab (Herceptin) is a monoclonal antibody that targets" exact="cancer" post="cells that over-express a protein called HER2 that is"/>
   <result pre="vessel formation (angiogenesis). Up to 20 % of women with" exact="breast cancer" post="have tumours with high levels of HER2, and many"/>
   <result pre="formation (angiogenesis). Up to 20 % of women with breast" exact="cancer" post="have tumours with high levels of HER2, and many"/>
   <result pre="combination with standard first-line chemotherapy for the treatment of HER2-positive" exact="breast cancer" post="[ 8, 9]. Pertuzumab is another HER2 receptor inhibitor"/>
   <result pre="with standard first-line chemotherapy for the treatment of HER2-positive breast" exact="cancer" post="[ 8, 9]. Pertuzumab is another HER2 receptor inhibitor"/>
   <result pre="States Food and Drug Administration (FDA) for use in metastatic" exact="breast cancer." post="Other targeted agents currently being studied in breast cancer"/>
   <result pre="metastatic breast cancer. Other targeted agents currently being studied in" exact="breast cancer" post="include other HER2-directed agents (lapatinib); HER3 agents, which inhibit"/>
   <result pre="breast cancer. Other targeted agents currently being studied in breast" exact="cancer" post="include other HER2-directed agents (lapatinib); HER3 agents, which inhibit"/>
   <result pre="evaluated in patients with refractory CNS metastases from HER2-positive metastatic" exact="breast cancer," post="given its ability to achieve therapeutic levels in cerebrospinal"/>
   <result pre="frequently to determine drug efficacy. Table 2 Imaging of metastatic" exact="breast cancer" post="Location Imaging modalities Remarks CNS MRI • Modality of"/>
   <result pre="to determine drug efficacy. Table 2 Imaging of metastatic breast" exact="cancer" post="Location Imaging modalities Remarks CNS MRI • Modality of"/>
   <result pre="computed tomography (MDCT) MDCT is the workhorse for monitoring metastatic" exact="breast cancer." post="Liver metastases occur in more than 50 % patients"/>
   <result pre="Liver metastases occur in more than 50 % patients with" exact="breast cancer," post="and are seen as hypodense lesions. Restaging MDCT scans"/>
   <result pre="we routinely perform non-contrast imaging of the abdomen in all" exact="breast cancer" post="patients, as breast cancer metastases can sometimes remain occult"/>
   <result pre="routinely perform non-contrast imaging of the abdomen in all breast" exact="cancer" post="patients, as breast cancer metastases can sometimes remain occult"/>
   <result pre="imaging of the abdomen in all breast cancer patients, as" exact="breast cancer" post="metastases can sometimes remain occult on the portal venous"/>
   <result pre="of the abdomen in all breast cancer patients, as breast" exact="cancer" post="metastases can sometimes remain occult on the portal venous"/>
   <result pre="of MDCT in assessing treatment response in liver metastasis from" exact="breast cancer." post="The Response Evaluation Criteria in Solid Tumours (RECIST) is"/>
   <result pre="RECIST was inadequate for assessing response to targeted therapies in" exact="breast cancer" post="liver metastasis. In their study of 39 patients with"/>
   <result pre="was inadequate for assessing response to targeted therapies in breast" exact="cancer" post="liver metastasis. In their study of 39 patients with"/>
   <result pre="was better [ 18]. Fig. 1 65-year-old woman with triple-positive" exact="breast cancer" post="with multiple hepatic metastases treated with systemic chemotherapy. a"/>
   <result pre="better [ 18]. Fig. 1 65-year-old woman with triple-positive breast" exact="cancer" post="with multiple hepatic metastases treated with systemic chemotherapy. a"/>
   <result pre="lesions in right lobe A classic finding seen in treated" exact="breast cancer" post="metastases is hepatic capsular retraction, or &quot;pseudocirrhosis&quot; (Fig. 1)."/>
   <result pre="in right lobe A classic finding seen in treated breast" exact="cancer" post="metastases is hepatic capsular retraction, or &quot;pseudocirrhosis&quot; (Fig. 1)."/>
   <result pre="such cases. Fig. 2 58-year-old woman with estrogen receptor-positive metastatic" exact="breast cancer" post="treated with trastuzumab. a Axial contrast-enhanced CT image of"/>
   <result pre="cases. Fig. 2 58-year-old woman with estrogen receptor-positive metastatic breast" exact="cancer" post="treated with trastuzumab. a Axial contrast-enhanced CT image of"/>
   <result pre="pseudoprogression Fig. 3 82-year-old woman with estrogen and progesterone receptor-positive" exact="breast cancer" post="with bony metastases being treated with systemic chemotherapy. a"/>
   <result pre="Fig. 3 82-year-old woman with estrogen and progesterone receptor-positive breast" exact="cancer" post="with bony metastases being treated with systemic chemotherapy. a"/>
   <result pre="improved clinical status and tumour marker levels Thoracic metastases in" exact="breast cancer" post="can involve pulmonary parenchyma, airways, pleura and thoracic lymph"/>
   <result pre="clinical status and tumour marker levels Thoracic metastases in breast" exact="cancer" post="can involve pulmonary parenchyma, airways, pleura and thoracic lymph"/>
   <result pre="nodes [ 23]. Imaging patterns of lung parenchymal metastases from" exact="breast cancer" post="include solitary or multiple lung nodules, endobronchial nodules, lymphangitic"/>
   <result pre="[ 23]. Imaging patterns of lung parenchymal metastases from breast" exact="cancer" post="include solitary or multiple lung nodules, endobronchial nodules, lymphangitic"/>
   <result pre="endobronchial nodules, lymphangitic carcinomatosis and air–space consolidation. Pleural disease from" exact="breast cancer" post="usually manifests as pleural nodularity, thickening and effusions. Metastatic"/>
   <result pre="nodules, lymphangitic carcinomatosis and air–space consolidation. Pleural disease from breast" exact="cancer" post="usually manifests as pleural nodularity, thickening and effusions. Metastatic"/>
   <result pre="However, a solitary pulmonary nodule appearing in a patient with" exact="breast cancer" post="is not always suggestive of metastatic disease, as more"/>
   <result pre="a solitary pulmonary nodule appearing in a patient with breast" exact="cancer" post="is not always suggestive of metastatic disease, as more"/>
   <result pre="air component during measurement) have been described in the primary" exact="lung cancer" post="literature [ 25]. Magnetic resonance Imaging (MRI) Breast MRI"/>
   <result pre="component during measurement) have been described in the primary lung" exact="cancer" post="literature [ 25]. Magnetic resonance Imaging (MRI) Breast MRI"/>
   <result pre="MRI in this setting varies with the molecular subtype of" exact="breast cancer," post="the pattern of enhancement on pre-treatment MRI and the"/>
   <result pre="with HER2+ or triple-negative status, and lower accuracy with luminal-type" exact="breast cancer," post="low nuclear grade and diffuse non-mass-like enhancement on initial"/>
   <result pre="a few studies to predict early response to treatment in" exact="breast cancer" post="[ 35]. Fig. 5 46-year-old woman with metastatic hormone"/>
   <result pre="few studies to predict early response to treatment in breast" exact="cancer" post="[ 35]. Fig. 5 46-year-old woman with metastatic hormone"/>
   <result pre="[ 35]. Fig. 5 46-year-old woman with metastatic hormone receptor-positive" exact="breast cancer." post="a Axial fat-suppressed T1-weighted MR image in venous phase"/>
   <result pre="decreased rCBV [ 36]. Fig. 6 62-year-old woman with metastatic" exact="breast cancer" post="and new complaint of numbness and tingling in her"/>
   <result pre="rCBV [ 36]. Fig. 6 62-year-old woman with metastatic breast" exact="cancer" post="and new complaint of numbness and tingling in her"/>
   <result pre="and specificity of FDG-PET/CT in predicting histopathologic response in primary" exact="breast cancer" post="is 81 and 79 %, respectively [ 40]. Similar"/>
   <result pre="specificity of FDG-PET/CT in predicting histopathologic response in primary breast" exact="cancer" post="is 81 and 79 %, respectively [ 40]. Similar"/>
   <result pre="(MDP) bone scintigraphy Bone is the most common site of" exact="breast cancer" post="metastasis. Bone scintigraphy is the most widely used modality"/>
   <result pre="bone scintigraphy Bone is the most common site of breast" exact="cancer" post="metastasis. Bone scintigraphy is the most widely used modality"/>
   <result pre="anatomically based criteria [ 47]. Fig. 8 61-year-old woman with" exact="breast cancer" post="and osseous metastases being treated with capecitabine. a Pretreatment"/>
   <result pre="based criteria [ 47]. Fig. 8 61-year-old woman with breast" exact="cancer" post="and osseous metastases being treated with capecitabine. a Pretreatment"/>
   <result pre="consideration. Fig. 9 69-year-old woman with metastatic hormone receptor-positive, HER2/neu-positive" exact="breast cancer" post="being treated with paclitaxel. Axial contrast-enhanced lung window CT"/>
   <result pre="Fig. 9 69-year-old woman with metastatic hormone receptor-positive, HER2/neu-positive breast" exact="cancer" post="being treated with paclitaxel. Axial contrast-enhanced lung window CT"/>
   <result pre="side effects of chemotherapy, and are associated with several cytotoxic" exact="breast cancer" post="drugs including doxorubicin, docetaxel, paclitaxel and platinum agents. CT"/>
   <result pre="effects of chemotherapy, and are associated with several cytotoxic breast" exact="cancer" post="drugs including doxorubicin, docetaxel, paclitaxel and platinum agents. CT"/>
   <result pre="carry an increased risk of thrombus formation [ 51]. Hemorrhagic" exact="cystitis" post="is a well-known complication of cyclophosphamide, manifesting radiologically as"/>
   <result pre="proliferative effects on the uterine endometrium increase the risk of" exact="endometrial cancer" post="[ 53]. On transvaginal US, endometrial carcinomas are typically"/>
   <result pre="effects on the uterine endometrium increase the risk of endometrial" exact="cancer" post="[ 53]. On transvaginal US, endometrial carcinomas are typically"/>
   <result pre="[ 55]. Fig. 10 72-year-old woman with metastatic hormone receptor-positive" exact="breast cancer" post="being treated with tamoxifen. a Sagittal contrast-enhanced CT image"/>
   <result pre="55]. Fig. 10 72-year-old woman with metastatic hormone receptor-positive breast" exact="cancer" post="being treated with tamoxifen. a Sagittal contrast-enhanced CT image"/>
   <result pre="arrow) in descending branch of right pulmonary artery suggestive of" exact="pulmonary embolism." post="The patient had no complaints of chest pain Tamoxifen"/>
   <result pre="changes associated with tamoxifen include preexisting conditions such as diabetes," exact="obesity" post="and hepatic steatosis. Fatty liver may rarely progress to"/>
   <result pre="[ 58]. Fig. 11 72-year-old woman with metastatic hormone receptor-positive" exact="breast cancer" post="being treated with tamoxifen. Axial contrast-enhanced CT image of"/>
   <result pre="58]. Fig. 11 72-year-old woman with metastatic hormone receptor-positive breast" exact="cancer" post="being treated with tamoxifen. Axial contrast-enhanced CT image of"/>
   <result pre="scan and echocardiogram are used for determination of LVEF in" exact="breast cancer" post="patients before and after chemotherapy [ 64]. The biochemical"/>
   <result pre="and echocardiogram are used for determination of LVEF in breast" exact="cancer" post="patients before and after chemotherapy [ 64]. The biochemical"/>
   <result pre="effects of lapatinib include fatigue, nausea, rash, diarrhoea, neutropenia, hepatotoxicity," exact="interstitial lung disease" post="and pneumonitis [ 67]. Fig. 12 67-year-old woman with"/>
   <result pre="of lapatinib include fatigue, nausea, rash, diarrhoea, neutropenia, hepatotoxicity, interstitial" exact="lung disease" post="and pneumonitis [ 67]. Fig. 12 67-year-old woman with"/>
   <result pre="pneumonitis [ 67]. Fig. 12 67-year-old woman with metastatic HER2/neu-positive" exact="breast cancer" post="being treated with trastuzumab. Patient had prior radiotherapy in"/>
   <result pre="[ 67]. Fig. 12 67-year-old woman with metastatic HER2/neu-positive breast" exact="cancer" post="being treated with trastuzumab. Patient had prior radiotherapy in"/>
   <result pre="field suggestive of radiation recall pneumonitis Conclusions Systemic treatment for" exact="breast cancer" post="includes a combination of cytotoxic, hormonal and molecular-targeted therapies"/>
   <result pre="suggestive of radiation recall pneumonitis Conclusions Systemic treatment for breast" exact="cancer" post="includes a combination of cytotoxic, hormonal and molecular-targeted therapies"/>
   <result pre="SH Howard SA Jagannathan JP DiPiro PJ Metastatic patterns of" exact="breast cancer" post="subtypes: what radiologists should know in the era of"/>
   <result pre="Howard SA Jagannathan JP DiPiro PJ Metastatic patterns of breast" exact="cancer" post="subtypes: what radiologists should know in the era of"/>
   <result pre="subtypes: what radiologists should know in the era of personalized" exact="cancer" post="medicine Clin Radiol 2015 70 1 10 10.1016/j.crad.2014.08.015 25300558"/>
   <result pre="Tamoxifen (ici46,474) as a targeted therapy to treat and prevent" exact="breast cancer." post="Br J Pharmacol 147(Suppl 1):S269–S276 4. Rugo HS The"/>
   <result pre="cancer. Br J Pharmacol 147(Suppl 1):S269–S276 4. Rugo HS The" exact="breast cancer" post="continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving"/>
   <result pre="Br J Pharmacol 147(Suppl 1):S269–S276 4. Rugo HS The breast" exact="cancer" post="continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving"/>
   <result pre="1):S269–S276 4. Rugo HS The breast cancer continuum in hormone-receptor-positive" exact="breast cancer" post="in postmenopausal women: evolving management options focusing on aromatase"/>
   <result pre="4. Rugo HS The breast cancer continuum in hormone-receptor-positive breast" exact="cancer" post="in postmenopausal women: evolving management options focusing on aromatase"/>
   <result pre="endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive" exact="breast cancer" post="Cancer 2007 110 244 254 10.1002/cncr.22789 17538978 6. Cataliotti"/>
   <result pre="therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast" exact="cancer" post="Cancer 2007 110 244 254 10.1002/cncr.22789 17538978 6. Cataliotti"/>
   <result pre="of its use in the management of hormone receptor-positive metastatic" exact="breast cancer" post="in postmenopausal women Drugs 2011 71 363 380 10.2165/11204810-000000000-00000"/>
   <result pre="its use in the management of hormone receptor-positive metastatic breast" exact="cancer" post="in postmenopausal women Drugs 2011 71 363 380 10.2165/11204810-000000000-00000"/>
   <result pre="in oncology: considerations for use, and progress to date in" exact="breast cancer" post="Drugs 2013 73 505 515 10.1007/s40265-013-0044-0 23605692 11. Abdel-Razeq"/>
   <result pre="oncology: considerations for use, and progress to date in breast" exact="cancer" post="Drugs 2013 73 505 515 10.1007/s40265-013-0044-0 23605692 11. Abdel-Razeq"/>
   <result pre="H, Marei L (2011) Current neoadjuvant treatment options for HER2-positive" exact="breast cancer." post="Biologics 5:87–94 12. Lin NU Dieras V Paul D"/>
   <result pre="study of lapatinib in patients with brain metastases from HER2-positive" exact="breast cancer" post="Clin Cancer Res 2009 15 1452 1459 10.1158/1078-0432.CCR-08-1080 19228746"/>
   <result pre="of lapatinib in patients with brain metastases from HER2-positive breast" exact="cancer" post="Clin Cancer Res 2009 15 1452 1459 10.1158/1078-0432.CCR-08-1080 19228746"/>
   <result pre="J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic" exact="breast cancer" post="(cleopatra study): overall survival results from a randomised, double-blind,"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast" exact="cancer" post="(cleopatra study): overall survival results from a randomised, double-blind,"/>
   <result pre="et al. Contrast-enhanced computed tomography evaluation of hepatic metastases in" exact="breast cancer" post="patients before and after cytotoxic chemotherapy or targeted therapy"/>
   <result pre="al. Contrast-enhanced computed tomography evaluation of hepatic metastases in breast" exact="cancer" post="patients before and after cytotoxic chemotherapy or targeted therapy"/>
   <result pre="Lee SL Chang ED Na SJ et al. Pseudocirrhosis of" exact="breast cancer" post="metastases to the liver treated by chemotherapy Cancer Res"/>
   <result pre="SL Chang ED Na SJ et al. Pseudocirrhosis of breast" exact="cancer" post="metastases to the liver treated by chemotherapy Cancer Res"/>
   <result pre="to chemotherapy mimicking progressive disease in patients with small cell" exact="lung cancer" post="Eur Radiol 2009 19 193 200 10.1007/s00330-008-1115-6 18677488 23."/>
   <result pre="chemotherapy mimicking progressive disease in patients with small cell lung" exact="cancer" post="Eur Radiol 2009 19 193 200 10.1007/s00330-008-1115-6 18677488 23."/>
   <result pre="JI Kim HH Park SH et al. Thoracic manifestations of" exact="breast cancer" post="and its therapy Radiographics 2004 24 1269 1285 10.1148/rg.245035062"/>
   <result pre="Kim HH Park SH et al. Thoracic manifestations of breast" exact="cancer" post="and its therapy Radiographics 2004 24 1269 1285 10.1148/rg.245035062"/>
   <result pre="and surgical resection of solitary pulmonary nodules in patients with" exact="breast cancer" post="Mol Clin Oncol 2013 1 117 123 24649133 25."/>
   <result pre="surgical resection of solitary pulmonary nodules in patients with breast" exact="cancer" post="Mol Clin Oncol 2013 1 117 123 24649133 25."/>
   <result pre="GJ Saborrian MH Leitch AM MRI vs. histologic measurement of" exact="breast cancer" post="following chemotherapy: comparison with x-ray mammography and palpation J"/>
   <result pre="Saborrian MH Leitch AM MRI vs. histologic measurement of breast" exact="cancer" post="following chemotherapy: comparison with x-ray mammography and palpation J"/>
   <result pre="imaging for predicting response after neoadjuvant chemotherapy in locally advanced" exact="breast cancer" post="Ann Surg Oncol 2013 20 2562 2568 10.1245/s10434-013-2925-6 23463090"/>
   <result pre="for predicting response after neoadjuvant chemotherapy in locally advanced breast" exact="cancer" post="Ann Surg Oncol 2013 20 2562 2568 10.1245/s10434-013-2925-6 23463090"/>
   <result pre="Lobbes M, Prevos R, Smidt M (2012) Response monitoring of" exact="breast cancer" post="patients receiving neoadjuvant chemotherapy using breast MRI – a"/>
   <result pre="M, Prevos R, Smidt M (2012) Response monitoring of breast" exact="cancer" post="patients receiving neoadjuvant chemotherapy using breast MRI – a"/>
   <result pre="10.2214/AJR.10.4392 20566794 35. Thoeny HC Ross BD Predicting and monitoring" exact="cancer" post="treatment response with diffusion-weighted MRI J Magn Reson Imaging"/>
   <result pre="early response to neoadjuvant chemotherapy in stage ii and iii" exact="breast cancer" post="by [18f]fluorodeoxyglucose positron emission tomography J Clin Oncol 2006"/>
   <result pre="response to neoadjuvant chemotherapy in stage ii and iii breast" exact="cancer" post="by [18f]fluorodeoxyglucose positron emission tomography J Clin Oncol 2006"/>
   <result pre="Riedinger JM et al. [18F]FDG-PET predicts complete pathological response of" exact="breast cancer" post="to neoadjuvant chemotherapy Eur J Nucl Med Mol Imaging"/>
   <result pre="JM et al. [18F]FDG-PET predicts complete pathological response of breast" exact="cancer" post="to neoadjuvant chemotherapy Eur J Nucl Med Mol Imaging"/>
   <result pre="emission tomography for the monitoring of response to therapy in" exact="breast cancer" post="Oncologist 2015 20 94 104 10.1634/theoncologist.2014-0342 25561512 41. Avril"/>
   <result pre="tomography for the monitoring of response to therapy in breast" exact="cancer" post="Oncologist 2015 20 94 104 10.1634/theoncologist.2014-0342 25561512 41. Avril"/>
   <result pre="Avril N Sassen S Roylance R Response to therapy in" exact="breast cancer" post="J Nucl Med 2009 50 Suppl 1 55S 63S"/>
   <result pre="N Sassen S Roylance R Response to therapy in breast" exact="cancer" post="J Nucl Med 2009 50 Suppl 1 55S 63S"/>
   <result pre="Podoloff DA Hortobagyi GN Ueno NT Bone imaging in metastatic" exact="breast cancer" post="J Clin Oncol 2004 22 2942 2953 10.1200/JCO.2004.08.181 15254062"/>
   <result pre="DA Hortobagyi GN Ueno NT Bone imaging in metastatic breast" exact="cancer" post="J Clin Oncol 2004 22 2942 2953 10.1200/JCO.2004.08.181 15254062"/>
   <result pre="46. Malhotra P Berman CG Evaluation of bone metastases in" exact="lung cancer." post="Improved sensitivity and specificity of PET over bone scanning"/>
   <result pre="GC Kim DK Sim YJ Clinical features of docetaxel chemotherapy-related" exact="lymphedema" post="Lymphat Res Biol 2014 12 197 202 10.1089/lrb.2013.0037 25144149"/>
   <result pre="10.1080/00365590701570953 18781541 53. Swerdlow AJ Jones ME Tamoxifen treatment for" exact="breast cancer" post="and risk of endometrial cancer: a case–control study J"/>
   <result pre="18781541 53. Swerdlow AJ Jones ME Tamoxifen treatment for breast" exact="cancer" post="and risk of endometrial cancer: a case–control study J"/>
   <result pre="Kung R Transvaginal US and hysterosonography in postmenopausal women with" exact="breast cancer" post="receiving tamoxifen: correlation with hysteroscopy and pathologic study Radiographics"/>
   <result pre="R Transvaginal US and hysterosonography in postmenopausal women with breast" exact="cancer" post="receiving tamoxifen: correlation with hysteroscopy and pathologic study Radiographics"/>
   <result pre="HE, Jeong NJ, Lee Y et al (2014) Radiation recall" exact="dermatitis" post="and pneumonitis induced by trastuzumab (herceptin ®). Int J"/>
   <result pre="Dermatol 53:e159–e160 61. Yeh ET Bickford CL Cardiovascular complications of" exact="cancer" post="therapy: incidence, pathogenesis, diagnosis, and management J Am Coll"/>
   <result pre="Sarzyczny-Slota D Nowara E Cardiac side effects of trastuzumab in" exact="breast cancer" post="patients—single center experiences Contemp Oncol (Pozn) 2013 17 190"/>
   <result pre="D Nowara E Cardiac side effects of trastuzumab in breast" exact="cancer" post="patients—single center experiences Contemp Oncol (Pozn) 2013 17 190"/>
   <result pre="J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122"/>
   <result pre="Piccart-Gebhart M et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="M et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4730993/results/search/disease/results.xml">
   <result pre="Press Limited, provided the work is properly attributed. Abstract Breast" exact="cancer" post="is a multifaceted disease exhibiting both intertumoral and intratumoral"/>
   <result pre="research has advanced the understanding of the molecular substructure of" exact="breast cancer," post="directing the development of new therapeutic strategies against these"/>
   <result pre="development, commercialization, and marketing of diagnostic assays to assist in" exact="breast cancer" post="patient care. More recently, multigene signature assays, such as"/>
   <result pre="commercialization, and marketing of diagnostic assays to assist in breast" exact="cancer" post="patient care. More recently, multigene signature assays, such as"/>
   <result pre="This review provides an overview of the current state of" exact="breast cancer" post="management and the use of companion diagnostics to direct"/>
   <result pre="review provides an overview of the current state of breast" exact="cancer" post="management and the use of companion diagnostics to direct"/>
   <result pre="companion diagnostics to direct personalized approaches in the treatment of" exact="breast cancer." post="Keywords HER2 precision medicine in vitro diagnostics estrogen receptor"/>
   <result pre="medicine in vitro diagnostics estrogen receptor multigene assay Introduction Breast" exact="cancer" post="is the second leading cause of cancer mortality in"/>
   <result pre="assay Introduction Breast cancer is the second leading cause of" exact="cancer" post="mortality in women in the USA, with ~40,000 deaths"/>
   <result pre="The American Cancer Society estimates 232,000 new cases of invasive" exact="breast cancer" post="and ~60,000 cases of ductal carcinoma in situ will"/>
   <result pre="American Cancer Society estimates 232,000 new cases of invasive breast" exact="cancer" post="and ~60,000 cases of ductal carcinoma in situ will"/>
   <result pre="cases of invasive breast cancer and ~60,000 cases of ductal" exact="carcinoma in situ" post="will occur this year. 1 Advances in molecular diagnostics"/>
   <result pre="this year. 1 Advances in molecular diagnostics have revealed that" exact="breast cancer" post="is not a single disease entity; rather, it is"/>
   <result pre="year. 1 Advances in molecular diagnostics have revealed that breast" exact="cancer" post="is not a single disease entity; rather, it is"/>
   <result pre="Growing knowledge of the molecular underpinnings comprising the etiology of" exact="cancer" post="has driven the field of personalized or &quot;precision&quot; medicine"/>
   <result pre="is the ultimate goal in modern precision medicine. Several targeted" exact="cancer" post="therapies are currently utilized in standard oncological care as"/>
   <result pre="diagnostics&quot;, has emerged and is now the foundation of personalized" exact="cancer" post="medicine. According to the US Food and Drug Administration"/>
   <result pre="diagnostic tool was first used to predict response to a" exact="breast cancer" post="therapy in the 1970s, when a high degree of"/>
   <result pre="tool was first used to predict response to a breast" exact="cancer" post="therapy in the 1970s, when a high degree of"/>
   <result pre="and ushering a new era of personalized medicine. Overview of" exact="breast cancer" post="management Surgery is the first course of action for"/>
   <result pre="ushering a new era of personalized medicine. Overview of breast" exact="cancer" post="management Surgery is the first course of action for"/>
   <result pre="obtained via a core or fine needle biopsy. For early-stage" exact="breast cancer," post="surgery consists of resection of the primary tumor (lumpectomy)"/>
   <result pre="the axillary lymph nodes are negative. 7 For more advanced" exact="breast cancer," post="either locally invasive or metastatic, surgery options include lumpectomy"/>
   <result pre="on axillary tumor burden and the molecular etiology of the" exact="cancer" post="should be considered. 10 Radiological treatment is indicated after"/>
   <result pre="Multiple clinical and pathological features used in the management of" exact="breast cancer" post="are predictive indicators of both patient prognosis and likely"/>
   <result pre="clinical and pathological features used in the management of breast" exact="cancer" post="are predictive indicators of both patient prognosis and likely"/>
   <result pre="receptor status, and HER2 overexpression are collectively considered when constructing" exact="breast cancer" post="indices and criteria. 11– 14 Additionally, the increasingly popular"/>
   <result pre="status, and HER2 overexpression are collectively considered when constructing breast" exact="cancer" post="indices and criteria. 11– 14 Additionally, the increasingly popular"/>
   <result pre="used for patient prognosis. Modern molecular profiling has subsequently categorized" exact="breast cancer" post="into primarily four intrinsic subtypes, luminal A, luminal B,"/>
   <result pre="for patient prognosis. Modern molecular profiling has subsequently categorized breast" exact="cancer" post="into primarily four intrinsic subtypes, luminal A, luminal B,"/>
   <result pre="care after surgery in pre- and postmenopausal women. For early-stage" exact="breast cancer," post="adjuvant therapy is used to eradicate possible micrometastatic tumors"/>
   <result pre="to progression, and the overall survival in patients with metastatic" exact="breast cancer," post="as well as disease-free and overall survival in patients"/>
   <result pre="as disease-free and overall survival in patients with localized invasive" exact="breast cancer." post="25– 29 Patients also benefit from three other HER2"/>
   <result pre="which have been approved for use for treatment of HER2-positive" exact="breast cancer." post="30– 32 Triple-negative breast cancer, which lacks the expression"/>
   <result pre="use for treatment of HER2-positive breast cancer. 30– 32 Triple-negative" exact="breast cancer," post="which lacks the expression of the estrogen receptor, progesterone"/>
   <result pre="is the only option for these patients. Companion diagnostics in" exact="breast cancer" post="All FDA-approved companion diagnostics were utilized in breast cancer"/>
   <result pre="the only option for these patients. Companion diagnostics in breast" exact="cancer" post="All FDA-approved companion diagnostics were utilized in breast cancer"/>
   <result pre="in breast cancer All FDA-approved companion diagnostics were utilized in" exact="breast cancer" post="test for the presence of HER2 overexpression either at"/>
   <result pre="breast cancer All FDA-approved companion diagnostics were utilized in breast" exact="cancer" post="test for the presence of HER2 overexpression either at"/>
   <result pre="assessing the presence of the estrogen and progesterone receptors in" exact="breast cancer." post="First standardized and validated by Harvey et al, 34"/>
   <result pre="in shorter time to relapse and reduced overall survival. In" exact="breast cancer," post="HER2 receptor overexpression results primarily from amplification of the"/>
   <result pre="proliferation, invasion, and survival. 38 Aberrant levels of HER2 in" exact="breast cancer" post="correlate with an aggressive phenotype and poor prognosis, including"/>
   <result pre="invasion, and survival. 38 Aberrant levels of HER2 in breast" exact="cancer" post="correlate with an aggressive phenotype and poor prognosis, including"/>
   <result pre="extends to those patients with small (&amp;lt;1 cm), node-negative, HER2-positive" exact="breast cancer," post="which was shown to have 2.68 times greater risk"/>
   <result pre="was the first FDA-approved biologic for the treatment of HER2-positive" exact="breast cancer" post="and has been shown to significantly improve survival in"/>
   <result pre="the first FDA-approved biologic for the treatment of HER2-positive breast" exact="cancer" post="and has been shown to significantly improve survival in"/>
   <result pre="of HER2, preventing receptor dimerization. Trastuzumab inhibits growth and induces" exact="cancer" post="cell death by multiple mechanisms of action, including: 1)"/>
   <result pre="transduction, 4) inhibition of tumor-induced angiogenesis, and 5) inhibition of" exact="cancer" post="treatment-induced DNA damage repair. 47– 49 Enrollment for the"/>
   <result pre="a commercial test to identify the overexpression of HER2 in" exact="breast cancer" post="samples. The results of the Phase III clinical trial"/>
   <result pre="commercial test to identify the overexpression of HER2 in breast" exact="cancer" post="samples. The results of the Phase III clinical trial"/>
   <result pre="simultaneous FDA approval for use in women with HER2-positive metastatic" exact="breast cancer." post="Due to the high prognostic and predictive value of"/>
   <result pre="in vitro companion diagnostic devices to detect HER2 overexpression in" exact="breast cancer" post="(three with premarket approvals withdrawn) ( Table 1). Of"/>
   <result pre="vitro companion diagnostic devices to detect HER2 overexpression in breast" exact="cancer" post="(three with premarket approvals withdrawn) ( Table 1). Of"/>
   <result pre="made in the molecular diagnostics and therapeutic interventions utilized in" exact="breast cancer" post="patient care. However, challenges do exist, particularly in stratifying"/>
   <result pre="in the molecular diagnostics and therapeutic interventions utilized in breast" exact="cancer" post="patient care. However, challenges do exist, particularly in stratifying"/>
   <result pre="However, this approach results in exposing a large fraction of" exact="breast cancer" post="patients to potentially life-threatening chemotherapy-associated toxicities who would otherwise"/>
   <result pre="this approach results in exposing a large fraction of breast" exact="cancer" post="patients to potentially life-threatening chemotherapy-associated toxicities who would otherwise"/>
   <result pre="in understanding the molecular signaling pathways and genetic signatures of" exact="breast cancer" post="have progressed the field forward resulting in new methodologies"/>
   <result pre="understanding the molecular signaling pathways and genetic signatures of breast" exact="cancer" post="have progressed the field forward resulting in new methodologies"/>
   <result pre="in a paradigm shift in the management and treatment of" exact="breast cancer," post="specifically in the care of early-stage breast cancer. Although"/>
   <result pre="treatment of breast cancer, specifically in the care of early-stage" exact="breast cancer." post="Although these assays are not companion diagnostics per se"/>
   <result pre="16 cancer-related genes and five reference genes. 52, 53 The" exact="cancer" post="genes assessed in this panel are primarily associated with"/>
   <result pre="predicted in the Oncotype DX test are likely to experience" exact="breast cancer" post="recurrence within 10 years and thus would benefit from"/>
   <result pre="in the Oncotype DX test are likely to experience breast" exact="cancer" post="recurrence within 10 years and thus would benefit from"/>
   <result pre="analysis in their recommendations for testing estrogen receptor-positive, HER2-negative, node-negative" exact="breast cancer" post="patients. Oncotype DX is currently marketed as a laboratory"/>
   <result pre="in their recommendations for testing estrogen receptor-positive, HER2-negative, node-negative breast" exact="cancer" post="patients. Oncotype DX is currently marketed as a laboratory"/>
   <result pre="50-gene expression panel which distinguishes the four intrinsic subtypes of" exact="breast cancer" post="(luminal A, luminal B, HER2-enriched, and basal-like). The concept"/>
   <result pre="expression panel which distinguishes the four intrinsic subtypes of breast" exact="cancer" post="(luminal A, luminal B, HER2-enriched, and basal-like). The concept"/>
   <result pre="category. Multiple validation studies have confirmed this methodology to predict" exact="breast cancer" post="recurrence in estrogen receptor-positive, postmenopausal breast cancer patients receiving"/>
   <result pre="Multiple validation studies have confirmed this methodology to predict breast" exact="cancer" post="recurrence in estrogen receptor-positive, postmenopausal breast cancer patients receiving"/>
   <result pre="methodology to predict breast cancer recurrence in estrogen receptor-positive, postmenopausal" exact="breast cancer" post="patients receiving endocrine therapy. 73– 76 Prosigna is approved"/>
   <result pre="to predict breast cancer recurrence in estrogen receptor-positive, postmenopausal breast" exact="cancer" post="patients receiving endocrine therapy. 73– 76 Prosigna is approved"/>
   <result pre="clinical laboratories supports its use as a decentralized test for" exact="breast cancer" post="risk stratification. 77 Conclusion Over the last 2 decades,"/>
   <result pre="laboratories supports its use as a decentralized test for breast" exact="cancer" post="risk stratification. 77 Conclusion Over the last 2 decades,"/>
   <result pre="advances have been made in the management and treatment of" exact="breast cancer." post="Not only have new drugs and biologics become available"/>
   <result pre="available but also the overall model for managing and treating" exact="breast cancer" post="patients has changed. A &quot;one size fits all&quot; approach"/>
   <result pre="but also the overall model for managing and treating breast" exact="cancer" post="patients has changed. A &quot;one size fits all&quot; approach"/>
   <result pre="in the past and the era of precision medicine in" exact="breast cancer" post="oncology is upon us. Use of tailored approaches will"/>
   <result pre="the past and the era of precision medicine in breast" exact="cancer" post="oncology is upon us. Use of tailored approaches will"/>
   <result pre="study of tamoxifen: report of 74 patients with stage IV" exact="breast cancer" post="Cancer Treat Rep 1976 60 10 1431 1435 798626"/>
   <result pre="of tamoxifen: report of 74 patients with stage IV breast" exact="cancer" post="Cancer Treat Rep 1976 60 10 1431 1435 798626"/>
   <result pre="trial evaluating tamoxifen in the treatment of patients with node-negative" exact="breast cancer" post="who have estrogen-receptor-positive tumors N Engl J Med 1989"/>
   <result pre="evaluating tamoxifen in the treatment of patients with node-negative breast" exact="cancer" post="who have estrogen-receptor-positive tumors N Engl J Med 1989"/>
   <result pre="levels on the response to tamoxifen and chemotherapy in primary" exact="breast cancer" post="J Clin Oncol 1983 1 4 227 241 6366135"/>
   <result pre="on the response to tamoxifen and chemotherapy in primary breast" exact="cancer" post="J Clin Oncol 1983 1 4 227 241 6366135"/>
   <result pre="B Redmond C Brown A et al. Treatment of primary" exact="breast cancer" post="with chemotherapy and tamoxifen N Engl J Med 1981"/>
   <result pre="Redmond C Brown A et al. Treatment of primary breast" exact="cancer" post="with chemotherapy and tamoxifen N Engl J Med 1981"/>
   <result pre="10 Voutsadakis IA Spadafora S Axillary lymph node management in" exact="breast cancer" post="with positive sentinel lymph node biopsy World J Clin"/>
   <result pre="Voutsadakis IA Spadafora S Axillary lymph node management in breast" exact="cancer" post="with positive sentinel lymph node biopsy World J Clin"/>
   <result pre="HJ et al. NCCN Task Force Report: adjuvant therapy for" exact="breast cancer" post="J Natl Compr Canc Netw 2006 4 1 S1"/>
   <result pre="et al. NCCN Task Force Report: adjuvant therapy for breast" exact="cancer" post="J Natl Compr Canc Netw 2006 4 1 S1"/>
   <result pre="improves the Nottingham Prognostic Index up to 5 years after" exact="breast cancer" post="diagnosis J Clin Oncol 2010 28 27 4129 4134"/>
   <result pre="the Nottingham Prognostic Index up to 5 years after breast" exact="cancer" post="diagnosis J Clin Oncol 2010 28 27 4129 4134"/>
   <result pre="index, HER2 status, and prognosis of patients with luminal B" exact="breast cancer" post="J Natl Cancer Inst 2009 101 10 736 750"/>
   <result pre="HER2 status, and prognosis of patients with luminal B breast" exact="cancer" post="J Natl Cancer Inst 2009 101 10 736 750"/>
   <result pre="20 Rouzier R Perou CM Symmans WF et al. Breast" exact="cancer" post="molecular subtypes respond differently to preoperative chemotherapy Clin Cancer"/>
   <result pre="21 Sotiriou C Neo SY McShane LM et al. Breast" exact="cancer" post="classification and prognosis based on gene expression profiles from"/>
   <result pre="tamoxifen therapy beyond five years in patients with lymph node-positive" exact="breast cancer." post="Eastern Cooperative Oncology Group J Natl Cancer Inst 1996"/>
   <result pre="with chemotherapy is effective in women with small, node-negative, HER2-positive" exact="breast cancer" post="Cancer 2011 117 24 5461 5468 21681735 26 Piccart-Gebhart"/>
   <result pre="chemotherapy is effective in women with small, node-negative, HER2-positive breast" exact="cancer" post="Cancer 2011 117 24 5461 5468 21681735 26 Piccart-Gebhart"/>
   <result pre="Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1659 1672"/>
   <result pre="B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1659 1672"/>
   <result pre="Eiermann W Robert N et al. Adjuvant trastuzumab in HER2-positive" exact="breast cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="W Robert N et al. Adjuvant trastuzumab in HER2-positive breast" exact="cancer" post="N Engl J Med 2011 365 14 1273 1283"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="D et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="D Gianni L et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="between estrogen receptor, progesterone receptor, and patient characteristics in human" exact="breast cancer" post="J Clin Oncol 1984 2 10 1102 1109 6491696"/>
   <result pre="estrogen receptor, progesterone receptor, and patient characteristics in human breast" exact="cancer" post="J Clin Oncol 1984 2 10 1102 1109 6491696"/>
   <result pre="ligand-binding assay for predicting response to adjuvant endocrine therapy in" exact="breast cancer" post="J Clin Oncol 1999 17 5 1474 1481 10334533"/>
   <result pre="assay for predicting response to adjuvant endocrine therapy in breast" exact="cancer" post="J Clin Oncol 1999 17 5 1474 1481 10334533"/>
   <result pre="Task Force Report: Estrogen receptor and progesterone receptor testing in" exact="breast cancer" post="by immunohistochemistry J Natl Compr Canc Netw 2009 7"/>
   <result pre="Force Report: Estrogen receptor and progesterone receptor testing in breast" exact="cancer" post="by immunohistochemistry J Natl Compr Canc Netw 2009 7"/>
   <result pre="recommendations for immunohistochemical testing of estrogen and progesterone receptors in" exact="breast cancer" post="J Clin Oncol 2010 28 16 2784 2795 20404251"/>
   <result pre="for immunohistochemical testing of estrogen and progesterone receptors in breast" exact="cancer" post="J Clin Oncol 2010 28 16 2784 2795 20404251"/>
   <result pre="DJ Detection and quantitation of HER-2/neu gene amplification in human" exact="breast cancer" post="archival material using fluorescence in situ hybridization Oncogene 1996"/>
   <result pre="Detection and quantitation of HER-2/neu gene amplification in human breast" exact="cancer" post="archival material using fluorescence in situ hybridization Oncogene 1996"/>
   <result pre="et al. Activating HER2 mutations in HER2 gene amplification negative" exact="breast cancer" post="Cancer Discov 2013 3 2 224 237 23220880 42"/>
   <result pre="al. Activating HER2 mutations in HER2 gene amplification negative breast" exact="cancer" post="Cancer Discov 2013 3 2 224 237 23220880 42"/>
   <result pre="KR et al. High risk of recurrence for patients with" exact="breast cancer" post="who have human epidermal growth factor receptor 2-positive, node-negative"/>
   <result pre="et al. High risk of recurrence for patients with breast" exact="cancer" post="who have human epidermal growth factor receptor 2-positive, node-negative"/>
   <result pre="Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced" exact="breast cancer" post="(NOAH): follow-up of a randomised controlled superiority trial with"/>
   <result pre="and adjuvant trastuzumab in patients with HER2-positive locally advanced breast" exact="cancer" post="(NOAH): follow-up of a randomised controlled superiority trial with"/>
   <result pre="behind trastuzumab therapy for human epidermal growth factor receptor 2-positive" exact="breast cancer" post="J Clin Oncol 2009 27 34 5838 5847 19884552"/>
   <result pre="trastuzumab therapy for human epidermal growth factor receptor 2-positive breast" exact="cancer" post="J Clin Oncol 2009 27 34 5838 5847 19884552"/>
   <result pre="Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing" exact="breast cancer" post="Ann Oncol 2007 18 6 977 984 17229773 50"/>
   <result pre="mechanism of action, resistance and future perspectives in HER2-overexpressing breast" exact="cancer" post="Ann Oncol 2007 18 6 977 984 17229773 50"/>
   <result pre="a 21-gene recurrence score prognostic assay in patients with early" exact="breast cancer" post="treated with tamoxifen Oncologist 2007 12 6 631 635"/>
   <result pre="21-gene recurrence score prognostic assay in patients with early breast" exact="cancer" post="treated with tamoxifen Oncologist 2007 12 6 631 635"/>
   <result pre="al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative" exact="breast cancer" post="N Engl J Med 2004 351 27 2817 2826"/>
   <result pre="A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast" exact="cancer" post="N Engl J Med 2004 351 27 2817 2826"/>
   <result pre="and benefit of chemotherapy in women with node-negative, estrogen receptor-positive" exact="breast cancer" post="J Clin Oncol 2006 24 23 3726 3734 16720680"/>
   <result pre="benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast" exact="cancer" post="J Clin Oncol 2006 24 23 3726 3734 16720680"/>
   <result pre="21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive" exact="breast cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast" exact="cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="21-gene recurrence score in node-negative and node-positive postmenopausal patients with" exact="breast cancer" post="treated with anastrozole or tamoxifen: a TransATAC study J"/>
   <result pre="recurrence score in node-negative and node-positive postmenopausal patients with breast" exact="cancer" post="treated with anastrozole or tamoxifen: a TransATAC study J"/>
   <result pre="et al. Prospective validation of a 21-gene expression assay in" exact="breast cancer" post="N Engl J Med 2015 373 21 2005 2014"/>
   <result pre="al. Prospective validation of a 21-gene expression assay in breast" exact="cancer" post="N Engl J Med 2015 373 21 2005 2014"/>
   <result pre="update of recommendations for the use of tumor markers in" exact="breast cancer" post="J Clin Oncol 2007 25 33 5287 5312 17954709"/>
   <result pre="of recommendations for the use of tumor markers in breast" exact="cancer" post="J Clin Oncol 2007 25 33 5287 5312 17954709"/>
   <result pre="MJ et al. Gene expression profiling predicts clinical outcome of" exact="breast cancer" post="Nature 2002 415 6871 530 536 11823860 66 van"/>
   <result pre="et al. Gene expression profiling predicts clinical outcome of breast" exact="cancer" post="Nature 2002 415 6871 530 536 11823860 66 van"/>
   <result pre="al. A gene-expression signature as a predictor of survival in" exact="breast cancer" post="N Engl J Med 2002 347 25 1999 2009"/>
   <result pre="A gene-expression signature as a predictor of survival in breast" exact="cancer" post="N Engl J Med 2002 347 25 1999 2009"/>
   <result pre="utility of a 70-gene prognostic signature for women with node-negative" exact="breast cancer" post="J Natl Cancer Inst 2006 98 17 1183 1192"/>
   <result pre="of a 70-gene prognostic signature for women with node-negative breast" exact="cancer" post="J Natl Cancer Inst 2006 98 17 1183 1192"/>
   <result pre="JM Retel VP et al. A prospective evaluation of a" exact="breast cancer" post="prognosis signature in the observational RASTER study Int J"/>
   <result pre="Retel VP et al. A prospective evaluation of a breast" exact="cancer" post="prognosis signature in the observational RASTER study Int J"/>
   <result pre="G et al. The 70-gene prognosis-signature predicts disease outcome in" exact="breast cancer" post="patients with 1–3 positive lymph nodes in an independent"/>
   <result pre="et al. The 70-gene prognosis-signature predicts disease outcome in breast" exact="cancer" post="patients with 1–3 positive lymph nodes in an independent"/>
   <result pre="Mullins M Cheang MC et al. Supervised risk predictor of" exact="breast cancer" post="based on intrinsic subtypes J Clin Oncol 2009 27"/>
   <result pre="M Cheang MC et al. Supervised risk predictor of breast" exact="cancer" post="based on intrinsic subtypes J Clin Oncol 2009 27"/>
   <result pre="with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive" exact="breast cancer" post="Clin Cancer Res 2010 16 21 5222 5232 20837693"/>
   <result pre="immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast" exact="cancer" post="Clin Cancer Res 2010 16 21 5222 5232 20837693"/>
   <result pre="recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early" exact="breast cancer" post="Clin Cancer Res 2014 20 5 1298 1305 24520097"/>
   <result pre="after endocrine therapy in postmenopausal women with endocrine-responsive early breast" exact="cancer" post="Clin Cancer Res 2014 20 5 1298 1305 24520097"/>
   <result pre="M Greil R et al. Predicting distant recurrence in receptor-positive" exact="breast cancer" post="patients with limited clinicopathological risk: using the PAM50 Risk"/>
   <result pre="Greil R et al. Predicting distant recurrence in receptor-positive breast" exact="cancer" post="patients with limited clinicopathological risk: using the PAM50 Risk"/>
   <result pre="a combined analysis of patients from the Austrian breast and" exact="colorectal cancer" post="study group 8 and arimidex, tamoxifen alone or in"/>
   <result pre="combined analysis of patients from the Austrian breast and colorectal" exact="cancer" post="study group 8 and arimidex, tamoxifen alone or in"/>
   <result pre="FDA-approved (active and withdrawn) companion diagnostics for use in HER-positive" exact="breast cancer" post="a Drug trade name (generic name) Device trade name"/>
   <result pre="(active and withdrawn) companion diagnostics for use in HER-positive breast" exact="cancer" post="a Drug trade name (generic name) Device trade name"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4734963/results/search/disease/results.xml">
   <result pre="medium, provided the original work is properly cited. Abstract Gastric" exact="cancer" post="is a global health burden and has the highest"/>
   <result pre="Genome Atlas (TCGA) project, showed the molecular landscape of gastric" exact="cancer" post="through a comprehensive molecular evaluation of 295 primary gastric"/>
   <result pre="295 primary gastric cancers. The proposed molecular classification divided gastric" exact="cancer" post="into four subtypes: Epstein-Barr virus–positive, microsatellite unstable, genomic stable,"/>
   <result pre="Translational medical research Cancer genomics Cancer genetics Target therapy Gastric" exact="cancer" post="(GC) is one of the most common and fatal"/>
   <result pre="In Korea, GC is the second most common malignancy after" exact="thyroid cancer." post="It was ranked as the third cause of cancer"/>
   <result pre="thyroid cancer. It was ranked as the third cause of" exact="cancer" post="mortality in 2012 [ 2]. An estimate of 35,000"/>
   <result pre="Program that began in 1999, the proportion of early gastric" exact="cancer" post="(EGC) has increased, and the prognosis of EGC is"/>
   <result pre="been established as a standard treatment for locally advanced gastric" exact="cancer" post="(AGC), and has improved the prognosis of AGC ["/>
   <result pre="of SWI/SNF complex and acts as a tumor suppressor in" exact="cancer" post="[ 39]. Recently, it was reported that EZH2 inhibitor"/>
   <result pre="to chemotherapy in an adjuvant setting [ 41], like MSI" exact="colon cancer" post="[ 46, 47]. Additionally, a recent phase II study"/>
   <result pre="chemotherapy in an adjuvant setting [ 41], like MSI colon" exact="cancer" post="[ 46, 47]. Additionally, a recent phase II study"/>
   <result pre="in melanoma [ 48] and PD-1 antibody in non-small cell" exact="lung cancer" post="[ 49]. The legitimate explanation might be that immune"/>
   <result pre="melanoma [ 48] and PD-1 antibody in non-small cell lung" exact="cancer" post="[ 49]. The legitimate explanation might be that immune"/>
   <result pre="checkpoint inhibitor as well as chemotherapy in GC, as in" exact="colon cancer" post="[ 50]. There is no consensus on the definition"/>
   <result pre="inhibitor as well as chemotherapy in GC, as in colon" exact="cancer" post="[ 50]. There is no consensus on the definition"/>
   <result pre="derived from a recent EGFR biomarker study in non-small cell" exact="lung cancer" post="patients receiving gefitinib, where EGFR mutation and amplification correlated"/>
   <result pre="from a recent EGFR biomarker study in non-small cell lung" exact="cancer" post="patients receiving gefitinib, where EGFR mutation and amplification correlated"/>
   <result pre="inhibitor of MEK1/MEK2, downstream of KRAS, for KRAS-mutant non-small cell" exact="lung cancer" post="demonstrated promising efficacy and thereby warrants further clinical investigation"/>
   <result pre="of MEK1/MEK2, downstream of KRAS, for KRAS-mutant non-small cell lung" exact="cancer" post="demonstrated promising efficacy and thereby warrants further clinical investigation"/>
   <result pre="amplification had a favorable response to crizotinib (PF-02341066), a MET/anaplastic" exact="lymphoma" post="kinase tyrosine kinase inhibitor [ 28]. Furthermore, rilotumumab (AMG"/>
   <result pre="growth and metastasis, it is a therapeutic target for many" exact="cancer" post="types. Bevacizumab, a monoclonal antibody that inhibits VEGF (VEGF-A),"/>
   <result pre="antibody that inhibits VEGF (VEGF-A), showed survival benefits in advanced" exact="colorectal cancer" post="[ 73] and non-small cell lung cancer [ 74]."/>
   <result pre="that inhibits VEGF (VEGF-A), showed survival benefits in advanced colorectal" exact="cancer" post="[ 73] and non-small cell lung cancer [ 74]."/>
   <result pre="benefits in advanced colorectal cancer [ 73] and non-small cell" exact="lung cancer" post="[ 74]. Also, a phase II trial that showed"/>
   <result pre="in advanced colorectal cancer [ 73] and non-small cell lung" exact="cancer" post="[ 74]. Also, a phase II trial that showed"/>
   <result pre="II trial that showed efficacy of bevacizumab for advanced gastro-esophageal" exact="cancer" post="seemed to reinforce the success of targeted therapy against"/>
   <result pre="success of targeted therapy against the VEGF pathway in gastric" exact="cancer" post="[ 75]. Despite initial enthusiasm regarding its use, bevacizumab"/>
   <result pre="initiate tumorigenesis through self-renewal and differentiation are emerging concepts in" exact="cancer" post="research. Such cells activate EMT, oncogenic pathways, and embryogenic"/>
   <result pre="Notch, and Hedgehog pathways are crucial to the maintenance of" exact="cancer" post="stem cells. Transcriptional factors such as Snail, Slug, Twist,"/>
   <result pre="EGFR [ 81, 82]. Also, its downstream signaling pathway, PI3K/Akt/mTOR," exact="aids" post="in cancer stem cell maintenance [ 83]. Thus, targeting"/>
   <result pre="81, 82]. Also, its downstream signaling pathway, PI3K/Akt/mTOR, aids in" exact="cancer" post="stem cell maintenance [ 83]. Thus, targeting this pathway"/>
   <result pre="such as metformin would inhibit cellular transformation and selectively kill" exact="cancer" post="stem cells, as previously demonstrated in breast cancer ["/>
   <result pre="and selectively kill cancer stem cells, as previously demonstrated in" exact="breast cancer" post="[ 84]. Also, a recent report showed that patients"/>
   <result pre="selectively kill cancer stem cells, as previously demonstrated in breast" exact="cancer" post="[ 84]. Also, a recent report showed that patients"/>
   <result pre="report showed that patients with GC treated with metformin for" exact="diabetes mellitus" post="had better survival compared to those treated with diabetic"/>
   <result pre="the potential of exploiting genomic alteration in future development of" exact="cancer" post="stem cell-directed therapies. CONCLUSIONS AND FUTURE PERSPECTIVES Through extraordinary"/>
   <result pre="targeted therapy in GC remains inferior to those of other" exact="cancer" post="types such as lung, breast, and colon cancer in"/>
   <result pre="those of other cancer types such as lung, breast, and" exact="colon cancer" post="in terms of genetic sequencing and molecular therapeutics ["/>
   <result pre="of other cancer types such as lung, breast, and colon" exact="cancer" post="in terms of genetic sequencing and molecular therapeutics ["/>
   <result pre="Jung KW Won YJ Oh CM et al. Prediction of" exact="cancer" post="incidence and mortality in Korea, 2015 Cancer Res Treat"/>
   <result pre="4 Lee KS Oh DK Han MA et al. Gastric" exact="cancer" post="screening in Korea: report on the national cancer screening"/>
   <result pre="al. Gastric cancer screening in Korea: report on the national" exact="cancer" post="screening program in 2008 Cancer Res Treat 2011 43"/>
   <result pre="Suh M Choi KS Lee YY Jun JK Trends in" exact="cancer" post="screening rates among Korean men and women: results from"/>
   <result pre="63 24078663 8 collab: Japanese Gastric Cancer Association Japanese gastric" exact="cancer" post="treatment guidelines 2010 (ver. 3) Gastric Cancer 2011 14"/>
   <result pre="Yang HK et al. Adjuvant capecitabine and oxaliplatin for gastric" exact="cancer" post="after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised"/>
   <result pre="Yang HK et al. Adjuvant capecitabine plus oxaliplatin for gastric" exact="cancer" post="after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label,"/>
   <result pre="Sasako M Yamaguchi T et al. Adjuvant chemotherapy for gastric" exact="cancer" post="with S-1, an oral fluoropyrimidine N Engl J Med"/>
   <result pre="S-1 versus surgery alone in stage II or III gastric" exact="cancer" post="J Clin Oncol 2011 29 4387 93 22010012 15"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial Lancet"/>
   <result pre="19 Choi YY Noh SH Cheong JH Evolution of gastric" exact="cancer" post="treatment: from the golden age of surgery to an"/>
   <result pre="of pembrolizumab (Pembro; MK-3475) in patients (pts) with advanced gastric" exact="cancer" post="Ann Oncol 2014 25 Suppl 4 LBA15 22 Mueller"/>
   <result pre="or in combination with chemotherapy in wild-type and mutated human" exact="gastrointestinal cancer" post="cell lines Cancer Chemother Pharmacol 2012 69 1601 15"/>
   <result pre="in combination with chemotherapy in wild-type and mutated human gastrointestinal" exact="cancer" post="cell lines Cancer Chemother Pharmacol 2012 69 1601 15"/>
   <result pre="Huntsman DG Carneiro F Lewis FR et al. Early gastric" exact="cancer" post="in young, asymptomatic carriers of germ-line E-cadherin mutations N"/>
   <result pre="or without cetuximab for patients with previously untreated advanced gastric" exact="cancer" post="(EXPAND): a randomised, open-label phase 3 trial Lancet Oncol"/>
   <result pre="or without panitumumab for patients with previously untreated advanced oesophagogastric" exact="cancer" post="(REAL3): a randomised, open-label phase 3 trial Lancet Oncol"/>
   <result pre="paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric" exact="cancer" post="in Asian populations: TyTAN: a randomized, phase III study"/>
   <result pre="Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric" exact="cancer" post="Clin Cancer Res 2015 21 2453 61 25712685 31"/>
   <result pre="of all amgen-sponsored clinical studies of rilotumumab in advanced gastric" exact="cancer" post="[Internet] New York PR Newswire Association LLC 2014 [cited"/>
   <result pre="Rabkin CS Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric" exact="cancer" post="differs based on sex and anatomic location Gastroenterology 2009"/>
   <result pre="identifies frequent mutation of ARID1A in molecular subtypes of gastric" exact="cancer" post="Nat Genet 2011 43 1219 23 22037554 40 Bitler"/>
   <result pre="Lee J Nebozhyn M et al. Molecular analysis of gastric" exact="cancer" post="identifies subtypes associated with distinct clinical outcomes Nat Med"/>
   <result pre="as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for" exact="colon cancer" post="N Engl J Med 2003 349 247 57 12867608"/>
   <result pre="a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon" exact="cancer" post="N Engl J Med 2003 349 247 57 12867608"/>
   <result pre="marker for lack of efficacy of fluorouracil-based adjuvant therapy in" exact="colon cancer" post="J Clin Oncol 2010 28 3219 26 20498393 48"/>
   <result pre="for lack of efficacy of fluorouracil-based adjuvant therapy in colon" exact="cancer" post="J Clin Oncol 2010 28 3219 26 20498393 48"/>
   <result pre="mutational landscape determines sensitivity to PD-1 blockade in non-small cell" exact="lung cancer" post="Science 2015 348 124 8 25765070 50 collab: National"/>
   <result pre="landscape determines sensitivity to PD-1 blockade in non-small cell lung" exact="cancer" post="Science 2015 348 124 8 25765070 50 collab: National"/>
   <result pre="Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN guidelines):" exact="colon cancer," post="version 2.2015 [Internet] Fort Washington National Comprehensive Cancer Network"/>
   <result pre="the E-cadherin gene predict poor survival of patients with gastric" exact="cancer" post="J Clin Oncol 2013 31 868 75 23341533 54"/>
   <result pre="and comprehensive molecular profiling identify new driver mutations in gastric" exact="cancer" post="Nat Genet 2014 46 573 82 24816253 55 Kakiuchi"/>
   <result pre="Das K et al. Identification of molecular subtypes of gastric" exact="cancer" post="with different responses to PI3-kinase inhibitors and 5-fluorouracil Gastroenterology"/>
   <result pre="145 554 65 23684942 61 Grabsch HI Tan P Gastric" exact="cancer" post="pathology and underlying molecular mechanisms Dig Surg 2013 30"/>
   <result pre="receptors EGFR and ERBB2 on survival in stage II/III gastric" exact="cancer" post="Clin Cancer Res 2012 18 5992 6000 22977193 64"/>
   <result pre="gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell" exact="lung cancer" post="in Asia (IPASS) J Clin Oncol 2011 29 2866"/>
   <result pre="versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung" exact="cancer" post="in Asia (IPASS) J Clin Oncol 2011 29 2866"/>
   <result pre="rare and related to DNA mismatch repair deficiency in gastric" exact="cancer" post="from the East and the West: results from a"/>
   <result pre="C et al. Mutations of the BRAF gene in human" exact="cancer" post="Nature 2002 417 949 54 12068308 71 Puzanov I"/>
   <result pre="JW Soung YH et al. BRAF and KRAS mutations in" exact="stomach cancer" post="Oncogene 2003 22 6942 5 14534542 73 Hurwitz H"/>
   <result pre="Soung YH et al. BRAF and KRAS mutations in stomach" exact="cancer" post="Oncogene 2003 22 6942 5 14534542 73 Hurwitz H"/>
   <result pre="et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic" exact="colorectal cancer" post="N Engl J Med 2004 350 2335 42 15175435"/>
   <result pre="al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal" exact="cancer" post="N Engl J Med 2004 350 2335 42 15175435"/>
   <result pre="MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell" exact="lung cancer" post="N Engl J Med 2006 355 2542 50 17167137"/>
   <result pre="et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung" exact="cancer" post="N Engl J Med 2006 355 2542 50 17167137"/>
   <result pre="CW Anant S Cancer stem cells: a novel paradigm for" exact="cancer" post="prevention and treatment Mini Rev Med Chem 2010 10"/>
   <result pre="system and signal transduction pathways regulating epithelial mesenchymal transition of" exact="cancer" post="J Biomed Sci 2012 19 67 22827778 81 Bierie"/>
   <result pre="HL Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of" exact="cancer" post="Nat Rev Cancer 2006 6 506 20 16794634 82"/>
   <result pre="Zhang H et al. Activation of the PTEN/mTOR/STAT3 pathway in" exact="breast cancer" post="stem-like cells is required for viability and maintenance Proc"/>
   <result pre="H et al. Activation of the PTEN/mTOR/STAT3 pathway in breast" exact="cancer" post="stem-like cells is required for viability and maintenance Proc"/>
   <result pre="HA Iliopoulos D Tsichlis PN Struhl K Metformin selectively targets" exact="cancer" post="stem cells, and acts together with chemotherapy to block"/>
   <result pre="Cumulative metformin use and its impact on survival in gastric" exact="cancer" post="patients after gastrectomy Ann Surg 2015 10 22 [Epub]."/>
   <result pre="S Okumura T Tu S et al. Identification of gastric" exact="cancer" post="stem cells using the cell surface marker CD44 Stem"/>
   <result pre="countries; b Amgen-sponsored clinical trials of rilotumumab in advanced gastric" exact="cancer" post="were terminated based on the pre-planned safety review by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4735094/results/search/disease/results.xml">
   <result pre="pmcid: 4735094 1736 doi: 10.1186/s40064-016-1736-1 : Research Patterns in target-directed" exact="breast cancer" post="research Torres Sofia (416) 480-5145 sofia.torres@sunnybrook.ca Simmons Christine christine.simmons@bccancer.bc.ca"/>
   <result pre="4735094 1736 doi: 10.1186/s40064-016-1736-1 : Research Patterns in target-directed breast" exact="cancer" post="research Torres Sofia (416) 480-5145 sofia.torres@sunnybrook.ca Simmons Christine christine.simmons@bccancer.bc.ca"/>
   <result pre="Clinical trials Target-directed research Biomarkers Patient profiling Randomized trials Breast" exact="cancer" post="Funding http://dx.doi.org/10.13039/100009009 Novartis Pharmaceuticals Canada Background Breast cancer (BC)"/>
   <result pre="trials Breast cancer Funding http://dx.doi.org/10.13039/100009009 Novartis Pharmaceuticals Canada Background Breast" exact="cancer" post="(BC) is a significant health concern, with approximately 256,140"/>
   <result pre="has received the highest allotment of US national expenditure for" exact="cancer" post="treatment (National Cancer Institute 2012). For over a decade,"/>
   <result pre="Lessons learned over the past decade of target-directed research in" exact="breast cancer" post="Lesson Examples Trial populations Conduct trials in either positively-selected"/>
   <result pre="learned over the past decade of target-directed research in breast" exact="cancer" post="Lesson Examples Trial populations Conduct trials in either positively-selected"/>
   <result pre="= 19); bTrials in mixed populations were also excluded. BC" exact="breast cancer" post="Populations and classes under development The majority of trials"/>
   <result pre="19); bTrials in mixed populations were also excluded. BC breast" exact="cancer" post="Populations and classes under development The majority of trials"/>
   <result pre="to destroy specific cell types and/or deliver toxic drugs to" exact="cancer" post="cells (National Cancer Institute 2014). All non-randomized, non-systemic, non-therapeutic,"/>
   <result pre="Immunotherapy/cancer vaccines: Drugs that target the immune system to destroy" exact="cancer" post="cells or interfere with growth of specific cancer cells"/>
   <result pre="to destroy cancer cells or interfere with growth of specific" exact="cancer" post="cells Allogeneic GM-CSF-secreting breast cancer vaccine, autologous dendritic cell-adenovirus"/>
   <result pre="or interfere with growth of specific cancer cells Allogeneic GM-CSF-secreting" exact="breast cancer" post="vaccine, autologous dendritic cell-adenovirus p53 vaccine, GSK2302024A, HER-2/neu peptide"/>
   <result pre="interfere with growth of specific cancer cells Allogeneic GM-CSF-secreting breast" exact="cancer" post="vaccine, autologous dendritic cell-adenovirus p53 vaccine, GSK2302024A, HER-2/neu peptide"/>
   <result pre="(antibody) and a cytotoxic drug, delivered only to the targeted" exact="cancer" post="cell T-DM1 AEZS-108, Glembatumumab vedotin Other targeted therapies: Drugs"/>
   <result pre="2011. Abbreviations Akt protein kinase B AR androgen receptor BC" exact="breast cancer" post="CT.gov clinicaltrials.gov CDK cyclin-dependent kinase EGFR epidermal growth factor"/>
   <result pre="Abbreviations Akt protein kinase B AR androgen receptor BC breast" exact="cancer" post="CT.gov clinicaltrials.gov CDK cyclin-dependent kinase EGFR epidermal growth factor"/>
   <result pre="21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive" exact="breast cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast" exact="cancer" post="on chemotherapy: a retrospective analysis of a randomised trial"/>
   <result pre="10.1016/S1470-2045(09)70314-6 20005174 Anderson WF Katki HA Rosenberg PS Incidence of" exact="breast cancer" post="in the United States: current and future trends J"/>
   <result pre="20005174 Anderson WF Katki HA Rosenberg PS Incidence of breast" exact="cancer" post="in the United States: current and future trends J"/>
   <result pre="sunitinib versus capecitabine in patients with previously treated HER2-negative advanced" exact="breast cancer" post="Breast Cancer Res Treat 2010 121 1 121 131"/>
   <result pre="versus capecitabine in patients with previously treated HER2-negative advanced breast" exact="cancer" post="Breast Cancer Res Treat 2010 121 1 121 131"/>
   <result pre="C score to decision making in clinical practice in early" exact="breast cancer" post="Br J Cancer 2012 106 11 1760 1765 10.1038/bjc.2012.166"/>
   <result pre="score to decision making in clinical practice in early breast" exact="cancer" post="Br J Cancer 2012 106 11 1760 1765 10.1038/bjc.2012.166"/>
   <result pre="Gelber RD Piccart-Gebhart M Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="RD Piccart-Gebhart M Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet"/>
   <result pre="P Lebwohl D Hortobagyi GN Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2012 366 6 520 529"/>
   <result pre="Lebwohl D Hortobagyi GN Everolimus in postmenopausal hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2012 366 6 520 529"/>
   <result pre="G Swain SM Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="Swain SM Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="oral regimen for patients with HER2-negative locally advanced or metastatic" exact="breast cancer" post="J Clin Oncol 2012 30 13 1484 1491 10.1200/JCO.2011.36.7771"/>
   <result pre="regimen for patients with HER2-negative locally advanced or metastatic breast" exact="cancer" post="J Clin Oncol 2012 30 13 1484 1491 10.1200/JCO.2011.36.7771"/>
   <result pre="Begley CG Ellis LM Drug development: Raise standards for preclinical" exact="cancer" post="research Nature 2012 483 7391 531 533 10.1038/483531a 22460880"/>
   <result pre="MJ Haybittle JL Reading the prognosis of the individual with" exact="breast cancer" post="Eur J Cancer 2007 43 10 1545 1547 10.1016/j.ejca.2007.01.003"/>
   <result pre="Haybittle JL Reading the prognosis of the individual with breast" exact="cancer" post="Eur J Cancer 2007 43 10 1545 1547 10.1016/j.ejca.2007.01.003"/>
   <result pre="second-line treatment of human epidermal growth factor receptor 2-negative metastatic" exact="breast cancer" post="J Clin Oncol 2011 29 32 4286 4293 10.1200/JCO.2010.34.1255"/>
   <result pre="treatment of human epidermal growth factor receptor 2-negative metastatic breast" exact="cancer" post="J Clin Oncol 2011 29 32 4286 4293 10.1200/JCO.2010.34.1255"/>
   <result pre="FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive" exact="breast cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast" exact="cancer" post="(Z1041): a randomised, controlled, phase 3 trial Lancet Oncol"/>
   <result pre="lapatinib plus capecitabine versus capecitabine alone in women with advanced" exact="breast cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="plus capecitabine versus capecitabine alone in women with advanced breast" exact="cancer" post="that has progressed on trastuzumab: updated efficacy and biomarker"/>
   <result pre="Canadian Cancer Society’s Steering Committee on Cancer Statistics (2013) Canadian" exact="cancer" post="statistics 2013. Canadian Cancer Society, Toronto, ON. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/canadian-cancer-statistics-2013-EN.pdf. Accessed"/>
   <result pre="MC Nielsen TO Moorman PG Earp HS Millikan RC Race," exact="breast cancer" post="subtypes, and survival in the Carolina breast cancer study"/>
   <result pre="Nielsen TO Moorman PG Earp HS Millikan RC Race, breast" exact="cancer" post="subtypes, and survival in the Carolina breast cancer study"/>
   <result pre="RC Race, breast cancer subtypes, and survival in the Carolina" exact="breast cancer" post="study JAMA 2006 295 21 2492 2502 10.1001/jama.295.21.2492 16757721"/>
   <result pre="Race, breast cancer subtypes, and survival in the Carolina breast" exact="cancer" post="study JAMA 2006 295 21 2492 2502 10.1001/jama.295.21.2492 16757721"/>
   <result pre="of cetuximab in combination with carboplatin in stage IV triple-negative" exact="breast cancer" post="J Clin Oncol 2012 30 21 2615 2623 10.1200/JCO.2010.34.5579"/>
   <result pre="cetuximab in combination with carboplatin in stage IV triple-negative breast" exact="cancer" post="J Clin Oncol 2012 30 21 2615 2623 10.1200/JCO.2010.34.5579"/>
   <result pre="data from Celldex Therapeutic’s CDX-011 phase 2 study in metastatic" exact="breast cancer" post="supports overall survival benefit in patients with high GPNMB"/>
   <result pre="from Celldex Therapeutic’s CDX-011 phase 2 study in metastatic breast" exact="cancer" post="supports overall survival benefit in patients with high GPNMB"/>
   <result pre="A study of CDX-011 (CR011-vcMMAE) in patients with advanced GPNMB-expressing" exact="breast cancer" post="(EMERGE). ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01156753. Accessed 29 May 2014 ClinicalTrials.gov (2013)"/>
   <result pre="study of CDX-011 (CR011-vcMMAE) in patients with advanced GPNMB-expressing breast" exact="cancer" post="(EMERGE). ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01156753. Accessed 29 May 2014 ClinicalTrials.gov (2013)"/>
   <result pre="assessment in determining the need for chemotherapy in women with" exact="breast cancer" post="that involves no more than 3 lymph nodes. ClinicalTrials.gov."/>
   <result pre="in determining the need for chemotherapy in women with breast" exact="cancer" post="that involves no more than 3 lymph nodes. ClinicalTrials.gov."/>
   <result pre="chemotherapy in treating women who have undergone surgery for node-negative" exact="breast cancer" post="(The TAILORx Trial). ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT00310180. Accessed 11 Sept 2014"/>
   <result pre="in treating women who have undergone surgery for node-negative breast" exact="cancer" post="(The TAILORx Trial). ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT00310180. Accessed 11 Sept 2014"/>
   <result pre="vedotin (CDX-011) in patients with metastatic, gpNMB over-expressing, triple negative" exact="breast cancer" post="(METRIC). ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT01997333. Accessed 29 May 2014 ClinicalTrials.gov (2014d)"/>
   <result pre="(CDX-011) in patients with metastatic, gpNMB over-expressing, triple negative breast" exact="cancer" post="(METRIC). ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT01997333. Accessed 29 May 2014 ClinicalTrials.gov (2014d)"/>
   <result pre="with or without chemotherapy in treating patients with invasive RxPONDER" exact="breast cancer." post="ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT01272037. Accessed 11 Sept 2014 ClinicalTrials.gov (2015) I-SPY"/>
   <result pre="2 TRIAL: neoadjuvant and personalized adaptive novel agents to treat" exact="breast cancer." post="ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01042379. Accessed 24 Aug 2015 Cortazar P Zhang"/>
   <result pre="and comparison with the Genomic Health recurrence score in early" exact="breast cancer" post="J Clin Oncol 2011 29 32 4273 4278 10.1200/JCO.2010.31.2835"/>
   <result pre="comparison with the Genomic Health recurrence score in early breast" exact="cancer" post="J Clin Oncol 2011 29 32 4273 4278 10.1200/JCO.2010.31.2835"/>
   <result pre="Wang YC Dowsett M Ingle J Peto R Relevance of" exact="breast cancer" post="hormone receptors and other factors to the efficacy of"/>
   <result pre="YC Dowsett M Ingle J Peto R Relevance of breast" exact="cancer" post="hormone receptors and other factors to the efficacy of"/>
   <result pre="AU Hortobagyi GN Giordano SH Prognosis of women with metastatic" exact="breast cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="Hortobagyi GN Giordano SH Prognosis of women with metastatic breast" exact="cancer" post="by HER2 status and trastuzumab treatment: an institutional-based review"/>
   <result pre="DeSantis C Ma J Bryan L Jemal A (2014) Breast" exact="cancer" post="statistics CA Cancer J Clin 2013 64 1 52"/>
   <result pre="Collaborative Group Effects of chemotherapy and hormonal therapy for early" exact="breast cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="Group Effects of chemotherapy and hormonal therapy for early breast" exact="cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="trial evaluating tamoxifen in the treatment of patients with node-negative" exact="breast cancer" post="who have estrogen-receptor-positive tumors N Engl J Med 1989"/>
   <result pre="evaluating tamoxifen in the treatment of patients with node-negative breast" exact="cancer" post="who have estrogen-receptor-positive tumors N Engl J Med 1989"/>
   <result pre="484 10.1056/NEJM198902233200802 2644532 Foulkes WD Smith IE Reis-Filho JS Triple-negative" exact="breast cancer" post="N Engl J Med 2010 363 20 1938 1948"/>
   <result pre="10.1056/NEJM198902233200802 2644532 Foulkes WD Smith IE Reis-Filho JS Triple-negative breast" exact="cancer" post="N Engl J Med 2010 363 20 1938 1948"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="H versus CT alone, in patients with HER2-positive locally advanced" exact="breast cancer." post="J Clin Oncol 31(15 suppl):abstr 503 Gianni L Pienkowski"/>
   <result pre="2 years versus 1 year of adjuvant trastuzumab for HER2-positive" exact="breast cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="years versus 1 year of adjuvant trastuzumab for HER2-positive breast" exact="cancer" post="(HERA): an open-label, randomised controlled trial Lancet 2013 382"/>
   <result pre="versus stopping at 5 years in 6,953 women with early" exact="breast cancer" post="J Clin Oncol 2013 31 5 10.1200/JCO.2012.47.5301 23169505 Guan"/>
   <result pre="stopping at 5 years in 6,953 women with early breast" exact="cancer" post="J Clin Oncol 2013 31 5 10.1200/JCO.2012.47.5301 23169505 Guan"/>
   <result pre="the treatment of human epidermal growth factor receptor 2-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 2013 31 16 1947 1953 10.1200/JCO.2011.40.5241"/>
   <result pre="treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 2013 31 16 1947 1953 10.1200/JCO.2011.40.5241"/>
   <result pre="23509322 Hamburg MA (2011) Proposal to withdraw approval for the" exact="breast cancer" post="indication for AVASTIN (bevacizumab): decision of the commissioner. Department"/>
   <result pre="Hamburg MA (2011) Proposal to withdraw approval for the breast" exact="cancer" post="indication for AVASTIN (bevacizumab): decision of the commissioner. Department"/>
   <result pre="O, Winer EP (2012) The natural history of hormone receptor-positive" exact="breast cancer." post="Oncology (Williston Park) 26(8):688–694, 696 Mackey J, Ramos-Vazquez M,"/>
   <result pre="the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic" exact="breast cancer." post="Cancer Res 73(24 Supplement):abstr S5-04 Marty M Cognetti F"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="administered as first-line treatment: the M77001 study group J"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="administered as first-line treatment: the M77001 study group J"/>
   <result pre="first-line treatment of human epidermal growth factor receptor 2-negative metastatic" exact="breast cancer" post="J Clin Oncol 2010 28 20 3239 3247 10.1200/JCO.2008.21.6457"/>
   <result pre="treatment of human epidermal growth factor receptor 2-negative metastatic breast" exact="cancer" post="J Clin Oncol 2010 28 20 3239 3247 10.1200/JCO.2008.21.6457"/>
   <result pre="with bevacizumab plus capecitabine in patients with previously treated metastatic" exact="breast cancer" post="J Clin Oncol 2005 23 4 792 799 10.1200/JCO.2005.05.098"/>
   <result pre="bevacizumab plus capecitabine in patients with previously treated metastatic breast" exact="cancer" post="J Clin Oncol 2005 23 4 792 799 10.1200/JCO.2005.05.098"/>
   <result pre="Davidson NE Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic" exact="breast cancer" post="N Engl J Med 2007 357 26 2666 2676"/>
   <result pre="NE Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast" exact="cancer" post="N Engl J Med 2007 357 26 2666 2676"/>
   <result pre="Cancer Institute (2012) Cancer trends progress report—2011/2012 update: costs of" exact="cancer" post="care. National Cancer Institute, NIH, DHHS. http://progressreport.cancer.gov/doc_detail.asp?pid=1&amp;amp;did=2009&amp;amp;chid=95&amp;amp;coid=926&amp;amp;mid=. Accessed 19"/>
   <result pre="19 May 2014 National Cancer Institute (2013) A snapshot of" exact="breast cancer." post="http://www.cancer.gov/researchandfunding/snapshots/breast#footnote1. Accessed 19 May 2014 National Cancer Institute (2014)"/>
   <result pre="19 May 2014 National Cancer Institute (2014) NCI dictionary of" exact="cancer" post="terms: targeted therapy. http://www.cancer.gov/dictionary?cdrid=270742. Accessed 10 July 2014 O’Shaughnessy"/>
   <result pre="weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2007 106 S32 S33 O’Shaughnessy"/>
   <result pre="irinotecan/carboplatin with or without cetuximab in patients with metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2007 106 S32 S33 O’Shaughnessy"/>
   <result pre="iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative" exact="breast cancer" post="(TNBC). J Clin Oncol 29(15 suppl):abstr 1007 O’Shaughnessy J"/>
   <result pre="(BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast" exact="cancer" post="(TNBC). J Clin Oncol 29(15 suppl):abstr 1007 O’Shaughnessy J"/>
   <result pre="Sherman BM Bradley C Iniparib plus chemotherapy in metastatic triple-negative" exact="breast cancer" post="N Engl J Med 2011 364 3 205 214"/>
   <result pre="BM Bradley C Iniparib plus chemotherapy in metastatic triple-negative breast" exact="cancer" post="N Engl J Med 2011 364 3 205 214"/>
   <result pre="N A multigene assay to predict recurrence of tamoxifen-treated, node-negative" exact="breast cancer" post="N Engl J Med 2004 351 27 2817 2826"/>
   <result pre="A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast" exact="cancer" post="N Engl J Med 2004 351 27 2817 2826"/>
   <result pre="and benefit of chemotherapy in women with node-negative, estrogen receptor-positive" exact="breast cancer" post="J Clin Oncol 2006 24 23 3726 3734 10.1200/JCO.2005.04.7985"/>
   <result pre="benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast" exact="cancer" post="J Clin Oncol 2006 24 23 3726 3734 10.1200/JCO.2005.04.7985"/>
   <result pre="Ellis MJ Perou CM Bernard PS Supervised risk predictor of" exact="breast cancer" post="based on intrinsic subtypes J Clin Oncol 2009 27"/>
   <result pre="MJ Perou CM Bernard PS Supervised risk predictor of breast" exact="cancer" post="based on intrinsic subtypes J Clin Oncol 2009 27"/>
   <result pre="response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive" exact="breast cancer." post="Survival follow-up analysis of the NeoALTTO study (BIG 1-06)."/>
   <result pre="(T + L) in the adjuvant treatment of HER2-positive early" exact="breast cancer" post="(EBC). J Clin Oncol 32(15 suppl):abstr LBA4 Prat A"/>
   <result pre="+ L) in the adjuvant treatment of HER2-positive early breast" exact="cancer" post="(EBC). J Clin Oncol 32(15 suppl):abstr LBA4 Prat A"/>
   <result pre="Phenotypic and molecular characterization of the claudin-low intrinsic subtype of" exact="breast cancer" post="Breast Cancer Res 2010 12 5 R68 10.1186/bcr2635 20813035"/>
   <result pre="and molecular characterization of the claudin-low intrinsic subtype of breast" exact="cancer" post="Breast Cancer Res 2010 12 5 R68 10.1186/bcr2635 20813035"/>
   <result pre="R Pathological complete response and accelerated drug approval in early" exact="breast cancer" post="N Engl J Med 2012 366 26 2438 2441"/>
   <result pre="Pathological complete response and accelerated drug approval in early breast" exact="cancer" post="N Engl J Med 2012 366 26 2438 2441"/>
   <result pre="in making decisions about adjuvant therapy for women with early" exact="breast cancer" post="J Clin Oncol 2001 19 4 980 991 11181660"/>
   <result pre="making decisions about adjuvant therapy for women with early breast" exact="cancer" post="J Clin Oncol 2001 19 4 980 991 11181660"/>
   <result pre="human epidermal growth factor receptor 2-negative, locally recurrent or metastatic" exact="breast cancer" post="J Clin Oncol 2011 29 10 1252 1260 10.1200/JCO.2010.28.0982"/>
   <result pre="epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast" exact="cancer" post="J Clin Oncol 2011 29 10 1252 1260 10.1200/JCO.2010.28.0982"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="Kurzrock R Equipoise lost: ethics, costs, and the regulation of" exact="cancer" post="clinical research J Clin Oncol 2010 28 17 2925"/>
   <result pre="MC Baselga J Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic" exact="breast cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="Baselga J Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast" exact="cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="of tamoxifen as single adjuvant agent in management of early" exact="breast cancer." post="Analysis at six years by Nolvadex Adjuvant Trial Organisation"/>
   <result pre="R Friend SH Gene expression profiling predicts clinical outcome of" exact="breast cancer" post="Nature 2002 415 6871 530 536 10.1038/415530a 11823860 van"/>
   <result pre="Friend SH Gene expression profiling predicts clinical outcome of breast" exact="cancer" post="Nature 2002 415 6871 530 536 10.1038/415530a 11823860 van"/>
   <result pre="R A gene-expression signature as a predictor of survival in" exact="breast cancer" post="N Engl J Med 2002 347 25 1999 2009"/>
   <result pre="A gene-expression signature as a predictor of survival in breast" exact="cancer" post="N Engl J Med 2002 347 25 1999 2009"/>
   <result pre="MW Olsen S Blackwell K Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="Olsen S Blackwell K Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="as a single agent in first-line treatment of HER2-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 2002 20 3 719 726 10.1200/JCO.20.3.719"/>
   <result pre="a single agent in first-line treatment of HER2-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 2002 20 3 719 726 10.1200/JCO.20.3.719"/>
   <result pre="A population-based validation of the prognostic model PREDICT for early" exact="breast cancer" post="Eur J Surg Oncol 2011 37 5 411 417"/>
   <result pre="population-based validation of the prognostic model PREDICT for early breast" exact="cancer" post="Eur J Surg Oncol 2011 37 5 411 417"/>
   <result pre="Lu J Trastuzumab in the adjuvant treatment of HER2-positive early" exact="breast cancer" post="patients: a meta-analysis of published randomized controlled trials PLoS"/>
   <result pre="J Trastuzumab in the adjuvant treatment of HER2-positive early breast" exact="cancer" post="patients: a meta-analysis of published randomized controlled trials PLoS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4736909/results/search/disease/results.xml">
   <result pre="gastric cancer, it is still the third leading cause of" exact="cancer" post="death worldwide. Patients often miss the opportunity for a"/>
   <result pre="often miss the opportunity for a surgical cure, because the" exact="cancer" post="has already developed into advanced cancer when identified. Compared"/>
   <result pre="surgical cure, because the cancer has already developed into advanced" exact="cancer" post="when identified. Compared to best supportive care, chemotherapy can"/>
   <result pre="receptor 2 (HER2), can significantly improve survival in advanced gastric" exact="cancer" post="patients with HER2 overexpression. Second-line treatment of advanced gastric"/>
   <result pre="cancer patients with HER2 overexpression. Second-line treatment of advanced gastric" exact="cancer" post="with ramucirumab, an antibody targeting VEGFR-2, alone or in"/>
   <result pre="kinase inhibitor, apatinib, can improve the survival of advanced gastric" exact="cancer" post="patients after second-line chemotherapy failure. Unfortunately, none of the"/>
   <result pre="summarize targeted therapies for advanced gastric cancer. 1. Introduction Gastric" exact="cancer" post="is the third leading cause of cancer death worldwide,"/>
   <result pre="1. Introduction Gastric cancer is the third leading cause of" exact="cancer" post="death worldwide, followed by lung cancer and liver cancer."/>
   <result pre="the third leading cause of cancer death worldwide, followed by" exact="lung cancer" post="and liver cancer. Gastric cancer is a common cancer,"/>
   <result pre="third leading cause of cancer death worldwide, followed by lung" exact="cancer" post="and liver cancer. Gastric cancer is a common cancer,"/>
   <result pre="cause of cancer death worldwide, followed by lung cancer and" exact="liver cancer." post="Gastric cancer is a common cancer, especially in East"/>
   <result pre="death worldwide, followed by lung cancer and liver cancer. Gastric" exact="cancer" post="is a common cancer, especially in East Asia, Middle"/>
   <result pre="and South America [ 1]. Annually, emerging cases of gastric" exact="cancer" post="in China account for 44.2% of the global emerging"/>
   <result pre="data on HER2, VEGR, EGFR, mTOR, MET, and other common" exact="cancer" post="targets or signaling pathways, this review attempts to expound"/>
   <result pre="to expound the advance of molecular targeted therapy for gastric" exact="cancer" post="in recent years. 2. Anti-HER2-Targeted Cancer Therapy 2.1. Trastuzumab"/>
   <result pre="4]. Trastuzumab was approved for the treatment of advanced gastric" exact="cancer" post="by the US Food and Drug Administration (FDA) in"/>
   <result pre="is approved for use only in patients with metastatic gastric" exact="cancer" post="with HER2 overexpression, which is defined as an immunohistochemistry"/>
   <result pre="can expand the overall survival of patients with advanced gastric" exact="cancer" post="to more than 1 year and prove the important"/>
   <result pre="year and prove the important role of trastuzumab in gastric" exact="cancer" post="therapy. An additional ToGA study on Chinese [ 6]"/>
   <result pre="chemotherapy could improve the overall survival of patients with gastric" exact="cancer" post="and the patients had a good drug tolerance. Two"/>
   <result pre="[ 8] and SP (S-1/cisplatin) [ 9] for advanced gastric" exact="cancer" post="therapy, respectively. The efficacy, PFS, and OS of the"/>
   <result pre="that trastuzumab plus XELOX or SP can also treat gastric" exact="cancer" post="efficiently and safely. We expect further phase III clinical"/>
   <result pre="of gastric cancers that overexpress EGFR or HER2 and enhancing" exact="cancer" post="cell apoptosis [ 10]. In 2013, at the ASCO"/>
   <result pre="as a first-line treatment for advanced or metastatic HER2-positive gastric" exact="cancer" post="patients (LOGiC Trial) [ 11]. The investigation showed that"/>
   <result pre="CapeOx+P arm. Toxicity profiles were similar except for increased overall" exact="diarrhea" post="and skin toxicity with CapeOx+L. These results indicate that"/>
   <result pre="first-line treatment had no survival benefit for HER2-positive advanced gastric" exact="cancer" post="patients, though certain subgroups showed improvement. TyTAN research is"/>
   <result pre="lapatinib in combination with chemotherapy to treat advanced HER2-positive gastric" exact="cancer" post="as a second-line treatment [ 12]. Two hundred sixty-one"/>
   <result pre="in the second-line treatment of patients with HER2-positive advanced gastric" exact="cancer" post="but did not significantly improve OS in the intent-to-treat"/>
   <result pre="efficacy of lapatinib plus capecitabine in patients with HER2-positive gastric" exact="cancer" post="as second-line treatment was merely 11.1% [ 13]; in"/>
   <result pre="bevacizumab to capecitabine-cisplatin in the first-line treatment of advanced gastric" exact="cancer" post="[ 15]. Seven hundred and seventy-four patients with advanced"/>
   <result pre="could not significantly improve the overall survival of advanced gastric" exact="cancer" post="patients. Another phase III AVATAR study from China also"/>
   <result pre="not significantly improve overall survival in patients with advanced gastric" exact="cancer" post="[ 16]. One of the reasons for the failure"/>
   <result pre="studies did not screen for important characteristics of the gastric" exact="cancer" post="population. Biomarkers are urgently needed to select more suitable"/>
   <result pre="population. Biomarkers are urgently needed to select more suitable gastric" exact="cancer" post="patients for bevacizumab treatment. We are looking forward to"/>
   <result pre="to more in-depth basic research on molecular typing of gastric" exact="cancer" post="cells. Based on studies such as AVAGAST, the US"/>
   <result pre="the FDA has approved bevacizumab for the treatment of advanced" exact="colorectal cancer" post="and advanced lung cancer. 3.2. Apatinib Apatinib is a"/>
   <result pre="FDA has approved bevacizumab for the treatment of advanced colorectal" exact="cancer" post="and advanced lung cancer. 3.2. Apatinib Apatinib is a"/>
   <result pre="bevacizumab for the treatment of advanced colorectal cancer and advanced" exact="lung cancer." post="3.2. Apatinib Apatinib is a small molecule tyrosine kinase"/>
   <result pre="phase II study that treated patients with metastatic adenocarcinoma gastric" exact="cancer" post="with apatinib at the 2011 ASCO annual meeting ["/>
   <result pre="[ 18]. One hundred and forty-four patients with advanced gastric" exact="cancer" post="who failed at least two chemotherapeutic regimens were enrolled."/>
   <result pre="PFS and OS in heavily pretreated patients with metastatic gastric" exact="cancer" post="who had experienced treatment failure with two or more"/>
   <result pre="a phase III clinical study of treating metastatic adenocarcinoma gastric" exact="cancer" post="with apatinib [ 19]. Two hundred and seventy-three patients"/>
   <result pre="[ 19]. Two hundred and seventy-three patients with advanced gastric" exact="cancer" post="who did not respond to second-line chemotherapy treatment were"/>
   <result pre="cancer. In Asia, the number of patients with advanced gastric" exact="cancer" post="who have experienced treatment failure with second-line chemotherapy is"/>
   <result pre="only antiangiogenic drug that has been approved for advanced gastric" exact="cancer" post="[ 23]. The REGARD study compared the efficacy and"/>
   <result pre="of ramucirumab versus placebo in the treatment of advanced gastric" exact="cancer" post="(adenocarcinoma of the gastroesophageal junction) after a first-line chemotherapy"/>
   <result pre="first-line chemotherapy, such as platinum or fluoropyrimidine drugs, but had" exact="cancer" post="progression after chemotherapy, were randomly divided into a ramucirumab"/>
   <result pre="similar in the two groups. For patients with advanced gastric" exact="cancer" post="and esophageal and gastric adenocarcinoma, who failed first-line chemotherapy,"/>
   <result pre="paclitaxel significantly improved the overall survival of patients with gastric" exact="cancer" post="after failure of first-line chemotherapy treatment. Compared with treatment"/>
   <result pre="HR = 0.807, P = 0.017). Treatment of advanced gastric" exact="cancer" post="with ramucirumab alone or in combination with second-line paclitaxel"/>
   <result pre="Interestingly, the AVAGAST study revealed that treatment of advanced gastric" exact="cancer" post="with bevacizumab combined with first-line capecitabine/cisplatin showed no survival"/>
   <result pre="survival benefit, and similar results were obtained in advanced gastric" exact="cancer" post="patients receiving first-line treatment with ramucirumab combined with the"/>
   <result pre="human endostatin, which was approved for the treatment of non-small-cell" exact="lung cancer" post="by China's Food and Drug Administration (CFDA) supervision bureau"/>
   <result pre="endostatin, which was approved for the treatment of non-small-cell lung" exact="cancer" post="by China's Food and Drug Administration (CFDA) supervision bureau"/>
   <result pre="for the treatment of newly diagnosed patients with advanced gastric" exact="cancer" post="[ 26]. A total of 165 patients with advanced"/>
   <result pre="[ 26]. A total of 165 patients with advanced gastric" exact="cancer" post="randomly received chemotherapy treatment with Endostar combined with the"/>
   <result pre="conclusion is that the treatment of newly diagnosed advanced gastric" exact="cancer" post="patients with Endostar combined with the SOX regimen is"/>
   <result pre="and effective. Few studies on the treatment of advanced gastric" exact="cancer" post="with Endostatin combined with chemotherapy agents have been reported,"/>
   <result pre="regorafenib treated mouse xenografts models, which were constructed by gastric" exact="cancer" post="cells, so antiangiogenesis maybe the major driving force of"/>
   <result pre="driving force of regorafenib when performing antitumor function in gastric" exact="cancer" post="[ 28]. To test the application value of regorafenib"/>
   <result pre="placebo-controlled study was carried out. The proportion of advanced gastric" exact="cancer" post="in all enrolled patients was 85/147; at the endpoint,"/>
   <result pre="keenly functional molecular targets answer to regorafenib in advanced gastric" exact="cancer" post="patients? And how to use it accurately? More clinical"/>
   <result pre="total of 904 patients with locally advanced or metastatic gastric" exact="cancer" post="or gastroesophageal junction carcinoma were enrolled. These patients were"/>
   <result pre="0.32). the conclusion is that the treatment of advanced gastric" exact="cancer" post="with the combination of cetuximab and XP regimens does"/>
   <result pre="= 0.013). EGFR is expressed in epithelial cells of gastric" exact="cancer" post="at a relatively high level, and the mutation rate"/>
   <result pre="high level, and the mutation rate of KRAS in gastric" exact="cancer" post="is much lower than that in colorectal cancer (4.2%)"/>
   <result pre="KRAS in gastric cancer is much lower than that in" exact="colorectal cancer" post="(4.2%) [ 33], and therefore EGFR-targeted therapy is the"/>
   <result pre="in gastric cancer is much lower than that in colorectal" exact="cancer" post="(4.2%) [ 33], and therefore EGFR-targeted therapy is the"/>
   <result pre="spot. Judging from the current studies, treatment of metastatic gastric" exact="cancer" post="with either small molecule TKI or monoclonal antibodies showed"/>
   <result pre="EGFR overexpressed tumor cells experiments in vitro, nimotuzumab showed remarkable" exact="cancer" post="reversing effects such as antiproliferation, antiangiogenesis and promotes apoptosis"/>
   <result pre="extracellular EGFR, displaying high killing effect in the EGFR positive" exact="cancer" post="cells. But nimotuzumab displays a longer half-life, higher dose-effect"/>
   <result pre="nimotuzumab and irinotecan as a second line treatment with advanced" exact="cancer" post="have had been approved (ClinicalTrials.gov Identifier: NCT01813253), aiming to"/>
   <result pre="(Cisplatin and S-1) treated patients with unresectable and metastatic gastric" exact="cancer" post="[ 37]. The results showed that neither NCS (nimotuzumab"/>
   <result pre="the rapamycin (mTOR) signaling pathway is frequently activated in gastric" exact="cancer" post="cells. Preclinical research showed that, in in vitro studies"/>
   <result pre="signaling pathway can inhibit the proliferation and metastasis of gastric" exact="cancer" post="cells [ 38]. Everolimus (RAD001) is an oral mTOR"/>
   <result pre="and safety of everolimus in the treatment of advanced gastric" exact="cancer" post="[ 39]. Fifty-three advanced gastric cancer patients with previous"/>
   <result pre="treatment of advanced gastric cancer [ 39]. Fifty-three advanced gastric" exact="cancer" post="patients with previous chemotherapy failure were treated with everolimus"/>
   <result pre="The treated patients usually had grades 3-4 adverse reactions, including" exact="anemia" post="and hyponatremia and increase of the serum level of"/>
   <result pre="monotherapy has a good disease control rate for advanced gastric" exact="cancer" post="patients with the failure of previous chemotherapy. Unfortunately, an"/>
   <result pre="that everolimus did not improve the survival of advanced gastric" exact="cancer" post="patients who had failed previous chemotherapy [ 40]. Six"/>
   <result pre="[ 41] and hormone receptor positive and HER2-negative advanced postmenopausal" exact="breast cancer" post="patients (July, 2012) [ 42] for the use of"/>
   <result pre="41] and hormone receptor positive and HER2-negative advanced postmenopausal breast" exact="cancer" post="patients (July, 2012) [ 42] for the use of"/>
   <result pre="signal pathways are activated upon HGF induction to promote gastric" exact="cancer" post="cell proliferation, survival, and migration [ 43]. MET gene"/>
   <result pre="with ECX scheme (epirubicin/cisplatin/capecitabine) in the treatment of advanced gastric" exact="cancer" post="(adenocarcinoma of the gastroesophageal junction) [ 44]. A total"/>
   <result pre="safety of treatment of metastatic HER2 −MET + advanced gastric" exact="cancer" post="(adenocarcinoma of the gastroesophageal junction) with first-line mFOLFOX6 combined"/>
   <result pre="reactions, such as the reduction of neutrophils, thrombocytopenia, edema, and" exact="pulmonary embolism," post="were not significantly increased in the onartuzumab group. The"/>
   <result pre="HGF/MET-targeted monoclonal antibodies for the first-line treatment of advanced gastric" exact="cancer" post="has been nearly stopped. The possible reasons for obtaining"/>
   <result pre="accurate enough prediction of MET protein expression; there is gastric" exact="cancer" post="heterogeneity, and so on. 6.3. Foretinib Foretinib (GSK1363089) is"/>
   <result pre="showed that foretinib could effectively inhibit the growth of gastric" exact="cancer" post="cells by blocking the signal transduction pathway of tyrosine"/>
   <result pre="could not improve the survival of patients with advanced gastric" exact="cancer" post="without previous chemotherapy [ 48]. The exact effect of"/>
   <result pre="further study. 7. Conclusion Along with the development of gastric" exact="cancer" post="research, more and more targeted drugs are being developed"/>
   <result pre="have been completed or are being carried out for gastric" exact="cancer" post="therapy, and these results have gradually changed the clinical"/>
   <result pre="and ramucirumab (second line) for the treatment of advanced gastric" exact="cancer" post="[ 49]. Trastuzumab improves the survival of patients with"/>
   <result pre="for gastric cancer. We look forward to discovering more gastric" exact="cancer" post="driver genes and to designing corresponding targeted drugs for"/>
   <result pre="future basic research. We also anticipate greater progress of gastric" exact="cancer" post="research in selected appropriate patients with targeted therapy. Conflict"/>
   <result pre="Siegel R. L. Ferlay J. Lortet-Tieulent J. Jemal A. Global" exact="cancer" post="statistics, 2012 CA—A Cancer Journal for Clinicians 2015 65"/>
   <result pre="H. Zhang S. He J. Annual report on status of" exact="cancer" post="in China Chinese Journal of Cancer Research 2011 27"/>
   <result pre="Croxtall J. D. McKeage K. Trastuzumab: in HER2-positive metastatic gastric" exact="cancer" post="Drugs 2010 70 17 2259 2267 10.2165/11205900-000000000-00000 21080742 5"/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial The"/>
   <result pre="trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric" exact="cancer" post="European Journal of Cancer 2015 51 4 482 488"/>
   <result pre="trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric" exact="cancer" post="(HERBIS-1) British Journal of Cancer 2014 110 5 1163"/>
   <result pre="EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric" exact="cancer" post="cells and is synergistic with trastuzumab in vitro and"/>
   <result pre="paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric" exact="cancer" post="in Asian populations: TyTAN—a randomized, phase III study Journal"/>
   <result pre="S. S. Vascular endothelial growth factor a inhibition in gastric" exact="cancer" post="Gastric Cancer 2015 18 1 33 42 10.1007/s10120-014-0397-4 24993497"/>
   <result pre="Geng R. Li J. Apatinib for the treatment of gastric" exact="cancer" post="Expert Opinion on Pharmacotherapy 2015 16 1 117 122"/>
   <result pre="S. J. et al. FDA approval summary: ramucirumab for gastric" exact="cancer" post="Clinical Cancer Research 2015 21 15 3372 3376 26048277"/>
   <result pre="with Endostar and S-1 combined with oxaliplatin in advanced gastric" exact="cancer" post="OncoTargets and Therapy 2013 6 925 929 10.2147/OTT.S46487 23926435"/>
   <result pre="the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric" exact="cancer" post="Journal of Experimental &amp;amp; Clinical Cancer Research 2015 34"/>
   <result pre="double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric" exact="cancer" post="(AOGC)-a study by the Australasian Gastrointestinal Trials Group (AGITG):"/>
   <result pre="D. Chau I. Targeting the human EGFR family in esophagogastric" exact="cancer" post="Nature Reviews Clinical Oncology 2011 8 8 492 503"/>
   <result pre="or without cetuximab for patients with previously untreated advanced gastric" exact="cancer" post="(EXPAND): a randomised, open-label phase 3 trial The Lancet"/>
   <result pre="or without panitumumab for patients with previously untreated advanced oesophagogastric" exact="cancer" post="(REAL3): a randomised, open-label phase 3 trial The Lancet"/>
   <result pre="rare and related to DNA mismatch repair deficiency in gastric" exact="cancer" post="from the East and the West: results from a"/>
   <result pre="factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived" exact="cancer" post="Journal of Immunotherapy 2003 26 2 139 148 10.1097/00002371-200303000-00006"/>
   <result pre="irinotecan alone as second-line therapy for patients with advanced gastric" exact="cancer" post="Gastric Cancer 2015 18 4 824 832 10.1007/s10120-014-0420-9 25185971"/>
   <result pre="A. mTOR as a therapeutic target in patients with gastric" exact="cancer" post="International Journal of Cancer 2012 130 3 491 496"/>
   <result pre="study of everolimus in patients with previously treated metastatic gastric" exact="cancer" post="Journal of Clinical Oncology 2010 28 11 1904 1910"/>
   <result pre="R. Devine R. Sein N. George B. New agents in" exact="renal cell carcinoma" post="Targeted Oncology 2014 9 3 183 193 10.1007/s11523-013-0303-8 24243495"/>
   <result pre="Leo A. Challenges in the management of advanced, ER-positive, HER2-negative" exact="breast cancer" post="Nature Reviews Clinical Oncology 2015 12 9 541 552"/>
   <result pre="A. Challenges in the management of advanced, ER-positive, HER2-negative breast" exact="cancer" post="Nature Reviews Clinical Oncology 2015 12 9 541 552"/>
   <result pre="10.1038/nrclinonc.2015.99 43 Lordick F. Targeting the HGF/MET pathway in gastric" exact="cancer" post="The Lancet Oncology 2014 15 9 914 916 10.1016/S1470-2045(14)70273-6"/>
   <result pre="multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric" exact="cancer" post="cell lines by blocking inter-receptor tyrosine kinase networks Investigational"/>
   <result pre="oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric" exact="cancer" post="PLoS ONE 2013 8 3 10.1371/journal.pone.0054014 49 Elimova E."/>
   <result pre="Wadhwa R. Shiozaki H. et al. Molecular biomarkers in gastric" exact="cancer" post="Journal of the National Comprehensive Cancer Network 2015 13"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4738716/results/search/disease/results.xml">
   <result pre="work is properly cited. Abstract Tumors act systemically to sustain" exact="cancer" post="progression, affecting the physiological processes in the host and"/>
   <result pre="samples from seven healthy female donors and 29 women with" exact="breast cancer" post="including 14 triple-negative breast cancers and 15 hormone-dependent breast"/>
   <result pre="from seven healthy female donors and 29 women with breast" exact="cancer" post="including 14 triple-negative breast cancers and 15 hormone-dependent breast"/>
   <result pre="analysis revealed distinct molecular signatures in the blood of HER2−" exact="breast cancer" post="patients according to ER/PR status. Our data showed the"/>
   <result pre="revealed distinct molecular signatures in the blood of HER2− breast" exact="cancer" post="patients according to ER/PR status. Our data showed the"/>
   <result pre="Our data showed the implication of immune signaling in both" exact="breast cancer" post="subtypes with an enrichment of these processes in the"/>
   <result pre="data showed the implication of immune signaling in both breast" exact="cancer" post="subtypes with an enrichment of these processes in the"/>
   <result pre="tumors. Overall, our data indicate that the presence of triple-negative" exact="breast cancer" post="is associated with an enrichment of altered systemic immune-related"/>
   <result pre="Overall, our data indicate that the presence of triple-negative breast" exact="cancer" post="is associated with an enrichment of altered systemic immune-related"/>
   <result pre="and clinical characteristics. Despite the advances in molecular classification of" exact="breast cancer" post="[ 2– 5], identifying of clinically relevant subgroups is"/>
   <result pre="clinical characteristics. Despite the advances in molecular classification of breast" exact="cancer" post="[ 2– 5], identifying of clinically relevant subgroups is"/>
   <result pre="growth factor receptor 2 (HER2) along with clinicopathological variables. Currently," exact="breast cancer" post="is categorized into three main therapeutic groups: ER-positive (ER+),"/>
   <result pre="factor receptor 2 (HER2) along with clinicopathological variables. Currently, breast" exact="cancer" post="is categorized into three main therapeutic groups: ER-positive (ER+),"/>
   <result pre="three main therapeutic groups: ER-positive (ER+), HER2-positive (HER2+), and triple-negative" exact="breast cancer" post="(TNBC/ER−PR−HER2−). ER+ tumors account for about 70% of breast"/>
   <result pre="main therapeutic groups: ER-positive (ER+), HER2-positive (HER2+), and triple-negative breast" exact="cancer" post="(TNBC/ER−PR−HER2−). ER+ tumors account for about 70% of breast"/>
   <result pre="breast cancer (TNBC/ER−PR−HER2−). ER+ tumors account for about 70% of" exact="breast cancer" post="that respond well to endocrine therapy and have a"/>
   <result pre="cancer (TNBC/ER−PR−HER2−). ER+ tumors account for about 70% of breast" exact="cancer" post="that respond well to endocrine therapy and have a"/>
   <result pre="tumors. Overall, overexpression of HER2, identified in about 20% of" exact="breast cancer," post="is associated with a more aggressive phenotype but, however,"/>
   <result pre="on peripheral blood revealed specific signatures related to lymphomas and" exact="leukemia" post="as well as inflammatory and autoimmune diseases [ 8–"/>
   <result pre="[ 8– 10]. Gene expression signatures in peripheral blood of" exact="breast cancer" post="patients were associated with early detection of tumors ["/>
   <result pre="8– 10]. Gene expression signatures in peripheral blood of breast" exact="cancer" post="patients were associated with early detection of tumors ["/>
   <result pre="was to evaluate the mRNA-peripheral blood profile of two HER2−" exact="breast cancer" post="subtypes, including hormone-dependent breast cancer (ER+PR+HER2−) and triple-negative breast"/>
   <result pre="to evaluate the mRNA-peripheral blood profile of two HER2− breast" exact="cancer" post="subtypes, including hormone-dependent breast cancer (ER+PR+HER2−) and triple-negative breast"/>
   <result pre="blood profile of two HER2− breast cancer subtypes, including hormone-dependent" exact="breast cancer" post="(ER+PR+HER2−) and triple-negative breast cancer (TNBC/ER−PR−HER2−), known to have"/>
   <result pre="profile of two HER2− breast cancer subtypes, including hormone-dependent breast" exact="cancer" post="(ER+PR+HER2−) and triple-negative breast cancer (TNBC/ER−PR−HER2−), known to have"/>
   <result pre="breast cancer subtypes, including hormone-dependent breast cancer (ER+PR+HER2−) and triple-negative" exact="breast cancer" post="(TNBC/ER−PR−HER2−), known to have the best and the worst"/>
   <result pre="cancer subtypes, including hormone-dependent breast cancer (ER+PR+HER2−) and triple-negative breast" exact="cancer" post="(TNBC/ER−PR−HER2−), known to have the best and the worst"/>
   <result pre="and Methods 2.1. Blood Sample Collection and Processing Twenty-nine female" exact="breast cancer" post="patients were recruited for this study between August 2010"/>
   <result pre="Methods 2.1. Blood Sample Collection and Processing Twenty-nine female breast" exact="cancer" post="patients were recruited for this study between August 2010"/>
   <result pre="met the following criteria: (a) were recently diagnosed with invasive" exact="breast cancer," post="(b) had negative HER2 status (HER2−) in the primary"/>
   <result pre="Tukey's post hoc test. When two groups were considered (all" exact="breast cancer" post="samples, named as BC, versus CTR) differences in gene"/>
   <result pre="post hoc test. When two groups were considered (all breast" exact="cancer" post="samples, named as BC, versus CTR) differences in gene"/>
   <result pre="ER+PR+ and ER−PR− subtypes were approximately equally distributed among HER2−" exact="breast cancer" post="cases (51.7% and 48.3%, resp.). ER+PR+HER2− and ER−PR−HER2− groups"/>
   <result pre="and ER−PR− subtypes were approximately equally distributed among HER2− breast" exact="cancer" post="cases (51.7% and 48.3%, resp.). ER+PR+HER2− and ER−PR−HER2− groups"/>
   <result pre="transcriptional profiles of blood samples from 14 patients with triple-negative" exact="breast cancer" post="(TNBC/ER−PR−HER2−), 15 patients with hormone-dependent breast cancer (ER+PR+HER2−), and"/>
   <result pre="profiles of blood samples from 14 patients with triple-negative breast" exact="cancer" post="(TNBC/ER−PR−HER2−), 15 patients with hormone-dependent breast cancer (ER+PR+HER2−), and"/>
   <result pre="patients with triple-negative breast cancer (TNBC/ER−PR−HER2−), 15 patients with hormone-dependent" exact="breast cancer" post="(ER+PR+HER2−), and seven healthy donors (CTR). Microarray-based gene expression"/>
   <result pre="with triple-negative breast cancer (TNBC/ER−PR−HER2−), 15 patients with hormone-dependent breast" exact="cancer" post="(ER+PR+HER2−), and seven healthy donors (CTR). Microarray-based gene expression"/>
   <result pre="that occur in the blood cells of the patients with" exact="breast cancer" post="pathology, we further considered all 29 blood samples from"/>
   <result pre="occur in the blood cells of the patients with breast" exact="cancer" post="pathology, we further considered all 29 blood samples from"/>
   <result pre="cancer pathology, we further considered all 29 blood samples from" exact="breast cancer" post="patients as a whole group (BC). A disease signature"/>
   <result pre="pathology, we further considered all 29 blood samples from breast" exact="cancer" post="patients as a whole group (BC). A disease signature"/>
   <result pre="transcriptional changes observed in the peripheral blood of patients with" exact="breast cancer," post="we analyzed our data using IPA software. We ran"/>
   <result pre="differences observed in the peripheral blood cells of patients with" exact="breast cancer" post="we further focused on the implications of immune cells"/>
   <result pre="observed in the peripheral blood cells of patients with breast" exact="cancer" post="we further focused on the implications of immune cells"/>
   <result pre="significant biofunctions induced by innate and adaptive immune cells in" exact="breast cancer" post="patients (Additional file 1). By evaluating the genes involved"/>
   <result pre="biofunctions induced by innate and adaptive immune cells in breast" exact="cancer" post="patients (Additional file 1). By evaluating the genes involved"/>
   <result pre="8.11 E − 08), as upstream regulators when comparing all" exact="breast cancer" post="samples with healthy donors ( Table 3). The relationship"/>
   <result pre="E − 08), as upstream regulators when comparing all breast" exact="cancer" post="samples with healthy donors ( Table 3). The relationship"/>
   <result pre="transcriptional profiles in the peripheral blood cells of HER2 negative" exact="breast cancer" post="patients according to ER/PR status to evaluate whether there"/>
   <result pre="profiles in the peripheral blood cells of HER2 negative breast" exact="cancer" post="patients according to ER/PR status to evaluate whether there"/>
   <result pre="well as the immune response in all blood samples from" exact="breast cancer" post="patients, with an enrichment of these processes in the"/>
   <result pre="as the immune response in all blood samples from breast" exact="cancer" post="patients, with an enrichment of these processes in the"/>
   <result pre="of cancer, with immune cells being recognized to facilitate the" exact="cancer" post="progression. Inflammatory cells and inflammatory mediators including chemokines, cytokines,"/>
   <result pre="that CAFs production of CXCL1, CXCL2, PTGS2/COX-2, and IL-6 in" exact="breast cancer" post="can modulate the functions of immune cells in TME"/>
   <result pre="CAFs production of CXCL1, CXCL2, PTGS2/COX-2, and IL-6 in breast" exact="cancer" post="can modulate the functions of immune cells in TME"/>
   <result pre="IL-8, and PTGS2/COX-2 in the peripheral blood of patients with" exact="breast cancer" post="both when considering the subtypes individually and when considering"/>
   <result pre="and PTGS2/COX-2 in the peripheral blood of patients with breast" exact="cancer" post="both when considering the subtypes individually and when considering"/>
   <result pre="both when considering the subtypes individually and when considering all" exact="breast cancer" post="samples as a group. Furthermore, we found that PTGS2/COX-2's"/>
   <result pre="when considering the subtypes individually and when considering all breast" exact="cancer" post="samples as a group. Furthermore, we found that PTGS2/COX-2's"/>
   <result pre="was identified as a possible predictive marker of micrometastasis of" exact="breast cancer" post="in the bone marrow [ 27], currently there are"/>
   <result pre="identified as a possible predictive marker of micrometastasis of breast" exact="cancer" post="in the bone marrow [ 27], currently there are"/>
   <result pre="to show its overexpression in the blood of patients with" exact="breast cancer." post="In preneoplastic lesions, proinflammatory cytokines and chemokines secreted by"/>
   <result pre="investigated the role of TREM1 in the peripheral blood of" exact="breast cancer" post="patients. Cross talk between innate and adaptive immune systems"/>
   <result pre="the role of TREM1 in the peripheral blood of breast" exact="cancer" post="patients. Cross talk between innate and adaptive immune systems"/>
   <result pre="systems has already been demonstrated to have profound effects on" exact="cancer" post="development, including breast carcinogenesis [ 40, 41]. The immune"/>
   <result pre="accumulation of leucocytes in the blood of the patients with" exact="breast cancer" post="(Additional file 1). The set of cytokines, chemokines, and"/>
   <result pre="of leucocytes in the blood of the patients with breast" exact="cancer" post="(Additional file 1). The set of cytokines, chemokines, and"/>
   <result pre="and biomediators identified as upregulated in peripheral blood cells of" exact="breast cancer" post="patients have been shown to stimulate innate peripheral blood"/>
   <result pre="biomediators identified as upregulated in peripheral blood cells of breast" exact="cancer" post="patients have been shown to stimulate innate peripheral blood"/>
   <result pre="TME. It is known that leucocytes represent crucial regulators of" exact="cancer" post="development by altering local homeostasis and declining immune balance"/>
   <result pre="inhibition of B lymphocytes maturation. The interactions between TME and" exact="cancer" post="cells represent intrinsic features of breast cancer subtypes. In"/>
   <result pre="interactions between TME and cancer cells represent intrinsic features of" exact="breast cancer" post="subtypes. In a recent study, Camp et al. ["/>
   <result pre="between TME and cancer cells represent intrinsic features of breast" exact="cancer" post="subtypes. In a recent study, Camp et al. ["/>
   <result pre="45] identified specific microenvironment features when comparing basal-like with luminal" exact="breast cancer" post="subtypes. They observed that basal-like cells respond to stromal"/>
   <result pre="identified specific microenvironment features when comparing basal-like with luminal breast" exact="cancer" post="subtypes. They observed that basal-like cells respond to stromal"/>
   <result pre="these molecules in the peripheral blood cells of patients with" exact="breast cancer" post="regardless of subtype. Furthermore, validation of our results on"/>
   <result pre="molecules in the peripheral blood cells of patients with breast" exact="cancer" post="regardless of subtype. Furthermore, validation of our results on"/>
   <result pre="better understanding of the role of immune system in HER2−" exact="breast cancer" post="subtypes, allowing new immunotherapeutic approaches. In conclusion, our data"/>
   <result pre="understanding of the role of immune system in HER2− breast" exact="cancer" post="subtypes, allowing new immunotherapeutic approaches. In conclusion, our data"/>
   <result pre="show distinct molecular signatures in the blood of HER2 negative" exact="breast cancer" post="patients according to ER/PR status. We noticed a significant"/>
   <result pre="distinct molecular signatures in the blood of HER2 negative breast" exact="cancer" post="patients according to ER/PR status. We noticed a significant"/>
   <result pre="R. E. et al. Distinct types of diffuse large B-cell" exact="lymphoma" post="identified by gene expression profiling Nature 2000 403 6769"/>
   <result pre="Gene expression profiling of relevant biomarkers for treatment evaluation in" exact="multiple sclerosis" post="Journal of Neuroimmunology 2004 152 1-2 126 139 10.1016/j.jneuroim.2004.03.004"/>
   <result pre="Moore J. H. Aune T. M. Gene expression signatures for" exact="autoimmune disease" post="in peripheral blood mononuclear cells Arthritis Research and Therapy"/>
   <result pre="Sahni N. S. Tibshirani R. et al. Early detection of" exact="breast cancer" post="based on gene-expression patterns in peripheral blood cells Breast"/>
   <result pre="N. S. Tibshirani R. et al. Early detection of breast" exact="cancer" post="based on gene-expression patterns in peripheral blood cells Breast"/>
   <result pre="expression profiling of peripheral blood cells for early detection of" exact="breast cancer" post="Breast Cancer Research 2010 12 1, article R7 10.1186/bcr2472"/>
   <result pre="profiling of peripheral blood cells for early detection of breast" exact="cancer" post="Breast Cancer Research 2010 12 1, article R7 10.1186/bcr2472"/>
   <result pre="local and systemic immune profiles underlie lymph node metastasis in" exact="breast cancer" post="patients International Journal of Cancer 2013 132 11 2537"/>
   <result pre="and systemic immune profiles underlie lymph node metastasis in breast" exact="cancer" post="patients International Journal of Cancer 2013 132 11 2537"/>
   <result pre="Strasner A. et al. Tumour-infiltrating regulatory T cells stimulate mammary" exact="cancer" post="metastasis through RANKL-RANK signalling Nature 2011 470 7335 548"/>
   <result pre="10.1038/nature09707 21326202 20 Lewis C. E. Hughes R. Inflammation and" exact="breast cancer." post="Microenvironmental factors regulating macrophage function in breast tumours: hypoxia"/>
   <result pre="M. Autelli R. et al. Expression of Cox-2 in human" exact="breast cancer" post="cells as a critical determinant of epithelial-to-mesenchymal transition and"/>
   <result pre="Autelli R. et al. Expression of Cox-2 in human breast" exact="cancer" post="cells as a critical determinant of epithelial-to-mesenchymal transition and"/>
   <result pre="Gendler S. J. Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in" exact="breast cancer" post="cells in an in vivo model of spontaneous metastatic"/>
   <result pre="S. J. Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast" exact="cancer" post="cells in an in vivo model of spontaneous metastatic"/>
   <result pre="cancer cells in an in vivo model of spontaneous metastatic" exact="breast cancer" post="Molecular Cancer Research 2004 2 11 632 642 15561779"/>
   <result pre="cells in an in vivo model of spontaneous metastatic breast" exact="cancer" post="Molecular Cancer Research 2004 2 11 632 642 15561779"/>
   <result pre="inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine" exact="breast cancer" post="model PLoS ONE 2013 8 5 10.1371/journal.pone.0063451 27 Zhu"/>
   <result pre="blocks M2 macrophage differentiation and suppresses metastasis in murine breast" exact="cancer" post="model PLoS ONE 2013 8 5 10.1371/journal.pone.0063451 27 Zhu"/>
   <result pre="L. W. C. Possible predictive markers related to micro-metastasis in" exact="breast cancer" post="patients Oncology Reports 2006 15 5 1217 1223 16596190"/>
   <result pre="W. C. Possible predictive markers related to micro-metastasis in breast" exact="cancer" post="patients Oncology Reports 2006 15 5 1217 1223 16596190"/>
   <result pre="role for cyclooxygenase-2 in regulating vascular channel formation by human" exact="breast cancer" post="cells Breast Cancer Research 2006 8 6, article R69"/>
   <result pre="for cyclooxygenase-2 in regulating vascular channel formation by human breast" exact="cancer" post="cells Breast Cancer Research 2006 8 6, article R69"/>
   <result pre="Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in" exact="cancer" post="patients: a prognostic marker for lung metastases from solid"/>
   <result pre="1411 1415 18505088 40 Disis M. L. Immune regulation of" exact="cancer" post="Journal of Clinical Oncology 2010 28 29 4531 4538"/>
   <result pre="20516428 41 DeNardo D. G. Coussens L. M. Inflammation and" exact="breast cancer." post="Balancing immune response: crosstalk between adaptive and innate immune"/>
   <result pre="immune response: crosstalk between adaptive and innate immune cells during" exact="breast cancer" post="progression Breast Cancer Research 2007 9, article 212 10.1186/bcr1746"/>
   <result pre="response: crosstalk between adaptive and innate immune cells during breast" exact="cancer" post="progression Breast Cancer Research 2007 9, article 212 10.1186/bcr1746"/>
   <result pre="Coussens L. M. Paradoxical roles of the immune system during" exact="cancer" post="development Nature Reviews Cancer 2006 6 1 24 37"/>
   <result pre="21131600 Figure 1 Stroma evaluation for ER−PR−HER2− (TNBC) and ER+PR+HER2−" exact="breast cancer" post="subtypes: (a) TNBC mammary carcinoma (40x): black star, viable"/>
   <result pre="Figure 1 Stroma evaluation for ER−PR−HER2− (TNBC) and ER+PR+HER2− breast" exact="cancer" post="subtypes: (a) TNBC mammary carcinoma (40x): black star, viable"/>
   <result pre="their target molecules, evaluated in the peripheral blood cells of" exact="breast cancer" post="patients compared with healthy donors (Ingenuity Pathway Analysis). Table"/>
   <result pre="target molecules, evaluated in the peripheral blood cells of breast" exact="cancer" post="patients compared with healthy donors (Ingenuity Pathway Analysis). Table"/>
   <result pre="regulators predicted by IPA in the peripheral blood cells of" exact="breast cancer" post="patients compared with healthy donors. Upstream regulator Fold change"/>
   <result pre="predicted by IPA in the peripheral blood cells of breast" exact="cancer" post="patients compared with healthy donors. Upstream regulator Fold change"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4739616/results/search/disease/results.xml">
   <result pre="signaling pathway plays an important role in processes critical for" exact="breast cancer" post="progression and its upregulation confers increased resistance of cancer"/>
   <result pre="pathway plays an important role in processes critical for breast" exact="cancer" post="progression and its upregulation confers increased resistance of cancer"/>
   <result pre="breast cancer progression and its upregulation confers increased resistance of" exact="cancer" post="cells to chemotherapy and radiation. The present study aimed"/>
   <result pre="a constituent of species in the plant genera Drosera, toward" exact="breast cancer" post="cells and defining the involvement of PI3K/Akt inhibition in"/>
   <result pre="constituent of species in the plant genera Drosera, toward breast" exact="cancer" post="cells and defining the involvement of PI3K/Akt inhibition in"/>
   <result pre="The results showed that ramentaceone exhibited high antiproliferative activity toward" exact="breast cancer" post="cells, in particular HER2-overexpressing breast cancer cells. The mode"/>
   <result pre="results showed that ramentaceone exhibited high antiproliferative activity toward breast" exact="cancer" post="cells, in particular HER2-overexpressing breast cancer cells. The mode"/>
   <result pre="high antiproliferative activity toward breast cancer cells, in particular HER2-overexpressing" exact="breast cancer" post="cells. The mode of cell death induced by ramentaceone"/>
   <result pre="antiproliferative activity toward breast cancer cells, in particular HER2-overexpressing breast" exact="cancer" post="cells. The mode of cell death induced by ramentaceone"/>
   <result pre="protein and inhibited the phosphorylation of the Akt protein in" exact="breast cancer" post="cells. The expression of the anti-apoptotic Bcl-2 protein was"/>
   <result pre="and inhibited the phosphorylation of the Akt protein in breast" exact="cancer" post="cells. The expression of the anti-apoptotic Bcl-2 protein was"/>
   <result pre="In conclusion, our results indicate that ramentaceone induces apoptosis in" exact="breast cancer" post="cells through PI3K/Akt signaling inhibition. These findings suggest further"/>
   <result pre="conclusion, our results indicate that ramentaceone induces apoptosis in breast" exact="cancer" post="cells through PI3K/Akt signaling inhibition. These findings suggest further"/>
   <result pre="further investigation of ramentaceone as a potential therapeutic agent in" exact="breast cancer" post="therapy, in particular HER2-positive breast cancer. Funding This work"/>
   <result pre="investigation of ramentaceone as a potential therapeutic agent in breast" exact="cancer" post="therapy, in particular HER2-positive breast cancer. Funding This work"/>
   <result pre="potential therapeutic agent in breast cancer therapy, in particular HER2-positive" exact="breast cancer." post="Funding This work was supported by the grant of"/>
   <result pre="Availability All relevant data are within the paper. Introduction Breast" exact="cancer" post="is one of the most frequently diagnosed malignancies in"/>
   <result pre="population [ 1]. One of the major barriers in effective" exact="cancer" post="treatment is the decreased potential of cancer cells to"/>
   <result pre="barriers in effective cancer treatment is the decreased potential of" exact="cancer" post="cells to undergo apoptosis. One of the main regulators"/>
   <result pre="undergo apoptosis. One of the main regulators of apoptosis in" exact="breast cancer" post="cells is the phosphoinositide 3-kinase (PI3K)/Akt pathway. PI3K/Akt signaling"/>
   <result pre="apoptosis. One of the main regulators of apoptosis in breast" exact="cancer" post="cells is the phosphoinositide 3-kinase (PI3K)/Akt pathway. PI3K/Akt signaling"/>
   <result pre="migration. Activation of the PI3K/Akt pathway has been associated with" exact="breast cancer" post="development and confers resistance of breast cancer cells to"/>
   <result pre="Activation of the PI3K/Akt pathway has been associated with breast" exact="cancer" post="development and confers resistance of breast cancer cells to"/>
   <result pre="been associated with breast cancer development and confers resistance of" exact="breast cancer" post="cells to conventional therapies, in particular HER2-directed therapy. HER2-overexpressing"/>
   <result pre="associated with breast cancer development and confers resistance of breast" exact="cancer" post="cells to conventional therapies, in particular HER2-directed therapy. HER2-overexpressing"/>
   <result pre="cancer cells to conventional therapies, in particular HER2-directed therapy. HER2-overexpressing" exact="breast cancer" post="accounts for 30% of breast cancer occurrences and is"/>
   <result pre="cells to conventional therapies, in particular HER2-directed therapy. HER2-overexpressing breast" exact="cancer" post="accounts for 30% of breast cancer occurrences and is"/>
   <result pre="particular HER2-directed therapy. HER2-overexpressing breast cancer accounts for 30% of" exact="breast cancer" post="occurrences and is associated with increased resistance to chemotherapy,"/>
   <result pre="HER2-directed therapy. HER2-overexpressing breast cancer accounts for 30% of breast" exact="cancer" post="occurrences and is associated with increased resistance to chemotherapy,"/>
   <result pre="molecule has been shown to increase the efficacy of HER2-overexpressing" exact="breast cancer" post="treatment [ 4]. These findings warrant the search for"/>
   <result pre="has been shown to increase the efficacy of HER2-overexpressing breast" exact="cancer" post="treatment [ 4]. These findings warrant the search for"/>
   <result pre="has been determined against different cell lines including murine lymphocytic" exact="leukemia" post="(P-388) [ 10], human prostate cancer (LNCaP) [ 11]"/>
   <result pre="cell lines including murine lymphocytic leukemia (P-388) [ 10], human" exact="prostate cancer" post="(LNCaP) [ 11] and human promyelocytic leukemia (HL-60) ["/>
   <result pre="lines including murine lymphocytic leukemia (P-388) [ 10], human prostate" exact="cancer" post="(LNCaP) [ 11] and human promyelocytic leukemia (HL-60) ["/>
   <result pre="10], human prostate cancer (LNCaP) [ 11] and human promyelocytic" exact="leukemia" post="(HL-60) [ 12]. Our research regarding the effects of"/>
   <result pre="[ 12]. Our research regarding the effects of ramentaceone on" exact="leukemia" post="HL-60 cells showed that ramentaceone induces cell death in"/>
   <result pre="various cell lines examined, ramentaceone displayed high activity towards the" exact="breast cancer" post="cell line, MCF-7 [ 9]. Due to the high"/>
   <result pre="cell lines examined, ramentaceone displayed high activity towards the breast" exact="cancer" post="cell line, MCF-7 [ 9]. Due to the high"/>
   <result pre="[ 9]. Due to the high activity of ramentaceone towards" exact="breast cancer" post="cells, in our present study we focused on determining"/>
   <result pre="9]. Due to the high activity of ramentaceone towards breast" exact="cancer" post="cells, in our present study we focused on determining"/>
   <result pre="determining the mechanism of cell death induced by ramentaceone in" exact="breast cancer" post="cells. Materials and Methods Extraction and isolation The source"/>
   <result pre="the mechanism of cell death induced by ramentaceone in breast" exact="cancer" post="cells. Materials and Methods Extraction and isolation The source"/>
   <result pre="was 0.5%). Cell Culture The BT474, SKBR3, MCF-7 and MDA-MB-231" exact="breast cancer" post="cell lines were purchased from Cell Line Services (Germany)."/>
   <result pre="0.5%). Cell Culture The BT474, SKBR3, MCF-7 and MDA-MB-231 breast" exact="cancer" post="cell lines were purchased from Cell Line Services (Germany)."/>
   <result pre="+ (Top-bottom)/1 + 10LogEC50-X. Results Antiproliferative effects of ramentaceone towards" exact="breast cancer" post="cells The effects of ramentaceone ( Fig 1) on"/>
   <result pre="(Top-bottom)/1 + 10LogEC50-X. Results Antiproliferative effects of ramentaceone towards breast" exact="cancer" post="cells The effects of ramentaceone ( Fig 1) on"/>
   <result pre="effects of ramentaceone ( Fig 1) on the proliferation of" exact="breast cancer" post="cells were determined with the use of the MTT"/>
   <result pre="of ramentaceone ( Fig 1) on the proliferation of breast" exact="cancer" post="cells were determined with the use of the MTT"/>
   <result pre="assay. HER2-positive (BT474 and SKBR3) and HER2-negative (MCF-7 and MDA-MB-231)" exact="breast cancer" post="cells were treated with increasing concentrations of ramentaceone. Ramentaceone"/>
   <result pre="HER2-positive (BT474 and SKBR3) and HER2-negative (MCF-7 and MDA-MB-231) breast" exact="cancer" post="cells were treated with increasing concentrations of ramentaceone. Ramentaceone"/>
   <result pre="in vivo [ 13]. Moreover, analysis performed using samples from" exact="breast cancer" post="patients showed that the clonogenic assay predicted the clinical"/>
   <result pre="vivo [ 13]. Moreover, analysis performed using samples from breast" exact="cancer" post="patients showed that the clonogenic assay predicted the clinical"/>
   <result pre="agents [ 14], indicating the potential of ramentaceone in HER2-positive" exact="breast cancer" post="therapy. Fig 1 Structure of ramentaceone (5-hydroxy-7-methyl-1,4-naphthoquinone). Fig 2"/>
   <result pre="[ 14], indicating the potential of ramentaceone in HER2-positive breast" exact="cancer" post="therapy. Fig 1 Structure of ramentaceone (5-hydroxy-7-methyl-1,4-naphthoquinone). Fig 2"/>
   <result pre="(5-hydroxy-7-methyl-1,4-naphthoquinone). Fig 2 Effects of ramentaceone on the viability of" exact="breast cancer" post="cells. (A) Cytotoxic activity of ramentaceone toward HER2-overexpressing (BT474"/>
   <result pre="Fig 2 Effects of ramentaceone on the viability of breast" exact="cancer" post="cells. (A) Cytotoxic activity of ramentaceone toward HER2-overexpressing (BT474"/>
   <result pre="toward HER2-overexpressing (BT474 and SKBR3) and HER2-negative (MCF-7 and MDA-MB-231)" exact="breast cancer" post="cells. Cells were treated with ramentaceone (0–15 μM) for"/>
   <result pre="HER2-overexpressing (BT474 and SKBR3) and HER2-negative (MCF-7 and MDA-MB-231) breast" exact="cancer" post="cells. Cells were treated with ramentaceone (0–15 μM) for"/>
   <result pre="= 3). (B) Influence of ramentaceone on clonogenicity of HER2-positive" exact="breast cancer" post="cells, SKBR3 and BT474. Cells were treated with ramentaceone"/>
   <result pre="3). (B) Influence of ramentaceone on clonogenicity of HER2-positive breast" exact="cancer" post="cells, SKBR3 and BT474. Cells were treated with ramentaceone"/>
   <result pre="cells. Inhibition of the PI3K/Akt signaling pathway by ramentaceone in" exact="breast cancer" post="cells To elucidate the mechanism of ramentaceone-induced cell death,"/>
   <result pre="Inhibition of the PI3K/Akt signaling pathway by ramentaceone in breast" exact="cancer" post="cells To elucidate the mechanism of ramentaceone-induced cell death,"/>
   <result pre="the involvement of ramentaceone in PI3K/Akt signaling was examined. Breast" exact="cancer" post="cells were treated with ramentaceone in the concentration range"/>
   <result pre="PI3K/Akt signaling proteins. (A) Concentration-dependent inhibition of PI3K/Akt signaling. Breast" exact="cancer" post="cells were treated with ramentaceone (0–15 μM) for 24"/>
   <result pre="Fig 4 Inhibition of phosphoinositide-3-kinase (PI3-kinase) activity by ramentaceone in" exact="breast cancer" post="cells. The AlphaScreen technology was used to determine enzyme"/>
   <result pre="4 Inhibition of phosphoinositide-3-kinase (PI3-kinase) activity by ramentaceone in breast" exact="cancer" post="cells. The AlphaScreen technology was used to determine enzyme"/>
   <result pre="of three independent experiments. Induction of apoptosis by ramentaceone in" exact="breast cancer" post="cells The ability to induce apoptosis in cancer cells"/>
   <result pre="three independent experiments. Induction of apoptosis by ramentaceone in breast" exact="cancer" post="cells The ability to induce apoptosis in cancer cells"/>
   <result pre="in breast cancer cells The ability to induce apoptosis in" exact="cancer" post="cells is a desired feature of a potential chemotherapeutic"/>
   <result pre="agent. To determine whether ramentaceone induces apoptotic-mediated cell death in" exact="breast cancer" post="cells a characteristic feature of apoptotic cell death, namely"/>
   <result pre="To determine whether ramentaceone induces apoptotic-mediated cell death in breast" exact="cancer" post="cells a characteristic feature of apoptotic cell death, namely"/>
   <result pre="a dose-dependent increase in apoptosis induction in HER2-positive and HER2-negative" exact="breast cancer" post="cells. In accordance to the results of the MTT"/>
   <result pre="dose-dependent increase in apoptosis induction in HER2-positive and HER2-negative breast" exact="cancer" post="cells. In accordance to the results of the MTT"/>
   <result pre="Fig 5). Fig 5 Induction of apoptosis by ramentaceone in" exact="breast cancer" post="cells. Apoptotic changes in plasma membrane induced by ramentaceone."/>
   <result pre="5). Fig 5 Induction of apoptosis by ramentaceone in breast" exact="cancer" post="cells. Apoptotic changes in plasma membrane induced by ramentaceone."/>
   <result pre="proteins and anti-apoptotic Bcl-2 protein were examined in ramentaceoone-treated HER2-positive" exact="breast cancer" post="cells. BT474 and SKBR3 cells were treated for 24"/>
   <result pre="and anti-apoptotic Bcl-2 protein were examined in ramentaceoone-treated HER2-positive breast" exact="cancer" post="cells. BT474 and SKBR3 cells were treated for 24"/>
   <result pre="on expression levels Bcl-2 family proteins and caspase activity in" exact="breast cancer" post="cells. (A) Effects of ramentaceone on the expression levels"/>
   <result pre="expression levels Bcl-2 family proteins and caspase activity in breast" exact="cancer" post="cells. (A) Effects of ramentaceone on the expression levels"/>
   <result pre="in ramentaceone-induced apoptosis, Akt expression was transiently silenced in HER2-overexpressing" exact="breast cancer" post="cells. BT474 and SKBR3 cells were transiently transfected with"/>
   <result pre="ramentaceone-induced apoptosis, Akt expression was transiently silenced in HER2-overexpressing breast" exact="cancer" post="cells. BT474 and SKBR3 cells were transiently transfected with"/>
   <result pre="phosphoinositide 3-kinase (PI3K) signaling pathway is of central importance in" exact="breast cancer" post="and plays an important role in processes critical for"/>
   <result pre="3-kinase (PI3K) signaling pathway is of central importance in breast" exact="cancer" post="and plays an important role in processes critical for"/>
   <result pre="cancer and plays an important role in processes critical for" exact="cancer" post="progression including proliferation, survival, motility, angiogenesis and metabolism. Hyperactivation"/>
   <result pre="PI3K/Akt signaling has been associated with an altered response of" exact="cancer" post="cells to therapy such as chemotherapy and radiation ["/>
   <result pre="was further confirmed by silencing the expression of Akt in" exact="breast cancer" post="cells with Akt siRNA and showing that knockdown of"/>
   <result pre="further confirmed by silencing the expression of Akt in breast" exact="cancer" post="cells with Akt siRNA and showing that knockdown of"/>
   <result pre="results confirm that ramentaceone induces apoptosis through PI3K/Akt inhibition in" exact="breast cancer" post="cells. PI3K/Akt activation renders breast cancer cells resistant to"/>
   <result pre="confirm that ramentaceone induces apoptosis through PI3K/Akt inhibition in breast" exact="cancer" post="cells. PI3K/Akt activation renders breast cancer cells resistant to"/>
   <result pre="through PI3K/Akt inhibition in breast cancer cells. PI3K/Akt activation renders" exact="breast cancer" post="cells resistant to apoptosis, which is a major barrier"/>
   <result pre="PI3K/Akt inhibition in breast cancer cells. PI3K/Akt activation renders breast" exact="cancer" post="cells resistant to apoptosis, which is a major barrier"/>
   <result pre="resistant to apoptosis, which is a major barrier in efficient" exact="breast cancer" post="treatment [ 18]. In particular PI3K/Akt upregulation confers resistance"/>
   <result pre="to apoptosis, which is a major barrier in efficient breast" exact="cancer" post="treatment [ 18]. In particular PI3K/Akt upregulation confers resistance"/>
   <result pre="[ 18]. In particular PI3K/Akt upregulation confers resistance of HER2-overexpressing" exact="breast cancer" post="cells to apoptosis induced by HER2- directed therapy. In"/>
   <result pre="18]. In particular PI3K/Akt upregulation confers resistance of HER2-overexpressing breast" exact="cancer" post="cells to apoptosis induced by HER2- directed therapy. In"/>
   <result pre="This points to the promising potential of ramentaceone in HER2-positive" exact="breast cancer" post="therapy in particular adjuvant therapy. Compounds comprising a quinone"/>
   <result pre="points to the promising potential of ramentaceone in HER2-positive breast" exact="cancer" post="therapy in particular adjuvant therapy. Compounds comprising a quinone"/>
   <result pre="significant anti-proliferative and anti-cancer activity in various animal models and" exact="cancer" post="cell lines [ 28– 30], including breast cancer ["/>
   <result pre="animal models and cancer cell lines [ 28– 30], including" exact="breast cancer" post="[ 31– 33]. Studies performed by Kuo et al."/>
   <result pre="models and cancer cell lines [ 28– 30], including breast" exact="cancer" post="[ 31– 33]. Studies performed by Kuo et al."/>
   <result pre="previous research revealed high antiproliferative activity of plumbagin towards HER2-overexpressing" exact="breast cancer" post="cells [ 27]. The results presented herein show that"/>
   <result pre="research revealed high antiproliferative activity of plumbagin towards HER2-overexpressing breast" exact="cancer" post="cells [ 27]. The results presented herein show that"/>
   <result pre="that ramentaceone exerts higher anti-clonogenic and pro-apoptotic activity towards HER2-overexpressing" exact="breast cancer" post="cells in comparison with plumbagin. Due to the structural"/>
   <result pre="ramentaceone exerts higher anti-clonogenic and pro-apoptotic activity towards HER2-overexpressing breast" exact="cancer" post="cells in comparison with plumbagin. Due to the structural"/>
   <result pre="these compounds, further research into the activity of ramentaceone toward" exact="breast cancer" post="is warranted. In conclusion, our research shows that ramentaceone"/>
   <result pre="compounds, further research into the activity of ramentaceone toward breast" exact="cancer" post="is warranted. In conclusion, our research shows that ramentaceone"/>
   <result pre="on ramentaceone as a potential agent in the treatment of" exact="breast cancer," post="in particular HER2-overexpressing breast cancer. This work was supported"/>
   <result pre="agent in the treatment of breast cancer, in particular HER2-overexpressing" exact="breast cancer." post="This work was supported by the grant of the"/>
   <result pre="D , Hung MC ( 2000) Overexpression of ErbB2 in" exact="cancer" post="and ErbB2-targeting strategies. Oncogene 19: 6115– 6121. 11156524 3"/>
   <result pre="Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium" exact="tuberculosis" post=". Phytomedicine 13: 630– 635. 16987644 7 Mahapatra A"/>
   <result pre="et al. ( 2007) Activity of 7-methyljuglone derivatives against Mycobacterium" exact="tuberculosis" post="and as subversive substrates for mycothiol disulfide reductase ."/>
   <result pre="SE ( 1985) The human tumor clonogenic assay in human" exact="breast cancer." post="J Clin Oncol 3: 92– 97. 3965634 15 Hennessy"/>
   <result pre=", Mills GB ( 2005) Exploiting the PI3K/AKT pathway for" exact="cancer" post="drug discovery. Nat Rev Drug Discov 4: 988– 1004."/>
   <result pre=", et al. ( 2009) Suppression of HER2/HER3-mediated growth of" exact="breast cancer" post="cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and"/>
   <result pre="et al. ( 2009) Suppression of HER2/HER3-mediated growth of breast" exact="cancer" post="cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and"/>
   <result pre="Viallet J , Lipton A ( 2007) Synergistic inhibition of" exact="breast cancer" post="cell lines with a dual inhibitor of EGFR-HER-2/neu and"/>
   <result pre="J , Lipton A ( 2007) Synergistic inhibition of breast" exact="cancer" post="cell lines with a dual inhibitor of EGFR-HER-2/neu and"/>
   <result pre="evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing" exact="breast cancer" post="cells . Cancer Chemother Pharmacol 65: 697– 706. doi:"/>
   <result pre="of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast" exact="cancer" post="cells . Cancer Chemother Pharmacol 65: 697– 706. doi:"/>
   <result pre="Pardee AB , Li CJ ( 2003) Selective killing of" exact="cancer" post="cells by beta-lapachone: direct checkpoint activation as a strategy"/>
   <result pre="cells by beta-lapachone: direct checkpoint activation as a strategy against" exact="cancer" post=". Proc Natl Acad Sci USA 100: 2674– 2678."/>
   <result pre="reductase and the relation to induction of apoptosis in human" exact="cancer" post="cells . J Biol Chem 281: 5593– 5603. 16354662"/>
   <result pre=", Lojkowska E ( 2012) Plumbagin induces apoptosis in Her2-overexpressing" exact="breast cancer" post="cells through the mitochondrial-mediated pathway . J Nat Prod"/>
   <result pre="Lojkowska E ( 2012) Plumbagin induces apoptosis in Her2-overexpressing breast" exact="cancer" post="cells through the mitochondrial-mediated pathway . J Nat Prod"/>
   <result pre="2014) Plumbagin downregulates Wnt signaling independent of p53 in human" exact="colorectal cancer" post="cells . J Nat Prod 77: 1130– 1134. doi:"/>
   <result pre="Plumbagin downregulates Wnt signaling independent of p53 in human colorectal" exact="cancer" post="cells . J Nat Prod 77: 1130– 1134. doi:"/>
   <result pre="D , Sarkar FH ( 2008) Plumbagin-induced apoptosis of human" exact="breast cancer" post="cells is mediated by inactivation of NF-kappaB and Bcl-2"/>
   <result pre=", Sarkar FH ( 2008) Plumbagin-induced apoptosis of human breast" exact="cancer" post="cells is mediated by inactivation of NF-kappaB and Bcl-2"/>
   <result pre="2011) Plumbagin inhibits invasion and migration of breast and gastric" exact="cancer" post="cells by downregulating the expression of chemokine receptor CXCR4"/>
   <result pre="reduces human breast cancer-induced osteolytic bone metastasis in mice through" exact="suppression" post="of RANKL signaling . Mol Cancer Ther 11: 350–"/>
   <result pre="autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in" exact="breast cancer" post="cells . Mol Cancer Ther 5: 3209– 3221. 17172425"/>
   <result pre="by inhibiting the AKT/mammalian target of rapamycin pathway in breast" exact="cancer" post="cells . Mol Cancer Ther 5: 3209– 3221. 17172425"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4740402/results/search/disease/results.xml">
   <result pre="detailed studies, however, revealed that the underlying molecular mechanisms of" exact="cancer" post="cell- and cardiomyocyte-biology display a substantial degree of similarity"/>
   <result pre="Force T . Molecular mechanisms of cardiovascular toxicity of targeted" exact="cancer" post="therapeutics. Circ Res. 2010; 106: 21– 34. doi: 10.1161/CIRCRESAHA.109.206920"/>
   <result pre="R , Beahm C , et al. Cardiotoxicity of the" exact="cancer" post="therapeutic agent imatinib mesylate. Nat Med. 2006; 12: 908–"/>
   <result pre="P , et al. Sorafenib has potent antitumor activity against" exact="multiple myeloma" post="In Vitro, Ex Vivo, and In Vivo in the"/>
   <result pre="at a late stage enhances imatinib-induced cytotoxicity In human malignant" exact="glioma" post="cells . Int J Cancer. 2009; 124: 1060– 1071."/>
   <result pre="potentiates the antitumor effect of the multikinase inhibitor sorafenib in" exact="hepatocellular carcinoma" post=". Int J Cancer. 2012; 131: 548– 557. doi:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4741577/results/search/disease/results.xml">
   <result pre="protein ovarian carcinoma HER2 immunotoxin INTRODUCTION Xenograft models of human" exact="cancer" post="are indispensable tools for evaluation of efficacy of novel"/>
   <result pre="marker and advanced molecular target for a targeted therapy of" exact="cancer" post="[ 7]. This receptor is overexpressed in a range"/>
   <result pre="limited to breast, ovarian, endometrial, colon, prostate, cervical, and non-small-cell" exact="lung cancer." post="HER2 is implicated in disease initiation and progression, is"/>
   <result pre="necessary to carry out preclinical evaluations. Recently, a HER2-expressing mouse" exact="breast cancer" post="cell line 4T1 transfected with GFP has been used"/>
   <result pre="to carry out preclinical evaluations. Recently, a HER2-expressing mouse breast" exact="cancer" post="cell line 4T1 transfected with GFP has been used"/>
   <result pre="(+++) in the tumor tissue (Fig. 3). Fluorescence signal from" exact="cancer" post="cells was easily detected in vivo by epifluorescence imaging"/>
   <result pre="planar epi-illumination geometry. Single injection of 4D5scFv-ETA resulted in a" exact="suppression" post="of the tumor growth with the tumor growth inhibition"/>
   <result pre="the other hand, a tremendous evolution of targeted therapy of" exact="cancer" post="demands a variety of tumor models expressing different molecular"/>
   <result pre="the &quot;window of tissue transparency&quot; [ 17]. A number of" exact="cancer" post="cell lines expressing red or far-red fluorescent proteins providing"/>
   <result pre="which are colorectal, pancreas and epidermoid carcinomas, breast adenocarcinoma, Lewis" exact="lung carcinoma," post="etc. [ 4, 18– 20]. The brightness of Katushka"/>
   <result pre="we have created the first fluorescent model of human HER2-overexpressing" exact="ovarian cancer." post="Due to far-red emission this model can be easily"/>
   <result pre="no conflict of interest. References REFERENCES 1 Hoffman RM Imaging" exact="cancer" post="dynamics in vivo at the tumor and cellular level"/>
   <result pre="18787963 2 Weissleder R Scaling down imaging: molecular mapping of" exact="cancer" post="in mice Nat Rev Cancer 2002 2 11 8"/>
   <result pre="imaging and magnetic resonance imaging on an orthotopic model of" exact="pancreatic cancer" post="Cancer Res 2005 65 9829 33 16267005 4 Yang"/>
   <result pre="and magnetic resonance imaging on an orthotopic model of pancreatic" exact="cancer" post="Cancer Res 2005 65 9829 33 16267005 4 Yang"/>
   <result pre="5 Bouvet M Hoffman RM Clinically-relevent orthotopic metastatic models of" exact="pancreatic cancer" post="imageable with fluorescent genetic reporters Minerva Chir 2009 64"/>
   <result pre="Bouvet M Hoffman RM Clinically-relevent orthotopic metastatic models of pancreatic" exact="cancer" post="imageable with fluorescent genetic reporters Minerva Chir 2009 64"/>
   <result pre="lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic" exact="breast cancer" post="mouse model Anticancer Res 2013 33 419 24 23393332"/>
   <result pre="nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast" exact="cancer" post="mouse model Anticancer Res 2013 33 419 24 23393332"/>
   <result pre="(RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in" exact="ovarian cancer" post="cells Clin Cancer Res 1998 4 2545 50 9796989"/>
   <result pre="immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian" exact="cancer" post="cells Clin Cancer Res 1998 4 2545 50 9796989"/>
   <result pre="McCluskey AJ Olive AJ Starnbach MN Collier RJ Targeting HER2-positive" exact="cancer" post="cells with receptor-redirected anthrax protective antigen Mol Oncol 2013"/>
   <result pre="Starnbach MN Collier RJ Targeting HER2-positive cancer cells with receptor-redirected" exact="anthrax" post="protective antigen Mol Oncol 2013 7 440 451 23290417"/>
   <result pre="JB Raman V Noninvasive optical tracking of red fluorescent protein-expressing" exact="cancer" post="cells in a model of metastatic breast cancer Neoplasia"/>
   <result pre="red fluorescent protein-expressing cancer cells in a model of metastatic" exact="breast cancer" post="Neoplasia 2006 8 796 806 17032496 21 Scherbo D"/>
   <result pre="fluorescent protein-expressing cancer cells in a model of metastatic breast" exact="cancer" post="Neoplasia 2006 8 796 806 17032496 21 Scherbo D"/>
   <result pre="Barnase as a new therapeutic agent triggering apoptosis in human" exact="cancer" post="cells PLoS ONE 2008 3 e2434 18560598 24 Mironova"/>
   <result pre="EF Stremovskiy OA Lukyanov KA Chudakov DM Deyev SM Targeting" exact="cancer" post="cells by using an antireceptor antibody-photosensitizer fusion protein Proc"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4741657/results/search/disease/results.xml">
   <result pre="metastatic breast cancers: targeted sequencing results in patients with refractory" exact="breast cancer" post="Park Yeon Hee 1 2 Shin Hyun-Tae 3 Jung"/>
   <result pre="breast cancers: targeted sequencing results in patients with refractory breast" exact="cancer" post="Park Yeon Hee 1 2 Shin Hyun-Tae 3 Jung"/>
   <result pre="author and source are credited. Abstract In women with metastatic" exact="breast cancer" post="(MBC), introduction of the anti-HER2 (human epidermal growth factor"/>
   <result pre="and source are credited. Abstract In women with metastatic breast" exact="cancer" post="(MBC), introduction of the anti-HER2 (human epidermal growth factor"/>
   <result pre="and clinicopathological analyses in a cohort of patients with refractory" exact="breast cancer" post="to anti-HER2 therapies to identify the molecular basis for"/>
   <result pre="clinicopathological analyses in a cohort of patients with refractory breast" exact="cancer" post="to anti-HER2 therapies to identify the molecular basis for"/>
   <result pre="resistance to HER2-directed therapy. Functional validation is warranted. refractory metastatic" exact="breast cancer" post="next generation sequencing (NGS) targeted sequencing HER2 mutation HER"/>
   <result pre="to HER2-directed therapy. Functional validation is warranted. refractory metastatic breast" exact="cancer" post="next generation sequencing (NGS) targeted sequencing HER2 mutation HER"/>
   <result pre="sequencing (NGS) targeted sequencing HER2 mutation HER pathway INTRODUCTION Metastatic" exact="breast cancer" post="(MBC) is an incurable disease with a 2- to"/>
   <result pre="(NGS) targeted sequencing HER2 mutation HER pathway INTRODUCTION Metastatic breast" exact="cancer" post="(MBC) is an incurable disease with a 2- to"/>
   <result pre="aggressive cancers and to develop more effective therapies. Progress in" exact="cancer" post="genomics has raised hopes of more precise identification of"/>
   <result pre="patients with refractory disease who have only limited options for" exact="cancer" post="treatments. The HER pathway plays a critical role in"/>
   <result pre="HER pathway plays a critical role in the pathogenesis of" exact="breast cancer," post="especially in patients with HER2 overexpression [ 11]. HER-2,"/>
   <result pre="breast cancers, Bose et al. estimated that about 1.6% of" exact="breast cancer" post="patients possess a HER2 mutation [ 13]. They found"/>
   <result pre="cancers, Bose et al. estimated that about 1.6% of breast" exact="cancer" post="patients possess a HER2 mutation [ 13]. They found"/>
   <result pre="ERBB2 copy number and gene expression of twenty seven metastatic" exact="breast cancer" post="patients. ERBB2 gene expression is significantly higher in patients"/>
   <result pre="copy number and gene expression of twenty seven metastatic breast" exact="cancer" post="patients. ERBB2 gene expression is significantly higher in patients"/>
   <result pre="directed therapy and new resistance mechanism of HER2 pathway in" exact="breast cancer." post="Furthermore, this finding was supported by GRB2 downregulation, which"/>
   <result pre="panel). Lim et al., reported down-regulation of GRB2 in heregulin-stimulated-HER2-overexpressing" exact="breast cancer" post="cells that lead to reduced proliferation through inactivation of"/>
   <result pre="Lim et al., reported down-regulation of GRB2 in heregulin-stimulated-HER2-overexpressing breast" exact="cancer" post="cells that lead to reduced proliferation through inactivation of"/>
   <result pre="at multiple points early in the natural history of HER2-positive" exact="breast cancer" post="can abrogate drug resistance. For this reason, double-blockades may"/>
   <result pre="multiple points early in the natural history of HER2-positive breast" exact="cancer" post="can abrogate drug resistance. For this reason, double-blockades may"/>
   <result pre="(SMC) from March 2013 to November 2014. The patients with" exact="breast cancer" post="who progressed after or were refractory to conventional treatments,"/>
   <result pre="from March 2013 to November 2014. The patients with breast" exact="cancer" post="who progressed after or were refractory to conventional treatments,"/>
   <result pre="(Agilent Technologies, Santa Clara, CA, USA). Sequencing using a customized" exact="cancer" post="panel (CancerSCAN™) Genomic DNA (250 ng) from each tissue"/>
   <result pre="TruSeq Rapid SBS Kit (Illumina). Variants detection using the customized" exact="cancer" post="panel (CancerSCAN™) Sequence reads were mapped to the human"/>
   <result pre="We normalized each patient's gene expression data to publically available" exact="breast cancer" post="data. Gene expression data from the TCGA BRCA project"/>
   <result pre="normalized each patient's gene expression data to publically available breast" exact="cancer" post="data. Gene expression data from the TCGA BRCA project"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="G et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 109 119 22149875"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 109 119 22149875"/>
   <result pre="Y Yardley D et al. Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2012 366 520 529 22149876"/>
   <result pre="Yardley D et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2012 366 520 529 22149876"/>
   <result pre="letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced" exact="breast cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2015"/>
   <result pre="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast" exact="cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2015"/>
   <result pre="A Zhang H Zhao R et al. Clonal evolution in" exact="breast cancer" post="revealed by single nucleus genome sequencing Nature 2014 512"/>
   <result pre="Zhang H Zhao R et al. Clonal evolution in breast" exact="cancer" post="revealed by single nucleus genome sequencing Nature 2014 512"/>
   <result pre="et al. Activating HER2 mutations in HER2 gene amplification negative" exact="breast cancer" post="Cancer Discov 2013 3 224 237 23220880 14 Lim"/>
   <result pre="al. Activating HER2 mutations in HER2 gene amplification negative breast" exact="cancer" post="Cancer Discov 2013 3 224 237 23220880 14 Lim"/>
   <result pre="Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing" exact="breast cancer" post="cells Oncogene 2000 19 6271 6276 11175341 15 Hegde"/>
   <result pre="downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast" exact="cancer" post="cells Oncogene 2000 19 6271 6276 11175341 15 Hegde"/>
   <result pre="TM Delineation of molecular mechanisms of sensitivity to lapatinib in" exact="breast cancer" post="cell lines using global gene expression profiles Mol Cancer"/>
   <result pre="Delineation of molecular mechanisms of sensitivity to lapatinib in breast" exact="cancer" post="cell lines using global gene expression profiles Mol Cancer"/>
   <result pre="of the HER2 receptor, and response to anti-HER2 therapies in" exact="breast cancer" post="J Natl Cancer Inst 2007 99 628 638 17440164"/>
   <result pre="the HER2 receptor, and response to anti-HER2 therapies in breast" exact="cancer" post="J Natl Cancer Inst 2007 99 628 638 17440164"/>
   <result pre="FE An oncogenic isoform of HER2 associated with locally disseminated" exact="breast cancer" post="and trastuzumab resistance Mol Cancer Ther 2009 8 2152"/>
   <result pre="An oncogenic isoform of HER2 associated with locally disseminated breast" exact="cancer" post="and trastuzumab resistance Mol Cancer Ther 2009 8 2152"/>
   <result pre="C Guix M Dugger T Engelman JA Arteaga CL Human" exact="breast cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="Guix M Dugger T Engelman JA Arteaga CL Human breast" exact="cancer" post="cells selected for resistance to trastuzumab in vivo overexpress"/>
   <result pre="in patients with human epidermal growth factor receptor 2-positive metastatic" exact="breast cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="patients with human epidermal growth factor receptor 2-positive metastatic breast" exact="cancer" post="that progressed during prior trastuzumab therapy J Clin Oncol"/>
   <result pre="trastuzumab in women with locally advanced, inflammatory, or early HER2-positive" exact="breast cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="in women with locally advanced, inflammatory, or early HER2-positive breast" exact="cancer" post="(NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet"/>
   <result pre="adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive" exact="breast cancer" post="in the North Central Cancer Treatment Group N9831 trial"/>
   <result pre="trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast" exact="cancer" post="in the North Central Cancer Treatment Group N9831 trial"/>
   <result pre="growth factor receptor 2 (HER2) levels in patients with HER2-positive" exact="breast cancer" post="receiving chemotherapy with or without trastuzumab: results from North"/>
   <result pre="factor receptor 2 (HER2) levels in patients with HER2-positive breast" exact="cancer" post="receiving chemotherapy with or without trastuzumab: results from North"/>
   <result pre="Wolmark N HER2 status and benefit from adjuvant trastuzumab in" exact="breast cancer" post="N Engl J Med 2008 358 1409 1411 18367751"/>
   <result pre="N HER2 status and benefit from adjuvant trastuzumab in breast" exact="cancer" post="N Engl J Med 2008 358 1409 1411 18367751"/>
   <result pre="Sensitive detection of somatic point mutations in impure and heterogeneous" exact="cancer" post="samples Nat Biotechnol 2013 31 213 219 23396013 39"/>
   <result pre="Huh N Park T Personalized identification of altered pathways in" exact="cancer" post="using accumulated normal tissue data Bioinformatics 2014 30 i422"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4742525/results/search/disease/results.xml">
   <result pre="pone.0148101.pdf Abstract Background Gastric and esophageal adenocarcinomas are major global" exact="cancer" post="burdens. These cancer forms are characterized by a poor"/>
   <result pre="Gastric and esophageal adenocarcinomas are major global cancer burdens. These" exact="cancer" post="forms are characterized by a poor prognosis and a"/>
   <result pre="revealed that the prognostic impact of EGFR was significant in" exact="esophageal cancer" post="(p = 0.014), but non-significant in gastric cancer. Of"/>
   <result pre="that the prognostic impact of EGFR was significant in esophageal" exact="cancer" post="(p = 0.014), but non-significant in gastric cancer. Of"/>
   <result pre="with EGFR, increased expression of HER3 is seen in several" exact="cancer" post="forms[ 18] and although it has a severely impaired"/>
   <result pre="HER2 with lapatinib, but where inhibition of HER3 sensitized HER2-positive" exact="breast cancer" post="cells to lapatinib[ 59]. A study by Tao et"/>
   <result pre="with lapatinib, but where inhibition of HER3 sensitized HER2-positive breast" exact="cancer" post="cells to lapatinib[ 59]. A study by Tao et"/>
   <result pre="their potential prognostic values. However, as patients with gastric and" exact="esophageal cancer" post="are increasingly being treated with neoadjuvant therapy, future studies"/>
   <result pre="potential prognostic values. However, as patients with gastric and esophageal" exact="cancer" post="are increasingly being treated with neoadjuvant therapy, future studies"/>
   <result pre="correlated with shorter OS in gastric as well as other" exact="cancer" post="forms[ 17, 19, 26], but also with longer, or"/>
   <result pre="EGFR[ 26, 27, 32] or HER3 [ 27] in upper" exact="gastrointestinal cancer." post="Of note, comparatively few studies related to EGFR and"/>
   <result pre="few studies related to EGFR and HER3 expression in upper" exact="gastrointestinal cancer" post="have included the esophagus, which is somewhat surprising considering"/>
   <result pre="studies related to EGFR and HER3 expression in upper gastrointestinal" exact="cancer" post="have included the esophagus, which is somewhat surprising considering"/>
   <result pre="elimination of the tumour bulk, but not affect the proliferative" exact="cancer" post="stem cell-like population. While the lack of consistent results"/>
   <result pre="suitability of EGFR and HER3 as druggable targets in upper" exact="gastrointestinal cancer," post="it is noteworthy that many of the studies used"/>
   <result pre="69]. Of note, the true effects of trastuzumab on HER2-overexpressing" exact="breast cancer" post="were discovered synchronously with the development of an optimal"/>
   <result pre="Of note, the true effects of trastuzumab on HER2-overexpressing breast" exact="cancer" post="were discovered synchronously with the development of an optimal"/>
   <result pre="for assessment of EGFR or HER3 status in gastric or" exact="esophageal cancer." post="To our best knowledge, we have used the best"/>
   <result pre="and major patterns in GLOBOCAN 2012 . International journal of" exact="cancer" post="Journal international du cancer. 2014 doi: 10.1002/ijc.29210 . 25220842"/>
   <result pre="F , Bertuccio P , et al. Trends in oesophageal" exact="cancer" post="incidence and mortality in Europe. International journal of cancer"/>
   <result pre="oesophageal cancer incidence and mortality in Europe. International journal of" exact="cancer" post="Journal international du cancer. 2008; 122( 5): 1118– 29."/>
   <result pre="alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction" exact="cancer" post="(ToGA): a phase 3, open-label, randomised controlled trial ."/>
   <result pre="Hsieh AC , Moasser MM . Targeting HER proteins in" exact="cancer" post="therapy and the role of the non-target HER3. British"/>
   <result pre="of HER3, the unpretentious member of the HER family, in" exact="cancer" post="biology and cancer therapeutics . Seminars in cell &amp;amp;"/>
   <result pre="unpretentious member of the HER family, in cancer biology and" exact="cancer" post="therapeutics . Seminars in cell &amp;amp; developmental biology. 2010;"/>
   <result pre="Y , Pines G . The ERBB network: at last," exact="cancer" post="therapy meets systems biology. Nature reviews Cancer. 2012; 12("/>
   <result pre="is associated with a decreased survival in gastric cancer. Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
   <result pre="Ragnhammar P , Edler D . HER3 expression in primary" exact="colorectal cancer" post="including corresponding metastases in lymph node and liver ."/>
   <result pre="P , Edler D . HER3 expression in primary colorectal" exact="cancer" post="including corresponding metastases in lymph node and liver ."/>
   <result pre="into its functions and role in signaling, tumor biology, and" exact="cancer" post="therapy. Clinical cancer research: an official journal of the"/>
   <result pre="and role in signaling, tumor biology, and cancer therapy. Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
   <result pre="receptors EGFR and ERBB2 on survival in stage II/III gastric" exact="cancer" post=". Clinical cancer research: an official journal of the"/>
   <result pre="ERBB2 on survival in stage II/III gastric cancer . Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
   <result pre="HER3 dimerization patterns guide targeted inhibition in two histotypes of" exact="esophageal cancer" post=". International journal of cancer Journal international du cancer."/>
   <result pre="dimerization patterns guide targeted inhibition in two histotypes of esophageal" exact="cancer" post=". International journal of cancer Journal international du cancer."/>
   <result pre="in two histotypes of esophageal cancer . International journal of" exact="cancer" post="Journal international du cancer. 2014; 135( 7): 1517– 30."/>
   <result pre="and pathological response predict survival in patients with locally advanced" exact="esophageal cancer" post="treated with preoperative chemoradiotherapy . Clinical cancer research: an"/>
   <result pre="pathological response predict survival in patients with locally advanced esophageal" exact="cancer" post="treated with preoperative chemoradiotherapy . Clinical cancer research: an"/>
   <result pre="locally advanced esophageal cancer treated with preoperative chemoradiotherapy . Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
   <result pre=", et al. MET amplification leads to gefitinib resistance in" exact="lung cancer" post="by activating ERBB3 signaling . Science. 2007; 316( 5827):"/>
   <result pre="et al. MET amplification leads to gefitinib resistance in lung" exact="cancer" post="by activating ERBB3 signaling . Science. 2007; 316( 5827):"/>
   <result pre=", Shiovitz S , Phipps AI . Molecular phenotypes of" exact="colorectal cancer" post="and potential clinical applications. Gastroenterology report. 2015 doi: 10.1093/gastro/gov046"/>
   <result pre="Shiovitz S , Phipps AI . Molecular phenotypes of colorectal" exact="cancer" post="and potential clinical applications. Gastroenterology report. 2015 doi: 10.1093/gastro/gov046"/>
   <result pre="of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric" exact="cancer" post=". BMC research notes. 2014; 7: 271 doi: 10.1186/1756-0500-7-271"/>
   <result pre="phase II study of gefitinib in second-line treatment of advanced" exact="esophageal cancer" post="patients . Journal of clinical oncology: official journal of"/>
   <result pre="II study of gefitinib in second-line treatment of advanced esophageal" exact="cancer" post="patients . Journal of clinical oncology: official journal of"/>
   <result pre="models of head and neck squamous cell carcinoma . Molecular" exact="cancer" post="therapeutics. 2014; 13( 7): 1826– 36. doi: 10.1158/1535-7163.MCT-13-1093 ;"/>
   <result pre="evidence of gene expression, cellular, and clinical response . Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
   <result pre="A , Mansoor W , et al. Gefitinib for oesophageal" exact="cancer" post="progressing after chemotherapy (COG): a phase 3, multicentre, double-blind,"/>
   <result pre="monoclonal antibody, in patients with advanced solid tumors . Clinical" exact="cancer" post="research: an official journal of the American Association for"/>
   <result pre="the response to inhibitors of the PI3K-Akt pathway in triple-negative" exact="breast cancer" post=". Science signaling. 2014; 7( 318): ra29 doi: 10.1126/scisignal.2005125"/>
   <result pre="response to inhibitors of the PI3K-Akt pathway in triple-negative breast" exact="cancer" post=". Science signaling. 2014; 7( 318): ra29 doi: 10.1126/scisignal.2005125"/>
   <result pre=", et al. Biomarker analysis in stage III-IV (M0) gastric" exact="cancer" post="patients who received curative surgery followed by adjuvant 5-fluorouracil"/>
   <result pre="Aguiar S , et al. ErbB family immunohistochemical expression in" exact="colorectal cancer" post="patients with higher risk of recurrence after radical surgery"/>
   <result pre="S , et al. ErbB family immunohistochemical expression in colorectal" exact="cancer" post="patients with higher risk of recurrence after radical surgery"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4743179/results/search/disease/results.xml">
   <result pre="pmcid: 4743179 IJMPO-36-189 doi: 10.4103/0971-5851.166757 : Conference Review Breast and" exact="gastrointestinal cancer" post="updates from ASCO 2015 Dawood Shaheenah [], Department of"/>
   <result pre="4743179 IJMPO-36-189 doi: 10.4103/0971-5851.166757 : Conference Review Breast and gastrointestinal" exact="cancer" post="updates from ASCO 2015 Dawood Shaheenah [], Department of"/>
   <result pre="efficacy of anti PD-1 agents in colorectal, hepatocellular and gastric" exact="cancer" post="were presented. In breast cancer we saw data on"/>
   <result pre="agents in colorectal, hepatocellular and gastric cancer were presented. In" exact="breast cancer" post="we saw data on a new and exciting therapeutic"/>
   <result pre="in colorectal, hepatocellular and gastric cancer were presented. In breast" exact="cancer" post="we saw data on a new and exciting therapeutic"/>
   <result pre="presented that has given women with hormone receptor positive metastatic" exact="breast cancer" post="another therapeutic option. Furthermore data on strategies to further"/>
   <result pre="that has given women with hormone receptor positive metastatic breast" exact="cancer" post="another therapeutic option. Furthermore data on strategies to further"/>
   <result pre="and various strategies to improve endocrine therapy among patients with" exact="breast cancer" post="were presented. ASCO breast cancer colorectal cancer immunotherapy INTRODUCTION"/>
   <result pre="various strategies to improve endocrine therapy among patients with breast" exact="cancer" post="were presented. ASCO breast cancer colorectal cancer immunotherapy INTRODUCTION"/>
   <result pre="endocrine therapy among patients with breast cancer were presented. ASCO" exact="breast cancer" post="colorectal cancer immunotherapy INTRODUCTION Every year, one goes to"/>
   <result pre="therapy among patients with breast cancer were presented. ASCO breast" exact="cancer" post="colorectal cancer immunotherapy INTRODUCTION Every year, one goes to"/>
   <result pre="among patients with breast cancer were presented. ASCO breast cancer" exact="colorectal cancer" post="immunotherapy INTRODUCTION Every year, one goes to American Society"/>
   <result pre="patients with breast cancer were presented. ASCO breast cancer colorectal" exact="cancer" post="immunotherapy INTRODUCTION Every year, one goes to American Society"/>
   <result pre="professionals that are involved in the care of patients with" exact="cancer" post="who attend this prestigious symposium is something we all"/>
   <result pre="efficacy of anti PD-1 agents in colorectal, hepatocellular, and gastric" exact="cancer" post="were presented. In breast cancer, we saw data on"/>
   <result pre="agents in colorectal, hepatocellular, and gastric cancer were presented. In" exact="breast cancer," post="we saw data on a new and exciting therapeutic"/>
   <result pre="were presented that has given women with hormone receptor-positive metastatic" exact="breast cancer" post="as another therapeutic option. With the plethora of data"/>
   <result pre="presented that has given women with hormone receptor-positive metastatic breast" exact="cancer" post="as another therapeutic option. With the plethora of data"/>
   <result pre="seen significant strides in the management of women with metastatic" exact="breast cancer" post="converting an essentially noncurable disease into a chronic one."/>
   <result pre="significant strides in the management of women with metastatic breast" exact="cancer" post="converting an essentially noncurable disease into a chronic one."/>
   <result pre="been introduced, each providing an option for women with metastatic" exact="breast cancer." post="Based on improvement in overall survival, Eribulin has recently"/>
   <result pre="approval for the treatment of women with heavily pretreated metastatic" exact="breast cancer." post="This year at ASCO, Perez et al. presented the"/>
   <result pre="phase III BEACON trial[ 1] that randomized women with advanced" exact="breast cancer" post="whose disease had progressed on anthracyclines, taxanes, and capecitabine"/>
   <result pre="III BEACON trial[ 1] that randomized women with advanced breast" exact="cancer" post="whose disease had progressed on anthracyclines, taxanes, and capecitabine"/>
   <result pre="Chemotherapy is the standard of care among women with triple-negative" exact="breast cancer" post="in both the early stage and the advanced setting."/>
   <result pre="is the standard of care among women with triple-negative breast" exact="cancer" post="in both the early stage and the advanced setting."/>
   <result pre="setting. Ixabepilone has been extensively investigated among women with metastatic" exact="breast cancer" post="with meta-analysis indicating that it may be particularly useful"/>
   <result pre="Ixabepilone has been extensively investigated among women with metastatic breast" exact="cancer" post="with meta-analysis indicating that it may be particularly useful"/>
   <result pre="that it may be particularly useful among women with triple-negative" exact="breast cancer." post="Yardley et al.[ 2] presented the results of the"/>
   <result pre="III TITAN trial that randomized women with early stage triple-negative" exact="breast cancer" post="who had received adriamycin and cyclophosphamide (AC) to either"/>
   <result pre="TITAN trial that randomized women with early stage triple-negative breast" exact="cancer" post="who had received adriamycin and cyclophosphamide (AC) to either"/>
   <result pre="has often been used among women with hormone receptor-positive ductal" exact="carcinoma in situ" post="(DCIS), following locoregional management where it has been shown"/>
   <result pre="efficacy of endocrine therapy among women with hormone receptor-positive metastatic" exact="breast cancer." post="Dickler et al.[ 4] presented the results of the"/>
   <result pre="trial that enrolled over 300 women with hormone receptor-positive metastatic" exact="breast cancer," post="the authors reported that the addition of bevacizumab to"/>
   <result pre="combination with letrozole as first-line therapy for hormone receptor-positive metastatic" exact="breast cancer." post="Turner et al.[ 5] presented, as a late-breaking abstract,"/>
   <result pre="hormone receptor-positive metastatic human epidermal growth factor receptor 2 (HER2)-negative" exact="breast cancer" post="that had progressed on prior endocrine therapy. Premenopausal women"/>
   <result pre="receptor-positive metastatic human epidermal growth factor receptor 2 (HER2)-negative breast" exact="cancer" post="that had progressed on prior endocrine therapy. Premenopausal women"/>
   <result pre="bevacizumab has a role among women with metastatic hormone receptor-positive" exact="breast cancer?" post="In an endocrine resistant population, should everolimus or palbociclib"/>
   <result pre="growth factor receptor 2 therapy strategies The landscape of HER2-positive" exact="breast cancer" post="has certainly changed over the last two decades. The"/>
   <result pre="factor receptor 2 therapy strategies The landscape of HER2-positive breast" exact="cancer" post="has certainly changed over the last two decades. The"/>
   <result pre="III MARIANNE trial that randomized women with HER2 positive metastatic" exact="breast cancer" post="to trastuzumab and taxane, TDM-1 plus placebo or TDM-1"/>
   <result pre="MARIANNE trial that randomized women with HER2 positive metastatic breast" exact="cancer" post="to trastuzumab and taxane, TDM-1 plus placebo or TDM-1"/>
   <result pre="significantly improves prognostic outcome among women with early stage HER2-positive" exact="breast cancer." post="The HERA trial is not reported significant benefit when"/>
   <result pre="placebo-controlled ExteNET trial that randomized patients with stage I-III HER2-positive" exact="breast cancer" post="who had completed adjuvant chemotherapy and trastuzumab to receive"/>
   <result pre="ExteNET trial that randomized patients with stage I-III HER2-positive breast" exact="cancer" post="who had completed adjuvant chemotherapy and trastuzumab to receive"/>
   <result pre="we can determine the impact on clinical practice. Refining triple-negative" exact="breast cancer" post="at the molecular level Triple-negative breast cancer is considered"/>
   <result pre="can determine the impact on clinical practice. Refining triple-negative breast" exact="cancer" post="at the molecular level Triple-negative breast cancer is considered"/>
   <result pre="practice. Refining triple-negative breast cancer at the molecular level Triple-negative" exact="breast cancer" post="is considered the most aggressive subtype of breast cancer."/>
   <result pre="Refining triple-negative breast cancer at the molecular level Triple-negative breast" exact="cancer" post="is considered the most aggressive subtype of breast cancer."/>
   <result pre="Triple-negative breast cancer is considered the most aggressive subtype of" exact="breast cancer." post="We know that it not only associated with a"/>
   <result pre="important questions were addressed with regards to this subtype of" exact="breast cancer." post="Pathological complete response is an important surrogate marker for"/>
   <result pre="surrogate marker for prognostic outcome, especially among patients with triple-negative" exact="breast cancer." post="Patients with triple-negative breast cancer who have residual disease"/>
   <result pre="especially among patients with triple-negative breast cancer. Patients with triple-negative" exact="breast cancer" post="who have residual disease postpreoperative chemotherapy are known to"/>
   <result pre="among patients with triple-negative breast cancer. Patients with triple-negative breast" exact="cancer" post="who have residual disease postpreoperative chemotherapy are known to"/>
   <result pre="biomarkers in the residual tumors of 131 patients with triple-negative" exact="breast cancer" post="who had received preoperative chemotherapy. The authors demonstrated that"/>
   <result pre="in the residual tumors of 131 patients with triple-negative breast" exact="cancer" post="who had received preoperative chemotherapy. The authors demonstrated that"/>
   <result pre="systemic therapy. Can we use the heterogeneous biology of triple-negative" exact="breast cancer" post="to identify a specific target for therapeutic intervention in"/>
   <result pre="therapy. Can we use the heterogeneous biology of triple-negative breast" exact="cancer" post="to identify a specific target for therapeutic intervention in"/>
   <result pre="at targeting androgen receptor among patients with metastatic triple receptor-negative" exact="breast cancer." post="The initial results of this study were first presented"/>
   <result pre="metastatic cancer. Three cohorts of patients were enrolled: Patients with" exact="colorectal cancer" post="whose tumors were mismatch repair (MMR) proficient, patients with"/>
   <result pre="cancer. Three cohorts of patients were enrolled: Patients with colorectal" exact="cancer" post="whose tumors were mismatch repair (MMR) proficient, patients with"/>
   <result pre="cancer whose tumors were mismatch repair (MMR) proficient, patients with" exact="colorectal cancer" post="whose tumors were MMR-deficient, and patients with other cancers"/>
   <result pre="whose tumors were mismatch repair (MMR) proficient, patients with colorectal" exact="cancer" post="whose tumors were MMR-deficient, and patients with other cancers"/>
   <result pre="efficacy of the anti-pd-1 inhibitor nivolumab among patients with advanced" exact="hepatocellular carcinoma" post="whose Child–Pugh score was &amp;lt;7 and who had progressed"/>
   <result pre="and who had progressed on prior systemic therapy. Patients with" exact="hepatitis" post="B were allowed to enroll in the study, so"/>
   <result pre="overall survival were 1.9 months and 11.4 months, respectively. Colorectal" exact="cancer" post="updates Several important abstracts were presented regarding the management"/>
   <result pre="important abstracts were presented regarding the management of patients with" exact="colorectal cancer." post="Yanhong et al.[ 13] presented the results of the"/>
   <result pre="trial that randomized nearly 500 patients with locally advanced rectal" exact="cancer" post="to received 5-Fluorouracil and radiation therapy, mFOLFOX-6 and radiation"/>
   <result pre="phase III SIRFLOX trial that randomized 530 patients with metastatic" exact="colorectal cancer" post="and liver metastases to received first line mFOLFOX6 with"/>
   <result pre="III SIRFLOX trial that randomized 530 patients with metastatic colorectal" exact="cancer" post="and liver metastases to received first line mFOLFOX6 with"/>
   <result pre="radioembolization in an earlier line setting among patients with metastatic" exact="colorectal cancer." post="Approximately, 5% of the patients with metastatic colorectal cancer"/>
   <result pre="metastatic colorectal cancer. Approximately, 5% of the patients with metastatic" exact="colorectal cancer" post="have HER2-positive disease. The role of anti HER2 therapy"/>
   <result pre="colorectal cancer. Approximately, 5% of the patients with metastatic colorectal" exact="cancer" post="have HER2-positive disease. The role of anti HER2 therapy"/>
   <result pre="role of anti HER2 therapy among patients with HER2-positive metastatic" exact="colorectal cancer" post="has recently been the focus of research. Siena et"/>
   <result pre="of anti HER2 therapy among patients with HER2-positive metastatic colorectal" exact="cancer" post="has recently been the focus of research. Siena et"/>
   <result pre="of trastuzumab and lapatinib among 25 patients HER2 amplified metastatic" exact="colorectal cancer" post="that were resistant to standard therapeutic regimens. The authors"/>
   <result pre="trastuzumab and lapatinib among 25 patients HER2 amplified metastatic colorectal" exact="cancer" post="that were resistant to standard therapeutic regimens. The authors"/>
   <result pre="treatment of physician's choice (TPC) in patients (pts) with advanced" exact="breast cancer" post="(aBC) whose disease has progressed following anthracycline (A), taxane"/>
   <result pre="of physician's choice (TPC) in patients (pts) with advanced breast" exact="cancer" post="(aBC) whose disease has progressed following anthracycline (A), taxane"/>
   <result pre="versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative" exact="breast cancer" post="(TNBC): Preliminary toxicity of a Sarah Cannon Research Institute"/>
   <result pre="weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast" exact="cancer" post="(TNBC): Preliminary toxicity of a Sarah Cannon Research Institute"/>
   <result pre="Verma S Iwata H et al. Palbociclib in hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2015 373 209 19 26030518"/>
   <result pre="S Iwata H et al. Palbociclib in hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2015 373 209 19 26030518"/>
   <result pre="and alterations in these parameters after neoadjuvant chemotherapy in triple-negative" exact="breast cancer" post="J Clin Oncol 2015 33 Suppl; abstr 510 9"/>
   <result pre="alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast" exact="cancer" post="J Clin Oncol 2015 33 Suppl; abstr 510 9"/>
   <result pre="(ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative" exact="breast cancer" post="(TNBC) J Clin Oncol 2015 33 Suppl; abstr 1003"/>
   <result pre="an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast" exact="cancer" post="(TNBC) J Clin Oncol 2015 33 Suppl; abstr 1003"/>
   <result pre="safety and antitumor activity of nivolumab in patients with advanced" exact="hepatocellular carcinoma" post="(HCC): CA209-040 J Clin Oncol 2015 33 Suppl; abstr"/>
   <result pre="PD-L1 expression and clinical outcomes in patients with advanced gastric" exact="cancer" post="treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in"/>
   <result pre="or without radiation in neoadjuvant treatment of local advanced rectal" exact="cancer" post="(FOWARC study): Preliminary results J Clin Oncol 2015 33"/>
   <result pre="radiation therapy (SIRT) ± bev in patients (pts) with metastatic" exact="colorectal cancer" post="(mCRC) J Clin Oncol 2015 33 Suppl; abstr 3502"/>
   <result pre="therapy (SIRT) ± bev in patients (pts) with metastatic colorectal" exact="cancer" post="(mCRC) J Clin Oncol 2015 33 Suppl; abstr 3502"/>
   <result pre="Bencardino K et al. Trastuzumab and lapatinib in HER2-amplified metastatic" exact="colorectal cancer" post="patients (mCRC): The HERACLES trial J Clin Oncol 2015"/>
   <result pre="K et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal" exact="cancer" post="patients (mCRC): The HERACLES trial J Clin Oncol 2015"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4745781/results/search/disease/results.xml">
   <result pre="pmid: 26336133 : Research Paper Identification of therapeutic targets in" exact="ovarian cancer" post="through active tyrosine kinase profiling Montero Juan Carlos 1"/>
   <result pre="26336133 : Research Paper Identification of therapeutic targets in ovarian" exact="cancer" post="through active tyrosine kinase profiling Montero Juan Carlos 1"/>
   <result pre="activation status of a set of pro-oncogenic tyrosine kinases in" exact="ovarian cancer" post="patient samples was analyzed to define potential therapeutic targets."/>
   <result pre="status of a set of pro-oncogenic tyrosine kinases in ovarian" exact="cancer" post="patient samples was analyzed to define potential therapeutic targets."/>
   <result pre="family receptor tyrosine kinases, especially HER2, was observed. Studies in" exact="ovarian cancer" post="cell lines confirmed the activation of HER2. Moreover, knockdown"/>
   <result pre="receptor tyrosine kinases, especially HER2, was observed. Studies in ovarian" exact="cancer" post="cell lines confirmed the activation of HER2. Moreover, knockdown"/>
   <result pre="potentiated the action of drugs used in the therapy of" exact="ovarian cancer." post="T-DM1 provoked cell cycle arrest in mitosis, and caused"/>
   <result pre="phospho-BUBR1 in cells treated with the drug. Prolonged treatment of" exact="ovarian cancer" post="cells with T-DM1 provoked the appearance of multinucleated cells"/>
   <result pre="in cells treated with the drug. Prolonged treatment of ovarian" exact="cancer" post="cells with T-DM1 provoked the appearance of multinucleated cells"/>
   <result pre="these data indicate that HER2 represents an important oncogene in" exact="ovarian cancer," post="and suggest that targeting this tyrosine kinase with T-DM1"/>
   <result pre="ovarian tumors with high content of HER2. tyrosine kinases HER2" exact="ovarian cancer" post="T-DM1 INTRODUCTION Ovarian cancer represents the leading cause of"/>
   <result pre="tumors with high content of HER2. tyrosine kinases HER2 ovarian" exact="cancer" post="T-DM1 INTRODUCTION Ovarian cancer represents the leading cause of"/>
   <result pre="of HER2. tyrosine kinases HER2 ovarian cancer T-DM1 INTRODUCTION Ovarian" exact="cancer" post="represents the leading cause of death from gynecological malignancies"/>
   <result pre="and chemotherapeutic treatments have resulted in improvements in outcome, metastatic" exact="ovarian cancer" post="is still incurable mainly due to the lack of"/>
   <result pre="chemotherapeutic treatments have resulted in improvements in outcome, metastatic ovarian" exact="cancer" post="is still incurable mainly due to the lack of"/>
   <result pre="potential molecular targets that may augment survival of patients with" exact="ovarian cancer." post="In this respect, several reports have identified potential therapeutic"/>
   <result pre="chemotherapy for the treatment of patients with platinum-resistant recurrent epithelial" exact="ovarian cancer." post="The platelet-derived growth factor receptors (PDGFR) and their ligands"/>
   <result pre="family of receptor tyrosine kinases may represent alternative targets in" exact="ovarian cancer" post="[ 1]. In fact, the epidermal growth factor receptor"/>
   <result pre="of receptor tyrosine kinases may represent alternative targets in ovarian" exact="cancer" post="[ 1]. In fact, the epidermal growth factor receptor"/>
   <result pre="the related ErbB2/HER2 transmembrane tyrosine kinase has been reported in" exact="ovarian cancer" post="[ 11]. The success of therapies against this receptor"/>
   <result pre="related ErbB2/HER2 transmembrane tyrosine kinase has been reported in ovarian" exact="cancer" post="[ 11]. The success of therapies against this receptor"/>
   <result pre="therapies against this receptor in other tumoral pathologies, especially in" exact="breast cancer" post="[ 12], led to the development of clinical studies"/>
   <result pre="against this receptor in other tumoral pathologies, especially in breast" exact="cancer" post="[ 12], led to the development of clinical studies"/>
   <result pre="on the efficacy of trastuzumab, an antibody against HER2, in" exact="ovarian cancer" post="patients indicated that 7% of treated patients responded to"/>
   <result pre="the efficacy of trastuzumab, an antibody against HER2, in ovarian" exact="cancer" post="patients indicated that 7% of treated patients responded to"/>
   <result pre="another HER family receptor, HER3, as a potential target in" exact="ovarian cancer" post="[ 16]. RNAi against this receptor reduced ovarian cancer"/>
   <result pre="HER family receptor, HER3, as a potential target in ovarian" exact="cancer" post="[ 16]. RNAi against this receptor reduced ovarian cancer"/>
   <result pre="in ovarian cancer [ 16]. RNAi against this receptor reduced" exact="ovarian cancer" post="cell growth in vitro and an antibody against HER3"/>
   <result pre="ovarian cancer [ 16]. RNAi against this receptor reduced ovarian" exact="cancer" post="cell growth in vitro and an antibody against HER3"/>
   <result pre="against HER3 reduced tumor growth in mice xenografted with human" exact="ovarian cancer" post="cells. More recently, HER3 has been reported to be"/>
   <result pre="HER3 reduced tumor growth in mice xenografted with human ovarian" exact="cancer" post="cells. More recently, HER3 has been reported to be"/>
   <result pre="relevant player implicated in the facilitation of hematogenous spread of" exact="ovarian cancer" post="[ 17]. Because of the relevance of tyrosine kinases"/>
   <result pre="player implicated in the facilitation of hematogenous spread of ovarian" exact="cancer" post="[ 17]. Because of the relevance of tyrosine kinases"/>
   <result pre="to evaluate the expression of several of these kinases in" exact="ovarian cancer" post="was carried out. From the whole tyrosine kinase kinome,"/>
   <result pre="evaluate the expression of several of these kinases in ovarian" exact="cancer" post="was carried out. From the whole tyrosine kinase kinome,"/>
   <result pre="molecule HER2 inhibitor lapatinib. RESULTS Active tyrosine kinase profiling in" exact="ovarian cancer" post="Given the relevance of tyrosine kinases in cancer initiation/progression,"/>
   <result pre="HER2 inhibitor lapatinib. RESULTS Active tyrosine kinase profiling in ovarian" exact="cancer" post="Given the relevance of tyrosine kinases in cancer initiation/progression,"/>
   <result pre="in ovarian cancer Given the relevance of tyrosine kinases in" exact="cancer" post="initiation/progression, we designed a study to evaluate the activation"/>
   <result pre="to evaluate the activation status of several tyrosine kinases in" exact="ovarian cancer." post="We decided to study activation status rather than expression"/>
   <result pre="since a more accurate evaluation of their potential relevance in" exact="cancer" post="initiation/progression is the analysis of their functionality, which is"/>
   <result pre="BGJ398, AZD4547 FGFR3 Dovitinib, BGJ398, AZD4547 FGFR4 BGJ398, AZD4547 Sixteen" exact="ovarian cancer" post="tumors, whose patient characteristics are shown in Table 2,"/>
   <result pre="AZD4547 FGFR3 Dovitinib, BGJ398, AZD4547 FGFR4 BGJ398, AZD4547 Sixteen ovarian" exact="cancer" post="tumors, whose patient characteristics are shown in Table 2,"/>
   <result pre="1C shows that the most frequently activated tyrosine kinases in" exact="ovarian cancer" post="samples were HER2 (95% of patients), HER3 (80%), EGFR"/>
   <result pre="shows that the most frequently activated tyrosine kinases in ovarian" exact="cancer" post="samples were HER2 (95% of patients), HER3 (80%), EGFR"/>
   <result pre="different tyrosine kinases (TKs) in tumor samples from patients with" exact="ovarian cancer" post="A. 2D map detailing the positions of the different"/>
   <result pre="tyrosine kinases (TKs) in tumor samples from patients with ovarian" exact="cancer" post="A. 2D map detailing the positions of the different"/>
   <result pre="shown by black squares. HER2 knockdown restricts the proliferation of" exact="ovarian cancer" post="cells The above studies indicated that HER receptors, particularly"/>
   <result pre="by black squares. HER2 knockdown restricts the proliferation of ovarian" exact="cancer" post="cells The above studies indicated that HER receptors, particularly"/>
   <result pre="particularly HER2, were constitutively active in a large proportion of" exact="ovarian cancer" post="samples. To investigate the relevance of these receptors in"/>
   <result pre="HER2, were constitutively active in a large proportion of ovarian" exact="cancer" post="samples. To investigate the relevance of these receptors in"/>
   <result pre="cancer samples. To investigate the relevance of these receptors in" exact="ovarian cancer" post="proliferation, we used four ovarian carcinoma cell lines on"/>
   <result pre="samples. To investigate the relevance of these receptors in ovarian" exact="cancer" post="proliferation, we used four ovarian carcinoma cell lines on"/>
   <result pre="only HER family receptor expressed and activated in all four" exact="ovarian cancer" post="cell lines (Figure 2A and 2B). This last observation"/>
   <result pre="HER family receptor expressed and activated in all four ovarian" exact="cancer" post="cell lines (Figure 2A and 2B). This last observation"/>
   <result pre="kinase. Figure 2 Relevance of HER2 in the proliferation of" exact="ovarian cancer" post="cells Activation A. and total levels B. of EGFR,"/>
   <result pre="Figure 2 Relevance of HER2 in the proliferation of ovarian" exact="cancer" post="cells Activation A. and total levels B. of EGFR,"/>
   <result pre="levels B. of EGFR, HER2, HER3 and HER4 in four" exact="ovarian cancer" post="cell lines cultured for 12 hours in the presence"/>
   <result pre="B. of EGFR, HER2, HER3 and HER4 in four ovarian" exact="cancer" post="cell lines cultured for 12 hours in the presence"/>
   <result pre="anti-HER2 antibody. D. HER2 knockdown effect on the proliferation of" exact="ovarian cancer" post="cells. Cells were infected with the indicated shRNAs. After"/>
   <result pre="antibody. D. HER2 knockdown effect on the proliferation of ovarian" exact="cancer" post="cells. Cells were infected with the indicated shRNAs. After"/>
   <result pre="explore the relevance of HER2 in controlling the proliferation of" exact="ovarian cancer" post="cells, we knocked down HER2 levels in the four"/>
   <result pre="the relevance of HER2 in controlling the proliferation of ovarian" exact="cancer" post="cells, we knocked down HER2 levels in the four"/>
   <result pre="cancer cells, we knocked down HER2 levels in the four" exact="ovarian cancer" post="cell lines by the use of RNAi. From the"/>
   <result pre="cells, we knocked down HER2 levels in the four ovarian" exact="cancer" post="cell lines by the use of RNAi. From the"/>
   <result pre="in A2780 or IGROV1 cells. Pharmacological targeting of HER2 in" exact="ovarian cancer" post="The antiproliferative effects observed using the genetic targeting of"/>
   <result pre="A2780 or IGROV1 cells. Pharmacological targeting of HER2 in ovarian" exact="cancer" post="The antiproliferative effects observed using the genetic targeting of"/>
   <result pre="antiproliferative effects observed using the genetic targeting of HER2 in" exact="ovarian cancer" post="cells suggested that pharmacologically acting on this receptor could"/>
   <result pre="effects observed using the genetic targeting of HER2 in ovarian" exact="cancer" post="cells suggested that pharmacologically acting on this receptor could"/>
   <result pre="acting on this receptor could exert an antitumoral action in" exact="ovarian cancer." post="We therefore concentrated in evaluating the effect of highly"/>
   <result pre="specific drugs approved for the targeting of HER2. The four" exact="ovarian cancer" post="cell lines were treated with trastuzumab, pertuzumab, lapatinib or"/>
   <result pre="drugs approved for the targeting of HER2. The four ovarian" exact="cancer" post="cell lines were treated with trastuzumab, pertuzumab, lapatinib or"/>
   <result pre="or pertuzumab did not affect the proliferation of the four" exact="ovarian cancer" post="cell lines analyzed (Figure 3A). In contrast, a strong"/>
   <result pre="pertuzumab did not affect the proliferation of the four ovarian" exact="cancer" post="cell lines analyzed (Figure 3A). In contrast, a strong"/>
   <result pre="action of T-DM1. Dose response curves performed on the four" exact="ovarian cancer" post="cell lines confirmed the high degree of sensitivity of"/>
   <result pre="of T-DM1. Dose response curves performed on the four ovarian" exact="cancer" post="cell lines confirmed the high degree of sensitivity of"/>
   <result pre="range (IC 50=20 pM), while for the rest of the" exact="ovarian cancer" post="cell lines the IC 50 values were &amp;gt; 10"/>
   <result pre="(IC 50=20 pM), while for the rest of the ovarian" exact="cancer" post="cell lines the IC 50 values were &amp;gt; 10"/>
   <result pre="of different drugs targeting HER2 on the proliferation of four" exact="ovarian cancer" post="cell lines. Cells were treated with 1 μM lapatinib"/>
   <result pre="different drugs targeting HER2 on the proliferation of four ovarian" exact="cancer" post="cell lines. Cells were treated with 1 μM lapatinib"/>
   <result pre="Dose-response studies of the effects of T-DM1 on the four" exact="ovarian cancer" post="cell lines. Cells were counted and results plotted as"/>
   <result pre="studies of the effects of T-DM1 on the four ovarian" exact="cancer" post="cell lines. Cells were counted and results plotted as"/>
   <result pre="of the combination of T-DM1 with chemotherapeutic agents used in" exact="ovarian cancer" post="(carboplatin, cisplatin, docetaxel and vinorelbine). SKOV3 cells were treated"/>
   <result pre="the combination of T-DM1 with chemotherapeutic agents used in ovarian" exact="cancer" post="(carboplatin, cisplatin, docetaxel and vinorelbine). SKOV3 cells were treated"/>
   <result pre="20]. Therefore, it is possible that its antitumoral action on" exact="ovarian cancer" post="cells could be restricted in the in vitro conditions."/>
   <result pre="Therefore, it is possible that its antitumoral action on ovarian" exact="cancer" post="cells could be restricted in the in vitro conditions."/>
   <result pre="data indicated that T-DM1 exerted an important antitumoral effect on" exact="ovarian cancer" post="cells which clearly outweighd the effect of trastuzumab. Most"/>
   <result pre="indicated that T-DM1 exerted an important antitumoral effect on ovarian" exact="cancer" post="cells which clearly outweighd the effect of trastuzumab. Most"/>
   <result pre="T-DM1 potentiated the action of chemotherapeutical drugs used in the" exact="ovarian cancer" post="clinic was investigated. To this end, combinations of T-DM1"/>
   <result pre="potentiated the action of chemotherapeutical drugs used in the ovarian" exact="cancer" post="clinic was investigated. To this end, combinations of T-DM1"/>
   <result pre="were observed (Figure 3E and Supplementary Figure 2). T-DM1 arrests" exact="ovarian cancer" post="cells in mitosis The decrease in cell number caused"/>
   <result pre="observed (Figure 3E and Supplementary Figure 2). T-DM1 arrests ovarian" exact="cancer" post="cells in mitosis The decrease in cell number caused"/>
   <result pre="investigate the mechanism of the antiproliferative effect of T-DM1 on" exact="ovarian cancer," post="SKOV3 cells were stained with propidium iodide and analyzed"/>
   <result pre="of p27 was also observed. T-DM1 causes mitotic catastrophe of" exact="ovarian cancer" post="cells Morphologically, T-DM1 caused progressive cell rounding in cultures"/>
   <result pre="p27 was also observed. T-DM1 causes mitotic catastrophe of ovarian" exact="cancer" post="cells Morphologically, T-DM1 caused progressive cell rounding in cultures"/>
   <result pre="by progression into cell death. DISCUSSION The dismal prognosis of" exact="ovarian cancer" post="in the metastatic setting has driven much research with"/>
   <result pre="progression into cell death. DISCUSSION The dismal prognosis of ovarian" exact="cancer" post="in the metastatic setting has driven much research with"/>
   <result pre="outcome [ 2]. Given the relevance of tyrosine kinases in" exact="cancer" post="initiation/progression and the benefits of their targeting in other"/>
   <result pre="tyrosine kinases in tumor samples surgically resected from patients with" exact="ovarian cancer." post="Antibody array analyses of the ovarian tumoral samples indicated"/>
   <result pre="the pathophysiology of these tumors, then a substantial proportion of" exact="ovarian cancer" post="patients could benefit from the targeting of HER2. Because"/>
   <result pre="pathophysiology of these tumors, then a substantial proportion of ovarian" exact="cancer" post="patients could benefit from the targeting of HER2. Because"/>
   <result pre="studies aimed at defining the biological relevance of HER2 in" exact="ovarian cancer" post="were performed using model cell lines bearing different complements"/>
   <result pre="aimed at defining the biological relevance of HER2 in ovarian" exact="cancer" post="were performed using model cell lines bearing different complements"/>
   <result pre="HER2 overexpression, other factors may contribute to HER2 dependency in" exact="ovarian cancer." post="In this respect, it is interesting that targeting the"/>
   <result pre="analyses of the effect of several approved anti-HER2 agents on" exact="ovarian cancer" post="cell lines showed limited efficacy of trastuzumab or pertuzumab,"/>
   <result pre="of the effect of several approved anti-HER2 agents on ovarian" exact="cancer" post="cell lines showed limited efficacy of trastuzumab or pertuzumab,"/>
   <result pre="strong antitumoral properties both in vitro and in vivo on" exact="ovarian cancer" post="cells. Because of this, we undertook a comprehensive study"/>
   <result pre="antitumoral properties both in vitro and in vivo on ovarian" exact="cancer" post="cells. Because of this, we undertook a comprehensive study"/>
   <result pre="undertook a comprehensive study to characterize the molecular response of" exact="ovarian cancer" post="cells to T-DM1. Dose-response curves indicated that the most"/>
   <result pre="a comprehensive study to characterize the molecular response of ovarian" exact="cancer" post="cells to T-DM1. Dose-response curves indicated that the most"/>
   <result pre="lead to mitotic catastrophe, which has also been reported in" exact="breast cancer" post="[ 24]. Interestingly, T-DM1 synergized with docetaxel and vinorelbine."/>
   <result pre="to mitotic catastrophe, which has also been reported in breast" exact="cancer" post="[ 24]. Interestingly, T-DM1 synergized with docetaxel and vinorelbine."/>
   <result pre="describes the activation status of several druggable tyrosine kinases in" exact="ovarian cancer." post="The study reports frequent activation of HER2 in the"/>
   <result pre="T-DM1, either alone or in combination, for the therapy of" exact="ovarian cancer." post="MATERIALS AND METHODS Reagents and antibodies Cell culture media,"/>
   <result pre="of different tyrosine kinases was evaluated by antibody arrays in" exact="ovarian cancer" post="samples from patients of the University Hospital of Salamanca."/>
   <result pre="different tyrosine kinases was evaluated by antibody arrays in ovarian" exact="cancer" post="samples from patients of the University Hospital of Salamanca."/>
   <result pre="the ECL Plus Western Blotting Detection System (GE Lifesciences). Breast" exact="cancer" post="cell lysates from BT474 cells were used as the"/>
   <result pre="Accuri C6 flow cytometer. Analyses of mitochondrial membrane potential in" exact="ovarian cancer" post="cell lines has been described [ 35]. Immunofluorescence microscopy"/>
   <result pre="C6 flow cytometer. Analyses of mitochondrial membrane potential in ovarian" exact="cancer" post="cell lines has been described [ 35]. Immunofluorescence microscopy"/>
   <result pre="TA Carden CP Kaye SB Beyond chemotherapy: targeted therapies in" exact="ovarian cancer" post="Nat Rev Cancer 2009 9 167 181 19238149 2"/>
   <result pre="Carden CP Kaye SB Beyond chemotherapy: targeted therapies in ovarian" exact="cancer" post="Nat Rev Cancer 2009 9 167 181 19238149 2"/>
   <result pre="reduces tumor burden and ascites in athymic mouse model of" exact="ovarian cancer" post="Am J Pathol 2002 161 1917 1924 12414537 4"/>
   <result pre="tumor burden and ascites in athymic mouse model of ovarian" exact="cancer" post="Am J Pathol 2002 161 1917 1924 12414537 4"/>
   <result pre="et al. Incorporation of bevacizumab in the primary treatment of" exact="ovarian cancer" post="N Engl J Med 2011 365 2473 2483 22204724"/>
   <result pre="al. Incorporation of bevacizumab in the primary treatment of ovarian" exact="cancer" post="N Engl J Med 2011 365 2473 2483 22204724"/>
   <result pre="R et al. A phase 3 trial of bevacizumab in" exact="ovarian cancer" post="N Engl J Med 2011 365 2484 2496 22204725"/>
   <result pre="et al. A phase 3 trial of bevacizumab in ovarian" exact="cancer" post="N Engl J Med 2011 365 2484 2496 22204725"/>
   <result pre="value of epidermal growth factor receptor mRNA expression in primary" exact="ovarian cancer" post="Br J Cancer 1996 73 301 306 8562334 10"/>
   <result pre="of epidermal growth factor receptor mRNA expression in primary ovarian" exact="cancer" post="Br J Cancer 1996 73 301 306 8562334 10"/>
   <result pre="Antitumor effect and potentiation of cytotoxic drugs activity in human" exact="cancer" post="cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective"/>
   <result pre="ErbB/epidermal growth factor (EGF) receptor family and its ligands in" exact="ovarian cancer" post="Biochim Biophys Acta 2008 1785 232 265 18291115 12"/>
   <result pre="growth factor (EGF) receptor family and its ligands in ovarian" exact="cancer" post="Biochim Biophys Acta 2008 1785 232 265 18291115 12"/>
   <result pre="18291115 12 Ocana A Pandiella A Targeting HER receptors in" exact="cancer" post="Curr Pharm Des 2013 19 808 817 22973952 13"/>
   <result pre="antibody, trastuzumab, in patients with recurrent or refractory ovarian or" exact="primary peritoneal carcinoma" post="with overexpression of HER2: a phase II trial of"/>
   <result pre="et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant" exact="ovarian cancer," post="fallopian tube cancer, or primary peritoneal cancer J Clin"/>
   <result pre="Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer," exact="fallopian tube cancer," post="or primary peritoneal cancer J Clin Oncol 2010 28"/>
   <result pre="in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal" exact="cancer" post="J Clin Oncol 2010 28 1215 1223 19901115 15"/>
   <result pre="the molecular response to trastuzumab, pertuzumab and combination therapy in" exact="ovarian cancer" post="Br J Cancer 2012 106 1779 1789 22549178 16"/>
   <result pre="molecular response to trastuzumab, pertuzumab and combination therapy in ovarian" exact="cancer" post="Br J Cancer 2012 106 1779 1789 22549178 16"/>
   <result pre="An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in" exact="ovarian cancer" post="cells Cancer Cell 2010 17 298 310 20227043 17"/>
   <result pre="activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian" exact="cancer" post="cells Cancer Cell 2010 17 298 310 20227043 17"/>
   <result pre="RV Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive" exact="breast cancer" post="J Med Chem 2014 57 6949 6964 24967516 20"/>
   <result pre="Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast" exact="cancer" post="J Med Chem 2014 57 6949 6964 24967516 20"/>
   <result pre="S Giordano A Cell cycle kinases as therapeutic targets for" exact="cancer" post="Nat Rev Drug Discov 2009 8 547 566 19568282"/>
   <result pre="Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant" exact="breast cancer" post="cells in vivo Breast Cancer Res 2011 13 R46"/>
   <result pre="causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast" exact="cancer" post="cells in vivo Breast Cancer Res 2011 13 R46"/>
   <result pre="Dicker DT Humphreys R El-Deiry WS Off-target lapatinib activity sensitizes" exact="colon cancer" post="cells through TRAIL death receptor up-regulation Sci Transl Med"/>
   <result pre="DT Humphreys R El-Deiry WS Off-target lapatinib activity sensitizes colon" exact="cancer" post="cells through TRAIL death receptor up-regulation Sci Transl Med"/>
   <result pre="Ocana A Diaz-Rodriguez E Esparis-Ogando A Pandiella A Neuregulins and" exact="cancer" post="Clin Cancer Res 2008 14 3237 3241 18519747 29"/>
   <result pre="conjugate, given every 3 weeks to patients with HER2-positive metastatic" exact="breast cancer" post="J Clin Oncol 2010 28 2698 2704 20421541 31"/>
   <result pre="given every 3 weeks to patients with HER2-positive metastatic breast" exact="cancer" post="J Clin Oncol 2010 28 2698 2704 20421541 31"/>
   <result pre="inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing" exact="breast cancer" post="cells J Natl Cancer Inst 2010 102 1432 1446"/>
   <result pre="on caspase-independent cell death and DNA damage in HER2-overexpressing breast" exact="cancer" post="cells J Natl Cancer Inst 2010 102 1432 1446"/>
   <result pre="of mTORC1 over mTORC2 in the regulation of proliferation of" exact="ovarian cancer" post="cells: therapeutic implications Mol Cancer Ther 2012 11 1342"/>
   <result pre="mTORC1 over mTORC2 in the regulation of proliferation of ovarian" exact="cancer" post="cells: therapeutic implications Mol Cancer Ther 2012 11 1342"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4747990/results/search/disease/results.xml">
   <result pre="treatment Cancer chemotherapy Clinical practice guideline Introduction Recent developments in" exact="cancer" post="chemotherapy have improved the survival of patients with a"/>
   <result pre="the intervention was for treatment of nausea or vomiting after" exact="cancer" post="therapy, and nausea and/or vomiting outcomes were reported. This"/>
   <result pre="21 CQs: CQ1. How is the emetic risk induced by" exact="cancer" post="chemotherapy categorized? Recommendation (Grade A): the emetic risk induced"/>
   <result pre="chemotherapy categorized? Recommendation (Grade A): the emetic risk induced by" exact="cancer" post="chemotherapy is classified as high, moderate, low, and minimum"/>
   <result pre="prescribed in accordance with these categories. The emetic risks of" exact="cancer" post="chemotherapy depend on the potential emetogenicity of combined chemotherapeutic"/>
   <result pre="acute emesis within 24 h of initiation and/or administration of" exact="cancer" post="chemotherapy and is categorized as follows: High emetic risk:"/>
   <result pre="as adjuvant treatments with tegafur-uracil and/or leucovorin and capecitabine for" exact="colorectal cancer," post="S-1 for gastric cancer, and tegafur-uracil for breast and"/>
   <result pre="Japan CQ4. How should acute nausea and vomiting induced by" exact="cancer" post="chemotherapy be prevented? Recommendation (Grade A): a triple regimen"/>
   <result pre="and dexamethasone is recommended for acute emesis during highly emetic" exact="cancer" post="chemotherapy. Recommendation (Grade A): regimens containing 5HT 3 receptor"/>
   <result pre="dexamethasone are basically recommended for acute emesis during moderately emetic" exact="cancer" post="chemotherapy. For particular chemotherapeutic regimens, addition of an NK1"/>
   <result pre="h. Management and control of CINV are essential for successful" exact="cancer" post="chemotherapy, because unfavorable side effects of nausea and vomiting"/>
   <result pre="regimens was taken from clinical trials of other highly emetic" exact="cancer" post="agents, and suggests no additional effects of dexamethasone after"/>
   <result pre="its efficacy and safety. Fig. 1 Antiemetic treatments for intravenous" exact="cancer" post="chemotherapy. a High emetic risk: in the absence of"/>
   <result pre="sodium phosphate CQ5. How should delayed nausea and vomiting after" exact="cancer" post="chemotherapy be prevented? Recommendation (Grade A): a combined regimen"/>
   <result pre="is recommended for treatment of delayed emesis during highly emetic" exact="cancer" post="chemotherapy. Recommendation (Grade A): single administration of dexamethasone is"/>
   <result pre="dexamethasone is basically recommended for delayed emesis during moderately emetic" exact="cancer" post="chemotherapy. However, regimens of NK1 antagonist and/or dexamethasone are"/>
   <result pre="are effective treatments for prevention of nausea and vomiting during" exact="cancer" post="chemotherapy; seven drugs are approved in Japan: granisetron, palonosetron,"/>
   <result pre="regimens. Corticosteroid has been used as an antiemetic prophylactic during" exact="cancer" post="chemotherapy for 25 years [ 12], although its mechanism"/>
   <result pre="dexamethasone (4–20 mg/day) has been approved as antiemetic treatment during" exact="cancer" post="chemotherapy in Japan. However, the efficacy of high-dose dexamethasone"/>
   <result pre="A systematic review of antiemetic treatments for patients with advanced" exact="cancer" post="showed that metoclopramide is superior to placebo and equivalent"/>
   <result pre="16]. Moreover, a randomized clinical controlled study of 51 advanced" exact="cancer" post="patients showed no significant effects of additional dexamethasone for"/>
   <result pre="occurs immediately before treatment, and reflects previous negative experiences of" exact="cancer" post="chemotherapy [ 22– 24], although nausea is more common"/>
   <result pre="emetic effects of CINV. The NCCN guideline also suggests that" exact="bowel obstruction," post="vestibulopathy, brain metastasis, electrolyte dysbolism, uremia, opioid use, gastric"/>
   <result pre="for pediatric patients. In the last three decades, advances in" exact="cancer" post="treatment, for example high dose methotrexate, cytarabine, cyclophosphamide, and"/>
   <result pre="patients. Proper antiemetic treatments also enable pediatric patients to receive" exact="cancer" post="chemotherapy without decline in QOL. CQ16. Is it possible"/>
   <result pre="accurate assessment of patient conditions. Symptoms of anorexia, pyrosis, and" exact="dyspepsia" post="are caused by several factors related to digestive dysfunction,"/>
   <result pre="as a result of the following conditions: Partial or complete" exact="bowel obstruction" post="Vestibulopathy Brain metastasis Electrolyte dysbolism (hypercalcemia, hyponatremia, and hyperglycemia)"/>
   <result pre="doses should not be reduced in chemotherapeutic regimens for malignant" exact="lymphoma" post="that include corticosteroid, despite concomitant use of aprepitant. Moreover,"/>
   <result pre="and vomiting are observed for 31 and 20 % of" exact="cancer" post="patients, respectively [ 43]. Accordingly, the 2009 NCCN guidelines"/>
   <result pre="Indicators of Supportive Treatment Project recommends symptom evaluations for all" exact="cancer" post="patients, at every outpatient visit, and within 24 h"/>
   <result pre="for several days under conditions of highly or moderately emetogenic" exact="cancer" post="chemotherapy [ 44]. Moreover, complete responses were reportedly not"/>
   <result pre="ensuing effects on quality of life. CQ20. How is occlusive" exact="ileus" post="managed in cancer patients with advanced and metastatic status,"/>
   <result pre="quality of life. CQ20. How is occlusive ileus managed in" exact="cancer" post="patients with advanced and metastatic status, including carcinomatous peritonitis?"/>
   <result pre="a result of advanced oncological status. However, 50 % of" exact="colon cancer" post="patients and 6–34 % of gynecologic cancer patients suffer"/>
   <result pre="result of advanced oncological status. However, 50 % of colon" exact="cancer" post="patients and 6–34 % of gynecologic cancer patients suffer"/>
   <result pre="% of colon cancer patients and 6–34 % of gynecologic" exact="cancer" post="patients suffer from benign bowel obstructions [ 47], so"/>
   <result pre="for opioid-induced emesis are important for successful pain control among" exact="cancer" post="patients. Moreover, differential diagnosis of other causes is important"/>
   <result pre="foreign studies reporting high-level evidence that was acceptable for Japanese" exact="cancer" post="patients. Therefore, these recommendations for standard therapy, depending on"/>
   <result pre="N 4-behenoyl-1-1-beta- d-arabinofuranosylcytosine and its phase II study in adult" exact="acute leukemia." post="Current chemotherapy and immunotherapy. In: Proceedings of the 12th"/>
   <result pre="14. Grunberg SM Antiemetic activity of corticosteroids in patients receiving" exact="cancer" post="chemotherapy: dosing, efficacy, and tolerability analysis Ann Oncol 2007"/>
   <result pre="antiemetics in the treatment of nausea in patients with far-advanced" exact="cancer" post="Support Care Cancer 2004 12 432 440 10.1007/s00520-004-0629-y 15108099"/>
   <result pre="with or without cisplatin in patients with advanced or metastatic" exact="biliary tract cancer" post="(ABC): results of a multicenter randomized phase III trial"/>
   <result pre="without cisplatin in patients with advanced or metastatic biliary tract" exact="cancer" post="(ABC): results of a multicenter randomized phase III trial"/>
   <result pre="Behavioral treatment for the anticipatory nausea and vomiting induced by" exact="cancer" post="chemotherapy N Engl J Med 1982 307 1476 1480"/>
   <result pre="Black PM et al. Predicting development of anticipatory nausea in" exact="cancer" post="patients: prospective examination of right clinical characteristics J Pain"/>
   <result pre="course of anticipatory nausea in women receiving adjuvant chemotherapy for" exact="breast cancer" post="Cancer 1988 62 2607 2613 10.1002/1097-0142(19881215)62:12&amp;lt;2607::AID-CNCR2820621226&amp;gt;3.0.CO;2-S 3191461 25. Alba"/>
   <result pre="of anticipatory nausea in women receiving adjuvant chemotherapy for breast" exact="cancer" post="Cancer 1988 62 2607 2613 10.1002/1097-0142(19881215)62:12&amp;lt;2607::AID-CNCR2820621226&amp;gt;3.0.CO;2-S 3191461 25. Alba"/>
   <result pre="of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated" exact="cancer" post="patients: a randomized double-blind trial of the Italian Oncology"/>
   <result pre="et al. Safety of ondansetron loading doses in children with" exact="cancer" post="Support Care Cancer 2008 16 469 475 10.1007/s00520-007-0338-4 17940810"/>
   <result pre="C De Conno F Ventafridda V et al. Management of" exact="bowel obstruction" post="in advanced and terminal cancer patients Ann Oncol 1993"/>
   <result pre="et al. Management of bowel obstruction in advanced and terminal" exact="cancer" post="patients Ann Oncol 1993 4 15 21 8435356"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4750533/results/search/disease/results.xml">
   <result pre="pmid: 26698230 doi: 10.3892/ijo.2015.3306 ijo-48-03-0869 : Articles Akt inhibitors in" exact="cancer" post="treatment: The long journey from drug discovery to clinical"/>
   <result pre="non-commercial and no modifications or adaptations are made. Abstract Targeted" exact="cancer" post="therapies are used to inhibit the growth, progression, and"/>
   <result pre="as Akt, plays a central role in many types of" exact="cancer" post="and has been validated as a therapeutic target nearly"/>
   <result pre="World Health Organization (WHO) states that one defining feature of" exact="cancer" post="is the rapid creation of abnormal cells that grow"/>
   <result pre="indicated that in 2012, approximately 14.1 million new cases of" exact="cancer" post="were diagnosed in worldwide. Among these cases, 7.4 million"/>
   <result pre="age-standardized incidence rate points out that there are 205 new" exact="cancer" post="cases for every 100,000 males worldwide, and 165 for"/>
   <result pre="( 1). According to WHO, lung, prostate, colorectal, stomach and" exact="liver cancer" post="are the most common types of cancer in males,"/>
   <result pre="1). According to WHO, lung, prostate, colorectal, stomach and liver" exact="cancer" post="are the most common types of cancer in males,"/>
   <result pre="stomach and liver cancer are the most common types of" exact="cancer" post="in males, while breast, colorectal, lung, uterine cervix and"/>
   <result pre="cancer in males, while breast, colorectal, lung, uterine cervix and" exact="stomach cancer" post="are the most common among females. Statistics also indicate"/>
   <result pre="in males, while breast, colorectal, lung, uterine cervix and stomach" exact="cancer" post="are the most common among females. Statistics also indicate"/>
   <result pre="there is expected to be a 70% increase in new" exact="cancer" post="cases over the next two decades. The American Cancer"/>
   <result pre="2015, projecting that there will be an estimated 1,658,370 new" exact="cancer" post="cases diagnosed and 589,430 cancer-related deaths in the US"/>
   <result pre="past decades, a growing body of evidence has indicated that" exact="cancer" post="patients can be cured by novel molecular target therapies"/>
   <result pre="transduction pathway and its involvement in the development and progression" exact="cancer" post="are discussed. Furthermore, the most relevant studies focusing on"/>
   <result pre="Akt signaling cascade is frequently impaired in many types of" exact="cancer" post="and, in some cases, that it is associated with"/>
   <result pre="considering this signaling pathway as a strong target candidate for" exact="cancer" post="therapy or even cancer prevention ( 6, 7). The"/>
   <result pre="as a strong target candidate for cancer therapy or even" exact="cancer" post="prevention ( 6, 7). The Akt structure consists of"/>
   <result pre="PIP3 ( 11, 12). PI3K is overexpressed in ovarian and" exact="cervical cancer" post="and has mutations associated with breast cancer, glioblastoma and"/>
   <result pre="( 11, 12). PI3K is overexpressed in ovarian and cervical" exact="cancer" post="and has mutations associated with breast cancer, glioblastoma and"/>
   <result pre="in ovarian and cervical cancer and has mutations associated with" exact="breast cancer," post="glioblastoma and gastric cancer ( 13, 14). The activation"/>
   <result pre="and has mutations associated with breast cancer, glioblastoma and gastric" exact="cancer" post="( 13, 14). The activation of Akt firstly involves"/>
   <result pre="function ( 23). Strong evidence indicates a significant association between" exact="schizophrenia" post="and a decrease in Akt1 levels ( 24). As"/>
   <result pre="a decrease in Akt1 levels ( 24). As previously demonstrated," exact="hyperglycemia" post="and reduced glucose transport in muscle are present in"/>
   <result pre="Akt2 has been shown to correlate with the aggressiveness of" exact="cancer" post="and poor survival rates, and is frequently detected in"/>
   <result pre="samples revealed that Akt3 protein expression was upregulated in androgen-independent" exact="prostate cancer" post="cell lines, estrogen receptor-deficient breast cancer cells ( 41)"/>
   <result pre="revealed that Akt3 protein expression was upregulated in androgen-independent prostate" exact="cancer" post="cell lines, estrogen receptor-deficient breast cancer cells ( 41)"/>
   <result pre="was upregulated in androgen-independent prostate cancer cell lines, estrogen receptor-deficient" exact="breast cancer" post="cells ( 41) and in primary ovarian cancers ("/>
   <result pre="upregulated in androgen-independent prostate cancer cell lines, estrogen receptor-deficient breast" exact="cancer" post="cells ( 41) and in primary ovarian cancers ("/>
   <result pre="( 42). Akt is considered as an attractive target for" exact="cancer" post="therapy and multiple attempts to identify specific inhibitors with"/>
   <result pre="it was observed to inhibit the growth of the human" exact="colon cancer" post="cell line, Caco-2, in a dose-dependent manner, while the"/>
   <result pre="was observed to inhibit the growth of the human colon" exact="cancer" post="cell line, Caco-2, in a dose-dependent manner, while the"/>
   <result pre="shown to inhibit the proliferation of various hematologic neoplasia, with" exact="acute lymphoblastic leukemia" post="cell lines being the most sensitive ( 50), but"/>
   <result pre="to inhibit the proliferation of various hematologic neoplasia, with acute" exact="lymphoblastic leukemia" post="cell lines being the most sensitive ( 50), but"/>
   <result pre="inhibit the proliferation of various hematologic neoplasia, with acute lymphoblastic" exact="leukemia" post="cell lines being the most sensitive ( 50), but"/>
   <result pre="compound was terminated due to the associated side-effect of transient" exact="hyperglycemia" post="( 52). Compounds with heterocyclic 6-5 fused rings Virtual,"/>
   <result pre="Akt substrates and to induce marked antitumor responses in various" exact="cancer" post="cell lines ( 55). The pyrrolopyrimidine scaffold was used"/>
   <result pre="μmol/l and the highest frequency of sensitivity was observed in" exact="breast cancer" post="cells. AZD5363 significantly enhanced the antitumor activity of docetaxel,"/>
   <result pre="and the highest frequency of sensitivity was observed in breast" exact="cancer" post="cells. AZD5363 significantly enhanced the antitumor activity of docetaxel,"/>
   <result pre="enhanced the antitumor activity of docetaxel, lapatinib and trastuzumab in" exact="breast cancer" post="xenografts. The activity of AZD5363 in human epidermal growth"/>
   <result pre="the antitumor activity of docetaxel, lapatinib and trastuzumab in breast" exact="cancer" post="xenografts. The activity of AZD5363 in human epidermal growth"/>
   <result pre="of AZD5363 in human epidermal growth factor receptor 2 (HER2)-amplified" exact="breast cancer" post="cells was enhanced by the addition of a pan-erbB"/>
   <result pre="AZD5363 in human epidermal growth factor receptor 2 (HER2)-amplified breast" exact="cancer" post="cells was enhanced by the addition of a pan-erbB"/>
   <result pre="has been shown to inhibit Akt signaling in both human" exact="cancer" post="cell lines and in tumor xenograft models, resulting in"/>
   <result pre="the blockade of cell cycle progression the decreased viability of" exact="cancer" post="cell lines ( 63). Ipatasertib is currently under evaluation"/>
   <result pre="to estimate the efficacy of this combination in metastatic triple-negative" exact="breast cancer" post="patients is in progress ( 64). A-674563 and A-443654"/>
   <result pre="estimate the efficacy of this combination in metastatic triple-negative breast" exact="cancer" post="patients is in progress ( 64). A-674563 and A-443654"/>
   <result pre="proliferation, and induces the apoptosis of a range of human" exact="cancer" post="cell lines, but is still in preclinical studies ("/>
   <result pre="that the hematological cell lines were the most sensitive, mostly" exact="acute lymphoblastic leukemia," post="non-Hodgkin's lymphoma and chronic lymphocytic leukemia ( 74). In"/>
   <result pre="the hematological cell lines were the most sensitive, mostly acute" exact="lymphoblastic leukemia," post="non-Hodgkin's lymphoma and chronic lymphocytic leukemia ( 74). In"/>
   <result pre="lines were the most sensitive, mostly acute lymphoblastic leukemia, non-Hodgkin's" exact="lymphoma" post="and chronic lymphocytic leukemia ( 74). In a clinical"/>
   <result pre="the most sensitive, mostly acute lymphoblastic leukemia, non-Hodgkin's lymphoma and" exact="chronic lymphocytic leukemia" post="( 74). In a clinical study, afuresertib (PKB112835) was"/>
   <result pre="sensitive, mostly acute lymphoblastic leukemia, non-Hodgkin's lymphoma and chronic lymphocytic" exact="leukemia" post="( 74). In a clinical study, afuresertib (PKB112835) was"/>
   <result pre="clinical efficacy in a number of hematological malignancies, particularly in" exact="multiple myeloma" post="( 77). A phase I/II study on afuresertib in"/>
   <result pre="in combination with trametinib (MEK inhibitor) in various types of" exact="cancer" post="( 74). 5. Allosteric inhibitors ATP-competitive inhibitors are non-selective"/>
   <result pre="lapatinib (dual EGFR/HER2 inhibitor) in lung NCI-H460 or ovarian A2780" exact="cancer" post="cell lines ( 84). MK-2206 has been extensively investigated,"/>
   <result pre="inhibitors, such as trastuzumab or lapatinib, in various types of" exact="breast cancer" post="( 88). The clinical evaluation of MK-2206 for the"/>
   <result pre="such as trastuzumab or lapatinib, in various types of breast" exact="cancer" post="( 88). The clinical evaluation of MK-2206 for the"/>
   <result pre="clinical evaluation of MK-2206 for the treatment of acute myelogenous" exact="leukemia" post="proved to be largely unsatisfactory ( 89). The combination"/>
   <result pre="the desired level of clinical activity in patients with advanced" exact="colorectal cancer" post="( 90). Alkylphospholipids (ALPs) Structurally based on the scaffold"/>
   <result pre="desired level of clinical activity in patients with advanced colorectal" exact="cancer" post="( 90). Alkylphospholipids (ALPs) Structurally based on the scaffold"/>
   <result pre="clinical studies against soft tissue sarcomas ( 98) and advanced" exact="colorectal cancer" post="( 99); however, the doses required for the antitumor"/>
   <result pre="studies against soft tissue sarcomas ( 98) and advanced colorectal" exact="cancer" post="( 99); however, the doses required for the antitumor"/>
   <result pre="be effective and tolerable as a local treatment for cutaneous" exact="breast cancer" post="( 100). The clinical use of miltefosine is restricted"/>
   <result pre="effective and tolerable as a local treatment for cutaneous breast" exact="cancer" post="( 100). The clinical use of miltefosine is restricted"/>
   <result pre="is one of the few therapeutic solutions for visceral and" exact="cutaneous leishmaniasis" post="( 101). The replacement of the choline moiety of"/>
   <result pre="one of the few therapeutic solutions for visceral and cutaneous" exact="leishmaniasis" post="( 101). The replacement of the choline moiety of"/>
   <result pre="tumors. As a single therapy, perifosine proved useful only in" exact="sarcoma" post="and Waldenstrom macroglobulinemia. It is currently in clinical development"/>
   <result pre="It is currently in clinical development for the treatment of" exact="colorectal cancer" post="in combination with capecitabine and of multiple myeloma in"/>
   <result pre="is currently in clinical development for the treatment of colorectal" exact="cancer" post="in combination with capecitabine and of multiple myeloma in"/>
   <result pre="treatment of colorectal cancer in combination with capecitabine and of" exact="multiple myeloma" post="in combination with bortezomib and dexamethasone or in combination"/>
   <result pre="paclitaxel, docetaxel, lenalinomide or gemcitabine in various other types of" exact="cancer" post="( 91). Erucylphosphocholine (ErPC) is a long chain and"/>
   <result pre="104). ErPC and ErPC3 have been tested in various other" exact="cancer" post="types of cancer, including acute myeloid leukemia, chronic lymphocytic"/>
   <result pre="been tested in various other cancer types of cancer, including" exact="acute myeloid leukemia," post="chronic lymphocytic leukemia, colorectal cancer and oral squamous cell"/>
   <result pre="tested in various other cancer types of cancer, including acute" exact="myeloid leukemia," post="chronic lymphocytic leukemia, colorectal cancer and oral squamous cell"/>
   <result pre="various other cancer types of cancer, including acute myeloid leukemia," exact="chronic lymphocytic leukemia," post="colorectal cancer and oral squamous cell carcinoma ( 105)."/>
   <result pre="types of cancer, including acute myeloid leukemia, chronic lymphocytic leukemia," exact="colorectal cancer" post="and oral squamous cell carcinoma ( 105). Preclinical data"/>
   <result pre="of cancer, including acute myeloid leukemia, chronic lymphocytic leukemia, colorectal" exact="cancer" post="and oral squamous cell carcinoma ( 105). Preclinical data"/>
   <result pre="has exhibited potent oral anticancer activity against various types of" exact="cancer" post="and no significant toxicity ( 110). SR13668 has been"/>
   <result pre="erlotinib in a non-small-cell lung cancers and with paclitaxel in" exact="breast cancer" post="( 116). Thiourea derivatives High-throughput fluorescence polarization binding assay"/>
   <result pre="in a non-small-cell lung cancers and with paclitaxel in breast" exact="cancer" post="( 116). Thiourea derivatives High-throughput fluorescence polarization binding assay"/>
   <result pre="(TCN), NSC 154020] that potently inhibited Akt signaling in human" exact="cancer" post="cells, leading to the inhibition of cell growth and"/>
   <result pre="PIP3 activation ( 122). Treatment of T cell acute lymphocytic" exact="leukemia" post="cells with 10 μM TCN has been shown to"/>
   <result pre="causing cell cycle arrest and caspase-dependent apoptosis ( 123). In" exact="prostate cancer" post="cells, TCN was shown to increase the apoptosis induced"/>
   <result pre="cell cycle arrest and caspase-dependent apoptosis ( 123). In prostate" exact="cancer" post="cells, TCN was shown to increase the apoptosis induced"/>
   <result pre="( 126). API-1 was shown to induce apoptosis in tested" exact="cancer" post="cell lines by synergizing with TNF-related apoptosis-inducing ligand (TRAIL)"/>
   <result pre="types and were most potent in leukemia, breast, endometrial and" exact="colorectal cancer" post="cell lines ( 130). Only the core structure of"/>
   <result pre="and were most potent in leukemia, breast, endometrial and colorectal" exact="cancer" post="cell lines ( 130). Only the core structure of"/>
   <result pre="inhibitor approved, but only for the treatment of visceral and" exact="cutaneous leishmaniasis," post="and not for the treatment of cancer. The compounds"/>
   <result pre="have been reported in patients with PTEN-deficient metastatic pancreatic and" exact="colorectal cancer" post="( 143, 144). In addition to the loss of"/>
   <result pre="been reported in patients with PTEN-deficient metastatic pancreatic and colorectal" exact="cancer" post="( 143, 144). In addition to the loss of"/>
   <result pre="response and clinical benefit were observed in patients with PIK3CA-mutant" exact="colorectal cancer" post="( 145), as well as gynecological malignancies (cervical and"/>
   <result pre="and clinical benefit were observed in patients with PIK3CA-mutant colorectal" exact="cancer" post="( 145), as well as gynecological malignancies (cervical and"/>
   <result pre="and mTOR, are the focus of intensive research for targeted" exact="cancer" post="therapy ( 32). However, thus far a limited number"/>
   <result pre="Martelli AM et al. Akt as a therapeutic target in" exact="cancer" post="Expert Opin Ther Targets 12 1139 1165 2008 10.1517/14728222.12.9.1139"/>
   <result pre="Testa JR Perturbations of the AKT signaling pathway in human" exact="cancer" post="Oncogene 24 7455 7464 2005 10.1038/sj.onc.1209085 16288292 8 Song"/>
   <result pre="Y Kuniyasu H AKT plays a crucial role in gastric" exact="cancer" post="(Review) Oncol Lett 10 607 611 2015 26622541 13"/>
   <result pre="GB Gray JW PIK3CA is implicated as an oncogene in" exact="ovarian cancer" post="Nat Genet 21 99 102 1999 10.1038/5042 9916799 14"/>
   <result pre="Gray JW PIK3CA is implicated as an oncogene in ovarian" exact="cancer" post="Nat Genet 21 99 102 1999 10.1038/5042 9916799 14"/>
   <result pre="Cejas P Belda-Iniesta C González-Barón M PI3K/Akt signalling pathway and" exact="cancer" post="Cancer Treat Rev 30 193 204 2004 10.1016/j.ctrv.2003.07.007 15023437"/>
   <result pre="2013 10.1002/ajmg.a.36101 24039187 24 Emamian ES AKT/GSK3 signaling pathway and" exact="schizophrenia" post="Front Mol Neurosci 5 33 2012 10.3389/fnmol.2012.00033 22435049 25"/>
   <result pre="644 2012 22200790 32 Carnero A The PKB/AKT pathway in" exact="cancer" post="Curr Pharm Des 16 34 44 2010 10.2174/138161210789941865 20214616"/>
   <result pre="JE Inhibition of Akt signaling by the lignan matairesinol sensitizes" exact="prostate cancer" post="cells to TRAIL-induced apoptosis Oncogene 29 898 908 2010"/>
   <result pre="Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate" exact="cancer" post="cells to TRAIL-induced apoptosis Oncogene 29 898 908 2010"/>
   <result pre="Akt2 overexpression plays a critical role in the establishment of" exact="colorectal cancer" post="metastasis Proc Natl Acad Sci USA 105 20315 20320"/>
   <result pre="overexpression plays a critical role in the establishment of colorectal" exact="cancer" post="metastasis Proc Natl Acad Sci USA 105 20315 20320"/>
   <result pre="RG Sandusky GE et al. Increased AKT activity contributes to" exact="prostate cancer" post="progression by dramatically accelerating prostate tumor growth and diminishing"/>
   <result pre="Sandusky GE et al. Increased AKT activity contributes to prostate" exact="cancer" post="progression by dramatically accelerating prostate tumor growth and diminishing"/>
   <result pre="Chen SC Wang CT Chan TM et al. AKT3 promotes" exact="prostate cancer" post="proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2"/>
   <result pre="SC Wang CT Chan TM et al. AKT3 promotes prostate" exact="cancer" post="proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2"/>
   <result pre="RB A specific role for AKT3 in the genesis of" exact="ovarian cancer" post="through modulation of G(2)-M phase transition Cancer Res 66"/>
   <result pre="A specific role for AKT3 in the genesis of ovarian" exact="cancer" post="through modulation of G(2)-M phase transition Cancer Res 66"/>
   <result pre="R AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in" exact="acute lymphoblastic leukemia" post="cell lines Blood 113 1723 1729 2009 10.1182/blood-2008-02-137737 19064730"/>
   <result pre="AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute" exact="lymphoblastic leukemia" post="cell lines Blood 113 1723 1729 2009 10.1182/blood-2008-02-137737 19064730"/>
   <result pre="inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic" exact="leukemia" post="cell lines Blood 113 1723 1729 2009 10.1182/blood-2008-02-137737 19064730"/>
   <result pre="Brown KK Kumar R Mechanism and management of AKT inhibitor-induced" exact="hyperglycemia" post="Clin Cancer Res 15 217 225 2009 10.1158/1078-0432.CCR-08-1253 19118049"/>
   <result pre="AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified" exact="breast cancer" post="models Int J Oncol 47 446 454 2015 26095475"/>
   <result pre="inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast" exact="cancer" post="models Int J Oncol 47 446 454 2015 26095475"/>
   <result pre="A Dual inhibition of autophagy and the AKT pathway in" exact="prostate cancer" post="Autophagy 9 1119 1120 2013 10.4161/auto.24921 23670050 62 Blake"/>
   <result pre="Dual inhibition of autophagy and the AKT pathway in prostate" exact="cancer" post="Autophagy 9 1119 1120 2013 10.4161/auto.24921 23670050 62 Blake"/>
   <result pre="(Pac) as front-line treatment for patients (pts) with metastatic triple-negative" exact="breast cancer" post="(TNBC) ASCO Meet Abstr 33 TPS1111 2015 65 Luo"/>
   <result pre="as front-line treatment for patients (pts) with metastatic triple-negative breast" exact="cancer" post="(TNBC) ASCO Meet Abstr 33 TPS1111 2015 65 Luo"/>
   <result pre="inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in" exact="multiple myeloma" post="Blood 124 2190 2195 2014 10.1182/blood-2014-03-559963 25075128 78 Faiman"/>
   <result pre="10.1182/blood-2014-03-559963 25075128 78 Faiman B Richards T Innovative agents in" exact="multiple myeloma" post="J Adv Pract Oncol 5 193 202 2014 25089218"/>
   <result pre="Nielsen DL A systematic review of dual targeting in HER2-positive" exact="breast cancer" post="Cancer Treat Rev 40 259 270 2014 10.1016/j.ctrv.2013.09.002 24080156"/>
   <result pre="DL A systematic review of dual targeting in HER2-positive breast" exact="cancer" post="Cancer Treat Rev 40 259 270 2014 10.1016/j.ctrv.2013.09.002 24080156"/>
   <result pre="oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous" exact="leukemia" post="Clin Cancer Res 20 2226 2235 2014 10.1158/1078-0432.CCR-13-1978 24583795"/>
   <result pre="study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with" exact="colorectal cancer" post="Invest New Drugs 33 720 728 2015 10.1007/s10637-015-0212-z 25637165"/>
   <result pre="of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal" exact="cancer" post="Invest New Drugs 33 720 728 2015 10.1007/s10637-015-0212-z 25637165"/>
   <result pre="uses lipid rafts as membrane gateways to induce apoptosis in" exact="lymphoma" post="cells Mol Cancer Ther 6 2337 2345 2007 10.1158/1535-7163.MCT-07-0202"/>
   <result pre="F Lipid raft-mediated Akt signaling as a therapeutic target in" exact="mantle cell lymphoma" post="Blood Cancer J 3 e118 2013 10.1038/bcj.2013.15 23727661 96"/>
   <result pre="raft-mediated Akt signaling as a therapeutic target in mantle cell" exact="lymphoma" post="Blood Cancer J 3 e118 2013 10.1038/bcj.2013.15 23727661 96"/>
   <result pre="of its pharmacology and therapeutic efficacy in the treatment of" exact="leishmaniasis" post="J Antimicrob Chemother 67 2576 2597 2012 10.1093/jac/dks275 22833634"/>
   <result pre="2597 2012 10.1093/jac/dks275 22833634 102 Orlowski RZ Novel agents for" exact="multiple myeloma" post="to overcome resistance in phase III clinical trials Semin"/>
   <result pre="effects of erufosine on proliferation, wound healing and apoptosis in" exact="colorectal cancer" post="cell lines Oncol Rep 31 1407 1416 2014 24366062"/>
   <result pre="of erufosine on proliferation, wound healing and apoptosis in colorectal" exact="cancer" post="cell lines Oncol Rep 31 1407 1416 2014 24366062"/>
   <result pre="Jendrossek V The Akt-inhibitor Erufosine induces apoptotic cell death in" exact="prostate cancer" post="cells and increases the short term effects of ionizing"/>
   <result pre="V The Akt-inhibitor Erufosine induces apoptotic cell death in prostate" exact="cancer" post="cells and increases the short term effects of ionizing"/>
   <result pre="A et al. (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses" exact="colon cancer" post="growth in vitro and in vivo Cancer Prev Res"/>
   <result pre="et al. (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon" exact="cancer" post="growth in vitro and in vivo Cancer Prev Res"/>
   <result pre="Jong L McCormick DL Pharmacokinetics and enhanced bioavailability of candidate" exact="cancer" post="preventative agent, SR13668 in dogs and monkeys Cancer Chemother"/>
   <result pre="C Synthesis and apoptotic activity of new pyrazole derivatives in" exact="cancer" post="cell lines Bioorg Med Chem 23 5799 5808 2015"/>
   <result pre="small molecule inhibitor of Akt signaling with antitumor activity in" exact="cancer" post="cells overexpressing Akt Cancer Res 64 4394 4399 2004"/>
   <result pre="al. Preclinical testing of the Akt inhibitor triciribine in T-cell" exact="acute lymphoblastic leukemia" post="J Cell Physiol 226 822 831 2011 10.1002/jcp.22407 20857426"/>
   <result pre="Preclinical testing of the Akt inhibitor triciribine in T-cell acute" exact="lymphoblastic leukemia" post="J Cell Physiol 226 822 831 2011 10.1002/jcp.22407 20857426"/>
   <result pre="testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic" exact="leukemia" post="J Cell Physiol 226 822 831 2011 10.1002/jcp.22407 20857426"/>
   <result pre="are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in" exact="prostate cancer" post="cells Mol Pharmacol 77 378 387 2010 10.1124/mol.109.060475 20018812"/>
   <result pre="novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate" exact="cancer" post="cells Mol Pharmacol 77 378 387 2010 10.1124/mol.109.060475 20018812"/>
   <result pre="Akt2 contributes to decreases in cell survival and proliferation in" exact="hepatocellular carcinoma" post="cells Free Radic Biol Med 53 1 11 2012"/>
   <result pre="Meric-Bernstam F Biomarkers of response to Akt inhibitor MK-2206 in" exact="breast cancer" post="Clin Cancer Res 18 5816 5828 2012 10.1158/1078-0432.CCR-12-1141 22932669"/>
   <result pre="F Biomarkers of response to Akt inhibitor MK-2206 in breast" exact="cancer" post="Clin Cancer Res 18 5816 5828 2012 10.1158/1078-0432.CCR-12-1141 22932669"/>
   <result pre="of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust" exact="suppression" post="of the Akt pathway in surrogate and tumor tissues"/>
   <result pre="of Akt inhibitors. Therapeutic regimen Indication Status GSK690693 Hematological neoplasia," exact="acute lymphoblastic leukemia" post="Clinical development terminated due to hyperglycemia AZD5363 monotherapy Breast"/>
   <result pre="Akt inhibitors. Therapeutic regimen Indication Status GSK690693 Hematological neoplasia, acute" exact="lymphoblastic leukemia" post="Clinical development terminated due to hyperglycemia AZD5363 monotherapy Breast"/>
   <result pre="inhibitors. Therapeutic regimen Indication Status GSK690693 Hematological neoplasia, acute lymphoblastic" exact="leukemia" post="Clinical development terminated due to hyperglycemia AZD5363 monotherapy Breast"/>
   <result pre="Hematological neoplasia, acute lymphoblastic leukemia Clinical development terminated due to" exact="hyperglycemia" post="AZD5363 monotherapy Breast cancer, gastric cancer, prostate cancer Phase"/>
   <result pre="terminated due to hyperglycemia AZD5363 monotherapy Breast cancer, gastric cancer," exact="prostate cancer" post="Phase I/phase II clinical trials Afuresertib (GSK2110183) monotherapy Relapsed"/>
   <result pre="due to hyperglycemia AZD5363 monotherapy Breast cancer, gastric cancer, prostate" exact="cancer" post="Phase I/phase II clinical trials Afuresertib (GSK2110183) monotherapy Relapsed"/>
   <result pre="I/phase II clinical trials Afuresertib (GSK2110183) monotherapy Relapsed or refractory" exact="multiple myeloma" post="Phase I/phase II clinical trials Afuresertib (GSK2110183) in combination"/>
   <result pre="(GSK2110183) in combination with bortezomib or dexamethasone Relapsed or refractory" exact="multiple myeloma" post="Phase I/Phase II clinical trials Uprosertib (GSK2141795) monotherapy Relapsed"/>
   <result pre="I/Phase II clinical trials Uprosertib (GSK2141795) monotherapy Relapsed or refractory" exact="multiple myeloma" post="Phase I/phase II clinical trials Uprosertib (GSK2141795) in combination"/>
   <result pre="trials Uprosertib (GSK2141795) in combination with trametinib Relapsed or refractory" exact="multiple myeloma" post="Phase I/phase II clinical trials Ipatasertib (GDC-0068, RG7440) monotherapy"/>
   <result pre="Phase I/phase II clinical trials Ipatasertib (GDC-0068, RG7440) monotherapy Triple-negative" exact="breast cancer" post="Phase I/phase II clinical trials MK-2206 in combination with"/>
   <result pre="I/phase II clinical trials Ipatasertib (GDC-0068, RG7440) monotherapy Triple-negative breast" exact="cancer" post="Phase I/phase II clinical trials MK-2206 in combination with"/>
   <result pre="trials MK-2206 in combination with gefitinib or erlotinib Advanced non-small-cell" exact="lung carcinoma" post="Phase I/phase II clinical trials MK-2206 monotherapy Acute myelogenous"/>
   <result pre="carcinoma Phase I/phase II clinical trials MK-2206 monotherapy Acute myelogenous" exact="leukemia" post="Unsatisfactory clinical results Usage limited to topical application due"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4751719/results/search/disease/results.xml">
   <result pre="in this article, unless otherwise stated. Abstract Background Patients with" exact="breast cancer" post="(BC) undergoing neoadjuvant chemotherapy (NACT) may experience metastatic relapse"/>
   <result pre="this article, unless otherwise stated. Abstract Background Patients with breast" exact="cancer" post="(BC) undergoing neoadjuvant chemotherapy (NACT) may experience metastatic relapse"/>
   <result pre="supplementary material, which is available to authorized users. Keywords Breast" exact="cancer" post="Circulating tumor cells Disseminated tumor cells Minimal residual disease"/>
   <result pre="tumors and now has become a standard treatment in primary" exact="breast cancer" post="(BC). Because no difference between NACT and adjuvant treatment"/>
   <result pre="and now has become a standard treatment in primary breast" exact="cancer" post="(BC). Because no difference between NACT and adjuvant treatment"/>
   <result pre="invasive tumor (&amp;lt;0.5 cm), and 3 = residual noninvasive tumor only; ductal" exact="carcinoma in situ" post="(DCIS)], and pCR (defined as no evidence of residual"/>
   <result pre="(DCIS)], and pCR (defined as no evidence of residual invasive" exact="cancer" post="and DCIS, both in breast and axilla; regression according"/>
   <result pre="of the disease. In this regard, signaling pathways that maintain" exact="cancer" post="stem cells are attractive targets for these therapies. One"/>
   <result pre="pathway, which was shown to have effective inhibitory effects on" exact="cancer" post="stem cells in vitro and in vivo, and combination"/>
   <result pre="relate to the ability of this agent to target the" exact="cancer" post="stem cell population in a process that does not"/>
   <result pre="(PD1/PDL1)], may provide additional new tools for immunological targeting of" exact="cancer" post="stem cells [ 86]. Conclusions CTCs were eradicated effectively"/>
   <result pre="after NACT.(PDF 34 kb) Abbreviations ALDH1 aldehyde dehydrogenase 1 BC" exact="breast cancer" post="BM bone marrow CTC circulating tumor cell DCIS ductal"/>
   <result pre="NACT.(PDF 34 kb) Abbreviations ALDH1 aldehyde dehydrogenase 1 BC breast" exact="cancer" post="BM bone marrow CTC circulating tumor cell DCIS ductal"/>
   <result pre="cancer BM bone marrow CTC circulating tumor cell DCIS ductal" exact="carcinoma in situ" post="DTC disseminated tumor cell EMT epithelial–mesenchymal transition EpCAM epithelial"/>
   <result pre="R Kuerer H Valero V et al. Measurement of residual" exact="breast cancer" post="burden to predict survival after neoadjuvant chemotherapy J Clin"/>
   <result pre="Kuerer H Valero V et al. Measurement of residual breast" exact="cancer" post="burden to predict survival after neoadjuvant chemotherapy J Clin"/>
   <result pre="neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified" exact="breast cancer" post="intrinsic subtypes: a landmark and two-step approach analyses from"/>
   <result pre="chemotherapy is an independent predictive factor irrespective of simplified breast" exact="cancer" post="intrinsic subtypes: a landmark and two-step approach analyses from"/>
   <result pre="The role and clinical relevance of disseminated tumor cells in" exact="breast cancer" post="Cancers. 2014 6 143 52 10.3390/cancers6010143 24434543 7. Joosse"/>
   <result pre="role and clinical relevance of disseminated tumor cells in breast" exact="cancer" post="Cancers. 2014 6 143 52 10.3390/cancers6010143 24434543 7. Joosse"/>
   <result pre="et al. A pooled analysis of bone marrow micrometastasis in" exact="breast cancer" post="N Engl J Med. 2005 353 793 802 10.1056/NEJMoa050434"/>
   <result pre="al. A pooled analysis of bone marrow micrometastasis in breast" exact="cancer" post="N Engl J Med. 2005 353 793 802 10.1056/NEJMoa050434"/>
   <result pre="Persistence of disseminated tumor cells in the bone marrow of" exact="breast cancer" post="patients predicts increased risk for relapse – a European"/>
   <result pre="of disseminated tumor cells in the bone marrow of breast" exact="cancer" post="patients predicts increased risk for relapse – a European"/>
   <result pre="et al. Persistent tumor cells in bone marrow of non-metastatic" exact="breast cancer" post="after primary surgery are associated with inferior outcome BMC"/>
   <result pre="al. Persistent tumor cells in bone marrow of non-metastatic breast" exact="cancer" post="after primary surgery are associated with inferior outcome BMC"/>
   <result pre="of disseminated tumor cells after neoadjuvant treatment for locally advanced" exact="breast cancer" post="predicts poor survival Breast Cancer Res. 2012 14 117"/>
   <result pre="disseminated tumor cells after neoadjuvant treatment for locally advanced breast" exact="cancer" post="predicts poor survival Breast Cancer Res. 2012 14 117"/>
   <result pre="a monitoring tool for adjuvant therapy in patients with primary" exact="breast cancer" post="Breast Cancer Res Treat. 2014 144 353 60 10.1007/s10549-014-2853-6"/>
   <result pre="monitoring tool for adjuvant therapy in patients with primary breast" exact="cancer" post="Breast Cancer Res Treat. 2014 144 353 60 10.1007/s10549-014-2853-6"/>
   <result pre="mRNA-positive cells detected by real-time polymerase chain reaction in node-negative" exact="breast cancer" post="patients J Clin Oncol. 2006 24 3756 62 10.1200/JCO.2005.04.5948"/>
   <result pre="cells detected by real-time polymerase chain reaction in node-negative breast" exact="cancer" post="patients J Clin Oncol. 2006 24 3756 62 10.1200/JCO.2005.04.5948"/>
   <result pre="RNA-positive cells in the peripheral blood of women with early-stage" exact="breast cancer" post="Clin Breast Cancer. 2007 7 883 9 10.3816/CBC.2007.n.054 18269779"/>
   <result pre="cells in the peripheral blood of women with early-stage breast" exact="cancer" post="Clin Breast Cancer. 2007 7 883 9 10.3816/CBC.2007.n.054 18269779"/>
   <result pre="circulating tumor cells after adjuvant chemotherapy in patients with early" exact="breast cancer" post="J Clin Oncol. 2009 27 2177 84 10.1200/JCO.2008.18.0497 19332733"/>
   <result pre="tumor cells after adjuvant chemotherapy in patients with early breast" exact="cancer" post="J Clin Oncol. 2009 27 2177 84 10.1200/JCO.2008.18.0497 19332733"/>
   <result pre="Single circulating tumor cell detection and overall survival in nonmetastatic" exact="breast cancer" post="Ann Oncol. 2010 21 729 33 10.1093/annonc/mdp391 19850639 19."/>
   <result pre="circulating tumor cell detection and overall survival in nonmetastatic breast" exact="cancer" post="Ann Oncol. 2010 21 729 33 10.1093/annonc/mdp391 19850639 19."/>
   <result pre="al. Circulating tumor cells predict survival in early average-to-high risk" exact="breast cancer" post="patients. J Natl Cancer Inst 2014;106:dju066. doi: 10.1093/jnci/dju066. 21."/>
   <result pre="Circulating tumor cells predict survival in early average-to-high risk breast" exact="cancer" post="patients. J Natl Cancer Inst 2014;106:dju066. doi: 10.1093/jnci/dju066. 21."/>
   <result pre="nonapoptotic disseminated tumor cells in the bone marrow of primary" exact="breast cancer" post="patients after neoadjuvant chemotherapy Breast Cancer Res. 2013 15"/>
   <result pre="disseminated tumor cells in the bone marrow of primary breast" exact="cancer" post="patients after neoadjuvant chemotherapy Breast Cancer Res. 2013 15"/>
   <result pre="of occult tumor cells in blood and bone marrow in" exact="breast cancer" post="Int J Cancer. 2006 118 2013 9 10.1002/ijc.21576 16287086"/>
   <result pre="occult tumor cells in blood and bone marrow in breast" exact="cancer" post="Int J Cancer. 2006 118 2013 9 10.1002/ijc.21576 16287086"/>
   <result pre="(CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in" exact="breast cancer" post="Ann Oncol. 2007 18 1484 92 10.1093/annonc/mdm206 17761704 25."/>
   <result pre="for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast" exact="cancer" post="Ann Oncol. 2007 18 1484 92 10.1093/annonc/mdm206 17761704 25."/>
   <result pre="zoledronate on persisting isolated tumour cells in patients with early" exact="breast cancer" post="Anticancer Res. 2010 30 1807 13 20592383 26. Hoffman"/>
   <result pre="on persisting isolated tumour cells in patients with early breast" exact="cancer" post="Anticancer Res. 2010 30 1807 13 20592383 26. Hoffman"/>
   <result pre="Influence of zoledronic acid on disseminated tumor cells in primary" exact="breast cancer" post="patients Ann Oncol. 2012 23 2271 7 10.1093/annonc/mdr612 22383680"/>
   <result pre="of zoledronic acid on disseminated tumor cells in primary breast" exact="cancer" post="patients Ann Oncol. 2012 23 2271 7 10.1093/annonc/mdr612 22383680"/>
   <result pre="D Giuliano A McNamara G et al. Most early disseminated" exact="cancer" post="cells detected in bone marrow of breast cancer patients"/>
   <result pre="Most early disseminated cancer cells detected in bone marrow of" exact="breast cancer" post="patients have a putative breast cancer stem cell phenotype"/>
   <result pre="early disseminated cancer cells detected in bone marrow of breast" exact="cancer" post="patients have a putative breast cancer stem cell phenotype"/>
   <result pre="in bone marrow of breast cancer patients have a putative" exact="breast cancer" post="stem cell phenotype Clin Cancer Res. 2006 12 5615"/>
   <result pre="bone marrow of breast cancer patients have a putative breast" exact="cancer" post="stem cell phenotype Clin Cancer Res. 2006 12 5615"/>
   <result pre="H Cohen EN Mego M Giordano A et al. Primary" exact="breast cancer" post="patients with high risk clinicopathologic features have high percentages"/>
   <result pre="Cohen EN Mego M Giordano A et al. Primary breast" exact="cancer" post="patients with high risk clinicopathologic features have high percentages"/>
   <result pre="marrow epithelial cells with ALDH activity and CD44 +CD24 lo" exact="cancer" post="stem cell phenotype Eur J Cancer. 2011 47 1527"/>
   <result pre="Expression of stem cell and epithelial-mesenchymal transition markers in primary" exact="breast cancer" post="patients with circulating tumor cells Breast Cancer Res. 2012"/>
   <result pre="of stem cell and epithelial-mesenchymal transition markers in primary breast" exact="cancer" post="patients with circulating tumor cells Breast Cancer Res. 2012"/>
   <result pre="cell and epithelial-mesenchymal transition markers are frequently expressed in metastatic" exact="breast cancer" post="patients with circulating tumor cells Breast Cancer Res. 2009"/>
   <result pre="and epithelial-mesenchymal transition markers are frequently expressed in metastatic breast" exact="cancer" post="patients with circulating tumor cells Breast Cancer Res. 2009"/>
   <result pre="analysis of PIK3CA in circulating tumor cells an metastases in" exact="breast cancer" post="reveals heterogeneity, discordance and mutation persistence in cultured disseminated"/>
   <result pre="of PIK3CA in circulating tumor cells an metastases in breast" exact="cancer" post="reveals heterogeneity, discordance and mutation persistence in cultured disseminated"/>
   <result pre="ERalpha-status of disseminated tumour cells in bone marrow of primary" exact="breast cancer" post="patients Breast Cancer Res. 2008 10 R76 10.1186/bcr2143 18793387"/>
   <result pre="of disseminated tumour cells in bone marrow of primary breast" exact="cancer" post="patients Breast Cancer Res. 2008 10 R76 10.1186/bcr2143 18793387"/>
   <result pre="and characterization of circulating tumor cells in blood of primary" exact="breast cancer" post="patients by RT-PCR and comparison to status of bone"/>
   <result pre="characterization of circulating tumor cells in blood of primary breast" exact="cancer" post="patients by RT-PCR and comparison to status of bone"/>
   <result pre="challenges in the molecular characterization of circulating tumour cells in" exact="breast cancer" post="Br J Cancer. 2013 108 2426 32 10.1038/bjc.2013.265 23756869"/>
   <result pre="in the molecular characterization of circulating tumour cells in breast" exact="cancer" post="Br J Cancer. 2013 108 2426 32 10.1038/bjc.2013.265 23756869"/>
   <result pre="cell and epithelial-mesenchymal transition markers in circulating tumor cells of" exact="breast cancer" post="patients Biomed Res Int 2014 2014 415721 10.1155/2014/415721 24895575"/>
   <result pre="and epithelial-mesenchymal transition markers in circulating tumor cells of breast" exact="cancer" post="patients Biomed Res Int 2014 2014 415721 10.1155/2014/415721 24895575"/>
   <result pre="of disseminated tumor cells in the bone marrow of early" exact="breast cancer" post="patients is independent from primary tumor and predicts higher"/>
   <result pre="disseminated tumor cells in the bone marrow of early breast" exact="cancer" post="patients is independent from primary tumor and predicts higher"/>
   <result pre="and HER2 expression of circulating tumor cells: prospective monitoring in" exact="breast cancer" post="patients treated in the neoadjuvant GeparQuattro trial Clin Cancer"/>
   <result pre="HER2 expression of circulating tumor cells: prospective monitoring in breast" exact="cancer" post="patients treated in the neoadjuvant GeparQuattro trial Clin Cancer"/>
   <result pre="associated with the response to neoadjuvant chemotherapy in local advanced" exact="breast cancer?" post="A meta-analysis Oncol Res Treat. 2014 37 250 4"/>
   <result pre="methods for detection of circulating tumor cells (CTCs) in metastatic" exact="breast cancer" post="(MBC): AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex Cell Search"/>
   <result pre="for detection of circulating tumor cells (CTCs) in metastatic breast" exact="cancer" post="(MBC): AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex Cell Search"/>
   <result pre="with the Cell Search System and AdnaTest Breast in metastatic" exact="breast cancer" post="patients: the DETECT study Breast Cancer Res. 2012 14"/>
   <result pre="the Cell Search System and AdnaTest Breast in metastatic breast" exact="cancer" post="patients: the DETECT study Breast Cancer Res. 2012 14"/>
   <result pre="Swaby RF et al. Lapatinib with trastuzumab for HER2-positive early" exact="breast cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="RF et al. Lapatinib with trastuzumab for HER2-positive early breast" exact="cancer" post="(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase"/>
   <result pre="J Leppien G Kaufmann M et al. Histologic regression of" exact="breast cancer" post="after primary (neoadjuvant) chemotherapy [in German] Geburtshilfe Frauenheilkd. 1994"/>
   <result pre="Leppien G Kaufmann M et al. Histologic regression of breast" exact="cancer" post="after primary (neoadjuvant) chemotherapy [in German] Geburtshilfe Frauenheilkd. 1994"/>
   <result pre="disseminated tumor cells in bone marrow of patients with primary" exact="breast cancer" post="and its clinical implementation Cancer. 2006 107 885 92"/>
   <result pre="tumor cells in bone marrow of patients with primary breast" exact="cancer" post="and its clinical implementation Cancer. 2006 107 885 92"/>
   <result pre="preparations and bone marrow of patients with high-risk or metastatic" exact="breast cancer" post="after receiving dose-intensive or high-dose chemotherapy Clin Cancer Res."/>
   <result pre="and bone marrow of patients with high-risk or metastatic breast" exact="cancer" post="after receiving dose-intensive or high-dose chemotherapy Clin Cancer Res."/>
   <result pre="Fodstad O et al. Standardization of the immunocytochemical detection of" exact="cancer" post="cells in BM and blood: I. Establishment of objective"/>
   <result pre="Albert WH The clinical significance of circulating tumour cells in" exact="breast cancer" post="and colorectal cancer patients Anticancer Res. 2007 27 1337"/>
   <result pre="WH The clinical significance of circulating tumour cells in breast" exact="cancer" post="and colorectal cancer patients Anticancer Res. 2007 27 1337"/>
   <result pre="clinical significance of circulating tumour cells in breast cancer and" exact="colorectal cancer" post="patients Anticancer Res. 2007 27 1337 41 17593628 58."/>
   <result pre="significance of circulating tumour cells in breast cancer and colorectal" exact="cancer" post="patients Anticancer Res. 2007 27 1337 41 17593628 58."/>
   <result pre="circulating tumor cells predicts worse prognosis in patients with primary" exact="ovarian cancer" post="Clin Chem. 2014 60 1282 9 10.1373/clinchem.2014.224808 25015375 59."/>
   <result pre="tumor cells predicts worse prognosis in patients with primary ovarian" exact="cancer" post="Clin Chem. 2014 60 1282 9 10.1373/clinchem.2014.224808 25015375 59."/>
   <result pre="PA Hudis CA Ladanyi M Chen B HER-2 testing in" exact="breast cancer" post="using immunohistochemical analysis and fluorescence in situ hybridization: a"/>
   <result pre="Hudis CA Ladanyi M Chen B HER-2 testing in breast" exact="cancer" post="using immunohistochemical analysis and fluorescence in situ hybridization: a"/>
   <result pre="Eidtmann H Eiermann W et al. Response-guided neoadjuvant chemotherapy for" exact="breast cancer" post="J Clin Oncol. 2013 31 3623 30 10.1200/JCO.2012.45.0940 24002511"/>
   <result pre="H Eiermann W et al. Response-guided neoadjuvant chemotherapy for breast" exact="cancer" post="J Clin Oncol. 2013 31 3623 30 10.1200/JCO.2012.45.0940 24002511"/>
   <result pre="tumor cells reflects the response to neoadjuvant systemic therapy in" exact="breast cancer" post="Breast Cancer Res. 2006 8 R60 10.1186/bcr1611 17062129 65."/>
   <result pre="cells reflects the response to neoadjuvant systemic therapy in breast" exact="cancer" post="Breast Cancer Res. 2006 8 R60 10.1186/bcr1611 17062129 65."/>
   <result pre="Ye X Weinberg RA Epithelial-mesenchymal plasticity: a central regulator of" exact="cancer" post="progression Trends Cell Biol 2015 25 675 86 10.1016/j.tcb.2015.07.012"/>
   <result pre="induced and spontaneous apoptosis of disseminated tumor cells in primary" exact="breast cancer" post="patients BMC Cancer. 2014 14 394 10.1186/1471-2407-14-394 24894702 68."/>
   <result pre="and spontaneous apoptosis of disseminated tumor cells in primary breast" exact="cancer" post="patients BMC Cancer. 2014 14 394 10.1186/1471-2407-14-394 24894702 68."/>
   <result pre="copy number changes in disseminated tumor cells of patients with" exact="breast cancer" post="Int J Cancer. 2012 131 405 15 10.1002/ijc.26444 69."/>
   <result pre="number changes in disseminated tumor cells of patients with breast" exact="cancer" post="Int J Cancer. 2012 131 405 15 10.1002/ijc.26444 69."/>
   <result pre="M Brauch H Prevalence of CD44 +/CD24 −/low cells in" exact="breast cancer" post="may not be associated with clinical outcome but may"/>
   <result pre="Brauch H Prevalence of CD44 +/CD24 −/low cells in breast" exact="cancer" post="may not be associated with clinical outcome but may"/>
   <result pre="status after DTC-guided secondary adjuvant treatment With docetaxel in early" exact="breast cancer" post="J Clin Oncol. 2014 32 3848 57 10.1200/JCO.2014.56.9327 25366688"/>
   <result pre="after DTC-guided secondary adjuvant treatment With docetaxel in early breast" exact="cancer" post="J Clin Oncol. 2014 32 3848 57 10.1200/JCO.2014.56.9327 25366688"/>
   <result pre="disseminated tumor cells in the bone marrow of primary, non-metastatic" exact="breast cancer" post="patients after a 7-year follow-up Arch Gynecol Obstet. 2015"/>
   <result pre="tumor cells in the bone marrow of primary, non-metastatic breast" exact="cancer" post="patients after a 7-year follow-up Arch Gynecol Obstet. 2015"/>
   <result pre="al. Circulating tumor cells, disease progression, and survival in metastatic" exact="breast cancer" post="N Engl J Med. 2004 351 781 91 10.1056/NEJMoa040766"/>
   <result pre="Circulating tumor cells, disease progression, and survival in metastatic breast" exact="cancer" post="N Engl J Med. 2004 351 781 91 10.1056/NEJMoa040766"/>
   <result pre="Rigaud M Mesenchymal and stemness circulating tumor cells in early" exact="breast cancer" post="diagnosis BMC Cancer. 2012 12 114 10.1186/1471-2407-12-114 22443102 78."/>
   <result pre="M Mesenchymal and stemness circulating tumor cells in early breast" exact="cancer" post="diagnosis BMC Cancer. 2012 12 114 10.1186/1471-2407-12-114 22443102 78."/>
   <result pre="after the completion of adjuvant chemotherapy in patients with operable" exact="breast cancer" post="Ann Oncol. 2003 14 849 55 10.1093/annonc/mdg259 12796021 79."/>
   <result pre="the completion of adjuvant chemotherapy in patients with operable breast" exact="cancer" post="Ann Oncol. 2003 14 849 55 10.1093/annonc/mdg259 12796021 79."/>
   <result pre="Huth JF et al. Circulating tumor cells in patients with" exact="breast cancer" post="dormancy Clin Cancer Res. 2004 10 8152 62 10.1158/1078-0432.CCR-04-1110"/>
   <result pre="JF et al. Circulating tumor cells in patients with breast" exact="cancer" post="dormancy Clin Cancer Res. 2004 10 8152 62 10.1158/1078-0432.CCR-04-1110"/>
   <result pre="Zhang MS. Effects of an mTOR inhibitor RAD001 on human" exact="breast cancer" post="stem cells in vitro and in vivo. J Clin"/>
   <result pre="MS. Effects of an mTOR inhibitor RAD001 on human breast" exact="cancer" post="stem cells in vitro and in vivo. J Clin"/>
   <result pre="Osborne CK Wu MF et al. Intrinsic resistance of tumorigenic" exact="breast cancer" post="cells to chemotherapy J Natl Cancer Inst. 2008 100"/>
   <result pre="CK Wu MF et al. Intrinsic resistance of tumorigenic breast" exact="cancer" post="cells to chemotherapy J Natl Cancer Inst. 2008 100"/>
   <result pre="Q Dawsey SJ Bersano-Begey TF et al. HER2 drives luminal" exact="breast cancer" post="stems cells in the absence of HER2 amplification: implications"/>
   <result pre="Dawsey SJ Bersano-Begey TF et al. HER2 drives luminal breast" exact="cancer" post="stems cells in the absence of HER2 amplification: implications"/>
   <result pre="C Weinberg RA et al. Identification of selective inhibitors of" exact="cancer" post="stem cells by high-throughput screening Cell. 2009 138 645"/>
   <result pre="Misra K A novel approach for overcoming drug resistance in" exact="breast cancer" post="chemotherapy by targeting new synthetic curcumin analogues against aldehyde"/>
   <result pre="K A novel approach for overcoming drug resistance in breast" exact="cancer" post="chemotherapy by targeting new synthetic curcumin analogues against aldehyde"/>
   <result pre="N Zhang X Xu Y et al. Concise review: targeting" exact="cancer" post="stem cells using immunologic approaches Stem Cells. 2015 33"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4752991/results/search/disease/results.xml">
   <result pre="Hedgehog pathways. This review describes the role of FOXM1 in" exact="breast cancer." post="This includes how FOXM1 impacts on different subtypes of"/>
   <result pre="cancer. This includes how FOXM1 impacts on different subtypes of" exact="breast cancer," post="that is, luminal/estrogen receptor positive (ER+), expressing human epidermal"/>
   <result pre="(ER+), expressing human epidermal growth factor receptor 2 (HER2), basal-like" exact="breast cancer" post="(BBC), and triple negative breast cancer (TNBC). The review"/>
   <result pre="expressing human epidermal growth factor receptor 2 (HER2), basal-like breast" exact="cancer" post="(BBC), and triple negative breast cancer (TNBC). The review"/>
   <result pre="receptor 2 (HER2), basal-like breast cancer (BBC), and triple negative" exact="breast cancer" post="(TNBC). The review also describes different tested preclinical therapeutic"/>
   <result pre="2 (HER2), basal-like breast cancer (BBC), and triple negative breast" exact="cancer" post="(TNBC). The review also describes different tested preclinical therapeutic"/>
   <result pre="activity is a logical next step in biomarker-driven approaches against" exact="breast cancer" post="but will not be without its challenges due to"/>
   <result pre="is a logical next step in biomarker-driven approaches against breast" exact="cancer" post="but will not be without its challenges due to"/>
   <result pre="liver [ 3], lung [ 4], prostate [ 5], and" exact="colorectal cancer" post="[ 6]. More importantly, different pathways have been elucidated"/>
   <result pre="[ 3], lung [ 4], prostate [ 5], and colorectal" exact="cancer" post="[ 6]. More importantly, different pathways have been elucidated"/>
   <result pre="and (1) hormone and growth factor receptors pathways associated with" exact="breast cancer" post="and (2) resistance to breast cancer therapies. We will"/>
   <result pre="(1) hormone and growth factor receptors pathways associated with breast" exact="cancer" post="and (2) resistance to breast cancer therapies. We will"/>
   <result pre="receptors pathways associated with breast cancer and (2) resistance to" exact="breast cancer" post="therapies. We will first briefly discuss the structure of"/>
   <result pre="pathways associated with breast cancer and (2) resistance to breast" exact="cancer" post="therapies. We will first briefly discuss the structure of"/>
   <result pre="The first evidence of a correlation between FOXM1 and human" exact="cancer" post="was reported by Teh et al. in 2002 ["/>
   <result pre="a high level of stability or expression of FoxM1 in" exact="cancer" post="cells initiated through different pathways, (3) enhanced transcription of"/>
   <result pre="invasion, and premetastatic niche formation [ 33] but other key" exact="cancer" post="hallmarks as well ( Figure 1)—reprogramming of energy metabolism;"/>
   <result pre="of Breast Cancer The effect of FOXM1 on biology of" exact="breast cancer" post="was evaluated in 236 women with breast cancer. Expression"/>
   <result pre="Breast Cancer The effect of FOXM1 on biology of breast" exact="cancer" post="was evaluated in 236 women with breast cancer. Expression"/>
   <result pre="biology of breast cancer was evaluated in 236 women with" exact="breast cancer." post="Expression of FOXM1 was associated with larger tumor size,"/>
   <result pre="size, lymphovascular invasion, lymph nodes metastases, and higher stage of" exact="breast cancer." post="There was no significant impact of FoxM1 expression on"/>
   <result pre="no significant impact of FoxM1 expression on survival when all" exact="breast cancer" post="histologies were analyzed; however, in a subgroup of patients"/>
   <result pre="significant impact of FoxM1 expression on survival when all breast" exact="cancer" post="histologies were analyzed; however, in a subgroup of patients"/>
   <result pre="37]. The complex and diverse ways in which FOXM1 promotes" exact="breast cancer" post="tumorigenesis are depicted in Figure 2. Yang et al."/>
   <result pre="The complex and diverse ways in which FOXM1 promotes breast" exact="cancer" post="tumorigenesis are depicted in Figure 2. Yang et al."/>
   <result pre="2. Yang et al. demonstrated that FOXM1 promoted EMT in" exact="breast cancer" post="by binding and activation of the promoter of SLUG"/>
   <result pre="Yang et al. demonstrated that FOXM1 promoted EMT in breast" exact="cancer" post="by binding and activation of the promoter of SLUG"/>
   <result pre="gene [ 38]. Xue et al. showed that FOXM1 promotes" exact="breast cancer" post="metastases by activation of the TGF- β pathway through"/>
   <result pre="[ 38]. Xue et al. showed that FOXM1 promotes breast" exact="cancer" post="metastases by activation of the TGF- β pathway through"/>
   <result pre="promoter led to activation of the AKT pathway and increased" exact="breast cancer" post="tumorigenesis [ 42]. Nestal de Moraes et al. ["/>
   <result pre="led to activation of the AKT pathway and increased breast" exact="cancer" post="tumorigenesis [ 42]. Nestal de Moraes et al. ["/>
   <result pre="survivin by interacting with their promoters, contributing to chemoresistance of" exact="breast cancer" post="cells to docetaxel, paclitaxel, and epirubicin. Moreover, coexpression of"/>
   <result pre="by interacting with their promoters, contributing to chemoresistance of breast" exact="cancer" post="cells to docetaxel, paclitaxel, and epirubicin. Moreover, coexpression of"/>
   <result pre="was associated with poor outcomes of women with stage III" exact="breast cancer" post="with significantly reduced 5- and 10-year survival rates versus"/>
   <result pre="associated with poor outcomes of women with stage III breast" exact="cancer" post="with significantly reduced 5- and 10-year survival rates versus"/>
   <result pre="survival rates versus women with tumors without these features. Breast" exact="cancer" post="encompasses a heterogeneous group of entities that vary greatly"/>
   <result pre="Sørlie et al. [ 44] and later confirmed in the" exact="cancer" post="genome atlas published in 2012 [ 45]. Human breast"/>
   <result pre="subtypes: normal breast-like, luminal A, luminal B, HER2/Neu-enriched, and basal-like" exact="breast cancer" post="(BBC). 4.2. FOXM1 and Luminal/Estrogen Receptor Positive (ER+) Breast"/>
   <result pre="normal breast-like, luminal A, luminal B, HER2/Neu-enriched, and basal-like breast" exact="cancer" post="(BBC). 4.2. FOXM1 and Luminal/Estrogen Receptor Positive (ER+) Breast"/>
   <result pre="research about the Forkhead box family and growth factors in" exact="breast cancer" post="emerged in 2000. Jackson et al. provided the first"/>
   <result pre="about the Forkhead box family and growth factors in breast" exact="cancer" post="emerged in 2000. Jackson et al. provided the first"/>
   <result pre="FOXM1 is a physiologic regulator of ER α expression in" exact="breast cancer" post="cells, both at the protein and at mRNA levels."/>
   <result pre="is a physiologic regulator of ER α expression in breast" exact="cancer" post="cells, both at the protein and at mRNA levels."/>
   <result pre="et al. studied the effects of ER β expression on" exact="breast cancer" post="[ 55]. Their investigations showed that ER β had"/>
   <result pre="al. studied the effects of ER β expression on breast" exact="cancer" post="[ 55]. Their investigations showed that ER β had"/>
   <result pre="had an antiproliferative effect through repression of FOXM1 expression in" exact="breast cancer" post="cells; this effect was mediated by an estrogen-response element"/>
   <result pre="an antiproliferative effect through repression of FOXM1 expression in breast" exact="cancer" post="cells; this effect was mediated by an estrogen-response element"/>
   <result pre="target of ER α. The correlation between FOXM1 and ER+" exact="breast cancer" post="has also been shown on the genetic level. Ahn"/>
   <result pre="of ER α. The correlation between FOXM1 and ER+ breast" exact="cancer" post="has also been shown on the genetic level. Ahn"/>
   <result pre="which was found to be of prognostic value in ER+" exact="breast cancer" post="patients in that FOXM1 suggested poorer prognosis [ 56]."/>
   <result pre="was found to be of prognostic value in ER+ breast" exact="cancer" post="patients in that FOXM1 suggested poorer prognosis [ 56]."/>
   <result pre="of HER2 can be seen in up to 25% of" exact="breast cancer" post="cases and has been shown to correlate with high"/>
   <result pre="HER2 can be seen in up to 25% of breast" exact="cancer" post="cases and has been shown to correlate with high"/>
   <result pre="a positive correlation between HER2 status and FOXM1 expression in" exact="breast cancer" post="specimens, in comparison to normal breast tissue [ 60]."/>
   <result pre="positive correlation between HER2 status and FOXM1 expression in breast" exact="cancer" post="specimens, in comparison to normal breast tissue [ 60]."/>
   <result pre="60]. Additionally, their work verified the overexpression of FOXM1 in" exact="breast cancer" post="on both the RNA and protein level. Francis et"/>
   <result pre="Additionally, their work verified the overexpression of FOXM1 in breast" exact="cancer" post="on both the RNA and protein level. Francis et"/>
   <result pre="be a downstream target and marker of HER2 overexpression in" exact="breast cancer." post="This study also had translational implications by showing a"/>
   <result pre="develop quickly and represents a challenge in the treatment of" exact="breast cancer." post="4.4. FOXM1, Basal-Like Breast Cancer (BBC), and Triple Negative"/>
   <result pre="Breast Cancer (BBC), and Triple Negative Breast Cancer (TNBC) Basal-like" exact="breast cancer" post="(BBC) is an aggressive phenotype of breast malignancies that"/>
   <result pre="Cancer (BBC), and Triple Negative Breast Cancer (TNBC) Basal-like breast" exact="cancer" post="(BBC) is an aggressive phenotype of breast malignancies that"/>
   <result pre="ER and PR. Although differences between these two types of" exact="breast cancer" post="have been demonstrated, BBC and TNBC overlap significantly ["/>
   <result pre="and PR. Although differences between these two types of breast" exact="cancer" post="have been demonstrated, BBC and TNBC overlap significantly ["/>
   <result pre="of effective therapy. Although TNBC accounts for only 15% of" exact="breast cancer" post="subtypes, it causes 25% of breast cancer-related deaths due"/>
   <result pre="effective therapy. Although TNBC accounts for only 15% of breast" exact="cancer" post="subtypes, it causes 25% of breast cancer-related deaths due"/>
   <result pre="that has been shown to be essential in EMT in" exact="breast cancer" post="[ 67]. Arora et al. incorporated these two concepts"/>
   <result pre="has been shown to be essential in EMT in breast" exact="cancer" post="[ 67]. Arora et al. incorporated these two concepts"/>
   <result pre="NF-kappaB inhibitor, halted proliferation, induced apoptosis, and reversed EMT in" exact="breast cancer," post="in particular TNBC. Interestingly, their work revealed a downregulatory"/>
   <result pre="Therapeutics Taking into consideration the significant role of FOXM1 in" exact="breast cancer" post="biology this transcription factor could become an attractive target"/>
   <result pre="Taking into consideration the significant role of FOXM1 in breast" exact="cancer" post="biology this transcription factor could become an attractive target"/>
   <result pre="biology this transcription factor could become an attractive target for" exact="cancer" post="treatment. Herein, we describe some breast cancer therapeutic strategies"/>
   <result pre="an attractive target for cancer treatment. Herein, we describe some" exact="breast cancer" post="therapeutic strategies targeting FOXM1. A FOXM1-specific small interfering RNA"/>
   <result pre="attractive target for cancer treatment. Herein, we describe some breast" exact="cancer" post="therapeutic strategies targeting FOXM1. A FOXM1-specific small interfering RNA"/>
   <result pre="expression of FOXM1 proteins in vivo [ 71]. Treatment of" exact="breast cancer" post="cells with adenoviral vector expressing short hairpin downregulating FOXM1"/>
   <result pre="of FOXM1 proteins in vivo [ 71]. Treatment of breast" exact="cancer" post="cells with adenoviral vector expressing short hairpin downregulating FOXM1"/>
   <result pre="vector expressing short hairpin downregulating FOXM1 led to inhibition of" exact="breast cancer" post="tumor formation [ 72]. Overexpression of microRNA miR802 led"/>
   <result pre="expressing short hairpin downregulating FOXM1 led to inhibition of breast" exact="cancer" post="tumor formation [ 72]. Overexpression of microRNA miR802 led"/>
   <result pre="miR802 led to downregulation of FOXM1 and inhibited proliferation of" exact="breast cancer" post="cells [ 73]. A thiazole ring containing thiostrepton, an"/>
   <result pre="led to downregulation of FOXM1 and inhibited proliferation of breast" exact="cancer" post="cells [ 73]. A thiazole ring containing thiostrepton, an"/>
   <result pre="[ 74], was shown to induce arrest and death of" exact="breast cancer" post="cells through downregulating FOXM1 expression [ 75]. As stated"/>
   <result pre="74], was shown to induce arrest and death of breast" exact="cancer" post="cells through downregulating FOXM1 expression [ 75]. As stated"/>
   <result pre="fruit of a traditional Chinese medicine, has anticarcinogenic activity in" exact="breast cancer" post="[ 77]. Recent experiments showed that it can induce"/>
   <result pre="of a traditional Chinese medicine, has anticarcinogenic activity in breast" exact="cancer" post="[ 77]. Recent experiments showed that it can induce"/>
   <result pre="77]. Recent experiments showed that it can induce apoptosis of" exact="breast cancer" post="cells by reducing the expression of FOXM1 [ 78]."/>
   <result pre="Recent experiments showed that it can induce apoptosis of breast" exact="cancer" post="cells by reducing the expression of FOXM1 [ 78]."/>
   <result pre="to play a critical role in development of resistance to" exact="breast cancer" post="therapeutics. FOXM1 is a downstream target of 14-3-3 ζ,"/>
   <result pre="play a critical role in development of resistance to breast" exact="cancer" post="therapeutics. FOXM1 is a downstream target of 14-3-3 ζ,"/>
   <result pre="of 14-3-3 ζ, a marker of endocrine therapy resistance in" exact="breast cancer" post="malignancy [ 79]. FOXM1 was found to contribute to"/>
   <result pre="14-3-3 ζ, a marker of endocrine therapy resistance in breast" exact="cancer" post="malignancy [ 79]. FOXM1 was found to contribute to"/>
   <result pre="found to contribute to cisplatin (a platinum agent) resistance in" exact="breast cancer" post="cells. The effect was thought to be mediated by"/>
   <result pre="to contribute to cisplatin (a platinum agent) resistance in breast" exact="cancer" post="cells. The effect was thought to be mediated by"/>
   <result pre="to these agents [ 81]. FOXM1 caused doxorubicin resistance in" exact="breast cancer" post="by enhancing DNA repair. The nuclear factor NF-kappa-B1 (NF"/>
   <result pre="these agents [ 81]. FOXM1 caused doxorubicin resistance in breast" exact="cancer" post="by enhancing DNA repair. The nuclear factor NF-kappa-B1 (NF"/>
   <result pre="interacted with FOXM1 in the presence of doxorubicin to protect" exact="breast cancer" post="cells from DNA damage [ 82]. Epirubicin could activate"/>
   <result pre="with FOXM1 in the presence of doxorubicin to protect breast" exact="cancer" post="cells from DNA damage [ 82]. Epirubicin could activate"/>
   <result pre="progression to metastatic stage, and development of resistance to subsequent" exact="cancer" post="therapy, and thus it could be an attractive target"/>
   <result pre="FOXM1 targeted agents are available, appropriate clinical testing in different" exact="breast cancer" post="subtypes is warranted, most likely in a biomarker-driven setting."/>
   <result pre="targeted agents are available, appropriate clinical testing in different breast" exact="cancer" post="subtypes is warranted, most likely in a biomarker-driven setting."/>
   <result pre="there is no clear biomarker developed to assess sensitivity of" exact="breast cancer" post="to FOXM1 inhibition. This could be a goal of"/>
   <result pre="is no clear biomarker developed to assess sensitivity of breast" exact="cancer" post="to FOXM1 inhibition. This could be a goal of"/>
   <result pre="goal of early pilot studies, especially in the most challenging" exact="breast cancer" post="subtype, triple negative disease. Acknowledgment The authors thank Pradip"/>
   <result pre="of early pilot studies, especially in the most challenging breast" exact="cancer" post="subtype, triple negative disease. Acknowledgment The authors thank Pradip"/>
   <result pre="factor stimulates the proliferation of tumor cells during development of" exact="lung cancer" post="Cancer Research 2006 66 4 2153 2161 10.1158/0008-5472.CAN-05-3003 16489016"/>
   <result pre="stimulates the proliferation of tumor cells during development of lung" exact="cancer" post="Cancer Research 2006 66 4 2153 2161 10.1158/0008-5472.CAN-05-3003 16489016"/>
   <result pre="transcription factor contributes to the development and growth of mouse" exact="colorectal cancer" post="Gastroenterology 2007 132 4 1420 1431 10.1053/j.gastro.2007.01.036 17408638 7"/>
   <result pre="factor contributes to the development and growth of mouse colorectal" exact="cancer" post="Gastroenterology 2007 132 4 1420 1431 10.1053/j.gastro.2007.01.036 17408638 7"/>
   <result pre="W.-F. The emerging roles of forkhead box (Fox) proteins in" exact="cancer" post="Nature Reviews Cancer 2007 7 11 847 859 10.1038/nrc2223"/>
   <result pre="12183437 26 Halasi M. Gartel A. L. FOX(M1) news—it is" exact="cancer" post="Molecular Cancer Therapeutics 2013 12 3 245 254 10.1158/1535-7163.mct-12-0712"/>
   <result pre="Medema R. H. FoxM1: at the crossroads of ageing and" exact="cancer" post="Biochimica et Biophysica Acta 2007 1775 1 92 102"/>
   <result pre="conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's" exact="lymphoma" post="Genes Chromosomes and Cancer 2011 50 5 313 326"/>
   <result pre="associated with aggressive phenotype and poor prognosis in estrogen receptor-positive" exact="breast cancer" post="Journal of Korean Medical Science 2015 30 4 390"/>
   <result pre="with aggressive phenotype and poor prognosis in estrogen receptor-positive breast" exact="cancer" post="Journal of Korean Medical Science 2015 30 4 390"/>
   <result pre="factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive" exact="breast cancer" post="by expansion of stem-like cancer cells Breast Cancer Research"/>
   <result pre="FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast" exact="cancer" post="by expansion of stem-like cancer cells Breast Cancer Research"/>
   <result pre="invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like" exact="cancer" post="cells Breast Cancer Research 2014 16 5 p. 436"/>
   <result pre="mesenchymal transition by stimulating the transcription of Slug in human" exact="breast cancer" post="Cancer Letters 2013 340 1 104 112 10.1016/j.canlet.2013.07.004 23856032"/>
   <result pre="transition by stimulating the transcription of Slug in human breast" exact="cancer" post="Cancer Letters 2013 340 1 104 112 10.1016/j.canlet.2013.07.004 23856032"/>
   <result pre="al. Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF- β-dependent" exact="cancer" post="metastasis The Journal of Clinical Investigation 2014 124 2"/>
   <result pre="down-regulation leads to inhibition of proliferation, migration and invasion of" exact="breast cancer" post="cells through the modulation of extra-cellular matrix degrading factors"/>
   <result pre="leads to inhibition of proliferation, migration and invasion of breast" exact="cancer" post="cells through the modulation of extra-cellular matrix degrading factors"/>
   <result pre="FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in" exact="breast cancer" post="Oncogene 2012 31 14 1845 1858 10.1038/onc.2011.368 21860419 42"/>
   <result pre="represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast" exact="cancer" post="Oncogene 2012 31 14 1845 1858 10.1038/onc.2011.368 21860419 42"/>
   <result pre="L. et al. FOXM1 targets XIAP and Survivin to modulate" exact="breast cancer" post="survival and chemoresistance Cellular Signalling 2015 27 12 2496"/>
   <result pre="et al. FOXM1 targets XIAP and Survivin to modulate breast" exact="cancer" post="survival and chemoresistance Cellular Signalling 2015 27 12 2496"/>
   <result pre="Page D. L. Weaver D. et al. Prognostic factors in" exact="breast cancer." post="College of American Pathologists Consensus Statement 1999 Archives of"/>
   <result pre="transcription factor FKHR after epidermal growth factor treatment in human" exact="breast cancer" post="cells Oncogene 2000 19 40 4574 4581 10.1038/sj.onc.1203825 11030146"/>
   <result pre="factor FKHR after epidermal growth factor treatment in human breast" exact="cancer" post="cells Oncogene 2000 19 40 4574 4581 10.1038/sj.onc.1203825 11030146"/>
   <result pre="protein regulates the transcription of the estrogen receptor α in" exact="breast cancer" post="cells The Journal of Biological Chemistry 2006 281 35"/>
   <result pre="regulates the transcription of the estrogen receptor α in breast" exact="cancer" post="cells The Journal of Biological Chemistry 2006 281 35"/>
   <result pre="by the estrogen receptor alpha at the protein level, in" exact="breast cancer" post="Hippokratia 2006 10 3 128 132 20351808 51 Paik"/>
   <result pre="the estrogen receptor alpha at the protein level, in breast" exact="cancer" post="Hippokratia 2006 10 3 128 132 20351808 51 Paik"/>
   <result pre="C.-J. et al. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent" exact="breast cancer" post="cell proliferation and tumorigenesis Breast Cancer Research 2008 10"/>
   <result pre="et al. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast" exact="cancer" post="cell proliferation and tumorigenesis Breast Cancer Research 2008 10"/>
   <result pre="target of ER α and has a critical role in" exact="breast cancer" post="endocrine sensitivity and resistance Oncogene 2010 29 20 2983"/>
   <result pre="of ER α and has a critical role in breast" exact="cancer" post="endocrine sensitivity and resistance Oncogene 2010 29 20 2983"/>
   <result pre="expression through targeting ER α to control cell proliferation in" exact="breast cancer" post="The American Journal of Pathology 2011 179 3 1148"/>
   <result pre="through targeting ER α to control cell proliferation in breast" exact="cancer" post="The American Journal of Pathology 2011 179 3 1148"/>
   <result pre="discrimination using a 70-gene signature among patients with estrogen receptor-positive" exact="breast cancer" post="and an intermediate 21-gene recurrence score International Journal of"/>
   <result pre="using a 70-gene signature among patients with estrogen receptor-positive breast" exact="cancer" post="and an intermediate 21-gene recurrence score International Journal of"/>
   <result pre="of FOXM1 binding reveals co-binding with estrogen receptor alpha in" exact="breast cancer" post="cells Genome Biology 2013 14 1, article R6 10.1186/gb-2013-14-1-r6"/>
   <result pre="FOXM1 binding reveals co-binding with estrogen receptor alpha in breast" exact="cancer" post="cells Genome Biology 2013 14 1, article R6 10.1186/gb-2013-14-1-r6"/>
   <result pre="of the Forkhead transcription factor FOXM1 and HER2 in human" exact="breast cancer" post="BMC Cancer 2008 8, article 42 10.1186/1471-2407-8-42 61 Francis"/>
   <result pre="the Forkhead transcription factor FOXM1 and HER2 in human breast" exact="cancer" post="BMC Cancer 2008 8, article 42 10.1186/1471-2407-8-42 61 Francis"/>
   <result pre="is a downstream target and marker of HER2 overexpression in" exact="breast cancer" post="International Journal of Oncology 2009 35 1 57 68"/>
   <result pre="a downstream target and marker of HER2 overexpression in breast" exact="cancer" post="International Journal of Oncology 2009 35 1 57 68"/>
   <result pre="Foulkes W. D. Smith I. E. Reis-Filho J. S. Triple-negative" exact="breast cancer" post="The New England Journal of Medicine 2010 363 20"/>
   <result pre="W. D. Smith I. E. Reis-Filho J. S. Triple-negative breast" exact="cancer" post="The New England Journal of Medicine 2010 363 20"/>
   <result pre="Y.-J. An J. Lee Y. Kim A. Epithelial-mesenchymal transition in" exact="breast cancer" post="correlates with high histological grade and triple-negative phenotype Histopathology"/>
   <result pre="An J. Lee Y. Kim A. Epithelial-mesenchymal transition in breast" exact="cancer" post="correlates with high histological grade and triple-negative phenotype Histopathology"/>
   <result pre="essential for epithelial-mesenchymal transition and metastasis in a model of" exact="breast cancer" post="progression The Journal of Clinical Investigation 2004 114 4"/>
   <result pre="for epithelial-mesenchymal transition and metastasis in a model of breast" exact="cancer" post="progression The Journal of Clinical Investigation 2004 114 4"/>
   <result pre="proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in" exact="breast cancer" post="PLoS ONE 2014 9 6 10.1371/journal.pone.0098370 69 Craig D."/>
   <result pre="induce apoptosis and reverse epithelial to mesenchymal transition in breast" exact="cancer" post="PLoS ONE 2014 9 6 10.1371/journal.pone.0098370 69 Craig D."/>
   <result pre="et al. Genome and transcriptome sequencing in prospective metastatic triple-negative" exact="breast cancer" post="uncovers therapeutic vulnerabilities Molecular Cancer Therapeutics 2013 12 1"/>
   <result pre="al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast" exact="cancer" post="uncovers therapeutic vulnerabilities Molecular Cancer Therapeutics 2013 12 1"/>
   <result pre="is an oncogenic kinase essential for mitotic progression in basal-like" exact="breast cancer" post="cells eLife 2014 3 10.7554/elife.01763 71 Wang M. Gartel"/>
   <result pre="an oncogenic kinase essential for mitotic progression in basal-like breast" exact="cancer" post="cells eLife 2014 3 10.7554/elife.01763 71 Wang M. Gartel"/>
   <result pre="2014 3 10.7554/elife.01763 71 Wang M. Gartel A. L. The" exact="suppression" post="of FOXM1 and its targets in breast cancer xenograft"/>
   <result pre="A. L. The suppression of FOXM1 and its targets in" exact="breast cancer" post="xenograft tumors by siRNA Oncotarget 2011 2 12 1218"/>
   <result pre="L. The suppression of FOXM1 and its targets in breast" exact="cancer" post="xenograft tumors by siRNA Oncotarget 2011 2 12 1218"/>
   <result pre="FOXM1 transcription factor suppresses cell proliferation and tumor growth of" exact="breast cancer" post="Cancer Gene Therapy 2013 20 2 117 124 10.1038/cgt.2012.94"/>
   <result pre="transcription factor suppresses cell proliferation and tumor growth of breast" exact="cancer" post="Cancer Gene Therapy 2013 20 2 117 124 10.1038/cgt.2012.94"/>
   <result pre="124 10.1038/cgt.2012.94 23306612 73 Yuan F. Wang W. MicroRNA-802 suppresses" exact="breast cancer" post="proliferation through downregulation of FoxM1 Molecular Medicine Reports 2015"/>
   <result pre="10.1038/cgt.2012.94 23306612 73 Yuan F. Wang W. MicroRNA-802 suppresses breast" exact="cancer" post="proliferation through downregulation of FoxM1 Molecular Medicine Reports 2015"/>
   <result pre="R. C. Constantinidou D. Lam E. W.-F. Thiostrepton selectively targets" exact="breast cancer" post="cells through inhibition of forkhead box M1 expression Molecular"/>
   <result pre="C. Constantinidou D. Lam E. W.-F. Thiostrepton selectively targets breast" exact="cancer" post="cells through inhibition of forkhead box M1 expression Molecular"/>
   <result pre="on regulation of MiR-200 family and JNK1 in MCF7 human" exact="breast cancer" post="cells International Journal of Molecular Sciences 2014 15 6"/>
   <result pre="regulation of MiR-200 family and JNK1 in MCF7 human breast" exact="cancer" post="cells International Journal of Molecular Sciences 2014 15 6"/>
   <result pre="Liu F. Quan M.-F. Sheng X.-F. Ren K.-Q. Casticin induces" exact="breast cancer" post="cell apoptosis by inhibiting the expression of forkhead box"/>
   <result pre="F. Quan M.-F. Sheng X.-F. Ren K.-Q. Casticin induces breast" exact="cancer" post="cell apoptosis by inhibiting the expression of forkhead box"/>
   <result pre="L. J. et al. FOXM1 confers acquired cisplatin resistance in" exact="breast cancer" post="cells Molecular Cancer Research 2010 8 1 24 34"/>
   <result pre="J. et al. FOXM1 confers acquired cisplatin resistance in breast" exact="cancer" post="cells Molecular Cancer Research 2010 8 1 24 34"/>
   <result pre="Jennings N. B. et al. FOXM1 mediates Dox resistance in" exact="breast cancer" post="by enhancing DNA repair Carcinogenesis 2012 33 10 1843"/>
   <result pre="N. B. et al. FOXM1 mediates Dox resistance in breast" exact="cancer" post="by enhancing DNA repair Carcinogenesis 2012 33 10 1843"/>
   <result pre="al. ATM and p53 regulate FOXM1 expression via E2F in" exact="breast cancer" post="epirubicin treatment and resistance Molecular Cancer Therapeutics 2011 10"/>
   <result pre="ATM and p53 regulate FOXM1 expression via E2F in breast" exact="cancer" post="epirubicin treatment and resistance Molecular Cancer Therapeutics 2011 10"/>
   <result pre="Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and" exact="breast cancer" post="paclitaxel resistance Oncogene 2015 10.1038/onc.2015.152 87 Gartel A. L."/>
   <result pre="targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast" exact="cancer" post="paclitaxel resistance Oncogene 2015 10.1038/onc.2015.152 87 Gartel A. L."/>
   <result pre="FOXM1 ( ∗ ). Bcl-2: B-cell lymphoma/leukemia-2 protein; Bmi-1: B" exact="lymphoma" post="Mo-MLV insertion region 1 homolog; Cav-1: caveolin-1; CEP55: centrosomal"/>
   <result pre="2 Schematic diagram of the biological role of FOXM1 in" exact="breast cancer" post="tumorigenesis. Recent research has shown that the effects of"/>
   <result pre="Schematic diagram of the biological role of FOXM1 in breast" exact="cancer" post="tumorigenesis. Recent research has shown that the effects of"/>
   <result pre="Recent research has shown that the effects of FOXM1 on" exact="breast cancer" post="tumorigenesis are mediated by a number of diverse biological"/>
   <result pre="research has shown that the effects of FOXM1 on breast" exact="cancer" post="tumorigenesis are mediated by a number of diverse biological"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4754120/results/search/disease/results.xml">
   <result pre="Cancer Symposium (SABCS) annual meeting highlighted the latest discoveries in" exact="breast cancer" post="research and as ever provided a unique opportunity for"/>
   <result pre="Symposium (SABCS) annual meeting highlighted the latest discoveries in breast" exact="cancer" post="research and as ever provided a unique opportunity for"/>
   <result pre="clinical sciences, mainly because of the advent of new technologies," exact="cancer" post="researchers are making rapid progress that is having significant"/>
   <result pre="factor kappa-B ligand (RANKL) inhibitor as an adjuvant treatment for" exact="breast cancer" post="in postmenopausal women. In the educational session, there was"/>
   <result pre="kappa-B ligand (RANKL) inhibitor as an adjuvant treatment for breast" exact="cancer" post="in postmenopausal women. In the educational session, there was"/>
   <result pre="educational session, there was significant emphasis on the role of" exact="metabolic syndrome" post="and lifestyle on breast cancer outcome. SABCS breast cancer"/>
   <result pre="emphasis on the role of metabolic syndrome and lifestyle on" exact="breast cancer" post="outcome. SABCS breast cancer Metabolic Syndromes The ‘Metabolic Syndrome"/>
   <result pre="on the role of metabolic syndrome and lifestyle on breast" exact="cancer" post="outcome. SABCS breast cancer Metabolic Syndromes The ‘Metabolic Syndrome"/>
   <result pre="of metabolic syndrome and lifestyle on breast cancer outcome. SABCS" exact="breast cancer" post="Metabolic Syndromes The ‘Metabolic Syndrome and Obesity in Breast"/>
   <result pre="metabolic syndrome and lifestyle on breast cancer outcome. SABCS breast" exact="cancer" post="Metabolic Syndromes The ‘Metabolic Syndrome and Obesity in Breast"/>
   <result pre="Douglas Yee who discussed the various metabolic pathways involved in" exact="breast cancer" post="progression and the potential to target key components of"/>
   <result pre="Yee who discussed the various metabolic pathways involved in breast" exact="cancer" post="progression and the potential to target key components of"/>
   <result pre="levels of insulin and insulin like growth factors (IGFs) increase" exact="breast cancer" post="risk and poor outcome in patients. This has led"/>
   <result pre="of insulin and insulin like growth factors (IGFs) increase breast" exact="cancer" post="risk and poor outcome in patients. This has led"/>
   <result pre="the development of therapies that target the IGF receptor for" exact="breast cancer." post="In contrast to receptor targeting strategies, the inhibition of"/>
   <result pre="signaling pathways such as mTORC1 have been successful in HR-positive" exact="breast cancer." post="In the same session, Dr Mantzoros discussed recent insights"/>
   <result pre="Mantzoros discussed recent insights into the role of adiponectin in" exact="breast cancer" post="especially the potential link between adiponectin and breast carcinoma."/>
   <result pre="discussed recent insights into the role of adiponectin in breast" exact="cancer" post="especially the potential link between adiponectin and breast carcinoma."/>
   <result pre="be one of the key factors in the connection between" exact="obesity" post="and breast cancer. Pamela Goodwin discussed the potential use"/>
   <result pre="of the key factors in the connection between obesity and" exact="breast cancer." post="Pamela Goodwin discussed the potential use of metformin to"/>
   <result pre="Pamela Goodwin discussed the potential use of metformin to improve" exact="breast cancer" post="outcomes. Obesity is associated with increased risk of breast"/>
   <result pre="Goodwin discussed the potential use of metformin to improve breast" exact="cancer" post="outcomes. Obesity is associated with increased risk of breast"/>
   <result pre="breast cancer outcomes. Obesity is associated with increased risk of" exact="breast cancer" post="in premenopausal triple-negative breast cancer (TNBC) and postmenopausal mainly"/>
   <result pre="cancer outcomes. Obesity is associated with increased risk of breast" exact="cancer" post="in premenopausal triple-negative breast cancer (TNBC) and postmenopausal mainly"/>
   <result pre="associated with increased risk of breast cancer in premenopausal triple-negative" exact="breast cancer" post="(TNBC) and postmenopausal mainly oestrogen receptor positive (ER+). Metformin,"/>
   <result pre="with increased risk of breast cancer in premenopausal triple-negative breast" exact="cancer" post="(TNBC) and postmenopausal mainly oestrogen receptor positive (ER+). Metformin,"/>
   <result pre="used to treat type-2 diabetes, has been associated with lower" exact="breast cancer" post="risk and improved outcomes in observational studies. Dr Goodwin"/>
   <result pre="to treat type-2 diabetes, has been associated with lower breast" exact="cancer" post="risk and improved outcomes in observational studies. Dr Goodwin"/>
   <result pre="set up to examine the impact of metformin in early" exact="breast cancer" post="survivors. Subjects were randomly assigned to metformin or a"/>
   <result pre="up to examine the impact of metformin in early breast" exact="cancer" post="survivors. Subjects were randomly assigned to metformin or a"/>
   <result pre="2014 doi:10.1093/annonc/mdu385 - ESO-ESMO 2nd international consensus guidelines for advanced" exact="breast cancer" post="(ABC2)† F Cardoso et al): All ABC patients should"/>
   <result pre="doi:10.1093/annonc/mdu385 - ESO-ESMO 2nd international consensus guidelines for advanced breast" exact="cancer" post="(ABC2)† F Cardoso et al): All ABC patients should"/>
   <result pre="Endocrine therapy is a well-tolerated treatment for hormone receptor-positive (HR+)" exact="breast cancer" post="and is offered as first-line treatment to patients with"/>
   <result pre="therapy is a well-tolerated treatment for hormone receptor-positive (HR+) breast" exact="cancer" post="and is offered as first-line treatment to patients with"/>
   <result pre="therapies has been tested in various ongoing trials. Within HR+" exact="breast cancer," post="there is molecular diversity that can influence responsiveness to"/>
   <result pre="have uncovered potential mechanisms of endocrine therapy resistance in HR+" exact="breast cancer" post="leading to new treatment options. These include the cell"/>
   <result pre="uncovered potential mechanisms of endocrine therapy resistance in HR+ breast" exact="cancer" post="leading to new treatment options. These include the cell"/>
   <result pre="understand which patients will benefit from which sequence/combination. In advanced" exact="breast cancer," post="there still remains controversies and variations in practice for"/>
   <result pre="arm in the first-line treatment of women with HER-2 metastatic" exact="breast cancer." post="There was also a significant improvement in the progression-free"/>
   <result pre="III EMILIA study evaluated T-DM1 in patients with HER-2-positive metastatic" exact="breast cancer" post="who had previously received Herceptin and a taxane-based chemotherapy."/>
   <result pre="EMILIA study evaluated T-DM1 in patients with HER-2-positive metastatic breast" exact="cancer" post="who had previously received Herceptin and a taxane-based chemotherapy."/>
   <result pre="provided convincing evidence that TDM-1 is efficacious in refractory metastatic" exact="breast cancer" post="and provides clinicians with an effective new treatment in"/>
   <result pre="convincing evidence that TDM-1 is efficacious in refractory metastatic breast" exact="cancer" post="and provides clinicians with an effective new treatment in"/>
   <result pre="that T-DM1 improved OS for heavily pretreated patients with HER-2-positive" exact="breast cancer." post="All the patients enrolled in TH3RESA had been previously"/>
   <result pre="survival in heavily pretreated patients. This is significant as many" exact="breast cancer" post="therapies increase progression-free survival but not overall survival’, continued"/>
   <result pre="in heavily pretreated patients. This is significant as many breast" exact="cancer" post="therapies increase progression-free survival but not overall survival’, continued"/>
   <result pre="oestrogen receptor are more common in patients with advanced, ER+" exact="breast cancer" post="and they result in the cells becoming independent of"/>
   <result pre="receptor are more common in patients with advanced, ER+ breast" exact="cancer" post="and they result in the cells becoming independent of"/>
   <result pre="for healthy women who may be at risk of developing" exact="breast cancer" post="is still an open question. Early Breast Cancer The"/>
   <result pre="healthy women who may be at risk of developing breast" exact="cancer" post="is still an open question. Early Breast Cancer The"/>
   <result pre="trial examining adjuvant denosumab (Xgeva, Amgen) as a treatment for" exact="breast cancer" post="was presented by Michael Gnant, MD, from the Medical"/>
   <result pre="examining adjuvant denosumab (Xgeva, Amgen) as a treatment for breast" exact="cancer" post="was presented by Michael Gnant, MD, from the Medical"/>
   <result pre="adjuvant AI therapy in 3000-plus postmenopausal women with early-stage hormone-receptor-positive" exact="breast cancer." post="Denosumab is approved as a treatment to increase bone"/>
   <result pre="is approved as a treatment to increase bone mass in" exact="breast cancer" post="patients receiving endocrine therapy who are at high risk"/>
   <result pre="approved as a treatment to increase bone mass in breast" exact="cancer" post="patients receiving endocrine therapy who are at high risk"/>
   <result pre="denosumab increased DFS in AI-treated postmenopausal women with early HR+" exact="breast cancer" post="[Hazard ratio (ITT): 0.82 (95% CI (confidence interval): 0.66–1.00;"/>
   <result pre="increased DFS in AI-treated postmenopausal women with early HR+ breast" exact="cancer" post="[Hazard ratio (ITT): 0.82 (95% CI (confidence interval): 0.66–1.00;"/>
   <result pre="denosumab should be made available to postmenopausal patients with HR+" exact="breast cancer" post="on AIs. Dr Gnant explained that there is already"/>
   <result pre="should be made available to postmenopausal patients with HR+ breast" exact="cancer" post="on AIs. Dr Gnant explained that there is already"/>
   <result pre="the bone marrow micro-environment may reduce the chance of dormant" exact="cancer" post="cells of waking up’. Patients with residual disease after"/>
   <result pre="presented by Dr Toi, found that capecitabine improved outcomes for" exact="breast cancer" post="patients with residual disease after neoadjuvant chemotherapy. After two"/>
   <result pre="by Dr Toi, found that capecitabine improved outcomes for breast" exact="cancer" post="patients with residual disease after neoadjuvant chemotherapy. After two"/>
   <result pre="combination) looked at disease recurrence in postmenopausal women with ductal" exact="carcinoma in situ" post="(DCIS) treated with either tamoxifen or the AI anastrozole."/>
   <result pre="as if not better than mastectomy for patients with early" exact="breast cancer." post="Data was collected from a study which compared the"/>
   <result pre="with mastectomy (without radiation therapy) in women with early stage" exact="breast cancer." post="By analysing data from the Netherlands Cancer Registry (37,207"/>
   <result pre="data from the Netherlands Cancer Registry (37,207 women with early" exact="breast cancer" post="between 2000 and 2004 to estimate ten-year OS, and"/>
   <result pre="from the Netherlands Cancer Registry (37,207 women with early breast" exact="cancer" post="between 2000 and 2004 to estimate ten-year OS, and"/>
   <result pre="should be the treatment of choice, especially in T1N0 stage" exact="breast cancer" post="when it is medically feasible and according to the"/>
   <result pre="be the treatment of choice, especially in T1N0 stage breast" exact="cancer" post="when it is medically feasible and according to the"/>
   <result pre="in the shared decision-making process and improve the quality of" exact="breast cancer" post="care. In the early breast cancer setting, the Multidisciplinary"/>
   <result pre="the shared decision-making process and improve the quality of breast" exact="cancer" post="care. In the early breast cancer setting, the Multidisciplinary"/>
   <result pre="improve the quality of breast cancer care. In the early" exact="breast cancer" post="setting, the Multidisciplinary Approach to Novel Therapies in Cardiology"/>
   <result pre="the quality of breast cancer care. In the early breast" exact="cancer" post="setting, the Multidisciplinary Approach to Novel Therapies in Cardiology"/>
   <result pre="mentioned. This is a study for patients with HER-2-positve early-stage" exact="breast cancer." post="It is the first randomised controlled study to evaluate"/>
   <result pre="Prophylactic beta blockade preserves left ventricular ejection fraction in HER-2-overexpresssing" exact="breast cancer" post="patients receiving trastuzumab: Primary results of the MANTICORE randomised"/>
   <result pre="beta blockade preserves left ventricular ejection fraction in HER-2-overexpresssing breast" exact="cancer" post="patients receiving trastuzumab: Primary results of the MANTICORE randomised"/>
   <result pre="prognostic. Next generation sequencing has redefined the landscape of primary" exact="breast cancer" post="subtypes into many molecularly defined subgroups and now the"/>
   <result pre="Next generation sequencing has redefined the landscape of primary breast" exact="cancer" post="subtypes into many molecularly defined subgroups and now the"/>
   <result pre="cancers will be important. To date at least ten primary" exact="breast cancer" post="subtypes exist. In breast cancer 40 mutational drivers have"/>
   <result pre="will be important. To date at least ten primary breast" exact="cancer" post="subtypes exist. In breast cancer 40 mutational drivers have"/>
   <result pre="date at least ten primary breast cancer subtypes exist. In" exact="breast cancer" post="40 mutational drivers have been identified. These mutations segregate"/>
   <result pre="at least ten primary breast cancer subtypes exist. In breast" exact="cancer" post="40 mutational drivers have been identified. These mutations segregate"/>
   <result pre="tumour histological subtype i.e. ER+, TNBC, etc. Apart from interpatient" exact="breast cancer" post="heterogeneity it is accepted that most tumours are made"/>
   <result pre="histological subtype i.e. ER+, TNBC, etc. Apart from interpatient breast" exact="cancer" post="heterogeneity it is accepted that most tumours are made"/>
   <result pre="The evolution of the clonal composition has particular significance for" exact="cancer" post="medicine. Over the last five years next generation sequencing"/>
   <result pre="So far, TILs have not been investigated in invasive lobular" exact="breast cancer" post="(ILBC). The group of Dr Desmedt therefore decided to"/>
   <result pre="far, TILs have not been investigated in invasive lobular breast" exact="cancer" post="(ILBC). The group of Dr Desmedt therefore decided to"/>
   <result pre="said her laboratory uses a systems biology approach to study" exact="breast cancer" post="using high-dimensional data in integrated approaches. She discussed data"/>
   <result pre="her laboratory uses a systems biology approach to study breast" exact="cancer" post="using high-dimensional data in integrated approaches. She discussed data"/>
   <result pre="integrated approaches. She discussed data indicating that intratumour heterogeneity in" exact="breast cancer" post="arises in response to neoadjuvant therapy. This heterogeneity probably"/>
   <result pre="approaches. She discussed data indicating that intratumour heterogeneity in breast" exact="cancer" post="arises in response to neoadjuvant therapy. This heterogeneity probably"/>
   <result pre="resistance to chemotherapy and stratification is important to better understand" exact="breast cancer." post="Data from the phase III DBCG77B clinical trial, presented"/>
   <result pre="demonstrated that premenopausal women with the luminal A subtype of" exact="breast cancer" post="had comparable ten-year DFS rates regardless of whether or"/>
   <result pre="that premenopausal women with the luminal A subtype of breast" exact="cancer" post="had comparable ten-year DFS rates regardless of whether or"/>
   <result pre="adjuvant chemotherapy. Luminal A is a relatively common subtype of" exact="breast cancer," post="with high expression of the oestrogen (ER) and progesterone"/>
   <result pre="and 1983, 1146 premenopausal women who had lymph node-positive invasive" exact="breast cancer" post="that was larger than 5 cm were randomised to"/>
   <result pre="1983, 1146 premenopausal women who had lymph node-positive invasive breast" exact="cancer" post="that was larger than 5 cm were randomised to"/>
   <result pre="phase II CALGB/Alliance 40603 clinical trial indicated that patients with" exact="cancer" post="TNBC who had a pathologic complete response (pCR) after"/>
   <result pre="are of prognostic relevance in early as well as metastatic" exact="breast cancer." post="Persisting CTCs immediately after chemotherapy are known to indicate"/>
   <result pre="implicated increased levels of the enzyme APOBEC3B in oestrogen receptor–positive" exact="breast cancer" post="with poor patient outcomes. Dr Rueben Harris wanted to"/>
   <result pre="increased levels of the enzyme APOBEC3B in oestrogen receptor–positive breast" exact="cancer" post="with poor patient outcomes. Dr Rueben Harris wanted to"/>
   <result pre="APOBEC3B levels in tumours samples from patients with recurrent ER+" exact="breast cancer." post="They found that patients with high levels of APOBEC3B"/>
   <result pre="mutations in these genes have been implicated in cancer. In" exact="breast cancer," post="they have been associated with various molecular subtypes, prognosis,"/>
   <result pre="inhibitor. Dr Finn explained that pre-clinical studies identified that ER+" exact="breast cancer" post="models were most sensitive to growth inhibition with palbociclib"/>
   <result pre="Dr Finn explained that pre-clinical studies identified that ER+ breast" exact="cancer" post="models were most sensitive to growth inhibition with palbociclib"/>
   <result pre="inhibiting proliferation in combination with tamoxifen [ 1]. Sensitive ER+" exact="breast cancer" post="cell lines treated with the combination went into senescence."/>
   <result pre="proliferation in combination with tamoxifen [ 1]. Sensitive ER+ breast" exact="cancer" post="cell lines treated with the combination went into senescence."/>
   <result pre="plus letrozole as first line therapy for advanced postmenopausal ER+" exact="breast cancer." post="In more advanced settings a benefit was seen in"/>
   <result pre="there are several other CDK 4/6 inhibitors in development in" exact="breast cancer" post="and other malignancies including abemaciclib (LY2835219, EliLilly) and ribociclib"/>
   <result pre="are several other CDK 4/6 inhibitors in development in breast" exact="cancer" post="and other malignancies including abemaciclib (LY2835219, EliLilly) and ribociclib"/>
   <result pre="therapeutic targets in the reactivation of the immune response against" exact="cancer" post=". Avelumab an anti-PD-L1 antibody was tested in a"/>
   <result pre="in a cohort of patients with locally advanced or metastatic" exact="breast cancer" post="refractory to or progressing after standard-of-care therapy. The main"/>
   <result pre="a cohort of patients with locally advanced or metastatic breast" exact="cancer" post="refractory to or progressing after standard-of-care therapy. The main"/>
   <result pre="clinical response to Avelumab. Immunotherapy is a promising tool for" exact="breast cancer" post="clinicians and over the next few years there will"/>
   <result pre="response to Avelumab. Immunotherapy is a promising tool for breast" exact="cancer" post="clinicians and over the next few years there will"/>
   <result pre="the use of genome sequencing to identify driver mutations in" exact="breast cancer" post="was held on the final day of this year’s"/>
   <result pre="use of genome sequencing to identify driver mutations in breast" exact="cancer" post="was held on the final day of this year’s"/>
   <result pre="4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human" exact="breast cancer" post="cell lines in vitro Breast Cancer Res 2005 11"/>
   <result pre="inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast" exact="cancer" post="cell lines in vitro Breast Cancer Res 2005 11"/>
   <result pre="letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced" exact="breast cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2015"/>
   <result pre="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast" exact="cancer" post="(PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2015"/>
   <result pre="10.1016/S1470-2045(14)71159-3 25524798 3. Turner et al. Palbociclib in hormone-receptor–positive advanced" exact="breast cancer" post="N Engl J Med 2015 373 3 209 19"/>
   <result pre="25524798 3. Turner et al. Palbociclib in hormone-receptor–positive advanced breast" exact="cancer" post="N Engl J Med 2015 373 3 209 19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4758093/results/search/disease/results.xml">
   <result pre="otherwise stated. Abstract Background Vinorelbine constitutes effective chemotherapy for metastatic" exact="breast cancer" post="(MBC) and acts synergistically with trastuzumab in HER-2/ neu"/>
   <result pre="stated. Abstract Background Vinorelbine constitutes effective chemotherapy for metastatic breast" exact="cancer" post="(MBC) and acts synergistically with trastuzumab in HER-2/ neu"/>
   <result pre="events (AE) were grade 1 and 2 in severity with" exact="diarrhea" post="being the most commonly observed AE Conclusion In this"/>
   <result pre="Metastatic Breast Cancer HER-2/ neu Lapatinib Vinorelbine Chemotherapy Background Breast" exact="cancer" post="is a heterogeneous disease encompassing distinct biological subtypes with"/>
   <result pre="histories. The human epidermal growth factor receptor-2 (HER-2/ neu) positive" exact="breast cancer" post="subtype accounts for 10–15 % of all breast cancer"/>
   <result pre="The human epidermal growth factor receptor-2 (HER-2/ neu) positive breast" exact="cancer" post="subtype accounts for 10–15 % of all breast cancer"/>
   <result pre="positive breast cancer subtype accounts for 10–15 % of all" exact="breast cancer" post="cases. In the pre-trastuzumab-era, early-stage HER-2/ neu positive disease"/>
   <result pre="breast cancer subtype accounts for 10–15 % of all breast" exact="cancer" post="cases. In the pre-trastuzumab-era, early-stage HER-2/ neu positive disease"/>
   <result pre="neu positive disease had the second poorest prognosis after triple-negative" exact="breast cancer" post="[ 1] thus leading to an accumulation of HER-2/"/>
   <result pre="positive disease had the second poorest prognosis after triple-negative breast" exact="cancer" post="[ 1] thus leading to an accumulation of HER-2/"/>
   <result pre="prolonged disease control [ 9– 11]. In HER-2/ neu positive" exact="breast cancer," post="a prolongation of PFS by the continuation of trastuzumab"/>
   <result pre="multiple-lines; TML) [ 12]. Vinorelbine constitutes effective chemotherapy for metastatic" exact="breast cancer" post="(MBC) and acts synergistically with trastuzumab in HER-2/ neu"/>
   <result pre="TML) [ 12]. Vinorelbine constitutes effective chemotherapy for metastatic breast" exact="cancer" post="(MBC) and acts synergistically with trastuzumab in HER-2/ neu"/>
   <result pre="investigational agents, females pregnant or lactating, and those with a" exact="peripheral neuropathy" post="of grade 2 or greater were also excluded. Any"/>
   <result pre="agents, females pregnant or lactating, and those with a peripheral" exact="neuropathy" post="of grade 2 or greater were also excluded. Any"/>
   <result pre="profiles. Three serious adverse events have been reported (humerus fracture," exact="pulmonary embolism" post="and hypertension), all of them were considered unrelated to"/>
   <result pre="0 (0) 0 (0) 4 (3.4) Discussion Treatment of metastatic" exact="cancer" post="is characterized by the onset of treatment resistance, which"/>
   <result pre="knowledge to the field or therapy of HER2/ neu metastatic" exact="breast cancer." post="Conclusion The present study was set out to evaluate"/>
   <result pre="with HER-2/ neu- positive MBC. In this heavily pretreated patient" exact="breast cancer" post="population, combination of vinorelbine plus lapatinib showed encouraging activity"/>
   <result pre="HER-2/ neu- positive MBC. In this heavily pretreated patient breast" exact="cancer" post="population, combination of vinorelbine plus lapatinib showed encouraging activity"/>
   <result pre="plus vinorelbine in the treatment of patients with ErbB2-positive metastatic" exact="breast cancer" post="pretreated with anti-HER2 therapy Ann Oncol 2013 24 1"/>
   <result pre="vinorelbine in the treatment of patients with ErbB2-positive metastatic breast" exact="cancer" post="pretreated with anti-HER2 therapy Ann Oncol 2013 24 1"/>
   <result pre="Age/race differences in HER2 testing and in incidence rates for" exact="breast cancer" post="triple subtypes: a population-based study and first report Cancer"/>
   <result pre="differences in HER2 testing and in incidence rates for breast" exact="cancer" post="triple subtypes: a population-based study and first report Cancer"/>
   <result pre="of trastuzumab with chemotherapeutic drugs used in the treatment of" exact="breast cancer" post="J Natl Cancer Inst 2004 96 10 739 749"/>
   <result pre="trastuzumab with chemotherapeutic drugs used in the treatment of breast" exact="cancer" post="J Natl Cancer Inst 2004 96 10 739 749"/>
   <result pre="activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic" exact="breast cancer" post="J Clin Oncol 2001 19 10 2722 2730 11352965"/>
   <result pre="of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast" exact="cancer" post="J Clin Oncol 2001 19 10 2722 2730 11352965"/>
   <result pre="Zielinski CC Optimal strategies for the treatment of metastatic triple-negative" exact="breast cancer" post="with currently approved agents Ann Oncol 2012 23 Suppl"/>
   <result pre="CC Optimal strategies for the treatment of metastatic triple-negative breast" exact="cancer" post="with currently approved agents Ann Oncol 2012 23 Suppl"/>
   <result pre="S et al. Third consensus on medical treatment of metastatic" exact="breast cancer" post="Ann Oncol 2009 20 11 1771 1785 10.1093/annonc/mdp261 19608616"/>
   <result pre="et al. Third consensus on medical treatment of metastatic breast" exact="cancer" post="Ann Oncol 2009 20 11 1771 1785 10.1093/annonc/mdp261 19608616"/>
   <result pre="KL et al. ESO-ESMO 2nd international consensus guidelines for advanced" exact="breast cancer" post="(ABC2)dagger Ann Oncol 2014 25 10 1871 1888 10.1093/annonc/mdu385"/>
   <result pre="et al. ESO-ESMO 2nd international consensus guidelines for advanced breast" exact="cancer" post="(ABC2)dagger Ann Oncol 2014 25 10 1871 1888 10.1093/annonc/mdu385"/>
   <result pre="lapatinib and vinorelbine in women with previously treated HER2-positive metastatic" exact="breast cancer" post="Asia Pac J Clin Oncol 2014 10 4 368"/>
   <result pre="and vinorelbine in women with previously treated HER2-positive metastatic breast" exact="cancer" post="Asia Pac J Clin Oncol 2014 10 4 368"/>
   <result pre="of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2014 143 3 493 505"/>
   <result pre="lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2014 143 3 493 505"/>
   <result pre="A et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="V Guardino E et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="Guardino E et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="Kaufman B et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="B et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="lapatinib plus vinorelbine in patients with locally advanced or metastatic" exact="breast cancer" post="overexpressing HER2 Br J Cancer 2012 106 4 673"/>
   <result pre="plus vinorelbine in patients with locally advanced or metastatic breast" exact="cancer" post="overexpressing HER2 Br J Cancer 2012 106 4 673"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4758788/results/search/disease/results.xml">
   <result pre="Expression profile analysis of long noncoding RNA in HER-2-enriched subtype" exact="breast cancer" post="by next-generation sequencing and bioinformatics Yang Fan Lyu Shixu"/>
   <result pre="profile analysis of long noncoding RNA in HER-2-enriched subtype breast" exact="cancer" post="by next-generation sequencing and bioinformatics Yang Fan Lyu Shixu"/>
   <result pre="Background Human epidermal growth factor receptor 2 ( HER-2)-enriched subtype" exact="breast cancer" post="is associated with a more aggressive phenotype and shorter"/>
   <result pre="Human epidermal growth factor receptor 2 ( HER-2)-enriched subtype breast" exact="cancer" post="is associated with a more aggressive phenotype and shorter"/>
   <result pre="essential roles in tumorigenesis and occupy a central place in" exact="cancer" post="progression. Notably, few studies have focused on the dysregulation"/>
   <result pre="focused on the dysregulation of LncRNAs in the HER-2-enriched subtype" exact="breast cancer." post="In this study, we analyzed the expression profile of"/>
   <result pre="profile of LncRNAs and mRNAs in this particular subtype of" exact="breast cancer." post="Methods Seven pairs of HER-2-enriched subtype breast cancer and"/>
   <result pre="subtype of breast cancer. Methods Seven pairs of HER-2-enriched subtype" exact="breast cancer" post="and normal tissue were sequenced. We screened out differently"/>
   <result pre="of breast cancer. Methods Seven pairs of HER-2-enriched subtype breast" exact="cancer" post="and normal tissue were sequenced. We screened out differently"/>
   <result pre="regulation of actin cytoskeleton were highly related with HER-2-enriched subtype" exact="breast cancer." post="Coexpression network recognized LINC00636, LINC01405, ADARB2-AS1, ST8SIA6-AS1, LINC00511, and"/>
   <result pre="candidate therapeutic targets and new molecular biomarkers for HER-2-enriched subtype" exact="breast cancer." post="Keywords ncRNA breast cancer gene ontology pathway analysis coexpression"/>
   <result pre="new molecular biomarkers for HER-2-enriched subtype breast cancer. Keywords ncRNA" exact="breast cancer" post="gene ontology pathway analysis coexpression network Background Breast cancer,"/>
   <result pre="molecular biomarkers for HER-2-enriched subtype breast cancer. Keywords ncRNA breast" exact="cancer" post="gene ontology pathway analysis coexpression network Background Breast cancer,"/>
   <result pre="and/or amplification with a lack of hormone receptor. HER-2-enriched subtype" exact="breast cancer" post="is associated with a more aggressive phenotype and shorter"/>
   <result pre="amplification with a lack of hormone receptor. HER-2-enriched subtype breast" exact="cancer" post="is associated with a more aggressive phenotype and shorter"/>
   <result pre="underlying molecular mechanisms of the malignant phenotype of HER-2-enriched subtype" exact="breast cancer" post="need to be elucidated, and new therapeutic targets need"/>
   <result pre="molecular mechanisms of the malignant phenotype of HER-2-enriched subtype breast" exact="cancer" post="need to be elucidated, and new therapeutic targets need"/>
   <result pre="essential roles in tumorigenesis and occupied a central place in" exact="cancer" post="progression. 8, 9 Notably, few studies have focused on"/>
   <result pre="focused on the dysregulation of LncRNAs in the HER-2-enriched subtype" exact="breast cancer." post="In this study, we sequenced the expression profile of"/>
   <result pre="profile of LncRNAs and messenger RNAs (mRNAs) in HER-2-enriched subtype" exact="breast cancer" post="samples and adjacent nontumorous tissue. More than 1,300 LncRNAs"/>
   <result pre="of LncRNAs and messenger RNAs (mRNAs) in HER-2-enriched subtype breast" exact="cancer" post="samples and adjacent nontumorous tissue. More than 1,300 LncRNAs"/>
   <result pre="illustrated the pathways occupying a central place in HER-2-enriched subtype" exact="breast cancer." post="Coexpression network revealed several LncRNAs having important regulation and"/>
   <result pre="candidate therapeutic targets and new molecular biomarkers for HER-2-enriched subtype" exact="breast cancer." post="Materials and methods Patient samples Written informed consent was"/>
   <result pre="Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China. Seven" exact="breast cancer" post="patients who received modified radical mastectomy were included in"/>
   <result pre="Medical University, Wenzhou, Zhejiang, People’s Republic of China. Seven breast" exact="cancer" post="patients who received modified radical mastectomy were included in"/>
   <result pre="in this study. All patients were diagnosed with HER-2-enriched subtype" exact="breast cancer" post="by pathology and immunohistochemistry (IHC) after surgery. IHC results"/>
   <result pre="this study. All patients were diagnosed with HER-2-enriched subtype breast" exact="cancer" post="by pathology and immunohistochemistry (IHC) after surgery. IHC results"/>
   <result pre="receptor and progesterone receptor were regarded as having HER-2-enriched subtype" exact="breast cancer." post="Primary breast cancer tissues and their adjacent normal breast"/>
   <result pre="receptor were regarded as having HER-2-enriched subtype breast cancer. Primary" exact="breast cancer" post="tissues and their adjacent normal breast tissues were snap-freezed"/>
   <result pre="were regarded as having HER-2-enriched subtype breast cancer. Primary breast" exact="cancer" post="tissues and their adjacent normal breast tissues were snap-freezed"/>
   <result pre="analysis between the differently expressed LncRNAs and mRNAs associated with" exact="cancer" post="was constructed. 13 LncRNAs and mRNAs with Pearson’s correlation"/>
   <result pre="samples. Results LncRNAs and mRNAs expression profiles in HER-2-enriched subtype" exact="breast cancer" post="Volcano plot was used for assessing gene expression variation"/>
   <result pre="Results LncRNAs and mRNAs expression profiles in HER-2-enriched subtype breast" exact="cancer" post="Volcano plot was used for assessing gene expression variation"/>
   <result pre="used for assessing gene expression variation between the HER-2-enriched subtype" exact="breast cancer" post="and adjacent normal tissue ( Figure 1A). Genes with"/>
   <result pre="for assessing gene expression variation between the HER-2-enriched subtype breast" exact="cancer" post="and adjacent normal tissue ( Figure 1A). Genes with"/>
   <result pre="the expression of LncRNAs and mRNAs in the HER-2-enriched subtype" exact="breast cancer" post="samples ( Figure 1D and E). The most dysregulated"/>
   <result pre="expression of LncRNAs and mRNAs in the HER-2-enriched subtype breast" exact="cancer" post="samples ( Figure 1D and E). The most dysregulated"/>
   <result pre="illustrate the key pathways in the process of HER-2-enriched subtype" exact="breast cancer" post="( Figure 3). Our finding indicated that the MAPK"/>
   <result pre="the key pathways in the process of HER-2-enriched subtype breast" exact="cancer" post="( Figure 3). Our finding indicated that the MAPK"/>
   <result pre="Coexpression network Coexpression network was constructed for HER-2 enriched subtype" exact="breast cancer" post="group and adjacent normal tissue group, using expressed LncRNAs"/>
   <result pre="network Coexpression network was constructed for HER-2 enriched subtype breast" exact="cancer" post="group and adjacent normal tissue group, using expressed LncRNAs"/>
   <result pre="Then, Shen et al 22 researched LncRNAs’ expression in triple-negative" exact="breast cancer" post="and found that a lot of LncRNAs were differently"/>
   <result pre="Shen et al 22 researched LncRNAs’ expression in triple-negative breast" exact="cancer" post="and found that a lot of LncRNAs were differently"/>
   <result pre="found that a lot of LncRNAs were differently expressed. Breast" exact="cancer" post="is a molecularly heterogeneous disease, and so LncRNAs’ expression"/>
   <result pre="first comprehensive description of differentially expressed LncRNAs in HER-2-enriched subtype" exact="breast cancer." post="We sequenced seven pairs of HER-2-enriched subtype breast cancer"/>
   <result pre="subtype breast cancer. We sequenced seven pairs of HER-2-enriched subtype" exact="breast cancer" post="and normal tissue and found significantly differently expressed genes."/>
   <result pre="breast cancer. We sequenced seven pairs of HER-2-enriched subtype breast" exact="cancer" post="and normal tissue and found significantly differently expressed genes."/>
   <result pre="regulation of actin cytoskeleton were highly related with HER-2-enriched subtype" exact="breast cancer." post="It has been reported that MAPK signaling pathway could"/>
   <result pre="Agents targeting the PI3K-Akt pathway could restore sensitivity to standard" exact="breast cancer" post="therapies, including endocrine, HER-2-targeted agents, and chemotherapy. 24 Guerram"/>
   <result pre="targeting the PI3K-Akt pathway could restore sensitivity to standard breast" exact="cancer" post="therapies, including endocrine, HER-2-targeted agents, and chemotherapy. 24 Guerram"/>
   <result pre="targeting inhibited apoptotic and metabolic signaling pathways could lead to" exact="cancer" post="cell death, especially in HER-2-overexpressed breast cancer. It was"/>
   <result pre="pathways could lead to cancer cell death, especially in HER-2-overexpressed" exact="breast cancer." post="It was also pointed out that suppressed actin cytoskeleton"/>
   <result pre="out that suppressed actin cytoskeleton pathway inhibited cell motility in" exact="breast cancer." post="26 These reports are consistent with our finding that"/>
   <result pre="network showed six LncRNAs as core genes in HER-2-enriched subtype" exact="breast cancer." post="Except for LINC00511 (also known as onco-LncRNA-12), there is"/>
   <result pre="the other LncRNAs. LINC00511 was reported to be upregulated in" exact="breast cancer" post="and led to lung cancer cell growth decrease when"/>
   <result pre="other LncRNAs. LINC00511 was reported to be upregulated in breast" exact="cancer" post="and led to lung cancer cell growth decrease when"/>
   <result pre="reported to be upregulated in breast cancer and led to" exact="lung cancer" post="cell growth decrease when LINC00511 was knocked down. 27"/>
   <result pre="to be upregulated in breast cancer and led to lung" exact="cancer" post="cell growth decrease when LINC00511 was knocked down. 27"/>
   <result pre="Limitations Our study still has several limitations. For one thing," exact="breast cancer" post="is a highly heterogeneous disease while our sample size"/>
   <result pre="Our study still has several limitations. For one thing, breast" exact="cancer" post="is a highly heterogeneous disease while our sample size"/>
   <result pre="might not represent robust LncRNAs expression signature in HER-2-enriched subtype" exact="breast cancer." post="Another limitation is that the functions of these core"/>
   <result pre="expression profiles were sequenced and analyze in HER-2 enriched subtype" exact="breast cancer" post="in this study. These results analyze the functions of"/>
   <result pre="profiles were sequenced and analyze in HER-2 enriched subtype breast" exact="cancer" post="in this study. These results analyze the functions of"/>
   <result pre="therapeutic targets and new molecular biomarkers for HER-2 enriched subtype" exact="breast cancer." post="Acknowledgments This study was funded by Key Project of"/>
   <result pre="the management of brain metastases in patients with HER2-positive metastatic" exact="breast cancer" post="Breast Cancer Res Treat 2013 137 1 1 12"/>
   <result pre="management of brain metastases in patients with HER2-positive metastatic breast" exact="cancer" post="Breast Cancer Res Treat 2013 137 1 1 12"/>
   <result pre="MM Krop IE The evolving landscape of HER2 targeting in" exact="breast cancer" post="JAMA Oncol 2015 1 8 1154 1161 26204261 7"/>
   <result pre="Krop IE The evolving landscape of HER2 targeting in breast" exact="cancer" post="JAMA Oncol 2015 1 8 1154 1161 26204261 7"/>
   <result pre="al. Long non-coding RNA HOTAIR reprograms chromatin state to promote" exact="cancer" post="metastasis Nature 2010 464 7291 1071 1076 20393566 9"/>
   <result pre="Long noncoding RNA GAS5 suppresses the migration and invasion of" exact="hepatocellular carcinoma" post="cells via miR-21 Tumour Biol Epub 2015 9 24"/>
   <result pre="al. CASC15-S is a tumor suppressor lncRNA at the 6p22" exact="neuroblastoma" post="susceptibility locus Cancer Res 2015 75 15 3155 3166"/>
   <result pre="Lee AK Cardo-Vila M et al. PRUNE2 is a human" exact="prostate cancer" post="suppressor regulated by the intronic long noncoding RNA PCA3"/>
   <result pre="AK Cardo-Vila M et al. PRUNE2 is a human prostate" exact="cancer" post="suppressor regulated by the intronic long noncoding RNA PCA3"/>
   <result pre="promotes cell proliferation and survival by activating MAPK signaling in" exact="hepatocellular carcinoma" post="Oncotarget 2015 6 32 33791 33804 26393879 19 Li"/>
   <result pre="RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in" exact="hepatocellular carcinoma" post="Oncogene Epub 2015 6 15 10.1038/onc.2015.223 20 Li T"/>
   <result pre="al. Amplification of long noncoding RNA ZFAS1 promotes metastasis in" exact="hepatocellular carcinoma" post="Cancer Res 2015 75 15 3181 3191 26069248 21"/>
   <result pre="et al. Identification of novel long non-coding RNAs in triple-negative" exact="breast cancer" post="Oncotarget 2015 6 25 21730 21739 26078338 23 Adeyinka"/>
   <result pre="al. Identification of novel long non-coding RNAs in triple-negative breast" exact="cancer" post="Oncotarget 2015 6 25 21730 21739 26078338 23 Adeyinka"/>
   <result pre="Activated mitogen-activated protein kinase expression during human breast tumorigenesis and" exact="breast cancer" post="progression Clin Cancer Res 2002 8 6 1747 1753"/>
   <result pre="mitogen-activated protein kinase expression during human breast tumorigenesis and breast" exact="cancer" post="progression Clin Cancer Res 2002 8 6 1747 1753"/>
   <result pre="Abraham J PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for" exact="breast cancer" post="therapies? Expert Rev Anticancer Ther 2015 15 1 51"/>
   <result pre="J PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast" exact="cancer" post="therapies? Expert Rev Anticancer Ther 2015 15 1 51"/>
   <result pre="IIA in the treatment of HER2-overexpressed breast cancer: induction of" exact="cancer" post="cell death by targeting apoptotic and metabolic signaling pathways"/>
   <result pre="by regulating the genes in the actin cytoskeleton pathway in" exact="breast cancer" post="Mol Cancer Res 2013 11 3 240 250 23339187"/>
   <result pre="regulating the genes in the actin cytoskeleton pathway in breast" exact="cancer" post="Mol Cancer Res 2013 11 3 240 250 23339187"/>
   <result pre="and mRNAs that are significantly differently expressed in HER-2-enriched subtype" exact="breast cancer" post="(FC &amp;gt;2 and FDR &amp;lt;0.05), the blue points represent"/>
   <result pre="mRNAs that are significantly differently expressed in HER-2-enriched subtype breast" exact="cancer" post="(FC &amp;gt;2 and FDR &amp;lt;0.05), the blue points represent"/>
   <result pre="according to RNA sequencing in seven pairs of HER-2-enriched subtype" exact="breast cancer." post="( D, E) Differentially expressed LncRNAs and mRNAs in"/>
   <result pre="highest k-core-scoring hub. ( C) Core LncRNAs in HER-2-enriched subtype" exact="breast cancer" post="are listed by the difference k-core scoring between tumor"/>
   <result pre="k-core-scoring hub. ( C) Core LncRNAs in HER-2-enriched subtype breast" exact="cancer" post="are listed by the difference k-core scoring between tumor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4759568/results/search/disease/results.xml">
   <result pre="conserved gene-gene relationships derived from gene co-expression network analysis on" exact="breast cancer" post="data Bourdakou Marilena M. 1 2 Athanasiadis Emmanouil I."/>
   <result pre="gene-gene relationships derived from gene co-expression network analysis on breast" exact="cancer" post="data Bourdakou Marilena M. 1 2 Athanasiadis Emmanouil I."/>
   <result pre="of statistical co-expression networks to highlight and prioritize genes for" exact="breast cancer" post="subtypes and stages in terms of: (i) classification efficiency,"/>
   <result pre="statistical co-expression networks to highlight and prioritize genes for breast" exact="cancer" post="subtypes and stages in terms of: (i) classification efficiency,"/>
   <result pre="drug discovery pipelines from a systems point of view. Breast" exact="cancer" post="is a major public health problem, since it remains"/>
   <result pre="public health problem, since it remains the most frequently diagnosed" exact="cancer" post="and ranked second as a cause of death in"/>
   <result pre="been made to avoid the disease 1. This happens because" exact="breast cancer" post="is a complex disease with many contributing factors affecting"/>
   <result pre="made to avoid the disease 1. This happens because breast" exact="cancer" post="is a complex disease with many contributing factors affecting"/>
   <result pre="studies have been conducted, neither the exact etiology of the" exact="breast cancer," post="nor the mechanisms behind the heterogeneity from patient to"/>
   <result pre="are known. For this, the diagnosis and the treatment of" exact="breast cancer" post="remain a both challenging and fascinating task 2. With"/>
   <result pre="known. For this, the diagnosis and the treatment of breast" exact="cancer" post="remain a both challenging and fascinating task 2. With"/>
   <result pre="many bioinformatics data analysis pipelines have been developed to identify" exact="breast cancer" post="related genes and discover gene signatures for prognosis and"/>
   <result pre="bioinformatics data analysis pipelines have been developed to identify breast" exact="cancer" post="related genes and discover gene signatures for prognosis and"/>
   <result pre="discover gene signatures for prognosis and treatment prediction. However, since" exact="breast cancer" post="is a complex disease, it should be determined not"/>
   <result pre="gene signatures for prognosis and treatment prediction. However, since breast" exact="cancer" post="is a complex disease, it should be determined not"/>
   <result pre="networks to highlight and prioritize significant genes at four different" exact="breast cancer" post="molecular subtypes, including Luminal A, Luminal B, HER2 and"/>
   <result pre="to highlight and prioritize significant genes at four different breast" exact="cancer" post="molecular subtypes, including Luminal A, Luminal B, HER2 and"/>
   <result pre="TCGA data as training set and a number of Breast" exact="cancer" post="datasets from the transcriptional data repository Gene Expression Omnibus"/>
   <result pre="in all networks. With the proposed pipeline, we concluded to" exact="breast cancer" post="specific network patterns per subtype and stage. Analyzing each"/>
   <result pre="all networks. With the proposed pipeline, we concluded to breast" exact="cancer" post="specific network patterns per subtype and stage. Analyzing each"/>
   <result pre="Interestingly, all the derived network patterns include genes found in" exact="breast cancer" post="specific regions of significant somatic copy number alterations (SCNA)"/>
   <result pre="all the derived network patterns include genes found in breast" exact="cancer" post="specific regions of significant somatic copy number alterations (SCNA)"/>
   <result pre="repurposing pipeline, revealing drugs that have the potential to suppress" exact="breast cancer" post="specifically for each molecular subtype and stage of the"/>
   <result pre="pipeline, revealing drugs that have the potential to suppress breast" exact="cancer" post="specifically for each molecular subtype and stage of the"/>
   <result pre="first 100 genes (see Methods). The maximum average score for" exact="breast cancer" post="stages ( Table 1) and subtypes ( Table 2)"/>
   <result pre="100 genes (see Methods). The maximum average score for breast" exact="cancer" post="stages ( Table 1) and subtypes ( Table 2)"/>
   <result pre="Finally we concluded in the common pattern across all the" exact="breast cancer" post="stages ( Fig. 6). We repeated the same procedure"/>
   <result pre="we concluded in the common pattern across all the breast" exact="cancer" post="stages ( Fig. 6). We repeated the same procedure"/>
   <result pre="( Fig. 6). We repeated the same procedure for the" exact="breast cancer" post="subtypes for all possible pair combinations ( Fig. 7)."/>
   <result pre="Fig. 6). We repeated the same procedure for the breast" exact="cancer" post="subtypes for all possible pair combinations ( Fig. 7)."/>
   <result pre="has been reported to inhibit tumor growth and angiogenesis in" exact="cancer" post="cells 19, while suggesting the development of PPAR agonists"/>
   <result pre="in acute and chronic inflammation and has been associated with" exact="cancer" post="progression 20. It also plays an etiologic role in"/>
   <result pre="an etiologic role in the development of cognitive difficulties in" exact="breast cancer" post="patients. For the case of SPP1 (Stage IV), metastasis-associated"/>
   <result pre="etiologic role in the development of cognitive difficulties in breast" exact="cancer" post="patients. For the case of SPP1 (Stage IV), metastasis-associated"/>
   <result pre="caused by metastatic spread from the primary tumor in human" exact="breast cancer" post="21. We have also revealed three common pathways found"/>
   <result pre="by metastatic spread from the primary tumor in human breast" exact="cancer" post="21. We have also revealed three common pathways found"/>
   <result pre="aforementioned pathways was recently proposed as a potential biomarker of" exact="breast cancer" post="22. For the case of Luminal A, Luminal B,"/>
   <result pre="pathways was recently proposed as a potential biomarker of breast" exact="cancer" post="22. For the case of Luminal A, Luminal B,"/>
   <result pre="glycerolipid metabolism, fatty acid metabolism, complement and coagulation cascades and" exact="bladder cancer" post="for HER2 and small cell lung cancer and metabolism"/>
   <result pre="metabolism, fatty acid metabolism, complement and coagulation cascades and bladder" exact="cancer" post="for HER2 and small cell lung cancer and metabolism"/>
   <result pre="coagulation cascades and bladder cancer for HER2 and small cell" exact="lung cancer" post="and metabolism of xenobiotics by cytochrome p450 for TN."/>
   <result pre="cascades and bladder cancer for HER2 and small cell lung" exact="cancer" post="and metabolism of xenobiotics by cytochrome p450 for TN."/>
   <result pre="be overexpressed in the majority of TN breast and HER2-enriched" exact="cancer" post="carcinomas, while in cases of Luminal A and B"/>
   <result pre="investigate their contribution regarding the discovery of potential drugs for" exact="breast cancer" post="subtypes and stages. Actually, genes that constitute the common"/>
   <result pre="their contribution regarding the discovery of potential drugs for breast" exact="cancer" post="subtypes and stages. Actually, genes that constitute the common"/>
   <result pre="20 drug list from LINCS with 25 known FDA-approved Breast" exact="cancer" post="therapeutic drugs ( http://www.cancer.gov/about-cancer/treatment/drugs/breast - Drugs Used to Treat"/>
   <result pre="drug list from LINCS and the 25 known FDA-approved Breast" exact="cancer" post="therapeutic drugs ( Supplementary Figs 54–61). LINCS Drug Names"/>
   <result pre="Supplementary Table 1) In synopsis, the unique drugs for the" exact="breast cancer" post="stages were 63 and for the breast cancer subtypes"/>
   <result pre="Table 1) In synopsis, the unique drugs for the breast" exact="cancer" post="stages were 63 and for the breast cancer subtypes"/>
   <result pre="for the breast cancer stages were 63 and for the" exact="breast cancer" post="subtypes 58, as we have located common drugs across"/>
   <result pre="the breast cancer stages were 63 and for the breast" exact="cancer" post="subtypes 58, as we have located common drugs across"/>
   <result pre="included in the list of the 25 known FDA-approved Breast" exact="cancer" post="therapeutic drugs. We performed a Hypergeometric distribution test in"/>
   <result pre="from 20,413 chemical reagents. Twenty two out of twenty five" exact="breast cancer" post="drugs are also included in LINCS database. Finally, from"/>
   <result pre="20,413 chemical reagents. Twenty two out of twenty five breast" exact="cancer" post="drugs are also included in LINCS database. Finally, from"/>
   <result pre="drugs extracted from our analysis with the 25 FDA approved" exact="breast cancer" post="drugs, with their target genes and finally with the"/>
   <result pre="extracted from our analysis with the 25 FDA approved breast" exact="cancer" post="drugs, with their target genes and finally with the"/>
   <result pre="to outline small paths that are of great importance in" exact="breast cancer" post="stages and subtypes. Each network consists of four sub-networks,"/>
   <result pre="outline small paths that are of great importance in breast" exact="cancer" post="stages and subtypes. Each network consists of four sub-networks,"/>
   <result pre="from LINCS and the green cycles the 25 FDA Breast" exact="cancer" post="Drugs. Edges between the two cycles represent their structural"/>
   <result pre="Fig. 8, one drug out of 25 FDA approved Breast" exact="cancer" post="drugs, Gemcitabine, was proposed as repurposed drug by the"/>
   <result pre="Gemcitabine, was proposed as repurposed drug by the LINCS for" exact="breast cancer" post="stage I. Furthermore, Gemcitabine is quite similar (tanimoto 31"/>
   <result pre="was proposed as repurposed drug by the LINCS for breast" exact="cancer" post="stage I. Furthermore, Gemcitabine is quite similar (tanimoto 31"/>
   <result pre="has been used to study differentiation and apoptosis processes in" exact="myeloid leukemia" post="cells, plant tumor cells (crown-gall) and other cancers. Moreover,"/>
   <result pre="been used to study differentiation and apoptosis processes in myeloid" exact="leukemia" post="cells, plant tumor cells (crown-gall) and other cancers. Moreover,"/>
   <result pre="interact with three genes (ATF3, FOS and EGR1) of the" exact="breast cancer" post="stage I network pattern ( Fig. 9). As shown"/>
   <result pre="with three genes (ATF3, FOS and EGR1) of the breast" exact="cancer" post="stage I network pattern ( Fig. 9). As shown"/>
   <result pre="Fig. 10, one drug out of 25 FDA approved Breast" exact="cancer" post="drugs, Palbociclib, was found as repurposed drug from LINCS"/>
   <result pre="drugs, Palbociclib, was found as repurposed drug from LINCS for" exact="breast cancer" post="stage II. Gemcitabine (Breast cancer drug) has quite similar"/>
   <result pre="Palbociclib, was found as repurposed drug from LINCS for breast" exact="cancer" post="stage II. Gemcitabine (Breast cancer drug) has quite similar"/>
   <result pre="drug from LINCS for breast cancer stage II. Gemcitabine (Breast" exact="cancer" post="drug) has quite similar structure (greater than 70%) with"/>
   <result pre="has quite similar structure (greater than 70%) with Capecitabine (Breast" exact="cancer" post="drug) and Cladribine (repurposed drug from LINCS) which is"/>
   <result pre="tumor cell proliferation. As shown in Fig. 11, Megestrol (Breast" exact="cancer" post="drug) has quite similar structure (greater than 70%) with"/>
   <result pre="as mTOR which is also target gene of Everolimus Breast" exact="cancer" post="drug. Finally, the gene (FOS) from the breast cancer"/>
   <result pre="Everolimus Breast cancer drug. Finally, the gene (FOS) from the" exact="breast cancer" post="stage II pattern, physically interacts with JUN, a target"/>
   <result pre="Breast cancer drug. Finally, the gene (FOS) from the breast" exact="cancer" post="stage II pattern, physically interacts with JUN, a target"/>
   <result pre="physically interacts with JUN, a target gene of Vinblastine Breast" exact="cancer" post="drug and with NR3C1, a target gene of Megestrol"/>
   <result pre="drug and with NR3C1, a target gene of Megestrol Breast" exact="cancer" post="drug ( Fig. 11). As shown in Fig. 12,"/>
   <result pre="Fig. 12, one drug out of 25 FDA approved Breast" exact="cancer" post="drugs, Gemcitabine, was found as repurposed drug from LINCS"/>
   <result pre="drugs, Gemcitabine, was found as repurposed drug from LINCS for" exact="breast cancer" post="stage III. Letrozole (Breast cancer drug) has similar structure"/>
   <result pre="Gemcitabine, was found as repurposed drug from LINCS for breast" exact="cancer" post="stage III. Letrozole (Breast cancer drug) has similar structure"/>
   <result pre="drug from LINCS for breast cancer stage III. Letrozole (Breast" exact="cancer" post="drug) has similar structure (greater than 60%) with Ruxolitinib"/>
   <result pre="LINCS) a drug for the treatment of intermediate or high-risk" exact="myelofibrosis" post="( Fig. 13). Furthermore, Pyrvinium-pamoate (repurposed drug from LINCS)"/>
   <result pre="to be greater than 60% structurally similar with Vinblastine (Breast" exact="cancer" post="drug). Pyrvinium-pamoate (PP) is an FDA-approved antihelmintic drug that"/>
   <result pre="FDA-approved antihelmintic drug that inhibits WNT signaling. Four genes from" exact="breast cancer" post="stage III network pattern (KRT8, KRT17, KRT18 and HOXC10)"/>
   <result pre="antihelmintic drug that inhibits WNT signaling. Four genes from breast" exact="cancer" post="stage III network pattern (KRT8, KRT17, KRT18 and HOXC10)"/>
   <result pre="physically interact with EGFR, a target gene of Lapatinib Breast" exact="cancer" post="drug which is quite similar (greater than 50%) to"/>
   <result pre="60%) with 6-(1,3-Benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine (repurposed small molecule from LINCS). As in" exact="breast cancer" post="stages I and III one drug out of 25"/>
   <result pre="with 6-(1,3-Benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine (repurposed small molecule from LINCS). As in breast" exact="cancer" post="stages I and III one drug out of 25"/>
   <result pre="and III one drug out of 25 FDA approved Breast" exact="cancer" post="drugs – Gemcitabine – was found as repurposed drug"/>
   <result pre="Gemcitabine – was found as repurposed drug from LINCS for" exact="breast cancer" post="stage IV ( Fig. 14). A repurposed drug from"/>
   <result pre="– was found as repurposed drug from LINCS for breast" exact="cancer" post="stage IV ( Fig. 14). A repurposed drug from"/>
   <result pre="found to be structurally similar with Everolimus and Vinblastine Breast" exact="cancer" post="drugs (greater than 70%). On the other hand, as"/>
   <result pre="a chemotherapy drug and it is used to treat bowel" exact="cancer" post="and it is also topoisomerase I inhibitor ( Fig."/>
   <result pre="LINCS) has greater than 60% similar structure with Eribulin Breast" exact="cancer" post="drug. Selamectin is a topical parasiticide and antihelminthic used"/>
   <result pre="Negative pattern. TOP2A is a target gene of two Breast" exact="cancer" post="drugs (Epirubicin and Doxorubicin) and of two repurposed drugs"/>
   <result pre="17). TYMS is also a target gene of three Breast" exact="cancer" post="drugs (Fluorouracil, Gemcitabine and Capecitabine) and physically interacts with"/>
   <result pre="Fig. 18 two drugs out of 25 FDA approved Breast" exact="cancer" post="drugs – Gemcitabine and Palbociclib – were also found"/>
   <result pre="– were also found as repurposed drugs from LINCS for" exact="breast cancer" post="Luminal A ( Fig. 18). Two genes from the"/>
   <result pre="were also found as repurposed drugs from LINCS for breast" exact="cancer" post="Luminal A ( Fig. 18). Two genes from the"/>
   <result pre="(HDAC) and it is used to treat cutaneous T cell" exact="lymphoma" post="(CTCL). Furthermore, HIST1H2BL from the Luminal A pattern physically"/>
   <result pre="was quite structurally similar (greater than 70%) to Gemcitabine Breast" exact="cancer" post="drug and Tunicamycin (greater than 60%), which is a"/>
   <result pre="EGFR with ERBB2 are target genes of Lapatinib - Breast" exact="cancer" post="drug ( Fig. 21). Moreover, Benzamide (repurposed drug from"/>
   <result pre="to be structurally similar (greater than 70%) to Vinblastine (Breast" exact="cancer" post="drug). Benzamide is an off-white solid and it is"/>
   <result pre="LINCS) has similar structure (more than 60%) with Palbociclib Breast" exact="cancer" post="drug ( Fig. 21). ZM-241385 is an antagonist ligand"/>
   <result pre="and CENPA and is a target gene of three Breast" exact="cancer" post="drugs (Fluorouracil, Capecitabine and Gemcitabine). Gemcitabine, as previously described,"/>
   <result pre="Capecitabine and Gemcitabine). Gemcitabine, as previously described, is a Breast" exact="cancer" post="drug that was also found as a repurposed drug"/>
   <result pre="of white blood cells. Furthermore, Palbociclib is also a Breast" exact="cancer" post="drug that was found from the drug repurposing analysis"/>
   <result pre="structurally similar to Dasatinib (more than 60%), which is a" exact="cancer" post="drug used to treat acute lymphoblastic leukemia. Discussion In"/>
   <result pre="than 60%), which is a cancer drug used to treat" exact="acute lymphoblastic leukemia." post="Discussion In the present work, we used eleven network"/>
   <result pre="60%), which is a cancer drug used to treat acute" exact="lymphoblastic leukemia." post="Discussion In the present work, we used eleven network"/>
   <result pre="in identifying significant genes and gene-gene links related to different" exact="breast cancer" post="stages and subtypes. During this assessment, we demonstrated that"/>
   <result pre="identifying significant genes and gene-gene links related to different breast" exact="cancer" post="stages and subtypes. During this assessment, we demonstrated that"/>
   <result pre="During this assessment, we demonstrated that in most cases of" exact="breast cancer" post="stages and subtypes, the statistical co-expression networks produce either"/>
   <result pre="this assessment, we demonstrated that in most cases of breast" exact="cancer" post="stages and subtypes, the statistical co-expression networks produce either"/>
   <result pre="genes (in terms of maximum classification accuracy achieved) for each" exact="breast cancer" post="stage and subtype than the conventional statistical approach or"/>
   <result pre="(in terms of maximum classification accuracy achieved) for each breast" exact="cancer" post="stage and subtype than the conventional statistical approach or"/>
   <result pre="dominance of statistical networks is profound in the analysis of" exact="breast cancer" post="subtypes, whereas in the case of stage analysis, the"/>
   <result pre="of statistical networks is profound in the analysis of breast" exact="cancer" post="subtypes, whereas in the case of stage analysis, the"/>
   <result pre="pathway has been reported as a possible important predictor of" exact="breast cancer" post="response to neoadjuvant chemotherapy 34. Five dehydrogenase (ADH) isoenzymes"/>
   <result pre="has been reported as a possible important predictor of breast" exact="cancer" post="response to neoadjuvant chemotherapy 34. Five dehydrogenase (ADH) isoenzymes"/>
   <result pre="dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenases (ALDH) genes from the" exact="breast cancer" post="Stage III network pattern were involved in the glycolysis"/>
   <result pre="(ADH) isoenzymes and aldehyde dehydrogenases (ALDH) genes from the breast" exact="cancer" post="Stage III network pattern were involved in the glycolysis"/>
   <result pre="gluconeogenesis pathway. It has been reported that patients with advanced" exact="breast cancer" post="had changes in the activity of ADH isoenzymes and"/>
   <result pre="pathway. It has been reported that patients with advanced breast" exact="cancer" post="had changes in the activity of ADH isoenzymes and"/>
   <result pre="activity of ADH isoenzymes and ALDH 35. Furthermore, from the" exact="breast cancer" post="Stage IV pattern, we have found an exclusive pathway"/>
   <result pre="of ADH isoenzymes and ALDH 35. Furthermore, from the breast" exact="cancer" post="Stage IV pattern, we have found an exclusive pathway"/>
   <result pre="in vivo tumor cell growth 36. For the case of" exact="breast cancer" post="subtypes, we have found seven exclusive subtype-related pathways, including"/>
   <result pre="vivo tumor cell growth 36. For the case of breast" exact="cancer" post="subtypes, we have found seven exclusive subtype-related pathways, including"/>
   <result pre="glycerolipid metabolism, fatty acid metabolism, complement and coagulation cascades and" exact="bladder cancer" post="for HER2 and small cell lung cancer and metabolism"/>
   <result pre="metabolism, fatty acid metabolism, complement and coagulation cascades and bladder" exact="cancer" post="for HER2 and small cell lung cancer and metabolism"/>
   <result pre="coagulation cascades and bladder cancer for HER2 and small cell" exact="lung cancer" post="and metabolism of xenobiotics by cytochrome p450 for Triple"/>
   <result pre="cascades and bladder cancer for HER2 and small cell lung" exact="cancer" post="and metabolism of xenobiotics by cytochrome p450 for Triple"/>
   <result pre="prognosis and may be a novel therapeutic target in HER2-overexpressing" exact="breast cancer" post="cells 38. Moreover, from the Triple Negative pattern we"/>
   <result pre="and may be a novel therapeutic target in HER2-overexpressing breast" exact="cancer" post="cells 38. Moreover, from the Triple Negative pattern we"/>
   <result pre="p450 pathway. Cytochromes P450 (CYPs) play a pivotal role in" exact="cancer" post="formation and cancer treatment as they participate in the"/>
   <result pre="P450 (CYPs) play a pivotal role in cancer formation and" exact="cancer" post="treatment as they participate in the inactivation and activation"/>
   <result pre="Furthermore, all the derived network patterns include genes found in" exact="breast cancer" post="specific regions of significant somatic copy number alterations (SCNA)"/>
   <result pre="all the derived network patterns include genes found in breast" exact="cancer" post="specific regions of significant somatic copy number alterations (SCNA)"/>
   <result pre="16. These results are fully aligned to the up-to-date recognized" exact="cancer" post="hallmarks related to cell growth, metabolism, immune system, inflammation"/>
   <result pre="reposition pipeline, so as to propose potential anticancer drugs for" exact="breast cancer" post="stages and subtypes. Based on this analysis, we have"/>
   <result pre="pipeline, so as to propose potential anticancer drugs for breast" exact="cancer" post="stages and subtypes. Based on this analysis, we have"/>
   <result pre="analysis, we have concluded to 63 potential unique drugs for" exact="breast cancer" post="stages and 58 for breast cancer subtypes. In order"/>
   <result pre="we have concluded to 63 potential unique drugs for breast" exact="cancer" post="stages and 58 for breast cancer subtypes. In order"/>
   <result pre="potential unique drugs for breast cancer stages and 58 for" exact="breast cancer" post="subtypes. In order to elucidate potential anti-breast cancer properties"/>
   <result pre="unique drugs for breast cancer stages and 58 for breast" exact="cancer" post="subtypes. In order to elucidate potential anti-breast cancer properties"/>
   <result pre="for breast cancer subtypes. In order to elucidate potential anti-breast" exact="cancer" post="properties of these drugs, we compared their molecular structure"/>
   <result pre="inhibit the progression of many cancers, including prostate, colon and" exact="breast cancer." post="One study found that carcinogen-induced mammary tumors in mice"/>
   <result pre="drug from LINCS) has been found similar with Vinblastine Breast" exact="cancer" post="drug and Idarubicin with Doxorubicin and Epirubicin respectively. Sepantronium"/>
   <result pre="(survivin inhibitor YM155) has been investigated as potential drug of" exact="breast cancer" post="subtypes 42. Finally, Idarubicin was also investigated for its"/>
   <result pre="inhibitor YM155) has been investigated as potential drug of breast" exact="cancer" post="subtypes 42. Finally, Idarubicin was also investigated for its"/>
   <result pre="Idarubicin was also investigated for its mechanism of action in" exact="breast cancer" post="and it has been reported that is effective in"/>
   <result pre="was also investigated for its mechanism of action in breast" exact="cancer" post="and it has been reported that is effective in"/>
   <result pre="and it has been reported that is effective in elderly" exact="breast cancer" post="patients 43. For Stage II, Cladribine (repurposed drug) was"/>
   <result pre="it has been reported that is effective in elderly breast" exact="cancer" post="patients 43. For Stage II, Cladribine (repurposed drug) was"/>
   <result pre="similar with Triciribine (repurposed drug) and Gemcitabine and Capecitabine Breast" exact="cancer" post="drugs. In clinical trial (June, 2015) triciribine phosphate, combined"/>
   <result pre="cyclophosphamide, used as a treatment to patients with stage IIB-IV" exact="breast cancer" post="( https://clinicaltrials.gov). Moreover, Wortmannin (repurposed drug) was found structurally"/>
   <result pre="used as a treatment to patients with stage IIB-IV breast" exact="cancer" post="( https://clinicaltrials.gov). Moreover, Wortmannin (repurposed drug) was found structurally"/>
   <result pre="have been found structurally similar with Letrozole and Vinblastine Breast" exact="cancer" post="drugs respectively. An ongoing clinical trial (October, 2015) has"/>
   <result pre="women with advanced (Stage III) or metastatic (Stage IV) HER2-negative" exact="breast cancer" post="who received treatment with Capecitabine in combination with Ruxolitinib"/>
   <result pre="with advanced (Stage III) or metastatic (Stage IV) HER2-negative breast" exact="cancer" post="who received treatment with Capecitabine in combination with Ruxolitinib"/>
   <result pre="Pyrvinium-pamoate is reported to be a potential drug for aggressive" exact="breast cancer" post="46. Finally, in Stage IV, Homoharringtonine (repurposed drug) was"/>
   <result pre="is reported to be a potential drug for aggressive breast" exact="cancer" post="46. Finally, in Stage IV, Homoharringtonine (repurposed drug) was"/>
   <result pre="found to be structurally similar with Everolimus and Vinblastine Breast" exact="cancer" post="drugs, and Irinotecan (repurposed drug) with Vinblastine Breast cancer"/>
   <result pre="Breast cancer drugs, and Irinotecan (repurposed drug) with Vinblastine Breast" exact="cancer" post="drug and Quizartinib repurposed small molecule. Irinotecan has been"/>
   <result pre="to find its objective response rate in patients with metastatic" exact="breast cancer" post="(Stage IV) ( https://clinicaltrials.gov). In case of repurposed drugs"/>
   <result pre="find its objective response rate in patients with metastatic breast" exact="cancer" post="(Stage IV) ( https://clinicaltrials.gov). In case of repurposed drugs"/>
   <result pre="(Stage IV) ( https://clinicaltrials.gov). In case of repurposed drugs for" exact="breast cancer" post="subtypes, we have found that Etoposide and Teniposide (repurposed"/>
   <result pre="IV) ( https://clinicaltrials.gov). In case of repurposed drugs for breast" exact="cancer" post="subtypes, we have found that Etoposide and Teniposide (repurposed"/>
   <result pre="and Teniposide (repurposed drugs) as structurally similar with two Breast" exact="cancer" post="drugs Epirubicin and Doxorubicin in Triple Negative subtype. The"/>
   <result pre="as effective drug in Chinese women with heavily pretreated metastatic" exact="breast cancer" post="47. TOP2A is also an up-regulated gene in the"/>
   <result pre="effective drug in Chinese women with heavily pretreated metastatic breast" exact="cancer" post="47. TOP2A is also an up-regulated gene in the"/>
   <result pre="Negative pattern which is a target gene of three Breast" exact="cancer" post="drugs (Fluorouracil, Gemcitabine and Capecitabine). TOP2A and TYMS were"/>
   <result pre="and TYMS were found significant up-regulated genes in Triple Negative" exact="breast cancer" post="cells, as compared to normal cells 48. In Luminal"/>
   <result pre="TYMS were found significant up-regulated genes in Triple Negative breast" exact="cancer" post="cells, as compared to normal cells 48. In Luminal"/>
   <result pre="in combination with Tamoxifen, may treats patients with hormone therapy-resistant" exact="breast cancer" post="49. In Luminal B, F10 and EGFR genes from"/>
   <result pre="combination with Tamoxifen, may treats patients with hormone therapy-resistant breast" exact="cancer" post="49. In Luminal B, F10 and EGFR genes from"/>
   <result pre="genes of Menadione (repurposed drug from LINCS) and Lapatinib Breast" exact="cancer" post="drug. Menadione has been examined on its antiproliferative action"/>
   <result pre="drug. Menadione has been examined on its antiproliferative action on" exact="breast cancer" post="cells 50. Finally in HER2 subtype, Palbociclib is also"/>
   <result pre="Menadione has been examined on its antiproliferative action on breast" exact="cancer" post="cells 50. Finally in HER2 subtype, Palbociclib is also"/>
   <result pre="50. Finally in HER2 subtype, Palbociclib is also a Breast" exact="cancer" post="drug that was found from the drug repurposing analysis"/>
   <result pre="has been reported to have anti-tumor effect in HER2 positive" exact="breast cancer" post="with Trastuzumab resistance 51. Finally, the action of the"/>
   <result pre="been reported to have anti-tumor effect in HER2 positive breast" exact="cancer" post="with Trastuzumab resistance 51. Finally, the action of the"/>
   <result pre="they have been derived from significantly relevant genes related to" exact="breast cancer" post="stages and subtypes. Methods Datasets and preprocessing Reference Set"/>
   <result pre="have been derived from significantly relevant genes related to breast" exact="cancer" post="stages and subtypes. Methods Datasets and preprocessing Reference Set"/>
   <result pre="have selected a subset of tumor data containing information regarding" exact="breast cancer" post="staging, HER2, ER and PR status with their corresponding"/>
   <result pre="selected a subset of tumor data containing information regarding breast" exact="cancer" post="staging, HER2, ER and PR status with their corresponding"/>
   <result pre="in order to select the Differentially Expressed Genes (DEGs) in" exact="breast cancer" post="samples compared with the normal ones 52. The top"/>
   <result pre="order to select the Differentially Expressed Genes (DEGs) in breast" exact="cancer" post="samples compared with the normal ones 52. The top"/>
   <result pre="conserved gene-gene relationships derived from gene co-expression network analysis on" exact="breast cancer" post="data. Sci. Rep. 6, 20518; doi: 10.1038/srep20518 (2016). Supplementary"/>
   <result pre="gene-gene relationships derived from gene co-expression network analysis on breast" exact="cancer" post="data. Sci. Rep. 6, 20518; doi: 10.1038/srep20518 (2016). Supplementary"/>
   <result pre="References Howell A. et al. Risk determination and prevention of" exact="breast cancer." post="Breast Cancer Res 16, 446 10.1186/s13058-014-0446-2 ( 2014). 25467785"/>
   <result pre="approaches for prioritizing driver mutations and significantly mutated genes in" exact="cancer" post="genomes . Briefings in bioinformatics 10.1093/bib/bbv068 ( 2015). Cheng"/>
   <result pre="2012). 22796662 Pujana M. A. et al. Network modeling links" exact="breast cancer" post="susceptibility and centrosome dysfunction. Nat Genet 39, 1338– 1349"/>
   <result pre="22796662 Pujana M. A. et al. Network modeling links breast" exact="cancer" post="susceptibility and centrosome dysfunction. Nat Genet 39, 1338– 1349"/>
   <result pre="proliferator-activated receptor alpha (PPARalpha) suppresses hypoxia-inducible factor-1alpha (HIF-1alpha) signaling in" exact="cancer" post="cells . The Journal of biological chemistry 287, 35161–"/>
   <result pre="Janelsins M. C. et al. Differential expression of cytokines in" exact="breast cancer" post="patients receiving different chemotherapies: implications for cognitive impairment research"/>
   <result pre="M. C. et al. Differential expression of cytokines in breast" exact="cancer" post="patients receiving different chemotherapies: implications for cognitive impairment research"/>
   <result pre="al. Prognostic significance of the metastasis-associated protein osteopontin in human" exact="breast cancer" post=". Cancer research 62, 3417– 3427 ( 2002). 12067984"/>
   <result pre="Prognostic significance of the metastasis-associated protein osteopontin in human breast" exact="cancer" post=". Cancer research 62, 3417– 3427 ( 2002). 12067984"/>
   <result pre="12067984 Yen T. Y. et al. Using a cell line" exact="breast cancer" post="progression system to identify biomarker candidates. Journal of proteomics"/>
   <result pre="Yen T. Y. et al. Using a cell line breast" exact="cancer" post="progression system to identify biomarker candidates. Journal of proteomics"/>
   <result pre="48 candidate genes in tumor and matched normal tissues from" exact="breast cancer" post="patients . Breast cancer research and treatment 149, 767–"/>
   <result pre="candidate genes in tumor and matched normal tissues from breast" exact="cancer" post="patients . Breast cancer research and treatment 149, 767–"/>
   <result pre="and matched normal tissues from breast cancer patients . Breast" exact="cancer" post="research and treatment 149, 767– 779 10.1007/s10549-015-3276-8 ( 2015)."/>
   <result pre="H. et al. Estrogen receptor alpha-coupled Bmi1 regulation pathway in" exact="breast cancer" post="and its clinical implications . BMC cancer 14, 122"/>
   <result pre="et al. Estrogen receptor alpha-coupled Bmi1 regulation pathway in breast" exact="cancer" post="and its clinical implications . BMC cancer 14, 122"/>
   <result pre="pathway in breast cancer and its clinical implications . BMC" exact="cancer" post="14, 122 10.1186/1471-2407-14-122 ( 2014). 24559156 Ji Q. et"/>
   <result pre="Q. et al. Selective loss of AKR1C1 and AKR1C2 in" exact="breast cancer" post="and their potential effect on progesterone signaling . Cancer"/>
   <result pre="et al. Selective loss of AKR1C1 and AKR1C2 in breast" exact="cancer" post="and their potential effect on progesterone signaling . Cancer"/>
   <result pre="al. PPAR signaling pathway may be an important predictor of" exact="breast cancer" post="response to neoadjuvant chemotherapy . Cancer chemotherapy and pharmacology"/>
   <result pre="PPAR signaling pathway may be an important predictor of breast" exact="cancer" post="response to neoadjuvant chemotherapy . Cancer chemotherapy and pharmacology"/>
   <result pre="and aldehyde dehydrogenase (ALDH) in the sera of patients with" exact="breast cancer" post=". Journal of clinical laboratory analysis 20, 105– 108"/>
   <result pre="aldehyde dehydrogenase (ALDH) in the sera of patients with breast" exact="cancer" post=". Journal of clinical laboratory analysis 20, 105– 108"/>
   <result pre="&amp;amp; Wang J. H. Links between Toll-like receptor 4 and" exact="breast cancer." post="Oncoimmunology 2, e22945 10.4161/onci.22945 ( 2013). 23526132 Amelio I."/>
   <result pre="Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing" exact="breast cancer" post="cells . Breast Cancer Res 12, R96 10.1186/bcr2777 ("/>
   <result pre="acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast" exact="cancer" post="cells . Breast Cancer Res 12, R96 10.1186/bcr2777 ("/>
   <result pre="( 2006). 16550168 Wang E. et al. Predictive genomics: a" exact="cancer" post="hallmark network framework for predicting tumor clinical phenotypes using"/>
   <result pre="tumor clinical phenotypes using genome sequencing data . Seminars in" exact="cancer" post="biology 30, 4– 12 10.1016/j.semcancer.2014.04.002 ( 2015). 24747696 Lubecka-Pietruszewska"/>
   <result pre="DNA methylation-silenced tumour suppressor genes and inhibits cell growth in" exact="breast cancer" post="cells . Eur J Pharmacol 723, 276– 287 10.1016/j.ejphar.2013.11.021"/>
   <result pre="methylation-silenced tumour suppressor genes and inhibits cell growth in breast" exact="cancer" post="cells . Eur J Pharmacol 723, 276– 287 10.1016/j.ejphar.2013.11.021"/>
   <result pre="and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in" exact="breast cancer" post="cells . British journal of pharmacology 172, 214– 234"/>
   <result pre="XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast" exact="cancer" post="cells . British journal of pharmacology 172, 214– 234"/>
   <result pre="Kleve M. G. &amp;amp; Gealt M. A. Wortmannin induces MCF-7" exact="breast cancer" post="cell death via the apoptotic pathway, involving chromatin condensation,"/>
   <result pre="M. G. &amp;amp; Gealt M. A. Wortmannin induces MCF-7 breast" exact="cancer" post="cell death via the apoptotic pathway, involving chromatin condensation,"/>
   <result pre="generation of reactive oxygen species, and membrane blebbing . Breast" exact="cancer" post="(Dove Medical Press) 4, 103– 113 10.2147/bctt.s31712 ( 2012)."/>
   <result pre="et al. Wortmannin inhibits proliferation and induces apoptosis of MCF-7" exact="breast cancer" post="cells. European journal of gynaecological oncology 33, 367– 369"/>
   <result pre="al. Wortmannin inhibits proliferation and induces apoptosis of MCF-7 breast" exact="cancer" post="cells. European journal of gynaecological oncology 33, 367– 369"/>
   <result pre="W. et al. The antihelmintic drug pyrvinium pamoate targets aggressive" exact="breast cancer." post="PLoS One 8, e71508 10.1371/journal.pone.0071508 ( 2013). 24013655 Yuan"/>
   <result pre="P. et al. Oral etoposide monotherapy is effective for metastatic" exact="breast cancer" post="with heavy prior therapy . Chin Med J (Engl)"/>
   <result pre="et al. Oral etoposide monotherapy is effective for metastatic breast" exact="cancer" post="with heavy prior therapy . Chin Med J (Engl)"/>
   <result pre="22490573 Komatsu M. et al. Molecular features of triple negative" exact="breast cancer" post="cells by genome-wide gene expression profiling analysis . International"/>
   <result pre="Komatsu M. et al. Molecular features of triple negative breast" exact="cancer" post="cells by genome-wide gene expression profiling analysis . International"/>
   <result pre="with tamoxifen for the treatment of patients with hormone therapy-resistant" exact="breast cancer" post=". British journal of cancer 104, 1828– 1835 10.1038/bjc.2011.156"/>
   <result pre="tamoxifen for the treatment of patients with hormone therapy-resistant breast" exact="cancer" post=". British journal of cancer 104, 1828– 1835 10.1038/bjc.2011.156"/>
   <result pre="patients with hormone therapy-resistant breast cancer . British journal of" exact="cancer" post="104, 1828– 1835 10.1038/bjc.2011.156 ( 2011). 21559012 Marchionatti A."/>
   <result pre="Talamoni N. G. Antiproliferative action of menadione and 1,25(OH)2D3 on" exact="breast cancer" post="cells. The Journal of steroid biochemistry and molecular biology"/>
   <result pre="N. G. Antiproliferative action of menadione and 1,25(OH)2D3 on breast" exact="cancer" post="cells. The Journal of steroid biochemistry and molecular biology"/>
   <result pre="al. Abstract 724: Anti-tumor effect of Dasatinib in HER2 positive" exact="breast cancer" post="with Trastuzumab resistance . Cancer research 75, 724– 724"/>
   <result pre="Abstract 724: Anti-tumor effect of Dasatinib in HER2 positive breast" exact="cancer" post="with Trastuzumab resistance . Cancer research 75, 724– 724"/>
   <result pre="2014). 25390635 Cui Q. et al. A map of human" exact="cancer" post="signaling. Molecular systems biology 3, 152 10.1038/msb4100200 ( 2007)."/>
   <result pre="workflow was followed eight times for each of the four" exact="breast cancer" post="subtypes and stages – initially TCGA mRNA Breast cancer"/>
   <result pre="was followed eight times for each of the four breast" exact="cancer" post="subtypes and stages – initially TCGA mRNA Breast cancer"/>
   <result pre="breast cancer subtypes and stages – initially TCGA mRNA Breast" exact="cancer" post="gene expression datasets were statistically analyzed by means of"/>
   <result pre="training set the TCGA datasets, tested on a number of" exact="breast cancer" post="GEO datasets available for each subtype and stage. Using"/>
   <result pre="set the TCGA datasets, tested on a number of breast" exact="cancer" post="GEO datasets available for each subtype and stage. Using"/>
   <result pre="test set the expression values from GEO independent datasets for" exact="breast cancer" post="stages. Figure 3 Box plots of the mean accuracy"/>
   <result pre="set the expression values from GEO independent datasets for breast" exact="cancer" post="stages. Figure 3 Box plots of the mean accuracy"/>
   <result pre="test set the expression values from GEO independent datasets for" exact="breast cancer" post="subtypes. Figure 4 Mean accuracy rates of the top"/>
   <result pre="set the expression values from GEO independent datasets for breast" exact="cancer" post="subtypes. Figure 4 Mean accuracy rates of the top"/>
   <result pre="the Genenet network inference method and the Initial for each" exact="breast cancer" post="stage. Figure 5 Mean accuracy rates of the top"/>
   <result pre="Genenet network inference method and the Initial for each breast" exact="cancer" post="stage. Figure 5 Mean accuracy rates of the top"/>
   <result pre="the MRNETB network inference method and the Initial for each" exact="breast cancer" post="subtype. Figure 6 Network pattern for each breast cancer"/>
   <result pre="MRNETB network inference method and the Initial for each breast" exact="cancer" post="subtype. Figure 6 Network pattern for each breast cancer"/>
   <result pre="each breast cancer subtype. Figure 6 Network pattern for each" exact="breast cancer" post="stage and the common edges across them. Figure 7"/>
   <result pre="breast cancer subtype. Figure 6 Network pattern for each breast" exact="cancer" post="stage and the common edges across them. Figure 7"/>
   <result pre="common edges across them. Figure 7 Network pattern for each" exact="breast cancer" post="subtype and the common interactions across Luminal A and"/>
   <result pre="edges across them. Figure 7 Network pattern for each breast" exact="cancer" post="subtype and the common interactions across Luminal A and"/>
   <result pre="Luminal A and Luminal B. Figure 8 Super Network for" exact="breast cancer" post="Stage I- consists of 4 sub-networks: 1) two drug"/>
   <result pre="A and Luminal B. Figure 8 Super Network for breast" exact="cancer" post="Stage I- consists of 4 sub-networks: 1) two drug"/>
   <result pre="drugs from LINCS and with green cycle the 25 therapeutic" exact="breast cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="from LINCS and with green cycle the 25 therapeutic breast" exact="cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="round rectangles). One out of the 25 FDA approved Breast" exact="cancer" post="drugs (Gemcitabine), was found in the top 20 drug"/>
   <result pre="found in the top 20 drug list from LINCS from" exact="breast cancer" post="stage I (dark magenta). Figure 9 Highlighted target genes"/>
   <result pre="in the top 20 drug list from LINCS from breast" exact="cancer" post="stage I (dark magenta). Figure 9 Highlighted target genes"/>
   <result pre="Highlighted target genes that physically interact with genes from the" exact="breast cancer" post="stage I common network pattern and their corresponding repurposed"/>
   <result pre="target genes that physically interact with genes from the breast" exact="cancer" post="stage I common network pattern and their corresponding repurposed"/>
   <result pre="repurposed drugs from LINCS, along with their structurally similar Breast" exact="cancer" post="drugs. Figure 10 Super Network for breast cancer Stage"/>
   <result pre="structurally similar Breast cancer drugs. Figure 10 Super Network for" exact="breast cancer" post="Stage II- consists of 4 sub-networks: 1) two drug"/>
   <result pre="similar Breast cancer drugs. Figure 10 Super Network for breast" exact="cancer" post="Stage II- consists of 4 sub-networks: 1) two drug"/>
   <result pre="drugs from LINCS and with green cycle the 25 therapeutic" exact="breast cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="from LINCS and with green cycle the 25 therapeutic breast" exact="cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="round rectangles). One out of the 25 FDA approved Breast" exact="cancer" post="drugs (Palbociclib), was found in the top 20 drug"/>
   <result pre="found in the top 20 drug list from LINCS from" exact="breast cancer" post="stage II (deep pink). Figure 11 Highlighted target genes"/>
   <result pre="in the top 20 drug list from LINCS from breast" exact="cancer" post="stage II (deep pink). Figure 11 Highlighted target genes"/>
   <result pre="Highlighted target genes that physically interact with genes from the" exact="breast cancer" post="stage II common network pattern and their corresponding repurposed"/>
   <result pre="target genes that physically interact with genes from the breast" exact="cancer" post="stage II common network pattern and their corresponding repurposed"/>
   <result pre="repurposed drugs from LINCS, along with their structurally similar Breast" exact="cancer" post="drugs. Figure 12 Super Network for breast cancer Stage"/>
   <result pre="structurally similar Breast cancer drugs. Figure 12 Super Network for" exact="breast cancer" post="Stage III- consists of 4 sub-networks: 1) two drug"/>
   <result pre="similar Breast cancer drugs. Figure 12 Super Network for breast" exact="cancer" post="Stage III- consists of 4 sub-networks: 1) two drug"/>
   <result pre="drugs from LINCS and with green cycle the 25 therapeutic" exact="breast cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="from LINCS and with green cycle the 25 therapeutic breast" exact="cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="round rectangles). One out of the 25 FDA approved Breast" exact="cancer" post="drugs (Gemcitabine), was found in the top 20 drug"/>
   <result pre="found in the top 20 drug list from LINCS from" exact="breast cancer" post="stage III (dark magenta). Figure 13 Highlighted target genes"/>
   <result pre="in the top 20 drug list from LINCS from breast" exact="cancer" post="stage III (dark magenta). Figure 13 Highlighted target genes"/>
   <result pre="Highlighted target genes that physically interact with genes from the" exact="breast cancer" post="stage III common network pattern and their corresponding repurposed"/>
   <result pre="target genes that physically interact with genes from the breast" exact="cancer" post="stage III common network pattern and their corresponding repurposed"/>
   <result pre="repurposed drugs from LINCS, along with their structurally similar Breast" exact="cancer" post="drugs. Figure 14 Super Network for breast cancer Stage"/>
   <result pre="structurally similar Breast cancer drugs. Figure 14 Super Network for" exact="breast cancer" post="Stage IV- consists of 4 sub-networks: 1) two drug"/>
   <result pre="similar Breast cancer drugs. Figure 14 Super Network for breast" exact="cancer" post="Stage IV- consists of 4 sub-networks: 1) two drug"/>
   <result pre="drugs from LINCS and with green cycle the 25 therapeutic" exact="breast cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="from LINCS and with green cycle the 25 therapeutic breast" exact="cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="(purple round rectangles). One from the 25 FDA approved Breast" exact="cancer" post="drugs (Gemcitabine), was found in the top 20 drug"/>
   <result pre="found in the top 20 drug list from LINCS from" exact="breast cancer" post="stage IV (dark magenta). Figure 15 Highlighted target genes"/>
   <result pre="in the top 20 drug list from LINCS from breast" exact="cancer" post="stage IV (dark magenta). Figure 15 Highlighted target genes"/>
   <result pre="Highlighted target genes that physical interact with genes from the" exact="breast cancer" post="stage IV common network pattern and their corresponding repurposed"/>
   <result pre="target genes that physical interact with genes from the breast" exact="cancer" post="stage IV common network pattern and their corresponding repurposed"/>
   <result pre="corresponding repurposed drugs from LINCS with the structurally similar Breast" exact="cancer" post="drugs. Figure 16 Super Network for Triple Negative breast"/>
   <result pre="Breast cancer drugs. Figure 16 Super Network for Triple Negative" exact="breast cancer" post="- consists of 4 sub-networks: 1) two drug –"/>
   <result pre="cancer drugs. Figure 16 Super Network for Triple Negative breast" exact="cancer" post="- consists of 4 sub-networks: 1) two drug –"/>
   <result pre="drugs from LINCS and with green cycle the 25 therapeutic" exact="breast cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="from LINCS and with green cycle the 25 therapeutic breast" exact="cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="genes that physical interact with genes from the Triple Negative" exact="breast cancer" post="subtype common network pattern and their corresponding repurposed drugs"/>
   <result pre="that physical interact with genes from the Triple Negative breast" exact="cancer" post="subtype common network pattern and their corresponding repurposed drugs"/>
   <result pre="corresponding repurposed drugs from LINCS with the structurally similar Breast" exact="cancer" post="drugs. Figure 18 Super Network for Luminal A breast"/>
   <result pre="Breast cancer drugs. Figure 18 Super Network for Luminal A" exact="breast cancer" post="subtype- consists of 4 sub-networks: 1) two drug –"/>
   <result pre="cancer drugs. Figure 18 Super Network for Luminal A breast" exact="cancer" post="subtype- consists of 4 sub-networks: 1) two drug –"/>
   <result pre="drugs from LINCS and with green cycle the 25 therapeutic" exact="breast cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="from LINCS and with green cycle the 25 therapeutic breast" exact="cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="(purple round rectangles). Two from the 25 FDA approved Breast" exact="cancer" post="drugs (Gemcitabine and Palbociclib), was found in the top"/>
   <result pre="the top 20 drug list from LINCS from Luminal A" exact="breast cancer" post="(dark magenta and deep pink respectively). Figure 19 Highlighted"/>
   <result pre="top 20 drug list from LINCS from Luminal A breast" exact="cancer" post="(dark magenta and deep pink respectively). Figure 19 Highlighted"/>
   <result pre="genes that physical interact with genes from the Luminal A" exact="breast cancer" post="subtype common network pattern and their corresponding repurposed drugs"/>
   <result pre="that physical interact with genes from the Luminal A breast" exact="cancer" post="subtype common network pattern and their corresponding repurposed drugs"/>
   <result pre="corresponding repurposed drugs from LINCS with the structurally similar Breast" exact="cancer" post="drugs. Figure 20 Super Network for Luminal B breast"/>
   <result pre="Breast cancer drugs. Figure 20 Super Network for Luminal B" exact="breast cancer" post="subtype- consists of 4 sub-networks: 1) two drug –"/>
   <result pre="cancer drugs. Figure 20 Super Network for Luminal B breast" exact="cancer" post="subtype- consists of 4 sub-networks: 1) two drug –"/>
   <result pre="drugs from LINCS and with green cycle the 25 therapeutic" exact="breast cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="from LINCS and with green cycle the 25 therapeutic breast" exact="cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="genes that physical interact with genes from the Luminal B" exact="breast cancer" post="subtype common network pattern and their corresponding repurposed drugs"/>
   <result pre="that physical interact with genes from the Luminal B breast" exact="cancer" post="subtype common network pattern and their corresponding repurposed drugs"/>
   <result pre="corresponding repurposed drugs from LINCS with the structurally similar Breast" exact="cancer" post="drugs. Figure 22 Super Network for HER2 breast cancer"/>
   <result pre="similar Breast cancer drugs. Figure 22 Super Network for HER2" exact="breast cancer" post="subtype- consists of 4 sub-networks: 1) two drug –"/>
   <result pre="Breast cancer drugs. Figure 22 Super Network for HER2 breast" exact="cancer" post="subtype- consists of 4 sub-networks: 1) two drug –"/>
   <result pre="drugs from LINCS and with green cycle the 25 therapeutic" exact="breast cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="from LINCS and with green cycle the 25 therapeutic breast" exact="cancer" post="drugs 2) drug – target network: grey round rectangles"/>
   <result pre="(purple round rectangles). Two from the 25 FDA approved Breast" exact="cancer" post="drugs (Gemcitabine and Palbociclib), were found in the top"/>
   <result pre="in the top 20 drug list from LINCS from HER2" exact="breast cancer" post="(dark magenta and deep pink respectively). One target gene"/>
   <result pre="the top 20 drug list from LINCS from HER2 breast" exact="cancer" post="(dark magenta and deep pink respectively). One target gene"/>
   <result pre="target genes that physical interact with genes from the HER2" exact="breast cancer" post="subtype common network pattern and their corresponding repurposed drugs"/>
   <result pre="genes that physical interact with genes from the HER2 breast" exact="cancer" post="subtype common network pattern and their corresponding repurposed drugs"/>
   <result pre="corresponding repurposed drugs from LINCS with the structurally similar Breast" exact="cancer" post="drugs. Table 1 Mean Score of each re-ranking method"/>
   <result pre="Mean Score of each re-ranking method for the case of" exact="breast cancer" post="stages. Re-rankingMethods Score @Stage I Score @Stage II Score"/>
   <result pre="Score of each re-ranking method for the case of breast" exact="cancer" post="stages. Re-rankingMethods Score @Stage I Score @Stage II Score"/>
   <result pre="Mean Score of each re-ranking method for the case of" exact="breast cancer" post="subtypes. Re-rankingMethods Score @ TripleNegative Score @Luminal A Score"/>
   <result pre="Score of each re-ranking method for the case of breast" exact="cancer" post="subtypes. Re-rankingMethods Score @ TripleNegative Score @Luminal A Score"/>
   <result pre="3 Common and exclusive significant pathways for the case of" exact="breast cancer" post="stages. Stage Pathways P-value Genes Stage I cell communication"/>
   <result pre="Common and exclusive significant pathways for the case of breast" exact="cancer" post="stages. Stage Pathways P-value Genes Stage I cell communication"/>
   <result pre="4 Common and exclusive significant pathways for the case of" exact="breast cancer" post="subtypes. Subtype Term P-value Genes Luminal A cell communication"/>
   <result pre="Common and exclusive significant pathways for the case of breast" exact="cancer" post="subtypes. Subtype Term P-value Genes Luminal A cell communication"/>
   <result pre="0.02328 AOC3;ADH4;TPO;ADH1C;MAOB;ADH1A * complement and coagulation cascades 0.024164 C7;F10;F12;PROS1;CFI;PLAUR;C4BPA *" exact="bladder cancer" post="0.026558 FIGF;CDKN2A;MMP1;E2F1;MMP9 Triple Negative cell cycle 1.14E-10 PLK1;BUB1B;CDC25C;PKMYT1;CCNA2;CDC20;CCNB2;CCNB1;CCNE2;PTTG1;CCNE1;PTTG2;CHEK1;BUB1;MAD2L1 cell"/>
   <result pre="AOC3;ADH4;TPO;ADH1C;MAOB;ADH1A * complement and coagulation cascades 0.024164 C7;F10;F12;PROS1;CFI;PLAUR;C4BPA * bladder" exact="cancer" post="0.026558 FIGF;CDKN2A;MMP1;E2F1;MMP9 Triple Negative cell cycle 1.14E-10 PLK1;BUB1B;CDC25C;PKMYT1;CCNA2;CDC20;CCNB2;CCNB1;CCNE2;PTTG1;CCNE1;PTTG2;CHEK1;BUB1;MAD2L1 cell"/>
   <result pre="interaction 7.92E-05 COL1A1;LAMA2;COL11A1;COL5A2;LAMA3;COL4A6;FN1;HMMR focal adhesion 0.003057 COL1A1;LAMA2;CAV2;CAV1;COL11A1;COL5A2;LAMA3;COL4A6;FN1 * small cell" exact="lung cancer" post="0.002403 CCNE2;LAMA2;CCNE1;LAMA3;COL4A6;FN1 * metabolism of xenobiotics by cytochrome p450"/>
   <result pre="7.92E-05 COL1A1;LAMA2;COL11A1;COL5A2;LAMA3;COL4A6;FN1;HMMR focal adhesion 0.003057 COL1A1;LAMA2;CAV2;CAV1;COL11A1;COL5A2;LAMA3;COL4A6;FN1 * small cell lung" exact="cancer" post="0.002403 CCNE2;LAMA2;CCNE1;LAMA3;COL4A6;FN1 * metabolism of xenobiotics by cytochrome p450"/>
   <result pre="specific Breast Cancer Subtype. Table 5 Drug List for all" exact="breast cancer" post="stages – X represents the appearance of the drug"/>
   <result pre="Breast Cancer Subtype. Table 5 Drug List for all breast" exact="cancer" post="stages – X represents the appearance of the drug"/>
   <result pre="TPCA-1 X trichostatin-a X Table 6 Drug List for all" exact="breast cancer" post="subtypes – X represents the appearance of the drug"/>
   <result pre="X trichostatin-a X Table 6 Drug List for all breast" exact="cancer" post="subtypes – X represents the appearance of the drug"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4763414/results/search/disease/results.xml">
   <result pre="Prognostic value of ERBB4 expression in patients with triple negative" exact="breast cancer" post="Kim Ji-Yeon jyeon25.kim@samsung.com Jung Hae Hyun haehyun.jung@sbri.co.kr Do In-Gu"/>
   <result pre="value of ERBB4 expression in patients with triple negative breast" exact="cancer" post="Kim Ji-Yeon jyeon25.kim@samsung.com Jung Hae Hyun haehyun.jung@sbri.co.kr Do In-Gu"/>
   <result pre="available in this article, unless otherwise stated. Abstract Background Triple-negative" exact="breast cancer" post="(TNBC) is known for aggressive biologic features and poor"/>
   <result pre="in this article, unless otherwise stated. Abstract Background Triple-negative breast" exact="cancer" post="(TNBC) is known for aggressive biologic features and poor"/>
   <result pre="84 TNBC patients in the validation consort were selected from" exact="breast cancer" post="patients who received curative surgery since 2005 to 2010."/>
   <result pre="TNBC patients in the validation consort were selected from breast" exact="cancer" post="patients who received curative surgery since 2005 to 2010."/>
   <result pre="which is available to authorized users. Keywords ERBB4 Triple negative" exact="breast cancer" post="nCounter expression assay Funding Samsung Biomedical Research Institute SBRI"/>
   <result pre="is available to authorized users. Keywords ERBB4 Triple negative breast" exact="cancer" post="nCounter expression assay Funding Samsung Biomedical Research Institute SBRI"/>
   <result pre="Biomedical Research Institute SBRI GL1-B2-251-1-2 Im Young-Hyuck Background Triple negative" exact="breast cancer" post="(TNBC), defined as the absence of both hormone receptor"/>
   <result pre="Research Institute SBRI GL1-B2-251-1-2 Im Young-Hyuck Background Triple negative breast" exact="cancer" post="(TNBC), defined as the absence of both hormone receptor"/>
   <result pre="% of breast cancers and defines a unique subtype of" exact="breast cancer" post="[ 7]. Indeed, ERBB2 overexpression is the therapeutic target"/>
   <result pre="of breast cancers and defines a unique subtype of breast" exact="cancer" post="[ 7]. Indeed, ERBB2 overexpression is the therapeutic target"/>
   <result pre="role of ERBB2, research on other HER family genes in" exact="breast cancer" post="is now ongoing. According to previous research, overexpression of"/>
   <result pre="of ERBB2, research on other HER family genes in breast" exact="cancer" post="is now ongoing. According to previous research, overexpression of"/>
   <result pre="prognosis and negatively correlated with estrogen receptor (ER) expression in" exact="breast cancer" post="[ 12, 13]. In terms of ERBB4, intracellular domain"/>
   <result pre="and negatively correlated with estrogen receptor (ER) expression in breast" exact="cancer" post="[ 12, 13]. In terms of ERBB4, intracellular domain"/>
   <result pre="of ERBB4, intracellular domain 4ICD of ERBB4 promotes apoptosis of" exact="breast cancer" post="cells and cytosolic expression of 4ICD is associated with"/>
   <result pre="ERBB4, intracellular domain 4ICD of ERBB4 promotes apoptosis of breast" exact="cancer" post="cells and cytosolic expression of 4ICD is associated with"/>
   <result pre="study reported that ERBB4 expression is positively related to ER-positive" exact="breast cancer" post="[ 17– 19]. Patients with breast cancer showing co-expression"/>
   <result pre="reported that ERBB4 expression is positively related to ER-positive breast" exact="cancer" post="[ 17– 19]. Patients with breast cancer showing co-expression"/>
   <result pre="related to ER-positive breast cancer [ 17– 19]. Patients with" exact="breast cancer" post="showing co-expression of ERBB4 and ER have fewer recurrences"/>
   <result pre="to ER-positive breast cancer [ 17– 19]. Patients with breast" exact="cancer" post="showing co-expression of ERBB4 and ER have fewer recurrences"/>
   <result pre="recurrences and improved survival compared to patients diagnosed with ER-positive" exact="breast cancer" post="without ERBB4 expression [ 20, 21]. Some studies have"/>
   <result pre="and improved survival compared to patients diagnosed with ER-positive breast" exact="cancer" post="without ERBB4 expression [ 20, 21]. Some studies have"/>
   <result pre="retrospective analysis of the clinical records of patients with invasive" exact="breast cancer" post="who received adjuvant chemotherapy after curative surgery at Samsung"/>
   <result pre="analysis of the clinical records of patients with invasive breast" exact="cancer" post="who received adjuvant chemotherapy after curative surgery at Samsung"/>
   <result pre="Center between 2000 and 2004. Women who were diagnosed with" exact="breast cancer" post="at stage I to IIIC by diagnostic examination (breast"/>
   <result pre="between 2000 and 2004. Women who were diagnosed with breast" exact="cancer" post="at stage I to IIIC by diagnostic examination (breast"/>
   <result pre="To validate our data, we retrospectively reviewed clinical records of" exact="breast cancer" post="patients who received curative surgery at Samsung Medical Center"/>
   <result pre="validate our data, we retrospectively reviewed clinical records of breast" exact="cancer" post="patients who received curative surgery at Samsung Medical Center"/>
   <result pre="of curative surgery to the detection of distant relapse of" exact="breast cancer." post="DRFS was analyzed by the Kaplan-Meier (KM) method. Univariate"/>
   <result pre="This validation cohort was composed of patients diagnosed with invasive" exact="breast cancer" post="who received curative surgery from 2005 to 2010, regardless"/>
   <result pre="validation cohort was composed of patients diagnosed with invasive breast" exact="cancer" post="who received curative surgery from 2005 to 2010, regardless"/>
   <result pre="In the training cohort, the median age at diagnosis of" exact="breast cancer" post="was 46.4 years (range, 23.5-74.1). Most patients were diagnosed"/>
   <result pre="the training cohort, the median age at diagnosis of breast" exact="cancer" post="was 46.4 years (range, 23.5-74.1). Most patients were diagnosed"/>
   <result pre="patients in the validation cohort had a higher stage of" exact="breast cancer" post="than those in the training cohort ( p &amp;lt; 0.001). Gene"/>
   <result pre="in the validation cohort had a higher stage of breast" exact="cancer" post="than those in the training cohort ( p &amp;lt; 0.001). Gene"/>
   <result pre="(stage I/IIA) and an advanced-stage group (stage IIB/IIIA/IIIC). In early-stage" exact="breast cancer," post="ERBB4 expression did not affect patient survival (5Y DRFS,"/>
   <result pre="validation set. Patients in the validation set with high ERBB4-expressing" exact="breast cancer" post="(cut-off value (log2 scale) = 1.3, the same as that used"/>
   <result pre="set. Patients in the validation set with high ERBB4-expressing breast" exact="cancer" post="(cut-off value (log2 scale) = 1.3, the same as that used"/>
   <result pre="control group. In contrast of TNBC, this analysis showed that" exact="breast cancer" post="with high ERBB4 expression had better prognosis than that"/>
   <result pre="group. In contrast of TNBC, this analysis showed that breast" exact="cancer" post="with high ERBB4 expression had better prognosis than that"/>
   <result pre="was good prognostic indicator of ER positive and/or HER2 positive" exact="breast cancer." post="Fig. 4 Survival analysis in the validation set ("/>
   <result pre="5b) and in subgroup analyses according to early-stage and advanced-stage" exact="breast cancer" post="(Additional file 2: Figure S3A and 3B). Fig. 5"/>
   <result pre="and in subgroup analyses according to early-stage and advanced-stage breast" exact="cancer" post="(Additional file 2: Figure S3A and 3B). Fig. 5"/>
   <result pre="in TNBC. Many studies on HER family gene expression in" exact="breast cancer" post="have previously been performed. Although most of these studies"/>
   <result pre="TNBC. Many studies on HER family gene expression in breast" exact="cancer" post="have previously been performed. Although most of these studies"/>
   <result pre="have previously been performed. Although most of these studies involved" exact="breast cancer" post="with EGFR or ERBB2 overexpression, some researchers have conducted"/>
   <result pre="previously been performed. Although most of these studies involved breast" exact="cancer" post="with EGFR or ERBB2 overexpression, some researchers have conducted"/>
   <result pre="genes, including ERBB4. These studies revealed that ERBB4 overexpression in" exact="breast cancer" post="is correlated with hormone receptor positivity [ 13, 20]"/>
   <result pre="including ERBB4. These studies revealed that ERBB4 overexpression in breast" exact="cancer" post="is correlated with hormone receptor positivity [ 13, 20]"/>
   <result pre="overexpression was reported to be associated with favorable prognosis in" exact="breast cancer" post="patients [ 14], especially in cases of ER-positive ["/>
   <result pre="was reported to be associated with favorable prognosis in breast" exact="cancer" post="patients [ 14], especially in cases of ER-positive ["/>
   <result pre="especially in cases of ER-positive [ 18, 31] and/or ERBB2-amplified" exact="breast cancer" post="[ 20, 32]. In contrast, Bieche et al. showed"/>
   <result pre="in cases of ER-positive [ 18, 31] and/or ERBB2-amplified breast" exact="cancer" post="[ 20, 32]. In contrast, Bieche et al. showed"/>
   <result pre="32]. In contrast, Bieche et al. showed that ERBB4-expression of" exact="breast cancer" post="more than that of normal breast tissue had extremely"/>
   <result pre="In contrast, Bieche et al. showed that ERBB4-expression of breast" exact="cancer" post="more than that of normal breast tissue had extremely"/>
   <result pre="normal breast tissue had extremely poor prognosis compared with ERBB4-underexpressing" exact="breast cancer" post="[ 17]. This study also included subgroup analysis that"/>
   <result pre="breast tissue had extremely poor prognosis compared with ERBB4-underexpressing breast" exact="cancer" post="[ 17]. This study also included subgroup analysis that"/>
   <result pre="ERBB4 overexpression as a marker for poor prognosis in ER-negative" exact="breast cancer." post="In our study, HER family gene expression was measured"/>
   <result pre="IHC. Therefore, although this study was conducted on triple negative" exact="breast cancer," post="we were able to detect RNA expression of ERBB2"/>
   <result pre="against EGFR and ERBB2 RTK have successfully been used as" exact="cancer" post="drugs, for example cetuximab [ 33] and panitumumab ["/>
   <result pre="TDM-1[ 36] have been used in anti-HER2 therapy for ERBB2-overexpressing" exact="breast cancer." post="However, the biologic role of ERBB4 and its potential"/>
   <result pre="role of ERBB4 and its potential as a target for" exact="cancer" post="drugs has not been clearly identified. Some studies have"/>
   <result pre="influenced by patient’s characteristics like age, comorbidities as well as" exact="breast cancer" post="characteristics, DRFS might be more reliable indicator for breast"/>
   <result pre="by patient’s characteristics like age, comorbidities as well as breast" exact="cancer" post="characteristics, DRFS might be more reliable indicator for breast"/>
   <result pre="be useful to predict response to therapy for triple negative" exact="breast cancer." post="Moreover, we expect that further clinical trials on RTKs"/>
   <result pre="on RTKs would benefit patients suffering from refractory triple negative" exact="breast cancer" post="with high ERBB4 expression. Conclusions Our research suggests that"/>
   <result pre="RTKs would benefit patients suffering from refractory triple negative breast" exact="cancer" post="with high ERBB4 expression. Conclusions Our research suggests that"/>
   <result pre="be useful to predict response to therapy for triple negative" exact="breast cancer." post="Additional files LINK Additional file 1: Table S1. Baseline"/>
   <result pre="Validation set ( N = 84). (C) Group consisting of non-triple negative" exact="breast cancer" post="( N = 52). Figure S2. Relationship among expression of the"/>
   <result pre="set ( N = 84). (C) Group consisting of non-triple negative breast" exact="cancer" post="( N = 52). Figure S2. Relationship among expression of the"/>
   <result pre="Abbreviations HER Human epidermal growth factor receptor TNBC Triple negative" exact="breast cancer" post="ESR1 estrogen receptor 1 EGFR Epidermal growth factor receptor"/>
   <result pre="HER Human epidermal growth factor receptor TNBC Triple negative breast" exact="cancer" post="ESR1 estrogen receptor 1 EGFR Epidermal growth factor receptor"/>
   <result pre="References References 1. Foulkes WD Smith IE Reis-Filho JS Triple-negative" exact="breast cancer" post="N Engl J Med 2010 363 20 1938 1948"/>
   <result pre="References 1. Foulkes WD Smith IE Reis-Filho JS Triple-negative breast" exact="cancer" post="N Engl J Med 2010 363 20 1938 1948"/>
   <result pre="P Lomans J Dalesio O Nusse R Neu-protein overexpression in" exact="breast cancer." post="Association with comedo-type ductal carcinoma in situ and limited"/>
   <result pre="R Neu-protein overexpression in breast cancer. Association with comedo-type ductal" exact="carcinoma in situ" post="and limited prognostic value in stage II breast cancer"/>
   <result pre="carcinoma in situ and limited prognostic value in stage II" exact="breast cancer" post="N Engl J Med 1988 319 19 1239 1245"/>
   <result pre="in situ and limited prognostic value in stage II breast" exact="cancer" post="N Engl J Med 1988 319 19 1239 1245"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 N Engl J Med 2001 344"/>
   <result pre="Jackisch C et al. Trastuzumab after adjuvant chemotherapy in HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1659 1672"/>
   <result pre="C et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1659 1672"/>
   <result pre="A et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic" exact="breast cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast" exact="cancer" post="N Engl J Med 2012 366 2 109 119"/>
   <result pre="Kaufman B et al. Lapatinib plus capecitabine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="B et al. Lapatinib plus capecitabine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2006 355 26 2733 2743"/>
   <result pre="relationship to the estrogen receptor status in 1029 patients with" exact="breast cancer" post="Breast Cancer Res Treat 2002 71 1 67 75"/>
   <result pre="to the estrogen receptor status in 1029 patients with breast" exact="cancer" post="Breast Cancer Res Treat 2002 71 1 67 75"/>
   <result pre="Yamamoto Y Iwase H Association of ErbB1-4 expression in invasive" exact="breast cancer" post="with clinicopathological characteristics and prognosis Breast Cancer 2014 21"/>
   <result pre="Y Iwase H Association of ErbB1-4 expression in invasive breast" exact="cancer" post="with clinicopathological characteristics and prognosis Breast Cancer 2014 21"/>
   <result pre="the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for" exact="breast cancer" post="patients The American journal of pathology 2009 175 5"/>
   <result pre="HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast" exact="cancer" post="patients The American journal of pathology 2009 175 5"/>
   <result pre="intracellular domain 4ICD is a BH3-only protein promoting apoptosis of" exact="breast cancer" post="cells Cancer Res 2006 66 12 6412 6420 10.1158/0008-5472.CAN-05-2368"/>
   <result pre="domain 4ICD is a BH3-only protein promoting apoptosis of breast" exact="cancer" post="cells Cancer Res 2006 66 12 6412 6420 10.1158/0008-5472.CAN-05-2368"/>
   <result pre="MAPK pathways are potential good prognostic markers in node-positive, triple-negative" exact="breast cancer" post="Ann Oncol 2014 25 10 1973 1979 10.1093/annonc/mdu247 25009009"/>
   <result pre="pathways are potential good prognostic markers in node-positive, triple-negative breast" exact="cancer" post="Ann Oncol 2014 25 10 1973 1979 10.1093/annonc/mdu247 25009009"/>
   <result pre="Elenius K Cleavable ErbB4 isoform in estrogen receptor-regulated growth of" exact="breast cancer" post="cells Cancer Res 2005 65 4 1384 1393 10.1158/0008-5472.CAN-04-3150"/>
   <result pre="K Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast" exact="cancer" post="cells Cancer Res 2005 65 4 1384 1393 10.1158/0008-5472.CAN-04-3150"/>
   <result pre="is a feature of the endocrine responsive phenotype in clinical" exact="breast cancer" post="Oncogene 1998 17 15 1949 1957 10.1038/sj.onc.1202107 9788438 20."/>
   <result pre="a feature of the endocrine responsive phenotype in clinical breast" exact="cancer" post="Oncogene 1998 17 15 1949 1957 10.1038/sj.onc.1202107 9788438 20."/>
   <result pre="Bundred NJ Absence of HER4 expression predicts recurrence of ductal" exact="carcinoma in situ" post="of the breast Clin Cancer Res 2005 11 6"/>
   <result pre="Expression of the HER1-4 family of receptor tyrosine kinases in" exact="breast cancer" post="J Pathol 2003 200 3 290 297 10.1002/path.1370 12845624"/>
   <result pre="of the HER1-4 family of receptor tyrosine kinases in breast" exact="cancer" post="J Pathol 2003 200 3 290 297 10.1002/path.1370 12845624"/>
   <result pre="G Troester MA Tse CK Edmiston S et al. Race," exact="breast cancer" post="subtypes, and survival in the Carolina Breast Cancer Study"/>
   <result pre="Troester MA Tse CK Edmiston S et al. Race, breast" exact="cancer" post="subtypes, and survival in the Carolina Breast Cancer Study"/>
   <result pre="growth factor receptor as a potential therapeutic target in triple-negative" exact="breast cancer" post="Ann Oncol 2009 20 5 862 867 10.1093/annonc/mdn710 19150933"/>
   <result pre="factor receptor as a potential therapeutic target in triple-negative breast" exact="cancer" post="Ann Oncol 2009 20 5 862 867 10.1093/annonc/mdn710 19150933"/>
   <result pre="with cisplatin versus cisplatin alone in patients with metastatic triple-negative" exact="breast cancer" post="J Clin Oncol 2013 31 20 2586 2592 10.1200/JCO.2012.46.2408"/>
   <result pre="cisplatin versus cisplatin alone in patients with metastatic triple-negative breast" exact="cancer" post="J Clin Oncol 2013 31 20 2586 2592 10.1200/JCO.2012.46.2408"/>
   <result pre="of a combination of cetuximab and taxane for &quot;triple negative&quot;" exact="breast cancer" post="patients Breast 2014 23 4 435 438 10.1016/j.breast.2014.03.003 24836394"/>
   <result pre="a combination of cetuximab and taxane for &quot;triple negative&quot; breast" exact="cancer" post="patients Breast 2014 23 4 435 438 10.1016/j.breast.2014.03.003 24836394"/>
   <result pre="alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative" exact="breast cancer" post="Clin Breast Cancer 2015 15 1 8 15 10.1016/j.clbc.2014.07.007"/>
   <result pre="or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast" exact="cancer" post="Clin Breast Cancer 2015 15 1 8 15 10.1016/j.clbc.2014.07.007"/>
   <result pre="28. Bloom HJ Richardson WW Histological grading and prognosis in" exact="breast cancer;" post="a study of 1409 cases of which 359 have"/>
   <result pre="Sara H Kallioniemi OP Elenius K Role of ErbB4 in" exact="breast cancer" post="J Mammary Gland Biol Neoplasia 2008 13 2 259"/>
   <result pre="H Kallioniemi OP Elenius K Role of ErbB4 in breast" exact="cancer" post="J Mammary Gland Biol Neoplasia 2008 13 2 259"/>
   <result pre="T Simes RJ et al. Cetuximab for the treatment of" exact="colorectal cancer" post="N Engl J Med 2007 357 20 2040 2048"/>
   <result pre="Simes RJ et al. Cetuximab for the treatment of colorectal" exact="cancer" post="N Engl J Med 2007 357 20 2040 2048"/>
   <result pre="Jassem J et al. Panitumumab-FOLFOX4 treatment and RAS mutations in" exact="colorectal cancer" post="N Engl J Med 2013 369 11 1023 1034"/>
   <result pre="J et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal" exact="cancer" post="N Engl J Med 2013 369 11 1023 1034"/>
   <result pre="WC Horn L et al. AZD9291 in EGFR inhibitor-resistant non-small-cell" exact="lung cancer" post="N Engl J Med 2015 372 18 1689 1699"/>
   <result pre="Horn L et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung" exact="cancer" post="N Engl J Med 2015 372 18 1689 1699"/>
   <result pre="V Guardino E et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
   <result pre="Guardino E et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med 2012 367 19 1783 1791"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4763476/results/search/disease/results.xml">
   <result pre="original author and source are credited. pone.0149432.pdf Abstract Background Metastatic" exact="breast cancer" post="(MBC) remains a devastating and incurable disease. Over the"/>
   <result pre="author and source are credited. pone.0149432.pdf Abstract Background Metastatic breast" exact="cancer" post="(MBC) remains a devastating and incurable disease. Over the"/>
   <result pre="January 2000 and December 2013. Data were obtained from the" exact="breast cancer" post="database of Samsung Medical Center. Results Among the 806"/>
   <result pre="2000 and December 2013. Data were obtained from the breast" exact="cancer" post="database of Samsung Medical Center. Results Among the 806"/>
   <result pre="survival benefit was not maintained in patients with triple negative" exact="breast cancer" post="(TNBC). Conclusions Although not conclusive, we could speculate that"/>
   <result pre="benefit was not maintained in patients with triple negative breast" exact="cancer" post="(TNBC). Conclusions Although not conclusive, we could speculate that"/>
   <result pre="within the paper and its Supporting Information files. Introduction Breast" exact="cancer" post="is the most common female cancer and one of"/>
   <result pre="Information files. Introduction Breast cancer is the most common female" exact="cancer" post="and one of the leading causes of death among"/>
   <result pre="estimated that 30–50% of patients with early to locally advanced" exact="breast cancer" post="at diagnosis experience relapse despite the use of adjuvant"/>
   <result pre="that 30–50% of patients with early to locally advanced breast" exact="cancer" post="at diagnosis experience relapse despite the use of adjuvant"/>
   <result pre="after surgery [ 3]. In addition, 5–10% of patients with" exact="breast cancer" post="present with metastatic disease at diagnosis [ 4, 5]."/>
   <result pre="surgery [ 3]. In addition, 5–10% of patients with breast" exact="cancer" post="present with metastatic disease at diagnosis [ 4, 5]."/>
   <result pre="over the past decade, the survival of patients with metastatic" exact="breast cancer" post="(MBC) has improved slowly [ 6, 7]. Potential explanation"/>
   <result pre="the past decade, the survival of patients with metastatic breast" exact="cancer" post="(MBC) has improved slowly [ 6, 7]. Potential explanation"/>
   <result pre="January 2000 and December 2013. Data were obtained from the" exact="breast cancer" post="database of Samsung Medical Center. We excluded patients with"/>
   <result pre="2000 and December 2013. Data were obtained from the breast" exact="cancer" post="database of Samsung Medical Center. We excluded patients with"/>
   <result pre="status, year of diagnosis with MBC, and medical treatment. Breast" exact="cancer" post="is a heterogeneous disease that is classified according to"/>
   <result pre="as HER2+ regardless of ER and/or PgR), and triple negative" exact="breast cancer" post="(TNBC) (defined as lacking ER, PgR, and HER2 expression)."/>
   <result pre="HER2+ regardless of ER and/or PgR), and triple negative breast" exact="cancer" post="(TNBC) (defined as lacking ER, PgR, and HER2 expression)."/>
   <result pre="(29) 50 (77) 5 (19) SD, standard deviation; MBC, metastatic" exact="breast cancer;" post="DRFI, distant recurrence-free interval. Trends in clinical trials for"/>
   <result pre="recurrence-free interval. Trends in clinical trials for patients with metastatic" exact="breast cancer" post="Fig 2 shows trends in clinical trials of treatments"/>
   <result pre="interval. Trends in clinical trials for patients with metastatic breast" exact="cancer" post="Fig 2 shows trends in clinical trials of treatments"/>
   <result pre="(1.04–1.67) Values in parentheses are 95% confidence intervals. MBC, metastatic" exact="breast cancer;" post="DRFI, DRFI, distant recurrence-free interval. Subgroup analysis Fig 4"/>
   <result pre="TNBC. Discussion Recent epidemiological data indicate significant worldwide decreases in" exact="breast cancer" post="mortality over the past few decades [ 19, 20]."/>
   <result pre="Discussion Recent epidemiological data indicate significant worldwide decreases in breast" exact="cancer" post="mortality over the past few decades [ 19, 20]."/>
   <result pre="in clinical trials. Our findings, although not conclusive, suggest that" exact="breast cancer" post="survival is improved by enrollment in clinical trials. The"/>
   <result pre="clinical trials. Our findings, although not conclusive, suggest that breast" exact="cancer" post="survival is improved by enrollment in clinical trials. The"/>
   <result pre="however, this was not maintained in patients with triple negative" exact="breast cancer." post="Our finding suggest that development of targeted therapeutics available"/>
   <result pre="Chemotherapies and hormone therapies prescribed for the treatment of metastatic" exact="breast cancer" post="for the time cohort. (DOCX) LINK Click here for"/>
   <result pre="and hormone therapies prescribed for the treatment of metastatic breast" exact="cancer" post="for the time cohort. (DOCX) LINK Click here for"/>
   <result pre="for additional data file. S2 Table Clinical trials for metastatic" exact="breast cancer." post="(DOCX) LINK Click here for additional data file. References"/>
   <result pre="AD , Murray CJ . Global and regional estimates of" exact="cancer" post="mortality and incidence by site: II. Results for the"/>
   <result pre="Haidinger R , Hudis CA , et al. The global" exact="breast cancer" post="burden: variations in epidemiology and survival. Clin Breast Cancer."/>
   <result pre="R , Hudis CA , et al. The global breast" exact="cancer" post="burden: variations in epidemiology and survival. Clin Breast Cancer."/>
   <result pre="of patients with complete remission following combination chemotherapy for metastatic" exact="breast cancer" post=". J Clin Oncol. 1996; 14: 2197– 2205. 8708708"/>
   <result pre="patients with complete remission following combination chemotherapy for metastatic breast" exact="cancer" post=". J Clin Oncol. 1996; 14: 2197– 2205. 8708708"/>
   <result pre=", Sledge GW Jr. The role of chemotherapy for metastatic" exact="breast cancer." post="Hematol Oncol Clin North Am. 1999; 13: 415– 434."/>
   <result pre="Docetaxel (Taxotere): an effective agent in the management of second-line" exact="breast cancer." post="Semin Oncol. 1995; 22: 22– 28. 8604449 6 Giordano"/>
   <result pre="Kau SW , Yang Y , Hortobagyi GN . Is" exact="breast cancer" post="survival improving? Cancer. 2004; 100: 44– 52. 14692023 7"/>
   <result pre="SW , Yang Y , Hortobagyi GN . Is breast" exact="cancer" post="survival improving? Cancer. 2004; 100: 44– 52. 14692023 7"/>
   <result pre="on survival in a population-based cohort of women with metastatic" exact="breast cancer" post=". Cancer. 2007; 110: 973– 979. 17647245 8 Cheng"/>
   <result pre="survival in a population-based cohort of women with metastatic breast" exact="cancer" post=". Cancer. 2007; 110: 973– 979. 17647245 8 Cheng"/>
   <result pre="of survival and prospect of cure in patients with metastatic" exact="breast cancer." post="Breast Cancer. 2012; 19: 191– 199. doi: 10.1007/s12282-011-0276-3 21567170"/>
   <result pre="of chemotherapy plus a monoclonal antibody against HER2 for metastatic" exact="breast cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre="chemotherapy plus a monoclonal antibody against HER2 for metastatic breast" exact="cancer" post="that overexpresses HER2 . N Engl J Med. 2001;"/>
   <result pre=", Picciolo A , Healey JH . Orthopedic emergencies in" exact="cancer" post="patients. Semin Oncol. 2000; 27: 299– 310. 10864218 15"/>
   <result pre="phase III study of docetaxel compared with paclitaxel in metastatic" exact="breast cancer" post=". J Clin Oncol. 2005; 23: 5542– 5551. 16110015"/>
   <result pre="III study of docetaxel compared with paclitaxel in metastatic breast" exact="cancer" post=". J Clin Oncol. 2005; 23: 5542– 5551. 16110015"/>
   <result pre="al. Effect of screening and adjuvant therapy on mortality from" exact="breast cancer." post="N Engl J Med. 2005; 353: 1784– 1792. 16251534"/>
   <result pre="G , Altwegg T , et al. Population-based study of" exact="breast cancer" post="survival in Cote d'Or (France): prognostic factors and relative"/>
   <result pre=", Altwegg T , et al. Population-based study of breast" exact="cancer" post="survival in Cote d'Or (France): prognostic factors and relative"/>
   <result pre="JH , et al. Survival in patients with metastatic recurrent" exact="breast cancer" post="after adjuvant chemotherapy: little evidence of improvement over the"/>
   <result pre=", et al. Survival in patients with metastatic recurrent breast" exact="cancer" post="after adjuvant chemotherapy: little evidence of improvement over the"/>
   <result pre=", et al. Prognostic factors in 1,038 women with metastatic" exact="breast cancer." post="Ann Oncol. 2008; 19: 2012– 2019. doi: 10.1093/annonc/mdn424 18641006"/>
   <result pre=", et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic" exact="breast cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast" exact="cancer" post="(CLEOPATRA study): overall survival results from a randomised, double-blind,"/>
   <result pre="Baselga J , et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer." post="N Engl J Med. 2012; 367: 1783– 1791. doi:"/>
   <result pre="Sahmoud T , et al. Everolimus in postmenopausal hormone-receptor-positive advanced" exact="breast cancer." post="N Engl J Med. 2012; 366: 520– 529. doi:"/>
   <result pre="Stage at diagnosis is a key explanation of differences in" exact="breast cancer" post="survival across Europe . Int J Cancer. 2003; 106:"/>
   <result pre="at diagnosis is a key explanation of differences in breast" exact="cancer" post="survival across Europe . Int J Cancer. 2003; 106:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4764922/results/search/disease/results.xml">
   <result pre="Article TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced" exact="breast cancer" post="cell invasion Chevalier Clément 1 * † Collin Guillaume"/>
   <result pre="TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast" exact="cancer" post="cell invasion Chevalier Clément 1 * † Collin Guillaume"/>
   <result pre="of this license, visit http://creativecommons.org/licenses/by/4.0/ Abstract ERBB2 overexpression in human" exact="breast cancer" post="leads to invasive carcinoma but the mechanism is not"/>
   <result pre="this license, visit http://creativecommons.org/licenses/by/4.0/ Abstract ERBB2 overexpression in human breast" exact="cancer" post="leads to invasive carcinoma but the mechanism is not"/>
   <result pre="metastatic progression of ERBB2-positive breast cancers. ERBB2 overexpression in human" exact="breast cancer" post="leads to invasion and metastasis. Here the authors report"/>
   <result pre="progression of ERBB2-positive breast cancers. ERBB2 overexpression in human breast" exact="cancer" post="leads to invasion and metastasis. Here the authors report"/>
   <result pre="leads to tumour cell invasion. Genetic and epigenetic alterations in" exact="breast cancer" post="cells eventually result in invasive carcinoma. The ERBB2 oncogene"/>
   <result pre="to tumour cell invasion. Genetic and epigenetic alterations in breast" exact="cancer" post="cells eventually result in invasive carcinoma. The ERBB2 oncogene"/>
   <result pre="that has become the standard care for patients with ERBB2-positive" exact="breast cancer." post="However, 50% of these patients respond poorly and/or develop"/>
   <result pre="recently identified as a gene relevant to bone metastasis in" exact="breast cancer" post="17 and we observed that TOM1L1, which is located"/>
   <result pre="identified as a gene relevant to bone metastasis in breast" exact="cancer" post="17 and we observed that TOM1L1, which is located"/>
   <result pre="located on chromosome 17q22, is frequently co-amplified with ERBB2 in" exact="breast cancer" post="18, suggesting that TOM1L1 could have a pro-oncogenic function."/>
   <result pre="on chromosome 17q22, is frequently co-amplified with ERBB2 in breast" exact="cancer" post="18, suggesting that TOM1L1 could have a pro-oncogenic function."/>
   <result pre="transforming activity 25. In contrast with the observations in human" exact="breast cancer," post="in transgenic mice, Srcasm inhibits Fyn-induced neoplasia via kinase"/>
   <result pre="associated with worse prognosis in patients with oestrogen receptor-positive (ER+)" exact="breast cancer." post="We next demonstrate that TOM1L1 enhances ERBB2-induced cell invasiveness"/>
   <result pre="ERBB2-positive breast cancers. Results TOM1L1 is co-expressed with ERBB2 in" exact="breast cancer" post="We first confirmed that in breast cancer, the ERBB2"/>
   <result pre="breast cancers. Results TOM1L1 is co-expressed with ERBB2 in breast" exact="cancer" post="We first confirmed that in breast cancer, the ERBB2"/>
   <result pre="with ERBB2 in breast cancer We first confirmed that in" exact="breast cancer," post="the ERBB2 locus at 17q12 (37.85 Mb) is frequently co-amplified"/>
   <result pre="with TOM1L1 transcript upregulation ( Supplementary Table 2). Moreover, in" exact="breast cancer" post="samples, TOM1L1 protein expression, assessed by immunohistochemistry (IHC) ("/>
   <result pre="TOM1L1 transcript upregulation ( Supplementary Table 2). Moreover, in breast" exact="cancer" post="samples, TOM1L1 protein expression, assessed by immunohistochemistry (IHC) ("/>
   <result pre="1d). Finally, metastasis-free survival was reduced in patients with ERBB2+/ER+" exact="breast cancer" post="in which TOM1L1 was also amplified compared with those"/>
   <result pre="Finally, metastasis-free survival was reduced in patients with ERBB2+/ER+ breast" exact="cancer" post="in which TOM1L1 was also amplified compared with those"/>
   <result pre="regulates ERBB2-induced cell invasion We next investigated TOM1L1 role in" exact="breast cancer" post="by manipulating its expression level in ERBB2+/ER+/TOM1L1− SKBR3 cells"/>
   <result pre="ERBB2-induced cell invasion We next investigated TOM1L1 role in breast" exact="cancer" post="by manipulating its expression level in ERBB2+/ER+/TOM1L1− SKBR3 cells"/>
   <result pre="not have any effect on growth and migration of these" exact="breast cancer" post="cells ( Supplementary Fig. 1a,b). In contrast, TOM1L1 overexpression"/>
   <result pre="have any effect on growth and migration of these breast" exact="cancer" post="cells ( Supplementary Fig. 1a,b). In contrast, TOM1L1 overexpression"/>
   <result pre="cells ( Fig. 3a,b) and in HCC-1954 cells (another ERBB2+/ER+/TOM1L1−" exact="breast cancer" post="cell line) ( Supplementary Fig. 2d,e). When injected in"/>
   <result pre="( Fig. 3a,b) and in HCC-1954 cells (another ERBB2+/ER+/TOM1L1− breast" exact="cancer" post="cell line) ( Supplementary Fig. 2d,e). When injected in"/>
   <result pre="upregulated in some breast cancers 29 and mainly in ERBB2+" exact="breast cancer" post="cell lines ( Fig. 3f). In support to this"/>
   <result pre="in some breast cancers 29 and mainly in ERBB2+ breast" exact="cancer" post="cell lines ( Fig. 3f). In support to this"/>
   <result pre="tumour cells by overexpressing TOM1L1 in the ERBB2- and TOM1L1-negative" exact="breast cancer" post="cell line MDA-MB-231 ( Supplementary Fig. 6). We found"/>
   <result pre="cells by overexpressing TOM1L1 in the ERBB2- and TOM1L1-negative breast" exact="cancer" post="cell line MDA-MB-231 ( Supplementary Fig. 6). We found"/>
   <result pre="the original identification of the endosomal protein TSG101 in human" exact="breast cancer." post="Conversely, our study demonstrates a pro-tumoural function for the"/>
   <result pre="pro-tumoural function for the GAT-containing trafficking protein TOM1L1 in human" exact="breast cancer" post="and shows that its pro-oncogenic activity is induced by"/>
   <result pre="function for the GAT-containing trafficking protein TOM1L1 in human breast" exact="cancer" post="and shows that its pro-oncogenic activity is induced by"/>
   <result pre="the plasma membrane in invadopodia structures for the promotion of" exact="cancer" post="cell invasion. The findings that this TOM1L1 pro-invasive activity"/>
   <result pre="in transformed fibroblasts and that TOM1L1 is amplified in other" exact="cancer" post="types ( www.bioportal.com) suggest that TOM1L1 upregulation may define"/>
   <result pre="been identified as a key regulator of MT1-MMP trafficking in" exact="breast cancer" post="35 and could also be an interesting candidate. It"/>
   <result pre="identified as a key regulator of MT1-MMP trafficking in breast" exact="cancer" post="35 and could also be an interesting candidate. It"/>
   <result pre="is not known why TOM1L1 is not tyrosine-phosphorylated in ERBB2-positive" exact="cancer" post="cells. One hypothesis is that ERBB2 might not require"/>
   <result pre="report also shows that ERBB2 expression promotes invadopodia formation in" exact="breast cancer" post="cells. This is in accordance with data demonstrating that"/>
   <result pre="also shows that ERBB2 expression promotes invadopodia formation in breast" exact="cancer" post="cells. This is in accordance with data demonstrating that"/>
   <result pre="frequently co-amplified and define a subgroup of patients with ER-positive" exact="cancer" post="with worse prognosis. Crosstalk between ER, ERBB2 and invasive"/>
   <result pre="that ERBB2 exploits the trafficking function of TOM1L1 to promote" exact="cancer" post="cell invasion. These results highlight that regulators of protein"/>
   <result pre="al. TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced" exact="breast cancer" post="cell invasion. Nat. Commun. 7:10765 doi: 10.1038/ncomms10765 (2016). Supplementary"/>
   <result pre="TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast" exact="cancer" post="cell invasion. Nat. Commun. 7:10765 doi: 10.1038/ncomms10765 (2016). Supplementary"/>
   <result pre="D. &amp;amp; Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in" exact="breast cancer." post="Oncogene 19, 6102– 6114 ( 2000). 11156523 Guo W."/>
   <result pre="Worzfeld T. et al. ErbB-2 signals through Plexin-B1 to promote" exact="breast cancer" post="metastasis. J. Clin. Invest. 122, 1296– 1305 ( 2012)."/>
   <result pre="T. et al. ErbB-2 signals through Plexin-B1 to promote breast" exact="cancer" post="metastasis. J. Clin. Invest. 122, 1296– 1305 ( 2012)."/>
   <result pre="1296– 1305 ( 2012). 22378040 Johnson E. et al. HER2/ErbB2-induced" exact="breast cancer" post="cell migration and invasion require p120 catenin activation of"/>
   <result pre="1305 ( 2012). 22378040 Johnson E. et al. HER2/ErbB2-induced breast" exact="cancer" post="cell migration and invasion require p120 catenin activation of"/>
   <result pre="501– 507 ( 2010). 20043086 Rafn B. et al. ErbB2-driven" exact="breast cancer" post="cell invasion depends on a complex signalling network activating"/>
   <result pre="507 ( 2010). 20043086 Rafn B. et al. ErbB2-driven breast" exact="cancer" post="cell invasion depends on a complex signalling network activating"/>
   <result pre="( 2012). 22209238 Smid M. et al. Genes associated with" exact="breast cancer" post="metastatic to bone. J. Clin. Oncol. 24, 2261– 2267"/>
   <result pre="2012). 22209238 Smid M. et al. Genes associated with breast" exact="cancer" post="metastatic to bone. J. Clin. Oncol. 24, 2261– 2267"/>
   <result pre="et al. Genomic and expression profiling of chromosome 17 in" exact="breast cancer" post="reveals complex patterns of alterations and novel candidate genes"/>
   <result pre="al. Genomic and expression profiling of chromosome 17 in breast" exact="cancer" post="reveals complex patterns of alterations and novel candidate genes"/>
   <result pre="Guedj M. L. et al. A refined molecular taxomony of" exact="breast cancer." post="Oncogene 31, 1196– 11206 ( 2012). 21785460 Wolf K."/>
   <result pre="Multi-step pericellular proteolysis controls the transition from individual to collective" exact="cancer" post="cell invasion . Nat. Cell Biol. 9, 893– 904"/>
   <result pre="of lapatinib is independent of EGFR expression level in HER2-overexpressing" exact="breast cancer" post="cells . Mol. Cancer Ther. 7, 1846– 1850 ("/>
   <result pre="lapatinib is independent of EGFR expression level in HER2-overexpressing breast" exact="cancer" post="cells . Mol. Cancer Ther. 7, 1846– 1850 ("/>
   <result pre="et al. Differential expression of novel tyrosine kinase substrates during" exact="breast cancer" post="development. Mol. Cell. Proteomics 6, 2072– 2087 ( 2007)."/>
   <result pre="al. Differential expression of novel tyrosine kinase substrates during breast" exact="cancer" post="development. Mol. Cell. Proteomics 6, 2072– 2087 ( 2007)."/>
   <result pre="variable effects on the invasive properties of different triple negative" exact="breast cancer" post="cell lines . PLoS ONE 10, e0118854 ( 2015)."/>
   <result pre="effects on the invasive properties of different triple negative breast" exact="cancer" post="cell lines . PLoS ONE 10, e0118854 ( 2015)."/>
   <result pre="2015). 25803821 Wiercinska E. et al. The TGF-β/Smad pathway induces" exact="breast cancer" post="cell invasion through upregulation of matrix metalloproteinase 2 and"/>
   <result pre="25803821 Wiercinska E. et al. The TGF-β/Smad pathway induces breast" exact="cancer" post="cell invasion through upregulation of matrix metalloproteinase 2 and"/>
   <result pre="14644164 Ginestier C. et al. CXCR1 blockade selectively targets human" exact="breast cancer" post="stem cells in vitro and in xenografts . J."/>
   <result pre="Ginestier C. et al. CXCR1 blockade selectively targets human breast" exact="cancer" post="stem cells in vitro and in xenografts . J."/>
   <result pre="S. &amp;amp; Roche S. Analysis of SRC oncogenic signalling in" exact="colorectal cancer" post="by stable isotope labeling with heavy amino acids in"/>
   <result pre="&amp;amp; Roche S. Analysis of SRC oncogenic signalling in colorectal" exact="cancer" post="by stable isotope labeling with heavy amino acids in"/>
   <result pre="the project. Figure 1 TOM1L1 is co-expressed with ERBB2 in" exact="breast cancer." post="( a) The ERBB2 and TOM1L1 loci are frequently"/>
   <result pre="a) The ERBB2 and TOM1L1 loci are frequently co-amplified in" exact="breast cancer." post="Upper part: cumulative array-CGH copy number frequency plots of"/>
   <result pre="co-amplification. ( b) Representative images showing TOM1L1 protein expression in" exact="breast cancer" post="samples with absence (A), weak (B), moderate (C) and"/>
   <result pre="( b) Representative images showing TOM1L1 protein expression in breast" exact="cancer" post="samples with absence (A), weak (B), moderate (C) and"/>
   <result pre="ERBB2 and tubulin (used as loading control) expression in 12" exact="breast cancer" post="cell lines. ( e) Kaplan–Meier survival analysis of patients"/>
   <result pre="and tubulin (used as loading control) expression in 12 breast" exact="cancer" post="cell lines. ( e) Kaplan–Meier survival analysis of patients"/>
   <result pre="lines. ( e) Kaplan–Meier survival analysis of patients with ERBB2+/ER+" exact="breast cancer" post="from the database of ref. 27. Patients were stratified"/>
   <result pre="( e) Kaplan–Meier survival analysis of patients with ERBB2+/ER+ breast" exact="cancer" post="from the database of ref. 27. Patients were stratified"/>
   <result pre="( f) Western blot analysis of TOLLIP expression in 12" exact="breast cancer" post="cell lines. Note that TOLLIP is preferentially expressed in"/>
   <result pre="f) Western blot analysis of TOLLIP expression in 12 breast" exact="cancer" post="cell lines. Note that TOLLIP is preferentially expressed in"/>
   <result pre="t-test). ( d) Western blot showing MT1-MMP expression in 12" exact="breast cancer" post="cell lines. Tubulin is used as loading control. Lysates"/>
   <result pre="( d) Western blot showing MT1-MMP expression in 12 breast" exact="cancer" post="cell lines. Tubulin is used as loading control. Lysates"/>
   <result pre="blot showing expression of the indicated proteins in seven ERBB2+" exact="breast cancer" post="cell lines. Blots are the same as those presented"/>
   <result pre="showing expression of the indicated proteins in seven ERBB2+ breast" exact="cancer" post="cell lines. Blots are the same as those presented"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4769490/results/search/disease/results.xml">
   <result pre="doi: 10.1186/s13058-016-0686-4 : Research Article Mcl-1 confers protection of Her2-positive" exact="breast cancer" post="cells to hypoxia: therapeutic implications Bashari Muhammad Hasan Fan"/>
   <result pre="10.1186/s13058-016-0686-4 : Research Article Mcl-1 confers protection of Her2-positive breast" exact="cancer" post="cells to hypoxia: therapeutic implications Bashari Muhammad Hasan Fan"/>
   <result pre="stated. Abstract Background Molecular mechanisms leading to the adaptation of" exact="breast cancer" post="(BC) cells to hypoxia are largely unknown. The anti-apoptotic"/>
   <result pre="Abstract Background Molecular mechanisms leading to the adaptation of breast" exact="cancer" post="(BC) cells to hypoxia are largely unknown. The anti-apoptotic"/>
   <result pre="supplementary material, which is available to authorized users. Keywords Breast" exact="cancer" post="Myeloid cell leukemia-1 Hypoxia Apoptosis Funding DAAD-Indonesian German Scholarship"/>
   <result pre="DAAD-Indonesian German Scholarship Programme (IGSP) B. Braun Stiftungs Background Breast" exact="cancer" post="(BC) is the most common malignancy and the second"/>
   <result pre="receptor (EGFR) and HER2 [ 7]. Basal-like BC or triple-negative" exact="breast cancer" post="(TNBC) is characterized by ER-negative, PR-negative, and Her2-negative tumors"/>
   <result pre="(EGFR) and HER2 [ 7]. Basal-like BC or triple-negative breast" exact="cancer" post="(TNBC) is characterized by ER-negative, PR-negative, and Her2-negative tumors"/>
   <result pre="being a possible exception [ 12]. Hypoxic conditions develop during" exact="cancer" post="progression because of rapidly proliferating tumor cells that reduce"/>
   <result pre="activation. In contrast, blockade of NOXA induction results in the" exact="suppression" post="of apoptosis [ 19, 20]. Several past studies indicated"/>
   <result pre="20]. Several past studies indicated that Mcl-1 is an important" exact="cancer" post="target. Specifically, Mcl-1 is amplified in many cancers including"/>
   <result pre="therapeutic target. Indeed, Mcl-1 is the current focus of widespread" exact="cancer" post="drug development efforts, and a number of Mcl-1 inhibitors"/>
   <result pre="efforts, and a number of Mcl-1 inhibitors are in the" exact="cancer" post="drug development pipeline worldwide [ 30]. In this study"/>
   <result pre="are currently validated in advanced clinical trials in solid tumors," exact="acute myeloid leukemia" post="(AML), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL)"/>
   <result pre="currently validated in advanced clinical trials in solid tumors, acute" exact="myeloid leukemia" post="(AML), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL)"/>
   <result pre="validated in advanced clinical trials in solid tumors, acute myeloid" exact="leukemia" post="(AML), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL)"/>
   <result pre="advanced clinical trials in solid tumors, acute myeloid leukemia (AML)," exact="chronic lymphocytic leukemia" post="(CLL), and non-Hodgkin lymphoma (NHL) ( https://clinicaltrials.gov). Similar to"/>
   <result pre="trials in solid tumors, acute myeloid leukemia (AML), chronic lymphocytic" exact="leukemia" post="(CLL), and non-Hodgkin lymphoma (NHL) ( https://clinicaltrials.gov). Similar to"/>
   <result pre="acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and non-Hodgkin" exact="lymphoma" post="(NHL) ( https://clinicaltrials.gov). Similar to previous data, our own"/>
   <result pre="of targeting agents and are the current focus of widespread" exact="cancer" post="drug development efforts. However, the clinical development of Mcl-1"/>
   <result pre="cells under hypoxic conditions. (PDF 1580 kb) Abbreviations BC Breast" exact="cancer" post="BH3 Bcl-2 homology 3 CI Combination index DKFZ German"/>
   <result pre="receptor SD Standard deviation siRNA Small interfering RNA TNBC Triple-negative" exact="breast cancer" post="Competing interests MA and MHC are employees of Eutropics,"/>
   <result pre="SD Standard deviation siRNA Small interfering RNA TNBC Triple-negative breast" exact="cancer" post="Competing interests MA and MHC are employees of Eutropics,"/>
   <result pre="Gerstenhauer M et al. Ki-67 is a prognostic parameter in" exact="breast cancer" post="patients: results of a large population-based cohort of a"/>
   <result pre="M et al. Ki-67 is a prognostic parameter in breast" exact="cancer" post="patients: results of a large population-based cohort of a"/>
   <result pre="cancer patients: results of a large population-based cohort of a" exact="cancer" post="registry Breast Cancer Res Treat. 2013 139 539 52"/>
   <result pre="23674192 3. Ellis MJ Perou CM The genomic landscape of" exact="breast cancer" post="as a therapeutic roadmap Cancer Discov. 2013 3 27"/>
   <result pre="3. Ellis MJ Perou CM The genomic landscape of breast" exact="cancer" post="as a therapeutic roadmap Cancer Discov. 2013 3 27"/>
   <result pre="genes required for the growth and survival of HER2 positive" exact="breast cancer" post="cells Mol Oncol. 2013 7 392 401 10.1016/j.molonc.2012.10.012 23253899"/>
   <result pre="required for the growth and survival of HER2 positive breast" exact="cancer" post="cells Mol Oncol. 2013 7 392 401 10.1016/j.molonc.2012.10.012 23253899"/>
   <result pre="9. Yarden Y Biology of HER2 and its importance in" exact="breast cancer" post="Oncology. 2001 61 Suppl 2 1 13 10.1159/000055396 11694782"/>
   <result pre="Yarden Y Biology of HER2 and its importance in breast" exact="cancer" post="Oncology. 2001 61 Suppl 2 1 13 10.1159/000055396 11694782"/>
   <result pre="al. Studies of the HER-2/neu proto-oncogene in human breast and" exact="ovarian cancer" post="Science. 1989 244 707 12 10.1126/science.2470152 2470152 11. Verma"/>
   <result pre="Studies of the HER-2/neu proto-oncogene in human breast and ovarian" exact="cancer" post="Science. 1989 244 707 12 10.1126/science.2470152 2470152 11. Verma"/>
   <result pre="M Baselga J et al. Trastuzumab emtansine for HER2-positive advanced" exact="breast cancer" post="N Engl J Med. 2012 367 1783 91 10.1056/NEJMoa1209124"/>
   <result pre="Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast" exact="cancer" post="N Engl J Med. 2012 367 1783 91 10.1056/NEJMoa1209124"/>
   <result pre="study of lapatinib in patients with brain metastases from HER2-positive" exact="breast cancer" post="Clin Cancer Res. 2009 15 1452 9 10.1158/1078-0432.CCR-08-1080 19228746"/>
   <result pre="of lapatinib in patients with brain metastases from HER2-positive breast" exact="cancer" post="Clin Cancer Res. 2009 15 1452 9 10.1158/1078-0432.CCR-08-1080 19228746"/>
   <result pre="of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor" exact="suppression" post="and chemosensitization Mol Cell Biol. 2007 27 4006 17"/>
   <result pre="M A survey of the anti-apoptotic Bcl-2 subfamily expression in" exact="cancer" post="types provides a platform to predict the efficacy of"/>
   <result pre="a platform to predict the efficacy of Bcl-2 antagonists in" exact="cancer" post="therapy Cell Death Dis. 2010 1 e40 10.1038/cddis.2010.18 21364647"/>
   <result pre="through the MAPK-Elk-1 signalling pathway contributing to cell survival in" exact="breast cancer" post="Oncogene. 2011 30 2367 78 10.1038/onc.2010.616 21258408 25. Schacter"/>
   <result pre="the MAPK-Elk-1 signalling pathway contributing to cell survival in breast" exact="cancer" post="Oncogene. 2011 30 2367 78 10.1038/onc.2010.616 21258408 25. Schacter"/>
   <result pre="Estrogen regulation of anti-apoptotic Bcl-2 family member Mcl-1 expression in" exact="breast cancer" post="cells PLoS One. 2014 9 e100364 10.1371/journal.pone.0100364 24971890 26."/>
   <result pre="regulation of anti-apoptotic Bcl-2 family member Mcl-1 expression in breast" exact="cancer" post="cells PLoS One. 2014 9 e100364 10.1371/journal.pone.0100364 24971890 26."/>
   <result pre="Fesik SW Small molecule Mcl-1 inhibitors for the treatment of" exact="cancer" post="Pharmacol Ther. 2015 145 76 84 10.1016/j.pharmthera.2014.08.003 25172548 31."/>
   <result pre="W et al. Profound prevention of experimental brain metastases of" exact="breast cancer" post="by temozolomide in an MGMT-dependent manner Clin Cancer Res."/>
   <result pre="et al. Profound prevention of experimental brain metastases of breast" exact="cancer" post="by temozolomide in an MGMT-dependent manner Clin Cancer Res."/>
   <result pre="S Antonini E Goldschmidt H et al. Targeting Mcl-1 for" exact="multiple myeloma" post="(MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers"/>
   <result pre="HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in" exact="breast cancer" post="cell lines Breast Cancer. 2010 4 35 41 20697531"/>
   <result pre="CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast" exact="cancer" post="cell lines Breast Cancer. 2010 4 35 41 20697531"/>
   <result pre="Holliday DL Speirs V Choosing the right cell line for" exact="breast cancer" post="research Breast Cancer Res. 2011 13 215 10.1186/bcr2889 21884641"/>
   <result pre="DL Speirs V Choosing the right cell line for breast" exact="cancer" post="research Breast Cancer Res. 2011 13 215 10.1186/bcr2889 21884641"/>
   <result pre="E Martinello R Milani A Redana S et al. Metastatic" exact="breast cancer" post="subtypes and central nervous system metastases Breast. 2014 23"/>
   <result pre="Martinello R Milani A Redana S et al. Metastatic breast" exact="cancer" post="subtypes and central nervous system metastases Breast. 2014 23"/>
   <result pre="targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified" exact="breast cancer" post="brain metastases Proc Natl Acad Sci U S A."/>
   <result pre="of HER2 and VEGFR2 for effective treatment of HER2-amplified breast" exact="cancer" post="brain metastases Proc Natl Acad Sci U S A."/>
   <result pre="BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in" exact="chronic lymphocytic leukemia" post="Blood. 2009 113 4403 13 10.1182/blood-2008-08-173310 19008458 52. Konopleva"/>
   <result pre="BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic" exact="leukemia" post="Blood. 2009 113 4403 13 10.1182/blood-2008-08-173310 19008458 52. Konopleva"/>
   <result pre="apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in" exact="acute myeloid leukemia" post="Cancer Cell. 2006 10 375 88 10.1016/j.ccr.2006.10.006 17097560 53."/>
   <result pre="sensitivity and resistance to the BH3 mimetic ABT-737 in acute" exact="myeloid leukemia" post="Cancer Cell. 2006 10 375 88 10.1016/j.ccr.2006.10.006 17097560 53."/>
   <result pre="and resistance to the BH3 mimetic ABT-737 in acute myeloid" exact="leukemia" post="Cancer Cell. 2006 10 375 88 10.1016/j.ccr.2006.10.006 17097560 53."/>
   <result pre="An antiapoptotic BCL-2 family expression index predicts the response of" exact="chronic lymphocytic leukemia" post="to ABT-737 Blood. 2011 118 3579 90 10.1182/blood-2011-03-340364 21772052"/>
   <result pre="BCL-2 family expression index predicts the response of chronic lymphocytic" exact="leukemia" post="to ABT-737 Blood. 2011 118 3579 90 10.1182/blood-2011-03-340364 21772052"/>
   <result pre="cell leukemia-1 is an important apoptotic survival factor in triple-negative" exact="breast cancer" post="Cell Death Differ. 2015 22 2098 106 10.1038/cdd.2015.73 26045046"/>
   <result pre="leukemia-1 is an important apoptotic survival factor in triple-negative breast" exact="cancer" post="Cell Death Differ. 2015 22 2098 106 10.1038/cdd.2015.73 26045046"/>
   <result pre="and Aurora kinase A as novel treatment targets in antiestrogen-resistant" exact="breast cancer" post="cells Oncogene. 2015 6 4199 210 10.1038/onc.2014.351 25362855 57."/>
   <result pre="Aurora kinase A as novel treatment targets in antiestrogen-resistant breast" exact="cancer" post="cells Oncogene. 2015 6 4199 210 10.1038/onc.2014.351 25362855 57."/>
   <result pre="screen identifies proteasome addiction as a vulnerability of basal-like triple-negative" exact="breast cancer" post="cells Cancer Cell. 2013 24 182 96 10.1016/j.ccr.2013.07.008 23948298"/>
   <result pre="identifies proteasome addiction as a vulnerability of basal-like triple-negative breast" exact="cancer" post="cells Cancer Cell. 2013 24 182 96 10.1016/j.ccr.2013.07.008 23948298"/>
   <result pre="enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and" exact="ovarian cancer" post="cell lines that overexpress erbB-2 Cancer Res. 2001 61"/>
   <result pre="tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian" exact="cancer" post="cell lines that overexpress erbB-2 Cancer Res. 2001 61"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4770148/results/search/disease/results.xml">
   <result pre="genetically engineered mouse model as a preclinical tool for HER2" exact="breast cancer" post="Creedon Helen 1 Balderstone Lucy A. 1 * Muir"/>
   <result pre="engineered mouse model as a preclinical tool for HER2 breast" exact="cancer" post="Creedon Helen 1 Balderstone Lucy A. 1 * Muir"/>
   <result pre="the utility of a genetically engineered mouse model of HER2-driven" exact="breast cancer" post="(MMTV-NIC) to define mechanisms of resistance to the pan-HER"/>
   <result pre="utility of a genetically engineered mouse model of HER2-driven breast" exact="cancer" post="(MMTV-NIC) to define mechanisms of resistance to the pan-HER"/>
   <result pre="study demonstrates the utility of a transgenic mouse model of" exact="breast cancer" post="to define mechanisms of resistance to a pan-HER family"/>
   <result pre="demonstrates the utility of a transgenic mouse model of breast" exact="cancer" post="to define mechanisms of resistance to a pan-HER family"/>
   <result pre="and identifies a link with EMT. KEY WORDS HER2 Breast" exact="cancer" post="Resistance Epithelial-to-mesenchymal transition Funding Cancer Research UK http://search.crossref.org/fundref?q=501100000321 C157/A15703"/>
   <result pre="have had a significant impact on the treatment of HER2-positive" exact="breast cancer" post="( Arteaga et al., 2012); these include antibodies directed"/>
   <result pre="had a significant impact on the treatment of HER2-positive breast" exact="cancer" post="( Arteaga et al., 2012); these include antibodies directed"/>
   <result pre="preclinical tool to study response and resistance mechanisms in HER2-positive" exact="breast cancer." post="We have used the MMTV-NIC (Neu-IRES-Cre) model ( Ursini-Siegel"/>
   <result pre="whose role in the management of both early and metastatic" exact="breast cancer" post="is well established ( Gajria et al., 2010; Ghersi"/>
   <result pre="role in the management of both early and metastatic breast" exact="cancer" post="is well established ( Gajria et al., 2010; Ghersi"/>
   <result pre="PI3K pathway as a major determinant of trastuzumab resistance in" exact="breast cancer" post=". Cancer Cell 12, 395- 402. 10.1016/j.ccr.2007.08.030 17936563 Creedon"/>
   <result pre="pathway as a major determinant of trastuzumab resistance in breast" exact="cancer" post=". Cancer Cell 12, 395- 402. 10.1016/j.ccr.2007.08.030 17936563 Creedon"/>
   <result pre="to HER2 (human epidermal growth factor receptor 2)-targeted therapies in" exact="breast cancer" post=". Biochem. Soc. Trans. 42, 822- 830. 10.1042/BST20140109 25109964"/>
   <result pre="HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast" exact="cancer" post=". Biochem. Soc. Trans. 42, 822- 830. 10.1042/BST20140109 25109964"/>
   <result pre="with trastuzumab response and survival in patients with HER2-positive metastatic" exact="breast cancer" post=". Am. J. Pathol. 177, 1647- 1656. 10.2353/ajpath.2010.090885 20813970"/>
   <result pre="trastuzumab response and survival in patients with HER2-positive metastatic breast" exact="cancer" post=". Am. J. Pathol. 177, 1647- 1656. 10.2353/ajpath.2010.090885 20813970"/>
   <result pre="( 2005). A systematic review of taxane-containing regimens for metastatic" exact="breast cancer." post="Br. J. Cancer 93, 293- 301. 10.1038/sj.bjc.6602680 16052223 Guo"/>
   <result pre="ERBB3: a unique agent for simultaneous ERBB receptor blockade in" exact="cancer" post=". Clin. Cancer Res. 16, 1159- 1169. 10.1158/1078-0432.CCR-09-2353 20145185"/>
   <result pre="transition signaling confers acquired resistance to lapatinib in HER2-positive gastric" exact="cancer" post=". Oncogene 33, 3334- 3341. 10.1038/onc.2013.285 23873022 Korkaya H."/>
   <result pre="of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+" exact="breast cancer" post="by expanding the cancer stem cell population . Mol."/>
   <result pre="an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast" exact="cancer" post="by expanding the cancer stem cell population . Mol."/>
   <result pre="mediates trastuzumab resistance in HER2+ breast cancer by expanding the" exact="cancer" post="stem cell population . Mol. Cell 47, 570- 584."/>
   <result pre="signaling enhances delivery of chemotherapy in a mouse model of" exact="pancreatic cancer" post=". Science 324, 1457- 1461. 10.1126/science.1171362 19460966 Oliveras-Ferraros C."/>
   <result pre="enhances delivery of chemotherapy in a mouse model of pancreatic" exact="cancer" post=". Science 324, 1457- 1461. 10.1126/science.1171362 19460966 Oliveras-Ferraros C."/>
   <result pre="of mammary tumors in a conditional mouse model for hereditary" exact="breast cancer" post=". Proc. Natl. Acad. Sci. USA 104, 12117- 12122."/>
   <result pre="mammary tumors in a conditional mouse model for hereditary breast" exact="cancer" post=". Proc. Natl. Acad. Sci. USA 104, 12117- 12122."/>
   <result pre="( 2006). The mighty mouse: genetically engineered mouse models in" exact="cancer" post="drug development. Nat. Rev. Drug Discov. 5, 741- 754."/>
   <result pre="10.1038/nrd2110 16915232 Singh A. and Settleman J. ( 2010). EMT," exact="cancer" post="stem cells and drug resistance: an emerging axis of"/>
   <result pre="resistance: an emerging axis of evil in the war on" exact="cancer" post=". Oncogene 29, 4741- 4751. 10.1038/onc.2010.215 20531305 Singh M."/>
   <result pre="is essential for tumour progression in mouse models of human" exact="breast cancer" post=". EMBO J. 27, 910- 920. 10.1038/emboj.2008.22 18273058 van"/>
   <result pre="essential for tumour progression in mouse models of human breast" exact="cancer" post=". EMBO J. 27, 910- 920. 10.1038/emboj.2008.22 18273058 van"/>
   <result pre="( 2012). Using genetically engineered mouse models to validate candidate" exact="cancer" post="genes and test new therapeutic approaches . Curr. Opin."/>
   <result pre="and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant" exact="breast cancer" post=". Cancer Res. 72, 4417- 4428. 10.1158/0008-5472.CAN-12-1339-T 22773664 Xia"/>
   <result pre="induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast" exact="cancer" post=". Cancer Res. 72, 4417- 4428. 10.1158/0008-5472.CAN-12-1339-T 22773664 Xia"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4772532/results/search/disease/results.xml">
   <result pre="26925829 35 doi: 10.1186/s12976-016-0035-4 : Review Toward precision medicine of" exact="breast cancer" post="Carels Nicolas nicolas.carels@cdts.fiocruz.br Spinassé Lizânia Borges lizaspinasse@gmail.com Tilli Tatiana"/>
   <result pre="35 doi: 10.1186/s12976-016-0035-4 : Review Toward precision medicine of breast" exact="cancer" post="Carels Nicolas nicolas.carels@cdts.fiocruz.br Spinassé Lizânia Borges lizaspinasse@gmail.com Tilli Tatiana"/>
   <result pre="technologies are helping in understanding the dynamics of tumorigenesis and" exact="cancer" post="progression with the aim of developing precision medicine methods."/>
   <result pre="We first address the current state of the art in" exact="breast cancer" post="therapies and challenges in order to progress towards its"/>
   <result pre="first address the current state of the art in breast" exact="cancer" post="therapies and challenges in order to progress towards its"/>
   <result pre="discuss the challenge of pharmacogenetics in the clinical practice of" exact="cancer" post="therapy. All these issues are explored within the context"/>
   <result pre="of TBioMed on &quot;Biophysical Models of Cell Behavior&quot;. Background Breast" exact="cancer" post="(BC) is a global disease; it is the most"/>
   <result pre="(BC) is a global disease; it is the most common" exact="cancer" post="in women (accounting for 25 % of all cancers),"/>
   <result pre="neoplasia in women and the main cause of death from" exact="cancer" post="in the country. This fact has been associated with"/>
   <result pre="PM remains an indispensable route to decrease the toxicity of" exact="cancer" post="treatment and to increase its benefit to patients. A"/>
   <result pre="to patients. A mutation-oriented approach is not expected to solve" exact="cancer" post="therapy because if genome destabilization is effectively due to"/>
   <result pre="informatics and mathematical modeling constitutes a new opportunity to improve" exact="cancer" post="therapies through PM. Thus, it is the aim of"/>
   <result pre="the prospective of PM applied to BC. Review Incidence of" exact="breast cancer" post="and prevention Cancer incidence varies among countries mainly according"/>
   <result pre="prospective of PM applied to BC. Review Incidence of breast" exact="cancer" post="and prevention Cancer incidence varies among countries mainly according"/>
   <result pre="to lifestyle, which explains as much as 75-85 % of" exact="cancer" post="etiology, with the most significant parameters being: physical inactivity,"/>
   <result pre="birth, and enhanced alcohol consumption [ 6]. Lifestyle’s influence on" exact="cancer" post="likelihood has been demonstrated by statistics from people migrating"/>
   <result pre="an adopted country starting to mimic the risk profile and" exact="cancer" post="incidence of their adopted country (especially USA). For instance,"/>
   <result pre="their more industrialized, Western counterparts [ 7]. Countries with lower" exact="cancer" post="incidence were associated with a nutrition mostly based on"/>
   <result pre="fats. The compounds that have been most cited as being" exact="cancer" post="protective include those that belong to phenolics comprised of"/>
   <result pre="10]. The main action of these compounds is to prevent" exact="cancer" post="development by promoting anti-oxidant and anti-inflammatory effects as well"/>
   <result pre="exact contribution of a diet based on plant products to" exact="cancer" post="prevention is difficult to unwrap [ 11]. Examples of"/>
   <result pre="to unwrap [ 11]. Examples of plant compounds used in" exact="cancer" post="therapy are: curcumin, genistein, resveratrol and catechins. Mammary gland"/>
   <result pre="in regard to how to proceed with specific therapies. When" exact="cancer" post="cells express estrogen receptors, they depend on estrogen for"/>
   <result pre="both receptors are hormone receptor-positive (HR+) cells [ 15]. HER2+" exact="cancer" post="cells respond to biological agents such as the monoclonal"/>
   <result pre="receptors in several cell lines used as molecular markers for" exact="breast cancer" post="diagnosis Cell line Histological subtype ER/PR a HER2 b"/>
   <result pre="in several cell lines used as molecular markers for breast" exact="cancer" post="diagnosis Cell line Histological subtype ER/PR a HER2 b"/>
   <result pre="being invested in molecular characterization of malignant cells. In particular," exact="breast cancer" post="stem cells (BCSC) generated substantial interest because they are"/>
   <result pre="invested in molecular characterization of malignant cells. In particular, breast" exact="cancer" post="stem cells (BCSC) generated substantial interest because they are"/>
   <result pre="different CDs have been identified. The surface cell markers epithelium" exact="cancer" post="adhesive molecule (Ep-CAM) and CD49f (α-6 integrin) were investigated"/>
   <result pre="mechanical and optoplasmonic transduction will soon allow the detection of" exact="cancer" post="biomarkers in serum at ultra-low concentrations such as ~10"/>
   <result pre="enter into hyper-proliferative and inflammatory processes. The prevailing model for" exact="cancer" post="development is that mutations in genes for tumor suppressors"/>
   <result pre="uncontrolled division and growth. The evolution of a cell toward" exact="cancer" post="is a cumulative process that occurs on a phenotypic"/>
   <result pre="the tumor growth rate may remain unaffected [ 32]. Some" exact="cancer" post="cells acquire the ability to penetrate the walls of"/>
   <result pre="properties necessary for malignant cell dispersion [ 33]. Ultimately, incurable" exact="cancer" post="leads to cachexia (a profound and marked state of"/>
   <result pre="and accelerated demise [ 34]. Consequence of tumor heterogeneity on" exact="cancer" post="evolution and drug resistance Whole-cancer genomes carry thousands to"/>
   <result pre="another driven by shifting selective pressures, mutational processes, and disrupted" exact="cancer" post="genes. The compilation of mutational signatures from model systems"/>
   <result pre="extensive catalogue of mutations in 30 of the most common" exact="cancer" post="types. The procedure uncovered more than 20 signatures of"/>
   <result pre="somatic mutations found in all derived tumor cells. All extant" exact="cancer" post="cells in the analyzed sample can trace a genealogy"/>
   <result pre="chemotherapeutic treatments [ 47]. Their persistence helps to explain the" exact="cancer" post="recurrence following apparently successful treatment. BCSCs seem to be"/>
   <result pre="be able to exhibit certain forms of dormancy enabling latent" exact="cancer" post="cells to persist for years or even decades after"/>
   <result pre="[ 44]. All these concepts together reinforce the notion that" exact="cancer" post="treatment should be considered as a shift away from"/>
   <result pre="is based on the intra- and inter-tumor heterogeneity. Hallmarks of" exact="cancer" post="The concept of a cancer hallmark tends to rationalize"/>
   <result pre="and inter-tumor heterogeneity. Hallmarks of cancer The concept of a" exact="cancer" post="hallmark tends to rationalize the complexity of neoplastic diseases"/>
   <result pre="the complexity of neoplastic diseases in properties common to all" exact="cancer" post="forms and that govern the transformation of normal into"/>
   <result pre="into malignant cells. Hallmarks are acquired functional capabilities that allow" exact="cancer" post="cells to survive, proliferate, and disseminate; these functions are"/>
   <result pre="of multistep tumorigenesis. According to Hanahan and Weinberg [ 50]," exact="cancer" post="hallmarks include: (i)   Sustaining proliferative signaling allowing malignant"/>
   <result pre="the cell cycle as well as cell growth. By contrast," exact="cancer" post="cells can generate their own growth signals. Over-expressed growth"/>
   <result pre="in an autocrine proliferative stimulation. The numerous signaling molecules affecting" exact="cancer" post="cells operate as nodes in interaction networks forming integrated"/>
   <result pre="interphase. Ultimately, signals of growth inhibition are funneled through the" exact="retinoblastoma" post="protein (pRB), which prevents the inappropriate transition from G1"/>
   <result pre="multiplication to about 60–70 doublings that can be overcome in" exact="cancer" post="cell by pRB and p53 tumor suppressor disabling and"/>
   <result pre="stabilizes mutant genomes and confers the unlimited replicative capacity that" exact="cancer" post="cells need in order to clonally expand; (v)  "/>
   <result pre="margins of certain tumors may undergo EMT suggesting that these" exact="cancer" post="cells are subject to micro-environmental stimuli distinct from those"/>
   <result pre="cell intravasation into nearby blood and lymphatic vessels, transit of" exact="cancer" post="cells through lymphatic and hematogenous systems; (iii) the escape"/>
   <result pre="of invasion and metastasis that needs to be overcome by" exact="cancer" post="cells in order to progress. The role of contextual"/>
   <result pre="(often via an EMT) implies the possibility of reversibility since" exact="cancer" post="cells that have disseminated from a primary tumor to"/>
   <result pre="of distinct signaling programs; (vii)   Abnormal metabolic pathways. Most" exact="cancer" post="cells use abnormal metabolic pathways to generate energy. A"/>
   <result pre="Some tumors have been found to contain two subpopulations of" exact="cancer" post="cells that differ in their pathways of energy supply"/>
   <result pre="75, 76]. Glutamine may also be converted into lactate in" exact="cancer" post="cells in vitro [ 77]. The tumor anaerobic metabolism"/>
   <result pre="than in the immune-competent controls [ 78, 79]. Highly immunogenic" exact="cancer" post="cells seem to evade immune destruction by disabling challenging"/>
   <result pre="by disabling challenging components of the immune system. For example," exact="cancer" post="cells may paralyze infiltrating CTLs and NK cells, by"/>
   <result pre="supply epidermal growth factor (EGF) to BC cells, while the" exact="cancer" post="cells reciprocally stimulate the macrophages in such a way"/>
   <result pre="hallmark capabilities), infiltrating immune cells (which supply mitogenic signals to" exact="cancer" post="cells and proteolytic enzymes that release bioactive mitogenic agents"/>
   <result pre="targeting such driving oncogenic signals [ 88]. Molecular targets for" exact="breast cancer" post="treatments As outlined above, BC resembles a Darwinian evolutionary"/>
   <result pre="such driving oncogenic signals [ 88]. Molecular targets for breast" exact="cancer" post="treatments As outlined above, BC resembles a Darwinian evolutionary"/>
   <result pre="identified in BC along with evidence supporting drug combinations for" exact="cancer" post="control, which deserve to be briefly listed below and"/>
   <result pre="of key proteins in signaling pathways for the investigation of" exact="cancer" post="therapies The fibroblast growth factor (FGF) signaling pathway induces"/>
   <result pre="cancer therapies The fibroblast growth factor (FGF) signaling pathway induces" exact="cancer" post="cell proliferation, apoptosis evasion, facilitation of an invasive phenotype"/>
   <result pre="implicated in a broad range of human malignancies and promotes" exact="cancer" post="progression in tumors driven by FGF/FGFR oncogenic mutations or"/>
   <result pre="effectors: AKT1 and AKT2; (ii) the PI3K activator: Kirsten rat" exact="sarcoma" post="homolog (KRAS); and (iii) the negative PI3K regulators: phosphatase"/>
   <result pre="the inhibition of PI3K signaling via negative feedback of some" exact="cancer" post="cells signaling circuitry. mTOR senses and integrates diverse nutritional"/>
   <result pre="may represent a potential therapeutic target for patients with refractory" exact="pancreatic cancer." post="A potent Hh inhibitor can successfully inhibit tumor growth"/>
   <result pre="the stage for clinical trials in humans [ 106]. Breast" exact="cancer" post="therapies Drug therapy They are five stages (0 to"/>
   <result pre="in developing stratified oncology. SM means analyzing large groups of" exact="cancer" post="patients in order to predict which treatments these cancer"/>
   <result pre="of cancer patients in order to predict which treatments these" exact="cancer" post="patients are most likely to respond to. It involves"/>
   <result pre="to respond to. It involves looking in detail at the" exact="cancer" post="cells and their genetic make up. Nowadays, science is"/>
   <result pre="a significant technological advance for improving the understanding of malignant" exact="neoplasm" post="because cancer is basically viewed as a genome disease."/>
   <result pre="technological advance for improving the understanding of malignant neoplasm because" exact="cancer" post="is basically viewed as a genome disease. As outlined"/>
   <result pre="epigenetic landscape. The most significant impact of next-generation sequencing on" exact="cancer" post="genomics has been the ability to re-sequence, analyze and"/>
   <result pre="now possible to sequence multiple patient samples of a given" exact="cancer" post="type. NGS sequencing is useful to understand the affected"/>
   <result pre="NGS sequencing is useful to understand the affected pathways behind" exact="cancer" post="development. This requires a preliminary investigation to map genes"/>
   <result pre="allows one to infer how early in the path toward" exact="cancer" post="development that particular mutation occurred [ 127]. Exome is"/>
   <result pre="researches is to distinguish between driver mutations that lead to" exact="cancer" post="development and passenger mutations, which are functionally neutral and"/>
   <result pre="is to find genes, which are recurrently mutated in large" exact="cancer" post="samples. Initially, cancer genes such as p53, Myc, PTEN"/>
   <result pre="genes, which are recurrently mutated in large cancer samples. Initially," exact="cancer" post="genes such as p53, Myc, PTEN and IDH1 were"/>
   <result pre="dinucleotides throughout the genome tend to be methylated. However, in" exact="cancer" post="cells, CpG islands preceding tumor suppressor gene promoters are"/>
   <result pre="numbers of cells through NGS has enabled deep analysis between" exact="cancer" post="and epigenetic dysregulation [ 130]. According to the landscape"/>
   <result pre="tumor sequencing might reveal; it is not yet clear whether" exact="cancer" post="somatic alterations identified are recurrently affecting specific genes and"/>
   <result pre="Rb. Incorporation of miRNA regulation into current models of molecular" exact="cancer" post="pathogenesis is essential to achieve a complete understanding of"/>
   <result pre="would likely promote oncogenesis and thus may be over-expressed in" exact="cancer" post="cells. Likewise, miRNAs with anti-proliferative and pro-apoptotic activity are"/>
   <result pre="as tumor suppressor genes and thus may be under-expressed in" exact="cancer" post="cells [ 147]. Proteome profiling Proteomes carry biological information"/>
   <result pre="revealing 233 hub proteins, each associated with three or more" exact="cancer" post="census genes and &quot;cell cycle&quot; the only significantly enriched"/>
   <result pre="signatures, and (iv) it predicts a higher cellular heterogeneity in" exact="cancer" post="stem cells compared to ordinary cancer cells. The higher"/>
   <result pre="higher cellular heterogeneity in cancer stem cells compared to ordinary" exact="cancer" post="cells. The higher entropy of pluripotent SCs compared to"/>
   <result pre="with the consequence that a drug cocktail is necessary for" exact="cancer" post="control or eradication. Relationship between disease and protein networks"/>
   <result pre="impair the normal cell functioning. However, in the case of" exact="cancer" post="cells the few dysregulated genes encoding hubs may play"/>
   <result pre="is expected to break down attractors that are essential for" exact="cancer" post="progression and to bring cellular activity in alternative attractors"/>
   <result pre="an in silico evaluation, [ 134] classified drugs involved in" exact="cancer" post="therapy [ 175] could be separated into two general"/>
   <result pre="differentially expressed genes, in addition to being induced by specific" exact="cancer" post="pathways, are interacting with each other apparently in a"/>
   <result pre="treatment regimen as combinatorial therapies are required to target different" exact="cancer" post="cells and it makes difficult to interpret the treatment"/>
   <result pre="system [ 188]. In this context, the PM management of" exact="cancer" post="implies the prescription of target-specific therapeutics that is best"/>
   <result pre="are related to oncology. Actually, nearly half of the recent" exact="cancer" post="drug approvals (48 %) are first class, i.e., interesting"/>
   <result pre="can have an impact on how the pharmaceutical industry develops" exact="cancer" post="drugs by identifying the genes and their isoforms involved"/>
   <result pre="endoxifen and 4-hydroxy-tamoxifen are potent anti-estrogenic metabolites with a higher" exact="suppression" post="rate of cell proliferation compared to tamoxifen, which brings"/>
   <result pre="few genes had only limited success in the control of" exact="cancer" post="disease and its prognosis. The identification of BC molecular"/>
   <result pre="genome level, the number of possible dysregulated pathways leading to" exact="cancer" post="is much smaller, which inevitably implies phenotypic redundancy at"/>
   <result pre="arsenal of target specific drugs should be sufficient to control" exact="cancer" post="with marginal negative side effects to patients [ 134]."/>
   <result pre="experiments, describing response to 138 anticancer drugs across almost 700" exact="cancer" post="cell lines [ 207]; another interesting resource in that"/>
   <result pre="of those patients with a favorable molecular profile in their" exact="cancer" post="cells, i.e., those patients with the highest likelihood of"/>
   <result pre="for cocktail therapies that should affect essential pathways/mechanisms resulting in" exact="cancer" post="cell death with minimal side effects for normal cells."/>
   <result pre="and acquired resistance, tumor heterogeneity, adaptation, and genetic instability of" exact="cancer" post="cells. Finally, pharmacogenetics is another PM dimension that cannot"/>
   <result pre="available for a same target. Conclusions The fundamental recognition that" exact="cancer" post="is caused by the unregulated expansion of cells because"/>
   <result pre="regulation of other genes. What must be considered is that" exact="cancer" post="is a disease of cellular regulation pathways. Consequently, we"/>
   <result pre="we propose that it is the signaling phenotype of dysregulated" exact="cancer" post="cells that is the key feature to be addressed"/>
   <result pre="feature to be addressed in order to achieve success in" exact="cancer" post="precision therapy. The characterization of cancer-activated protein networks will"/>
   <result pre="action of chemotherapy. A key challenge associated with PM of" exact="cancer" post="diseases is the heterogeneity of tumors and progressive phenotype"/>
   <result pre="biopsy will allow the non-invasive diagnosis and real-time monitoring of" exact="cancer" post="evolution. Despite its apparent high costs, PM must be"/>
   <result pre="makes irreversible the ongoing trend toward the PM approach of" exact="cancer" post="[ 209]. Collaborative international programs with the purpose of"/>
   <result pre="serve as guidance to clinical decisions. Abbreviations A adenine BC" exact="breast cancer" post="BCSC breast cancer stem cell CAM cell adhesion molecules"/>
   <result pre="as guidance to clinical decisions. Abbreviations A adenine BC breast" exact="cancer" post="BCSC breast cancer stem cell CAM cell adhesion molecules"/>
   <result pre="to clinical decisions. Abbreviations A adenine BC breast cancer BCSC" exact="breast cancer" post="stem cell CAM cell adhesion molecules CAR chimeric antigen"/>
   <result pre="clinical decisions. Abbreviations A adenine BC breast cancer BCSC breast" exact="cancer" post="stem cell CAM cell adhesion molecules CAR chimeric antigen"/>
   <result pre="Dos Santos JW Herrera AC Victorino VJ et al. Breast" exact="cancer" post="in Brazil: epidemiology and treatment challenges Breast Cancer 2015"/>
   <result pre="and in future — the promise and challenges of personalised" exact="cancer" post="medicine: a position paper by the European Society for"/>
   <result pre="F Center MM Ferlay J Ward E Forman D Global" exact="cancer" post="statistics CA Cancer J Clin 2011 61 2 69"/>
   <result pre="Heys SD Plant phenolics in the prevention and treatment of" exact="cancer" post="Adv Exp Med Biol 2010 698 36 51 10.1007/978-1-4419-7347-4_4"/>
   <result pre="10.1007/978-1-4419-7347-4_4 21520702 8. Liu RH Potential synergism of phytochemicals in" exact="cancer" post="prevention: mechanisms of action J Nutr 2004 134 3479S"/>
   <result pre="Molecular targets of dietary agents for prevention and therapy of" exact="cancer" post="Biochem Pharmacol 2006 71 1397 1421 10.1016/j.bcp.2006.02.009 16563357 11."/>
   <result pre="NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive" exact="breast cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast" exact="cancer" post="N Engl J Med 2005 353 16 1673 1684"/>
   <result pre="et al. Somatic cell fusions reveal extensive heterogeneity in basal-like" exact="breast cancer" post="Cell Reports 2015 11 1549 1563 10.1016/j.celrep.2015.05.011 26051943 18."/>
   <result pre="al. Somatic cell fusions reveal extensive heterogeneity in basal-like breast" exact="cancer" post="Cell Reports 2015 11 1549 1563 10.1016/j.celrep.2015.05.011 26051943 18."/>
   <result pre="Chakravarthy AB Shyr Y et al. Identification of human triple-negative" exact="breast cancer" post="subtypes and preclinical models for selection of targeted therapies"/>
   <result pre="AB Shyr Y et al. Identification of human triple-negative breast" exact="cancer" post="subtypes and preclinical models for selection of targeted therapies"/>
   <result pre="P Detection of circulating tumor cells in blood of metastatic" exact="breast cancer" post="patients using a combination of cytokeratin and EpCAM antibodies"/>
   <result pre="Detection of circulating tumor cells in blood of metastatic breast" exact="cancer" post="patients using a combination of cytokeratin and EpCAM antibodies"/>
   <result pre="Cancer 2012 12 206 10.1186/1471-2407-12-206 22646670 22. Mannello F Understanding" exact="breast cancer" post="stem cell heterogeneity: time to move on to a"/>
   <result pre="2012 12 206 10.1186/1471-2407-12-206 22646670 22. Mannello F Understanding breast" exact="cancer" post="stem cell heterogeneity: time to move on to a"/>
   <result pre="Silva RA González MU Ramos D et al. Detection of" exact="cancer" post="biomarkers in serum using a hybrid mechanical and optoplasmonic"/>
   <result pre="2737 2772 10.1007/s11538-007-9253-6 17874270 33. Bacac M Stamenkovic I Metastatic" exact="cancer" post="cell Annu Rev Pathol 2008 3 221 247 10.1146/annurev.pathmechdis.3.121806.151523"/>
   <result pre="DE Baracos VE Tuszynski JA Modeling the energetic cost of" exact="cancer" post="as a result of altered energy metabolism: implications for"/>
   <result pre="Schinzel AC et al. Initial genome sequencing and analysis of" exact="multiple myeloma" post="Nature 2011 471 467 472 10.1038/nature09837 21430775 36. Alexandrov"/>
   <result pre="Behjati S et al. Signatures of mutational processes in human" exact="cancer" post="Nature 2013 500 415 421 10.1038/nature12477 23945592 37. Roberts"/>
   <result pre="Swanton C The causes and consequences of genetic heterogeneity in" exact="cancer" post="evolution Nature 2013 501 7467 338 345 10.1038/nature12625 24048066"/>
   <result pre="Swanton C Targeting chromosomal instability and tumour heterogeneity in HER2-positive" exact="breast cancer" post="J Cell Biochem 2010 111 4 782 790 10.1002/jcb.22781"/>
   <result pre="C Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast" exact="cancer" post="J Cell Biochem 2010 111 4 782 790 10.1002/jcb.22781"/>
   <result pre="A Roh W Shi X et al. Clonal evolution in" exact="breast cancer" post="revealed by single nucleus genome sequencing Nature 2014 512"/>
   <result pre="Roh W Shi X et al. Clonal evolution in breast" exact="cancer" post="revealed by single nucleus genome sequencing Nature 2014 512"/>
   <result pre="DC et al. The origin and evolution of mutations in" exact="acute myeloid leukemia" post="Cell 2012 150 264 278 10.1016/j.cell.2012.06.023 22817890 44. de"/>
   <result pre="et al. The origin and evolution of mutations in acute" exact="myeloid leukemia" post="Cell 2012 150 264 278 10.1016/j.cell.2012.06.023 22817890 44. de"/>
   <result pre="al. The origin and evolution of mutations in acute myeloid" exact="leukemia" post="Cell 2012 150 264 278 10.1016/j.cell.2012.06.023 22817890 44. de"/>
   <result pre="10.1186/gm505 24267946 45. Greaves M Maley CC Clonal evolution in" exact="cancer" post="Nature 2012 481 306 313 10.1038/nature10762 22258609 46. Gerlinger"/>
   <result pre="883 892 10.1056/NEJMoa1113205 22397650 47. Singh A Settleman J EMT," exact="cancer" post="stem cells and drug resistance: an emerging axis of"/>
   <result pre="resistance: an emerging axis of evil in the war on" exact="cancer" post="Oncogene 2010 29 4741 4751 10.1038/onc.2010.215 20531305 48. Demidenko"/>
   <result pre="361 371 10.1083/jcb.200503165 16247032 55. Cooper S Shayman JA Revisiting" exact="retinoblastoma" post="protein phosphorylation during the mammalian cell cycle Cell Mol"/>
   <result pre="11361093 56. Burkhart DL Sage J Cellular mechanisms of tumour" exact="suppression" post="by the retinoblastoma gene Nat Rev Cancer 2008 8"/>
   <result pre="DL Sage J Cellular mechanisms of tumour suppression by the" exact="retinoblastoma" post="gene Nat Rev Cancer 2008 8 671 682 10.1038/nrc2399"/>
   <result pre="20029423 58. Artandi SE DePinho RA Telomeres and telomerase in" exact="cancer" post="Carcinogenesis 2010 31 9 18 10.1093/carcin/bgp268 19887512 59. Blasco"/>
   <result pre="10.1093/carcin/bgp268 19887512 59. Blasco MA Telomeres and human disease: ageing," exact="cancer" post="and beyond Nat Rev Genet 2005 6 611 622"/>
   <result pre="and telomere length in normal breast, preneoplastic lesions, and invasive" exact="cancer" post="Am J Clin Oncol 2010 33 341 345 10.1097/COC.0b013e3181b0c4c2"/>
   <result pre="transition interactome gene-expression signature is associated with claudin-low and metaplastic" exact="breast cancer" post="subtypes Proc Natl Acad Sci U S A 2010"/>
   <result pre="interactome gene-expression signature is associated with claudin-low and metaplastic breast" exact="cancer" post="subtypes Proc Natl Acad Sci U S A 2010"/>
   <result pre="A Kirchner T Heterogeneous expression of Wnt/beta-catenin target genes within" exact="colorectal cancer" post="Int J Cancer 2007 121 1941 1948 10.1002/ijc.22916 17631641"/>
   <result pre="Kirchner T Heterogeneous expression of Wnt/beta-catenin target genes within colorectal" exact="cancer" post="Int J Cancer 2007 121 1941 1948 10.1002/ijc.22916 17631641"/>
   <result pre="Talmadge JE Fidler IJ AACR centennial series: the biology of" exact="cancer" post="metastasis: historical perspective Cancer Res 2010 70 5649 5669"/>
   <result pre="Roy F Involvement of members of the cadherin superfamily in" exact="cancer" post="Cold Spring Harb Perspect Biol 2009 1 a003129 10.1101/cshperspect.a003129"/>
   <result pre="10.1101/sqb.2005.70.018 16869748 71. Wilson WR Hay MP Targeting hypoxia in" exact="cancer" post="therapy Nat Rev Cancer 2011 11 393 410 10.1038/nrc3064"/>
   <result pre="Thompson CB Tumor suppressors and cell metabolism: a recipe for" exact="cancer" post="growth Genes Dev 2009 23 537 548 10.1101/gad.1756509 19270154"/>
   <result pre="548 10.1101/gad.1756509 19270154 74. Warburg O On the origin of" exact="cancer" post="cells Science 1956 123 309 314 10.1126/science.123.3191.309 13298683 75."/>
   <result pre="from the Warburg effect to symbiotic energy fuel exchange in" exact="cancer" post="cells Radiother Oncol 2009 92 329 333 10.1016/j.radonc.2009.06.025 19604589"/>
   <result pre="CM Schreiber RD Smyth MJ Immune-mediated dormancy: an equilibrium with" exact="cancer" post="J Leukoc Biol 2008 84 988 993 10.1189/jlb.1107774 18515327"/>
   <result pre="83. Grivennikov SI Greten FR Karin M Immunity, inflammation, and" exact="cancer" post="Cell 2010 140 883 899 10.1016/j.cell.2010.01.025 20303878 84. Galluzzi"/>
   <result pre="C Joyce JA Cysteine cathepsin proteases as pharmacological targets in" exact="cancer" post="Trends Pharmacol Sci 2008 29 22 28 10.1016/j.tips.2007.10.011 18037508"/>
   <result pre="90. Bhowmick NA Neilson EG Moses HL Stromal fibroblasts in" exact="cancer" post="initiation and progression Nature 2004 432 332 337 10.1038/nature03096"/>
   <result pre="D Baselga J Piccart M Emerging targeted agents in metastatic" exact="breast cancer" post="Nat Rev Clin Oncol 2013 10 4 191 210"/>
   <result pre="Baselga J Piccart M Emerging targeted agents in metastatic breast" exact="cancer" post="Nat Rev Clin Oncol 2013 10 4 191 210"/>
   <result pre="Molife LR de Bono JS FGF receptor inhibitors: role in" exact="cancer" post="therapy Curr Oncol Rep 2012 14 2 111 119"/>
   <result pre="F Soria JC Fibroblast growth factor receptor inhibitors as a" exact="cancer" post="treatment: From a biologic rationale to medical perspectives Cancer"/>
   <result pre="et al. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in" exact="cancer" post="therapy: advances and perspectives Curr Pharm Des 2012 18"/>
   <result pre="Lippman SM El-Naggar AK Targeting the MAPK-RAS-RAF signaling pathway in" exact="cancer" post="therapy Expert Opin Ther Targets 2012 16 1 103"/>
   <result pre="ES The history and future of targeting cyclin-dependent kinases in" exact="cancer" post="therapy Nat Rev Drug Discov 2015 14 2 130"/>
   <result pre="M Hedgehog signaling pathway as a new therapeutic target in" exact="pancreatic cancer" post="World J Gastroenterol 2014 20 9 2335 2342 10.3748/wjg.v20.i9.2335"/>
   <result pre="Hedgehog signaling pathway as a new therapeutic target in pancreatic" exact="cancer" post="World J Gastroenterol 2014 20 9 2335 2342 10.3748/wjg.v20.i9.2335"/>
   <result pre="JN Moon RT WNT signalling pathways as therapeutic targets in" exact="cancer" post="Nat Rev Cancer 2013 13 11 26 10.1038/nrc3419 23258168"/>
   <result pre="Jain S Santa-Maria CA Gradishar WJ The role of ovarian" exact="suppression" post="in premenopausal women with hormone receptor-positive early-stage breast cancer"/>
   <result pre="of ovarian suppression in premenopausal women with hormone receptor-positive early-stage" exact="breast cancer" post="Oncology 2015 29 7 473 478 26178334 108. Goel"/>
   <result pre="ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast" exact="cancer" post="Oncology 2015 29 7 473 478 26178334 108. Goel"/>
   <result pre="A Beith J LHRH agonists for adjuvant therapy of early" exact="breast cancer" post="in premenopausal women Cochrane Database Syst Rev 2009 4"/>
   <result pre="Beith J LHRH agonists for adjuvant therapy of early breast" exact="cancer" post="in premenopausal women Cochrane Database Syst Rev 2009 4"/>
   <result pre="of the cost-effectiveness of hormone therapy, chemotherapy, and targetedtherapy for" exact="breast cancer" post="Breast Cancer Res Treat 2015 151 1 27 40"/>
   <result pre="the cost-effectiveness of hormone therapy, chemotherapy, and targetedtherapy for breast" exact="cancer" post="Breast Cancer Res Treat 2015 151 1 27 40"/>
   <result pre="Santeufemia DA Basso SM Current medical treatment of estrogen receptor-positive" exact="breast cancer" post="World J Biol Chem 2015 6 3 231 239"/>
   <result pre="DA Basso SM Current medical treatment of estrogen receptor-positive breast" exact="cancer" post="World J Biol Chem 2015 6 3 231 239"/>
   <result pre="Verma S Iwata H et al. Palbociclib in hormone-receptor-positive advanced" exact="breast cancer" post="N Engl J Med 2015 373 3 209 219"/>
   <result pre="S Iwata H et al. Palbociclib in hormone-receptor-positive advanced breast" exact="cancer" post="N Engl J Med 2015 373 3 209 219"/>
   <result pre="26030518 112. Zelnak AB O’Regan RM Optimizing endocrine therapy for" exact="breast cancer" post="J Natl Compr Canc Netw 2015 13 8 e56"/>
   <result pre="112. Zelnak AB O’Regan RM Optimizing endocrine therapy for breast" exact="cancer" post="J Natl Compr Canc Netw 2015 13 8 e56"/>
   <result pre="e64 26285250 113. Mittendorf EA Peoples GE Singletary SE Breast" exact="cancer" post="vaccines: promise for the future or pipe dream? Cancer"/>
   <result pre="Minchella I et al. Immune approaches to the treatment of" exact="breast cancer," post="around the corner? Breast Cancer Res 2014 16 1"/>
   <result pre="Chen L Whole-exome sequencing reveals recurrent somatic mutation networks in" exact="cancer" post="Cancer Lett 2013 340 2 270 276 10.1016/j.canlet.2012.11.002 23153794"/>
   <result pre="Bianconi G Severini S Teschendorff AE Differential network entropy reveals" exact="cancer" post="system hallmarks Sci Rep 2012 2 802 10.1038/srep00802 23150773"/>
   <result pre="optimized protein targets for drug development toward the control of" exact="cancer" post="diseases PLoS One 2015 10 1 e0115054 10.1371/journal.pone.0115054 25625699"/>
   <result pre="on the calculation of network entropy for protein-protein interactions in" exact="breast cancer" post="cell lines EPJ Nonlinear Biomed Physics 2015 3 6"/>
   <result pre="the calculation of network entropy for protein-protein interactions in breast" exact="cancer" post="cell lines EPJ Nonlinear Biomed Physics 2015 3 6"/>
   <result pre="RA Haupt LM Griffiths LR Gene expression profiling in human" exact="breast cancer" post="– toward personalised therapeutics? Open Breast Cancer J 2010"/>
   <result pre="Haupt LM Griffiths LR Gene expression profiling in human breast" exact="cancer" post="– toward personalised therapeutics? Open Breast Cancer J 2010"/>
   <result pre="can tumor gene expression profiling improve outcomes in patients with" exact="breast cancer?" post="Genet Med 2009 11 1 66 73 10.1097/GIM.0b013e3181928f56 19125125"/>
   <result pre="138. Abba MC Lacunza E Butti M Aldaz CM Breast" exact="cancer" post="biomarker discovery in the functional genomic age: A systematic"/>
   <result pre="cancer-related gene mutations in Canadian and Saudi Arabian patients with" exact="breast cancer" post="Anticancer Res 2015 35 2601 2610 25964535 144. Bartel"/>
   <result pre="gene mutations in Canadian and Saudi Arabian patients with breast" exact="cancer" post="Anticancer Res 2015 35 2601 2610 25964535 144. Bartel"/>
   <result pre="145. Wang V Wu W MicroRNA: A new player in" exact="breast cancer" post="development J Cancer Mol 2007 3 5 133 138"/>
   <result pre="Wang V Wu W MicroRNA: A new player in breast" exact="cancer" post="development J Cancer Mol 2007 3 5 133 138"/>
   <result pre="et al. MicroRNAs exhibit high frequency genomic alterations in human" exact="cancer" post="Proc Natl Acad Sci U S A 2006 103"/>
   <result pre="147. Kent OA Mendell JT A small piece in the" exact="cancer" post="puzzle: microRNAs as tumor suppressors and oncogenes Oncogene 2006"/>
   <result pre="KM Irie HY et al. The proteomic landscape of triple-negative" exact="breast cancer" post="Cell Rep 2015 11 4 630 644 10.1016/j.celrep.2015.03.050 25892236"/>
   <result pre="Irie HY et al. The proteomic landscape of triple-negative breast" exact="cancer" post="Cell Rep 2015 11 4 630 644 10.1016/j.celrep.2015.03.050 25892236"/>
   <result pre="E Tuszynski JA Molecular signaling network complexity is correlated with" exact="cancer" post="patient survivability Proc Natl Acad Sci U S A"/>
   <result pre="AE Severini S Increased entropy of signal transduction in the" exact="cancer" post="metastasis phenotype BMC Syst Biol 2010 4 104 10.1186/1752-0509-4-104"/>
   <result pre="prognostic molecular markers of the reactive stroma of breast and" exact="prostate cancer" post="using information theoretic approach Int J Innovative Res Comput"/>
   <result pre="molecular markers of the reactive stroma of breast and prostate" exact="cancer" post="using information theoretic approach Int J Innovative Res Comput"/>
   <result pre="Ragan MA Gene regulatory network inference: evaluation and application to" exact="ovarian cancer" post="allows the prioritization of drug targets Genome Med 2012"/>
   <result pre="MA Gene regulatory network inference: evaluation and application to ovarian" exact="cancer" post="allows the prioritization of drug targets Genome Med 2012"/>
   <result pre="22548828 172. Fumiã HF Martins ML Boolean network model for" exact="cancer" post="pathways: predicting carcinogenesis and targeted therapy outcomes PLoS One"/>
   <result pre="al. Subtype and pathway specific responses to anticancer compounds in" exact="breast cancer" post="Proc Natl Sci Acad USA 2012 109 2724 10.1073/pnas.1018854108"/>
   <result pre="Subtype and pathway specific responses to anticancer compounds in breast" exact="cancer" post="Proc Natl Sci Acad USA 2012 109 2724 10.1073/pnas.1018854108"/>
   <result pre="2012 109 2724 10.1073/pnas.1018854108 176. Parise CA Caggiano V Breast" exact="cancer" post="survival defined by the ER/PR/HER2 subtypes and a surrogate"/>
   <result pre="10.1517/14656566.6.9.1463 16086635 190. Workman P New drug targets for genomic" exact="cancer" post="therapy: successes, limitations, opportunities and future challenges Curr Cancer"/>
   <result pre="Collaborative Group) Effects of chemotherapy and hormonal therapy for early" exact="breast cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="Group) Effects of chemotherapy and hormonal therapy for early breast" exact="cancer" post="on recurrence and 15-year survival: an overview of the"/>
   <result pre="Flockhart DA Skaar TC Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in" exact="breast cancer" post="cells with potency similar to 4-hydroxy-tamoxifen Cancer Chemother Pharmacol"/>
   <result pre="DA Skaar TC Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast" exact="cancer" post="cells with potency similar to 4-hydroxy-tamoxifen Cancer Chemother Pharmacol"/>
   <result pre="Kasai Y Kemeny M et al. Increasing tamoxifen dose in" exact="breast cancer" post="patients based on CYP2D6 genotypes and endoxifen levels: effect"/>
   <result pre="Y Kemeny M et al. Increasing tamoxifen dose in breast" exact="cancer" post="patients based on CYP2D6 genotypes and endoxifen levels: effect"/>
   <result pre="Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of" exact="breast cancer" post="genomic analyses in the clinical routine Genome Med 2015"/>
   <result pre="(SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast" exact="cancer" post="genomic analyses in the clinical routine Genome Med 2015"/>
   <result pre="Beyond laser microdissection technology: follow the yellow brick road for" exact="cancer" post="research Am J Cancer Res 2014 4 1 1"/>
   <result pre="in Cancer (GDSC): a resource for therapeutic biomarker discovery in" exact="cancer" post="cells Nucleic Acids Res 2013 41 D955 D961 10.1093/nar/gks1111"/>
   <result pre="K Fumagalli D et al. The AURORA initiative for metastatic" exact="breast cancer" post="Br J Cancer 2014 111 10 1881 1887 10.1038/bjc.2014.341"/>
   <result pre="Fumagalli D et al. The AURORA initiative for metastatic breast" exact="cancer" post="Br J Cancer 2014 111 10 1881 1887 10.1038/bjc.2014.341"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
